Vaccine/Sample,Dose,Geography Type,Geography,Survey Year,Dimension Type,Dimension,Estimate (%),95% CI (%),Sample Size
HPV,"≥1 Dose, Males",States/Local Areas,New York,2023,Age,13-17 Years,81.5,75.2 to 86.5,289
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2023,Age,13-17 Years,90.2,86.8 to 92.8,559
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2023,Age,13-17 Years,93.6,90.9 to 95.5,559
≥1 Dose MenACWY,,States/Local Areas,New York,2023,Age,13-17 Years,95.3,92.7 to 97.0,559
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2023,Age,13-17 Years,79.4,74.8 to 83.3,559
HPV,"Up-to-Date, Males",States/Local Areas,New York,2023,Age,13-17 Years,67.8,60.8 to 74.2,289
HPV,"≥1 Dose, Females",States/Local Areas,New York,2023,Age,13-17 Years,77.2,70.1 to 83.0,270
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2023,Age,13-17 Years,68.6,63.5 to 73.2,559
≥3 Doses HepB,,States/Local Areas,New York,2023,Age,13-17 Years,94.2,91.1 to 96.3,559
≥2 Doses MMR,,States/Local Areas,New York,2023,Age,13-17 Years,94.6,91.8 to 96.5,559
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2023,Age,13-17 Years,95.5,92.9 to 97.2,559
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2023,Age,13-17 Years,95.0,92.1 to 96.8,512
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2023,Age,13-17 Years,97.7,95.4 to 98.9,512
Varicella,History of disease,States/Local Areas,New York,2023,Age,13-17 Years,9.8,7.0 to 13.6,559
≥2 Doses Hep A,,States/Local Areas,New York,2023,Age,13-17 Years,89.0,85.5 to 91.8,559
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2023,Age,13-15 Years,90.2,85.9 to 93.3,350
≥1 Dose MenACWY,,States/Local Areas,New York,2023,Age,13-15 Years,96.6,94.1 to 98.1,350
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2023,Age,13-15 Years,61.7,55.2 to 67.8,350
HPV,"Up-to-Date, Females",States/Local Areas,New York,2023,Age,13-15 Years,63.0,53.5 to 71.6,168
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2023,Age,13-15 Years,93.9,89.7 to 96.4,320
HPV,"Up-to-Date, Females",States/Local Areas,New York,2023,Age,13-17 Years,69.3,62.0 to 75.8,270
HPV,"Up-to-Date, Males",States/Local Areas,New York,2023,Age,13-15 Years,60.5,51.4 to 68.9,182
HPV,"≥2 Doses, Females",States/Local Areas,New York,2022,Age,13-17 Years,69.0,62.0 to 75.3,263
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Insurance Coverage,Uninsured,88.3,68.1 to 96.4,36
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Insurance Coverage,Other,91.0,87.0 to 93.8,365
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Insurance Coverage,Any Medicaid,89.2,86.4 to 91.4,897
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Insurance Coverage,Private Insurance Only,92.6,90.8 to 94.0,1581
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Uninsured,40.1,23.3 to 59.6,36
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Other,58.8,52.1 to 65.2,365
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Any Medicaid,69.9,65.9 to 73.7,897
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Uninsured,47.9,28.7 to 67.8,36
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Insurance Coverage,Uninsured,82.9,53.5 to 95.4,36
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Private Insurance Only,61.1,57.9 to 64.2,1581
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Other,72.1,65.5 to 77.8,365
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Insurance Coverage,Other,95.7,93.0 to 97.4,365
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Any Medicaid,79.7,76.0 to 82.9,897
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Insurance Coverage,Private Insurance Only,73.3,70.3 to 76.2,1581
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Insurance Coverage,Any Medicaid,93.9,91.7 to 95.6,897
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Insurance Coverage,Private Insurance Only,95.4,94.0 to 96.5,1581
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Poverty,Below Poverty Level,88.8,85.3 to 91.6,533
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Poverty,Living At or Above Poverty Level,91.9,90.4 to 93.2,2180
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Poverty,Living At or Above Poverty Level,63.0,60.3 to 65.6,2180
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Poverty,Below Poverty Level,67.8,62.4 to 72.7,533
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Poverty,Living At or Above Poverty Level,95.4,94.1 to 96.3,2180
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Poverty,Below Poverty Level,94.3,92.0 to 96.0,533
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Poverty,Living At or Above Poverty Level,73.7,71.1 to 76.1,2180
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Poverty,Below Poverty Level,81.3,76.5 to 85.2,533
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.7,67.4 to 73.8,1333
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",70.4,63.7 to 76.4,322
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.6,85.0 to 92.9,435
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Race and Ethnicity,Hispanic,89.7,86.8 to 92.0,789
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.7,85.4 to 92.8,322
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Race and Ethnicity,Hispanic,95.2,93.5 to 96.5,789
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.8,91.0 to 94.3,1333
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.8,93.1 to 96.2,1333
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",94.3,90.9 to 96.5,322
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",68.8,62.6 to 74.3,435
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,Hispanic,70.1,65.7 to 74.2,789
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",61.8,55.0 to 68.2,322
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",82.7,77.2 to 87.0,435
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.4,90.3 to 96.8,435
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Principal City,89.9,88.0 to 91.5,1728
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.7,90.4 to 94.4,1005
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,Hispanic,82.3,78.5 to 85.5,789
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",59.3,55.9 to 62.7,1333
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Principal City,94.7,93.2 to 95.8,1728
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Urbanicity,Living In a Non-MSA,87.1,77.7 to 92.9,146
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Non-Principal City,96.0,94.2 to 97.2,1005
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Principal City,68.8,65.8 to 71.5,1728
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Urbanicity,Living In a Non-MSA,51.8,41.2 to 62.3,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Non-Principal City,58.3,54.4 to 62.1,1005
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Principal City,78.7,76.0 to 81.2,1728
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Urbanicity,Living In a Non-MSA,63.0,51.5 to 73.2,146
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Urbanicity,Living In a MSA Non-Principal City,71.7,68.0 to 75.2,1005
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Urbanicity,Living In a Non-MSA,92.4,85.9 to 96.1,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018-2022,Overall,Overall,63.5,61.2 to 65.8,2879
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018-2022,Overall,Overall,75.0,72.8 to 77.1,2879
≥1 Dose MenACWY,,States/Local Areas,New York,2022,Age,13-17 Years,96.5,94.2 to 97.9,536
≥1 Dose MenACWY,,States/Local Areas,New York,2020,Age,13-17 Years,93.7,90.8 to 95.7,729
≥1 Dose MenACWY,,States/Local Areas,New York,2018,Age,13-17 Years,94.9,92.0 to 96.8,535
≥1 Dose MenACWY,,States/Local Areas,New York,2019,Age,13-17 Years,95.0,92.3 to 96.8,498
HPV,"≥3 Doses, Females",States/Local Areas,New York,2011,Age,13-15 Years,28.8,22.7 to 35.7,248
≥1 Dose MenACWY,,States/Local Areas,New York,2021,Age,13-17 Years,93.8,90.8 to 95.9,581
≥2 Doses MMR,,States/Local Areas,New York,2022,Age,13-17 Years,95.3,92.5 to 97.1,536
≥2 Doses MMR,,States/Local Areas,New York,2021,Age,13-17 Years,94.2,90.9 to 96.3,581
HPV,"≥3 Doses, Females",States/Local Areas,New York,2009,Age,13-15 Years,28.2,20.5 to 37.5,167
HPV,"≥3 Doses, Females",States/Local Areas,New York,2010,Age,13-15 Years,30.0,22.9 to 38.1,200
HPV,"≥3 Doses, Females",States/Local Areas,New York,2008,Age,13-15 Years,28.7,20.9 to 38.0,174
HPV,"≥3 Doses, Females",States/Local Areas,New York,2013,Age,13-15 Years,38.0,29.9 to 46.8,205
HPV,"≥3 Doses, Females",States/Local Areas,New York,2012,Age,13-15 Years,35.3,26.8 to 44.9,191
HPV,"≥3 Doses, Females",States/Local Areas,New York,2014,Age,13-15 Years,29.7,21.8 to 39.1,171
HPV,"≥3 Doses, Females",States/Local Areas,New York,2015,Age,13-15 Years,41.5,33.1 to 50.5,169
≥2 Doses MMR,,States/Local Areas,New York,2017,Age,13-17 Years,94.1,91.7 to 95.9,651
≥2 Doses MMR,,States/Local Areas,New York,2018,Age,13-17 Years,95.2,92.4 to 97.0,535
≥2 Doses MMR,,States/Local Areas,New York,2019,Age,13-17 Years,92.4,88.6 to 95.1,498
HPV,"≥3 Doses, Males and Females",States/Local Areas,New York,2014,Age,13-17 Years,34.2,29.5 to 39.1,594
HPV,"≥3 Doses, Males and Females",States/Local Areas,New York,2015,Age,13-17 Years,42.6,38.2 to 47.0,665
≥2 Doses MMR,,States/Local Areas,New York,2020,Age,13-17 Years,94.4,91.8 to 96.2,729
HPV,"≥3 Doses, Males and Females",States/Local Areas,New York,2013,Age,13-17 Years,32.0,27.8 to 36.4,710
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2022,Age,13-17 Years,90.4,86.9 to 93.0,536
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2021,Age,13-17 Years,87.3,83.4 to 90.4,581
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2020,Age,13-17 Years,93.0,90.2 to 95.1,729
≥1 Dose MenACWY,,States/Local Areas,New York,2017,Age,13-17 Years,89.3,85.9 to 91.9,651
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2019,Age,13-17 Years,93.4,90.5 to 95.4,498
≥2 Doses MMR,,States/Local Areas,New York,2016,Age,13-17 Years,92.9,90.2 to 94.9,655
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2016,Age,13-17 Years,91.1,88.2 to 93.4,655
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018,Age,13-17 Years,91.7,88.7 to 94.0,535
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2017,Age,13-17 Years,92.9,90.3 to 94.8,651
≥2 Doses MMR,,States/Local Areas,New York,2013,Age,13-17 Years,93.3,90.3 to 95.4,710
≥2 Doses MMR,,States/Local Areas,New York,2012,Age,13-17 Years,93.8,90.6 to 96.0,627
≥2 Doses MMR,,States/Local Areas,New York,2015,Age,13-17 Years,94.6,92.6 to 96.1,665
≥2 Doses MMR,,States/Local Areas,New York,2014,Age,13-17 Years,91.6,88.2 to 94.1,594
≥1 Dose MenACWY,,States/Local Areas,New York,2013,Age,13-17 Years,83.3,79.7 to 86.4,710
≥1 Dose MenACWY,,States/Local Areas,New York,2014,Age,13-17 Years,79.6,75.1 to 83.5,594
≥1 Dose MenACWY,,States/Local Areas,New York,2015,Age,13-17 Years,86.2,82.9 to 89.0,665
≥1 Dose MenACWY,,States/Local Areas,New York,2016,Age,13-17 Years,89.2,86.0 to 91.8,655
HPV,"≥3 Doses, Males and Females",States/Local Areas,New York,2011,Age,13-17 Years,17.4,14.6 to 20.5,840
HPV,"≥3 Doses, Males and Females",States/Local Areas,New York,2012,Age,13-17 Years,22.2,18.1 to 26.9,627
≥1 Dose MenACWY,,States/Local Areas,New York,2022,Age,13-15 Years,96.0,93.3 to 97.7,320
≥1 Dose MenACWY,,States/Local Areas,New York,2012,Age,13-17 Years,78.5,74.1 to 82.3,627
≥1 Dose MenACWY,,States/Local Areas,New York,2010,Age,13-17 Years,71.2,66.5 to 75.4,701
≥1 Dose MenACWY,,States/Local Areas,New York,2011,Age,13-17 Years,74.9,70.9 to 78.5,840
≥1 Dose MenACWY,,States/Local Areas,New York,2008,Age,13-17 Years,56.0,51.1 to 60.8,600
≥1 Dose MenACWY,,States/Local Areas,New York,2009,Age,13-17 Years,62.9,57.7 to 67.8,539
≥1 Dose MenACWY,,States/Local Areas,New York,2018-2022,Overall,Overall,94.8,93.7 to 95.7,2879
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018-2022,Overall,Overall,91.2,89.8 to 92.4,2879
Varicella,History of disease,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,12.5,8.3 to 18.4,261
Varicella,History of disease,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,13.4,9.6 to 18.4,291
Varicella,History of disease,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,13.7,10.0 to 18.6,313
Varicella,History of disease,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,51.1,43.5 to 58.7,269
Varicella,History of disease,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,10.0,6.8 to 14.4,281
Varicella,History of disease,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,50.1,42.9 to 57.2,293
Varicella,History of disease,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,10.3,6.8 to 15.2,257
Varicella,History of disease,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,6.7,4.2 to 10.5,381
Varicella,History of disease,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,7.8,4.6 to 13.0,297
Varicella,History of disease,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,23.5,18.6 to 29.2,312
Varicella,History of disease,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,20.5,15.6 to 26.4,300
Varicella,History of disease,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,27.2,22.7 to 32.1,435
Varicella,History of disease,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,31.8,26.6 to 37.6,388
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2019,Age,13-15 Years,60.9,47.6 to 72.7,84
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2020,Age,13-15 Years,72.1,60.0 to 81.6,108
Varicella,History of disease,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,22.5,16.9 to 29.3,288
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2018,Age,13-15 Years,48.7,34.7 to 62.8,71
Varicella,History of disease,States/Local Areas,New Jersey,2009,Age,13-17 Years,46.3,40.6 to 52.0,427
Varicella,History of disease,States/Local Areas,New Jersey,2008,Age,13-17 Years,53.1,46.9 to 59.3,390
Varicella,History of disease,States/Local Areas,New Jersey,2010,Age,13-17 Years,44.7,38.2 to 51.4,399
Varicella,History of disease,States/Local Areas,New Jersey,2011,Age,13-17 Years,32.8,27.6 to 38.4,432
Varicella,History of disease,States/Local Areas,New Jersey,2013,Age,13-17 Years,20.5,15.4 to 26.7,322
Varicella,History of disease,States/Local Areas,New Jersey,2012,Age,13-17 Years,25.1,19.6 to 31.4,330
Varicella,History of disease,States/Local Areas,New Jersey,2014,Age,13-17 Years,16.8,12.2 to 22.8,328
Varicella,History of disease,States/Local Areas,New Jersey,2015,Age,13-17 Years,15.7,11.6 to 20.9,364
Varicella,History of disease,States/Local Areas,New Jersey,2016,Age,13-17 Years,10.3,7.4 to 14.2,422
Varicella,History of disease,States/Local Areas,New Jersey,2018,Age,13-17 Years,13.8,9.7 to 19.3,351
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2020,Age,13-15 Years,47.4,34.9 to 60.3,109
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2019,Age,13-15 Years,42.3,30.2 to 55.5,99
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2018,Age,13-15 Years,43.2,32.0 to 55.2,105
Varicella,History of disease,States/Local Areas,New Jersey,2019,Age,13-17 Years,6.9,4.1 to 11.3,331
Varicella,History of disease,States/Local Areas,New Jersey,2017,Age,13-17 Years,11.8,8.2 to 16.6,366
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Poverty,Living At or Above Poverty Level,32.0,28.5 to 35.7,1025
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Poverty,Below Poverty Level,38.0,31.6 to 44.9,297
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Poverty,Living At or Above Poverty Level,60.2,56.3 to 63.9,1025
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Poverty,Below Poverty Level,64.1,57.4 to 70.4,297
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Poverty,Living At or Above Poverty Level,52.5,48.7 to 56.3,1025
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Poverty,Below Poverty Level,64.3,57.7 to 70.3,297
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"White, Non-Hispanic",44.1,40.0 to 48.4,822
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",64.1,58.4 to 69.5,376
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.1,81.8 to 95.9,98
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,Hispanic,95.9,90.1 to 98.4,76
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.1,85.7 to 93.3,376
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,Hispanic,73.5,59.1 to 84.1,76
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.9,86.0 to 91.2,822
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"White, Non-Hispanic",53.8,49.6 to 58.0,822
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",65.1,59.3 to 70.5,376
≥2 Doses MMR,,HHS Regions/National,Region 8,2014,Age,13-17 Years,88.5,86.2 to 90.5,2290
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",38.4,27.3 to 50.9,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,Hispanic,47.3,32.4 to 62.7,76
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",37.3,31.9 to 43.1,376
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.7,49.4 to 72.7,98
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",72.9,61.4 to 82.0,98
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Principal City,88.5,81.5 to 93.1,214
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,Hispanic,70.5,56.1 to 81.8,76
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Race and Ethnicity,"White, Non-Hispanic",27.7,24.1 to 31.7,822
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Non-Principal City,91.5,87.8 to 94.2,496
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Non-Principal City,59.9,54.4 to 65.2,496
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Principal City,69.5,61.6 to 76.4,214
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a Non-MSA,57.8,53.0 to 62.4,662
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Principal City,42.5,34.6 to 50.8,214
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Non-Principal City,34.7,29.7 to 40.1,496
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a Non-MSA,28.5,24.3 to 33.2,662
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Principal City,62.9,54.7 to 70.4,214
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a MSA Non-Principal City,54.7,49.2 to 60.1,496
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a Non-MSA,51.7,46.9 to 56.4,662
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Overall,Overall,33.3,30.2 to 36.5,1372
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Urbanicity,Living In a Non-MSA,89.1,85.7 to 91.8,662
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Overall,Overall,54.8,51.5 to 58.0,1372
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Overall,Overall,89.9,87.6 to 91.7,1372
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Overall,Overall,60.6,57.4 to 63.8,1372
Varicella,History of disease,States/Local Areas,Kentucky,2012,Age,13-17 Years,33.9,27.4 to 41.0,333
Varicella,History of disease,States/Local Areas,Kentucky,2013,Age,13-17 Years,28.2,22.4 to 34.9,291
Varicella,History of disease,States/Local Areas,Kentucky,2010,Age,13-17 Years,48.0,41.8 to 54.3,309
Varicella,History of disease,States/Local Areas,Kentucky,2011,Age,13-17 Years,45.9,39.3 to 52.6,382
Varicella,History of disease,States/Local Areas,Kentucky,2015,Age,13-17 Years,19.1,14.5 to 24.7,330
Varicella,History of disease,States/Local Areas,Kentucky,2014,Age,13-17 Years,20.6,15.6 to 26.7,335
Varicella,History of disease,States/Local Areas,Maine,2008,Age,13-17 Years,69.4,63.5 to 74.7,333
Varicella,History of disease,States/Local Areas,Maine,2009,Age,13-17 Years,61.8,55.1 to 68.0,299
Varicella,History of disease,States/Local Areas,Maine,2014,Age,13-17 Years,20.1,15.6 to 25.5,341
Varicella,History of disease,States/Local Areas,Maine,2018,Age,13-17 Years,6.6,4.3 to 10.0,317
Varicella,History of disease,States/Local Areas,Maine,2015,Age,13-17 Years,18.8,14.6 to 24.0,374
Varicella,History of disease,States/Local Areas,Maine,2010,Age,13-17 Years,50.4,44.1 to 56.8,312
Varicella,History of disease,States/Local Areas,Maine,2011,Age,13-17 Years,38.0,32.4 to 43.9,411
Varicella,History of disease,States/Local Areas,Maine,2013,Age,13-17 Years,30.8,25.4 to 36.8,343
Varicella,History of disease,States/Local Areas,Maine,2012,Age,13-17 Years,34.8,28.6 to 41.5,319
Varicella,History of disease,States/Local Areas,Maine,2016,Age,13-17 Years,15.4,11.4 to 20.6,347
Varicella,History of disease,States/Local Areas,Maine,2019,Age,13-17 Years,10.1,6.5 to 15.3,316
Varicella,History of disease,States/Local Areas,Maine,2020,Age,13-17 Years,9.8,6.8 to 14.1,372
Varicella,History of disease,States/Local Areas,Maine,2021,Age,13-17 Years,7.4,4.5 to 11.9,293
Varicella,History of disease,States/Local Areas,Maine,2022,Age,13-17 Years,6.8,3.9 to 11.6,268
Varicella,History of disease,States/Local Areas,Maine,2017,Age,13-17 Years,13.5,10.1 to 17.9,347
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2019,Age,13-15 Years,42.1,30.3 to 55.0,95
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2020,Age,13-15 Years,60.0,48.9 to 70.2,108
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2018,Age,13-15 Years,44.8,33.2 to 57.0,100
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2023,Age,13-17 Years,92.3,87.4 to 95.3,273
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2023,Age,13-15 Years,54.5,42.6 to 65.9,92
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2023,Age,13-17 Years,75.1,64.4 to 83.5,118
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2023,Age,13-15 Years,96.8,93.0 to 98.6,149
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2023,Age,13-15 Years,68.9,53.7 to 80.9,66
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2023,Age,13-15 Years,61.3,51.9 to 70.0,158
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2023,Age,13-15 Years,90.2,83.0 to 94.6,158
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2023,Age,13-15 Years,90.3,83.3 to 94.5,158
≥2 Doses Hep A,,States/Local Areas,New Hampshire,2023,Age,13-17 Years,89.3,83.7 to 93.1,273
Varicella,History of disease,States/Local Areas,New Hampshire,2023,Age,13-17 Years,4.9,2.8 to 8.5,273
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2023,Age,13-17 Years,97.1,94.2 to 98.5,259
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2023,Age,13-17 Years,96.1,93.2 to 97.8,259
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2023,Age,13-17 Years,96.3,93.5 to 98.0,273
≥2 Doses MMR,,States/Local Areas,New Hampshire,2023,Age,13-17 Years,96.2,92.7 to 98.0,273
≥3 Doses HepB,,States/Local Areas,New Hampshire,2023,Age,13-17 Years,94.8,90.7 to 97.1,273
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2023,Age,13-17 Years,70.6,63.8 to 76.5,273
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2023,Age,13-17 Years,66.2,57.3 to 74.2,155
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2023,Age,13-17 Years,87.6,78.5 to 93.2,118
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2023,Age,13-17 Years,85.6,80.2 to 89.7,273
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2023,Age,13-17 Years,93.4,89.1 to 96.1,273
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2023,Age,13-17 Years,91.8,87.0 to 95.0,273
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2023,Age,13-17 Years,83.7,76.4 to 89.1,155
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Hampshire,2022,Age,13-17 Years,76.7,69.9 to 82.4,225
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2022,Age,13-17 Years,75.9,66.1 to 83.6,116
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2022,Age,13-17 Years,77.7,67.5 to 85.4,109
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Overall,Overall,81.1,78.5 to 83.4,1524
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a Non-MSA,94.5,91.7 to 96.3,608
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Overall,Overall,69.6,66.7 to 72.3,1524
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a Non-MSA,77.5,72.9 to 81.6,608
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Non-Principal City,83.3,79.7 to 86.3,716
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Principal City,81.7,74.4 to 87.2,200
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a Non-MSA,65.6,60.5 to 70.3,608
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Non-Principal City,72.6,68.6 to 76.2,716
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Principal City,68.6,60.5 to 75.8,200
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a Non-MSA,81.5,77.3 to 85.2,608
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.8,90.2 to 94.7,716
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Principal City,89.1,82.5 to 93.5,200
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,Hispanic,84.6,73.6 to 91.6,87
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.4,92.0 to 96.2,716
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Urbanicity,Living In a MSA Principal City,96.6,92.9 to 98.4,200
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.4,84.6 to 95.4,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.4,65.2 to 71.5,1287
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.5,76.5 to 91.4,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",77.9,68.3 to 85.2,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,Hispanic,69.9,57.0 to 80.3,87
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.3,86.0 to 90.3,1287
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.0,93.3 to 96.2,1287
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,Hispanic,84.9,73.6 to 91.9,87
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,Hispanic,93.9,87.6 to 97.2,87
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",95.1,88.2 to 98.0,133
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Race and Ethnicity,"White, Non-Hispanic",80.3,77.5 to 82.9,1287
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Poverty,Below Poverty Level,78.2,67.4 to 86.1,105
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Poverty,Living At or Above Poverty Level,81.3,78.6 to 83.7,1375
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Poverty,Below Poverty Level,82.5,72.5 to 89.5,105
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Poverty,Living At or Above Poverty Level,89.0,86.9 to 90.9,1375
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Poverty,Below Poverty Level,66.5,55.1 to 76.2,105
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Poverty,Living At or Above Poverty Level,69.9,66.9 to 72.8,1375
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Poverty,Living At or Above Poverty Level,94.5,92.8 to 95.8,1375
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Poverty,Below Poverty Level,95.1,86.4 to 98.3,105
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Private Insurance Only,90.7,88.6 to 92.5,1058
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Any Medicaid,83.9,78.6 to 88.0,361
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Private Insurance Only,83.9,81.1 to 86.4,1058
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Any Medicaid,76.7,70.9 to 81.6,361
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Other,88.3,75.3 to 94.9,72
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Other,73.6,59.2 to 84.3,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Private Insurance Only,72.5,69.2 to 75.6,1058
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Uninsured,74.5,49.0 to 89.9,33
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Uninsured,68.9,45.1 to 85.6,33
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Any Medicaid,66.0,59.8 to 71.7,361
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Other,56.1,41.8 to 69.4,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Uninsured,61.0,38.7 to 79.4,33
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Private Insurance Only,95.9,94.2 to 97.0,1058
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Any Medicaid,92.9,89.1 to 95.4,361
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Other,93.1,79.3 to 98.0,72
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Insurance Coverage,Uninsured,89.4,64.3 to 97.5,33
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2009,Age,13-17 Years,67.8,61.6 to 73.5,307
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2008,Age,13-17 Years,54.6,47.3 to 61.7,300
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2011,Age,13-17 Years,80.6,74.9 to 85.3,385
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2010,Age,13-17 Years,73.8,68.1 to 78.8,350
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2012,Age,13-17 Years,83.1,76.7 to 88.0,278
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2022,Age,13-15 Years,87.2,78.5 to 92.7,134
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2017,Age,13-17 Years,95.1,91.6 to 97.2,333
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018,Age,13-17 Years,97.5,94.9 to 98.8,303
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2016,Age,13-17 Years,95.3,91.5 to 97.5,313
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Hampshire,2012,Age,13-17 Years,18.7,14.0 to 24.6,278
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Hampshire,2011,Age,13-17 Years,23.2,18.7 to 28.3,385
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2016,Age,13-17 Years,88.0,83.1 to 91.6,313
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2015,Age,13-17 Years,87.7,82.5 to 91.5,295
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2014,Age,13-17 Years,90.6,86.9 to 93.4,402
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2013,Age,13-17 Years,85.6,80.6 to 89.4,345
≥2 Doses MMR,,States/Local Areas,New Hampshire,2016,Age,13-17 Years,98.5,95.9 to 99.5,313
≥2 Doses MMR,,States/Local Areas,New Hampshire,2014,Age,13-17 Years,97.2,94.8 to 98.5,402
≥2 Doses MMR,,States/Local Areas,New Hampshire,2015,Age,13-17 Years,97.1,93.6 to 98.7,295
≥2 Doses MMR,,States/Local Areas,New Hampshire,2012,Age,13-17 Years,97.5,94.7 to 98.8,278
≥2 Doses MMR,,States/Local Areas,New Hampshire,2013,Age,13-17 Years,97.4,94.0 to 98.9,345
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2019,Age,13-17 Years,94.2,89.9 to 96.8,333
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2017,Age,13-17 Years,87.9,82.9 to 91.6,333
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2020,Age,13-17 Years,94.5,91.4 to 96.5,381
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2021,Age,13-17 Years,94.9,90.5 to 97.3,282
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2022,Age,13-17 Years,92.8,87.9 to 95.8,225
≥2 Doses MMR,,States/Local Areas,New Hampshire,2019,Age,13-17 Years,95.6,91.7 to 97.7,333
≥2 Doses MMR,,States/Local Areas,New Hampshire,2018,Age,13-17 Years,98.8,96.9 to 99.5,303
≥2 Doses MMR,,States/Local Areas,New Hampshire,2017,Age,13-17 Years,97.0,93.2 to 98.7,333
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Hampshire,2013,Age,13-17 Years,30.1,24.8 to 35.9,345
≥2 Doses MMR,,States/Local Areas,New Hampshire,2020,Age,13-17 Years,98.8,97.3 to 99.5,381
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Hampshire,2015,Age,13-17 Years,49.2,42.5 to 55.9,295
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Hampshire,2014,Age,13-17 Years,41.3,35.7 to 47.1,402
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2015,Age,13-15 Years,37.8,26.0 to 51.3,75
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2014,Age,13-15 Years,41.0,30.9 to 51.9,115
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2013,Age,13-15 Years,31.7,22.1 to 43.2,98
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018-2022,Overall,Overall,88.4,86.3 to 90.2,1524
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018-2022,Overall,Overall,94.8,93.2 to 96.0,1524
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Hampshire,2018,Age,13-17 Years,69.2,62.1 to 75.4,303
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2022,Age,13-17 Years,97.3,94.1 to 98.8,208
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2019,Age,13-17 Years,80.0,71.6 to 86.3,154
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2020,Age,13-17 Years,83.2,76.1 to 88.5,183
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2021,Age,13-17 Years,86.9,79.0 to 92.1,133
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2022,Age,13-17 Years,85.8,76.1 to 92.0,109
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Hampshire,2017,Age,13-17 Years,63.4,57.2 to 69.2,333
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Hampshire,2016,Age,13-17 Years,58.3,51.6 to 64.6,313
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2016,Age,13-17 Years,69.3,60.1 to 77.1,152
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2015,Age,13-17 Years,69.8,61.4 to 77.1,158
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2014,Age,13-17 Years,56.1,48.2 to 63.7,221
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2013,Age,13-17 Years,41.4,33.4 to 50.0,177
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2017,Age,13-17 Years,73.3,64.7 to 80.4,160
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Hampshire,2019,Age,13-17 Years,64.4,57.5 to 70.8,333
≥3 Doses HepB,,States/Local Areas,New Hampshire,2008,Age,13-17 Years,92.7,88.2 to 95.5,300
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2022,Age,13-15 Years,98.5,95.3 to 99.5,125
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2008,Age,13-17 Years,54.4,44.3 to 64.1,151
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2009,Age,13-17 Years,60.0,51.3 to 68.2,150
≥3 Doses HepB,,States/Local Areas,New Hampshire,2009,Age,13-17 Years,94.7,91.6 to 96.7,307
≥3 Doses HepB,,States/Local Areas,New Hampshire,2010,Age,13-17 Years,96.9,94.1 to 98.4,350
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2011,Age,13-17 Years,88.2,83.0 to 92.0,260
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2010,Age,13-17 Years,76.8,69.1 to 83.1,193
≥3 Doses HepB,,States/Local Areas,New Hampshire,2012,Age,13-17 Years,97.3,94.6 to 98.7,278
≥3 Doses HepB,,States/Local Areas,New Hampshire,2011,Age,13-17 Years,95.7,92.8 to 97.5,385
≥3 Doses HepB,,States/Local Areas,New Hampshire,2014,Age,13-17 Years,96.5,93.6 to 98.1,402
≥3 Doses HepB,,States/Local Areas,New Hampshire,2013,Age,13-17 Years,95.7,92.1 to 97.7,345
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2008,Age,13-17 Years,93.2,85.7 to 96.9,130
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2012,Age,13-17 Years,92.9,87.9 to 96.0,190
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2013,Age,13-17 Years,91.6,86.5 to 94.9,247
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2009,Age,13-15 Years,65.8,54.6 to 75.5,103
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2008,Age,13-15 Years,40.9,28.7 to 54.4,87
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2012,Age,13-17 Years,97.9,94.8 to 99.1,190
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2011,Age,13-17 Years,98.6,96.6 to 99.5,260
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2009,Age,13-17 Years,67.7,58.0 to 76.0,138
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2008,Age,13-17 Years,44.6,34.2 to 55.5,130
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2009,Age,13-17 Years,97.1,92.9 to 98.8,138
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2010,Age,13-17 Years,97.5,93.1 to 99.1,193
≥3 Doses HepB,,States/Local Areas,New Hampshire,2017,Age,13-17 Years,95.4,91.7 to 97.5,333
≥3 Doses HepB,,States/Local Areas,New Hampshire,2019,Age,13-17 Years,94.2,89.4 to 96.8,333
≥3 Doses HepB,,States/Local Areas,New Hampshire,2018,Age,13-17 Years,97.3,94.7 to 98.6,303
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2019,Age,13-17 Years,93.5,88.6 to 96.4,318
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2020,Age,13-17 Years,98.9,97.1 to 99.6,349
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2021,Age,13-17 Years,98.0,94.7 to 99.2,263
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2018,Age,13-17 Years,96.6,92.2 to 98.5,276
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2020,Age,13-17 Years,99.8,98.7 to 100.0,349
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2019,Age,13-17 Years,96.5,92.2 to 98.4,318
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2018,Age,13-17 Years,98.3,94.5 to 99.5,276
≥3 Doses HepB,,States/Local Areas,New Hampshire,2016,Age,13-17 Years,97.7,95.4 to 98.9,313
≥3 Doses HepB,,States/Local Areas,New Hampshire,2015,Age,13-17 Years,97.8,94.3 to 99.2,295
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2016,Age,13-17 Years,98.8,96.2 to 99.6,269
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2015,Age,13-17 Years,99.1,96.4 to 99.8,246
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2014,Age,13-17 Years,97.8,95.4 to 98.9,332
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2013,Age,13-17 Years,97.3,92.9 to 99.0,247
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2017,Age,13-17 Years,94.8,90.4 to 97.2,277
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2010,Age,13-17 Years,49.6,41.4 to 57.7,173
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2011,Age,13-17 Years,65.8,57.7 to 73.0,191
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2017,Age,13-17 Years,97.7,94.6 to 99.0,277
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2014,Age,13-17 Years,94.7,90.9 to 97.0,332
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2016,Age,13-17 Years,94.4,89.6 to 97.0,269
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2015,Age,13-17 Years,95.8,91.5 to 98.0,246
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2012,Age,13-17 Years,52.2,41.7 to 62.5,121
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2013,Age,13-17 Years,68.0,59.2 to 75.6,168
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2014,Age,13-17 Years,71.0,63.4 to 77.7,181
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2015,Age,13-17 Years,74.2,64.4 to 82.0,137
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2012,Age,13-15 Years,95.6,90.8 to 97.9,116
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2013,Age,13-15 Years,93.6,86.4 to 97.1,158
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2010,Age,13-15 Years,80.9,71.8 to 87.5,129
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2011,Age,13-15 Years,92.3,86.5 to 95.8,169
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2020,Age,13-15 Years,99.9,99.1 to 100.0,204
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2021,Age,13-15 Years,98.5,95.5 to 99.5,166
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2015,Age,13-17 Years,96.5,92.8 to 98.3,295
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2012,Age,13-17 Years,95.2,91.6 to 97.3,278
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2011,Age,13-17 Years,91.9,88.2 to 94.5,385
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2014,Age,13-17 Years,95.6,92.4 to 97.5,402
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2013,Age,13-17 Years,93.9,90.0 to 96.3,345
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2015,Age,13-15 Years,94.8,88.5 to 97.7,150
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2014,Age,13-15 Years,97.3,94.1 to 98.8,216
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2018,Age,13-15 Years,95.2,88.0 to 98.2,164
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2019,Age,13-15 Years,94.5,86.3 to 97.9,186
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2009,Age,13-17 Years,85.1,79.8 to 89.2,307
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2010,Age,13-17 Years,87.5,82.8 to 91.0,350
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2017,Age,13-15 Years,94.7,88.1 to 97.7,177
Varicella,≥2 Doses with no disease history,States/Local Areas,New Hampshire,2016,Age,13-15 Years,94.3,86.8 to 97.7,160
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2020,Age,13-17 Years,99.0,97.4 to 99.6,381
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2021,Age,13-17 Years,98.2,95.2 to 99.3,282
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2022,Age,13-17 Years,97.5,94.5 to 98.9,225
HPV,"≥3 Doses, Males",States/Local Areas,New Hampshire,2015,Age,13-15 Years,42.4,31.4 to 54.2,96
HPV,"≥3 Doses, Males",States/Local Areas,New Hampshire,2014,Age,13-15 Years,23.2,15.9 to 32.5,130
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2019,Age,13-17 Years,93.8,89.2 to 96.6,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2017,Age,13-17 Years,95.6,92.1 to 97.6,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2016,Age,13-17 Years,96.4,92.5 to 98.3,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2014,Age,13-17 Years,95.5,92.4 to 97.3,402
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2015,Age,13-17 Years,94.3,89.8 to 96.9,295
≥3 Doses HepB,,States/Local Areas,New Hampshire,2020,Age,13-17 Years,96.2,93.4 to 97.8,381
≥3 Doses HepB,,States/Local Areas,New Hampshire,2021,Age,13-17 Years,96.9,93.9 to 98.4,282
≥3 Doses HepB,,States/Local Areas,New Hampshire,2022,Age,13-17 Years,93.7,89.2 to 96.4,225
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2022,Age,13-17 Years,98.4,95.9 to 99.4,208
Varicella,≥1 Dose with no disease history,States/Local Areas,New Hampshire,2021,Age,13-17 Years,99.2,97.3 to 99.8,263
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2018,Age,13-17 Years,75.1,65.2 to 82.9,152
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2012,Age,13-17 Years,20.5,14.2 to 28.7,157
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2020,Age,13-17 Years,81.8,74.3 to 87.5,198
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2021,Age,13-17 Years,82.4,73.5 to 88.7,149
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2019,Age,13-17 Years,70.4,60.2 to 79.0,179
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2015,Age,13-15 Years,85.8,78.6 to 90.8,171
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2014,Age,13-15 Years,89.1,83.9 to 92.8,245
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2012,Age,13-15 Years,81.6,72.2 to 88.4,145
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2013,Age,13-15 Years,84.0,76.6 to 89.3,194
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2017,Age,13-17 Years,75.2,67.3 to 81.6,173
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2016,Age,13-17 Years,70.6,61.9 to 78.1,161
HPV,"≥1 Dose, Females",States/Local Areas,New Hampshire,2018,Age,13-17 Years,79.7,70.5 to 86.7,151
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2008,Age,13-17 Years,45.5,35.4 to 56.0,151
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2016,Age,13-15 Years,85.0,78.2 to 90.0,186
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2011,Age,13-17 Years,52.8,44.2 to 61.3,191
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2010,Age,13-17 Years,46.9,38.8 to 55.1,173
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2020,Age,13-15 Years,90.3,85.0 to 93.9,219
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2009,Age,13-17 Years,53.0,44.1 to 61.7,150
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2012,Age,13-17 Years,43.6,33.6 to 54.1,121
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2013,Age,13-17 Years,57.2,48.4 to 65.6,168
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2019,Age,13-15 Years,85.7,77.9 to 91.1,196
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018,Age,13-15 Years,83.7,76.3 to 89.1,182
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2017,Age,13-15 Years,84.5,77.4 to 89.7,211
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2017,Age,13-17 Years,74.2,68.5 to 79.2,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2016,Age,13-17 Years,69.9,63.7 to 75.5,313
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2019,Age,13-17 Years,75.1,68.5 to 80.7,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2021,Age,13-17 Years,97.0,92.8 to 98.8,282
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2022,Age,13-17 Years,93.4,88.8 to 96.2,225
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2018,Age,13-17 Years,77.4,70.8 to 82.8,303
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2018,Age,13-17 Years,98.5,97.0 to 99.2,303
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2009,Age,13-17 Years,88.0,82.7 to 91.8,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2008,Age,13-17 Years,84.2,77.1 to 89.4,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2012,Age,13-17 Years,97.0,94.2 to 98.5,278
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2013,Age,13-17 Years,97.6,95.1 to 98.8,345
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2008,Age,13-15 Years,49.7,40.0 to 59.4,172
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2009,Age,13-15 Years,66.3,58.1 to 73.7,182
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2011,Age,13-17 Years,97.2,94.8 to 98.5,385
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2010,Age,13-17 Years,95.9,93.0 to 97.6,350
HPV,"≥1 Dose, Males",States/Local Areas,New Hampshire,2022,Age,13-17 Years,85.7,76.8 to 91.5,116
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2020,Age,13-17 Years,82.5,77.5 to 86.6,381
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2021,Age,13-17 Years,84.6,78.9 to 89.0,282
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Hampshire,2022,Age,13-17 Years,85.7,79.6 to 90.3,225
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2019,Age,13-17 Years,95.1,90.8 to 97.4,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Hampshire,2020,Age,13-17 Years,95.5,92.5 to 97.4,381
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2010,Age,13-15 Years,69.8,61.9 to 76.8,187
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2011,Age,13-15 Years,79.1,70.5 to 85.7,215
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2021,Age,13-15 Years,86.4,79.2 to 91.4,178
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2017,Age,13-17 Years,66.5,58.0 to 74.0,173
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2016,Age,13-17 Years,62.7,53.5 to 71.0,161
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2015,Age,13-17 Years,59.7,49.4 to 69.2,137
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2014,Age,13-17 Years,61.2,53.1 to 68.7,181
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2008,Age,13-15 Years,23.8,12.9 to 39.7,85
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2010,Age,13-15 Years,28.1,18.9 to 39.6,86
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2009,Age,13-15 Years,30.4,20.6 to 42.4,86
≥2 Doses MMR,,States/Local Areas,New Hampshire,2021,Age,13-17 Years,97.2,93.8 to 98.7,282
≥2 Doses MMR,,States/Local Areas,New Hampshire,2022,Age,13-17 Years,97.8,95.4 to 99.0,225
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2011,Age,13-15 Years,40.1,29.7 to 51.5,108
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2022,Age,13-17 Years,90.5,84.7 to 94.2,225
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2019,Age,13-17 Years,86.0,80.4 to 90.2,333
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2018,Age,13-17 Years,86.2,81.0 to 90.2,303
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2020,Age,13-17 Years,91.1,87.5 to 93.7,381
≥1 Dose MenACWY,,States/Local Areas,New Hampshire,2021,Age,13-17 Years,88.1,82.8 to 91.9,282
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2012,Age,13-15 Years,94.7,89.7 to 97.4,145
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2011,Age,13-15 Years,95.9,91.9 to 98.0,215
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2008,Age,13-15 Years,62.1,51.9 to 71.4,172
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2010,Age,13-15 Years,90.8,85.2 to 94.4,187
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2009,Age,13-15 Years,77.7,70.4 to 83.6,182
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2019,Age,13-17 Years,67.7,58.1 to 76.0,154
HPV,"≥2 Doses, Females",States/Local Areas,New Hampshire,2018,Age,13-17 Years,68.3,58.2 to 76.9,151
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2017,Age,13-15 Years,92.5,87.3 to 95.7,211
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2016,Age,13-15 Years,93.4,87.1 to 96.8,186
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2015,Age,13-15 Years,92.3,85.2 to 96.2,171
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2014,Age,13-15 Years,94.9,90.7 to 97.2,245
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2013,Age,13-15 Years,95.1,88.9 to 97.9,194
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2018,Age,13-17 Years,70.0,59.9 to 78.4,152
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2017,Age,13-17 Years,60.4,51.3 to 68.9,160
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2016,Age,13-17 Years,54.1,44.5 to 63.4,152
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2012,Age,13-17 Years,12.2,7.6 to 18.9,157
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2013,Age,13-17 Years,28.5,21.4 to 37.0,177
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2014,Age,13-17 Years,46.9,39.1 to 54.8,221
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2015,Age,13-17 Years,55.1,46.0 to 63.9,158
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2019,Age,13-15 Years,92.3,85.1 to 96.2,196
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2020,Age,13-15 Years,94.1,89.2 to 96.8,219
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2021,Age,13-15 Years,95.6,89.4 to 98.2,178
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2018,Age,13-15 Years,97.4,92.9 to 99.1,182
≥2 Doses MMR,,States/Local Areas,New Hampshire,2011,Age,13-17 Years,97.0,94.4 to 98.4,385
≥2 Doses MMR,,States/Local Areas,New Hampshire,2010,Age,13-17 Years,97.2,94.6 to 98.6,350
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2015,Age,13-17 Years,92.4,87.5 to 95.5,295
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2018,Age,13-17 Years,96.9,92.9 to 98.7,303
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2016,Age,13-17 Years,95.2,91.1 to 97.5,313
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2017,Age,13-17 Years,95.7,92.0 to 97.7,333
Varicella,≥2 Doses or history of disease,States/Local Areas,New Hampshire,2008,Age,13-17 Years,76.1,69.2 to 81.8,300
HPV,"≥3 Doses, Males",States/Local Areas,New Hampshire,2013,Age,13-15 Years,17.3,10.0 to 28.3,96
HPV,"≥3 Doses, Males",States/Local Areas,New Hampshire,2013,Age,13-17 Years,17.8,12.0 to 25.4,177
HPV,"≥3 Doses, Males",States/Local Areas,New Hampshire,2015,Age,13-17 Years,47.1,38.2 to 56.2,158
HPV,"≥3 Doses, Males",States/Local Areas,New Hampshire,2014,Age,13-17 Years,33.0,25.9 to 41.0,221
≥2 Doses Hep A,,States/Local Areas,New Hampshire,2022,Age,13-17 Years,86.7,80.9 to 90.9,225
≥2 Doses Hep A,,States/Local Areas,New Hampshire,2021,Age,13-17 Years,84.1,78.5 to 88.5,282
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2010,Age,13-17 Years,42.2,34.4 to 50.4,173
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2015,Age,13-17 Years,51.4,41.5 to 61.3,137
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2009,Age,13-17 Years,39.8,31.3 to 48.8,150
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2008,Age,13-17 Years,23.2,15.3 to 33.5,151
≥2 Doses Hep A,,States/Local Areas,New Hampshire,2020,Age,13-17 Years,77.8,72.6 to 82.2,381
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2012,Age,13-17 Years,34.5,25.5 to 44.7,121
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2011,Age,13-17 Years,46.0,37.8 to 54.4,191
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2014,Age,13-17 Years,50.1,41.8 to 58.4,181
HPV,"≥3 Doses, Females",States/Local Areas,New Hampshire,2013,Age,13-17 Years,43.2,34.9 to 51.9,168
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2012,Age,13-17 Years,96.3,93.3 to 98.0,278
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2016,Age,13-17 Years,51.2,44.6 to 57.8,313
HPV,"≥2 Doses, Males",States/Local Areas,New Hampshire,2019,Age,13-17 Years,61.2,51.2 to 70.4,179
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2009,Age,13-17 Years,72.2,66.2 to 77.5,307
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2010,Age,13-17 Years,87.9,83.5 to 91.3,350
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2011,Age,13-17 Years,95.0,91.9 to 96.9,385
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2022,Age,13-15 Years,90.6,83.6 to 94.8,134
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2008,Age,13-17 Years,53.1,45.8 to 60.2,300
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2019,Age,13-17 Years,63.2,56.2 to 69.6,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2020,Age,13-17 Years,68.8,63.1 to 73.9,381
≥2 Doses MMR,,States/Local Areas,New Hampshire,2009,Age,13-17 Years,95.2,92.1 to 97.1,307
≥2 Doses MMR,,States/Local Areas,New Hampshire,2008,Age,13-17 Years,94.9,90.0 to 97.5,300
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2014,Age,13-17 Years,94.4,91.1 to 96.6,402
Tetanus,≥1 Dose Tdap,States/Local Areas,New Hampshire,2013,Age,13-17 Years,94.7,91.0 to 97.0,345
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2021,Age,13-17 Years,72.3,65.7 to 78.1,282
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2022,Age,13-17 Years,76.2,69.4 to 82.0,225
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2018,Age,13-17 Years,67.4,60.4 to 73.8,303
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2017,Age,13-17 Years,59.9,53.7 to 65.8,333
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2022,Age,13-17 Years,65.1,56.9 to 72.5,182
HPV,"≥2 Doses, Males and Females",States/Local Areas,Colorado,2022,Age,13-17 Years,67.2,61.2 to 72.7,342
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2012,Age,13-17 Years,81.6,74.0 to 87.3,236
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2013,Age,13-17 Years,78.5,72.2 to 83.6,265
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2008,Age,13-17 Years,33.5,25.6 to 42.6,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2022,Age,13-15 Years,95.6,91.8 to 97.6,191
≥3 Doses HepB,,States/Local Areas,Colorado,2010,Age,13-17 Years,93.1,89.6 to 95.5,317
≥3 Doses HepB,,States/Local Areas,Colorado,2009,Age,13-17 Years,91.2,87.5 to 93.9,411
≥3 Doses HepB,,States/Local Areas,Colorado,2019,Age,13-17 Years,92.6,86.5 to 96.1,262
≥3 Doses HepB,,States/Local Areas,Colorado,2008,Age,13-17 Years,94.6,91.0 to 96.8,347
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2020,Age,13-17 Years,95.4,91.7 to 97.5,327
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2019,Age,13-17 Years,93.4,87.7 to 96.6,238
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2021,Age,13-17 Years,94.5,90.8 to 96.8,277
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2020,Age,13-17 Years,93.2,89.1 to 95.9,327
≥3 Doses HepB,,States/Local Areas,Colorado,2011,Age,13-17 Years,88.5,82.2 to 92.8,431
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2019,Age,13-17 Years,95.4,89.5 to 98.0,238
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2018,Age,13-17 Years,97.0,94.3 to 98.5,256
≥3 Doses HepB,,States/Local Areas,Colorado,2018,Age,13-17 Years,93.5,88.4 to 96.4,278
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2018,Age,13-17 Years,90.7,84.6 to 94.6,256
≥3 Doses HepB,,States/Local Areas,Colorado,2017,Age,13-17 Years,89.2,84.3 to 92.6,354
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2016,Age,13-17 Years,97.1,94.3 to 98.6,283
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2015,Age,13-17 Years,96.9,94.2 to 98.3,293
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2013,Age,13-17 Years,95.1,90.9 to 97.4,265
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2014,Age,13-17 Years,94.8,90.6 to 97.2,322
≥3 Doses HepB,,States/Local Areas,Colorado,2016,Age,13-17 Years,91.6,86.4 to 94.9,322
≥3 Doses HepB,,States/Local Areas,Colorado,2015,Age,13-17 Years,93.2,89.6 to 95.6,354
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2021,Age,13-15 Years,94.6,90.3 to 97.0,184
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2020,Age,13-15 Years,92.6,86.0 to 96.3,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2012,Age,13-15 Years,81.3,71.0 to 88.6,148
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2013,Age,13-15 Years,81.4,73.8 to 87.2,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2010,Age,13-15 Years,68.5,58.9 to 76.7,134
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2011,Age,13-15 Years,81.8,71.1 to 89.2,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2009,Age,13-15 Years,54.6,44.7 to 64.2,147
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2017,Age,13-17 Years,95.6,92.3 to 97.5,309
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2014,Age,13-17 Years,83.7,78.0 to 88.1,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2016,Age,13-17 Years,90.3,85.0 to 93.9,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2015,Age,13-17 Years,91.6,87.5 to 94.4,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2017,Age,13-17 Years,89.7,85.2 to 92.9,309
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2011,Age,13-17 Years,45.9,35.8 to 56.3,220
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2010,Age,13-17 Years,52.5,43.5 to 61.4,166
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2012,Age,13-17 Years,61.4,50.2 to 71.5,156
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2013,Age,13-17 Years,58.2,49.4 to 66.4,163
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2014,Age,13-17 Years,62.5,53.9 to 70.3,189
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2015,Age,13-17 Years,65.3,56.7 to 73.0,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2014,Age,13-15 Years,86.2,79.1 to 91.1,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2019,Age,13-15 Years,93.8,85.9 to 97.4,156
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2015,Age,13-15 Years,91.7,86.5 to 95.0,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2017,Age,13-15 Years,88.7,82.8 to 92.7,215
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2018,Age,13-15 Years,89.5,80.0 to 94.8,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2016,Age,13-15 Years,88.9,80.9 to 93.8,172
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2010,Age,13-17 Years,78.7,73.2 to 83.4,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2009,Age,13-17 Years,79.8,74.4 to 84.2,411
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2012,Age,13-17 Years,86.5,80.6 to 90.8,311
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2011,Age,13-17 Years,84.1,78.0 to 88.8,431
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2013,Age,13-17 Years,82.5,77.3 to 86.8,331
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2014,Age,13-17 Years,87.2,82.5 to 90.8,394
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2008,Age,13-15 Years,54.2,41.7 to 66.2,101
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2022,Age,13-17 Years,93.1,89.4 to 95.5,342
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2021,Age,13-17 Years,95.0,91.5 to 97.0,298
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2020,Age,13-17 Years,93.8,90.0 to 96.2,354
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2017,Age,13-17 Years,91.1,87.1 to 93.9,354
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2018,Age,13-17 Years,91.7,86.1 to 95.1,278
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2016,Age,13-17 Years,91.4,86.7 to 94.6,322
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2015,Age,13-17 Years,93.1,89.7 to 95.4,354
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2019,Age,13-17 Years,94.2,89.2 to 97.0,262
HPV,"≥3 Doses, Males",States/Local Areas,Colorado,2014,Age,13-15 Years,23.7,15.4 to 34.6,119
HPV,"≥3 Doses, Males",States/Local Areas,Colorado,2015,Age,13-15 Years,30.6,21.1 to 42.1,108
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2015,Age,13-17 Years,46.0,37.5 to 54.7,180
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2008,Age,13-17 Years,77.4,70.8 to 82.8,347
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2017,Age,13-17 Years,53.8,47.4 to 60.0,354
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018,Age,13-17 Years,62.5,55.0 to 69.4,278
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2019,Age,13-17 Years,63.5,55.3 to 71.0,262
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2013,Age,13-17 Years,87.1,82.0 to 90.9,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2014,Age,13-17 Years,90.2,86.0 to 93.3,394
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2012,Age,13-17 Years,93.2,88.7 to 96.0,311
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2016,Age,13-17 Years,48.0,41.0 to 55.0,322
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2008,Age,13-17 Years,63.0,56.0 to 69.5,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2022,Age,13-15 Years,91.9,86.3 to 95.3,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2011,Age,13-17 Years,84.7,78.0 to 89.6,431
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2010,Age,13-17 Years,85.7,80.9 to 89.5,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2009,Age,13-17 Years,76.6,70.9 to 81.5,411
≥2 Doses MMR,,States/Local Areas,Colorado,2008,Age,13-17 Years,91.0,86.8 to 94.0,347
≥2 Doses MMR,,States/Local Areas,Colorado,2009,Age,13-17 Years,88.6,84.5 to 91.7,411
≥2 Doses MMR,,States/Local Areas,Colorado,2010,Age,13-17 Years,92.6,88.6 to 95.2,317
≥2 Doses MMR,,States/Local Areas,Colorado,2011,Age,13-17 Years,88.1,81.9 to 92.4,431
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2015,Age,13-17 Years,93.3,89.7 to 95.7,354
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2019,Age,13-17 Years,62.2,51.2 to 72.2,153
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2022,Age,13-17 Years,65.7,59.7 to 71.3,342
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2021,Age,13-17 Years,69.2,62.1 to 75.5,298
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2020,Age,13-17 Years,66.4,59.9 to 72.4,354
HPV,"≥3 Doses, Males",States/Local Areas,Colorado,2013,Age,13-17 Years,9.9,6.0 to 15.7,168
HPV,"≥3 Doses, Males",States/Local Areas,Colorado,2014,Age,13-17 Years,21.9,15.7 to 29.7,205
HPV,"≥3 Doses, Males",States/Local Areas,Colorado,2015,Age,13-17 Years,37.1,28.8 to 46.2,174
≥2 Doses Hep A,,States/Local Areas,Colorado,2022,Age,13-17 Years,85.5,81.1 to 89.1,342
≥2 Doses Hep A,,States/Local Areas,Colorado,2021,Age,13-17 Years,88.4,83.4 to 92.0,298
≥2 Doses Hep A,,States/Local Areas,Colorado,2020,Age,13-17 Years,84.6,79.4 to 88.8,354
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2012,Age,13-17 Years,38.0,27.6 to 49.6,156
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2013,Age,13-17 Years,39.1,30.9 to 48.1,163
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2014,Age,13-17 Years,42.1,33.7 to 50.9,189
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2010,Age,13-17 Years,40.9,32.5 to 49.9,166
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2011,Age,13-17 Years,25.3,18.4 to 33.8,220
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2008,Age,13-17 Years,19.0,12.7 to 27.4,181
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2009,Age,13-17 Years,32.5,24.3 to 41.8,198
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2014,Age,13-15 Years,41.1,30.7 to 52.4,114
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2015,Age,13-15 Years,34.7,24.9 to 45.9,108
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2013,Age,13-15 Years,30.0,21.0 to 40.7,109
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2010,Age,13-15 Years,39.7,29.3 to 51.0,101
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2009,Age,13-15 Years,30.4,20.9 to 42.0,123
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2012,Age,13-15 Years,26.2,15.8 to 40.1,92
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2011,Age,13-15 Years,17.2,10.4 to 27.2,129
HPV,"≥3 Doses, Females",States/Local Areas,Colorado,2008,Age,13-15 Years,19.5,11.8 to 30.4,112
≥1 Dose MenACWY,,States/Local Areas,Colorado,2022,Age,13-17 Years,83.6,78.7 to 87.6,342
≥2 Doses MMR,,States/Local Areas,Colorado,2022,Age,13-17 Years,91.6,87.8 to 94.3,342
≥2 Doses MMR,,States/Local Areas,Colorado,2021,Age,13-17 Years,95.6,92.5 to 97.5,298
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018,Age,13-17 Years,84.9,78.7 to 89.6,278
≥1 Dose MenACWY,,States/Local Areas,Colorado,2019,Age,13-17 Years,89.4,84.0 to 93.1,262
≥1 Dose MenACWY,,States/Local Areas,Colorado,2021,Age,13-17 Years,84.8,78.5 to 89.5,298
≥1 Dose MenACWY,,States/Local Areas,Colorado,2020,Age,13-17 Years,87.3,82.1 to 91.2,354
HPV,"≥3 Doses, Males and Females",States/Local Areas,Colorado,2015,Age,13-17 Years,41.4,35.4 to 47.8,354
HPV,"≥3 Doses, Males and Females",States/Local Areas,Colorado,2014,Age,13-17 Years,31.8,26.4 to 37.7,394
HPV,"≥3 Doses, Males and Females",States/Local Areas,Colorado,2013,Age,13-17 Years,24.2,19.3 to 29.8,331
≥2 Doses MMR,,States/Local Areas,Colorado,2020,Age,13-17 Years,94.0,90.5 to 96.3,354
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2022,Age,13-17 Years,92.4,88.6 to 95.0,342
≥2 Doses MMR,,States/Local Areas,Colorado,2018,Age,13-17 Years,92.7,87.2 to 96.0,278
≥2 Doses MMR,,States/Local Areas,Colorado,2019,Age,13-17 Years,91.0,84.3 to 95.1,262
HPV,"≥3 Doses, Males and Females",States/Local Areas,Colorado,2012,Age,13-17 Years,25.7,18.6 to 34.4,311
HPV,"≥3 Doses, Males and Females",States/Local Areas,Colorado,2011,Age,13-17 Years,13.9,10.1 to 18.8,431
≥1 Dose MenACWY,,States/Local Areas,Colorado,2017,Age,13-17 Years,82.4,77.2 to 86.6,354
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2021,Age,13-17 Years,90.2,84.7 to 93.8,298
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2020,Age,13-17 Years,90.0,85.1 to 93.4,354
≥1 Dose MenACWY,,States/Local Areas,Colorado,2016,Age,13-17 Years,77.5,71.3 to 82.7,322
≥1 Dose MenACWY,,States/Local Areas,Colorado,2015,Age,13-17 Years,85.6,80.7 to 89.3,354
≥1 Dose MenACWY,,States/Local Areas,Colorado,2013,Age,13-17 Years,73.6,67.6 to 78.8,331
≥1 Dose MenACWY,,States/Local Areas,Colorado,2014,Age,13-17 Years,76.8,71.6 to 81.4,394
≥2 Doses MMR,,States/Local Areas,Colorado,2017,Age,13-17 Years,90.2,85.4 to 93.6,354
≥2 Doses MMR,,States/Local Areas,Colorado,2016,Age,13-17 Years,91.5,86.8 to 94.6,322
≥2 Doses MMR,,States/Local Areas,Colorado,2014,Age,13-17 Years,92.1,88.1 to 94.8,394
≥2 Doses MMR,,States/Local Areas,Colorado,2015,Age,13-17 Years,92.3,88.6 to 94.9,354
≥2 Doses MMR,,States/Local Areas,Colorado,2012,Age,13-17 Years,94.6,90.4 to 97.0,311
≥2 Doses MMR,,States/Local Areas,Colorado,2013,Age,13-17 Years,92.4,88.3 to 95.2,331
≥1 Dose MenACWY,,States/Local Areas,Colorado,2010,Age,13-17 Years,59.6,53.0 to 65.8,317
≥1 Dose MenACWY,,States/Local Areas,Colorado,2011,Age,13-17 Years,64.4,57.1 to 71.0,431
≥1 Dose MenACWY,,States/Local Areas,Colorado,2008,Age,13-17 Years,32.4,26.3 to 39.1,347
≥1 Dose MenACWY,,States/Local Areas,Colorado,2009,Age,13-17 Years,53.7,47.5 to 59.9,411
≥1 Dose MenACWY,,States/Local Areas,Colorado,2012,Age,13-17 Years,73.2,66.1 to 79.2,311
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2013,Age,13-15 Years,87.7,81.1 to 92.3,211
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2019,Age,13-15 Years,92.0,84.7 to 96.0,170
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2020,Age,13-15 Years,88.6,80.7 to 93.6,206
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2021,Age,13-15 Years,87.4,79.5 to 92.5,196
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2016,Age,13-17 Years,58.8,49.2 to 67.8,168
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2015,Age,13-17 Years,63.2,54.5 to 71.1,174
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2013,Age,13-17 Years,33.5,25.5 to 42.5,168
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2014,Age,13-17 Years,40.7,32.8 to 49.1,205
HPV,"≥2 Doses, Males and Females",States/Local Areas,Colorado,2017,Age,13-17 Years,57.3,50.9 to 63.4,354
HPV,"≥2 Doses, Males and Females",States/Local Areas,Colorado,2016,Age,13-17 Years,52.1,45.1 to 59.1,322
HPV,"≥2 Doses, Males and Females",States/Local Areas,Colorado,2018,Age,13-17 Years,66.0,58.6 to 72.7,278
HPV,"≥2 Doses, Males and Females",States/Local Areas,Colorado,2019,Age,13-17 Years,68.8,61.0 to 75.7,262
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2011,Age,13-17 Years,13.6,7.8 to 22.7,211
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2022,Age,13-17 Years,81.1,72.9 to 87.3,160
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2021,Age,13-17 Years,82.1,72.2 to 89.0,135
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2020,Age,13-17 Years,81.2,73.1 to 87.4,167
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2012,Age,13-17 Years,31.3,20.2 to 45.0,155
≥3 Doses HepB,,States/Local Areas,Colorado,2022,Age,13-17 Years,91.9,88.3 to 94.4,342
≥3 Doses HepB,,States/Local Areas,Colorado,2021,Age,13-17 Years,93.8,89.4 to 96.5,298
≥3 Doses HepB,,States/Local Areas,Colorado,2020,Age,13-17 Years,91.9,87.5 to 94.9,354
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2022,Age,13-17 Years,94.4,91.0 to 96.6,321
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2019,Age,13-17 Years,85.1,75.2 to 91.5,109
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2008,Age,13-17 Years,85.3,77.2 to 90.9,140
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2010,Age,13-17 Years,94.8,90.4 to 97.2,190
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2009,Age,13-17 Years,86.6,79.2 to 91.6,202
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2012,Age,13-17 Years,95.0,87.8 to 98.1,236
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2011,Age,13-17 Years,94.5,89.2 to 97.3,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2008,Age,13-17 Years,42.2,31.7 to 53.4,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2009,Age,13-17 Years,54.4,45.4 to 63.2,202
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2017,Age,13-17 Years,74.4,65.9 to 81.4,169
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2016,Age,13-17 Years,68.3,57.9 to 77.1,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2022,Age,13-17 Years,92.6,88.8 to 95.2,321
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2021,Age,13-17 Years,96.8,94.0 to 98.3,277
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2018,Age,13-17 Years,72.3,61.6 to 81.0,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2010,Age,13-17 Years,65.3,57.1 to 72.6,190
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2011,Age,13-17 Years,74.0,65.1 to 81.3,274
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2009,Age,13-17 Years,52.7,43.7 to 61.4,198
≥3 Doses HepB,,States/Local Areas,Colorado,2013,Age,13-17 Years,92.3,88.2 to 95.0,331
≥3 Doses HepB,,States/Local Areas,Colorado,2014,Age,13-17 Years,95.1,91.8 to 97.1,394
≥3 Doses HepB,,States/Local Areas,Colorado,2012,Age,13-17 Years,96.4,93.7 to 98.0,311
≥1 Dose MenACWY,,States/Local Areas,Colorado,2016,Age,13-15 Years,72.8,64.2 to 80.0,199
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2021,Age,13-17 Years,78.0,69.1 to 85.0,163
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2020,Age,13-17 Years,81.9,74.0 to 87.7,187
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2019,Age,13-17 Years,75.6,64.9 to 83.8,153
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2017,Age,13-17 Years,69.8,61.4 to 77.1,185
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2018,Age,13-17 Years,81.9,73.0 to 88.3,147
≥1 Dose MenACWY,,States/Local Areas,Colorado,2017,Age,13-15 Years,81.4,74.7 to 86.6,235
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2018,Age,13-17 Years,93.2,88.1 to 96.1,278
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2017,Age,13-17 Years,90.2,85.5 to 93.4,354
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2016,Age,13-17 Years,88.9,83.6 to 92.6,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2014,Age,13-17 Years,92.4,88.5 to 95.1,394
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2015,Age,13-17 Years,95.3,92.6 to 97.1,354
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2017,Age,13-17 Years,72.1,66.2 to 77.3,354
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2016,Age,13-17 Years,63.5,56.5 to 69.9,322
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018,Age,13-17 Years,77.2,70.4 to 82.8,278
≥1 Dose MenACWY,,States/Local Areas,Colorado,2014,Age,13-15 Years,76.7,69.7 to 82.4,233
≥1 Dose MenACWY,,States/Local Areas,Colorado,2015,Age,13-15 Years,81.2,74.3 to 86.6,216
≥1 Dose MenACWY,,States/Local Areas,Colorado,2013,Age,13-15 Years,73.4,65.8 to 79.9,211
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2008,Age,13-17 Years,24.5,17.5 to 33.2,181
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2012,Age,13-17 Years,44.9,34.1 to 56.3,156
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2013,Age,13-17 Years,50.0,41.2 to 58.7,163
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018,Age,13-15 Years,85.1,76.5 to 91.0,167
≥1 Dose MenACWY,,States/Local Areas,Colorado,2019,Age,13-15 Years,87.2,79.8 to 92.2,170
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2019,Age,13-17 Years,92.1,86.5 to 95.5,262
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2020,Age,13-17 Years,92.2,87.9 to 95.0,354
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2019,Age,13-17 Years,80.2,73.1 to 85.8,262
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2022,Age,13-17 Years,92.8,89.0 to 95.3,342
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2021,Age,13-17 Years,91.9,86.6 to 95.2,298
≥1 Dose MenACWY,,States/Local Areas,Colorado,2012,Age,13-15 Years,74.9,66.0 to 82.1,186
≥1 Dose MenACWY,,States/Local Areas,Colorado,2010,Age,13-15 Years,58.5,50.3 to 66.3,204
≥1 Dose MenACWY,,States/Local Areas,Colorado,2011,Age,13-15 Years,64.1,54.2 to 72.9,254
≥1 Dose MenACWY,,States/Local Areas,Colorado,2008,Age,13-15 Years,37.1,28.9 to 46.2,209
≥1 Dose MenACWY,,States/Local Areas,Colorado,2009,Age,13-15 Years,50.8,42.8 to 58.7,250
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2022,Age,13-17 Years,78.3,70.8 to 84.3,182
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2008,Age,13-17 Years,77.4,70.9 to 82.9,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2009,Age,13-17 Years,83.6,78.8 to 87.5,411
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2010,Age,13-17 Years,46.2,37.5 to 55.2,166
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2011,Age,13-17 Years,32.9,24.8 to 42.3,220
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2009,Age,13-17 Years,42.7,34.0 to 51.9,198
≥1 Dose MenACWY,,States/Local Areas,Colorado,2020,Age,13-15 Years,86.1,78.4 to 91.3,206
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2012,Age,13-17 Years,93.3,88.8 to 96.1,311
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2013,Age,13-17 Years,90.5,85.9 to 93.8,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2010,Age,13-17 Years,89.6,85.3 to 92.8,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2011,Age,13-17 Years,87.4,80.7 to 92.0,431
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2014,Age,13-17 Years,55.1,46.4 to 63.6,189
≥1 Dose MenACWY,,States/Local Areas,Colorado,2021,Age,13-15 Years,82.0,73.4 to 88.3,196
≥1 Dose MenACWY,,States/Local Areas,Colorado,2022,Age,13-15 Years,82.9,76.0 to 88.0,205
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2022,Age,13-17 Years,79.7,74.3 to 84.2,342
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2021,Age,13-17 Years,80.0,73.6 to 85.2,298
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2020,Age,13-17 Years,81.6,76.1 to 86.0,354
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2017,Age,13-17 Years,54.1,45.0 to 63.0,169
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2016,Age,13-17 Years,54.1,43.8 to 64.1,154
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2015,Age,13-17 Years,57.7,48.9 to 66.0,180
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2018,Age,13-17 Years,62.4,51.3 to 72.2,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2010,Age,13-15 Years,84.1,77.7 to 89.0,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2009,Age,13-15 Years,72.8,65.2 to 79.3,250
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2019,Age,13-17 Years,75.6,64.5 to 84.1,109
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2012,Age,13-15 Years,91.7,84.6 to 95.6,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2011,Age,13-15 Years,87.8,77.8 to 93.7,254
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2008,Age,13-15 Years,69.0,60.4 to 76.3,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2017,Age,13-15 Years,86.3,79.1 to 91.2,235
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2016,Age,13-15 Years,86.8,78.9 to 92.0,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2014,Age,13-15 Years,89.3,83.8 to 93.1,233
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2015,Age,13-15 Years,93.0,88.6 to 95.8,216
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2017,Age,13-17 Years,60.3,51.6 to 68.5,185
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2016,Age,13-17 Years,50.2,40.7 to 59.7,168
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2018,Age,13-17 Years,69.5,59.4 to 78.0,147
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2014,Age,13-17 Years,30.8,23.5 to 39.1,205
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2013,Age,13-17 Years,21.7,15.1 to 30.2,168
HPV,"≥2 Doses, Males",States/Local Areas,Colorado,2015,Age,13-17 Years,52.7,43.7 to 61.4,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018,Age,13-15 Years,91.1,83.5 to 95.4,167
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018,Age,13-17 Years,90.3,85.2 to 93.8,278
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2017,Age,13-17 Years,88.6,83.6 to 92.2,354
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2019,Age,13-17 Years,91.3,85.8 to 94.8,262
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2016,Age,13-17 Years,87.5,82.1 to 91.4,322
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2022,Age,13-15 Years,69.0,56.9 to 78.9,91
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2021,Age,13-15 Years,65.6,52.2 to 76.9,95
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2017,Age,13-17 Years,53.1,44.1 to 62.0,169
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2018,Age,13-17 Years,59.0,48.0 to 69.2,131
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2019,Age,13-17 Years,70.4,58.3 to 80.2,109
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2020,Age,13-17 Years,69.4,60.0 to 77.4,167
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2019,Age,13-15 Years,55.3,41.5 to 68.3,100
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2016,Age,13-17 Years,44.0,34.7 to 53.7,168
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2022,Age,13-15 Years,58.6,48.0 to 68.5,114
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2021,Age,13-15 Years,61.3,48.2 to 73.0,101
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2017,Age,13-17 Years,54.4,45.6 to 62.9,185
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2020,Age,13-15 Years,64.0,51.7 to 74.7,111
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2018,Age,13-15 Years,66.8,52.5 to 78.6,80
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2022,Age,13-17 Years,69.4,60.4 to 77.1,160
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2021,Age,13-17 Years,68.6,57.5 to 77.9,135
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2022,Age,13-15 Years,63.4,55.5 to 70.6,205
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2021,Age,13-17 Years,69.8,60.3 to 77.8,163
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2018,Age,13-17 Years,65.8,55.6 to 74.8,147
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2019,Age,13-17 Years,56.9,45.8 to 67.4,153
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2020,Age,13-17 Years,63.6,54.3 to 72.0,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2019,Age,13-15 Years,62.4,52.3 to 71.5,170
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2022,Age,13-17 Years,62.3,54.0 to 69.9,182
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2021,Age,13-15 Years,63.6,54.3 to 72.0,196
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2016,Age,13-17 Years,52.1,41.9 to 62.2,154
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2020,Age,13-15 Years,64.8,56.0 to 72.7,206
Varicella,History of disease,States/Local Areas,Colorado,2017,Age,13-17 Years,13.6,9.6 to 19.0,354
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2019,Age,13-15 Years,70.2,55.3 to 81.7,70
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2020,Age,13-15 Years,65.6,52.7 to 76.6,95
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2018,Age,13-15 Years,54.9,41.3 to 67.8,87
Varicella,History of disease,States/Local Areas,Colorado,2022,Age,13-17 Years,5.9,3.7 to 9.4,342
Varicella,History of disease,States/Local Areas,Colorado,2021,Age,13-17 Years,8.1,4.7 to 13.9,298
Varicella,History of disease,States/Local Areas,Colorado,2020,Age,13-17 Years,8.9,5.7 to 13.6,354
Varicella,History of disease,States/Local Areas,Colorado,2009,Age,13-17 Years,55.6,49.4 to 61.7,411
Varicella,History of disease,States/Local Areas,Colorado,2008,Age,13-17 Years,60.9,53.8 to 67.5,347
Varicella,History of disease,States/Local Areas,Colorado,2018,Age,13-17 Years,10.4,6.4 to 16.6,278
Varicella,History of disease,States/Local Areas,Colorado,2019,Age,13-17 Years,12.3,7.6 to 19.3,262
Varicella,History of disease,States/Local Areas,Colorado,2016,Age,13-17 Years,11.8,8.0 to 17.1,322
Varicella,History of disease,States/Local Areas,Colorado,2012,Age,13-17 Years,26.6,19.5 to 35.1,311
Varicella,History of disease,States/Local Areas,Colorado,2013,Age,13-17 Years,18.7,14.5 to 23.9,331
Varicella,History of disease,States/Local Areas,Colorado,2010,Age,13-17 Years,38.8,32.7 to 45.3,317
Varicella,History of disease,States/Local Areas,Colorado,2011,Age,13-17 Years,39.0,32.2 to 46.2,431
Varicella,History of disease,States/Local Areas,Colorado,2015,Age,13-17 Years,18.0,13.7 to 23.3,354
Varicella,History of disease,States/Local Areas,Colorado,2014,Age,13-17 Years,21.5,16.6 to 27.3,394
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2011,Age,13-17 Years,49.0,43.7 to 54.3,732
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2010,Age,13-17 Years,44.1,39.4 to 48.8,616
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2017,Age,13-17 Years,83.9,80.9 to 86.6,1140
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2013,Age,13-17 Years,67.4,62.8 to 71.7,858
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2014,Age,13-17 Years,70.7,66.5 to 74.5,1015
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2015,Age,13-17 Years,76.8,73.1 to 80.1,1170
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2016,Age,13-17 Years,79.7,76.1 to 82.8,1137
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2015,Age,13-15 Years,76.3,71.5 to 80.4,784
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2014,Age,13-15 Years,76.1,71.2 to 80.4,634
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2018,Age,13-15 Years,90.8,87.3 to 93.3,656
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2019,Age,13-15 Years,91.7,88.2 to 94.2,731
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2017,Age,13-15 Years,87.2,83.4 to 90.2,726
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2016,Age,13-15 Years,83.1,78.7 to 86.7,743
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2010,Age,13-17 Years,74.9,71.8 to 77.8,1291
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2009,Age,13-17 Years,78.6,75.8 to 81.2,1250
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2012,Age,13-15 Years,67.3,61.2 to 72.9,539
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2013,Age,13-15 Years,67.5,61.6 to 72.9,590
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2011,Age,13-15 Years,56.9,50.8 to 62.8,599
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2010,Age,13-15 Years,54.7,49.0 to 60.3,438
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2008,Age,13-15 Years,32.4,25.4 to 40.2,311
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2009,Age,13-15 Years,44.0,37.7 to 50.4,341
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2012,Age,13-17 Years,78.2,74.3 to 81.6,1285
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2011,Age,13-17 Years,75.6,72.2 to 78.8,1528
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2013,Age,13-17 Years,77.6,74.0 to 80.7,1251
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2007,Age,13-17 Years,78.1,68.9 to 85.2,165
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2020,Age,13-17 Years,92.6,90.6 to 94.2,1446
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2021,Age,13-17 Years,92.8,90.3 to 94.7,1154
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2022,Age,13-17 Years,92.1,89.6 to 94.0,1048
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2015,Age,13-17 Years,81.4,78.3 to 84.2,1451
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2014,Age,13-17 Years,78.6,75.3 to 81.6,1362
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2012,Age,13-15 Years,5.2,2.9 to 9.2,394
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2014,Age,13-15 Years,16.0,12.1 to 20.9,436
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2019,Age,13-17 Years,91.2,88.5 to 93.4,1256
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2017,Age,13-17 Years,86.2,83.5 to 88.5,1340
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2018,Age,13-17 Years,89.2,86.6 to 91.3,1191
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2016,Age,13-17 Years,83.4,80.4 to 86.0,1394
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2008,Age,13-17 Years,77.0,74.0 to 79.8,1295
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2006,Age,13-17 Years,77.9,69.8 to 84.3,165
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2013,Age,13-17 Years,9.4,7.1 to 12.4,659
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2012,Age,13-17 Years,5.3,3.4 to 8.1,681
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2015,Age,13-17 Years,24.4,20.1 to 29.2,760
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2014,Age,13-17 Years,16.3,13.0 to 20.1,717
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2015,Age,13-15 Years,20.3,15.9 to 25.6,502
HPV,"≥3 Doses, Males",HHS Regions/National,Region 7,2013,Age,13-15 Years,8.5,5.9 to 12.2,416
≥2 Doses Hep A,,HHS Regions/National,Region 7,2020,Age,13-17 Years,76.6,73.5 to 79.5,1446
≥2 Doses Hep A,,HHS Regions/National,Region 7,2022,Age,13-17 Years,83.9,80.7 to 86.7,1048
≥2 Doses Hep A,,HHS Regions/National,Region 7,2021,Age,13-17 Years,82.6,79.4 to 85.5,1154
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2010,Age,13-17 Years,30.1,26.1 to 34.4,616
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2012,Age,13-17 Years,33.1,28.0 to 38.5,604
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2011,Age,13-17 Years,31.3,26.6 to 36.4,732
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2013,Age,13-17 Years,31.7,27.0 to 36.8,592
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2014,Age,13-17 Years,31.6,27.2 to 36.4,645
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2015,Age,13-17 Years,37.9,33.0 to 43.1,691
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2008,Age,13-17 Years,18.1,14.5 to 22.3,608
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2009,Age,13-17 Years,26.2,22.2 to 30.6,607
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2016,Age,13-15 Years,70.1,65.7 to 74.2,876
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2012,Age,13-15 Years,58.6,53.4 to 63.7,755
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2013,Age,13-15 Years,61.2,56.3 to 65.9,790
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2015,Age,13-15 Years,70.4,66.0 to 74.4,925
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2014,Age,13-15 Years,66.4,61.7 to 70.8,815
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2016,Age,13-17 Years,88.2,85.7 to 90.3,1394
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2014,Age,13-17 Years,85.1,82.2 to 87.5,1362
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2015,Age,13-17 Years,88.4,85.8 to 90.6,1451
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2017,Age,13-17 Years,66.2,61.3 to 70.7,624
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2016,Age,13-17 Years,60.7,55.7 to 65.5,664
≥3 Doses HepB,,HHS Regions/National,Region 7,2022,Age,13-17 Years,90.8,88.2 to 93.0,1048
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2018,Age,13-17 Years,70.1,65.1 to 74.7,548
≥3 Doses HepB,,HHS Regions/National,Region 7,2020,Age,13-17 Years,92.2,90.0 to 94.0,1446
≥3 Doses HepB,,HHS Regions/National,Region 7,2021,Age,13-17 Years,93.1,90.8 to 94.9,1154
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2022,Age,13-17 Years,94.5,92.4 to 96.1,979
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2021,Age,13-17 Years,95.4,93.2 to 96.9,1073
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 7,2019,Age,13-17 Years,57.6,53.7 to 61.4,1256
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2013,Age,13-17 Years,26.0,21.8 to 30.6,659
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2014,Age,13-17 Years,31.0,26.6 to 35.9,717
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2015,Age,13-17 Years,44.8,39.9 to 49.9,760
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2016,Age,13-17 Years,50.2,45.3 to 55.1,730
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2012,Age,13-17 Years,19.1,14.7 to 24.6,681
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2017,Age,13-17 Years,57.0,52.1 to 61.7,716
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2018,Age,13-17 Years,62.7,57.7 to 67.5,643
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2019,Age,13-17 Years,69.4,64.2 to 74.1,648
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2020,Age,13-17 Years,69.0,64.4 to 73.2,795
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2021,Age,13-17 Years,74.6,69.4 to 79.2,619
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 7,2018,Age,13-17 Years,51.3,47.6 to 54.9,1191
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2019,Age,13-17 Years,71.5,66.3 to 76.2,608
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 7,2017,Age,13-17 Years,49.1,45.7 to 52.5,1340
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2022,Age,13-17 Years,91.5,88.9 to 93.5,979
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2020,Age,13-17 Years,73.7,68.7 to 78.1,651
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2021,Age,13-17 Years,81.3,76.5 to 85.3,535
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2011,Age,13-17 Years,6.2,4.3 to 8.9,796
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2022,Age,13-17 Years,80.1,75.5 to 84.0,503
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 7,2016,Age,13-17 Years,43.6,40.2 to 47.1,1394
≥3 Doses HepB,,HHS Regions/National,Region 7,2012,Age,13-17 Years,90.2,87.4 to 92.4,1285
≥3 Doses HepB,,HHS Regions/National,Region 7,2011,Age,13-17 Years,89.7,86.8 to 92.0,1528
≥3 Doses HepB,,HHS Regions/National,Region 7,2013,Age,13-17 Years,90.4,87.5 to 92.7,1251
≥3 Doses HepB,,HHS Regions/National,Region 7,2014,Age,13-17 Years,89.0,86.2 to 91.3,1362
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2009,Age,13-17 Years,39.4,34.8 to 44.2,607
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2007,Age,13-17 Years,52.0,32.1 to 71.3,36
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2012,Age,13-17 Years,64.6,59.3 to 69.6,810
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2008,Age,13-17 Years,33.3,28.6 to 38.3,608
≥3 Doses HepB,,HHS Regions/National,Region 7,2008,Age,13-17 Years,82.5,79.8 to 84.9,1295
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2007,Age,13-17 Years,22.9,14.6 to 34.0,81
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2008,Age,13-17 Years,67.1,60.9 to 72.8,414
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2010,Age,13-17 Years,82.5,78.3 to 86.1,617
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2009,Age,13-17 Years,81.1,76.7 to 84.9,477
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2008,Age,13-17 Years,29.4,23.5 to 36.0,414
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2009,Age,13-17 Years,42.4,37.2 to 47.8,477
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2006,Age,13-17 Years,50.3,32.3 to 68.2,40
≥3 Doses HepB,,HHS Regions/National,Region 7,2007,Age,13-17 Years,84.2,76.2 to 89.8,165
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2011,Age,13-17 Years,86.1,81.5 to 89.7,831
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2010,Age,13-17 Years,49.8,45.0 to 54.5,617
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2011,Age,13-17 Years,54.6,49.4 to 59.6,831
≥3 Doses HepB,,HHS Regions/National,Region 7,2006,Age,13-17 Years,70.2,61.2 to 77.9,165
≥3 Doses HepB,,HHS Regions/National,Region 7,2010,Age,13-17 Years,89.8,87.7 to 91.6,1291
≥3 Doses HepB,,HHS Regions/National,Region 7,2009,Age,13-17 Years,84.8,82.1 to 87.2,1250
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2022,Age,13-15 Years,92.8,89.4 to 95.2,609
≥3 Doses HepB,,HHS Regions/National,Region 7,2017,Age,13-17 Years,91.5,89.4 to 93.3,1340
≥3 Doses HepB,,HHS Regions/National,Region 7,2018,Age,13-17 Years,90.9,88.6 to 92.7,1191
≥3 Doses HepB,,HHS Regions/National,Region 7,2019,Age,13-17 Years,92.0,89.4 to 94.0,1256
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2019,Age,13-17 Years,94.4,91.8 to 96.2,1116
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2012,Age,13-17 Years,90.6,85.6 to 94.0,810
≥3 Doses HepB,,HHS Regions/National,Region 7,2016,Age,13-17 Years,90.8,88.7 to 92.5,1394
≥3 Doses HepB,,HHS Regions/National,Region 7,2015,Age,13-17 Years,90.2,87.7 to 92.2,1451
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2018,Age,13-17 Years,94.3,92.1 to 96.0,1026
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2019,Age,13-17 Years,90.3,87.3 to 92.6,1116
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2020,Age,13-17 Years,91.7,89.6 to 93.5,1291
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2021,Age,13-17 Years,92.3,89.6 to 94.3,1073
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2018,Age,13-17 Years,87.5,84.6 to 89.9,1026
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2020,Age,13-17 Years,95.4,93.7 to 96.7,1291
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2017,Age,13-17 Years,95.3,93.5 to 96.7,1140
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2013,Age,13-17 Years,92.9,89.9 to 95.0,858
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2014,Age,13-17 Years,89.7,86.4 to 92.2,1015
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2015,Age,13-17 Years,94.1,92.0 to 95.7,1170
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2016,Age,13-17 Years,94.9,92.8 to 96.3,1137
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2020,Age,13-15 Years,92.4,89.6 to 94.5,807
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2021,Age,13-15 Years,91.5,87.7 to 94.3,671
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2012,Age,13-17 Years,53.1,47.4 to 58.7,604
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2013,Age,13-17 Years,49.7,44.2 to 55.3,592
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2014,Age,13-17 Years,49.8,44.7 to 54.9,645
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2015,Age,13-17 Years,60.2,55.0 to 65.2,691
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2007,Age,13-17 Years,70.7,61.7 to 78.3,165
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2006,Age,13-17 Years,64.7,56.4 to 72.2,165
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2010,Age,13-17 Years,38.8,34.3 to 43.5,616
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2011,Age,13-17 Years,39.2,34.1 to 44.4,732
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2009,Age,13-17 Years,32.0,27.7 to 36.5,607
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2020,Age,13-15 Years,84.2,80.4 to 87.3,894
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2012,Age,13-17 Years,42.4,37.0 to 48.1,604
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2013,Age,13-17 Years,41.7,36.4 to 47.2,592
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2017,Age,13-15 Years,76.8,72.7 to 80.4,833
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2018,Age,13-15 Years,81.5,77.2 to 85.1,726
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2019,Age,13-15 Years,85.1,81.4 to 88.1,799
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2017,Age,13-17 Years,87.8,85.0 to 90.1,1340
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2017,Age,13-17 Years,61.5,58.0 to 64.8,1340
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2016,Age,13-17 Years,55.3,51.8 to 58.8,1394
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2022,Age,13-17 Years,76.0,70.6 to 80.6,545
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2012,Age,13-17 Years,88.0,85.2 to 90.3,1285
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2013,Age,13-17 Years,83.9,80.9 to 86.5,1251
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2010,Age,13-17 Years,77.1,74.1 to 79.9,1291
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2011,Age,13-17 Years,82.6,79.7 to 85.2,1528
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2009,Age,13-15 Years,46.9,42.5 to 51.3,727
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2008,Age,13-15 Years,33.2,29.2 to 37.6,783
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2008,Age,13-17 Years,26.0,21.7 to 30.9,608
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2007,Age,13-17 Years,18.4,11.0 to 29.1,81
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2011,Age,13-15 Years,60.2,55.6 to 64.7,933
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2010,Age,13-15 Years,54.7,50.5 to 58.8,775
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2006,Age,13-15 Years,23.2,13.5 to 36.8,91
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2007,Age,13-15 Years,30.8,20.9 to 42.9,95
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2018,Age,13-17 Years,88.1,85.2 to 90.5,1191
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2019,Age,13-17 Years,90.1,87.4 to 92.2,1256
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2020,Age,13-17 Years,89.3,86.8 to 91.4,1446
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2019,Age,13-17 Years,70.4,66.8 to 73.8,1256
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2018,Age,13-17 Years,66.4,62.8 to 69.7,1191
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2021,Age,13-17 Years,92.0,89.5 to 94.0,1154
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2008,Age,13-17 Years,68.4,65.0 to 71.5,1295
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2009,Age,13-17 Years,74.3,71.2 to 77.1,1250
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2017,Age,13-17 Years,54.9,50.0 to 59.8,624
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2016,Age,13-17 Years,48.9,43.9 to 53.9,664
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2015,Age,13-17 Years,49.3,44.0 to 54.6,691
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2014,Age,13-17 Years,40.6,35.8 to 45.7,645
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2020,Age,13-17 Years,71.3,67.9 to 74.4,1446
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2021,Age,13-17 Years,77.9,74.4 to 81.0,1154
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2021,Age,13-15 Years,90.1,86.8 to 92.7,715
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2018,Age,13-17 Years,57.2,51.9 to 62.2,548
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2019,Age,13-17 Years,57.6,51.9 to 63.0,608
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2006,Age,13-15 Years,22.2,14.0 to 33.5,91
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2007,Age,13-15 Years,46.9,35.2 to 59.1,95
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2012,Age,13-15 Years,85.0,81.0 to 88.2,755
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2011,Age,13-15 Years,80.0,75.9 to 83.5,933
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2009,Age,13-15 Years,61.9,57.5 to 66.1,727
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2010,Age,13-15 Years,67.5,63.3 to 71.5,775
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2008,Age,13-15 Years,47.2,42.8 to 51.7,783
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2022,Age,13-17 Years,92.5,90.2 to 94.3,1048
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2017,Age,13-15 Years,84.8,80.9 to 88.0,833
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2016,Age,13-15 Years,84.9,81.3 to 87.9,876
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2015,Age,13-15 Years,84.1,80.2 to 87.3,925
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2014,Age,13-15 Years,84.0,80.0 to 87.2,815
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2013,Age,13-15 Years,80.1,75.8 to 83.7,790
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2018,Age,13-17 Years,45.6,40.7 to 50.7,643
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2017,Age,13-17 Years,43.6,38.9 to 48.4,716
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2016,Age,13-17 Years,38.6,34.0 to 43.4,730
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2015,Age,13-17 Years,34.6,30.0 to 39.6,760
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2019,Age,13-15 Years,88.0,84.3 to 90.8,799
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2020,Age,13-15 Years,85.9,82.1 to 89.1,894
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2021,Age,13-15 Years,89.5,85.9 to 92.2,715
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2018,Age,13-15 Years,85.9,81.6 to 89.3,726
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2017,Age,13-17 Years,77.3,74.2 to 80.2,1340
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2018,Age,13-17 Years,80.9,77.7 to 83.7,1191
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2019,Age,13-17 Years,86.1,83.2 to 88.5,1256
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2020,Age,13-17 Years,86.4,83.7 to 88.7,1446
≥2 Doses MMR,,HHS Regions/National,Region 7,2021,Age,13-17 Years,92.5,90.0 to 94.5,1154
≥2 Doses MMR,,HHS Regions/National,Region 7,2022,Age,13-17 Years,91.3,88.7 to 93.4,1048
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2011,Age,13-15 Years,25.7,19.9 to 32.4,443
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2010,Age,13-15 Years,28.2,23.3 to 33.7,379
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2009,Age,13-15 Years,22.6,18.0 to 27.9,362
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2008,Age,13-15 Years,15.7,11.4 to 21.2,360
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2022,Age,13-17 Years,90.7,88.0 to 92.8,1048
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2021,Age,13-17 Years,90.4,87.8 to 92.5,1154
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2011,Age,13-17 Years,2.3,1.3 to 4.0,796
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2012,Age,13-17 Years,11.0,8.0 to 14.8,681
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2013,Age,13-17 Years,16.6,13.5 to 20.4,659
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2014,Age,13-17 Years,23.8,19.7 to 28.3,717
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2012,Age,13-15 Years,26.3,20.6 to 32.9,361
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2013,Age,13-15 Years,22.7,18.0 to 28.3,374
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2015,Age,13-15 Years,30.3,24.7 to 36.6,423
HPV,"≥3 Doses, Females",HHS Regions/National,Region 7,2014,Age,13-15 Years,24.3,19.2 to 30.3,379
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2012,Age,13-17 Years,61.4,57.3 to 65.4,1285
≥2 Doses MMR,,HHS Regions/National,Region 7,2016,Age,13-17 Years,89.6,87.3 to 91.6,1394
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 7,2011,Age,13-17 Years,15.6,13.1 to 18.4,1528
≥2 Doses MMR,,HHS Regions/National,Region 7,2014,Age,13-17 Years,87.7,84.8 to 90.2,1362
≥2 Doses MMR,,HHS Regions/National,Region 7,2015,Age,13-17 Years,89.0,86.3 to 91.3,1451
≥2 Doses MMR,,HHS Regions/National,Region 7,2012,Age,13-17 Years,88.8,85.7 to 91.3,1285
≥2 Doses MMR,,HHS Regions/National,Region 7,2013,Age,13-17 Years,89.0,86.2 to 91.2,1251
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2007,Age,13-17 Years,26.9,19.7 to 35.4,165
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2022,Age,13-17 Years,91.4,89.0 to 93.4,1048
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2006,Age,13-17 Years,19.3,12.6 to 28.5,165
≥2 Doses MMR,,HHS Regions/National,Region 7,2018,Age,13-17 Years,90.8,88.4 to 92.7,1191
≥2 Doses MMR,,HHS Regions/National,Region 7,2017,Age,13-17 Years,90.7,88.4 to 92.5,1340
≥2 Doses MMR,,HHS Regions/National,Region 7,2019,Age,13-17 Years,91.8,89.2 to 93.8,1256
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2019,Age,13-17 Years,88.3,85.4 to 90.6,1256
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2020,Age,13-17 Years,87.9,85.3 to 90.2,1446
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2021,Age,13-17 Years,90.2,87.6 to 92.4,1154
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 7,2012,Age,13-17 Years,18.8,16.0 to 22.0,1285
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 7,2013,Age,13-17 Years,20.2,17.6 to 23.2,1251
≥2 Doses MMR,,HHS Regions/National,Region 7,2020,Age,13-17 Years,92.9,90.9 to 94.4,1446
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 7,2015,Age,13-17 Years,31.0,27.7 to 34.5,1451
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 7,2014,Age,13-17 Years,23.8,20.9 to 26.8,1362
HPV,"≥2 Doses, Females",HHS Regions/National,Region 7,2022,Age,13-17 Years,66.5,61.0 to 71.5,503
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2016,Age,13-17 Years,86.2,83.6 to 88.4,1394
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2010,Age,13-17 Years,52.6,49.3 to 55.9,1291
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2011,Age,13-17 Years,57.2,53.6 to 60.8,1528
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2008,Age,13-17 Years,32.8,29.6 to 36.2,1295
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2009,Age,13-17 Years,45.2,41.9 to 48.6,1250
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2013,Age,13-17 Years,62.5,58.8 to 66.2,1251
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2014,Age,13-17 Years,65.4,61.7 to 68.9,1362
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2015,Age,13-17 Years,70.7,67.3 to 74.0,1451
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2016,Age,13-17 Years,70.8,67.4 to 74.0,1394
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2018,Age,13-17 Years,86.6,83.7 to 89.2,1191
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2017,Age,13-17 Years,86.8,84.0 to 89.2,1340
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2022,Age,13-15 Years,90.9,87.6 to 93.4,654
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2022,Age,13-17 Years,78.0,74.5 to 81.1,1048
HPV,"≥1 Dose, Males",HHS Regions/National,Region 7,2023,Age,13-17 Years,77.7,72.2 to 82.4,577
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2023,Age,13-15 Years,57.5,49.7 to 65.0,328
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2023,Age,13-17 Years,63.3,57.3 to 68.9,562
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2023,Age,13-15 Years,89.6,85.2 to 92.8,631
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2023,Age,13-15 Years,56.4,50.9 to 61.8,674
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2023,Age,13-15 Years,55.4,47.7 to 62.9,346
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2023,Age,13-15 Years,89.3,85.4 to 92.3,674
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2023,Age,13-15 Years,89.1,85.1 to 92.1,674
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 7,2023,Age,13-17 Years,91.2,88.5 to 93.4,1139
≥2 Doses Hep A,,HHS Regions/National,Region 7,2023,Age,13-17 Years,86.8,83.7 to 89.3,1139
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 7,2023,Age,13-17 Years,90.7,87.8 to 93.0,1071
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 7,2023,Age,13-17 Years,93.8,91.4 to 95.5,1071
≥3 Doses HepB,,HHS Regions/National,Region 7,2023,Age,13-17 Years,91.1,88.3 to 93.3,1139
Varicella,History of disease,HHS Regions/National,Region 7,2023,Age,13-17 Years,5.4,3.8 to 7.8,1139
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2023,Age,13-17 Years,60.7,54.7 to 66.4,577
≥2 Doses MMR,,HHS Regions/National,Region 7,2023,Age,13-17 Years,90.3,87.3 to 92.6,1139
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2023,Age,13-17 Years,62.0,57.8 to 66.0,1139
HPV,"≥1 Dose, Females",HHS Regions/National,Region 7,2023,Age,13-17 Years,79.8,74.5 to 84.2,562
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 7,2023,Age,13-17 Years,78.7,75.0 to 82.0,1139
≥1 Dose MenACWY,,HHS Regions/National,Region 7,2023,Age,13-17 Years,90.1,87.2 to 92.4,1139
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 7,2023,Age,13-17 Years,90.6,87.7 to 92.8,1139
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2023,Age,13-17 Years,89.4,86.4 to 91.8,1139
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 7,2022,Age,13-17 Years,65.2,61.3 to 68.9,1048
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2022,Age,13-17 Years,64.0,58.4 to 69.3,545
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2018,Age,13-17 Years,62.7,57.1 to 67.9,895
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2019,Age,13-17 Years,67.4,61.7 to 72.6,950
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2021,Age,13-15 Years,69.9,62.4 to 76.6,550
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2022,Age,13-15 Years,69.5,61.9 to 76.2,456
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2017,Age,13-17 Years,66.2,61.4 to 70.6,989
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2018,Age,13-15 Years,63.0,56.3 to 69.2,576
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2021,Age,13-17 Years,73.9,68.2 to 78.8,898
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2022,Age,13-17 Years,75.4,69.9 to 80.2,778
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2019,Age,13-15 Years,58.8,51.3 to 65.9,669
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2020,Age,13-15 Years,64.6,58.2 to 70.4,661
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2021,Age,13-15 Years,66.4,59.4 to 72.8,636
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2022,Age,13-15 Years,69.4,62.6 to 75.5,491
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2021,Age,13-17 Years,69.5,64.0 to 74.5,1025
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2019,Age,13-15 Years,58.5,53.1 to 63.8,1209
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2022,Age,13-17 Years,74.8,69.7 to 79.3,817
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2021,Age,13-15 Years,68.1,63.0 to 72.8,1186
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2020,Age,13-15 Years,64.9,60.6 to 69.0,1297
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2022,Age,13-15 Years,69.5,64.4 to 74.1,947
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2018,Age,13-17 Years,64.1,58.9 to 69.0,1007
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2017,Age,13-17 Years,60.5,56.1 to 64.8,1118
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2019,Age,13-17 Years,64.8,59.3 to 70.0,1084
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2020,Age,13-17 Years,69.5,64.9 to 73.7,1132
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2016,Age,13-17 Years,49.3,44.7 to 54.0,1080
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2019,Age,13-15 Years,58.2,50.2 to 65.9,540
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2020,Age,13-15 Years,65.3,59.2 to 70.9,636
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2018,Age,13-15 Years,56.9,49.8 to 63.8,564
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2016,Age,13-17 Years,61.0,56.2 to 65.5,1017
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2020,Age,13-17 Years,72.6,68.1 to 76.7,1015
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2023,Age,13-17 Years,82.3,72.9 to 88.9,128
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2023,Age,13-17 Years,67.9,57.3 to 76.9,128
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2023,Age,13-15 Years,88.1,79.1 to 93.6,140
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2023,Age,13-15 Years,58.4,44.0 to 71.5,70
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2023,Age,13-15 Years,58.4,45.3 to 70.5,83
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2023,Age,13-15 Years,58.4,48.8 to 67.5,153
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2023,Age,13-15 Years,90.4,84.4 to 94.3,153
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2023,Age,13-15 Years,88.2,79.9 to 93.3,153
≥2 Doses Hep A,,States/Local Areas,Nebraska,2023,Age,13-17 Years,87.4,81.5 to 91.6,272
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2023,Age,13-17 Years,90.9,85.3 to 94.5,272
Varicella,History of disease,States/Local Areas,Nebraska,2023,Age,13-17 Years,8.4,4.9 to 14.0,272
≥3 Doses HepB,,States/Local Areas,Nebraska,2023,Age,13-17 Years,89.6,84.2 to 93.3,272
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2023,Age,13-17 Years,94.2,89.9 to 96.8,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2023,Age,13-17 Years,90.1,84.0 to 94.0,251
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2023,Age,13-17 Years,66.9,56.5 to 75.9,144
≥2 Doses MMR,,States/Local Areas,Nebraska,2023,Age,13-17 Years,93.7,89.7 to 96.2,272
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2023,Age,13-17 Years,67.4,60.1 to 73.9,272
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2023,Age,13-17 Years,83.9,77.7 to 88.6,272
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2023,Age,13-17 Years,92.2,88.1 to 95.0,272
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2023,Age,13-17 Years,89.5,83.5 to 93.5,272
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2023,Age,13-17 Years,93.6,89.1 to 96.3,272
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2023,Age,13-17 Years,85.4,76.3 to 91.5,144
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2022,Age,13-17 Years,73.9,63.9 to 82.0,113
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nebraska,2022,Age,13-17 Years,65.8,58.4 to 72.4,247
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2009,Age,13-17 Years,53.2,46.8 to 59.6,286
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2008,Age,13-17 Years,37.2,31.8 to 42.9,365
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2011,Age,13-17 Years,76.0,69.9 to 81.2,368
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2010,Age,13-17 Years,65.7,59.3 to 71.6,307
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2012,Age,13-17 Years,75.5,68.9 to 81.1,328
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2022,Age,13-15 Years,88.8,81.2 to 93.5,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2017,Age,13-17 Years,92.3,87.5 to 95.4,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018,Age,13-17 Years,89.0,83.3 to 92.9,295
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2016,Age,13-17 Years,86.8,81.5 to 90.8,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nebraska,2012,Age,13-17 Years,21.7,16.8 to 27.6,328
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nebraska,2011,Age,13-17 Years,16.6,12.6 to 21.5,368
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2016,Age,13-17 Years,80.2,74.6 to 84.8,330
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2015,Age,13-17 Years,78.1,73.0 to 82.5,393
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2014,Age,13-17 Years,74.1,67.9 to 79.5,321
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2013,Age,13-17 Years,77.5,71.9 to 82.3,301
≥2 Doses MMR,,States/Local Areas,Nebraska,2016,Age,13-17 Years,89.7,84.7 to 93.2,330
≥2 Doses MMR,,States/Local Areas,Nebraska,2014,Age,13-17 Years,94.5,90.3 to 96.9,321
≥2 Doses MMR,,States/Local Areas,Nebraska,2015,Age,13-17 Years,92.2,88.7 to 94.8,393
≥2 Doses MMR,,States/Local Areas,Nebraska,2012,Age,13-17 Years,90.6,85.5 to 94.0,328
≥2 Doses MMR,,States/Local Areas,Nebraska,2013,Age,13-17 Years,92.3,88.4 to 94.9,301
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2019,Age,13-17 Years,91.2,85.6 to 94.7,285
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2017,Age,13-17 Years,84.8,79.4 to 89.0,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2020,Age,13-17 Years,91.3,87.3 to 94.1,405
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2021,Age,13-17 Years,92.3,88.0 to 95.1,315
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2022,Age,13-17 Years,90.1,84.9 to 93.6,247
≥2 Doses MMR,,States/Local Areas,Nebraska,2019,Age,13-17 Years,91.4,85.9 to 94.9,285
≥2 Doses MMR,,States/Local Areas,Nebraska,2018,Age,13-17 Years,93.1,88.8 to 95.8,295
≥2 Doses MMR,,States/Local Areas,Nebraska,2017,Age,13-17 Years,93.4,88.8 to 96.2,324
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nebraska,2013,Age,13-17 Years,30.3,24.8 to 36.5,301
≥2 Doses MMR,,States/Local Areas,Nebraska,2020,Age,13-17 Years,91.1,86.9 to 94.0,405
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nebraska,2015,Age,13-17 Years,40.0,34.5 to 45.9,393
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nebraska,2014,Age,13-17 Years,32.8,26.8 to 39.4,321
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2015,Age,13-15 Years,41.2,31.0 to 52.3,113
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2014,Age,13-15 Years,41.0,29.1 to 54.2,85
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2013,Age,13-15 Years,28.6,19.4 to 40.0,86
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2008,Age,13-15 Years,19.7,13.2 to 28.3,122
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2010,Age,13-15 Years,42.9,31.7 to 54.9,89
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2009,Age,13-15 Years,33.3,22.2 to 46.6,78
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2022,Age,13-17 Years,88.3,82.5 to 92.4,247
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2012,Age,13-15 Years,37.9,26.1 to 51.2,84
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2011,Age,13-15 Years,28.6,19.4 to 40.0,115
≥2 Doses MMR,,States/Local Areas,Nebraska,2021,Age,13-17 Years,94.0,90.1 to 96.5,315
≥2 Doses MMR,,States/Local Areas,Nebraska,2022,Age,13-17 Years,90.6,85.4 to 94.0,247
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Overall,Overall,87.1,84.8 to 89.1,1547
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Overall,Overall,90.8,88.8 to 92.4,1547
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2022,Age,13-17 Years,57.1,46.8 to 66.9,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Overall,Overall,79.2,76.5 to 81.7,1547
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a Non-MSA,89.0,84.8 to 92.1,478
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Overall,Overall,63.1,60.0 to 66.1,1547
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a Non-MSA,71.3,65.6 to 76.3,478
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,80.1,73.8 to 85.3,316
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Principal City,83.7,80.1 to 86.7,753
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a Non-MSA,51.9,46.3 to 57.5,478
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,65.1,58.1 to 71.5,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Principal City,69.1,64.8 to 73.0,753
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,88.5,82.8 to 92.5,316
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a Non-MSA,84.1,79.3 to 87.9,478
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Principal City,88.5,85.3 to 91.1,753
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",63.1,59.4 to 66.5,1149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,Hispanic,87.5,81.5 to 91.7,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Principal City,91.3,88.5 to 93.4,753
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.3,86.9 to 95.5,316
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.7,79.9 to 95.0,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",48.5,33.7 to 63.5,54
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",77.1,65.9 to 85.5,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",58.8,47.1 to 69.7,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,Hispanic,70.1,62.8 to 76.5,237
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",87.2,84.5 to 89.5,1149
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.9,58.3 to 85.2,54
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.8,88.4 to 92.8,1149
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,Hispanic,90.0,84.3 to 93.8,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,Hispanic,88.5,82.2 to 92.7,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.5,80.7 to 96.5,54
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.7,88.7 to 97.6,107
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",77.9,74.6 to 80.9,1149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.2,57.7 to 84.6,54
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Poverty,Below Poverty Level,78.1,70.0 to 84.5,202
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Poverty,Below Poverty Level,84.0,76.5 to 89.4,202
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Poverty,Living At or Above Poverty Level,79.4,76.4 to 82.1,1308
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Poverty,Living At or Above Poverty Level,87.7,85.3 to 89.8,1308
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Poverty,Below Poverty Level,61.0,52.5 to 68.9,202
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Poverty,Living At or Above Poverty Level,63.5,60.2 to 66.8,1308
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Poverty,Living At or Above Poverty Level,90.9,88.7 to 92.7,1308
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Poverty,Below Poverty Level,88.9,82.2 to 93.2,202
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Private Insurance Only,86.7,83.7 to 89.2,1027
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Any Medicaid,84.8,79.6 to 88.9,364
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Private Insurance Only,78.3,74.9 to 81.5,1027
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Any Medicaid,80.2,74.6 to 84.9,364
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Other,98.5,95.9 to 99.5,89
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Other,83.4,71.6 to 90.9,89
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 8,2011,Age,13-17 Years,14.4,12.2 to 17.0,2242
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Private Insurance Only,63.9,60.1 to 67.6,1027
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Uninsured,93.5,83.4 to 97.6,67
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Uninsured,80.5,66.4 to 89.6,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Any Medicaid,62.5,56.2 to 68.3,364
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Other,62.1,48.9 to 73.7,89
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Uninsured,57.7,43.2 to 71.0,67
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Private Insurance Only,90.9,88.5 to 92.9,1027
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Any Medicaid,89.0,84.1 to 92.5,364
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Other,96.3,87.7 to 99.0,89
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018-2022,Insurance Coverage,Uninsured,92.8,80.5 to 97.6,67
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2020,Age,13-17 Years,82.9,76.0 to 88.1,221
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2021,Age,13-17 Years,79.7,70.8 to 86.3,168
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2018,Age,13-17 Years,70.9,61.1 to 79.0,161
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2012,Age,13-17 Years,19.6,13.6 to 27.3,182
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nebraska,2018,Age,13-17 Years,64.4,57.3 to 70.9,295
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2019,Age,13-17 Years,74.0,63.2 to 82.5,132
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2020,Age,13-17 Years,82.3,74.1 to 88.3,184
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2021,Age,13-17 Years,85.9,77.6 to 91.4,147
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2022,Age,13-17 Years,76.2,65.9 to 84.1,134
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2011,Age,13-17 Years,14.2,7.8 to 24.3,194
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nebraska,2017,Age,13-17 Years,62.8,56.4 to 68.7,324
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nebraska,2016,Age,13-17 Years,52.1,45.5 to 58.6,330
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2019,Age,13-17 Years,73.9,63.5 to 82.2,153
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2017,Age,13-17 Years,70.0,61.6 to 77.3,179
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2016,Age,13-17 Years,58.3,49.3 to 66.8,179
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2015,Age,13-17 Years,54.3,46.4 to 62.0,209
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2014,Age,13-17 Years,39.5,30.8 to 48.9,167
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2013,Age,13-17 Years,38.2,29.9 to 47.2,160
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nebraska,2019,Age,13-17 Years,62.5,55.1 to 69.3,285
≥3 Doses HepB,,States/Local Areas,Nebraska,2008,Age,13-17 Years,90.6,86.1 to 93.8,365
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2022,Age,13-15 Years,91.2,84.6 to 95.1,148
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2008,Age,13-17 Years,29.5,23.0 to 37.0,186
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2011,Age,13-17 Years,76.4,67.8 to 83.3,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2010,Age,13-17 Years,59.8,49.9 to 68.9,145
≥3 Doses HepB,,States/Local Areas,Nebraska,2012,Age,13-17 Years,90.0,84.5 to 93.7,328
≥3 Doses HepB,,States/Local Areas,Nebraska,2011,Age,13-17 Years,94.0,90.0 to 96.4,368
≥3 Doses HepB,,States/Local Areas,Nebraska,2014,Age,13-17 Years,93.9,89.6 to 96.5,321
≥3 Doses HepB,,States/Local Areas,Nebraska,2013,Age,13-17 Years,93.8,90.1 to 96.2,301
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2015,Age,13-15 Years,76.8,70.0 to 82.5,247
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2014,Age,13-15 Years,73.5,65.5 to 80.3,186
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2012,Age,13-15 Years,74.7,66.2 to 81.6,188
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2013,Age,13-15 Years,79.0,71.8 to 84.8,179
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2017,Age,13-17 Years,72.0,62.5 to 79.8,145
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2016,Age,13-17 Years,69.4,59.8 to 77.6,151
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2021,Age,13-17 Years,94.4,90.6 to 96.7,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2022,Age,13-17 Years,89.1,83.3 to 93.0,232
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2008,Age,13-17 Years,24.4,18.4 to 31.5,186
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2016,Age,13-15 Years,81.1,73.5 to 86.8,199
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2017,Age,13-17 Years,95.3,91.2 to 97.6,324
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2016,Age,13-17 Years,90.8,86.1 to 94.0,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2014,Age,13-17 Years,85.6,79.8 to 89.9,321
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2015,Age,13-17 Years,90.5,86.1 to 93.6,393
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2018,Age,13-17 Years,80.6,70.8 to 87.7,134
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2022,Age,13-17 Years,93.2,88.0 to 96.2,232
≥3 Doses HepB,,States/Local Areas,Nebraska,2020,Age,13-17 Years,90.6,86.1 to 93.7,405
≥3 Doses HepB,,States/Local Areas,Nebraska,2021,Age,13-17 Years,92.9,89.0 to 95.5,315
≥3 Doses HepB,,States/Local Areas,Nebraska,2022,Age,13-17 Years,90.2,84.9 to 93.8,247
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2009,Age,13-17 Years,78.8,73.1 to 83.5,286
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2008,Age,13-17 Years,71.5,65.6 to 76.7,365
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2012,Age,13-17 Years,85.2,79.1 to 89.8,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2013,Age,13-17 Years,88.7,83.6 to 92.4,301
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2011,Age,13-17 Years,87.3,82.1 to 91.1,368
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2010,Age,13-17 Years,82.7,77.1 to 87.1,307
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2011,Age,13-17 Years,40.6,31.7 to 50.2,174
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2010,Age,13-17 Years,48.5,39.1 to 57.9,148
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2020,Age,13-15 Years,88.2,81.8 to 92.6,238
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2009,Age,13-17 Years,40.7,31.9 to 50.1,143
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2012,Age,13-17 Years,58.3,47.4 to 68.5,146
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2013,Age,13-17 Years,55.3,45.9 to 64.3,141
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2019,Age,13-15 Years,87.7,78.6 to 93.3,181
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018,Age,13-15 Years,86.2,78.4 to 91.5,181
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2017,Age,13-15 Years,82.9,75.0 to 88.7,190
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2017,Age,13-17 Years,71.0,64.8 to 76.5,324
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2016,Age,13-17 Years,63.7,57.2 to 69.8,330
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2019,Age,13-17 Years,73.9,66.7 to 80.1,285
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2021,Age,13-17 Years,94.0,90.1 to 96.4,315
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2022,Age,13-17 Years,91.5,86.4 to 94.8,247
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2018,Age,13-17 Years,75.6,68.9 to 81.3,295
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2018,Age,13-17 Years,91.1,85.7 to 94.6,295
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2010,Age,13-15 Years,76.4,68.7 to 82.6,175
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2011,Age,13-15 Years,78.5,70.9 to 84.5,243
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2008,Age,13-15 Years,44.5,37.5 to 51.8,227
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2009,Age,13-15 Years,64.4,55.9 to 72.2,162
HPV,"≥1 Dose, Males",States/Local Areas,Nebraska,2022,Age,13-17 Years,85.7,76.2 to 91.8,113
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2020,Age,13-17 Years,82.6,77.5 to 86.8,405
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2021,Age,13-17 Years,82.7,76.8 to 87.3,315
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nebraska,2022,Age,13-17 Years,81.1,74.3 to 86.4,247
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2019,Age,13-17 Years,92.7,87.1 to 96.0,285
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nebraska,2020,Age,13-17 Years,93.3,89.7 to 95.7,405
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2017,Age,13-17 Years,63.3,53.6 to 72.0,145
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2016,Age,13-17 Years,54.8,45.2 to 64.1,151
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2015,Age,13-17 Years,55.5,46.9 to 63.7,184
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2014,Age,13-17 Years,51.2,41.8 to 60.5,154
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2021,Age,13-15 Years,89.4,83.1 to 93.6,196
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2018,Age,13-17 Years,68.0,57.7 to 76.8,134
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2012,Age,13-15 Years,84.4,77.0 to 89.8,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2011,Age,13-15 Years,84.3,77.3 to 89.4,243
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2008,Age,13-15 Years,55.2,47.8 to 62.3,227
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2010,Age,13-15 Years,81.9,73.8 to 87.8,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2009,Age,13-15 Years,64.2,55.6 to 71.9,162
HPV,"≥2 Doses, Females",States/Local Areas,Nebraska,2019,Age,13-17 Years,63.0,52.3 to 72.6,132
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2019,Age,13-15 Years,90.4,81.8 to 95.2,181
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2020,Age,13-15 Years,94.5,89.7 to 97.1,238
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2021,Age,13-15 Years,91.2,85.3 to 94.9,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2018,Age,13-15 Years,91.6,85.4 to 95.3,181
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2013,Age,13-15 Years,86.8,79.4 to 91.7,179
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2018,Age,13-17 Years,60.9,51.0 to 70.1,161
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2017,Age,13-17 Years,62.3,53.7 to 70.1,179
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2016,Age,13-17 Years,49.4,40.5 to 58.4,179
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2012,Age,13-17 Years,11.6,7.4 to 17.7,182
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2017,Age,13-15 Years,89.2,81.5 to 94.0,190
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2016,Age,13-15 Years,89.1,82.8 to 93.3,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2015,Age,13-15 Years,85.8,79.3 to 90.5,247
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2014,Age,13-15 Years,84.5,76.9 to 89.9,186
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2019,Age,13-17 Years,86.3,79.9 to 90.9,285
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2018,Age,13-17 Years,84.0,78.0 to 88.6,295
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2020,Age,13-17 Years,87.3,82.5 to 91.0,405
≥1 Dose MenACWY,,States/Local Areas,Nebraska,2021,Age,13-17 Years,89.7,84.9 to 93.1,315
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2013,Age,13-17 Years,26.4,19.4 to 34.9,160
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2014,Age,13-17 Years,31.0,23.0 to 40.4,167
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2015,Age,13-17 Years,46.9,39.2 to 54.7,209
≥3 Doses HepB,,States/Local Areas,Nebraska,2009,Age,13-17 Years,90.5,85.9 to 93.7,286
≥3 Doses HepB,,States/Local Areas,Nebraska,2010,Age,13-17 Years,92.8,88.7 to 95.5,307
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2009,Age,13-17 Years,49.4,40.2 to 58.6,143
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2008,Age,13-17 Years,86.1,78.3 to 91.4,126
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2012,Age,13-17 Years,82.2,74.9 to 87.7,224
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2013,Age,13-17 Years,84.6,78.3 to 89.3,215
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2009,Age,13-15 Years,47.0,36.0 to 58.4,89
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2008,Age,13-15 Years,39.6,29.7 to 50.3,109
≥3 Doses HepB,,States/Local Areas,Nebraska,2017,Age,13-17 Years,96.4,93.4 to 98.1,324
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2012,Age,13-17 Years,94.3,88.2 to 97.3,224
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2011,Age,13-17 Years,94.7,89.1 to 97.5,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2009,Age,13-17 Years,47.8,38.4 to 57.3,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2008,Age,13-17 Years,36.7,27.7 to 46.8,126
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2009,Age,13-17 Years,91.4,84.8 to 95.3,124
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2010,Age,13-17 Years,92.5,86.1 to 96.1,145
≥3 Doses HepB,,States/Local Areas,Nebraska,2019,Age,13-17 Years,93.8,88.9 to 96.7,285
≥3 Doses HepB,,States/Local Areas,Nebraska,2018,Age,13-17 Years,91.9,87.1 to 95.0,295
≥3 Doses HepB,,States/Local Areas,Nebraska,2016,Age,13-17 Years,91.2,86.7 to 94.3,330
≥3 Doses HepB,,States/Local Areas,Nebraska,2015,Age,13-17 Years,92.5,88.9 to 95.0,393
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2019,Age,13-17 Years,89.5,83.6 to 93.5,260
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2020,Age,13-17 Years,87.7,82.6 to 91.4,368
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2021,Age,13-17 Years,94.0,90.2 to 96.4,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2018,Age,13-17 Years,91.8,86.5 to 95.2,250
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2020,Age,13-17 Years,93.3,89.5 to 95.8,368
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2019,Age,13-17 Years,95.0,90.1 to 97.5,260
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2018,Age,13-17 Years,95.3,90.8 to 97.7,250
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2016,Age,13-17 Years,96.8,93.1 to 98.6,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2015,Age,13-17 Years,97.0,93.7 to 98.6,321
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2014,Age,13-17 Years,96.8,93.2 to 98.5,247
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2013,Age,13-17 Years,96.1,91.9 to 98.2,215
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2020,Age,13-15 Years,86.0,79.1 to 90.9,220
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2021,Age,13-15 Years,93.1,87.7 to 96.2,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2017,Age,13-17 Years,93.0,87.7 to 96.1,271
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2010,Age,13-17 Years,52.3,42.8 to 61.6,148
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2011,Age,13-17 Years,59.0,48.8 to 68.4,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Nebraska,2017,Age,13-17 Years,98.2,96.2 to 99.2,271
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2014,Age,13-17 Years,83.5,76.8 to 88.5,247
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2016,Age,13-17 Years,86.7,80.6 to 91.0,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2015,Age,13-17 Years,88.7,83.6 to 92.3,321
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2012,Age,13-17 Years,67.5,56.8 to 76.6,146
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2013,Age,13-17 Years,65.1,55.5 to 73.7,141
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2014,Age,13-17 Years,59.6,50.2 to 68.3,154
HPV,"≥1 Dose, Females",States/Local Areas,Nebraska,2015,Age,13-17 Years,67.3,58.9 to 74.6,184
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2012,Age,13-15 Years,81.4,71.8 to 88.2,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2013,Age,13-15 Years,87.1,79.3 to 92.2,136
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2010,Age,13-15 Years,67.3,56.2 to 76.7,104
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2011,Age,13-15 Years,80.3,70.4 to 87.4,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2015,Age,13-15 Years,89.7,83.3 to 93.8,207
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2014,Age,13-15 Years,85.1,76.3 to 91.0,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2018,Age,13-15 Years,94.0,86.9 to 97.4,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2019,Age,13-15 Years,90.6,83.1 to 95.0,172
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2009,Age,13-17 Years,77.9,72.3 to 82.7,286
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2010,Age,13-17 Years,81.2,75.2 to 86.0,307
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2017,Age,13-15 Years,90.6,82.3 to 95.3,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Nebraska,2016,Age,13-15 Years,90.1,83.5 to 94.2,168
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2012,Age,13-17 Years,88.2,83.0 to 92.0,328
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2011,Age,13-17 Years,85.9,80.3 to 90.1,368
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2014,Age,13-17 Years,87.5,82.2 to 91.4,321
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2013,Age,13-17 Years,88.9,84.2 to 92.4,301
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2020,Age,13-17 Years,88.7,84.1 to 92.2,405
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2021,Age,13-17 Years,94.5,90.9 to 96.7,315
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2022,Age,13-17 Years,89.5,83.9 to 93.3,247
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2019,Age,13-17 Years,90.3,84.8 to 94.0,285
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2018,Age,13-17 Years,92.9,88.3 to 95.8,295
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2016,Age,13-17 Years,89.0,83.9 to 92.6,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2017,Age,13-17 Years,94.1,89.6 to 96.7,324
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2013,Age,13-15 Years,20.6,13.0 to 31.0,93
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2013,Age,13-17 Years,19.7,13.4 to 27.9,160
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2012,Age,13-17 Years,7.0,4.0 to 11.8,182
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2015,Age,13-17 Years,32.2,25.4 to 39.8,209
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2014,Age,13-17 Years,22.8,15.9 to 31.5,167
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2015,Age,13-17 Years,90.7,86.5 to 93.8,393
Varicella,≥2 Doses or history of disease,States/Local Areas,Nebraska,2008,Age,13-17 Years,78.3,73.0 to 82.8,365
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018,Age,13-15 Years,90.1,85.6 to 93.3,334
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2020,Age,13-15 Years,92.5,87.5 to 95.6,249
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,32.2,24.7 to 40.7,166
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,29.3,22.6 to 37.1,187
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,44.1,35.1 to 53.6,223
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,73.2,66.7 to 78.8,440
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,72.2,66.4 to 77.4,365
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,55.5,47.5 to 63.3,208
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,90.0,84.8 to 93.6,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,79.3,72.1 to 85.0,345
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,78.9,73.5 to 83.4,373
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,80.0,74.6 to 84.5,441
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,41.1,32.6 to 50.1,174
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,24.5,16.5 to 34.7,165
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2019,Age,13-15 Years,92.8,88.4 to 95.6,282
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,70.2,61.8 to 77.5,200
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,62.7,57.4 to 67.7,479
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,61.4,55.8 to 66.6,448
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,93.4,90.5 to 95.4,529
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,66.3,61.4 to 70.9,529
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,19.3,13.1 to 27.5,200
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2012,Age,13-15 Years,64.7,55.0 to 73.3,210
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2013,Age,13-15 Years,80.4,73.3 to 86.0,209
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,94.9,91.7 to 96.8,479
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,94.8,91.7 to 96.7,448
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,91.6,87.8 to 94.3,496
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,95.9,93.2 to 97.6,435
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,86.3,81.0 to 90.3,389
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,89.0,84.1 to 92.5,366
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,90.2,85.5 to 93.5,343
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2016,Age,13-15 Years,89.6,80.5 to 94.8,93
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2018,Age,13-15 Years,94.6,82.0 to 98.5,105
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2017,Age,13-15 Years,87.9,76.2 to 94.3,101
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2013,Age,13-15 Years,82.2,69.7 to 90.2,104
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2012,Age,13-15 Years,73.2,62.0 to 82.0,144
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2010,Age,13-15 Years,64.0,54.1 to 72.8,145
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2011,Age,13-15 Years,72.1,62.9 to 79.8,187
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2008,Age,13-15 Years,23.4,15.6 to 33.6,101
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,90.4,84.9 to 94.1,256
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,93.6,84.0 to 97.6,144
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,90.6,83.5 to 94.9,271
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2013,Age,13-15 Years,21.4,11.9 to 35.4,66
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,88.3,80.4 to 93.2,160
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,90.3,85.8 to 93.5,283
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,92.9,85.6 to 96.6,192
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,91.3,84.3 to 95.3,157
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,88.0,80.8 to 92.8,204
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,68.6,62.5 to 74.1,389
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,79.9,74.6 to 84.3,366
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,69.0,63.0 to 74.4,343
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,26.1,18.0 to 36.4,133
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,41.6,32.3 to 51.5,136
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,19.8,12.7 to 29.6,115
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,17.0,9.6 to 28.3,144
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,79.6,72.6 to 85.2,287
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,78.6,73.1 to 83.1,407
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,87.8,81.8 to 92.0,274
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,83.9,76.1 to 89.6,209
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,61.4,55.2 to 67.2,343
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,8.7,4.9 to 15.0,271
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2018,Age,13-15 Years,63.0,43.2 to 79.3,55
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2019,Age,13-15 Years,68.5,49.5 to 82.8,47
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2020,Age,13-15 Years,71.0,56.6 to 82.2,93
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,47.9,41.8 to 54.0,389
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2014,Age,13-15 Years,23.3,13.8 to 36.5,87
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,47.7,38.4 to 57.3,147
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,24.7,17.4 to 33.9,181
HPV,"≥3 Doses, Males",States/Local Areas,IL-City of Chicago,2015,Age,13-15 Years,37.5,27.0 to 49.4,91
≥2 Doses Hep A,,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,91.5,82.2 to 96.1,144
≥2 Doses Hep A,,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,87.1,80.4 to 91.8,256
≥2 Doses Hep A,,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,79.7,71.9 to 85.8,271
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,28.4,20.5 to 38.0,175
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,15.6,11.1 to 21.4,199
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,11.2,6.5 to 18.6,173
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,37.8,27.8 to 49.1,143
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,52.6,41.9 to 63.0,141
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,38.6,27.4 to 51.2,94
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,79.4,74.0 to 83.8,407
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,76.6,70.5 to 81.8,366
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,83.8,77.5 to 88.6,287
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,91.2,84.7 to 95.0,209
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,71.4,65.2 to 76.8,389
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,71.8,65.6 to 77.3,343
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,85.4,72.8 to 92.7,98
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,84.9,74.4 to 91.6,95
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,89.9,84.1 to 93.8,241
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,96.6,88.2 to 99.1,135
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,79.7,66.0 to 88.8,76
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2008,Age,13-15 Years,45.9,37.9 to 54.0,221
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2009,Age,13-15 Years,60.0,51.9 to 67.6,239
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,80.7,65.1 to 90.3,74
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,93.9,88.5 to 96.8,241
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,91.9,85.7 to 95.6,256
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,93.6,83.6 to 97.7,144
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,91.6,85.2 to 95.3,271
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,40.2,30.3 to 50.9,144
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,68.9,60.1 to 76.6,204
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,61.9,51.9 to 71.1,157
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,82.9,68.8 to 91.4,94
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,36.2,28.8 to 44.2,199
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,81.5,68.5 to 89.9,86
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,81.2,69.0 to 89.4,119
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,86.8,70.0 to 94.9,72
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,85.9,76.2 to 92.1,142
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,67.3,57.2 to 76.1,192
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,79.2,62.0 to 89.9,72
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,86.7,76.9 to 92.8,129
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,78.8,66.1 to 87.6,109
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,64.9,54.4 to 74.2,133
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,50.0,38.5 to 61.5,115
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,68.1,58.5 to 76.3,136
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,66.8,52.0 to 79.0,81
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,65.9,55.1 to 75.2,160
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,98.2,94.9 to 99.4,170
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,85.0,77.1 to 90.5,204
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,92.8,86.7 to 96.2,160
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,91.9,84.4 to 96.0,192
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,78.1,69.0 to 85.2,141
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,70.8,62.0 to 78.3,147
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,61.4,50.6 to 71.2,143
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,61.8,48.5 to 73.5,94
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,93.2,83.0 to 97.5,135
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,89.7,82.0 to 94.4,248
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,88.0,80.0 to 93.1,153
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,91.5,83.6 to 95.7,248
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,91.9,83.7 to 96.2,170
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,94.9,89.3 to 97.7,153
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,93.0,86.7 to 96.5,232
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,91.3,83.3 to 95.6,165
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,93.8,89.5 to 96.4,246
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,96.0,90.1 to 98.5,131
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,50.6,41.5 to 59.7,175
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,47.0,37.8 to 56.5,181
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,86.0,77.7 to 91.5,178
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,85.4,78.4 to 90.4,232
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,90.8,82.9 to 95.3,178
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,88.7,83.5 to 92.4,246
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,89.4,81.2 to 94.3,131
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,91.6,87.0 to 94.7,283
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,93.6,87.6 to 96.8,157
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,72.2,63.3 to 79.6,216
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,79.4,70.0 to 86.5,165
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,28.6,20.8 to 37.9,173
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,93.8,89.3 to 96.5,287
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,89.0,82.8 to 93.2,274
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,92.9,86.7 to 96.4,209
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,79.3,70.8 to 85.8,145
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,66.2,58.6 to 73.1,272
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,62.4,54.0 to 70.1,200
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2021,Age,13-15 Years,96.7,82.7 to 99.5,88
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2020,Age,13-15 Years,89.4,78.7 to 95.1,159
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,88.7,81.4 to 93.4,216
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,86.6,80.4 to 91.1,272
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,19.8,13.6 to 27.8,145
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,39.7,32.1 to 47.8,211
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,80.3,71.7 to 86.7,211
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,86.4,79.7 to 91.2,200
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2022,Age,13-15 Years,90.5,83.2 to 94.8,150
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,90.6,86.2 to 93.7,407
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2019,Age,13-15 Years,87.5,76.4 to 93.8,96
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2009,Age,13-15 Years,42.4,32.8 to 52.7,142
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2015,Age,13-15 Years,88.5,82.2 to 92.8,162
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2014,Age,13-15 Years,86.2,77.9 to 91.8,158
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2013,Age,13-15 Years,87.8,78.4 to 93.4,126
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,27.8,18.9 to 38.9,144
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,44.3,34.0 to 55.2,133
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,29.1,19.8 to 40.5,115
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,65.4,50.5 to 77.8,98
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,65.3,49.6 to 78.2,74
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2010,Age,13-15 Years,69.2,61.4 to 76.0,226
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2009,Age,13-15 Years,57.1,48.9 to 64.8,239
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2021,Age,13-15 Years,93.7,83.0 to 97.8,94
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,62.1,52.8 to 70.6,147
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,73.2,61.5 to 82.3,95
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,69.2,55.4 to 80.3,76
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2008,Age,13-15 Years,48.6,40.6 to 56.7,221
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,44.5,33.9 to 55.5,143
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,49.2,36.8 to 61.8,94
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,83.0,75.4 to 88.6,256
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,82.9,71.6 to 90.4,144
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,86.3,79.9 to 91.0,271
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,92.1,86.8 to 95.3,256
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,92.7,83.5 to 96.9,144
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,81.1,71.5 to 88.0,160
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,94.0,89.0 to 96.9,271
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,92.1,83.3 to 96.4,160
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,36.7,28.2 to 46.1,181
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,41.0,32.2 to 50.4,175
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,27.4,21.0 to 34.8,199
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2020,Age,13-15 Years,89.7,81.5 to 94.5,171
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,68.8,58.6 to 77.4,141
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018,Age,13-15 Years,91.4,82.4 to 96.1,118
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,95.8,89.4 to 98.4,192
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2019,Age,13-15 Years,94.0,85.9 to 97.6,100
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,81.9,73.9 to 87.8,204
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,73.1,63.2 to 81.2,157
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2013,Age,13-15 Years,79.6,69.4 to 87.0,126
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2012,Age,13-15 Years,77.4,69.0 to 84.0,183
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,87.9,81.5 to 92.3,274
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,90.4,85.6 to 93.8,283
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,93.7,88.4 to 96.7,204
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,94.6,89.4 to 97.3,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,84.1,75.3 to 90.2,192
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,20.5,14.1 to 28.8,173
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2015,Age,13-15 Years,81.0,73.6 to 86.7,185
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2014,Age,13-15 Years,83.9,75.3 to 89.9,175
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,84.7,74.4 to 91.3,137
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2010,Age,13-15 Years,66.9,59.0 to 73.9,226
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2011,Age,13-15 Years,70.5,62.4 to 77.4,250
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2016,Age,13-15 Years,86.7,77.2 to 92.6,104
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2017,Age,13-15 Years,90.3,79.4 to 95.7,120
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,58.7,52.5 to 64.7,389
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,69.5,63.2 to 75.1,366
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,69.8,63.9 to 75.1,407
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,44.2,38.0 to 50.5,343
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2022,Age,13-15 Years,91.0,84.6 to 94.9,161
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,92.0,88.3 to 94.7,407
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,88.8,83.9 to 92.3,366
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,66.4,51.4 to 78.8,86
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,84.6,79.1 to 88.8,389
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,83.4,78.3 to 87.5,343
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,84.6,77.9 to 89.6,274
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,89.7,83.3 to 93.9,209
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018,Age,13-15 Years,93.0,82.6 to 97.4,118
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2011,Age,13-15 Years,68.1,60.3 to 75.0,250
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2012,Age,13-15 Years,77.8,69.2 to 84.5,183
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,78.5,71.8 to 84.0,287
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,64.2,53.6 to 73.6,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,65.0,54.8 to 73.9,192
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,66.6,57.7 to 74.4,204
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2019,Age,13-15 Years,94.9,87.6 to 98.0,100
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2020,Age,13-15 Years,87.9,78.9 to 93.5,171
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2021,Age,13-15 Years,88.8,75.6 to 95.3,94
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,69.2,55.0 to 80.6,94
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,64.7,51.5 to 76.0,109
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,54.9,40.6 to 68.4,81
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,53.9,44.1 to 63.4,136
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2016,Age,13-15 Years,85.2,74.2 to 92.1,104
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2017,Age,13-15 Years,93.9,87.4 to 97.1,120
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2015,Age,13-15 Years,85.9,78.6 to 91.0,185
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2014,Age,13-15 Years,84.0,75.4 to 90.0,175
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,55.7,45.6 to 65.3,157
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,69.2,60.9 to 76.4,256
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,70.4,59.0 to 79.7,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,72.3,64.2 to 79.1,271
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,87.2,81.7 to 91.1,283
HPV,"≥2 Doses, Males",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,68.9,57.3 to 78.4,137
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,69.5,61.1 to 76.7,256
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,77.0,70.3 to 82.6,287
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2022,Age,13-15 Years,91.5,85.2 to 95.3,161
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,84.2,75.2 to 90.3,157
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2009,Age,13-17 Years,58.4,52.2 to 64.3,389
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2008,Age,13-17 Years,41.1,35.1 to 47.5,343
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,72.2,66.1 to 77.5,407
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,63.8,57.4 to 69.8,366
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,90.4,82.0 to 95.2,160
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,90.5,84.9 to 94.2,204
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,93.0,85.5 to 96.8,192
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,83.4,76.6 to 88.5,274
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,83.3,76.1 to 88.7,209
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,82.8,77.1 to 87.3,283
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,91.1,84.6 to 95.0,157
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,14.0,9.8 to 19.7,407
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,27.4,20.8 to 35.1,287
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,88.4,82.7 to 92.4,287
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,88.8,82.3 to 93.2,209
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,90.1,84.1 to 94.0,274
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,91.6,87.1 to 94.6,283
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,86.2,78.4 to 91.5,204
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,92.6,86.6 to 96.0,157
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,90.0,80.3 to 95.2,144
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,89.7,83.4 to 93.8,271
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,92.9,86.0 to 96.5,160
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,93.7,88.2 to 96.7,192
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,92.1,86.5 to 95.5,256
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,92.2,82.2 to 96.8,144
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,89.1,82.6 to 93.4,256
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2009,Age,13-15 Years,15.4,9.4 to 24.2,114
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2010,Age,13-15 Years,27.6,18.0 to 39.7,113
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2011,Age,13-15 Years,25.1,15.5 to 38.1,111
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2012,Age,13-15 Years,38.7,26.3 to 52.8,97
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,90.5,85.2 to 94.1,256
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,88.9,79.7 to 94.3,144
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,88.2,81.4 to 92.8,271
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,90.9,83.4 to 95.2,204
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,92.0,85.2 to 95.8,160
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,94.9,89.1 to 97.6,192
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,39.1,32.0 to 46.7,274
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,44.6,37.9 to 51.5,283
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,91.6,85.4 to 95.3,271
HPV,"≥2 Doses, Females",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,70.1,57.6 to 80.2,119
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2015,Age,13-15 Years,42.6,31.0 to 55.0,94
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2014,Age,13-15 Years,42.8,30.0 to 56.6,88
HPV,"≥3 Doses, Females",States/Local Areas,IL-City of Chicago,2013,Age,13-15 Years,35.6,22.5 to 51.2,60
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Any Medicaid,88.4,83.8 to 91.9,496
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Private Insurance Only,93.4,89.6 to 95.9,470
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Any Medicaid,68.8,62.9 to 74.1,496
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Private Insurance Only,69.0,62.3 to 75.0,470
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Any Medicaid,83.9,78.8 to 88.0,496
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Private Insurance Only,82.6,76.5 to 87.4,470
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Any Medicaid,87.7,83.1 to 91.2,496
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Living At or Above Poverty Level,91.5,87.6 to 94.2,667
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Insurance Coverage,Private Insurance Only,95.9,93.2 to 97.6,470
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Living At or Above Poverty Level,70.0,64.6 to 74.9,667
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Below Poverty Level,88.4,82.9 to 92.3,313
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Below Poverty Level,71.2,63.8 to 77.6,313
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Below Poverty Level,84.1,77.4 to 89.0,313
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Living At or Above Poverty Level,94.6,91.6 to 96.5,667
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Living At or Above Poverty Level,84.2,79.5 to 88.0,667
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Poverty,Below Poverty Level,84.0,77.7 to 88.8,313
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,Hispanic,87.1,82.1 to 90.9,460
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",78.8,71.2 to 84.9,218
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"White, Non-Hispanic",81.2,71.4 to 88.2,261
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.7,86.2 to 98.1,84
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",85.4,78.3 to 90.5,218
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,Hispanic,91.2,87.5 to 93.9,460
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,Hispanic,90.1,85.7 to 93.2,460
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",88.3,82.2 to 92.5,218
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"White, Non-Hispanic",97.1,93.9 to 98.7,261
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"White, Non-Hispanic",96.2,92.5 to 98.1,261
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",77.5,62.7 to 87.6,84
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",61.4,53.0 to 69.2,218
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,Hispanic,71.6,65.6 to 76.9,460
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",98.3,93.4 to 99.6,84
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.1,77.9 to 95.9,84
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Urbanicity,Living In a MSA Principal City,90.2,87.3 to 92.5,1023
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.3,60.8 to 78.4,261
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Urbanicity,Living In a MSA Principal City,91.0,88.3 to 93.2,1023
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Urbanicity,Living In a MSA Principal City,68.2,64.0 to 72.2,1023
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Urbanicity,Living In a MSA Principal City,83.5,79.9 to 86.6,1023
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Overall,Overall,83.5,79.9 to 86.6,1023
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2018-2022,Overall,Overall,68.2,64.0 to 72.2,1023
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,88.3,81.2 to 93.0,204
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,87.4,80.3 to 92.2,204
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,90.0,82.8 to 94.4,204
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,88.5,81.4 to 93.1,204
HPV,"≥1 Dose, Females",States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,91.4,83.6 to 95.7,108
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,74.6,65.8 to 81.8,204
≥2 Doses MMR,,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,86.6,79.6 to 91.5,204
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,70.9,57.2 to 81.6,96
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,82.2,73.5 to 88.4,204
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,91.9,85.4 to 95.7,193
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,81.0,71.9 to 87.6,193
≥3 Doses HepB,,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,86.1,78.5 to 91.3,204
≥2 Doses Hep A,,States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,78.9,70.1 to 85.6,204
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2023,Age,13-15 Years,88.1,79.3 to 93.4,134
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2023,Age,13-15 Years,91.3,82.0 to 96.0,134
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2023,Age,13-15 Years,75.6,65.0 to 83.8,134
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2023,Age,13-15 Years,76.7,60.4 to 87.7,60
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-City of Chicago,2023,Age,13-15 Years,84.9,73.8 to 91.9,128
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,78.4,66.6 to 86.8,108
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2023,Age,13-15 Years,74.7,59.8 to 85.4,74
HPV,"≥1 Dose, Males",States/Local Areas,IL-City of Chicago,2023,Age,13-17 Years,85.6,72.9 to 92.9,96
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-City of Chicago,2018-2022,Overall,Overall,90.2,87.3 to 92.5,1023
≥1 Dose MenACWY,,States/Local Areas,IL-City of Chicago,2018-2022,Overall,Overall,91.0,88.3 to 93.2,1023
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2014,Age,13-15 Years,75.4,68.5 to 81.1,289
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2015,Age,13-15 Years,76.4,70.2 to 81.7,316
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,97.1,93.5 to 98.7,350
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,57.4,49.4 to 65.0,215
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,66.0,58.2 to 73.0,217
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,97.1,94.9 to 98.4,413
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,94.1,90.3 to 96.5,350
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2017,Age,13-15 Years,88.7,83.3 to 92.5,283
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2016,Age,13-15 Years,79.9,73.2 to 85.3,258
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,70.6,63.7 to 76.7,261
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,94.7,91.4 to 96.8,428
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,96.7,94.5 to 98.0,434
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,94.7,90.8 to 97.0,374
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,72.5,64.8 to 79.1,238
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,76.0,68.6 to 82.2,224
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,62.3,55.2 to 68.8,268
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,20.5,12.6 to 31.4,180
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,69.2,61.6 to 75.9,242
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,55.4,50.3 to 60.3,529
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,75.0,66.0 to 82.3,190
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,74.2,66.0 to 81.0,210
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,81.6,73.2 to 87.8,175
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,52.0,46.7 to 57.3,479
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,50.9,45.3 to 56.4,448
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,56.9,49.2 to 64.4,231
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,39.1,32.0 to 46.7,242
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,31.4,23.3 to 40.8,175
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,40.0,32.7 to 47.8,227
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,67.7,60.9 to 73.9,264
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,56.9,51.1 to 62.4,442
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,94.0,89.1 to 96.8,440
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,97.0,94.3 to 98.4,373
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,95.5,92.2 to 97.5,365
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,95.7,92.9 to 97.4,441
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2022,Age,13-15 Years,92.5,86.4 to 96.0,210
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,49.8,41.6 to 58.1,187
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,63.1,55.4 to 70.3,274
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,72.6,61.0 to 81.8,163
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,87.4,80.5 to 92.1,187
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,82.7,74.1 to 88.9,140
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,42.2,33.2 to 51.8,140
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,28.4,20.0 to 38.7,163
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,93.0,88.6 to 95.7,274
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,88.3,80.2 to 93.4,223
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,26.6,19.2 to 35.6,200
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,80.0,73.2 to 85.5,242
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,60.9,51.6 to 69.4,223
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,96.1,93.7 to 97.6,479
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,33.8,26.2 to 42.4,166
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,96.4,93.3 to 98.1,349
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,95.2,92.0 to 97.2,435
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,89.9,83.6 to 93.9,345
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,96.3,93.3 to 98.0,442
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,95.0,92.5 to 96.7,529
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,93.3,89.0 to 96.0,391
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,94.9,91.4 to 97.0,394
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,94.2,90.8 to 96.4,413
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,94.1,91.1 to 96.1,466
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,96.7,93.5 to 98.4,394
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,97.3,93.7 to 98.9,391
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,96.4,93.9 to 97.9,466
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,95.7,93.4 to 97.3,448
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,93.4,90.5 to 95.5,496
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,96.7,93.8 to 98.3,366
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,95.6,92.4 to 97.5,399
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,96.1,92.2 to 98.1,242
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,95.2,91.5 to 97.3,344
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2020,Age,13-15 Years,95.6,91.9 to 97.7,232
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2021,Age,13-15 Years,95.7,91.5 to 97.8,251
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2011,Age,13-15 Years,64.6,55.3 to 73.0,182
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2010,Age,13-15 Years,51.7,42.0 to 61.3,138
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2012,Age,13-15 Years,67.0,55.4 to 76.8,147
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2013,Age,13-15 Years,84.4,76.8 to 89.9,160
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,94.7,92.1 to 96.5,427
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,52.7,43.7 to 61.5,223
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,36.8,29.4 to 44.9,187
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,98.4,96.9 to 99.2,427
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,81.7,76.1 to 86.3,344
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,92.7,89.3 to 95.1,366
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,84.0,79.3 to 87.8,399
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,51.2,42.3 to 60.0,174
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,36.2,26.8 to 46.7,165
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,60.0,52.9 to 66.8,254
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,61.2,53.3 to 68.6,208
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2019,Age,13-15 Years,92.8,87.6 to 95.9,256
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2014,Age,13-15 Years,82.3,75.3 to 87.6,240
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2015,Age,13-15 Years,84.2,78.0 to 88.8,272
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2009,Age,13-15 Years,42.7,32.3 to 53.8,104
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2018,Age,13-15 Years,95.2,91.3 to 97.4,303
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2016,Age,13-15 Years,94.1,89.6 to 96.7,215
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2017,Age,13-15 Years,93.8,89.9 to 96.2,260
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,86.7,81.8 to 90.4,349
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,85.9,81.4 to 89.5,435
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,76.8,71.3 to 81.5,441
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,75.9,69.0 to 81.7,345
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,95.2,91.9 to 97.2,428
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,94.6,91.4 to 96.6,434
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,94.6,91.0 to 96.8,374
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2008,Age,13-15 Years,35.1,23.8 to 48.3,109
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,74.7,69.2 to 79.6,373
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,78.9,73.8 to 83.3,365
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,94.2,90.4 to 96.5,442
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,75.8,69.6 to 81.0,440
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,94.8,92.2 to 96.6,529
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,94.1,91.2 to 96.0,448
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,95.3,93.0 to 96.9,479
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,86.9,82.9 to 90.1,496
HPV,"≥3 Doses, Males",States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,15.8,9.6 to 24.9,175
HPV,"≥3 Doses, Males",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,23.6,17.7 to 30.6,242
HPV,"≥3 Doses, Males",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,21.8,15.9 to 29.2,227
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,52.5,44.7 to 60.2,242
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,60.4,52.0 to 68.1,238
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,47.9,40.8 to 55.0,268
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2018,Age,13-15 Years,50.4,41.4 to 59.4,163
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,62.3,53.7 to 70.1,210
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,66.6,57.5 to 74.6,175
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,62.1,52.9 to 70.5,190
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2022,Age,13-15 Years,67.0,58.7 to 74.4,222
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2019,Age,13-15 Years,47.7,40.5 to 54.9,282
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,63.3,54.2 to 71.6,199
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2021,Age,13-15 Years,57.4,49.8 to 64.6,261
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2020,Age,13-15 Years,55.6,47.4 to 63.5,249
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2019,Age,13-15 Years,45.9,36.3 to 55.8,156
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,58.6,50.3 to 66.4,224
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,50.1,43.0 to 57.2,264
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2020,Age,13-15 Years,57.9,46.8 to 68.2,142
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,42.6,35.2 to 50.3,231
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2021,Age,13-15 Years,56.5,45.7 to 66.7,132
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2022,Age,13-15 Years,66.5,54.5 to 76.8,122
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,43.6,36.1 to 51.4,215
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2021,Age,13-15 Years,58.2,47.7 to 68.1,129
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2022,Age,13-15 Years,67.6,55.7 to 77.6,100
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,49.8,41.8 to 57.7,217
Varicella,History of disease,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,33.2,27.3 to 39.7,349
Varicella,History of disease,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,38.5,31.6 to 45.9,345
Varicella,History of disease,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,49.6,43.7 to 55.5,373
Varicella,History of disease,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,37.0,31.1 to 43.4,441
Varicella,History of disease,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,18.0,14.4 to 22.1,496
Varicella,History of disease,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,23.0,18.5 to 28.2,435
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,53.4,45.0 to 61.5,200
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,54.3,47.1 to 61.2,261
Varicella,History of disease,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,11.1,8.2 to 15.1,479
Varicella,History of disease,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,12.6,9.6 to 16.4,529
Varicella,History of disease,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,18.8,14.6 to 23.8,448
Varicella,History of disease,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,66.2,59.6 to 72.1,440
Varicella,History of disease,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,63.5,57.7 to 69.0,365
Varicella,History of disease,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,12.9,9.4 to 17.4,442
Varicella,History of disease,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,5.5,3.5 to 8.4,428
Varicella,History of disease,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,6.0,3.5 to 9.8,434
Varicella,History of disease,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,7.3,4.4 to 12.0,374
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2019,Age,13-15 Years,49.5,39.1 to 60.0,126
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2020,Age,13-15 Years,53.1,41.1 to 64.7,107
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2018,Age,13-15 Years,52.7,43.9 to 61.4,171
HPV,"≥3 Doses, Males",States/Local Areas,IL-Rest of state,2015,Age,13-15 Years,20.0,13.8 to 28.1,149
HPV,"≥3 Doses, Males",States/Local Areas,IL-Rest of state,2014,Age,13-15 Years,21.3,14.1 to 30.7,152
≥2 Doses Hep A,,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,76.6,71.3 to 81.1,428
≥2 Doses Hep A,,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,82.7,77.2 to 87.0,374
≥2 Doses Hep A,,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,79.0,73.6 to 83.5,434
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,36.2,27.3 to 46.1,223
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,13.3,8.2 to 20.9,200
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,25.4,18.7 to 33.6,166
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,38.6,31.9 to 45.8,254
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,32.6,24.7 to 41.6,174
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,46.5,38.5 to 54.7,208
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,16.9,10.8 to 25.4,165
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,25.3,19.0 to 32.9,187
Varicella,History of disease,HHS Regions/National,Region 8,2008,Age,13-17 Years,65.7,61.9 to 69.3,1854
Varicella,History of disease,HHS Regions/National,Region 8,2014,Age,13-17 Years,25.4,22.6 to 28.5,2290
Varicella,History of disease,HHS Regions/National,Region 8,2009,Age,13-17 Years,59.7,56.3 to 63.0,1974
Varicella,History of disease,HHS Regions/National,Region 8,2006,Age,13-17 Years,75.3,63.3 to 84.4,118
Varicella,History of disease,HHS Regions/National,Region 8,2011,Age,13-17 Years,43.6,39.6 to 47.6,2242
Varicella,History of disease,HHS Regions/National,Region 8,2010,Age,13-17 Years,48.6,45.1 to 52.1,1890
Varicella,History of disease,HHS Regions/National,Region 8,2013,Age,13-17 Years,28.6,25.7 to 31.7,1913
Varicella,History of disease,HHS Regions/National,Region 8,2012,Age,13-17 Years,33.9,30.0 to 38.1,1936
Varicella,History of disease,HHS Regions/National,Region 8,2018,Age,13-17 Years,11.9,9.4 to 14.8,1746
Varicella,History of disease,HHS Regions/National,Region 8,2007,Age,13-17 Years,67.7,54.8 to 78.3,112
Varicella,History of disease,HHS Regions/National,Region 8,2016,Age,13-17 Years,15.7,13.4 to 18.4,2022
Varicella,History of disease,HHS Regions/National,Region 8,2015,Age,13-17 Years,20.3,17.8 to 23.2,2120
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2018,Age,13-15 Years,50.1,42.5 to 57.7,520
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2020,Age,13-15 Years,60.0,53.0 to 66.6,576
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2019,Age,13-15 Years,58.4,50.7 to 65.7,507
Varicella,History of disease,HHS Regions/National,Region 8,2017,Age,13-17 Years,14.1,11.7 to 16.7,2108
Varicella,History of disease,HHS Regions/National,Region 8,2022,Age,13-17 Years,7.5,5.7 to 9.7,1736
Varicella,History of disease,HHS Regions/National,Region 8,2021,Age,13-17 Years,9.2,7.0 to 12.1,1789
Varicella,History of disease,HHS Regions/National,Region 8,2019,Age,13-17 Years,10.6,8.2 to 13.7,1845
Varicella,History of disease,HHS Regions/National,Region 8,2020,Age,13-17 Years,9.4,7.4 to 11.9,2007
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2021,Age,13-17 Years,65.0,59.7 to 70.0,949
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2016,Age,13-17 Years,33.5,28.6 to 38.7,1069
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2020,Age,13-15 Years,55.8,50.9 to 60.5,1211
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2021,Age,13-15 Years,60.4,55.3 to 65.4,1112
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2022,Age,13-17 Years,58.3,53.3 to 63.2,902
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2019,Age,13-15 Years,54.6,49.1 to 59.9,1129
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2020,Age,13-15 Years,51.9,45.2 to 58.5,635
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2019,Age,13-15 Years,51.1,43.5 to 58.6,622
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2022,Age,13-15 Years,60.3,55.6 to 64.8,1085
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2020,Age,13-17 Years,54.2,49.0 to 59.3,1050
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2019,Age,13-17 Years,51.7,45.8 to 57.5,1005
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2017,Age,13-17 Years,45.0,40.2 to 49.9,1126
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2018,Age,13-17 Years,52.3,46.8 to 57.7,901
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2020,Age,13-17 Years,62.6,57.3 to 67.6,957
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2022,Age,13-15 Years,55.5,49.1 to 61.8,584
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2021,Age,13-15 Years,58.7,51.6 to 65.5,585
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2022,Age,13-17 Years,65.5,60.3 to 70.4,834
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2021,Age,13-17 Years,65.0,59.2 to 70.3,840
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2018,Age,13-15 Years,51.8,44.6 to 59.0,538
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2016,Age,13-17 Years,48.1,42.6 to 53.7,953
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2018,Age,13-15 Years,48.6,42.0 to 55.3,345
Varicella,History of disease,HHS Regions/National,Region 7,2020,Age,13-17 Years,10.3,8.3 to 12.6,1446
Varicella,History of disease,HHS Regions/National,Region 7,2019,Age,13-17 Years,9.8,7.8 to 12.2,1256
Varicella,History of disease,HHS Regions/National,Region 7,2021,Age,13-17 Years,7.1,5.4 to 9.4,1154
Varicella,History of disease,HHS Regions/National,Region 7,2022,Age,13-17 Years,6.4,4.8 to 8.5,1048
Varicella,History of disease,HHS Regions/National,Region 7,2017,Age,13-17 Years,14.2,12.0 to 16.6,1340
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2019,Age,13-15 Years,58.2,51.4 to 64.7,386
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2020,Age,13-15 Years,54.1,47.4 to 60.8,407
Varicella,History of disease,HHS Regions/National,Region 7,2015,Age,13-17 Years,19.9,17.1 to 23.1,1451
Varicella,History of disease,HHS Regions/National,Region 7,2016,Age,13-17 Years,18.3,15.9 to 21.0,1394
Varicella,History of disease,HHS Regions/National,Region 7,2007,Age,13-17 Years,77.5,68.4 to 84.6,165
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2016,Age,13-17 Years,43.7,38.8 to 48.7,664
Varicella,History of disease,HHS Regions/National,Region 7,2012,Age,13-17 Years,38.3,34.4 to 42.4,1285
Varicella,History of disease,HHS Regions/National,Region 7,2013,Age,13-17 Years,31.2,27.8 to 34.8,1251
Varicella,History of disease,HHS Regions/National,Region 7,2010,Age,13-17 Years,50.1,46.8 to 53.3,1291
Varicella,History of disease,HHS Regions/National,Region 7,2011,Age,13-17 Years,46.4,42.8 to 50.0,1528
Varicella,History of disease,HHS Regions/National,Region 7,2009,Age,13-17 Years,62.9,59.6 to 66.0,1250
Varicella,History of disease,HHS Regions/National,Region 7,2006,Age,13-17 Years,74.6,65.6 to 82.0,165
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2007,Age,13-17 Years,34.5,26.3 to 43.6,165
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2018,Age,13-17 Years,47.6,44.0 to 51.2,1191
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2017,Age,13-17 Years,44.2,40.9 to 47.6,1340
Varicella,History of disease,HHS Regions/National,Region 7,2018,Age,13-17 Years,13.3,10.9 to 16.1,1191
Varicella,History of disease,HHS Regions/National,Region 7,2014,Age,13-17 Years,27.1,23.9 to 30.5,1362
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2012,Age,13-17 Years,85.8,82.9 to 88.3,1285
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2013,Age,13-17 Years,82.4,79.3 to 85.1,1251
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2014,Age,13-17 Years,82.1,79.1 to 84.8,1362
Varicella,History of disease,HHS Regions/National,Region 7,2008,Age,13-17 Years,67.5,64.1 to 70.7,1295
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2006,Age,13-17 Years,13.7,8.8 to 20.7,165
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2016,Age,13-17 Years,39.3,36.0 to 42.8,1394
≥2 Doses MMR,,HHS Regions/National,Region 7,2007,Age,13-17 Years,85.1,76.5 to 91.0,165
≥2 Doses MMR,,HHS Regions/National,Region 7,2006,Age,13-17 Years,87.1,80.2 to 91.8,165
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2010,Age,13-17 Years,68.5,65.2 to 71.6,1291
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2009,Age,13-17 Years,59.9,56.6 to 63.2,1250
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2011,Age,13-17 Years,78.7,75.6 to 81.5,1528
≥2 Doses MMR,,HHS Regions/National,Region 7,2008,Age,13-17 Years,85.3,82.5 to 87.6,1295
≥2 Doses MMR,,HHS Regions/National,Region 7,2009,Age,13-17 Years,86.6,83.9 to 88.9,1250
≥2 Doses MMR,,HHS Regions/National,Region 7,2010,Age,13-17 Years,88.3,85.9 to 90.3,1291
≥2 Doses MMR,,HHS Regions/National,Region 7,2011,Age,13-17 Years,87.5,84.4 to 90.0,1528
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2008,Age,13-17 Years,44.3,40.9 to 47.7,1295
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2022,Age,13-15 Years,90.3,86.9 to 93.0,654
HPV,"≥2 Doses, Males",HHS Regions/National,Region 7,2019,Age,13-17 Years,57.6,52.2 to 62.9,648
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2021,Age,13-17 Years,62.2,58.3 to 66.0,1154
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2022,Age,13-17 Years,64.2,60.3 to 67.9,1048
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2019,Age,13-17 Years,55.6,51.7 to 59.5,1256
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 7,2015,Age,13-17 Years,86.3,83.5 to 88.6,1451
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2020,Age,13-17 Years,56.6,53.0 to 60.1,1446
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2017,Age,13-17 Years,50.5,45.6 to 55.4,624
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2018,Age,13-15 Years,41.8,35.7 to 48.3,381
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2021,Age,13-17 Years,66.2,60.5 to 71.4,535
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2022,Age,13-17 Years,64.7,59.2 to 69.9,503
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2021,Age,13-15 Years,66.1,59.0 to 72.5,333
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2022,Age,13-15 Years,60.4,53.4 to 66.9,326
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2022,Age,13-15 Years,61.4,56.4 to 66.1,654
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2021,Age,13-15 Years,53.8,46.8 to 60.5,382
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2022,Age,13-15 Years,62.5,55.4 to 69.1,328
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2019,Age,13-15 Years,51.1,44.3 to 58.0,413
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2020,Age,13-15 Years,50.2,44.1 to 56.3,487
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2021,Age,13-17 Years,58.5,53.0 to 63.7,619
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2019,Age,13-15 Years,54.7,49.8 to 59.5,799
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2022,Age,13-17 Years,63.6,58.0 to 68.9,545
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2021,Age,13-15 Years,59.9,54.9 to 64.7,715
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 7,2020,Age,13-15 Years,52.1,47.5 to 56.6,894
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2018,Age,13-17 Years,42.5,37.7 to 47.5,643
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2017,Age,13-17 Years,38.2,33.7 to 42.9,716
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2019,Age,13-17 Years,55.8,50.4 to 61.1,648
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2020,Age,13-17 Years,53.7,48.9 to 58.5,795
HPV,"Up-to-Date, Males",HHS Regions/National,Region 7,2016,Age,13-17 Years,35.2,30.6 to 40.0,730
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2020,Age,13-17 Years,59.7,54.4 to 64.8,651
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2018,Age,13-17 Years,52.9,47.7 to 58.1,548
HPV,"Up-to-Date, Females",HHS Regions/National,Region 7,2019,Age,13-17 Years,55.5,49.9 to 61.0,608
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,76.6,69.2 to 82.7,267
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,76.1,66.2 to 83.8,151
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,77.2,65.5 to 85.8,116
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,92.3,87.6 to 95.3,240
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,76.1,68.0 to 82.8,227
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2023,Age,13-15 Years,76.3,67.3 to 83.4,142
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2023,Age,13-15 Years,95.1,91.0 to 97.4,266
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2023,Age,13-15 Years,68.2,56.8 to 77.8,135
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2023,Age,13-15 Years,72.4,65.2 to 78.6,277
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2023,Age,13-15 Years,94.2,90.3 to 96.5,277
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2023,Age,13-15 Years,94.4,90.4 to 96.8,277
≥2 Doses Hep A,,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,93.3,89.5 to 95.8,467
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,2.9,1.6 to 5.3,467
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,95.7,93.1 to 97.3,452
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,95.8,93.3 to 97.4,467
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,97.7,96.1 to 98.6,452
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,80.1,73.5 to 85.3,240
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,97.4,95.8 to 98.3,467
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,93.1,89.3 to 95.6,467
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,78.1,73.0 to 82.5,467
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,88.6,81.3 to 93.3,227
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,90.5,86.4 to 93.4,467
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,95.5,92.9 to 97.2,467
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,94.2,91.2 to 96.2,467
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2023,Age,13-17 Years,93.8,90.8 to 95.8,467
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Urbanicity,Living In a MSA Principal City,91.1,88.9 to 92.8,1339
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",76.1,70.5 to 80.9,394
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",96.4,91.9 to 98.4,165
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,Hispanic,88.0,81.9 to 92.2,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.0,83.5 to 94.1,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",76.6,72.0 to 80.7,490
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",72.7,63.2 to 80.5,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,Hispanic,70.4,63.0 to 76.8,290
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",92.2,88.7 to 94.6,490
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.2,89.4 to 95.7,394
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.1,86.7 to 94.1,394
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.4,86.8 to 93.1,490
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,Hispanic,93.8,89.1 to 96.5,290
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",93.4,87.8 to 96.5,165
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,Hispanic,91.4,86.2 to 94.8,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",87.3,82.8 to 90.7,394
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.1,85.3 to 92.0,490
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Living At or Above Poverty Level,88.5,85.6 to 90.9,916
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Below Poverty Level,89.3,84.7 to 92.7,361
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Below Poverty Level,93.8,90.1 to 96.1,361
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Living At or Above Poverty Level,92.9,90.2 to 94.9,916
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Below Poverty Level,74.6,68.7 to 79.7,361
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Living At or Above Poverty Level,75.6,71.8 to 79.0,916
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Below Poverty Level,91.7,87.7 to 94.5,361
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Any Medicaid,92.1,88.9 to 94.5,606
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Poverty,Living At or Above Poverty Level,91.4,88.7 to 93.5,916
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Private Insurance Only,93.7,90.2 to 95.9,532
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Private Insurance Only,88.6,84.4 to 91.7,532
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Any Medicaid,87.8,84.1 to 90.8,606
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Other,96.5,92.6 to 98.3,143
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Uninsured,93.8,86.9 to 97.2,58
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Other,89.8,83.4 to 93.9,143
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Uninsured,92.7,77.9 to 97.9,58
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Private Insurance Only,78.8,74.1 to 83.0,532
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Any Medicaid,73.1,68.4 to 77.3,606
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Other,81.2,72.9 to 87.4,143
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Uninsured,46.7,31.1 to 63.0,58
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Private Insurance Only,89.9,86.0 to 92.8,532
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Any Medicaid,90.4,87.1 to 92.9,606
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Uninsured,97.3,90.9 to 99.3,58
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Insurance Coverage,Other,95.2,87.5 to 98.2,143
Varicella,History of disease,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,7.6,5.0 to 11.4,485
Varicella,History of disease,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,5.5,3.4 to 8.6,599
Varicella,History of disease,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,9.1,5.9 to 13.9,502
Varicella,History of disease,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,7.1,4.2 to 11.7,492
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2018,Age,13-15 Years,64.6,52.0 to 75.4,119
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2020,Age,13-15 Years,52.9,40.9 to 64.6,156
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2019,Age,13-15 Years,53.3,42.0 to 64.3,150
Varicella,History of disease,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,23.7,18.8 to 29.5,393
Varicella,History of disease,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,22.9,17.8 to 28.8,444
Varicella,History of disease,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,35.7,30.2 to 41.5,371
Varicella,History of disease,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,27.3,22.3 to 32.9,493
Varicella,History of disease,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,16.1,12.2 to 21.0,442
Varicella,History of disease,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,42.2,35.3 to 49.4,255
Varicella,History of disease,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,8.5,5.0 to 14.0,412
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2021,Age,13-15 Years,91.7,86.5 to 94.9,346
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2020,Age,13-15 Years,92.8,86.2 to 96.4,280
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,98.1,95.6 to 99.2,382
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,97.7,95.0 to 98.9,466
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,98.6,96.4 to 99.5,439
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,97.0,93.7 to 98.6,466
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,96.0,92.7 to 97.9,382
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,92.0,88.2 to 94.7,571
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,94.5,90.4 to 97.0,466
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,96.7,94.1 to 98.1,466
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,93.5,90.1 to 95.8,526
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,93.8,90.2 to 96.2,492
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,95.5,92.3 to 97.4,489
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,97.8,94.3 to 99.2,303
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,93.8,89.3 to 96.5,371
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,96.1,92.2 to 98.1,255
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2022,Age,13-15 Years,94.1,89.4 to 96.8,284
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,95.9,91.1 to 98.1,238
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,97.9,94.4 to 99.2,141
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,48.2,39.9 to 56.5,179
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,67.6,57.6 to 76.3,141
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,98.1,95.8 to 99.2,357
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,95.6,91.4 to 97.8,337
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,81.0,74.6 to 86.1,238
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,85.7,79.5 to 90.2,357
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,90.4,84.4 to 94.3,303
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,45.2,36.8 to 53.9,168
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,52.4,41.6 to 62.9,114
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,95.3,91.6 to 97.4,393
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,93.9,89.7 to 96.5,493
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,93.1,88.4 to 96.0,444
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,94.8,91.1 to 97.0,442
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,61.7,55.5 to 67.6,492
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,63.0,55.1 to 70.2,270
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,73.4,65.3 to 80.2,249
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,54.9,46.8 to 62.8,286
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,52.8,44.8 to 60.6,270
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,42.7,34.3 to 51.5,224
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,45.4,36.8 to 54.3,219
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,18.8,13.1 to 26.2,222
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,65.1,54.4 to 74.5,213
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,77.3,70.6 to 82.8,322
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,79.4,70.4 to 86.1,233
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,55.4,49.6 to 61.0,526
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,55.5,49.6 to 61.2,489
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,74.2,66.1 to 80.9,223
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,7.2,4.1 to 12.3,246
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,75.6,68.3 to 81.6,277
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,75.7,66.8 to 82.9,269
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,91.6,87.4 to 94.5,452
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,77.3,69.2 to 83.8,243
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,56.6,49.0 to 63.8,412
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,94.0,90.4 to 96.3,571
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,97.1,94.8 to 98.4,452
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,95.0,92.3 to 96.8,485
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,92.2,88.6 to 94.8,599
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,95.1,90.7 to 97.4,502
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,74.5,65.0 to 82.1,199
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,74.7,67.1 to 81.0,262
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2014,Age,13-15 Years,97.3,93.9 to 98.8,265
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2015,Age,13-15 Years,95.1,91.8 to 97.1,292
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,69.9,62.1 to 76.7,240
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,67.1,58.3 to 74.9,219
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2016,Age,13-15 Years,93.6,89.0 to 96.3,312
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,37.1,29.2 to 45.8,168
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,94.4,91.3 to 96.4,492
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,94.6,91.1 to 96.8,442
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,95.3,92.4 to 97.2,526
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,90.7,86.2 to 93.9,489
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,62.3,56.6 to 67.6,526
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,65.0,59.2 to 70.4,489
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2012,Age,13-15 Years,88.5,82.1 to 92.8,242
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2013,Age,13-15 Years,88.7,81.9 to 93.2,276
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2017,Age,13-15 Years,94.2,89.7 to 96.8,297
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018,Age,13-15 Years,94.6,90.1 to 97.2,240
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2019,Age,13-15 Years,94.4,89.6 to 97.1,293
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,43.5,33.3 to 54.3,114
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2020,Age,13-15 Years,93.6,87.8 to 96.8,304
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,47.9,39.4 to 56.5,175
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,43.9,35.4 to 52.7,247
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2009,Age,13-15 Years,66.8,57.3 to 75.1,157
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2008,Age,13-15 Years,57.8,49.7 to 65.5,201
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2011,Age,13-15 Years,83.2,75.7 to 88.7,294
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2010,Age,13-15 Years,82.3,76.6 to 86.9,240
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,50.0,40.9 to 59.0,171
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,51.1,42.1 to 60.2,220
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,82.3,76.7 to 86.8,337
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,85.1,79.1 to 89.6,255
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,92.3,86.8 to 95.6,412
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,92.6,89.4 to 94.9,599
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,69.7,62.6 to 76.0,412
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,75.3,69.7 to 80.2,492
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,91.4,87.2 to 94.3,393
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,93.7,89.7 to 96.2,444
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,84.5,79.0 to 88.8,371
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,89.2,84.5 to 92.6,493
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,97.2,94.6 to 98.5,502
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,94.9,91.3 to 97.1,492
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,76.4,71.6 to 80.7,599
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,77.6,71.4 to 82.7,502
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018,Age,13-15 Years,86.6,78.2 to 92.1,240
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,55.7,46.6 to 64.4,223
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,54.9,46.2 to 63.4,222
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,62.6,54.4 to 70.1,240
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,61.4,52.6 to 69.5,219
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,74.5,69.0 to 79.2,485
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,67.3,57.3 to 75.9,199
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,64.4,55.5 to 72.4,243
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2021,Age,13-15 Years,92.8,88.5 to 95.6,363
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2013,Age,13-15 Years,86.9,80.1 to 91.7,276
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2014,Age,13-15 Years,95.7,91.6 to 97.8,265
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2015,Age,13-15 Years,93.0,88.8 to 95.7,292
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2016,Age,13-15 Years,91.1,85.9 to 94.5,312
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2017,Age,13-15 Years,90.9,84.9 to 94.7,297
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2012,Age,13-15 Years,88.9,82.7 to 93.1,242
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2011,Age,13-15 Years,82.8,75.7 to 88.2,294
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2009,Age,13-15 Years,69.8,60.2 to 77.9,157
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2010,Age,13-15 Years,80.0,73.3 to 85.3,240
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,94.0,90.4 to 96.4,485
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2008,Age,13-15 Years,55.6,47.6 to 63.3,201
Varicella,History of disease,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,13.2,9.5 to 18.0,526
Varicella,History of disease,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,11.0,8.0 to 14.9,492
Varicella,History of disease,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,46.8,40.6 to 53.1,337
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2022,Age,13-15 Years,66.8,59.8 to 73.2,302
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,42.5,32.4 to 53.3,213
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,46.4,38.9 to 54.0,270
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,66.3,56.7 to 74.8,233
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,56.9,48.1 to 65.3,249
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,55.6,47.4 to 63.6,240
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2022,Age,13-15 Years,66.7,56.6 to 75.5,146
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2021,Age,13-15 Years,68.2,58.5 to 76.5,166
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,54.4,45.6 to 62.9,219
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,68.5,61.5 to 74.8,322
Varicella,History of disease,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,9.6,6.6 to 13.8,489
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,42.1,34.5 to 50.2,286
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2020,Age,13-15 Years,55.1,46.4 to 63.5,304
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2021,Age,13-15 Years,65.3,58.6 to 71.4,363
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,65.4,57.7 to 72.4,262
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2019,Age,13-15 Years,53.7,45.5 to 61.6,293
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,61.6,51.4 to 70.9,199
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,58.9,50.0 to 67.3,243
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,65.6,56.4 to 73.8,269
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,65.9,57.6 to 73.3,223
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,67.5,59.9 to 74.3,277
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2018,Age,13-15 Years,36.4,24.5 to 50.3,121
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,46.5,38.7 to 54.5,270
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,48.5,40.5 to 56.5,286
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,49.8,42.2 to 57.5,270
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,46.4,36.0 to 57.2,213
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,11.4,7.1 to 17.8,222
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,34.1,26.4 to 42.8,219
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,25.7,18.8 to 34.1,224
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2020,Age,13-15 Years,57.3,44.8 to 69.0,148
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2019,Age,13-15 Years,54.0,42.4 to 65.2,143
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2021,Age,13-15 Years,91.3,87.0 to 94.3,363
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2020,Age,13-15 Years,94.3,89.1 to 97.1,304
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2019,Age,13-15 Years,92.6,87.3 to 95.8,293
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2022,Age,13-15 Years,67.0,56.9 to 75.7,156
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2021,Age,13-15 Years,62.1,52.9 to 70.6,197
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Other,84.3,73.5 to 91.3,162
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Uninsured,87.7,65.7 to 96.4,35
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,92.5,89.2 to 94.9,607
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,94.6,92.8 to 96.0,1686
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Other,52.6,41.8 to 63.3,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,64.8,59.5 to 69.7,607
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,62.6,59.2 to 65.9,1686
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Uninsured,87.7,65.7 to 96.4,35
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Other,65.8,54.8 to 75.4,162
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Uninsured,58.6,35.4 to 78.5,35
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Other,89.2,80.7 to 94.2,162
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,77.9,73.3 to 82.0,607
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,74.7,71.5 to 77.6,1686
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,95.2,93.6 to 96.4,1686
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,94.0,92.4 to 95.3,2180
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,94.4,91.6 to 96.3,607
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Poverty,Below Poverty Level,88.0,81.5 to 92.4,219
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,60.3,57.3 to 63.2,2180
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Poverty,Below Poverty Level,68.4,59.8 to 75.9,219
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,94.4,92.8 to 95.6,2180
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Poverty,Below Poverty Level,92.4,87.0 to 95.7,219
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Poverty,Below Poverty Level,85.6,79.0 to 90.4,219
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,72.5,69.7 to 75.2,2180
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",75.6,65.4 to 83.5,177
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",73.7,70.6 to 76.5,1814
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,Hispanic,93.3,87.5 to 96.5,244
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.9,81.1 to 93.8,255
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,Hispanic,94.2,87.8 to 97.3,244
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",85.2,75.4 to 91.5,177
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.4,92.7 to 95.8,1814
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.6,94.2 to 96.7,1814
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",92.1,86.3 to 95.5,177
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,Hispanic,66.3,57.5 to 74.1,244
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",60.1,51.0 to 68.5,255
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",64.6,54.0 to 73.9,177
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",74.4,65.7 to 81.5,255
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,Hispanic,81.3,74.2 to 86.8,244
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.1,79.4 to 92.2,255
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",61.2,57.9 to 64.4,1814
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,94.6,89.2 to 97.4,267
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.3,91.5 to 94.7,2130
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,89.1,83.0 to 93.2,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,89.4,83.2 to 93.5,319
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,91.7,86.1 to 95.2,319
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,75.9,68.8 to 81.8,319
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,76.1,66.0 to 83.9,149
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,63.9,56.1 to 71.0,319
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,89.6,83.5 to 93.7,319
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,92.7,87.3 to 95.9,319
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,62.2,51.1 to 72.2,170
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,93.9,88.4 to 96.9,304
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,91.2,85.7 to 94.8,319
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,90.9,85.2 to 94.5,304
≥2 Doses Hep A,,States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,83.5,76.7 to 88.6,319
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2023,Age,13-15 Years,92.1,84.5 to 96.2,188
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2023,Age,13-15 Years,89.2,80.6 to 94.3,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2023,Age,13-15 Years,63.1,52.7 to 72.3,188
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2023,Age,13-15 Years,63.7,49.2 to 76.0,88
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2023,Age,13-15 Years,92.1,84.8 to 96.0,180
HPV,"Up-to-Date, Males",States/Local Areas,PA-Rest of state,2023,Age,13-15 Years,62.5,47.6 to 75.3,100
HPV,"Up-to-Date, Females",States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,65.7,54.7 to 75.2,149
HPV,"≥1 Dose, Males",States/Local Areas,PA-Rest of state,2023,Age,13-17 Years,75.7,65.2 to 83.9,170
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,67.7,60.0 to 74.5,262
HPV,"≥2 Doses, Females",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,67.1,58.8 to 74.4,223
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,67.4,61.8 to 72.5,485
HPV,"≥3 Doses, Males",States/Local Areas,PA-Rest of state,2013,Age,13-15 Years,15.5,9.1 to 25.3,149
HPV,"≥3 Doses, Males",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,24.9,18.2 to 33.0,219
HPV,"≥3 Doses, Males",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,37.7,30.2 to 45.7,270
HPV,"≥3 Doses, Males",States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,15.4,10.1 to 22.6,224
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,94.5,89.2 to 97.3,179
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,95.0,91.8 to 97.0,489
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,93.0,89.5 to 95.4,526
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,96.3,93.3 to 98.0,412
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,96.9,94.5 to 98.3,492
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,92.3,87.8 to 95.3,492
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,72.4,66.5 to 77.6,337
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,92.2,88.3 to 94.9,485
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,92.5,88.9 to 95.0,599
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,95.0,91.3 to 97.2,502
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,87.8,83.4 to 91.1,371
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,81.3,74.6 to 86.5,255
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2019,Age,13-15 Years,96.7,92.7 to 98.5,280
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2018,Age,13-15 Years,96.2,92.2 to 98.2,228
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2014,Age,13-15 Years,93.9,87.0 to 97.3,232
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2015,Age,13-15 Years,93.2,87.2 to 96.4,263
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,55.0,45.9 to 63.8,171
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,57.0,47.9 to 65.8,220
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,60.0,51.2 to 68.2,222
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,65.1,56.3 to 72.9,223
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2016,Age,13-15 Years,94.0,89.7 to 96.6,288
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2017,Age,13-15 Years,96.1,92.0 to 98.1,273
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,92.7,87.9 to 95.7,393
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,89.6,84.9 to 92.9,493
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,94.0,90.2 to 96.4,444
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,95.6,92.0 to 97.6,442
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,91.9,87.9 to 94.6,469
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,91.4,86.3 to 94.7,431
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,92.2,87.4 to 95.3,354
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,94.8,90.6 to 97.2,371
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,48.8,40.0 to 57.6,247
HPV,"≥1 Dose, Females",States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,51.1,42.5 to 59.6,175
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,94.5,91.0 to 96.7,439
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2012,Age,13-15 Years,93.1,87.9 to 96.2,193
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2013,Age,13-15 Years,92.5,86.0 to 96.1,233
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2011,Age,13-15 Years,86.9,78.5 to 92.4,232
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2010,Age,13-15 Years,83.7,76.7 to 89.0,175
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2008,Age,13-15 Years,51.1,41.2 to 61.0,128
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Rest of state,2009,Age,13-15 Years,65.3,53.0 to 75.9,102
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,96.8,94.3 to 98.3,469
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,97.7,93.7 to 99.2,431
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,97.1,91.9 to 99.0,354
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,99.5,98.6 to 99.8,371
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,97.9,95.5 to 99.1,412
≥3 Doses HepB,,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,94.7,90.7 to 97.0,492
≥2 Doses Hep A,,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,85.3,79.7 to 89.5,502
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,43.6,34.7 to 52.9,171
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,39.9,31.7 to 48.8,247
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,44.7,35.9 to 53.9,220
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,46.7,37.9 to 55.8,223
HPV,"≥3 Doses, Males",States/Local Areas,PA-Rest of state,2014,Age,13-15 Years,19.1,11.7 to 29.6,133
HPV,"≥3 Doses, Males",States/Local Areas,PA-Rest of state,2015,Age,13-15 Years,35.9,26.4 to 46.5,164
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,26.5,19.5 to 34.9,168
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,39.1,29.2 to 49.9,114
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,42.2,33.9 to 50.9,175
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,46.4,37.9 to 55.1,222
≥2 Doses Hep A,,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,86.2,81.9 to 89.6,599
≥2 Doses Hep A,,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,86.7,82.2 to 90.2,485
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,50.3,44.5 to 56.0,489
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,51.8,44.3 to 59.2,412
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,88.6,84.2 to 91.9,393
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,89.9,85.3 to 93.2,444
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,93.4,89.7 to 95.8,442
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,95.4,91.7 to 97.5,337
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,94.3,89.5 to 97.0,255
HPV,"≥2 Doses, Males",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,59.2,50.4 to 67.5,249
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,48.7,43.0 to 54.5,526
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,81.0,75.7 to 85.4,493
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,74.5,68.5 to 79.6,371
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,68.3,61.1 to 74.7,255
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,97.0,94.6 to 98.4,371
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,93.5,88.9 to 96.3,493
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,66.0,59.4 to 72.0,502
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,57.9,51.6 to 63.9,492
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,51.7,45.4 to 57.9,337
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2022,Age,13-15 Years,93.2,87.8 to 96.3,302
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,65.6,60.1 to 70.8,485
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,68.0,62.9 to 72.7,599
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,92.5,88.9 to 95.0,492
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2008,Age,13-15 Years,30.6,21.1 to 42.2,101
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2011,Age,13-15 Years,29.3,20.4 to 40.1,156
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2010,Age,13-15 Years,39.6,29.5 to 50.6,115
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2009,Age,13-15 Years,26.7,17.1 to 39.3,68
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2012,Age,13-15 Years,27.1,18.4 to 37.9,106
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2013,Age,13-15 Years,34.9,24.8 to 46.5,127
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2014,Age,13-15 Years,43.0,31.3 to 55.5,132
HPV,"≥3 Doses, Females",States/Local Areas,PA-Rest of state,2015,Age,13-15 Years,42.3,31.4 to 53.9,128
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,35.5,29.7 to 41.7,442
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,41.9,36.2 to 47.8,492
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,95.4,91.3 to 97.6,502
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,95.8,93.1 to 97.5,489
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,96.4,93.4 to 98.0,412
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,95.7,92.5 to 97.6,492
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,92.6,88.5 to 95.3,492
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,92.3,87.9 to 95.2,442
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,94.0,90.4 to 96.4,485
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,91.4,88.1 to 93.9,599
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,95.8,92.7 to 97.7,502
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,93.9,89.9 to 96.3,492
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,93.4,88.9 to 96.1,393
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,94.3,90.3 to 96.7,444
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,20.6,16.2 to 25.9,493
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,23.6,18.5 to 29.6,393
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,90.0,84.1 to 93.8,412
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,90.5,85.9 to 93.7,489
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,92.9,89.3 to 95.3,526
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2015,Age,13-17 Years,95.2,92.3 to 97.1,492
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2013,Age,13-17 Years,90.2,85.4 to 93.6,444
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2014,Age,13-17 Years,95.6,92.9 to 97.3,442
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2012,Age,13-17 Years,88.9,84.3 to 92.3,393
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2010,Age,13-17 Years,79.1,73.6 to 83.7,371
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2011,Age,13-17 Years,83.2,78.0 to 87.4,493
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2008,Age,13-17 Years,58.7,52.4 to 64.8,337
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2009,Age,13-17 Years,71.4,64.3 to 77.5,255
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,92.3,88.7 to 94.7,526
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2022,Age,13-15 Years,94.9,90.8 to 97.3,302
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Overall,Overall,93.0,91.4 to 94.4,2490
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Overall,Overall,94.4,93.0 to 95.5,2490
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,97.6,93.4 to 99.1,267
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,91.5,81.5 to 96.3,93
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.9,92.3 to 95.2,2130
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,68.7,61.3 to 75.3,267
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,61.3,58.2 to 64.3,2130
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,51.3,39.3 to 63.2,93
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,81.2,74.8 to 86.2,267
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,61.4,49.0 to 72.4,93
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.4,71.5 to 77.0,2130
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Overall,Overall,61.9,59.1 to 64.6,2490
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,85.5,74.1 to 92.4,93
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Rest of state,2018-2022,Overall,Overall,74.7,72.2 to 77.1,2490
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,94.6,91.4 to 96.6,485
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,92.6,89.0 to 95.0,599
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2020,Age,13-17 Years,95.7,92.2 to 97.7,502
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2017,Age,13-17 Years,93.7,90.1 to 96.0,489
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2018,Age,13-17 Years,94.5,90.7 to 96.7,412
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2019,Age,13-17 Years,94.0,90.0 to 96.5,492
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2021,Age,13-17 Years,92.8,89.6 to 95.1,599
≥1 Dose MenACWY,,States/Local Areas,PA-Rest of state,2022,Age,13-17 Years,94.7,91.5 to 96.7,485
≥2 Doses MMR,,States/Local Areas,PA-Rest of state,2016,Age,13-17 Years,93.4,90.4 to 95.5,526
Varicella,History of disease,States/Local Areas,Hawaii,2018,Age,13-17 Years,9.5,6.5 to 13.5,327
Varicella,History of disease,States/Local Areas,Hawaii,2016,Age,13-17 Years,17.1,12.5 to 22.8,317
Varicella,History of disease,States/Local Areas,Hawaii,2017,Age,13-17 Years,11.7,8.0 to 16.9,314
Varicella,History of disease,States/Local Areas,Hawaii,2014,Age,13-17 Years,17.4,13.2 to 22.6,363
Varicella,History of disease,States/Local Areas,Hawaii,2013,Age,13-17 Years,17.5,12.7 to 23.7,315
Varicella,History of disease,States/Local Areas,Hawaii,2012,Age,13-17 Years,28.9,22.8 to 35.8,342
Varicella,History of disease,States/Local Areas,Hawaii,2010,Age,13-17 Years,31.2,25.8 to 37.1,320
Varicella,History of disease,States/Local Areas,Hawaii,2011,Age,13-17 Years,25.5,20.1 to 31.7,339
Varicella,History of disease,States/Local Areas,Hawaii,2015,Age,13-17 Years,14.6,10.8 to 19.4,340
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2019,Age,13-15 Years,64.5,50.2 to 76.7,82
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2020,Age,13-15 Years,60.5,46.9 to 72.5,73
Varicella,History of disease,States/Local Areas,Hawaii,2022,Age,13-17 Years,7.2,4.2 to 12.2,237
Varicella,History of disease,States/Local Areas,Hawaii,2021,Age,13-17 Years,9.2,5.7 to 14.3,258
Varicella,History of disease,States/Local Areas,Hawaii,2020,Age,13-17 Years,8.3,5.2 to 13.1,290
Varicella,History of disease,States/Local Areas,Hawaii,2019,Age,13-17 Years,8.6,5.3 to 13.7,304
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2018,Age,13-15 Years,58.9,47.1 to 69.9,98
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2018,Age,13-15 Years,NA,,
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,5.9,3.6 to 9.4,428
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,6.1,4.0 to 9.3,458
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,9.6,6.7 to 13.6,332
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,12.7,9.8 to 16.3,547
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,14.5,11.1 to 18.7,485
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,13.9,9.2 to 20.6,231
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-15 Years,32.6,22.7 to 44.4,124
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,35.9,24.9 to 48.6,107
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2021,Age,13-15 Years,82.5,71.3 to 90.0,160
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,89.7,84.3 to 93.4,333
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,92.9,87.9 to 96.0,231
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2019,Age,13-15 Years,78.6,67.3 to 86.7,121
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,29.3,23.5 to 36.0,261
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,95.2,92.6 to 96.9,418
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,82.3,74.6 to 88.0,261
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,92.9,87.0 to 96.2,205
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,66.1,60.7 to 71.2,418
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,61.3,53.2 to 68.8,205
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,75.6,70.9 to 79.8,475
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,14.9,9.6 to 22.4,175
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,93.0,90.4 to 94.9,547
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,92.8,89.6 to 95.0,485
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,92.8,89.4 to 95.2,332
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,92.7,89.4 to 95.0,475
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,88.8,85.3 to 91.6,428
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,88.6,82.9 to 92.6,218
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,84.3,75.9 to 90.1,240
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,79.7,71.7 to 85.9,211
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,89.8,85.8 to 92.7,404
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,93.6,90.8 to 95.6,431
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,96.4,93.2 to 98.1,299
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,90.8,87.7 to 93.2,458
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,33.2,25.3 to 42.2,156
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,28.7,22.7 to 35.7,262
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,79.8,74.7 to 84.0,404
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,82.6,78.1 to 86.3,431
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,77.9,72.1 to 82.8,299
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,22.5,14.5 to 33.1,116
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,26.4,20.3 to 33.5,232
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,84.9,76.7 to 90.5,245
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2009,Age,13-15 Years,32.3,24.6 to 41.0,167
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2013,Age,13-15 Years,78.4,70.8 to 84.4,183
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2012,Age,13-15 Years,77.9,72.2 to 82.7,296
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2010,Age,13-15 Years,69.3,59.5 to 77.7,134
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2011,Age,13-15 Years,72.5,65.8 to 78.2,260
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2015,Age,13-15 Years,82.6,77.0 to 87.0,287
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2016,Age,13-15 Years,75.1,68.2 to 80.9,261
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,47.9,41.3 to 54.6,333
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,66.7,59.3 to 73.4,231
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,80.0,74.7 to 84.4,332
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,78.7,74.5 to 82.4,547
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,71.0,66.2 to 75.5,485
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,80.1,72.1 to 86.2,218
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,83.7,79.4 to 87.2,458
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,80.9,76.1 to 85.0,428
HPV,"≥3 Doses, Males",States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,11.8,7.9 to 17.3,236
≥2 Doses Hep A,,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,78.9,70.6 to 85.4,245
HPV,"≥3 Doses, Males",States/Local Areas,U.S. Virgin Islands,2015,Age,13-15 Years,13.0,8.2 to 20.1,154
HPV,"≥3 Doses, Females",States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,9.1,5.5 to 14.6,262
HPV,"≥3 Doses, Females",States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,8.3,5.2 to 13.0,232
HPV,"≥3 Doses, Females",States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,9.5,5.6 to 15.5,156
HPV,"≥3 Doses, Females",States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,16.4,11.3 to 23.2,222
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2021,Age,13-15 Years,82.3,72.7 to 89.0,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,22.6,17.9 to 28.1,428
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,72.0,67.3 to 76.3,547
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,76.4,70.9 to 81.2,332
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,94.0,91.4 to 95.8,485
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,63.5,58.3 to 68.4,485
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,34.9,28.9 to 41.3,333
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,62.8,55.2 to 69.7,231
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,86.1,80.5 to 90.3,333
HPV,"≥2 Doses, Males",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,41.4,29.8 to 54.1,107
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,90.9,85.7 to 94.3,231
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,45.5,36.6 to 54.6,245
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,34.6,26.7 to 43.5,218
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,82.0,77.7 to 85.6,458
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,10.5,6.7 to 15.9,285
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,40.1,32.5 to 48.1,227
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,35.5,28.8 to 42.8,236
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,17.2,11.5 to 24.9,176
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,74.3,61.1 to 84.2,113
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,52.0,39.8 to 63.9,111
HPV,"≥2 Doses, Males and Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,40.2,31.9 to 49.1,218
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2018,Age,13-15 Years,NA,,
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,19.0,13.2 to 26.4,227
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,45.7,33.0 to 58.9,113
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2019,Age,13-15 Years,34.6,20.7 to 51.7,58
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,38.9,27.7 to 51.4,111
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2013,Age,13-15 Years,75.0,67.6 to 81.1,202
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2016,Age,13-15 Years,74.1,67.0 to 80.2,271
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2015,Age,13-15 Years,80.3,75.0 to 84.8,305
HPV,"≥2 Doses, Males",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,26.7,20.1 to 34.6,227
HPV,"≥2 Doses, Males",States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,18.6,13.7 to 24.8,236
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2019,Age,13-15 Years,75.4,64.4 to 83.8,124
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2010,Age,13-15 Years,72.1,63.1 to 79.7,143
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2009,Age,13-15 Years,43.0,34.8 to 51.6,206
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2012,Age,13-15 Years,75.1,69.4 to 80.0,333
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2011,Age,13-15 Years,66.6,59.9 to 72.7,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,71.8,63.2 to 79.1,245
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2021,Age,13-15 Years,81.0,70.9 to 88.2,163
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,30.3,22.9 to 38.7,201
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,25.8,19.5 to 33.3,222
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,82.7,74.9 to 88.4,245
HPV,"≥1 Dose, Males and Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,48.8,40.2 to 57.6,218
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,81.8,74.3 to 87.6,218
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,45.9,34.0 to 58.4,107
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2009,Age,13-15 Years,22.1,15.9 to 29.8,206
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2010,Age,13-15 Years,31.7,23.4 to 41.4,143
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2011,Age,13-15 Years,30.8,24.8 to 37.5,290
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,69.4,57.4 to 79.3,132
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,75.6,70.6 to 80.1,485
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,78.7,71.5 to 84.4,231
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,78.2,73.7 to 82.0,547
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,73.5,67.0 to 79.1,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,81.6,76.7 to 85.6,428
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,83.1,78.8 to 86.6,458
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,82.0,76.8 to 86.2,332
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2013,Age,13-15 Years,35.6,28.4 to 43.5,202
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2012,Age,13-15 Years,37.2,31.3 to 43.6,333
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2016,Age,13-15 Years,55.3,48.0 to 62.4,271
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2015,Age,13-15 Years,54.9,48.3 to 61.5,305
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,17.7,12.0 to 25.4,156
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,16.4,11.7 to 22.7,262
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,17.3,12.5 to 23.4,232
HPV,"≥2 Doses, Females",States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,13.1,7.5 to 21.9,116
HPV,"≥1 Dose, Males and Females",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,41.9,36.2 to 47.7,428
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2019,Age,13-15 Years,74.4,63.5 to 82.9,124
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,43.8,35.6 to 52.4,201
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,90.2,84.0 to 94.2,211
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,40.4,33.0 to 48.3,222
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,88.1,80.4 to 93.0,245
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2021,Age,13-15 Years,42.4,29.0 to 57.1,101
Varicella,History of disease,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,26.3,20.5 to 33.1,333
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,33.3,22.7 to 46.0,111
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2019,Age,13-15 Years,30.8,17.9 to 47.7,66
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2021,Age,13-15 Years,58.6,41.2 to 74.0,62
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,26.6,19.5 to 35.0,201
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2021,Age,13-15 Years,49.0,37.9 to 60.3,163
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,45.3,33.3 to 57.8,132
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,94.4,88.1 to 97.4,89
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,87.3,74.7 to 94.1,89
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,90.0,81.5 to 94.9,89
HPV,"≥1 Dose, Males",States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,68.0,49.4 to 82.2,55
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,44.2,30.4 to 59.0,89
HPV,"≥1 Dose, Males and Females",States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,68.6,54.4 to 79.9,89
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,88.7,76.0 to 95.2,89
HPV,"Up-to-Date, Males",States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,38.7,22.0 to 58.6,55
≥3 Doses HepB,,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,84.8,70.0 to 93.0,89
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,88.2,73.9 to 95.2,87
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,84.8,71.2 to 92.6,87
≥2 Doses Hep A,,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,79.8,65.5 to 89.1,89
Varicella,≥2 Doses or history of disease,States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,84.9,71.4 to 92.7,89
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2023,Age,13-15 Years,86.9,73.9 to 93.9,56
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2023,Age,13-15 Years,92.6,83.8 to 96.8,56
HPV,"Up-to-Date, Males and Females",States/Local Areas,U.S. Virgin Islands,2023,Age,13-15 Years,45.9,28.5 to 64.4,56
Varicella,≥2 Doses with no disease history,States/Local Areas,U.S. Virgin Islands,2023,Age,13-15 Years,85.3,69.5 to 93.7,55
HPV,"≥1 Dose, Females",States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,69.2,47.0 to 85.0,34
Varicella,≥1 Dose with no disease history,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,91.2,84.4 to 95.2,240
HPV,"≥2 Doses, Males and Females",States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,28.4,23.3 to 34.1,428
HPV,"Up-to-Date, Females",States/Local Areas,U.S. Virgin Islands,2023,Age,13-17 Years,49.7,29.0 to 70.5,34
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,60.3,49.2 to 70.4,192
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,73.0,62.2 to 81.6,188
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2023,Age,13-15 Years,62.2,48.0 to 74.6,123
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2023,Age,13-15 Years,85.4,76.2 to 91.4,226
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2023,Age,13-15 Years,53.5,43.8 to 63.0,246
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2023,Age,13-15 Years,45.7,32.7 to 59.2,123
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2023,Age,13-15 Years,85.0,76.8 to 90.6,246
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2023,Age,13-15 Years,82.4,74.0 to 88.5,246
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,86.0,79.8 to 90.5,380
≥2 Doses Hep A,,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,86.4,80.5 to 90.7,380
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,84.5,77.7 to 89.4,346
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,88.5,82.2 to 92.8,346
Varicella,History of disease,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,9.9,5.8 to 16.5,380
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,83.3,76.7 to 88.3,380
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,53.0,42.0 to 63.8,188
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,85.1,78.9 to 89.8,380
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,56.6,48.7 to 64.1,380
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,77.6,67.6 to 85.3,192
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,85.0,78.6 to 89.7,380
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,75.3,68.1 to 81.3,380
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,85.8,79.8 to 90.2,380
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2023,Age,13-17 Years,82.2,75.5 to 87.4,380
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,53.8,44.1 to 63.2,228
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,58.9,51.6 to 65.8,384
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Uninsured,79.6,71.4 to 85.9,377
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,58.7,53.9 to 63.3,1444
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Other,48.5,40.1 to 56.9,422
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Uninsured,37.9,29.8 to 46.6,377
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,85.3,82.9 to 87.5,2252
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,84.2,80.3 to 87.4,1444
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Other,87.6,82.4 to 91.4,422
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,47.3,44.4 to 50.1,3263
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Poverty,Below Poverty Level,64.5,58.6 to 70.0,1032
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Poverty,Below Poverty Level,84.4,79.1 to 88.6,1032
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,87.8,84.2 to 90.6,1444
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,84.8,82.7 to 86.6,3263
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,88.4,86.3 to 90.2,2252
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,72.8,68.3 to 76.8,1444
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,64.2,61.0 to 67.3,2252
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Other,66.2,57.8 to 73.7,422
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Uninsured,59.4,50.7 to 67.6,377
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Other,89.9,85.2 to 93.2,422
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Uninsured,82.4,74.7 to 88.2,377
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,47.5,44.2 to 50.8,2252
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Overall,Overall,50.6,48.0 to 53.1,4495
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Overall,Overall,66.9,64.5 to 69.2,4495
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,82.3,74.2 to 88.3,326
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,71.0,66.7 to 74.9,1835
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,64.4,61.3 to 67.3,2334
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,65.8,56.5 to 74.0,326
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,53.4,48.8 to 57.8,1835
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,48.9,45.7 to 52.1,2334
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,49.7,40.4 to 59.0,326
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,88.1,85.0 to 90.7,1835
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.5,85.3 to 89.4,2334
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,88.1,82.2 to 92.2,326
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,84.1,80.5 to 87.1,1835
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,85.3,82.9 to 87.4,2334
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",44.0,40.0 to 48.1,1644
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.0,86.9 to 94.0,368
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",65.0,57.5 to 71.8,368
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,Hispanic,73.0,69.6 to 76.3,2149
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",51.5,43.9 to 59.1,368
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,Hispanic,55.3,51.4 to 59.1,2149
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",49.2,41.4 to 57.0,334
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.9,82.8 to 88.5,1644
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.3,81.5 to 91.5,334
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.1,82.1 to 87.6,1644
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,Hispanic,88.7,86.1 to 90.8,2149
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",83.1,76.3 to 88.3,334
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,Hispanic,84.4,81.3 to 87.0,2149
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.6,80.4 to 91.0,368
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",58.4,54.3 to 62.4,1644
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Poverty,Below Poverty Level,76.9,71.4 to 81.6,1032
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,64.5,61.7 to 67.1,3263
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Poverty,Below Poverty Level,89.1,84.6 to 92.4,1032
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",67.1,59.2 to 74.2,334
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,87.0,85.0 to 88.7,3263
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018-2022,Overall,Overall,84.6,82.7 to 86.3,4495
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018-2022,Overall,Overall,87.8,86.1 to 89.3,4495
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,85.2,81.4 to 88.3,729
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2022,Age,13-15 Years,83.7,75.7 to 89.5,239
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,61.9,55.3 to 68.1,297
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,78.5,72.9 to 83.2,490
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,48.1,41.1 to 55.2,305
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,35.6,28.2 to 43.7,338
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,83.1,79.4 to 86.2,917
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,16.8,12.5 to 22.3,490
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,83.9,80.0 to 87.2,729
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,85.3,81.9 to 88.1,946
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,84.5,79.6 to 88.4,491
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,87.0,83.4 to 89.9,855
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,87.3,82.7 to 90.9,517
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,88.9,84.8 to 91.9,491
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,87.4,82.8 to 90.9,517
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,90.1,87.0 to 92.4,946
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,85.0,81.2 to 88.2,729
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,84.4,80.2 to 87.8,855
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,84.5,78.6 to 89.0,384
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,87.4,82.8 to 90.9,527
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,84.1,80.3 to 87.3,832
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,82.9,79.2 to 86.1,917
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,83.8,79.7 to 87.2,832
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,83.5,78.7 to 87.4,606
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,32.1,28.2 to 36.2,946
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,24.4,19.8 to 29.7,491
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,86.0,81.7 to 89.4,606
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,86.0,80.4 to 90.2,384
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,89.7,85.4 to 92.8,527
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,85.7,82.1 to 88.7,846
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,83.1,79.3 to 86.3,846
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,18.0,14.7 to 21.7,855
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,91.4,88.0 to 93.8,606
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,84.8,81.1 to 87.9,832
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,84.5,79.2 to 88.7,527
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,84.1,80.4 to 87.2,846
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,86.3,82.9 to 89.0,917
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,79.7,73.0 to 85.1,384
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2010,Age,13-15 Years,30.1,20.7 to 41.5,94
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2009,Age,13-15 Years,21.7,13.8 to 32.4,109
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2011,Age,13-15 Years,32.7,21.6 to 46.0,137
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,64.2,53.2 to 73.9,156
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2019,Age,13-15 Years,42.7,34.4 to 51.3,255
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,54.2,44.8 to 63.2,239
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2020,Age,13-15 Years,48.9,39.1 to 58.8,198
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,22.5,17.7 to 28.3,401
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2018,Age,13-15 Years,34.1,27.5 to 41.4,334
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,63.3,52.2 to 73.1,156
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,55.5,47.4 to 63.3,299
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2021,Age,13-15 Years,44.2,34.5 to 54.4,186
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2022,Age,13-15 Years,47.8,35.4 to 60.5,136
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,40.2,33.9 to 46.8,394
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,39.2,32.5 to 46.4,328
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2021,Age,13-15 Years,44.4,32.9 to 56.6,139
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2022,Age,13-15 Years,58.3,45.2 to 70.3,103
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2019,Age,13-15 Years,49.4,41.0 to 57.9,245
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,46.9,40.5 to 53.4,419
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,48.6,42.0 to 55.3,402
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,33.1,27.6 to 39.2,452
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,52.6,44.6 to 60.5,307
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,37.0,31.3 to 43.1,498
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,44.8,38.4 to 51.4,430
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,52.5,42.8 to 62.0,228
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2020,Age,13-15 Years,51.0,43.8 to 58.1,386
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2020,Age,13-15 Years,53.3,43.0 to 63.3,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2019,Age,13-15 Years,46.1,40.2 to 52.1,500
HPV,"Up-to-Date, Males",States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,46.0,37.9 to 54.3,288
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2021,Age,13-15 Years,44.3,36.7 to 52.1,325
HPV,"Up-to-Date, Females",States/Local Areas,TX-Rest of state,2018,Age,13-15 Years,44.1,36.1 to 52.5,253
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2022,Age,13-15 Years,53.3,44.2 to 62.2,239
Varicella,History of disease,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,7.3,4.6 to 11.4,527
Varicella,History of disease,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,11.5,8.3 to 15.7,606
Varicella,History of disease,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,10.0,6.0 to 16.2,384
Varicella,History of disease,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,10.9,8.2 to 14.4,832
Varicella,History of disease,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,13.0,10.3 to 16.2,917
Varicella,History of disease,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,50.6,43.9 to 57.2,297
Varicella,History of disease,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,35.5,30.1 to 41.2,490
Varicella,History of disease,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,32.1,27.8 to 36.6,855
Varicella,History of disease,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,24.1,19.4 to 29.5,517
Varicella,History of disease,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,25.0,20.2 to 30.4,491
Varicella,History of disease,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,56.7,49.5 to 63.6,305
Varicella,History of disease,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,21.4,18.0 to 25.3,946
Varicella,History of disease,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,18.6,15.0 to 22.9,729
Varicella,History of disease,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,68.4,60.3 to 75.5,338
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2014,Age,13-15 Years,33.8,24.5 to 44.7,140
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2015,Age,13-15 Years,42.5,34.6 to 50.8,275
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2012,Age,13-15 Years,26.1,19.7 to 33.8,283
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2013,Age,13-15 Years,38.4,28.7 to 49.1,155
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,43.4,37.0 to 50.1,394
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,24.2,18.0 to 31.5,263
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,25.4,19.2 to 32.7,277
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,52.0,45.3 to 58.6,402
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,13.8,9.8 to 19.2,422
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2013,Age,13-15 Years,89.4,84.0 to 93.2,341
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2014,Age,13-15 Years,89.6,84.4 to 93.2,301
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2015,Age,13-15 Years,86.2,81.9 to 89.6,599
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2016,Age,13-15 Years,84.4,79.5 to 88.4,460
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,38.0,32.1 to 44.2,452
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,39.2,33.4 to 45.4,498
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,30.9,25.8 to 36.5,493
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,27.3,21.9 to 33.4,401
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2020,Age,13-15 Years,84.5,78.4 to 89.1,386
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2017,Age,13-15 Years,80.3,75.0 to 84.7,527
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2019,Age,13-15 Years,84.7,79.8 to 88.6,500
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,50.1,43.6 to 56.6,419
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2021,Age,13-15 Years,89.5,83.9 to 93.2,325
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,70.1,64.0 to 75.6,527
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,58.0,53.4 to 62.4,917
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,85.9,82.5 to 88.7,917
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2011,Age,13-15 Years,82.7,76.2 to 87.7,297
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2012,Age,13-15 Years,85.1,79.9 to 89.2,539
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2009,Age,13-15 Years,63.2,54.6 to 71.1,206
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2010,Age,13-15 Years,75.7,68.3 to 81.8,198
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2008,Age,13-15 Years,48.5,37.8 to 59.5,204
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,86.0,80.3 to 90.2,384
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,43.0,35.0 to 51.2,228
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,49.1,42.8 to 55.5,453
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,43.3,36.4 to 50.4,328
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,62.2,57.6 to 66.6,832
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,90.1,85.9 to 93.1,527
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,63.7,57.3 to 69.6,430
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,89.9,86.9 to 92.3,946
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,89.5,85.4 to 92.5,491
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,88.0,84.6 to 90.8,729
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,85.9,82.4 to 88.8,846
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,54.5,49.9 to 59.1,846
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,85.5,81.8 to 88.6,832
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,69.0,61.9 to 75.4,384
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,72.3,67.0 to 77.0,606
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,87.8,83.6 to 91.0,606
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2011,Age,13-15 Years,79.9,71.8 to 86.0,297
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2010,Age,13-15 Years,70.2,62.6 to 76.9,198
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2009,Age,13-15 Years,49.4,40.8 to 58.1,206
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2008,Age,13-15 Years,37.6,27.9 to 48.3,204
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,61.6,51.7 to 70.6,228
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,88.0,84.3 to 90.9,855
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,83.1,77.7 to 87.4,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,88.6,84.7 to 91.5,490
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,67.8,59.6 to 75.0,288
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,75.0,68.4 to 80.6,305
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,80.1,73.0 to 85.6,338
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,90.2,86.0 to 93.2,517
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2014,Age,13-15 Years,90.5,85.5 to 93.9,301
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2015,Age,13-15 Years,90.6,87.0 to 93.2,599
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2016,Age,13-15 Years,86.1,81.5 to 89.7,460
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2012,Age,13-15 Years,87.5,82.2 to 91.4,539
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2013,Age,13-15 Years,90.9,85.7 to 94.3,341
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,35.7,27.2 to 45.2,141
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,38.9,30.5 to 48.1,229
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,30.8,22.9 to 40.0,155
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2020,Age,13-15 Years,90.4,85.7 to 93.7,386
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,41.4,35.0 to 48.1,433
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,45.9,37.5 to 54.5,240
HPV,"≥2 Doses, Females",States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,19.5,11.9 to 30.4,154
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,46.8,42.0 to 51.6,729
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,86.3,82.0 to 89.8,606
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2018,Age,13-15 Years,84.9,80.3 to 88.5,587
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2019,Age,13-15 Years,83.2,78.1 to 87.3,500
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,84.2,80.6 to 87.3,917
≥1 Dose MenACWY,,States/Local Areas,TX-Rest of state,2017,Age,13-15 Years,82.0,76.7 to 86.3,527
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,84.5,79.2 to 88.6,527
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,80.3,73.7 to 85.6,384
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,55.9,49.2 to 62.4,394
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,58.9,52.4 to 65.1,453
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,90.7,87.2 to 93.2,761
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,53.3,46.2 to 60.2,328
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,62.7,56.2 to 68.8,419
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,84.0,77.4 to 88.9,356
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,79.0,72.1 to 84.6,356
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,40.6,36.3 to 45.2,846
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,88.5,83.2 to 92.2,491
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,8.7,5.2 to 14.2,261
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,76.8,66.2 to 84.9,156
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,75.2,68.0 to 81.2,299
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,44.6,40.2 to 49.1,917
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,35.1,30.6 to 39.9,729
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,53.3,47.0 to 59.6,498
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,69.5,61.6 to 76.3,307
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,72.6,63.1 to 80.4,239
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,53.2,46.9 to 59.4,452
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,34.4,27.3 to 42.3,263
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,33.7,26.8 to 41.5,277
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,38.7,33.1 to 44.6,493
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,40.6,34.2 to 47.2,401
HPV,"≥1 Dose, Males",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,23.3,18.1 to 29.6,422
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,60.7,54.0 to 67.1,402
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,87.8,82.6 to 91.6,297
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,87.3,82.1 to 91.2,305
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,50.0,45.3 to 54.6,832
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2021,Age,13-15 Years,86.9,80.1 to 91.7,309
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,86.7,80.5 to 91.2,338
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,83.6,79.5 to 87.0,832
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2022,Age,13-15 Years,78.0,69.3 to 84.7,225
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,47.8,37.2 to 58.7,139
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,30.4,19.2 to 44.5,127
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2019,Age,13-15 Years,85.3,80.1 to 89.4,460
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,78.2,62.5 to 88.5,127
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,91.8,85.6 to 95.5,155
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,89.7,80.9 to 94.7,139
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,91.3,83.0 to 95.7,322
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,85.9,82.4 to 88.8,846
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2008,Age,13-15 Years,32.4,18.9 to 49.6,90
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,79.8,74.9 to 83.9,598
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,31.1,21.4 to 42.7,154
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,59.4,50.3 to 67.8,155
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,73.0,65.4 to 79.5,322
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,85.1,81.3 to 88.2,729
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,93.7,89.9 to 96.1,598
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,86.3,81.7 to 89.8,491
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,90.3,86.1 to 93.3,517
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,89.6,85.8 to 92.5,490
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,87.5,84.0 to 90.4,855
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,33.9,25.7 to 43.3,155
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,89.3,85.9 to 92.0,787
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,82.0,77.9 to 85.5,787
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,92.8,89.1 to 95.2,545
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,81.0,76.5 to 84.8,761
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,87.1,82.6 to 90.6,545
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,85.1,79.6 to 89.2,491
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,91.9,88.7 to 94.2,726
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,48.7,40.6 to 56.8,228
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,51.5,44.8 to 58.1,433
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,55.9,47.2 to 64.2,240
≥3 Doses HepB,,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,85.7,82.3 to 88.5,946
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,93.4,88.8 to 96.2,376
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,92.8,87.6 to 96.0,391
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,94.3,91.6 to 96.2,742
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,93.4,90.1 to 95.6,606
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,84.2,80.1 to 87.5,726
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,48.2,39.4 to 57.0,229
HPV,"≥1 Dose, Females",States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,47.7,38.3 to 57.2,141
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,80.0,74.0 to 84.9,376
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,79.2,73.0 to 84.3,391
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,82.4,78.2 to 85.9,742
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,80.4,75.8 to 84.4,606
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2020,Age,13-15 Years,86.5,80.4 to 91.0,348
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,81.1,74.7 to 86.2,384
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,88.6,84.5 to 91.7,606
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2018,Age,13-15 Years,83.0,77.9 to 87.1,519
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,86.2,81.1 to 90.0,527
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2011,Age,13-15 Years,77.2,66.9 to 85.0,212
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2010,Age,13-15 Years,62.2,52.4 to 71.1,126
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2012,Age,13-15 Years,83.4,77.5 to 88.0,417
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2013,Age,13-15 Years,84.3,77.4 to 89.4,267
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2009,Age,13-15 Years,47.8,36.3 to 59.5,116
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2014,Age,13-15 Years,80.9,72.9 to 87.0,240
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2015,Age,13-15 Years,84.0,79.1 to 88.0,488
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2017,Age,13-15 Years,84.7,79.3 to 88.9,462
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Rest of state,2016,Age,13-15 Years,87.0,82.4 to 90.6,390
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,86.4,82.9 to 89.3,846
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,84.1,80.2 to 87.3,729
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,85.0,80.3 to 88.8,491
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,86.2,82.8 to 89.0,946
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,79.9,74.2 to 84.6,297
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,77.4,70.9 to 82.8,305
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,82.6,77.1 to 86.9,490
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,86.3,82.8 to 89.2,855
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,84.2,79.3 to 88.2,517
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,84.4,80.7 to 87.4,917
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,83.0,78.9 to 86.5,832
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,78.0,70.4 to 84.1,338
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,6.5,4.2 to 9.8,422
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,15.2,10.6 to 21.3,277
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,16.5,11.2 to 23.6,263
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,23.5,19.1 to 28.6,493
≥2 Doses Hep A,,States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,84.5,79.2 to 88.6,527
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2014,Age,13-15 Years,16.1,9.8 to 25.2,161
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2012,Age,13-15 Years,4.8,2.8 to 8.2,256
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2013,Age,13-15 Years,17.2,11.4 to 25.0,186
≥2 Doses Hep A,,States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,87.2,82.8 to 90.6,606
≥2 Doses Hep A,,States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,79.7,72.8 to 85.1,384
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,32.3,24.2 to 41.6,229
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,30.1,24.3 to 36.5,433
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,41.0,34.9 to 47.4,453
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,24.4,17.3 to 33.3,155
HPV,"≥3 Doses, Males",States/Local Areas,TX-Rest of state,2015,Age,13-15 Years,24.1,18.6 to 30.5,324
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,32.8,25.6 to 40.9,228
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,39.8,31.7 to 48.5,240
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2021,Age,13-15 Years,87.9,81.8 to 92.1,325
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2016,Age,13-17 Years,30.7,26.4 to 35.4,729
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,36.6,32.4 to 41.0,846
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2018,Age,13-17 Years,41.9,37.5 to 46.4,917
Varicella,History of disease,States/Local Areas,TX-Rest of state,2017,Age,13-17 Years,14.4,11.5 to 18.0,846
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2015,Age,13-17 Years,85.4,81.9 to 88.4,946
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,84.6,79.2 to 88.7,297
HPV,"≥2 Doses, Males",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,48.1,41.6 to 54.6,430
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,82.3,76.2 to 87.1,305
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,81.1,73.9 to 86.6,338
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2022,Age,13-17 Years,57.8,50.5 to 64.7,384
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2019,Age,13-17 Years,46.7,42.1 to 51.3,832
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2020,Age,13-17 Years,54.0,48.3 to 59.7,606
HPV,"≥3 Doses, Females",States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,27.0,19.4 to 36.2,141
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2014,Age,13-17 Years,88.5,84.4 to 91.7,491
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2013,Age,13-17 Years,86.0,81.3 to 89.7,517
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2012,Age,13-17 Years,82.9,78.8 to 86.3,855
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2008,Age,13-17 Years,40.6,32.7 to 49.0,338
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2022,Age,13-15 Years,84.1,76.3 to 89.7,239
≥2 Doses MMR,,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,88.0,84.0 to 91.2,490
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2010,Age,13-17 Years,71.5,65.3 to 77.0,297
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2009,Age,13-17 Years,57.8,50.7 to 64.5,305
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2011,Age,13-17 Years,81.1,76.3 to 85.2,490
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Rest of state,2021,Age,13-17 Years,50.0,43.8 to 56.2,527
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Rest of state,2018,Age,13-15 Years,81.2,76.2 to 85.4,587
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2021,Age,13-15 Years,68.7,56.6 to 78.7,96
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2022,Age,13-15 Years,70.7,57.6 to 81.1,76
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2016,Age,13-17 Years,46.3,36.9 to 55.9,152
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2019,Age,13-15 Years,47.5,35.2 to 60.1,108
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2020,Age,13-17 Years,71.8,63.9 to 78.6,183
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2020,Age,13-15 Years,62.4,51.2 to 72.4,106
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2018,Age,13-15 Years,65.6,52.8 to 76.4,92
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2021,Age,13-17 Years,77.0,67.6 to 84.4,133
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2022,Age,13-17 Years,76.6,66.4 to 84.4,109
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2019,Age,13-17 Years,67.4,57.8 to 75.7,154
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2018,Age,13-17 Years,66.4,56.3 to 75.1,151
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2016,Age,13-17 Years,56.5,47.3 to 65.2,161
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2017,Age,13-17 Years,63.0,54.5 to 70.8,173
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2021,Age,13-15 Years,74.9,62.8 to 84.1,82
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2022,Age,13-15 Years,73.6,58.9 to 84.5,58
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2019,Age,13-17 Years,59.1,49.1 to 68.4,179
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2020,Age,13-17 Years,65.8,57.6 to 73.2,198
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2017,Age,13-17 Years,56.9,47.8 to 65.6,160
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2018,Age,13-17 Years,68.5,58.4 to 77.1,152
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2019,Age,13-15 Years,51.5,42.3 to 60.6,196
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2022,Age,13-17 Years,75.9,66.1 to 83.6,116
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2021,Age,13-15 Years,71.7,63.3 to 78.8,178
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2022,Age,13-15 Years,72.0,62.5 to 79.9,134
HPV,"Up-to-Date, Males",States/Local Areas,New Hampshire,2021,Age,13-17 Years,67.8,58.2 to 76.1,149
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Hampshire,2020,Age,13-15 Years,63.9,56.3 to 71.0,219
Varicella,History of disease,States/Local Areas,New Hampshire,2009,Age,13-17 Years,53.9,47.5 to 60.3,307
Varicella,History of disease,States/Local Areas,New Hampshire,2017,Age,13-17 Years,17.5,13.1 to 22.9,333
Varicella,History of disease,States/Local Areas,New Hampshire,2012,Age,13-17 Years,31.6,25.4 to 38.5,278
Varicella,History of disease,States/Local Areas,New Hampshire,2013,Age,13-17 Years,26.9,21.9 to 32.5,345
Varicella,History of disease,States/Local Areas,New Hampshire,2011,Age,13-17 Years,30.8,25.5 to 36.6,385
Varicella,History of disease,States/Local Areas,New Hampshire,2010,Age,13-17 Years,46.1,40.3 to 51.9,350
Varicella,History of disease,States/Local Areas,New Hampshire,2016,Age,13-17 Years,14.5,10.5 to 19.6,313
Varicella,History of disease,States/Local Areas,New Hampshire,2015,Age,13-17 Years,15.6,11.4 to 20.9,295
Varicella,History of disease,States/Local Areas,New Hampshire,2008,Age,13-17 Years,56.8,49.6 to 63.8,300
Varicella,History of disease,States/Local Areas,New Hampshire,2014,Age,13-17 Years,17.2,13.3 to 22.0,402
Varicella,History of disease,States/Local Areas,New Hampshire,2018,Age,13-17 Years,9.4,5.8 to 14.7,303
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2019,Age,13-15 Years,55.9,42.5 to 68.5,88
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2020,Age,13-15 Years,65.3,54.6 to 74.7,113
HPV,"Up-to-Date, Females",States/Local Areas,New Hampshire,2018,Age,13-15 Years,62.7,49.8 to 74.1,90
Varicella,History of disease,States/Local Areas,New Hampshire,2020,Age,13-17 Years,9.7,6.5 to 14.2,381
Varicella,History of disease,States/Local Areas,New Hampshire,2021,Age,13-17 Years,9.0,5.4 to 14.7,282
Varicella,History of disease,States/Local Areas,New Hampshire,2022,Age,13-17 Years,7.4,4.4 to 12.3,225
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2023,Age,13-17 Years,72.3,63.1 to 80.0,161
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2023,Age,13-15 Years,66.1,53.6 to 76.8,92
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2023,Age,13-15 Years,63.8,51.8 to 74.3,99
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2023,Age,13-15 Years,94.4,88.1 to 97.5,182
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2023,Age,13-15 Years,65.0,56.4 to 72.6,191
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2023,Age,13-15 Years,90.8,84.4 to 94.7,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2023,Age,13-15 Years,91.1,84.5 to 95.0,191
≥2 Doses Hep A,,States/Local Areas,Minnesota,2023,Age,13-17 Years,90.2,85.1 to 93.7,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2023,Age,13-17 Years,92.3,87.4 to 95.3,325
≥3 Doses HepB,,States/Local Areas,Minnesota,2023,Age,13-17 Years,94.2,90.0 to 96.7,325
Varicella,History of disease,States/Local Areas,Minnesota,2023,Age,13-17 Years,6.7,4.0 to 10.8,325
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2023,Age,13-17 Years,96.0,92.0 to 98.1,303
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2023,Age,13-17 Years,91.7,86.5 to 95.0,303
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2023,Age,13-17 Years,66.1,56.9 to 74.2,164
≥2 Doses MMR,,States/Local Areas,Minnesota,2023,Age,13-17 Years,93.4,88.8 to 96.2,325
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2023,Age,13-17 Years,69.2,62.7 to 74.9,325
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2023,Age,13-17 Years,83.6,74.6 to 89.9,161
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2023,Age,13-17 Years,84.2,78.8 to 88.4,325
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2023,Age,13-17 Years,91.4,86.8 to 94.5,325
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2023,Age,13-17 Years,93.7,89.4 to 96.3,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2023,Age,13-17 Years,91.2,86.2 to 94.5,325
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2023,Age,13-17 Years,84.7,77.8 to 89.7,164
HPV,"≥2 Doses, Males and Females",States/Local Areas,Minnesota,2022,Age,13-17 Years,69.8,63.4 to 75.5,331
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2022,Age,13-17 Years,73.5,65.0 to 80.7,179
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2012,Age,13-15 Years,23.6,13.8 to 37.3,102
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2011,Age,13-15 Years,32.6,22.4 to 44.8,102
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2022,Age,13-17 Years,94.6,90.8 to 96.9,331
≥2 Doses MMR,,States/Local Areas,Minnesota,2021,Age,13-17 Years,95.2,89.9 to 97.8,296
≥2 Doses MMR,,States/Local Areas,Minnesota,2022,Age,13-17 Years,96.2,92.8 to 98.1,331
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2015,Age,13-15 Years,44.1,32.8 to 56.1,104
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2014,Age,13-15 Years,34.8,23.2 to 48.6,81
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2013,Age,13-15 Years,32.7,22.9 to 44.4,105
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018,Age,13-17 Years,88.9,83.5 to 92.8,285
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2019,Age,13-17 Years,86.9,79.9 to 91.7,276
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2020,Age,13-17 Years,94.3,90.5 to 96.7,330
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2021,Age,13-17 Years,91.3,86.1 to 94.6,296
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2022,Age,13-17 Years,65.8,56.1 to 74.4,152
≥2 Doses MMR,,States/Local Areas,Minnesota,2012,Age,13-17 Years,94.3,90.7 to 96.5,322
≥2 Doses MMR,,States/Local Areas,Minnesota,2013,Age,13-17 Years,94.0,89.8 to 96.5,369
≥2 Doses MMR,,States/Local Areas,Minnesota,2016,Age,13-17 Years,91.3,86.7 to 94.4,375
≥2 Doses MMR,,States/Local Areas,Minnesota,2014,Age,13-17 Years,93.9,88.9 to 96.8,286
≥2 Doses MMR,,States/Local Areas,Minnesota,2015,Age,13-17 Years,95.8,92.3 to 97.7,366
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2016,Age,13-17 Years,85.2,80.1 to 89.1,375
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2015,Age,13-17 Years,83.6,78.2 to 87.9,366
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2014,Age,13-17 Years,75.5,69.0 to 81.0,286
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2013,Age,13-17 Years,66.3,59.9 to 72.2,369
HPV,"≥3 Doses, Males and Females",States/Local Areas,Minnesota,2012,Age,13-17 Years,18.1,13.1 to 24.4,322
HPV,"≥3 Doses, Males and Females",States/Local Areas,Minnesota,2011,Age,13-17 Years,17.6,13.2 to 23.0,327
HPV,"≥3 Doses, Males and Females",States/Local Areas,Minnesota,2013,Age,13-17 Years,22.7,17.9 to 28.4,369
≥2 Doses MMR,,States/Local Areas,Minnesota,2020,Age,13-17 Years,97.1,94.2 to 98.6,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Minnesota,2015,Age,13-17 Years,33.2,27.8 to 39.1,366
HPV,"≥3 Doses, Males and Females",States/Local Areas,Minnesota,2014,Age,13-17 Years,27.7,21.7 to 34.6,286
≥2 Doses MMR,,States/Local Areas,Minnesota,2018,Age,13-17 Years,97.1,94.2 to 98.5,285
≥2 Doses MMR,,States/Local Areas,Minnesota,2019,Age,13-17 Years,97.0,93.3 to 98.6,276
≥2 Doses MMR,,States/Local Areas,Minnesota,2017,Age,13-17 Years,95.1,91.9 to 97.1,356
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2017,Age,13-17 Years,87.5,82.4 to 91.3,356
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2020,Age,13-17 Years,92.8,88.3 to 95.6,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2021,Age,13-17 Years,90.5,85.0 to 94.1,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2022,Age,13-17 Years,93.8,90.0 to 96.2,331
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2022,Age,13-15 Years,93.5,87.2 to 96.8,188
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2012,Age,13-17 Years,66.6,59.4 to 73.0,322
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2009,Age,13-17 Years,43.9,38.1 to 49.9,336
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2008,Age,13-17 Years,38.9,33.0 to 45.1,338
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2011,Age,13-17 Years,63.1,55.9 to 69.7,327
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2010,Age,13-17 Years,57.0,50.6 to 63.2,310
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2016,Age,13-17 Years,89.7,85.0 to 93.1,375
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2014,Age,13-17 Years,42.5,32.7 to 52.9,134
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2013,Age,13-17 Years,37.6,29.1 to 46.9,167
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2015,Age,13-17 Years,44.5,35.9 to 53.4,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018,Age,13-17 Years,90.7,85.3 to 94.2,285
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2017,Age,13-17 Years,87.5,82.2 to 91.4,356
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2019,Age,13-17 Years,90.0,83.2 to 94.2,276
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2012,Age,13-17 Years,33.1,24.0 to 43.7,164
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2011,Age,13-17 Years,35.1,26.6 to 44.7,159
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2009,Age,13-17 Years,27.0,20.3 to 34.9,164
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2008,Age,13-17 Years,14.7,10.1 to 20.7,167
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2010,Age,13-17 Years,37.8,29.3 to 47.1,139
≥2 Doses Hep A,,States/Local Areas,Minnesota,2020,Age,13-17 Years,81.6,75.7 to 86.4,330
≥2 Doses Hep A,,States/Local Areas,Minnesota,2022,Age,13-17 Years,92.8,88.8 to 95.4,331
≥2 Doses Hep A,,States/Local Areas,Minnesota,2021,Age,13-17 Years,91.2,87.4 to 94.0,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Overall,Overall,79.7,77.0 to 82.2,1518
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a Non-MSA,90.7,86.0 to 93.9,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Overall,Overall,63.9,60.7 to 67.0,1518
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a Non-MSA,72.6,65.3 to 78.9,316
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,78.9,74.0 to 83.1,543
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Principal City,82.9,79.0 to 86.2,659
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a Non-MSA,56.2,48.5 to 63.7,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,63.0,57.6 to 68.1,543
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Principal City,67.2,62.5 to 71.6,659
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a Non-MSA,93.4,89.1 to 96.1,316
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Principal City,91.6,88.4 to 93.9,659
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.8,85.7 to 92.9,543
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.7,89.0 to 95.2,543
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",63.7,60.1 to 67.2,1165
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,Hispanic,80.7,69.7 to 88.4,113
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Urbanicity,Living In a MSA Principal City,91.0,87.7 to 93.6,659
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",93.2,85.6 to 96.9,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.7,78.0 to 92.3,167
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",63.6,49.6 to 75.6,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,Hispanic,54.1,42.6 to 65.2,113
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",72.0,62.3 to 80.1,167
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",92.5,83.9 to 96.7,73
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.4,88.9 to 93.3,1165
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.3,90.0 to 94.1,1165
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,Hispanic,86.7,76.2 to 93.0,113
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",85.2,71.4 to 93.0,73
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,Hispanic,87.8,77.8 to 93.7,113
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.2,88.0 to 97.3,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.7,67.2 to 89.5,73
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",78.3,75.1 to 81.2,1165
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Poverty,Below Poverty Level,79.9,67.8 to 88.3,96
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Poverty,Living At or Above Poverty Level,79.0,76.0 to 81.6,1373
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Poverty,Living At or Above Poverty Level,91.5,89.2 to 93.3,1373
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Poverty,Below Poverty Level,88.8,77.8 to 94.7,96
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Poverty,Below Poverty Level,61.8,49.2 to 73.0,96
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Poverty,Living At or Above Poverty Level,63.3,59.9 to 66.5,1373
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Poverty,Living At or Above Poverty Level,92.4,90.3 to 94.1,1373
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Poverty,Below Poverty Level,82.8,70.5 to 90.6,96
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Private Insurance Only,92.1,89.7 to 94.0,1092
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Any Medicaid,92.0,87.5 to 94.9,348
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Any Medicaid,81.6,75.7 to 86.3,348
≥2 Doses MMR,,HHS Regions/National,Region 8,2016,Age,13-17 Years,88.0,85.4 to 90.2,2022
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Private Insurance Only,80.5,77.3 to 83.3,1092
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Other,78.8,54.9 to 91.9,49
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Other,59.7,39.8 to 76.8,49
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Private Insurance Only,66.4,62.7 to 69.9,1092
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Any Medicaid,61.6,54.7 to 68.0,348
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Other,44.8,27.6 to 63.2,49
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Private Insurance Only,92.5,90.1 to 94.3,1092
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Any Medicaid,90.8,85.8 to 94.2,348
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Insurance Coverage,Other,85.1,64.6 to 94.7,49
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2008,Age,13-15 Years,15.2,9.4 to 23.6,102
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2009,Age,13-15 Years,27.2,18.5 to 38.2,90
HPV,"≥3 Doses, Females",States/Local Areas,Minnesota,2010,Age,13-15 Years,40.4,29.6 to 52.2,88
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018-2022,Overall,Overall,91.3,89.2 to 93.0,1518
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018-2022,Overall,Overall,91.6,89.5 to 93.3,1518
HPV,"≥3 Doses, Males",States/Local Areas,Minnesota,2015,Age,13-15 Years,23.5,16.4 to 32.4,132
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2015,Age,13-17 Years,91.8,87.1 to 94.8,366
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2017,Age,13-17 Years,92.2,87.9 to 95.1,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2018,Age,13-17 Years,94.2,89.5 to 96.8,285
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2016,Age,13-17 Years,89.5,84.4 to 93.1,375
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2008,Age,13-17 Years,74.9,69.2 to 79.8,338
HPV,"≥3 Doses, Males",States/Local Areas,Minnesota,2013,Age,13-17 Years,8.6,5.1 to 14.3,202
HPV,"≥3 Doses, Males",States/Local Areas,Minnesota,2014,Age,13-17 Years,13.6,8.0 to 22.1,152
HPV,"≥3 Doses, Males",States/Local Areas,Minnesota,2015,Age,13-17 Years,22.4,16.6 to 29.7,187
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2009,Age,13-17 Years,82.4,77.4 to 86.5,336
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2010,Age,13-17 Years,82.7,77.5 to 87.0,310
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2020,Age,13-17 Years,97.3,94.5 to 98.7,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2021,Age,13-17 Years,97.0,94.0 to 98.5,296
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2022,Age,13-17 Years,96.4,92.9 to 98.2,331
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2008,Age,13-15 Years,42.7,32.1 to 54.0,93
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2009,Age,13-15 Years,66.7,56.1 to 75.8,106
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2019,Age,13-17 Years,95.6,91.4 to 97.8,276
≥3 Doses HepB,,States/Local Areas,Minnesota,2008,Age,13-17 Years,89.7,85.4 to 92.9,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2019,Age,13-15 Years,96.7,90.3 to 98.9,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2020,Age,13-15 Years,98.6,96.1 to 99.5,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2021,Age,13-15 Years,97.0,92.7 to 98.8,174
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2012,Age,13-17 Years,89.8,84.9 to 93.2,322
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2011,Age,13-17 Years,88.9,83.0 to 93.0,327
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2014,Age,13-17 Years,88.7,82.9 to 92.7,286
Varicella,≥2 Doses or history of disease,States/Local Areas,Minnesota,2013,Age,13-17 Years,90.4,85.0 to 93.9,369
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2012,Age,13-15 Years,92.5,86.7 to 95.9,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2013,Age,13-15 Years,88.3,79.7 to 93.5,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2010,Age,13-15 Years,74.3,64.5 to 82.1,109
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2011,Age,13-15 Years,90.4,80.2 to 95.6,134
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2015,Age,13-15 Years,88.6,81.4 to 93.3,205
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2014,Age,13-15 Years,84.3,75.0 to 90.6,136
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2017,Age,13-15 Years,95.0,89.9 to 97.6,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2018,Age,13-15 Years,97.3,94.0 to 98.8,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2016,Age,13-15 Years,88.0,80.4 to 92.9,198
≥3 Doses HepB,,States/Local Areas,Minnesota,2009,Age,13-17 Years,90.9,86.8 to 93.7,336
≥3 Doses HepB,,States/Local Areas,Minnesota,2010,Age,13-17 Years,92.8,88.5 to 95.6,310
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2022,Age,13-15 Years,98.5,95.8 to 99.4,180
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2008,Age,13-17 Years,84.8,76.2 to 90.6,138
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2011,Age,13-17 Years,81.9,72.9 to 88.4,197
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2010,Age,13-17 Years,68.0,59.6 to 75.5,166
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2012,Age,13-17 Years,97.8,94.7 to 99.1,205
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2011,Age,13-17 Years,94.2,84.2 to 98.0,197
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2008,Age,13-17 Years,38.1,29.2 to 47.8,138
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2009,Age,13-17 Years,59.3,50.1 to 67.9,145
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2009,Age,13-17 Years,91.5,84.9 to 95.4,145
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2010,Age,13-17 Years,92.7,87.6 to 95.8,166
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2008,Age,13-17 Years,33.6,26.4 to 41.6,167
≥3 Doses HepB,,States/Local Areas,Minnesota,2017,Age,13-17 Years,95.7,93.0 to 97.3,356
≥3 Doses HepB,,States/Local Areas,Minnesota,2012,Age,13-17 Years,94.1,90.4 to 96.5,322
≥3 Doses HepB,,States/Local Areas,Minnesota,2011,Age,13-17 Years,93.3,87.4 to 96.5,327
≥3 Doses HepB,,States/Local Areas,Minnesota,2014,Age,13-17 Years,93.5,88.9 to 96.3,286
≥3 Doses HepB,,States/Local Areas,Minnesota,2013,Age,13-17 Years,95.8,92.3 to 97.8,369
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2013,Age,13-15 Years,89.9,83.2 to 94.1,230
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2019,Age,13-17 Years,68.6,57.2 to 78.1,129
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2014,Age,13-17 Years,36.6,27.4 to 46.8,152
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2013,Age,13-17 Years,13.1,8.4 to 19.8,202
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2018,Age,13-17 Years,65.8,54.7 to 75.4,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2012,Age,13-15 Years,85.2,75.5 to 91.5,206
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2011,Age,13-15 Years,90.5,83.2 to 94.9,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2008,Age,13-15 Years,53.3,45.4 to 61.0,203
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2010,Age,13-15 Years,84.3,76.5 to 89.8,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2009,Age,13-15 Years,68.2,60.2 to 75.2,204
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2017,Age,13-17 Years,50.8,41.8 to 59.7,174
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2016,Age,13-17 Years,52.4,43.4 to 61.1,174
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2015,Age,13-17 Years,51.3,42.5 to 60.1,179
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2014,Age,13-17 Years,53.9,43.6 to 63.8,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2020,Age,13-17 Years,81.0,75.0 to 85.8,330
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2021,Age,13-17 Years,79.9,73.2 to 85.2,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2022,Age,13-17 Years,86.9,82.3 to 90.5,331
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2012,Age,13-17 Years,46.0,35.7 to 56.8,164
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2013,Age,13-17 Years,45.8,36.7 to 55.2,167
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2011,Age,13-17 Years,46.0,36.3 to 56.1,159
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2010,Age,13-17 Years,43.3,34.4 to 52.7,139
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2020,Age,13-15 Years,95.7,90.6 to 98.1,213
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2009,Age,13-17 Years,34.7,27.2 to 43.0,164
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2017,Age,13-17 Years,91.1,86.4 to 94.3,356
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2016,Age,13-17 Years,91.8,87.5 to 94.8,375
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2014,Age,13-17 Years,89.9,84.4 to 93.6,286
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2015,Age,13-17 Years,92.6,88.4 to 95.4,366
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2012,Age,13-17 Years,90.2,83.5 to 94.3,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2013,Age,13-17 Years,93.9,89.4 to 96.5,369
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2011,Age,13-17 Years,90.1,82.8 to 94.4,327
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2010,Age,13-17 Years,93.2,89.2 to 95.7,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2009,Age,13-17 Years,90.3,85.7 to 93.5,336
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2008,Age,13-17 Years,88.7,84.2 to 92.0,338
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2016,Age,13-15 Years,89.6,83.3 to 93.7,227
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2018,Age,13-17 Years,76.7,70.0 to 82.3,285
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2012,Age,13-15 Years,60.6,51.1 to 69.3,206
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2013,Age,13-15 Years,67.2,58.9 to 74.5,230
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2018,Age,13-15 Years,92.4,85.7 to 96.1,168
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2019,Age,13-15 Years,85.9,76.5 to 92.0,165
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2017,Age,13-17 Years,68.1,61.9 to 73.7,356
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2016,Age,13-17 Years,59.1,53.0 to 65.0,375
HPV,"≥2 Doses, Females",States/Local Areas,Minnesota,2008,Age,13-17 Years,27.9,21.3 to 35.5,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Minnesota,2019,Age,13-17 Years,73.8,66.0 to 80.4,276
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2021,Age,13-17 Years,93.1,88.3 to 96.0,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2022,Age,13-17 Years,94.2,90.3 to 96.5,331
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2017,Age,13-15 Years,89.4,82.9 to 93.7,225
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2021,Age,13-15 Years,88.0,80.0 to 93.1,182
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2019,Age,13-17 Years,91.7,85.4 to 95.4,276
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2020,Age,13-17 Years,94.5,90.8 to 96.7,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Minnesota,2018,Age,13-17 Years,94.3,90.3 to 96.7,285
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2009,Age,13-17 Years,44.9,36.5 to 53.5,164
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2012,Age,13-17 Years,82.9,75.3 to 88.5,205
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2013,Age,13-17 Years,86.3,79.1 to 91.3,256
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2016,Age,13-17 Years,97.3,94.5 to 98.7,299
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2015,Age,13-17 Years,95.3,91.1 to 97.6,305
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2014,Age,13-17 Years,95.0,89.7 to 97.7,223
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2013,Age,13-17 Years,94.6,88.6 to 97.5,256
≥3 Doses HepB,,States/Local Areas,Minnesota,2016,Age,13-17 Years,92.3,87.9 to 95.2,375
≥3 Doses HepB,,States/Local Areas,Minnesota,2015,Age,13-17 Years,93.2,88.7 to 96.0,366
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2012,Age,13-17 Years,59.4,48.8 to 69.2,164
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2013,Age,13-17 Years,59.3,49.8 to 68.1,167
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2014,Age,13-17 Years,67.0,57.1 to 75.7,134
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2015,Age,13-17 Years,65.5,56.2 to 73.7,179
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2019,Age,13-17 Years,98.9,96.1 to 99.7,256
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2018,Age,13-17 Years,93.3,87.9 to 96.3,249
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2020,Age,13-17 Years,98.4,96.5 to 99.3,300
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2019,Age,13-17 Years,95.3,90.7 to 97.7,256
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2020,Age,13-17 Years,97.0,94.0 to 98.6,300
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2021,Age,13-17 Years,96.8,93.6 to 98.4,276
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2017,Age,13-17 Years,97.5,93.4 to 99.0,307
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2014,Age,13-17 Years,85.6,78.5 to 90.7,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2016,Age,13-17 Years,86.8,80.6 to 91.3,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2015,Age,13-17 Years,89.9,84.3 to 93.7,305
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2017,Age,13-17 Years,90.8,85.8 to 94.2,307
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2010,Age,13-17 Years,51.3,42.0 to 60.5,139
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2011,Age,13-17 Years,55.5,45.5 to 65.1,159
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2018,Age,13-17 Years,96.0,92.3 to 98.0,249
HPV,"≥2 Doses, Males and Females",States/Local Areas,Minnesota,2019,Age,13-17 Years,61.5,53.4 to 69.0,276
≥3 Doses HepB,,States/Local Areas,Minnesota,2018,Age,13-17 Years,93.8,88.7 to 96.7,285
≥3 Doses HepB,,States/Local Areas,Minnesota,2019,Age,13-17 Years,95.8,91.2 to 98.1,276
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2020,Age,13-17 Years,80.1,72.2 to 86.3,184
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2021,Age,13-17 Years,75.1,65.7 to 82.6,161
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2019,Age,13-17 Years,71.9,60.6 to 81.1,147
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2016,Age,13-17 Years,60.1,51.6 to 68.0,201
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2015,Age,13-17 Years,57.1,48.3 to 65.4,187
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2014,Age,13-17 Years,43.9,34.4 to 53.9,152
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2013,Age,13-17 Years,22.0,16.0 to 29.4,202
HPV,"≥2 Doses, Males and Females",States/Local Areas,Minnesota,2017,Age,13-17 Years,50.6,44.3 to 56.9,356
HPV,"≥2 Doses, Males and Females",States/Local Areas,Minnesota,2016,Age,13-17 Years,48.8,42.7 to 54.9,375
≥3 Doses HepB,,States/Local Areas,Minnesota,2020,Age,13-17 Years,96.4,93.6 to 98.0,330
≥3 Doses HepB,,States/Local Areas,Minnesota,2021,Age,13-17 Years,96.1,92.8 to 97.9,296
≥3 Doses HepB,,States/Local Areas,Minnesota,2022,Age,13-17 Years,95.7,92.3 to 97.7,331
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2022,Age,13-17 Years,98.1,96.3 to 99.0,314
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2010,Age,13-15 Years,54.9,46.5 to 63.0,180
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2011,Age,13-15 Years,65.4,56.4 to 73.4,204
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2017,Age,13-17 Years,66.0,56.8 to 74.2,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Minnesota,2021,Age,13-17 Years,98.6,96.0 to 99.5,276
Varicella,≥2 Doses with no disease history,States/Local Areas,Minnesota,2022,Age,13-17 Years,96.2,92.6 to 98.1,314
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2016,Age,13-17 Years,58.1,49.0 to 66.7,174
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2018,Age,13-17 Years,84.9,76.7 to 90.6,131
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2008,Age,13-15 Years,42.0,34.4 to 49.9,203
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2009,Age,13-15 Years,48.4,40.7 to 56.2,204
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2015,Age,13-15 Years,83.7,76.7 to 88.9,236
≥1 Dose MenACWY,,States/Local Areas,Minnesota,2014,Age,13-15 Years,74.4,66.2 to 81.2,169
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2022,Age,13-17 Years,88.0,81.7 to 92.3,179
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2017,Age,13-17 Years,70.1,61.6 to 77.4,182
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2019,Age,13-17 Years,75.8,64.4 to 84.4,129
HPV,"≥2 Doses, Males and Females",States/Local Areas,Minnesota,2018,Age,13-17 Years,63.1,55.6 to 70.1,285
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2020,Age,13-17 Years,81.9,72.0 to 88.8,146
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2021,Age,13-17 Years,84.8,74.4 to 91.4,135
HPV,"≥1 Dose, Females",States/Local Areas,Minnesota,2022,Age,13-17 Years,85.8,78.3 to 91.0,152
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2012,Age,13-17 Years,15.2,9.1 to 24.5,158
HPV,"≥1 Dose, Males",States/Local Areas,Minnesota,2018,Age,13-17 Years,68.8,58.5 to 77.6,154
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2019,Age,13-17 Years,56.8,48.8 to 64.6,276
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2020,Age,13-17 Years,69.2,62.5 to 75.1,330
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2021,Age,13-17 Years,65.7,58.4 to 72.3,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2022,Age,13-17 Years,68.6,62.1 to 74.5,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2015,Age,13-17 Years,90.4,85.7 to 93.6,366
≥2 Doses MMR,,States/Local Areas,Minnesota,2011,Age,13-17 Years,90.3,84.3 to 94.2,327
≥2 Doses MMR,,States/Local Areas,Minnesota,2010,Age,13-17 Years,93.5,88.9 to 96.3,310
≥2 Doses MMR,,States/Local Areas,Minnesota,2009,Age,13-17 Years,90.7,86.6 to 93.6,336
≥2 Doses MMR,,States/Local Areas,Minnesota,2008,Age,13-17 Years,90.1,85.5 to 93.3,338
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2019,Age,13-17 Years,54.7,43.5 to 65.4,147
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2009,Age,13-17 Years,52.0,46.0 to 58.0,336
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2010,Age,13-17 Years,70.3,64.0 to 75.8,310
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2011,Age,13-17 Years,82.5,75.7 to 87.8,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2022,Age,13-15 Years,93.2,86.9 to 96.6,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2008,Age,13-17 Years,40.7,34.8 to 46.8,338
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2017,Age,13-17 Years,46.9,40.7 to 53.3,356
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2018,Age,13-17 Years,58.8,51.2 to 66.0,285
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2012,Age,13-17 Years,85.6,78.4 to 90.7,322
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2014,Age,13-17 Years,87.2,81.3 to 91.4,286
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2013,Age,13-17 Years,91.4,86.8 to 94.5,369
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2016,Age,13-17 Years,44.1,38.1 to 50.3,375
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2019,Age,13-15 Years,90.5,80.5 to 95.6,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2020,Age,13-15 Years,93.7,88.5 to 96.6,213
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2021,Age,13-15 Years,89.2,81.7 to 93.8,182
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2017,Age,13-17 Years,50.4,41.6 to 59.2,182
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2016,Age,13-17 Years,45.3,37.1 to 53.9,201
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2018,Age,13-17 Years,60.6,50.2 to 70.1,154
HPV,"≥2 Doses, Males",States/Local Areas,Minnesota,2015,Age,13-17 Years,36.2,28.4 to 44.8,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2017,Age,13-15 Years,88.5,81.7 to 93.0,225
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2016,Age,13-15 Years,91.0,85.1 to 94.8,227
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2015,Age,13-15 Years,90.7,85.0 to 94.3,236
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2014,Age,13-15 Years,87.4,80.0 to 92.3,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Minnesota,2018,Age,13-15 Years,90.3,82.6 to 94.8,168
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2016,Age,13-17 Years,46.4,36.9 to 56.2,181
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2022,Age,13-15 Years,60.0,46.1 to 72.4,91
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2021,Age,13-15 Years,43.2,28.0 to 59.8,78
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2017,Age,13-17 Years,45.3,36.2 to 54.7,193
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2018,Age,13-17 Years,52.9,42.8 to 62.7,160
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2019,Age,13-17 Years,55.5,43.4 to 66.9,158
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2018,Age,13-15 Years,38.6,27.7 to 50.8,107
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2022,Age,13-17 Years,64.4,53.6 to 73.9,149
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2021,Age,13-17 Years,49.1,36.9 to 61.5,127
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2020,Age,13-17 Years,52.7,42.4 to 62.9,162
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2017,Age,13-17 Years,39.4,30.8 to 48.8,222
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2020,Age,13-15 Years,49.4,36.6 to 62.2,122
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2016,Age,13-17 Years,34.5,26.3 to 43.8,195
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2022,Age,13-15 Years,38.0,25.7 to 52.1,92
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2021,Age,13-15 Years,53.1,39.1 to 66.6,123
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2018,Age,13-17 Years,40.5,31.7 to 49.9,177
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2019,Age,13-17 Years,56.4,44.3 to 67.8,171
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2020,Age,13-17 Years,50.5,40.7 to 60.3,193
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2022,Age,13-15 Years,49.3,39.5 to 59.2,183
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2018,Age,13-15 Years,43.4,31.5 to 56.1,101
HPV,"≥3 Doses, Males",States/Local Areas,Florida,2014,Age,13-15 Years,21.5,11.8 to 35.8,111
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2018,Age,13-17 Years,97.7,94.4 to 99.1,303
≥3 Doses HepB,,States/Local Areas,Florida,2018,Age,13-17 Years,97.6,94.0 to 99.1,337
≥3 Doses HepB,,States/Local Areas,Florida,2019,Age,13-17 Years,95.6,90.9 to 97.9,329
≥3 Doses HepB,,States/Local Areas,Florida,2017,Age,13-17 Years,95.9,92.6 to 97.8,415
≥3 Doses HepB,,States/Local Areas,Florida,2016,Age,13-17 Years,96.2,93.2 to 97.9,376
≥3 Doses HepB,,States/Local Areas,Florida,2015,Age,13-17 Years,95.4,90.7 to 97.7,321
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2016,Age,13-17 Years,98.4,96.1 to 99.4,326
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2015,Age,13-17 Years,95.7,89.8 to 98.3,266
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2013,Age,13-17 Years,94.8,88.9 to 97.7,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2014,Age,13-17 Years,97.1,92.4 to 98.9,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2021,Age,13-15 Years,94.2,85.9 to 97.8,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2020,Age,13-15 Years,94.2,88.2 to 97.2,213
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2012,Age,13-15 Years,76.5,65.6 to 84.8,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2013,Age,13-15 Years,75.2,65.3 to 83.0,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2010,Age,13-15 Years,51.7,41.4 to 61.9,130
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2011,Age,13-15 Years,69.0,59.9 to 76.7,206
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2009,Age,13-15 Years,43.9,35.0 to 53.2,165
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2017,Age,13-17 Years,97.8,95.3 to 99.0,358
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2014,Age,13-17 Years,81.9,74.9 to 87.3,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2016,Age,13-17 Years,92.2,87.6 to 95.2,326
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2015,Age,13-17 Years,83.8,77.1 to 88.9,266
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2017,Age,13-17 Years,89.3,84.1 to 93.0,358
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2011,Age,13-17 Years,50.0,41.3 to 58.7,240
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2010,Age,13-17 Years,41.1,31.5 to 51.4,147
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2012,Age,13-17 Years,39.4,29.8 to 49.8,150
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2013,Age,13-17 Years,49.7,39.7 to 59.7,157
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2014,Age,13-17 Years,57.2,46.7 to 67.2,173
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2015,Age,13-17 Years,62.5,52.5 to 71.6,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2019,Age,13-15 Years,96.1,90.8 to 98.4,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2014,Age,13-15 Years,79.3,69.8 to 86.3,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2015,Age,13-15 Years,85.0,76.2 to 91.0,167
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2017,Age,13-15 Years,94.6,90.0 to 97.2,218
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2018,Age,13-15 Years,97.1,91.9 to 99.0,194
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2016,Age,13-15 Years,92.4,85.4 to 96.2,200
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2010,Age,13-17 Years,69.1,62.3 to 75.1,344
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2009,Age,13-17 Years,71.2,65.3 to 76.5,412
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2012,Age,13-17 Years,81.1,73.8 to 86.7,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2011,Age,13-17 Years,78.4,72.9 to 83.1,483
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2013,Age,13-17 Years,81.2,74.8 to 86.2,323
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2014,Age,13-17 Years,86.3,80.6 to 90.4,363
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2008,Age,13-15 Years,20.4,12.7 to 31.3,87
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2022,Age,13-17 Years,98.0,96.0 to 99.0,307
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2021,Age,13-17 Years,95.7,91.2 to 98.0,312
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2020,Age,13-17 Years,95.2,91.6 to 97.4,355
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2017,Age,13-17 Years,90.8,86.1 to 93.9,415
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2018,Age,13-17 Years,94.8,90.7 to 97.1,337
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2016,Age,13-17 Years,93.3,89.3 to 95.8,376
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2015,Age,13-17 Years,87.1,81.5 to 91.2,321
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2019,Age,13-17 Years,93.9,88.3 to 96.9,329
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2008,Age,13-17 Years,65.2,57.0 to 72.6,284
HPV,"≥3 Doses, Males",States/Local Areas,Florida,2015,Age,13-15 Years,23.6,15.3 to 34.4,99
HPV,"≥3 Doses, Males",States/Local Areas,Florida,2013,Age,13-17 Years,13.2,8.1 to 20.6,166
HPV,"≥3 Doses, Males",States/Local Areas,Florida,2014,Age,13-17 Years,17.5,10.8 to 27.0,190
HPV,"≥3 Doses, Males",States/Local Areas,Florida,2015,Age,13-17 Years,19.8,13.7 to 27.6,160
≥2 Doses Hep A,,States/Local Areas,Florida,2022,Age,13-17 Years,81.3,74.0 to 86.9,307
≥2 Doses Hep A,,States/Local Areas,Florida,2021,Age,13-17 Years,75.4,67.1 to 82.2,312
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2011,Age,13-17 Years,35.3,27.3 to 44.1,240
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2012,Age,13-17 Years,25.3,17.6 to 35.0,150
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2013,Age,13-17 Years,34.3,25.3 to 44.6,157
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2014,Age,13-17 Years,28.5,20.3 to 38.4,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2017,Age,13-17 Years,42.3,35.9 to 49.0,415
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018,Age,13-17 Years,46.5,39.7 to 53.5,337
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2019,Age,13-17 Years,56.0,47.4 to 64.2,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2012,Age,13-17 Years,86.8,80.8 to 91.1,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2013,Age,13-17 Years,84.8,78.5 to 89.5,323
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2014,Age,13-17 Years,90.7,85.6 to 94.1,363
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2016,Age,13-17 Years,40.4,34.0 to 47.1,376
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2019,Age,13-17 Years,58.0,45.9 to 69.2,171
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2008,Age,13-17 Years,29.0,22.6 to 36.2,284
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2022,Age,13-15 Years,95.2,91.4 to 97.4,183
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2011,Age,13-17 Years,77.5,71.8 to 82.3,483
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2010,Age,13-17 Years,61.9,55.3 to 68.1,344
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2009,Age,13-17 Years,47.2,41.2 to 53.3,412
≥2 Doses MMR,,States/Local Areas,Florida,2008,Age,13-17 Years,92.3,85.8 to 96.0,284
≥2 Doses MMR,,States/Local Areas,Florida,2009,Age,13-17 Years,90.4,84.9 to 94.1,412
≥2 Doses MMR,,States/Local Areas,Florida,2010,Age,13-17 Years,94.2,89.6 to 96.9,344
≥2 Doses MMR,,States/Local Areas,Florida,2011,Age,13-17 Years,93.9,89.8 to 96.4,483
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2015,Age,13-17 Years,87.3,81.6 to 91.4,321
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2022,Age,13-17 Years,58.9,51.2 to 66.2,307
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2021,Age,13-17 Years,49.0,40.7 to 57.2,312
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2020,Age,13-17 Years,51.6,44.4 to 58.7,355
≥2 Doses Hep A,,States/Local Areas,Florida,2020,Age,13-17 Years,78.2,71.8 to 83.5,355
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2015,Age,13-17 Years,36.8,28.1 to 46.5,161
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2010,Age,13-17 Years,24.9,16.9 to 35.1,147
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2008,Age,13-17 Years,20.2,13.3 to 29.6,149
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2009,Age,13-17 Years,24.6,18.1 to 32.5,216
Varicella,History of disease,States/Local Areas,Florida,2018,Age,13-17 Years,10.3,6.9 to 15.1,337
Varicella,History of disease,States/Local Areas,Florida,2008,Age,13-17 Years,56.3,48.2 to 64.1,284
Varicella,History of disease,States/Local Areas,Florida,2009,Age,13-17 Years,53.1,47.0 to 59.1,412
Varicella,History of disease,States/Local Areas,Florida,2017,Age,13-17 Years,13.3,9.6 to 18.2,415
Varicella,History of disease,States/Local Areas,Florida,2016,Age,13-17 Years,13.6,9.6 to 19.0,376
Varicella,History of disease,States/Local Areas,Florida,2012,Age,13-17 Years,29.2,22.7 to 36.7,325
Varicella,History of disease,States/Local Areas,Florida,2013,Age,13-17 Years,21.7,16.3 to 28.1,323
Varicella,History of disease,States/Local Areas,Florida,2010,Age,13-17 Years,44.3,37.9 to 50.8,344
Varicella,History of disease,States/Local Areas,Florida,2011,Age,13-17 Years,36.4,30.7 to 42.6,483
Varicella,History of disease,States/Local Areas,Florida,2015,Age,13-17 Years,20.1,14.8 to 26.7,321
Varicella,History of disease,States/Local Areas,Florida,2014,Age,13-17 Years,24.0,18.0 to 31.2,363
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2019,Age,13-15 Years,53.4,38.1 to 68.0,111
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2021,Age,13-17 Years,48.8,38.1 to 59.6,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2020,Age,13-15 Years,49.9,40.7 to 59.1,225
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2019,Age,13-15 Years,53.5,42.9 to 63.9,215
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2022,Age,13-17 Years,53.5,42.6 to 64.1,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2021,Age,13-15 Years,48.0,37.3 to 58.9,201
Varicella,History of disease,States/Local Areas,Florida,2020,Age,13-17 Years,7.7,4.6 to 12.6,355
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2019,Age,13-15 Years,53.7,39.0 to 67.7,104
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2020,Age,13-15 Years,50.4,37.6 to 63.1,103
Varicella,History of disease,States/Local Areas,Oklahoma,2009,Age,13-17 Years,56.1,50.0 to 62.0,336
Varicella,History of disease,States/Local Areas,Oklahoma,2017,Age,13-17 Years,15.7,11.4 to 21.2,338
Varicella,History of disease,States/Local Areas,Oklahoma,2012,Age,13-17 Years,28.5,23.0 to 34.7,322
Varicella,History of disease,States/Local Areas,Oklahoma,2013,Age,13-17 Years,25.5,20.8 to 30.8,426
Varicella,History of disease,States/Local Areas,Oklahoma,2010,Age,13-17 Years,46.8,40.5 to 53.3,300
Varicella,History of disease,States/Local Areas,Oklahoma,2011,Age,13-17 Years,37.0,30.8 to 43.6,360
Varicella,History of disease,States/Local Areas,Oklahoma,2014,Age,13-17 Years,23.4,18.4 to 29.3,356
Varicella,History of disease,States/Local Areas,Oklahoma,2008,Age,13-17 Years,61.6,55.2 to 67.6,292
Varicella,History of disease,States/Local Areas,Oklahoma,2018,Age,13-17 Years,7.0,4.7 to 10.2,360
Varicella,History of disease,States/Local Areas,Oklahoma,2016,Age,13-17 Years,9.4,6.2 to 13.9,281
Varicella,History of disease,States/Local Areas,Oklahoma,2015,Age,13-17 Years,14.5,10.3 to 19.9,291
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2019,Age,13-15 Years,35.5,25.0 to 47.5,98
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2020,Age,13-15 Years,37.2,27.1 to 48.4,110
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2018,Age,13-15 Years,34.5,23.9 to 46.8,87
Varicella,History of disease,States/Local Areas,Oklahoma,2019,Age,13-17 Years,13.3,9.6 to 18.2,369
Varicella,History of disease,States/Local Areas,Oklahoma,2020,Age,13-17 Years,9.5,6.4 to 13.8,338
Varicella,History of disease,States/Local Areas,Oklahoma,2022,Age,13-17 Years,10.6,6.4 to 17.0,249
Varicella,History of disease,States/Local Areas,Oklahoma,2021,Age,13-17 Years,8.1,5.0 to 13.1,240
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2022,Age,13-15 Years,40.7,29.0 to 53.4,88
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2021,Age,13-15 Years,51.9,38.5 to 65.0,74
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2018,Age,13-15 Years,27.6,19.3 to 37.9,112
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2022,Age,13-17 Years,46.5,35.4 to 58.0,109
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2021,Age,13-17 Years,55.1,44.5 to 65.4,114
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2019,Age,13-15 Years,41.4,30.8 to 52.8,116
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2020,Age,13-15 Years,42.1,31.1 to 53.9,105
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2017,Age,13-17 Years,45.6,36.5 to 54.9,156
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2016,Age,13-17 Years,43.6,33.6 to 54.1,127
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2019,Age,13-17 Years,42.4,33.6 to 51.7,168
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2018,Age,13-17 Years,43.9,35.2 to 53.1,157
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2020,Age,13-17 Years,47.0,38.1 to 56.2,165
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2022,Age,13-15 Years,41.9,28.2 to 57.0,65
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2021,Age,13-15 Years,48.8,35.9 to 61.8,77
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2019,Age,13-17 Years,41.2,33.1 to 49.9,201
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2020,Age,13-17 Years,44.6,35.8 to 53.8,173
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2017,Age,13-17 Years,37.5,29.5 to 46.3,182
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2018,Age,13-17 Years,32.1,25.2 to 39.9,203
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2019,Age,13-15 Years,38.5,30.9 to 46.8,214
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2022,Age,13-17 Years,45.8,36.0 to 56.0,140
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2021,Age,13-15 Years,50.3,40.9 to 59.7,151
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2022,Age,13-15 Years,41.2,32.1 to 51.1,153
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2016,Age,13-17 Years,35.0,26.1 to 45.2,154
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2013,Age,13-17 Years,17.3,12.3 to 23.7,242
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2012,Age,13-17 Years,10.6,6.3 to 17.3,155
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2014,Age,13-17 Years,19.9,13.8 to 27.9,186
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2015,Age,13-17 Years,35.7,27.4 to 45.1,162
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2013,Age,13-15 Years,20.4,14.0 to 28.8,161
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2014,Age,13-15 Years,20.8,12.8 to 32.1,108
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2015,Age,13-17 Years,32.2,23.8 to 41.9,129
HPV,"≥3 Doses, Males",States/Local Areas,Oklahoma,2015,Age,13-15 Years,34.6,24.4 to 46.5,104
≥2 Doses Hep A,,States/Local Areas,Oklahoma,2021,Age,13-17 Years,91.4,86.6 to 94.6,240
≥2 Doses Hep A,,States/Local Areas,Oklahoma,2022,Age,13-17 Years,89.1,82.8 to 93.2,249
≥2 Doses Hep A,,States/Local Areas,Oklahoma,2020,Age,13-17 Years,92.9,89.4 to 95.4,338
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2012,Age,13-17 Years,38.4,29.5 to 48.1,167
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2011,Age,13-17 Years,27.7,19.9 to 37.1,175
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2013,Age,13-17 Years,35.4,27.6 to 44.0,184
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2014,Age,13-17 Years,36.4,27.9 to 46.0,170
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2010,Age,13-17 Years,31.1,23.5 to 39.9,163
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2008,Age,13-17 Years,16.6,10.9 to 24.4,141
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2009,Age,13-17 Years,16.2,10.8 to 23.4,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2022,Age,13-17 Years,46.2,38.7 to 53.8,249
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2021,Age,13-17 Years,56.7,49.3 to 63.8,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2011,Age,13-17 Years,66.0,59.4 to 72.0,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2010,Age,13-17 Years,54.8,48.3 to 61.2,300
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2009,Age,13-17 Years,35.1,29.6 to 41.1,336
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2019,Age,13-17 Years,41.8,35.7 to 48.1,369
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2020,Age,13-17 Years,45.8,39.4 to 52.3,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2015,Age,13-17 Years,84.4,79.0 to 88.6,291
≥2 Doses MMR,,States/Local Areas,Oklahoma,2008,Age,13-17 Years,90.2,85.9 to 93.3,292
≥2 Doses MMR,,States/Local Areas,Oklahoma,2009,Age,13-17 Years,86.9,82.2 to 90.6,336
≥2 Doses MMR,,States/Local Areas,Oklahoma,2010,Age,13-17 Years,87.9,83.1 to 91.5,300
≥2 Doses MMR,,States/Local Areas,Oklahoma,2011,Age,13-17 Years,91.2,86.6 to 94.3,360
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2019,Age,13-17 Years,44.9,36.6 to 53.6,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2008,Age,13-17 Years,28.6,23.3 to 34.5,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2022,Age,13-15 Years,89.8,83.4 to 93.9,153
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2016,Age,13-17 Years,39.2,32.4 to 46.4,281
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2013,Age,13-17 Years,78.1,72.8 to 82.5,426
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2014,Age,13-17 Years,82.6,77.4 to 86.8,356
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018,Age,13-17 Years,37.9,32.2 to 43.9,360
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2017,Age,13-17 Years,41.4,35.3 to 47.8,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2012,Age,13-17 Years,77.1,71.0 to 82.2,322
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2020,Age,13-15 Years,39.5,32.0 to 47.6,215
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2021,Age,13-17 Years,58.2,47.9 to 67.8,126
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2022,Age,13-15 Years,46.5,34.5 to 58.9,86
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2021,Age,13-15 Years,57.0,44.0 to 69.1,99
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2020,Age,13-15 Years,44.5,33.2 to 56.5,105
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2019,Age,13-15 Years,48.0,35.6 to 60.6,102
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2022,Age,13-15 Years,58.2,43.8 to 71.4,69
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2021,Age,13-15 Years,47.6,35.5 to 59.9,122
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2020,Age,13-17 Years,51.6,42.0 to 61.1,186
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2016,Age,13-17 Years,37.0,28.4 to 46.5,161
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2017,Age,13-17 Years,52.9,43.6 to 62.0,164
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2022,Age,13-17 Years,63.8,52.8 to 73.5,117
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2021,Age,13-17 Years,54.9,44.6 to 64.8,175
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2018,Age,13-15 Years,52.1,40.7 to 63.3,100
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2018,Age,13-17 Years,49.4,40.3 to 58.5,162
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2019,Age,13-17 Years,55.6,45.4 to 65.4,157
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2018,Age,13-17 Years,52.7,43.9 to 61.3,172
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2017,Age,13-17 Years,45.3,36.5 to 54.4,180
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2020,Age,13-17 Years,48.6,39.4 to 57.9,183
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2019,Age,13-17 Years,50.3,40.2 to 60.4,156
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2020,Age,13-15 Years,44.4,36.2 to 53.0,216
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2022,Age,13-15 Years,52.2,42.8 to 61.5,155
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2021,Age,13-17 Years,58.0,47.6 to 67.8,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2021,Age,13-15 Years,52.1,43.1 to 60.9,221
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2022,Age,13-17 Years,55.4,45.5 to 64.8,142
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2019,Age,13-15 Years,53.1,44.2 to 61.9,205
Varicella,History of disease,States/Local Areas,Nevada,2009,Age,13-17 Years,49.2,42.8 to 55.7,336
Varicella,History of disease,States/Local Areas,Nevada,2008,Age,13-17 Years,56.7,49.3 to 63.9,235
Varicella,History of disease,States/Local Areas,Nevada,2014,Age,13-17 Years,25.4,20.1 to 31.6,351
Varicella,History of disease,States/Local Areas,Nevada,2015,Age,13-17 Years,18.6,13.8 to 24.4,372
Varicella,History of disease,States/Local Areas,Nevada,2016,Age,13-17 Years,19.0,14.1 to 25.1,330
Varicella,History of disease,States/Local Areas,Nevada,2010,Age,13-17 Years,49.0,42.9 to 55.2,330
Varicella,History of disease,States/Local Areas,Nevada,2011,Age,13-17 Years,41.4,34.0 to 49.2,412
Varicella,History of disease,States/Local Areas,Nevada,2013,Age,13-17 Years,27.1,21.6 to 33.4,335
Varicella,History of disease,States/Local Areas,Nevada,2012,Age,13-17 Years,29.8,24.3 to 36.1,329
Varicella,History of disease,States/Local Areas,Nevada,2018,Age,13-17 Years,13.7,9.7 to 19.1,334
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2018,Age,13-15 Years,47.9,36.5 to 59.5,101
Varicella,History of disease,States/Local Areas,Nevada,2022,Age,13-17 Years,7.9,4.5 to 13.3,259
Varicella,History of disease,States/Local Areas,Nevada,2021,Age,13-17 Years,7.7,4.7 to 12.3,333
Varicella,History of disease,States/Local Areas,Nevada,2020,Age,13-17 Years,7.5,4.6 to 12.0,369
Varicella,History of disease,States/Local Areas,Nevada,2019,Age,13-17 Years,12.4,8.4 to 18.1,313
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2020,Age,13-15 Years,44.3,32.8 to 56.5,111
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2019,Age,13-15 Years,57.9,45.1 to 69.7,103
Varicella,History of disease,States/Local Areas,Nevada,2017,Age,13-17 Years,12.0,8.4 to 16.9,344
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2016,Age,13-17 Years,43.0,34.2 to 52.3,169
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2023,Age,13-17 Years,60.4,49.7 to 70.2,136
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2023,Age,13-17 Years,91.7,86.8 to 94.9,243
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2023,Age,13-17 Years,92.6,87.8 to 95.6,243
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2023,Age,13-17 Years,62.9,55.2 to 69.9,243
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2023,Age,13-17 Years,60.4,52.8 to 67.6,243
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2023,Age,13-17 Years,60.4,49.3 to 70.6,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2023,Age,13-17 Years,38.4,31.1 to 46.3,243
≥2 Doses MMR,,States/Local Areas,Mississippi,2023,Age,13-17 Years,90.7,85.4 to 94.2,243
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2023,Age,13-17 Years,37.6,27.7 to 48.6,136
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2023,Age,13-17 Years,90.0,84.4 to 93.8,227
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2023,Age,13-17 Years,95.7,91.9 to 97.8,227
Varicella,History of disease,States/Local Areas,Mississippi,2023,Age,13-17 Years,8.1,4.4 to 14.2,243
≥3 Doses HepB,,States/Local Areas,Mississippi,2023,Age,13-17 Years,91.4,86.5 to 94.6,243
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2023,Age,13-17 Years,90.8,85.6 to 94.3,243
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2023,Age,13-15 Years,32.0,19.9 to 47.2,80
≥2 Doses Hep A,,States/Local Areas,Mississippi,2023,Age,13-17 Years,72.2,65.1 to 78.4,243
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2023,Age,13-15 Years,92.8,87.3 to 96.1,144
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2023,Age,13-15 Years,63.0,53.2 to 71.9,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2023,Age,13-15 Years,32.8,23.8 to 43.2,144
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2023,Age,13-15 Years,33.4,21.2 to 48.4,64
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2023,Age,13-15 Years,89.1,81.2 to 93.9,135
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2023,Age,13-17 Years,39.3,29.0 to 50.7,107
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Uninsured,88.1,76.9 to 94.3,61
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Other,87.2,75.4 to 93.8,105
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Any Medicaid,91.1,87.5 to 93.8,589
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Private Insurance Only,88.9,85.5 to 91.6,617
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Other,25.0,16.4 to 36.3,105
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Uninsured,25.2,13.8 to 41.5,61
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Any Medicaid,37.1,32.4 to 42.0,589
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Private Insurance Only,30.9,26.5 to 35.8,617
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Uninsured,55.4,40.0 to 69.9,61
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Uninsured,50.9,35.8 to 65.9,61
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Other,44.9,33.6 to 56.8,105
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Other,61.1,48.6 to 72.3,105
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Private Insurance Only,45.6,40.7 to 50.5,617
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Any Medicaid,63.6,58.8 to 68.2,589
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Any Medicaid,63.8,58.9 to 68.4,589
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018-2022,Insurance Coverage,Private Insurance Only,57.1,52.1 to 61.9,617
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Poverty,Below Poverty Level,92.6,87.9 to 95.6,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018-2022,Poverty,Living At or Above Poverty Level,88.3,85.4 to 90.7,1025
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2022,Age,13-17 Years,39.8,28.8 to 52.0,116
HPV,"≥2 Doses, Males and Females",States/Local Areas,Mississippi,2022,Age,13-17 Years,38.7,30.8 to 47.1,232
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2012,Age,13-15 Years,15.5,8.8 to 26.0,99
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2011,Age,13-15 Years,21.4,11.5 to 36.4,101
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2010,Age,13-15 Years,20.5,12.8 to 31.1,119
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2022,Age,13-17 Years,55.5,47.1 to 63.5,232
≥2 Doses MMR,,States/Local Areas,Mississippi,2022,Age,13-17 Years,90.6,85.1 to 94.2,232
≥2 Doses MMR,,States/Local Areas,Mississippi,2021,Age,13-17 Years,92.3,87.1 to 95.5,303
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018,Age,13-17 Years,64.0,57.2 to 70.3,285
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2019,Age,13-17 Years,60.3,52.6 to 67.5,270
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2021,Age,13-17 Years,60.2,53.1 to 66.9,303
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2020,Age,13-17 Years,63.5,56.4 to 70.0,282
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2013,Age,13-15 Years,22.3,13.5 to 34.4,93
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2014,Age,13-15 Years,26.4,16.9 to 38.6,107
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2015,Age,13-15 Years,24.0,16.8 to 33.1,129
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2022,Age,13-17 Years,37.4,26.9 to 49.3,116
≥2 Doses MMR,,States/Local Areas,Mississippi,2016,Age,13-17 Years,94.7,91.2 to 96.8,377
≥2 Doses MMR,,States/Local Areas,Mississippi,2015,Age,13-17 Years,92.3,88.5 to 94.9,364
≥2 Doses MMR,,States/Local Areas,Mississippi,2014,Age,13-17 Years,93.4,89.6 to 95.9,356
≥2 Doses MMR,,States/Local Areas,Mississippi,2012,Age,13-17 Years,95.6,92.6 to 97.4,321
≥2 Doses MMR,,States/Local Areas,Mississippi,2013,Age,13-17 Years,92.3,87.4 to 95.4,284
HPV,"≥3 Doses, Males and Females",States/Local Areas,Mississippi,2014,Age,13-17 Years,16.1,11.7 to 21.6,356
HPV,"≥3 Doses, Males and Females",States/Local Areas,Mississippi,2015,Age,13-17 Years,22.9,18.1 to 28.5,364
≥2 Doses MMR,,States/Local Areas,Mississippi,2020,Age,13-17 Years,95.2,91.1 to 97.5,282
HPV,"≥3 Doses, Males and Females",States/Local Areas,Mississippi,2013,Age,13-17 Years,14.6,10.4 to 20.2,284
HPV,"≥3 Doses, Males and Females",States/Local Areas,Mississippi,2011,Age,13-17 Years,9.8,5.9 to 15.9,345
HPV,"≥3 Doses, Males and Females",States/Local Areas,Mississippi,2012,Age,13-17 Years,7.3,4.6 to 11.3,321
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2016,Age,13-17 Years,57.4,51.0 to 63.5,377
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2015,Age,13-17 Years,55.3,49.3 to 61.2,364
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2013,Age,13-17 Years,50.1,43.2 to 56.9,284
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2014,Age,13-17 Years,46.0,39.6 to 52.6,356
≥2 Doses MMR,,States/Local Areas,Mississippi,2018,Age,13-17 Years,94.2,89.9 to 96.7,285
≥2 Doses MMR,,States/Local Areas,Mississippi,2019,Age,13-17 Years,92.1,86.9 to 95.3,270
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2022,Age,13-17 Years,87.0,80.3 to 91.6,232
≥2 Doses MMR,,States/Local Areas,Mississippi,2017,Age,13-17 Years,96.2,93.7 to 97.7,347
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2017,Age,13-17 Years,63.0,56.9 to 68.7,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2019,Age,13-17 Years,90.4,84.4 to 94.2,270
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2021,Age,13-17 Years,89.1,83.5 to 92.9,303
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2020,Age,13-17 Years,93.0,88.9 to 95.6,282
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2016,Age,13-17 Years,82.0,76.5 to 86.5,377
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2012,Age,13-17 Years,40.7,33.8 to 47.9,321
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2022,Age,13-15 Years,53.6,42.9 to 63.9,147
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2010,Age,13-17 Years,26.0,21.0 to 31.7,354
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2011,Age,13-17 Years,34.2,27.8 to 41.2,345
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2008,Age,13-17 Years,14.8,10.9 to 19.8,404
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2009,Age,13-17 Years,19.3,15.5 to 23.7,438
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018,Age,13-17 Years,90.0,84.8 to 93.6,285
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2017,Age,13-17 Years,92.4,88.6 to 95.0,347
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2015,Age,13-17 Years,24.4,18.4 to 31.6,205
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2009,Age,13-17 Years,8.1,4.9 to 13.0,191
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2012,Age,13-17 Years,12.1,7.3 to 19.3,160
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2011,Age,13-17 Years,19.6,11.9 to 30.5,167
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2013,Age,13-17 Years,25.2,17.6 to 34.8,148
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2014,Age,13-17 Years,24.6,17.2 to 33.9,160
HPV,"≥3 Doses, Females",States/Local Areas,Mississippi,2010,Age,13-17 Years,20.0,13.8 to 28.2,176
≥2 Doses Hep A,,States/Local Areas,Mississippi,2020,Age,13-17 Years,55.0,48.0 to 61.8,282
≥2 Doses Hep A,,States/Local Areas,Mississippi,2021,Age,13-17 Years,52.5,45.4 to 59.5,303
≥2 Doses Hep A,,States/Local Areas,Mississippi,2022,Age,13-17 Years,64.8,56.8 to 72.1,232
HPV,"≥3 Doses, Males",States/Local Areas,Mississippi,2015,Age,13-15 Years,20.5,12.6 to 31.6,105
≥3 Doses HepB,,States/Local Areas,Mississippi,2010,Age,13-17 Years,83.2,77.9 to 87.4,354
≥3 Doses HepB,,States/Local Areas,Mississippi,2009,Age,13-17 Years,78.6,73.9 to 82.7,438
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2021,Age,13-15 Years,94.7,88.2 to 97.7,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2020,Age,13-15 Years,94.0,87.4 to 97.3,165
HPV,"≥3 Doses, Males",States/Local Areas,Mississippi,2015,Age,13-17 Years,21.4,14.5 to 30.4,159
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2022,Age,13-17 Years,90.0,84.5 to 93.7,232
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2021,Age,13-17 Years,91.9,86.7 to 95.2,303
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2020,Age,13-17 Years,95.5,91.4 to 97.7,282
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2010,Age,13-17 Years,66.8,61.1 to 72.0,354
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2009,Age,13-17 Years,63.8,58.3 to 68.9,438
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2008,Age,13-17 Years,68.6,63.0 to 73.6,404
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2012,Age,13-17 Years,67.8,60.7 to 74.1,321
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2011,Age,13-17 Years,61.2,54.2 to 67.7,345
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2013,Age,13-17 Years,68.5,61.8 to 74.5,284
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2014,Age,13-17 Years,69.1,62.6 to 74.9,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2017,Age,13-17 Years,91.1,87.2 to 93.9,347
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2018,Age,13-17 Years,90.4,85.7 to 93.7,285
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2016,Age,13-17 Years,79.9,74.3 to 84.5,377
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2015,Age,13-17 Years,78.4,73.2 to 82.8,364
Varicella,≥2 Doses or history of disease,States/Local Areas,Mississippi,2019,Age,13-17 Years,91.6,86.3 to 94.9,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2012,Age,13-15 Years,52.3,40.4 to 64.0,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2013,Age,13-15 Years,56.0,45.7 to 65.8,132
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2011,Age,13-15 Years,35.8,25.1 to 48.1,133
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2010,Age,13-15 Years,26.4,18.3 to 36.4,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2009,Age,13-15 Years,14.8,8.8 to 23.9,125
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2014,Age,13-15 Years,59.8,50.4 to 68.5,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2015,Age,13-15 Years,76.1,68.2 to 82.5,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2017,Age,13-15 Years,96.0,92.2 to 98.0,177
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2016,Age,13-15 Years,88.0,81.5 to 92.4,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2019,Age,13-15 Years,94.7,88.0 to 97.8,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2018,Age,13-15 Years,90.4,82.5 to 95.0,143
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2010,Age,13-17 Years,69.4,60.7 to 77.0,162
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2009,Age,13-17 Years,47.2,38.7 to 55.9,176
≥3 Doses HepB,,States/Local Areas,Mississippi,2008,Age,13-17 Years,60.8,55.0 to 66.2,404
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2011,Age,13-17 Years,81.5,73.1 to 87.7,194
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2009,Age,13-17 Years,12.2,7.6 to 18.9,176
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2008,Age,13-17 Years,40.0,31.0 to 49.8,138
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2012,Age,13-17 Years,91.6,84.4 to 95.7,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2010,Age,13-17 Years,24.7,17.7 to 33.3,162
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2011,Age,13-17 Years,32.9,24.3 to 42.8,194
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2009,Age,13-17 Years,22.9,16.5 to 30.9,191
≥3 Doses HepB,,States/Local Areas,Mississippi,2017,Age,13-17 Years,94.6,91.2 to 96.7,347
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2022,Age,13-15 Years,89.5,81.3 to 94.4,140
Varicella,History of disease,States/Local Areas,Mississippi,2009,Age,13-17 Years,58.8,53.2 to 64.1,438
Varicella,History of disease,States/Local Areas,Mississippi,2008,Age,13-17 Years,65.3,59.6 to 70.5,404
Varicella,History of disease,States/Local Areas,Mississippi,2017,Age,13-17 Years,17.6,13.2 to 23.0,347
Varicella,History of disease,States/Local Areas,Mississippi,2018,Age,13-17 Years,15.0,10.7 to 20.5,285
Varicella,History of disease,States/Local Areas,Mississippi,2019,Age,13-17 Years,8.9,5.8 to 13.5,270
Varicella,History of disease,States/Local Areas,Mississippi,2020,Age,13-17 Years,11.1,7.4 to 16.3,282
Varicella,History of disease,States/Local Areas,Mississippi,2021,Age,13-17 Years,7.6,4.9 to 11.6,303
Varicella,History of disease,States/Local Areas,Mississippi,2012,Age,13-17 Years,37.9,31.2 to 45.0,321
Varicella,History of disease,States/Local Areas,Mississippi,2013,Age,13-17 Years,29.0,23.2 to 35.5,284
Varicella,History of disease,States/Local Areas,Mississippi,2010,Age,13-17 Years,55.9,49.9 to 61.7,354
Varicella,History of disease,States/Local Areas,Mississippi,2011,Age,13-17 Years,42.2,35.5 to 49.2,345
Varicella,History of disease,States/Local Areas,Mississippi,2015,Age,13-17 Years,24.2,19.5 to 29.8,364
Varicella,History of disease,States/Local Areas,Mississippi,2014,Age,13-17 Years,28.3,22.6 to 34.7,356
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2020,Age,13-15 Years,30.4,20.7 to 42.3,89
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2018,Age,13-15 Years,35.1,23.5 to 48.9,77
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2012,Age,13-17 Years,48.1,38.6 to 57.8,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2013,Age,13-17 Years,55.7,47.4 to 63.6,200
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2008,Age,13-17 Years,15.8,10.6 to 23.0,187
≥3 Doses HepB,,States/Local Areas,Mississippi,2012,Age,13-17 Years,93.5,87.3 to 96.8,321
≥3 Doses HepB,,States/Local Areas,Mississippi,2011,Age,13-17 Years,95.3,92.6 to 97.1,345
≥3 Doses HepB,,States/Local Areas,Mississippi,2013,Age,13-17 Years,95.9,92.8 to 97.7,284
≥3 Doses HepB,,States/Local Areas,Mississippi,2014,Age,13-17 Years,91.7,87.3 to 94.6,356
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2016,Age,13-17 Years,95.6,91.1 to 97.9,314
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2015,Age,13-17 Years,95.4,91.8 to 97.5,278
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2013,Age,13-17 Years,94.8,87.9 to 97.8,200
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2014,Age,13-17 Years,96.2,92.4 to 98.1,265
≥3 Doses HepB,,States/Local Areas,Mississippi,2016,Age,13-17 Years,93.5,90.2 to 95.7,377
≥3 Doses HepB,,States/Local Areas,Mississippi,2015,Age,13-17 Years,92.1,88.1 to 94.8,364
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2018,Age,13-17 Years,94.5,89.4 to 97.2,242
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2019,Age,13-17 Years,94.0,88.6 to 97.0,242
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2018,Age,13-17 Years,88.8,83.3 to 92.6,242
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2020,Age,13-17 Years,97.0,93.2 to 98.7,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2019,Age,13-17 Years,90.7,85.0 to 94.4,242
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2021,Age,13-17 Years,91.3,85.6 to 94.8,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2020,Age,13-17 Years,94.9,90.3 to 97.4,251
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2017,Age,13-17 Years,97.9,95.5 to 99.0,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2014,Age,13-17 Years,56.9,49.1 to 64.5,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2016,Age,13-17 Years,75.8,69.3 to 81.3,314
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2015,Age,13-17 Years,71.5,65.0 to 77.1,278
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2017,Age,13-17 Years,89.2,84.5 to 92.6,288
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2011,Age,13-17 Years,31.9,22.6 to 43.0,167
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2010,Age,13-17 Years,34.0,26.2 to 42.6,176
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2012,Age,13-17 Years,39.7,29.8 to 50.6,160
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2013,Age,13-17 Years,53.1,43.6 to 62.3,148
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2015,Age,13-17 Years,52.4,44.4 to 60.2,205
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2014,Age,13-17 Years,45.8,36.5 to 55.4,160
≥3 Doses HepB,,States/Local Areas,Mississippi,2018,Age,13-17 Years,91.9,87.3 to 94.9,285
≥3 Doses HepB,,States/Local Areas,Mississippi,2019,Age,13-17 Years,89.1,83.4 to 93.1,270
HPV,"≥2 Doses, Males and Females",States/Local Areas,Mississippi,2019,Age,13-17 Years,33.2,26.2 to 40.9,270
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2021,Age,13-17 Years,54.3,44.6 to 63.7,157
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2020,Age,13-17 Years,59.2,49.1 to 68.6,142
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2019,Age,13-17 Years,43.1,33.2 to 53.5,144
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2016,Age,13-17 Years,43.6,35.1 to 52.4,209
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2015,Age,13-17 Years,38.9,30.4 to 48.0,159
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2013,Age,13-17 Years,13.6,8.2 to 21.6,136
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2014,Age,13-17 Years,26.5,19.3 to 35.3,196
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2018,Age,13-17 Years,44.7,35.5 to 54.2,149
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2017,Age,13-17 Years,43.6,35.3 to 52.2,188
HPV,"≥2 Doses, Males and Females",States/Local Areas,Mississippi,2018,Age,13-17 Years,34.8,28.5 to 41.8,285
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2022,Age,13-17 Years,60.6,48.7 to 71.3,116
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2021,Age,13-17 Years,58.3,47.9 to 68.0,146
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2020,Age,13-17 Years,50.9,41.3 to 60.3,140
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2012,Age,13-17 Years,20.9,13.2 to 31.6,161
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2019,Age,13-17 Years,56.3,45.3 to 66.6,126
HPV,"≥2 Doses, Males and Females",States/Local Areas,Mississippi,2017,Age,13-17 Years,35.3,29.6 to 41.5,347
HPV,"≥2 Doses, Males and Females",States/Local Areas,Mississippi,2016,Age,13-17 Years,35.4,29.5 to 41.8,377
≥3 Doses HepB,,States/Local Areas,Mississippi,2022,Age,13-17 Years,92.5,87.3 to 95.7,232
≥3 Doses HepB,,States/Local Areas,Mississippi,2021,Age,13-17 Years,91.0,85.9 to 94.4,303
≥3 Doses HepB,,States/Local Areas,Mississippi,2020,Age,13-17 Years,94.5,89.6 to 97.2,282
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2022,Age,13-17 Years,92.9,87.7 to 96.0,218
HPV,"≥1 Dose, Males",States/Local Areas,Mississippi,2022,Age,13-17 Years,61.4,50.1 to 71.6,116
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2009,Age,13-15 Years,20.3,15.4 to 26.3,281
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2008,Age,13-15 Years,15.5,10.7 to 22.1,244
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2011,Age,13-15 Years,34.6,26.5 to 43.8,216
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2010,Age,13-15 Years,27.6,21.3 to 34.9,227
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2017,Age,13-17 Years,56.0,46.9 to 64.7,159
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2016,Age,13-17 Years,47.8,38.7 to 57.0,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Mississippi,2022,Age,13-17 Years,89.0,83.1 to 93.1,218
Varicella,≥1 Dose with no disease history,States/Local Areas,Mississippi,2021,Age,13-17 Years,94.6,89.7 to 97.3,274
HPV,"≥1 Dose, Females",States/Local Areas,Mississippi,2018,Age,13-17 Years,59.2,49.3 to 68.3,136
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2008,Age,13-17 Years,28.7,23.7 to 34.3,404
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2009,Age,13-17 Years,29.1,24.5 to 34.1,438
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2012,Age,13-17 Years,56.8,49.5 to 63.8,321
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2013,Age,13-17 Years,61.0,54.2 to 67.5,284
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2010,Age,13-17 Years,34.6,29.1 to 40.6,354
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2011,Age,13-17 Years,43.4,36.6 to 50.5,345
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2014,Age,13-15 Years,46.8,38.7 to 55.0,230
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2015,Age,13-15 Years,57.5,49.9 to 64.7,234
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2008,Age,13-17 Years,9.1,5.1 to 15.5,187
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2016,Age,13-15 Years,59.3,51.1 to 67.1,222
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2012,Age,13-15 Years,42.3,33.0 to 52.1,184
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2013,Age,13-15 Years,49.7,40.9 to 58.6,174
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2017,Age,13-17 Years,94.9,91.9 to 96.8,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2016,Age,13-17 Years,83.0,77.5 to 87.3,377
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2015,Age,13-17 Years,76.8,71.2 to 81.5,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2014,Age,13-17 Years,71.1,64.5 to 77.0,356
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2013,Age,13-15 Years,65.4,56.4 to 73.4,174
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2012,Age,13-17 Years,11.2,6.2 to 19.4,161
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2012,Age,13-15 Years,58.6,48.8 to 67.9,184
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2011,Age,13-15 Years,37.7,29.5 to 46.7,216
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2009,Age,13-15 Years,24.6,19.2 to 31.0,281
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2010,Age,13-15 Years,30.5,23.9 to 38.0,227
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2008,Age,13-15 Years,22.8,17.0 to 29.8,244
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2017,Age,13-17 Years,42.0,33.4 to 51.0,159
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2016,Age,13-17 Years,38.5,29.9 to 47.8,168
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2014,Age,13-17 Years,30.6,22.6 to 39.9,160
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2015,Age,13-17 Years,37.2,29.8 to 45.2,205
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2021,Age,13-15 Years,60.8,51.9 to 69.1,189
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2019,Age,13-17 Years,34.1,23.9 to 46.0,126
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2018,Age,13-17 Years,40.6,31.2 to 50.7,136
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2019,Age,13-17 Years,90.4,84.4 to 94.2,270
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2020,Age,13-17 Years,93.3,89.3 to 95.9,282
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2018,Age,13-17 Years,91.8,86.8 to 95.0,285
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2019,Age,13-17 Years,49.5,42.0 to 57.1,270
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2022,Age,13-17 Years,87.4,80.7 to 92.0,232
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Mississippi,2021,Age,13-17 Years,90.5,85.0 to 94.1,303
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2017,Age,13-15 Years,64.2,56.4 to 71.3,208
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2018,Age,13-15 Years,65.9,56.8 to 73.9,165
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2019,Age,13-15 Years,55.3,45.3 to 64.8,160
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2017,Age,13-17 Years,49.6,43.4 to 55.9,347
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2016,Age,13-17 Years,45.6,39.4 to 52.0,377
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2018,Age,13-17 Years,51.7,44.9 to 58.5,285
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2022,Age,13-17 Years,61.0,52.8 to 68.6,232
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2021,Age,13-17 Years,56.2,49.2 to 63.1,303
HPV,"≥1 Dose, Males and Females",States/Local Areas,Mississippi,2020,Age,13-17 Years,55.2,48.2 to 61.9,282
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2009,Age,13-17 Years,14.9,10.0 to 21.7,191
≥1 Dose MenACWY,,States/Local Areas,Mississippi,2020,Age,13-15 Years,60.9,51.9 to 69.2,177
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2010,Age,13-17 Years,24.9,18.1 to 33.3,176
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2011,Age,13-17 Years,22.9,14.8 to 33.5,167
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2012,Age,13-17 Years,22.3,15.5 to 30.9,160
HPV,"≥2 Doses, Females",States/Local Areas,Mississippi,2013,Age,13-17 Years,35.6,26.9 to 45.4,148
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2017,Age,13-15 Years,93.2,88.3 to 96.2,208
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2016,Age,13-15 Years,92.4,86.7 to 95.8,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2014,Age,13-15 Years,81.3,73.6 to 87.2,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2015,Age,13-15 Years,85.9,79.7 to 90.5,234
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2014,Age,13-17 Years,16.2,10.4 to 24.5,196
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2017,Age,13-17 Years,29.0,21.8 to 37.4,188
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2016,Age,13-17 Years,32.5,24.8 to 41.2,209
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2018,Age,13-17 Years,29.3,21.4 to 38.8,149
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2015,Age,13-17 Years,29.6,21.8 to 38.8,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2019,Age,13-15 Years,89.3,80.8 to 94.3,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2020,Age,13-15 Years,90.4,84.3 to 94.3,177
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2021,Age,13-15 Years,90.8,84.2 to 94.8,189
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2018,Age,13-15 Years,88.3,80.6 to 93.2,165
≥2 Doses MMR,,States/Local Areas,Mississippi,2008,Age,13-17 Years,94.5,91.6 to 96.5,404
≥2 Doses MMR,,States/Local Areas,Mississippi,2009,Age,13-17 Years,93.1,90.0 to 95.3,438
≥2 Doses MMR,,States/Local Areas,Mississippi,2010,Age,13-17 Years,87.8,82.6 to 91.7,354
≥2 Doses MMR,,States/Local Areas,Mississippi,2011,Age,13-17 Years,94.8,90.8 to 97.2,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2011,Age,13-17 Years,36.9,30.4 to 43.8,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2010,Age,13-17 Years,29.0,23.8 to 34.9,354
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2009,Age,13-17 Years,22.6,18.4 to 27.3,438
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2008,Age,13-17 Years,19.6,15.3 to 24.7,404
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2022,Age,13-15 Years,85.3,76.0 to 91.4,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2017,Age,13-17 Years,28.8,23.5 to 34.8,347
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2018,Age,13-17 Years,32.6,26.4 to 39.5,285
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2012,Age,13-17 Years,53.5,46.2 to 60.7,321
HPV,"≥2 Doses, Males",States/Local Areas,Mississippi,2019,Age,13-17 Years,32.3,23.4 to 42.7,144
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2013,Age,13-17 Years,60.2,53.3 to 66.6,284
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2014,Age,13-17 Years,70.8,64.2 to 76.7,356
Varicella,History of disease,States/Local Areas,Mississippi,2016,Age,13-17 Years,17.0,13.0 to 22.0,377
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2016,Age,13-17 Years,29.1,23.6 to 35.2,377
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2019,Age,13-17 Years,30.5,23.7 to 38.3,270
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2020,Age,13-17 Years,31.9,25.9 to 38.5,282
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2022,Age,13-17 Years,38.5,30.7 to 46.9,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2021,Age,13-17 Years,32.7,26.5 to 39.6,303
Tetanus,≥1 Dose Tdap,States/Local Areas,Mississippi,2015,Age,13-17 Years,74.7,69.0 to 79.7,364
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2020,Age,13-15 Years,45.5,33.8 to 57.7,92
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2022,Age,13-15 Years,63.5,51.8 to 73.7,102
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2021,Age,13-15 Years,56.4,44.3 to 67.7,93
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2018,Age,13-15 Years,43.6,31.2 to 56.8,79
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2022,Age,13-17 Years,59.5,49.2 to 69.0,142
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2021,Age,13-17 Years,49.5,39.6 to 59.3,135
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2017,Age,13-17 Years,50.1,40.6 to 59.6,150
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2016,Age,13-17 Years,27.9,20.8 to 36.4,186
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2020,Age,13-17 Years,60.3,50.5 to 69.3,155
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2019,Age,13-15 Years,36.1,25.9 to 47.9,94
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2016,Age,13-17 Years,52.5,43.6 to 61.2,189
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2019,Age,13-15 Years,43.3,34.8 to 52.2,179
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2022,Age,13-17 Years,61.0,51.6 to 69.7,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2021,Age,13-15 Years,52.7,44.0 to 61.2,176
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2020,Age,13-15 Years,49.9,41.2 to 58.6,182
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2022,Age,13-15 Years,61.2,52.5 to 69.3,191
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2021,Age,13-17 Years,55.5,46.2 to 64.5,155
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2018,Age,13-17 Years,53.0,43.3 to 62.5,146
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2019,Age,13-17 Years,51.3,41.4 to 61.2,138
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2022,Age,13-15 Years,58.7,45.6 to 70.7,89
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2021,Age,13-15 Years,49.0,36.8 to 61.4,83
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2018,Age,13-17 Years,43.9,34.7 to 53.6,144
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2017,Age,13-17 Years,48.1,39.1 to 57.3,176
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2019,Age,13-17 Years,42.3,33.5 to 51.6,159
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2020,Age,13-17 Years,48.8,39.4 to 58.2,152
Varicella,History of disease,States/Local Areas,Montana,2009,Age,13-17 Years,61.3,54.9 to 67.3,306
Varicella,History of disease,States/Local Areas,Montana,2008,Age,13-17 Years,70.5,64.4 to 76.0,299
Varicella,History of disease,States/Local Areas,Montana,2017,Age,13-17 Years,21.4,16.5 to 27.2,326
Varicella,History of disease,States/Local Areas,Montana,2018,Age,13-17 Years,16.9,12.2 to 22.8,290
Varicella,History of disease,States/Local Areas,Montana,2012,Age,13-17 Years,48.1,41.5 to 54.8,325
Varicella,History of disease,States/Local Areas,Montana,2013,Age,13-17 Years,40.0,33.7 to 46.5,320
Varicella,History of disease,States/Local Areas,Montana,2010,Age,13-17 Years,55.3,49.3 to 61.2,333
Varicella,History of disease,States/Local Areas,Montana,2011,Age,13-17 Years,52.0,43.3 to 60.6,385
Varicella,History of disease,States/Local Areas,Montana,2014,Age,13-17 Years,33.6,27.6 to 40.1,367
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2018,Age,13-15 Years,46.3,34.9 to 58.1,97
Varicella,History of disease,States/Local Areas,Montana,2016,Age,13-17 Years,26.7,21.3 to 33.0,375
Varicella,History of disease,States/Local Areas,Montana,2015,Age,13-17 Years,27.7,23.0 to 32.9,406
Varicella,History of disease,States/Local Areas,Montana,2019,Age,13-17 Years,19.2,14.1 to 25.7,297
Varicella,History of disease,States/Local Areas,Montana,2020,Age,13-17 Years,10.4,6.9 to 15.3,307
Varicella,History of disease,States/Local Areas,Montana,2022,Age,13-17 Years,7.3,4.6 to 11.4,297
Varicella,History of disease,States/Local Areas,Montana,2021,Age,13-17 Years,11.6,7.6 to 17.3,290
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2019,Age,13-15 Years,49.8,37.2 to 62.4,85
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2020,Age,13-15 Years,55.1,42.5 to 67.1,90
≥1 Dose MenACWY,,States/Local Areas,Montana,2017,Age,13-17 Years,71.2,64.9 to 76.8,326
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2019,Age,13-17 Years,90.1,85.1 to 93.5,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2021,Age,13-17 Years,88.8,83.6 to 92.5,290
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2020,Age,13-17 Years,87.0,80.7 to 91.4,307
HPV,"≥3 Doses, Males and Females",States/Local Areas,Montana,2014,Age,13-17 Years,27.5,22.0 to 33.7,367
HPV,"≥3 Doses, Males and Females",States/Local Areas,Montana,2015,Age,13-17 Years,28.1,23.1 to 33.6,406
≥2 Doses MMR,,States/Local Areas,Montana,2020,Age,13-17 Years,95.5,92.6 to 97.3,307
HPV,"≥3 Doses, Males and Females",States/Local Areas,Montana,2013,Age,13-17 Years,18.5,14.3 to 23.6,320
≥2 Doses MMR,,States/Local Areas,Montana,2016,Age,13-17 Years,86.6,81.3 to 90.6,375
≥2 Doses MMR,,States/Local Areas,Montana,2015,Age,13-17 Years,90.1,86.2 to 93.0,406
≥2 Doses MMR,,States/Local Areas,Montana,2014,Age,13-17 Years,85.0,80.0 to 88.9,367
≥2 Doses MMR,,States/Local Areas,Montana,2012,Age,13-17 Years,88.9,84.2 to 92.3,325
≥2 Doses MMR,,States/Local Areas,Montana,2013,Age,13-17 Years,90.5,85.6 to 93.8,320
≥2 Doses MMR,,States/Local Areas,Montana,2018,Age,13-17 Years,92.3,88.2 to 95.1,290
≥2 Doses MMR,,States/Local Areas,Montana,2019,Age,13-17 Years,87.1,81.4 to 91.2,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2022,Age,13-17 Years,89.6,84.5 to 93.2,297
≥2 Doses MMR,,States/Local Areas,Montana,2017,Age,13-17 Years,95.4,91.6 to 97.5,326
≥1 Dose MenACWY,,States/Local Areas,Montana,2012,Age,13-17 Years,58.6,51.9 to 65.0,325
≥1 Dose MenACWY,,States/Local Areas,Montana,2022,Age,13-15 Years,82.9,75.6 to 88.3,191
≥1 Dose MenACWY,,States/Local Areas,Montana,2010,Age,13-17 Years,40.2,34.4 to 46.2,333
≥1 Dose MenACWY,,States/Local Areas,Montana,2011,Age,13-17 Years,39.8,31.8 to 48.5,385
≥1 Dose MenACWY,,States/Local Areas,Montana,2008,Age,13-17 Years,17.8,13.1 to 23.6,299
≥1 Dose MenACWY,,States/Local Areas,Montana,2009,Age,13-17 Years,26.9,21.7 to 32.9,306
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2012,Age,13-17 Years,41.6,32.0 to 51.9,150
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2011,Age,13-17 Years,39.8,28.6 to 52.2,204
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2013,Age,13-17 Years,28.3,21.0 to 37.0,149
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2014,Age,13-17 Years,42.9,34.1 to 52.2,197
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2008,Age,13-17 Years,8.6,4.8 to 15.1,142
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2009,Age,13-17 Years,21.9,15.3 to 30.2,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018,Age,13-17 Years,86.7,81.2 to 90.8,290
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2017,Age,13-17 Years,90.4,85.8 to 93.7,326
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2016,Age,13-17 Years,85.7,80.4 to 89.7,375
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2015,Age,13-17 Years,34.8,27.2 to 43.1,192
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2010,Age,13-17 Years,33.2,25.1 to 42.3,163
≥2 Doses Hep A,,States/Local Areas,Montana,2020,Age,13-17 Years,82.7,77.4 to 87.0,307
HPV,"≥3 Doses, Males",States/Local Areas,Montana,2014,Age,13-15 Years,15.9,9.0 to 26.6,109
≥2 Doses Hep A,,States/Local Areas,Montana,2021,Age,13-17 Years,81.4,75.9 to 85.8,290
≥2 Doses Hep A,,States/Local Areas,Montana,2022,Age,13-17 Years,80.7,74.9 to 85.5,297
HPV,"≥3 Doses, Males",States/Local Areas,Montana,2015,Age,13-15 Years,24.1,16.5 to 33.9,130
≥3 Doses HepB,,States/Local Areas,Montana,2010,Age,13-17 Years,84.4,79.2 to 88.5,333
≥3 Doses HepB,,States/Local Areas,Montana,2009,Age,13-17 Years,76.2,70.1 to 81.4,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2021,Age,13-15 Years,94.3,89.2 to 97.1,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2020,Age,13-15 Years,93.1,86.0 to 96.7,172
HPV,"≥3 Doses, Males",States/Local Areas,Montana,2013,Age,13-17 Years,9.4,5.6 to 15.1,171
HPV,"≥3 Doses, Males",States/Local Areas,Montana,2014,Age,13-17 Years,13.0,7.8 to 20.8,170
HPV,"≥3 Doses, Males",States/Local Areas,Montana,2015,Age,13-17 Years,21.7,15.7 to 29.3,214
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2008,Age,13-17 Years,73.7,67.7 to 79.0,299
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2010,Age,13-17 Years,73.8,68.3 to 78.7,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2009,Age,13-17 Years,72.2,66.2 to 77.6,306
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2012,Age,13-17 Years,79.9,74.0 to 84.8,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2011,Age,13-17 Years,76.9,68.9 to 83.3,385
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2013,Age,13-17 Years,75.1,68.9 to 80.5,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2014,Age,13-17 Years,75.0,68.9 to 80.3,367
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2017,Age,13-17 Years,93.8,89.9 to 96.3,326
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2018,Age,13-17 Years,92.0,87.6 to 94.9,290
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2016,Age,13-17 Years,87.6,82.3 to 91.5,375
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2015,Age,13-17 Years,80.7,75.7 to 84.9,406
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2022,Age,13-17 Years,95.3,91.9 to 97.3,297
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2021,Age,13-17 Years,95.5,92.5 to 97.4,290
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2020,Age,13-17 Years,93.8,89.7 to 96.3,307
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2012,Age,13-15 Years,66.4,55.7 to 75.6,125
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2013,Age,13-15 Years,62.1,51.1 to 71.9,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2011,Age,13-15 Years,58.6,43.3 to 72.5,128
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2010,Age,13-15 Years,46.5,35.8 to 57.6,98
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2009,Age,13-15 Years,36.9,25.0 to 50.6,70
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2019,Age,13-17 Years,90.3,85.2 to 93.8,297
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2014,Age,13-15 Years,67.2,57.4 to 75.7,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2015,Age,13-15 Years,75.3,67.3 to 81.8,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2019,Age,13-15 Years,87.5,78.9 to 93.0,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2018,Age,13-15 Years,90.4,82.8 to 94.8,155
≥3 Doses HepB,,States/Local Areas,Montana,2008,Age,13-17 Years,75.2,69.4 to 80.1,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2017,Age,13-15 Years,92.4,85.3 to 96.2,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2016,Age,13-15 Years,81.3,72.0 to 88.1,188
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2022,Age,13-15 Years,96.4,91.9 to 98.5,174
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2009,Age,13-17 Years,35.0,26.8 to 44.2,146
≥3 Doses HepB,,States/Local Areas,Montana,2012,Age,13-17 Years,89.8,85.4 to 92.9,325
≥3 Doses HepB,,States/Local Areas,Montana,2011,Age,13-17 Years,86.7,80.4 to 91.2,385
≥3 Doses HepB,,States/Local Areas,Montana,2013,Age,13-17 Years,91.6,87.4 to 94.5,320
≥3 Doses HepB,,States/Local Areas,Montana,2014,Age,13-17 Years,87.0,82.3 to 90.5,367
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2010,Age,13-17 Years,41.4,32.8 to 50.6,146
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2011,Age,13-17 Years,51.8,39.1 to 64.4,193
≥3 Doses HepB,,States/Local Areas,Montana,2017,Age,13-17 Years,93.1,88.9 to 95.7,326
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2010,Age,13-17 Years,82.9,74.8 to 88.8,146
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2009,Age,13-17 Years,69.4,58.9 to 78.1,111
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2012,Age,13-17 Years,61.3,52.1 to 69.7,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2013,Age,13-17 Years,58.6,49.9 to 66.8,191
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2008,Age,13-17 Years,17.8,12.0 to 25.5,142
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2012,Age,13-17 Years,93.4,87.4 to 96.6,175
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2011,Age,13-17 Years,79.9,68.0 to 88.2,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2008,Age,13-17 Years,10.9,6.0 to 19.1,93
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2009,Age,13-17 Years,28.3,19.7 to 38.9,111
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2008,Age,13-17 Years,70.1,58.4 to 79.7,93
≥3 Doses HepB,,States/Local Areas,Montana,2016,Age,13-17 Years,88.8,84.3 to 92.1,375
≥3 Doses HepB,,States/Local Areas,Montana,2015,Age,13-17 Years,88.2,84.2 to 91.4,406
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2016,Age,13-17 Years,91.9,86.5 to 95.2,285
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2015,Age,13-17 Years,94.8,90.8 to 97.1,283
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2013,Age,13-17 Years,82.7,73.8 to 89.1,191
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2014,Age,13-17 Years,84.2,77.4 to 89.2,252
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2018,Age,13-17 Years,95.8,91.6 to 97.9,245
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2019,Age,13-17 Years,94.4,89.2 to 97.1,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2018,Age,13-17 Years,90.4,85.2 to 93.9,245
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2020,Age,13-17 Years,95.6,91.7 to 97.8,278
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2019,Age,13-17 Years,88.0,81.9 to 92.3,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2021,Age,13-17 Years,94.9,91.5 to 97.0,262
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2020,Age,13-17 Years,93.1,88.5 to 95.9,278
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2017,Age,13-17 Years,96.6,91.8 to 98.6,256
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2014,Age,13-17 Years,62.4,54.4 to 69.8,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2016,Age,13-17 Years,83.1,76.3 to 88.2,285
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2015,Age,13-17 Years,73.3,66.7 to 79.0,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2017,Age,13-17 Years,92.1,87.3 to 95.2,256
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2011,Age,13-17 Years,52.9,41.0 to 64.4,204
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2010,Age,13-17 Years,45.5,36.9 to 54.4,163
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2012,Age,13-17 Years,55.1,45.2 to 64.6,150
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2013,Age,13-17 Years,45.8,36.5 to 55.4,149
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2015,Age,13-17 Years,55.0,46.5 to 63.3,192
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2014,Age,13-17 Years,57.2,47.8 to 66.0,197
≥3 Doses HepB,,States/Local Areas,Montana,2018,Age,13-17 Years,88.9,83.6 to 92.6,290
≥3 Doses HepB,,States/Local Areas,Montana,2019,Age,13-17 Years,87.6,81.7 to 91.9,297
HPV,"≥2 Doses, Males and Females",States/Local Areas,Montana,2019,Age,13-17 Years,50.3,43.4 to 57.1,297
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2016,Age,13-17 Years,43.0,34.5 to 51.9,186
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2015,Age,13-17 Years,46.0,38.2 to 54.1,214
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2013,Age,13-17 Years,23.8,16.6 to 32.8,171
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2014,Age,13-17 Years,33.3,24.9 to 43.1,170
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2021,Age,13-17 Years,79.1,70.9 to 85.4,155
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2020,Age,13-17 Years,68.6,58.8 to 77.0,152
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2019,Age,13-17 Years,57.6,48.0 to 66.7,159
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2018,Age,13-17 Years,66.2,56.7 to 74.5,144
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2017,Age,13-17 Years,66.4,57.5 to 74.2,176
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2019,Age,13-17 Years,70.0,60.4 to 78.0,138
HPV,"≥2 Doses, Males and Females",States/Local Areas,Montana,2018,Age,13-17 Years,51.2,44.4 to 58.0,290
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2022,Age,13-17 Years,80.0,70.8 to 86.9,142
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2021,Age,13-17 Years,71.3,61.3 to 79.5,135
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2020,Age,13-17 Years,79.0,69.9 to 86.0,155
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2012,Age,13-17 Years,16.8,10.9 to 25.0,175
HPV,"≥2 Doses, Males and Females",States/Local Areas,Montana,2017,Age,13-17 Years,54.6,48.0 to 61.1,326
HPV,"≥2 Doses, Males and Females",States/Local Areas,Montana,2016,Age,13-17 Years,45.4,39.2 to 51.8,375
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2022,Age,13-17 Years,83.4,75.6 to 89.0,155
≥1 Dose MenACWY,,States/Local Areas,Montana,2009,Age,13-15 Years,28.0,21.2 to 35.8,176
≥1 Dose MenACWY,,States/Local Areas,Montana,2008,Age,13-15 Years,21.2,14.4 to 30.1,168
≥3 Doses HepB,,States/Local Areas,Montana,2022,Age,13-17 Years,90.2,85.7 to 93.4,297
≥3 Doses HepB,,States/Local Areas,Montana,2021,Age,13-17 Years,91.2,86.6 to 94.4,290
≥3 Doses HepB,,States/Local Areas,Montana,2020,Age,13-17 Years,92.1,88.0 to 94.9,307
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2022,Age,13-17 Years,96.2,93.1 to 98.0,267
≥1 Dose MenACWY,,States/Local Areas,Montana,2011,Age,13-15 Years,42.6,32.1 to 53.8,220
≥1 Dose MenACWY,,States/Local Areas,Montana,2010,Age,13-15 Years,39.4,32.1 to 47.1,195
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2008,Age,13-17 Years,69.1,62.6 to 74.8,299
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2009,Age,13-17 Years,81.1,75.8 to 85.4,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2012,Age,13-17 Years,92.2,88.0 to 95.1,325
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2013,Age,13-17 Years,87.0,81.3 to 91.2,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2010,Age,13-17 Years,84.5,79.9 to 88.2,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2011,Age,13-17 Years,90.2,83.5 to 94.4,385
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2017,Age,13-17 Years,64.5,54.7 to 73.3,150
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2016,Age,13-17 Years,68.2,59.6 to 75.7,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2022,Age,13-17 Years,95.0,91.3 to 97.1,267
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2021,Age,13-17 Years,96.4,93.0 to 98.1,262
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2018,Age,13-17 Years,66.5,56.6 to 75.2,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2012,Age,13-15 Years,91.5,85.6 to 95.2,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2011,Age,13-15 Years,85.0,74.6 to 91.7,220
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2009,Age,13-15 Years,78.1,70.9 to 83.9,176
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2010,Age,13-15 Years,83.7,77.3 to 88.5,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2008,Age,13-15 Years,58.1,49.2 to 66.4,168
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2017,Age,13-17 Years,54.9,45.2 to 64.2,150
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2016,Age,13-17 Years,57.7,48.8 to 66.1,189
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2014,Age,13-17 Years,51.0,41.9 to 60.1,197
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2015,Age,13-17 Years,41.8,33.7 to 50.2,192
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2019,Age,13-17 Years,92.2,87.7 to 95.1,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2020,Age,13-17 Years,87.4,81.1 to 91.7,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2018,Age,13-17 Years,89.8,85.0 to 93.2,290
≥1 Dose MenACWY,,States/Local Areas,Montana,2021,Age,13-15 Years,76.3,67.8 to 83.1,176
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2019,Age,13-17 Years,63.7,56.8 to 70.0,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2022,Age,13-17 Years,90.5,85.5 to 93.9,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2021,Age,13-17 Years,90.1,85.3 to 93.5,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2022,Age,13-17 Years,81.8,76.0 to 86.4,297
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2021,Age,13-17 Years,75.3,68.9 to 80.7,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2020,Age,13-17 Years,73.7,67.1 to 79.4,307
≥1 Dose MenACWY,,States/Local Areas,Montana,2018,Age,13-15 Years,71.2,62.4 to 78.6,176
≥1 Dose MenACWY,,States/Local Areas,Montana,2019,Age,13-15 Years,71.8,63.2 to 79.1,179
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2017,Age,13-17 Years,65.5,58.9 to 71.5,326
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2016,Age,13-17 Years,55.3,48.9 to 61.5,375
≥1 Dose MenACWY,,States/Local Areas,Montana,2017,Age,13-15 Years,69.1,60.6 to 76.4,202
≥1 Dose MenACWY,,States/Local Areas,Montana,2012,Age,13-15 Years,61.6,53.2 to 69.4,205
≥1 Dose MenACWY,,States/Local Areas,Montana,2013,Age,13-15 Years,51.9,43.3 to 60.5,187
≥1 Dose MenACWY,,States/Local Areas,Montana,2014,Age,13-15 Years,57.6,49.2 to 65.7,225
≥1 Dose MenACWY,,States/Local Areas,Montana,2015,Age,13-15 Years,67.4,60.1 to 74.0,243
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2008,Age,13-17 Years,13.3,8.3 to 20.5,142
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018,Age,13-17 Years,66.4,59.6 to 72.5,290
≥1 Dose MenACWY,,States/Local Areas,Montana,2016,Age,13-15 Years,66.0,57.8 to 73.5,235
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2017,Age,13-17 Years,91.0,86.4 to 94.1,326
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2016,Age,13-17 Years,86.9,81.7 to 90.8,375
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2015,Age,13-17 Years,91.2,87.4 to 94.0,406
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2014,Age,13-17 Years,86.5,81.2 to 90.5,367
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2009,Age,13-17 Years,28.6,21.0 to 37.6,146
≥1 Dose MenACWY,,States/Local Areas,Montana,2020,Age,13-15 Years,70.6,61.3 to 78.4,182
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2010,Age,13-17 Years,40.1,31.7 to 49.1,163
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2011,Age,13-17 Years,49.8,38.1 to 61.6,204
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2012,Age,13-17 Years,46.5,36.8 to 56.6,150
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2013,Age,13-17 Years,37.9,29.4 to 47.2,149
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2019,Age,13-15 Years,90.4,83.9 to 94.5,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2020,Age,13-15 Years,83.9,74.7 to 90.2,182
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2021,Age,13-15 Years,88.5,81.2 to 93.2,176
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2014,Age,13-17 Years,19.1,12.6 to 27.8,170
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2013,Age,13-17 Years,17.2,11.2 to 25.4,171
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2013,Age,13-15 Years,86.4,78.5 to 91.7,187
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2012,Age,13-17 Years,10.0,5.4 to 17.5,175
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2019,Age,13-17 Years,56.2,46.2 to 65.8,138
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2018,Age,13-17 Years,56.1,46.3 to 65.4,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2017,Age,13-15 Years,88.1,81.7 to 92.5,202
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2016,Age,13-15 Years,82.4,74.6 to 88.2,235
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2014,Age,13-15 Years,82.4,74.8 to 88.1,225
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2015,Age,13-15 Years,91.3,85.8 to 94.7,243
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2017,Age,13-17 Years,54.3,45.2 to 63.2,176
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2016,Age,13-17 Years,33.7,26.0 to 42.4,186
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2018,Age,13-17 Years,46.5,37.1 to 56.1,144
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2015,Age,13-17 Years,33.3,26.1 to 41.4,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018,Age,13-15 Years,85.5,77.7 to 90.9,176
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2019,Age,13-17 Years,44.5,35.6 to 53.8,159
≥2 Doses MMR,,States/Local Areas,Montana,2008,Age,13-17 Years,84.1,78.6 to 88.3,299
≥2 Doses MMR,,States/Local Areas,Montana,2009,Age,13-17 Years,81.0,75.1 to 85.9,306
≥2 Doses MMR,,States/Local Areas,Montana,2010,Age,13-17 Years,88.8,84.1 to 92.3,333
≥2 Doses MMR,,States/Local Areas,Montana,2011,Age,13-17 Years,89.1,82.5 to 93.5,385
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2011,Age,13-17 Years,85.0,78.0 to 90.0,385
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2010,Age,13-17 Years,76.1,70.6 to 80.8,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2009,Age,13-17 Years,63.8,57.6 to 69.6,306
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2008,Age,13-17 Years,44.2,37.8 to 50.7,299
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2022,Age,13-15 Years,88.8,82.1 to 93.3,191
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2017,Age,13-17 Years,49.1,42.5 to 55.7,326
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018,Age,13-17 Years,48.4,41.6 to 55.2,290
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2012,Age,13-17 Years,90.2,85.7 to 93.3,325
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2016,Age,13-17 Years,39.9,33.8 to 46.4,375
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2013,Age,13-17 Years,84.3,78.6 to 88.7,320
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2014,Age,13-17 Years,84.7,79.4 to 88.9,367
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2019,Age,13-17 Years,46.7,40.0 to 53.5,297
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2020,Age,13-17 Years,54.4,47.6 to 61.0,307
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2022,Age,13-17 Years,60.3,53.4 to 66.8,297
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2021,Age,13-17 Years,52.6,45.8 to 59.3,290
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2015,Age,13-17 Years,89.5,85.2 to 92.6,406
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2023,Age,13-17 Years,55.9,45.6 to 65.7,138
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Other,86.4,79.0 to 91.5,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Uninsured,85.7,70.4 to 93.8,48
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Any Medicaid,88.3,85.1 to 90.9,659
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Private Insurance Only,85.1,81.4 to 88.2,632
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Other,35.1,27.9 to 43.0,217
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Uninsured,42.3,26.0 to 60.5,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Any Medicaid,54.8,50.1 to 59.4,659
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Private Insurance Only,38.1,33.6 to 42.7,632
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Uninsured,74.9,58.3 to 86.5,48
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Uninsured,76.7,61.9 to 87.0,48
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Other,56.0,47.7 to 64.0,217
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Other,78.1,70.8 to 84.1,217
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Any Medicaid,74.7,70.5 to 78.5,659
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Private Insurance Only,58.6,53.9 to 63.1,632
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Private Insurance Only,72.4,67.9 to 76.4,632
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Poverty,Living At or Above Poverty Level,86.8,84.3 to 88.9,1240
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Insurance Coverage,Any Medicaid,84.9,81.3 to 87.9,659
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Poverty,Below Poverty Level,86.2,80.8 to 90.3,276
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Poverty,Living At or Above Poverty Level,44.6,41.2 to 48.1,1240
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Poverty,Below Poverty Level,49.0,41.8 to 56.1,276
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Poverty,Living At or Above Poverty Level,77.7,74.8 to 80.4,1240
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Poverty,Below Poverty Level,84.3,78.6 to 88.7,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Poverty,Living At or Above Poverty Level,64.8,61.5 to 68.0,1240
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",77.1,64.9 to 86.0,67
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Poverty,Below Poverty Level,70.2,63.4 to 76.3,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"White, Non-Hispanic",61.6,57.5 to 65.5,841
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,Hispanic,85.7,78.5 to 90.8,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.7,84.8 to 91.7,426
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.4,81.3 to 96.3,67
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,Hispanic,86.8,80.2 to 91.4,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.3,82.2 to 88.0,841
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"White, Non-Hispanic",74.7,71.0 to 78.1,841
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.5,68.1 to 88.9,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,Hispanic,49.0,41.4 to 56.8,222
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",50.1,44.2 to 56.0,426
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",52.5,39.3 to 65.4,67
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",66.1,60.4 to 71.4,426
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,Hispanic,75.8,68.1 to 82.1,222
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.5,76.5 to 85.7,426
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Race and Ethnicity,"White, Non-Hispanic",40.9,36.9 to 45.0,841
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Principal City,87.1,82.9 to 90.4,408
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Non-Principal City,85.5,81.7 to 88.6,582
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Principal City,81.0,76.1 to 85.1,408
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Non-Principal City,78.5,74.3 to 82.2,582
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a Non-MSA,77.8,73.3 to 81.8,566
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Principal City,49.1,43.4 to 54.8,408
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a Non-MSA,43.9,38.8 to 49.1,566
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Non-Principal City,44.4,39.5 to 49.4,582
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Principal City,68.8,63.3 to 73.8,408
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a MSA Non-Principal City,62.9,58.1 to 67.4,582
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a Non-MSA,68.6,63.6 to 73.2,566
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2018-2022,Overall,Overall,45.7,42.7 to 48.8,1556
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Urbanicity,Living In a Non-MSA,88.3,84.7 to 91.2,566
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018-2022,Overall,Overall,66.4,63.5 to 69.2,1556
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018-2022,Overall,Overall,86.8,84.6 to 88.7,1556
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018-2022,Overall,Overall,79.1,76.6 to 81.4,1556
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2023,Age,13-17 Years,85.0,79.5 to 89.2,281
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2023,Age,13-17 Years,85.1,79.6 to 89.3,281
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2023,Age,13-17 Years,74.3,67.7 to 79.9,281
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2023,Age,13-17 Years,63.7,56.5 to 70.2,281
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2023,Age,13-17 Years,71.7,62.3 to 79.6,143
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2023,Age,13-17 Years,44.2,37.2 to 51.4,281
≥2 Doses MMR,,States/Local Areas,Oklahoma,2023,Age,13-17 Years,87.6,82.2 to 91.5,281
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2023,Age,13-17 Years,39.4,30.1 to 49.6,138
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2023,Age,13-17 Years,85.3,79.2 to 89.9,256
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2023,Age,13-17 Years,93.0,88.6 to 95.8,256
Varicella,History of disease,States/Local Areas,Oklahoma,2023,Age,13-17 Years,8.6,5.5 to 13.1,281
≥3 Doses HepB,,States/Local Areas,Oklahoma,2023,Age,13-17 Years,86.5,81.2 to 90.4,281
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2023,Age,13-17 Years,86.6,80.9 to 90.8,281
≥2 Doses Hep A,,States/Local Areas,Oklahoma,2023,Age,13-17 Years,91.4,86.7 to 94.6,281
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2023,Age,13-15 Years,85.2,77.6 to 90.6,160
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2023,Age,13-15 Years,70.2,61.0 to 78.0,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oklahoma,2023,Age,13-15 Years,36.1,27.6 to 45.6,160
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2023,Age,13-15 Years,87.2,79.4 to 92.4,147
HPV,"Up-to-Date, Males",States/Local Areas,Oklahoma,2023,Age,13-15 Years,34.2,23.3 to 47.0,83
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2023,Age,13-17 Years,49.2,39.2 to 59.2,143
HPV,"Up-to-Date, Females",States/Local Areas,Oklahoma,2023,Age,13-15 Years,38.2,25.8 to 52.4,77
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2022,Age,13-17 Years,46.5,36.6 to 56.7,140
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oklahoma,2022,Age,13-17 Years,47.5,39.9 to 55.1,249
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2022,Age,13-17 Years,48.5,37.2 to 59.8,109
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2012,Age,13-17 Years,63.8,56.9 to 70.2,322
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2022,Age,13-15 Years,84.5,76.6 to 90.1,153
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2010,Age,13-17 Years,42.6,36.4 to 49.1,300
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2011,Age,13-17 Years,55.3,48.6 to 61.8,360
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2008,Age,13-17 Years,25.1,20.0 to 30.9,292
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2009,Age,13-17 Years,29.5,24.4 to 35.2,336
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2017,Age,13-17 Years,86.7,81.7 to 90.5,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018,Age,13-17 Years,87.1,81.9 to 90.9,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2016,Age,13-17 Years,89.6,84.2 to 93.3,281
≥2 Doses MMR,,States/Local Areas,Oklahoma,2015,Age,13-17 Years,93.4,89.9 to 95.8,291
≥2 Doses MMR,,States/Local Areas,Oklahoma,2014,Age,13-17 Years,92.1,88.4 to 94.7,356
≥2 Doses MMR,,States/Local Areas,Oklahoma,2016,Age,13-17 Years,90.5,85.7 to 93.8,281
≥2 Doses MMR,,States/Local Areas,Oklahoma,2012,Age,13-17 Years,93.1,89.7 to 95.4,322
≥2 Doses MMR,,States/Local Areas,Oklahoma,2013,Age,13-17 Years,89.5,85.5 to 92.4,426
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oklahoma,2011,Age,13-17 Years,14.5,10.5 to 19.8,360
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oklahoma,2012,Age,13-17 Years,24.2,18.9 to 30.4,322
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2022,Age,13-17 Years,89.6,84.6 to 93.1,249
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2016,Age,13-17 Years,73.6,66.6 to 79.6,281
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2015,Age,13-17 Years,68.1,61.4 to 74.2,291
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2013,Age,13-17 Years,66.2,60.7 to 71.3,426
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2014,Age,13-17 Years,70.8,64.8 to 76.2,356
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2019,Age,13-17 Years,88.0,83.7 to 91.3,369
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2021,Age,13-17 Years,85.4,79.4 to 89.9,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2020,Age,13-17 Years,83.8,78.3 to 88.2,338
≥2 Doses MMR,,States/Local Areas,Oklahoma,2019,Age,13-17 Years,90.4,86.3 to 93.4,369
≥2 Doses MMR,,States/Local Areas,Oklahoma,2018,Age,13-17 Years,87.7,82.9 to 91.3,360
≥2 Doses MMR,,States/Local Areas,Oklahoma,2017,Age,13-17 Years,89.9,85.5 to 93.1,338
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oklahoma,2014,Age,13-17 Years,28.0,22.5 to 34.2,356
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oklahoma,2015,Age,13-17 Years,34.0,27.9 to 40.7,291
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oklahoma,2013,Age,13-17 Years,26.1,21.3 to 31.5,426
≥2 Doses MMR,,States/Local Areas,Oklahoma,2020,Age,13-17 Years,90.8,86.9 to 93.6,338
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2008,Age,13-15 Years,17.9,11.0 to 28.0,101
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2011,Age,13-15 Years,25.0,16.0 to 36.8,122
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2012,Age,13-15 Years,41.1,30.0 to 53.3,108
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2013,Age,13-15 Years,30.9,22.1 to 41.4,118
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2014,Age,13-15 Years,36.9,26.5 to 48.6,112
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2015,Age,13-15 Years,33.5,22.4 to 46.8,73
≥2 Doses MMR,,States/Local Areas,Oklahoma,2022,Age,13-17 Years,89.1,83.1 to 93.1,249
≥2 Doses MMR,,States/Local Areas,Oklahoma,2021,Age,13-17 Years,91.8,87.4 to 94.8,240
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2010,Age,13-15 Years,28.3,18.6 to 40.7,85
HPV,"≥3 Doses, Females",States/Local Areas,Oklahoma,2009,Age,13-15 Years,20.2,13.2 to 29.8,103
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2016,Age,13-17 Years,50.3,40.3 to 60.2,154
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2015,Age,13-17 Years,52.9,44.0 to 61.6,162
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2013,Age,13-17 Years,45.2,37.9 to 52.7,242
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2014,Age,13-17 Years,43.2,34.6 to 52.2,186
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oklahoma,2019,Age,13-17 Years,46.7,40.5 to 53.0,369
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2022,Age,13-15 Years,86.2,77.3 to 92.0,142
≥3 Doses HepB,,States/Local Areas,Oklahoma,2010,Age,13-17 Years,91.7,87.6 to 94.6,300
≥3 Doses HepB,,States/Local Areas,Oklahoma,2009,Age,13-17 Years,87.1,82.4 to 90.7,336
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2008,Age,13-17 Years,83.1,73.6 to 89.6,113
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2010,Age,13-17 Years,95.4,90.6 to 97.8,157
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2009,Age,13-17 Years,87.6,80.5 to 92.3,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2008,Age,13-17 Years,15.7,9.6 to 24.6,113
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2009,Age,13-17 Years,26.3,19.9 to 33.8,169
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2011,Age,13-17 Years,95.2,91.4 to 97.4,235
≥3 Doses HepB,,States/Local Areas,Oklahoma,2008,Age,13-17 Years,88.9,84.0 to 92.4,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2010,Age,13-17 Years,42.9,34.4 to 51.8,157
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2011,Age,13-17 Years,48.4,40.2 to 56.8,235
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2012,Age,13-17 Years,95.8,92.2 to 97.8,222
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2012,Age,13-17 Years,65.1,57.1 to 72.3,222
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2009,Age,13-17 Years,40.1,31.9 to 48.9,158
≥3 Doses HepB,,States/Local Areas,Oklahoma,2012,Age,13-17 Years,95.0,91.9 to 96.9,322
≥3 Doses HepB,,States/Local Areas,Oklahoma,2011,Age,13-17 Years,92.7,88.5 to 95.4,360
≥3 Doses HepB,,States/Local Areas,Oklahoma,2013,Age,13-17 Years,92.6,89.0 to 95.1,426
≥3 Doses HepB,,States/Local Areas,Oklahoma,2014,Age,13-17 Years,93.3,90.0 to 95.6,356
≥3 Doses HepB,,States/Local Areas,Oklahoma,2017,Age,13-17 Years,90.2,85.9 to 93.4,338
≥3 Doses HepB,,States/Local Areas,Oklahoma,2019,Age,13-17 Years,88.9,84.3 to 92.3,369
≥3 Doses HepB,,States/Local Areas,Oklahoma,2018,Age,13-17 Years,88.0,83.3 to 91.5,360
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2019,Age,13-17 Years,87.8,83.1 to 91.3,318
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2021,Age,13-17 Years,90.0,85.1 to 93.4,220
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2020,Age,13-17 Years,89.9,85.1 to 93.3,301
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2018,Age,13-17 Years,79.6,73.9 to 84.4,325
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2020,Age,13-17 Years,95.9,92.4 to 97.8,301
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2017,Age,13-17 Years,92.1,87.5 to 95.1,291
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2019,Age,13-17 Years,94.0,90.4 to 96.3,318
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2018,Age,13-17 Years,92.4,88.2 to 95.1,325
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2016,Age,13-17 Years,93.5,88.2 to 96.5,249
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2015,Age,13-17 Years,98.2,96.2 to 99.2,249
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2013,Age,13-17 Years,95.7,92.1 to 97.7,322
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2014,Age,13-17 Years,95.5,91.6 to 97.6,272
≥3 Doses HepB,,States/Local Areas,Oklahoma,2016,Age,13-17 Years,90.4,85.6 to 93.8,281
≥3 Doses HepB,,States/Local Areas,Oklahoma,2015,Age,13-17 Years,95.3,92.3 to 97.1,291
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2012,Age,13-15 Years,73.1,64.0 to 80.7,158
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2013,Age,13-15 Years,67.9,60.0 to 74.9,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2011,Age,13-15 Years,47.1,37.5 to 57.0,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2010,Age,13-15 Years,47.9,37.6 to 58.3,107
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2008,Age,13-15 Years,19.0,11.4 to 29.9,90
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2009,Age,13-15 Years,25.2,18.4 to 33.5,127
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2017,Age,13-17 Years,80.3,74.5 to 85.1,291
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2011,Age,13-17 Years,49.8,40.0 to 59.6,175
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2010,Age,13-17 Years,47.4,38.8 to 56.2,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2016,Age,13-17 Years,78.3,71.4 to 83.9,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2015,Age,13-17 Years,77.6,70.8 to 83.2,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2013,Age,13-17 Years,67.3,60.9 to 73.2,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2014,Age,13-17 Years,82.4,76.6 to 87.0,272
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2012,Age,13-17 Years,55.1,45.5 to 64.3,167
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2013,Age,13-17 Years,54.8,46.1 to 63.3,184
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2015,Age,13-17 Years,58.1,47.9 to 67.7,129
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2014,Age,13-17 Years,65.3,56.3 to 73.3,170
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2021,Age,13-15 Years,91.4,85.9 to 94.9,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2020,Age,13-15 Years,88.1,81.4 to 92.5,199
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2008,Age,13-17 Years,67.6,61.3 to 73.3,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2018,Age,13-15 Years,84.7,77.6 to 89.9,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2019,Age,13-15 Years,89.5,83.1 to 93.6,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2014,Age,13-15 Years,86.2,79.4 to 91.1,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2015,Age,13-15 Years,83.5,75.4 to 89.3,158
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2022,Age,13-17 Years,86.9,80.5 to 91.4,249
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2021,Age,13-17 Years,90.8,86.3 to 93.9,240
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2020,Age,13-17 Years,90.9,86.5 to 94.0,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2017,Age,13-15 Years,84.6,77.7 to 89.6,186
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2016,Age,13-15 Years,79.8,71.2 to 86.4,164
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2010,Age,13-17 Years,69.7,63.3 to 75.4,300
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2009,Age,13-17 Years,67.6,61.8 to 73.0,336
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2012,Age,13-17 Years,75.0,68.9 to 80.3,322
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2011,Age,13-17 Years,67.5,60.9 to 73.5,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2013,Age,13-17 Years,75.6,70.4 to 80.2,426
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2014,Age,13-17 Years,86.5,82.0 to 90.1,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2019,Age,13-17 Years,89.4,85.3 to 92.5,369
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2018,Age,13-17 Years,81.0,75.6 to 85.5,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2016,Age,13-17 Years,80.3,74.0 to 85.4,281
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2017,Age,13-17 Years,83.4,78.3 to 87.5,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Oklahoma,2015,Age,13-17 Years,80.8,74.9 to 85.7,291
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2012,Age,13-15 Years,68.7,59.7 to 76.5,209
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2013,Age,13-15 Years,68.8,62.0 to 74.9,279
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2017,Age,13-17 Years,87.5,82.5 to 91.1,338
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2016,Age,13-17 Years,90.9,85.6 to 94.4,281
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2015,Age,13-17 Years,86.3,80.9 to 90.3,291
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2014,Age,13-17 Years,84.7,79.7 to 88.6,356
≥3 Doses HepB,,States/Local Areas,Oklahoma,2022,Age,13-17 Years,89.6,83.6 to 93.6,249
≥3 Doses HepB,,States/Local Areas,Oklahoma,2021,Age,13-17 Years,90.4,85.9 to 93.6,240
≥3 Doses HepB,,States/Local Areas,Oklahoma,2020,Age,13-17 Years,91.0,87.0 to 93.9,338
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2018,Age,13-17 Years,66.3,57.1 to 74.4,157
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2021,Age,13-17 Years,69.3,59.2 to 77.9,126
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2020,Age,13-17 Years,67.6,58.8 to 75.4,173
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2018,Age,13-17 Years,52.3,44.0 to 60.4,203
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2012,Age,13-17 Years,24.4,17.6 to 32.8,155
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2019,Age,13-17 Years,60.7,52.2 to 68.6,201
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2017,Age,13-17 Years,60.9,52.0 to 69.1,182
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2008,Age,13-17 Years,35.5,27.3 to 44.7,141
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oklahoma,2018,Age,13-17 Years,41.2,35.4 to 47.3,360
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2019,Age,13-17 Years,70.8,62.0 to 78.3,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Oklahoma,2022,Age,13-17 Years,85.4,78.4 to 90.4,229
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2022,Age,13-17 Years,70.4,59.2 to 79.6,109
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2011,Age,13-17 Years,8.9,5.1 to 15.1,185
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2021,Age,13-17 Years,75.6,65.6 to 83.5,114
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2020,Age,13-17 Years,63.2,54.4 to 71.3,165
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oklahoma,2017,Age,13-17 Years,43.9,37.7 to 50.4,338
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oklahoma,2016,Age,13-17 Years,43.2,36.1 to 50.5,281
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2019,Age,13-17 Years,65.6,59.6 to 71.2,369
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2018,Age,13-17 Years,59.1,52.9 to 65.0,360
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2022,Age,13-17 Years,91.6,87.3 to 94.5,249
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2021,Age,13-17 Years,87.3,81.8 to 91.3,240
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2018,Age,13-17 Years,87.6,82.4 to 91.4,360
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2017,Age,13-17 Years,58.5,52.1 to 64.6,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2016,Age,13-17 Years,56.9,49.5 to 63.9,281
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2014,Age,13-15 Years,74.2,66.6 to 80.5,220
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2015,Age,13-15 Years,68.1,59.3 to 75.8,177
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2017,Age,13-17 Years,56.0,46.7 to 64.9,156
HPV,"≥1 Dose, Females",States/Local Areas,Oklahoma,2016,Age,13-17 Years,63.8,53.0 to 73.4,127
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2016,Age,13-15 Years,69.7,60.2 to 77.7,179
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2021,Age,13-17 Years,94.4,90.4 to 96.8,220
Varicella,≥1 Dose with no disease history,States/Local Areas,Oklahoma,2022,Age,13-17 Years,93.4,87.7 to 96.6,229
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2012,Age,13-17 Years,78.8,72.8 to 83.8,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2013,Age,13-17 Years,81.3,76.3 to 85.4,426
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2010,Age,13-17 Years,66.4,60.1 to 72.2,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2011,Age,13-17 Years,69.9,63.4 to 75.7,360
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2009,Age,13-17 Years,20.3,14.4 to 27.8,158
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2020,Age,13-15 Years,77.1,69.6 to 83.2,215
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2010,Age,13-17 Years,38.9,30.6 to 47.9,163
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2011,Age,13-17 Years,37.3,28.2 to 47.5,175
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2012,Age,13-17 Years,49.5,40.1 to 59.0,167
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2013,Age,13-17 Years,46.5,38.0 to 55.1,184
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2019,Age,13-15 Years,77.5,69.9 to 83.7,214
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018,Age,13-15 Years,72.8,64.6 to 79.6,199
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2017,Age,13-15 Years,67.3,59.3 to 74.5,212
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2019,Age,13-17 Years,89.8,85.7 to 92.8,369
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2020,Age,13-17 Years,87.5,82.6 to 91.2,338
HPV,"≥1 Dose, Males",States/Local Areas,Oklahoma,2022,Age,13-17 Years,67.9,57.6 to 76.7,140
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2009,Age,13-15 Years,35.7,28.7 to 43.3,209
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2008,Age,13-15 Years,29.6,22.8 to 37.4,179
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2008,Age,13-17 Years,29.3,21.7 to 38.2,141
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2011,Age,13-15 Years,58.4,50.4 to 66.0,254
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2010,Age,13-15 Years,46.1,37.8 to 54.5,168
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2008,Age,13-17 Years,59.5,53.1 to 65.5,292
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oklahoma,2009,Age,13-17 Years,55.5,49.3 to 61.5,336
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2017,Age,13-17 Years,48.4,39.2 to 57.7,156
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2016,Age,13-17 Years,50.8,40.2 to 61.3,127
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2014,Age,13-17 Years,50.8,41.6 to 60.0,170
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2015,Age,13-17 Years,43.4,33.9 to 53.5,129
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2022,Age,13-17 Years,69.1,61.7 to 75.7,249
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2021,Age,13-17 Years,72.4,65.4 to 78.5,240
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oklahoma,2020,Age,13-17 Years,65.5,59.3 to 71.2,338
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2021,Age,13-15 Years,78.2,69.7 to 84.8,151
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2019,Age,13-17 Years,48.5,39.4 to 57.7,168
HPV,"≥2 Doses, Females",States/Local Areas,Oklahoma,2018,Age,13-17 Years,47.3,38.4 to 56.4,157
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2012,Age,13-15 Years,82.2,75.0 to 87.7,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2011,Age,13-15 Years,65.7,57.6 to 72.9,254
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2009,Age,13-15 Years,43.5,36.1 to 51.2,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2010,Age,13-15 Years,61.3,52.8 to 69.3,168
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2008,Age,13-15 Years,33.8,26.7 to 41.7,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2017,Age,13-15 Years,82.3,75.2 to 87.7,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2016,Age,13-15 Years,91.1,85.4 to 94.7,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2014,Age,13-15 Years,86.1,79.8 to 90.6,220
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2015,Age,13-15 Years,85.8,78.7 to 90.8,177
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2012,Age,13-17 Years,14.8,9.7 to 21.8,155
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2018,Age,13-17 Years,35.4,28.2 to 43.3,203
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2017,Age,13-17 Years,39.7,31.5 to 48.5,182
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2016,Age,13-17 Years,35.9,26.9 to 46.0,154
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2013,Age,13-15 Years,83.1,76.9 to 87.8,279
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2015,Age,13-17 Years,40.1,31.5 to 49.3,162
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2019,Age,13-15 Years,87.1,81.2 to 91.4,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2020,Age,13-15 Years,82.7,75.7 to 88.0,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2021,Age,13-15 Years,82.6,73.8 to 88.8,151
Tetanus,≥1 Dose Tdap,States/Local Areas,Oklahoma,2018,Age,13-15 Years,83.0,75.0 to 88.9,199
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2014,Age,13-17 Years,30.2,22.7 to 39.1,186
HPV,"≥2 Doses, Males",States/Local Areas,Oklahoma,2013,Age,13-17 Years,31.1,24.7 to 38.4,242
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2019,Age,13-17 Years,77.3,71.5 to 82.2,369
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2018,Age,13-17 Years,72.9,67.0 to 78.1,360
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2017,Age,13-17 Years,71.1,64.9 to 76.6,338
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2020,Age,13-17 Years,80.0,74.2 to 84.7,338
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2021,Age,13-17 Years,82.7,76.9 to 87.3,240
≥1 Dose MenACWY,,States/Local Areas,Oklahoma,2022,Age,13-17 Years,82.2,75.8 to 87.3,249
Varicella,History of disease,States/Local Areas,Tennessee,2015,Age,13-17 Years,19.7,14.9 to 25.7,325
Varicella,History of disease,States/Local Areas,Tennessee,2016,Age,13-17 Years,16.4,11.7 to 22.5,291
Varicella,History of disease,States/Local Areas,Tennessee,2018,Age,13-17 Years,16.8,11.7 to 23.4,284
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2016,Age,13-17 Years,36.9,28.1 to 46.6,136
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2017,Age,13-17 Years,47.7,38.3 to 57.2,168
Varicella,History of disease,States/Local Areas,Tennessee,2012,Age,13-17 Years,32.8,26.3 to 39.9,331
Varicella,History of disease,States/Local Areas,Tennessee,2013,Age,13-17 Years,27.7,22.3 to 33.8,304
Varicella,History of disease,States/Local Areas,Tennessee,2010,Age,13-17 Years,45.6,39.4 to 51.8,320
Varicella,History of disease,States/Local Areas,Tennessee,2011,Age,13-17 Years,38.1,31.9 to 44.7,424
Varicella,History of disease,States/Local Areas,Tennessee,2009,Age,13-17 Years,51.0,45.0 to 57.0,397
Varicella,History of disease,States/Local Areas,Tennessee,2014,Age,13-17 Years,20.2,15.4 to 26.1,339
Varicella,History of disease,States/Local Areas,Tennessee,2017,Age,13-17 Years,10.3,7.1 to 14.8,338
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2019,Age,13-15 Years,53.4,40.0 to 66.3,78
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2020,Age,13-15 Years,46.0,35.0 to 57.4,109
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2018,Age,13-15 Years,45.4,33.1 to 58.3,92
Varicella,History of disease,States/Local Areas,Tennessee,2008,Age,13-17 Years,67.3,61.5 to 72.7,360
Varicella,History of disease,States/Local Areas,Tennessee,2020,Age,13-17 Years,8.9,6.0 to 13.1,338
Varicella,History of disease,States/Local Areas,Tennessee,2019,Age,13-17 Years,10.1,6.4 to 15.7,261
Varicella,History of disease,States/Local Areas,Tennessee,2021,Age,13-17 Years,10.0,6.3 to 15.4,315
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2019,Age,13-15 Years,40.7,29.1 to 53.6,85
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2020,Age,13-15 Years,59.7,47.3 to 71.0,96
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2021,Age,13-15 Years,48.1,35.9 to 60.5,101
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2022,Age,13-15 Years,62.2,47.9 to 74.7,92
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2016,Age,13-17 Years,35.2,26.5 to 44.9,155
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2020,Age,13-17 Years,49.4,40.4 to 58.5,170
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2018,Age,13-15 Years,39.4,28.3 to 51.7,96
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2021,Age,13-17 Years,64.4,54.2 to 73.5,141
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2022,Age,13-17 Years,65.9,54.4 to 75.9,106
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2018,Age,13-17 Years,47.5,37.4 to 57.8,137
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2019,Age,13-17 Years,50.5,40.1 to 60.8,126
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2021,Age,13-15 Years,63.3,49.9 to 74.9,87
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2022,Age,13-15 Years,56.5,41.3 to 70.6,68
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2019,Age,13-15 Years,46.6,37.6 to 55.9,163
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2022,Age,13-17 Years,62.9,52.0 to 72.7,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2021,Age,13-15 Years,55.8,46.6 to 64.7,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2020,Age,13-15 Years,52.4,44.0 to 60.7,205
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2021,Age,13-17 Years,48.8,39.3 to 58.4,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2022,Age,13-15 Years,59.5,49.1 to 69.0,160
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2018,Age,13-17 Years,41.5,32.2 to 51.4,147
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2017,Age,13-17 Years,31.1,23.0 to 40.6,170
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2019,Age,13-17 Years,35.8,26.7 to 46.0,135
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2020,Age,13-17 Years,56.3,46.9 to 65.3,168
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018,Age,13-17 Years,44.4,37.4 to 51.6,284
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2017,Age,13-17 Years,39.2,32.8 to 46.1,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2012,Age,13-17 Years,77.4,70.6 to 82.9,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2013,Age,13-17 Years,80.0,74.1 to 84.9,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2014,Age,13-17 Years,86.0,80.9 to 89.9,339
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2023,Age,13-17 Years,73.1,61.6 to 82.1,123
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2023,Age,13-17 Years,60.2,48.5 to 70.9,123
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2023,Age,13-15 Years,86.1,75.5 to 92.6,122
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2023,Age,13-15 Years,56.6,40.4 to 71.6,65
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2023,Age,13-15 Years,45.1,30.8 to 60.3,66
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2023,Age,13-15 Years,50.4,39.4 to 61.4,131
≥1 Dose MenACWY,,States/Local Areas,Missouri,2023,Age,13-15 Years,85.1,75.5 to 91.4,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2023,Age,13-15 Years,85.4,75.7 to 91.6,131
≥2 Doses Hep A,,States/Local Areas,Missouri,2023,Age,13-17 Years,86.7,80.3 to 91.2,246
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2023,Age,13-17 Years,89.8,83.8 to 93.8,246
≥3 Doses HepB,,States/Local Areas,Missouri,2023,Age,13-17 Years,90.8,84.3 to 94.7,246
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2023,Age,13-17 Years,93.7,88.5 to 96.7,234
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2023,Age,13-17 Years,89.3,83.1 to 93.4,234
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2023,Age,13-17 Years,55.2,43.7 to 66.1,123
≥2 Doses MMR,,States/Local Areas,Missouri,2023,Age,13-17 Years,87.5,81.0 to 92.0,246
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2023,Age,13-17 Years,57.7,49.5 to 65.4,246
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2023,Age,13-17 Years,78.3,67.3 to 86.4,123
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2023,Age,13-17 Years,75.6,67.9 to 82.0,246
≥1 Dose MenACWY,,States/Local Areas,Missouri,2023,Age,13-17 Years,88.0,81.8 to 92.3,246
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2023,Age,13-17 Years,88.7,82.5 to 92.9,246
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2023,Age,13-17 Years,88.0,81.7 to 92.3,246
HPV,"≥2 Doses, Males and Females",States/Local Areas,Missouri,2022,Age,13-17 Years,61.0,53.8 to 67.8,284
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2022,Age,13-17 Years,56.3,45.8 to 66.3,140
≥1 Dose MenACWY,,States/Local Areas,Missouri,2020,Age,13-17 Years,85.3,79.9 to 89.5,397
≥1 Dose MenACWY,,States/Local Areas,Missouri,2021,Age,13-17 Years,90.4,85.7 to 93.7,340
≥1 Dose MenACWY,,States/Local Areas,Missouri,2019,Age,13-17 Years,84.8,78.9 to 89.2,288
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018,Age,13-17 Years,78.3,72.0 to 83.5,319
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2015,Age,13-15 Years,22.6,13.5 to 35.4,91
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2014,Age,13-15 Years,21.5,13.7 to 32.0,117
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2013,Age,13-15 Years,19.1,11.6 to 30.0,82
≥2 Doses MMR,,States/Local Areas,Missouri,2021,Age,13-17 Years,88.3,82.9 to 92.2,340
≥2 Doses MMR,,States/Local Areas,Missouri,2022,Age,13-17 Years,89.3,83.6 to 93.2,284
≥1 Dose MenACWY,,States/Local Areas,Missouri,2022,Age,13-17 Years,90.1,84.6 to 93.7,284
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2008,Age,13-15 Years,13.9,7.6 to 24.0,97
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2010,Age,13-15 Years,24.7,16.9 to 34.6,105
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2009,Age,13-15 Years,14.2,8.5 to 22.8,105
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2011,Age,13-15 Years,25.6,15.5 to 39.3,114
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2012,Age,13-15 Years,29.1,18.9 to 41.9,92
HPV,"≥3 Doses, Males and Females",States/Local Areas,Missouri,2013,Age,13-17 Years,16.5,12.0 to 22.1,280
≥2 Doses MMR,,States/Local Areas,Missouri,2020,Age,13-17 Years,92.6,88.5 to 95.3,397
HPV,"≥3 Doses, Males and Females",States/Local Areas,Missouri,2015,Age,13-17 Years,28.2,22.1 to 35.3,300
HPV,"≥3 Doses, Males and Females",States/Local Areas,Missouri,2014,Age,13-17 Years,19.6,15.0 to 25.2,361
≥1 Dose MenACWY,,States/Local Areas,Missouri,2014,Age,13-17 Years,63.3,56.6 to 69.6,361
≥1 Dose MenACWY,,States/Local Areas,Missouri,2013,Age,13-17 Years,60.7,53.4 to 67.5,280
≥1 Dose MenACWY,,States/Local Areas,Missouri,2015,Age,13-17 Years,69.7,62.8 to 75.8,300
≥1 Dose MenACWY,,States/Local Areas,Missouri,2016,Age,13-17 Years,66.2,59.6 to 72.2,360
≥2 Doses MMR,,States/Local Areas,Missouri,2014,Age,13-17 Years,83.9,77.8 to 88.5,361
≥2 Doses MMR,,States/Local Areas,Missouri,2015,Age,13-17 Years,85.9,79.9 to 90.3,300
≥2 Doses MMR,,States/Local Areas,Missouri,2016,Age,13-17 Years,87.2,82.4 to 90.9,360
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2022,Age,13-17 Years,66.0,56.2 to 74.5,144
≥1 Dose MenACWY,,States/Local Areas,Missouri,2009,Age,13-17 Years,45.5,39.6 to 51.4,374
≥1 Dose MenACWY,,States/Local Areas,Missouri,2008,Age,13-17 Years,35.3,29.6 to 41.5,351
≥1 Dose MenACWY,,States/Local Areas,Missouri,2011,Age,13-17 Years,54.6,48.0 to 61.0,402
≥1 Dose MenACWY,,States/Local Areas,Missouri,2010,Age,13-17 Years,49.2,43.3 to 55.1,347
≥2 Doses MMR,,States/Local Areas,Missouri,2019,Age,13-17 Years,90.4,84.8 to 94.1,288
≥2 Doses MMR,,States/Local Areas,Missouri,2018,Age,13-17 Years,89.4,84.8 to 92.7,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2020,Age,13-17 Years,84.2,78.6 to 88.6,397
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2021,Age,13-17 Years,89.6,84.6 to 93.1,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2019,Age,13-17 Years,82.4,76.2 to 87.2,288
≥1 Dose MenACWY,,States/Local Areas,Missouri,2017,Age,13-17 Years,74.3,68.3 to 79.5,335
≥2 Doses MMR,,States/Local Areas,Missouri,2017,Age,13-17 Years,87.6,83.1 to 91.1,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2022,Age,13-17 Years,90.0,85.2 to 93.3,284
HPV,"≥3 Doses, Males and Females",States/Local Areas,Missouri,2012,Age,13-17 Years,18.6,13.6 to 24.7,292
HPV,"≥3 Doses, Males and Females",States/Local Areas,Missouri,2011,Age,13-17 Years,15.1,10.9 to 20.6,402
≥2 Doses MMR,,States/Local Areas,Missouri,2013,Age,13-17 Years,88.3,82.6 to 92.4,280
≥2 Doses MMR,,States/Local Areas,Missouri,2012,Age,13-17 Years,87.0,80.4 to 91.7,292
≥1 Dose MenACWY,,States/Local Areas,Missouri,2022,Age,13-15 Years,90.0,83.2 to 94.2,179
≥1 Dose MenACWY,,States/Local Areas,Missouri,2012,Age,13-17 Years,58.3,50.5 to 65.6,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2016,Age,13-17 Years,83.9,78.7 to 88.0,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2017,Age,13-17 Years,80.1,74.1 to 85.0,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018,Age,13-17 Years,80.6,74.4 to 85.6,319
HPV,"≥2 Doses, Males and Females",States/Local Areas,Washington,2016,Age,13-17 Years,53.0,46.5 to 59.4,361
HPV,"≥2 Doses, Males and Females",States/Local Areas,Washington,2019,Age,13-17 Years,56.3,48.4 to 63.9,304
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2016,Age,13-17 Years,58.9,49.9 to 67.3,193
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2015,Age,13-17 Years,46.8,38.9 to 54.8,208
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2013,Age,13-17 Years,29.8,22.4 to 38.4,197
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2014,Age,13-17 Years,53.8,44.9 to 62.4,195
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2012,Age,13-17 Years,14.9,9.7 to 22.2,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2021,Age,13-15 Years,94.1,88.7 to 97.0,206
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2019,Age,13-15 Years,93.8,87.0 to 97.2,178
≥3 Doses HepB,,States/Local Areas,Washington,2019,Age,13-17 Years,90.1,85.0 to 93.6,304
≥3 Doses HepB,,States/Local Areas,Washington,2017,Age,13-17 Years,90.0,85.9 to 93.1,339
≥3 Doses HepB,,States/Local Areas,Washington,2010,Age,13-17 Years,86.1,81.4 to 89.7,361
≥3 Doses HepB,,States/Local Areas,Washington,2009,Age,13-17 Years,84.4,79.2 to 88.5,321
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2009,Age,13-17 Years,60.0,50.9 to 68.5,158
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2008,Age,13-17 Years,46.5,37.1 to 56.1,135
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2010,Age,13-17 Years,64.3,55.4 to 72.4,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2011,Age,13-17 Years,65.6,56.6 to 73.6,189
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2010,Age,13-17 Years,84.8,76.4 to 90.5,152
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2009,Age,13-17 Years,80.0,70.2 to 87.2,130
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2008,Age,13-17 Years,78.9,67.7 to 87.0,89
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2011,Age,13-17 Years,88.7,81.2 to 93.4,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2022,Age,13-15 Years,89.4,80.5 to 94.5,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2009,Age,13-17 Years,50.1,40.4 to 59.7,130
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2008,Age,13-17 Years,26.6,17.1 to 39.0,89
≥3 Doses HepB,,States/Local Areas,Washington,2012,Age,13-17 Years,86.5,80.2 to 91.0,353
≥3 Doses HepB,,States/Local Areas,Washington,2011,Age,13-17 Years,88.8,83.7 to 92.4,346
≥3 Doses HepB,,States/Local Areas,Washington,2013,Age,13-17 Years,89.4,84.4 to 92.9,360
≥3 Doses HepB,,States/Local Areas,Washington,2014,Age,13-17 Years,87.0,82.3 to 90.6,374
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2012,Age,13-17 Years,73.9,64.8 to 81.4,209
≥3 Doses HepB,,States/Local Areas,Washington,2016,Age,13-17 Years,88.3,83.2 to 92.0,361
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2012,Age,13-17 Years,89.7,80.5 to 94.8,209
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2018,Age,13-17 Years,94.6,90.3 to 97.0,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2017,Age,13-15 Years,91.4,85.4 to 95.1,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2020,Age,13-15 Years,91.8,84.9 to 95.7,255
≥3 Doses HepB,,States/Local Areas,Washington,2015,Age,13-17 Years,85.0,79.9 to 88.9,396
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2016,Age,13-17 Years,84.9,78.4 to 89.7,295
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2015,Age,13-17 Years,79.1,72.7 to 84.4,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2013,Age,13-17 Years,71.6,62.9 to 78.9,228
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2014,Age,13-17 Years,77.8,71.0 to 83.3,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2017,Age,13-17 Years,92.0,88.0 to 94.8,289
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2011,Age,13-17 Years,66.5,57.1 to 74.7,162
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2010,Age,13-17 Years,69.3,61.5 to 76.2,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2019,Age,13-17 Years,91.0,85.5 to 94.5,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2021,Age,13-17 Years,89.7,83.7 to 93.6,323
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2020,Age,13-17 Years,92.4,87.6 to 95.5,381
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2018,Age,13-17 Years,85.0,78.4 to 89.8,249
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2020,Age,13-17 Years,96.2,92.5 to 98.1,381
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2017,Age,13-17 Years,95.2,92.0 to 97.2,289
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2012,Age,13-17 Years,64.5,53.9 to 73.8,155
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2013,Age,13-17 Years,60.7,50.6 to 69.9,163
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2014,Age,13-17 Years,65.8,56.6 to 74.0,179
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2016,Age,13-17 Years,91.7,85.5 to 95.4,295
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2015,Age,13-17 Years,92.0,87.3 to 95.1,299
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2013,Age,13-17 Years,92.6,86.7 to 96.0,228
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2014,Age,13-17 Years,91.3,86.5 to 94.5,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2018,Age,13-15 Years,88.6,80.7 to 93.5,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2015,Age,13-15 Years,78.9,70.5 to 85.4,190
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2014,Age,13-15 Years,79.6,70.7 to 86.4,174
≥1 Dose MenACWY,,States/Local Areas,Washington,2016,Age,13-15 Years,72.1,64.0 to 79.0,236
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2016,Age,13-17 Years,70.9,62.4 to 78.3,168
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2019,Age,13-17 Years,94.9,90.0 to 97.5,270
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2015,Age,13-17 Years,65.8,57.3 to 73.4,188
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2017,Age,13-17 Years,72.6,63.9 to 79.9,178
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2018,Age,13-17 Years,74.6,64.9 to 82.4,153
≥1 Dose MenACWY,,States/Local Areas,Washington,2012,Age,13-15 Years,71.0,61.8 to 78.8,207
≥1 Dose MenACWY,,States/Local Areas,Washington,2013,Age,13-15 Years,80.5,72.5 to 86.6,219
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2016,Age,13-17 Years,89.5,84.4 to 93.0,361
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2015,Age,13-17 Years,89.3,84.7 to 92.7,396
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2014,Age,13-17 Years,89.4,84.7 to 92.8,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2013,Age,13-17 Years,90.6,85.5 to 94.0,360
≥3 Doses HepB,,States/Local Areas,Washington,2021,Age,13-17 Years,90.6,85.5 to 94.1,349
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2020,Age,13-17 Years,72.4,62.9 to 80.2,215
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2022,Age,13-17 Years,94.3,88.3 to 97.3,254
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2017,Age,13-17 Years,71.2,62.4 to 78.6,161
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2018,Age,13-17 Years,68.2,57.3 to 77.4,133
HPV,"≥2 Doses, Males and Females",States/Local Areas,Washington,2017,Age,13-17 Years,59.9,53.5 to 66.0,339
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2021,Age,13-17 Years,95.0,90.1 to 97.5,323
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2011,Age,13-17 Years,8.9,5.1 to 15.2,184
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2022,Age,13-17 Years,88.3,80.4 to 93.3,131
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2020,Age,13-17 Years,76.8,67.5 to 84.1,202
HPV,"≥2 Doses, Males and Females",States/Local Areas,Washington,2018,Age,13-17 Years,54.1,46.6 to 61.3,286
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2022,Age,13-17 Years,88.3,81.5 to 92.7,254
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2021,Age,13-17 Years,80.9,72.7 to 87.1,191
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2019,Age,13-17 Years,75.2,65.3 to 82.9,147
≥3 Doses HepB,,States/Local Areas,Washington,2018,Age,13-17 Years,90.1,84.8 to 93.7,286
≥3 Doses HepB,,States/Local Areas,Washington,2008,Age,13-17 Years,81.3,75.6 to 85.9,275
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2016,Age,13-17 Years,58.5,49.1 to 67.4,168
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2015,Age,13-17 Years,55.8,47.4 to 63.9,188
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2014,Age,13-17 Years,54.1,44.8 to 63.1,179
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2022,Age,13-17 Years,82.7,74.1 to 88.9,149
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2019,Age,13-17 Years,69.1,58.4 to 78.0,157
≥1 Dose MenACWY,,States/Local Areas,Washington,2009,Age,13-15 Years,58.0,50.3 to 65.4,209
≥1 Dose MenACWY,,States/Local Areas,Washington,2008,Age,13-15 Years,38.4,30.6 to 46.8,175
≥1 Dose MenACWY,,States/Local Areas,Washington,2011,Age,13-15 Years,70.7,61.8 to 78.2,208
≥1 Dose MenACWY,,States/Local Areas,Washington,2010,Age,13-15 Years,65.4,57.8 to 72.2,215
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2021,Age,13-17 Years,77.2,67.4 to 84.7,158
≥1 Dose MenACWY,,States/Local Areas,Washington,2019,Age,13-15 Years,84.1,76.1 to 89.8,198
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2017,Age,13-17 Years,71.9,65.8 to 77.3,339
≥1 Dose MenACWY,,States/Local Areas,Washington,2018,Age,13-15 Years,79.6,70.8 to 86.2,192
≥1 Dose MenACWY,,States/Local Areas,Washington,2017,Age,13-15 Years,85.0,78.0 to 90.1,192
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2008,Age,13-17 Years,41.0,31.8 to 50.9,135
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2010,Age,13-17 Years,60.4,52.1 to 68.1,175
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2011,Age,13-17 Years,56.5,47.1 to 65.5,162
≥1 Dose MenACWY,,States/Local Areas,Washington,2020,Age,13-15 Years,87.3,80.5 to 92.0,276
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2009,Age,13-17 Years,49.1,40.4 to 58.0,158
≥1 Dose MenACWY,,States/Local Areas,Washington,2015,Age,13-15 Years,74.5,67.3 to 80.6,237
≥1 Dose MenACWY,,States/Local Areas,Washington,2014,Age,13-15 Years,81.4,74.0 to 87.0,214
≥3 Doses HepB,,States/Local Areas,Washington,2020,Age,13-17 Years,89.5,84.2 to 93.2,417
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2012,Age,13-17 Years,54.6,44.4 to 64.4,155
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2013,Age,13-17 Years,52.3,42.4 to 62.0,163
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2016,Age,13-17 Years,64.8,58.5 to 70.6,361
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2017,Age,13-17 Years,91.6,87.4 to 94.4,339
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2009,Age,13-17 Years,76.3,70.1 to 81.5,321
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2008,Age,13-17 Years,64.2,57.4 to 70.5,275
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2010,Age,13-17 Years,82.8,77.9 to 86.8,361
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2011,Age,13-17 Years,84.1,78.2 to 88.7,346
≥3 Doses HepB,,States/Local Areas,Washington,2022,Age,13-17 Years,91.2,85.4 to 94.9,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2012,Age,13-17 Years,89.5,83.7 to 93.4,353
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018,Age,13-17 Years,82.0,75.2 to 87.3,286
≥1 Dose MenACWY,,States/Local Areas,Washington,2010,Age,13-17 Years,67.6,61.9 to 72.8,361
≥1 Dose MenACWY,,States/Local Areas,Washington,2011,Age,13-17 Years,69.4,62.7 to 75.4,346
≥1 Dose MenACWY,,States/Local Areas,Washington,2009,Age,13-17 Years,55.8,49.4 to 62.0,321
≥1 Dose MenACWY,,States/Local Areas,Washington,2008,Age,13-17 Years,40.0,33.5 to 46.8,275
≥1 Dose MenACWY,,States/Local Areas,Washington,2022,Age,13-15 Years,88.5,82.0 to 92.8,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2017,Age,13-17 Years,88.6,83.8 to 92.1,339
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2015,Age,13-17 Years,85.3,80.2 to 89.3,396
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2016,Age,13-17 Years,86.8,81.5 to 90.7,361
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2020,Age,13-17 Years,91.1,86.2 to 94.4,417
≥2 Doses MMR,,States/Local Areas,Washington,2019,Age,13-17 Years,93.7,89.2 to 96.4,304
≥2 Doses MMR,,States/Local Areas,Washington,2017,Age,13-17 Years,91.5,87.4 to 94.3,339
≥2 Doses MMR,,States/Local Areas,Washington,2018,Age,13-17 Years,88.3,82.6 to 92.3,286
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2019,Age,13-17 Years,89.8,85.1 to 93.1,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2021,Age,13-17 Years,87.4,81.6 to 91.5,349
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2022,Age,13-17 Years,94.9,91.3 to 97.1,280
≥2 Doses MMR,,States/Local Areas,Washington,2015,Age,13-17 Years,88.1,83.5 to 91.5,396
≥2 Doses MMR,,States/Local Areas,Washington,2014,Age,13-17 Years,88.2,83.7 to 91.6,374
HPV,"≥3 Doses, Males and Females",States/Local Areas,Washington,2012,Age,13-17 Years,24.1,18.9 to 30.3,353
HPV,"≥3 Doses, Males and Females",States/Local Areas,Washington,2013,Age,13-17 Years,28.4,22.8 to 34.8,360
HPV,"≥3 Doses, Males and Females",States/Local Areas,Washington,2014,Age,13-17 Years,34.0,28.1 to 40.5,374
HPV,"≥3 Doses, Males and Females",States/Local Areas,Washington,2015,Age,13-17 Years,36.3,30.9 to 42.1,396
HPV,"≥3 Doses, Males and Females",States/Local Areas,Washington,2011,Age,13-17 Years,19.8,15.3 to 25.3,346
≥2 Doses MMR,,States/Local Areas,Washington,2016,Age,13-17 Years,88.9,84.0 to 92.5,361
≥1 Dose MenACWY,,States/Local Areas,Washington,2016,Age,13-17 Years,75.1,68.9 to 80.5,361
≥1 Dose MenACWY,,States/Local Areas,Washington,2015,Age,13-17 Years,75.4,69.9 to 80.1,396
≥1 Dose MenACWY,,States/Local Areas,Washington,2013,Age,13-17 Years,79.0,72.8 to 84.1,360
≥1 Dose MenACWY,,States/Local Areas,Washington,2014,Age,13-17 Years,82.1,76.7 to 86.5,374
≥1 Dose MenACWY,,States/Local Areas,Washington,2012,Age,13-17 Years,71.2,64.2 to 77.3,353
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2011,Age,13-15 Years,34.7,24.8 to 46.2,103
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2009,Age,13-15 Years,33.7,24.6 to 44.1,110
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2010,Age,13-15 Years,40.7,31.0 to 51.2,108
≥2 Doses MMR,,States/Local Areas,Washington,2012,Age,13-17 Years,86.6,80.5 to 91.1,353
≥2 Doses MMR,,States/Local Areas,Washington,2013,Age,13-17 Years,89.9,85.0 to 93.2,360
≥1 Dose MenACWY,,States/Local Areas,Washington,2021,Age,13-17 Years,85.4,79.8 to 89.6,349
≥1 Dose MenACWY,,States/Local Areas,Washington,2022,Age,13-17 Years,90.1,85.1 to 93.6,280
≥1 Dose MenACWY,,States/Local Areas,Washington,2018,Age,13-17 Years,83.7,77.5 to 88.5,286
≥1 Dose MenACWY,,States/Local Areas,Washington,2020,Age,13-17 Years,88.1,82.7 to 91.9,417
≥1 Dose MenACWY,,States/Local Areas,Washington,2017,Age,13-17 Years,82.6,77.2 to 87.0,339
≥2 Doses MMR,,States/Local Areas,Washington,2020,Age,13-17 Years,92.2,87.1 to 95.4,417
≥1 Dose MenACWY,,States/Local Areas,Washington,2021,Age,13-15 Years,87.4,81.3 to 91.7,218
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2019,Age,13-17 Years,90.8,86.2 to 93.9,304
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018,Age,13-17 Years,71.3,64.2 to 77.6,286
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2022,Age,13-17 Years,85.4,79.9 to 89.7,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2020,Age,13-17 Years,93.1,88.2 to 96.0,417
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2012,Age,13-15 Years,83.8,75.1 to 89.9,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2011,Age,13-15 Years,78.0,69.1 to 84.9,208
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2019,Age,13-17 Years,72.0,64.9 to 78.2,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2021,Age,13-17 Years,89.8,84.1 to 93.6,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2018,Age,13-17 Years,86.6,80.2 to 91.1,286
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2009,Age,13-15 Years,68.2,60.7 to 74.9,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2010,Age,13-15 Years,77.9,70.6 to 83.9,215
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2022,Age,13-17 Years,96.3,93.0 to 98.0,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2008,Age,13-15 Years,39.4,31.7 to 47.7,175
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2017,Age,13-17 Years,61.4,52.4 to 69.7,178
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2018,Age,13-17 Years,60.2,50.1 to 69.6,153
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2020,Age,13-17 Years,74.6,68.1 to 80.1,417
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2021,Age,13-17 Years,79.0,72.8 to 84.1,349
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2019,Age,13-15 Years,91.1,85.5 to 94.6,198
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2016,Age,13-17 Years,47.7,38.9 to 56.6,193
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2017,Age,13-17 Years,58.5,49.3 to 67.2,161
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2017,Age,13-15 Years,87.2,80.4 to 91.8,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018,Age,13-15 Years,80.6,71.5 to 87.4,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2020,Age,13-15 Years,89.7,83.1 to 93.9,276
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2018,Age,13-17 Years,48.1,37.5 to 58.9,133
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2016,Age,13-15 Years,84.8,77.8 to 90.0,236
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2015,Age,13-15 Years,88.5,82.3 to 92.7,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2014,Age,13-15 Years,87.9,81.8 to 92.2,214
≥2 Doses MMR,,States/Local Areas,Washington,2021,Age,13-17 Years,93.2,88.9 to 96.0,349
≥2 Doses MMR,,States/Local Areas,Washington,2022,Age,13-17 Years,94.1,88.7 to 97.0,280
≥1 Dose MenACWY,,States/Local Areas,Washington,2019,Age,13-17 Years,83.3,77.1 to 88.1,304
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2013,Age,13-15 Years,39.9,28.1 to 53.0,97
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2015,Age,13-15 Years,43.3,33.3 to 53.9,121
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2014,Age,13-15 Years,41.6,30.3 to 53.9,105
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2012,Age,13-15 Years,25.8,16.9 to 37.4,86
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2015,Age,13-17 Years,41.2,33.7 to 49.2,208
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2013,Age,13-15 Years,88.1,80.6 to 93.0,219
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2014,Age,13-17 Years,41.8,33.4 to 50.8,195
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2013,Age,13-17 Years,18.0,12.5 to 25.1,197
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2012,Age,13-17 Years,9.6,5.3 to 16.6,198
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2019,Age,13-17 Years,64.4,53.6 to 74.0,147
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2022,Age,13-17 Years,71.9,62.5 to 79.8,149
HPV,"≥2 Doses, Females",States/Local Areas,Washington,2022,Age,13-17 Years,71.0,59.8 to 80.2,131
HPV,"≥2 Doses, Males and Females",States/Local Areas,Washington,2022,Age,13-17 Years,71.5,64.3 to 77.7,280
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Overall,Overall,76.6,73.8 to 79.2,1636
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Overall,Overall,60.7,57.5 to 63.9,1636
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Urbanicity,Living In a Non-MSA,78.7,68.5 to 86.3,152
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Principal City,79.1,75.2 to 82.5,859
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Non-Principal City,75.2,70.5 to 79.4,625
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Principal City,64.5,60.1 to 68.7,859
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Non-Principal City,56.9,51.5 to 62.1,625
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Principal City,88.8,85.8 to 91.2,859
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Urbanicity,Living In a Non-MSA,68.4,57.9 to 77.4,152
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Non-Principal City,86.4,82.4 to 89.7,625
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Urbanicity,Living In a Non-MSA,70.6,60.2 to 79.2,152
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Principal City,90.4,87.4 to 92.8,859
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Urbanicity,Living In a Non-MSA,55.5,44.8 to 65.8,152
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.9,86.4 to 92.6,625
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",83.9,77.2 to 88.9,291
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",76.5,69.1 to 82.6,291
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,Hispanic,83.4,77.2 to 88.2,294
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.7,64.2 to 90.6,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,"White, Non-Hispanic",55.7,51.4 to 59.8,1003
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,Hispanic,70.5,63.4 to 76.7,294
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.8,82.8 to 88.3,1003
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.3,53.4 to 68.7,291
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",82.4,62.5 to 92.9,48
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.7,86.8 to 91.9,1003
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Race and Ethnicity,Hispanic,89.6,84.3 to 93.3,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.3,69.3 to 94.6,48
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Race and Ethnicity,Hispanic,90.5,85.4 to 93.9,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.0,79.3 to 90.8,291
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,"White, Non-Hispanic",73.5,69.7 to 77.0,1003
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",85.9,69.5 to 94.2,48
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Poverty,Below Poverty Level,80.8,73.1 to 86.7,193
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Poverty,Living At or Above Poverty Level,75.5,72.4 to 78.4,1392
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Poverty,Living At or Above Poverty Level,86.9,84.4 to 89.1,1392
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Poverty,Below Poverty Level,82.4,74.8 to 88.0,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Insurance Coverage,Other,90.4,82.2 to 95.0,143
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Insurance Coverage,Any Medicaid,61.8,56.4 to 67.0,544
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Insurance Coverage,Private Insurance Only,60.8,56.5 to 65.0,930
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Insurance Coverage,Other,62.3,50.8 to 72.5,143
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Insurance Coverage,Private Insurance Only,90.6,87.6 to 92.9,930
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Insurance Coverage,Any Medicaid,87.7,83.8 to 90.8,544
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Poverty,Below Poverty Level,63.4,54.5 to 71.6,193
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018-2022,Poverty,Living At or Above Poverty Level,59.4,55.9 to 62.9,1392
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Poverty,Below Poverty Level,83.5,76.0 to 89.0,193
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Insurance Coverage,Any Medicaid,85.1,80.9 to 88.5,544
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Poverty,Living At or Above Poverty Level,90.2,87.9 to 92.1,1392
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Insurance Coverage,Private Insurance Only,88.3,85.3 to 90.8,930
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Insurance Coverage,Any Medicaid,78.1,73.3 to 82.3,544
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Insurance Coverage,Private Insurance Only,76.2,72.4 to 79.7,930
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2018-2022,Insurance Coverage,Other,78.6,68.6 to 86.1,143
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Insurance Coverage,Other,83.0,73.0 to 89.9,143
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2018-2022,Overall,Overall,89.1,86.9 to 91.0,1636
≥1 Dose MenACWY,,States/Local Areas,Washington,2018-2022,Overall,Overall,86.2,83.8 to 88.2,1636
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2021,Age,13-17 Years,65.5,55.8 to 74.0,191
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2020,Age,13-15 Years,50.6,38.8 to 62.4,134
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2021,Age,13-15 Years,65.9,52.2 to 77.4,96
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2022,Age,13-15 Years,65.2,52.4 to 76.1,88
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2016,Age,13-17 Years,55.2,45.8 to 64.2,168
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2022,Age,13-15 Years,65.9,56.2 to 74.4,174
Varicella,History of disease,States/Local Areas,Washington,2021,Age,13-17 Years,7.1,4.1 to 11.9,349
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2022,Age,13-17 Years,71.1,61.6 to 79.0,149
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2019,Age,13-17 Years,46.5,35.7 to 57.7,157
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2019,Age,13-15 Years,45.7,32.8 to 59.2,107
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2016,Age,13-17 Years,44.0,35.4 to 52.9,193
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2018,Age,13-15 Years,45.4,32.3 to 59.2,84
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2022,Age,13-17 Years,71.0,59.8 to 80.2,131
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2020,Age,13-17 Years,65.4,55.7 to 73.9,202
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2021,Age,13-17 Years,70.1,60.1 to 78.5,158
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2017,Age,13-17 Years,53.7,44.6 to 62.6,161
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2020,Age,13-17 Years,53.0,43.6 to 62.1,215
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2018,Age,13-17 Years,47.0,36.5 to 57.8,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2019,Age,13-15 Years,53.0,43.1 to 62.7,198
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2021,Age,13-15 Years,61.6,52.6 to 70.0,218
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2019,Age,13-17 Years,60.4,49.5 to 70.4,147
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2018,Age,13-17 Years,56.3,46.2 to 65.9,153
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2017,Age,13-17 Years,56.8,47.9 to 65.3,178
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2019,Age,13-15 Years,60.9,46.6 to 73.7,91
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2020,Age,13-15 Years,55.7,47.3 to 63.7,276
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2012,Age,13-17 Years,84.0,77.7 to 88.8,353
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2011,Age,13-17 Years,80.4,74.5 to 85.3,346
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2013,Age,13-17 Years,82.1,75.8 to 86.9,360
HPV,"≥3 Doses, Males",States/Local Areas,Washington,2013,Age,13-15 Years,14.1,8.2 to 23.1,122
≥2 Doses Hep A,,States/Local Areas,Washington,2021,Age,13-17 Years,86.2,80.6 to 90.4,349
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2010,Age,13-17 Years,45.5,37.3 to 53.9,175
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2015,Age,13-17 Years,45.1,36.9 to 53.5,188
HPV,"≥3 Doses, Males",States/Local Areas,Washington,2015,Age,13-15 Years,30.1,21.3 to 40.7,116
HPV,"≥3 Doses, Males",States/Local Areas,Washington,2014,Age,13-15 Years,27.6,18.0 to 39.7,109
≥2 Doses Hep A,,States/Local Areas,Washington,2022,Age,13-17 Years,84.7,78.1 to 89.6,280
≥2 Doses Hep A,,States/Local Areas,Washington,2020,Age,13-17 Years,87.3,81.6 to 91.4,417
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2009,Age,13-17 Years,35.4,27.6 to 44.1,158
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2008,Age,13-17 Years,23.8,16.1 to 33.7,135
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2013,Age,13-17 Years,45.3,35.8 to 55.2,163
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2014,Age,13-17 Years,43.8,34.8 to 53.3,179
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2012,Age,13-17 Years,43.5,34.1 to 53.4,155
HPV,"≥3 Doses, Females",States/Local Areas,Washington,2011,Age,13-17 Years,40.0,31.4 to 49.3,162
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2019,Age,13-17 Years,92.0,87.1 to 95.2,304
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2018,Age,13-17 Years,86.5,80.6 to 90.9,286
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2016,Age,13-17 Years,88.1,82.8 to 92.0,361
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2017,Age,13-17 Years,93.2,89.7 to 95.5,339
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2015,Age,13-17 Years,84.7,79.7 to 88.6,396
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2014,Age,13-17 Years,83.3,77.8 to 87.6,374
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2010,Age,13-17 Years,84.7,80.0 to 88.5,361
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2009,Age,13-17 Years,80.8,75.1 to 85.4,321
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2008,Age,13-17 Years,76.3,70.0 to 81.6,275
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2016,Age,13-15 Years,86.2,77.4 to 91.9,194
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2021,Age,13-17 Years,90.4,84.8 to 94.1,349
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2012,Age,13-15 Years,75.5,64.4 to 84.0,138
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2013,Age,13-15 Years,77.0,66.3 to 85.1,153
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2011,Age,13-15 Years,73.3,62.6 to 81.8,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2010,Age,13-15 Years,69.8,59.2 to 78.6,110
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2009,Age,13-15 Years,51.7,40.8 to 62.4,99
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2008,Age,13-15 Years,27.4,16.2 to 42.6,66
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2022,Age,13-17 Years,89.4,83.3 to 93.5,280
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2020,Age,13-17 Years,93.3,88.9 to 96.0,417
HPV,"≥3 Doses, Males",States/Local Areas,Washington,2013,Age,13-17 Years,12.5,8.1 to 18.6,197
HPV,"≥3 Doses, Males",States/Local Areas,Washington,2015,Age,13-17 Years,28.0,21.5 to 35.6,208
HPV,"≥3 Doses, Males",States/Local Areas,Washington,2014,Age,13-17 Years,24.6,17.6 to 33.3,195
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2017,Age,13-17 Years,55.2,48.8 to 61.5,339
≥2 Doses MMR,,States/Local Areas,Washington,2011,Age,13-17 Years,87.6,82.2 to 91.6,346
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2018,Age,13-17 Years,51.6,44.2 to 58.9,286
HPV,"≥2 Doses, Males",States/Local Areas,Washington,2019,Age,13-17 Years,48.6,37.6 to 59.6,157
≥2 Doses MMR,,States/Local Areas,Washington,2009,Age,13-17 Years,84.5,79.4 to 88.6,321
≥2 Doses MMR,,States/Local Areas,Washington,2008,Age,13-17 Years,78.0,71.7 to 83.3,275
≥2 Doses MMR,,States/Local Areas,Washington,2010,Age,13-17 Years,85.2,80.5 to 89.0,361
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2010,Age,13-17 Years,70.6,64.9 to 75.6,361
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2009,Age,13-17 Years,60.1,53.8 to 66.2,321
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2011,Age,13-17 Years,75.0,68.2 to 80.7,346
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2022,Age,13-15 Years,94.3,89.5 to 97.0,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2008,Age,13-17 Years,34.7,28.7 to 41.2,275
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2016,Age,13-17 Years,49.5,43.0 to 55.9,361
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2021,Age,13-15 Years,91.7,86.5 to 95.0,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2012,Age,13-17 Years,86.0,80.1 to 90.3,353
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2013,Age,13-17 Years,86.2,80.4 to 90.4,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2014,Age,13-17 Years,88.5,83.8 to 92.0,374
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2021,Age,13-17 Years,67.8,61.0 to 74.0,349
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2022,Age,13-17 Years,71.1,63.9 to 77.3,280
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2020,Age,13-17 Years,59.0,52.2 to 65.5,417
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2021,Age,13-15 Years,57.7,45.6 to 69.0,122
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2022,Age,13-15 Years,66.5,52.1 to 78.3,86
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2019,Age,13-17 Years,53.3,45.4 to 61.1,304
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2020,Age,13-15 Years,52.3,39.6 to 64.7,84
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2019,Age,13-15 Years,47.6,35.5 to 60.0,87
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2018,Age,13-15 Years,46.7,35.2 to 58.6,103
Varicella,History of disease,States/Local Areas,Guam,2019,Age,13-17 Years,25.2,19.3 to 32.2,278
Varicella,History of disease,States/Local Areas,Guam,2020,Age,13-17 Years,23.1,17.9 to 29.4,300
Varicella,History of disease,States/Local Areas,Guam,2021,Age,13-17 Years,21.8,15.8 to 29.4,225
Varicella,History of disease,States/Local Areas,Guam,2022,Age,13-17 Years,14.6,9.6 to 21.5,240
Varicella,History of disease,States/Local Areas,Guam,2017,Age,13-17 Years,36.0,30.3 to 42.1,382
Varicella,History of disease,States/Local Areas,Guam,2016,Age,13-17 Years,36.0,31.1 to 41.2,535
Varicella,History of disease,States/Local Areas,Guam,2018,Age,13-17 Years,33.4,27.3 to 40.1,309
Varicella,History of disease,States/Local Areas,Guam,2015,Age,13-17 Years,45.9,40.3 to 51.6,419
Varicella,History of disease,States/Local Areas,Guam,2013,Age,13-17 Years,51.4,45.3 to 57.5,363
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2017,Age,13-17 Years,48.2,39.5 to 56.9,185
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2019,Age,13-17 Years,45.2,35.5 to 55.2,139
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2018,Age,13-17 Years,47.9,38.8 to 57.2,159
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2016,Age,13-17 Years,55.8,48.0 to 63.4,242
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2022,Age,13-15 Years,45.0,31.0 to 59.9,74
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2021,Age,13-15 Years,46.4,30.6 to 62.9,51
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2022,Age,13-15 Years,37.2,25.1 to 51.3,73
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2021,Age,13-15 Years,50.6,37.2 to 63.8,79
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2016,Age,13-17 Years,33.2,27.0 to 40.1,293
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2020,Age,13-17 Years,53.6,43.7 to 63.3,143
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2022,Age,13-17 Years,42.7,31.6 to 54.5,120
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2021,Age,13-17 Years,52.9,40.8 to 64.7,94
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2018,Age,13-15 Years,45.0,34.1 to 56.5,98
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2020,Age,13-15 Years,47.9,36.4 to 59.6,95
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2017,Age,13-17 Years,37.5,29.9 to 45.9,197
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2019,Age,13-15 Years,35.3,24.8 to 47.4,92
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2022,Age,13-15 Years,40.5,31.0 to 50.8,147
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2020,Age,13-17 Years,41.7,33.0 to 51.0,157
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2019,Age,13-17 Years,42.6,33.0 to 52.8,139
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2018,Age,13-17 Years,43.5,34.6 to 52.9,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2020,Age,13-15 Years,50.1,41.4 to 58.7,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2021,Age,13-15 Years,48.8,38.4 to 59.3,130
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2022,Age,13-17 Years,46.2,35.4 to 57.3,120
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2019,Age,13-15 Years,40.9,32.7 to 49.7,179
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2021,Age,13-17 Years,54.9,44.1 to 65.2,131
HPV,"≥3 Doses, Males",States/Local Areas,Guam,2015,Age,13-15 Years,25.7,18.0 to 35.2,129
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2013,Age,13-17 Years,72.7,66.7 to 77.9,363
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2018,Age,13-17 Years,71.6,64.9 to 77.4,309
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2016,Age,13-17 Years,70.9,65.7 to 75.6,535
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2017,Age,13-17 Years,72.4,66.5 to 77.5,382
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2019,Age,13-15 Years,69.5,60.4 to 77.4,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2015,Age,13-15 Years,54.8,45.1 to 64.1,147
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2019,Age,13-17 Years,76.2,70.1 to 81.4,278
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2015,Age,13-17 Years,73.6,68.2 to 78.3,419
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2022,Age,13-17 Years,72.3,63.8 to 79.4,240
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2021,Age,13-17 Years,68.9,60.7 to 76.1,225
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2020,Age,13-17 Years,74.8,68.2 to 80.5,300
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2018,Age,13-15 Years,60.7,50.6 to 69.9,148
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2016,Age,13-15 Years,55.5,47.2 to 63.5,216
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2017,Age,13-15 Years,58.0,48.3 to 67.1,160
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2013,Age,13-15 Years,40.6,30.8 to 51.1,121
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2021,Age,13-15 Years,63.5,51.4 to 74.1,109
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2020,Age,13-15 Years,69.7,59.7 to 78.2,145
≥3 Doses HepB,,States/Local Areas,Guam,2013,Age,13-17 Years,84.5,79.2 to 88.6,363
≥3 Doses HepB,,States/Local Areas,Guam,2015,Age,13-17 Years,82.2,77.3 to 86.2,419
≥3 Doses HepB,,States/Local Areas,Guam,2016,Age,13-17 Years,75.7,70.6 to 80.1,535
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2013,Age,13-17 Years,43.7,35.5 to 52.3,186
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2022,Age,13-15 Years,71.9,59.9 to 81.5,132
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2015,Age,13-17 Years,68.9,60.7 to 76.1,192
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2013,Age,13-17 Years,69.1,60.3 to 76.6,164
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2013,Age,13-17 Years,74.2,65.6 to 81.3,186
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2015,Age,13-17 Years,79.9,73.0 to 85.4,234
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2016,Age,13-17 Years,77.7,71.5 to 83.0,338
≥3 Doses HepB,,States/Local Areas,Guam,2017,Age,13-17 Years,81.2,76.1 to 85.5,382
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2017,Age,13-17 Years,56.8,49.2 to 64.1,256
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2017,Age,13-17 Years,77.7,70.7 to 83.5,256
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2015,Age,13-17 Years,51.2,43.5 to 58.8,234
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2016,Age,13-17 Years,54.5,47.8 to 61.0,338
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2018,Age,13-17 Years,79.2,71.6 to 85.2,214
≥3 Doses HepB,,States/Local Areas,Guam,2019,Age,13-17 Years,81.3,75.1 to 86.2,278
≥3 Doses HepB,,States/Local Areas,Guam,2018,Age,13-17 Years,77.5,70.8 to 83.0,309
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2018,Age,13-17 Years,65.5,56.0 to 73.9,159
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2017,Age,13-17 Years,69.3,60.4 to 77.0,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2022,Age,13-17 Years,67.5,58.2 to 75.7,204
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2021,Age,13-17 Years,77.2,68.0 to 84.3,181
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2016,Age,13-17 Years,76.9,70.0 to 82.5,242
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2021,Age,13-17 Years,60.3,50.9 to 68.9,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2020,Age,13-17 Years,67.2,59.3 to 74.3,233
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2019,Age,13-17 Years,68.2,60.6 to 75.0,210
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2020,Age,13-17 Years,81.4,74.6 to 86.7,233
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2018,Age,13-17 Years,57.3,49.0 to 65.2,214
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2019,Age,13-17 Years,82.0,75.3 to 87.3,210
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2019,Age,13-17 Years,60.5,50.3 to 69.9,139
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2022,Age,13-17 Years,78.7,69.5 to 85.7,204
≥3 Doses HepB,,States/Local Areas,Guam,2022,Age,13-17 Years,80.3,72.0 to 86.6,240
≥3 Doses HepB,,States/Local Areas,Guam,2021,Age,13-17 Years,81.8,74.4 to 87.4,225
≥3 Doses HepB,,States/Local Areas,Guam,2020,Age,13-17 Years,84.9,79.5 to 89.1,300
HPV,"≥2 Doses, Males and Females",States/Local Areas,Guam,2019,Age,13-17 Years,45.1,38.1 to 52.3,278
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2022,Age,13-17 Years,63.5,50.5 to 74.8,120
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2021,Age,13-17 Years,75.3,64.2 to 83.9,94
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2020,Age,13-17 Years,76.3,66.9 to 83.7,143
HPV,"≥2 Doses, Males and Females",States/Local Areas,Guam,2018,Age,13-17 Years,48.1,41.6 to 54.8,309
HPV,"≥2 Doses, Males and Females",States/Local Areas,Guam,2017,Age,13-17 Years,47.7,41.7 to 53.8,382
HPV,"≥2 Doses, Males and Females",States/Local Areas,Guam,2016,Age,13-17 Years,50.1,44.8 to 55.4,535
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2013,Age,13-17 Years,21.8,15.7 to 29.6,199
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2015,Age,13-17 Years,52.2,44.4 to 59.9,227
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2016,Age,13-17 Years,58.5,51.4 to 65.3,293
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2018,Age,13-17 Years,66.1,56.2 to 74.8,150
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2019,Age,13-17 Years,65.8,55.8 to 74.6,139
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2017,Age,13-17 Years,65.7,57.3 to 73.2,197
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2013,Age,13-17 Years,83.4,78.3 to 87.4,363
≥1 Dose MenACWY,,States/Local Areas,Guam,2017,Age,13-15 Years,65.1,57.1 to 72.4,231
≥1 Dose MenACWY,,States/Local Areas,Guam,2016,Age,13-15 Years,76.2,70.3 to 81.2,323
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2021,Age,13-17 Years,65.4,54.4 to 75.0,131
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2020,Age,13-17 Years,61.0,51.3 to 69.8,157
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2022,Age,13-17 Years,75.1,64.7 to 83.3,120
≥1 Dose MenACWY,,States/Local Areas,Guam,2015,Age,13-15 Years,74.2,67.2 to 80.2,242
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2015,Age,13-17 Years,82.8,78.0 to 86.7,419
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2017,Age,13-17 Years,79.0,73.4 to 83.7,382
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2016,Age,13-17 Years,79.0,74.4 to 82.9,535
≥1 Dose MenACWY,,States/Local Areas,Guam,2013,Age,13-15 Years,70.1,62.1 to 77.1,225
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2013,Age,13-17 Years,45.2,36.5 to 54.2,164
≥1 Dose MenACWY,,States/Local Areas,Guam,2021,Age,13-15 Years,67.1,56.1 to 76.5,130
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2018,Age,13-17 Years,65.8,59.0 to 72.0,309
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2017,Age,13-17 Years,67.5,61.4 to 73.0,382
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2016,Age,13-17 Years,67.4,62.4 to 72.1,535
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2018,Age,13-17 Years,73.2,66.2 to 79.1,309
≥1 Dose MenACWY,,States/Local Areas,Guam,2020,Age,13-15 Years,73.2,64.6 to 80.3,179
≥1 Dose MenACWY,,States/Local Areas,Guam,2019,Age,13-15 Years,71.5,62.8 to 78.8,179
≥1 Dose MenACWY,,States/Local Areas,Guam,2018,Age,13-15 Years,63.3,54.5 to 71.2,201
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2018,Age,13-17 Years,49.7,40.5 to 58.9,159
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2019,Age,13-17 Years,45.2,35.5 to 55.2,139
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2015,Age,13-17 Years,50.5,42.3 to 58.8,192
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2017,Age,13-17 Years,52.8,44.0 to 61.4,185
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2016,Age,13-17 Years,61.1,53.4 to 68.4,242
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2022,Age,13-17 Years,69.8,61.5 to 77.0,240
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2021,Age,13-17 Years,70.0,62.2 to 76.8,225
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2020,Age,13-17 Years,68.3,61.5 to 74.4,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2022,Age,13-17 Years,76.7,68.7 to 83.1,240
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2021,Age,13-17 Years,74.4,66.4 to 81.0,225
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2019,Age,13-17 Years,63.3,56.2 to 69.9,278
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2020,Age,13-17 Years,76.0,69.6 to 81.3,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2019,Age,13-17 Years,79.1,72.7 to 84.4,278
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2018,Age,13-15 Years,68.8,60.0 to 76.5,201
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2019,Age,13-17 Years,43.8,36.9 to 51.0,278
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2018,Age,13-17 Years,45.6,39.2 to 52.3,309
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2017,Age,13-17 Years,42.7,36.9 to 48.8,382
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2013,Age,13-17 Years,8.6,5.3 to 13.8,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2015,Age,13-15 Years,78.6,71.9 to 84.0,242
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2017,Age,13-15 Years,73.0,65.1 to 79.7,231
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2016,Age,13-15 Years,77.7,71.8 to 82.7,323
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2013,Age,13-15 Years,73.5,65.8 to 80.0,225
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2015,Age,13-17 Years,38.0,30.8 to 45.8,227
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2018,Age,13-17 Years,46.7,37.5 to 56.2,150
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2017,Age,13-17 Years,42.9,34.8 to 51.3,197
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2016,Age,13-17 Years,39.7,33.0 to 46.8,293
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2015,Age,13-17 Years,79.6,74.7 to 83.8,419
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2022,Age,13-17 Years,44.6,36.7 to 52.7,240
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2021,Age,13-17 Years,54.0,45.9 to 61.8,225
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2020,Age,13-17 Years,47.4,40.7 to 54.2,300
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2016,Age,13-17 Years,44.2,39.0 to 49.5,535
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2021,Age,13-15 Years,68.9,57.8 to 78.2,130
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2020,Age,13-15 Years,76.5,68.1 to 83.1,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2019,Age,13-15 Years,78.5,70.4 to 84.9,179
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2019,Age,13-17 Years,45.0,35.3 to 55.2,139
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2013,Age,13-17 Years,73.8,68.1 to 78.9,363
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2022,Age,13-15 Years,77.8,67.7 to 85.4,147
HPV,"≥2 Doses, Males",States/Local Areas,Guam,2022,Age,13-17 Years,46.2,35.4 to 57.3,120
HPV,"≥2 Doses, Females",States/Local Areas,Guam,2022,Age,13-17 Years,46.6,35.1 to 58.6,120
HPV,"≥2 Doses, Males and Females",States/Local Areas,Guam,2022,Age,13-17 Years,46.4,38.4 to 54.5,240
≥2 Doses Hep A,,States/Local Areas,Guam,2022,Age,13-17 Years,72.2,63.7 to 79.4,240
≥2 Doses Hep A,,States/Local Areas,Guam,2021,Age,13-17 Years,68.5,60.2 to 75.7,225
HPV,"≥3 Doses, Females",States/Local Areas,Guam,2013,Age,13-17 Years,33.6,25.9 to 42.4,164
HPV,"≥3 Doses, Males",States/Local Areas,Guam,2015,Age,13-17 Years,22.4,16.7 to 29.4,227
HPV,"≥3 Doses, Females",States/Local Areas,Guam,2015,Age,13-17 Years,37.0,29.5 to 45.1,192
≥2 Doses Hep A,,States/Local Areas,Guam,2020,Age,13-17 Years,65.2,58.4 to 71.5,300
≥2 Doses MMR,,States/Local Areas,Guam,2022,Age,13-17 Years,79.3,71.4 to 85.4,240
≥2 Doses MMR,,States/Local Areas,Guam,2021,Age,13-17 Years,78.7,71.0 to 84.7,225
≥1 Dose MenACWY,,States/Local Areas,Guam,2022,Age,13-17 Years,65.2,56.6 to 72.9,240
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Guam,2023,Age,13-17 Years,73.0,61.1 to 82.3,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2023,Age,13-17 Years,69.0,57.0 to 78.8,131
≥1 Dose MenACWY,,States/Local Areas,Guam,2023,Age,13-17 Years,67.6,56.3 to 77.1,131
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2023,Age,13-17 Years,51.9,40.6 to 63.0,131
HPV,"≥1 Dose, Males",States/Local Areas,Guam,2023,Age,13-17 Years,81.9,67.7 to 90.7,70
HPV,"≥1 Dose, Males and Females",States/Local Areas,Guam,2023,Age,13-17 Years,76.1,65.4 to 84.3,131
≥2 Doses MMR,,States/Local Areas,Guam,2023,Age,13-17 Years,64.0,52.0 to 74.4,131
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2023,Age,13-17 Years,57.0,41.0 to 71.7,70
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2023,Age,13-17 Years,67.6,55.0 to 78.0,108
Varicella,≥1 Dose with no disease history,States/Local Areas,Guam,2023,Age,13-17 Years,72.4,59.8 to 82.3,108
Varicella,History of disease,States/Local Areas,Guam,2023,Age,13-17 Years,21.4,13.0 to 33.2,131
≥3 Doses HepB,,States/Local Areas,Guam,2023,Age,13-17 Years,66.0,53.9 to 76.3,131
≥2 Doses Hep A,,States/Local Areas,Guam,2023,Age,13-17 Years,60.2,48.5 to 70.8,131
Varicella,≥2 Doses or history of disease,States/Local Areas,Guam,2023,Age,13-17 Years,74.5,63.6 to 83.1,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2023,Age,13-15 Years,67.4,51.9 to 79.8,75
≥1 Dose MenACWY,,States/Local Areas,Guam,2023,Age,13-15 Years,57.9,42.9 to 71.6,75
HPV,"Up-to-Date, Males and Females",States/Local Areas,Guam,2023,Age,13-15 Years,56.5,41.6 to 70.3,75
HPV,"Up-to-Date, Males",States/Local Areas,Guam,2023,Age,13-15 Years,60.2,38.3 to 78.6,37
HPV,"≥1 Dose, Females",States/Local Areas,Guam,2023,Age,13-17 Years,69.6,52.9 to 82.3,61
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2023,Age,13-15 Years,52.7,32.9 to 71.6,38
Varicella,≥2 Doses with no disease history,States/Local Areas,Guam,2023,Age,13-15 Years,68.1,51.5 to 81.0,61
HPV,"Up-to-Date, Females",States/Local Areas,Guam,2023,Age,13-17 Years,46.2,30.9 to 62.2,61
HPV,"≥3 Doses, Females",States/Local Areas,Guam,2013,Age,13-15 Years,34.3,24.5 to 45.7,102
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2019,Age,13-17 Years,78.7,72.3 to 84.0,278
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2017,Age,13-17 Years,77.3,71.6 to 82.1,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2018,Age,13-17 Years,70.2,63.2 to 76.3,309
≥1 Dose MenACWY,,States/Local Areas,Guam,2013,Age,13-17 Years,72.4,66.4 to 77.7,363
≥1 Dose MenACWY,,States/Local Areas,Guam,2015,Age,13-17 Years,76.2,71.1 to 80.7,419
≥1 Dose MenACWY,,States/Local Areas,Guam,2016,Age,13-17 Years,77.1,72.6 to 81.1,535
≥2 Doses MMR,,States/Local Areas,Guam,2015,Age,13-17 Years,82.5,77.7 to 86.5,419
≥2 Doses MMR,,States/Local Areas,Guam,2017,Age,13-17 Years,80.2,74.9 to 84.5,382
≥2 Doses MMR,,States/Local Areas,Guam,2016,Age,13-17 Years,75.3,70.3 to 79.7,535
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2022,Age,13-17 Years,72.6,64.3 to 79.5,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2021,Age,13-17 Years,72.7,64.7 to 79.4,225
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2020,Age,13-17 Years,74.5,68.0 to 80.0,300
≥1 Dose MenACWY,,States/Local Areas,Guam,2017,Age,13-17 Years,68.3,62.2 to 73.9,382
≥2 Doses MMR,,States/Local Areas,Guam,2019,Age,13-17 Years,81.7,75.6 to 86.5,278
≥2 Doses MMR,,States/Local Areas,Guam,2018,Age,13-17 Years,76.3,69.9 to 81.8,309
HPV,"≥3 Doses, Males and Females",States/Local Areas,Guam,2013,Age,13-17 Years,18.8,14.5 to 23.9,363
≥2 Doses MMR,,States/Local Areas,Guam,2020,Age,13-17 Years,80.5,74.7 to 85.3,300
HPV,"≥3 Doses, Females",States/Local Areas,Guam,2015,Age,13-15 Years,40.5,30.6 to 51.3,113
≥1 Dose MenACWY,,States/Local Areas,Guam,2021,Age,13-17 Years,71.0,62.9 to 77.9,225
≥1 Dose MenACWY,,States/Local Areas,Guam,2020,Age,13-17 Years,70.4,63.6 to 76.3,300
≥1 Dose MenACWY,,States/Local Areas,Guam,2019,Age,13-17 Years,73.2,66.5 to 79.0,278
≥1 Dose MenACWY,,States/Local Areas,Guam,2018,Age,13-17 Years,68.9,62.1 to 75.0,309
≥2 Doses MMR,,States/Local Areas,Guam,2013,Age,13-17 Years,84.8,79.7 to 88.8,363
Tetanus,≥1 Dose Tdap,States/Local Areas,Guam,2016,Age,13-17 Years,77.5,72.9 to 81.6,535
≥1 Dose MenACWY,,States/Local Areas,Guam,2022,Age,13-15 Years,65.9,54.9 to 75.5,147
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2023,Age,13-15 Years,65.2,54.0 to 75.0,93
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2023,Age,13-17 Years,60.8,52.0 to 68.9,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2023,Age,13-15 Years,95.0,90.3 to 97.4,168
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2023,Age,13-15 Years,52.2,40.7 to 63.4,91
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2023,Age,13-15 Years,58.8,50.7 to 66.5,184
≥1 Dose MenACWY,,States/Local Areas,Maine,2023,Age,13-15 Years,90.5,83.3 to 94.7,184
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2023,Age,13-15 Years,86.0,78.8 to 91.1,184
≥2 Doses Hep A,,States/Local Areas,Maine,2023,Age,13-17 Years,84.7,79.8 to 88.6,322
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2023,Age,13-17 Years,96.3,93.2 to 98.0,292
Varicella,History of disease,States/Local Areas,Maine,2023,Age,13-17 Years,8.9,6.0 to 13.1,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2023,Age,13-17 Years,94.1,90.5 to 96.4,292
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2023,Age,13-17 Years,94.6,91.3 to 96.7,322
≥2 Doses MMR,,States/Local Areas,Maine,2023,Age,13-17 Years,94.6,91.3 to 96.7,322
≥3 Doses HepB,,States/Local Areas,Maine,2023,Age,13-17 Years,90.1,85.9 to 93.2,322
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2023,Age,13-17 Years,61.2,55.0 to 67.1,322
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2023,Age,13-17 Years,73.3,64.9 to 80.3,161
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2023,Age,13-17 Years,61.7,52.9 to 69.8,161
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2023,Age,13-17 Years,72.6,66.6 to 77.8,322
≥1 Dose MenACWY,,States/Local Areas,Maine,2023,Age,13-17 Years,92.6,88.2 to 95.4,322
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2023,Age,13-17 Years,89.7,85.1 to 93.0,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2023,Age,13-17 Years,90.8,86.4 to 93.9,322
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2023,Age,13-17 Years,71.9,63.1 to 79.3,161
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2022,Age,13-17 Years,66.8,57.6 to 74.8,142
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2022,Age,13-17 Years,67.0,56.7 to 75.9,126
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maine,2022,Age,13-17 Years,66.9,60.1 to 73.0,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Overall,Overall,72.0,69.2 to 74.7,1566
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Overall,Overall,59.0,56.0 to 61.9,1566
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Urbanicity,Living In a Non-MSA,89.1,85.7 to 91.8,620
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Principal City,75.2,68.1 to 81.0,250
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Non-Principal City,73.3,69.1 to 77.1,696
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Urbanicity,Living In a Non-MSA,68.9,64.2 to 73.2,620
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Principal City,63.9,56.5 to 70.8,250
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Non-Principal City,58.9,54.4 to 63.2,696
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Urbanicity,Living In a Non-MSA,56.9,52.0 to 61.6,620
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Principal City,88.7,83.7 to 92.2,250
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.8,88.0 to 93.1,696
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Urbanicity,Living In a Non-MSA,89.8,86.4 to 92.4,620
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Race and Ethnicity,"White, Non-Hispanic",59.2,56.0 to 62.3,1356
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Principal City,90.5,85.5 to 93.9,250
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.6,89.7 to 94.7,696
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.4,80.0 to 92.3,117
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",71.9,60.8 to 80.8,117
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Race and Ethnicity,Hispanic,54.8,40.1 to 68.8,64
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",59.3,48.3 to 69.5,117
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.6,89.7 to 93.2,1356
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.7,88.7 to 92.4,1356
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Race and Ethnicity,Hispanic,78.6,62.6 to 88.9,64
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Race and Ethnicity,Hispanic,86.0,68.7 to 94.5,64
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.3,79.7 to 94.6,117
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Race and Ethnicity,"White, Non-Hispanic",72.1,69.1 to 74.9,1356
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Poverty,Below Poverty Level,66.5,57.1 to 74.8,158
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Race and Ethnicity,Hispanic,69.7,53.9 to 81.9,64
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Poverty,Living At or Above Poverty Level,72.5,69.5 to 75.3,1360
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Poverty,Living At or Above Poverty Level,90.1,88.0 to 91.9,1360
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Poverty,Below Poverty Level,87.6,80.8 to 92.2,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Poverty,Below Poverty Level,57.1,47.6 to 66.1,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Poverty,Living At or Above Poverty Level,59.2,56.0 to 62.4,1360
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Poverty,Living At or Above Poverty Level,91.1,89.0 to 92.8,1360
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Poverty,Below Poverty Level,89.1,82.3 to 93.5,158
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Insurance Coverage,Private Insurance Only,91.1,88.6 to 93.1,943
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Insurance Coverage,Any Medicaid,90.8,87.5 to 93.3,496
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Insurance Coverage,Other,82.8,70.7 to 90.6,83
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Any Medicaid,71.9,66.8 to 76.5,496
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Private Insurance Only,72.6,69.0 to 76.0,943
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Other,68.7,56.0 to 79.1,83
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Uninsured,65.4,47.6 to 79.7,44
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Insurance Coverage,Uninsured,71.2,53.5 to 84.2,44
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Private Insurance Only,59.4,55.5 to 63.1,943
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Any Medicaid,58.8,53.4 to 64.0,496
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Uninsured,59.6,42.1 to 75.0,44
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018-2022,Insurance Coverage,Other,55.1,42.3 to 67.2,83
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Insurance Coverage,Private Insurance Only,92.1,89.6 to 94.0,943
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Insurance Coverage,Any Medicaid,90.3,86.7 to 93.0,496
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Insurance Coverage,Other,89.5,78.8 to 95.2,83
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Insurance Coverage,Uninsured,80.5,64.6 to 90.4,44
≥1 Dose MenACWY,,States/Local Areas,Maine,2013,Age,13-15 Years,67.0,59.1 to 74.1,207
≥1 Dose MenACWY,,States/Local Areas,Maine,2012,Age,13-15 Years,74.1,66.3 to 80.6,205
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2008,Age,13-17 Years,28.8,21.6 to 37.3,169
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2017,Age,13-17 Years,79.6,71.9 to 85.7,163
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2021,Age,13-17 Years,96.7,93.1 to 98.5,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2022,Age,13-17 Years,94.7,89.9 to 97.3,251
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2016,Age,13-17 Years,73.1,64.4 to 80.3,170
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2017,Age,13-17 Years,86.0,80.6 to 90.0,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2016,Age,13-17 Years,90.0,86.1 to 92.9,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2015,Age,13-17 Years,91.0,87.0 to 93.8,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2014,Age,13-17 Years,85.8,80.5 to 89.8,341
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2018,Age,13-17 Years,68.8,59.2 to 77.0,160
≥3 Doses HepB,,States/Local Areas,Maine,2020,Age,13-17 Years,94.9,91.4 to 97.0,372
≥3 Doses HepB,,States/Local Areas,Maine,2021,Age,13-17 Years,92.5,87.7 to 95.5,293
≥3 Doses HepB,,States/Local Areas,Maine,2022,Age,13-17 Years,95.3,91.5 to 97.5,268
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2022,Age,13-17 Years,98.1,94.6 to 99.3,251
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2018,Age,13-17 Years,61.4,51.6 to 70.4,157
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2012,Age,13-17 Years,25.3,18.3 to 34.0,157
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2020,Age,13-17 Years,72.7,63.9 to 80.0,165
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2021,Age,13-17 Years,80.2,70.7 to 87.2,137
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2022,Age,13-17 Years,81.3,71.1 to 88.5,126
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maine,2017,Age,13-17 Years,62.8,56.9 to 68.4,347
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maine,2016,Age,13-17 Years,61.4,55.1 to 67.3,347
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maine,2018,Age,13-17 Years,55.0,48.1 to 61.7,317
≥1 Dose MenACWY,,States/Local Areas,Maine,2011,Age,13-15 Years,65.0,57.1 to 72.2,250
≥1 Dose MenACWY,,States/Local Areas,Maine,2010,Age,13-15 Years,60.1,52.1 to 67.6,200
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2010,Age,13-17 Years,78.4,72.3 to 83.4,312
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2011,Age,13-17 Years,78.6,72.7 to 83.4,411
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2013,Age,13-17 Years,85.6,80.7 to 89.5,343
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2022,Age,13-17 Years,74.6,65.7 to 81.8,142
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2013,Age,13-17 Years,55.4,46.4 to 64.0,162
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2012,Age,13-17 Years,53.4,43.7 to 62.9,162
≥1 Dose MenACWY,,States/Local Areas,Maine,2019,Age,13-15 Years,87.4,80.7 to 92.0,194
≥1 Dose MenACWY,,States/Local Areas,Maine,2018,Age,13-15 Years,82.0,73.9 to 88.0,179
≥1 Dose MenACWY,,States/Local Areas,Maine,2017,Age,13-15 Years,86.6,80.4 to 91.0,217
≥1 Dose MenACWY,,States/Local Areas,Maine,2016,Age,13-15 Years,82.4,75.0 to 88.0,215
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2018,Age,13-17 Years,65.0,58.1 to 71.3,317
≥1 Dose MenACWY,,States/Local Areas,Maine,2020,Age,13-15 Years,94.6,90.5 to 97.0,225
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2009,Age,13-17 Years,37.5,29.1 to 46.8,140
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2010,Age,13-17 Years,42.0,33.1 to 51.5,144
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2011,Age,13-17 Years,50.6,42.3 to 58.8,211
≥1 Dose MenACWY,,States/Local Areas,Maine,2014,Age,13-15 Years,71.5,63.4 to 78.5,201
≥1 Dose MenACWY,,States/Local Areas,Maine,2015,Age,13-15 Years,76.1,68.6 to 82.3,224
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2019,Age,13-17 Years,64.9,54.8 to 73.9,154
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2017,Age,13-17 Years,75.8,70.2 to 80.6,347
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2016,Age,13-17 Years,70.0,63.9 to 75.4,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2012,Age,13-17 Years,84.7,78.6 to 89.3,319
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2019,Age,13-17 Years,65.1,58.2 to 71.4,316
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2021,Age,13-17 Years,91.3,86.4 to 94.5,293
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2022,Age,13-17 Years,97.1,94.4 to 98.5,268
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2018,Age,13-17 Years,88.1,82.7 to 92.0,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2008,Age,13-17 Years,75.0,69.1 to 80.1,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2009,Age,13-17 Years,75.7,69.4 to 81.0,299
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2020,Age,13-17 Years,74.4,68.8 to 79.3,372
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2021,Age,13-17 Years,77.5,71.1 to 82.8,293
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maine,2022,Age,13-17 Years,77.9,71.4 to 83.2,268
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2019,Age,13-17 Years,93.8,89.7 to 96.3,316
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maine,2020,Age,13-17 Years,94.4,90.7 to 96.6,372
≥1 Dose MenACWY,,States/Local Areas,Maine,2009,Age,13-15 Years,48.7,40.1 to 57.3,175
≥1 Dose MenACWY,,States/Local Areas,Maine,2008,Age,13-15 Years,39.7,32.0 to 47.9,189
≥1 Dose MenACWY,,States/Local Areas,Maine,2021,Age,13-15 Years,89.4,82.8 to 93.7,183
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2017,Age,13-17 Years,67.2,58.7 to 74.7,163
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2016,Age,13-17 Years,68.1,59.4 to 75.7,170
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2014,Age,13-17 Years,52.9,44.2 to 61.5,165
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2015,Age,13-17 Years,53.9,45.1 to 62.4,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2009,Age,13-15 Years,57.8,49.0 to 66.1,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2010,Age,13-15 Years,65.7,57.5 to 72.9,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2008,Age,13-15 Years,51.0,42.7 to 59.2,189
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2011,Age,13-15 Years,70.7,62.8 to 77.5,250
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2012,Age,13-15 Years,81.4,73.6 to 87.2,205
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2019,Age,13-17 Years,57.1,47.0 to 66.5,154
HPV,"≥2 Doses, Females",States/Local Areas,Maine,2018,Age,13-17 Years,56.5,46.7 to 65.9,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2013,Age,13-15 Years,79.9,72.8 to 85.6,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2017,Age,13-15 Years,86.2,79.3 to 91.0,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2016,Age,13-15 Years,86.1,80.3 to 90.4,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2014,Age,13-15 Years,84.6,77.3 to 89.9,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2015,Age,13-15 Years,85.1,78.3 to 90.0,224
≥1 Dose MenACWY,,States/Local Areas,Maine,2019,Age,13-17 Years,89.1,84.4 to 92.5,316
≥1 Dose MenACWY,,States/Local Areas,Maine,2018,Age,13-17 Years,83.1,77.2 to 87.7,317
≥1 Dose MenACWY,,States/Local Areas,Maine,2020,Age,13-17 Years,93.7,90.2 to 96.0,372
≥1 Dose MenACWY,,States/Local Areas,Maine,2021,Age,13-17 Years,88.2,83.0 to 92.0,293
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2013,Age,13-17 Years,31.1,23.8 to 39.4,181
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2014,Age,13-17 Years,42.5,34.0 to 51.5,176
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2017,Age,13-17 Years,58.7,50.3 to 66.6,184
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2016,Age,13-17 Years,55.0,46.2 to 63.5,177
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2012,Age,13-17 Years,17.4,11.5 to 25.5,157
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2018,Age,13-17 Years,53.5,43.8 to 62.9,157
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2015,Age,13-17 Years,58.7,50.2 to 66.6,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2019,Age,13-15 Years,91.3,85.8 to 94.8,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2020,Age,13-15 Years,94.0,88.7 to 96.9,225
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2021,Age,13-15 Years,88.6,81.2 to 93.3,183
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018,Age,13-15 Years,85.8,78.0 to 91.1,179
≥1 Dose MenACWY,,States/Local Areas,Maine,2022,Age,13-15 Years,97.0,93.4 to 98.6,163
≥1 Dose MenACWY,,States/Local Areas,Maine,2012,Age,13-17 Years,73.7,67.1 to 79.3,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2016,Age,13-17 Years,87.5,83.1 to 90.9,347
≥1 Dose MenACWY,,States/Local Areas,Maine,2010,Age,13-17 Years,56.4,49.9 to 62.6,312
≥1 Dose MenACWY,,States/Local Areas,Maine,2011,Age,13-17 Years,64.9,58.8 to 70.5,411
≥1 Dose MenACWY,,States/Local Areas,Maine,2008,Age,13-17 Years,35.6,29.9 to 41.7,333
≥1 Dose MenACWY,,States/Local Areas,Maine,2009,Age,13-17 Years,47.3,40.7 to 54.1,299
≥2 Doses MMR,,States/Local Areas,Maine,2013,Age,13-17 Years,88.8,83.6 to 92.5,343
≥2 Doses MMR,,States/Local Areas,Maine,2012,Age,13-17 Years,94.1,90.6 to 96.3,319
≥2 Doses MMR,,States/Local Areas,Maine,2015,Age,13-17 Years,95.1,91.2 to 97.3,374
≥2 Doses MMR,,States/Local Areas,Maine,2014,Age,13-17 Years,95.0,91.3 to 97.2,341
≥2 Doses MMR,,States/Local Areas,Maine,2016,Age,13-17 Years,95.6,92.6 to 97.5,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2019,Age,13-17 Years,91.9,87.8 to 94.7,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2017,Age,13-17 Years,85.1,79.8 to 89.3,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018,Age,13-17 Years,85.8,80.1 to 90.0,317
≥1 Dose MenACWY,,States/Local Areas,Maine,2013,Age,13-17 Years,71.2,65.3 to 76.5,343
≥1 Dose MenACWY,,States/Local Areas,Maine,2014,Age,13-17 Years,73.6,67.6 to 78.9,341
≥1 Dose MenACWY,,States/Local Areas,Maine,2015,Age,13-17 Years,77.7,71.9 to 82.5,374
≥1 Dose MenACWY,,States/Local Areas,Maine,2016,Age,13-17 Years,83.5,78.1 to 87.8,347
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maine,2012,Age,13-17 Years,26.6,21.1 to 33.0,319
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maine,2011,Age,13-17 Years,21.6,17.1 to 26.8,411
≥1 Dose MenACWY,,States/Local Areas,Maine,2017,Age,13-17 Years,83.9,78.8 to 88.0,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2020,Age,13-17 Years,93.3,89.4 to 95.9,372
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2021,Age,13-17 Years,89.7,84.4 to 93.4,293
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2022,Age,13-17 Years,94.4,90.1 to 96.9,268
≥2 Doses MMR,,States/Local Areas,Maine,2019,Age,13-17 Years,94.2,90.0 to 96.6,316
≥2 Doses MMR,,States/Local Areas,Maine,2018,Age,13-17 Years,94.6,90.5 to 97.0,317
≥2 Doses MMR,,States/Local Areas,Maine,2017,Age,13-17 Years,96.3,93.6 to 97.8,347
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maine,2013,Age,13-17 Years,31.3,26.0 to 37.2,343
≥2 Doses MMR,,States/Local Areas,Maine,2020,Age,13-17 Years,95.8,91.9 to 97.9,372
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maine,2015,Age,13-17 Years,45.4,39.5 to 51.5,374
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maine,2014,Age,13-17 Years,35.1,29.5 to 41.1,341
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2013,Age,13-15 Years,35.7,26.1 to 46.7,99
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2014,Age,13-15 Years,35.6,25.3 to 47.4,94
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2015,Age,13-15 Years,37.8,27.9 to 48.8,116
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2011,Age,13-15 Years,38.1,27.9 to 49.5,127
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2012,Age,13-15 Years,37.7,27.4 to 49.2,114
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2010,Age,13-15 Years,31.3,22.0 to 42.3,98
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2009,Age,13-15 Years,22.5,14.7 to 33.0,91
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2008,Age,13-15 Years,21.9,14.0 to 32.6,102
≥1 Dose MenACWY,,States/Local Areas,Maine,2022,Age,13-17 Years,96.3,93.0 to 98.0,268
≥2 Doses MMR,,States/Local Areas,Maine,2021,Age,13-17 Years,94.9,90.9 to 97.2,293
≥2 Doses MMR,,States/Local Areas,Maine,2022,Age,13-17 Years,94.0,89.2 to 96.8,268
≥1 Dose MenACWY,,States/Local Areas,Maine,2018-2022,Overall,Overall,90.1,88.2 to 91.7,1566
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2018-2022,Overall,Overall,91.0,89.1 to 92.6,1566
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2021,Age,13-17 Years,61.5,54.5 to 68.0,293
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2022,Age,13-17 Years,66.2,59.4 to 72.4,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2020,Age,13-17 Years,63.5,57.5 to 69.1,372
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2008,Age,13-17 Years,81.8,76.8 to 85.9,333
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2013,Age,13-15 Years,12.4,7.2 to 20.5,108
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2013,Age,13-17 Years,17.6,12.4 to 24.4,181
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2012,Age,13-17 Years,12.1,7.2 to 19.8,157
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2015,Age,13-17 Years,44.1,35.8 to 52.8,186
≥2 Doses Hep A,,States/Local Areas,Maine,2020,Age,13-17 Years,86.0,81.6 to 89.5,372
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2010,Age,13-17 Years,32.9,24.8 to 42.2,144
≥2 Doses Hep A,,States/Local Areas,Maine,2022,Age,13-17 Years,91.1,86.6 to 94.2,268
≥2 Doses Hep A,,States/Local Areas,Maine,2021,Age,13-17 Years,84.5,78.6 to 89.0,293
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2013,Age,13-17 Years,45.8,37.2 to 54.6,162
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2014,Age,13-17 Years,43.0,34.7 to 51.8,165
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2012,Age,13-17 Years,41.8,32.6 to 51.7,162
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2011,Age,13-17 Years,44.5,36.4 to 52.8,211
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2008,Age,13-17 Years,21.4,14.9 to 29.8,169
HPV,"≥3 Doses, Females",States/Local Areas,Maine,2009,Age,13-17 Years,28.0,20.6 to 37.0,140
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2020,Age,13-17 Years,75.9,68.6 to 82.0,207
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2021,Age,13-17 Years,74.9,65.7 to 82.3,156
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2017,Age,13-17 Years,72.2,63.9 to 79.2,184
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maine,2019,Age,13-17 Years,53.8,46.8 to 60.5,316
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2013,Age,13-17 Years,42.2,33.9 to 50.9,181
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2014,Age,13-17 Years,53.1,44.1 to 61.9,176
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2015,Age,13-17 Years,65.8,57.5 to 73.2,188
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2016,Age,13-17 Years,67.1,58.4 to 74.8,177
HPV,"≥1 Dose, Males",States/Local Areas,Maine,2019,Age,13-17 Years,65.2,55.7 to 73.7,162
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2010,Age,13-17 Years,91.7,84.3 to 95.8,164
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2009,Age,13-17 Years,91.8,84.3 to 95.9,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2009,Age,13-17 Years,48.7,38.7 to 58.9,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2008,Age,13-17 Years,40.4,30.2 to 51.4,105
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2011,Age,13-17 Years,95.4,91.2 to 97.6,253
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2012,Age,13-17 Years,95.3,90.5 to 97.8,217
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2008,Age,13-17 Years,40.3,32.2 to 49.0,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2013,Age,13-17 Years,71.0,63.2 to 77.6,237
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2012,Age,13-17 Years,75.6,67.5 to 82.2,217
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2008,Age,13-17 Years,89.7,81.5 to 94.5,105
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2010,Age,13-17 Years,58.0,49.2 to 66.3,164
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2011,Age,13-17 Years,69.6,62.4 to 76.0,253
≥3 Doses HepB,,States/Local Areas,Maine,2013,Age,13-17 Years,88.8,83.7 to 92.5,343
≥3 Doses HepB,,States/Local Areas,Maine,2014,Age,13-17 Years,90.8,86.6 to 93.9,341
≥3 Doses HepB,,States/Local Areas,Maine,2011,Age,13-17 Years,91.5,87.3 to 94.3,411
≥3 Doses HepB,,States/Local Areas,Maine,2012,Age,13-17 Years,93.6,89.7 to 96.1,319
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2009,Age,13-17 Years,44.4,35.3 to 53.8,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2022,Age,13-15 Years,94.7,89.0 to 97.5,156
≥3 Doses HepB,,States/Local Areas,Maine,2008,Age,13-17 Years,81.4,76.0 to 85.7,333
≥3 Doses HepB,,States/Local Areas,Maine,2010,Age,13-17 Years,89.3,84.2 to 92.8,312
≥3 Doses HepB,,States/Local Areas,Maine,2009,Age,13-17 Years,84.4,78.3 to 89.0,299
≥3 Doses HepB,,States/Local Areas,Maine,2017,Age,13-17 Years,94.3,91.0 to 96.4,347
≥3 Doses HepB,,States/Local Areas,Maine,2019,Age,13-17 Years,93.5,89.0 to 96.2,316
≥3 Doses HepB,,States/Local Areas,Maine,2018,Age,13-17 Years,94.5,91.1 to 96.6,317
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2013,Age,13-17 Years,93.6,87.9 to 96.8,237
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2014,Age,13-17 Years,97.7,94.4 to 99.1,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2015,Age,13-17 Years,97.8,94.5 to 99.2,301
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2016,Age,13-17 Years,97.3,94.9 to 98.6,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2019,Age,13-17 Years,91.5,86.0 to 94.9,289
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2020,Age,13-17 Years,95.7,92.1 to 97.7,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2021,Age,13-17 Years,94.6,90.8 to 96.9,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2018,Age,13-17 Years,91.3,85.9 to 94.7,291
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2020,Age,13-17 Years,97.1,93.8 to 98.7,338
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2019,Age,13-17 Years,95.2,90.8 to 97.6,289
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2018,Age,13-17 Years,97.3,93.5 to 98.9,291
≥3 Doses HepB,,States/Local Areas,Maine,2015,Age,13-17 Years,94.6,91.4 to 96.7,374
≥3 Doses HepB,,States/Local Areas,Maine,2016,Age,13-17 Years,93.5,89.8 to 95.9,347
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2015,Age,13-17 Years,66.0,57.3 to 73.7,186
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2014,Age,13-17 Years,66.8,58.2 to 74.4,165
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2013,Age,13-17 Years,60.2,51.2 to 68.6,162
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2012,Age,13-17 Years,61.7,52.0 to 70.6,162
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2011,Age,13-15 Years,71.4,62.8 to 78.7,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2010,Age,13-15 Years,62.7,52.7 to 71.8,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2013,Age,13-15 Years,69.1,59.5 to 77.3,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2012,Age,13-15 Years,78.1,69.4 to 84.8,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2017,Age,13-17 Years,93.7,89.8 to 96.1,298
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2011,Age,13-17 Years,56.1,47.8 to 64.1,211
HPV,"≥1 Dose, Females",States/Local Areas,Maine,2010,Age,13-17 Years,54.6,45.0 to 63.8,144
Varicella,≥1 Dose with no disease history,States/Local Areas,Maine,2017,Age,13-17 Years,97.3,94.7 to 98.6,298
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2014,Age,13-17 Years,84.1,78.2 to 88.7,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2015,Age,13-17 Years,84.6,79.0 to 89.0,301
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2016,Age,13-17 Years,90.1,85.9 to 93.2,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2009,Age,13-15 Years,51.1,39.1 to 63.0,89
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2020,Age,13-15 Years,97.0,92.5 to 98.9,208
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2021,Age,13-15 Years,94.3,88.8 to 97.1,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2019,Age,13-15 Years,90.2,82.0 to 94.9,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2014,Age,13-15 Years,85.3,77.3 to 90.7,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2015,Age,13-15 Years,88.5,81.8 to 93.0,190
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2013,Age,13-17 Years,79.9,74.0 to 84.8,343
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2014,Age,13-17 Years,87.3,82.4 to 91.0,341
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2011,Age,13-17 Years,81.1,76.2 to 85.2,411
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2012,Age,13-17 Years,84.1,78.3 to 88.6,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2018,Age,13-15 Years,93.9,86.9 to 97.3,170
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2016,Age,13-15 Years,91.7,86.2 to 95.1,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2017,Age,13-15 Years,94.0,89.0 to 96.8,191
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2019,Age,13-17 Years,92.3,87.4 to 95.5,316
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2018,Age,13-17 Years,91.9,86.8 to 95.1,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2016,Age,13-17 Years,91.7,88.0 to 94.3,347
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2017,Age,13-17 Years,94.5,91.1 to 96.7,347
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2015,Age,13-17 Years,87.5,82.8 to 91.1,374
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2010,Age,13-17 Years,79.2,73.6 to 83.8,312
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2009,Age,13-17 Years,80.4,74.7 to 85.1,299
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2020,Age,13-17 Years,96.2,92.8 to 98.0,372
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2021,Age,13-17 Years,95.0,91.5 to 97.1,293
Varicella,≥2 Doses or history of disease,States/Local Areas,Maine,2022,Age,13-17 Years,95.1,90.6 to 97.5,268
Varicella,≥2 Doses with no disease history,States/Local Areas,Maine,2008,Age,13-15 Years,43.9,32.1 to 56.5,80
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2015,Age,13-17 Years,46.7,38.4 to 55.1,188
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2014,Age,13-17 Years,27.5,20.6 to 35.7,176
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2015,Age,13-15 Years,40.3,30.1 to 51.5,108
HPV,"≥3 Doses, Males",States/Local Areas,Maine,2014,Age,13-15 Years,25.3,17.0 to 35.9,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2019,Age,13-17 Years,52.6,45.7 to 59.4,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2018,Age,13-17 Years,50.7,43.9 to 57.5,317
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2017,Age,13-17 Years,59.2,53.2 to 65.0,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2012,Age,13-17 Years,79.5,73.0 to 84.9,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2013,Age,13-17 Years,83.0,77.8 to 87.2,343
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2014,Age,13-17 Years,85.4,80.1 to 89.4,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2022,Age,13-15 Years,96.9,93.6 to 98.5,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2008,Age,13-17 Years,43.0,36.9 to 49.3,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2011,Age,13-17 Years,69.2,63.3 to 74.6,411
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2010,Age,13-17 Years,63.2,56.6 to 69.3,312
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2009,Age,13-17 Years,54.0,47.2 to 60.6,299
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2016,Age,13-17 Years,56.0,49.8 to 62.1,347
HPV,"≥2 Doses, Males",States/Local Areas,Maine,2019,Age,13-17 Years,50.6,41.2 to 60.0,162
Tetanus,≥1 Dose Tdap,States/Local Areas,Maine,2015,Age,13-17 Years,87.7,83.1 to 91.1,374
≥2 Doses MMR,,States/Local Areas,Maine,2008,Age,13-17 Years,92.6,88.9 to 95.2,333
≥2 Doses MMR,,States/Local Areas,Maine,2009,Age,13-17 Years,89.4,84.7 to 92.8,299
≥2 Doses MMR,,States/Local Areas,Maine,2010,Age,13-17 Years,93.7,89.4 to 96.3,312
≥2 Doses MMR,,States/Local Areas,Maine,2011,Age,13-17 Years,94.9,91.6 to 96.9,411
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2020,Age,13-15 Years,60.9,53.2 to 68.1,225
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2019,Age,13-17 Years,56.6,46.5 to 66.1,154
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2018,Age,13-17 Years,52.0,42.2 to 61.5,160
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2021,Age,13-17 Years,55.5,45.9 to 64.8,156
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2019,Age,13-15 Years,38.1,27.4 to 50.1,99
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2020,Age,13-17 Years,62.4,53.4 to 70.7,165
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2020,Age,13-15 Years,61.9,51.4 to 71.4,117
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2021,Age,13-15 Years,48.6,36.6 to 60.7,93
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2022,Age,13-15 Years,59.8,47.5 to 71.1,85
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2016,Age,13-17 Years,48.2,39.6 to 56.9,177
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2016,Age,13-17 Years,64.3,55.5 to 72.3,170
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2019,Age,13-17 Years,48.9,39.6 to 58.3,162
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2020,Age,13-17 Years,64.6,56.5 to 71.9,207
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2017,Age,13-17 Years,57.0,48.6 to 65.0,184
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2018,Age,13-17 Years,49.5,40.0 to 59.0,157
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2017,Age,13-17 Years,61.5,52.8 to 69.6,163
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2021,Age,13-15 Years,64.1,51.3 to 75.1,90
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2022,Age,13-15 Years,57.5,44.3 to 69.7,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2019,Age,13-15 Years,40.0,31.8 to 48.7,194
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2022,Age,13-17 Years,66.8,57.6 to 74.8,142
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2021,Age,13-15 Years,56.1,47.2 to 64.7,183
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maine,2022,Age,13-15 Years,58.7,49.7 to 67.2,163
HPV,"Up-to-Date, Males",States/Local Areas,Maine,2018,Age,13-15 Years,42.8,30.3 to 56.2,79
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2021,Age,13-17 Years,67.8,57.9 to 76.4,137
HPV,"Up-to-Date, Females",States/Local Areas,Maine,2022,Age,13-17 Years,65.6,55.2 to 74.6,126
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2023,Age,13-17 Years,76.2,67.9 to 82.9,198
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Uninsured,84.1,69.7 to 92.4,76
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Other,88.5,83.0 to 92.4,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Any Medicaid,89.1,83.9 to 92.8,290
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Private Insurance Only,90.6,87.9 to 92.7,970
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Other,54.4,47.5 to 61.2,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Uninsured,33.4,21.9 to 47.3,76
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Any Medicaid,63.5,56.3 to 70.1,290
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Private Insurance Only,52.0,48.1 to 55.9,970
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Uninsured,63.2,48.7 to 75.6,76
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Uninsured,54.7,40.7 to 67.9,76
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Other,70.7,64.1 to 76.5,316
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Private Insurance Only,65.3,61.4 to 69.0,970
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Insurance Coverage,Any Medicaid,78.2,71.8 to 83.5,290
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Other,84.5,79.1 to 88.7,316
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Any Medicaid,85.5,79.7 to 89.9,290
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Insurance Coverage,Private Insurance Only,82.2,78.8 to 85.1,970
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Poverty,Below Poverty Level,90.2,85.0 to 93.8,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Poverty,Living At or Above Poverty Level,89.3,86.9 to 91.3,1380
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Poverty,Living At or Above Poverty Level,51.8,48.5 to 55.1,1380
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Poverty,Below Poverty Level,62.8,54.8 to 70.1,229
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Poverty,Below Poverty Level,86.8,81.0 to 91.0,229
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Poverty,Living At or Above Poverty Level,81.6,78.8 to 84.1,1380
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Poverty,Living At or Above Poverty Level,66.4,63.1 to 69.4,1380
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Poverty,Below Poverty Level,76.5,69.2 to 82.4,229
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,Hispanic,79.0,72.1 to 84.6,258
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.9,57.2 to 85.8,48
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",65.2,61.8 to 68.6,1180
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",84.0,74.7 to 90.3,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.9,72.9 to 97.4,48
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,Hispanic,88.7,82.7 to 92.8,258
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,Hispanic,87.1,81.4 to 91.2,258
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.0,76.1 to 97.0,48
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.5,88.2 to 92.4,1180
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",80.5,77.4 to 83.3,1180
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",52.4,42.9 to 61.8,166
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",57.7,41.4 to 72.4,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,Hispanic,66.4,59.0 to 73.0,258
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",66.7,57.0 to 75.2,166
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.1,71.9 to 87.8,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.0,86.1 to 92.8,529
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Principal City,90.3,86.9 to 92.9,625
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",50.2,46.6 to 53.7,1180
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a Non-MSA,77.7,72.5 to 82.3,498
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,80.9,76.3 to 84.7,529
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Principal City,86.2,82.4 to 89.3,625
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a Non-MSA,45.6,39.9 to 51.5,498
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,51.4,46.2 to 56.7,529
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Principal City,60.5,55.8 to 65.1,625
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a Non-MSA,64.4,58.6 to 69.7,498
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,64.9,59.8 to 69.8,529
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a MSA Principal City,73.7,69.2 to 77.7,625
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Urbanicity,Living In a Non-MSA,87.6,83.2 to 91.0,498
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018-2022,Overall,Overall,68.4,65.5 to 71.1,1652
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018-2022,Overall,Overall,53.8,50.8 to 56.8,1652
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2023,Age,13-17 Years,89.3,84.2 to 92.9,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2023,Age,13-17 Years,88.6,83.4 to 92.3,373
≥1 Dose MenACWY,,States/Local Areas,Kansas,2023,Age,13-17 Years,90.7,85.7 to 94.0,373
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2023,Age,13-17 Years,75.4,69.3 to 80.6,373
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2023,Age,13-17 Years,74.5,65.1 to 82.1,175
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2023,Age,13-17 Years,60.4,53.8 to 66.6,373
≥2 Doses MMR,,States/Local Areas,Kansas,2023,Age,13-17 Years,88.6,83.5 to 92.3,373
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2023,Age,13-17 Years,61.3,52.2 to 69.6,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2023,Age,13-17 Years,88.8,83.4 to 92.5,354
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2023,Age,13-17 Years,91.2,86.0 to 94.6,354
≥3 Doses HepB,,States/Local Areas,Kansas,2023,Age,13-17 Years,89.4,84.4 to 93.0,373
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2023,Age,13-17 Years,89.2,84.1 to 92.8,373
≥2 Doses Hep A,,States/Local Areas,Kansas,2023,Age,13-17 Years,87.4,82.3 to 91.2,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2023,Age,13-15 Years,91.0,85.6 to 94.5,241
≥1 Dose MenACWY,,States/Local Areas,Kansas,2023,Age,13-15 Years,92.4,87.2 to 95.6,241
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2023,Age,13-15 Years,58.5,50.3 to 66.3,241
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2023,Age,13-15 Years,60.1,48.9 to 70.4,127
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2023,Age,13-17 Years,59.4,49.6 to 68.6,175
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2023,Age,13-15 Years,56.9,44.8 to 68.1,114
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2023,Age,13-15 Years,89.6,83.0 to 93.8,234
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kansas,2022,Age,13-17 Years,61.9,55.1 to 68.3,310
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2022,Age,13-17 Years,60.5,51.3 to 69.0,173
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2011,Age,13-17 Years,84.4,78.6 to 88.9,399
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2010,Age,13-17 Years,81.9,77.2 to 85.9,373
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2013,Age,13-17 Years,86.8,81.5 to 90.8,287
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2012,Age,13-17 Years,93.7,89.8 to 96.1,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2022,Age,13-17 Years,73.4,67.0 to 79.1,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2009,Age,13-17 Years,74.5,67.8 to 80.2,252
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2008,Age,13-17 Years,69.9,63.4 to 75.6,271
≥1 Dose MenACWY,,States/Local Areas,Kansas,2008,Age,13-15 Years,23.2,17.0 to 30.9,162
≥1 Dose MenACWY,,States/Local Areas,Kansas,2009,Age,13-15 Years,38.0,29.9 to 46.8,159
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2022,Age,13-17 Years,73.4,64.5 to 80.7,173
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2013,Age,13-17 Years,29.9,21.6 to 39.9,133
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2012,Age,13-17 Years,32.8,23.9 to 43.2,157
≥1 Dose MenACWY,,States/Local Areas,Kansas,2010,Age,13-15 Years,54.0,46.7 to 61.1,226
≥1 Dose MenACWY,,States/Local Areas,Kansas,2011,Age,13-15 Years,48.1,39.1 to 57.1,226
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2021,Age,13-17 Years,76.5,69.6 to 82.3,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2020,Age,13-17 Years,63.3,57.0 to 69.3,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2018,Age,13-17 Years,90.2,85.1 to 93.7,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2020,Age,13-17 Years,89.5,84.7 to 92.9,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2019,Age,13-17 Years,93.0,89.6 to 95.4,381
≥1 Dose MenACWY,,States/Local Areas,Kansas,2021,Age,13-15 Years,86.0,77.9 to 91.5,180
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2022,Age,13-17 Years,89.5,84.0 to 93.3,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2021,Age,13-17 Years,91.1,85.9 to 94.6,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2019,Age,13-17 Years,65.9,59.5 to 71.9,381
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2010,Age,13-15 Years,77.2,70.9 to 82.5,226
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2009,Age,13-15 Years,60.5,51.5 to 68.9,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2011,Age,13-15 Years,80.5,72.0 to 86.9,226
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2012,Age,13-15 Years,94.1,88.2 to 97.1,196
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2015,Age,13-17 Years,43.6,35.2 to 52.3,176
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2014,Age,13-17 Years,30.4,22.4 to 39.8,158
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2017,Age,13-17 Years,40.0,31.1 to 49.7,150
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2016,Age,13-17 Years,50.1,40.9 to 59.2,156
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2018,Age,13-17 Years,41.6,32.4 to 51.5,138
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2008,Age,13-15 Years,46.3,37.8 to 55.0,162
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2019,Age,13-17 Years,48.5,39.0 to 58.0,182
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2015,Age,13-15 Years,86.5,79.6 to 91.3,227
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2014,Age,13-15 Years,80.8,72.8 to 86.9,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2017,Age,13-15 Years,89.5,83.3 to 93.6,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2016,Age,13-15 Years,84.5,77.4 to 89.7,215
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2014,Age,13-17 Years,23.5,16.6 to 32.1,194
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2013,Age,13-17 Years,19.3,12.7 to 28.4,154
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2013,Age,13-15 Years,82.7,75.5 to 88.1,180
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2012,Age,13-17 Years,11.1,6.1 to 19.4,183
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018,Age,13-15 Years,88.3,81.1 to 93.0,186
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2015,Age,13-17 Years,26.3,19.6 to 34.3,199
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2018,Age,13-17 Years,47.5,38.4 to 56.8,159
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2017,Age,13-17 Years,34.7,27.0 to 43.2,188
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2016,Age,13-17 Years,29.1,21.5 to 38.1,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2021,Age,13-15 Years,88.8,81.7 to 93.4,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2020,Age,13-15 Years,87.5,80.8 to 92.2,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2019,Age,13-15 Years,92.9,88.3 to 95.7,238
≥2 Doses MMR,,States/Local Areas,Kansas,2022,Age,13-17 Years,91.9,87.7 to 94.8,310
≥2 Doses MMR,,States/Local Areas,Kansas,2021,Age,13-17 Years,94.6,90.0 to 97.2,300
≥1 Dose MenACWY,,States/Local Areas,Kansas,2022,Age,13-17 Years,85.9,80.0 to 90.3,310
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018-2022,Overall,Overall,89.5,87.5 to 91.3,1652
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018-2022,Overall,Overall,82.3,79.8 to 84.5,1652
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2022,Age,13-17 Years,63.4,53.1 to 72.6,137
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2015,Age,13-15 Years,28.6,19.4 to 40.1,98
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2014,Age,13-15 Years,16.9,10.2 to 26.6,95
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2013,Age,13-15 Years,15.0,8.3 to 25.6,84
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2009,Age,13-15 Years,23.5,14.0 to 36.6,74
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2010,Age,13-15 Years,21.8,14.1 to 32.2,102
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2011,Age,13-15 Years,19.6,12.6 to 29.3,114
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2012,Age,13-15 Years,19.1,10.8 to 31.6,97
≥1 Dose MenACWY,,States/Local Areas,Kansas,2021,Age,13-17 Years,86.0,79.8 to 90.5,300
≥1 Dose MenACWY,,States/Local Areas,Kansas,2020,Age,13-17 Years,83.3,77.8 to 87.7,364
≥1 Dose MenACWY,,States/Local Areas,Kansas,2019,Age,13-17 Years,80.7,75.1 to 85.3,381
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018,Age,13-17 Years,75.3,69.1 to 80.6,297
≥1 Dose MenACWY,,States/Local Areas,Kansas,2014,Age,13-17 Years,65.1,58.4 to 71.3,352
≥1 Dose MenACWY,,States/Local Areas,Kansas,2013,Age,13-17 Years,55.9,49.0 to 62.5,287
≥1 Dose MenACWY,,States/Local Areas,Kansas,2015,Age,13-17 Years,63.7,57.6 to 69.4,375
≥1 Dose MenACWY,,States/Local Areas,Kansas,2016,Age,13-17 Years,69.7,63.5 to 75.3,322
≥2 Doses MMR,,States/Local Areas,Kansas,2014,Age,13-17 Years,84.6,78.9 to 88.9,352
≥2 Doses MMR,,States/Local Areas,Kansas,2015,Age,13-17 Years,87.6,82.6 to 91.4,375
≥2 Doses MMR,,States/Local Areas,Kansas,2016,Age,13-17 Years,89.8,85.2 to 93.1,322
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2022,Age,13-17 Years,89.2,83.7 to 93.0,310
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2021,Age,13-17 Years,87.8,81.7 to 92.1,300
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2020,Age,13-17 Years,89.4,84.6 to 92.8,364
≥1 Dose MenACWY,,States/Local Areas,Kansas,2017,Age,13-17 Years,72.1,65.8 to 77.6,338
≥2 Doses MMR,,States/Local Areas,Kansas,2017,Age,13-17 Years,89.4,84.5 to 92.8,338
≥2 Doses MMR,,States/Local Areas,Kansas,2019,Age,13-17 Years,90.0,85.6 to 93.2,381
≥2 Doses MMR,,States/Local Areas,Kansas,2018,Age,13-17 Years,86.5,80.5 to 90.9,297
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kansas,2014,Age,13-17 Years,22.1,17.1 to 28.0,352
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kansas,2015,Age,13-17 Years,24.9,20.1 to 30.5,375
≥2 Doses MMR,,States/Local Areas,Kansas,2020,Age,13-17 Years,92.3,88.2 to 95.0,364
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kansas,2013,Age,13-17 Years,14.4,10.0 to 20.2,287
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2019,Age,13-17 Years,91.9,88.3 to 94.5,381
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2017,Age,13-17 Years,89.7,84.9 to 93.1,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2018,Age,13-17 Years,89.4,84.2 to 93.0,297
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kansas,2011,Age,13-17 Years,11.0,8.1 to 14.8,399
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kansas,2012,Age,13-17 Years,14.5,9.9 to 20.8,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2016,Age,13-17 Years,87.3,82.1 to 91.2,322
≥1 Dose MenACWY,,States/Local Areas,Kansas,2009,Age,13-17 Years,38.3,31.7 to 45.4,252
≥1 Dose MenACWY,,States/Local Areas,Kansas,2008,Age,13-17 Years,25.6,20.0 to 32.3,271
≥1 Dose MenACWY,,States/Local Areas,Kansas,2011,Age,13-17 Years,47.7,41.1 to 54.3,399
≥1 Dose MenACWY,,States/Local Areas,Kansas,2010,Age,13-17 Years,50.2,44.5 to 55.9,373
≥2 Doses MMR,,States/Local Areas,Kansas,2013,Age,13-17 Years,86.9,81.6 to 90.8,287
≥2 Doses MMR,,States/Local Areas,Kansas,2012,Age,13-17 Years,88.6,83.2 to 92.4,340
≥1 Dose MenACWY,,States/Local Areas,Kansas,2022,Age,13-15 Years,88.2,81.0 to 92.9,188
≥1 Dose MenACWY,,States/Local Areas,Kansas,2012,Age,13-17 Years,55.9,48.6 to 63.1,340
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2015,Age,13-15 Years,80.8,72.2 to 87.2,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2014,Age,13-15 Years,78.6,69.0 to 85.9,168
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2009,Age,13-17 Years,81.3,75.5 to 86.0,252
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2010,Age,13-17 Years,82.9,78.2 to 86.8,373
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2019,Age,13-17 Years,89.9,85.5 to 93.1,381
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2008,Age,13-15 Years,26.9,16.2 to 41.1,63
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2022,Age,13-17 Years,91.1,86.4 to 94.3,310
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2021,Age,13-17 Years,92.9,87.5 to 96.1,300
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2020,Age,13-17 Years,92.4,87.9 to 95.3,364
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2014,Age,13-17 Years,84.1,78.6 to 88.3,352
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2013,Age,13-17 Years,87.7,83.1 to 91.2,287
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2011,Age,13-17 Years,79.9,73.4 to 85.2,399
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2012,Age,13-17 Years,87.3,82.3 to 91.1,340
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2015,Age,13-17 Years,85.8,80.6 to 89.8,375
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2018,Age,13-17 Years,85.2,79.1 to 89.7,297
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2016,Age,13-17 Years,91.3,86.8 to 94.4,322
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2017,Age,13-17 Years,89.1,84.2 to 92.6,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Kansas,2008,Age,13-17 Years,75.6,69.0 to 81.2,271
HPV,"≥3 Doses, Males",States/Local Areas,Kansas,2014,Age,13-17 Years,19.5,13.2 to 27.9,194
HPV,"≥3 Doses, Males",States/Local Areas,Kansas,2015,Age,13-17 Years,18.5,12.7 to 26.1,199
≥2 Doses Hep A,,States/Local Areas,Kansas,2022,Age,13-17 Years,85.3,79.3 to 89.8,310
≥2 Doses Hep A,,States/Local Areas,Kansas,2021,Age,13-17 Years,83.9,77.3 to 88.9,300
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2014,Age,13-17 Years,24.8,17.6 to 33.6,158
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2013,Age,13-17 Years,21.0,13.9 to 30.3,133
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2012,Age,13-17 Years,25.1,16.9 to 35.5,157
HPV,"≥3 Doses, Males",States/Local Areas,Kansas,2014,Age,13-15 Years,18.5,11.0 to 29.3,126
HPV,"≥3 Doses, Males",States/Local Areas,Kansas,2015,Age,13-15 Years,14.6,9.1 to 22.8,129
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2009,Age,13-17 Years,27.7,18.6 to 39.2,117
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2008,Age,13-17 Years,15.6,9.1 to 25.3,137
≥2 Doses Hep A,,States/Local Areas,Kansas,2020,Age,13-17 Years,82.9,77.8 to 87.1,364
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2015,Age,13-17 Years,31.7,24.3 to 40.2,176
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2011,Age,13-17 Years,21.9,16.0 to 29.2,198
HPV,"≥2 Doses, Males",States/Local Areas,Kansas,2019,Age,13-17 Years,54.7,45.7 to 63.4,199
HPV,"≥3 Doses, Females",States/Local Areas,Kansas,2010,Age,13-17 Years,25.1,18.6 to 33.0,170
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2012,Age,13-17 Years,92.2,88.2 to 94.9,340
≥3 Doses HepB,,States/Local Areas,Kansas,2014,Age,13-17 Years,86.7,81.6 to 90.5,352
≥3 Doses HepB,,States/Local Areas,Kansas,2013,Age,13-17 Years,89.5,84.4 to 93.1,287
≥3 Doses HepB,,States/Local Areas,Kansas,2011,Age,13-17 Years,86.6,80.4 to 91.1,399
≥3 Doses HepB,,States/Local Areas,Kansas,2012,Age,13-17 Years,91.3,85.9 to 94.7,340
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2011,Age,13-17 Years,60.9,51.0 to 69.9,212
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2010,Age,13-17 Years,65.6,57.4 to 73.0,174
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2009,Age,13-17 Years,44.1,33.9 to 54.9,117
≥3 Doses HepB,,States/Local Areas,Kansas,2017,Age,13-17 Years,89.8,85.2 to 93.1,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2022,Age,13-15 Years,90.4,83.5 to 94.6,176
≥3 Doses HepB,,States/Local Areas,Kansas,2019,Age,13-17 Years,92.1,88.1 to 94.8,381
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2018,Age,13-17 Years,91.6,86.3 to 95.0,257
≥3 Doses HepB,,States/Local Areas,Kansas,2015,Age,13-17 Years,86.8,81.6 to 90.7,375
≥3 Doses HepB,,States/Local Areas,Kansas,2016,Age,13-17 Years,90.2,85.9 to 93.3,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2021,Age,13-17 Years,92.4,86.6 to 95.8,278
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2020,Age,13-17 Years,91.5,86.6 to 94.8,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2019,Age,13-17 Years,88.9,84.0 to 92.4,332
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2020,Age,13-17 Years,96.2,92.8 to 98.0,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2018,Age,13-17 Years,83.1,76.4 to 88.3,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2019,Age,13-17 Years,93.2,89.1 to 95.8,332
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2014,Age,13-17 Years,88.2,82.0 to 92.5,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2013,Age,13-17 Years,96.1,92.0 to 98.1,187
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2015,Age,13-17 Years,93.5,88.7 to 96.3,285
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2016,Age,13-17 Years,95.1,90.9 to 97.4,262
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2014,Age,13-17 Years,38.3,29.3 to 48.1,158
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2015,Age,13-17 Years,50.9,42.2 to 59.5,176
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2013,Age,13-17 Years,39.9,30.6 to 50.1,133
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2012,Age,13-17 Years,42.7,32.7 to 53.4,157
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2019,Age,13-15 Years,90.5,84.4 to 94.3,214
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2009,Age,13-15 Years,47.3,33.6 to 61.4,63
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2010,Age,13-15 Years,71.0,61.5 to 79.1,125
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2011,Age,13-15 Years,64.3,51.4 to 75.4,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2013,Age,13-15 Years,83.9,76.1 to 89.5,126
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2012,Age,13-15 Years,79.2,68.5 to 87.0,134
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2010,Age,13-17 Years,40.2,32.0 to 48.9,170
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2011,Age,13-17 Years,37.2,29.0 to 46.3,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2017,Age,13-17 Years,87.2,81.6 to 91.3,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2014,Age,13-17 Years,77.1,69.9 to 83.1,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2017,Age,13-17 Years,94.3,90.3 to 96.7,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2015,Age,13-17 Years,81.5,75.1 to 86.6,285
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2016,Age,13-17 Years,89.2,83.6 to 93.0,262
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2021,Age,13-15 Years,92.1,84.0 to 96.3,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2020,Age,13-15 Years,92.8,86.3 to 96.4,205
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2018,Age,13-15 Years,85.7,77.0 to 91.5,167
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2016,Age,13-15 Years,90.9,85.3 to 94.5,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2017,Age,13-15 Years,90.8,84.6 to 94.6,196
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kansas,2017,Age,13-17 Years,37.3,31.3 to 43.7,338
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kansas,2016,Age,13-17 Years,39.3,33.1 to 45.9,322
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2018,Age,13-17 Years,64.0,54.9 to 72.2,159
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2022,Age,13-17 Years,73.5,63.6 to 81.6,137
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2021,Age,13-17 Years,83.2,74.4 to 89.5,140
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2020,Age,13-17 Years,66.4,56.6 to 74.9,163
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kansas,2018,Age,13-17 Years,44.6,38.1 to 51.4,297
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2019,Age,13-17 Years,70.0,61.4 to 77.3,199
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kansas,2019,Age,13-17 Years,51.6,45.1 to 58.1,381
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2021,Age,13-17 Years,70.2,59.7 to 78.9,160
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2020,Age,13-17 Years,60.4,51.9 to 68.4,201
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2014,Age,13-17 Years,32.8,24.9 to 41.9,194
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2013,Age,13-17 Years,25.1,17.5 to 34.6,154
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2015,Age,13-17 Years,36.0,28.3 to 44.4,199
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2016,Age,13-17 Years,41.7,32.9 to 51.0,166
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2017,Age,13-17 Years,49.8,41.3 to 58.2,188
≥3 Doses HepB,,States/Local Areas,Kansas,2018,Age,13-17 Years,85.8,79.9 to 90.2,297
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2013,Age,13-17 Years,80.7,73.9 to 86.1,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2012,Age,13-17 Years,78.7,71.0 to 84.9,211
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2009,Age,13-17 Years,78.4,67.1 to 86.6,91
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2010,Age,13-17 Years,88.4,82.2 to 92.6,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2008,Age,13-17 Years,62.5,49.4 to 73.9,87
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2008,Age,13-17 Years,26.9,16.7 to 40.3,87
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2009,Age,13-17 Years,46.4,35.1 to 58.0,91
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2011,Age,13-17 Years,89.0,77.9 to 94.9,212
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2012,Age,13-17 Years,96.3,91.6 to 98.5,211
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2008,Age,13-17 Years,30.1,21.8 to 40.0,137
≥3 Doses HepB,,States/Local Areas,Kansas,2009,Age,13-17 Years,76.1,69.5 to 81.6,252
≥3 Doses HepB,,States/Local Areas,Kansas,2010,Age,13-17 Years,88.2,84.0 to 91.4,373
≥3 Doses HepB,,States/Local Areas,Kansas,2008,Age,13-17 Years,71.4,64.7 to 77.3,271
≥1 Dose MenACWY,,States/Local Areas,Kansas,2017,Age,13-15 Years,71.7,64.0 to 78.4,229
≥1 Dose MenACWY,,States/Local Areas,Kansas,2016,Age,13-15 Years,68.2,60.4 to 75.2,215
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2018,Age,13-17 Years,60.5,50.4 to 69.8,138
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2017,Age,13-17 Years,55.2,45.3 to 64.7,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Kansas,2022,Age,13-17 Years,90.4,85.4 to 93.9,291
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2021,Age,13-17 Years,92.6,86.8 to 95.9,278
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2016,Age,13-17 Years,62.4,53.1 to 70.9,156
≥1 Dose MenACWY,,States/Local Areas,Kansas,2015,Age,13-15 Years,64.9,57.0 to 72.0,227
≥1 Dose MenACWY,,States/Local Areas,Kansas,2014,Age,13-15 Years,65.2,56.4 to 73.0,221
HPV,"≥1 Dose, Females",States/Local Areas,Kansas,2019,Age,13-17 Years,61.7,51.9 to 70.6,182
Varicella,≥1 Dose with no disease history,States/Local Areas,Kansas,2022,Age,13-17 Years,94.2,89.9 to 96.8,291
≥3 Doses HepB,,States/Local Areas,Kansas,2022,Age,13-17 Years,90.8,86.0 to 94.1,310
≥3 Doses HepB,,States/Local Areas,Kansas,2021,Age,13-17 Years,93.1,88.4 to 96.0,300
≥3 Doses HepB,,States/Local Areas,Kansas,2020,Age,13-17 Years,92.7,89.0 to 95.3,364
HPV,"≥1 Dose, Males",States/Local Areas,Kansas,2012,Age,13-17 Years,13.5,8.0 to 22.0,183
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2014,Age,13-17 Years,84.3,78.6 to 88.7,352
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2015,Age,13-17 Years,89.6,85.2 to 92.8,375
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2017,Age,13-17 Years,91.4,87.2 to 94.4,338
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kansas,2016,Age,13-17 Years,88.8,84.0 to 92.3,322
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2008,Age,13-17 Years,21.4,14.1 to 31.1,137
≥1 Dose MenACWY,,States/Local Areas,Kansas,2013,Age,13-15 Years,51.6,43.2 to 60.0,180
≥1 Dose MenACWY,,States/Local Areas,Kansas,2012,Age,13-15 Years,52.6,43.0 to 62.1,196
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2011,Age,13-17 Years,28.8,21.7 to 37.2,198
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2010,Age,13-17 Years,37.3,29.3 to 46.1,170
HPV,"≥2 Doses, Females",States/Local Areas,Kansas,2009,Age,13-17 Years,35.3,25.5 to 46.4,117
≥1 Dose MenACWY,,States/Local Areas,Kansas,2020,Age,13-15 Years,80.0,72.5 to 85.9,232
≥1 Dose MenACWY,,States/Local Areas,Kansas,2019,Age,13-15 Years,80.0,72.9 to 85.5,238
≥1 Dose MenACWY,,States/Local Areas,Kansas,2018,Age,13-15 Years,73.5,65.3 to 80.4,186
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2017,Age,13-17 Years,52.4,46.0 to 58.8,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2016,Age,13-17 Years,51.8,45.2 to 58.3,322
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kansas,2018,Age,13-17 Years,62.3,55.5 to 68.6,297
Varicella,History of disease,States/Local Areas,Kansas,2017,Age,13-17 Years,15.0,11.1 to 20.0,338
Varicella,History of disease,States/Local Areas,Kansas,2016,Age,13-17 Years,19.8,14.9 to 25.7,322
Varicella,History of disease,States/Local Areas,Kansas,2009,Age,13-17 Years,65.2,58.3 to 71.5,252
Varicella,History of disease,States/Local Areas,Kansas,2018,Age,13-17 Years,12.1,8.5 to 16.9,297
Varicella,History of disease,States/Local Areas,Kansas,2008,Age,13-17 Years,66.6,59.5 to 73.0,271
Varicella,History of disease,States/Local Areas,Kansas,2014,Age,13-17 Years,30.4,24.4 to 37.1,352
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2018,Age,13-15 Years,32.8,22.8 to 44.7,93
Varicella,History of disease,States/Local Areas,Kansas,2019,Age,13-17 Years,9.3,6.4 to 13.3,381
Varicella,History of disease,States/Local Areas,Kansas,2022,Age,13-17 Years,7.2,4.2 to 12.1,310
Varicella,History of disease,States/Local Areas,Kansas,2021,Age,13-17 Years,7.1,4.0 to 12.3,300
Varicella,History of disease,States/Local Areas,Kansas,2020,Age,13-17 Years,10.3,7.3 to 14.5,364
Varicella,History of disease,States/Local Areas,Kansas,2015,Age,13-17 Years,23.2,18.5 to 28.6,375
Varicella,History of disease,States/Local Areas,Kansas,2011,Age,13-17 Years,48.7,42.1 to 55.4,399
Varicella,History of disease,States/Local Areas,Kansas,2010,Age,13-17 Years,50.3,44.7 to 56.0,373
Varicella,History of disease,States/Local Areas,Kansas,2013,Age,13-17 Years,36.3,29.9 to 43.2,287
Varicella,History of disease,States/Local Areas,Kansas,2012,Age,13-17 Years,40.3,33.3 to 47.7,340
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2020,Age,13-17 Years,53.3,46.9 to 59.6,364
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2022,Age,13-17 Years,60.7,53.8 to 67.1,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2021,Age,13-17 Years,64.3,56.8 to 71.1,300
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2014,Age,13-17 Years,79.8,73.5 to 84.8,352
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2013,Age,13-17 Years,84.6,79.0 to 88.9,287
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2015,Age,13-17 Years,87.3,82.4 to 91.0,375
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2019,Age,13-17 Years,49.5,43.0 to 56.1,381
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2018,Age,13-17 Years,40.7,34.3 to 47.5,297
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2017,Age,13-17 Years,34.4,28.6 to 40.7,338
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2016,Age,13-17 Years,35.6,29.6 to 42.1,322
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2009,Age,13-17 Years,63.6,56.6 to 70.0,252
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2010,Age,13-17 Years,76.8,71.8 to 81.2,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2011,Age,13-17 Years,79.1,73.0 to 84.1,399
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2008,Age,13-17 Years,46.8,40.1 to 53.7,271
Tetanus,≥1 Dose Tdap,States/Local Areas,Kansas,2022,Age,13-15 Years,90.4,83.5 to 94.6,188
≥2 Doses MMR,,States/Local Areas,Kansas,2011,Age,13-17 Years,86.6,79.7 to 91.4,399
≥2 Doses MMR,,States/Local Areas,Kansas,2010,Age,13-17 Years,91.3,87.4 to 94.0,373
≥2 Doses MMR,,States/Local Areas,Kansas,2009,Age,13-17 Years,84.2,78.3 to 88.8,252
≥2 Doses MMR,,States/Local Areas,Kansas,2008,Age,13-17 Years,84.1,78.3 to 88.6,271
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2023,Age,13-17 Years,75.1,66.6 to 82.0,179
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2023,Age,13-17 Years,65.7,56.7 to 73.7,156
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2023,Age,13-15 Years,93.9,88.5 to 96.8,201
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2023,Age,13-15 Years,62.6,51.4 to 72.6,108
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2023,Age,13-15 Years,59.1,51.1 to 66.7,211
≥1 Dose MenACWY,,States/Local Areas,Alabama,2023,Age,13-15 Years,85.9,79.0 to 90.7,211
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2023,Age,13-15 Years,90.6,84.1 to 94.6,211
≥2 Doses Hep A,,States/Local Areas,Alabama,2023,Age,13-17 Years,84.7,79.1 to 89.0,335
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2023,Age,13-15 Years,55.4,44.0 to 66.2,103
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2023,Age,13-17 Years,92.1,87.7 to 95.0,335
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2023,Age,13-17 Years,91.7,87.1 to 94.7,317
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2023,Age,13-17 Years,93.8,89.3 to 96.5,317
Varicella,History of disease,States/Local Areas,Alabama,2023,Age,13-17 Years,4.8,2.8 to 8.3,335
≥3 Doses HepB,,States/Local Areas,Alabama,2023,Age,13-17 Years,87.7,82.3 to 91.7,335
≥2 Doses MMR,,States/Local Areas,Alabama,2023,Age,13-17 Years,93.4,89.1 to 96.1,335
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2023,Age,13-17 Years,55.0,46.3 to 63.5,179
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2023,Age,13-17 Years,83.2,75.1 to 89.0,156
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2023,Age,13-17 Years,60.3,54.0 to 66.2,335
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2023,Age,13-17 Years,79.0,73.3 to 83.8,335
≥1 Dose MenACWY,,States/Local Areas,Alabama,2023,Age,13-17 Years,86.7,81.8 to 90.4,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2023,Age,13-17 Years,90.1,85.2 to 93.5,335
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2023,Age,13-17 Years,91.6,86.9 to 94.7,335
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Insurance Coverage,Private Insurance Only,64.4,60.3 to 68.3,806
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Insurance Coverage,Private Insurance Only,84.1,80.9 to 86.9,806
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Insurance Coverage,Other,85.2,75.7 to 91.4,138
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Insurance Coverage,Any Medicaid,92.0,88.8 to 94.4,521
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Insurance Coverage,Private Insurance Only,93.5,91.0 to 95.3,806
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Insurance Coverage,Other,46.9,37.0 to 57.1,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Insurance Coverage,Any Medicaid,61.8,56.8 to 66.5,521
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Insurance Coverage,Private Insurance Only,50.2,46.0 to 54.4,806
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Insurance Coverage,Other,60.1,49.5 to 69.9,138
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Insurance Coverage,Any Medicaid,80.1,75.9 to 83.7,521
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Insurance Coverage,Other,76.7,66.4 to 84.6,138
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Insurance Coverage,Any Medicaid,87.2,83.6 to 90.1,521
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Poverty,Below Poverty Level,79.5,73.1 to 84.7,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Poverty,Living At or Above Poverty Level,91.8,89.6 to 93.6,1182
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Poverty,Below Poverty Level,91.1,86.0 to 94.5,258
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Poverty,Living At or Above Poverty Level,51.6,48.2 to 55.1,1182
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2018,Age,13-17 Years,56.0,46.3 to 65.2,155
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2016,Age,13-17 Years,51.7,45.3 to 58.0,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2017,Age,13-17 Years,58.0,52.0 to 63.9,367
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018,Age,13-17 Years,64.7,58.1 to 70.7,327
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2015,Age,13-17 Years,50.4,41.1 to 59.6,165
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2016,Age,13-17 Years,48.4,39.3 to 57.6,153
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2017,Age,13-17 Years,54.4,46.0 to 62.7,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2008,Age,13-15 Years,46.3,39.0 to 53.8,252
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2009,Age,13-15 Years,59.0,50.5 to 67.0,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2010,Age,13-15 Years,67.0,58.7 to 74.3,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2011,Age,13-15 Years,73.4,65.9 to 79.7,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2012,Age,13-15 Years,85.3,76.5 to 91.1,184
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2013,Age,13-17 Years,10.9,6.7 to 17.3,165
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2014,Age,13-17 Years,16.1,11.1 to 22.7,206
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2015,Age,13-17 Years,30.3,22.7 to 39.2,196
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2019,Age,13-17 Years,57.3,47.5 to 66.5,143
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2013,Age,13-15 Years,89.2,83.0 to 93.3,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2014,Age,13-15 Years,87.0,80.0 to 91.8,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2015,Age,13-15 Years,91.6,85.3 to 95.4,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2016,Age,13-15 Years,94.5,90.5 to 96.9,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2017,Age,13-15 Years,89.6,84.2 to 93.3,238
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2016,Age,13-17 Years,32.2,24.5 to 41.1,180
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2017,Age,13-17 Years,41.4,32.9 to 50.4,174
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2018,Age,13-17 Years,50.1,40.8 to 59.5,172
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2019,Age,13-17 Years,43.9,34.5 to 53.9,153
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018,Age,13-15 Years,87.1,79.3 to 92.3,197
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2019,Age,13-15 Years,91.6,85.8 to 95.1,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2020,Age,13-15 Years,92.9,87.4 to 96.1,184
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2021,Age,13-15 Years,91.7,84.4 to 95.8,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Poverty,Below Poverty Level,62.6,55.4 to 69.3,258
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Poverty,Below Poverty Level,86.0,80.4 to 90.2,258
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Poverty,Living At or Above Poverty Level,83.8,81.1 to 86.2,1182
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Poverty,Living At or Above Poverty Level,67.4,64.1 to 70.5,1182
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"White, Non-Hispanic",49.5,45.8 to 53.2,1012
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,Hispanic,77.1,66.0 to 85.4,101
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.1,74.1 to 85.0,273
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"White, Non-Hispanic",64.6,61.0 to 68.1,1012
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",95.2,87.5 to 98.2,108
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,Hispanic,83.0,72.1 to 90.3,101
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",94.8,90.9 to 97.1,273
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.7,79.9 to 93.9,108
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,Hispanic,83.6,72.8 to 90.7,101
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.8,81.6 to 90.7,273
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.6,87.9 to 92.7,1012
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"White, Non-Hispanic",82.8,79.9 to 85.4,1012
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",60.9,49.9 to 70.9,108
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,Hispanic,56.2,44.5 to 67.3,101
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",62.5,55.7 to 68.8,273
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",75.6,65.5 to 83.5,108
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a Non-MSA,91.3,86.6 to 94.5,311
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.2,85.3 to 92.2,555
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Principal City,93.8,91.2 to 95.7,628
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a Non-MSA,45.9,39.0 to 53.1,311
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Non-Principal City,51.3,46.3 to 56.3,555
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Principal City,60.9,56.2 to 65.3,628
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a Non-MSA,81.4,75.3 to 86.2,311
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Non-Principal City,83.1,79.1 to 86.5,555
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Principal City,86.9,83.5 to 89.7,628
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a Non-MSA,64.0,57.1 to 70.4,311
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Non-Principal City,67.4,62.5 to 71.9,555
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Urbanicity,Living In a MSA Principal City,76.3,72.3 to 80.0,628
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018-2022,Overall,Overall,91.6,89.6 to 93.2,1494
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018-2022,Overall,Overall,54.5,51.4 to 57.5,1494
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2018-2022,Overall,Overall,70.7,67.8 to 73.3,1494
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018-2022,Overall,Overall,84.4,82.1 to 86.5,1494
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2009,Age,13-17 Years,68.5,62.2 to 74.2,339
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2010,Age,13-17 Years,68.5,62.2 to 74.2,296
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2011,Age,13-17 Years,69.8,63.8 to 75.2,403
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2012,Age,13-17 Years,76.9,69.8 to 82.8,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2013,Age,13-17 Years,84.6,79.4 to 88.8,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2014,Age,13-17 Years,83.3,78.0 to 87.6,378
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2008,Age,13-17 Years,63.7,57.8 to 69.2,406
≥2 Doses Hep A,,States/Local Areas,Alabama,2021,Age,13-17 Years,83.0,77.5 to 87.3,304
≥2 Doses Hep A,,States/Local Areas,Alabama,2022,Age,13-17 Years,77.4,70.9 to 82.7,269
≥2 Doses Hep A,,States/Local Areas,Alabama,2020,Age,13-17 Years,74.1,67.7 to 79.5,298
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2019,Age,13-15 Years,92.5,85.7 to 96.2,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2020,Age,13-15 Years,93.7,88.0 to 96.8,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2021,Age,13-15 Years,95.4,89.0 to 98.1,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2009,Age,13-15 Years,37.9,28.2 to 48.6,108
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2010,Age,13-15 Years,45.6,36.0 to 55.5,126
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2011,Age,13-15 Years,63.0,53.6 to 71.5,172
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2012,Age,13-15 Years,70.0,59.4 to 78.9,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2013,Age,13-15 Years,80.3,71.4 to 86.9,148
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2019,Age,13-17 Years,95.1,91.1 to 97.3,296
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2020,Age,13-17 Years,95.2,91.7 to 97.3,298
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2021,Age,13-17 Years,96.1,92.2 to 98.1,304
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2022,Age,13-17 Years,93.5,88.7 to 96.4,269
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2008,Age,13-15 Years,18.0,12.0 to 26.1,135
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2015,Age,13-17 Years,89.2,84.8 to 92.5,361
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2017,Age,13-17 Years,87.9,83.6 to 91.1,367
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2016,Age,13-17 Years,88.0,83.5 to 91.4,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Alabama,2018,Age,13-17 Years,90.3,85.5 to 93.6,327
HPV,"≥3 Doses, Males",States/Local Areas,Alabama,2014,Age,13-17 Years,9.0,5.2 to 15.0,206
HPV,"≥3 Doses, Males",States/Local Areas,Alabama,2015,Age,13-17 Years,22.6,15.7 to 31.4,196
HPV,"≥3 Doses, Males",States/Local Areas,Alabama,2015,Age,13-15 Years,20.3,12.8 to 30.5,126
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2012,Age,13-17 Years,17.8,10.3 to 29.1,171
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2022,Age,13-17 Years,96.4,92.4 to 98.4,252
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2019,Age,13-17 Years,69.6,60.0 to 77.8,143
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alabama,2016,Age,13-17 Years,40.2,34.0 to 46.6,333
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alabama,2017,Age,13-17 Years,47.8,41.7 to 53.9,367
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alabama,2018,Age,13-17 Years,53.0,46.2 to 59.6,327
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alabama,2019,Age,13-17 Years,50.5,43.5 to 57.5,296
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2020,Age,13-17 Years,70.4,60.8 to 78.6,135
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2021,Age,13-17 Years,76.8,67.1 to 84.3,135
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2022,Age,13-17 Years,77.2,68.3 to 84.2,139
≥3 Doses HepB,,States/Local Areas,Alabama,2012,Age,13-17 Years,96.4,93.8 to 97.9,317
≥3 Doses HepB,,States/Local Areas,Alabama,2013,Age,13-17 Years,93.9,90.3 to 96.3,317
≥3 Doses HepB,,States/Local Areas,Alabama,2014,Age,13-17 Years,91.4,87.1 to 94.3,378
≥3 Doses HepB,,States/Local Areas,Alabama,2015,Age,13-17 Years,94.1,90.2 to 96.5,361
≥3 Doses HepB,,States/Local Areas,Alabama,2016,Age,13-17 Years,96.0,93.3 to 97.6,333
≥3 Doses HepB,,States/Local Areas,Alabama,2020,Age,13-17 Years,93.5,89.5 to 96.1,298
≥3 Doses HepB,,States/Local Areas,Alabama,2021,Age,13-17 Years,92.4,88.3 to 95.1,304
≥3 Doses HepB,,States/Local Areas,Alabama,2022,Age,13-17 Years,93.0,88.0 to 96.0,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2019,Age,13-17 Years,97.4,94.0 to 98.9,276
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2020,Age,13-17 Years,97.4,95.0 to 98.7,277
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2019,Age,13-17 Years,94.7,90.4 to 97.1,276
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2020,Age,13-17 Years,94.9,91.1 to 97.1,277
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2021,Age,13-17 Years,95.8,91.6 to 98.0,282
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2021,Age,13-17 Years,97.6,94.4 to 99.0,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2022,Age,13-17 Years,93.0,87.8 to 96.0,252
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2016,Age,13-17 Years,54.2,45.1 to 63.1,153
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2017,Age,13-17 Years,61.1,52.6 to 69.0,193
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2018,Age,13-17 Years,69.1,59.9 to 77.0,155
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2018,Age,13-17 Years,94.6,89.8 to 97.2,295
≥3 Doses HepB,,States/Local Areas,Alabama,2017,Age,13-17 Years,91.7,87.8 to 94.4,367
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2018,Age,13-17 Years,89.3,84.0 to 92.9,295
≥3 Doses HepB,,States/Local Areas,Alabama,2018,Age,13-17 Years,94.2,89.7 to 96.8,327
≥3 Doses HepB,,States/Local Areas,Alabama,2019,Age,13-17 Years,95.7,91.2 to 98.0,296
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2013,Age,13-17 Years,96.1,90.9 to 98.3,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2014,Age,13-17 Years,97.1,93.2 to 98.8,298
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2015,Age,13-17 Years,97.2,93.0 to 98.9,295
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2016,Age,13-17 Years,98.2,96.2 to 99.2,295
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2017,Age,13-17 Years,96.3,93.3 to 98.0,321
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2014,Age,13-17 Years,78.4,71.9 to 83.7,298
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2015,Age,13-17 Years,86.6,81.2 to 90.6,295
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2016,Age,13-17 Years,86.5,81.5 to 90.3,295
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2017,Age,13-17 Years,86.1,81.3 to 89.8,321
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2011,Age,13-17 Years,49.5,40.4 to 58.7,180
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2012,Age,13-17 Years,46.6,36.5 to 57.0,146
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2013,Age,13-17 Years,54.7,45.4 to 63.6,152
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2014,Age,13-17 Years,54.7,45.3 to 63.7,172
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2015,Age,13-17 Years,57.7,48.3 to 66.6,165
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2010,Age,13-17 Years,45.8,36.9 to 55.0,143
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2008,Age,13-17 Years,32.8,25.5 to 41.1,185
HPV,"≥1 Dose, Females",States/Local Areas,Alabama,2009,Age,13-17 Years,49.4,40.8 to 58.1,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2012,Age,13-17 Years,68.1,59.1 to 76.0,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2013,Age,13-17 Years,79.1,72.3 to 84.5,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2008,Age,13-17 Years,71.2,61.7 to 79.2,181
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2009,Age,13-17 Years,90.2,84.1 to 94.1,160
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2010,Age,13-17 Years,88.7,81.4 to 93.4,164
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2011,Age,13-17 Years,94.8,91.5 to 96.9,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Alabama,2012,Age,13-17 Years,97.4,92.4 to 99.2,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2008,Age,13-17 Years,17.1,12.1 to 23.7,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2009,Age,13-17 Years,34.0,26.3 to 42.7,160
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2010,Age,13-17 Years,43.5,35.0 to 52.3,164
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2011,Age,13-17 Years,56.4,48.6 to 63.8,257
≥3 Doses HepB,,States/Local Areas,Alabama,2011,Age,13-17 Years,90.0,85.4 to 93.3,403
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2022,Age,13-15 Years,95.4,88.6 to 98.2,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2014,Age,13-15 Years,82.7,75.0 to 88.5,167
≥3 Doses HepB,,States/Local Areas,Alabama,2008,Age,13-17 Years,68.2,62.3 to 73.5,406
≥3 Doses HepB,,States/Local Areas,Alabama,2009,Age,13-17 Years,82.9,78.1 to 86.7,339
≥3 Doses HepB,,States/Local Areas,Alabama,2010,Age,13-17 Years,89.3,84.5 to 92.7,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2015,Age,13-15 Years,88.8,82.4 to 93.1,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2017,Age,13-15 Years,90.3,85.2 to 93.7,210
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2016,Age,13-15 Years,92.9,88.5 to 95.7,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Alabama,2018,Age,13-15 Years,91.9,85.6 to 95.6,175
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2022,Age,13-17 Years,76.4,67.0 to 83.7,130
≥1 Dose MenACWY,,States/Local Areas,Alabama,2008,Age,13-15 Years,36.9,29.9 to 44.5,252
≥1 Dose MenACWY,,States/Local Areas,Alabama,2009,Age,13-15 Years,42.1,34.2 to 50.5,192
≥1 Dose MenACWY,,States/Local Areas,Alabama,2010,Age,13-15 Years,45.0,37.2 to 53.1,188
≥1 Dose MenACWY,,States/Local Areas,Alabama,2011,Age,13-15 Years,65.6,57.6 to 72.9,237
≥1 Dose MenACWY,,States/Local Areas,Alabama,2012,Age,13-15 Years,60.1,50.7 to 68.8,184
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2019,Age,13-17 Years,61.6,51.5 to 70.9,153
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2020,Age,13-17 Years,64.3,55.1 to 72.5,163
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2021,Age,13-17 Years,80.2,72.1 to 86.4,169
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2017,Age,13-17 Years,55.1,46.4 to 63.5,174
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2008,Age,13-17 Years,70.1,64.6 to 75.0,406
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2018,Age,13-17 Years,60.4,50.9 to 69.1,172
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2013,Age,13-17 Years,18.4,12.5 to 26.4,165
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2014,Age,13-17 Years,27.6,21.0 to 35.4,206
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2015,Age,13-17 Years,39.4,31.2 to 48.3,196
HPV,"≥1 Dose, Males",States/Local Areas,Alabama,2016,Age,13-17 Years,49.2,40.5 to 58.1,180
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2014,Age,13-17 Years,90.9,86.3 to 94.0,378
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2015,Age,13-17 Years,94.6,90.9 to 96.8,361
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2016,Age,13-17 Years,92.8,88.9 to 95.3,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2017,Age,13-17 Years,89.7,85.5 to 92.8,367
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2018,Age,13-17 Years,92.3,87.4 to 95.4,327
≥1 Dose MenACWY,,States/Local Areas,Alabama,2013,Age,13-15 Years,70.7,62.6 to 77.7,187
≥1 Dose MenACWY,,States/Local Areas,Alabama,2014,Age,13-15 Years,69.8,61.4 to 77.0,207
≥1 Dose MenACWY,,States/Local Areas,Alabama,2015,Age,13-15 Years,67.1,58.9 to 74.4,221
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2009,Age,13-17 Years,71.6,65.5 to 77.0,339
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2010,Age,13-17 Years,79.4,73.8 to 84.1,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2011,Age,13-17 Years,82.8,77.9 to 86.8,403
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2012,Age,13-17 Years,87.2,80.9 to 91.6,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2013,Age,13-17 Years,90.6,85.7 to 93.9,317
≥1 Dose MenACWY,,States/Local Areas,Alabama,2021,Age,13-15 Years,89.9,82.7 to 94.3,188
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2014,Age,13-17 Years,40.7,32.1 to 50.0,172
≥1 Dose MenACWY,,States/Local Areas,Alabama,2020,Age,13-15 Years,83.0,75.8 to 88.4,184
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2009,Age,13-17 Years,36.7,28.7 to 45.4,166
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2010,Age,13-17 Years,31.3,23.7 to 40.2,143
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2011,Age,13-17 Years,38.3,29.8 to 47.5,180
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2012,Age,13-17 Years,36.9,27.4 to 47.4,146
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2013,Age,13-17 Years,46.6,37.6 to 55.7,152
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2008,Age,13-17 Years,22.3,16.1 to 30.0,185
≥1 Dose MenACWY,,States/Local Areas,Alabama,2016,Age,13-15 Years,74.3,66.4 to 80.8,192
≥1 Dose MenACWY,,States/Local Areas,Alabama,2017,Age,13-15 Years,78.0,71.1 to 83.6,238
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018,Age,13-15 Years,80.4,73.1 to 86.1,197
≥1 Dose MenACWY,,States/Local Areas,Alabama,2019,Age,13-15 Years,85.9,79.3 to 90.6,186
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2019,Age,13-17 Years,94.0,90.0 to 96.5,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2020,Age,13-17 Years,92.2,87.6 to 95.2,298
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2021,Age,13-17 Years,94.6,89.8 to 97.2,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alabama,2022,Age,13-17 Years,94.2,90.2 to 96.6,269
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2019,Age,13-17 Years,65.6,58.6 to 71.9,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2020,Age,13-17 Years,67.3,60.7 to 73.3,298
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2021,Age,13-17 Years,78.5,72.4 to 83.6,304
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alabama,2022,Age,13-17 Years,76.8,70.5 to 82.0,269
≥1 Dose MenACWY,,States/Local Areas,Alabama,2022,Age,13-15 Years,85.3,77.9 to 90.5,157
Varicella,History of disease,States/Local Areas,Alabama,2020,Age,13-17 Years,7.1,4.4 to 11.2,298
Varicella,History of disease,States/Local Areas,Alabama,2021,Age,13-17 Years,7.1,4.3 to 11.4,304
Varicella,History of disease,States/Local Areas,Alabama,2022,Age,13-17 Years,7.7,4.5 to 12.9,269
Varicella,History of disease,States/Local Areas,Alabama,2008,Age,13-17 Years,56.1,50.3 to 61.8,406
Varicella,History of disease,States/Local Areas,Alabama,2016,Age,13-17 Years,11.1,7.7 to 15.7,333
Varicella,History of disease,States/Local Areas,Alabama,2017,Age,13-17 Years,12.6,9.1 to 17.2,367
Varicella,History of disease,States/Local Areas,Alabama,2009,Age,13-17 Years,52.2,46.0 to 58.4,339
Varicella,History of disease,States/Local Areas,Alabama,2010,Age,13-17 Years,44.3,38.0 to 50.8,296
Varicella,History of disease,States/Local Areas,Alabama,2011,Age,13-17 Years,30.8,25.7 to 36.4,403
Varicella,History of disease,States/Local Areas,Alabama,2012,Age,13-17 Years,27.6,21.9 to 34.3,317
Varicella,History of disease,States/Local Areas,Alabama,2013,Age,13-17 Years,26.6,21.2 to 32.8,317
Varicella,History of disease,States/Local Areas,Alabama,2015,Age,13-17 Years,19.7,15.1 to 25.2,361
Varicella,History of disease,States/Local Areas,Alabama,2014,Age,13-17 Years,22.9,17.9 to 28.7,378
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2018,Age,13-17 Years,52.0,42.4 to 61.4,155
Varicella,History of disease,States/Local Areas,Alabama,2018,Age,13-17 Years,9.4,6.1 to 14.3,327
Varicella,History of disease,States/Local Areas,Alabama,2019,Age,13-17 Years,7.6,4.4 to 12.9,296
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2021,Age,13-15 Years,62.5,49.9 to 73.7,86
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2022,Age,13-15 Years,57.2,44.4 to 69.2,84
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2016,Age,13-17 Years,46.5,37.4 to 55.7,153
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2021,Age,13-17 Years,66.6,57.7 to 74.5,169
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2022,Age,13-17 Years,58.7,48.4 to 68.3,130
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2019,Age,13-15 Years,45.8,37.2 to 54.5,186
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2021,Age,13-15 Years,63.0,54.5 to 70.8,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2020,Age,13-15 Years,55.0,46.5 to 63.1,184
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2017,Age,13-17 Years,47.2,38.9 to 55.7,193
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2020,Age,13-17 Years,57.0,47.2 to 66.2,135
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2019,Age,13-17 Years,52.2,42.5 to 61.8,143
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2021,Age,13-17 Years,58.2,47.9 to 67.8,135
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2022,Age,13-17 Years,59.8,50.0 to 68.8,139
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2018,Age,13-15 Years,49.8,38.1 to 61.6,101
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2019,Age,13-15 Years,43.6,32.0 to 56.1,91
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2019,Age,13-15 Years,47.9,36.1 to 60.0,95
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2018,Age,13-15 Years,45.6,33.6 to 58.2,96
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2020,Age,13-15 Years,51.3,39.9 to 62.7,99
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2017,Age,13-17 Years,33.7,25.7 to 42.7,174
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2021,Age,13-15 Years,63.5,51.7 to 73.8,102
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2022,Age,13-15 Years,66.4,52.9 to 77.7,73
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2016,Age,13-17 Years,24.7,17.9 to 32.9,180
HPV,"Up-to-Date, Females",States/Local Areas,Alabama,2020,Age,13-15 Years,58.7,46.3 to 70.0,85
≥2 Doses MMR,,States/Local Areas,Alabama,2012,Age,13-17 Years,95.5,91.2 to 97.8,317
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2019,Age,13-17 Years,47.3,40.4 to 54.3,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2013,Age,13-17 Years,87.3,82.1 to 91.1,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2014,Age,13-17 Years,88.6,84.0 to 92.1,378
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2015,Age,13-17 Years,93.3,89.2 to 95.9,361
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2020,Age,13-17 Years,52.9,46.3 to 59.4,298
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2021,Age,13-17 Years,62.5,55.6 to 68.8,304
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2022,Age,13-17 Years,59.2,52.2 to 65.9,269
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2008,Age,13-17 Years,13.2,8.8 to 19.3,185
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2009,Age,13-17 Years,25.2,18.6 to 33.2,166
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2010,Age,13-17 Years,20.0,13.9 to 27.9,143
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2012,Age,13-17 Years,31.1,22.1 to 41.8,146
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2013,Age,13-17 Years,39.6,31.0 to 48.8,152
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2014,Age,13-17 Years,35.3,27.1 to 44.5,172
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2015,Age,13-17 Years,40.8,32.0 to 50.3,165
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2011,Age,13-17 Years,31.2,23.3 to 40.3,180
≥2 Doses MMR,,States/Local Areas,Alabama,2008,Age,13-17 Years,89.8,85.7 to 92.8,406
≥2 Doses MMR,,States/Local Areas,Alabama,2009,Age,13-17 Years,91.4,87.0 to 94.4,339
≥2 Doses MMR,,States/Local Areas,Alabama,2010,Age,13-17 Years,93.5,89.3 to 96.1,296
≥2 Doses MMR,,States/Local Areas,Alabama,2011,Age,13-17 Years,89.1,83.6 to 92.9,403
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2022,Age,13-15 Years,95.4,89.4 to 98.1,157
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2008,Age,13-17 Years,44.0,38.4 to 49.8,406
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2009,Age,13-17 Years,57.6,51.4 to 63.6,339
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2010,Age,13-17 Years,68.4,62.0 to 74.2,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2011,Age,13-17 Years,74.4,68.8 to 79.2,403
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2012,Age,13-17 Years,81.7,75.0 to 87.0,317
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2017,Age,13-17 Years,40.3,34.4 to 46.5,367
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2018,Age,13-17 Years,50.2,43.4 to 56.9,327
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2020,Age,13-15 Years,41.9,33.4 to 50.9,191
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2018,Age,13-17 Years,38.1,29.2 to 47.9,160
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2019,Age,13-17 Years,41.4,31.9 to 51.7,159
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2017,Age,13-17 Years,32.9,25.3 to 41.5,193
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2020,Age,13-17 Years,40.5,31.5 to 50.2,156
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2021,Age,13-15 Years,57.6,48.2 to 66.6,191
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2019,Age,13-15 Years,44.3,35.5 to 53.5,209
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2022,Age,13-17 Years,48.3,38.2 to 58.6,130
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2017,Age,13-17 Years,42.1,33.4 to 51.3,163
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2018,Age,13-17 Years,48.6,38.7 to 58.7,150
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2019,Age,13-17 Years,48.0,38.0 to 58.2,166
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2022,Age,13-15 Years,43.6,31.5 to 56.6,84
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2019,Age,13-15 Years,44.4,32.6 to 57.0,102
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2022,Age,13-15 Years,68.4,54.6 to 79.6,82
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2021,Age,13-15 Years,60.7,47.0 to 72.8,87
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2022,Age,13-15 Years,54.7,45.1 to 64.0,166
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2020,Age,13-17 Years,49.8,39.7 to 59.9,148
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2022,Age,13-17 Years,62.5,51.8 to 72.2,141
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2018,Age,13-15 Years,37.2,26.2 to 49.7,102
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2020,Age,13-15 Years,36.7,26.1 to 48.7,99
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2021,Age,13-17 Years,62.5,52.1 to 71.9,144
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2019,Age,13-15 Years,44.2,31.9 to 57.2,107
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2016,Age,13-17 Years,41.3,32.4 to 50.7,154
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2021,Age,13-17 Years,60.2,49.9 to 69.7,160
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2021,Age,13-15 Years,55.0,42.1 to 67.4,104
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2016,Age,13-17 Years,20.3,13.9 to 28.7,163
Varicella,History of disease,States/Local Areas,Utah,2018,Age,13-17 Years,11.8,8.1 to 17.0,310
Varicella,History of disease,States/Local Areas,Utah,2017,Age,13-17 Years,12.6,9.1 to 17.2,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2008,Age,13-17 Years,77.0,70.4 to 82.5,222
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2014,Age,13-17 Years,76.5,70.8 to 81.4,398
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2015,Age,13-17 Years,73.5,67.5 to 78.7,357
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2017,Age,13-17 Years,84.8,79.8 to 88.7,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2016,Age,13-17 Years,73.4,67.0 to 79.0,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2020,Age,13-17 Years,89.4,84.6 to 92.9,304
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2022,Age,13-17 Years,90.0,83.9 to 93.9,271
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2013,Age,13-17 Years,76.1,69.7 to 81.6,301
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2012,Age,13-17 Years,73.2,66.5 to 79.1,345
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2011,Age,13-17 Years,74.8,68.3 to 80.4,393
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2009,Age,13-17 Years,76.1,70.3 to 81.1,339
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2010,Age,13-17 Years,77.4,71.3 to 82.5,325
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2017,Age,13-15 Years,86.1,78.8 to 91.2,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2016,Age,13-15 Years,75.2,66.7 to 82.1,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2020,Age,13-15 Years,87.9,81.1 to 92.5,179
≥3 Doses HepB,,States/Local Areas,Utah,2015,Age,13-17 Years,86.2,81.2 to 90.0,357
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2008,Age,13-15 Years,26.4,14.4 to 43.4,53
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2009,Age,13-15 Years,38.9,28.7 to 50.2,104
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2013,Age,13-15 Years,64.5,54.1 to 73.7,139
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2012,Age,13-15 Years,64.9,53.7 to 74.8,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2010,Age,13-15 Years,60.3,48.5 to 70.9,110
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2011,Age,13-15 Years,58.8,47.7 to 69.2,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2018,Age,13-15 Years,91.8,85.4 to 95.6,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2014,Age,13-15 Years,73.5,64.4 to 81.0,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2015,Age,13-15 Years,65.8,56.8 to 73.7,181
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2021,Age,13-17 Years,93.2,88.6 to 96.0,304
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2014,Age,13-17 Years,59.2,50.7 to 67.1,199
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2013,Age,13-17 Years,44.3,35.0 to 54.0,151
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2012,Age,13-17 Years,44.3,34.4 to 54.8,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2016,Age,13-17 Years,68.9,61.7 to 75.3,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2015,Age,13-17 Years,67.4,60.5 to 73.7,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2014,Age,13-17 Years,68.1,60.9 to 74.5,286
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2013,Age,13-17 Years,62.2,53.5 to 70.2,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2017,Age,13-17 Years,82.6,77.0 to 87.1,308
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2010,Age,13-17 Years,39.2,31.0 to 48.0,170
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2011,Age,13-17 Years,53.3,42.8 to 63.5,170
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2016,Age,13-17 Years,83.0,76.3 to 88.1,265
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2015,Age,13-17 Years,88.5,83.4 to 92.2,288
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2014,Age,13-17 Years,90.0,84.2 to 93.8,286
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2013,Age,13-17 Years,91.1,84.4 to 95.0,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2018,Age,13-17 Years,86.4,80.7 to 90.6,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2020,Age,13-17 Years,92.8,88.1 to 95.8,275
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2020,Age,13-17 Years,88.3,82.9 to 92.1,275
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2021,Age,13-17 Years,92.3,87.3 to 95.5,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2019,Age,13-17 Years,85.9,79.7 to 90.5,298
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2018,Age,13-17 Years,95.8,91.7 to 97.9,274
≥3 Doses HepB,,States/Local Areas,Utah,2019,Age,13-17 Years,88.1,82.5 to 92.0,325
HPV,"≥2 Doses, Males and Females",States/Local Areas,Utah,2019,Age,13-17 Years,48.3,41.1 to 55.6,325
≥3 Doses HepB,,States/Local Areas,Utah,2017,Age,13-17 Years,88.1,83.4 to 91.6,356
≥3 Doses HepB,,States/Local Areas,Utah,2016,Age,13-17 Years,83.0,77.4 to 87.4,317
≥3 Doses HepB,,States/Local Areas,Utah,2018,Age,13-17 Years,90.9,85.8 to 94.4,310
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2012,Age,13-17 Years,92.0,85.7 to 95.7,222
≥3 Doses HepB,,States/Local Areas,Utah,2012,Age,13-17 Years,85.5,79.6 to 89.9,345
≥3 Doses HepB,,States/Local Areas,Utah,2011,Age,13-17 Years,88.2,81.7 to 92.5,393
≥3 Doses HepB,,States/Local Areas,Utah,2014,Age,13-17 Years,84.7,79.6 to 88.6,398
≥3 Doses HepB,,States/Local Areas,Utah,2013,Age,13-17 Years,88.6,83.6 to 92.2,301
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2009,Age,13-17 Years,32.5,24.7 to 41.4,159
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2012,Age,13-17 Years,59.2,50.3 to 67.5,222
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2009,Age,13-17 Years,77.7,67.8 to 85.2,133
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2010,Age,13-17 Years,87.2,78.5 to 92.7,148
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2011,Age,13-17 Years,54.5,45.6 to 63.2,229
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2010,Age,13-17 Years,50.3,40.8 to 59.7,148
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2008,Age,13-17 Years,17.1,10.3 to 27.2,109
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2022,Age,13-15 Years,93.9,87.4 to 97.1,152
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2011,Age,13-17 Years,85.7,77.0 to 91.5,229
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2008,Age,13-17 Years,67.5,53.7 to 78.7,71
≥3 Doses HepB,,States/Local Areas,Utah,2009,Age,13-17 Years,80.6,74.9 to 85.4,339
≥3 Doses HepB,,States/Local Areas,Utah,2010,Age,13-17 Years,87.5,82.8 to 91.0,325
≥3 Doses HepB,,States/Local Areas,Utah,2008,Age,13-17 Years,70.2,63.1 to 76.5,222
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2019,Age,13-15 Years,88.3,80.2 to 93.4,190
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2008,Age,13-17 Years,22.4,12.7 to 36.4,71
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2009,Age,13-17 Years,35.3,26.6 to 45.1,133
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2021,Age,13-15 Years,92.6,85.2 to 96.4,175
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2021,Age,13-17 Years,82.8,74.7 to 88.8,144
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2019,Age,13-17 Years,75.0,65.0 to 82.9,166
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2018,Age,13-17 Years,57.2,47.8 to 66.2,160
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2020,Age,13-17 Years,65.6,55.4 to 74.6,156
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2017,Age,13-17 Years,54.7,46.2 to 62.9,193
HPV,"≥3 Doses, Males",States/Local Areas,Utah,2015,Age,13-15 Years,18.7,10.9 to 30.3,113
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2015,Age,13-17 Years,24.6,17.7 to 33.1,171
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2011,Age,13-17 Years,20.4,14.2 to 28.3,170
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2014,Age,13-17 Years,26.0,19.4 to 33.8,199
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2013,Age,13-17 Years,20.5,13.8 to 29.4,151
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2009,Age,13-17 Years,19.5,13.0 to 28.1,159
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2012,Age,13-17 Years,24.1,16.8 to 33.4,163
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2010,Age,13-17 Years,22.2,15.7 to 30.5,170
HPV,"≥3 Doses, Males",States/Local Areas,Utah,2014,Age,13-15 Years,14.4,8.5 to 23.4,121
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2017,Age,13-17 Years,94.4,90.6 to 96.7,308
≥2 Doses Hep A,,States/Local Areas,Utah,2021,Age,13-17 Years,94.3,90.5 to 96.7,304
≥2 Doses Hep A,,States/Local Areas,Utah,2020,Age,13-17 Years,88.1,82.5 to 92.0,304
≥2 Doses Hep A,,States/Local Areas,Utah,2022,Age,13-17 Years,87.6,80.7 to 92.2,271
HPV,"≥3 Doses, Males",States/Local Areas,Utah,2014,Age,13-17 Years,12.4,7.9 to 19.0,199
HPV,"≥3 Doses, Males",States/Local Areas,Utah,2015,Age,13-17 Years,19.9,13.4 to 28.6,186
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2018,Age,13-17 Years,88.0,82.9 to 91.8,310
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2019,Age,13-17 Years,86.8,80.9 to 91.1,325
Varicella,History of disease,States/Local Areas,Utah,2016,Age,13-17 Years,14.6,10.8 to 19.5,317
Varicella,History of disease,States/Local Areas,Utah,2015,Age,13-17 Years,18.7,14.2 to 24.2,357
Varicella,History of disease,States/Local Areas,Utah,2013,Age,13-17 Years,36.9,30.6 to 43.7,301
Varicella,History of disease,States/Local Areas,Utah,2012,Age,13-17 Years,34.4,28.2 to 41.2,345
Varicella,History of disease,States/Local Areas,Utah,2011,Age,13-17 Years,44.6,37.5 to 51.8,393
Varicella,History of disease,States/Local Areas,Utah,2010,Age,13-17 Years,54.5,48.1 to 60.7,325
Varicella,History of disease,States/Local Areas,Utah,2009,Age,13-17 Years,63.0,56.9 to 68.8,339
Varicella,History of disease,States/Local Areas,Utah,2014,Age,13-17 Years,26.5,21.6 to 32.1,398
Varicella,History of disease,States/Local Areas,Utah,2008,Age,13-17 Years,70.4,63.2 to 76.7,222
Varicella,History of disease,States/Local Areas,Utah,2019,Age,13-17 Years,6.1,3.7 to 9.8,325
Varicella,History of disease,States/Local Areas,Utah,2020,Age,13-17 Years,9.9,6.4 to 15.2,304
Varicella,History of disease,States/Local Areas,Utah,2021,Age,13-17 Years,10.8,6.9 to 16.5,304
Varicella,History of disease,States/Local Areas,Utah,2022,Age,13-17 Years,8.6,4.9 to 14.7,271
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2020,Age,13-15 Years,48.1,35.5 to 61.0,92
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2018,Age,13-15 Years,40.2,28.0 to 53.8,92
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2013,Age,13-17 Years,30.9,22.8 to 40.4,151
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2012,Age,13-17 Years,39.0,29.5 to 49.3,163
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2009,Age,13-17 Years,25.7,18.5 to 34.5,159
≥1 Dose MenACWY,,States/Local Areas,Utah,2020,Age,13-15 Years,93.4,88.6 to 96.2,191
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2011,Age,13-17 Years,40.9,30.6 to 52.1,170
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2010,Age,13-17 Years,32.9,25.2 to 41.8,170
≥1 Dose MenACWY,,States/Local Areas,Utah,2013,Age,13-15 Years,63.0,54.2 to 71.0,190
≥1 Dose MenACWY,,States/Local Areas,Utah,2012,Age,13-15 Years,57.1,47.8 to 66.0,211
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2008,Age,13-17 Years,62.7,54.9 to 69.9,222
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2009,Age,13-17 Years,73.2,67.1 to 78.6,339
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2016,Age,13-17 Years,83.9,78.5 to 88.2,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2014,Age,13-17 Years,88.4,83.9 to 91.8,398
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2015,Age,13-17 Years,83.6,77.9 to 88.0,357
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2012,Age,13-17 Years,84.9,78.2 to 89.8,345
≥1 Dose MenACWY,,States/Local Areas,Utah,2010,Age,13-15 Years,54.9,46.6 to 62.9,201
≥1 Dose MenACWY,,States/Local Areas,Utah,2011,Age,13-15 Years,63.2,54.1 to 71.5,251
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2021,Age,13-17 Years,79.1,70.4 to 85.8,160
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2019,Age,13-17 Years,63.0,52.5 to 72.3,159
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2011,Age,13-17 Years,84.5,77.7 to 89.5,393
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2010,Age,13-17 Years,77.3,71.2 to 82.5,325
≥1 Dose MenACWY,,States/Local Areas,Utah,2008,Age,13-15 Years,32.9,25.1 to 41.9,144
≥1 Dose MenACWY,,States/Local Areas,Utah,2009,Age,13-15 Years,44.6,36.9 to 52.5,218
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2022,Age,13-17 Years,71.0,60.3 to 79.7,130
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2021,Age,13-17 Years,94.1,89.6 to 96.7,304
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2019,Age,13-17 Years,68.8,61.6 to 75.2,325
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2022,Age,13-17 Years,73.0,65.6 to 79.3,271
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018,Age,13-17 Years,66.7,60.2 to 72.6,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2019,Age,13-17 Years,88.4,82.5 to 92.6,325
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2016,Age,13-17 Years,40.9,32.4 to 50.1,163
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2015,Age,13-17 Years,40.9,32.4 to 49.9,186
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2014,Age,13-17 Years,28.6,21.3 to 37.2,199
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2013,Age,13-17 Years,11.0,6.4 to 18.3,150
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2020,Age,13-17 Years,71.7,62.0 to 79.8,148
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2022,Age,13-17 Years,75.2,64.3 to 83.6,141
HPV,"≥2 Doses, Males and Females",States/Local Areas,Utah,2017,Age,13-17 Years,40.0,34.1 to 46.3,356
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2021,Age,13-17 Years,95.8,91.5 to 97.9,274
HPV,"≥2 Doses, Males and Females",States/Local Areas,Utah,2016,Age,13-17 Years,34.5,28.6 to 41.0,317
HPV,"≥2 Doses, Males and Females",States/Local Areas,Utah,2018,Age,13-17 Years,45.6,38.8 to 52.6,310
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2022,Age,13-17 Years,89.0,82.5 to 93.3,254
≥3 Doses HepB,,States/Local Areas,Utah,2021,Age,13-17 Years,94.3,90.3 to 96.7,304
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2022,Age,13-17 Years,92.2,85.5 to 95.9,254
≥3 Doses HepB,,States/Local Areas,Utah,2022,Age,13-17 Years,86.8,80.0 to 91.5,271
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2016,Age,13-17 Years,49.7,43.1 to 56.2,317
≥1 Dose MenACWY,,States/Local Areas,Utah,2017,Age,13-15 Years,88.3,82.9 to 92.1,229
≥3 Doses HepB,,States/Local Areas,Utah,2020,Age,13-17 Years,88.4,83.2 to 92.2,304
≥1 Dose MenACWY,,States/Local Areas,Utah,2018,Age,13-15 Years,89.8,83.2 to 94.0,194
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2017,Age,13-17 Years,58.8,52.6 to 64.8,356
≥1 Dose MenACWY,,States/Local Areas,Utah,2019,Age,13-15 Years,87.2,79.4 to 92.3,209
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2018,Age,13-17 Years,76.7,68.3 to 83.4,150
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2017,Age,13-17 Years,63.1,53.9 to 71.5,163
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2016,Age,13-17 Years,58.8,49.2 to 67.8,154
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2019,Age,13-17 Years,94.1,90.0 to 96.6,298
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2015,Age,13-17 Years,47.8,38.6 to 57.1,171
≥1 Dose MenACWY,,States/Local Areas,Utah,2016,Age,13-15 Years,79.7,72.4 to 85.5,207
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2013,Age,13-17 Years,88.2,82.6 to 92.1,301
≥1 Dose MenACWY,,States/Local Areas,Utah,2014,Age,13-15 Years,65.6,57.5 to 72.9,241
≥1 Dose MenACWY,,States/Local Areas,Utah,2015,Age,13-15 Years,66.7,58.3 to 74.1,212
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2017,Age,13-17 Years,91.6,87.7 to 94.3,356
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2017,Age,13-17 Years,34.8,27.1 to 43.4,193
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2016,Age,13-17 Years,24.1,17.1 to 32.7,163
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2018,Age,13-17 Years,39.9,30.9 to 49.6,160
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2019,Age,13-17 Years,51.9,41.7 to 61.9,166
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2015,Age,13-17 Years,33.7,25.6 to 42.9,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2020,Age,13-15 Years,92.6,87.6 to 95.6,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018,Age,13-15 Years,89.7,82.9 to 93.9,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2017,Age,13-15 Years,90.9,85.7 to 94.3,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2019,Age,13-15 Years,86.7,78.1 to 92.3,209
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2018,Age,13-17 Years,51.5,41.5 to 61.4,150
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2012,Age,13-15 Years,76.9,66.7 to 84.8,211
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2011,Age,13-15 Years,84.9,75.7 to 91.1,251
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2008,Age,13-15 Years,56.7,47.3 to 65.6,144
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2022,Age,13-17 Years,94.0,88.3 to 97.1,271
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2010,Age,13-15 Years,77.7,69.9 to 84.0,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2009,Age,13-15 Years,74.3,66.6 to 80.7,218
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2021,Age,13-17 Years,80.9,75.2 to 85.6,304
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2017,Age,13-17 Years,45.5,36.7 to 54.6,163
≥1 Dose MenACWY,,States/Local Areas,Utah,2021,Age,13-15 Years,92.7,86.9 to 96.1,191
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2016,Age,13-17 Years,45.5,36.3 to 54.9,154
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2014,Age,13-17 Years,40.0,31.9 to 48.8,199
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2015,Age,13-17 Years,35.9,27.6 to 45.1,171
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2020,Age,13-17 Years,91.3,86.7 to 94.4,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2018,Age,13-17 Years,90.4,85.5 to 93.8,310
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2020,Age,13-17 Years,68.6,61.6 to 74.8,304
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2014,Age,13-17 Years,19.6,13.6 to 27.3,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2013,Age,13-15 Years,85.7,78.1 to 91.0,190
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2016,Age,13-15 Years,87.6,81.0 to 92.1,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2014,Age,13-15 Years,89.1,83.3 to 93.0,241
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2015,Age,13-15 Years,79.3,71.2 to 85.6,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Overall,Overall,90.2,88.2 to 92.0,1442
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2023,Age,13-17 Years,74.0,62.8 to 82.8,138
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2023,Age,13-17 Years,57.8,44.5 to 70.1,110
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2023,Age,13-15 Years,95.5,85.1 to 98.8,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2023,Age,13-15 Years,54.2,42.9 to 65.1,152
HPV,"Up-to-Date, Females",States/Local Areas,Tennessee,2023,Age,13-15 Years,52.7,36.9 to 68.0,72
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2023,Age,13-15 Years,82.6,72.8 to 89.4,152
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2023,Age,13-15 Years,92.1,84.8 to 96.0,152
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2023,Age,13-17 Years,96.0,90.5 to 98.4,248
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2023,Age,13-15 Years,56.1,40.4 to 70.6,80
≥2 Doses Hep A,,States/Local Areas,Tennessee,2023,Age,13-17 Years,91.5,85.4 to 95.2,248
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2023,Age,13-17 Years,95.6,89.6 to 98.2,232
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2023,Age,13-17 Years,97.3,94.1 to 98.8,232
≥3 Doses HepB,,States/Local Areas,Tennessee,2023,Age,13-17 Years,96.5,93.2 to 98.2,248
HPV,"Up-to-Date, Males",States/Local Areas,Tennessee,2023,Age,13-17 Years,52.4,41.2 to 63.3,138
≥2 Doses MMR,,States/Local Areas,Tennessee,2023,Age,13-17 Years,95.4,90.0 to 98.0,248
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2023,Age,13-17 Years,55.0,46.4 to 63.4,248
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2023,Age,13-17 Years,81.5,69.5 to 89.5,110
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2023,Age,13-17 Years,85.7,79.3 to 90.4,248
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2023,Age,13-17 Years,77.7,69.8 to 84.0,248
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2023,Age,13-17 Years,94.1,89.7 to 96.7,248
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2023,Age,13-17 Years,92.5,87.5 to 95.7,248
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Overall,Overall,69.2,66.2 to 72.0,1442
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Overall,Overall,52.4,49.2 to 55.7,1442
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a Non-MSA,86.3,79.6 to 91.0,257
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Principal City,73.9,69.5 to 77.9,612
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Non-Principal City,65.4,60.4 to 70.1,573
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a Non-MSA,64.4,56.9 to 71.3,257
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Principal City,85.6,81.8 to 88.8,612
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Non-Principal City,49.3,44.2 to 54.5,573
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a Non-MSA,45.7,38.0 to 53.6,257
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Principal City,57.4,52.4 to 62.1,612
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Non-Principal City,83.0,78.8 to 86.6,573
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a Non-MSA,80.0,73.7 to 85.0,257
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.7,86.3 to 92.4,573
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Urbanicity,Living In a MSA Principal City,92.1,89.1 to 94.3,612
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.6,81.0 to 93.4,123
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.7,44.9 to 52.6,1021
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",68.9,58.1 to 77.9,123
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,Hispanic,77.8,69.0 to 84.6,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,Hispanic,58.3,48.0 to 68.0,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",52.8,41.8 to 63.5,123
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",63.4,54.1 to 71.8,150
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"White, Non-Hispanic",81.8,78.7 to 84.6,1021
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,Hispanic,91.4,84.6 to 95.3,148
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.8,77.1 to 90.2,150
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.3,86.6 to 91.5,1021
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.9,84.6 to 94.9,150
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,Hispanic,93.3,87.9 to 96.4,148
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",93.2,86.0 to 96.9,123
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"White, Non-Hispanic",64.7,61.0 to 68.3,1021
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Poverty,Living At or Above Poverty Level,67.6,64.2 to 70.8,1143
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",81.9,73.7 to 88.0,150
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Poverty,Below Poverty Level,72.2,64.6 to 78.7,253
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Poverty,Below Poverty Level,82.8,76.3 to 87.8,253
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Poverty,Below Poverty Level,50.5,42.9 to 58.2,253
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Poverty,Living At or Above Poverty Level,83.4,80.6 to 85.9,1143
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Poverty,Living At or Above Poverty Level,52.1,48.4 to 55.7,1143
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Poverty,Below Poverty Level,91.4,86.2 to 94.7,253
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Any Medicaid,87.7,83.3 to 91.0,439
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Poverty,Living At or Above Poverty Level,89.7,87.3 to 91.7,1143
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Private Insurance Only,83.5,80.1 to 86.4,814
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Any Medicaid,74.9,69.4 to 79.7,439
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Other,58.9,47.9 to 69.1,123
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Private Insurance Only,67.6,63.5 to 71.3,814
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Other,76.3,65.6 to 84.4,123
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Uninsured,64.8,50.8 to 76.7,66
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Uninsured,71.5,57.4 to 82.3,66
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Any Medicaid,58.2,52.3 to 63.9,439
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Private Insurance Only,52.0,47.7 to 56.3,814
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Other,40.0,29.7 to 51.3,123
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Private Insurance Only,90.3,87.5 to 92.6,814
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Uninsured,37.7,24.5 to 53.1,66
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Any Medicaid,91.8,87.9 to 94.5,439
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Uninsured,81.7,69.4 to 89.8,66
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018-2022,Insurance Coverage,Other,88.1,79.2 to 93.4,123
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018-2022,Overall,Overall,83.7,81.3 to 86.0,1442
HPV,"≥2 Doses, Males and Females",States/Local Areas,Tennessee,2022,Age,13-17 Years,65.6,57.7 to 72.6,244
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2022,Age,13-17 Years,65.2,54.3 to 74.7,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2016,Age,13-17 Years,36.0,29.7 to 42.8,291
≥2 Doses MMR,,States/Local Areas,Tennessee,2010,Age,13-17 Years,91.6,87.3 to 94.5,320
≥2 Doses MMR,,States/Local Areas,Tennessee,2011,Age,13-17 Years,86.6,80.8 to 90.8,424
≥2 Doses MMR,,States/Local Areas,Tennessee,2008,Age,13-17 Years,85.9,80.6 to 89.9,360
≥2 Doses MMR,,States/Local Areas,Tennessee,2009,Age,13-17 Years,85.2,79.5 to 89.6,397
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2010,Age,13-17 Years,58.7,52.4 to 64.8,320
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2009,Age,13-17 Years,48.0,42.0 to 54.0,397
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2011,Age,13-17 Years,67.6,61.0 to 73.6,424
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2008,Age,13-17 Years,34.3,28.5 to 40.5,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2022,Age,13-15 Years,90.1,82.0 to 94.8,160
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2019,Age,13-17 Years,39.5,30.1 to 49.9,135
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2021,Age,13-17 Years,56.5,49.4 to 63.3,315
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2022,Age,13-17 Years,64.4,56.5 to 71.6,244
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2019,Age,13-17 Years,43.0,35.9 to 50.4,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2015,Age,13-17 Years,79.7,73.8 to 84.5,325
HPV,"≥3 Doses, Males",States/Local Areas,Tennessee,2015,Age,13-17 Years,16.0,10.4 to 23.8,159
HPV,"≥3 Doses, Males",States/Local Areas,Tennessee,2014,Age,13-17 Years,14.0,8.6 to 21.9,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,Tennessee,2020,Age,13-17 Years,52.9,46.3 to 59.4,338
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2010,Age,13-17 Years,26.3,19.7 to 34.2,149
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2008,Age,13-17 Years,13.0,7.9 to 20.9,172
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2009,Age,13-17 Years,26.5,19.9 to 34.3,180
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2009,Age,13-17 Years,43.6,35.4 to 52.1,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2012,Age,13-17 Years,70.8,61.5 to 78.7,225
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2008,Age,13-17 Years,29.6,21.5 to 39.3,172
≥3 Doses HepB,,States/Local Areas,Tennessee,2008,Age,13-17 Years,82.4,76.1 to 87.2,360
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2019,Age,13-17 Years,94.1,89.3 to 96.8,236
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2012,Age,13-17 Years,92.9,85.9 to 96.6,225
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2008,Age,13-17 Years,72.0,62.4 to 79.8,133
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2010,Age,13-17 Years,86.1,79.3 to 91.0,185
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2009,Age,13-17 Years,78.9,70.7 to 85.2,186
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2011,Age,13-17 Years,92.7,85.3 to 96.5,260
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2009,Age,13-17 Years,33.6,26.0 to 42.1,186
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2008,Age,13-17 Years,22.9,16.4 to 31.1,133
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2010,Age,13-17 Years,54.7,46.4 to 62.6,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2011,Age,13-17 Years,61.3,52.0 to 69.8,260
≥3 Doses HepB,,States/Local Areas,Tennessee,2010,Age,13-17 Years,94.6,90.9 to 96.8,320
≥3 Doses HepB,,States/Local Areas,Tennessee,2009,Age,13-17 Years,87.4,82.4 to 91.1,397
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2022,Age,13-15 Years,90.0,81.7 to 94.8,152
≥3 Doses HepB,,States/Local Areas,Tennessee,2016,Age,13-17 Years,91.9,87.0 to 95.1,291
≥3 Doses HepB,,States/Local Areas,Tennessee,2017,Age,13-17 Years,91.2,86.1 to 94.5,338
≥3 Doses HepB,,States/Local Areas,Tennessee,2018,Age,13-17 Years,95.1,91.0 to 97.4,284
≥3 Doses HepB,,States/Local Areas,Tennessee,2019,Age,13-17 Years,94.2,89.6 to 96.8,261
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2018,Age,13-17 Years,98.2,95.1 to 99.4,244
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2019,Age,13-17 Years,91.6,86.5 to 94.8,236
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2020,Age,13-17 Years,93.3,89.0 to 96.0,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2021,Age,13-17 Years,94.7,90.7 to 97.1,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2018,Age,13-17 Years,93.1,88.4 to 95.9,244
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2020,Age,13-17 Years,97.5,94.3 to 98.9,306
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2017,Age,13-17 Years,97.4,94.8 to 98.7,297
≥3 Doses HepB,,States/Local Areas,Tennessee,2015,Age,13-17 Years,94.1,90.6 to 96.4,325
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2013,Age,13-17 Years,92.5,86.0 to 96.2,220
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2014,Age,13-17 Years,97.4,95.3 to 98.6,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2015,Age,13-17 Years,96.0,92.2 to 98.0,268
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2016,Age,13-17 Years,96.4,91.4 to 98.5,250
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2012,Age,13-17 Years,54.3,43.3 to 65.0,148
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2013,Age,13-17 Years,48.9,39.6 to 58.4,142
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2014,Age,13-17 Years,47.8,38.2 to 57.5,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2009,Age,13-15 Years,40.9,31.0 to 51.7,129
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2008,Age,13-15 Years,25.4,17.5 to 35.4,93
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2020,Age,13-15 Years,91.6,85.2 to 95.3,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2021,Age,13-15 Years,94.7,89.5 to 97.4,178
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2011,Age,13-17 Years,46.0,36.8 to 55.5,205
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2010,Age,13-17 Years,33.1,25.7 to 41.4,149
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2017,Age,13-17 Years,91.3,86.5 to 94.5,297
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2013,Age,13-17 Years,79.7,72.5 to 85.4,220
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2014,Age,13-17 Years,86.0,79.8 to 90.5,269
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2015,Age,13-17 Years,86.9,80.8 to 91.3,268
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2016,Age,13-17 Years,87.3,80.6 to 91.9,250
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2018,Age,13-15 Years,92.3,85.6 to 96.0,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2019,Age,13-15 Years,92.9,86.0 to 96.6,148
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2015,Age,13-17 Years,89.5,84.4 to 93.1,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2014,Age,13-17 Years,88.8,83.8 to 92.5,339
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2015,Age,13-15 Years,86.8,79.2 to 91.9,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2014,Age,13-15 Years,90.1,81.6 to 94.9,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2017,Age,13-15 Years,91.4,84.9 to 95.2,184
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2016,Age,13-15 Years,92.3,83.3 to 96.6,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2012,Age,13-15 Years,84.8,75.5 to 91.0,147
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2013,Age,13-15 Years,86.1,78.3 to 91.4,149
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2011,Age,13-15 Years,68.1,57.0 to 77.5,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2010,Age,13-15 Years,59.4,49.4 to 68.7,130
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2012,Age,13-17 Years,80.4,73.3 to 85.9,331
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2011,Age,13-17 Years,76.0,69.3 to 81.7,424
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2013,Age,13-17 Years,85.3,79.7 to 89.5,304
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2010,Age,13-17 Years,75.3,69.5 to 80.3,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2009,Age,13-17 Years,67.5,61.3 to 73.1,397
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2020,Age,13-17 Years,93.9,90.0 to 96.4,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2021,Age,13-17 Years,95.3,91.6 to 97.4,315
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2018,Age,13-17 Years,94.2,90.3 to 96.6,284
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2022,Age,13-17 Years,92.8,87.9 to 95.9,244
≥2 Doses Hep A,,States/Local Areas,Tennessee,2021,Age,13-17 Years,91.4,87.0 to 94.4,315
≥2 Doses Hep A,,States/Local Areas,Tennessee,2022,Age,13-17 Years,91.2,85.6 to 94.8,244
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2015,Age,13-17 Years,38.9,30.5 to 48.0,166
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2019,Age,13-17 Years,92.4,87.9 to 95.4,261
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2017,Age,13-17 Years,92.2,87.9 to 95.1,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2016,Age,13-17 Years,89.4,83.6 to 93.3,291
Varicella,≥2 Doses or history of disease,States/Local Areas,Tennessee,2008,Age,13-17 Years,74.8,69.2 to 79.7,360
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2012,Age,13-17 Years,28.6,20.2 to 38.8,148
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2011,Age,13-17 Years,27.2,19.7 to 36.2,205
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2013,Age,13-17 Years,35.9,27.4 to 45.5,142
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2014,Age,13-17 Years,20.1,14.2 to 27.6,154
≥2 Doses Hep A,,States/Local Areas,Tennessee,2020,Age,13-17 Years,81.9,76.2 to 86.4,338
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2011,Age,13-15 Years,62.1,53.5 to 70.1,261
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2010,Age,13-15 Years,53.3,45.2 to 61.2,193
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2012,Age,13-15 Years,74.9,66.3 to 82.0,198
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2013,Age,13-15 Years,67.2,58.9 to 74.6,182
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2013,Age,13-17 Years,85.1,79.9 to 89.2,304
≥3 Doses HepB,,States/Local Areas,Tennessee,2022,Age,13-17 Years,93.7,87.9 to 96.8,244
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2018,Age,13-17 Years,60.9,50.6 to 70.3,137
≥3 Doses HepB,,States/Local Areas,Tennessee,2020,Age,13-17 Years,93.5,89.3 to 96.2,338
≥3 Doses HepB,,States/Local Areas,Tennessee,2021,Age,13-17 Years,95.1,91.4 to 97.2,315
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2021,Age,13-17 Years,96.2,92.6 to 98.1,287
Varicella,≥1 Dose with no disease history,States/Local Areas,Tennessee,2022,Age,13-17 Years,94.4,89.1 to 97.2,233
HPV,"≥2 Doses, Males and Females",States/Local Areas,Tennessee,2016,Age,13-17 Years,39.8,33.4 to 46.5,291
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2012,Age,13-17 Years,20.3,12.9 to 30.5,183
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2013,Age,13-17 Years,28.9,21.4 to 37.7,162
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2014,Age,13-17 Years,30.5,22.7 to 39.5,185
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2015,Age,13-17 Years,38.2,29.7 to 47.4,159
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2016,Age,13-17 Years,55.3,46.1 to 64.3,155
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2019,Age,13-17 Years,54.3,44.0 to 64.2,135
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2020,Age,13-17 Years,73.9,65.4 to 80.8,168
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2021,Age,13-17 Years,69.3,59.8 to 77.4,174
HPV,"≥2 Doses, Males and Females",States/Local Areas,Tennessee,2018,Age,13-17 Years,48.9,41.8 to 56.0,284
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2019,Age,13-17 Years,69.9,59.5 to 78.6,126
HPV,"≥2 Doses, Males and Females",States/Local Areas,Tennessee,2017,Age,13-17 Years,44.2,37.6 to 51.1,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Tennessee,2022,Age,13-17 Years,92.3,87.0 to 95.6,233
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2020,Age,13-17 Years,69.4,60.6 to 77.1,170
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2021,Age,13-17 Years,81.6,72.9 to 87.9,141
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2022,Age,13-17 Years,74.4,63.3 to 83.0,106
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2017,Age,13-17 Years,49.6,40.2 to 59.2,170
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2018,Age,13-17 Years,63.7,54.2 to 72.2,147
HPV,"≥2 Doses, Males and Females",States/Local Areas,Tennessee,2019,Age,13-17 Years,46.0,38.8 to 53.4,261
≥3 Doses HepB,,States/Local Areas,Tennessee,2012,Age,13-17 Years,96.2,93.2 to 97.9,331
≥3 Doses HepB,,States/Local Areas,Tennessee,2011,Age,13-17 Years,92.1,86.3 to 95.6,424
≥3 Doses HepB,,States/Local Areas,Tennessee,2013,Age,13-17 Years,93.5,88.7 to 96.4,304
≥3 Doses HepB,,States/Local Areas,Tennessee,2014,Age,13-17 Years,93.3,89.6 to 95.8,339
HPV,"≥1 Dose, Males",States/Local Areas,Tennessee,2022,Age,13-17 Years,73.9,63.5 to 82.1,138
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2008,Age,13-17 Years,25.7,17.9 to 35.5,172
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2009,Age,13-15 Years,54.5,46.4 to 62.4,232
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2008,Age,13-15 Years,41.9,34.0 to 50.2,210
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2010,Age,13-17 Years,29.5,22.5 to 37.7,149
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2011,Age,13-17 Years,39.5,30.5 to 49.2,205
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2009,Age,13-17 Years,34.5,27.0 to 42.9,180
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2020,Age,13-15 Years,82.6,75.0 to 88.2,205
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2012,Age,13-17 Years,40.9,30.8 to 52.0,148
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2013,Age,13-17 Years,39.8,30.9 to 49.4,142
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2017,Age,13-15 Years,71.3,62.3 to 79.0,206
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018,Age,13-15 Years,81.9,74.1 to 87.8,188
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2019,Age,13-15 Years,85.8,78.0 to 91.2,163
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2015,Age,13-15 Years,77.3,69.6 to 83.4,198
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2014,Age,13-15 Years,73.1,64.8 to 80.1,207
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2016,Age,13-17 Years,90.6,85.6 to 94.0,291
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2014,Age,13-17 Years,88.3,83.4 to 91.9,339
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2015,Age,13-17 Years,85.9,80.4 to 90.0,325
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2016,Age,13-15 Years,78.7,70.3 to 85.1,166
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2017,Age,13-17 Years,62.8,53.4 to 71.3,168
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2016,Age,13-17 Years,55.3,45.4 to 64.7,136
HPV,"≥1 Dose, Females",States/Local Areas,Tennessee,2015,Age,13-17 Years,59.7,50.8 to 68.1,166
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2017,Age,13-17 Years,91.0,86.5 to 94.2,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2017,Age,13-17 Years,56.1,49.3 to 62.6,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2016,Age,13-17 Years,55.3,48.5 to 61.9,291
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2008,Age,13-17 Years,50.3,44.0 to 56.6,360
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2009,Age,13-17 Years,63.3,57.3 to 68.9,397
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2012,Age,13-17 Years,79.7,73.1 to 85.1,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2010,Age,13-17 Years,66.6,60.3 to 72.4,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2011,Age,13-17 Years,75.8,69.7 to 81.0,424
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2018,Age,13-17 Years,92.1,87.9 to 95.0,284
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2019,Age,13-17 Years,91.0,85.5 to 94.6,261
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2020,Age,13-17 Years,90.1,85.4 to 93.4,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2019,Age,13-17 Years,61.9,54.6 to 68.8,261
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2018,Age,13-17 Years,62.3,55.4 to 68.8,284
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2021,Age,13-17 Years,94.0,89.8 to 96.5,315
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2020,Age,13-17 Years,71.7,65.7 to 77.0,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2021,Age,13-17 Years,75.3,68.9 to 80.8,315
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2017,Age,13-17 Years,51.3,41.8 to 60.6,168
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2016,Age,13-17 Years,39.6,30.6 to 49.2,136
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2015,Age,13-17 Years,46.7,37.9 to 55.7,166
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2014,Age,13-17 Years,39.4,30.4 to 49.3,154
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2021,Age,13-15 Years,87.4,80.6 to 92.1,188
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2018,Age,13-17 Years,51.8,41.6 to 61.9,137
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2019,Age,13-17 Years,52.7,42.3 to 62.9,126
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2012,Age,13-15 Years,86.6,79.0 to 91.7,198
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2011,Age,13-15 Years,70.5,61.7 to 78.0,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2009,Age,13-15 Years,56.1,48.0 to 63.9,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2010,Age,13-15 Years,62.8,54.6 to 70.4,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2008,Age,13-15 Years,41.2,33.4 to 49.5,210
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Tennessee,2022,Age,13-17 Years,92.2,87.0 to 95.4,244
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2017,Age,13-15 Years,86.0,78.8 to 91.1,206
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2016,Age,13-15 Years,90.2,83.1 to 94.5,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2015,Age,13-15 Years,81.9,74.9 to 87.3,198
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2014,Age,13-15 Years,87.5,80.7 to 92.1,207
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2018,Age,13-17 Years,46.1,36.5 to 56.0,147
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2017,Age,13-17 Years,37.5,28.8 to 47.1,170
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2016,Age,13-17 Years,40.0,31.1 to 49.6,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2013,Age,13-15 Years,83.6,76.3 to 89.0,182
HPV,"≥1 Dose, Males and Females",States/Local Areas,Tennessee,2022,Age,13-17 Years,74.1,66.7 to 80.3,244
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2013,Age,13-17 Years,18.0,11.9 to 26.3,162
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2014,Age,13-17 Years,19.4,13.2 to 27.7,185
HPV,"≥2 Doses, Males",States/Local Areas,Tennessee,2015,Age,13-17 Years,26.0,18.7 to 34.8,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2019,Age,13-15 Years,91.5,83.9 to 95.6,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2020,Age,13-15 Years,85.4,78.4 to 90.5,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2021,Age,13-15 Years,92.2,86.2 to 95.8,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018,Age,13-15 Years,90.8,84.6 to 94.7,188
HPV,"≥2 Doses, Females",States/Local Areas,Tennessee,2022,Age,13-17 Years,65.9,54.4 to 75.9,106
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2022,Age,13-15 Years,81.3,71.9 to 88.1,160
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2010,Age,13-17 Years,50.6,44.4 to 56.8,320
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2011,Age,13-17 Years,63.3,56.7 to 69.5,424
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2008,Age,13-17 Years,36.5,30.7 to 42.8,360
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2009,Age,13-17 Years,52.1,46.1 to 58.1,397
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2016,Age,13-17 Years,89.3,84.1 to 92.9,291
≥2 Doses MMR,,States/Local Areas,Tennessee,2016,Age,13-17 Years,91.1,85.5 to 94.7,291
HPV,"≥3 Doses, Males and Females",States/Local Areas,Tennessee,2011,Age,13-17 Years,13.5,9.7 to 18.7,424
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2013,Age,13-17 Years,67.8,61.4 to 73.6,304
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2014,Age,13-17 Years,74.0,67.7 to 79.4,339
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2015,Age,13-17 Years,76.7,70.6 to 81.8,325
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2016,Age,13-17 Years,76.3,70.0 to 81.7,291
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2018,Age,13-17 Years,90.7,86.2 to 93.8,284
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2017,Age,13-17 Years,89.4,84.8 to 92.8,338
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2012,Age,13-17 Years,69.4,62.3 to 75.7,331
≥2 Doses MMR,,States/Local Areas,Tennessee,2014,Age,13-17 Years,93.9,90.3 to 96.2,339
≥2 Doses MMR,,States/Local Areas,Tennessee,2015,Age,13-17 Years,91.1,86.3 to 94.3,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2022,Age,13-17 Years,90.6,84.6 to 94.4,244
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2019,Age,13-17 Years,89.1,83.5 to 93.0,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2020,Age,13-17 Years,88.8,84.0 to 92.3,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Tennessee,2021,Age,13-17 Years,92.0,87.3 to 95.0,315
≥2 Doses MMR,,States/Local Areas,Tennessee,2012,Age,13-17 Years,90.0,83.8 to 94.0,331
≥2 Doses MMR,,States/Local Areas,Tennessee,2013,Age,13-17 Years,88.4,82.9 to 92.2,304
≥2 Doses MMR,,States/Local Areas,Tennessee,2018,Age,13-17 Years,93.6,89.1 to 96.3,284
≥2 Doses MMR,,States/Local Areas,Tennessee,2017,Age,13-17 Years,91.3,86.8 to 94.4,338
≥2 Doses MMR,,States/Local Areas,Tennessee,2019,Age,13-17 Years,93.0,88.2 to 95.9,261
HPV,"≥3 Doses, Males and Females",States/Local Areas,Tennessee,2012,Age,13-17 Years,16.2,11.7 to 22.1,331
HPV,"≥3 Doses, Males and Females",States/Local Areas,Tennessee,2013,Age,13-17 Years,22.4,17.3 to 28.5,304
≥2 Doses MMR,,States/Local Areas,Tennessee,2020,Age,13-17 Years,94.6,90.7 to 96.9,338
HPV,"≥3 Doses, Males and Females",States/Local Areas,Tennessee,2015,Age,13-17 Years,27.2,21.8 to 33.3,325
HPV,"≥3 Doses, Males and Females",States/Local Areas,Tennessee,2014,Age,13-17 Years,17.0,12.8 to 22.1,339
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2012,Age,13-15 Years,26.4,15.2 to 41.7,82
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2013,Age,13-15 Years,26.1,17.0 to 37.8,82
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2015,Age,13-15 Years,35.4,25.3 to 47.0,100
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2014,Age,13-15 Years,19.2,12.2 to 28.8,97
≥2 Doses MMR,,States/Local Areas,Tennessee,2021,Age,13-17 Years,95.1,91.3 to 97.2,315
≥2 Doses MMR,,States/Local Areas,Tennessee,2022,Age,13-17 Years,93.3,88.3 to 96.3,244
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2011,Age,13-15 Years,24.4,15.4 to 36.4,125
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2010,Age,13-15 Years,20.6,13.5 to 30.2,87
HPV,"≥3 Doses, Females",States/Local Areas,Tennessee,2009,Age,13-15 Years,23.6,15.7 to 33.9,105
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2022,Age,13-17 Years,82.9,76.2 to 88.0,244
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2021,Age,13-17 Years,88.1,82.9 to 91.9,315
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2018,Age,13-17 Years,85.2,79.7 to 89.4,284
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2019,Age,13-17 Years,79.3,72.8 to 84.6,261
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2020,Age,13-17 Years,83.2,77.7 to 87.5,338
≥1 Dose MenACWY,,States/Local Areas,Tennessee,2017,Age,13-17 Years,75.0,68.5 to 80.6,338
HPV,"≥1 Dose, Males",States/Local Areas,California,2023,Age,13-17 Years,70.4,58.5 to 80.0,128
HPV,"Up-to-Date, Females",States/Local Areas,California,2023,Age,13-17 Years,64.7,53.8 to 74.2,138
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2023,Age,13-15 Years,89.9,81.5 to 94.7,150
HPV,"Up-to-Date, Females",States/Local Areas,California,2023,Age,13-15 Years,66.1,51.9 to 77.9,83
HPV,"≥1 Dose, Females",States/Local Areas,California,2023,Age,13-17 Years,79.5,70.0 to 86.5,138
HPV,"Up-to-Date, Males",States/Local Areas,California,2023,Age,13-15 Years,47.0,33.3 to 61.2,83
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2023,Age,13-15 Years,56.1,45.7 to 66.0,166
≥1 Dose MenACWY,,States/Local Areas,California,2023,Age,13-15 Years,81.8,73.1 to 88.1,166
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2023,Age,13-15 Years,87.7,80.0 to 92.8,166
≥2 Doses Hep A,,States/Local Areas,California,2023,Age,13-17 Years,81.5,73.9 to 87.2,266
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2023,Age,13-17 Years,88.0,81.8 to 92.3,266
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2023,Age,13-17 Years,93.6,88.1 to 96.6,242
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2023,Age,13-17 Years,87.0,80.4 to 91.6,242
≥3 Doses HepB,,States/Local Areas,California,2023,Age,13-17 Years,86.4,79.1 to 91.4,266
≥2 Doses MMR,,States/Local Areas,California,2023,Age,13-17 Years,85.1,77.7 to 90.3,266
HPV,"Up-to-Date, Males",States/Local Areas,California,2023,Age,13-17 Years,50.8,39.3 to 62.3,128
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2023,Age,13-17 Years,57.6,49.4 to 65.4,266
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2023,Age,13-17 Years,74.8,67.2 to 81.1,266
≥1 Dose MenACWY,,States/Local Areas,California,2023,Age,13-17 Years,85.0,78.7 to 89.6,266
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2023,Age,13-17 Years,86.3,80.2 to 90.7,266
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2023,Age,13-17 Years,88.3,82.5 to 92.4,266
HPV,"≥2 Doses, Females",States/Local Areas,California,2022,Age,13-17 Years,60.8,50.1 to 70.6,140
HPV,"≥2 Doses, Males",States/Local Areas,California,2022,Age,13-17 Years,62.3,52.5 to 71.2,181
HPV,"≥2 Doses, Males and Females",States/Local Areas,California,2022,Age,13-17 Years,61.6,54.4 to 68.3,321
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Insurance Coverage,Other,86.5,66.8 to 95.3,132
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Insurance Coverage,Any Medicaid,86.8,82.2 to 90.3,528
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Insurance Coverage,Private Insurance Only,88.3,85.1 to 90.9,951
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Insurance Coverage,Other,53.3,36.9 to 69.1,132
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Insurance Coverage,Any Medicaid,62.5,56.9 to 67.8,528
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Insurance Coverage,Private Insurance Only,59.5,54.8 to 63.9,951
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Insurance Coverage,Other,77.7,59.8 to 89.1,132
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Insurance Coverage,Any Medicaid,80.3,75.5 to 84.4,528
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Insurance Coverage,Private Insurance Only,74.4,70.1 to 78.3,951
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Insurance Coverage,Other,84.0,64.3 to 93.8,132
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Insurance Coverage,Any Medicaid,87.0,82.7 to 90.3,528
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Insurance Coverage,Private Insurance Only,85.7,82.1 to 88.7,951
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Poverty,Below Poverty Level,83.2,76.6 to 88.2,251
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Poverty,Living At or Above Poverty Level,86.9,83.9 to 89.5,1338
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Poverty,Below Poverty Level,89.5,83.4 to 93.6,251
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Poverty,Living At or Above Poverty Level,59.2,55.3 to 63.1,1338
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Poverty,Below Poverty Level,65.3,57.5 to 72.4,251
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Poverty,Below Poverty Level,88.2,82.3 to 92.4,251
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Poverty,Living At or Above Poverty Level,84.6,81.4 to 87.3,1338
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Poverty,Living At or Above Poverty Level,75.6,72.0 to 78.8,1338
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,"White, Non-Hispanic",51.9,45.9 to 57.8,631
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,Hispanic,78.6,74.0 to 82.6,604
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.8,68.8 to 93.4,72
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,"White, Non-Hispanic",71.6,66.0 to 76.7,631
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.0,80.1 to 90.3,333
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Race and Ethnicity,Hispanic,87.1,83.0 to 90.4,604
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",88.0,71.4 to 95.6,72
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Race and Ethnicity,Hispanic,84.7,80.3 to 88.2,604
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",95.3,88.2 to 98.2,72
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Race and Ethnicity,"White, Non-Hispanic",84.8,80.0 to 88.5,631
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.1,84.7 to 92.3,631
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",65.8,58.1 to 72.8,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",72.5,55.2 to 85.0,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,Hispanic,61.0,55.8 to 66.0,604
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",76.5,69.0 to 82.6,333
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.2,81.5 to 91.3,333
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Urbanicity,Living In a Non-MSA,97.3,85.9 to 99.5,33
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Non-Principal City,86.8,82.8 to 90.0,801
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Principal City,87.8,84.1 to 90.7,806
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Urbanicity,Living In a Non-MSA,67.2,40.8 to 85.9,33
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Non-Principal City,60.9,55.8 to 65.6,801
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Principal City,59.3,54.4 to 64.1,806
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Urbanicity,Living In a Non-MSA,83.4,55.9 to 95.2,33
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Non-Principal City,85.9,81.9 to 89.1,801
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Principal City,85.6,81.7 to 88.7,806
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Urbanicity,Living In a Non-MSA,83.6,56.2 to 95.3,33
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Non-Principal City,77.1,72.5 to 81.1,801
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Urbanicity,Living In a MSA Principal City,76.4,72.0 to 80.2,806
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018-2022,Overall,Overall,87.5,84.9 to 89.7,1640
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018-2022,Overall,Overall,76.8,73.7 to 79.6,1640
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018-2022,Overall,Overall,60.2,56.7 to 63.6,1640
HPV,"≥3 Doses, Females",States/Local Areas,California,2013,Age,13-15 Years,49.2,35.9 to 62.5,85
HPV,"≥3 Doses, Females",States/Local Areas,California,2014,Age,13-15 Years,43.2,30.9 to 56.4,97
HPV,"≥3 Doses, Females",States/Local Areas,California,2015,Age,13-15 Years,41.5,29.1 to 55.2,93
≥1 Dose MenACWY,,States/Local Areas,California,2018-2022,Overall,Overall,85.7,83.0 to 88.0,1640
≥1 Dose MenACWY,,States/Local Areas,California,2013,Age,13-15 Years,82.8,75.4 to 88.3,195
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2017,Age,13-17 Years,85.5,79.4 to 90.0,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2016,Age,13-17 Years,85.1,79.2 to 89.5,327
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2014,Age,13-17 Years,90.3,85.3 to 93.7,356
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2015,Age,13-17 Years,88.3,82.9 to 92.2,350
HPV,"≥1 Dose, Males",States/Local Areas,California,2019,Age,13-17 Years,77.8,65.6 to 86.5,148
HPV,"≥1 Dose, Males",States/Local Areas,California,2018,Age,13-17 Years,78.4,69.2 to 85.5,177
≥1 Dose MenACWY,,States/Local Areas,California,2017,Age,13-15 Years,84.1,76.7 to 89.5,194
HPV,"≥1 Dose, Males",States/Local Areas,California,2016,Age,13-17 Years,67.3,58.4 to 75.2,184
HPV,"≥1 Dose, Males",States/Local Areas,California,2015,Age,13-17 Years,58.5,48.5 to 67.9,176
HPV,"≥1 Dose, Males",States/Local Areas,California,2013,Age,13-17 Years,50.9,41.3 to 60.4,161
HPV,"≥1 Dose, Males",States/Local Areas,California,2014,Age,13-17 Years,52.1,42.8 to 61.3,190
HPV,"≥1 Dose, Males",States/Local Areas,California,2017,Age,13-17 Years,68.2,59.3 to 76.0,171
HPV,"≥2 Doses, Males and Females",States/Local Areas,California,2018,Age,13-17 Years,59.6,52.3 to 66.4,356
HPV,"≥2 Doses, Males and Females",States/Local Areas,California,2019,Age,13-17 Years,62.5,53.5 to 70.8,274
HPV,"≥1 Dose, Females",States/Local Areas,California,2020,Age,13-17 Years,83.2,73.8 to 89.8,184
HPV,"≥1 Dose, Females",States/Local Areas,California,2021,Age,13-17 Years,80.5,68.9 to 88.5,146
HPV,"≥1 Dose, Females",States/Local Areas,California,2022,Age,13-17 Years,70.1,59.4 to 79.0,140
HPV,"≥1 Dose, Males",States/Local Areas,California,2011,Age,13-17 Years,13.0,8.7 to 19.1,313
HPV,"≥1 Dose, Males",States/Local Areas,California,2012,Age,13-17 Years,29.4,22.5 to 37.3,228
HPV,"≥2 Doses, Males and Females",States/Local Areas,California,2017,Age,13-17 Years,60.1,53.0 to 66.8,306
HPV,"≥2 Doses, Males and Females",States/Local Areas,California,2016,Age,13-17 Years,57.5,50.5 to 64.1,327
≥3 Doses HepB,,States/Local Areas,California,2020,Age,13-17 Years,89.3,84.1 to 92.9,403
≥3 Doses HepB,,States/Local Areas,California,2021,Age,13-17 Years,90.5,83.7 to 94.6,286
≥3 Doses HepB,,States/Local Areas,California,2022,Age,13-17 Years,86.0,79.8 to 90.5,321
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2022,Age,13-17 Years,89.9,84.7 to 93.4,303
HPV,"≥1 Dose, Females",States/Local Areas,California,2019,Age,13-17 Years,79.7,67.9 to 88.0,126
≥3 Doses HepB,,States/Local Areas,California,2011,Age,13-17 Years,89.9,85.9 to 92.8,583
HPV,"≥1 Dose, Females",States/Local Areas,California,2009,Age,13-17 Years,49.2,39.9 to 58.6,190
≥3 Doses HepB,,States/Local Areas,California,2013,Age,13-17 Years,92.6,87.4 to 95.8,309
≥3 Doses HepB,,States/Local Areas,California,2014,Age,13-17 Years,92.6,88.4 to 95.4,356
HPV,"≥1 Dose, Females",States/Local Areas,California,2010,Age,13-17 Years,56.1,46.9 to 64.9,163
HPV,"≥1 Dose, Females",States/Local Areas,California,2017,Age,13-17 Years,75.6,65.9 to 83.3,135
HPV,"≥1 Dose, Females",States/Local Areas,California,2016,Age,13-17 Years,78.0,68.5 to 85.3,143
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2021,Age,13-17 Years,93.2,86.0 to 96.8,267
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2022,Age,13-17 Years,84.9,78.6 to 89.6,303
HPV,"≥1 Dose, Females",States/Local Areas,California,2018,Age,13-17 Years,68.4,58.1 to 77.1,179
≥3 Doses HepB,,States/Local Areas,California,2008,Age,13-17 Years,89.9,83.8 to 93.8,316
≥3 Doses HepB,,States/Local Areas,California,2009,Age,13-17 Years,89.6,85.5 to 92.7,379
≥3 Doses HepB,,States/Local Areas,California,2010,Age,13-17 Years,89.0,83.5 to 92.8,330
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2022,Age,13-15 Years,83.7,74.0 to 90.3,174
≥3 Doses HepB,,States/Local Areas,California,2012,Age,13-17 Years,92.4,88.1 to 95.2,430
HPV,"≥1 Dose, Females",States/Local Areas,California,2008,Age,13-17 Years,46.6,36.1 to 57.5,150
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2010,Age,13-17 Years,57.3,48.7 to 65.4,197
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2011,Age,13-17 Years,66.5,60.4 to 72.1,410
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2008,Age,13-17 Years,92.9,87.4 to 96.1,143
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2009,Age,13-17 Years,88.0,81.6 to 92.4,214
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2010,Age,13-17 Years,90.8,84.1 to 94.8,197
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2012,Age,13-17 Years,75.3,68.7 to 81.0,324
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2013,Age,13-17 Years,79.0,71.8 to 84.7,242
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2020,Age,13-17 Years,92.7,87.7 to 95.8,370
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2019,Age,13-17 Years,85.8,77.3 to 91.5,254
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2020,Age,13-17 Years,85.8,79.6 to 90.3,370
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2021,Age,13-17 Years,88.3,80.6 to 93.2,267
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2012,Age,13-17 Years,94.5,89.6 to 97.2,324
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2011,Age,13-17 Years,86.1,80.5 to 90.3,410
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2008,Age,13-17 Years,46.0,35.0 to 57.4,143
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2009,Age,13-17 Years,56.9,48.2 to 65.2,214
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2019,Age,13-17 Years,94.0,86.6 to 97.4,254
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2019,Age,13-17 Years,87.8,80.3 to 92.7,274
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2020,Age,13-17 Years,90.2,84.8 to 93.9,403
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2019,Age,13-17 Years,78.7,70.6 to 85.1,274
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2021,Age,13-17 Years,90.9,84.7 to 94.7,286
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2022,Age,13-17 Years,88.1,82.5 to 92.1,321
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2020,Age,13-17 Years,78.2,71.8 to 83.4,403
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2021,Age,13-17 Years,81.7,73.7 to 87.7,286
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2022,Age,13-17 Years,72.2,65.2 to 78.2,321
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2009,Age,13-17 Years,76.7,71.0 to 81.5,379
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2008,Age,13-17 Years,71.3,64.1 to 77.5,316
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2012,Age,13-17 Years,92.7,88.5 to 95.5,430
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2013,Age,13-17 Years,91.4,85.9 to 94.9,309
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2010,Age,13-17 Years,81.2,75.7 to 85.6,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2011,Age,13-17 Years,87.0,83.1 to 90.1,583
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2017,Age,13-17 Years,71.9,65.4 to 77.5,306
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2016,Age,13-17 Years,72.6,66.1 to 78.2,327
HPV,"≥1 Dose, Males and Females",States/Local Areas,California,2018,Age,13-17 Years,73.5,66.7 to 79.4,356
≥1 Dose MenACWY,,States/Local Areas,California,2014,Age,13-15 Years,78.1,69.7 to 84.6,219
≥1 Dose MenACWY,,States/Local Areas,California,2015,Age,13-15 Years,78.0,69.6 to 84.5,215
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,California,2018,Age,13-17 Years,91.9,86.7 to 95.2,356
HPV,"≥2 Doses, Females",States/Local Areas,California,2008,Age,13-17 Years,36.8,26.8 to 48.0,150
≥1 Dose MenACWY,,States/Local Areas,California,2016,Age,13-15 Years,78.1,69.7 to 84.8,203
HPV,"≥1 Dose, Males",States/Local Areas,California,2020,Age,13-17 Years,73.3,64.2 to 80.8,219
HPV,"≥1 Dose, Males",States/Local Areas,California,2021,Age,13-17 Years,82.8,70.7 to 90.6,140
≥1 Dose MenACWY,,States/Local Areas,California,2012,Age,13-15 Years,74.9,67.6 to 81.1,271
≥1 Dose MenACWY,,States/Local Areas,California,2010,Age,13-15 Years,69.4,61.7 to 76.1,201
≥1 Dose MenACWY,,States/Local Areas,California,2011,Age,13-15 Years,76.1,70.0 to 81.4,356
≥1 Dose MenACWY,,States/Local Areas,California,2020,Age,13-15 Years,84.7,76.7 to 90.3,272
HPV,"≥2 Doses, Females",States/Local Areas,California,2009,Age,13-17 Years,37.1,28.9 to 46.3,190
HPV,"≥2 Doses, Females",States/Local Areas,California,2010,Age,13-17 Years,43.4,34.8 to 52.4,163
HPV,"≥2 Doses, Females",States/Local Areas,California,2011,Age,13-17 Years,54.2,46.8 to 61.3,270
HPV,"≥2 Doses, Females",States/Local Areas,California,2012,Age,13-17 Years,48.4,39.7 to 57.2,202
HPV,"≥2 Doses, Females",States/Local Areas,California,2013,Age,13-17 Years,57.3,47.2 to 66.9,148
≥1 Dose MenACWY,,States/Local Areas,California,2018,Age,13-15 Years,84.2,75.9 to 90.0,226
≥1 Dose MenACWY,,States/Local Areas,California,2019,Age,13-15 Years,93.8,88.7 to 96.7,170
HPV,"≥1 Dose, Males",States/Local Areas,California,2022,Age,13-17 Years,74.1,64.9 to 81.5,181
≥1 Dose MenACWY,,States/Local Areas,California,2008,Age,13-15 Years,50.4,40.8 to 60.0,190
≥1 Dose MenACWY,,States/Local Areas,California,2009,Age,13-15 Years,61.9,54.0 to 69.2,238
HPV,"≥2 Doses, Females",States/Local Areas,California,2014,Age,13-17 Years,61.5,51.3 to 70.7,166
HPV,"≥2 Doses, Females",States/Local Areas,California,2017,Age,13-17 Years,66.7,56.1 to 75.8,135
HPV,"≥2 Doses, Females",States/Local Areas,California,2016,Age,13-17 Years,66.6,56.0 to 75.7,143
≥1 Dose MenACWY,,States/Local Areas,California,2022,Age,13-15 Years,80.5,71.3 to 87.2,188
≥1 Dose MenACWY,,States/Local Areas,California,2021,Age,13-15 Years,88.2,77.7 to 94.1,182
HPV,"≥2 Doses, Females",States/Local Areas,California,2015,Age,13-17 Years,59.7,49.6 to 69.1,174
HPV,"≥2 Doses, Females",States/Local Areas,California,2018,Age,13-17 Years,56.0,45.9 to 65.7,179
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2008,Age,13-15 Years,48.7,39.2 to 58.3,190
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2009,Age,13-15 Years,64.8,57.1 to 71.8,238
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2010,Age,13-15 Years,76.7,69.3 to 82.7,201
HPV,"≥2 Doses, Females",States/Local Areas,California,2019,Age,13-17 Years,70.9,58.3 to 80.9,126
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2012,Age,13-15 Years,87.1,80.5 to 91.6,271
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2011,Age,13-15 Years,81.2,75.3 to 86.0,356
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2017,Age,13-15 Years,85.9,78.5 to 91.1,194
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2016,Age,13-15 Years,82.8,74.6 to 88.8,203
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2014,Age,13-15 Years,88.1,81.2 to 92.7,219
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2015,Age,13-15 Years,86.6,79.2 to 91.6,215
HPV,"≥2 Doses, Males",States/Local Areas,California,2012,Age,13-17 Years,19.3,13.7 to 26.5,228
HPV,"≥2 Doses, Males",States/Local Areas,California,2014,Age,13-17 Years,41.2,32.3 to 50.6,190
HPV,"≥2 Doses, Males",States/Local Areas,California,2013,Age,13-17 Years,33.2,24.3 to 43.5,161
HPV,"≥2 Doses, Males",States/Local Areas,California,2015,Age,13-17 Years,41.8,32.6 to 51.7,176
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2013,Age,13-15 Years,93.7,87.6 to 96.9,195
HPV,"≥2 Doses, Males",States/Local Areas,California,2017,Age,13-17 Years,53.7,44.3 to 62.8,171
HPV,"≥2 Doses, Males",States/Local Areas,California,2016,Age,13-17 Years,48.7,39.7 to 57.8,184
HPV,"≥2 Doses, Males",States/Local Areas,California,2018,Age,13-17 Years,62.9,52.7 to 72.2,177
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018,Age,13-15 Years,88.5,80.4 to 93.5,226
HPV,"≥3 Doses, Females",States/Local Areas,California,2008,Age,13-15 Years,16.6,9.6 to 27.0,93
HPV,"≥3 Doses, Females",States/Local Areas,California,2010,Age,13-15 Years,29.0,20.2 to 39.6,102
HPV,"≥3 Doses, Females",States/Local Areas,California,2009,Age,13-15 Years,15.4,9.9 to 23.1,120
HPV,"≥3 Doses, Females",States/Local Areas,California,2012,Age,13-15 Years,27.5,19.1 to 37.8,125
HPV,"≥3 Doses, Females",States/Local Areas,California,2011,Age,13-15 Years,37.8,29.0 to 47.4,173
≥1 Dose MenACWY,,States/Local Areas,California,2018,Age,13-17 Years,85.6,79.7 to 90.0,356
≥1 Dose MenACWY,,States/Local Areas,California,2019,Age,13-17 Years,89.4,83.0 to 93.6,274
≥1 Dose MenACWY,,States/Local Areas,California,2020,Age,13-17 Years,85.0,78.9 to 89.5,403
≥1 Dose MenACWY,,States/Local Areas,California,2021,Age,13-17 Years,87.0,79.5 to 92.1,286
≥1 Dose MenACWY,,States/Local Areas,California,2022,Age,13-17 Years,81.5,75.0 to 86.6,321
≥2 Doses MMR,,States/Local Areas,California,2021,Age,13-17 Years,89.3,81.9 to 93.9,286
≥2 Doses MMR,,States/Local Areas,California,2022,Age,13-17 Years,85.4,79.3 to 89.9,321
≥2 Doses MMR,,States/Local Areas,California,2020,Age,13-17 Years,86.6,80.9 to 90.7,403
HPV,"≥3 Doses, Males and Females",States/Local Areas,California,2013,Age,13-17 Years,30.8,24.6 to 37.9,309
HPV,"≥3 Doses, Males and Females",States/Local Areas,California,2014,Age,13-17 Years,39.2,32.8 to 46.0,356
HPV,"≥3 Doses, Males and Females",States/Local Areas,California,2015,Age,13-17 Years,38.7,32.2 to 45.7,350
≥2 Doses MMR,,States/Local Areas,California,2018,Age,13-17 Years,91.1,86.7 to 94.2,356
≥2 Doses MMR,,States/Local Areas,California,2019,Age,13-17 Years,87.4,79.4 to 92.5,274
≥1 Dose MenACWY,,States/Local Areas,California,2017,Age,13-17 Years,82.2,75.9 to 87.1,306
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2020,Age,13-17 Years,89.6,84.2 to 93.3,403
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2021,Age,13-17 Years,89.1,82.6 to 93.3,286
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2022,Age,13-17 Years,82.7,76.0 to 87.9,321
HPV,"≥3 Doses, Males and Females",States/Local Areas,California,2011,Age,13-17 Years,21.6,17.7 to 26.2,583
HPV,"≥3 Doses, Males and Females",States/Local Areas,California,2012,Age,13-17 Years,23.5,18.8 to 28.9,430
≥2 Doses MMR,,States/Local Areas,California,2013,Age,13-17 Years,91.5,86.2 to 94.9,309
≥1 Dose MenACWY,,States/Local Areas,California,2016,Age,13-17 Years,79.7,73.5 to 84.8,327
≥1 Dose MenACWY,,States/Local Areas,California,2015,Age,13-17 Years,77.2,70.8 to 82.5,350
≥1 Dose MenACWY,,States/Local Areas,California,2013,Age,13-17 Years,80.9,74.6 to 85.9,309
≥1 Dose MenACWY,,States/Local Areas,California,2014,Age,13-17 Years,79.3,73.0 to 84.5,356
≥2 Doses MMR,,States/Local Areas,California,2017,Age,13-17 Years,89.8,84.1 to 93.5,306
≥2 Doses MMR,,States/Local Areas,California,2016,Age,13-17 Years,88.7,83.7 to 92.3,327
≥2 Doses MMR,,States/Local Areas,California,2014,Age,13-17 Years,91.4,87.3 to 94.3,356
≥2 Doses MMR,,States/Local Areas,California,2015,Age,13-17 Years,87.6,82.2 to 91.6,350
≥1 Dose MenACWY,,States/Local Areas,California,2012,Age,13-17 Years,76.0,70.0 to 81.0,430
≥1 Dose MenACWY,,States/Local Areas,California,2008,Age,13-17 Years,48.0,40.6 to 55.5,316
≥1 Dose MenACWY,,States/Local Areas,California,2009,Age,13-17 Years,58.4,52.0 to 64.6,379
≥1 Dose MenACWY,,States/Local Areas,California,2010,Age,13-17 Years,66.7,60.5 to 72.3,330
≥1 Dose MenACWY,,States/Local Areas,California,2011,Age,13-17 Years,75.4,70.7 to 79.5,583
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2019,Age,13-15 Years,91.5,83.4 to 95.8,170
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2020,Age,13-15 Years,88.9,82.0 to 93.4,272
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2021,Age,13-15 Years,92.2,85.1 to 96.1,182
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2018,Age,13-17 Years,89.7,84.2 to 93.4,356
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2017,Age,13-17 Years,83.5,77.2 to 88.3,306
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2019,Age,13-17 Years,86.3,78.9 to 91.5,274
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2016,Age,13-17 Years,82.1,75.9 to 86.9,327
≥1 Dose MenACWY,,States/Local Areas,Alaska,2012,Age,13-17 Years,52.7,46.5 to 58.9,340
≥1 Dose MenACWY,,States/Local Areas,Alaska,2011,Age,13-17 Years,46.1,39.1 to 53.3,330
≥1 Dose MenACWY,,States/Local Areas,Alaska,2010,Age,13-17 Years,40.9,34.7 to 47.4,294
≥1 Dose MenACWY,,States/Local Areas,Alaska,2009,Age,13-17 Years,40.2,33.8 to 46.9,274
≥1 Dose MenACWY,,States/Local Areas,Alaska,2008,Age,13-17 Years,30.5,25.1 to 36.5,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2019,Age,13-17 Years,81.7,76.6 to 85.9,426
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2017,Age,13-17 Years,78.9,73.2 to 83.6,349
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018,Age,13-17 Years,79.6,74.3 to 84.0,392
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2016,Age,13-17 Years,79.4,74.1 to 83.9,392
≥2 Doses MMR,,States/Local Areas,Alaska,2017,Age,13-17 Years,91.4,87.7 to 94.1,349
≥2 Doses MMR,,States/Local Areas,Alaska,2016,Age,13-17 Years,91.6,87.5 to 94.4,392
≥2 Doses MMR,,States/Local Areas,Alaska,2015,Age,13-17 Years,88.4,83.9 to 91.8,350
≥2 Doses MMR,,States/Local Areas,Alaska,2014,Age,13-17 Years,89.0,84.5 to 92.3,377
≥2 Doses MMR,,States/Local Areas,Alaska,2013,Age,13-17 Years,92.0,87.4 to 95.0,320
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alaska,2012,Age,13-17 Years,17.0,12.8 to 22.4,340
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alaska,2011,Age,13-17 Years,20.3,15.1 to 26.6,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2022,Age,13-17 Years,83.0,76.0 to 88.2,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2021,Age,13-17 Years,81.7,75.3 to 86.8,268
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2020,Age,13-17 Years,85.8,80.2 to 90.0,302
≥1 Dose MenACWY,,States/Local Areas,Alaska,2017,Age,13-17 Years,68.4,62.5 to 73.8,349
≥1 Dose MenACWY,,States/Local Areas,Alaska,2016,Age,13-17 Years,67.0,61.1 to 72.4,392
≥1 Dose MenACWY,,States/Local Areas,Alaska,2015,Age,13-17 Years,55.7,49.5 to 61.8,350
≥1 Dose MenACWY,,States/Local Areas,Alaska,2014,Age,13-17 Years,56.9,50.7 to 62.9,377
≥1 Dose MenACWY,,States/Local Areas,Alaska,2013,Age,13-17 Years,55.2,48.7 to 61.6,320
≥2 Doses MMR,,States/Local Areas,Alaska,2022,Age,13-17 Years,91.4,85.2 to 95.1,240
≥2 Doses MMR,,States/Local Areas,Alaska,2021,Age,13-17 Years,91.8,86.8 to 95.1,268
≥1 Dose MenACWY,,States/Local Areas,Alaska,2021,Age,13-17 Years,75.2,68.5 to 81.0,268
≥1 Dose MenACWY,,States/Local Areas,Alaska,2020,Age,13-17 Years,77.7,71.0 to 83.2,302
≥1 Dose MenACWY,,States/Local Areas,Alaska,2019,Age,13-17 Years,74.9,69.5 to 79.5,426
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018,Age,13-17 Years,69.2,63.5 to 74.3,392
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alaska,2015,Age,13-17 Years,27.5,22.5 to 33.2,350
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alaska,2014,Age,13-17 Years,23.6,18.7 to 29.2,377
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alaska,2013,Age,13-17 Years,17.5,13.2 to 22.9,320
≥2 Doses MMR,,States/Local Areas,Alaska,2020,Age,13-17 Years,92.3,87.8 to 95.2,302
≥2 Doses MMR,,States/Local Areas,Alaska,2019,Age,13-17 Years,94.0,91.0 to 96.0,426
≥2 Doses MMR,,States/Local Areas,Alaska,2018,Age,13-17 Years,91.2,87.1 to 94.0,392
≥1 Dose MenACWY,,States/Local Areas,Alaska,2022,Age,13-17 Years,81.3,74.5 to 86.6,240
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2012,Age,13-15 Years,35.0,24.3 to 47.4,96
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2011,Age,13-15 Years,34.5,24.5 to 46.0,111
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2010,Age,13-15 Years,18.4,10.7 to 29.7,80
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2009,Age,13-15 Years,16.2,9.4 to 26.6,92
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2008,Age,13-15 Years,17.7,11.0 to 27.3,97
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2015,Age,13-15 Years,39.1,29.5 to 49.7,113
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2014,Age,13-15 Years,22.8,15.5 to 32.2,123
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2013,Age,13-15 Years,21.2,13.5 to 31.7,101
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2010,Age,13-17 Years,25.0,17.8 to 33.9,134
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2009,Age,13-17 Years,19.3,12.7 to 28.3,136
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2008,Age,13-17 Years,21.0,14.7 to 29.0,149
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2011,Age,13-17 Years,40.4,31.1 to 50.4,159
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2015,Age,13-17 Years,36.9,29.0 to 45.6,165
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2014,Age,13-17 Years,34.4,26.7 to 42.9,200
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2013,Age,13-17 Years,27.1,19.6 to 36.0,158
HPV,"≥3 Doses, Females",States/Local Areas,Alaska,2012,Age,13-17 Years,31.4,23.3 to 40.8,145
≥2 Doses Hep A,,States/Local Areas,Alaska,2022,Age,13-17 Years,93.2,88.5 to 96.0,240
≥2 Doses Hep A,,States/Local Areas,Alaska,2021,Age,13-17 Years,89.0,83.1 to 93.0,268
≥2 Doses Hep A,,States/Local Areas,Alaska,2020,Age,13-17 Years,91.0,85.8 to 94.4,302
HPV,"≥3 Doses, Males",States/Local Areas,Alaska,2015,Age,13-15 Years,14.3,8.5 to 23.0,108
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2018,Age,13-17 Years,93.0,89.1 to 95.6,344
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2021,Age,13-15 Years,88.3,80.3 to 93.3,156
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2020,Age,13-15 Years,91.5,85.4 to 95.2,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2019,Age,13-15 Years,91.8,86.5 to 95.1,237
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2013,Age,13-15 Years,89.2,82.3 to 93.7,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2012,Age,13-15 Years,84.7,77.0 to 90.2,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2011,Age,13-15 Years,64.6,52.2 to 75.3,125
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2010,Age,13-15 Years,54.1,43.0 to 64.7,98
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2009,Age,13-15 Years,53.1,41.6 to 64.3,88
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2022,Age,13-15 Years,90.6,82.2 to 95.2,142
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2013,Age,13-17 Years,80.7,73.8 to 86.1,220
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2012,Age,13-17 Years,73.6,65.4 to 80.4,194
HPV,"≥3 Doses, Males",States/Local Areas,Alaska,2015,Age,13-17 Years,18.8,13.2 to 26.1,185
HPV,"≥3 Doses, Males",States/Local Areas,Alaska,2014,Age,13-17 Years,13.3,8.2 to 20.9,177
HPV,"≥3 Doses, Males",States/Local Areas,Alaska,2013,Age,13-17 Years,8.5,4.8 to 14.6,162
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2008,Age,13-17 Years,77.4,71.9 to 82.1,304
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2014,Age,13-17 Years,83.4,78.3 to 87.6,377
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2013,Age,13-17 Years,87.1,82.3 to 90.8,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2012,Age,13-17 Years,85.2,80.0 to 89.2,340
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2011,Age,13-17 Years,78.7,71.5 to 84.4,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2010,Age,13-17 Years,74.1,68.2 to 79.3,294
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2009,Age,13-17 Years,77.1,70.8 to 82.4,274
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2018,Age,13-17 Years,90.3,86.3 to 93.2,392
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2016,Age,13-17 Years,90.3,85.9 to 93.5,392
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2017,Age,13-17 Years,90.9,87.0 to 93.8,349
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2015,Age,13-17 Years,87.8,83.1 to 91.3,350
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2022,Age,13-17 Years,57.8,49.9 to 65.4,240
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2021,Age,13-17 Years,56.2,48.8 to 63.3,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2020,Age,13-17 Years,54.9,47.8 to 61.8,302
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2019,Age,13-17 Years,52.6,46.9 to 58.2,426
≥2 Doses MMR,,States/Local Areas,Alaska,2012,Age,13-17 Years,90.6,86.6 to 93.5,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2012,Age,13-17 Years,77.1,71.7 to 81.7,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2011,Age,13-17 Years,65.6,58.3 to 72.3,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2010,Age,13-17 Years,63.9,57.6 to 69.8,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2009,Age,13-17 Years,55.8,49.0 to 62.4,274
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2008,Age,13-17 Years,42.1,36.2 to 48.3,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2022,Age,13-15 Years,79.5,70.1 to 86.5,156
≥2 Doses MMR,,States/Local Areas,Alaska,2011,Age,13-17 Years,88.6,82.6 to 92.7,330
≥2 Doses MMR,,States/Local Areas,Alaska,2010,Age,13-17 Years,87.8,82.6 to 91.7,294
≥2 Doses MMR,,States/Local Areas,Alaska,2009,Age,13-17 Years,87.4,82.2 to 91.2,274
≥2 Doses MMR,,States/Local Areas,Alaska,2008,Age,13-17 Years,84.4,79.3 to 88.5,304
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018,Age,13-17 Years,44.1,38.3 to 50.0,392
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2017,Age,13-17 Years,42.6,36.7 to 48.8,349
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2015,Age,13-17 Years,69.7,63.6 to 75.2,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2014,Age,13-17 Years,73.8,68.1 to 78.9,377
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2013,Age,13-17 Years,74.3,68.0 to 79.7,320
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2021,Age,13-15 Years,76.5,68.0 to 83.3,170
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2020,Age,13-15 Years,84.3,77.0 to 89.6,181
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2019,Age,13-15 Years,76.3,69.2 to 82.2,262
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018,Age,13-15 Years,75.9,68.7 to 81.8,243
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2019,Age,13-17 Years,50.1,42.2 to 58.0,218
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2015,Age,13-17 Years,30.3,23.1 to 38.6,185
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2014,Age,13-17 Years,25.9,18.9 to 34.4,177
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2013,Age,13-17 Years,17.8,11.9 to 25.8,162
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2017,Age,13-15 Years,71.5,63.3 to 78.4,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2016,Age,13-15 Years,73.3,65.6 to 79.8,231
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2015,Age,13-15 Years,66.0,58.1 to 73.1,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2014,Age,13-15 Years,71.9,64.6 to 78.2,227
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2013,Age,13-15 Years,67.7,59.3 to 75.1,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2012,Age,13-15 Years,71.0,63.4 to 77.6,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2011,Age,13-15 Years,63.0,53.6 to 71.5,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2010,Age,13-15 Years,63.1,54.9 to 70.6,176
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2009,Age,13-15 Years,55.5,47.2 to 63.5,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2008,Age,13-15 Years,44.7,37.1 to 52.6,191
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2013,Age,13-17 Years,77.8,71.9 to 82.8,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2012,Age,13-17 Years,78.5,73.2 to 83.0,340
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2011,Age,13-17 Years,70.5,63.1 to 76.9,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2010,Age,13-17 Years,76.2,70.4 to 81.1,294
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2009,Age,13-17 Years,70.1,63.6 to 75.8,274
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2008,Age,13-17 Years,28.3,20.9 to 37.1,149
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2018,Age,13-17 Years,80.6,75.4 to 85.0,392
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2017,Age,13-17 Years,80.5,74.9 to 85.1,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2016,Age,13-17 Years,80.7,75.5 to 85.1,392
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2015,Age,13-17 Years,74.5,68.6 to 79.6,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2014,Age,13-17 Years,77.3,71.8 to 81.9,377
≥1 Dose MenACWY,,States/Local Areas,Alaska,2019,Age,13-15 Years,71.0,63.8 to 77.3,262
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018,Age,13-15 Years,68.4,61.2 to 74.8,243
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2013,Age,13-17 Years,36.1,27.7 to 45.5,158
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2012,Age,13-17 Years,46.3,37.0 to 55.9,145
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2011,Age,13-17 Years,47.6,38.0 to 57.4,159
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2010,Age,13-17 Years,32.0,24.0 to 41.2,134
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2009,Age,13-17 Years,27.7,20.1 to 36.9,136
≥1 Dose MenACWY,,States/Local Areas,Alaska,2020,Age,13-15 Years,76.9,68.1 to 83.9,181
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2014,Age,13-17 Years,45.2,36.8 to 54.0,200
≥1 Dose MenACWY,,States/Local Areas,Alaska,2021,Age,13-15 Years,71.2,62.4 to 78.6,170
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2018,Age,13-17 Years,44.9,37.0 to 53.1,199
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2017,Age,13-17 Years,45.4,36.9 to 54.1,174
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2016,Age,13-17 Years,44.9,36.5 to 53.7,209
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2012,Age,13-17 Years,7.5,4.6 to 12.1,195
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2019,Age,13-17 Years,59.4,51.2 to 67.1,208
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2017,Age,13-17 Years,50.4,41.8 to 59.0,175
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2016,Age,13-17 Years,49.7,40.8 to 58.6,183
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2015,Age,13-17 Years,46.3,37.8 to 55.1,165
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2018,Age,13-17 Years,50.4,41.9 to 58.9,193
≥1 Dose MenACWY,,States/Local Areas,Alaska,2022,Age,13-15 Years,75.4,66.0 to 82.9,156
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2022,Age,13-17 Years,76.1,68.9 to 82.1,240
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2021,Age,13-17 Years,70.3,62.9 to 76.7,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2020,Age,13-17 Years,71.9,65.0 to 77.8,302
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2019,Age,13-17 Years,68.6,63.0 to 73.6,426
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2022,Age,13-17 Years,85.0,78.3 to 90.0,240
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2021,Age,13-17 Years,82.2,75.7 to 87.2,268
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2020,Age,13-17 Years,85.8,80.2 to 90.0,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2019,Age,13-17 Years,82.9,77.9 to 86.9,426
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2008,Age,13-15 Years,28.4,18.7 to 40.5,70
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2022,Age,13-17 Years,93.3,88.1 to 96.3,240
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2021,Age,13-17 Years,90.5,85.1 to 94.0,268
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2020,Age,13-17 Years,92.0,87.5 to 94.9,302
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2019,Age,13-17 Years,92.8,89.2 to 95.2,426
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2014,Age,13-15 Years,81.0,72.9 to 87.0,182
≥3 Doses HepB,,States/Local Areas,Alaska,2010,Age,13-17 Years,89.0,84.0 to 92.5,294
≥3 Doses HepB,,States/Local Areas,Alaska,2009,Age,13-17 Years,91.8,87.8 to 94.6,274
≥3 Doses HepB,,States/Local Areas,Alaska,2008,Age,13-17 Years,86.9,82.3 to 90.5,304
≥3 Doses HepB,,States/Local Areas,Alaska,2011,Age,13-17 Years,91.6,86.9 to 94.7,330
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2011,Age,13-17 Years,59.5,48.8 to 69.4,174
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2010,Age,13-17 Years,44.7,35.8 to 54.0,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2009,Age,13-17 Years,44.8,34.8 to 55.2,114
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2008,Age,13-17 Years,24.1,16.3 to 34.1,95
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2012,Age,13-17 Years,92.1,86.3 to 95.6,194
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2011,Age,13-17 Years,88.3,80.2 to 93.3,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2010,Age,13-17 Years,76.6,67.6 to 83.7,140
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2009,Age,13-17 Years,81.0,70.1 to 88.5,114
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2008,Age,13-17 Years,66.7,55.4 to 76.4,95
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2018,Age,13-15 Years,87.8,81.5 to 92.1,219
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2016,Age,13-15 Years,88.7,81.3 to 93.4,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2017,Age,13-15 Years,90.6,85.1 to 94.2,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2015,Age,13-15 Years,85.5,78.9 to 90.3,187
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2009,Age,13-17 Years,40.8,31.7 to 50.6,136
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2008,Age,13-17 Years,38.8,30.6 to 47.8,149
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2010,Age,13-17 Years,40.8,32.0 to 50.3,134
≥3 Doses HepB,,States/Local Areas,Alaska,2016,Age,13-17 Years,92.8,88.8 to 95.4,392
≥3 Doses HepB,,States/Local Areas,Alaska,2015,Age,13-17 Years,90.1,86.1 to 93.1,350
≥3 Doses HepB,,States/Local Areas,Alaska,2014,Age,13-17 Years,88.6,83.9 to 92.1,377
≥3 Doses HepB,,States/Local Areas,Alaska,2013,Age,13-17 Years,92.6,88.2 to 95.5,320
≥3 Doses HepB,,States/Local Areas,Alaska,2012,Age,13-17 Years,91.1,87.2 to 93.9,340
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2015,Age,13-17 Years,57.0,48.2 to 65.5,165
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2014,Age,13-17 Years,48.7,40.1 to 57.4,200
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2013,Age,13-17 Years,52.2,42.9 to 61.4,158
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2012,Age,13-17 Years,56.1,46.7 to 65.1,145
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2011,Age,13-17 Years,59.5,49.7 to 68.5,159
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2017,Age,13-17 Years,89.3,84.8 to 92.6,297
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2016,Age,13-17 Years,87.9,82.5 to 91.8,325
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2015,Age,13-17 Years,84.5,78.7 to 88.9,279
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2014,Age,13-17 Years,76.0,69.1 to 81.8,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2017,Age,13-17 Years,95.3,91.8 to 97.3,297
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2016,Age,13-17 Years,95.9,91.7 to 98.0,325
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2015,Age,13-17 Years,93.5,89.9 to 95.9,279
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2014,Age,13-17 Years,91.8,86.8 to 95.0,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2013,Age,13-17 Years,95.0,90.8 to 97.3,220
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2021,Age,13-17 Years,70.7,60.6 to 79.1,147
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2020,Age,13-17 Years,70.7,60.6 to 79.1,157
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2019,Age,13-17 Years,68.1,60.3 to 75.0,218
≥1 Dose MenACWY,,States/Local Areas,Alaska,2012,Age,13-15 Years,48.7,40.8 to 56.6,215
≥1 Dose MenACWY,,States/Local Areas,Alaska,2011,Age,13-15 Years,45.0,36.1 to 54.2,200
≥1 Dose MenACWY,,States/Local Areas,Alaska,2010,Age,13-15 Years,41.4,33.5 to 49.9,176
≥1 Dose MenACWY,,States/Local Areas,Alaska,2009,Age,13-15 Years,34.6,27.4 to 42.5,179
≥1 Dose MenACWY,,States/Local Areas,Alaska,2008,Age,13-15 Years,31.6,24.8 to 39.3,191
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2022,Age,13-17 Years,74.2,64.5 to 81.9,141
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2017,Age,13-17 Years,67.6,59.4 to 74.9,174
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2008,Age,13-17 Years,68.3,62.2 to 73.7,304
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2018,Age,13-17 Years,67.1,59.2 to 74.1,199
≥1 Dose MenACWY,,States/Local Areas,Alaska,2015,Age,13-15 Years,55.4,47.6 to 63.0,221
≥1 Dose MenACWY,,States/Local Areas,Alaska,2014,Age,13-15 Years,56.8,48.8 to 64.5,227
≥1 Dose MenACWY,,States/Local Areas,Alaska,2013,Age,13-15 Years,50.6,42.4 to 58.7,205
≥1 Dose MenACWY,,States/Local Areas,Alaska,2017,Age,13-15 Years,66.5,58.4 to 73.8,204
≥1 Dose MenACWY,,States/Local Areas,Alaska,2016,Age,13-15 Years,63.5,55.5 to 70.8,231
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018,Age,13-17 Years,66.4,60.7 to 71.7,392
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2017,Age,13-17 Years,64.5,58.4 to 70.1,349
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2016,Age,13-17 Years,61.1,55.0 to 66.9,392
≥3 Doses HepB,,States/Local Areas,Alaska,2019,Age,13-17 Years,91.7,88.3 to 94.2,426
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2018,Age,13-17 Years,89.0,84.5 to 92.3,344
≥3 Doses HepB,,States/Local Areas,Alaska,2018,Age,13-17 Years,89.5,85.3 to 92.6,392
≥3 Doses HepB,,States/Local Areas,Alaska,2017,Age,13-17 Years,91.4,87.6 to 94.0,349
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2018,Age,13-17 Years,65.7,57.2 to 73.2,193
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2017,Age,13-17 Years,61.1,52.3 to 69.3,175
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2016,Age,13-17 Years,61.9,53.0 to 70.0,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2022,Age,13-17 Years,92.6,86.9 to 95.9,220
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2021,Age,13-17 Years,93.8,89.1 to 96.6,244
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2021,Age,13-17 Years,89.6,83.9 to 93.5,244
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2020,Age,13-17 Years,91.2,86.4 to 94.4,278
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2019,Age,13-17 Years,91.9,88.0 to 94.6,380
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2020,Age,13-17 Years,96.0,92.0 to 98.0,278
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2019,Age,13-17 Years,96.3,93.5 to 98.0,380
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2019,Age,13-17 Years,69.0,60.8 to 76.1,208
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2012,Age,13-17 Years,14.1,9.4 to 20.7,195
≥3 Doses HepB,,States/Local Areas,Alaska,2022,Age,13-17 Years,92.1,86.8 to 95.3,240
≥3 Doses HepB,,States/Local Areas,Alaska,2021,Age,13-17 Years,90.5,85.6 to 93.9,268
≥3 Doses HepB,,States/Local Areas,Alaska,2020,Age,13-17 Years,93.9,89.6 to 96.4,302
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2022,Age,13-17 Years,94.5,89.2 to 97.3,220
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2022,Age,13-17 Years,78.3,66.6 to 86.6,99
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2021,Age,13-17 Years,69.8,58.8 to 79.0,121
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2020,Age,13-17 Years,73.0,63.3 to 81.0,145
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alaska,2019,Age,13-17 Years,54.6,48.9 to 60.2,426
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alaska,2018,Age,13-17 Years,47.6,41.8 to 53.5,392
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alaska,2017,Age,13-17 Years,47.8,41.7 to 53.9,349
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alaska,2016,Age,13-17 Years,47.3,41.1 to 53.5,392
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2016,Age,13-17 Years,60.3,51.7 to 68.4,209
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2015,Age,13-17 Years,41.6,33.4 to 50.3,185
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2014,Age,13-17 Years,37.9,29.7 to 46.8,177
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2013,Age,13-17 Years,27.6,20.4 to 36.2,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2016,Age,13-17 Years,43.3,37.2 to 49.6,392
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2020,Age,13-17 Years,53.4,43.3 to 63.2,157
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2019,Age,13-17 Years,47.5,39.7 to 55.5,218
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2018,Age,13-17 Years,42.9,35.1 to 51.1,199
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2020,Age,13-15 Years,55.2,46.2 to 63.9,181
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2021,Age,13-15 Years,48.1,39.1 to 57.3,170
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2019,Age,13-15 Years,51.2,44.0 to 58.4,262
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2022,Age,13-17 Years,54.1,43.7 to 64.1,141
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2021,Age,13-17 Years,52.1,42.2 to 61.8,147
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2019,Age,13-17 Years,57.8,49.6 to 65.6,208
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2020,Age,13-17 Years,56.5,46.5 to 66.0,145
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2017,Age,13-17 Years,45.7,37.3 to 54.3,175
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2022,Age,13-15 Years,52.5,42.5 to 62.2,156
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2018,Age,13-17 Years,45.3,37.0 to 53.9,193
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2019,Age,13-15 Years,48.1,38.4 to 57.9,140
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2018,Age,13-15 Years,43.0,32.9 to 53.7,117
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2022,Age,13-17 Years,61.9,49.6 to 72.8,99
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2021,Age,13-17 Years,60.5,49.5 to 70.6,121
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2016,Age,13-17 Years,39.1,30.9 to 48.0,209
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2022,Age,13-15 Years,45.2,32.6 to 58.4,88
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2021,Age,13-15 Years,46.6,35.0 to 58.7,97
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2017,Age,13-17 Years,39.8,31.6 to 48.7,174
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2020,Age,13-15 Years,51.6,39.2 to 63.8,97
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2016,Age,13-17 Years,47.8,39.0 to 56.8,183
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2022,Age,13-15 Years,59.1,44.2 to 72.5,68
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2021,Age,13-15 Years,49.9,36.3 to 63.5,73
Varicella,History of disease,States/Local Areas,Alaska,2022,Age,13-17 Years,10.0,5.9 to 16.5,240
Varicella,History of disease,States/Local Areas,Alaska,2021,Age,13-17 Years,8.3,5.1 to 13.2,268
Varicella,History of disease,States/Local Areas,Alaska,2020,Age,13-17 Years,8.9,5.5 to 14.1,302
Varicella,History of disease,States/Local Areas,Alaska,2014,Age,13-17 Years,30.9,25.4 to 37.0,377
Varicella,History of disease,States/Local Areas,Alaska,2015,Age,13-17 Years,21.5,16.7 to 27.1,350
Varicella,History of disease,States/Local Areas,Alaska,2013,Age,13-17 Years,33.4,27.5 to 39.9,320
Varicella,History of disease,States/Local Areas,Alaska,2012,Age,13-17 Years,43.8,37.7 to 50.1,340
Varicella,History of disease,States/Local Areas,Alaska,2011,Age,13-17 Years,47.3,40.2 to 54.4,330
Varicella,History of disease,States/Local Areas,Alaska,2010,Age,13-17 Years,53.2,46.7 to 59.6,294
Varicella,History of disease,States/Local Areas,Alaska,2008,Age,13-17 Years,70.3,64.5 to 75.5,304
Varicella,History of disease,States/Local Areas,Alaska,2009,Age,13-17 Years,58.6,51.8 to 65.0,274
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2020,Age,13-15 Years,59.5,46.6 to 71.2,84
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2018,Age,13-15 Years,39.8,30.2 to 50.3,126
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2019,Age,13-15 Years,54.6,44.0 to 64.8,122
Varicella,History of disease,States/Local Areas,Alaska,2019,Age,13-17 Years,10.4,7.4 to 14.3,426
Varicella,History of disease,States/Local Areas,Alaska,2018,Age,13-17 Years,11.5,8.3 to 15.7,392
Varicella,History of disease,States/Local Areas,Alaska,2017,Age,13-17 Years,15.2,11.3 to 20.1,349
Varicella,History of disease,States/Local Areas,Alaska,2016,Age,13-17 Years,19.9,15.3 to 25.6,392
≥2 Doses MMR,,States/Local Areas,Kentucky,2021,Age,13-17 Years,94.6,90.1 to 97.1,240
≥2 Doses MMR,,States/Local Areas,Kentucky,2022,Age,13-17 Years,92.0,86.5 to 95.3,276
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018,Age,13-17 Years,84.4,78.3 to 89.0,270
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2019,Age,13-17 Years,90.6,85.8 to 93.8,292
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2020,Age,13-17 Years,94.2,89.9 to 96.7,255
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2021,Age,13-17 Years,87.7,81.5 to 92.1,240
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2012,Age,13-15 Years,36.0,24.4 to 49.5,99
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2011,Age,13-15 Years,30.5,20.0 to 43.4,106
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2010,Age,13-15 Years,29.0,20.2 to 39.6,98
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2009,Age,13-15 Years,20.8,14.1 to 29.6,113
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2022,Age,13-17 Years,90.4,84.5 to 94.2,276
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Overall,Overall,53.1,49.9 to 56.3,1333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Overall,Overall,68.7,65.7 to 71.6,1333
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a Non-MSA,84.1,79.2 to 88.0,444
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Principal City,75.8,71.1 to 79.9,502
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Non-Principal City,72.8,67.2 to 77.7,387
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a Non-MSA,54.6,48.9 to 60.2,444
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Principal City,59.9,54.8 to 64.8,502
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Non-Principal City,55.2,49.2 to 61.1,387
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a Non-MSA,41.4,35.9 to 47.1,444
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Principal City,91.7,88.3 to 94.2,502
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.6,86.2 to 93.8,387
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a Non-MSA,85.1,80.4 to 88.8,444
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"White, Non-Hispanic",52.4,48.8 to 56.1,1033
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Principal City,87.3,83.2 to 90.6,502
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.8,86.7 to 93.8,387
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.4,81.7 to 94.1,118
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",69.7,59.2 to 78.6,118
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,Hispanic,44.5,33.4 to 56.3,104
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",67.5,54.4 to 78.2,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",51.3,40.7 to 61.9,118
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"White, Non-Hispanic",87.7,84.9 to 89.9,1033
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.2,86.5 to 91.3,1033
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",92.8,82.0 to 97.3,78
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,Hispanic,88.8,79.5 to 94.1,104
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,Hispanic,86.5,75.8 to 92.9,104
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.9,75.5 to 94.5,78
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.9,77.1 to 92.9,118
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"White, Non-Hispanic",66.9,63.4 to 70.2,1033
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",82.0,69.6 to 90.0,78
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Race and Ethnicity,Hispanic,71.5,60.4 to 80.6,104
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Poverty,Below Poverty Level,74.6,67.3 to 80.8,209
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Poverty,Living At or Above Poverty Level,67.1,63.6 to 70.4,1077
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Poverty,Living At or Above Poverty Level,90.2,87.7 to 92.2,1077
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Poverty,Below Poverty Level,86.5,80.0 to 91.1,209
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Poverty,Below Poverty Level,49.6,41.6 to 57.6,209
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Poverty,Living At or Above Poverty Level,53.3,49.7 to 56.9,1077
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Poverty,Living At or Above Poverty Level,87.5,84.8 to 89.8,1077
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Poverty,Below Poverty Level,88.8,83.0 to 92.8,209
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Private Insurance Only,91.3,88.4 to 93.6,743
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Any Medicaid,88.3,84.4 to 91.4,473
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Other,87.3,75.6 to 93.9,78
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Any Medicaid,70.6,65.6 to 75.2,473
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Private Insurance Only,68.4,64.2 to 72.3,743
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Other,64.8,51.0 to 76.5,78
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Uninsured,58.4,39.1 to 75.4,39
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Uninsured,76.3,54.2 to 89.8,39
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Private Insurance Only,56.6,52.3 to 60.8,743
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Any Medicaid,52.1,46.7 to 57.4,473
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Uninsured,29.5,16.3 to 47.5,39
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Other,41.0,28.0 to 55.4,78
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Private Insurance Only,89.1,85.8 to 91.6,743
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Any Medicaid,86.1,81.9 to 89.4,473
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Other,91.1,80.6 to 96.1,78
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Insurance Coverage,Uninsured,73.3,51.7 to 87.6,39
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2013,Age,13-15 Years,21.5,13.5 to 32.6,86
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2014,Age,13-15 Years,33.5,24.2 to 44.3,128
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2015,Age,13-15 Years,31.0,21.3 to 42.7,92
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2022,Age,13-17 Years,58.8,48.8 to 68.2,139
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kentucky,2013,Age,13-17 Years,16.6,12.3 to 22.0,291
≥2 Doses MMR,,States/Local Areas,Kentucky,2020,Age,13-17 Years,95.9,92.4 to 97.8,255
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kentucky,2015,Age,13-17 Years,26.4,21.4 to 32.2,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kentucky,2014,Age,13-17 Years,25.1,19.7 to 31.4,335
≥2 Doses MMR,,States/Local Areas,Kentucky,2018,Age,13-17 Years,91.7,86.9 to 94.9,270
≥2 Doses MMR,,States/Local Areas,Kentucky,2019,Age,13-17 Years,94.5,90.4 to 96.9,292
≥2 Doses MMR,,States/Local Areas,Kentucky,2017,Age,13-17 Years,91.6,87.1 to 94.7,372
≥2 Doses MMR,,States/Local Areas,Kentucky,2016,Age,13-17 Years,93.0,88.9 to 95.7,333
≥2 Doses MMR,,States/Local Areas,Kentucky,2015,Age,13-17 Years,93.2,89.5 to 95.6,330
≥2 Doses MMR,,States/Local Areas,Kentucky,2014,Age,13-17 Years,93.4,89.1 to 96.1,335
≥2 Doses MMR,,States/Local Areas,Kentucky,2012,Age,13-17 Years,93.0,88.4 to 95.8,333
≥2 Doses MMR,,States/Local Areas,Kentucky,2013,Age,13-17 Years,92.7,88.1 to 95.7,291
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2017,Age,13-17 Years,83.3,78.3 to 87.4,372
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2020,Age,13-17 Years,93.7,89.7 to 96.2,255
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2021,Age,13-17 Years,83.5,76.5 to 88.7,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2022,Age,13-17 Years,86.4,79.9 to 91.0,276
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kentucky,2012,Age,13-17 Years,18.0,13.1 to 24.0,333
HPV,"≥3 Doses, Males and Females",States/Local Areas,Kentucky,2011,Age,13-17 Years,15.3,11.3 to 20.4,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018,Age,13-17 Years,84.9,79.0 to 89.3,270
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2017,Age,13-17 Years,86.4,81.7 to 90.0,372
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2019,Age,13-17 Years,89.2,84.3 to 92.8,292
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2016,Age,13-17 Years,85.9,81.2 to 89.6,333
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2015,Age,13-17 Years,79.0,73.3 to 83.7,330
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2013,Age,13-17 Years,71.2,64.5 to 77.0,291
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2014,Age,13-17 Years,78.2,71.9 to 83.3,335
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018-2022,Overall,Overall,89.5,87.2 to 91.3,1333
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018-2022,Overall,Overall,87.5,85.1 to 89.6,1333
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2010,Age,13-17 Years,44.8,38.7 to 51.1,309
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2011,Age,13-17 Years,55.0,48.4 to 61.4,382
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2008,Age,13-17 Years,30.9,25.3 to 37.0,296
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2009,Age,13-17 Years,36.3,31.2 to 41.7,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2016,Age,13-17 Years,89.0,84.6 to 92.2,333
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2015,Age,13-17 Years,36.2,28.2 to 45.1,162
≥2 Doses Hep A,,States/Local Areas,Kentucky,2020,Age,13-17 Years,90.7,85.7 to 94.1,255
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2010,Age,13-17 Years,27.3,20.1 to 35.9,142
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2012,Age,13-17 Years,62.9,55.9 to 69.4,333
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2022,Age,13-15 Years,90.5,81.7 to 95.3,159
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2011,Age,13-17 Years,30.5,22.7 to 39.7,176
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2008,Age,13-17 Years,12.7,8.1 to 19.4,133
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2009,Age,13-17 Years,19.5,13.8 to 26.9,176
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2012,Age,13-17 Years,34.9,25.7 to 45.4,154
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2013,Age,13-17 Years,26.8,19.2 to 36.1,140
HPV,"≥3 Doses, Females",States/Local Areas,Kentucky,2014,Age,13-17 Years,37.5,28.8 to 47.0,174
HPV,"≥3 Doses, Males",States/Local Areas,Kentucky,2015,Age,13-15 Years,19.6,12.8 to 28.7,106
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2008,Age,13-17 Years,26.3,18.8 to 35.4,133
≥3 Doses HepB,,States/Local Areas,Kentucky,2017,Age,13-17 Years,93.2,89.3 to 95.7,372
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2020,Age,13-15 Years,98.2,95.2 to 99.3,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2021,Age,13-15 Years,96.8,91.8 to 98.8,128
≥2 Doses Hep A,,States/Local Areas,Kentucky,2022,Age,13-17 Years,90.0,84.1 to 93.9,276
≥2 Doses Hep A,,States/Local Areas,Kentucky,2021,Age,13-17 Years,91.5,86.4 to 94.8,240
HPV,"≥3 Doses, Males",States/Local Areas,Kentucky,2015,Age,13-17 Years,17.1,11.9 to 24.1,168
HPV,"≥3 Doses, Males",States/Local Areas,Kentucky,2014,Age,13-17 Years,13.3,7.9 to 21.3,161
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2017,Age,13-17 Years,90.1,85.6 to 93.3,372
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2016,Age,13-17 Years,90.2,85.8 to 93.3,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2018,Age,13-17 Years,91.6,87.1 to 94.7,270
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2015,Age,13-17 Years,82.4,77.0 to 86.8,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2020,Age,13-17 Years,96.8,93.6 to 98.4,255
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2021,Age,13-17 Years,95.3,90.8 to 97.7,240
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2022,Age,13-17 Years,94.4,89.5 to 97.1,276
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2008,Age,13-15 Years,23.9,14.5 to 36.8,64
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2019,Age,13-17 Years,95.2,91.3 to 97.3,292
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2012,Age,13-17 Years,71.7,65.1 to 77.5,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2011,Age,13-17 Years,69.6,63.4 to 75.1,382
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2013,Age,13-17 Years,76.0,69.6 to 81.4,291
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2014,Age,13-17 Years,81.0,75.0 to 85.9,335
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2014,Age,13-15 Years,82.5,74.7 to 88.2,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2015,Age,13-15 Years,84.3,76.8 to 89.7,167
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2016,Age,13-17 Years,88.0,82.7 to 91.8,273
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2015,Age,13-17 Years,78.3,71.9 to 83.6,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2017,Age,13-17 Years,96.2,92.5 to 98.1,321
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2014,Age,13-17 Years,76.1,68.8 to 82.1,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2017,Age,13-17 Years,88.7,83.7 to 92.4,321
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2011,Age,13-17 Years,46.0,36.5 to 55.8,176
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2010,Age,13-17 Years,40.1,31.4 to 49.5,142
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2012,Age,13-15 Years,62.9,52.7 to 72.1,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2013,Age,13-15 Years,71.6,61.9 to 79.7,132
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2011,Age,13-15 Years,48.8,38.7 to 59.0,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2010,Age,13-15 Years,40.2,31.3 to 49.9,129
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2009,Age,13-15 Years,25.5,18.3 to 34.3,136
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2008,Age,13-17 Years,74.5,68.3 to 79.9,296
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2010,Age,13-17 Years,69.1,63.1 to 74.6,309
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2009,Age,13-17 Years,68.2,62.8 to 73.2,393
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2017,Age,13-15 Years,94.2,89.1 to 97.0,207
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2016,Age,13-15 Years,90.2,83.2 to 94.4,174
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2018,Age,13-15 Years,91.3,84.4 to 95.3,137
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2012,Age,13-17 Years,51.2,40.8 to 61.6,154
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2013,Age,13-17 Years,47.6,37.9 to 57.4,140
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2015,Age,13-17 Years,57.4,48.6 to 65.7,162
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2014,Age,13-17 Years,52.1,42.7 to 61.4,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2016,Age,13-17 Years,96.1,91.9 to 98.1,273
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2015,Age,13-17 Years,97.8,95.7 to 98.9,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2013,Age,13-17 Years,96.9,93.1 to 98.7,210
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2014,Age,13-17 Years,94.6,89.3 to 97.3,265
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2018,Age,13-17 Years,96.2,92.4 to 98.1,230
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2019,Age,13-15 Years,95.8,91.4 to 98.0,175
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2019,Age,13-17 Years,96.7,92.7 to 98.5,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2018,Age,13-17 Years,90.0,84.7 to 93.6,230
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2020,Age,13-17 Years,98.9,95.9 to 99.7,236
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2019,Age,13-17 Years,94.7,90.6 to 97.1,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2020,Age,13-17 Years,96.5,93.1 to 98.3,236
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2021,Age,13-17 Years,94.6,89.5 to 97.3,209
≥3 Doses HepB,,States/Local Areas,Kentucky,2016,Age,13-17 Years,92.7,88.4 to 95.5,333
≥3 Doses HepB,,States/Local Areas,Kentucky,2015,Age,13-17 Years,92.8,89.2 to 95.3,330
≥3 Doses HepB,,States/Local Areas,Kentucky,2018,Age,13-17 Years,91.9,87.1 to 95.0,270
≥3 Doses HepB,,States/Local Areas,Kentucky,2019,Age,13-17 Years,95.8,92.1 to 97.9,292
≥3 Doses HepB,,States/Local Areas,Kentucky,2008,Age,13-17 Years,93.3,89.3 to 95.9,296
≥3 Doses HepB,,States/Local Areas,Kentucky,2010,Age,13-17 Years,94.4,90.4 to 96.8,309
≥3 Doses HepB,,States/Local Areas,Kentucky,2009,Age,13-17 Years,92.3,88.4 to 94.9,393
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kentucky,2016,Age,13-17 Years,40.8,34.6 to 47.3,333
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kentucky,2017,Age,13-17 Years,40.9,35.2 to 47.0,372
≥3 Doses HepB,,States/Local Areas,Kentucky,2020,Age,13-17 Years,96.1,92.9 to 97.9,255
≥3 Doses HepB,,States/Local Areas,Kentucky,2021,Age,13-17 Years,94.9,90.7 to 97.3,240
≥3 Doses HepB,,States/Local Areas,Kentucky,2022,Age,13-17 Years,88.2,81.5 to 92.7,276
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2022,Age,13-17 Years,95.4,90.8 to 97.7,252
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2019,Age,13-17 Years,79.8,71.0 to 86.4,144
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2018,Age,13-17 Years,56.9,50.0 to 63.5,270
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2016,Age,13-15 Years,88.2,82.2 to 92.4,210
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2017,Age,13-15 Years,82.9,76.2 to 88.0,232
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2008,Age,13-17 Years,20.7,14.2 to 29.2,133
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2016,Age,13-17 Years,48.0,41.7 to 54.4,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2017,Age,13-17 Years,49.6,43.5 to 55.6,372
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2018,Age,13-15 Years,83.7,75.2 to 89.7,150
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2019,Age,13-15 Years,89.8,83.1 to 94.0,187
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2014,Age,13-15 Years,86.0,80.0 to 90.4,232
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2015,Age,13-15 Years,83.9,76.8 to 89.0,198
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2016,Age,13-17 Years,54.8,45.6 to 63.7,151
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2021,Age,13-17 Years,95.9,91.0 to 98.2,209
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2022,Age,13-17 Years,93.8,88.4 to 96.8,252
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2017,Age,13-17 Years,54.9,46.0 to 63.5,169
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2018,Age,13-17 Years,58.6,48.8 to 67.7,130
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2012,Age,13-15 Years,68.2,59.4 to 75.8,209
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2013,Age,13-15 Years,72.0,63.3 to 79.2,175
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2016,Age,13-17 Years,91.3,87.3 to 94.1,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2017,Age,13-17 Years,88.5,84.0 to 91.9,372
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2015,Age,13-17 Years,86.1,81.0 to 89.9,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2014,Age,13-17 Years,89.5,84.6 to 93.0,335
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2022,Age,13-15 Years,95.3,87.3 to 98.4,145
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2009,Age,13-17 Years,31.0,23.8 to 39.2,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2010,Age,13-17 Years,40.7,32.4 to 49.5,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2011,Age,13-17 Years,43.8,35.7 to 52.3,225
≥3 Doses HepB,,States/Local Areas,Kentucky,2012,Age,13-17 Years,95.0,91.3 to 97.1,333
≥3 Doses HepB,,States/Local Areas,Kentucky,2011,Age,13-17 Years,96.4,93.0 to 98.2,382
≥3 Doses HepB,,States/Local Areas,Kentucky,2013,Age,13-17 Years,94.7,90.8 to 97.1,291
≥3 Doses HepB,,States/Local Areas,Kentucky,2014,Age,13-17 Years,94.3,89.9 to 96.8,335
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2010,Age,13-17 Years,86.1,78.8 to 91.2,161
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2009,Age,13-17 Years,84.8,77.5 to 90.1,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2012,Age,13-17 Years,57.3,48.8 to 65.3,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2013,Age,13-17 Years,66.5,58.5 to 73.7,210
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2012,Age,13-17 Years,92.5,86.6 to 96.0,223
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2011,Age,13-17 Years,92.3,85.9 to 95.9,225
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2009,Age,13-17 Years,23.9,17.8 to 31.4,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2008,Age,13-17 Years,18.4,11.6 to 28.0,95
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2008,Age,13-17 Years,74.7,63.9 to 83.1,95
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2020,Age,13-17 Years,68.5,58.3 to 77.2,127
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2021,Age,13-17 Years,73.7,63.3 to 81.9,129
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2017,Age,13-17 Years,44.4,36.3 to 52.8,203
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2016,Age,13-17 Years,41.6,33.2 to 50.5,182
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2015,Age,13-17 Years,34.8,27.0 to 43.4,168
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2013,Age,13-17 Years,19.0,12.6 to 27.5,151
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2014,Age,13-17 Years,23.7,16.6 to 32.7,161
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kentucky,2019,Age,13-17 Years,56.8,50.1 to 63.3,292
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kentucky,2018,Age,13-17 Years,46.0,39.3 to 52.9,270
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2020,Age,13-17 Years,83.1,74.6 to 89.2,128
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2021,Age,13-17 Years,66.8,54.5 to 77.1,111
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2022,Age,13-17 Years,70.6,60.3 to 79.2,139
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2018,Age,13-17 Years,55.2,45.6 to 64.4,140
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2019,Age,13-17 Years,69.3,60.1 to 77.2,148
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2018,Age,13-15 Years,34.9,24.3 to 47.3,77
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2021,Age,13-17 Years,48.9,37.2 to 60.7,111
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2022,Age,13-17 Years,57.5,47.5 to 67.0,139
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2017,Age,13-17 Years,44.7,36.2 to 53.5,169
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2019,Age,13-15 Years,47.8,36.6 to 59.1,103
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2021,Age,13-15 Years,38.8,24.6 to 55.1,61
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2022,Age,13-15 Years,51.8,38.3 to 64.9,75
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2018,Age,13-17 Years,45.4,35.7 to 55.4,130
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2019,Age,13-17 Years,61.8,52.2 to 70.5,144
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2016,Age,13-17 Years,39.7,30.9 to 49.3,151
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2019,Age,13-15 Years,59.0,46.6 to 70.4,84
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2020,Age,13-15 Years,61.9,48.5 to 73.8,79
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2022,Age,13-15 Years,51.4,42.1 to 60.5,159
Varicella,History of disease,States/Local Areas,Kentucky,2020,Age,13-17 Years,7.2,4.4 to 11.6,255
Varicella,History of disease,States/Local Areas,Kentucky,2021,Age,13-17 Years,13.2,8.7 to 19.6,240
Varicella,History of disease,States/Local Areas,Kentucky,2022,Age,13-17 Years,9.8,6.1 to 15.2,276
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2018,Age,13-15 Years,46.2,33.3 to 59.8,73
Varicella,History of disease,States/Local Areas,Kentucky,2018,Age,13-17 Years,16.3,11.7 to 22.4,270
Varicella,History of disease,States/Local Areas,Kentucky,2016,Age,13-17 Years,18.4,14.0 to 23.9,333
Varicella,History of disease,States/Local Areas,Kentucky,2017,Age,13-17 Years,12.1,8.8 to 16.3,372
Varicella,History of disease,States/Local Areas,Kentucky,2009,Age,13-17 Years,58.2,52.6 to 63.7,393
Varicella,History of disease,States/Local Areas,Kentucky,2019,Age,13-17 Years,8.5,5.6 to 12.6,292
Varicella,History of disease,States/Local Areas,Kentucky,2008,Age,13-17 Years,68.8,62.4 to 74.5,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2015,Age,13-17 Years,84.0,78.8 to 88.1,330
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2021,Age,13-17 Years,57.0,49.0 to 64.8,240
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2022,Age,13-17 Years,55.0,47.9 to 61.9,276
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2020,Age,13-17 Years,55.7,48.3 to 62.9,255
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2019,Age,13-15 Years,91.1,85.2 to 94.8,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2020,Age,13-15 Years,93.2,87.7 to 96.3,164
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2021,Age,13-15 Years,84.3,74.7 to 90.7,144
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2016,Age,13-17 Years,34.8,26.8 to 43.8,182
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2017,Age,13-17 Years,34.3,26.9 to 42.6,203
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2018,Age,13-17 Years,42.5,33.5 to 52.0,140
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2015,Age,13-17 Years,25.2,18.5 to 33.4,168
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2013,Age,13-15 Years,87.5,80.1 to 92.4,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2018,Age,13-15 Years,86.0,77.6 to 91.6,150
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2013,Age,13-17 Years,10.8,6.6 to 17.3,151
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2014,Age,13-17 Years,17.5,11.4 to 25.8,161
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2016,Age,13-15 Years,91.2,86.2 to 94.5,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2017,Age,13-15 Years,87.7,81.9 to 91.8,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2014,Age,13-15 Years,87.9,81.8 to 92.2,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2015,Age,13-15 Years,83.2,76.2 to 88.5,198
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2019,Age,13-17 Years,62.8,53.2 to 71.5,144
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2012,Age,13-15 Years,84.5,77.6 to 89.6,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2011,Age,13-15 Years,77.5,68.8 to 84.3,245
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2009,Age,13-15 Years,44.2,37.3 to 51.3,250
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2010,Age,13-15 Years,67.3,59.6 to 74.2,205
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2020,Age,13-15 Years,91.9,85.5 to 95.6,164
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2009,Age,13-17 Years,26.7,19.9 to 34.7,176
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2010,Age,13-17 Years,32.0,24.0 to 41.3,142
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2011,Age,13-17 Years,38.0,29.2 to 47.8,176
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2009,Age,13-15 Years,36.0,29.7 to 42.7,250
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2008,Age,13-15 Years,35.5,27.7 to 44.2,162
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2022,Age,13-17 Years,62.3,52.1 to 71.6,137
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2011,Age,13-15 Years,60.4,51.9 to 68.3,245
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2010,Age,13-15 Years,48.4,40.8 to 56.0,205
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2012,Age,13-17 Years,43.5,33.4 to 54.1,154
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2013,Age,13-17 Years,38.6,29.6 to 48.4,140
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2016,Age,13-17 Years,47.1,38.0 to 56.5,151
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2017,Age,13-17 Years,47.9,39.3 to 56.6,169
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2014,Age,13-17 Years,45.1,35.9 to 54.6,174
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2015,Age,13-17 Years,42.7,34.3 to 51.5,162
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2019,Age,13-17 Years,74.4,68.2 to 79.8,292
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2021,Age,13-17 Years,86.3,79.6 to 91.1,240
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2022,Age,13-17 Years,88.7,82.6 to 92.9,276
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2008,Age,13-15 Years,35.0,27.1 to 43.9,162
HPV,"≥2 Doses, Females",States/Local Areas,Kentucky,2018,Age,13-17 Years,49.7,39.9 to 59.5,130
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2021,Age,13-15 Years,86.6,77.9 to 92.2,144
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2019,Age,13-17 Years,91.2,86.5 to 94.3,292
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2020,Age,13-17 Years,94.4,90.5 to 96.7,255
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2018,Age,13-17 Years,86.6,80.8 to 90.8,270
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2008,Age,13-17 Years,82.0,76.2 to 86.6,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2009,Age,13-17 Years,80.7,75.5 to 85.1,393
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2022,Age,13-17 Years,66.4,59.3 to 72.8,276
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2012,Age,13-17 Years,86.0,80.6 to 90.0,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2013,Age,13-17 Years,88.2,82.7 to 92.1,291
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2010,Age,13-17 Years,86.1,81.2 to 89.9,309
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2011,Age,13-17 Years,87.7,83.0 to 91.3,382
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2020,Age,13-17 Years,75.6,69.0 to 81.3,255
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2021,Age,13-17 Years,70.3,62.4 to 77.1,240
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2019,Age,13-17 Years,51.1,41.7 to 60.4,148
≥2 Doses MMR,,States/Local Areas,Kentucky,2008,Age,13-17 Years,96.2,93.2 to 97.9,296
≥2 Doses MMR,,States/Local Areas,Kentucky,2009,Age,13-17 Years,93.3,90.1 to 95.6,393
≥2 Doses MMR,,States/Local Areas,Kentucky,2010,Age,13-17 Years,93.0,88.9 to 95.7,309
≥2 Doses MMR,,States/Local Areas,Kentucky,2011,Age,13-17 Years,95.3,92.0 to 97.3,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2012,Age,13-17 Years,80.0,73.8 to 85.0,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2017,Age,13-17 Years,37.7,32.1 to 43.7,372
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2018,Age,13-17 Years,42.6,35.9 to 49.5,270
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2019,Age,13-17 Years,54.9,48.2 to 61.4,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2013,Age,13-17 Years,84.4,78.6 to 88.9,291
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2014,Age,13-17 Years,85.5,79.9 to 89.7,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2022,Age,13-15 Years,88.7,79.2 to 94.1,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2008,Age,13-17 Years,28.1,22.6 to 34.3,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2011,Age,13-17 Years,70.0,63.6 to 75.6,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2010,Age,13-17 Years,53.1,46.7 to 59.3,309
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2009,Age,13-17 Years,37.5,32.1 to 43.1,393
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2016,Age,13-17 Years,34.0,28.0 to 40.5,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2019,Age,13-15 Years,52.8,44.4 to 61.1,187
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2022,Age,13-17 Years,52.6,42.4 to 62.5,137
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2021,Age,13-15 Years,50.6,40.3 to 60.9,144
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2020,Age,13-15 Years,44.9,33.1 to 57.2,85
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2016,Age,13-17 Years,28.5,21.0 to 37.3,182
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2021,Age,13-15 Years,62.1,48.9 to 73.7,83
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2022,Age,13-15 Years,51.0,38.5 to 63.3,84
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2020,Age,13-17 Years,65.5,55.2 to 74.6,128
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2020,Age,13-15 Years,52.8,43.7 to 61.8,164
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2021,Age,13-17 Years,64.8,54.2 to 74.2,129
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2018,Age,13-17 Years,39.9,31.1 to 49.4,140
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2017,Age,13-17 Years,31.1,24.0 to 39.2,203
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2019,Age,13-17 Years,48.3,39.0 to 57.7,148
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2020,Age,13-17 Years,46.4,36.4 to 56.6,127
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2023,Age,13-17 Years,50.0,39.7 to 60.3,149
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2023,Age,13-15 Years,94.7,89.3 to 97.4,178
HPV,"Up-to-Date, Females",States/Local Areas,Kentucky,2023,Age,13-15 Years,42.9,31.2 to 55.4,96
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2023,Age,13-15 Years,81.1,71.6 to 87.9,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2023,Age,13-15 Years,44.5,36.0 to 53.4,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2023,Age,13-15 Years,81.7,72.3 to 88.5,187
≥2 Doses Hep A,,States/Local Areas,Kentucky,2023,Age,13-17 Years,91.3,86.0 to 94.7,297
Varicella,≥2 Doses or history of disease,States/Local Areas,Kentucky,2023,Age,13-17 Years,96.2,93.1 to 97.9,297
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2023,Age,13-15 Years,46.2,34.3 to 58.6,91
≥3 Doses HepB,,States/Local Areas,Kentucky,2023,Age,13-17 Years,95.3,92.1 to 97.3,297
Varicella,≥1 Dose with no disease history,States/Local Areas,Kentucky,2023,Age,13-17 Years,96.4,93.1 to 98.1,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Kentucky,2023,Age,13-17 Years,95.9,92.7 to 97.8,283
HPV,"Up-to-Date, Males",States/Local Areas,Kentucky,2023,Age,13-17 Years,45.9,36.3 to 55.8,148
≥2 Doses MMR,,States/Local Areas,Kentucky,2023,Age,13-17 Years,95.4,92.2 to 97.4,297
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kentucky,2023,Age,13-17 Years,47.9,40.8 to 55.1,297
HPV,"≥1 Dose, Females",States/Local Areas,Kentucky,2023,Age,13-17 Years,69.9,59.5 to 78.6,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Kentucky,2023,Age,13-17 Years,66.0,58.7 to 72.5,297
≥1 Dose MenACWY,,States/Local Areas,Kentucky,2023,Age,13-17 Years,84.0,77.5 to 88.9,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Kentucky,2023,Age,13-17 Years,84.0,77.5 to 88.9,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Kentucky,2023,Age,13-17 Years,84.6,78.1 to 89.4,297
HPV,"≥1 Dose, Males",States/Local Areas,Kentucky,2023,Age,13-17 Years,62.2,51.9 to 71.5,148
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Uninsured,79.4,64.9 to 88.9,50
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Overall,Overall,88.4,86.2 to 90.3,1534
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Overall,Overall,89.0,86.7 to 90.8,1534
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Overall,Overall,63.6,60.5 to 66.5,1534
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Overall,Overall,79.0,76.4 to 81.5,1534
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Principal City,82.1,77.7 to 85.8,506
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Non-Principal City,77.5,74.1 to 80.5,1028
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Principal City,92.4,89.0 to 94.8,506
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.2,84.2 to 89.6,1028
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Principal City,66.5,61.2 to 71.4,506
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Non-Principal City,62.1,58.3 to 65.7,1028
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Principal City,91.1,87.5 to 93.7,506
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.0,84.1 to 89.5,1028
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"White, Non-Hispanic",62.9,58.9 to 66.7,897
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.8,78.9 to 92.0,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",74.0,65.0 to 81.3,167
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",62.5,55.2 to 69.2,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,Hispanic,68.0,60.3 to 74.9,238
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",62.7,53.5 to 71.1,167
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.3,83.8 to 93.1,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.4,86.3 to 91.8,897
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.0,87.1 to 92.3,897
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.7,82.1 to 91.7,232
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,Hispanic,86.5,79.9 to 91.2,238
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,Hispanic,88.6,82.7 to 92.6,238
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.3,77.2 to 90.8,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",81.3,75.0 to 86.3,232
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,"White, Non-Hispanic",77.6,74.0 to 80.9,897
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Race and Ethnicity,Hispanic,82.8,76.0 to 88.0,238
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Poverty,Below Poverty Level,80.8,74.0 to 86.2,239
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Poverty,Living At or Above Poverty Level,78.6,75.6 to 81.3,1248
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Poverty,Living At or Above Poverty Level,89.6,87.2 to 91.7,1248
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Poverty,Below Poverty Level,87.6,81.7 to 91.8,239
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Poverty,Below Poverty Level,61.8,53.9 to 69.1,239
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Poverty,Living At or Above Poverty Level,64.3,61.0 to 67.6,1248
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Poverty,Below Poverty Level,83.4,76.5 to 88.6,239
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Poverty,Living At or Above Poverty Level,89.7,87.3 to 91.7,1248
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Private Insurance Only,91.0,88.3 to 93.2,915
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Any Medicaid,86.6,82.3 to 89.9,497
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Other,89.8,77.7 to 95.7,72
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Private Insurance Only,78.2,74.7 to 81.3,915
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Any Medicaid,80.1,75.4 to 84.0,497
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Other,84.8,72.7 to 92.1,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Private Insurance Only,63.8,59.8 to 67.6,915
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Uninsured,84.6,71.6 to 92.3,50
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Uninsured,72.9,55.8 to 85.1,50
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Any Medicaid,64.0,58.7 to 68.9,497
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Uninsured,59.5,42.7 to 74.4,50
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018-2022,Insurance Coverage,Other,61.2,46.2 to 74.4,72
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Private Insurance Only,91.3,88.6 to 93.3,915
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Any Medicaid,85.5,81.2 to 89.0,497
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018-2022,Insurance Coverage,Other,88.0,75.4 to 94.6,72
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2023,Age,13-17 Years,90.6,85.5 to 94.1,293
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2023,Age,13-17 Years,91.3,86.3 to 94.6,293
≥1 Dose MenACWY,,States/Local Areas,Delaware,2023,Age,13-17 Years,89.0,83.5 to 92.9,293
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2023,Age,13-17 Years,84.4,78.8 to 88.8,293
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2023,Age,13-17 Years,70.6,61.0 to 78.7,143
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2023,Age,13-17 Years,85.2,77.1 to 90.8,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2023,Age,13-17 Years,73.0,66.6 to 78.5,293
≥2 Doses MMR,,States/Local Areas,Delaware,2023,Age,13-17 Years,96.1,93.4 to 97.7,293
≥3 Doses HepB,,States/Local Areas,Delaware,2023,Age,13-17 Years,89.0,83.5 to 92.9,293
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2023,Age,13-17 Years,97.5,95.1 to 98.7,279
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2023,Age,13-17 Years,94.8,91.0 to 97.1,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2023,Age,13-17 Years,94.6,90.6 to 96.9,279
≥2 Doses Hep A,,States/Local Areas,Delaware,2023,Age,13-17 Years,91.2,87.0 to 94.1,293
≥1 Dose MenACWY,,States/Local Areas,Delaware,2023,Age,13-15 Years,87.7,79.7 to 92.8,177
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2023,Age,13-15 Years,88.5,80.9 to 93.3,177
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2023,Age,13-15 Years,69.1,60.4 to 76.6,177
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2023,Age,13-15 Years,75.3,63.7 to 84.1,85
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2023,Age,13-15 Years,93.8,87.4 to 97.0,169
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2023,Age,13-15 Years,64.2,51.8 to 75.0,92
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2023,Age,13-17 Years,75.4,66.8 to 82.3,150
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2023,Age,13-17 Years,83.7,75.2 to 89.7,143
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2022,Age,13-17 Years,70.4,59.5 to 79.5,127
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2022,Age,13-17 Years,68.8,57.9 to 78.0,123
HPV,"≥2 Doses, Males and Females",States/Local Areas,Delaware,2022,Age,13-17 Years,69.6,62.0 to 76.3,250
≥1 Dose MenACWY,,States/Local Areas,Delaware,2017,Age,13-17 Years,90.5,85.7 to 93.7,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2021,Age,13-17 Years,89.6,85.0 to 93.0,310
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2020,Age,13-17 Years,85.4,79.7 to 89.7,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2019,Age,13-17 Years,89.7,84.5 to 93.2,308
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2017,Age,13-17 Years,89.6,84.5 to 93.2,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018,Age,13-17 Years,89.1,83.9 to 92.8,306
≥1 Dose MenACWY,,States/Local Areas,Delaware,2010,Age,13-17 Years,71.2,65.0 to 76.7,348
≥1 Dose MenACWY,,States/Local Areas,Delaware,2011,Age,13-17 Years,78.2,73.0 to 82.7,442
≥1 Dose MenACWY,,States/Local Areas,Delaware,2008,Age,13-17 Years,58.6,52.1 to 64.7,334
≥1 Dose MenACWY,,States/Local Areas,Delaware,2009,Age,13-17 Years,58.4,51.8 to 64.7,371
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2016,Age,13-17 Years,87.5,83.0 to 91.0,375
≥1 Dose MenACWY,,States/Local Areas,Delaware,2012,Age,13-17 Years,78.0,71.2 to 83.5,341
≥2 Doses MMR,,States/Local Areas,Delaware,2016,Age,13-17 Years,94.8,90.9 to 97.1,375
≥2 Doses MMR,,States/Local Areas,Delaware,2017,Age,13-17 Years,95.1,91.6 to 97.2,350
≥2 Doses MMR,,States/Local Areas,Delaware,2014,Age,13-17 Years,95.6,91.9 to 97.7,374
≥2 Doses MMR,,States/Local Areas,Delaware,2015,Age,13-17 Years,94.0,90.0 to 96.5,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2022,Age,13-17 Years,88.2,81.8 to 92.6,250
≥1 Dose MenACWY,,States/Local Areas,Delaware,2016,Age,13-17 Years,87.3,82.4 to 91.0,375
≥1 Dose MenACWY,,States/Local Areas,Delaware,2015,Age,13-17 Years,87.5,82.8 to 91.1,360
≥1 Dose MenACWY,,States/Local Areas,Delaware,2013,Age,13-17 Years,81.8,76.2 to 86.3,348
≥1 Dose MenACWY,,States/Local Areas,Delaware,2014,Age,13-17 Years,86.7,81.3 to 90.7,374
HPV,"≥3 Doses, Males and Females",States/Local Areas,Delaware,2012,Age,13-17 Years,30.1,24.3 to 36.6,341
HPV,"≥3 Doses, Males and Females",States/Local Areas,Delaware,2011,Age,13-17 Years,24.1,19.3 to 29.8,442
≥2 Doses MMR,,States/Local Areas,Delaware,2012,Age,13-17 Years,95.7,92.0 to 97.8,341
≥2 Doses MMR,,States/Local Areas,Delaware,2013,Age,13-17 Years,95.3,92.2 to 97.2,348
≥2 Doses MMR,,States/Local Areas,Delaware,2019,Age,13-17 Years,96.5,92.9 to 98.3,308
≥2 Doses MMR,,States/Local Areas,Delaware,2018,Age,13-17 Years,95.7,92.2 to 97.6,306
HPV,"≥3 Doses, Males and Females",States/Local Areas,Delaware,2015,Age,13-17 Years,47.8,41.8 to 53.9,360
HPV,"≥3 Doses, Males and Females",States/Local Areas,Delaware,2014,Age,13-17 Years,36.6,30.0 to 43.6,374
HPV,"≥3 Doses, Males and Females",States/Local Areas,Delaware,2013,Age,13-17 Years,34.6,28.8 to 40.9,348
≥2 Doses MMR,,States/Local Areas,Delaware,2020,Age,13-17 Years,94.6,90.6 to 96.9,360
≥2 Doses MMR,,States/Local Areas,Delaware,2022,Age,13-17 Years,93.9,88.4 to 96.8,250
≥2 Doses MMR,,States/Local Areas,Delaware,2021,Age,13-17 Years,92.5,87.2 to 95.7,310
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2010,Age,13-15 Years,44.4,32.6 to 56.9,89
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2009,Age,13-15 Years,36.8,25.4 to 50.0,99
≥1 Dose MenACWY,,States/Local Areas,Delaware,2019,Age,13-17 Years,89.0,83.8 to 92.6,308
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018,Age,13-17 Years,85.9,79.8 to 90.4,306
≥1 Dose MenACWY,,States/Local Areas,Delaware,2021,Age,13-17 Years,90.8,86.3 to 93.9,310
≥1 Dose MenACWY,,States/Local Areas,Delaware,2020,Age,13-17 Years,89.8,85.2 to 93.1,360
≥1 Dose MenACWY,,States/Local Areas,Delaware,2022,Age,13-17 Years,89.3,82.7 to 93.5,250
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2014,Age,13-15 Years,40.3,28.7 to 53.2,105
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2015,Age,13-15 Years,47.1,35.9 to 58.6,99
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2013,Age,13-15 Years,43.2,31.6 to 55.6,100
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2012,Age,13-15 Years,50.4,38.0 to 62.8,101
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2011,Age,13-15 Years,45.0,34.7 to 55.8,135
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2008,Age,13-15 Years,30.0,20.2 to 42.0,100
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2011,Age,13-17 Years,46.8,38.2 to 55.6,203
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2012,Age,13-17 Years,50.4,40.3 to 60.4,157
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2013,Age,13-17 Years,51.7,42.8 to 60.5,183
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2014,Age,13-17 Years,42.3,32.9 to 52.2,180
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2010,Age,13-17 Years,40.4,31.7 to 49.7,159
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2008,Age,13-17 Years,26.1,18.8 to 34.9,164
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2009,Age,13-17 Years,32.6,24.6 to 41.9,186
HPV,"≥3 Doses, Females",States/Local Areas,Delaware,2015,Age,13-17 Years,52.8,43.7 to 61.7,161
≥2 Doses Hep A,,States/Local Areas,Delaware,2020,Age,13-17 Years,78.7,72.7 to 83.7,360
≥2 Doses Hep A,,States/Local Areas,Delaware,2022,Age,13-17 Years,86.7,80.3 to 91.2,250
≥2 Doses Hep A,,States/Local Areas,Delaware,2021,Age,13-17 Years,85.7,79.7 to 90.1,310
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2012,Age,13-17 Years,10.7,6.7 to 16.7,184
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2013,Age,13-17 Years,18.1,12.3 to 26.0,165
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2014,Age,13-17 Years,31.0,22.2 to 41.5,194
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2015,Age,13-17 Years,43.0,35.2 to 51.1,199
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2013,Age,13-15 Years,14.7,8.6 to 24.1,106
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2012,Age,13-15 Years,11.9,6.9 to 19.7,121
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2014,Age,13-15 Years,26.3,16.3 to 39.7,126
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2008,Age,13-15 Years,40.9,30.2 to 52.5,102
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2022,Age,13-17 Years,93.3,87.9 to 96.4,250
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2021,Age,13-17 Years,93.6,89.0 to 96.3,310
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2020,Age,13-17 Years,94.3,90.4 to 96.7,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2016,Age,13-17 Years,93.3,89.7 to 95.7,375
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2018,Age,13-17 Years,94.5,89.8 to 97.1,306
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2017,Age,13-17 Years,91.6,86.9 to 94.7,350
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2015,Age,13-17 Years,92.6,88.7 to 95.3,360
HPV,"≥3 Doses, Males",States/Local Areas,Delaware,2015,Age,13-15 Years,43.5,34.1 to 53.4,129
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2008,Age,13-17 Years,71.5,65.6 to 76.8,334
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2019,Age,13-17 Years,94.3,89.5 to 97.0,308
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2010,Age,13-17 Years,81.9,76.5 to 86.2,348
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2009,Age,13-17 Years,76.2,70.3 to 81.2,371
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2012,Age,13-17 Years,89.7,84.3 to 93.4,341
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2011,Age,13-17 Years,85.7,81.3 to 89.2,442
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2013,Age,13-17 Years,84.8,79.2 to 89.1,348
Varicella,≥2 Doses or history of disease,States/Local Areas,Delaware,2014,Age,13-17 Years,91.8,87.3 to 94.8,374
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2014,Age,13-15 Years,91.7,84.9 to 95.6,202
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2015,Age,13-15 Years,92.6,87.1 to 95.9,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2016,Age,13-15 Years,93.2,87.4 to 96.5,200
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2018,Age,13-15 Years,97.6,94.0 to 99.0,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2017,Age,13-15 Years,88.8,81.1 to 93.6,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2021,Age,13-15 Years,91.3,83.8 to 95.6,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2020,Age,13-15 Years,92.4,85.8 to 96.1,207
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2020,Age,13-17 Years,96.5,93.2 to 98.2,333
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2018,Age,13-17 Years,96.5,92.0 to 98.5,283
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2012,Age,13-17 Years,67.2,56.8 to 76.1,157
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2013,Age,13-17 Years,68.7,60.1 to 76.1,183
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2014,Age,13-17 Years,67.6,57.7 to 76.1,180
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2015,Age,13-17 Years,67.6,58.7 to 75.4,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2017,Age,13-17 Years,90.3,85.1 to 93.9,307
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2011,Age,13-17 Years,60.2,51.3 to 68.5,203
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2010,Age,13-17 Years,63.9,54.9 to 72.0,159
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2016,Age,13-17 Years,92.4,88.4 to 95.1,335
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2015,Age,13-17 Years,91.0,86.2 to 94.2,301
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2017,Age,13-17 Years,96.1,92.1 to 98.1,307
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2014,Age,13-17 Years,90.2,85.0 to 93.7,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2012,Age,13-15 Years,90.5,83.2 to 94.8,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2013,Age,13-15 Years,84.5,76.4 to 90.2,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2010,Age,13-15 Years,75.8,66.2 to 83.3,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2011,Age,13-15 Years,83.4,76.0 to 88.8,201
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2009,Age,13-15 Years,55.9,44.7 to 66.6,123
≥3 Doses HepB,,States/Local Areas,Delaware,2016,Age,13-17 Years,94.5,90.8 to 96.7,375
≥3 Doses HepB,,States/Local Areas,Delaware,2015,Age,13-17 Years,94.4,90.6 to 96.8,360
≥3 Doses HepB,,States/Local Areas,Delaware,2017,Age,13-17 Years,94.4,90.2 to 96.9,350
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2016,Age,13-17 Years,97.8,94.9 to 99.0,335
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2015,Age,13-17 Years,97.1,92.8 to 98.8,301
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2013,Age,13-17 Years,97.5,94.5 to 98.9,264
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2014,Age,13-17 Years,97.2,93.0 to 98.9,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2019,Age,13-15 Years,94.8,88.5 to 97.8,177
≥3 Doses HepB,,States/Local Areas,Delaware,2019,Age,13-17 Years,93.2,88.7 to 95.9,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2018,Age,13-17 Years,94.1,89.2 to 96.9,283
≥3 Doses HepB,,States/Local Areas,Delaware,2018,Age,13-17 Years,94.3,90.7 to 96.5,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2019,Age,13-17 Years,93.9,88.8 to 96.8,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2021,Age,13-17 Years,93.0,88.1 to 96.0,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2020,Age,13-17 Years,93.6,89.3 to 96.3,333
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2019,Age,13-17 Years,96.4,92.0 to 98.4,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2022,Age,13-15 Years,94.2,88.4 to 97.1,133
≥3 Doses HepB,,States/Local Areas,Delaware,2010,Age,13-17 Years,92.1,87.7 to 95.0,348
≥3 Doses HepB,,States/Local Areas,Delaware,2009,Age,13-17 Years,91.4,86.7 to 94.5,371
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2009,Age,13-17 Years,51.5,42.4 to 60.5,186
≥3 Doses HepB,,States/Local Areas,Delaware,2011,Age,13-17 Years,96.3,93.8 to 97.8,442
≥3 Doses HepB,,States/Local Areas,Delaware,2008,Age,13-17 Years,95.2,91.9 to 97.2,334
≥3 Doses HepB,,States/Local Areas,Delaware,2013,Age,13-17 Years,95.6,92.3 to 97.6,348
≥3 Doses HepB,,States/Local Areas,Delaware,2014,Age,13-17 Years,93.5,88.9 to 96.3,374
≥3 Doses HepB,,States/Local Areas,Delaware,2012,Age,13-17 Years,94.8,90.9 to 97.0,341
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2010,Age,13-17 Years,67.8,59.8 to 75.0,200
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2011,Age,13-17 Years,79.2,73.1 to 84.1,306
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2019,Age,13-17 Years,75.6,66.2 to 83.1,145
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2010,Age,13-17 Years,88.2,80.4 to 93.1,200
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2009,Age,13-17 Years,84.0,75.1 to 90.1,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2012,Age,13-17 Years,84.9,77.5 to 90.2,240
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2013,Age,13-17 Years,79.8,72.8 to 85.4,264
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2008,Age,13-17 Years,46.8,37.9 to 56.0,164
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2018,Age,13-17 Years,77.3,67.6 to 84.7,157
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2016,Age,13-17 Years,78.3,70.5 to 84.5,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2022,Age,13-17 Years,92.7,87.0 to 96.1,234
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2021,Age,13-17 Years,97.1,93.5 to 98.7,287
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2017,Age,13-17 Years,76.2,67.0 to 83.4,161
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2012,Age,13-17 Years,95.2,88.9 to 98.0,240
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2011,Age,13-17 Years,92.9,87.6 to 96.0,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2008,Age,13-17 Years,35.3,26.6 to 45.2,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Delaware,2009,Age,13-17 Years,49.8,40.8 to 58.9,179
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2008,Age,13-17 Years,86.1,78.7 to 91.2,144
≥3 Doses HepB,,States/Local Areas,Delaware,2022,Age,13-17 Years,87.1,80.7 to 91.5,250
≥3 Doses HepB,,States/Local Areas,Delaware,2021,Age,13-17 Years,91.0,85.7 to 94.4,310
≥3 Doses HepB,,States/Local Areas,Delaware,2020,Age,13-17 Years,92.6,88.8 to 95.1,360
Varicella,≥1 Dose with no disease history,States/Local Areas,Delaware,2022,Age,13-17 Years,94.6,88.8 to 97.5,234
HPV,"≥2 Doses, Males and Females",States/Local Areas,Delaware,2019,Age,13-17 Years,63.7,57.0 to 69.9,308
HPV,"≥2 Doses, Males and Females",States/Local Areas,Delaware,2018,Age,13-17 Years,61.5,54.4 to 68.2,306
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2011,Age,13-17 Years,11.6,7.4 to 17.9,239
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2022,Age,13-17 Years,82.6,72.8 to 89.3,127
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2021,Age,13-17 Years,82.2,73.3 to 88.6,144
HPV,"≥1 Dose, Females",States/Local Areas,Delaware,2020,Age,13-17 Years,76.6,67.9 to 83.6,162
HPV,"≥2 Doses, Males and Females",States/Local Areas,Delaware,2016,Age,13-17 Years,61.3,55.2 to 67.0,375
HPV,"≥2 Doses, Males and Females",States/Local Areas,Delaware,2017,Age,13-17 Years,62.0,55.5 to 68.1,350
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2012,Age,13-17 Years,26.2,19.4 to 34.4,184
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2018,Age,13-17 Years,73.9,67.1 to 79.7,306
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2017,Age,13-17 Years,74.5,66.1 to 81.5,189
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2016,Age,13-17 Years,63.3,54.7 to 71.1,195
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2015,Age,13-17 Years,62.9,55.0 to 70.2,199
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2013,Age,13-17 Years,37.1,29.1 to 45.9,165
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2014,Age,13-17 Years,54.6,45.0 to 63.9,194
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2021,Age,13-17 Years,84.7,76.6 to 90.4,166
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2020,Age,13-17 Years,79.4,70.6 to 86.0,198
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2018,Age,13-17 Years,70.7,60.7 to 79.0,149
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2019,Age,13-17 Years,75.2,66.8 to 82.1,163
≥1 Dose MenACWY,,States/Local Areas,Delaware,2014,Age,13-15 Years,86.5,79.0 to 91.6,231
≥1 Dose MenACWY,,States/Local Areas,Delaware,2015,Age,13-15 Years,84.3,77.4 to 89.4,228
≥1 Dose MenACWY,,States/Local Areas,Delaware,2013,Age,13-15 Years,79.4,71.6 to 85.5,206
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2008,Age,13-17 Years,34.6,26.6 to 43.6,164
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2012,Age,13-17 Years,77.8,71.3 to 83.2,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2011,Age,13-17 Years,80.7,75.8 to 84.7,442
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2010,Age,13-17 Years,65.5,59.3 to 71.2,348
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2009,Age,13-17 Years,53.4,46.9 to 59.7,371
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2019,Age,13-17 Years,59.2,52.4 to 65.6,308
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2013,Age,13-17 Years,84.4,79.3 to 88.4,348
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2014,Age,13-17 Years,90.5,86.1 to 93.7,374
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2018,Age,13-17 Years,58.4,51.3 to 65.2,306
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2017,Age,13-17 Years,58.1,51.6 to 64.4,350
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2016,Age,13-17 Years,56.9,50.7 to 62.8,375
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2015,Age,13-17 Years,88.7,84.3 to 92.0,360
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2022,Age,13-17 Years,68.2,60.5 to 74.9,250
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2021,Age,13-17 Years,68.9,62.3 to 74.8,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2020,Age,13-17 Years,63.2,56.6 to 69.2,360
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2018,Age,13-17 Years,56.4,46.5 to 65.8,149
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2019,Age,13-15 Years,88.5,81.5 to 93.1,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2020,Age,13-15 Years,81.1,72.6 to 87.5,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2021,Age,13-15 Years,86.6,79.6 to 91.4,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2018,Age,13-15 Years,90.5,84.4 to 94.3,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2016,Age,13-15 Years,87.6,81.5 to 91.9,220
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2017,Age,13-15 Years,89.5,82.5 to 94.0,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2014,Age,13-15 Years,91.4,85.2 to 95.2,231
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2015,Age,13-15 Years,88.2,82.2 to 92.3,228
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2016,Age,13-17 Years,52.7,44.1 to 61.1,195
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2017,Age,13-17 Years,63.0,54.0 to 71.3,189
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2012,Age,13-17 Years,17.9,12.1 to 25.6,184
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2011,Age,13-17 Years,6.7,3.9 to 11.2,239
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2019,Age,13-17 Years,66.5,56.7 to 75.0,145
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2013,Age,13-15 Years,82.1,74.7 to 87.7,206
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2014,Age,13-17 Years,43.8,34.3 to 53.8,194
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2013,Age,13-17 Years,25.0,18.3 to 33.2,165
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2015,Age,13-17 Years,53.2,45.3 to 61.1,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2012,Age,13-15 Years,83.1,75.0 to 88.9,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2011,Age,13-15 Years,82.2,75.8 to 87.2,267
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2008,Age,13-15 Years,52.7,44.5 to 60.8,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2010,Age,13-15 Years,77.3,70.0 to 83.3,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2009,Age,13-15 Years,65.0,56.5 to 72.6,215
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2018,Age,13-17 Years,66.8,56.5 to 75.7,157
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2016,Age,13-17 Years,70.2,61.8 to 77.4,180
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2017,Age,13-17 Years,61.0,51.4 to 69.7,161
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2015,Age,13-17 Years,60.9,51.7 to 69.3,161
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2019,Age,13-17 Years,75.4,69.3 to 80.7,308
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2022,Age,13-17 Years,89.1,82.7 to 93.3,250
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2021,Age,13-17 Years,91.1,86.6 to 94.2,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2019,Age,13-17 Years,90.6,85.6 to 94.0,308
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2020,Age,13-17 Years,88.0,82.8 to 91.8,360
≥1 Dose MenACWY,,States/Local Areas,Delaware,2021,Age,13-15 Years,88.1,81.3 to 92.7,194
≥1 Dose MenACWY,,States/Local Areas,Delaware,2022,Age,13-15 Years,90.7,82.5 to 95.2,145
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2012,Age,13-17 Years,64.5,54.1 to 73.6,157
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2013,Age,13-17 Years,59.4,50.5 to 67.8,183
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2012,Age,13-17 Years,85.0,79.1 to 89.4,341
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2013,Age,13-17 Years,87.7,82.9 to 91.3,348
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2010,Age,13-17 Years,81.6,76.1 to 86.0,348
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2011,Age,13-17 Years,87.7,83.4 to 91.0,442
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2022,Age,13-17 Years,84.2,77.8 to 89.0,250
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2021,Age,13-17 Years,83.5,77.7 to 88.0,310
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2020,Age,13-17 Years,78.0,72.0 to 83.0,360
≥1 Dose MenACWY,,States/Local Areas,Delaware,2012,Age,13-15 Years,79.1,70.6 to 85.7,222
≥1 Dose MenACWY,,States/Local Areas,Delaware,2010,Age,13-15 Years,74.6,66.6 to 81.2,199
≥1 Dose MenACWY,,States/Local Areas,Delaware,2011,Age,13-15 Years,77.0,70.0 to 82.8,267
≥1 Dose MenACWY,,States/Local Areas,Delaware,2008,Age,13-15 Years,59.5,51.2 to 67.2,194
≥1 Dose MenACWY,,States/Local Areas,Delaware,2009,Age,13-15 Years,65.0,56.6 to 72.5,215
HPV,"≥1 Dose, Males",States/Local Areas,Delaware,2022,Age,13-17 Years,85.8,76.5 to 91.8,123
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2010,Age,13-17 Years,53.4,44.1 to 62.5,159
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2011,Age,13-17 Years,52.7,43.9 to 61.3,203
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2009,Age,13-17 Years,45.0,36.1 to 54.1,186
≥1 Dose MenACWY,,States/Local Areas,Delaware,2020,Age,13-15 Years,87.9,80.9 to 92.6,222
HPV,"≥2 Doses, Females",States/Local Areas,Delaware,2014,Age,13-17 Years,51.4,41.6 to 61.1,180
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2008,Age,13-17 Years,78.6,72.9 to 83.3,334
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2009,Age,13-17 Years,74.4,67.9 to 80.0,371
≥1 Dose MenACWY,,States/Local Areas,Delaware,2019,Age,13-15 Years,85.3,77.4 to 90.7,194
≥1 Dose MenACWY,,States/Local Areas,Delaware,2018,Age,13-15 Years,86.7,79.7 to 91.6,195
≥1 Dose MenACWY,,States/Local Areas,Delaware,2016,Age,13-15 Years,88.5,82.1 to 92.8,220
≥1 Dose MenACWY,,States/Local Areas,Delaware,2017,Age,13-15 Years,88.5,81.5 to 93.1,207
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2016,Age,13-17 Years,89.9,85.5 to 93.0,375
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2017,Age,13-17 Years,90.8,85.9 to 94.2,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2014,Age,13-17 Years,91.5,87.3 to 94.4,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2015,Age,13-17 Years,90.4,86.2 to 93.4,360
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2016,Age,13-17 Years,70.7,64.9 to 75.8,375
HPV,"≥1 Dose, Males and Females",States/Local Areas,Delaware,2017,Age,13-17 Years,75.3,69.3 to 80.5,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Delaware,2018,Age,13-17 Years,90.7,85.5 to 94.1,306
HPV,"≥2 Doses, Males",States/Local Areas,Delaware,2019,Age,13-17 Years,60.9,51.5 to 69.6,163
≥2 Doses MMR,,States/Local Areas,Delaware,2008,Age,13-17 Years,94.8,90.4 to 97.3,334
≥2 Doses MMR,,States/Local Areas,Delaware,2009,Age,13-17 Years,94.4,90.2 to 96.8,371
≥2 Doses MMR,,States/Local Areas,Delaware,2010,Age,13-17 Years,94.1,90.2 to 96.6,348
≥2 Doses MMR,,States/Local Areas,Delaware,2011,Age,13-17 Years,94.1,88.8 to 97.0,442
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2008,Age,13-17 Years,43.1,36.9 to 49.6,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Delaware,2022,Age,13-15 Years,88.9,80.3 to 94.0,145
HPV,"≥2 Doses, Males and Females",States/Local Areas,Kentucky,2022,Age,13-17 Years,55.6,48.5 to 62.5,276
HPV,"≥2 Doses, Males",States/Local Areas,Kentucky,2022,Age,13-17 Years,52.6,42.4 to 62.5,137
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Insurance Coverage,Other,87.4,83.1 to 90.7,705
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Insurance Coverage,Uninsured,80.0,72.9 to 85.6,548
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Insurance Coverage,Any Medicaid,84.7,81.4 to 87.5,2274
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Uninsured,38.9,31.7 to 46.5,548
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Insurance Coverage,Private Insurance Only,85.5,83.3 to 87.4,3327
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Other,48.5,41.5 to 55.5,705
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Private Insurance Only,48.6,45.6 to 51.6,3327
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Any Medicaid,59.2,55.1 to 63.2,2274
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Insurance Coverage,Uninsured,83.2,76.4 to 88.3,548
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Uninsured,60.6,52.9 to 67.7,548
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Other,67.4,60.4 to 73.7,705
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Private Insurance Only,65.1,62.2 to 67.9,3327
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Insurance Coverage,Any Medicaid,73.8,70.0 to 77.3,2274
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Insurance Coverage,Other,89.3,85.4 to 92.2,705
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Insurance Coverage,Private Insurance Only,88.6,86.7 to 90.2,3327
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Poverty,Living At or Above Poverty Level,85.0,83.2 to 86.7,4915
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Insurance Coverage,Any Medicaid,88.2,85.2 to 90.7,2274
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Poverty,Below Poverty Level,84.7,80.4 to 88.2,1639
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Poverty,Living At or Above Poverty Level,48.4,45.9 to 51.0,4915
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Poverty,Living At or Above Poverty Level,87.4,85.6 to 88.9,4915
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Poverty,Below Poverty Level,63.5,58.7 to 68.1,1639
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Poverty,Below Poverty Level,89.1,85.5 to 92.0,1639
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",67.9,61.0 to 74.1,532
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Poverty,Living At or Above Poverty Level,65.4,63.0 to 67.8,4915
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Poverty,Below Poverty Level,77.1,72.6 to 81.1,1639
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",59.5,55.7 to 63.2,2241
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.8,81.3 to 90.9,546
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Race and Ethnicity,Hispanic,84.5,82.0 to 86.7,3535
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",83.9,78.0 to 88.4,532
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Race and Ethnicity,Hispanic,88.7,86.6 to 90.5,3535
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.4,82.7 to 87.8,2241
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.8,82.9 to 91.5,532
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",86.3,83.4 to 88.8,2241
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",49.9,43.1 to 56.7,532
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,Hispanic,55.8,52.5 to 59.0,3535
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",52.1,45.2 to 59.0,546
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,Hispanic,73.4,70.5 to 76.2,3535
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",66.5,59.8 to 72.7,546
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",45.0,41.3 to 48.8,2241
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.1,87.4 to 93.8,546
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Principal City,84.9,82.3 to 87.1,4042
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,85.2,82.9 to 87.3,2486
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Urbanicity,Living In a Non-MSA,88.1,82.2 to 92.2,326
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.6,85.4 to 89.5,2486
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Principal City,88.6,86.3 to 90.5,4042
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Principal City,54.7,51.4 to 58.0,4042
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Urbanicity,Living In a Non-MSA,49.7,40.4 to 59.0,326
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,48.8,45.7 to 52.0,2486
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Urbanicity,Living In a Non-MSA,65.8,56.5 to 74.0,326
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,64.4,61.3 to 67.3,2486
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Urbanicity,Living In a MSA Principal City,72.3,69.2 to 75.2,4042
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Urbanicity,Living In a Non-MSA,82.3,74.2 to 88.3,326
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018-2022,Overall,Overall,51.5,49.3 to 53.7,6854
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018-2022,Overall,Overall,67.9,65.8 to 70.0,6854
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2023,Age,13-17 Years,82.9,77.0 to 87.5,872
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2023,Age,13-17 Years,86.1,80.9 to 90.0,872
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2023,Age,13-17 Years,76.0,69.8 to 81.3,872
≥1 Dose MenACWY,,States/Local Areas,Texas,2023,Age,13-17 Years,85.5,80.1 to 89.7,872
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2023,Age,13-17 Years,78.5,69.8 to 85.2,438
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2023,Age,13-17 Years,57.5,50.6 to 64.1,872
≥2 Doses MMR,,States/Local Areas,Texas,2023,Age,13-17 Years,85.0,79.6 to 89.1,872
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2023,Age,13-17 Years,53.9,44.2 to 63.4,434
≥3 Doses HepB,,States/Local Areas,Texas,2023,Age,13-17 Years,83.6,77.9 to 88.0,872
Varicella,History of disease,States/Local Areas,Texas,2023,Age,13-17 Years,10.0,6.2 to 15.5,872
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2023,Age,13-17 Years,88.5,83.1 to 92.4,796
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2023,Age,13-17 Years,84.5,78.7 to 89.0,796
≥2 Doses Hep A,,States/Local Areas,Texas,2023,Age,13-17 Years,86.0,80.9 to 89.8,872
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2023,Age,13-17 Years,86.1,80.8 to 90.1,872
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2023,Age,13-15 Years,82.9,75.6 to 88.4,555
≥1 Dose MenACWY,,States/Local Areas,Texas,2023,Age,13-15 Years,85.3,78.2 to 90.4,555
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2023,Age,13-15 Years,54.3,45.7 to 62.6,555
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2023,Age,13-15 Years,85.0,77.1 to 90.4,513
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2023,Age,13-15 Years,46.9,35.3 to 58.9,278
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2023,Age,13-17 Years,61.2,51.6 to 70.1,438
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2023,Age,13-15 Years,62.3,49.9 to 73.3,277
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2023,Age,13-17 Years,73.6,64.2 to 81.3,434
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2014,Age,13-17 Years,33.9,27.7 to 40.7,793
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2013,Age,13-17 Years,38.9,31.8 to 46.4,514
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2011,Age,13-17 Years,31.5,25.4 to 38.4,1057
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2012,Age,13-17 Years,30.3,25.3 to 35.8,798
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2013,Age,13-15 Years,17.0,11.8 to 23.7,371
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2014,Age,13-17 Years,17.7,13.1 to 23.6,859
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2015,Age,13-17 Years,24.0,20.4 to 28.1,1323
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2013,Age,13-17 Years,15.0,11.0 to 20.3,598
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2012,Age,13-17 Years,7.0,4.9 to 9.9,796
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2011,Age,13-17 Years,2.4,1.4 to 4.2,1167
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2009,Age,13-15 Years,47.7,39.1 to 56.5,541
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2016,Age,13-17 Years,83.9,80.9 to 86.5,1927
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2017,Age,13-17 Years,85.3,82.7 to 87.6,2256
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2014,Age,13-15 Years,81.0,74.4 to 86.3,816
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2015,Age,13-15 Years,83.0,79.1 to 86.3,1378
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2019,Age,13-17 Years,83.6,80.5 to 86.3,1850
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2019,Age,13-15 Years,85.4,81.6 to 88.6,1052
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2018,Age,13-15 Years,83.0,79.1 to 86.3,1169
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2010,Age,13-15 Years,63.2,56.0 to 69.8,730
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2011,Age,13-15 Years,77.5,70.0 to 83.5,1012
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2013,Age,13-15 Years,84.2,78.2 to 88.8,546
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2012,Age,13-15 Years,82.5,77.4 to 86.6,784
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2010,Age,13-17 Years,27.0,21.3 to 33.6,824
≥2 Doses Hep A,,States/Local Areas,Texas,2021,Age,13-17 Years,84.3,79.7 to 88.0,990
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2012,Age,13-15 Years,5.3,3.4 to 8.2,487
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2015,Age,13-15 Years,24.3,19.7 to 29.5,842
HPV,"≥3 Doses, Males",States/Local Areas,Texas,2014,Age,13-15 Years,17.5,12.0 to 25.0,526
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2009,Age,13-17 Years,23.4,18.1 to 29.9,696
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2008,Age,13-17 Years,9.7,5.8 to 15.6,370
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2015,Age,13-17 Years,40.9,36.0 to 46.0,1294
≥2 Doses Hep A,,States/Local Areas,Texas,2020,Age,13-17 Years,87.1,83.3 to 90.1,1141
≥2 Doses Hep A,,States/Local Areas,Texas,2022,Age,13-17 Years,80.6,74.7 to 85.4,794
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2015,Age,13-17 Years,85.1,82.3 to 87.5,2617
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2022,Age,13-17 Years,58.5,52.1 to 64.6,794
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2021,Age,13-17 Years,51.5,46.0 to 56.9,990
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2020,Age,13-17 Years,54.9,49.9 to 59.9,1141
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2019,Age,13-17 Years,48.4,44.9 to 52.0,1850
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2022,Age,13-17 Years,54.9,46.3 to 63.2,427
HPV,"≥2 Doses, Males and Females",States/Local Areas,Texas,2022,Age,13-17 Years,59.9,53.5 to 65.9,794
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2011,Age,13-17 Years,80.7,77.1 to 83.9,2224
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2009,Age,13-17 Years,57.2,52.0 to 62.3,1470
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2010,Age,13-17 Years,71.9,67.4 to 76.0,1709
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2022,Age,13-15 Years,84.4,77.5 to 89.4,488
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2008,Age,13-17 Years,40.8,34.0 to 48.1,840
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2019,Age,13-17 Years,49.6,44.6 to 54.6,953
≥2 Doses MMR,,States/Local Areas,Texas,2011,Age,13-17 Years,88.1,85.2 to 90.6,2224
≥2 Doses MMR,,States/Local Areas,Texas,2010,Age,13-17 Years,84.3,80.4 to 87.5,1709
≥2 Doses MMR,,States/Local Areas,Texas,2009,Age,13-17 Years,81.5,77.1 to 85.2,1470
≥2 Doses MMR,,States/Local Areas,Texas,2008,Age,13-17 Years,81.6,75.6 to 86.5,840
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2016,Age,13-17 Years,32.9,29.6 to 36.5,1927
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2017,Age,13-17 Years,39.7,36.5 to 43.0,2256
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2018,Age,13-17 Years,43.5,40.1 to 47.0,2079
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2014,Age,13-17 Years,88.2,84.8 to 91.0,1652
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2013,Age,13-17 Years,86.1,82.1 to 89.3,1112
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2012,Age,13-17 Years,82.5,79.0 to 85.6,1594
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2008,Age,13-17 Years,77.6,71.2 to 83.0,840
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2014,Age,13-17 Years,85.0,81.1 to 88.3,1652
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2015,Age,13-17 Years,85.4,82.7 to 87.7,2617
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2022,Age,13-17 Years,82.4,76.8 to 86.9,794
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2018,Age,13-17 Years,84.4,81.6 to 86.8,2079
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2021,Age,13-17 Years,85.8,81.4 to 89.3,990
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2020,Age,13-17 Years,88.2,84.7 to 91.0,1141
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2009,Age,13-17 Years,75.7,71.0 to 79.9,1470
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2010,Age,13-17 Years,79.5,75.4 to 83.0,1709
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2013,Age,13-17 Years,84.5,80.2 to 87.9,1112
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2011,Age,13-17 Years,82.6,78.7 to 86.0,2224
Varicella,≥2 Doses or history of disease,States/Local Areas,Texas,2012,Age,13-17 Years,85.7,82.6 to 88.2,1594
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2016,Age,13-15 Years,85.3,81.8 to 88.2,1028
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2017,Age,13-15 Years,83.8,79.9 to 87.0,1241
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2008,Age,13-15 Years,34.0,22.3 to 48.0,233
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2014,Age,13-17 Years,50.7,43.7 to 57.6,793
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2013,Age,13-17 Years,56.2,48.7 to 63.4,514
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2012,Age,13-17 Years,51.2,45.4 to 57.0,798
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2016,Age,13-17 Years,80.4,76.9 to 83.5,1621
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2015,Age,13-17 Years,81.6,78.3 to 84.5,2100
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2014,Age,13-17 Years,80.2,75.1 to 84.4,1300
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2013,Age,13-17 Years,79.4,74.1 to 83.9,834
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2017,Age,13-17 Years,82.9,80.0 to 85.5,1945
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2010,Age,13-17 Years,47.5,40.5 to 54.6,824
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2011,Age,13-17 Years,48.8,42.3 to 55.4,1057
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2021,Age,13-15 Years,87.2,81.3 to 91.5,557
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2020,Age,13-15 Years,86.6,81.3 to 90.6,661
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2016,Age,13-17 Years,93.2,90.8 to 95.1,1621
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2015,Age,13-17 Years,94.0,91.9 to 95.5,2100
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2014,Age,13-17 Years,93.4,89.7 to 95.8,1300
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2013,Age,13-17 Years,93.4,88.9 to 96.1,834
≥3 Doses HepB,,States/Local Areas,Texas,2015,Age,13-17 Years,85.3,82.6 to 87.7,2617
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2017,Age,13-17 Years,91.7,89.4 to 93.5,1945
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2020,Age,13-17 Years,92.4,89.3 to 94.7,1040
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2018,Age,13-17 Years,82.0,78.9 to 84.8,1797
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2021,Age,13-17 Years,84.7,80.1 to 88.5,924
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2020,Age,13-17 Years,86.7,82.9 to 89.9,1040
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2019,Age,13-17 Years,81.6,78.2 to 84.6,1666
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2018,Age,13-17 Years,89.5,86.9 to 91.6,1797
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2012,Age,13-17 Years,94.1,90.9 to 96.2,1145
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2019,Age,13-17 Years,90.1,87.6 to 92.2,1666
≥3 Doses HepB,,States/Local Areas,Texas,2016,Age,13-17 Years,84.5,81.6 to 87.0,1927
≥3 Doses HepB,,States/Local Areas,Texas,2019,Age,13-17 Years,83.8,80.8 to 86.5,1850
≥3 Doses HepB,,States/Local Areas,Texas,2018,Age,13-17 Years,83.5,80.7 to 85.9,2079
≥3 Doses HepB,,States/Local Areas,Texas,2017,Age,13-17 Years,84.7,82.2 to 87.0,2256
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2022,Age,13-15 Years,79.0,71.3 to 85.0,456
≥3 Doses HepB,,States/Local Areas,Texas,2009,Age,13-17 Years,86.1,82.3 to 89.1,1470
≥3 Doses HepB,,States/Local Areas,Texas,2010,Age,13-17 Years,87.2,83.5 to 90.1,1709
≥3 Doses HepB,,States/Local Areas,Texas,2008,Age,13-17 Years,86.5,81.3 to 90.4,840
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2009,Age,13-17 Years,89.3,83.6 to 93.2,736
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2010,Age,13-17 Years,92.2,88.0 to 95.0,981
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2008,Age,13-17 Years,79.4,66.6 to 88.2,315
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2011,Age,13-17 Years,73.1,67.5 to 78.1,1488
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2010,Age,13-17 Years,60.2,53.7 to 66.3,981
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2008,Age,13-17 Years,31.8,22.1 to 43.4,315
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2009,Age,13-17 Years,46.7,39.1 to 54.4,736
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2011,Age,13-17 Years,92.2,86.3 to 95.7,1488
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2008,Age,13-17 Years,31.6,23.2 to 41.5,370
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2012,Age,13-17 Years,79.1,74.9 to 82.8,1145
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2009,Age,13-17 Years,37.6,31.3 to 44.5,696
≥3 Doses HepB,,States/Local Areas,Texas,2014,Age,13-17 Years,85.8,82.0 to 88.9,1652
≥3 Doses HepB,,States/Local Areas,Texas,2013,Age,13-17 Years,89.8,86.2 to 92.5,1112
≥3 Doses HepB,,States/Local Areas,Texas,2011,Age,13-17 Years,89.6,86.9 to 91.9,2224
≥3 Doses HepB,,States/Local Areas,Texas,2012,Age,13-17 Years,87.6,84.6 to 90.1,1594
HPV,"≥2 Doses, Males and Females",States/Local Areas,Texas,2019,Age,13-17 Years,51.8,48.2 to 55.4,1850
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2017,Age,13-17 Years,55.2,50.5 to 59.9,1193
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2018,Age,13-17 Years,55.5,50.5 to 60.3,1110
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2019,Age,13-17 Years,64.2,59.0 to 69.1,897
HPV,"≥2 Doses, Males and Females",States/Local Areas,Texas,2018,Age,13-17 Years,46.4,43.0 to 49.9,2079
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2020,Age,13-17 Years,69.6,62.7 to 75.7,578
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2019,Age,13-17 Years,65.9,61.0 to 70.4,953
HPV,"≥2 Doses, Males and Females",States/Local Areas,Texas,2016,Age,13-17 Years,37.3,33.8 to 41.0,1927
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2022,Age,13-17 Years,77.8,68.6 to 84.9,367
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2011,Age,13-17 Years,10.4,7.5 to 14.2,1167
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2021,Age,13-17 Years,73.4,65.2 to 80.3,462
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2020,Age,13-17 Years,76.1,69.9 to 81.4,563
Varicella,≥2 Doses with no disease history,States/Local Areas,Texas,2022,Age,13-17 Years,80.4,74.4 to 85.3,733
HPV,"≥2 Doses, Males and Females",States/Local Areas,Texas,2017,Age,13-17 Years,44.2,40.8 to 47.5,2256
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2022,Age,13-17 Years,85.1,79.4 to 89.5,733
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2012,Age,13-17 Years,24.0,19.3 to 29.4,796
≥1 Dose MenACWY,,States/Local Areas,Texas,2020,Age,13-15 Years,90.2,86.2 to 93.2,715
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2009,Age,13-17 Years,32.3,26.3 to 39.0,696
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2011,Age,13-17 Years,39.3,33.0 to 46.1,1057
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2010,Age,13-17 Years,35.6,29.2 to 42.5,824
≥1 Dose MenACWY,,States/Local Areas,Texas,2019,Age,13-15 Years,85.1,81.3 to 88.2,1157
≥1 Dose MenACWY,,States/Local Areas,Texas,2018,Age,13-15 Years,85.5,82.0 to 88.4,1315
≥1 Dose MenACWY,,States/Local Areas,Texas,2017,Age,13-15 Years,83.3,79.5 to 86.5,1406
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2013,Age,13-17 Years,46.3,39.0 to 53.7,514
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2012,Age,13-17 Years,41.2,35.6 to 47.0,798
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2008,Age,13-17 Years,20.3,13.5 to 29.3,370
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2021,Age,13-17 Years,69.2,62.0 to 75.5,528
≥1 Dose MenACWY,,States/Local Areas,Texas,2010,Age,13-15 Years,72.3,66.7 to 77.3,1098
≥1 Dose MenACWY,,States/Local Areas,Texas,2011,Age,13-15 Years,81.3,75.4 to 86.1,1376
≥1 Dose MenACWY,,States/Local Areas,Texas,2008,Age,13-15 Years,38.9,30.4 to 48.1,513
≥1 Dose MenACWY,,States/Local Areas,Texas,2009,Age,13-15 Years,52.0,45.3 to 58.6,915
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2022,Age,13-17 Years,63.0,54.3 to 70.9,427
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2011,Age,13-17 Years,88.4,85.6 to 90.8,2224
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2010,Age,13-17 Years,83.2,79.3 to 86.4,1709
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2012,Age,13-17 Years,88.1,85.0 to 90.7,1594
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2009,Age,13-17 Years,75.8,71.0 to 80.1,1470
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2008,Age,13-17 Years,79.3,73.4 to 84.3,840
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2021,Age,13-17 Years,89.9,86.3 to 92.6,990
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2018,Age,13-17 Years,59.9,56.4 to 63.4,2079
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2019,Age,13-17 Years,65.1,61.5 to 68.4,1850
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2020,Age,13-17 Years,88.0,84.4 to 90.9,1141
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2019,Age,13-17 Years,86.5,83.7 to 88.9,1850
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2018,Age,13-17 Years,86.4,83.8 to 88.6,2079
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2016,Age,13-17 Years,44.3,39.4 to 49.4,1036
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2015,Age,13-17 Years,41.4,36.7 to 46.2,1323
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2014,Age,13-17 Years,36.6,30.4 to 43.2,859
HPV,"≥1 Dose, Males",States/Local Areas,Texas,2013,Age,13-17 Years,34.1,28.0 to 40.8,598
Varicella,≥1 Dose with no disease history,States/Local Areas,Texas,2021,Age,13-17 Years,88.2,83.7 to 91.6,924
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2018,Age,13-17 Years,64.6,59.5 to 69.3,969
≥3 Doses HepB,,States/Local Areas,Texas,2022,Age,13-17 Years,81.2,75.5 to 85.8,794
≥3 Doses HepB,,States/Local Areas,Texas,2021,Age,13-17 Years,84.4,79.8 to 88.1,990
≥3 Doses HepB,,States/Local Areas,Texas,2020,Age,13-17 Years,86.0,82.2 to 89.0,1141
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2015,Age,13-17 Years,60.1,54.9 to 65.1,1294
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2016,Age,13-17 Years,54.5,49.0 to 59.8,891
HPV,"≥1 Dose, Females",States/Local Areas,Texas,2017,Age,13-17 Years,60.4,55.4 to 65.3,1063
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2013,Age,13-17 Years,90.3,86.7 to 92.9,1112
≥1 Dose MenACWY,,States/Local Areas,Texas,2014,Age,13-15 Years,90.2,86.0 to 93.2,999
≥1 Dose MenACWY,,States/Local Areas,Texas,2015,Age,13-15 Years,90.0,87.1 to 92.2,1652
≥1 Dose MenACWY,,States/Local Areas,Texas,2013,Age,13-15 Years,91.0,86.6 to 94.0,696
≥1 Dose MenACWY,,States/Local Areas,Texas,2012,Age,13-15 Years,87.4,82.8 to 90.9,999
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2015,Age,13-17 Years,89.2,86.9 to 91.2,2617
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2014,Age,13-17 Years,89.5,86.1 to 92.2,1652
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2016,Age,13-17 Years,87.9,85.2 to 90.1,1927
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2016,Age,13-17 Years,49.3,45.6 to 53.0,1927
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2017,Age,13-17 Years,57.8,54.3 to 61.2,2256
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2017,Age,13-17 Years,86.3,83.7 to 88.5,2256
≥1 Dose MenACWY,,States/Local Areas,Texas,2016,Age,13-15 Years,86.5,83.0 to 89.3,1193
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2013,Age,13-15 Years,89.1,84.4 to 92.5,696
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2011,Age,13-17 Years,4.9,3.3 to 7.2,1167
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2012,Age,13-17 Years,14.2,10.6 to 18.8,796
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2016,Age,13-17 Years,31.1,26.7 to 35.8,1036
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2017,Age,13-17 Years,40.9,36.5 to 45.6,1193
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2018,Age,13-17 Years,41.9,37.3 to 46.7,1110
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2014,Age,13-15 Years,89.4,85.1 to 92.5,999
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2015,Age,13-15 Years,85.9,82.4 to 88.7,1652
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2016,Age,13-15 Years,84.8,81.1 to 87.9,1193
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2017,Age,13-15 Years,82.0,78.1 to 85.3,1406
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Texas,2022,Age,13-17 Years,86.3,81.4 to 90.1,794
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2008,Age,13-15 Years,48.3,38.9 to 57.7,513
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2010,Age,13-15 Years,75.8,70.4 to 80.5,1098
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2009,Age,13-15 Years,62.1,55.6 to 68.2,915
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2011,Age,13-15 Years,82.6,77.9 to 86.5,1376
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2012,Age,13-15 Years,84.7,80.2 to 88.3,999
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2019,Age,13-17 Years,54.2,49.0 to 59.2,897
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2018,Age,13-17 Years,51.1,46.1 to 56.2,969
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2014,Age,13-17 Years,44.2,37.5 to 51.3,793
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2015,Age,13-17 Years,50.4,45.2 to 55.5,1294
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2016,Age,13-17 Years,43.8,38.5 to 49.3,891
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2017,Age,13-17 Years,47.5,42.6 to 52.5,1063
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2022,Age,13-17 Years,70.3,64.0 to 75.8,794
≥1 Dose MenACWY,,States/Local Areas,Texas,2021,Age,13-15 Years,89.7,84.9 to 93.1,592
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2021,Age,13-17 Years,71.3,66.0 to 76.1,990
HPV,"≥1 Dose, Males and Females",States/Local Areas,Texas,2020,Age,13-17 Years,72.8,68.2 to 77.0,1141
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2014,Age,13-17 Years,26.0,20.6 to 32.1,859
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2013,Age,13-17 Years,25.2,19.7 to 31.5,598
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018,Age,13-15 Years,82.1,78.3 to 85.4,1315
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2021,Age,13-15 Years,87.5,82.2 to 91.4,592
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2020,Age,13-15 Years,84.8,79.5 to 89.0,715
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2019,Age,13-15 Years,85.7,82.0 to 88.7,1157
HPV,"≥2 Doses, Males",States/Local Areas,Texas,2015,Age,13-17 Years,32.9,28.6 to 37.4,1323
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2022,Age,13-15 Years,48.9,37.8 to 60.1,254
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2021,Age,13-15 Years,46.3,37.3 to 55.4,324
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2018,Age,13-15 Years,46.0,39.7 to 52.4,605
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2020,Age,13-15 Years,54.7,45.6 to 63.5,346
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2019,Age,13-15 Years,51.0,44.4 to 57.4,557
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2022,Age,13-15 Years,54.0,45.9 to 61.9,488
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2017,Age,13-17 Years,43.5,38.7 to 48.5,1063
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2016,Age,13-17 Years,39.7,34.4 to 45.1,891
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2020,Age,13-17 Years,52.9,45.8 to 59.9,578
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2019,Age,13-17 Years,46.3,41.4 to 51.4,953
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2017,Age,13-17 Years,36.0,31.8 to 40.5,1193
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2018,Age,13-17 Years,39.4,34.8 to 44.1,1110
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2022,Age,13-15 Years,58.7,47.0 to 69.5,234
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2021,Age,13-15 Years,46.5,36.3 to 57.1,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2020,Age,13-15 Years,52.0,45.7 to 58.3,715
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2021,Age,13-15 Years,46.4,39.6 to 53.3,592
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2022,Age,13-17 Years,53.7,45.2 to 62.1,427
HPV,"Up-to-Date, Males and Females",States/Local Areas,Texas,2019,Age,13-15 Years,48.2,43.6 to 52.7,1157
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2021,Age,13-17 Years,48.3,41.0 to 55.6,528
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2019,Age,13-17 Years,50.6,45.5 to 55.7,897
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2018,Age,13-17 Years,47.8,42.7 to 52.8,969
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2020,Age,13-17 Years,57.0,49.9 to 63.9,563
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2022,Age,13-17 Years,63.5,53.9 to 72.1,367
HPV,"Up-to-Date, Females",States/Local Areas,Texas,2021,Age,13-17 Years,54.8,46.6 to 62.7,462
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2018,Age,13-15 Years,36.7,31.3 to 42.4,710
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2020,Age,13-15 Years,49.7,40.9 to 58.4,369
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2019,Age,13-15 Years,45.4,39.1 to 51.8,600
HPV,"Up-to-Date, Males",States/Local Areas,Texas,2016,Age,13-17 Years,26.5,22.5 to 30.9,1036
≥1 Dose MenACWY,,States/Local Areas,Texas,2018-2022,Overall,Overall,88.0,86.6 to 89.4,6854
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018-2022,Overall,Overall,84.9,83.2 to 86.4,6854
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2019,Age,13-15 Years,42.5,30.6 to 55.3,101
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2020,Age,13-15 Years,57.6,45.7 to 68.7,121
Varicella,History of disease,States/Local Areas,Idaho,2019,Age,13-17 Years,9.9,6.3 to 15.2,332
Varicella,History of disease,States/Local Areas,Idaho,2020,Age,13-17 Years,15.1,10.8 to 20.6,376
Varicella,History of disease,States/Local Areas,Idaho,2021,Age,13-17 Years,10.1,6.6 to 15.4,334
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2018,Age,13-15 Years,45.2,32.7 to 58.2,74
Varicella,History of disease,States/Local Areas,Idaho,2014,Age,13-17 Years,30.5,24.4 to 37.2,341
Varicella,History of disease,States/Local Areas,Idaho,2015,Age,13-17 Years,31.4,25.7 to 37.8,356
Varicella,History of disease,States/Local Areas,Idaho,2011,Age,13-17 Years,52.2,45.0 to 59.3,385
Varicella,History of disease,States/Local Areas,Idaho,2010,Age,13-17 Years,61.9,55.7 to 67.7,318
Varicella,History of disease,States/Local Areas,Idaho,2012,Age,13-17 Years,41.6,35.4 to 48.1,357
Varicella,History of disease,States/Local Areas,Idaho,2013,Age,13-17 Years,46.2,38.9 to 53.7,272
Varicella,History of disease,States/Local Areas,Idaho,2017,Age,13-17 Years,20.0,15.2 to 25.7,353
Varicella,History of disease,States/Local Areas,Idaho,2016,Age,13-17 Years,20.3,15.6 to 25.9,358
Varicella,History of disease,States/Local Areas,Idaho,2022,Age,13-17 Years,12.1,7.6 to 18.7,251
Varicella,History of disease,States/Local Areas,Idaho,2018,Age,13-17 Years,17.4,12.6 to 23.5,291
Varicella,History of disease,States/Local Areas,Idaho,2008,Age,13-17 Years,74.2,67.9 to 79.7,268
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2016,Age,13-17 Years,43.4,34.9 to 52.3,166
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2022,Age,13-15 Years,73.2,59.1 to 83.8,69
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2021,Age,13-15 Years,62.2,49.6 to 73.4,99
Varicella,History of disease,States/Local Areas,Idaho,2009,Age,13-17 Years,61.7,53.8 to 69.1,227
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2017,Age,13-17 Years,52.1,42.3 to 61.7,162
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2022,Age,13-15 Years,53.6,40.3 to 66.3,89
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2021,Age,13-15 Years,59.9,48.4 to 70.4,119
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2016,Age,13-17 Years,30.0,22.7 to 38.4,192
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2020,Age,13-17 Years,57.4,48.4 to 66.0,197
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2022,Age,13-17 Years,75.0,65.0 to 82.9,121
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2021,Age,13-17 Years,63.7,53.6 to 72.7,153
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2018,Age,13-15 Years,46.7,35.5 to 58.3,95
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2019,Age,13-15 Years,34.1,24.3 to 45.5,116
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2020,Age,13-17 Years,51.8,42.2 to 61.2,179
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2019,Age,13-17 Years,40.7,31.7 to 50.4,177
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2018,Age,13-17 Years,39.2,30.7 to 48.4,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2019,Age,13-15 Years,38.2,30.3 to 46.8,217
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2022,Age,13-17 Years,59.2,48.3 to 69.3,130
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2021,Age,13-15 Years,61.0,52.6 to 68.9,218
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2021,Age,13-17 Years,76.0,67.6 to 82.8,181
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2020,Age,13-17 Years,69.4,60.2 to 77.3,179
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2017,Age,13-17 Years,56.7,47.6 to 65.3,191
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2014,Age,13-17 Years,32.0,24.0 to 41.2,185
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2013,Age,13-17 Years,34.5,25.1 to 45.2,148
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2015,Age,13-17 Years,44.2,35.5 to 53.2,179
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2016,Age,13-17 Years,54.7,46.0 to 63.1,192
HPV,"≥2 Doses, Males and Females",States/Local Areas,Idaho,2019,Age,13-17 Years,46.2,39.3 to 53.3,332
≥3 Doses HepB,,States/Local Areas,Idaho,2017,Age,13-17 Years,89.9,84.6 to 93.4,353
≥3 Doses HepB,,States/Local Areas,Idaho,2019,Age,13-17 Years,90.7,85.8 to 94.0,332
≥3 Doses HepB,,States/Local Areas,Idaho,2018,Age,13-17 Years,88.4,83.4 to 92.1,291
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2018,Age,13-17 Years,94.0,89.6 to 96.6,243
≥3 Doses HepB,,States/Local Areas,Idaho,2015,Age,13-17 Years,83.1,77.7 to 87.5,356
≥3 Doses HepB,,States/Local Areas,Idaho,2016,Age,13-17 Years,86.2,81.5 to 89.9,358
≥3 Doses HepB,,States/Local Areas,Idaho,2014,Age,13-17 Years,84.4,78.7 to 88.8,341
≥3 Doses HepB,,States/Local Areas,Idaho,2013,Age,13-17 Years,91.5,86.7 to 94.7,272
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2014,Age,13-17 Years,59.4,49.0 to 69.0,156
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2015,Age,13-17 Years,57.3,48.2 to 65.9,177
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2012,Age,13-17 Years,51.3,41.9 to 60.7,173
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2013,Age,13-17 Years,55.0,44.3 to 65.2,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2021,Age,13-17 Years,89.0,83.7 to 92.8,305
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2020,Age,13-17 Years,88.6,83.3 to 92.3,325
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2019,Age,13-17 Years,85.1,79.1 to 89.6,296
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2020,Age,13-17 Years,91.9,87.1 to 95.0,325
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2018,Age,13-17 Years,84.9,78.9 to 89.5,243
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2019,Age,13-17 Years,91.9,86.5 to 95.2,296
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2014,Age,13-17 Years,88.6,81.9 to 93.0,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2013,Age,13-17 Years,89.5,81.6 to 94.2,162
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2015,Age,13-17 Years,87.1,80.5 to 91.7,254
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2016,Age,13-17 Years,88.8,83.6 to 92.6,290
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2010,Age,13-17 Years,28.8,21.6 to 37.3,152
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2011,Age,13-17 Years,45.5,35.3 to 56.1,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2017,Age,13-17 Years,81.3,74.9 to 86.3,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2014,Age,13-17 Years,66.5,58.4 to 73.8,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2017,Age,13-17 Years,94.7,90.5 to 97.1,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2015,Age,13-17 Years,67.5,59.9 to 74.3,254
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2016,Age,13-17 Years,74.9,68.4 to 80.5,290
≥3 Doses HepB,,States/Local Areas,Idaho,2012,Age,13-17 Years,91.1,86.8 to 94.0,357
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2009,Age,13-17 Years,30.2,21.0 to 41.4,105
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2012,Age,13-17 Years,57.0,48.1 to 65.4,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2013,Age,13-17 Years,63.8,54.0 to 72.6,162
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2008,Age,13-17 Years,28.4,20.5 to 38.0,131
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2008,Age,13-17 Years,61.1,47.3 to 73.3,71
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2011,Age,13-17 Years,49.9,39.3 to 60.4,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2010,Age,13-17 Years,42.8,33.1 to 53.0,120
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2012,Age,13-17 Years,89.9,83.7 to 93.8,195
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2011,Age,13-17 Years,87.8,79.7 to 92.9,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2009,Age,13-17 Years,25.6,16.5 to 37.4,81
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2009,Age,13-17 Years,74.6,62.0 to 84.1,81
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2010,Age,13-17 Years,76.6,67.0 to 84.0,120
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2022,Age,13-15 Years,93.4,86.7 to 96.9,147
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2019,Age,13-15 Years,87.6,81.3 to 92.0,192
≥3 Doses HepB,,States/Local Areas,Idaho,2011,Age,13-17 Years,86.3,80.2 to 90.8,385
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2021,Age,13-15 Years,91.4,84.7 to 95.3,200
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2020,Age,13-15 Years,89.3,82.9 to 93.5,220
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2009,Age,13-15 Years,22.3,13.5 to 34.6,59
≥3 Doses HepB,,States/Local Areas,Idaho,2009,Age,13-17 Years,83.5,76.6 to 88.7,227
≥3 Doses HepB,,States/Local Areas,Idaho,2010,Age,13-17 Years,90.0,85.7 to 93.1,318
≥3 Doses HepB,,States/Local Areas,Idaho,2008,Age,13-17 Years,73.1,66.4 to 78.8,268
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2015,Age,13-15 Years,69.3,59.8 to 77.4,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2014,Age,13-15 Years,69.6,59.6 to 78.0,174
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2016,Age,13-15 Years,78.6,71.0 to 84.6,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2018,Age,13-15 Years,90.2,83.5 to 94.4,149
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2017,Age,13-15 Years,85.9,78.0 to 91.3,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2013,Age,13-15 Years,63.0,51.7 to 73.0,123
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2012,Age,13-15 Years,63.0,52.5 to 72.4,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2010,Age,13-15 Years,42.8,31.9 to 54.4,90
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2011,Age,13-15 Years,52.4,40.2 to 64.3,137
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2022,Age,13-17 Years,94.1,89.9 to 96.6,251
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2021,Age,13-17 Years,90.1,85.3 to 93.5,334
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2020,Age,13-17 Years,90.3,85.7 to 93.5,376
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2009,Age,13-17 Years,71.5,63.5 to 78.3,227
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2010,Age,13-17 Years,78.2,72.7 to 82.8,318
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2019,Age,13-17 Years,86.6,81.1 to 90.7,332
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2015,Age,13-17 Years,77.7,71.9 to 82.7,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2018,Age,13-17 Years,87.6,82.5 to 91.3,291
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2016,Age,13-17 Years,80.0,74.5 to 84.6,358
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2017,Age,13-17 Years,85.0,79.7 to 89.1,353
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2012,Age,13-17 Years,74.9,68.7 to 80.2,357
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2011,Age,13-17 Years,76.1,69.3 to 81.7,385
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2014,Age,13-17 Years,76.7,70.5 to 82.0,341
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2013,Age,13-17 Years,80.6,74.1 to 85.7,272
≥1 Dose MenACWY,,States/Local Areas,Idaho,2016,Age,13-15 Years,87.1,80.4 to 91.7,230
≥1 Dose MenACWY,,States/Local Areas,Idaho,2017,Age,13-15 Years,93.7,89.3 to 96.3,214
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2009,Age,13-17 Years,61.4,53.5 to 68.7,227
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2008,Age,13-17 Years,51.3,44.5 to 58.0,268
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2018,Age,13-17 Years,67.7,57.8 to 76.2,136
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2017,Age,13-17 Years,68.4,58.6 to 76.8,162
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2022,Age,13-17 Years,93.3,88.6 to 96.2,225
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2021,Age,13-17 Years,92.6,88.0 to 95.5,305
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2016,Age,13-17 Years,59.8,50.7 to 68.4,166
≥1 Dose MenACWY,,States/Local Areas,Idaho,2008,Age,13-15 Years,33.3,25.2 to 42.5,152
≥1 Dose MenACWY,,States/Local Areas,Idaho,2009,Age,13-15 Years,40.9,31.8 to 50.7,142
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2019,Age,13-17 Years,67.8,57.4 to 76.6,155
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2022,Age,13-17 Years,94.6,90.0 to 97.2,225
≥3 Doses HepB,,States/Local Areas,Idaho,2022,Age,13-17 Years,91.3,85.8 to 94.8,251
≥3 Doses HepB,,States/Local Areas,Idaho,2021,Age,13-17 Years,90.8,86.4 to 93.9,334
≥3 Doses HepB,,States/Local Areas,Idaho,2020,Age,13-17 Years,89.5,84.5 to 93.0,376
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2012,Age,13-17 Years,16.2,10.0 to 25.2,184
HPV,"≥2 Doses, Males and Females",States/Local Areas,Idaho,2017,Age,13-17 Years,51.2,44.5 to 57.8,353
HPV,"≥2 Doses, Males and Females",States/Local Areas,Idaho,2016,Age,13-17 Years,42.9,36.9 to 49.1,358
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2018,Age,13-17 Years,59.8,50.1 to 68.8,155
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2019,Age,13-17 Years,60.5,50.3 to 69.8,177
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2022,Age,13-17 Years,84.9,75.9 to 90.9,121
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2021,Age,13-17 Years,81.8,73.0 to 88.2,153
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2020,Age,13-17 Years,75.7,67.6 to 82.3,197
HPV,"≥2 Doses, Males and Females",States/Local Areas,Idaho,2018,Age,13-17 Years,45.5,38.9 to 52.3,291
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2014,Age,13-17 Years,80.7,74.6 to 85.6,341
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2015,Age,13-17 Years,84.3,78.7 to 88.7,356
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2017,Age,13-17 Years,90.1,85.4 to 93.4,353
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2016,Age,13-17 Years,89.8,85.6 to 92.9,358
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2008,Age,13-17 Years,22.1,15.0 to 31.3,131
≥1 Dose MenACWY,,States/Local Areas,Idaho,2015,Age,13-15 Years,84.9,77.7 to 90.1,217
≥1 Dose MenACWY,,States/Local Areas,Idaho,2014,Age,13-15 Years,82.8,74.8 to 88.6,230
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2022,Age,13-17 Years,77.0,67.3 to 84.4,130
≥1 Dose MenACWY,,States/Local Areas,Idaho,2010,Age,13-15 Years,42.9,35.5 to 50.6,204
≥1 Dose MenACWY,,States/Local Areas,Idaho,2011,Age,13-15 Years,49.8,41.1 to 58.5,250
≥1 Dose MenACWY,,States/Local Areas,Idaho,2012,Age,13-15 Years,68.8,60.5 to 76.0,212
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2011,Age,13-17 Years,63.3,56.1 to 70.0,385
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2010,Age,13-17 Years,58.0,51.8 to 64.0,318
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2012,Age,13-17 Years,70.7,64.6 to 76.2,357
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2013,Age,13-17 Years,82.5,75.8 to 87.7,272
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2011,Age,13-17 Years,38.7,29.0 to 49.4,176
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2010,Age,13-17 Years,22.1,15.7 to 30.3,152
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2009,Age,13-17 Years,23.7,15.6 to 34.5,105
≥1 Dose MenACWY,,States/Local Areas,Idaho,2020,Age,13-15 Years,88.6,82.3 to 92.9,253
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2018,Age,13-17 Years,89.3,84.1 to 93.0,291
≥1 Dose MenACWY,,States/Local Areas,Idaho,2019,Age,13-15 Years,88.7,82.6 to 92.8,217
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2017,Age,13-17 Years,62.4,55.7 to 68.6,353
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2016,Age,13-17 Years,57.2,50.9 to 63.3,358
≥1 Dose MenACWY,,States/Local Areas,Idaho,2013,Age,13-15 Years,79.1,70.2 to 85.9,180
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018,Age,13-17 Years,63.6,56.7 to 70.0,291
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2014,Age,13-17 Years,54.2,44.0 to 64.1,156
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018,Age,13-15 Years,90.9,84.7 to 94.7,169
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2012,Age,13-17 Years,41.6,32.4 to 51.4,173
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2013,Age,13-17 Years,45.8,35.6 to 56.4,124
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2022,Age,13-17 Years,80.8,74.4 to 85.9,251
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2021,Age,13-17 Years,78.8,72.9 to 83.7,334
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2020,Age,13-17 Years,72.5,66.4 to 77.8,376
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2022,Age,13-17 Years,90.7,84.9 to 94.4,251
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2021,Age,13-17 Years,91.4,86.4 to 94.7,334
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2019,Age,13-17 Years,64.0,56.8 to 70.7,332
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2020,Age,13-17 Years,87.7,82.5 to 91.5,376
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2019,Age,13-17 Years,89.3,84.0 to 93.0,332
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2015,Age,13-17 Years,43.5,34.8 to 52.5,177
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2017,Age,13-17 Years,58.1,48.3 to 67.4,162
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2016,Age,13-17 Years,48.7,39.9 to 57.6,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2008,Age,13-15 Years,34.9,26.7 to 44.1,152
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2010,Age,13-15 Years,53.5,45.8 to 61.1,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2009,Age,13-15 Years,40.9,31.8 to 50.7,142
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2011,Age,13-15 Years,58.4,49.5 to 66.8,250
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2012,Age,13-15 Years,69.1,60.9 to 76.2,212
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2018,Age,13-17 Years,49.6,39.8 to 59.5,136
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2019,Age,13-17 Years,50.0,39.8 to 60.1,155
≥1 Dose MenACWY,,States/Local Areas,Idaho,2021,Age,13-15 Years,90.4,83.9 to 94.5,218
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2014,Age,13-17 Years,22.8,15.9 to 31.7,185
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2013,Age,13-17 Years,21.6,14.1 to 31.6,148
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2016,Age,13-15 Years,88.9,82.9 to 92.9,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2017,Age,13-15 Years,90.0,83.9 to 94.0,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2015,Age,13-15 Years,85.8,78.9 to 90.7,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2014,Age,13-15 Years,75.7,67.5 to 82.4,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2013,Age,13-15 Years,79.5,71.0 to 86.0,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2019,Age,13-15 Years,87.2,80.6 to 91.9,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2020,Age,13-15 Years,86.6,79.8 to 91.4,253
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2021,Age,13-15 Years,92.6,86.7 to 96.0,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018,Age,13-15 Years,86.3,78.9 to 91.4,169
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2015,Age,13-17 Years,36.4,28.3 to 45.3,179
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2018,Age,13-17 Years,41.6,33.0 to 50.9,155
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2017,Age,13-17 Years,44.5,35.9 to 53.5,191
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2016,Age,13-17 Years,37.3,29.3 to 46.0,192
≥2 Doses MMR,,States/Local Areas,Idaho,2022,Age,13-17 Years,92.7,87.4 to 95.9,251
≥2 Doses MMR,,States/Local Areas,Idaho,2021,Age,13-17 Years,89.2,84.0 to 92.9,334
≥1 Dose MenACWY,,States/Local Areas,Idaho,2022,Age,13-17 Years,90.5,84.4 to 94.4,251
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2010,Age,13-15 Years,19.2,11.9 to 29.5,98
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2011,Age,13-15 Years,38.4,26.5 to 51.8,116
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2012,Age,13-15 Years,32.6,22.3 to 44.9,102
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2008,Age,13-15 Years,14.4,7.9 to 24.7,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2016,Age,13-17 Years,36.5,30.8 to 42.6,358
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2019,Age,13-17 Years,44.1,37.2 to 51.2,332
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018,Age,13-17 Years,43.4,36.9 to 50.2,291
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2017,Age,13-17 Years,44.1,37.6 to 50.7,353
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2014,Age,13-17 Years,70.8,64.1 to 76.7,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2013,Age,13-17 Years,74.6,67.4 to 80.6,272
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2012,Age,13-17 Years,64.5,58.2 to 70.4,357
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2009,Age,13-17 Years,38.6,31.4 to 46.3,227
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2010,Age,13-17 Years,49.2,43.0 to 55.3,318
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2011,Age,13-17 Years,58.3,51.0 to 65.2,385
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2008,Age,13-17 Years,31.7,25.7 to 38.3,268
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2022,Age,13-15 Years,88.8,80.4 to 93.9,158
≥2 Doses MMR,,States/Local Areas,Idaho,2011,Age,13-17 Years,79.9,72.9 to 85.5,385
≥2 Doses MMR,,States/Local Areas,Idaho,2010,Age,13-17 Years,84.2,79.0 to 88.3,318
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2019,Age,13-17 Years,42.6,33.5 to 52.3,177
≥2 Doses MMR,,States/Local Areas,Idaho,2009,Age,13-17 Years,83.7,76.8 to 88.9,227
≥2 Doses MMR,,States/Local Areas,Idaho,2008,Age,13-17 Years,73.2,66.4 to 79.0,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2020,Age,13-17 Years,54.5,47.9 to 61.0,376
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2008,Age,13-17 Years,77.5,71.3 to 82.7,268
HPV,"≥3 Doses, Males",States/Local Areas,Idaho,2014,Age,13-17 Years,17.2,11.3 to 25.2,185
HPV,"≥3 Doses, Males",States/Local Areas,Idaho,2015,Age,13-17 Years,26.4,19.3 to 35.0,179
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2015,Age,13-17 Years,30.3,22.8 to 39.0,177
HPV,"≥3 Doses, Males",States/Local Areas,Idaho,2014,Age,13-15 Years,20.1,12.3 to 30.9,118
≥2 Doses Hep A,,States/Local Areas,Idaho,2021,Age,13-17 Years,90.4,85.7 to 93.6,334
≥2 Doses Hep A,,States/Local Areas,Idaho,2022,Age,13-17 Years,91.1,85.7 to 94.7,251
≥2 Doses Hep A,,States/Local Areas,Idaho,2020,Age,13-17 Years,87.2,82.3 to 90.9,376
HPV,"≥3 Doses, Males",States/Local Areas,Idaho,2015,Age,13-15 Years,27.8,18.9 to 38.8,113
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2011,Age,13-17 Years,30.0,21.1 to 40.6,176
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2010,Age,13-17 Years,17.6,11.8 to 25.4,152
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2009,Age,13-17 Years,16.9,10.0 to 27.2,105
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2008,Age,13-17 Years,8.0,4.4 to 14.1,131
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2012,Age,13-17 Years,27.8,20.4 to 36.7,173
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2014,Age,13-17 Years,38.3,29.0 to 48.5,156
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2013,Age,13-17 Years,31.3,22.6 to 41.6,124
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2022,Age,13-17 Years,66.9,59.4 to 73.6,251
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2021,Age,13-17 Years,61.6,54.8 to 67.9,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2015,Age,13-17 Years,82.5,76.7 to 87.1,356
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2020,Age,13-15 Years,53.4,45.1 to 61.6,253
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2020,Age,13-15 Years,50.1,38.6 to 61.6,132
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2017,Age,13-17 Years,36.5,28.3 to 45.4,191
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2019,Age,13-17 Years,47.6,37.6 to 57.9,155
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2018,Age,13-17 Years,47.9,38.1 to 57.7,136
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2021,Age,13-17 Years,59.5,50.4 to 68.0,181
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2022,Age,13-15 Years,61.9,52.0 to 70.9,158
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2023,Age,13-17 Years,89.0,81.3 to 93.7,164
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2023,Age,13-17 Years,94.0,90.0 to 96.5,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2023,Age,13-17 Years,93.7,89.6 to 96.2,319
≥1 Dose MenACWY,,States/Local Areas,Virginia,2023,Age,13-17 Years,87.5,81.1 to 91.9,319
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2023,Age,13-17 Years,85.4,78.9 to 90.1,319
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2023,Age,13-17 Years,81.5,70.4 to 89.1,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2023,Age,13-17 Years,62.9,54.3 to 70.8,319
≥2 Doses MMR,,States/Local Areas,Virginia,2023,Age,13-17 Years,93.6,88.1 to 96.6,319
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2023,Age,13-17 Years,66.4,54.6 to 76.5,164
≥3 Doses HepB,,States/Local Areas,Virginia,2023,Age,13-17 Years,92.8,87.3 to 96.0,319
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2023,Age,13-17 Years,95.7,89.9 to 98.2,301
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2023,Age,13-17 Years,93.2,87.7 to 96.3,319
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2012,Age,13-17 Years,64.7,60.8 to 68.4,1936
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2023,Age,13-17 Years,92.7,86.9 to 96.1,301
≥2 Doses Hep A,,States/Local Areas,Virginia,2023,Age,13-17 Years,86.0,78.7 to 91.1,319
≥1 Dose MenACWY,,States/Local Areas,Virginia,2023,Age,13-15 Years,86.1,76.5 to 92.1,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2023,Age,13-15 Years,93.7,88.1 to 96.7,193
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2023,Age,13-15 Years,56.0,44.5 to 66.9,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2023,Age,13-15 Years,93.7,83.9 to 97.7,182
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2023,Age,13-15 Years,53.9,37.0 to 69.9,93
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2023,Age,13-17 Years,59.1,46.6 to 70.6,155
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2023,Age,13-15 Years,58.0,42.6 to 72.0,100
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2022,Age,13-17 Years,64.9,57.2 to 71.9,281
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2016,Age,13-17 Years,39.2,32.1 to 46.8,451
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2021,Age,13-15 Years,89.6,81.8 to 94.3,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2008,Age,13-17 Years,49.1,42.1 to 56.1,272
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2022,Age,13-15 Years,88.3,82.8 to 92.2,365
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2011,Age,13-17 Years,77.9,71.7 to 83.0,417
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2009,Age,13-17 Years,56.1,49.7 to 62.3,358
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2010,Age,13-17 Years,72.0,65.3 to 77.9,332
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018,Age,13-17 Years,54.9,45.4 to 64.0,327
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2017,Age,13-17 Years,59.0,51.1 to 66.6,413
≥2 Doses MMR,,States/Local Areas,Virginia,2011,Age,13-17 Years,90.6,86.5 to 93.5,417
≥2 Doses MMR,,States/Local Areas,Virginia,2010,Age,13-17 Years,86.0,80.1 to 90.3,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2012,Age,13-17 Years,88.7,83.6 to 92.4,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2014,Age,13-17 Years,91.2,86.4 to 94.4,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2013,Age,13-17 Years,83.6,76.0 to 89.1,302
≥2 Doses MMR,,States/Local Areas,Virginia,2008,Age,13-17 Years,83.0,76.7 to 87.9,272
≥2 Doses MMR,,States/Local Areas,Virginia,2009,Age,13-17 Years,90.2,84.9 to 93.8,358
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2021,Age,13-17 Years,64.9,57.6 to 71.5,566
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2022,Age,13-17 Years,62.7,57.4 to 67.7,595
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2020,Age,13-17 Years,56.4,50.0 to 62.5,677
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2019,Age,13-17 Years,62.6,51.2 to 72.8,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2019,Age,13-17 Years,55.2,46.9 to 63.2,363
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2022,Age,13-17 Years,64.1,56.7 to 70.9,314
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Poverty,Below Poverty Level,83.5,74.2 to 89.9,136
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Poverty,Living At or Above Poverty Level,85.7,83.0 to 88.0,2323
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Poverty,Living At or Above Poverty Level,73.1,69.8 to 76.2,2323
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Poverty,Below Poverty Level,82.1,71.8 to 89.2,136
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",76.5,68.4 to 83.0,240
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",72.4,68.3 to 76.1,1554
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.6,80.9 to 92.2,445
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,Hispanic,85.6,77.5 to 91.1,289
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,Hispanic,86.0,78.2 to 91.3,289
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.0,82.5 to 93.3,240
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",82.8,75.2 to 88.4,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.5,88.8 to 93.6,1554
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",51.2,42.8 to 59.6,445
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",86.1,82.8 to 88.8,1554
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,Hispanic,65.3,55.8 to 73.7,289
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",62.1,53.6 to 70.0,240
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,Hispanic,83.5,75.1 to 89.4,289
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",69.0,60.5 to 76.4,445
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.0,73.8 to 86.5,445
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",58.0,53.6 to 62.2,1554
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.2,86.3 to 91.6,1551
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a Non-MSA,50.4,38.3 to 62.4,117
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,91.0,87.0 to 93.8,860
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a Non-MSA,82.0,70.8 to 89.6,117
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,84.9,81.7 to 87.6,1551
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a Non-MSA,68.2,55.5 to 78.6,117
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,85.0,80.0 to 88.9,860
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,58.2,54.0 to 62.3,1551
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,62.2,56.1 to 67.9,860
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,73.1,69.2 to 76.7,1551
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,77.9,72.4 to 82.6,860
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Urbanicity,Living In a Non-MSA,87.8,76.8 to 94.0,117
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Overall,Overall,58.9,55.5 to 62.1,2528
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Overall,Overall,74.2,71.2 to 77.1,2528
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2014,Age,13-17 Years,79.5,72.4 to 85.1,350
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2015,Age,13-17 Years,73.7,65.9 to 80.3,385
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2017,Age,13-17 Years,87.7,81.2 to 92.2,413
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2016,Age,13-17 Years,81.1,74.3 to 86.4,451
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2020,Age,13-17 Years,93.2,89.4 to 95.6,677
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2022,Age,13-17 Years,89.8,86.1 to 92.5,595
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2013,Age,13-17 Years,73.8,65.3 to 80.9,302
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2012,Age,13-17 Years,77.9,71.4 to 83.3,334
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2011,Age,13-17 Years,71.0,64.7 to 76.5,417
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2009,Age,13-17 Years,71.0,64.9 to 76.4,358
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2010,Age,13-17 Years,63.6,56.7 to 69.9,332
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2017,Age,13-15 Years,94.2,87.9 to 97.4,243
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2020,Age,13-15 Years,93.4,87.9 to 96.5,396
≥3 Doses HepB,,States/Local Areas,Virginia,2015,Age,13-17 Years,89.2,83.0 to 93.3,385
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2008,Age,13-15 Years,36.1,25.1 to 48.8,90
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2009,Age,13-15 Years,41.2,31.8 to 51.3,132
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2013,Age,13-15 Years,66.5,54.2 to 76.9,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2012,Age,13-15 Years,69.6,59.3 to 78.2,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2010,Age,13-15 Years,49.5,39.3 to 59.8,138
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2011,Age,13-15 Years,57.6,48.1 to 66.5,199
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2018,Age,13-15 Years,88.9,79.0 to 94.4,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2014,Age,13-15 Years,79.8,70.5 to 86.8,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2015,Age,13-15 Years,71.6,60.5 to 80.6,211
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2021,Age,13-17 Years,93.7,88.9 to 96.5,566
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2014,Age,13-17 Years,59.2,48.6 to 69.1,166
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2013,Age,13-17 Years,51.9,39.3 to 64.3,155
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2012,Age,13-17 Years,50.9,40.1 to 61.6,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2016,Age,13-17 Years,78.2,70.7 to 84.3,402
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2015,Age,13-17 Years,67.3,58.2 to 75.2,321
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2014,Age,13-17 Years,76.4,68.4 to 82.8,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2013,Age,13-17 Years,68.0,58.3 to 76.3,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2017,Age,13-17 Years,86.2,79.1 to 91.2,371
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2010,Age,13-17 Years,54.0,44.3 to 63.5,162
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2011,Age,13-17 Years,46.9,37.6 to 56.4,176
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2016,Age,13-17 Years,90.4,84.0 to 94.4,402
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2015,Age,13-17 Years,91.7,84.6 to 95.7,321
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2014,Age,13-17 Years,93.0,87.0 to 96.4,299
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2013,Age,13-17 Years,96.1,88.6 to 98.7,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2018,Age,13-17 Years,85.7,77.5 to 91.3,288
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2020,Age,13-17 Years,94.9,91.4 to 97.0,633
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2020,Age,13-17 Years,92.5,88.5 to 95.2,633
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2021,Age,13-17 Years,93.4,88.3 to 96.3,535
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2019,Age,13-17 Years,91.7,85.7 to 95.3,330
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2018,Age,13-17 Years,93.4,88.0 to 96.5,288
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2017,Age,13-17 Years,97.2,93.0 to 98.9,371
≥3 Doses HepB,,States/Local Areas,Virginia,2019,Age,13-17 Years,92.8,87.1 to 96.1,363
HPV,"≥2 Doses, Males and Females",States/Local Areas,Virginia,2019,Age,13-17 Years,59.7,51.3 to 67.4,363
≥3 Doses HepB,,States/Local Areas,Virginia,2016,Age,13-17 Years,87.2,80.9 to 91.6,451
≥3 Doses HepB,,States/Local Areas,Virginia,2018,Age,13-17 Years,91.7,85.7 to 95.3,327
≥3 Doses HepB,,States/Local Areas,Virginia,2017,Age,13-17 Years,94.2,88.8 to 97.1,413
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2012,Age,13-17 Years,94.9,90.6 to 97.3,258
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2009,Age,13-17 Years,36.8,28.6 to 45.8,175
≥3 Doses HepB,,States/Local Areas,Virginia,2012,Age,13-17 Years,92.7,88.1 to 95.5,334
≥3 Doses HepB,,States/Local Areas,Virginia,2011,Age,13-17 Years,93.1,89.2 to 95.6,417
≥3 Doses HepB,,States/Local Areas,Virginia,2014,Age,13-17 Years,88.1,82.1 to 92.3,350
≥3 Doses HepB,,States/Local Areas,Virginia,2013,Age,13-17 Years,94.3,89.1 to 97.1,302
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2012,Age,13-17 Years,69.1,60.9 to 76.2,258
≥3 Doses HepB,,States/Local Areas,Virginia,2009,Age,13-17 Years,86.7,80.8 to 91.0,358
≥3 Doses HepB,,States/Local Areas,Virginia,2010,Age,13-17 Years,89.6,83.8 to 93.5,332
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2009,Age,13-17 Years,83.0,73.9 to 89.3,166
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2010,Age,13-17 Years,87.7,81.0 to 92.2,206
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2011,Age,13-17 Years,54.9,47.3 to 62.3,290
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2010,Age,13-17 Years,43.1,34.8 to 51.7,206
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2008,Age,13-17 Years,40.6,31.9 to 50.0,151
≥3 Doses HepB,,States/Local Areas,Virginia,2008,Age,13-17 Years,83.7,76.8 to 88.8,272
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2019,Age,13-15 Years,93.0,85.5 to 96.8,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2008,Age,13-17 Years,31.1,22.4 to 41.4,123
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2009,Age,13-17 Years,36.7,28.6 to 45.8,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2022,Age,13-15 Years,88.0,82.4 to 92.0,344
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2011,Age,13-17 Years,87.2,80.5 to 91.8,290
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2008,Age,13-17 Years,69.4,57.6 to 79.1,123
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2021,Age,13-15 Years,93.3,86.2 to 96.9,327
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2020,Age,13-17 Years,71.3,62.3 to 78.9,324
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2016,Age,13-17 Years,56.4,46.2 to 66.0,242
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2015,Age,13-17 Years,40.1,30.1 to 51.0,214
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2014,Age,13-17 Years,36.3,26.6 to 47.3,184
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2013,Age,13-17 Years,26.4,17.2 to 38.2,147
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2021,Age,13-17 Years,84.8,76.0 to 90.8,259
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2019,Age,13-17 Years,71.3,59.3 to 80.9,175
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2018,Age,13-17 Years,64.0,50.7 to 75.4,160
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2012,Age,13-17 Years,12.1,7.4 to 19.1,179
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2017,Age,13-17 Years,69.0,58.3 to 78.0,232
HPV,"≥2 Doses, Males and Females",States/Local Areas,Virginia,2018,Age,13-17 Years,57.8,48.3 to 66.8,327
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2022,Age,13-17 Years,89.0,85.1 to 92.0,557
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2020,Age,13-17 Years,76.2,68.0 to 82.9,353
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2022,Age,13-17 Years,80.4,73.8 to 85.7,281
HPV,"≥2 Doses, Males and Females",States/Local Areas,Virginia,2017,Age,13-17 Years,62.7,54.8 to 70.0,413
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2021,Age,13-17 Years,96.6,92.4 to 98.5,535
HPV,"≥2 Doses, Males and Females",States/Local Areas,Virginia,2016,Age,13-17 Years,43.3,36.0 to 50.9,451
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2008,Age,13-17 Years,21.2,14.7 to 29.6,151
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2009,Age,13-17 Years,24.6,17.8 to 32.9,175
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2010,Age,13-17 Years,41.5,32.1 to 51.5,162
HPV,"≥3 Doses, Males",States/Local Areas,Virginia,2014,Age,13-15 Years,20.5,11.1 to 34.8,111
HPV,"≥3 Doses, Males",States/Local Areas,Virginia,2015,Age,13-15 Years,25.0,14.5 to 39.5,139
Varicella,≥2 Doses with no disease history,States/Local Areas,Virginia,2016,Age,13-15 Years,80.3,70.8 to 87.3,262
≥2 Doses Hep A,,States/Local Areas,Virginia,2021,Age,13-17 Years,85.6,79.5 to 90.1,566
HPV,"≥3 Doses, Males",States/Local Areas,Virginia,2014,Age,13-17 Years,22.5,14.5 to 33.1,184
HPV,"≥3 Doses, Males",States/Local Areas,Virginia,2015,Age,13-17 Years,25.7,17.5 to 35.9,214
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2018,Age,13-17 Years,87.3,79.9 to 92.3,327
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2019,Age,13-17 Years,92.8,87.5 to 95.9,363
Varicella,≥2 Doses or history of disease,States/Local Areas,Virginia,2008,Age,13-17 Years,67.8,60.6 to 74.2,272
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2012,Age,13-17 Years,27.9,19.7 to 38.0,155
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2011,Age,13-17 Years,29.8,21.8 to 39.2,176
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2014,Age,13-17 Years,35.9,26.8 to 46.1,166
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2013,Age,13-17 Years,27.6,18.4 to 39.3,155
≥2 Doses Hep A,,States/Local Areas,Virginia,2020,Age,13-17 Years,81.1,75.6 to 85.6,677
≥2 Doses Hep A,,States/Local Areas,Virginia,2022,Age,13-17 Years,84.1,79.7 to 87.7,595
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2015,Age,13-17 Years,38.5,28.2 to 49.9,171
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2012,Age,13-15 Years,20.6,12.4 to 32.2,97
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2013,Age,13-15 Years,24.7,13.6 to 40.6,96
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2014,Age,13-15 Years,22.6,14.2 to 33.9,107
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2015,Age,13-15 Years,32.7,20.7 to 47.5,102
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2010,Age,13-15 Years,35.6,24.3 to 48.7,94
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2009,Age,13-15 Years,26.8,18.2 to 37.6,117
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2011,Age,13-15 Years,23.4,14.2 to 36.1,111
HPV,"≥2 Doses, Males and Females",States/Local Areas,Virginia,2022,Age,13-17 Years,64.5,59.2 to 69.5,595
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Other,79.7,70.7 to 86.5,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Uninsured,64.8,44.3 to 81.0,53
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Other,70.9,62.2 to 78.3,296
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Uninsured,82.8,65.2 to 92.5,53
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Private Insurance Only,75.2,71.5 to 78.6,1860
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Any Medicaid,75.4,68.3 to 81.3,319
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Private Insurance Only,87.0,84.0 to 89.4,1860
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Poverty,Living At or Above Poverty Level,89.4,86.9 to 91.4,2323
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Any Medicaid,81.8,75.3 to 86.9,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Poverty,Below Poverty Level,89.2,80.4 to 94.4,136
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Poverty,Living At or Above Poverty Level,58.7,55.2 to 62.2,2323
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Poverty,Below Poverty Level,57.9,46.7 to 68.3,136
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Any Medicaid,88.8,82.8 to 92.8,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Private Insurance Only,91.1,88.6 to 93.1,1860
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Uninsured,44.1,26.5 to 63.3,53
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Other,53.5,44.2 to 62.7,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Private Insurance Only,61.9,57.9 to 65.8,1860
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2018-2022,Insurance Coverage,Any Medicaid,56.2,48.6 to 63.5,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Other,84.9,76.3 to 90.7,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Insurance Coverage,Uninsured,89.8,69.8 to 97.1,53
HPV,"≥3 Doses, Females",States/Local Areas,Virginia,2008,Age,13-15 Years,20.1,12.9 to 30.0,99
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018,Age,13-17 Years,79.7,71.4 to 86.0,327
≥1 Dose MenACWY,,States/Local Areas,Virginia,2020,Age,13-17 Years,84.0,78.7 to 88.1,677
≥1 Dose MenACWY,,States/Local Areas,Virginia,2019,Age,13-17 Years,86.7,80.1 to 91.4,363
≥1 Dose MenACWY,,States/Local Areas,Virginia,2017,Age,13-17 Years,80.0,72.6 to 85.7,413
≥2 Doses MMR,,States/Local Areas,Virginia,2022,Age,13-17 Years,89.8,86.2 to 92.6,595
≥2 Doses MMR,,States/Local Areas,Virginia,2020,Age,13-17 Years,93.3,89.5 to 95.8,677
≥2 Doses MMR,,States/Local Areas,Virginia,2021,Age,13-17 Years,94.8,90.3 to 97.3,566
≥1 Dose MenACWY,,States/Local Areas,Virginia,2022,Age,13-17 Years,85.0,80.7 to 88.6,595
≥1 Dose MenACWY,,States/Local Areas,Virginia,2021,Age,13-17 Years,88.0,82.3 to 92.1,566
HPV,"≥3 Doses, Males and Females",States/Local Areas,Virginia,2012,Age,13-17 Years,14.5,10.3 to 20.0,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2020,Age,13-17 Years,90.9,86.5 to 94.0,677
HPV,"≥3 Doses, Males and Females",States/Local Areas,Virginia,2015,Age,13-17 Years,31.9,25.2 to 39.6,385
HPV,"≥3 Doses, Males and Females",States/Local Areas,Virginia,2014,Age,13-17 Years,29.0,22.8 to 36.2,350
HPV,"≥3 Doses, Males and Females",States/Local Areas,Virginia,2013,Age,13-17 Years,21.4,15.2 to 29.2,302
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2022,Age,13-17 Years,89.7,85.9 to 92.6,595
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2019,Age,13-17 Years,89.1,82.4 to 93.5,363
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2021,Age,13-17 Years,88.3,82.5 to 92.4,566
≥2 Doses MMR,,States/Local Areas,Virginia,2018,Age,13-17 Years,92.3,87.0 to 95.5,327
≥2 Doses MMR,,States/Local Areas,Virginia,2017,Age,13-17 Years,96.2,91.9 to 98.3,413
≥2 Doses MMR,,States/Local Areas,Virginia,2019,Age,13-17 Years,89.8,83.6 to 93.8,363
≥1 Dose MenACWY,,States/Local Areas,Virginia,2012,Age,13-17 Years,62.1,54.5 to 69.2,334
≥2 Doses MMR,,States/Local Areas,Virginia,2016,Age,13-17 Years,86.1,79.9 to 90.7,451
≥1 Dose MenACWY,,States/Local Areas,Virginia,2016,Age,13-17 Years,71.5,63.9 to 78.1,451
≥1 Dose MenACWY,,States/Local Areas,Virginia,2015,Age,13-17 Years,66.8,58.7 to 74.0,385
≥1 Dose MenACWY,,States/Local Areas,Virginia,2014,Age,13-17 Years,72.5,65.4 to 78.6,350
≥1 Dose MenACWY,,States/Local Areas,Virginia,2013,Age,13-17 Years,64.2,55.4 to 72.2,302
HPV,"≥3 Doses, Males and Females",States/Local Areas,Virginia,2011,Age,13-17 Years,15.6,11.4 to 21.0,417
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2016,Age,13-17 Years,87.1,81.0 to 91.5,451
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2015,Age,13-17 Years,82.2,74.8 to 87.8,385
≥2 Doses MMR,,States/Local Areas,Virginia,2013,Age,13-17 Years,92.0,85.5 to 95.8,302
≥2 Doses MMR,,States/Local Areas,Virginia,2012,Age,13-17 Years,89.1,83.6 to 92.9,334
≥2 Doses MMR,,States/Local Areas,Virginia,2014,Age,13-17 Years,88.4,82.4 to 92.6,350
≥2 Doses MMR,,States/Local Areas,Virginia,2015,Age,13-17 Years,87.0,80.5 to 91.6,385
≥1 Dose MenACWY,,States/Local Areas,Virginia,2022,Age,13-15 Years,82.5,76.5 to 87.3,365
≥1 Dose MenACWY,,States/Local Areas,Virginia,2008,Age,13-17 Years,43.8,37.1 to 50.8,272
≥1 Dose MenACWY,,States/Local Areas,Virginia,2009,Age,13-17 Years,48.1,41.9 to 54.4,358
≥1 Dose MenACWY,,States/Local Areas,Virginia,2011,Age,13-17 Years,61.8,55.6 to 67.7,417
≥1 Dose MenACWY,,States/Local Areas,Virginia,2010,Age,13-17 Years,54.5,47.6 to 61.2,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018,Age,13-17 Years,90.3,83.8 to 94.4,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2017,Age,13-17 Years,89.3,83.2 to 93.4,413
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018-2022,Overall,Overall,84.7,82.2 to 87.0,2528
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018-2022,Overall,Overall,89.7,87.5 to 91.5,2528
Varicella,History of disease,States/Local Areas,Iowa,2009,Age,13-17 Years,63.0,56.8 to 68.8,338
Varicella,History of disease,States/Local Areas,Iowa,2008,Age,13-17 Years,69.8,63.6 to 75.3,308
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2018,Age,13-17 Years,61.9,52.2 to 70.8,132
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2019,Age,13-17 Years,60.4,51.3 to 68.9,154
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2016,Age,13-17 Years,47.4,39.0 to 55.9,183
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2016,Age,13-17 Years,43.8,35.8 to 52.0,199
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2021,Age,13-15 Years,63.0,47.3 to 76.3,66
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2022,Age,13-15 Years,77.6,65.2 to 86.5,76
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2017,Age,13-17 Years,65.5,56.4 to 73.5,159
Varicella,History of disease,States/Local Areas,Iowa,2012,Age,13-17 Years,43.9,37.1 to 50.9,325
Varicella,History of disease,States/Local Areas,Iowa,2013,Age,13-17 Years,33.6,28.0 to 39.6,383
Varicella,History of disease,States/Local Areas,Iowa,2010,Age,13-17 Years,62.1,55.5 to 68.2,264
Varicella,History of disease,States/Local Areas,Iowa,2011,Age,13-17 Years,54.1,47.2 to 60.9,359
Varicella,History of disease,States/Local Areas,Iowa,2015,Age,13-17 Years,15.8,11.9 to 20.6,383
Varicella,History of disease,States/Local Areas,Iowa,2016,Age,13-17 Years,21.5,17.0 to 26.9,382
Varicella,History of disease,States/Local Areas,Iowa,2017,Age,13-17 Years,14.6,10.9 to 19.4,343
Varicella,History of disease,States/Local Areas,Iowa,2018,Age,13-17 Years,14.9,10.7 to 20.3,280
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2019,Age,13-15 Years,59.6,48.5 to 69.8,103
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2020,Age,13-15 Years,70.2,57.0 to 80.7,75
Varicella,History of disease,States/Local Areas,Iowa,2020,Age,13-17 Years,11.2,7.3 to 16.6,280
Varicella,History of disease,States/Local Areas,Iowa,2022,Age,13-17 Years,7.2,4.2 to 12.1,207
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2018,Age,13-15 Years,60.1,47.7 to 71.4,80
Varicella,History of disease,States/Local Areas,Iowa,2019,Age,13-17 Years,10.3,6.8 to 15.2,302
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2018,Age,13-17 Years,48.6,39.1 to 58.2,148
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2019,Age,13-17 Years,61.4,52.0 to 70.0,148
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2020,Age,13-17 Years,48.8,39.5 to 58.1,151
Varicella,History of disease,States/Local Areas,Iowa,2014,Age,13-17 Years,29.5,23.4 to 36.4,328
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2021,Age,13-15 Years,71.7,54.1 to 84.5,61
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2022,Age,13-15 Years,68.3,51.6 to 81.3,55
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2017,Age,13-17 Years,42.6,34.6 to 51.0,184
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2020,Age,13-15 Years,49.9,37.9 to 62.0,91
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2019,Age,13-15 Years,55.6,43.6 to 67.0,91
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2019,Age,13-15 Years,57.7,49.6 to 65.4,194
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2022,Age,13-17 Years,75.4,65.3 to 83.4,119
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2021,Age,13-15 Years,67.1,55.6 to 76.9,127
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2021,Age,13-17 Years,62.0,49.5 to 73.0,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2020,Age,13-15 Years,59.6,50.6 to 68.0,166
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2020,Age,13-17 Years,72.4,62.5 to 80.4,129
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2018,Age,13-15 Years,48.1,36.2 to 60.2,95
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2021,Age,13-17 Years,70.3,56.4 to 81.3,92
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2022,Age,13-17 Years,74.4,61.8 to 84.0,88
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2022,Age,13-15 Years,72.9,62.5 to 81.3,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2012,Age,13-15 Years,71.8,62.6 to 79.5,183
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2011,Age,13-15 Years,77.6,70.3 to 83.6,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2009,Age,13-15 Years,67.0,58.6 to 74.5,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2010,Age,13-15 Years,63.0,54.5 to 70.7,169
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2016,Age,13-17 Years,52.1,43.5 to 60.5,183
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2017,Age,13-17 Years,73.6,65.2 to 80.5,159
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2014,Age,13-17 Years,52.5,42.6 to 62.2,157
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2015,Age,13-17 Years,62.3,53.8 to 70.0,190
≥1 Dose MenACWY,,States/Local Areas,Iowa,2021,Age,13-15 Years,95.3,88.5 to 98.1,127
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2019,Age,13-17 Years,94.8,91.5 to 96.9,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2020,Age,13-17 Years,92.8,88.8 to 95.4,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2018,Age,13-17 Years,95.7,92.2 to 97.7,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2008,Age,13-17 Years,65.9,59.4 to 71.8,308
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2009,Age,13-17 Years,70.5,64.2 to 76.1,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2019,Age,13-17 Years,75.1,69.1 to 80.3,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2021,Age,13-17 Years,93.6,87.3 to 96.9,199
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2022,Age,13-17 Years,97.3,91.0 to 99.2,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2008,Age,13-15 Years,50.6,41.9 to 59.2,168
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2018,Age,13-17 Years,67.2,57.7 to 75.5,132
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2020,Age,13-17 Years,74.2,67.8 to 79.7,280
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2021,Age,13-17 Years,79.2,70.8 to 85.7,199
≥1 Dose MenACWY,,States/Local Areas,Iowa,2011,Age,13-15 Years,64.1,55.5 to 71.9,215
≥1 Dose MenACWY,,States/Local Areas,Iowa,2010,Age,13-15 Years,52.9,44.6 to 61.1,169
≥1 Dose MenACWY,,States/Local Areas,Iowa,2009,Age,13-15 Years,48.2,40.2 to 56.3,192
≥1 Dose MenACWY,,States/Local Areas,Iowa,2008,Age,13-15 Years,32.1,24.8 to 40.5,168
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2022,Age,13-17 Years,87.2,77.9 to 92.9,119
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2022,Age,13-17 Years,87.9,81.5 to 92.2,207
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2012,Age,13-17 Years,80.2,73.7 to 85.3,325
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2013,Age,13-17 Years,80.2,74.7 to 84.7,383
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2010,Age,13-17 Years,70.8,64.3 to 76.5,264
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2011,Age,13-17 Years,78.3,72.3 to 83.3,359
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2022,Age,13-17 Years,97.3,92.5 to 99.1,190
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2019,Age,13-17 Years,74.2,65.2 to 81.6,154
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018,Age,13-17 Years,73.4,67.0 to 78.9,280
≥1 Dose MenACWY,,States/Local Areas,Iowa,2014,Age,13-15 Years,70.4,61.1 to 78.3,178
≥1 Dose MenACWY,,States/Local Areas,Iowa,2015,Age,13-15 Years,76.0,69.0 to 81.9,252
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2016,Age,13-17 Years,64.4,55.9 to 72.2,183
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2017,Age,13-17 Years,89.1,86.6 to 91.1,2108
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2021,Age,13-17 Years,98.7,96.4 to 99.5,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2022,Age,13-17 Years,95.7,91.0 to 98.1,190
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2017,Age,13-17 Years,80.0,71.9 to 86.2,159
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2018,Age,13-17 Years,78.6,70.2 to 85.2,132
≥1 Dose MenACWY,,States/Local Areas,Iowa,2016,Age,13-15 Years,74.8,67.7 to 80.7,230
≥1 Dose MenACWY,,States/Local Areas,Iowa,2017,Age,13-15 Years,84.9,78.5 to 89.6,206
≥1 Dose MenACWY,,States/Local Areas,Iowa,2012,Age,13-15 Years,57.6,48.4 to 66.3,183
≥1 Dose MenACWY,,States/Local Areas,Iowa,2013,Age,13-15 Years,62.2,54.7 to 69.2,257
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2008,Age,13-17 Years,36.8,27.9 to 46.8,127
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2012,Age,13-17 Years,46.4,36.9 to 56.1,151
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2013,Age,13-17 Years,52.2,43.4 to 60.9,183
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018,Age,13-15 Years,89.4,81.7 to 94.1,175
≥1 Dose MenACWY,,States/Local Areas,Iowa,2019,Age,13-15 Years,92.9,87.6 to 96.0,194
≥1 Dose MenACWY,,States/Local Areas,Iowa,2020,Age,13-15 Years,92.3,86.6 to 95.6,166
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2009,Age,13-17 Years,37.9,30.1 to 46.5,174
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2010,Age,13-17 Years,43.1,34.1 to 52.6,128
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2011,Age,13-17 Years,51.5,41.5 to 61.4,169
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2016,Age,13-17 Years,60.7,54.8 to 66.3,382
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2017,Age,13-17 Years,71.4,65.6 to 76.5,343
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2016,Age,13-17 Years,91.0,87.2 to 93.7,382
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2017,Age,13-17 Years,94.2,90.8 to 96.5,343
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2015,Age,13-17 Years,89.6,84.8 to 93.0,383
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2014,Age,13-17 Years,80.1,73.3 to 85.6,328
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2016,Age,13-17 Years,95.6,92.4 to 97.5,302
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2015,Age,13-17 Years,94.4,90.3 to 96.8,317
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2013,Age,13-17 Years,93.0,87.6 to 96.1,258
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2014,Age,13-17 Years,93.2,88.7 to 95.9,237
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2018,Age,13-17 Years,97.6,94.1 to 99.1,235
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2019,Age,13-17 Years,98.8,96.7 to 99.6,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2018,Age,13-17 Years,94.0,89.4 to 96.6,235
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2020,Age,13-17 Years,96.9,93.8 to 98.5,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2019,Age,13-17 Years,96.8,94.1 to 98.2,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2020,Age,13-17 Years,96.1,93.0 to 97.9,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2021,Age,13-17 Years,97.1,94.0 to 98.6,187
≥3 Doses HepB,,States/Local Areas,Iowa,2016,Age,13-17 Years,94.0,90.7 to 96.2,382
≥3 Doses HepB,,States/Local Areas,Iowa,2015,Age,13-17 Years,93.4,89.9 to 95.7,383
≥3 Doses HepB,,States/Local Areas,Iowa,2018,Age,13-17 Years,95.5,92.1 to 97.5,280
≥3 Doses HepB,,States/Local Areas,Iowa,2017,Age,13-17 Years,96.0,93.0 to 97.8,343
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2022,Age,13-15 Years,96.8,91.9 to 98.8,120
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2010,Age,13-17 Years,38.5,29.1 to 48.9,105
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2011,Age,13-17 Years,49.8,40.4 to 59.3,172
≥3 Doses HepB,,States/Local Areas,Iowa,2012,Age,13-17 Years,93.8,89.4 to 96.4,325
≥3 Doses HepB,,States/Local Areas,Iowa,2011,Age,13-17 Years,91.8,86.5 to 95.1,359
≥3 Doses HepB,,States/Local Areas,Iowa,2013,Age,13-17 Years,93.9,89.8 to 96.4,383
≥3 Doses HepB,,States/Local Areas,Iowa,2014,Age,13-17 Years,95.5,92.7 to 97.2,328
≥3 Doses HepB,,States/Local Areas,Iowa,2008,Age,13-17 Years,79.2,73.9 to 83.6,308
≥3 Doses HepB,,States/Local Areas,Iowa,2010,Age,13-17 Years,87.4,82.4 to 91.2,264
≥3 Doses HepB,,States/Local Areas,Iowa,2009,Age,13-17 Years,79.8,74.3 to 84.4,338
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2009,Age,13-17 Years,42.4,34.3 to 51.1,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2010,Age,13-17 Years,84.2,74.7 to 90.6,105
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2009,Age,13-17 Years,81.4,72.5 to 87.8,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2012,Age,13-17 Years,62.1,53.3 to 70.2,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2013,Age,13-17 Years,62.1,54.5 to 69.1,258
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2012,Age,13-17 Years,89.0,82.1 to 93.5,187
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2011,Age,13-17 Years,86.3,77.9 to 91.9,172
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2009,Age,13-17 Years,35.4,26.4 to 45.6,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2008,Age,13-17 Years,23.5,15.1 to 34.7,90
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2008,Age,13-17 Years,68.4,56.4 to 78.4,90
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2017,Age,13-17 Years,63.2,55.0 to 70.7,184
HPV,"≥2 Doses, Males and Females",States/Local Areas,Iowa,2019,Age,13-17 Years,63.3,56.8 to 69.3,302
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2016,Age,13-17 Years,57.2,48.9 to 65.1,199
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2015,Age,13-17 Years,48.0,39.5 to 56.7,193
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2013,Age,13-17 Years,30.3,22.9 to 38.8,200
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2014,Age,13-17 Years,30.2,22.2 to 39.7,171
≥3 Doses HepB,,States/Local Areas,Iowa,2020,Age,13-17 Years,94.2,90.5 to 96.5,280
≥3 Doses HepB,,States/Local Areas,Iowa,2021,Age,13-17 Years,97.6,94.5 to 99.0,199
≥3 Doses HepB,,States/Local Areas,Iowa,2022,Age,13-17 Years,96.5,91.9 to 98.5,207
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2020,Age,13-17 Years,68.5,59.4 to 76.4,151
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2021,Age,13-17 Years,77.2,65.6 to 85.7,107
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2019,Age,13-17 Years,76.0,67.4 to 82.8,148
HPV,"≥2 Doses, Males and Females",States/Local Areas,Iowa,2018,Age,13-17 Years,58.8,51.9 to 65.4,280
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2020,Age,13-17 Years,80.1,70.6 to 87.1,129
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2021,Age,13-17 Years,81.3,67.7 to 90.0,92
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2022,Age,13-17 Years,88.6,78.5 to 94.3,88
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2018,Age,13-17 Years,68.4,58.7 to 76.7,148
HPV,"≥2 Doses, Males and Females",States/Local Areas,Iowa,2016,Age,13-17 Years,49.2,43.3 to 55.1,382
HPV,"≥2 Doses, Males and Females",States/Local Areas,Iowa,2017,Age,13-17 Years,61.1,55.0 to 66.8,343
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2012,Age,13-17 Years,19.4,12.7 to 28.4,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2022,Age,13-15 Years,95.5,85.9 to 98.7,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2008,Age,13-17 Years,43.5,37.4 to 49.9,308
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2011,Age,13-17 Years,74.7,68.4 to 80.2,359
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2010,Age,13-17 Years,64.2,57.6 to 70.4,264
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2009,Age,13-17 Years,61.2,54.9 to 67.1,338
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2016,Age,13-17 Years,45.5,39.7 to 51.5,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2012,Age,13-17 Years,77.8,71.3 to 83.2,325
≥2 Doses MMR,,States/Local Areas,Iowa,2008,Age,13-17 Years,86.4,81.7 to 90.1,308
≥2 Doses MMR,,States/Local Areas,Iowa,2009,Age,13-17 Years,88.1,83.8 to 91.4,338
≥2 Doses MMR,,States/Local Areas,Iowa,2010,Age,13-17 Years,83.0,77.2 to 87.5,264
≥2 Doses MMR,,States/Local Areas,Iowa,2011,Age,13-17 Years,88.3,82.3 to 92.5,359
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2017,Age,13-17 Years,53.7,47.6 to 59.8,343
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018,Age,13-17 Years,55.1,48.2 to 61.8,280
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2019,Age,13-17 Years,60.9,54.4 to 67.1,302
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2013,Age,13-17 Years,79.6,74.1 to 84.2,383
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2014,Age,13-17 Years,76.7,69.7 to 82.5,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2015,Age,13-17 Years,85.5,80.2 to 89.5,383
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2021,Age,13-17 Years,66.1,56.9 to 74.1,199
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2022,Age,13-17 Years,74.9,67.1 to 81.4,207
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2020,Age,13-17 Years,60.3,53.4 to 66.8,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2019,Age,13-15 Years,93.5,89.1 to 96.3,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2020,Age,13-15 Years,90.0,84.2 to 93.9,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2021,Age,13-15 Years,93.7,86.7 to 97.1,127
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018,Age,13-15 Years,94.6,89.5 to 97.3,175
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2016,Age,13-17 Years,46.5,38.4 to 54.7,199
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2017,Age,13-17 Years,49.1,40.9 to 57.4,184
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2018,Age,13-17 Years,50.7,41.1 to 60.3,148
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2015,Age,13-17 Years,37.0,29.2 to 45.6,193
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2012,Age,13-17 Years,13.5,8.2 to 21.3,174
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2013,Age,13-17 Years,24.0,17.5 to 32.0,200
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2014,Age,13-17 Years,26.7,19.1 to 36.0,171
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2016,Age,13-15 Years,90.1,84.8 to 93.6,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2017,Age,13-15 Years,92.8,87.9 to 95.8,206
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2014,Age,13-15 Years,83.9,75.2 to 89.9,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2015,Age,13-15 Years,87.3,80.7 to 91.9,252
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2013,Age,13-15 Years,76.5,69.2 to 82.4,257
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2019,Age,13-17 Years,62.8,53.7 to 71.1,154
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2019,Age,13-17 Years,63.7,54.4 to 72.1,148
≥3 Doses HepB,,States/Local Areas,Iowa,2019,Age,13-17 Years,94.0,89.6 to 96.6,302
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2008,Age,13-17 Years,41.9,32.6 to 51.9,127
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2016,Age,13-17 Years,81.6,76.1 to 86.1,302
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2015,Age,13-17 Years,80.4,74.5 to 85.1,317
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2017,Age,13-17 Years,97.2,94.6 to 98.5,294
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2014,Age,13-17 Years,70.4,62.4 to 77.2,237
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2017,Age,13-17 Years,88.9,83.9 to 92.4,294
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2011,Age,13-17 Years,53.5,43.5 to 63.3,169
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2010,Age,13-17 Years,48.2,38.9 to 57.7,128
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2012,Age,13-15 Years,60.7,49.5 to 70.9,120
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2013,Age,13-15 Years,63.1,54.2 to 71.1,197
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2011,Age,13-15 Years,52.1,40.8 to 63.1,125
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2010,Age,13-15 Years,43.8,32.4 to 55.9,78
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2009,Age,13-15 Years,37.5,26.5 to 50.0,82
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2012,Age,13-17 Years,57.5,47.7 to 66.7,151
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2013,Age,13-17 Years,57.0,48.2 to 65.4,183
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2015,Age,13-17 Years,66.7,58.3 to 74.2,190
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2014,Age,13-17 Years,59.5,49.3 to 68.9,157
HPV,"≥2 Doses, Males and Females",States/Local Areas,Hawaii,2022,Age,13-17 Years,76.2,69.5 to 81.9,237
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2022,Age,13-17 Years,81.8,72.4 to 88.5,109
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2022,Age,13-17 Years,70.9,60.9 to 79.2,128
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2023,Age,13-17 Years,53.2,43.3 to 62.9,153
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2023,Age,13-17 Years,75.1,66.7 to 81.9,161
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2012,Age,13-15 Years,84.7,76.8 to 90.3,197
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2017,Age,13-17 Years,35.0,27.2 to 43.6,191
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2016,Age,13-17 Years,23.9,17.5 to 31.9,205
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2018,Age,13-17 Years,31.7,22.9 to 42.1,124
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2015,Age,13-17 Years,30.8,22.9 to 39.9,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2013,Age,13-15 Years,92.7,87.8 to 95.7,194
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2013,Age,13-17 Years,12.3,8.0 to 18.7,178
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2014,Age,13-17 Years,19.3,13.5 to 26.7,223
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2019,Age,13-17 Years,47.7,38.5 to 57.1,151
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2011,Age,13-15 Years,90.3,83.0 to 94.7,227
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2022,Age,13-17 Years,65.5,58.0 to 72.3,294
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2017,Age,13-17 Years,39.2,31.0 to 48.2,169
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2021,Age,13-17 Years,64.8,56.9 to 71.9,261
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2018,Age,13-17 Years,55.5,44.6 to 65.9,117
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2019,Age,13-15 Years,93.6,88.1 to 96.6,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2020,Age,13-15 Years,87.0,78.5 to 92.5,184
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2017,Age,13-15 Years,84.8,77.8 to 89.8,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018,Age,13-15 Years,87.5,80.3 to 92.3,143
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2023,Age,13-17 Years,89.7,84.8 to 93.1,314
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2023,Age,13-17 Years,89.1,84.0 to 92.6,314
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2023,Age,13-17 Years,78.3,72.2 to 83.3,314
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2023,Age,13-17 Years,54.2,47.3 to 61.0,314
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2023,Age,13-17 Years,74.2,68.2 to 79.4,314
≥2 Doses MMR,,States/Local Areas,Wyoming,2023,Age,13-17 Years,92.4,88.3 to 95.1,314
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2023,Age,13-17 Years,55.1,45.6 to 64.3,161
Varicella,History of disease,States/Local Areas,Wyoming,2023,Age,13-17 Years,8.5,5.4 to 13.2,314
≥3 Doses HepB,,States/Local Areas,Wyoming,2023,Age,13-17 Years,91.0,86.4 to 94.2,314
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2023,Age,13-17 Years,94.0,89.4 to 96.7,286
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2023,Age,13-17 Years,89.7,84.7 to 93.2,286
≥2 Doses Hep A,,States/Local Areas,Wyoming,2023,Age,13-17 Years,77.9,71.7 to 83.1,314
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2023,Age,13-17 Years,90.6,86.0 to 93.8,314
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2023,Age,13-15 Years,88.0,80.9 to 92.7,179
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2023,Age,13-15 Years,74.6,66.1 to 81.5,179
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2023,Age,13-15 Years,46.2,34.5 to 58.4,95
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2023,Age,13-15 Years,47.9,38.9 to 56.9,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2023,Age,13-15 Years,89.8,83.3 to 93.9,166
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2023,Age,13-15 Years,49.9,36.5 to 63.2,84
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2023,Age,13-17 Years,73.3,64.3 to 80.7,153
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2015,Age,13-17 Years,47.7,38.3 to 57.3,162
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2019,Age,13-17 Years,98.4,96.3 to 99.3,283
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2016,Age,13-17 Years,50.4,41.5 to 59.3,168
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2017,Age,13-17 Years,50.0,41.1 to 58.8,169
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2018,Age,13-17 Years,67.2,56.4 to 76.4,117
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2019,Age,13-15 Years,78.5,70.5 to 84.7,179
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2017,Age,13-17 Years,46.9,40.8 to 53.1,360
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018,Age,13-15 Years,68.2,58.9 to 76.2,143
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2022,Age,13-17 Years,96.4,91.8 to 98.4,259
≥3 Doses HepB,,States/Local Areas,Wyoming,2020,Age,13-17 Years,92.4,87.8 to 95.3,324
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2022,Age,13-17 Years,93.0,88.1 to 96.0,259
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wyoming,2018,Age,13-17 Years,43.3,35.9 to 50.9,241
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2017,Age,13-17 Years,44.1,35.8 to 52.8,191
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2020,Age,13-17 Years,63.6,54.4 to 71.9,181
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2019,Age,13-17 Years,63.2,53.8 to 71.8,151
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wyoming,2016,Age,13-17 Years,30.4,25.2 to 36.2,373
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2020,Age,13-17 Years,65.5,55.4 to 74.4,143
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2022,Age,13-17 Years,66.9,55.8 to 76.5,134
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2021,Age,13-17 Years,93.9,88.4 to 96.9,232
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wyoming,2017,Age,13-17 Years,37.0,31.3 to 43.2,360
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2016,Age,13-15 Years,54.7,47.1 to 62.0,244
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2014,Age,13-15 Years,47.8,40.8 to 54.8,282
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2015,Age,13-15 Years,57.3,48.9 to 65.4,195
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2013,Age,13-15 Years,57.1,48.8 to 65.0,194
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2012,Age,13-15 Years,58.6,49.7 to 66.9,197
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2013,Age,13-17 Years,94.3,91.1 to 96.4,325
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2014,Age,13-17 Years,90.1,86.2 to 93.0,446
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2015,Age,13-17 Years,90.8,86.7 to 93.7,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2016,Age,13-17 Years,88.2,83.3 to 91.7,373
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2013,Age,13-17 Years,49.5,40.2 to 58.8,147
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2012,Age,13-17 Years,41.4,32.2 to 51.2,153
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2008,Age,13-17 Years,28.4,20.8 to 37.5,124
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2009,Age,13-17 Years,37.6,30.1 to 45.7,184
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2020,Age,13-15 Years,74.3,65.2 to 81.7,184
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2011,Age,13-17 Years,51.4,40.5 to 62.1,175
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2010,Age,13-17 Years,46.2,37.4 to 55.2,150
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2017,Age,13-15 Years,59.1,51.2 to 66.6,222
≥3 Doses HepB,,States/Local Areas,Wyoming,2022,Age,13-17 Years,93.5,88.5 to 96.4,294
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2017,Age,13-17 Years,88.7,83.8 to 92.3,360
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2016,Age,13-17 Years,43.4,37.5 to 49.5,373
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2008,Age,13-17 Years,79.1,73.1 to 84.1,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2009,Age,13-17 Years,82.8,78.0 to 86.7,375
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2021,Age,13-17 Years,61.7,50.5 to 71.9,124
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2010,Age,13-15 Years,55.3,46.8 to 63.4,174
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2011,Age,13-15 Years,69.1,58.7 to 77.8,227
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2008,Age,13-15 Years,34.8,27.4 to 43.0,169
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2009,Age,13-15 Years,53.4,46.1 to 60.6,227
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2019,Age,13-17 Years,55.2,46.3 to 63.8,178
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2022,Age,13-17 Years,64.1,53.9 to 73.2,160
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2011,Age,13-17 Years,90.8,85.3 to 94.4,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2010,Age,13-17 Years,88.6,83.9 to 92.0,295
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2020,Age,13-17 Years,64.6,57.8 to 70.8,324
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2018,Age,13-17 Years,90.6,85.5 to 94.0,241
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2012,Age,13-17 Years,88.4,83.0 to 92.2,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2019,Age,13-17 Years,92.7,88.1 to 95.6,329
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018,Age,13-17 Years,53.5,46.0 to 60.9,241
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2021,Age,13-17 Years,92.3,86.5 to 95.7,261
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2019,Age,13-17 Years,59.1,52.6 to 65.3,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2020,Age,13-17 Years,91.5,87.0 to 94.6,324
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2014,Age,13-17 Years,42.4,34.6 to 50.5,223
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2015,Age,13-17 Years,37.6,28.7 to 47.4,162
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2016,Age,13-17 Years,37.3,29.3 to 46.1,168
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2008,Age,13-15 Years,39.7,31.9 to 48.1,169
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wyoming,2022,Age,13-17 Years,90.4,85.1 to 94.0,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2010,Age,13-15 Years,83.0,75.9 to 88.3,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2009,Age,13-15 Years,71.5,64.7 to 77.5,227
≥3 Doses HepB,,States/Local Areas,Wyoming,2021,Age,13-17 Years,89.1,83.0 to 93.2,261
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2021,Age,13-15 Years,75.4,66.3 to 82.6,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2014,Age,13-15 Years,88.9,83.7 to 92.6,282
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2015,Age,13-15 Years,88.7,82.4 to 93.0,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2016,Age,13-15 Years,87.2,80.9 to 91.6,244
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2022,Age,13-17 Years,46.2,36.7 to 56.0,160
HPV,"≥2 Doses, Females",States/Local Areas,Wyoming,2022,Age,13-17 Years,53.6,42.6 to 64.2,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Poverty,Living At or Above Poverty Level,61.4,57.9 to 64.7,1271
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Poverty,Below Poverty Level,71.8,62.2 to 79.8,147
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Poverty,Living At or Above Poverty Level,73.0,69.8 to 75.9,1271
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Poverty,Below Poverty Level,65.5,55.7 to 74.1,147
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"White, Non-Hispanic",60.0,56.4 to 63.5,1153
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.5,83.1 to 95.9,103
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,Hispanic,88.6,81.2 to 93.4,177
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.2,86.7 to 91.3,1153
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,Hispanic,72.3,63.1 to 79.9,177
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",42.4,31.7 to 53.8,103
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"White, Non-Hispanic",71.4,68.1 to 74.5,1153
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,Hispanic,48.9,39.7 to 58.1,177
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"White, Non-Hispanic",44.5,41.0 to 48.1,1153
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,Hispanic,67.6,58.1 to 75.8,177
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",63.7,51.6 to 74.2,103
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",80.4,69.8 to 88.0,103
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.7,83.0 to 98.5,34
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a Non-MSA,43.4,39.6 to 47.3,990
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Principal City,90.2,86.7 to 92.9,425
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Non-Principal City,80.8,63.4 to 91.1,34
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a Non-MSA,62.1,58.2 to 65.9,990
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Principal City,78.5,73.7 to 82.7,425
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Non-Principal City,34.6,18.9 to 54.6,34
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Principal City,48.9,43.2 to 54.6,425
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a Non-MSA,68.0,64.2 to 71.7,990
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Non-Principal City,57.8,37.5 to 75.7,34
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a MSA Principal City,61.2,55.5 to 66.5,425
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Urbanicity,Living In a Non-MSA,88.4,85.4 to 90.9,990
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Overall,Overall,45.2,42.1 to 48.5,1449
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Overall,Overall,72.4,69.4 to 75.1,1449
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Overall,Overall,61.6,58.4 to 64.7,1449
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2012,Age,13-17 Years,11.2,7.2 to 17.1,180
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2014,Age,13-17 Years,29.3,22.5 to 37.2,223
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2013,Age,13-17 Years,16.6,11.4 to 23.6,178
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2015,Age,13-17 Years,37.1,28.8 to 46.2,169
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2016,Age,13-17 Years,36.9,29.2 to 45.3,205
HPV,"≥1 Dose, Males",States/Local Areas,Wyoming,2018,Age,13-17 Years,40.7,31.1 to 51.0,124
≥3 Doses HepB,,States/Local Areas,Wyoming,2017,Age,13-17 Years,92.9,88.7 to 95.7,360
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2021,Age,13-17 Years,68.0,56.9 to 77.3,137
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wyoming,2019,Age,13-17 Years,45.6,39.2 to 52.1,329
≥3 Doses HepB,,States/Local Areas,Wyoming,2014,Age,13-17 Years,91.2,87.2 to 94.0,446
≥3 Doses HepB,,States/Local Areas,Wyoming,2013,Age,13-17 Years,90.8,85.8 to 94.1,325
≥3 Doses HepB,,States/Local Areas,Wyoming,2011,Age,13-17 Years,90.9,84.2 to 95.0,364
≥3 Doses HepB,,States/Local Areas,Wyoming,2012,Age,13-17 Years,94.5,91.0 to 96.7,333
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2009,Age,13-17 Years,43.6,35.8 to 51.7,184
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2012,Age,13-17 Years,88.8,81.9 to 93.3,189
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2009,Age,13-17 Years,79.6,71.6 to 85.8,156
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2010,Age,13-17 Years,85.4,77.7 to 90.8,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2011,Age,13-17 Years,78.8,68.8 to 86.2,204
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2010,Age,13-17 Years,47.6,38.0 to 57.3,124
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2008,Age,13-17 Years,36.2,27.7 to 45.7,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2022,Age,13-15 Years,95.2,90.3 to 97.7,170
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2011,Age,13-17 Years,93.4,86.9 to 96.7,204
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2008,Age,13-17 Years,69.5,58.8 to 78.5,103
≥3 Doses HepB,,States/Local Areas,Wyoming,2009,Age,13-17 Years,79.7,74.5 to 84.1,375
≥3 Doses HepB,,States/Local Areas,Wyoming,2010,Age,13-17 Years,92.9,89.3 to 95.4,295
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2019,Age,13-15 Years,95.4,89.2 to 98.1,160
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2008,Age,13-17 Years,18.1,11.7 to 27.0,103
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2009,Age,13-17 Years,38.1,29.8 to 47.1,156
≥3 Doses HepB,,States/Local Areas,Wyoming,2008,Age,13-17 Years,80.9,75.1 to 85.7,280
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2021,Age,13-15 Years,89.3,81.8 to 93.9,151
≥3 Doses HepB,,States/Local Areas,Wyoming,2016,Age,13-17 Years,91.9,88.0 to 94.6,373
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2012,Age,13-17 Years,97.1,93.5 to 98.8,189
≥3 Doses HepB,,States/Local Areas,Wyoming,2018,Age,13-17 Years,91.1,86.4 to 94.3,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2018,Age,13-17 Years,95.4,91.0 to 97.7,207
≥3 Doses HepB,,States/Local Areas,Wyoming,2019,Age,13-17 Years,94.5,90.1 to 97.0,329
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2017,Age,13-17 Years,95.0,90.9 to 97.4,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2016,Age,13-15 Years,90.4,85.0 to 94.0,196
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2018,Age,13-15 Years,86.5,78.5 to 91.9,132
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2014,Age,13-17 Years,96.7,94.1 to 98.2,326
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2013,Age,13-17 Years,96.5,92.3 to 98.5,223
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2015,Age,13-17 Years,94.9,91.0 to 97.2,260
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2016,Age,13-17 Years,95.3,91.5 to 97.5,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2020,Age,13-17 Years,92.1,87.4 to 95.2,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2021,Age,13-17 Years,90.7,85.0 to 94.3,232
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2019,Age,13-17 Years,94.3,89.9 to 96.8,283
Varicella,≥1 Dose with no disease history,States/Local Areas,Wyoming,2020,Age,13-17 Years,96.2,92.8 to 98.1,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2018,Age,13-17 Years,88.3,82.2 to 92.5,207
≥3 Doses HepB,,States/Local Areas,Wyoming,2015,Age,13-17 Years,92.8,88.8 to 95.5,331
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2014,Age,13-17 Years,50.3,42.2 to 58.3,223
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2013,Age,13-17 Years,54.3,44.8 to 63.5,147
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2012,Age,13-17 Years,53.9,43.8 to 63.6,153
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2017,Age,13-15 Years,91.5,85.0 to 95.4,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2008,Age,13-15 Years,16.7,9.8 to 27.1,71
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2009,Age,13-15 Years,40.3,30.7 to 50.7,122
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2010,Age,13-15 Years,56.2,44.4 to 67.3,84
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2011,Age,13-15 Years,80.4,68.5 to 88.6,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2013,Age,13-15 Years,91.3,84.2 to 95.4,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2012,Age,13-15 Years,87.1,77.8 to 92.9,128
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2010,Age,13-17 Years,53.2,44.1 to 62.0,150
HPV,"≥1 Dose, Females",States/Local Areas,Wyoming,2011,Age,13-17 Years,60.9,50.1 to 70.8,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2017,Age,13-17 Years,90.7,85.7 to 94.1,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2014,Age,13-17 Years,87.4,82.5 to 91.1,326
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2013,Age,13-17 Years,90.1,84.6 to 93.7,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2015,Age,13-17 Years,85.7,79.5 to 90.2,260
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2016,Age,13-17 Years,88.9,83.9 to 92.4,292
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2021,Age,13-17 Years,91.6,86.5 to 94.9,261
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2020,Age,13-15 Years,89.5,81.5 to 94.3,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2014,Age,13-15 Years,90.4,84.7 to 94.1,219
Varicella,≥2 Doses with no disease history,States/Local Areas,Wyoming,2015,Age,13-15 Years,86.6,78.6 to 91.9,159
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2019,Age,13-17 Years,95.1,91.3 to 97.3,329
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2018,Age,13-17 Years,90.1,84.8 to 93.7,241
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2013,Age,13-17 Years,93.2,89.3 to 95.7,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2011,Age,13-17 Years,88.3,82.0 to 92.6,364
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2012,Age,13-17 Years,93.6,89.5 to 96.2,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2008,Age,13-17 Years,70.8,64.5 to 76.4,280
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2009,Age,13-17 Years,76.0,71.0 to 80.4,375
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2010,Age,13-17 Years,78.5,72.8 to 83.3,295
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2020,Age,13-17 Years,92.9,88.6 to 95.6,324
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2022,Age,13-17 Years,94.0,89.7 to 96.5,294
HPV,"≥3 Doses, Males",States/Local Areas,Wyoming,2014,Age,13-17 Years,12.2,7.6 to 18.9,223
HPV,"≥3 Doses, Males",States/Local Areas,Wyoming,2015,Age,13-17 Years,18.8,12.8 to 26.7,169
HPV,"≥3 Doses, Males",States/Local Areas,Wyoming,2013,Age,13-17 Years,8.4,4.9 to 14.1,178
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2011,Age,13-17 Years,40.9,30.7 to 52.1,175
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2012,Age,13-17 Years,30.3,22.4 to 39.6,153
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2014,Age,13-17 Years,33.6,26.4 to 41.6,223
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2013,Age,13-17 Years,42.1,33.2 to 51.5,147
HPV,"≥3 Doses, Males",States/Local Areas,Wyoming,2015,Age,13-15 Years,16.9,10.0 to 27.1,102
≥2 Doses Hep A,,States/Local Areas,Wyoming,2020,Age,13-17 Years,67.7,60.9 to 73.8,324
≥2 Doses Hep A,,States/Local Areas,Wyoming,2022,Age,13-17 Years,77.1,70.0 to 82.9,294
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2021,Age,13-17 Years,48.0,40.5 to 55.7,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2008,Age,13-17 Years,28.3,23.0 to 34.3,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2022,Age,13-15 Years,88.8,81.5 to 93.5,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2011,Age,13-17 Years,86.2,80.6 to 90.4,364
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2009,Age,13-17 Years,48.2,42.4 to 54.0,375
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2010,Age,13-17 Years,65.0,58.5 to 71.0,295
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2022,Age,13-17 Years,49.2,41.9 to 56.6,294
≥2 Doses MMR,,States/Local Areas,Wyoming,2010,Age,13-17 Years,90.0,85.5 to 93.2,295
≥2 Doses MMR,,States/Local Areas,Wyoming,2008,Age,13-17 Years,87.3,82.2 to 91.1,280
≥2 Doses MMR,,States/Local Areas,Wyoming,2009,Age,13-17 Years,87.4,83.2 to 90.7,375
≥2 Doses MMR,,States/Local Areas,Wyoming,2011,Age,13-17 Years,88.6,81.9 to 93.0,364
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2017,Age,13-17 Years,30.9,25.5 to 36.8,360
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018,Age,13-17 Years,42.0,34.7 to 49.7,241
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2019,Age,13-17 Years,41.5,35.3 to 48.0,329
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2020,Age,13-17 Years,44.8,38.3 to 51.4,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2014,Age,13-17 Years,89.1,85.1 to 92.1,446
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2013,Age,13-17 Years,92.3,88.8 to 94.8,325
HPV,"≥2 Doses, Males",States/Local Areas,Wyoming,2019,Age,13-17 Years,43.6,35.0 to 52.6,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2012,Age,13-17 Years,85.4,79.8 to 89.6,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2021,Age,13-15 Years,90.5,83.7 to 94.7,169
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2014,Age,13-17 Years,91.0,87.4 to 93.7,446
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2015,Age,13-17 Years,88.8,83.8 to 92.4,331
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2017,Age,13-17 Years,92.2,87.9 to 95.1,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Wyoming,2016,Age,13-17 Years,91.3,87.3 to 94.1,373
≥2 Doses Hep A,,States/Local Areas,Wyoming,2021,Age,13-17 Years,71.1,63.3 to 77.8,261
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2015,Age,13-17 Years,26.5,18.7 to 36.0,162
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2008,Age,13-17 Years,19.8,13.5 to 28.2,124
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2009,Age,13-17 Years,31.1,24.1 to 39.2,184
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2010,Age,13-17 Years,40.3,31.9 to 49.3,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2016,Age,13-17 Years,26.7,21.7 to 32.3,373
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2012,Age,13-15 Years,22.6,14.2 to 33.8,87
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2022,Age,13-17 Years,73.2,66.0 to 79.4,294
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2021,Age,13-17 Years,75.9,68.7 to 81.8,261
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wyoming,2011,Age,13-17 Years,20.8,15.2 to 27.9,364
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wyoming,2015,Age,13-17 Years,22.5,17.4 to 28.6,331
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wyoming,2014,Age,13-17 Years,22.6,18.2 to 27.7,446
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wyoming,2013,Age,13-17 Years,24.7,19.6 to 30.6,325
≥2 Doses MMR,,States/Local Areas,Wyoming,2013,Age,13-17 Years,90.6,85.8 to 93.9,325
≥2 Doses MMR,,States/Local Areas,Wyoming,2012,Age,13-17 Years,91.0,86.6 to 94.1,333
≥2 Doses MMR,,States/Local Areas,Wyoming,2014,Age,13-17 Years,90.1,86.1 to 93.1,446
≥2 Doses MMR,,States/Local Areas,Wyoming,2015,Age,13-17 Years,92.1,88.0 to 94.9,331
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wyoming,2012,Age,13-17 Years,16.0,11.9 to 21.1,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2020,Age,13-17 Years,87.7,82.2 to 91.7,324
≥2 Doses MMR,,States/Local Areas,Wyoming,2019,Age,13-17 Years,95.6,91.7 to 97.7,329
≥2 Doses MMR,,States/Local Areas,Wyoming,2017,Age,13-17 Years,92.7,88.7 to 95.3,360
≥2 Doses MMR,,States/Local Areas,Wyoming,2018,Age,13-17 Years,90.0,84.9 to 93.5,241
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2022,Age,13-17 Years,89.1,83.7 to 92.8,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2021,Age,13-17 Years,89.8,83.9 to 93.7,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2019,Age,13-17 Years,90.7,85.9 to 94.0,329
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2012,Age,13-17 Years,59.0,52.3 to 65.5,333
≥2 Doses MMR,,States/Local Areas,Wyoming,2016,Age,13-17 Years,92.1,88.4 to 94.6,373
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2014,Age,13-17 Years,55.6,49.9 to 61.2,446
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2013,Age,13-17 Years,63.1,56.7 to 69.1,325
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2015,Age,13-17 Years,58.7,52.1 to 64.9,331
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2016,Age,13-17 Years,54.2,48.1 to 60.1,373
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2022,Age,13-15 Years,71.4,61.6 to 79.5,188
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2008,Age,13-17 Years,32.8,27.2 to 39.0,280
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2009,Age,13-17 Years,47.8,42.0 to 53.6,375
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2011,Age,13-17 Years,60.8,52.4 to 68.5,364
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2010,Age,13-17 Years,51.5,45.0 to 57.9,295
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2015,Age,13-17 Years,87.9,83.2 to 91.4,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2017,Age,13-17 Years,86.4,81.2 to 90.3,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018,Age,13-17 Years,89.1,83.8 to 92.7,241
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2016,Age,13-17 Years,86.7,81.7 to 90.5,373
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2008,Age,13-15 Years,18.8,11.2 to 29.7,68
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Overall,Overall,89.3,87.1 to 91.1,1449
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2014,Age,13-15 Years,25.4,17.3 to 35.6,136
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2015,Age,13-15 Years,21.1,12.2 to 33.9,93
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2013,Age,13-15 Years,30.8,20.8 to 43.1,86
≥2 Doses MMR,,States/Local Areas,Wyoming,2021,Age,13-17 Years,91.3,86.1 to 94.6,261
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2017,Age,13-17 Years,60.7,54.5 to 66.6,360
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2019,Age,13-17 Years,73.9,67.9 to 79.2,329
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2020,Age,13-17 Years,73.3,66.9 to 78.9,324
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018,Age,13-17 Years,65.1,57.8 to 71.7,241
≥2 Doses MMR,,States/Local Areas,Wyoming,2022,Age,13-17 Years,93.6,89.2 to 96.3,294
≥2 Doses MMR,,States/Local Areas,Wyoming,2020,Age,13-17 Years,90.8,86.2 to 93.9,324
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2010,Age,13-15 Years,35.4,25.1 to 47.2,88
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2009,Age,13-15 Years,36.0,25.8 to 47.6,103
HPV,"≥3 Doses, Females",States/Local Areas,Wyoming,2011,Age,13-15 Years,31.5,21.1 to 44.1,113
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wyoming,2022,Age,13-17 Years,49.8,42.5 to 57.1,294
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Uninsured,60.2,46.0 to 73.0,79
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Other,60.6,48.5 to 71.6,113
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Other,76.4,64.6 to 85.2,113
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Uninsured,64.1,49.3 to 76.5,79
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Private Insurance Only,59.2,55.2 to 63.1,941
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Any Medicaid,68.1,61.4 to 74.1,316
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Private Insurance Only,69.6,65.8 to 73.2,941
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Poverty,Living At or Above Poverty Level,89.5,87.2 to 91.4,1271
≥1 Dose MenACWY,,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Any Medicaid,79.5,73.7 to 84.3,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Poverty,Below Poverty Level,89.2,81.1 to 94.1,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Poverty,Living At or Above Poverty Level,43.3,41.9 to 48.7,1271
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Poverty,Below Poverty Level,47.6,38.1 to 57.3,147
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Any Medicaid,90.4,86.0 to 93.6,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Private Insurance Only,89.3,86.5 to 91.5,941
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Uninsured,42.7,29.9 to 56.5,79
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Other,45.7,34.3 to 57.6,113
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Private Insurance Only,43.3,39.4 to 47.3,941
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Any Medicaid,50.3,43.5 to 57.0,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Other,89.1,76.6 to 95.4,113
Tetanus,≥1 Dose Tdap,States/Local Areas,Wyoming,2018-2022,Insurance Coverage,Uninsured,84.2,72.2 to 91.6,79
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2020,Age,13-17 Years,93.8,89.3 to 96.5,322
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2019,Age,13-17 Years,95.6,92.5 to 97.4,329
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018,Age,13-17 Years,91.7,86.9 to 94.8,308
≥2 Doses MMR,,States/Local Areas,Arkansas,2022,Age,13-17 Years,93.8,89.9 to 96.2,332
≥2 Doses MMR,,States/Local Areas,Arkansas,2021,Age,13-17 Years,94.0,90.0 to 96.4,314
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2021,Age,13-17 Years,96.1,93.0 to 97.9,314
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2022,Age,13-17 Years,95.4,92.2 to 97.3,332
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2015,Age,13-15 Years,31.3,21.9 to 42.6,99
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2014,Age,13-15 Years,23.7,14.7 to 35.8,105
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2013,Age,13-15 Years,21.1,12.6 to 33.1,96
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2014,Age,13-17 Years,64.8,58.5 to 70.6,368
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2013,Age,13-17 Years,40.4,34.1 to 47.0,312
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2015,Age,13-17 Years,81.5,76.4 to 85.7,362
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2016,Age,13-17 Years,89.1,84.9 to 92.2,352
≥2 Doses MMR,,States/Local Areas,Arkansas,2015,Age,13-17 Years,90.2,85.6 to 93.4,362
≥2 Doses MMR,,States/Local Areas,Arkansas,2014,Age,13-17 Years,88.6,83.9 to 92.1,368
≥2 Doses MMR,,States/Local Areas,Arkansas,2017,Age,13-17 Years,91.5,87.5 to 94.2,357
≥2 Doses MMR,,States/Local Areas,Arkansas,2016,Age,13-17 Years,89.5,85.2 to 92.7,352
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2022,Age,13-17 Years,93.6,90.2 to 95.9,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2021,Age,13-17 Years,94.9,90.8 to 97.2,314
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2020,Age,13-17 Years,94.2,90.5 to 96.5,322
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2017,Age,13-17 Years,91.7,87.4 to 94.7,357
≥2 Doses MMR,,States/Local Areas,Arkansas,2013,Age,13-17 Years,89.5,85.0 to 92.7,312
≥2 Doses MMR,,States/Local Areas,Arkansas,2019,Age,13-17 Years,94.8,91.6 to 96.8,329
≥2 Doses MMR,,States/Local Areas,Arkansas,2018,Age,13-17 Years,92.0,87.5 to 95.0,308
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arkansas,2015,Age,13-17 Years,25.0,20.2 to 30.5,362
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arkansas,2014,Age,13-17 Years,17.3,13.1 to 22.5,368
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arkansas,2013,Age,13-17 Years,14.3,10.4 to 19.4,312
≥2 Doses MMR,,States/Local Areas,Arkansas,2020,Age,13-17 Years,95.2,91.7 to 97.3,322
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2022,Age,13-17 Years,57.7,48.0 to 67.0,159
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2012,Age,13-15 Years,18.4,11.2 to 28.8,106
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2010,Age,13-15 Years,18.6,11.1 to 29.6,86
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2016,Age,13-17 Years,91.0,87.1 to 93.8,352
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2011,Age,13-17 Years,27.6,21.2 to 35.1,350
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2010,Age,13-17 Years,30.9,25.0 to 37.4,313
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2009,Age,13-17 Years,21.9,17.3 to 27.2,363
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2008,Age,13-17 Years,14.5,10.8 to 19.1,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2019,Age,13-17 Years,93.4,89.3 to 96.0,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2017,Age,13-17 Years,92.4,88.6 to 94.9,357
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018,Age,13-17 Years,90.2,85.4 to 93.5,308
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arkansas,2012,Age,13-17 Years,10.8,7.4 to 15.5,322
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arkansas,2011,Age,13-17 Years,7.8,4.6 to 12.8,350
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2012,Age,13-17 Years,37.5,30.9 to 44.7,322
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Overall,Overall,94.5,93.0 to 95.7,1605
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2014,Age,13-17 Years,74.3,68.2 to 79.7,368
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2013,Age,13-17 Years,72.3,66.2 to 77.6,312
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2011,Age,13-17 Years,70.8,63.6 to 77.1,350
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2012,Age,13-17 Years,67.8,60.9 to 74.0,322
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2015,Age,13-17 Years,87.2,82.3 to 90.8,362
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2008,Age,13-15 Years,20.2,12.8 to 30.4,111
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2022,Age,13-17 Years,93.2,89.2 to 95.8,332
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2021,Age,13-17 Years,94.3,90.0 to 96.8,314
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2020,Age,13-17 Years,96.2,92.4 to 98.1,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2011,Age,13-15 Years,54.1,41.7 to 66.1,147
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2010,Age,13-15 Years,27.1,19.5 to 36.4,134
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2013,Age,13-15 Years,61.6,51.9 to 70.5,142
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2012,Age,13-15 Years,56.1,46.1 to 65.7,159
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2009,Age,13-15 Years,25.3,16.2 to 37.2,120
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2019,Age,13-15 Years,95.4,91.2 to 97.7,197
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2015,Age,13-15 Years,88.0,81.4 to 92.5,182
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2010,Age,13-17 Years,37.9,28.5 to 48.3,135
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2013,Age,13-17 Years,59.6,51.9 to 66.8,220
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2012,Age,13-17 Years,53.3,44.8 to 61.6,228
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2018,Age,13-15 Years,90.6,82.8 to 95.0,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2016,Age,13-15 Years,92.2,86.9 to 95.4,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2017,Age,13-15 Years,91.0,85.3 to 94.6,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2014,Age,13-15 Years,71.2,61.8 to 79.1,174
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2021,Age,13-15 Years,93.8,87.0 to 97.2,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2020,Age,13-15 Years,96.8,89.3 to 99.1,176
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2009,Age,13-17 Years,34.6,26.6 to 43.5,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2011,Age,13-17 Years,47.2,36.8 to 57.8,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2010,Age,13-17 Years,27.4,20.6 to 35.4,178
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2008,Age,13-17 Years,22.4,16.2 to 30.2,185
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2012,Age,13-17 Years,91.8,85.4 to 95.5,228
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2019,Age,13-17 Years,97.3,94.6 to 98.7,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2009,Age,13-17 Years,21.9,14.6 to 31.4,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2008,Age,13-17 Years,17.8,11.6 to 26.4,143
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2011,Age,13-17 Years,93.5,88.6 to 96.4,203
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2022,Age,13-17 Years,94.3,90.2 to 96.8,313
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2010,Age,13-17 Years,89.3,83.4 to 93.3,178
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2009,Age,13-17 Years,82.8,75.4 to 88.3,165
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2008,Age,13-17 Years,84.9,77.5 to 90.1,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2022,Age,13-15 Years,93.5,88.5 to 96.4,187
≥3 Doses HepB,,States/Local Areas,Arkansas,2010,Age,13-17 Years,90.6,86.1 to 93.7,313
≥3 Doses HepB,,States/Local Areas,Arkansas,2009,Age,13-17 Years,88.0,83.3 to 91.6,363
≥3 Doses HepB,,States/Local Areas,Arkansas,2008,Age,13-17 Years,90.9,87.1 to 93.7,382
≥3 Doses HepB,,States/Local Areas,Arkansas,2011,Age,13-17 Years,88.7,82.6 to 92.8,350
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2014,Age,13-17 Years,92.0,86.7 to 95.3,291
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2013,Age,13-17 Years,94.8,90.4 to 97.2,220
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2015,Age,13-17 Years,95.7,91.3 to 97.9,294
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2016,Age,13-17 Years,94.0,90.0 to 96.4,303
≥3 Doses HepB,,States/Local Areas,Arkansas,2015,Age,13-17 Years,91.2,87.0 to 94.2,362
≥3 Doses HepB,,States/Local Areas,Arkansas,2016,Age,13-17 Years,90.7,86.6 to 93.6,352
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2015,Age,13-17 Years,63.5,54.7 to 71.4,162
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2014,Age,13-17 Years,54.6,45.5 to 63.4,183
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2013,Age,13-17 Years,44.3,35.3 to 53.6,157
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2012,Age,13-17 Years,41.2,31.0 to 52.2,156
≥3 Doses HepB,,States/Local Areas,Arkansas,2017,Age,13-17 Years,92.5,88.8 to 95.1,357
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2011,Age,13-17 Years,36.1,24.9 to 49.0,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2017,Age,13-17 Years,91.1,86.7 to 94.2,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2014,Age,13-17 Years,68.7,61.5 to 75.0,291
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2017,Age,13-17 Years,96.9,93.4 to 98.6,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2015,Age,13-17 Years,84.1,78.3 to 88.6,294
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2016,Age,13-17 Years,89.1,84.3 to 92.6,303
≥3 Doses HepB,,States/Local Areas,Arkansas,2019,Age,13-17 Years,95.7,92.8 to 97.5,329
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2018,Age,13-17 Years,90.2,84.8 to 93.8,273
≥3 Doses HepB,,States/Local Areas,Arkansas,2018,Age,13-17 Years,91.4,86.9 to 94.5,308
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2018,Age,13-17 Years,93.4,88.4 to 96.3,273
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2019,Age,13-17 Years,71.0,61.5 to 78.9,150
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2018,Age,13-17 Years,65.9,56.5 to 74.2,155
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2017,Age,13-17 Years,66.7,57.4 to 74.8,151
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2022,Age,13-17 Years,92.9,88.6 to 95.6,313
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2021,Age,13-17 Years,95.2,91.0 to 97.4,293
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2016,Age,13-17 Years,53.3,43.8 to 62.6,149
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2021,Age,13-17 Years,93.9,89.3 to 96.6,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2020,Age,13-17 Years,95.9,91.9 to 98.0,298
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2019,Age,13-17 Years,95.4,92.1 to 97.4,292
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2020,Age,13-17 Years,97.1,93.1 to 98.8,298
≥2 Doses Hep A,,States/Local Areas,Arkansas,2022,Age,13-17 Years,87.0,82.1 to 90.6,332
≥2 Doses Hep A,,States/Local Areas,Arkansas,2021,Age,13-17 Years,84.2,78.7 to 88.4,314
≥3 Doses HepB,,States/Local Areas,Arkansas,2012,Age,13-17 Years,92.6,88.5 to 95.3,322
HPV,"≥3 Doses, Males",States/Local Areas,Arkansas,2015,Age,13-17 Years,16.4,11.4 to 23.0,200
HPV,"≥3 Doses, Males",States/Local Areas,Arkansas,2014,Age,13-17 Years,11.4,6.9 to 18.4,185
HPV,"≥3 Doses, Males",States/Local Areas,Arkansas,2015,Age,13-15 Years,14.6,9.0 to 22.7,118
HPV,"≥3 Doses, Males",States/Local Areas,Arkansas,2014,Age,13-15 Years,12.4,6.8 to 21.5,110
≥3 Doses HepB,,States/Local Areas,Arkansas,2014,Age,13-17 Years,86.9,81.7 to 90.8,368
≥3 Doses HepB,,States/Local Areas,Arkansas,2013,Age,13-17 Years,91.2,86.6 to 94.3,312
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2008,Age,13-17 Years,70.9,65.4 to 75.8,382
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2018,Age,13-17 Years,91.4,86.7 to 94.6,308
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2016,Age,13-17 Years,90.5,86.2 to 93.6,352
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2017,Age,13-17 Years,92.3,88.5 to 95.0,357
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2010,Age,13-17 Years,60.2,53.6 to 66.4,313
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2009,Age,13-17 Years,65.3,59.6 to 70.7,363
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2019,Age,13-17 Years,96.0,93.0 to 97.7,329
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2009,Age,13-17 Years,13.8,8.7 to 21.1,176
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2010,Age,13-17 Years,19.6,13.2 to 28.2,135
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2011,Age,13-17 Years,15.5,9.1 to 25.1,152
≥2 Doses Hep A,,States/Local Areas,Arkansas,2020,Age,13-17 Years,77.9,71.7 to 83.1,322
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2014,Age,13-17 Years,23.4,16.7 to 31.6,183
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2013,Age,13-17 Years,24.4,17.3 to 33.2,157
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2012,Age,13-17 Years,18.3,12.1 to 26.6,156
HPV,"≥3 Doses, Females",States/Local Areas,Arkansas,2015,Age,13-17 Years,34.0,26.2 to 42.9,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2022,Age,13-17 Years,55.7,49.1 to 62.1,332
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2021,Age,13-17 Years,56.8,50.2 to 63.1,314
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2020,Age,13-17 Years,49.6,42.6 to 56.5,322
≥2 Doses MMR,,States/Local Areas,Arkansas,2011,Age,13-17 Years,87.7,82.2 to 91.7,350
≥2 Doses MMR,,States/Local Areas,Arkansas,2010,Age,13-17 Years,89.2,84.7 to 92.4,313
≥2 Doses MMR,,States/Local Areas,Arkansas,2009,Age,13-17 Years,85.9,81.2 to 89.5,363
≥2 Doses MMR,,States/Local Areas,Arkansas,2008,Age,13-17 Years,90.2,86.3 to 93.1,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2014,Age,13-17 Years,84.6,79.3 to 88.7,368
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2013,Age,13-17 Years,77.7,71.9 to 82.5,312
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2019,Age,13-17 Years,50.5,43.9 to 57.2,329
≥2 Doses MMR,,States/Local Areas,Arkansas,2012,Age,13-17 Years,89.5,84.1 to 93.2,322
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018,Age,13-17 Years,42.6,36.0 to 49.5,308
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2017,Age,13-17 Years,35.2,29.4 to 41.5,357
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2015,Age,13-17 Years,91.2,87.2 to 94.0,362
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2011,Age,13-17 Years,48.4,40.6 to 56.4,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2010,Age,13-17 Years,43.0,36.6 to 49.6,313
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2009,Age,13-17 Years,34.6,28.9 to 40.7,363
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2008,Age,13-17 Years,23.8,19.2 to 29.1,382
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2022,Age,13-15 Years,93.2,88.3 to 96.1,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2012,Age,13-17 Years,64.4,57.3 to 70.9,322
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2022,Age,13-17 Years,57.6,48.5 to 66.2,173
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arkansas,2022,Age,13-17 Years,57.7,51.0 to 64.0,332
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2023,Age,13-17 Years,95.1,91.2 to 97.3,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2023,Age,13-17 Years,92.4,87.7 to 95.4,333
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2023,Age,13-17 Years,94.5,90.5 to 96.8,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2023,Age,13-17 Years,74.8,68.9 to 79.9,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2023,Age,13-17 Years,52.9,46.1 to 59.6,333
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2023,Age,13-17 Years,74.4,65.5 to 81.6,150
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2023,Age,13-17 Years,51.6,42.2 to 60.9,183
≥2 Doses MMR,,States/Local Areas,Arkansas,2023,Age,13-17 Years,91.6,87.1 to 94.6,333
Varicella,History of disease,States/Local Areas,Arkansas,2023,Age,13-17 Years,8.6,5.3 to 13.7,333
≥3 Doses HepB,,States/Local Areas,Arkansas,2023,Age,13-17 Years,91.7,87.4 to 94.6,333
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2023,Age,13-17 Years,90.9,86.0 to 94.2,310
Varicella,≥1 Dose with no disease history,States/Local Areas,Arkansas,2023,Age,13-17 Years,92.1,87.4 to 95.1,310
Varicella,≥2 Doses or history of disease,States/Local Areas,Arkansas,2023,Age,13-17 Years,91.7,87.1 to 94.7,333
≥2 Doses Hep A,,States/Local Areas,Arkansas,2023,Age,13-17 Years,87.7,82.9 to 91.3,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2023,Age,13-15 Years,94.5,89.6 to 97.1,202
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2023,Age,13-15 Years,96.3,92.2 to 98.3,202
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2023,Age,13-15 Years,51.2,42.5 to 59.8,202
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2023,Age,13-15 Years,51.8,39.9 to 63.5,114
Varicella,≥2 Doses with no disease history,States/Local Areas,Arkansas,2023,Age,13-15 Years,93.9,88.7 to 96.8,187
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2023,Age,13-17 Years,54.3,44.5 to 63.8,150
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2023,Age,13-15 Years,50.6,38.1 to 63.0,88
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2023,Age,13-17 Years,75.2,66.9 to 82.0,183
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Overall,Overall,51.1,48.1 to 54.1,1605
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Overall,Overall,69.6,66.8 to 72.2,1605
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Overall,Overall,93.3,91.7 to 94.6,1605
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Principal City,73.7,69.1 to 77.8,557
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,70.7,65.6 to 75.2,502
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a Non-MSA,63.7,58.7 to 68.5,546
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Principal City,95.5,93.1 to 97.1,557
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.9,89.4 to 95.3,502
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a Non-MSA,95.0,92.6 to 96.7,546
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Principal City,58.0,53.0 to 62.9,557
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,50.1,44.7 to 55.5,502
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a Non-MSA,44.1,39.1 to 49.3,546
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Principal City,94.0,91.1 to 96.0,557
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.3,89.0 to 94.6,502
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Urbanicity,Living In a Non-MSA,93.5,90.7 to 95.4,546
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",95.4,89.8 to 97.9,132
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",70.8,61.2 to 78.9,132
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,Hispanic,49.6,40.5 to 58.6,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",61.4,52.2 to 69.8,143
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",51.4,41.2 to 61.6,132
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.8,92.1 to 95.2,1167
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.7,93.1 to 95.9,1167
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",95.2,89.4 to 97.9,143
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,Hispanic,92.1,84.8 to 96.0,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",95.2,89.6 to 97.8,143
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,Hispanic,90.3,83.2 to 94.6,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.6,81.7 to 94.3,132
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",66.9,63.6 to 70.0,1167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",77.8,69.3 to 84.5,143
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,Hispanic,70.7,61.8 to 78.2,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.5,45.1 to 52.0,1167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Poverty,Living At or Above Poverty Level,68.2,65.0 to 71.3,1242
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Poverty,Living At or Above Poverty Level,94.9,93.3 to 96.1,1242
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Poverty,Below Poverty Level,92.9,88.3 to 95.8,312
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Poverty,Below Poverty Level,50.1,43.5 to 56.7,312
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Poverty,Living At or Above Poverty Level,50.8,47.4 to 54.2,1242
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Poverty,Below Poverty Level,90.5,85.4 to 93.9,312
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Poverty,Living At or Above Poverty Level,94.1,92.5 to 95.4,1242
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Poverty,Below Poverty Level,72.9,66.7 to 78.3,312
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Private Insurance Only,95.1,93.1 to 96.5,752
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Any Medicaid,94.2,91.5 to 96.1,567
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Other,94.8,89.5 to 97.5,223
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Private Insurance Only,66.1,61.9 to 70.1,752
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Any Medicaid,73.4,68.8 to 77.5,567
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Other,70.5,63.0 to 77.0,223
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Private Insurance Only,49.3,44.9 to 53.7,752
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Uninsured,90.9,78.2 to 96.5,63
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Uninsured,61.4,46.7 to 74.3,63
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Any Medicaid,54.1,49.1 to 59.0,567
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Other,51.6,43.6 to 59.5,223
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Uninsured,36.4,23.7 to 51.5,63
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Private Insurance Only,94.5,92.4 to 96.1,752
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Any Medicaid,92.5,89.6 to 94.6,567
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Other,93.8,88.4 to 96.7,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018-2022,Insurance Coverage,Uninsured,87.2,74.5 to 94.1,63
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2023,Age,13-17 Years,63.8,49.9 to 75.7,112
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2023,Age,13-17 Years,32.1,21.8 to 44.4,100
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2023,Age,13-15 Years,97.1,92.3 to 99.0,129
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2023,Age,13-15 Years,23.8,13.8 to 37.9,64
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2023,Age,13-15 Years,40.1,29.3 to 52.0,132
≥1 Dose MenACWY,,States/Local Areas,Georgia,2023,Age,13-15 Years,91.8,83.5 to 96.1,132
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2023,Age,13-15 Years,86.2,76.0 to 92.4,132
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2023,Age,13-15 Years,60.6,43.7 to 75.3,68
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2023,Age,13-17 Years,94.5,89.4 to 97.3,212
≥2 Doses Hep A,,States/Local Areas,Georgia,2023,Age,13-17 Years,95.9,92.1 to 97.9,212
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2023,Age,13-17 Years,97.9,94.8 to 99.1,209
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2023,Age,13-17 Years,94.5,89.3 to 97.2,209
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2023,Age,13-17 Years,48.5,35.5 to 61.7,112
≥3 Doses HepB,,States/Local Areas,Georgia,2023,Age,13-17 Years,97.5,94.2 to 98.9,212
≥2 Doses MMR,,States/Local Areas,Georgia,2023,Age,13-17 Years,96.0,91.7 to 98.1,212
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2023,Age,13-17 Years,40.5,31.9 to 49.7,212
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2023,Age,13-17 Years,62.9,49.3 to 74.7,100
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2023,Age,13-17 Years,63.3,53.7 to 72.0,212
≥1 Dose MenACWY,,States/Local Areas,Georgia,2023,Age,13-17 Years,91.6,84.8 to 95.5,212
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2023,Age,13-17 Years,91.1,84.1 to 95.2,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2023,Age,13-17 Years,88.2,80.7 to 93.0,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Overall,Overall,92.2,90.3 to 93.8,1553
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Other,95.5,91.3 to 97.7,158
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Any Medicaid,92.3,88.3 to 95.1,430
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Private Insurance Only,92.5,89.8 to 94.5,886
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Uninsured,24.5,14.9 to 37.5,79
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Other,59.1,48.5 to 68.9,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Any Medicaid,60.4,54.6 to 65.9,430
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Uninsured,43.1,30.6 to 56.6,79
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Uninsured,88.3,77.2 to 94.4,79
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Private Insurance Only,54.3,50.0 to 58.5,886
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Other,72.9,63.2 to 80.7,158
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Any Medicaid,76.7,71.4 to 81.2,430
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Insurance Coverage,Private Insurance Only,70.1,66.0 to 73.8,886
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Other,95.3,89.5 to 98.0,158
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Any Medicaid,94.0,90.5 to 96.3,430
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Private Insurance Only,95.1,92.8 to 96.6,886
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Poverty,Living At or Above Poverty Level,92.3,90.1 to 94.1,1292
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Poverty,Below Poverty Level,93.0,87.8 to 96.0,215
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Poverty,Living At or Above Poverty Level,53.2,49.7 to 56.7,1292
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Poverty,Below Poverty Level,62.0,54.0 to 69.4,215
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Poverty,Below Poverty Level,96.4,92.2 to 98.4,215
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Poverty,Living At or Above Poverty Level,93.8,91.8 to 95.4,1292
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Poverty,Living At or Above Poverty Level,69.1,65.8 to 72.2,1292
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Poverty,Below Poverty Level,80.3,73.4 to 85.7,215
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,Hispanic,79.6,71.9 to 85.7,218
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.4,64.2 to 72.3,800
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",72.7,66.9 to 77.9,376
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.9,84.9 to 95.8,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,Hispanic,88.7,81.2 to 93.5,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.5,87.1 to 94.4,376
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,Hispanic,94.6,87.6 to 97.7,218
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.6,92.2 to 96.2,800
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.1,91.9 to 95.7,800
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",94.8,91.4 to 96.8,376
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",57.1,46.6 to 67.1,159
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,Hispanic,63.2,54.5 to 71.2,218
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",53.8,47.6 to 59.9,376
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",66.9,56.6 to 75.7,159
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.7,84.2 to 95.8,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,91.4,88.7 to 93.5,886
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a Non-MSA,91.9,86.0 to 95.4,192
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",53.8,49.4 to 58.1,800
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a Non-MSA,91.7,85.5 to 95.4,192
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.8,91.4 to 95.6,886
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a Non-MSA,53.6,44.3 to 62.6,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Principal City,94.0,90.2 to 96.3,475
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,51.6,47.3 to 55.8,886
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Principal City,63.5,57.7 to 68.8,475
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a Non-MSA,70.2,61.5 to 77.7,192
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Principal City,96.5,93.4 to 98.2,475
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,68.3,64.2 to 72.0,886
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Urbanicity,Living In a MSA Principal City,77.7,72.5 to 82.2,475
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018-2022,Overall,Overall,71.3,68.4 to 74.1,1553
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018-2022,Overall,Overall,55.4,52.2 to 58.6,1553
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018-2022,Insurance Coverage,Uninsured,83.1,71.1 to 90.8,79
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2022,Age,13-17 Years,58.1,48.3 to 67.3,174
HPV,"≥2 Doses, Males and Females",States/Local Areas,Georgia,2022,Age,13-17 Years,62.4,55.5 to 68.9,333
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2012,Age,13-15 Years,27.9,17.7 to 41.0,87
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2011,Age,13-15 Years,25.9,17.0 to 37.5,121
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2009,Age,13-15 Years,20.6,13.3 to 30.5,112
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2010,Age,13-15 Years,22.9,16.2 to 31.4,129
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2022,Age,13-17 Years,66.9,57.0 to 75.5,159
≥2 Doses MMR,,States/Local Areas,Georgia,2020,Age,13-17 Years,96.8,93.7 to 98.4,300
HPV,"≥3 Doses, Males and Females",States/Local Areas,Georgia,2013,Age,13-17 Years,24.0,18.3 to 30.9,253
HPV,"≥3 Doses, Males and Females",States/Local Areas,Georgia,2014,Age,13-17 Years,33.8,27.7 to 40.4,373
HPV,"≥3 Doses, Males and Females",States/Local Areas,Georgia,2015,Age,13-17 Years,29.9,24.6 to 35.7,374
≥2 Doses MMR,,States/Local Areas,Georgia,2018,Age,13-17 Years,97.0,93.4 to 98.7,345
≥2 Doses MMR,,States/Local Areas,Georgia,2019,Age,13-17 Years,96.2,93.1 to 98.0,315
≥1 Dose MenACWY,,States/Local Areas,Georgia,2017,Age,13-17 Years,95.3,91.9 to 97.3,343
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2020,Age,13-17 Years,90.8,85.4 to 94.3,300
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2021,Age,13-17 Years,92.7,87.1 to 95.9,260
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2022,Age,13-17 Years,91.1,86.0 to 94.5,333
≥2 Doses MMR,,States/Local Areas,Georgia,2016,Age,13-17 Years,97.1,93.7 to 98.6,367
≥2 Doses MMR,,States/Local Areas,Georgia,2017,Age,13-17 Years,97.7,94.7 to 99.1,343
≥2 Doses MMR,,States/Local Areas,Georgia,2015,Age,13-17 Years,95.5,91.9 to 97.5,374
≥2 Doses MMR,,States/Local Areas,Georgia,2014,Age,13-17 Years,96.4,93.2 to 98.1,373
≥2 Doses MMR,,States/Local Areas,Georgia,2012,Age,13-17 Years,96.1,92.0 to 98.1,328
≥2 Doses MMR,,States/Local Areas,Georgia,2013,Age,13-17 Years,96.4,91.6 to 98.5,253
HPV,"≥3 Doses, Males and Females",States/Local Areas,Georgia,2011,Age,13-17 Years,15.5,11.4 to 20.6,425
HPV,"≥3 Doses, Males and Females",States/Local Areas,Georgia,2012,Age,13-17 Years,16.5,12.2 to 22.1,328
≥1 Dose MenACWY,,States/Local Areas,Georgia,2016,Age,13-17 Years,91.4,87.1 to 94.4,367
≥1 Dose MenACWY,,States/Local Areas,Georgia,2015,Age,13-17 Years,87.0,81.6 to 90.9,374
≥1 Dose MenACWY,,States/Local Areas,Georgia,2014,Age,13-17 Years,74.9,68.4 to 80.5,373
≥1 Dose MenACWY,,States/Local Areas,Georgia,2013,Age,13-17 Years,76.9,69.3 to 83.2,253
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018,Age,13-17 Years,94.2,90.7 to 96.4,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2017,Age,13-17 Years,93.3,89.3 to 95.9,343
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2019,Age,13-17 Years,92.5,87.7 to 95.5,315
≥1 Dose MenACWY,,States/Local Areas,Georgia,2022,Age,13-15 Years,94.4,87.8 to 97.5,216
≥1 Dose MenACWY,,States/Local Areas,Georgia,2021,Age,13-15 Years,89.9,81.0 to 94.9,161
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2019,Age,13-17 Years,96.3,92.8 to 98.1,315
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2020,Age,13-17 Years,94.9,90.8 to 97.2,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2019,Age,13-17 Years,65.9,59.0 to 72.3,315
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2021,Age,13-17 Years,95.1,89.7 to 97.8,260
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2022,Age,13-17 Years,92.2,87.0 to 95.4,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2020,Age,13-17 Years,73.1,66.2 to 79.0,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2021,Age,13-17 Years,78.6,71.6 to 84.3,260
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2022,Age,13-17 Years,70.8,64.0 to 76.8,333
≥1 Dose MenACWY,,States/Local Areas,Georgia,2020,Age,13-15 Years,96.8,92.9 to 98.6,198
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2009,Age,13-17 Years,33.9,26.4 to 42.3,182
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2011,Age,13-17 Years,38.1,29.7 to 47.2,215
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2010,Age,13-17 Years,34.8,27.8 to 42.6,195
≥1 Dose MenACWY,,States/Local Areas,Georgia,2015,Age,13-15 Years,89.9,83.2 to 94.1,240
≥1 Dose MenACWY,,States/Local Areas,Georgia,2014,Age,13-15 Years,80.4,72.5 to 86.5,232
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2022,Age,13-17 Years,65.1,55.2 to 73.8,174
≥1 Dose MenACWY,,States/Local Areas,Georgia,2009,Age,13-15 Years,54.9,47.3 to 62.3,244
≥1 Dose MenACWY,,States/Local Areas,Georgia,2008,Age,13-15 Years,44.2,36.2 to 52.5,209
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2014,Age,13-17 Years,56.3,46.7 to 65.4,187
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2018,Age,13-17 Years,94.5,91.1 to 96.7,345
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018,Age,13-15 Years,93.8,89.2 to 96.5,226
≥1 Dose MenACWY,,States/Local Areas,Georgia,2019,Age,13-15 Years,94.8,90.2 to 97.3,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2008,Age,13-15 Years,43.9,36.0 to 52.1,209
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2018,Age,13-17 Years,58.8,49.5 to 67.5,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2016,Age,13-17 Years,67.3,60.9 to 73.2,367
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2017,Age,13-17 Years,64.3,57.5 to 70.6,343
HPV,"≥1 Dose, Males and Females",States/Local Areas,Georgia,2018,Age,13-17 Years,68.1,61.8 to 73.8,345
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2016,Age,13-17 Years,60.1,51.0 to 68.5,193
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2017,Age,13-17 Years,49.5,40.1 to 59.0,170
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2015,Age,13-17 Years,38.7,30.3 to 47.9,172
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2012,Age,13-15 Years,78.0,68.1 to 85.5,190
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2011,Age,13-15 Years,74.0,65.7 to 80.9,244
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2009,Age,13-15 Years,56.5,48.8 to 63.9,244
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2010,Age,13-15 Years,68.6,61.0 to 75.4,236
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2019,Age,13-17 Years,58.5,48.6 to 67.8,161
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2012,Age,13-17 Years,8.7,5.0 to 14.7,172
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2013,Age,13-15 Years,81.4,71.0 to 88.7,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2016,Age,13-15 Years,92.2,86.0 to 95.7,263
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2017,Age,13-15 Years,94.4,88.6 to 97.3,224
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2015,Age,13-15 Years,87.2,80.1 to 92.0,240
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2014,Age,13-15 Years,89.4,83.1 to 93.6,232
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2015,Age,13-17 Years,42.5,34.4 to 51.0,202
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2013,Age,13-17 Years,31.0,21.4 to 42.5,121
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2014,Age,13-17 Years,28.0,20.9 to 36.5,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2018,Age,13-15 Years,92.7,87.6 to 95.7,226
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2019,Age,13-15 Years,91.5,84.9 to 95.4,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2020,Age,13-15 Years,91.4,84.4 to 95.4,198
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2021,Age,13-15 Years,91.2,82.5 to 95.8,161
≥1 Dose MenACWY,,States/Local Areas,Georgia,2009,Age,13-17 Years,53.3,47.2 to 59.4,383
≥1 Dose MenACWY,,States/Local Areas,Georgia,2008,Age,13-17 Years,41.6,35.2 to 48.3,345
≥1 Dose MenACWY,,States/Local Areas,Georgia,2011,Age,13-17 Years,67.7,61.6 to 73.2,425
≥1 Dose MenACWY,,States/Local Areas,Georgia,2010,Age,13-17 Years,63.5,57.5 to 69.0,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2016,Age,13-17 Years,92.8,88.3 to 95.6,367
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2016,Age,13-17 Years,46.1,36.9 to 55.6,174
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2017,Age,13-17 Years,51.0,41.4 to 60.5,173
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2018,Age,13-17 Years,49.5,40.4 to 58.7,178
≥1 Dose MenACWY,,States/Local Areas,Georgia,2012,Age,13-17 Years,73.1,65.8 to 79.3,328
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2013,Age,13-15 Years,27.9,18.1 to 40.3,84
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2015,Age,13-15 Years,30.6,21.4 to 41.6,118
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2014,Age,13-15 Years,43.9,32.1 to 56.4,119
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018,Age,13-17 Years,94.8,91.4 to 97.0,345
≥1 Dose MenACWY,,States/Local Areas,Georgia,2019,Age,13-17 Years,95.5,92.2 to 97.5,315
≥1 Dose MenACWY,,States/Local Areas,Georgia,2020,Age,13-17 Years,96.2,92.6 to 98.1,300
≥1 Dose MenACWY,,States/Local Areas,Georgia,2021,Age,13-17 Years,92.5,86.8 to 95.9,260
≥1 Dose MenACWY,,States/Local Areas,Georgia,2022,Age,13-17 Years,93.0,88.1 to 95.9,333
≥2 Doses MMR,,States/Local Areas,Georgia,2021,Age,13-17 Years,95.5,90.0 to 98.0,260
≥2 Doses MMR,,States/Local Areas,Georgia,2022,Age,13-17 Years,95.2,91.2 to 97.4,333
≥1 Dose MenACWY,,States/Local Areas,Georgia,2018-2022,Overall,Overall,94.4,92.7 to 95.7,1553
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2008,Age,13-17 Years,14.1,9.5 to 20.4,167
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2012,Age,13-17 Years,36.8,27.6 to 47.1,156
HPV,"≥2 Doses, Females",States/Local Areas,Georgia,2013,Age,13-17 Years,42.3,32.4 to 52.9,132
≥1 Dose MenACWY,,States/Local Areas,Georgia,2013,Age,13-15 Years,78.3,68.5 to 85.8,160
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2016,Age,13-17 Years,95.9,92.7 to 97.7,367
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2017,Age,13-17 Years,96.1,92.8 to 97.9,343
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2015,Age,13-17 Years,91.6,86.9 to 94.8,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2014,Age,13-17 Years,87.5,82.2 to 91.4,373
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2009,Age,13-17 Years,73.0,67.1 to 78.2,383
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2008,Age,13-17 Years,70.9,64.5 to 76.5,345
≥1 Dose MenACWY,,States/Local Areas,Georgia,2012,Age,13-15 Years,72.4,62.5 to 80.6,190
≥1 Dose MenACWY,,States/Local Areas,Georgia,2011,Age,13-15 Years,64.4,56.0 to 72.0,244
≥1 Dose MenACWY,,States/Local Areas,Georgia,2010,Age,13-15 Years,70.6,63.5 to 76.8,236
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2020,Age,13-17 Years,68.1,58.2 to 76.7,166
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2021,Age,13-17 Years,74.9,63.7 to 83.6,142
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2019,Age,13-17 Years,63.4,53.5 to 72.3,154
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2018,Age,13-17 Years,65.6,56.5 to 73.7,178
≥1 Dose MenACWY,,States/Local Areas,Georgia,2016,Age,13-15 Years,93.1,88.0 to 96.1,263
≥1 Dose MenACWY,,States/Local Areas,Georgia,2017,Age,13-15 Years,95.7,90.8 to 98.1,224
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2012,Age,13-17 Years,87.9,82.5 to 91.8,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2013,Age,13-17 Years,85.1,77.7 to 90.3,253
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2011,Age,13-17 Years,76.6,70.5 to 81.7,425
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Georgia,2010,Age,13-17 Years,78.8,73.7 to 83.2,373
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2017,Age,13-17 Years,64.2,54.4 to 72.9,173
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2016,Age,13-17 Years,58.0,48.5 to 67.0,174
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2015,Age,13-17 Years,51.0,42.5 to 59.4,202
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2014,Age,13-17 Years,41.2,32.5 to 50.4,186
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2013,Age,13-17 Years,40.5,29.7 to 52.3,121
HPV,"≥2 Doses, Males and Females",States/Local Areas,Georgia,2018,Age,13-17 Years,54.1,47.5 to 60.5,345
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2020,Age,13-17 Years,78.1,68.4 to 85.5,134
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2021,Age,13-17 Years,82.5,73.8 to 88.8,118
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2022,Age,13-17 Years,76.8,67.3 to 84.2,159
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2011,Age,13-17 Years,7.3,4.3 to 12.1,210
HPV,"≥2 Doses, Males and Females",States/Local Areas,Georgia,2019,Age,13-17 Years,53.6,46.5 to 60.5,315
HPV,"≥2 Doses, Males and Females",States/Local Areas,Georgia,2016,Age,13-17 Years,52.9,46.4 to 59.4,367
HPV,"≥2 Doses, Males and Females",States/Local Areas,Georgia,2017,Age,13-17 Years,50.3,43.5 to 57.0,343
HPV,"≥1 Dose, Males",States/Local Areas,Georgia,2012,Age,13-17 Years,19.5,12.3 to 29.4,172
≥3 Doses HepB,,States/Local Areas,Georgia,2020,Age,13-17 Years,96.6,92.9 to 98.4,300
≥3 Doses HepB,,States/Local Areas,Georgia,2021,Age,13-17 Years,95.9,90.5 to 98.3,260
≥3 Doses HepB,,States/Local Areas,Georgia,2022,Age,13-17 Years,93.9,89.2 to 96.6,333
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2022,Age,13-17 Years,95.1,90.7 to 97.5,317
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2019,Age,13-17 Years,68.5,58.4 to 77.1,161
≥3 Doses HepB,,States/Local Areas,Georgia,2008,Age,13-17 Years,91.6,87.4 to 94.5,345
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2018,Age,13-17 Years,96.5,92.7 to 98.4,315
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2020,Age,13-17 Years,99.5,98.5 to 99.8,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2019,Age,13-17 Years,94.7,90.1 to 97.2,281
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2020,Age,13-17 Years,96.2,92.8 to 98.0,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2021,Age,13-17 Years,93.7,86.7 to 97.1,244
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2016,Age,13-17 Years,77.0,68.9 to 83.5,193
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2021,Age,13-17 Years,97.2,91.1 to 99.2,244
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2022,Age,13-17 Years,93.6,88.5 to 96.6,317
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2017,Age,13-17 Years,64.5,54.8 to 73.1,170
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2018,Age,13-17 Years,70.7,61.8 to 78.3,167
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2019,Age,13-17 Years,97.5,94.8 to 98.9,281
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2018,Age,13-17 Years,97.7,93.7 to 99.2,315
≥3 Doses HepB,,States/Local Areas,Georgia,2018,Age,13-17 Years,95.4,91.6 to 97.6,345
≥3 Doses HepB,,States/Local Areas,Georgia,2019,Age,13-17 Years,95.2,90.9 to 97.5,315
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2016,Age,13-17 Years,99.3,98.3 to 99.7,319
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2015,Age,13-17 Years,98.2,94.8 to 99.4,324
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2014,Age,13-17 Years,97.6,94.0 to 99.1,308
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2013,Age,13-17 Years,98.5,89.8 to 99.8,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2016,Age,13-17 Years,96.9,92.7 to 98.7,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2015,Age,13-17 Years,93.5,89.0 to 96.2,324
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2017,Age,13-17 Years,97.3,93.4 to 98.9,312
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2014,Age,13-17 Years,93.9,89.4 to 96.6,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2017,Age,13-17 Years,96.2,92.3 to 98.2,312
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2010,Age,13-17 Years,43.5,35.8 to 51.5,195
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2011,Age,13-17 Years,48.4,39.5 to 57.4,215
≥3 Doses HepB,,States/Local Areas,Georgia,2017,Age,13-17 Years,95.8,91.6 to 97.9,343
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2012,Age,13-17 Years,52.3,41.6 to 62.8,156
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2013,Age,13-17 Years,53.7,42.9 to 64.1,132
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2015,Age,13-17 Years,54.4,44.8 to 63.6,172
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2014,Age,13-17 Years,65.4,55.9 to 73.9,187
≥3 Doses HepB,,States/Local Areas,Georgia,2011,Age,13-17 Years,97.6,95.9 to 98.7,425
≥3 Doses HepB,,States/Local Areas,Georgia,2016,Age,13-17 Years,97.0,93.2 to 98.7,367
≥3 Doses HepB,,States/Local Areas,Georgia,2015,Age,13-17 Years,97.2,94.0 to 98.7,374
≥3 Doses HepB,,States/Local Areas,Georgia,2009,Age,13-17 Years,96.0,92.9 to 97.7,383
≥3 Doses HepB,,States/Local Areas,Georgia,2010,Age,13-17 Years,95.1,92.1 to 97.0,373
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2022,Age,13-15 Years,91.7,83.4 to 96.0,207
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2008,Age,13-17 Years,91.4,83.2 to 95.8,133
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2011,Age,13-17 Years,98.1,96.0 to 99.1,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2009,Age,13-17 Years,68.0,59.0 to 75.8,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2008,Age,13-17 Years,42.6,33.0 to 52.8,133
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2009,Age,13-17 Years,91.8,83.3 to 96.2,187
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2010,Age,13-17 Years,93.9,88.3 to 96.9,208
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2011,Age,13-17 Years,85.8,79.6 to 90.4,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2010,Age,13-17 Years,75.0,67.2 to 81.5,208
Varicella,≥1 Dose with no disease history,States/Local Areas,Georgia,2012,Age,13-17 Years,95.8,90.2 to 98.2,229
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2008,Age,13-17 Years,18.5,13.0 to 25.6,167
≥3 Doses HepB,,States/Local Areas,Georgia,2014,Age,13-17 Years,96.9,93.3 to 98.6,373
≥3 Doses HepB,,States/Local Areas,Georgia,2013,Age,13-17 Years,96.5,92.1 to 98.5,253
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2015,Age,13-17 Years,94.3,90.5 to 96.7,374
HPV,"≥1 Dose, Females",States/Local Areas,Georgia,2009,Age,13-17 Years,38.6,30.8 to 47.1,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2012,Age,13-17 Years,89.3,83.0 to 93.5,229
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2013,Age,13-17 Years,93.7,86.0 to 97.3,195
≥3 Doses HepB,,States/Local Areas,Georgia,2012,Age,13-17 Years,97.1,92.8 to 98.9,328
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2020,Age,13-15 Years,96.8,92.4 to 98.7,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2021,Age,13-15 Years,91.9,79.6 to 97.0,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2009,Age,13-15 Years,73.8,63.2 to 82.2,141
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2012,Age,13-15 Years,92.7,84.2 to 96.8,148
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2013,Age,13-15 Years,96.2,87.1 to 99.0,130
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2011,Age,13-15 Years,92.3,86.3 to 95.8,184
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2010,Age,13-15 Years,81.4,73.3 to 87.5,158
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2015,Age,13-15 Years,93.1,87.2 to 96.4,212
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2014,Age,13-15 Years,95.6,91.3 to 97.8,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2019,Age,13-15 Years,93.5,87.1 to 96.8,189
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2008,Age,13-17 Years,79.0,73.4 to 83.7,345
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2012,Age,13-17 Years,92.6,88.0 to 95.5,328
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2011,Age,13-17 Years,91.5,87.5 to 94.3,425
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2014,Age,13-17 Years,95.1,91.4 to 97.2,373
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2013,Age,13-17 Years,95.1,88.8 to 97.9,253
≥2 Doses Hep A,,States/Local Areas,Georgia,2021,Age,13-17 Years,88.9,81.9 to 93.4,260
≥2 Doses Hep A,,States/Local Areas,Georgia,2022,Age,13-17 Years,91.9,87.0 to 95.1,333
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2011,Age,13-17 Years,30.0,22.4 to 39.0,215
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2010,Age,13-17 Years,22.8,17.4 to 29.4,195
≥2 Doses Hep A,,States/Local Areas,Georgia,2020,Age,13-17 Years,91.1,86.3 to 94.4,300
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2015,Age,13-17 Years,32.3,24.6 to 41.2,172
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2017,Age,13-15 Years,97.0,91.9 to 98.9,209
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2016,Age,13-15 Years,96.5,90.4 to 98.8,230
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2018,Age,13-15 Years,95.0,89.0 to 97.8,205
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2020,Age,13-17 Years,96.3,93.0 to 98.1,300
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2021,Age,13-17 Years,94.0,87.4 to 97.3,260
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2022,Age,13-17 Years,94.0,89.1 to 96.8,333
Varicella,≥2 Doses with no disease history,States/Local Areas,Georgia,2008,Age,13-15 Years,49.4,38.1 to 60.8,104
HPV,"≥3 Doses, Males",States/Local Areas,Georgia,2014,Age,13-15 Years,18.1,11.3 to 27.9,113
HPV,"≥3 Doses, Males",States/Local Areas,Georgia,2015,Age,13-15 Years,29.7,20.6 to 40.7,122
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2019,Age,13-17 Years,95.2,90.9 to 97.5,315
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2009,Age,13-17 Years,85.3,80.3 to 89.2,383
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2010,Age,13-17 Years,86.5,81.8 to 90.2,373
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2017,Age,13-17 Years,96.6,93.1 to 98.4,343
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2016,Age,13-17 Years,97.3,93.5 to 98.9,367
Varicella,≥2 Doses or history of disease,States/Local Areas,Georgia,2018,Age,13-17 Years,96.8,93.2 to 98.5,345
HPV,"≥3 Doses, Males",States/Local Areas,Georgia,2013,Age,13-17 Years,15.3,8.7 to 25.4,121
HPV,"≥3 Doses, Males",States/Local Areas,Georgia,2015,Age,13-17 Years,27.5,20.6 to 35.6,202
HPV,"≥3 Doses, Males",States/Local Areas,Georgia,2014,Age,13-17 Years,21.0,14.7 to 29.1,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2015,Age,13-17 Years,90.2,85.5 to 93.5,374
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2012,Age,13-17 Years,29.0,20.9 to 38.7,156
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2014,Age,13-17 Years,47.1,37.7 to 56.8,187
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2013,Age,13-17 Years,33.2,24.5 to 43.2,132
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2020,Age,13-15 Years,45.6,34.0 to 57.8,111
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2012,Age,13-17 Years,80.5,73.9 to 85.8,328
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2017,Age,13-17 Years,45.7,39.1 to 52.5,343
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2018,Age,13-17 Years,49.6,43.1 to 56.1,345
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2019,Age,13-17 Years,49.7,42.7 to 56.8,315
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2014,Age,13-17 Years,86.1,80.6 to 90.2,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2013,Age,13-17 Years,82.0,74.4 to 87.7,253
HPV,"≥2 Doses, Males",States/Local Areas,Georgia,2019,Age,13-17 Years,48.7,38.8 to 58.7,154
≥2 Doses MMR,,States/Local Areas,Georgia,2011,Age,13-17 Years,97.6,95.6 to 98.7,425
≥2 Doses MMR,,States/Local Areas,Georgia,2010,Age,13-17 Years,94.8,91.8 to 96.7,373
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2016,Age,13-17 Years,45.6,39.2 to 52.2,367
≥2 Doses MMR,,States/Local Areas,Georgia,2009,Age,13-17 Years,93.0,88.5 to 95.8,383
≥2 Doses MMR,,States/Local Areas,Georgia,2008,Age,13-17 Years,92.8,87.3 to 96.0,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2009,Age,13-17 Years,50.8,44.7 to 56.9,383
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2010,Age,13-17 Years,62.2,56.2 to 67.9,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2011,Age,13-17 Years,68.0,61.8 to 73.6,425
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2022,Age,13-15 Years,91.5,84.2 to 95.6,216
Tetanus,≥1 Dose Tdap,States/Local Areas,Georgia,2008,Age,13-17 Years,37.8,31.6 to 44.4,345
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2009,Age,13-17 Years,21.8,15.9 to 29.1,182
HPV,"≥3 Doses, Females",States/Local Areas,Georgia,2008,Age,13-17 Years,8.1,5.0 to 12.9,167
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2020,Age,13-17 Years,54.9,47.7 to 62.0,300
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2021,Age,13-17 Years,60.9,52.8 to 68.4,260
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2022,Age,13-17 Years,61.5,54.5 to 67.9,333
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2017,Age,13-17 Years,45.0,35.8 to 54.5,170
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2018,Age,13-15 Years,44.3,33.4 to 55.8,113
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2021,Age,13-17 Years,66.6,55.6 to 76.0,118
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2022,Age,13-17 Years,65.9,56.0 to 74.6,159
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2017,Age,13-17 Years,46.4,37.0 to 56.1,173
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2016,Age,13-17 Years,36.2,27.8 to 45.6,174
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2021,Age,13-15 Years,54.5,40.0 to 68.3,95
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2022,Age,13-15 Years,55.0,43.3 to 66.1,125
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2021,Age,13-17 Years,55.4,43.9 to 66.3,142
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2019,Age,13-15 Years,45.0,36.7 to 53.7,210
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2022,Age,13-17 Years,57.2,47.4 to 66.4,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2021,Age,13-15 Years,58.7,48.0 to 68.6,161
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2020,Age,13-15 Years,49.5,40.6 to 58.5,198
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2018,Age,13-17 Years,45.6,36.7 to 54.8,178
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2019,Age,13-17 Years,43.5,33.9 to 53.6,154
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2020,Age,13-17 Years,51.2,41.5 to 60.8,166
HPV,"Up-to-Date, Males",States/Local Areas,Georgia,2019,Age,13-15 Years,38.0,27.2 to 50.1,105
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2020,Age,13-17 Years,58.8,48.0 to 68.8,134
HPV,"Up-to-Date, Males and Females",States/Local Areas,Georgia,2022,Age,13-15 Years,59.0,50.1 to 67.3,216
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Overall,Overall,70.2,67.3 to 72.9,1628
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a Non-MSA,77.8,71.3 to 83.2,313
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Overall,Overall,53.9,50.8 to 57.0,1628
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a Non-MSA,45.6,38.6 to 52.9,313
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Non-Principal City,72.5,68.3 to 76.4,696
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Principal City,78.9,74.5 to 82.6,619
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a Non-MSA,29.4,23.4 to 36.3,313
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Non-Principal City,54.5,49.8 to 59.1,696
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Principal City,64.4,59.5 to 69.1,619
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a Non-MSA,75.8,68.8 to 81.7,313
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Principal City,88.6,84.8 to 91.5,619
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.5,84.3 to 90.2,696
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Non-Principal City,86.0,82.5 to 88.9,696
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"White, Non-Hispanic",52.1,48.6 to 55.5,1272
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,Hispanic,67.2,54.1 to 78.1,107
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Urbanicity,Living In a MSA Principal City,88.3,84.4 to 91.3,619
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.0,80.6 to 94.0,143
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",68.5,57.8 to 77.5,143
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",68.2,57.8 to 77.1,106
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,Hispanic,52.1,39.9 to 64.0,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",49.5,39.3 to 59.7,143
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.6,79.7 to 92.7,106
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.4,82.8 to 87.8,1272
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.8,83.2 to 88.0,1272
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,Hispanic,82.6,69.3 to 90.9,107
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",82.2,73.0 to 88.7,106
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,Hispanic,85.1,73.6 to 92.1,107
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.5,78.6 to 93.0,143
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.0,75.5 to 90.0,106
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.2,64.9 to 71.4,1272
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Poverty,Below Poverty Level,71.3,63.0 to 78.5,206
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Poverty,Living At or Above Poverty Level,69.9,66.8 to 72.8,1385
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Poverty,Below Poverty Level,85.9,79.1 to 90.7,206
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Poverty,Living At or Above Poverty Level,86.2,83.7 to 88.4,1385
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Poverty,Below Poverty Level,58.0,49.5 to 66.0,206
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Poverty,Living At or Above Poverty Level,52.9,49.6 to 56.2,1385
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Poverty,Living At or Above Poverty Level,85.1,82.5 to 87.4,1385
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Poverty,Below Poverty Level,87.1,80.6 to 91.6,206
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Private Insurance Only,88.3,85.7 to 90.6,1032
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Any Medicaid,82.5,77.6 to 86.6,445
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Any Medicaid,71.0,65.4 to 76.0,445
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Private Insurance Only,71.2,67.7 to 74.6,1032
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Other,84.1,72.0 to 91.6,85
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Other,62.7,48.6 to 74.9,85
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Uninsured,53.6,38.4 to 68.2,66
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Uninsured,78.0,62.9 to 88.2,66
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Private Insurance Only,55.8,51.9 to 59.6,1032
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Any Medicaid,53.2,47.3 to 58.9,445
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Uninsured,34.9,21.4 to 51.5,66
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018-2022,Insurance Coverage,Other,48.3,34.8 to 62.1,85
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Private Insurance Only,86.7,83.9 to 89.1,1032
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Any Medicaid,83.9,79.2 to 87.7,445
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Uninsured,79.3,64.1 to 89.2,66
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Insurance Coverage,Other,84.4,72.4 to 91.8,85
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2021,Age,13-15 Years,87.1,80.0 to 92.0,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2020,Age,13-15 Years,80.2,72.3 to 86.3,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2019,Age,13-15 Years,81.8,73.9 to 87.7,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018,Age,13-15 Years,78.1,69.1 to 85.0,184
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018-2022,Overall,Overall,85.8,83.5 to 87.9,1628
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2018-2022,Overall,Overall,85.4,83.1 to 87.5,1628
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2011,Age,13-17 Years,37.7,28.9 to 47.3,191
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2010,Age,13-17 Years,34.4,27.0 to 42.7,170
≥1 Dose MenACWY,,States/Local Areas,Missouri,2020,Age,13-15 Years,80.9,73.1 to 86.8,258
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2009,Age,13-17 Years,24.8,18.6 to 32.3,173
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2014,Age,13-17 Years,87.8,82.8 to 91.5,361
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2015,Age,13-17 Years,86.6,81.0 to 90.7,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2016,Age,13-17 Years,85.7,80.6 to 89.6,360
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2017,Age,13-17 Years,80.1,74.1 to 85.0,335
≥1 Dose MenACWY,,States/Local Areas,Missouri,2013,Age,13-15 Years,60.1,50.7 to 68.7,174
≥1 Dose MenACWY,,States/Local Areas,Missouri,2012,Age,13-15 Years,57.5,48.0 to 66.5,188
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2008,Age,13-17 Years,23.3,16.3 to 32.3,158
≥1 Dose MenACWY,,States/Local Areas,Missouri,2015,Age,13-15 Years,68.2,59.6 to 75.7,199
≥1 Dose MenACWY,,States/Local Areas,Missouri,2014,Age,13-15 Years,63.2,54.9 to 70.9,230
≥1 Dose MenACWY,,States/Local Areas,Missouri,2010,Age,13-15 Years,49.6,42.1 to 57.2,205
≥1 Dose MenACWY,,States/Local Areas,Missouri,2011,Age,13-15 Years,58.1,49.8 to 65.9,249
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2009,Age,13-17 Years,74.7,69.3 to 79.4,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2008,Age,13-17 Years,67.9,61.9 to 73.4,351
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2011,Age,13-17 Years,82.5,76.9 to 87.0,402
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2010,Age,13-17 Years,76.3,70.5 to 81.2,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2013,Age,13-17 Years,82.8,76.8 to 87.5,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2012,Age,13-17 Years,89.9,84.6 to 93.6,292
≥1 Dose MenACWY,,States/Local Areas,Missouri,2008,Age,13-15 Years,34.8,27.6 to 42.7,226
≥1 Dose MenACWY,,States/Local Areas,Missouri,2009,Age,13-15 Years,45.4,37.7 to 53.3,214
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2022,Age,13-17 Years,93.8,89.3 to 96.4,266
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2018,Age,13-17 Years,67.0,57.6 to 75.3,144
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2021,Age,13-17 Years,95.4,90.6 to 97.8,316
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2022,Age,13-17 Years,90.7,85.2 to 94.3,266
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2016,Age,13-17 Years,55.0,45.7 to 64.0,174
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2017,Age,13-17 Years,62.7,53.8 to 70.8,170
≥3 Doses HepB,,States/Local Areas,Missouri,2020,Age,13-17 Years,91.5,86.5 to 94.7,397
≥3 Doses HepB,,States/Local Areas,Missouri,2021,Age,13-17 Years,90.7,85.7 to 94.1,340
≥3 Doses HepB,,States/Local Areas,Missouri,2022,Age,13-17 Years,88.1,82.4 to 92.2,284
HPV,"≥2 Doses, Males and Females",States/Local Areas,Missouri,2016,Age,13-17 Years,40.1,33.8 to 46.8,360
HPV,"≥2 Doses, Males and Females",States/Local Areas,Missouri,2017,Age,13-17 Years,44.4,38.2 to 50.8,335
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2022,Age,13-17 Years,68.0,57.5 to 76.9,140
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2019,Age,13-17 Years,74.2,64.1 to 82.2,140
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2019,Age,13-17 Years,64.1,53.8 to 73.3,148
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2012,Age,13-17 Years,21.7,13.4 to 33.2,142
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2020,Age,13-17 Years,71.0,61.5 to 79.0,175
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2021,Age,13-17 Years,78.8,70.4 to 85.3,156
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2022,Age,13-17 Years,80.3,71.8 to 86.7,144
HPV,"≥2 Doses, Males and Females",States/Local Areas,Missouri,2018,Age,13-17 Years,46.3,39.8 to 52.9,319
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2018,Age,13-17 Years,56.4,47.1 to 65.3,175
HPV,"≥2 Doses, Males and Females",States/Local Areas,Missouri,2019,Age,13-17 Years,56.0,48.4 to 63.2,288
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2017,Age,13-17 Years,53.1,43.8 to 62.1,165
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2014,Age,13-17 Years,27.9,20.3 to 37.1,185
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2013,Age,13-17 Years,20.5,13.8 to 29.2,145
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2015,Age,13-17 Years,44.7,35.2 to 54.5,159
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2016,Age,13-17 Years,48.3,39.1 to 57.5,186
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2016,Age,13-17 Years,51.6,45.0 to 58.1,360
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2017,Age,13-17 Years,57.8,51.3 to 64.0,335
≥1 Dose MenACWY,,States/Local Areas,Missouri,2019,Age,13-15 Years,82.6,74.9 to 88.2,186
≥1 Dose MenACWY,,States/Local Areas,Missouri,2018,Age,13-15 Years,79.8,71.2 to 86.4,184
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2013,Age,13-17 Years,38.1,28.6 to 48.6,135
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2012,Age,13-17 Years,40.4,30.8 to 50.8,150
≥1 Dose MenACWY,,States/Local Areas,Missouri,2016,Age,13-15 Years,65.6,57.2 to 73.1,232
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2020,Age,13-17 Years,69.9,63.5 to 75.6,397
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2021,Age,13-17 Years,76.2,70.0 to 81.5,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2022,Age,13-17 Years,74.0,67.2 to 79.8,284
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2015,Age,13-17 Years,43.4,33.4 to 54.0,141
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2014,Age,13-17 Years,36.3,28.0 to 45.4,176
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2016,Age,13-17 Years,44.7,35.6 to 54.1,174
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2017,Age,13-17 Years,50.1,41.3 to 58.8,170
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2008,Age,13-15 Years,43.8,36.1 to 51.7,226
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2010,Age,13-15 Years,60.6,52.8 to 67.9,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2009,Age,13-15 Years,59.3,51.5 to 66.6,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2011,Age,13-15 Years,79.6,71.7 to 85.7,249
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2012,Age,13-15 Years,86.8,79.2 to 91.8,188
≥1 Dose MenACWY,,States/Local Areas,Missouri,2017,Age,13-15 Years,73.1,64.9 to 80.0,208
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2018,Age,13-17 Years,61.6,55.0 to 67.8,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2018,Age,13-17 Years,82.0,76.0 to 86.8,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2020,Age,13-17 Years,86.0,80.7 to 90.1,397
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2019,Age,13-17 Years,85.2,79.3 to 89.6,288
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2021,Age,13-17 Years,91.0,86.0 to 94.3,340
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Missouri,2022,Age,13-17 Years,91.9,87.4 to 94.8,284
HPV,"≥1 Dose, Males and Females",States/Local Areas,Missouri,2019,Age,13-17 Years,69.0,61.9 to 75.4,288
≥1 Dose MenACWY,,States/Local Areas,Missouri,2021,Age,13-15 Years,89.8,83.4 to 93.9,212
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2018,Age,13-17 Years,56.1,46.5 to 65.3,144
HPV,"≥2 Doses, Females",States/Local Areas,Missouri,2019,Age,13-17 Years,57.6,46.6 to 67.8,140
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2013,Age,13-15 Years,78.7,70.4 to 85.2,174
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2014,Age,13-17 Years,20.1,13.5 to 28.8,185
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2015,Age,13-15 Years,80.6,72.6 to 86.7,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2014,Age,13-15 Years,85.3,78.1 to 90.5,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2016,Age,13-15 Years,81.3,74.3 to 86.8,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2017,Age,13-15 Years,76.1,67.8 to 82.8,208
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2015,Age,13-17 Years,33.7,24.9 to 43.7,159
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2018,Age,13-17 Years,36.9,28.5 to 46.1,175
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2016,Age,13-17 Years,35.8,27.5 to 45.0,186
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2017,Age,13-17 Years,39.0,30.5 to 48.2,165
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2020,Age,13-17 Years,68.8,60.0 to 76.4,222
HPV,"≥1 Dose, Males",States/Local Areas,Missouri,2021,Age,13-17 Years,73.8,64.4 to 81.4,184
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2012,Age,13-17 Years,87.5,76.5 to 93.8,188
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2008,Age,13-17 Years,31.6,23.8 to 40.7,158
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2013,Age,13-17 Years,58.6,49.8 to 66.9,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2012,Age,13-17 Years,53.6,43.9 to 63.0,188
≥3 Doses HepB,,States/Local Areas,Missouri,2017,Age,13-17 Years,88.4,83.9 to 91.8,335
≥3 Doses HepB,,States/Local Areas,Missouri,2019,Age,13-17 Years,90.3,84.7 to 94.0,288
≥3 Doses HepB,,States/Local Areas,Missouri,2018,Age,13-17 Years,90.7,86.3 to 93.7,319
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2018,Age,13-17 Years,93.7,89.1 to 96.5,284
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2014,Age,13-17 Years,47.5,38.5 to 56.7,176
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2015,Age,13-17 Years,59.3,49.0 to 68.8,141
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2013,Age,13-17 Years,46.1,35.9 to 56.8,135
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2012,Age,13-17 Years,51.6,41.1 to 61.8,150
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2010,Age,13-17 Years,41.4,33.4 to 49.8,170
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2011,Age,13-17 Years,49.5,40.0 to 59.1,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2017,Age,13-17 Years,76.9,70.7 to 82.1,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2015,Age,13-17 Years,68.6,61.1 to 75.3,247
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2016,Age,13-17 Years,71.9,64.8 to 78.0,299
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2014,Age,13-17 Years,63.8,56.0 to 70.9,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2017,Age,13-17 Years,93.9,89.9 to 96.4,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2020,Age,13-17 Years,91.0,86.5 to 94.0,353
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2021,Age,13-17 Years,89.1,83.3 to 93.0,316
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2019,Age,13-17 Years,87.9,81.1 to 92.4,254
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2020,Age,13-17 Years,95.0,91.1 to 97.3,353
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2018,Age,13-17 Years,85.0,79.4 to 89.3,284
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2019,Age,13-17 Years,92.6,86.4 to 96.1,254
≥3 Doses HepB,,States/Local Areas,Missouri,2015,Age,13-17 Years,89.5,84.3 to 93.1,300
≥3 Doses HepB,,States/Local Areas,Missouri,2016,Age,13-17 Years,89.2,85.0 to 92.4,360
≥3 Doses HepB,,States/Local Areas,Missouri,2014,Age,13-17 Years,85.4,79.4 to 89.9,361
≥3 Doses HepB,,States/Local Areas,Missouri,2013,Age,13-17 Years,88.1,81.8 to 92.4,280
≥3 Doses HepB,,States/Local Areas,Missouri,2011,Age,13-17 Years,88.9,83.2 to 92.8,402
≥3 Doses HepB,,States/Local Areas,Missouri,2012,Age,13-17 Years,87.9,82.1 to 92.0,292
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2014,Age,13-17 Years,86.4,79.6 to 91.2,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2013,Age,13-17 Years,90.4,84.0 to 94.4,198
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2015,Age,13-17 Years,93.4,89.0 to 96.1,247
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2016,Age,13-17 Years,93.7,89.5 to 96.4,299
HPV,"≥1 Dose, Females",States/Local Areas,Missouri,2009,Age,13-17 Years,32.7,25.5 to 40.8,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2011,Age,13-17 Years,46.7,37.9 to 55.6,226
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2010,Age,13-17 Years,44.3,36.7 to 52.1,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2022,Age,13-15 Years,92.4,84.2 to 96.6,165
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2008,Age,13-17 Years,62.7,51.5 to 72.7,111
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2009,Age,13-17 Years,42.3,33.4 to 51.7,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2008,Age,13-17 Years,31.0,20.7 to 43.6,111
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2011,Age,13-17 Years,81.9,73.3 to 88.2,226
≥3 Doses HepB,,States/Local Areas,Missouri,2008,Age,13-17 Years,87.0,82.4 to 90.5,351
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2009,Age,13-17 Years,78.6,70.6 to 84.9,140
Varicella,≥1 Dose with no disease history,States/Local Areas,Missouri,2010,Age,13-17 Years,76.9,69.3 to 83.1,193
≥3 Doses HepB,,States/Local Areas,Missouri,2009,Age,13-17 Years,89.7,84.8 to 93.2,374
≥3 Doses HepB,,States/Local Areas,Missouri,2010,Age,13-17 Years,90.9,87.0 to 93.7,347
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2018,Age,13-15 Years,89.2,82.3 to 93.6,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2019,Age,13-15 Years,90.0,82.1 to 94.6,172
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2019,Age,13-17 Years,89.1,83.0 to 93.2,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2016,Age,13-15 Years,75.9,67.1 to 83.0,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2017,Age,13-15 Years,80.1,72.0 to 86.3,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2020,Age,13-15 Years,92.2,86.2 to 95.7,231
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2021,Age,13-15 Years,88.4,80.4 to 93.4,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2015,Age,13-15 Years,67.0,57.6 to 75.1,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2014,Age,13-15 Years,70.9,61.8 to 78.5,176
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2008,Age,13-17 Years,77.4,72.1 to 82.0,351
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2020,Age,13-17 Years,91.9,87.9 to 94.7,397
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2021,Age,13-17 Years,89.8,84.4 to 93.5,340
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2022,Age,13-17 Years,91.3,86.1 to 94.6,284
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2009,Age,13-15 Years,44.6,34.4 to 55.3,107
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2008,Age,13-15 Years,32.8,20.5 to 48.0,81
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2010,Age,13-15 Years,47.7,38.4 to 57.1,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2011,Age,13-15 Years,48.2,37.9 to 58.7,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2013,Age,13-15 Years,57.5,46.6 to 67.8,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Missouri,2012,Age,13-15 Years,61.4,50.6 to 71.1,141
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2015,Age,13-17 Years,75.2,68.8 to 80.6,300
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2016,Age,13-17 Years,76.4,70.2 to 81.6,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2018,Age,13-17 Years,86.9,82.0 to 90.7,319
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2017,Age,13-17 Years,79.9,74.4 to 84.4,335
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2014,Age,13-17 Years,72.8,66.3 to 78.5,361
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2013,Age,13-17 Years,70.3,63.2 to 76.6,280
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2011,Age,13-17 Years,69.6,63.2 to 75.4,402
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2012,Age,13-17 Years,70.3,62.5 to 77.0,292
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2009,Age,13-17 Years,78.8,73.7 to 83.1,374
Varicella,≥2 Doses or history of disease,States/Local Areas,Missouri,2010,Age,13-17 Years,68.2,62.3 to 73.5,347
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2015,Age,13-17 Years,31.5,22.7 to 41.9,141
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2021,Age,13-17 Years,59.3,52.5 to 65.7,340
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2022,Age,13-17 Years,59.8,52.6 to 66.6,284
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2015,Age,13-17 Years,85.7,80.1 to 89.9,300
≥2 Doses Hep A,,States/Local Areas,Missouri,2020,Age,13-17 Years,77.6,71.6 to 82.6,397
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2010,Age,13-17 Years,25.5,19.3 to 33.0,170
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2014,Age,13-17 Years,28.3,20.9 to 37.2,176
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2013,Age,13-17 Years,28.8,20.7 to 38.6,135
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2011,Age,13-17 Years,30.8,22.6 to 40.4,191
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2012,Age,13-17 Years,34.5,25.5 to 44.7,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2020,Age,13-17 Years,53.6,46.9 to 60.1,397
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2019,Age,13-17 Years,54.3,46.8 to 61.7,288
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2009,Age,13-17 Years,19.9,14.2 to 27.0,173
HPV,"≥3 Doses, Females",States/Local Areas,Missouri,2008,Age,13-17 Years,15.1,9.8 to 22.6,158
HPV,"≥3 Doses, Males",States/Local Areas,Missouri,2015,Age,13-17 Years,25.1,17.1 to 35.1,159
HPV,"≥3 Doses, Males",States/Local Areas,Missouri,2014,Age,13-17 Years,11.3,6.7 to 18.4,185
≥2 Doses Hep A,,States/Local Areas,Missouri,2022,Age,13-17 Years,80.9,74.5 to 86.0,284
≥2 Doses Hep A,,States/Local Areas,Missouri,2021,Age,13-17 Years,79.6,73.5 to 84.6,340
HPV,"≥3 Doses, Males",States/Local Areas,Missouri,2015,Age,13-15 Years,19.0,11.2 to 30.4,108
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2016,Age,13-17 Years,35.8,29.8 to 42.4,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2014,Age,13-17 Years,86.1,80.8 to 90.0,361
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2013,Age,13-17 Years,81.5,75.5 to 86.4,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2012,Age,13-17 Years,88.0,82.3 to 92.1,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2009,Age,13-17 Years,60.1,54.3 to 65.7,374
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2010,Age,13-17 Years,66.0,60.0 to 71.5,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2011,Age,13-17 Years,79.6,73.8 to 84.4,402
≥2 Doses MMR,,States/Local Areas,Missouri,2011,Age,13-17 Years,85.5,79.7 to 89.9,402
≥2 Doses MMR,,States/Local Areas,Missouri,2010,Age,13-17 Years,88.1,83.6 to 91.4,347
≥2 Doses MMR,,States/Local Areas,Missouri,2009,Age,13-17 Years,86.2,81.0 to 90.1,374
≥2 Doses MMR,,States/Local Areas,Missouri,2008,Age,13-17 Years,84.2,79.0 to 88.4,351
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2022,Age,13-15 Years,88.3,81.4 to 92.9,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Missouri,2008,Age,13-17 Years,44.1,38.1 to 50.3,351
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2018,Age,13-17 Years,42.1,35.7 to 48.8,319
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2017,Age,13-17 Years,39.6,33.6 to 45.9,335
HPV,"≥2 Doses, Males",States/Local Areas,Missouri,2019,Age,13-17 Years,54.5,44.1 to 64.5,148
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2021,Age,13-15 Years,48.0,36.4 to 59.9,110
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2022,Age,13-15 Years,53.1,39.6 to 66.1,82
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2019,Age,13-15 Years,46.1,33.3 to 59.5,91
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2019,Age,13-17 Years,55.2,44.2 to 65.6,140
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2018,Age,13-17 Years,51.1,41.6 to 60.5,144
Varicella,History of disease,States/Local Areas,Missouri,2021,Age,13-17 Years,7.2,4.4 to 11.4,340
Varicella,History of disease,States/Local Areas,Missouri,2022,Age,13-17 Years,6.4,3.8 to 10.5,284
Varicella,History of disease,States/Local Areas,Missouri,2020,Age,13-17 Years,10.4,7.1 to 14.9,397
Varicella,History of disease,States/Local Areas,Missouri,2019,Age,13-17 Years,10.4,6.8 to 15.6,288
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2020,Age,13-17 Years,53.9,44.9 to 62.7,222
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2019,Age,13-17 Years,53.5,43.2 to 63.6,148
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2017,Age,13-17 Years,34.2,26.2 to 43.2,165
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2018,Age,13-17 Years,33.5,25.4 to 42.7,175
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2022,Age,13-15 Years,57.2,48.1 to 65.8,179
Varicella,History of disease,States/Local Areas,Missouri,2009,Age,13-17 Years,63.3,57.5 to 68.7,374
Varicella,History of disease,States/Local Areas,Missouri,2008,Age,13-17 Years,67.3,61.1 to 72.9,351
Varicella,History of disease,States/Local Areas,Missouri,2016,Age,13-17 Years,16.2,12.2 to 21.1,360
Varicella,History of disease,States/Local Areas,Missouri,2017,Age,13-17 Years,12.9,9.3 to 17.7,335
Varicella,History of disease,States/Local Areas,Missouri,2014,Age,13-17 Years,25.0,19.6 to 31.3,361
Varicella,History of disease,States/Local Areas,Missouri,2015,Age,13-17 Years,20.9,15.6 to 27.5,300
Varicella,History of disease,States/Local Areas,Missouri,2011,Age,13-17 Years,43.1,36.9 to 49.5,402
Varicella,History of disease,States/Local Areas,Missouri,2010,Age,13-17 Years,42.9,37.2 to 48.7,347
Varicella,History of disease,States/Local Areas,Missouri,2013,Age,13-17 Years,28.3,22.3 to 35.2,280
Varicella,History of disease,States/Local Areas,Missouri,2012,Age,13-17 Years,35.9,28.9 to 43.6,292
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2018,Age,13-15 Years,46.0,34.1 to 58.3,84
Varicella,History of disease,States/Local Areas,Missouri,2018,Age,13-17 Years,12.9,8.7 to 18.7,319
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2020,Age,13-15 Years,43.4,31.8 to 55.7,117
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2019,Age,13-15 Years,62.7,50.3 to 73.6,95
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2017,Age,13-17 Years,45.2,36.7 to 54.1,170
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2016,Age,13-17 Years,38.5,29.8 to 48.0,174
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2021,Age,13-17 Years,56.0,46.6 to 65.0,184
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2021,Age,13-17 Years,62.7,53.1 to 71.5,156
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2022,Age,13-17 Years,63.8,54.0 to 72.6,144
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2018,Age,13-15 Years,30.2,20.4 to 42.3,100
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2020,Age,13-17 Years,53.2,43.4 to 62.8,175
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2016,Age,13-17 Years,33.3,25.2 to 42.5,186
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2020,Age,13-15 Years,45.6,34.8 to 56.9,141
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2021,Age,13-15 Years,64.5,52.7 to 74.7,102
HPV,"Up-to-Date, Females",States/Local Areas,Missouri,2022,Age,13-15 Years,60.5,48.5 to 71.3,97
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2020,Age,13-15 Years,44.6,36.5 to 52.9,258
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2021,Age,13-15 Years,56.6,48.1 to 64.8,212
HPV,"Up-to-Date, Males",States/Local Areas,Missouri,2022,Age,13-17 Years,55.9,45.5 to 65.9,140
HPV,"Up-to-Date, Males and Females",States/Local Areas,Missouri,2019,Age,13-15 Years,54.8,45.5 to 63.8,186
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2023,Age,13-17 Years,89.7,83.9 to 93.6,275
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2023,Age,13-17 Years,90.1,84.4 to 93.9,275
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2023,Age,13-17 Years,91.1,85.4 to 94.7,275
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2023,Age,13-17 Years,82.9,76.2 to 88.1,275
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2023,Age,13-17 Years,72.3,65.1 to 78.5,275
≥2 Doses MMR,,States/Local Areas,South Dakota,2023,Age,13-17 Years,95.9,91.5 to 98.1,275
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2023,Age,13-17 Years,75.4,66.3 to 82.7,160
≥3 Doses HepB,,States/Local Areas,South Dakota,2023,Age,13-17 Years,96.4,93.1 to 98.2,275
Varicella,History of disease,States/Local Areas,South Dakota,2023,Age,13-17 Years,5.6,3.1 to 9.9,275
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2023,Age,13-17 Years,96.8,93.1 to 98.6,261
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2023,Age,13-17 Years,95.3,90.4 to 97.8,261
≥2 Doses Hep A,,States/Local Areas,South Dakota,2023,Age,13-17 Years,89.5,84.0 to 93.3,275
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2023,Age,13-17 Years,95.6,90.9 to 97.9,275
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2023,Age,13-15 Years,88.4,80.5 to 93.4,166
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2023,Age,13-15 Years,90.3,82.5 to 94.8,166
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2023,Age,13-15 Years,65.6,55.8 to 74.2,166
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2023,Age,13-15 Years,71.7,59.2 to 81.5,92
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2023,Age,13-17 Years,80.8,69.8 to 88.5,115
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2023,Age,13-15 Years,59.9,45.4 to 72.9,74
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2023,Age,13-15 Years,97.6,93.0 to 99.2,156
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2023,Age,13-17 Years,84.9,76.1 to 90.9,160
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2023,Age,13-17 Years,69.0,57.5 to 78.5,115
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Other,90.9,81.5 to 95.8,135
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Uninsured,81.0,64.9 to 90.7,51
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Any Medicaid,90.9,86.9 to 93.8,381
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Private Insurance Only,92.6,90.4 to 94.3,1100
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Uninsured,51.5,34.7 to 68.0,51
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Other,61.2,50.9 to 70.6,135
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Private Insurance Only,66.8,63.3 to 70.1,1100
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Any Medicaid,65.0,59.1 to 70.6,381
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Uninsured,75.3,57.8 to 87.2,51
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Other,74.5,64.3 to 82.5,135
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Uninsured,72.5,55.9 to 84.6,51
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Private Insurance Only,79.3,76.3 to 82.0,1100
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Any Medicaid,79.8,74.4 to 84.3,381
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Other,91.8,82.1 to 96.4,135
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Private Insurance Only,91.2,89.2 to 93.0,1100
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Poverty,Living At or Above Poverty Level,91.3,89.2 to 92.9,1467
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Insurance Coverage,Any Medicaid,93.0,89.5 to 95.3,381
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Poverty,Below Poverty Level,93.7,88.5 to 96.7,157
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Poverty,Living At or Above Poverty Level,65.0,61.9 to 67.9,1467
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Poverty,Living At or Above Poverty Level,90.4,88.4 to 92.1,1467
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Poverty,Below Poverty Level,66.3,57.2 to 74.3,157
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Poverty,Below Poverty Level,95.8,91.7 to 97.9,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Poverty,Below Poverty Level,83.7,75.6 to 89.5,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Poverty,Living At or Above Poverty Level,78.4,75.7 to 80.9,1467
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",77.0,74.1 to 79.7,1302
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,Hispanic,88.5,77.9 to 94.4,78
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.7,88.3 to 95.6,262
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,Hispanic,88.3,78.2 to 94.1,78
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.3,89.1 to 93.1,1302
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.2,88.0 to 92.0,1302
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,Hispanic,61.4,48.0 to 73.2,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",70.9,63.9 to 76.9,262
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,Hispanic,73.8,60.7 to 83.6,78
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.1,80.3 to 90.4,262
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",95.4,92.1 to 97.4,262
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",64.0,60.7 to 67.2,1302
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,88.8,84.9 to 91.8,512
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.6,87.7 to 95.6,276
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,91.3,87.8 to 93.9,512
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a Non-MSA,90.5,87.9 to 92.6,879
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.6,88.4 to 95.4,276
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,69.7,64.9 to 74.2,512
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a Non-MSA,60.7,56.5 to 64.6,879
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,68.8,61.6 to 75.1,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a Non-MSA,75.5,71.7 to 78.9,879
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,79.8,73.2 to 85.0,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,82.9,78.8 to 86.3,512
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Urbanicity,Living In a Non-MSA,93.0,90.6 to 94.8,879
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018-2022,Overall,Overall,65.2,62.4 to 67.9,1667
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018-2022,Overall,Overall,78.7,76.2 to 81.0,1667
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2008,Age,13-15 Years,26.4,18.2 to 36.6,103
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2009,Age,13-15 Years,46.8,34.7 to 59.2,83
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2010,Age,13-15 Years,57.1,45.0 to 68.4,92
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2011,Age,13-15 Years,39.7,22.7 to 59.6,102
≥2 Doses MMR,,States/Local Areas,South Dakota,2022,Age,13-17 Years,95.6,92.0 to 97.6,252
≥2 Doses MMR,,States/Local Areas,South Dakota,2021,Age,13-17 Years,98.0,96.0 to 99.0,445
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Dakota,2012,Age,13-17 Years,18.3,13.5 to 24.3,298
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2012,Age,13-17 Years,40.0,33.4 to 47.0,298
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2014,Age,13-15 Years,29.2,19.7 to 41.0,109
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2015,Age,13-15 Years,32.5,22.7 to 44.2,101
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2013,Age,13-15 Years,38.7,27.5 to 51.3,85
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2012,Age,13-15 Years,16.9,9.8 to 27.7,87
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Dakota,2014,Age,13-17 Years,28.1,22.5 to 34.6,358
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Dakota,2015,Age,13-17 Years,27.1,21.8 to 33.1,349
≥2 Doses MMR,,States/Local Areas,South Dakota,2020,Age,13-17 Years,97.6,95.1 to 98.8,317
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Dakota,2013,Age,13-17 Years,24.9,19.6 to 31.0,292
≥2 Doses MMR,,States/Local Areas,South Dakota,2019,Age,13-17 Years,93.4,88.8 to 96.2,313
≥2 Doses MMR,,States/Local Areas,South Dakota,2017,Age,13-17 Years,94.6,91.0 to 96.9,333
≥2 Doses MMR,,States/Local Areas,South Dakota,2018,Age,13-17 Years,97.2,94.9 to 98.5,340
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2021,Age,13-17 Years,95.6,92.3 to 97.5,445
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2020,Age,13-17 Years,91.5,86.8 to 94.6,317
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2019,Age,13-17 Years,90.0,85.2 to 93.4,313
≥2 Doses MMR,,States/Local Areas,South Dakota,2013,Age,13-17 Years,94.1,89.9 to 96.6,292
≥2 Doses MMR,,States/Local Areas,South Dakota,2012,Age,13-17 Years,89.5,84.5 to 93.0,298
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2022,Age,13-17 Years,93.5,88.6 to 96.4,252
≥2 Doses MMR,,States/Local Areas,South Dakota,2015,Age,13-17 Years,90.4,85.7 to 93.7,349
≥2 Doses MMR,,States/Local Areas,South Dakota,2014,Age,13-17 Years,94.8,90.8 to 97.1,358
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2016,Age,13-17 Years,79.4,73.1 to 84.5,342
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2017,Age,13-17 Years,79.5,73.6 to 84.4,333
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018,Age,13-17 Years,86.6,81.6 to 90.4,340
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2016,Age,13-17 Years,65.7,59.1 to 71.7,342
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2015,Age,13-17 Years,55.5,49.2 to 61.6,349
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2014,Age,13-17 Years,57.0,50.3 to 63.5,358
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2013,Age,13-17 Years,51.7,44.9 to 58.3,292
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Dakota,2011,Age,13-17 Years,25.2,17.8 to 34.4,355
≥2 Doses MMR,,States/Local Areas,South Dakota,2016,Age,13-17 Years,96.7,93.4 to 98.4,342
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2009,Age,13-17 Years,24.9,19.6 to 31.1,271
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2008,Age,13-17 Years,14.0,10.3 to 18.9,344
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2011,Age,13-17 Years,37.4,28.5 to 47.3,355
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2010,Age,13-17 Years,30.9,25.3 to 37.1,321
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2022,Age,13-15 Years,95.3,89.9 to 97.9,158
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018-2022,Overall,Overall,91.5,89.7 to 93.0,1667
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018-2022,Overall,Overall,91.2,89.4 to 92.6,1667
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2021,Age,13-17 Years,96.6,94.3 to 98.0,445
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2022,Age,13-17 Years,93.0,88.0 to 96.0,252
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2020,Age,13-17 Years,94.2,90.6 to 96.5,317
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2019,Age,13-17 Years,86.2,80.9 to 90.3,313
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018,Age,13-17 Years,85.3,80.5 to 89.0,340
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2017,Age,13-17 Years,74.5,68.4 to 79.9,333
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2023,Age,13-17 Years,84.1,71.4 to 91.8,77
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2023,Age,13-15 Years,64.5,45.6 to 79.8,45
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2023,Age,13-17 Years,71.2,56.3 to 82.6,78
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2023,Age,13-15 Years,94.9,84.3 to 98.5,88
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2023,Age,13-15 Years,61.5,42.4 to 77.6,46
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2023,Age,13-15 Years,63.1,49.7 to 74.8,91
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2023,Age,13-15 Years,95.4,86.1 to 98.6,91
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2023,Age,13-15 Years,92.2,83.2 to 96.5,91
≥2 Doses Hep A,,States/Local Areas,Connecticut,2023,Age,13-17 Years,94.8,88.9 to 97.6,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2023,Age,13-17 Years,96.4,90.2 to 98.7,148
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2023,Age,13-17 Years,96.7,90.8 to 98.8,155
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2023,Age,13-17 Years,98.9,95.8 to 99.7,148
≥3 Doses HepB,,States/Local Areas,Connecticut,2023,Age,13-17 Years,91.7,82.9 to 96.2,155
≥2 Doses MMR,,States/Local Areas,Connecticut,2023,Age,13-17 Years,99.0,96.1 to 99.7,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2023,Age,13-17 Years,71.2,61.2 to 79.5,155
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2023,Age,13-17 Years,79.3,65.4 to 88.6,78
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2023,Age,13-17 Years,71.2,56.9 to 82.2,77
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2023,Age,13-17 Years,81.7,72.8 to 88.2,155
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2023,Age,13-17 Years,97.3,92.1 to 99.1,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2023,Age,13-17 Years,93.3,85.5 to 97.0,155
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2023,Age,13-17 Years,93.3,85.5 to 97.0,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Other,92.9,85.7 to 96.6,211
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Any Medicaid,93.3,88.9 to 96.1,273
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Private Insurance Only,95.4,93.5 to 96.7,1000
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Uninsured,42.6,23.9 to 63.8,32
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Other,61.3,52.6 to 69.3,211
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Any Medicaid,69.4,62.1 to 75.8,273
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Uninsured,58.0,36.7 to 76.6,32
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Uninsured,82.3,59.4 to 93.7,32
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Private Insurance Only,61.0,57.2 to 64.6,1000
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Other,75.0,66.3 to 82.1,211
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Any Medicaid,82.2,75.6 to 87.4,273
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Private Insurance Only,75.1,71.7 to 78.2,1000
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Other,91.0,83.2 to 95.4,211
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Any Medicaid,91.8,86.7 to 95.1,273
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Private Insurance Only,95.3,93.4 to 96.7,1000
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Poverty,Living At or Above Poverty Level,94.9,93.2 to 96.2,1306
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Poverty,Below Poverty Level,92.4,84.8 to 96.4,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Poverty,Living At or Above Poverty Level,61.2,57.9 to 64.4,1306
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Poverty,Below Poverty Level,71.2,61.7 to 79.1,146
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Poverty,Below Poverty Level,87.9,79.0 to 93.3,146
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Poverty,Living At or Above Poverty Level,94.7,92.9 to 96.1,1306
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Poverty,Living At or Above Poverty Level,75.8,72.8 to 78.6,1306
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Poverty,Below Poverty Level,79.6,70.3 to 86.5,146
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,Hispanic,82.9,76.9 to 87.5,286
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"White, Non-Hispanic",72.7,69.0 to 76.1,955
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2018,Age,13-17 Years,89.6,87.0 to 91.7,1746
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.3,70.2 to 87.5,120
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.7,87.7 to 97.8,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,Hispanic,92.3,87.4 to 95.4,286
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,Hispanic,91.7,86.9 to 94.9,286
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",93.4,85.5 to 97.1,120
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.0,92.9 to 96.6,955
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.6,93.9 to 96.9,955
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.6,80.0 to 94.8,120
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.2,50.8 to 70.6,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,Hispanic,67.5,60.7 to 73.8,286
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",71.2,60.7 to 79.9,120
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",74.8,64.4 to 82.9,155
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.5,87.8 to 97.6,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Race and Ethnicity,"White, Non-Hispanic",58.6,54.7 to 62.4,955
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a Non-MSA,94.3,80.1 to 98.6,59
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Non-Principal City,95.7,94.0 to 96.9,1107
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Principal City,91.4,86.8 to 94.5,350
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a Non-MSA,53.4,37.1 to 69.0,59
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Non-Principal City,61.0,57.3 to 64.6,1107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Principal City,67.2,61.0 to 72.8,350
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a Non-MSA,98.9,92.3 to 99.8,59
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.6,92.5 to 96.1,1107
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Principal City,90.3,85.4 to 93.7,350
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a Non-MSA,70.3,54.1 to 82.7,59
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.3,70.9 to 77.5,1107
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Urbanicity,Living In a MSA Principal City,81.9,76.6 to 86.2,350
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018-2022,Overall,Overall,76.2,73.4 to 78.8,1516
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018-2022,Overall,Overall,62.4,59.3 to 65.3,1516
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Insurance Coverage,Uninsured,91.5,77.9 to 97.0,32
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018-2022,Overall,Overall,94.5,92.8 to 95.8,1516
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2010,Age,13-17 Years,45.5,37.2 to 54.1,182
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2009,Age,13-17 Years,44.7,36.4 to 53.3,191
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2008,Age,13-17 Years,23.3,16.4 to 32.0,143
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2011,Age,13-17 Years,43.0,34.6 to 51.9,223
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2014,Age,13-17 Years,48.5,39.5 to 57.5,185
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2013,Age,13-17 Years,40.1,31.4 to 49.4,157
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2012,Age,13-17 Years,43.6,33.5 to 54.2,141
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2015,Age,13-17 Years,55.2,46.1 to 64.0,155
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2013,Age,13-17 Years,23.4,16.5 to 32.2,171
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2012,Age,13-17 Years,8.5,4.9 to 14.4,182
≥2 Doses Hep A,,States/Local Areas,Connecticut,2021,Age,13-17 Years,87.6,83.0 to 91.1,340
≥2 Doses Hep A,,States/Local Areas,Connecticut,2022,Age,13-17 Years,90.9,85.3 to 94.5,258
≥2 Doses Hep A,,States/Local Areas,Connecticut,2020,Age,13-17 Years,77.8,72.0 to 82.6,331
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018-2022,Overall,Overall,93.6,91.7 to 95.1,1516
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2022,Age,13-17 Years,74.6,64.5 to 82.6,125
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2022,Age,13-17 Years,69.5,58.9 to 78.4,133
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2022,Age,13-17 Years,92.4,86.7 to 95.8,258
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2008,Age,13-15 Years,25.8,16.8 to 37.3,87
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2011,Age,13-15 Years,23.4,15.7 to 33.3,133
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2012,Age,13-15 Years,38.1,25.5 to 52.6,84
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2009,Age,13-15 Years,36.1,26.7 to 46.7,111
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2010,Age,13-15 Years,37.5,26.9 to 49.4,103
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2013,Age,13-15 Years,33.6,23.7 to 45.2,98
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2015,Age,13-15 Years,47.1,35.8 to 58.8,93
HPV,"≥3 Doses, Females",States/Local Areas,Connecticut,2014,Age,13-15 Years,36.9,26.4 to 48.8,111
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2012,Age,13-17 Years,88.8,84.5 to 92.1,323
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2014,Age,13-17 Years,94.9,91.0 to 97.2,386
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2013,Age,13-17 Years,90.6,85.5 to 94.0,328
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2015,Age,13-17 Years,93.5,89.5 to 96.0,358
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2016,Age,13-17 Years,93.9,89.9 to 96.4,357
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2009,Age,13-17 Years,68.1,61.8 to 73.9,351
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2008,Age,13-17 Years,45.2,38.2 to 52.4,292
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2011,Age,13-17 Years,81.1,75.6 to 85.7,453
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2010,Age,13-17 Years,72.0,66.4 to 77.0,408
≥2 Doses MMR,,States/Local Areas,Connecticut,2013,Age,13-17 Years,97.3,93.4 to 98.9,328
≥2 Doses MMR,,States/Local Areas,Connecticut,2012,Age,13-17 Years,96.6,93.1 to 98.3,323
≥2 Doses MMR,,States/Local Areas,Connecticut,2015,Age,13-17 Years,96.6,93.4 to 98.3,358
≥2 Doses MMR,,States/Local Areas,Connecticut,2014,Age,13-17 Years,97.7,94.6 to 99.0,386
≥2 Doses MMR,,States/Local Areas,Connecticut,2016,Age,13-17 Years,98.7,96.7 to 99.5,357
≥2 Doses MMR,,States/Local Areas,Connecticut,2017,Age,13-17 Years,96.9,93.5 to 98.5,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2020,Age,13-17 Years,94.0,89.6 to 96.5,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2021,Age,13-17 Years,93.9,89.3 to 96.6,340
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2017,Age,13-17 Years,94.9,91.4 to 97.0,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Connecticut,2011,Age,13-17 Years,22.2,17.6 to 27.5,453
HPV,"≥3 Doses, Males and Females",States/Local Areas,Connecticut,2012,Age,13-17 Years,25.6,19.8 to 32.5,323
HPV,"≥2 Doses, Males and Females",States/Local Areas,Connecticut,2022,Age,13-17 Years,72.0,64.8 to 78.3,258
≥2 Doses MMR,,States/Local Areas,Connecticut,2019,Age,13-17 Years,96.8,93.5 to 98.4,294
≥2 Doses MMR,,States/Local Areas,Connecticut,2018,Age,13-17 Years,95.9,92.3 to 97.8,293
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2022,Age,13-17 Years,92.7,87.7 to 95.8,258
≥2 Doses MMR,,States/Local Areas,Connecticut,2020,Age,13-17 Years,97.3,93.7 to 98.9,331
HPV,"≥3 Doses, Males and Females",States/Local Areas,Connecticut,2013,Age,13-17 Years,31.6,25.8 to 38.0,328
HPV,"≥3 Doses, Males and Females",States/Local Areas,Connecticut,2014,Age,13-17 Years,37.5,31.4 to 43.9,386
HPV,"≥3 Doses, Males and Females",States/Local Areas,Connecticut,2015,Age,13-17 Years,48.4,42.3 to 54.6,358
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2020,Age,13-17 Years,94.9,91.5 to 97.0,331
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2021,Age,13-17 Years,94.9,91.4 to 97.1,340
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2019,Age,13-17 Years,93.7,88.5 to 96.6,294
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018,Age,13-17 Years,92.1,86.6 to 95.5,293
≥2 Doses MMR,,States/Local Areas,Connecticut,2021,Age,13-17 Years,96.2,92.5 to 98.2,340
≥2 Doses MMR,,States/Local Areas,Connecticut,2022,Age,13-17 Years,95.7,91.4 to 97.9,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2016,Age,13-17 Years,93.9,89.6 to 96.5,357
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2019,Age,13-17 Years,96.5,93.1 to 98.3,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2017,Age,13-17 Years,94.9,91.9 to 96.8,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018,Age,13-17 Years,95.4,91.6 to 97.5,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2023,Age,13-15 Years,89.8,83.4 to 93.9,163
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2023,Age,13-15 Years,66.0,53.0 to 77.0,73
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2023,Age,13-17 Years,91.7,84.6 to 95.6,120
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2023,Age,13-15 Years,70.1,59.1 to 79.2,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2023,Age,13-15 Years,68.1,59.7 to 75.5,171
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2023,Age,13-15 Years,84.9,77.7 to 90.0,171
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2023,Age,13-15 Years,84.3,77.3 to 89.4,171
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2023,Age,13-17 Years,91.5,87.3 to 94.4,278
≥2 Doses Hep A,,States/Local Areas,Hawaii,2023,Age,13-17 Years,87.7,82.7 to 91.4,278
≥3 Doses HepB,,States/Local Areas,Hawaii,2023,Age,13-17 Years,89.3,84.3 to 92.8,278
Varicella,History of disease,States/Local Areas,Hawaii,2023,Age,13-17 Years,8.7,5.7 to 13.0,278
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2023,Age,13-17 Years,92.9,88.5 to 95.7,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2023,Age,13-17 Years,90.7,86.1 to 93.9,252
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2023,Age,13-17 Years,70.4,61.8 to 77.8,158
≥2 Doses MMR,,States/Local Areas,Hawaii,2023,Age,13-17 Years,91.5,87.2 to 94.4,278
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2023,Age,13-17 Years,87.4,82.4 to 91.0,278
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2023,Age,13-17 Years,70.4,64.0 to 76.1,278
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2023,Age,13-17 Years,86.2,81.0 to 90.1,278
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2023,Age,13-17 Years,85.9,80.5 to 89.9,278
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2023,Age,13-17 Years,86.8,81.7 to 90.6,278
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2023,Age,13-17 Years,83.3,75.6 to 88.8,158
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2023,Age,13-17 Years,70.3,60.4 to 78.6,120
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Overall,Overall,68.9,65.9 to 71.7,1416
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Overall,Overall,82.2,79.7 to 84.5,1416
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Principal City,82.5,77.8 to 86.3,471
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Non-Principal City,83.9,80.3 to 87.0,649
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a Non-MSA,77.5,71.6 to 82.5,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Principal City,69.1,63.8 to 73.9,471
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Non-Principal City,71.2,66.9 to 75.1,649
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a Non-MSA,62.4,55.6 to 68.7,296
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.5,83.9 to 90.3,649
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Principal City,84.6,80.3 to 88.2,471
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a Non-MSA,83.6,78.1 to 88.0,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a Non-MSA,84.7,79.4 to 88.9,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"White, Non-Hispanic",59.2,52.1 to 65.9,279
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.1,83.6 to 90.0,649
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Urbanicity,Living In a MSA Principal City,86.4,82.3 to 89.7,471
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.7,83.7 to 89.3,902
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",84.9,81.8 to 87.5,902
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,Hispanic,65.3,57.6 to 72.3,223
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",72.4,68.8 to 75.7,902
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.0,79.5 to 89.3,279
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"White, Non-Hispanic",80.6,74.6 to 85.5,279
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,Hispanic,88.3,82.6 to 92.3,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,Hispanic,87.1,81.4 to 91.3,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.6,83.6 to 89.1,902
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,"White, Non-Hispanic",73.1,66.4 to 78.9,279
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Race and Ethnicity,Hispanic,82.3,75.9 to 87.4,223
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Poverty,Below Poverty Level,81.2,71.8 to 88.0,138
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Poverty,Living At or Above Poverty Level,82.5,79.9 to 84.9,1240
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Poverty,Living At or Above Poverty Level,86.9,84.5 to 89.0,1240
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Poverty,Below Poverty Level,78.9,69.3 to 86.1,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Poverty,Below Poverty Level,60.3,50.2 to 69.6,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Poverty,Living At or Above Poverty Level,70.1,66.9 to 73.0,1240
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Poverty,Below Poverty Level,80.3,70.7 to 87.3,138
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Poverty,Living At or Above Poverty Level,87.3,85.0 to 89.3,1240
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Private Insurance Only,89.9,87.3 to 92.0,797
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Any Medicaid,82.9,78.2 to 86.8,443
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Private Insurance Only,84.9,81.9 to 87.6,797
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Other,79.5,70.6 to 86.3,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Any Medicaid,81.8,77.2 to 85.7,443
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Other,73.4,63.9 to 81.1,157
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Private Insurance Only,74.0,70.3 to 77.3,797
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Any Medicaid,66.1,60.6 to 71.2,443
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Other,58.6,49.1 to 67.4,157
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Private Insurance Only,90.0,87.5 to 92.1,797
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Any Medicaid,81.9,77.0 to 85.9,443
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Insurance Coverage,Other,86.4,78.7 to 91.6,157
≥2 Doses MMR,,States/Local Areas,Hawaii,2021,Age,13-17 Years,91.6,86.2 to 95.0,258
≥2 Doses MMR,,States/Local Areas,Hawaii,2022,Age,13-17 Years,92.2,87.2 to 95.3,237
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2008,Age,13-15 Years,18.0,11.7 to 26.6,100
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2010,Age,13-15 Years,34.2,24.3 to 45.8,85
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2009,Age,13-15 Years,39.3,28.4 to 51.5,75
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2011,Age,13-15 Years,46.0,33.9 to 58.7,86
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2012,Age,13-15 Years,27.7,18.2 to 39.7,86
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018,Age,13-17 Years,83.6,78.0 to 87.9,327
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2019,Age,13-17 Years,82.5,76.3 to 87.3,304
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2020,Age,13-17 Years,86.0,80.6 to 90.1,290
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2021,Age,13-17 Years,88.0,82.1 to 92.1,258
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2022,Age,13-17 Years,88.9,83.4 to 92.7,237
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2015,Age,13-15 Years,44.0,33.3 to 55.4,100
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2014,Age,13-15 Years,32.0,22.9 to 42.8,120
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2013,Age,13-15 Years,25.2,16.3 to 36.9,97
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2020,Age,13-17 Years,86.4,78.6 to 91.7,159
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2021,Age,13-17 Years,84.0,74.6 to 90.4,132
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2019,Age,13-17 Years,82.4,74.2 to 88.4,157
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2018,Age,13-17 Years,76.1,67.2 to 83.1,159
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2017,Age,13-17 Years,60.6,51.5 to 69.0,160
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2016,Age,13-17 Years,58.3,49.2 to 66.8,168
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2015,Age,13-17 Years,62.5,54.2 to 70.2,178
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2013,Age,13-17 Years,39.7,31.2 to 48.8,174
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2014,Age,13-17 Years,56.5,47.7 to 64.8,177
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2008,Age,13-17 Years,40.2,32.3 to 48.6,162
HPV,"≥2 Doses, Males and Females",States/Local Areas,Hawaii,2018,Age,13-17 Years,64.7,58.3 to 70.6,327
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2020,Age,13-17 Years,83.2,74.6 to 89.3,131
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2021,Age,13-17 Years,83.5,75.3 to 89.4,126
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2022,Age,13-17 Years,88.6,80.2 to 93.8,109
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2011,Age,13-17 Years,11.7,7.3 to 18.3,185
HPV,"≥2 Doses, Males and Females",States/Local Areas,Hawaii,2019,Age,13-17 Years,69.5,62.6 to 75.6,304
HPV,"≥2 Doses, Males and Females",States/Local Areas,Hawaii,2016,Age,13-17 Years,57.1,50.6 to 63.3,317
HPV,"≥2 Doses, Males and Females",States/Local Areas,Hawaii,2017,Age,13-17 Years,57.5,51.0 to 63.8,314
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2012,Age,13-17 Years,43.1,33.8 to 52.9,190
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2022,Age,13-17 Years,94.5,89.5 to 97.2,221
≥3 Doses HepB,,States/Local Areas,Hawaii,2020,Age,13-17 Years,95.6,92.3 to 97.5,290
≥3 Doses HepB,,States/Local Areas,Hawaii,2021,Age,13-17 Years,93.8,88.4 to 96.8,258
≥3 Doses HepB,,States/Local Areas,Hawaii,2022,Age,13-17 Years,92.4,87.3 to 95.5,237
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2019,Age,13-17 Years,76.3,66.2 to 84.1,147
≥3 Doses HepB,,States/Local Areas,Hawaii,2011,Age,13-17 Years,95.4,92.3 to 97.2,339
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2019,Age,13-17 Years,94.1,89.4 to 96.8,281
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2018,Age,13-17 Years,91.3,87.1 to 94.2,290
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2020,Age,13-17 Years,96.8,93.4 to 98.5,267
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2019,Age,13-17 Years,88.5,82.7 to 92.6,281
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2020,Age,13-17 Years,91.2,86.2 to 94.5,267
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2021,Age,13-17 Years,91.5,85.9 to 95.0,237
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2016,Age,13-17 Years,71.7,62.3 to 79.5,149
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2021,Age,13-17 Years,94.4,88.9 to 97.3,237
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2022,Age,13-17 Years,92.2,86.7 to 95.5,221
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2017,Age,13-17 Years,78.7,70.2 to 85.4,154
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2018,Age,13-17 Years,77.4,69.1 to 84.0,168
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2018,Age,13-17 Years,96.2,93.2 to 97.9,290
≥3 Doses HepB,,States/Local Areas,Hawaii,2018,Age,13-17 Years,93.4,89.9 to 95.7,327
≥3 Doses HepB,,States/Local Areas,Hawaii,2019,Age,13-17 Years,89.4,83.9 to 93.2,304
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2016,Age,13-17 Years,86.9,81.3 to 91.0,271
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2015,Age,13-17 Years,83.5,78.1 to 87.8,292
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2017,Age,13-17 Years,95.3,91.8 to 97.3,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2014,Age,13-17 Years,76.7,70.2 to 82.2,303
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2017,Age,13-17 Years,88.3,83.0 to 92.2,282
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2011,Age,13-17 Years,73.1,64.4 to 80.4,154
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2010,Age,13-17 Years,62.7,52.8 to 71.6,133
≥3 Doses HepB,,States/Local Areas,Hawaii,2017,Age,13-17 Years,91.2,87.1 to 94.2,314
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2013,Age,13-17 Years,52.7,42.6 to 62.5,141
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2012,Age,13-17 Years,64.6,54.7 to 73.4,152
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2015,Age,13-17 Years,71.3,62.7 to 78.6,162
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2014,Age,13-17 Years,60.4,51.6 to 68.6,186
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2016,Age,13-17 Years,95.8,92.5 to 97.6,271
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2015,Age,13-17 Years,94.1,90.2 to 96.5,292
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2013,Age,13-17 Years,97.5,92.1 to 99.2,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2014,Age,13-17 Years,93.9,89.8 to 96.5,303
≥3 Doses HepB,,States/Local Areas,Hawaii,2016,Age,13-17 Years,93.1,89.4 to 95.5,317
≥3 Doses HepB,,States/Local Areas,Hawaii,2015,Age,13-17 Years,93.0,89.2 to 95.6,340
≥3 Doses HepB,,States/Local Areas,Hawaii,2008,Age,13-17 Years,93.1,88.9 to 95.8,317
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2022,Age,13-15 Years,90.3,81.4 to 95.2,125
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2010,Age,13-17 Years,95.6,91.3 to 97.9,216
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2009,Age,13-17 Years,95.5,89.2 to 98.2,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2008,Age,13-17 Years,41.3,32.8 to 50.3,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2009,Age,13-17 Years,55.3,46.3 to 64.0,143
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2011,Age,13-17 Years,96.2,92.1 to 98.3,255
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2012,Age,13-17 Years,98.0,95.4 to 99.1,260
≥3 Doses HepB,,States/Local Areas,Hawaii,2010,Age,13-17 Years,93.9,90.2 to 96.2,320
≥3 Doses HepB,,States/Local Areas,Hawaii,2009,Age,13-17 Years,93.8,89.4 to 96.4,256
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2010,Age,13-17 Years,65.2,57.6 to 72.1,216
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2011,Age,13-17 Years,73.6,66.4 to 79.8,255
Varicella,≥1 Dose with no disease history,States/Local Areas,Hawaii,2008,Age,13-17 Years,89.7,82.4 to 94.3,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2013,Age,13-17 Years,83.3,76.8 to 88.3,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2012,Age,13-17 Years,76.0,68.8 to 81.9,260
HPV,"≥1 Dose, Females",States/Local Areas,Hawaii,2009,Age,13-17 Years,65.0,55.2 to 73.6,115
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2013,Age,13-17 Years,46.6,36.9 to 56.6,141
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2012,Age,13-17 Years,58.1,48.1 to 67.5,152
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2008,Age,13-15 Years,41.2,33.8 to 49.0,195
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2009,Age,13-15 Years,51.6,43.0 to 60.1,156
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2010,Age,13-15 Years,64.2,56.6 to 71.1,207
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2011,Age,13-15 Years,67.6,59.7 to 74.6,210
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2012,Age,13-15 Years,68.3,59.4 to 76.0,201
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2008,Age,13-17 Years,27.6,21.0 to 35.4,162
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2013,Age,13-15 Years,72.6,64.2 to 79.6,204
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2016,Age,13-17 Years,83.6,78.0 to 88.0,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2017,Age,13-17 Years,85.9,80.5 to 90.0,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2015,Age,13-17 Years,82.1,76.9 to 86.2,340
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2014,Age,13-17 Years,85.4,80.3 to 89.3,363
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2008,Age,13-17 Years,71.6,65.7 to 76.9,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2009,Age,13-17 Years,79.1,73.0 to 84.1,256
HPV,"≥1 Dose, Males",States/Local Areas,Hawaii,2022,Age,13-17 Years,84.2,74.8 to 90.5,128
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2016,Age,13-15 Years,74.8,66.8 to 81.4,190
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2017,Age,13-15 Years,83.6,76.2 to 89.1,189
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2013,Age,13-17 Years,82.1,76.2 to 86.8,315
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2012,Age,13-17 Years,79.8,73.8 to 84.7,342
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2010,Age,13-17 Years,78.6,72.7 to 83.4,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2011,Age,13-17 Years,79.4,73.4 to 84.4,339
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2014,Age,13-17 Years,49.3,40.7 to 58.0,186
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2018,Age,13-17 Years,86.5,81.4 to 90.4,327
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2020,Age,13-15 Years,84.6,77.2 to 89.9,171
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2009,Age,13-17 Years,50.4,40.6 to 60.2,115
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2010,Age,13-17 Years,50.6,41.2 to 60.0,133
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2011,Age,13-17 Years,63.2,53.6 to 71.8,154
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2016,Age,13-17 Years,64.8,58.3 to 70.8,317
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2017,Age,13-17 Years,69.4,63.0 to 75.1,314
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2018,Age,13-17 Years,76.7,70.8 to 81.8,327
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2015,Age,13-15 Years,77.9,70.8 to 83.7,207
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2014,Age,13-15 Years,77.3,70.2 to 83.1,237
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018,Age,13-15 Years,83.5,76.1 to 88.9,195
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2019,Age,13-15 Years,80.5,71.8 to 87.0,175
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2019,Age,13-17 Years,84.4,78.4 to 89.0,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2020,Age,13-17 Years,84.4,78.4 to 89.0,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2019,Age,13-17 Years,79.4,73.1 to 84.5,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2021,Age,13-17 Years,91.7,87.0 to 94.8,258
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Hawaii,2022,Age,13-17 Years,92.3,87.7 to 95.3,237
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2020,Age,13-17 Years,84.9,79.4 to 89.1,290
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2021,Age,13-17 Years,83.8,77.8 to 88.4,258
HPV,"≥1 Dose, Males and Females",States/Local Areas,Hawaii,2022,Age,13-17 Years,86.4,80.4 to 90.7,237
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2021,Age,13-15 Years,89.2,82.2 to 93.7,145
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2016,Age,13-17 Years,64.2,54.7 to 72.6,149
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2017,Age,13-17 Years,65.9,56.4 to 74.2,154
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2015,Age,13-17 Years,64.1,55.3 to 72.0,162
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2008,Age,13-15 Years,32.5,25.7 to 40.2,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2010,Age,13-15 Years,60.5,52.7 to 67.7,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2009,Age,13-15 Years,52.6,44.0 to 61.1,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2011,Age,13-15 Years,67.9,59.7 to 75.1,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2012,Age,13-15 Years,71.4,62.6 to 78.9,201
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2018,Age,13-17 Years,67.7,58.9 to 75.4,168
HPV,"≥2 Doses, Females",States/Local Areas,Hawaii,2019,Age,13-17 Years,69.9,59.6 to 78.5,147
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2013,Age,13-15 Years,80.2,73.1 to 85.9,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2016,Age,13-15 Years,80.8,73.5 to 86.5,190
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2017,Age,13-15 Years,84.2,76.7 to 89.6,189
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2015,Age,13-15 Years,76.1,68.8 to 82.1,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2014,Age,13-15 Years,82.1,75.4 to 87.3,237
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2013,Age,13-17 Years,29.0,21.6 to 37.7,174
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2014,Age,13-17 Years,47.1,38.4 to 55.9,177
≥2 Doses MMR,,States/Local Areas,Hawaii,2020,Age,13-17 Years,94.5,91.0 to 96.6,290
HPV,"≥3 Doses, Males and Females",States/Local Areas,Hawaii,2013,Age,13-17 Years,24.5,19.2 to 30.6,315
HPV,"≥3 Doses, Males and Females",States/Local Areas,Hawaii,2015,Age,13-17 Years,44.1,38.2 to 50.2,340
HPV,"≥3 Doses, Males and Females",States/Local Areas,Hawaii,2014,Age,13-17 Years,34.4,28.7 to 40.6,363
≥2 Doses MMR,,States/Local Areas,Hawaii,2018,Age,13-17 Years,93.7,90.5 to 95.9,327
≥2 Doses MMR,,States/Local Areas,Hawaii,2019,Age,13-17 Years,92.1,87.2 to 95.3,304
≥2 Doses MMR,,States/Local Areas,Hawaii,2016,Age,13-17 Years,93.0,89.1 to 95.6,317
≥2 Doses MMR,,States/Local Areas,Hawaii,2017,Age,13-17 Years,90.2,85.5 to 93.5,314
≥2 Doses MMR,,States/Local Areas,Hawaii,2015,Age,13-17 Years,91.5,87.5 to 94.3,340
≥2 Doses MMR,,States/Local Areas,Hawaii,2014,Age,13-17 Years,88.6,83.5 to 92.2,363
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2017,Age,13-17 Years,85.9,80.6 to 90.0,314
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2020,Age,13-17 Years,83.7,77.7 to 88.3,290
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2021,Age,13-17 Years,88.6,83.2 to 92.5,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2022,Age,13-17 Years,90.6,85.8 to 94.0,237
≥2 Doses MMR,,States/Local Areas,Hawaii,2013,Age,13-17 Years,90.4,84.9 to 94.1,315
≥2 Doses MMR,,States/Local Areas,Hawaii,2012,Age,13-17 Years,90.9,86.3 to 94.1,342
HPV,"≥3 Doses, Males and Females",States/Local Areas,Hawaii,2012,Age,13-17 Years,29.2,23.3 to 35.8,342
HPV,"≥3 Doses, Males and Females",States/Local Areas,Hawaii,2011,Age,13-17 Years,24.9,19.6 to 31.0,339
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2012,Age,13-17 Years,27.5,19.6 to 37.2,190
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018,Age,13-15 Years,84.3,77.3 to 89.4,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2019,Age,13-15 Years,80.3,71.4 to 87.0,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2020,Age,13-15 Years,82.0,73.8 to 88.0,171
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2021,Age,13-15 Years,89.6,83.3 to 93.8,145
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2016,Age,13-17 Years,50.3,41.5 to 59.1,168
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2017,Age,13-17 Years,49.7,40.9 to 58.5,160
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2018,Age,13-17 Years,61.8,52.5 to 70.4,159
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2022,Age,13-15 Years,86.5,78.3 to 91.9,137
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2012,Age,13-17 Years,70.4,63.7 to 76.3,342
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018,Age,13-17 Years,85.8,80.7 to 89.7,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2017,Age,13-17 Years,84.8,79.3 to 89.1,314
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2019,Age,13-17 Years,83.4,77.2 to 88.1,304
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2010,Age,13-17 Years,64.5,58.4 to 70.1,320
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2011,Age,13-17 Years,70.2,64.0 to 75.8,339
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2008,Age,13-17 Years,44.1,38.1 to 50.3,317
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2009,Age,13-17 Years,51.0,44.2 to 57.7,256
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2016,Age,13-17 Years,82.2,76.5 to 86.7,317
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2016,Age,13-17 Years,75.8,69.7 to 81.1,317
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2015,Age,13-17 Years,78.7,73.3 to 83.2,340
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2013,Age,13-17 Years,75.0,68.5 to 80.5,315
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2014,Age,13-17 Years,77.7,72.1 to 82.5,363
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2015,Age,13-17 Years,50.2,41.8 to 58.5,178
≥1 Dose MenACWY,,States/Local Areas,Hawaii,2018-2022,Overall,Overall,85.8,83.4 to 87.9,1416
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2018-2022,Overall,Overall,86.4,84.2 to 88.5,1416
≥3 Doses HepB,,States/Local Areas,Hawaii,2012,Age,13-17 Years,92.3,88.0 to 95.2,342
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2019,Age,13-15 Years,88.2,79.9 to 93.4,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2020,Age,13-15 Years,92.3,87.0 to 95.6,162
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2021,Age,13-15 Years,91.6,85.4 to 95.4,133
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2009,Age,13-15 Years,55.2,44.5 to 65.4,102
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2015,Age,13-17 Years,85.9,81.2 to 89.6,340
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2014,Age,13-15 Years,28.4,19.3 to 39.6,117
≥3 Doses HepB,,States/Local Areas,Hawaii,2013,Age,13-17 Years,90.2,84.5 to 94.0,315
≥3 Doses HepB,,States/Local Areas,Hawaii,2014,Age,13-17 Years,90.5,86.0 to 93.6,363
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2015,Age,13-15 Years,84.1,77.0 to 89.3,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2014,Age,13-15 Years,78.1,70.2 to 84.3,214
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2013,Age,13-15 Years,83.2,75.2 to 89.0,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2012,Age,13-15 Years,74.9,65.7 to 82.4,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2010,Age,13-15 Years,65.9,56.7 to 74.1,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2011,Age,13-15 Years,73.8,65.3 to 80.8,176
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2020,Age,13-17 Years,92.0,87.3 to 95.0,290
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2021,Age,13-17 Years,92.3,87.1 to 95.5,258
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2022,Age,13-17 Years,92.7,87.6 to 95.8,237
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2008,Age,13-15 Years,49.1,38.8 to 59.5,115
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2017,Age,13-15 Years,88.6,80.8 to 93.5,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2016,Age,13-15 Years,85.9,78.5 to 91.0,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Hawaii,2018,Age,13-15 Years,93.5,88.9 to 96.3,174
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2019,Age,13-17 Years,89.5,84.2 to 93.2,304
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2013,Age,13-15 Years,13.5,7.3 to 23.4,107
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2015,Age,13-15 Years,29.3,20.7 to 39.7,107
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2010,Age,13-17 Years,76.1,70.2 to 81.0,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2009,Age,13-17 Years,75.7,69.4 to 81.1,256
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2017,Age,13-17 Years,89.7,84.9 to 93.1,314
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2016,Age,13-17 Years,89.1,84.3 to 92.6,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2018,Age,13-17 Years,92.1,88.3 to 94.8,327
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2008,Age,13-17 Years,69.0,63.0 to 74.4,317
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2013,Age,13-17 Years,86.2,80.7 to 90.4,315
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2014,Age,13-17 Years,80.8,75.2 to 85.3,363
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2011,Age,13-17 Years,80.4,74.5 to 85.1,339
Varicella,≥2 Doses or history of disease,States/Local Areas,Hawaii,2012,Age,13-17 Years,82.9,77.4 to 87.3,342
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2012,Age,13-17 Years,15.6,9.4 to 24.7,190
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2013,Age,13-17 Years,15.1,10.0 to 22.1,174
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2015,Age,13-17 Years,36.2,28.6 to 44.6,178
HPV,"≥3 Doses, Males",States/Local Areas,Hawaii,2014,Age,13-17 Years,30.9,23.1 to 39.9,177
≥2 Doses Hep A,,States/Local Areas,Hawaii,2022,Age,13-17 Years,90.0,84.2 to 93.8,237
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2015,Age,13-17 Years,52.4,43.6 to 61.0,162
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2010,Age,13-17 Years,39.9,31.1 to 49.4,133
≥2 Doses Hep A,,States/Local Areas,Hawaii,2020,Age,13-17 Years,90.0,84.9 to 93.5,290
≥2 Doses Hep A,,States/Local Areas,Hawaii,2021,Age,13-17 Years,89.5,84.2 to 93.2,258
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2011,Age,13-17 Years,50.9,41.4 to 60.3,154
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2015,Age,13-17 Years,79.6,74.3 to 84.1,340
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2013,Age,13-17 Years,34.4,25.6 to 44.4,141
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2014,Age,13-17 Years,38.0,30.0 to 46.7,186
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2012,Age,13-17 Years,43.4,34.1 to 53.2,152
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2016,Age,13-17 Years,54.0,47.5 to 60.3,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2013,Age,13-17 Years,80.2,74.3 to 85.0,315
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2014,Age,13-17 Years,82.3,76.9 to 86.6,363
HPV,"≥2 Doses, Males",States/Local Areas,Hawaii,2019,Age,13-17 Years,69.1,59.6 to 77.2,157
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2012,Age,13-17 Years,74.1,67.8 to 79.5,342
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2017,Age,13-17 Years,54.7,48.2 to 61.0,314
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2018,Age,13-17 Years,60.7,54.2 to 66.8,327
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2019,Age,13-17 Years,66.0,59.0 to 72.3,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2022,Age,13-15 Years,88.5,81.3 to 93.2,137
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2008,Age,13-17 Years,32.0,26.5 to 38.0,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2011,Age,13-17 Years,67.7,61.2 to 73.5,339
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2010,Age,13-17 Years,58.1,51.9 to 64.1,320
Tetanus,≥1 Dose Tdap,States/Local Areas,Hawaii,2009,Age,13-17 Years,46.1,39.3 to 52.9,256
≥2 Doses MMR,,States/Local Areas,Hawaii,2010,Age,13-17 Years,93.7,90.2 to 96.1,320
≥2 Doses MMR,,States/Local Areas,Hawaii,2011,Age,13-17 Years,95.2,91.8 to 97.2,339
≥2 Doses MMR,,States/Local Areas,Hawaii,2008,Age,13-17 Years,91.4,86.9 to 94.4,317
≥2 Doses MMR,,States/Local Areas,Hawaii,2009,Age,13-17 Years,93.7,89.1 to 96.4,256
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2008,Age,13-17 Years,18.7,13.1 to 25.9,162
HPV,"≥3 Doses, Females",States/Local Areas,Hawaii,2009,Age,13-17 Years,38.9,29.8 to 48.8,115
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2020,Age,13-17 Years,73.9,67.6 to 79.4,290
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2021,Age,13-17 Years,69.3,62.3 to 75.5,258
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2022,Age,13-17 Years,74.2,67.3 to 80.1,237
Varicella,History of disease,States/Local Areas,Hawaii,2009,Age,13-17 Years,45.6,38.9 to 52.5,256
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2018,Age,13-17 Years,62.5,53.5 to 70.8,168
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2019,Age,13-17 Years,66.2,55.8 to 75.3,147
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2016,Age,13-17 Years,61.5,52.0 to 70.2,149
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2021,Age,13-15 Years,63.0,49.1 to 75.0,68
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2022,Age,13-15 Years,73.7,58.8 to 84.7,53
Varicella,History of disease,States/Local Areas,Hawaii,2008,Age,13-17 Years,47.3,41.2 to 53.4,317
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2017,Age,13-17 Years,62.7,53.3 to 71.2,154
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2019,Age,13-15 Years,56.9,44.4 to 68.6,93
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2018,Age,13-15 Years,61.3,49.5 to 72.0,97
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2021,Age,13-17 Years,69.0,59.0 to 77.5,126
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2022,Age,13-17 Years,79.4,69.6 to 86.7,109
HPV,"Up-to-Date, Females",States/Local Areas,Hawaii,2020,Age,13-17 Years,68.2,58.4 to 76.7,131
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2022,Age,13-15 Years,69.1,59.5 to 77.2,137
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2019,Age,13-15 Years,60.7,51.2 to 69.4,175
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2022,Age,13-17 Years,69.3,59.3 to 77.8,128
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2021,Age,13-15 Years,66.2,56.8 to 74.5,145
HPV,"Up-to-Date, Males and Females",States/Local Areas,Hawaii,2020,Age,13-15 Years,69.5,60.9 to 76.9,171
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2017,Age,13-17 Years,47.2,38.5 to 56.0,160
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2016,Age,13-17 Years,46.9,38.2 to 55.7,168
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2021,Age,13-15 Years,69.1,55.9 to 79.7,77
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2022,Age,13-15 Years,65.7,53.0 to 76.5,84
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2020,Age,13-15 Years,77.3,66.4 to 85.5,98
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2021,Age,13-17 Years,69.6,59.4 to 78.2,132
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2018,Age,13-17 Years,58.9,49.6 to 67.7,159
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2019,Age,13-17 Years,65.8,56.3 to 74.1,157
HPV,"Up-to-Date, Males",States/Local Areas,Hawaii,2020,Age,13-17 Years,79.3,70.7 to 85.8,159
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2023,Age,13-17 Years,66.7,56.7 to 75.3,146
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2023,Age,13-15 Years,66.8,53.8 to 77.7,87
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2023,Age,13-15 Years,82.8,73.3 to 89.4,166
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2023,Age,13-17 Years,82.3,73.1 to 88.8,146
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2023,Age,13-15 Years,64.0,51.2 to 75.0,92
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2023,Age,13-15 Years,65.3,56.3 to 73.4,179
≥1 Dose MenACWY,,States/Local Areas,Oregon,2023,Age,13-15 Years,79.1,70.1 to 86.0,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2023,Age,13-15 Years,83.6,75.0 to 89.7,179
≥2 Doses Hep A,,States/Local Areas,Oregon,2023,Age,13-17 Years,92.4,87.3 to 95.5,300
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2023,Age,13-17 Years,88.5,82.7 to 92.5,300
≥3 Doses HepB,,States/Local Areas,Oregon,2023,Age,13-17 Years,93.6,89.6 to 96.1,300
Varicella,History of disease,States/Local Areas,Oregon,2023,Age,13-17 Years,6.6,3.9 to 11.0,300
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2023,Age,13-17 Years,91.4,85.7 to 95.0,280
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2023,Age,13-17 Years,87.7,81.5 to 92.0,280
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2023,Age,13-17 Years,68.4,58.9 to 76.6,154
≥2 Doses MMR,,States/Local Areas,Oregon,2023,Age,13-17 Years,92.6,87.5 to 95.7,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2023,Age,13-17 Years,82.1,76.1 to 86.9,300
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2023,Age,13-17 Years,82.0,73.3 to 88.2,154
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2023,Age,13-17 Years,67.6,60.8 to 73.7,300
≥1 Dose MenACWY,,States/Local Areas,Oregon,2023,Age,13-17 Years,83.3,77.2 to 88.0,300
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2023,Age,13-17 Years,85.7,79.7 to 90.2,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2023,Age,13-17 Years,86.6,80.7 to 90.9,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Overall,Overall,78.3,75.6 to 80.8,1432
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a Non-MSA,83.9,75.3 to 90.0,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Overall,Overall,62.7,59.6 to 65.7,1432
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a Non-MSA,71.0,62.2 to 78.5,188
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Non-Principal City,75.0,70.0 to 79.5,450
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Principal City,81.8,78.3 to 84.8,794
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Non-Principal City,57.8,52.3 to 63.2,450
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a Non-MSA,58.0,49.0 to 66.4,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Principal City,66.6,62.5 to 70.4,794
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a Non-MSA,74.6,65.8 to 81.7,188
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Non-Principal City,82.0,77.5 to 85.8,450
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Principal City,86.4,83.1 to 89.1,794
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2010,Age,13-17 Years,38.2,29.2 to 48.0,129
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2020,Age,13-17 Years,87.4,82.0 to 91.4,308
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2021,Age,13-17 Years,85.6,79.6 to 90.1,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2019,Age,13-17 Years,90.2,84.8 to 93.8,270
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oregon,2012,Age,13-17 Years,20.8,16.0 to 26.5,381
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oregon,2011,Age,13-17 Years,20.1,14.9 to 26.4,362
≥2 Doses MMR,,States/Local Areas,Oregon,2013,Age,13-17 Years,92.3,88.5 to 94.9,364
≥2 Doses MMR,,States/Local Areas,Oregon,2012,Age,13-17 Years,92.6,88.5 to 95.3,381
≥2 Doses MMR,,States/Local Areas,Oregon,2016,Age,13-17 Years,88.5,83.2 to 92.3,318
≥1 Dose MenACWY,,States/Local Areas,Oregon,2012,Age,13-17 Years,58.3,51.9 to 64.4,381
≥1 Dose MenACWY,,States/Local Areas,Oregon,2014,Age,13-17 Years,68.4,62.1 to 74.1,399
≥1 Dose MenACWY,,States/Local Areas,Oregon,2013,Age,13-17 Years,65.3,59.3 to 70.8,364
≥1 Dose MenACWY,,States/Local Areas,Oregon,2015,Age,13-17 Years,75.2,69.3 to 80.3,353
≥1 Dose MenACWY,,States/Local Areas,Oregon,2016,Age,13-17 Years,70.5,64.2 to 76.2,318
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2022,Age,13-17 Years,90.7,86.1 to 93.9,263
≥2 Doses MMR,,States/Local Areas,Oregon,2014,Age,13-17 Years,86.1,80.6 to 90.2,399
≥2 Doses MMR,,States/Local Areas,Oregon,2015,Age,13-17 Years,91.3,86.8 to 94.4,353
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2016,Age,13-17 Years,83.2,77.0 to 88.0,318
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018,Age,13-17 Years,86.1,80.4 to 90.3,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2017,Age,13-17 Years,86.3,81.6 to 90.0,359
≥1 Dose MenACWY,,States/Local Areas,Oregon,2022,Age,13-15 Years,76.1,67.2 to 83.2,170
≥1 Dose MenACWY,,States/Local Areas,Oregon,2009,Age,13-17 Years,41.6,36.1 to 47.2,386
≥1 Dose MenACWY,,States/Local Areas,Oregon,2008,Age,13-17 Years,29.6,23.7 to 36.3,235
≥1 Dose MenACWY,,States/Local Areas,Oregon,2011,Age,13-17 Years,55.8,49.0 to 62.3,362
≥1 Dose MenACWY,,States/Local Areas,Oregon,2010,Age,13-17 Years,52.4,45.9 to 58.7,302
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oregon,2022,Age,13-17 Years,67.2,60.2 to 73.6,263
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2022,Age,13-17 Years,67.7,57.0 to 76.9,116
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2022,Age,13-17 Years,66.8,57.4 to 75.0,147
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2015,Age,13-15 Years,39.4,29.1 to 50.8,101
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2014,Age,13-15 Years,44.6,33.8 to 56.1,126
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2013,Age,13-15 Years,36.2,26.2 to 47.5,105
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2012,Age,13-15 Years,32.7,21.5 to 46.3,90
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2011,Age,13-15 Years,42.7,30.9 to 55.4,101
≥2 Doses MMR,,States/Local Areas,Oregon,2020,Age,13-17 Years,96.3,93.4 to 98.0,308
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oregon,2013,Age,13-17 Years,25.5,20.6 to 31.2,364
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oregon,2015,Age,13-17 Years,42.2,36.1 to 48.5,353
HPV,"≥3 Doses, Males and Females",States/Local Areas,Oregon,2014,Age,13-17 Years,27.4,22.2 to 33.2,399
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2009,Age,13-15 Years,26.9,19.1 to 36.3,125
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2010,Age,13-15 Years,29.5,18.6 to 43.4,75
≥2 Doses MMR,,States/Local Areas,Oregon,2017,Age,13-17 Years,89.8,85.3 to 93.1,359
≥2 Doses MMR,,States/Local Areas,Oregon,2018,Age,13-17 Years,93.2,88.2 to 96.2,297
≥2 Doses MMR,,States/Local Areas,Oregon,2019,Age,13-17 Years,96.0,92.5 to 97.9,270
≥1 Dose MenACWY,,States/Local Areas,Oregon,2022,Age,13-17 Years,80.3,73.8 to 85.4,263
≥1 Dose MenACWY,,States/Local Areas,Oregon,2021,Age,13-17 Years,82.4,76.4 to 87.1,294
≥1 Dose MenACWY,,States/Local Areas,Oregon,2020,Age,13-17 Years,87.5,82.4 to 91.2,308
≥1 Dose MenACWY,,States/Local Areas,Oregon,2017,Age,13-17 Years,77.0,71.5 to 81.8,359
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018,Age,13-17 Years,83.0,77.3 to 87.5,297
≥1 Dose MenACWY,,States/Local Areas,Oregon,2019,Age,13-17 Years,85.0,79.0 to 89.5,270
≥2 Doses MMR,,States/Local Areas,Oregon,2021,Age,13-17 Years,92.4,87.6 to 95.4,294
≥2 Doses MMR,,States/Local Areas,Oregon,2022,Age,13-17 Years,94.3,90.2 to 96.8,263
≥2 Doses Hep A,,States/Local Areas,Oregon,2020,Age,13-17 Years,95.6,92.3 to 97.6,308
HPV,"≥3 Doses, Males",States/Local Areas,Oregon,2014,Age,13-15 Years,13.0,8.0 to 20.5,133
HPV,"≥3 Doses, Males",States/Local Areas,Oregon,2013,Age,13-15 Years,10.2,5.7 to 17.5,131
HPV,"≥3 Doses, Males",States/Local Areas,Oregon,2015,Age,13-17 Years,35.7,27.7 to 44.6,185
HPV,"≥3 Doses, Males",States/Local Areas,Oregon,2014,Age,13-17 Years,12.3,8.2 to 18.0,206
HPV,"≥3 Doses, Males",States/Local Areas,Oregon,2013,Age,13-17 Years,12.2,8.0 to 18.2,200
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2019,Age,13-17 Years,95.1,91.3 to 97.3,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2019,Age,13-15 Years,92.7,86.1 to 96.3,162
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2018,Age,13-15 Years,93.3,86.8 to 96.7,152
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2015,Age,13-17 Years,88.6,84.3 to 91.9,353
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2017,Age,13-17 Years,88.3,83.9 to 91.6,359
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2016,Age,13-17 Years,83.7,77.8 to 88.3,318
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2018,Age,13-17 Years,89.9,85.2 to 93.2,297
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2008,Age,13-17 Years,70.8,63.6 to 77.1,235
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2020,Age,13-17 Years,94.4,90.7 to 96.7,308
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2021,Age,13-17 Years,93.2,88.2 to 96.1,294
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2022,Age,13-17 Years,92.8,88.3 to 95.6,263
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2014,Age,13-17 Years,79.4,73.5 to 84.3,399
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2013,Age,13-17 Years,88.6,84.5 to 91.7,364
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2011,Age,13-17 Years,75.0,68.4 to 80.7,362
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2012,Age,13-17 Years,81.7,76.3 to 86.0,381
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2009,Age,13-17 Years,73.6,68.3 to 78.3,386
Varicella,≥2 Doses or history of disease,States/Local Areas,Oregon,2010,Age,13-17 Years,77.8,72.0 to 82.7,302
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2016,Age,13-15 Years,86.2,78.7 to 91.3,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2017,Age,13-15 Years,86.1,78.9 to 91.0,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2015,Age,13-15 Years,86.5,80.1 to 91.1,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2014,Age,13-15 Years,78.7,70.2 to 85.3,217
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2020,Age,13-15 Years,93.2,87.6 to 96.4,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2021,Age,13-15 Years,91.7,84.7 to 95.7,178
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2014,Age,13-17 Years,64.6,55.5 to 72.8,193
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2015,Age,13-17 Years,70.0,61.3 to 77.4,168
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2013,Age,13-17 Years,66.3,57.5 to 74.1,164
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2012,Age,13-17 Years,58.5,49.0 to 67.5,160
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2014,Age,13-17 Years,74.7,67.7 to 80.5,328
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2013,Age,13-17 Years,84.3,79.0 to 88.5,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2015,Age,13-17 Years,85.6,80.3 to 89.6,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2016,Age,13-17 Years,81.3,74.7 to 86.5,274
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2010,Age,13-17 Years,54.1,44.4 to 63.4,129
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2011,Age,13-17 Years,68.6,59.6 to 76.5,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2017,Age,13-17 Years,86.1,81.0 to 90.1,301
≥3 Doses HepB,,States/Local Areas,Oregon,2015,Age,13-17 Years,91.6,87.4 to 94.5,353
≥3 Doses HepB,,States/Local Areas,Oregon,2016,Age,13-17 Years,89.1,83.5 to 92.9,318
≥3 Doses HepB,,States/Local Areas,Oregon,2018,Age,13-17 Years,93.5,88.8 to 96.3,297
≥3 Doses HepB,,States/Local Areas,Oregon,2019,Age,13-17 Years,95.1,90.7 to 97.5,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2009,Age,13-15 Years,55.6,46.6 to 64.2,151
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2008,Age,13-15 Years,29.0,18.9 to 41.8,70
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2010,Age,13-15 Years,65.5,55.1 to 74.6,118
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2011,Age,13-15 Years,65.3,55.8 to 73.7,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2013,Age,13-15 Years,87.0,81.0 to 91.3,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2012,Age,13-15 Years,77.9,69.0 to 84.8,180
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2015,Age,13-17 Years,48.9,40.1 to 57.9,168
≥2 Doses Hep A,,States/Local Areas,Oregon,2022,Age,13-17 Years,94.3,90.5 to 96.7,263
≥2 Doses Hep A,,States/Local Areas,Oregon,2021,Age,13-17 Years,94.8,90.6 to 97.2,294
HPV,"≥3 Doses, Males",States/Local Areas,Oregon,2015,Age,13-15 Years,37.3,26.9 to 49.1,109
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2009,Age,13-17 Years,32.2,25.1 to 40.1,200
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2008,Age,13-17 Years,14.3,8.7 to 22.4,106
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2014,Age,13-17 Years,43.1,34.4 to 52.3,193
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2013,Age,13-17 Years,39.5,31.2 to 48.6,164
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2011,Age,13-17 Years,38.5,29.1 to 48.9,176
HPV,"≥3 Doses, Females",States/Local Areas,Oregon,2012,Age,13-17 Years,38.6,29.8 to 48.1,160
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Overall,Overall,83.6,81.1 to 85.8,1432
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Overall,Overall,88.0,85.8 to 89.9,1432
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.0,85.2 to 92.0,450
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Urbanicity,Living In a MSA Principal City,88.2,85.2 to 90.7,794
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"White, Non-Hispanic",61.6,57.9 to 65.2,988
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",77.0,67.6 to 84.3,182
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Race and Ethnicity,Hispanic,84.4,78.4 to 88.9,239
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",77.2,68.3 to 84.1,182
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",60.9,51.6 to 69.5,182
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Race and Ethnicity,Hispanic,65.6,58.3 to 72.2,239
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"White, Non-Hispanic",83.8,80.9 to 86.4,988
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.5,86.9 to 91.6,988
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Race and Ethnicity,Hispanic,86.3,80.9 to 90.4,239
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",83.2,75.2 to 89.0,182
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Race and Ethnicity,Hispanic,87.6,82.0 to 91.6,239
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Race and Ethnicity,"White, Non-Hispanic",76.4,73.0 to 79.5,988
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Poverty,Living At or Above Poverty Level,78.2,75.2 to 80.9,1223
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Poverty,Below Poverty Level,78.7,70.7 to 85.0,173
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Poverty,Below Poverty Level,81.5,73.5 to 87.5,173
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Poverty,Living At or Above Poverty Level,83.8,81.1 to 86.1,1223
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Poverty,Below Poverty Level,56.9,48.0 to 65.4,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Poverty,Living At or Above Poverty Level,63.9,60.5 to 67.1,1223
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Poverty,Below Poverty Level,83.7,76.1 to 89.2,173
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Insurance Coverage,Any Medicaid,84.0,79.4 to 87.7,430
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Poverty,Living At or Above Poverty Level,88.8,86.5 to 90.8,1223
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Insurance Coverage,Private Insurance Only,84.6,81.4 to 87.3,858
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Insurance Coverage,Private Insurance Only,77.4,73.8 to 80.7,858
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Insurance Coverage,Any Medicaid,81.0,76.2 to 85.0,430
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018-2022,Insurance Coverage,Other,80.7,70.4 to 88.0,122
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018-2022,Insurance Coverage,Other,76.9,66.4 to 84.9,122
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Insurance Coverage,Private Insurance Only,64.6,60.7 to 68.3,858
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Insurance Coverage,Any Medicaid,62.6,56.9 to 67.9,430
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018-2022,Insurance Coverage,Other,56.7,45.7 to 67.2,122
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Insurance Coverage,Private Insurance Only,89.3,86.4 to 91.6,858
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Insurance Coverage,Any Medicaid,85.5,80.9 to 89.2,430
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018-2022,Insurance Coverage,Other,91.8,86.2 to 95.3,122
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2014,Age,13-17 Years,95.0,90.5 to 97.4,328
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2013,Age,13-17 Years,96.5,92.9 to 98.3,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2015,Age,13-17 Years,97.2,94.3 to 98.6,287
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2016,Age,13-17 Years,93.6,88.3 to 96.7,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2018,Age,13-17 Years,95.7,91.4 to 97.9,266
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2019,Age,13-17 Years,96.4,92.2 to 98.4,244
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2017,Age,13-17 Years,97.8,95.7 to 98.8,301
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2020,Age,13-17 Years,97.3,94.2 to 98.8,280
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2018,Age,13-17 Years,88.6,83.3 to 92.4,266
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2020,Age,13-17 Years,93.8,89.7 to 96.4,280
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2021,Age,13-17 Years,92.7,87.5 to 95.9,271
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2019,Age,13-17 Years,94.6,90.3 to 97.0,244
≥3 Doses HepB,,States/Local Areas,Oregon,2017,Age,13-17 Years,90.2,85.6 to 93.5,359
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2008,Age,13-17 Years,34.8,25.6 to 45.3,106
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2012,Age,13-17 Years,75.6,68.8 to 81.3,284
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2012,Age,13-17 Years,96.0,92.2 to 98.0,284
≥3 Doses HepB,,States/Local Areas,Oregon,2014,Age,13-17 Years,88.4,83.3 to 92.1,399
≥3 Doses HepB,,States/Local Areas,Oregon,2013,Age,13-17 Years,90.9,86.9 to 93.8,364
≥3 Doses HepB,,States/Local Areas,Oregon,2011,Age,13-17 Years,89.0,83.0 to 93.0,362
≥3 Doses HepB,,States/Local Areas,Oregon,2012,Age,13-17 Years,92.7,88.9 to 95.2,381
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2009,Age,13-17 Years,52.9,45.2 to 60.5,200
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2011,Age,13-17 Years,61.5,53.0 to 69.3,243
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2010,Age,13-17 Years,60.1,51.5 to 68.0,177
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2008,Age,13-17 Years,89.0,79.6 to 94.3,90
≥3 Doses HepB,,States/Local Areas,Oregon,2008,Age,13-17 Years,88.0,81.5 to 92.4,235
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2011,Age,13-17 Years,96.5,93.0 to 98.3,243
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2009,Age,13-17 Years,50.3,42.6 to 58.0,210
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2008,Age,13-17 Years,24.5,16.2 to 35.3,90
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2009,Age,13-17 Years,89.5,84.2 to 93.2,210
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2010,Age,13-17 Years,87.8,80.5 to 92.7,177
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2022,Age,13-15 Years,91.7,85.3 to 95.5,156
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oregon,2019,Age,13-17 Years,62.6,55.1 to 69.5,270
≥3 Doses HepB,,States/Local Areas,Oregon,2009,Age,13-17 Years,87.4,83.0 to 90.8,386
≥3 Doses HepB,,States/Local Areas,Oregon,2010,Age,13-17 Years,88.0,82.8 to 91.8,302
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2017,Age,13-17 Years,72.3,63.8 to 79.3,176
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2014,Age,13-17 Years,36.9,29.0 to 45.6,206
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2013,Age,13-17 Years,35.8,28.2 to 44.3,200
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2015,Age,13-17 Years,58.6,49.9 to 66.7,185
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2016,Age,13-17 Years,60.9,52.1 to 69.0,170
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2019,Age,13-17 Years,75.3,65.3 to 83.2,136
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2018,Age,13-17 Years,70.7,60.4 to 79.2,146
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2020,Age,13-17 Years,77.1,69.3 to 83.4,179
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2021,Age,13-17 Years,87.0,80.6 to 91.6,165
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oregon,2016,Age,13-17 Years,53.4,46.9 to 59.9,318
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oregon,2017,Age,13-17 Years,58.9,52.8 to 64.8,359
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2020,Age,13-17 Years,80.0,70.8 to 86.9,129
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2021,Age,13-17 Years,77.3,67.1 to 85.1,129
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2022,Age,13-17 Years,82.2,72.4 to 89.1,116
Varicella,≥2 Doses with no disease history,States/Local Areas,Oregon,2022,Age,13-17 Years,92.0,87.1 to 95.1,241
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2019,Age,13-17 Years,73.8,63.2 to 82.2,134
HPV,"≥2 Doses, Males and Females",States/Local Areas,Oregon,2018,Age,13-17 Years,64.7,57.9 to 71.0,297
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2012,Age,13-17 Years,14.5,9.5 to 21.4,221
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2022,Age,13-17 Years,94.8,90.7 to 97.1,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Oregon,2021,Age,13-17 Years,94.8,89.7 to 97.4,271
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2018,Age,13-17 Years,80.1,72.6 to 86.0,151
≥3 Doses HepB,,States/Local Areas,Oregon,2020,Age,13-17 Years,95.8,92.7 to 97.7,308
≥3 Doses HepB,,States/Local Areas,Oregon,2021,Age,13-17 Years,92.7,88.0 to 95.7,294
≥3 Doses HepB,,States/Local Areas,Oregon,2022,Age,13-17 Years,92.7,88.8 to 95.4,263
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2016,Age,13-17 Years,62.6,52.7 to 71.6,148
HPV,"≥1 Dose, Females",States/Local Areas,Oregon,2017,Age,13-17 Years,70.1,61.9 to 77.2,183
≥1 Dose MenACWY,,States/Local Areas,Oregon,2013,Age,13-15 Years,66.0,58.8 to 72.6,236
≥1 Dose MenACWY,,States/Local Areas,Oregon,2012,Age,13-15 Years,58.0,49.5 to 66.1,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2013,Age,13-15 Years,88.8,83.1 to 92.7,236
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2016,Age,13-17 Years,52.0,43.3 to 60.7,170
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2017,Age,13-17 Years,59.5,50.7 to 67.8,176
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2018,Age,13-17 Years,62.3,52.2 to 71.4,146
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2013,Age,13-17 Years,20.8,14.7 to 28.5,200
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2014,Age,13-17 Years,23.0,16.7 to 30.7,206
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2012,Age,13-17 Years,7.2,4.0 to 12.8,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2008,Age,13-15 Years,40.0,31.6 to 49.1,144
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2010,Age,13-15 Years,78.0,70.5 to 84.1,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2009,Age,13-15 Years,59.7,52.5 to 66.5,246
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2011,Age,13-15 Years,86.8,79.9 to 91.6,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2012,Age,13-15 Years,87.8,80.6 to 92.6,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2015,Age,13-15 Years,89.9,84.2 to 93.7,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2014,Age,13-15 Years,85.7,78.8 to 90.5,259
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2016,Age,13-15 Years,87.5,80.7 to 92.2,203
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2017,Age,13-15 Years,87.8,82.0 to 91.9,210
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2018,Age,13-17 Years,67.2,58.1 to 75.2,151
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2019,Age,13-17 Years,65.0,54.0 to 74.6,134
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2015,Age,13-17 Years,55.4,46.3 to 64.1,168
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2014,Age,13-17 Years,51.7,42.6 to 60.8,193
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2016,Age,13-17 Years,54.8,45.1 to 64.3,148
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2017,Age,13-17 Years,58.3,49.7 to 66.4,183
≥1 Dose MenACWY,,States/Local Areas,Oregon,2021,Age,13-15 Years,82.9,75.3 to 88.5,192
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2018,Age,13-17 Years,89.3,83.8 to 93.1,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2021,Age,13-17 Years,88.8,83.2 to 92.6,294
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2022,Age,13-17 Years,91.9,87.5 to 94.9,263
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2018,Age,13-17 Years,75.3,68.9 to 80.8,297
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2019,Age,13-17 Years,74.6,67.5 to 80.5,270
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2020,Age,13-17 Years,78.5,72.7 to 83.4,308
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2021,Age,13-17 Years,82.3,76.3 to 87.0,294
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2022,Age,13-17 Years,80.7,74.4 to 85.8,263
HPV,"≥1 Dose, Males",States/Local Areas,Oregon,2022,Age,13-17 Years,79.4,70.5 to 86.1,147
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2011,Age,13-17 Years,86.7,81.7 to 90.5,362
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2010,Age,13-17 Years,75.9,69.8 to 81.0,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2013,Age,13-17 Years,88.5,83.7 to 92.1,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2012,Age,13-17 Years,88.8,84.4 to 92.1,381
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2009,Age,13-17 Years,68.8,63.2 to 73.9,386
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2008,Age,13-17 Years,64.1,56.6 to 71.0,235
≥1 Dose MenACWY,,States/Local Areas,Oregon,2008,Age,13-15 Years,30.7,23.2 to 39.5,144
≥1 Dose MenACWY,,States/Local Areas,Oregon,2009,Age,13-15 Years,45.0,38.2 to 52.1,246
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2020,Age,13-17 Years,88.4,83.4 to 92.1,308
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2019,Age,13-17 Years,91.1,85.8 to 94.6,270
≥1 Dose MenACWY,,States/Local Areas,Oregon,2017,Age,13-15 Years,79.6,72.8 to 85.1,210
≥1 Dose MenACWY,,States/Local Areas,Oregon,2018,Age,13-15 Years,82.7,74.6 to 88.7,171
≥1 Dose MenACWY,,States/Local Areas,Oregon,2019,Age,13-15 Years,82.0,73.5 to 88.3,177
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2013,Age,13-17 Years,54.9,45.9 to 63.5,164
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2012,Age,13-17 Years,46.7,37.4 to 56.2,160
≥1 Dose MenACWY,,States/Local Areas,Oregon,2010,Age,13-15 Years,54.8,46.3 to 63.0,180
≥1 Dose MenACWY,,States/Local Areas,Oregon,2011,Age,13-15 Years,57.6,49.2 to 65.5,215
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2011,Age,13-17 Years,49.8,39.7 to 59.9,176
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2010,Age,13-17 Years,45.4,36.0 to 55.2,129
≥1 Dose MenACWY,,States/Local Areas,Oregon,2020,Age,13-15 Years,85.3,78.5 to 90.2,188
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2009,Age,13-17 Years,42.9,35.3 to 50.9,200
HPV,"≥2 Doses, Females",States/Local Areas,Oregon,2008,Age,13-17 Years,29.9,21.2 to 40.2,106
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2014,Age,13-17 Years,89.7,85.0 to 93.1,399
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2015,Age,13-17 Years,91.4,87.2 to 94.3,353
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2016,Age,13-17 Years,86.2,80.3 to 90.6,318
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Oregon,2017,Age,13-17 Years,88.4,83.8 to 91.8,359
≥1 Dose MenACWY,,States/Local Areas,Oregon,2016,Age,13-15 Years,71.1,63.3 to 77.8,203
≥1 Dose MenACWY,,States/Local Areas,Oregon,2015,Age,13-15 Years,76.4,68.9 to 82.5,210
≥1 Dose MenACWY,,States/Local Areas,Oregon,2014,Age,13-15 Years,69.0,61.1 to 76.0,259
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2016,Age,13-17 Years,61.7,55.2 to 67.9,318
HPV,"≥1 Dose, Males and Females",States/Local Areas,Oregon,2017,Age,13-17 Years,71.2,65.4 to 76.4,359
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2021,Age,13-17 Years,67.0,60.0 to 73.4,294
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2022,Age,13-17 Years,65.6,58.5 to 72.0,263
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2015,Age,13-17 Years,89.4,85.0 to 92.7,353
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2020,Age,13-17 Years,61.6,55.0 to 67.8,308
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2019,Age,13-17 Years,60.8,53.3 to 67.7,270
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2009,Age,13-17 Years,55.5,49.9 to 61.1,386
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2010,Age,13-17 Years,66.6,60.2 to 72.4,302
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2011,Age,13-17 Years,83.1,77.5 to 87.5,362
≥2 Doses MMR,,States/Local Areas,Oregon,2011,Age,13-17 Years,86.2,79.6 to 90.9,362
≥2 Doses MMR,,States/Local Areas,Oregon,2010,Age,13-17 Years,88.6,83.4 to 92.3,302
≥2 Doses MMR,,States/Local Areas,Oregon,2009,Age,13-17 Years,89.0,85.0 to 92.0,386
≥2 Doses MMR,,States/Local Areas,Oregon,2008,Age,13-17 Years,87.7,82.3 to 91.6,235
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2022,Age,13-15 Years,88.8,82.5 to 93.1,170
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2008,Age,13-17 Years,38.9,32.2 to 45.9,235
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2019,Age,13-17 Years,60.3,49.9 to 69.8,136
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2016,Age,13-17 Years,47.5,41.0 to 54.0,318
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2012,Age,13-17 Years,86.0,80.8 to 89.9,381
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2014,Age,13-17 Years,88.0,83.1 to 91.7,399
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2013,Age,13-17 Years,87.0,82.0 to 90.7,364
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2017,Age,13-17 Years,54.8,48.6 to 60.8,359
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2018,Age,13-17 Years,58.2,51.2 to 64.9,297
HPV,"≥2 Doses, Males",States/Local Areas,Oregon,2015,Age,13-17 Years,48.2,39.7 to 56.9,185
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2018,Age,13-15 Years,84.6,76.4 to 90.3,171
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2021,Age,13-15 Years,85.4,77.5 to 90.8,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2020,Age,13-15 Years,86.2,78.8 to 91.3,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Oregon,2019,Age,13-15 Years,89.3,81.2 to 94.2,177
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2023,Age,13-17 Years,94.9,88.2 to 97.9,201
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2023,Age,13-17 Years,96.6,90.2 to 98.8,201
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2023,Age,13-17 Years,92.7,86.3 to 96.2,201
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2023,Age,13-17 Years,96.4,90.2 to 98.7,201
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2023,Age,13-17 Years,84.2,76.0 to 90.0,201
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2023,Age,13-17 Years,81.4,68.3 to 89.8,102
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2023,Age,13-17 Years,94.0,85.8 to 97.6,99
≥3 Doses HepB,,States/Local Areas,Rhode Island,2023,Age,13-17 Years,92.3,84.1 to 96.4,201
≥2 Doses MMR,,States/Local Areas,Rhode Island,2023,Age,13-17 Years,98.3,95.6 to 99.3,201
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2023,Age,13-17 Years,97.9,92.5 to 99.4,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2023,Age,13-17 Years,96.4,91.5 to 98.5,189
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2023,Age,13-17 Years,96.6,92.0 to 98.6,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2023,Age,13-15 Years,96.5,85.2 to 99.2,111
≥2 Doses Hep A,,States/Local Areas,Rhode Island,2023,Age,13-17 Years,93.0,86.6 to 96.4,201
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2023,Age,13-15 Years,96.5,85.2 to 99.2,111
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2023,Age,13-15 Years,80.4,68.8 to 88.3,111
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2023,Age,13-15 Years,86.5,70.9 to 94.4,56
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2023,Age,13-15 Years,94.3,85.9 to 97.8,103
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2023,Age,13-15 Years,72.4,53.5 to 85.7,55
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2023,Age,13-17 Years,87.2,75.8 to 93.6,99
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2023,Age,13-17 Years,91.4,80.0 to 96.6,102
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Other,89.5,70.2 to 96.9,54
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Uninsured,90.2,68.2 to 97.5,37
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Any Medicaid,94.1,90.8 to 96.2,508
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Private Insurance Only,96.5,94.8 to 97.7,867
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Uninsured,68.9,49.9 to 83.1,37
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Other,83.2,68.1 to 91.9,54
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Private Insurance Only,85.4,82.2 to 88.1,867
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Any Medicaid,76.9,71.8 to 81.3,508
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Uninsured,91.7,75.1 to 97.6,37
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Other,90.9,76.1 to 96.9,54
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Uninsured,92.0,75.8 to 97.7,37
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Private Insurance Only,92.0,89.5 to 94.0,867
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Any Medicaid,91.6,87.7 to 94.3,508
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Other,91.5,76.3 to 97.3,54
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Private Insurance Only,97.7,95.8 to 98.8,867
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Poverty,Living At or Above Poverty Level,95.8,94.1 to 97.0,1187
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Insurance Coverage,Any Medicaid,95.2,92.2 to 97.1,508
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Poverty,Below Poverty Level,92.0,85.7 to 95.7,221
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Poverty,Living At or Above Poverty Level,83.5,80.6 to 86.1,1187
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Poverty,Living At or Above Poverty Level,97.1,95.4 to 98.2,1187
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Poverty,Below Poverty Level,72.5,64.4 to 79.3,221
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Poverty,Below Poverty Level,92.1,86.6 to 95.5,221
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Poverty,Below Poverty Level,90.5,84.0 to 94.5,221
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Poverty,Living At or Above Poverty Level,92.0,89.8 to 93.8,1187
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",97.4,92.3 to 99.2,82
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.4,86.4 to 91.8,918
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,Hispanic,93.7,89.1 to 96.5,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",98.8,95.7 to 99.7,131
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,Hispanic,95.6,92.5 to 97.4,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",96.0,90.8 to 98.3,82
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.1,92.9 to 96.7,918
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"White, Non-Hispanic",96.0,93.5 to 97.5,918
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",99.1,96.3 to 99.8,82
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,Hispanic,79.7,73.8 to 84.6,335
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",78.1,68.2 to 85.6,131
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",79.9,68.3 to 88.0,82
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,Hispanic,96.1,92.4 to 98.0,335
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.0,83.9 to 95.1,131
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"White, Non-Hispanic",83.3,79.9 to 86.2,918
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",99.2,96.6 to 99.8,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Principal City,95.3,92.4 to 97.1,416
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Non-Principal City,95.1,93.0 to 96.6,1050
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Principal City,96.8,94.1 to 98.2,416
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Non-Principal City,96.3,94.3 to 97.6,1050
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Principal City,84.5,79.6 to 88.4,416
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Non-Principal City,80.6,77.3 to 83.5,1050
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.9,87.2 to 92.1,1050
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Urbanicity,Living In a MSA Principal City,96.5,94.2 to 97.8,416
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018-2022,Overall,Overall,81.7,79.0 to 84.1,1466
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018-2022,Overall,Overall,91.8,89.8 to 93.4,1466
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2015,Age,13-17 Years,97.1,95.0 to 98.3,419
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2022,Age,13-17 Years,85.2,78.8 to 89.9,285
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2021,Age,13-17 Years,83.2,76.1 to 88.6,254
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2020,Age,13-17 Years,83.0,76.9 to 87.7,271
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2022,Age,13-15 Years,96.0,91.1 to 98.2,168
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2008,Age,13-17 Years,41.6,34.7 to 48.9,297
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2019,Age,13-17 Years,83.5,75.6 to 89.3,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2011,Age,13-17 Years,87.5,83.6 to 90.5,449
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2009,Age,13-17 Years,60.1,54.0 to 65.9,409
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2010,Age,13-17 Years,79.5,74.0 to 84.0,330
≥2 Doses MMR,,States/Local Areas,Rhode Island,2009,Age,13-17 Years,96.9,93.7 to 98.5,409
≥2 Doses MMR,,States/Local Areas,Rhode Island,2008,Age,13-17 Years,96.3,92.9 to 98.1,297
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2016,Age,13-17 Years,70.8,64.4 to 76.4,326
≥2 Doses MMR,,States/Local Areas,Rhode Island,2011,Age,13-17 Years,96.6,94.1 to 98.1,449
≥2 Doses MMR,,States/Local Areas,Rhode Island,2010,Age,13-17 Years,97.0,93.4 to 98.7,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2014,Age,13-17 Years,92.4,88.2 to 95.2,414
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2013,Age,13-17 Years,95.5,91.6 to 97.7,315
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2012,Age,13-17 Years,94.0,90.4 to 96.3,327
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2017,Age,13-17 Years,77.7,71.6 to 82.8,319
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2018,Age,13-17 Years,78.1,72.3 to 82.9,337
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2022,Age,13-17 Years,88.2,79.3 to 93.5,139
HPV,"≥2 Doses, Males and Females",States/Local Areas,Rhode Island,2022,Age,13-17 Years,86.6,80.5 to 91.0,285
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2022,Age,13-17 Years,85.2,75.7 to 91.4,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2019,Age,13-17 Years,78.9,72.5 to 84.2,319
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2017,Age,13-17 Years,94.1,90.2 to 96.5,319
HPV,"≥3 Doses, Males and Females",States/Local Areas,Rhode Island,2012,Age,13-17 Years,37.2,31.2 to 43.7,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2021,Age,13-17 Years,93.8,87.2 to 97.1,254
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2020,Age,13-17 Years,94.4,90.0 to 96.9,271
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2019,Age,13-17 Years,96.4,93.7 to 97.9,319
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2014,Age,13-15 Years,46.9,36.0 to 58.2,107
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2015,Age,13-15 Years,58.3,48.0 to 67.9,123
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2013,Age,13-15 Years,47.3,35.6 to 59.2,88
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2012,Age,13-15 Years,43.3,31.0 to 56.5,85
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2008,Age,13-15 Years,31.7,21.6 to 43.8,89
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2009,Age,13-15 Years,47.8,36.3 to 59.6,103
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2010,Age,13-15 Years,57.9,46.4 to 68.6,99
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2011,Age,13-15 Years,50.2,38.1 to 62.3,119
≥2 Doses MMR,,States/Local Areas,Rhode Island,2022,Age,13-17 Years,95.6,91.5 to 97.8,285
≥2 Doses MMR,,States/Local Areas,Rhode Island,2021,Age,13-17 Years,94.8,90.5 to 97.2,254
HPV,"≥3 Doses, Males and Females",States/Local Areas,Rhode Island,2014,Age,13-17 Years,48.2,42.4 to 54.0,414
HPV,"≥3 Doses, Males and Females",States/Local Areas,Rhode Island,2015,Age,13-17 Years,63.0,57.6 to 68.0,419
≥2 Doses MMR,,States/Local Areas,Rhode Island,2020,Age,13-17 Years,97.1,93.4 to 98.8,271
HPV,"≥3 Doses, Males and Females",States/Local Areas,Rhode Island,2013,Age,13-17 Years,49.7,43.2 to 56.2,315
≥2 Doses MMR,,States/Local Areas,Rhode Island,2019,Age,13-17 Years,96.1,92.2 to 98.1,319
≥2 Doses MMR,,States/Local Areas,Rhode Island,2017,Age,13-17 Years,95.6,92.0 to 97.6,319
≥2 Doses MMR,,States/Local Areas,Rhode Island,2018,Age,13-17 Years,97.8,95.5 to 99.0,337
≥2 Doses MMR,,States/Local Areas,Rhode Island,2013,Age,13-17 Years,95.6,91.6 to 97.7,315
≥2 Doses MMR,,States/Local Areas,Rhode Island,2012,Age,13-17 Years,97.0,93.6 to 98.7,327
≥2 Doses MMR,,States/Local Areas,Rhode Island,2015,Age,13-17 Years,97.4,95.1 to 98.6,419
≥2 Doses MMR,,States/Local Areas,Rhode Island,2014,Age,13-17 Years,97.9,95.5 to 99.0,414
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2022,Age,13-17 Years,95.1,91.3 to 97.3,285
HPV,"≥3 Doses, Males and Females",States/Local Areas,Rhode Island,2011,Age,13-17 Years,29.1,23.9 to 34.9,449
≥2 Doses MMR,,States/Local Areas,Rhode Island,2016,Age,13-17 Years,96.9,92.9 to 98.7,326
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2012,Age,13-17 Years,94.3,90.6 to 96.7,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2016,Age,13-17 Years,95.4,92.5 to 97.2,326
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2017,Age,13-17 Years,94.6,91.0 to 96.8,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018,Age,13-17 Years,96.3,93.2 to 98.0,337
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2016,Age,13-17 Years,96.4,93.2 to 98.1,326
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2015,Age,13-17 Years,97.7,95.6 to 98.8,419
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2014,Age,13-17 Years,94.1,89.9 to 96.6,414
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2013,Age,13-17 Years,92.0,87.6 to 94.9,315
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2009,Age,13-17 Years,75.7,70.2 to 80.5,409
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2008,Age,13-17 Years,62.6,55.3 to 69.5,297
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2011,Age,13-17 Years,88.9,84.0 to 92.4,449
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2010,Age,13-17 Years,83.5,78.2 to 87.6,330
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2022,Age,13-15 Years,97.0,92.8 to 98.8,168
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2021,Age,13-17 Years,92.8,86.3 to 96.3,254
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2022,Age,13-17 Years,96.2,92.4 to 98.1,285
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2020,Age,13-17 Years,96.2,92.2 to 98.2,271
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2019,Age,13-17 Years,98.2,96.5 to 99.1,319
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018,Age,13-17 Years,98.7,96.9 to 99.4,337
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018-2022,Overall,Overall,95.2,93.6 to 96.4,1466
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018-2022,Overall,Overall,96.4,94.9 to 97.5,1466
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2023,Age,13-15 Years,58.5,45.1 to 70.9,83
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2023,Age,13-17 Years,56.9,46.3 to 67.0,130
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2023,Age,13-17 Years,85.8,77.2 to 91.5,141
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Mexico,2018,Age,13-17 Years,61.3,54.5 to 67.6,295
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2022,Age,13-17 Years,88.7,82.4 to 93.0,257
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2019,Age,13-17 Years,64.5,55.4 to 72.7,200
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2020,Age,13-17 Years,80.1,72.5 to 85.9,166
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2021,Age,13-17 Years,82.0,73.2 to 88.3,168
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2022,Age,13-17 Years,83.3,73.9 to 89.7,148
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2011,Age,13-17 Years,11.3,7.2 to 17.1,222
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Mexico,2017,Age,13-17 Years,53.9,47.7 to 60.0,362
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Mexico,2016,Age,13-17 Years,46.6,40.6 to 52.8,374
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2017,Age,13-17 Years,60.3,51.9 to 68.1,202
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2008,Age,13-17 Years,48.3,38.4 to 58.4,143
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Mexico,2019,Age,13-17 Years,62.1,56.0 to 67.9,405
≥3 Doses HepB,,States/Local Areas,New Mexico,2008,Age,13-17 Years,83.1,76.5 to 88.1,310
≥3 Doses HepB,,States/Local Areas,New Mexico,2009,Age,13-17 Years,89.3,85.4 to 92.2,406
≥3 Doses HepB,,States/Local Areas,New Mexico,2010,Age,13-17 Years,86.4,81.0 to 90.5,332
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2022,Age,13-15 Years,89.9,82.3 to 94.5,173
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2008,Age,13-17 Years,69.0,58.7 to 77.8,132
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2012,Age,13-17 Years,60.5,52.1 to 68.3,238
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2013,Age,13-17 Years,72.5,65.7 to 78.3,272
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2011,Age,13-17 Years,70.7,62.7 to 77.5,266
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2010,Age,13-17 Years,55.7,47.0 to 64.1,174
≥3 Doses HepB,,States/Local Areas,New Mexico,2012,Age,13-17 Years,89.9,85.3 to 93.3,331
≥3 Doses HepB,,States/Local Areas,New Mexico,2011,Age,13-17 Years,90.1,85.8 to 93.3,431
≥3 Doses HepB,,States/Local Areas,New Mexico,2014,Age,13-17 Years,85.6,80.0 to 89.8,378
≥3 Doses HepB,,States/Local Areas,New Mexico,2013,Age,13-17 Years,93.4,89.5 to 96.0,357
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2009,Age,13-17 Years,53.1,45.0 to 60.9,195
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2012,Age,13-17 Years,94.2,88.7 to 97.1,238
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2011,Age,13-17 Years,93.8,88.1 to 96.9,266
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2009,Age,13-17 Years,42.4,34.8 to 50.4,201
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2008,Age,13-17 Years,24.3,16.5 to 34.3,132
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2009,Age,13-17 Years,77.0,69.1 to 83.5,201
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2010,Age,13-17 Years,83.6,75.4 to 89.4,174
≥3 Doses HepB,,States/Local Areas,New Mexico,2017,Age,13-17 Years,86.4,81.6 to 90.2,362
≥3 Doses HepB,,States/Local Areas,New Mexico,2019,Age,13-17 Years,87.0,81.9 to 90.8,405
≥3 Doses HepB,,States/Local Areas,New Mexico,2018,Age,13-17 Years,91.4,87.0 to 94.4,295
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2019,Age,13-17 Years,87.5,82.1 to 91.5,364
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2020,Age,13-17 Years,93.6,89.5 to 96.1,323
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2021,Age,13-17 Years,87.9,82.6 to 91.8,315
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2018,Age,13-17 Years,89.7,84.5 to 93.4,256
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2020,Age,13-17 Years,96.1,93.0 to 97.9,323
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2019,Age,13-17 Years,92.8,88.3 to 95.7,364
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2018,Age,13-17 Years,93.6,89.0 to 96.3,256
≥3 Doses HepB,,States/Local Areas,New Mexico,2016,Age,13-17 Years,89.8,85.6 to 92.9,374
≥3 Doses HepB,,States/Local Areas,New Mexico,2015,Age,13-17 Years,88.3,83.9 to 91.6,396
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2016,Age,13-17 Years,95.5,92.5 to 97.3,313
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2015,Age,13-17 Years,92.9,88.4 to 95.8,327
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2014,Age,13-17 Years,91.3,85.3 to 95.0,291
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2013,Age,13-17 Years,96.8,94.0 to 98.4,272
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2017,Age,13-17 Years,81.7,76.1 to 86.3,324
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2010,Age,13-17 Years,48.4,40.1 to 56.8,174
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2011,Age,13-17 Years,58.1,49.3 to 66.4,209
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2017,Age,13-17 Years,91.9,87.4 to 94.9,324
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2014,Age,13-17 Years,75.3,68.3 to 81.3,291
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2016,Age,13-17 Years,84.7,79.5 to 88.8,313
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2015,Age,13-17 Years,80.6,75.0 to 85.2,327
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2012,Age,13-17 Years,51.1,41.1 to 61.0,159
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2013,Age,13-17 Years,67.1,58.0 to 75.1,166
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2014,Age,13-17 Years,59.0,49.9 to 67.5,202
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2015,Age,13-17 Years,66.7,58.7 to 73.8,214
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2009,Age,13-15 Years,46.3,37.2 to 55.6,147
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2008,Age,13-15 Years,30.5,20.4 to 43.0,95
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2015,Age,13-17 Years,83.7,78.9 to 87.6,396
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2020,Age,13-15 Years,97.0,93.9 to 98.5,181
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2021,Age,13-15 Years,90.4,84.1 to 94.4,188
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2012,Age,13-17 Years,72.6,65.7 to 78.5,331
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2011,Age,13-17 Years,82.3,76.8 to 86.7,431
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2014,Age,13-17 Years,81.4,75.8 to 86.0,378
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2013,Age,13-17 Years,79.1,73.6 to 83.7,357
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2012,Age,13-15 Years,64.8,54.8 to 73.6,160
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2013,Age,13-15 Years,72.8,64.3 to 80.0,178
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2010,Age,13-15 Years,56.3,46.0 to 66.2,128
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2011,Age,13-15 Years,73.9,64.2 to 81.7,181
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2015,Age,13-15 Years,82.5,75.2 to 88.0,201
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2014,Age,13-15 Years,78.9,70.1 to 85.7,184
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2018,Age,13-15 Years,91.4,84.7 to 95.3,155
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2019,Age,13-15 Years,92.1,86.7 to 95.4,232
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2020,Age,13-17 Years,94.1,90.4 to 96.4,352
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2021,Age,13-17 Years,88.9,84.0 to 92.5,337
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2022,Age,13-17 Years,89.4,83.4 to 93.4,276
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2009,Age,13-17 Years,71.5,66.1 to 76.4,406
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2010,Age,13-17 Years,78.4,72.9 to 83.0,332
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2017,Age,13-15 Years,84.8,77.4 to 90.1,202
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2016,Age,13-15 Years,87.7,81.8 to 91.8,204
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2019,Age,13-17 Years,88.9,83.9 to 92.4,405
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2018,Age,13-17 Years,91.0,86.2 to 94.2,295
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2016,Age,13-17 Years,87.2,82.8 to 90.7,374
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2017,Age,13-17 Years,84.2,79.1 to 88.2,362
≥3 Doses HepB,,States/Local Areas,New Mexico,2020,Age,13-17 Years,92.2,88.0 to 95.0,352
≥3 Doses HepB,,States/Local Areas,New Mexico,2021,Age,13-17 Years,88.0,83.2 to 91.5,337
≥3 Doses HepB,,States/Local Areas,New Mexico,2022,Age,13-17 Years,88.4,82.3 to 92.6,276
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2022,Age,13-17 Years,91.1,85.0 to 94.9,257
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2021,Age,13-17 Years,91.0,86.2 to 94.3,315
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2012,Age,13-17 Years,20.2,13.3 to 29.6,172
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2020,Age,13-17 Years,74.7,66.5 to 81.5,186
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2021,Age,13-17 Years,79.9,72.3 to 85.9,169
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2018,Age,13-17 Years,72.8,64.4 to 79.8,156
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2019,Age,13-17 Years,81.7,74.7 to 87.2,205
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2016,Age,13-17 Years,57.9,49.3 to 66.1,203
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2015,Age,13-17 Years,54.3,45.7 to 62.5,182
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2014,Age,13-17 Years,42.8,33.9 to 52.2,176
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2013,Age,13-17 Years,31.4,24.4 to 39.4,191
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2008,Age,13-17 Years,34.2,25.2 to 44.4,143
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2016,Age,13-15 Years,77.6,70.8 to 83.2,237
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2017,Age,13-17 Years,86.9,81.7 to 90.8,362
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2016,Age,13-17 Years,88.1,83.5 to 91.6,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2014,Age,13-17 Years,88.7,83.2 to 92.5,378
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2015,Age,13-17 Years,91.4,87.4 to 94.3,396
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2015,Age,13-15 Years,70.5,63.2 to 76.9,247
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2014,Age,13-15 Years,75.4,67.6 to 81.9,232
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2012,Age,13-15 Years,50.0,41.2 to 58.7,206
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2013,Age,13-15 Years,71.1,63.5 to 77.7,219
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2017,Age,13-17 Years,73.6,65.1 to 80.7,160
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2016,Age,13-17 Years,63.1,54.4 to 71.1,171
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2018,Age,13-17 Years,70.7,60.5 to 79.2,139
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2017,Age,13-17 Years,66.9,60.9 to 72.4,362
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2016,Age,13-17 Years,60.5,54.4 to 66.3,374
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2010,Age,13-15 Years,53.7,45.6 to 61.7,201
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2011,Age,13-15 Years,68.4,60.7 to 75.3,259
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2008,Age,13-15 Years,44.7,36.5 to 53.2,192
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2009,Age,13-15 Years,52.3,45.1 to 59.4,252
HPV,"≥1 Dose, Males",States/Local Areas,New Mexico,2022,Age,13-17 Years,75.7,65.6 to 83.6,128
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2009,Age,13-17 Years,84.4,79.8 to 88.1,406
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2008,Age,13-17 Years,75.1,68.8 to 80.5,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2012,Age,13-17 Years,91.4,86.3 to 94.7,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2013,Age,13-17 Years,89.5,84.7 to 93.0,357
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2011,Age,13-17 Years,87.9,82.4 to 91.9,431
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2010,Age,13-17 Years,88.8,84.1 to 92.3,332
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2011,Age,13-17 Years,44.1,35.5 to 53.1,209
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2010,Age,13-17 Years,40.6,32.6 to 49.1,174
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2020,Age,13-15 Years,83.2,76.0 to 88.5,197
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2009,Age,13-17 Years,43.5,35.8 to 51.4,195
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2012,Age,13-17 Years,38.7,29.8 to 48.5,159
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2013,Age,13-17 Years,56.1,46.8 to 64.9,166
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2019,Age,13-15 Years,84.0,77.5 to 88.9,257
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018,Age,13-15 Years,75.9,67.3 to 82.9,177
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2017,Age,13-15 Years,75.6,67.9 to 81.9,220
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2019,Age,13-17 Years,73.3,67.4 to 78.4,405
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2021,Age,13-17 Years,90.8,85.8 to 94.2,337
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2022,Age,13-17 Years,87.2,81.0 to 91.5,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018,Age,13-17 Years,71.8,65.3 to 77.4,295
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2018,Age,13-17 Years,90.9,86.4 to 94.1,295
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2020,Age,13-17 Years,77.4,71.9 to 82.0,352
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2021,Age,13-17 Years,80.9,75.4 to 85.5,337
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2022,Age,13-17 Years,79.4,72.8 to 84.8,276
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2019,Age,13-17 Years,89.9,85.6 to 93.1,405
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2020,Age,13-17 Years,90.0,85.6 to 93.2,352
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2017,Age,13-17 Years,60.1,50.9 to 68.7,160
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2016,Age,13-17 Years,52.7,44.0 to 61.3,171
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2015,Age,13-17 Years,55.6,47.6 to 63.2,214
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2014,Age,13-17 Years,48.7,39.7 to 57.7,202
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2021,Age,13-15 Years,84.8,77.4 to 90.1,201
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2018,Age,13-17 Years,61.8,51.7 to 71.1,139
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2012,Age,13-15 Years,83.4,75.1 to 89.3,206
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2011,Age,13-15 Years,84.3,77.1 to 89.5,259
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2008,Age,13-15 Years,56.3,47.8 to 64.5,192
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2010,Age,13-15 Years,75.3,67.4 to 81.7,201
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2009,Age,13-15 Years,69.2,61.9 to 75.6,252
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2019,Age,13-17 Years,54.9,46.0 to 63.6,200
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2017,Age,13-15 Years,84.4,77.2 to 89.7,220
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2016,Age,13-15 Years,84.3,77.6 to 89.2,237
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2015,Age,13-15 Years,89.6,84.4 to 93.2,247
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2014,Age,13-15 Years,85.7,77.9 to 91.0,232
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2019,Age,13-15 Years,86.3,80.3 to 90.7,257
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2020,Age,13-15 Years,89.2,83.2 to 93.3,197
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2021,Age,13-15 Years,89.2,82.1 to 93.7,201
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018,Age,13-15 Years,86.5,79.4 to 91.4,177
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2013,Age,13-15 Years,88.4,82.2 to 92.7,219
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2018,Age,13-17 Years,60.7,51.5 to 69.1,156
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2017,Age,13-17 Years,47.9,39.8 to 56.0,202
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2016,Age,13-17 Years,40.8,32.9 to 49.2,203
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2012,Age,13-17 Years,12.8,7.3 to 21.5,172
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2013,Age,13-17 Years,27.0,20.4 to 34.8,191
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2014,Age,13-17 Years,33.2,24.9 to 42.6,176
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2012,Age,13-15 Years,24.9,15.8 to 36.9,95
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2011,Age,13-15 Years,32.5,23.4 to 43.2,130
≥2 Doses MMR,,States/Local Areas,New Mexico,2021,Age,13-17 Years,88.1,83.2 to 91.8,337
≥2 Doses MMR,,States/Local Areas,New Mexico,2022,Age,13-17 Years,90.0,84.0 to 93.9,276
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2021,Age,13-17 Years,84.6,79.4 to 88.7,337
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2015,Age,13-17 Years,49.9,41.5 to 58.3,182
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2019,Age,13-17 Years,83.5,78.2 to 87.6,405
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018,Age,13-17 Years,79.7,73.5 to 84.7,295
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2020,Age,13-17 Years,85.2,80.1 to 89.2,352
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2022,Age,13-17 Years,84.4,78.1 to 89.2,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Overall,Overall,76.6,74.0 to 79.0,1665
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Overall,Overall,58.9,56.0 to 61.8,1665
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a Non-MSA,88.3,84.2 to 91.4,481
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Non-Principal City,76.4,70.3 to 81.7,323
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a Non-MSA,73.7,68.7 to 78.1,481
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Principal City,78.0,74.4 to 81.2,861
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Non-Principal City,60.9,54.0 to 67.3,323
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a Non-MSA,51.7,46.2 to 57.1,481
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Principal City,61.6,57.6 to 65.5,861
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Non-Principal City,86.1,80.7 to 90.1,323
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a Non-MSA,84.8,80.4 to 88.4,481
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Principal City,82.0,78.5 to 85.0,861
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,Hispanic,79.2,75.7 to 82.3,921
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.4,85.5 to 93.7,323
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Urbanicity,Living In a MSA Principal City,85.9,82.7 to 88.6,861
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.2,79.8 to 92.1,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"White, Non-Hispanic",50.9,45.9 to 55.9,567
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.7,73.7 to 87.7,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",62.6,53.0 to 71.3,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,Hispanic,62.1,58.1 to 65.9,921
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"White, Non-Hispanic",81.7,77.5 to 85.4,567
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"White, Non-Hispanic",86.7,82.9 to 89.7,567
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,Hispanic,83.6,80.3 to 86.4,921
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,Hispanic,87.1,84.0 to 89.6,921
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.3,83.0 to 94.7,148
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.8,64.0 to 73.3,567
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Poverty,Below Poverty Level,80.0,74.8 to 84.4,411
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Poverty,Living At or Above Poverty Level,76.0,73.0 to 78.9,1199
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Poverty,Below Poverty Level,82.8,77.6 to 87.0,411
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Poverty,Living At or Above Poverty Level,84.1,81.3 to 86.4,1199
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Poverty,Below Poverty Level,60.3,54.4 to 66.0,411
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Poverty,Living At or Above Poverty Level,59.1,55.7 to 62.5,1199
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Poverty,Living At or Above Poverty Level,89.0,86.8 to 91.0,1199
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Poverty,Below Poverty Level,85.1,79.8 to 89.2,411
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Private Insurance Only,83.4,79.7 to 86.6,721
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Any Medicaid,83.9,80.5 to 86.8,794
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Private Insurance Only,73.2,69.1 to 77.0,721
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Any Medicaid,79.9,76.3 to 83.1,794
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Other,87.3,79.0 to 92.7,103
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Other,74.1,63.8 to 82.3,103
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Private Insurance Only,57.9,53.4 to 62.3,721
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Uninsured,68.1,47.7 to 83.4,47
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Uninsured,64.8,45.0 to 80.5,47
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Any Medicaid,60.0,55.8 to 64.1,794
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Other,60.3,48.7 to 70.8,103
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Uninsured,50.2,32.1 to 68.2,47
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Private Insurance Only,88.1,84.9 to 90.8,721
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Any Medicaid,86.9,83.6 to 89.6,794
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Other,92.3,85.8 to 96.0,103
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Insurance Coverage,Uninsured,76.1,54.8 to 89.3,47
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2012,Age,13-17 Years,54.2,47.2 to 61.1,331
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2022,Age,13-15 Years,84.1,75.9 to 89.8,185
≥2 Doses MMR,,States/Local Areas,New Mexico,2016,Age,13-17 Years,90.3,86.2 to 93.2,374
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2017,Age,13-17 Years,85.5,80.3 to 89.5,362
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018,Age,13-17 Years,88.1,83.2 to 91.7,295
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2016,Age,13-17 Years,84.3,79.2 to 88.4,374
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Mexico,2012,Age,13-17 Years,18.2,13.6 to 23.9,331
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Mexico,2011,Age,13-17 Years,15.7,11.9 to 20.4,431
≥2 Doses MMR,,States/Local Areas,New Mexico,2014,Age,13-17 Years,84.7,79.0 to 89.2,378
≥2 Doses MMR,,States/Local Areas,New Mexico,2015,Age,13-17 Years,88.8,84.3 to 92.1,396
≥2 Doses MMR,,States/Local Areas,New Mexico,2012,Age,13-17 Years,87.2,81.6 to 91.2,331
≥2 Doses MMR,,States/Local Areas,New Mexico,2013,Age,13-17 Years,92.3,88.7 to 94.9,357
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2016,Age,13-17 Years,77.8,72.5 to 82.4,374
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2015,Age,13-17 Years,72.5,67.0 to 77.5,396
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2014,Age,13-17 Years,75.1,69.2 to 80.3,378
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2013,Age,13-17 Years,70.9,65.0 to 76.1,357
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2019,Age,13-17 Years,87.8,83.3 to 91.2,405
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2017,Age,13-17 Years,78.0,72.4 to 82.8,362
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2020,Age,13-17 Years,89.3,84.9 to 92.6,352
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2021,Age,13-17 Years,87.8,82.5 to 91.7,337
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2022,Age,13-17 Years,84.1,77.6 to 89.0,276
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Mexico,2013,Age,13-17 Years,31.5,26.0 to 37.7,357
≥2 Doses MMR,,States/Local Areas,New Mexico,2020,Age,13-17 Years,93.4,89.7 to 95.9,352
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Mexico,2015,Age,13-17 Years,40.4,35.0 to 46.1,396
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Mexico,2014,Age,13-17 Years,31.4,25.7 to 37.8,378
≥2 Doses MMR,,States/Local Areas,New Mexico,2019,Age,13-17 Years,87.9,82.7 to 91.7,405
≥2 Doses MMR,,States/Local Areas,New Mexico,2018,Age,13-17 Years,90.4,85.6 to 93.6,295
≥2 Doses MMR,,States/Local Areas,New Mexico,2017,Age,13-17 Years,88.3,83.6 to 91.8,362
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2015,Age,13-15 Years,36.1,27.6 to 45.7,139
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2014,Age,13-15 Years,36.5,26.7 to 47.5,130
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2013,Age,13-15 Years,40.2,29.0 to 52.5,99
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2008,Age,13-15 Years,25.7,16.0 to 38.5,98
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2010,Age,13-15 Years,27.8,19.3 to 38.4,108
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2009,Age,13-15 Years,38.4,29.3 to 48.5,123
HPV,"≥2 Doses, Females",States/Local Areas,New Mexico,2022,Age,13-17 Years,65.2,54.7 to 74.4,148
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2009,Age,13-17 Years,51.2,45.6 to 56.8,406
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2008,Age,13-17 Years,39.6,33.3 to 46.3,310
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2011,Age,13-17 Years,64.8,58.5 to 70.5,431
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2010,Age,13-17 Years,52.9,46.6 to 59.0,332
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2018-2022,Overall,Overall,87.4,85.2 to 89.3,1665
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2018-2022,Overall,Overall,83.5,81.1 to 85.6,1665
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2020,Age,13-17 Years,64.8,56.1 to 72.6,166
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2016,Age,13-17 Years,37.0,29.3 to 45.3,203
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2020,Age,13-15 Years,48.6,37.2 to 60.1,106
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2019,Age,13-15 Years,54.8,43.8 to 65.3,121
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2019,Age,13-17 Years,53.8,44.9 to 62.5,200
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2018,Age,13-17 Years,58.4,48.2 to 67.9,139
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2017,Age,13-17 Years,55.0,45.8 to 63.9,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2022,Age,13-15 Years,58.5,49.4 to 67.1,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2019,Age,13-15 Years,51.8,44.1 to 59.4,257
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2022,Age,13-17 Years,57.8,47.3 to 67.7,128
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2021,Age,13-15 Years,54.0,45.5 to 62.2,201
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2019,Age,13-17 Years,65.7,57.4 to 73.1,205
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2020,Age,13-17 Years,53.7,45.0 to 62.2,186
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2017,Age,13-17 Years,41.9,34.1 to 50.2,202
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2018,Age,13-17 Years,55.6,46.4 to 64.4,156
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2016,Age,13-17 Years,49.0,40.4 to 57.7,171
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2018,Age,13-15 Years,51.8,39.6 to 63.9,90
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2021,Age,13-17 Years,62.9,53.5 to 71.3,168
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2022,Age,13-17 Years,63.8,53.3 to 73.2,148
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2022,Age,13-15 Years,84.8,76.6 to 90.5,185
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2008,Age,13-17 Years,50.4,43.7 to 57.0,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2019,Age,13-17 Years,59.8,53.7 to 65.7,405
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2020,Age,13-17 Years,59.2,53.0 to 65.1,352
≥2 Doses MMR,,States/Local Areas,New Mexico,2009,Age,13-17 Years,86.7,82.1 to 90.2,406
≥2 Doses MMR,,States/Local Areas,New Mexico,2008,Age,13-17 Years,84.2,78.2 to 88.7,310
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2014,Age,13-17 Years,83.3,77.4 to 88.0,378
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2013,Age,13-17 Years,85.6,80.5 to 89.6,357
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2021,Age,13-17 Years,57.9,51.5 to 64.1,337
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2022,Age,13-17 Years,60.8,53.3 to 67.7,276
≥2 Doses MMR,,States/Local Areas,New Mexico,2011,Age,13-17 Years,90.2,85.1 to 93.6,431
≥2 Doses MMR,,States/Local Areas,New Mexico,2010,Age,13-17 Years,85.8,80.3 to 89.9,332
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2015,Age,13-17 Years,85.9,81.1 to 89.6,396
≥2 Doses Hep A,,States/Local Areas,New Mexico,2022,Age,13-17 Years,87.3,81.0 to 91.8,276
≥2 Doses Hep A,,States/Local Areas,New Mexico,2021,Age,13-17 Years,87.8,83.0 to 91.4,337
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2010,Age,13-17 Years,31.1,23.7 to 39.5,174
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2015,Age,13-17 Years,40.6,33.3 to 48.3,214
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2009,Age,13-17 Years,35.4,28.2 to 43.3,195
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2008,Age,13-17 Years,23.2,15.4 to 33.4,143
HPV,"≥3 Doses, Males",States/Local Areas,New Mexico,2013,Age,13-15 Years,19.7,12.7 to 29.2,120
HPV,"≥3 Doses, Males",States/Local Areas,New Mexico,2013,Age,13-17 Years,19.2,13.5 to 26.6,191
HPV,"≥3 Doses, Males",States/Local Areas,New Mexico,2015,Age,13-17 Years,40.3,32.4 to 48.7,182
HPV,"≥3 Doses, Males",States/Local Areas,New Mexico,2014,Age,13-17 Years,23.3,16.1 to 32.4,176
≥2 Doses Hep A,,States/Local Areas,New Mexico,2020,Age,13-17 Years,89.3,84.8 to 92.6,352
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2008,Age,13-17 Years,68.6,62.0 to 74.5,310
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2012,Age,13-17 Years,30.3,22.4 to 39.6,159
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2011,Age,13-17 Years,29.7,22.6 to 38.0,209
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2014,Age,13-17 Years,39.9,31.5 to 49.0,202
HPV,"≥3 Doses, Females",States/Local Areas,New Mexico,2013,Age,13-17 Years,44.3,35.4 to 53.6,166
HPV,"≥3 Doses, Males",States/Local Areas,New Mexico,2015,Age,13-15 Years,40.4,30.4 to 51.3,108
HPV,"≥3 Doses, Males",States/Local Areas,New Mexico,2014,Age,13-15 Years,26.7,16.8 to 39.6,102
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2018,Age,13-17 Years,57.0,50.1 to 63.5,295
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2017,Age,13-17 Years,48.3,42.2 to 54.5,362
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2019,Age,13-17 Years,69.1,61.0 to 76.2,205
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2009,Age,13-17 Years,63.5,57.8 to 68.8,406
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2010,Age,13-17 Years,71.8,65.7 to 77.2,332
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2011,Age,13-17 Years,81.3,75.7 to 85.9,431
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2012,Age,13-17 Years,82.6,76.2 to 87.5,331
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2016,Age,13-17 Years,42.9,37.0 to 49.0,374
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2020,Age,13-15 Years,53.3,45.0 to 61.4,197
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2021,Age,13-15 Years,58.4,46.3 to 69.6,103
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2022,Age,13-15 Years,61.8,48.7 to 73.3,97
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2021,Age,13-15 Years,49.3,37.5 to 61.1,98
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2022,Age,13-15 Years,55.4,42.7 to 67.4,88
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2021,Age,13-17 Years,53.1,44.2 to 61.9,169
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2011,Age,13-15 Years,33.6,21.8 to 47.9,117
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2012,Age,13-15 Years,32.3,20.5 to 46.8,100
≥1 Dose MenACWY,,States/Local Areas,Nevada,2022,Age,13-17 Years,85.9,80.0 to 90.3,259
≥2 Doses MMR,,States/Local Areas,Nevada,2022,Age,13-17 Years,86.0,79.9 to 90.4,259
≥2 Doses MMR,,States/Local Areas,Nevada,2021,Age,13-17 Years,90.3,85.5 to 93.7,333
≥1 Dose MenACWY,,States/Local Areas,Nevada,2021,Age,13-17 Years,89.5,84.1 to 93.2,333
≥1 Dose MenACWY,,States/Local Areas,Nevada,2020,Age,13-17 Years,87.2,81.4 to 91.4,369
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018,Age,13-17 Years,80.6,75.1 to 85.1,334
≥1 Dose MenACWY,,States/Local Areas,Nevada,2019,Age,13-17 Years,87.0,81.2 to 91.2,313
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2009,Age,13-15 Years,12.4,7.0 to 21.2,113
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2010,Age,13-15 Years,22.4,14.6 to 32.6,100
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2023,Age,13-17 Years,50.7,41.0 to 60.3,171
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2013,Age,13-15 Years,24.7,16.1 to 35.8,98
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2014,Age,13-15 Years,30.3,21.3 to 41.1,119
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2015,Age,13-15 Years,37.4,27.3 to 48.7,119
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2016,Age,13-17 Years,87.1,81.8 to 91.0,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018,Age,13-17 Years,85.2,80.0 to 89.2,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2017,Age,13-17 Years,82.5,76.6 to 87.1,344
≥2 Doses MMR,,States/Local Areas,Nevada,2017,Age,13-17 Years,92.4,88.3 to 95.2,344
≥2 Doses MMR,,States/Local Areas,Nevada,2018,Age,13-17 Years,89.0,84.3 to 92.5,334
≥2 Doses MMR,,States/Local Areas,Nevada,2019,Age,13-17 Years,88.1,82.5 to 92.1,313
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nevada,2014,Age,13-17 Years,23.9,19.0 to 29.4,351
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nevada,2015,Age,13-17 Years,32.8,27.2 to 39.1,372
≥2 Doses MMR,,States/Local Areas,Nevada,2020,Age,13-17 Years,84.2,78.1 to 88.8,369
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nevada,2013,Age,13-17 Years,17.1,12.9 to 22.4,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2022,Age,13-17 Years,89.2,83.9 to 92.9,259
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2021,Age,13-17 Years,91.2,85.8 to 94.6,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2020,Age,13-17 Years,86.9,81.0 to 91.1,369
≥1 Dose MenACWY,,States/Local Areas,Nevada,2017,Age,13-17 Years,77.3,71.0 to 82.5,344
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2019,Age,13-17 Years,89.0,83.6 to 92.8,313
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nevada,2011,Age,13-17 Years,15.6,10.9 to 21.8,412
HPV,"≥3 Doses, Males and Females",States/Local Areas,Nevada,2012,Age,13-17 Years,20.5,15.1 to 27.1,329
≥2 Doses MMR,,States/Local Areas,Nevada,2013,Age,13-17 Years,92.8,88.5 to 95.6,335
≥2 Doses MMR,,States/Local Areas,Nevada,2012,Age,13-17 Years,94.0,90.7 to 96.2,329
≥2 Doses MMR,,States/Local Areas,Nevada,2015,Age,13-17 Years,90.0,85.3 to 93.4,372
≥2 Doses MMR,,States/Local Areas,Nevada,2014,Age,13-17 Years,87.4,83.0 to 90.9,351
≥2 Doses MMR,,States/Local Areas,Nevada,2016,Age,13-17 Years,89.5,84.5 to 93.0,330
≥1 Dose MenACWY,,States/Local Areas,Nevada,2013,Age,13-17 Years,64.0,57.7 to 69.9,335
≥1 Dose MenACWY,,States/Local Areas,Nevada,2014,Age,13-17 Years,66.5,60.4 to 72.1,351
≥1 Dose MenACWY,,States/Local Areas,Nevada,2015,Age,13-17 Years,78.0,72.3 to 82.8,372
≥1 Dose MenACWY,,States/Local Areas,Nevada,2016,Age,13-17 Years,78.7,72.8 to 83.7,330
≥1 Dose MenACWY,,States/Local Areas,Nevada,2022,Age,13-15 Years,82.6,73.8 to 88.8,155
≥1 Dose MenACWY,,States/Local Areas,Nevada,2012,Age,13-17 Years,66.3,59.8 to 72.4,329
≥1 Dose MenACWY,,States/Local Areas,Nevada,2010,Age,13-17 Years,54.2,48.0 to 60.3,330
≥1 Dose MenACWY,,States/Local Areas,Nevada,2011,Age,13-17 Years,60.3,52.9 to 67.3,412
≥1 Dose MenACWY,,States/Local Areas,Nevada,2008,Age,13-17 Years,29.6,23.3 to 36.9,235
≥1 Dose MenACWY,,States/Local Areas,Nevada,2009,Age,13-17 Years,39.5,33.4 to 45.9,336
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Uninsured,85.4,74.9 to 92.0,98
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Other,88.1,78.5 to 93.8,124
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Any Medicaid,86.9,82.8 to 90.2,497
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Private Insurance Only,89.7,86.7 to 92.2,889
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Uninsured,50.2,38.0 to 62.4,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Other,57.9,47.2 to 67.9,124
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Any Medicaid,58.5,52.9 to 63.9,497
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Uninsured,68.2,56.2 to 78.1,98
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Uninsured,86.1,75.6 to 92.5,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Private Insurance Only,51.0,46.8 to 55.3,889
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Other,78.7,69.2 to 85.8,124
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Other,86.1,76.7 to 92.1,124
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Any Medicaid,78.0,73.1 to 82.3,497
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Insurance Coverage,Private Insurance Only,66.0,61.9 to 69.9,889
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Any Medicaid,85.5,81.1 to 89.1,497
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Insurance Coverage,Private Insurance Only,86.4,83.3 to 89.1,889
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Poverty,Below Poverty Level,85.0,78.5 to 89.7,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Poverty,Living At or Above Poverty Level,89.2,86.8 to 91.2,1294
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Poverty,Living At or Above Poverty Level,51.6,48.1 to 55.1,1294
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Poverty,Below Poverty Level,62.0,54.4 to 69.0,261
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Poverty,Living At or Above Poverty Level,86.9,84.3 to 89.0,1294
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Poverty,Below Poverty Level,83.8,77.1 to 88.8,261
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Poverty,Living At or Above Poverty Level,69.5,66.2 to 72.6,1294
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Poverty,Below Poverty Level,76.5,69.4 to 82.4,261
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",68.2,57.0 to 77.6,116
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"White, Non-Hispanic",66.0,61.6 to 70.2,743
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.3,83.6 to 93.2,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.6,74.7 to 91.0,116
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,Hispanic,88.4,84.5 to 91.4,532
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,Hispanic,86.9,82.8 to 90.1,532
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.9,85.6 to 91.5,743
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.2,74.8 to 90.5,116
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.1,81.5 to 88.2,743
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,Hispanic,61.3,56.2 to 66.3,532
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",51.8,43.2 to 60.3,217
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",75.6,67.6 to 82.1,217
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",38.1,28.1 to 49.3,116
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",87.8,81.7 to 92.1,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Non-Principal City,88.3,83.2 to 92.0,300
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Principal City,88.4,85.7 to 90.6,1123
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,Hispanic,75.7,70.9 to 80.0,532
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Race and Ethnicity,"White, Non-Hispanic",50.9,46.2 to 55.5,743
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Principal City,86.7,83.8 to 89.0,1123
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Non-Principal City,85.7,80.4 to 89.8,300
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a Non-MSA,82.0,72.9 to 88.5,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Principal City,55.9,52.1 to 59.6,1123
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Non-Principal City,51.0,44.1 to 57.9,300
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a Non-MSA,46.0,36.8 to 55.5,185
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Principal City,72.0,68.5 to 75.2,1123
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2016,Age,13-17 Years,75.4,72.1 to 78.4,2022
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a MSA Non-Principal City,69.2,62.5 to 75.2,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a Non-MSA,70.3,61.0 to 78.2,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018-2022,Overall,Overall,54.1,51.0 to 57.2,1608
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Urbanicity,Living In a Non-MSA,88.0,79.2 to 93.4,185
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018-2022,Overall,Overall,71.3,68.4 to 74.0,1608
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018-2022,Overall,Overall,88.3,86.1 to 90.2,1608
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018-2022,Overall,Overall,86.1,83.7 to 88.1,1608
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2023,Age,13-17 Years,91.6,87.0 to 94.7,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2023,Age,13-17 Years,91.5,87.0 to 94.6,325
≥1 Dose MenACWY,,States/Local Areas,Nevada,2023,Age,13-17 Years,84.1,77.7 to 88.9,325
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2023,Age,13-17 Years,48.5,41.4 to 55.7,325
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2023,Age,13-17 Years,72.2,65.5 to 78.1,325
≥2 Doses MMR,,States/Local Areas,Nevada,2023,Age,13-17 Years,90.6,85.2 to 94.2,325
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2023,Age,13-17 Years,46.5,36.2 to 57.1,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2023,Age,13-17 Years,91.0,86.0 to 94.3,312
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2023,Age,13-17 Years,93.0,88.0 to 96.0,312
≥3 Doses HepB,,States/Local Areas,Nevada,2023,Age,13-17 Years,90.2,84.8 to 93.8,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2023,Age,13-17 Years,91.4,86.6 to 94.6,325
≥2 Doses Hep A,,States/Local Areas,Nevada,2023,Age,13-17 Years,91.1,85.8 to 94.5,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2023,Age,13-15 Years,89.5,82.6 to 93.9,197
≥1 Dose MenACWY,,States/Local Areas,Nevada,2023,Age,13-15 Years,87.6,80.5 to 92.3,197
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2023,Age,13-15 Years,44.1,35.2 to 53.4,197
HPV,"Up-to-Date, Males",States/Local Areas,Nevada,2023,Age,13-15 Years,43.7,30.7 to 57.6,91
HPV,"Up-to-Date, Females",States/Local Areas,Nevada,2023,Age,13-15 Years,44.5,32.9 to 56.8,106
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2023,Age,13-15 Years,92.3,86.1 to 95.8,187
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2023,Age,13-17 Years,76.0,67.6 to 82.7,171
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2023,Age,13-17 Years,68.7,58.2 to 77.6,154
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2022,Age,13-17 Years,63.8,52.8 to 73.5,117
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nevada,2022,Age,13-17 Years,60.3,53.0 to 67.2,259
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2022,Age,13-17 Years,57.0,47.2 to 66.4,142
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2015,Age,13-17 Years,42.5,33.7 to 51.8,176
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2010,Age,13-17 Years,25.9,19.1 to 34.1,165
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2009,Age,13-17 Years,17.4,11.4 to 25.7,159
≥2 Doses Hep A,,States/Local Areas,Nevada,2021,Age,13-17 Years,90.1,84.7 to 93.7,333
≥2 Doses Hep A,,States/Local Areas,Nevada,2022,Age,13-17 Years,86.0,80.0 to 90.4,259
HPV,"≥3 Doses, Males",States/Local Areas,Nevada,2015,Age,13-15 Years,22.9,15.6 to 32.4,124
HPV,"≥3 Doses, Males",States/Local Areas,Nevada,2014,Age,13-15 Years,19.1,12.2 to 28.7,107
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2013,Age,13-17 Years,27.4,20.0 to 36.5,150
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2014,Age,13-17 Years,32.5,24.9 to 41.1,184
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2011,Age,13-17 Years,30.9,21.7 to 41.9,189
HPV,"≥3 Doses, Females",States/Local Areas,Nevada,2012,Age,13-17 Years,37.2,27.6 to 47.8,159
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2013,Age,13-17 Years,74.6,67.4 to 80.6,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2012,Age,13-17 Years,69.4,61.1 to 76.6,225
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2008,Age,13-17 Years,64.8,53.0 to 75.0,104
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2017,Age,13-17 Years,88.7,83.9 to 92.2,344
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2016,Age,13-17 Years,87.6,82.3 to 91.6,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2018,Age,13-17 Years,88.6,83.8 to 92.1,334
≥2 Doses Hep A,,States/Local Areas,Nevada,2020,Age,13-17 Years,86.5,80.5 to 90.8,369
HPV,"≥3 Doses, Males",States/Local Areas,Nevada,2014,Age,13-17 Years,15.7,10.6 to 22.7,167
HPV,"≥3 Doses, Males",States/Local Areas,Nevada,2015,Age,13-17 Years,23.7,17.2 to 31.6,196
HPV,"≥3 Doses, Males",States/Local Areas,Nevada,2013,Age,13-17 Years,7.3,4.2 to 12.3,185
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2008,Age,13-17 Years,65.4,57.9 to 72.3,235
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2015,Age,13-17 Years,85.1,79.9 to 89.2,372
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2019,Age,13-17 Years,89.1,83.8 to 92.8,313
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2022,Age,13-17 Years,89.1,83.5 to 92.9,259
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2021,Age,13-17 Years,90.0,85.0 to 93.5,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2020,Age,13-17 Years,85.1,79.0 to 89.6,369
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2016,Age,13-15 Years,87.3,80.2 to 92.1,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2017,Age,13-15 Years,88.4,81.4 to 93.0,210
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2010,Age,13-17 Years,76.4,70.9 to 81.1,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2009,Age,13-17 Years,69.4,62.9 to 75.2,336
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2013,Age,13-17 Years,81.5,75.8 to 86.0,335
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2014,Age,13-17 Years,77.4,72.0 to 82.1,351
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2011,Age,13-17 Years,71.4,64.0 to 77.9,412
Varicella,≥2 Doses or history of disease,States/Local Areas,Nevada,2012,Age,13-17 Years,78.5,72.1 to 83.8,329
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2019,Age,13-15 Years,88.3,80.7 to 93.2,190
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2018,Age,13-15 Years,87.8,80.8 to 92.5,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2014,Age,13-15 Years,73.7,65.8 to 80.4,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2015,Age,13-15 Years,85.3,77.5 to 90.7,210
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2011,Age,13-15 Years,56.1,45.4 to 66.4,194
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2010,Age,13-15 Years,58.4,48.7 to 67.5,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2013,Age,13-15 Years,82.2,74.3 to 88.1,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2012,Age,13-15 Years,73.1,63.4 to 81.0,159
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2015,Age,13-17 Years,72.0,63.6 to 79.1,176
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2014,Age,13-17 Years,54.2,45.6 to 62.6,184
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2013,Age,13-17 Years,53.8,44.3 to 62.9,150
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2012,Age,13-17 Years,62.5,52.7 to 71.5,159
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2015,Age,13-17 Years,81.7,75.6 to 86.6,312
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2016,Age,13-17 Years,84.8,78.3 to 89.5,279
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2014,Age,13-17 Years,69.8,63.0 to 75.7,276
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2017,Age,13-17 Years,93.9,89.4 to 96.6,303
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2011,Age,13-17 Years,55.3,44.0 to 66.1,189
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2010,Age,13-17 Years,47.4,38.9 to 56.2,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2017,Age,13-17 Years,87.1,81.7 to 91.1,303
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2021,Age,13-15 Years,88.5,80.8 to 93.3,202
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2020,Age,13-15 Years,85.7,77.3 to 91.4,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2008,Age,13-15 Years,24.1,15.5 to 35.5,77
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2009,Age,13-15 Years,39.2,29.7 to 49.5,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2015,Age,13-17 Years,88.3,83.2 to 92.0,372
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2022,Age,13-17 Years,59.5,52.2 to 66.4,259
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2021,Age,13-17 Years,56.5,49.1 to 63.5,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2011,Age,13-17 Years,80.2,73.9 to 85.4,412
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2010,Age,13-17 Years,68.3,62.2 to 73.9,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2009,Age,13-17 Years,64.0,57.4 to 70.1,336
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2020,Age,13-17 Years,50.1,43.4 to 56.8,369
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2019,Age,13-17 Years,52.9,45.7 to 60.0,313
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2008,Age,13-17 Years,45.9,38.6 to 53.2,235
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2022,Age,13-15 Years,89.1,81.7 to 93.7,155
≥2 Doses MMR,,States/Local Areas,Nevada,2008,Age,13-17 Years,88.8,83.5 to 92.6,235
≥2 Doses MMR,,States/Local Areas,Nevada,2009,Age,13-17 Years,88.1,82.8 to 91.9,336
≥2 Doses MMR,,States/Local Areas,Nevada,2010,Age,13-17 Years,88.8,83.8 to 92.4,330
≥2 Doses MMR,,States/Local Areas,Nevada,2011,Age,13-17 Years,86.0,79.5 to 90.6,412
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2019,Age,13-17 Years,51.7,41.6 to 61.6,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2013,Age,13-17 Years,88.3,83.5 to 91.8,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2014,Age,13-17 Years,87.6,83.3 to 90.9,351
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2016,Age,13-17 Years,39.9,33.7 to 46.5,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2012,Age,13-17 Years,86.3,80.4 to 90.6,329
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2017,Age,13-17 Years,49.0,42.6 to 55.5,344
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nevada,2018,Age,13-17 Years,51.1,44.7 to 57.4,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2018,Age,13-15 Years,85.0,78.1 to 90.0,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2021,Age,13-15 Years,91.2,84.1 to 95.3,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2020,Age,13-15 Years,84.1,75.9 to 89.9,216
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2019,Age,13-15 Years,88.1,80.6 to 92.9,205
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2014,Age,13-17 Years,28.3,20.9 to 37.2,167
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2013,Age,13-17 Years,20.4,14.1 to 28.5,185
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2015,Age,13-17 Years,31.9,24.3 to 40.5,196
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2016,Age,13-17 Years,43.5,34.4 to 53.0,161
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2017,Age,13-17 Years,48.7,39.7 to 57.8,180
HPV,"≥2 Doses, Males",States/Local Areas,Nevada,2018,Age,13-17 Years,55.1,46.3 to 63.6,172
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2013,Age,13-15 Years,89.5,83.2 to 93.6,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2014,Age,13-15 Years,85.6,79.7 to 89.9,226
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2015,Age,13-15 Years,89.7,82.9 to 94.0,243
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2016,Age,13-15 Years,87.3,80.8 to 91.8,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2017,Age,13-15 Years,83.9,76.7 to 89.2,235
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2013,Age,13-17 Years,97.7,95.4 to 98.9,251
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2014,Age,13-17 Years,91.8,87.3 to 94.7,276
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2015,Age,13-17 Years,94.5,90.4 to 97.0,312
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2016,Age,13-17 Years,94.5,89.7 to 97.1,279
≥3 Doses HepB,,States/Local Areas,Nevada,2015,Age,13-17 Years,92.1,87.7 to 95.0,372
≥3 Doses HepB,,States/Local Areas,Nevada,2016,Age,13-17 Years,89.4,84.1 to 93.1,330
≥3 Doses HepB,,States/Local Areas,Nevada,2018,Age,13-17 Years,88.0,82.9 to 91.7,334
≥3 Doses HepB,,States/Local Areas,Nevada,2019,Age,13-17 Years,88.3,82.5 to 92.4,313
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2018,Age,13-17 Years,91.4,86.3 to 94.7,292
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2019,Age,13-17 Years,92.0,86.9 to 95.3,278
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2020,Age,13-17 Years,88.5,82.2 to 92.7,340
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2018,Age,13-17 Years,86.8,81.4 to 90.8,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2021,Age,13-17 Years,89.2,83.8 to 92.9,303
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2020,Age,13-17 Years,83.9,77.4 to 88.7,340
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2019,Age,13-17 Years,87.6,81.6 to 91.8,278
≥3 Doses HepB,,States/Local Areas,Nevada,2017,Age,13-17 Years,91.4,87.0 to 94.5,344
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2010,Age,13-17 Years,86.0,79.0 to 90.9,176
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2009,Age,13-17 Years,83.8,75.2 to 89.8,164
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2008,Age,13-17 Years,20.2,13.3 to 29.5,104
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2009,Age,13-17 Years,39.7,31.1 to 49.0,164
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2011,Age,13-17 Years,90.5,84.4 to 94.4,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2012,Age,13-17 Years,97.3,94.5 to 98.7,225
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2008,Age,13-17 Years,30.0,21.2 to 40.5,117
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2009,Age,13-17 Years,39.0,30.2 to 48.4,159
≥3 Doses HepB,,States/Local Areas,Nevada,2013,Age,13-17 Years,95.1,91.3 to 97.3,335
≥3 Doses HepB,,States/Local Areas,Nevada,2014,Age,13-17 Years,89.4,85.0 to 92.6,351
≥3 Doses HepB,,States/Local Areas,Nevada,2011,Age,13-17 Years,88.8,82.9 to 92.8,412
≥3 Doses HepB,,States/Local Areas,Nevada,2012,Age,13-17 Years,90.5,85.8 to 93.8,329
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2010,Age,13-17 Years,53.6,45.3 to 61.8,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2011,Age,13-17 Years,51.2,42.2 to 60.3,270
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2022,Age,13-15 Years,90.6,83.3 to 95.0,143
≥3 Doses HepB,,States/Local Areas,Nevada,2010,Age,13-17 Years,92.2,88.6 to 94.7,330
≥3 Doses HepB,,States/Local Areas,Nevada,2009,Age,13-17 Years,86.4,80.9 to 90.5,336
≥3 Doses HepB,,States/Local Areas,Nevada,2008,Age,13-17 Years,82.7,76.6 to 87.4,235
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nevada,2019,Age,13-17 Years,54.6,47.4 to 61.6,313
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2017,Age,13-17 Years,59.3,50.0 to 68.0,180
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2013,Age,13-17 Years,31.9,24.0 to 40.9,185
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2014,Age,13-17 Years,43.4,34.7 to 52.5,167
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2015,Age,13-17 Years,44.5,36.0 to 53.4,196
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2016,Age,13-17 Years,65.1,55.9 to 73.3,161
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2019,Age,13-17 Years,69.4,59.4 to 77.9,156
Varicella,≥2 Doses with no disease history,States/Local Areas,Nevada,2022,Age,13-17 Years,88.1,82.2 to 92.3,241
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nevada,2018,Age,13-17 Years,54.9,48.5 to 61.1,334
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nevada,2016,Age,13-17 Years,47.5,40.9 to 54.1,330
HPV,"≥2 Doses, Males and Females",States/Local Areas,Nevada,2017,Age,13-17 Years,52.9,46.4 to 59.3,344
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2022,Age,13-17 Years,78.2,68.0 to 85.8,117
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2021,Age,13-17 Years,75.8,65.9 to 83.5,175
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2020,Age,13-17 Years,74.6,65.1 to 82.3,186
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2019,Age,13-17 Years,68.3,58.1 to 77.0,157
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2018,Age,13-17 Years,66.0,57.3 to 73.7,172
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2021,Age,13-17 Years,76.4,66.6 to 84.0,158
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2020,Age,13-17 Years,65.7,56.0 to 74.3,183
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2012,Age,13-17 Years,11.6,7.1 to 18.3,170
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2021,Age,13-17 Years,93.8,88.9 to 96.6,303
Varicella,≥1 Dose with no disease history,States/Local Areas,Nevada,2022,Age,13-17 Years,90.3,85.0 to 93.9,241
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2018,Age,13-17 Years,66.0,57.1 to 74.0,162
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2019,Age,13-17 Years,57.6,47.3 to 67.3,157
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2009,Age,13-15 Years,73.6,65.6 to 80.2,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2010,Age,13-15 Years,82.4,75.4 to 87.7,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2008,Age,13-15 Years,44.9,36.0 to 54.1,148
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2011,Age,13-15 Years,82.8,74.3 to 88.9,268
Tetanus,≥1 Dose Tdap,States/Local Areas,Nevada,2012,Age,13-15 Years,88.8,82.4 to 93.2,207
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2018,Age,13-17 Years,54.7,45.5 to 63.5,162
≥1 Dose MenACWY,,States/Local Areas,Nevada,2021,Age,13-15 Years,87.6,80.0 to 92.6,221
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2014,Age,13-17 Years,43.5,35.2 to 52.1,184
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2015,Age,13-17 Years,57.6,48.5 to 66.3,176
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2016,Age,13-17 Years,51.6,42.5 to 60.7,169
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2017,Age,13-17 Years,57.3,48.0 to 66.2,164
≥1 Dose MenACWY,,States/Local Areas,Nevada,2011,Age,13-15 Years,59.3,50.3 to 67.8,268
≥1 Dose MenACWY,,States/Local Areas,Nevada,2010,Age,13-15 Years,58.8,50.8 to 66.3,204
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2020,Age,13-17 Years,87.3,81.4 to 91.5,369
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2019,Age,13-17 Years,89.7,84.3 to 93.4,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2018,Age,13-17 Years,87.2,82.3 to 90.8,334
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2018,Age,13-17 Years,66.0,59.8 to 71.7,334
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2022,Age,13-17 Years,90.3,85.3 to 93.8,259
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2021,Age,13-17 Years,91.4,86.1 to 94.8,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2019,Age,13-17 Years,68.9,61.8 to 75.1,313
≥1 Dose MenACWY,,States/Local Areas,Nevada,2009,Age,13-15 Years,39.8,32.3 to 47.7,218
≥1 Dose MenACWY,,States/Local Areas,Nevada,2008,Age,13-15 Years,27.5,19.9 to 36.7,148
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2022,Age,13-17 Years,75.0,68.3 to 80.7,259
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2021,Age,13-17 Years,76.1,69.3 to 81.7,333
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2020,Age,13-17 Years,70.1,63.3 to 76.1,369
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2016,Age,13-17 Years,64.9,58.5 to 70.8,330
HPV,"≥1 Dose, Males and Females",States/Local Areas,Nevada,2017,Age,13-17 Years,64.9,58.3 to 70.9,344
≥1 Dose MenACWY,,States/Local Areas,Nevada,2017,Age,13-15 Years,78.3,70.6 to 84.5,235
≥1 Dose MenACWY,,States/Local Areas,Nevada,2018,Age,13-15 Years,78.4,71.0 to 84.3,201
≥1 Dose MenACWY,,States/Local Areas,Nevada,2019,Age,13-15 Years,87.1,79.5 to 92.1,205
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2013,Age,13-17 Years,38.9,30.1 to 48.4,150
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2012,Age,13-17 Years,44.6,34.7 to 54.9,159
HPV,"≥1 Dose, Males",States/Local Areas,Nevada,2022,Age,13-17 Years,72.0,62.6 to 79.7,142
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2009,Age,13-17 Years,25.6,18.1 to 34.9,159
≥1 Dose MenACWY,,States/Local Areas,Nevada,2020,Age,13-15 Years,86.3,78.3 to 91.6,216
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2010,Age,13-17 Years,38.3,30.1 to 47.2,165
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2011,Age,13-17 Years,39.5,29.3 to 50.7,189
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2010,Age,13-17 Years,80.6,75.4 to 85.0,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2011,Age,13-17 Years,85.8,80.1 to 90.1,412
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2013,Age,13-17 Years,90.1,85.9 to 93.2,335
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2012,Age,13-17 Years,88.5,82.7 to 92.6,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2008,Age,13-17 Years,69.0,61.6 to 75.5,235
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2009,Age,13-17 Years,75.3,69.0 to 80.7,336
≥3 Doses HepB,,States/Local Areas,Nevada,2022,Age,13-17 Years,84.7,78.4 to 89.4,259
≥3 Doses HepB,,States/Local Areas,Nevada,2021,Age,13-17 Years,89.9,84.6 to 93.5,333
≥3 Doses HepB,,States/Local Areas,Nevada,2020,Age,13-17 Years,85.4,79.6 to 89.8,369
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2016,Age,13-17 Years,64.6,55.6 to 72.7,169
HPV,"≥1 Dose, Females",States/Local Areas,Nevada,2017,Age,13-17 Years,70.6,61.6 to 78.3,164
≥1 Dose MenACWY,,States/Local Areas,Nevada,2016,Age,13-15 Years,80.9,73.7 to 86.4,217
HPV,"≥2 Doses, Females",States/Local Areas,Nevada,2008,Age,13-17 Years,22.2,14.5 to 32.4,117
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2015,Age,13-17 Years,89.3,84.4 to 92.8,372
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2014,Age,13-17 Years,89.2,85.2 to 92.2,351
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2016,Age,13-17 Years,88.6,83.4 to 92.3,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Nevada,2017,Age,13-17 Years,84.8,79.1 to 89.1,344
≥1 Dose MenACWY,,States/Local Areas,Nevada,2013,Age,13-15 Years,68.4,60.5 to 75.3,222
≥1 Dose MenACWY,,States/Local Areas,Nevada,2012,Age,13-15 Years,66.5,58.2 to 73.9,207
≥1 Dose MenACWY,,States/Local Areas,Nevada,2014,Age,13-15 Years,65.5,57.8 to 72.5,226
≥1 Dose MenACWY,,States/Local Areas,Nevada,2015,Age,13-15 Years,80.2,73.2 to 85.7,243
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2023,Age,13-17 Years,72.9,62.4 to 81.4,131
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2023,Age,13-17 Years,88.8,82.1 to 93.2,249
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2023,Age,13-17 Years,91.4,85.1 to 95.2,249
≥1 Dose MenACWY,,States/Local Areas,Michigan,2023,Age,13-17 Years,93.5,87.7 to 96.7,249
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2023,Age,13-17 Years,79.6,72.4 to 85.3,249
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2023,Age,13-17 Years,86.6,75.4 to 93.1,118
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2023,Age,13-17 Years,73.2,65.5 to 79.7,249
≥2 Doses MMR,,States/Local Areas,Michigan,2023,Age,13-17 Years,95.3,91.1 to 97.6,249
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2023,Age,13-17 Years,65.7,54.5 to 75.3,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2023,Age,13-17 Years,95.3,91.0 to 97.6,237
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2023,Age,13-17 Years,97.6,94.2 to 99.1,237
≥3 Doses HepB,,States/Local Areas,Michigan,2023,Age,13-17 Years,95.0,90.5 to 97.4,249
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2023,Age,13-17 Years,95.5,91.5 to 97.7,249
≥2 Doses Hep A,,States/Local Areas,Michigan,2023,Age,13-17 Years,94.2,90.1 to 96.6,249
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2023,Age,13-15 Years,88.7,79.1 to 94.3,150
≥1 Dose MenACWY,,States/Local Areas,Michigan,2023,Age,13-15 Years,89.8,79.9 to 95.1,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2023,Age,13-15 Years,64.9,54.3 to 74.2,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2023,Age,13-15 Years,96.6,90.8 to 98.8,144
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2023,Age,13-15 Years,54.4,40.1 to 68.1,76
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2023,Age,13-15 Years,76.3,60.6 to 87.1,74
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2023,Age,13-17 Years,81.1,70.0 to 88.8,118
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2022,Age,13-17 Years,55.1,43.8 to 65.8,130
HPV,"≥2 Doses, Males and Females",States/Local Areas,Michigan,2022,Age,13-17 Years,63.6,55.7 to 70.8,257
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Uninsured,89.7,70.7 to 96.9,32
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Other,93.3,85.0 to 97.2,72
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Any Medicaid,88.4,84.0 to 91.8,449
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Private Insurance Only,91.6,89.1 to 93.5,1070
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Other,47.8,33.2 to 62.7,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Any Medicaid,61.7,55.7 to 67.3,449
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Private Insurance Only,62.6,58.8 to 66.2,1070
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Uninsured,85.8,65.4 to 95.1,32
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Uninsured,73.0,47.9 to 88.9,32
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Other,68.1,53.1 to 80.1,72
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Other,93.4,85.1 to 97.2,72
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Private Insurance Only,75.9,72.5 to 79.0,1070
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Insurance Coverage,Any Medicaid,76.7,71.3 to 81.3,449
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Any Medicaid,92.7,88.6 to 95.3,449
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Insurance Coverage,Private Insurance Only,94.4,92.0 to 96.0,1070
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Poverty,Below Poverty Level,86.7,78.9 to 91.9,204
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Poverty,Living At or Above Poverty Level,91.2,89.2 to 92.9,1363
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Poverty,Living At or Above Poverty Level,60.3,56.9 to 63.7,1363
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Poverty,Below Poverty Level,59.8,51.2 to 67.8,204
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Poverty,Below Poverty Level,90.6,83.6 to 94.8,204
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Poverty,Living At or Above Poverty Level,94.6,92.8 to 96.0,1363
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Poverty,Living At or Above Poverty Level,74.7,71.7 to 77.6,1363
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,Hispanic,78.7,67.7 to 86.7,119
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Poverty,Below Poverty Level,78.8,70.9 to 85.0,204
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"White, Non-Hispanic",74.4,71.1 to 77.4,1210
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",81.1,72.6 to 87.4,139
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.8,84.5 to 94.7,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,Hispanic,81.4,70.1 to 89.2,119
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.8,79.4 to 93.1,139
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,Hispanic,89.6,78.7 to 95.3,119
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.1,93.3 to 96.4,1210
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.3,90.2 to 93.9,1210
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.5,83.6 to 95.8,139
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",55.5,45.7 to 64.9,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,Hispanic,66.4,55.4 to 75.9,119
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",63.6,53.6 to 72.5,139
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",73.5,63.9 to 81.2,155
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.5,80.9 to 94.4,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Principal City,90.7,86.4 to 93.7,450
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Race and Ethnicity,"White, Non-Hispanic",59.9,56.3 to 63.4,1210
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Non-Principal City,91.1,88.4 to 93.3,896
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.5,92.1 to 96.1,896
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Principal City,92.3,87.9 to 95.2,450
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a Non-MSA,92.6,87.6 to 95.7,277
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Non-Principal City,59.7,55.5 to 63.8,896
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Principal City,64.0,58.1 to 69.5,450
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a Non-MSA,55.8,48.2 to 63.2,277
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Non-Principal City,75.6,71.9 to 78.9,896
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a MSA Principal City,76.2,70.8 to 80.9,450
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a Non-MSA,74.6,67.3 to 80.7,277
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018-2022,Overall,Overall,60.5,57.4 to 63.6,1623
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Urbanicity,Living In a Non-MSA,88.4,82.9 to 92.3,277
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018-2022,Overall,Overall,75.7,72.9 to 78.2,1623
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018-2022,Overall,Overall,90.6,88.6 to 92.3,1623
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018-2022,Overall,Overall,93.6,91.7 to 95.0,1623
≥1 Dose MenACWY,,States/Local Areas,Michigan,2022,Age,13-17 Years,91.2,85.2 to 94.9,257
≥2 Doses MMR,,States/Local Areas,Michigan,2022,Age,13-17 Years,93.4,88.0 to 96.5,257
≥2 Doses MMR,,States/Local Areas,Michigan,2021,Age,13-17 Years,88.9,83.0 to 92.9,358
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018,Age,13-17 Years,95.9,92.4 to 97.8,313
≥1 Dose MenACWY,,States/Local Areas,Michigan,2019,Age,13-17 Years,95.4,91.9 to 97.4,297
≥1 Dose MenACWY,,States/Local Areas,Michigan,2021,Age,13-17 Years,89.7,83.6 to 93.7,358
≥1 Dose MenACWY,,States/Local Areas,Michigan,2020,Age,13-17 Years,95.7,92.3 to 97.6,398
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2011,Age,13-15 Years,28.5,19.0 to 40.5,120
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2012,Age,13-15 Years,31.6,20.9 to 44.7,107
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2010,Age,13-15 Years,20.3,12.9 to 30.5,95
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2009,Age,13-15 Years,25.1,16.9 to 35.6,148
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2013,Age,13-15 Years,22.1,13.8 to 33.5,76
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2014,Age,13-15 Years,35.9,25.7 to 47.6,105
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2015,Age,13-15 Years,43.5,32.9 to 54.7,113
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2022,Age,13-17 Years,72.6,62.3 to 80.9,127
HPV,"≥3 Doses, Males and Females",States/Local Areas,Michigan,2014,Age,13-17 Years,31.3,25.4 to 37.8,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Michigan,2015,Age,13-17 Years,37.7,31.9 to 43.9,373
≥2 Doses MMR,,States/Local Areas,Michigan,2020,Age,13-17 Years,94.9,91.1 to 97.1,398
HPV,"≥3 Doses, Males and Females",States/Local Areas,Michigan,2013,Age,13-17 Years,20.8,15.9 to 26.8,307
≥2 Doses MMR,,States/Local Areas,Michigan,2018,Age,13-17 Years,91.0,85.6 to 94.5,313
≥2 Doses MMR,,States/Local Areas,Michigan,2019,Age,13-17 Years,95.2,91.4 to 97.4,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2022,Age,13-17 Years,92.7,88.0 to 95.7,257
≥2 Doses MMR,,States/Local Areas,Michigan,2017,Age,13-17 Years,97.4,94.1 to 98.9,328
≥1 Dose MenACWY,,States/Local Areas,Michigan,2017,Age,13-17 Years,93.5,89.4 to 96.1,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2021,Age,13-17 Years,85.4,79.0 to 90.1,358
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2020,Age,13-17 Years,91.9,87.5 to 94.8,398
HPV,"≥3 Doses, Males and Females",States/Local Areas,Michigan,2011,Age,13-17 Years,15.5,11.6 to 20.6,398
HPV,"≥3 Doses, Males and Females",States/Local Areas,Michigan,2012,Age,13-17 Years,17.6,12.9 to 23.6,368
≥1 Dose MenACWY,,States/Local Areas,Michigan,2013,Age,13-17 Years,90.7,85.9 to 93.9,307
≥1 Dose MenACWY,,States/Local Areas,Michigan,2014,Age,13-17 Years,90.7,86.0 to 94.0,330
≥1 Dose MenACWY,,States/Local Areas,Michigan,2015,Age,13-17 Years,95.0,91.9 to 97.0,373
≥1 Dose MenACWY,,States/Local Areas,Michigan,2016,Age,13-17 Years,95.0,91.8 to 97.0,283
≥2 Doses MMR,,States/Local Areas,Michigan,2015,Age,13-17 Years,95.1,91.5 to 97.2,373
≥2 Doses MMR,,States/Local Areas,Michigan,2014,Age,13-17 Years,92.2,87.0 to 95.4,330
≥2 Doses MMR,,States/Local Areas,Michigan,2016,Age,13-17 Years,96.4,93.6 to 97.9,283
≥2 Doses MMR,,States/Local Areas,Michigan,2013,Age,13-17 Years,94.0,89.6 to 96.6,307
≥2 Doses MMR,,States/Local Areas,Michigan,2012,Age,13-17 Years,95.0,91.2 to 97.2,368
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018,Age,13-17 Years,93.8,89.8 to 96.3,313
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2017,Age,13-17 Years,93.4,89.2 to 96.0,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2019,Age,13-17 Years,89.2,84.2 to 92.8,297
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2016,Age,13-17 Years,93.6,89.4 to 96.2,283
≥1 Dose MenACWY,,States/Local Areas,Michigan,2010,Age,13-17 Years,70.9,64.5 to 76.5,304
≥1 Dose MenACWY,,States/Local Areas,Michigan,2011,Age,13-17 Years,77.9,71.5 to 83.3,398
≥1 Dose MenACWY,,States/Local Areas,Michigan,2008,Age,13-17 Years,39.9,33.9 to 46.2,320
≥1 Dose MenACWY,,States/Local Areas,Michigan,2009,Age,13-17 Years,52.6,47.0 to 58.1,446
≥1 Dose MenACWY,,States/Local Areas,Michigan,2012,Age,13-17 Years,87.5,82.6 to 91.1,368
≥1 Dose MenACWY,,States/Local Areas,Michigan,2022,Age,13-15 Years,92.3,85.1 to 96.2,165
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2008,Age,13-17 Years,13.5,8.5 to 20.7,143
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2009,Age,13-17 Years,22.9,16.6 to 30.7,220
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2010,Age,13-17 Years,25.2,18.1 to 33.9,145
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2013,Age,13-17 Years,34.5,25.8 to 44.4,131
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2014,Age,13-17 Years,40.9,32.2 to 50.2,172
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2011,Age,13-17 Years,31.6,23.7 to 40.8,185
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2012,Age,13-17 Years,32.2,23.7 to 42.1,171
HPV,"≥3 Doses, Females",States/Local Areas,Michigan,2015,Age,13-17 Years,47.2,38.2 to 56.4,168
≥2 Doses Hep A,,States/Local Areas,Michigan,2020,Age,13-17 Years,85.0,80.2 to 88.8,398
≥2 Doses Hep A,,States/Local Areas,Michigan,2021,Age,13-17 Years,84.6,78.4 to 89.2,358
≥2 Doses Hep A,,States/Local Areas,Michigan,2022,Age,13-17 Years,88.1,81.5 to 92.5,257
HPV,"≥3 Doses, Males",States/Local Areas,Michigan,2015,Age,13-15 Years,25.9,18.2 to 35.6,132
HPV,"≥3 Doses, Males",States/Local Areas,Michigan,2014,Age,13-15 Years,20.5,11.9 to 33.1,90
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2019,Age,13-17 Years,95.8,92.0 to 97.9,297
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2017,Age,13-17 Years,96.4,93.0 to 98.1,328
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2016,Age,13-17 Years,96.6,93.9 to 98.1,283
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2018,Age,13-17 Years,94.1,89.7 to 96.7,313
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2010,Age,13-17 Years,81.1,75.6 to 85.7,304
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2009,Age,13-17 Years,74.9,69.8 to 79.3,446
HPV,"≥3 Doses, Males",States/Local Areas,Michigan,2015,Age,13-17 Years,28.6,22.0 to 36.3,205
HPV,"≥3 Doses, Males",States/Local Areas,Michigan,2014,Age,13-17 Years,22.1,15.0 to 31.4,158
HPV,"≥3 Doses, Males",States/Local Areas,Michigan,2013,Age,13-17 Years,7.7,4.3 to 13.6,176
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2008,Age,13-17 Years,77.4,71.7 to 82.2,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2015,Age,13-17 Years,94.2,90.9 to 96.3,373
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2008,Age,13-15 Years,41.0,28.7 to 54.5,76
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2022,Age,13-17 Years,92.6,86.5 to 96.1,257
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2021,Age,13-17 Years,90.2,84.7 to 93.8,358
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2020,Age,13-17 Years,95.6,92.2 to 97.5,398
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2013,Age,13-17 Years,94.1,90.6 to 96.4,307
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2014,Age,13-17 Years,92.2,87.6 to 95.2,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2011,Age,13-17 Years,87.1,81.9 to 91.0,398
Varicella,≥2 Doses or history of disease,States/Local Areas,Michigan,2012,Age,13-17 Years,91.2,86.9 to 94.2,368
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2017,Age,13-15 Years,95.1,88.6 to 98.0,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2016,Age,13-15 Years,96.0,91.1 to 98.2,141
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2018,Age,13-15 Years,96.3,92.6 to 98.2,177
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2021,Age,13-15 Years,90.1,81.8 to 94.8,216
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2020,Age,13-15 Years,96.2,92.1 to 98.2,215
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2011,Age,13-15 Years,85.0,77.4 to 90.3,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2010,Age,13-15 Years,69.3,58.6 to 78.3,125
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2013,Age,13-15 Years,91.5,85.1 to 95.3,142
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2012,Age,13-15 Years,90.2,83.0 to 94.6,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2014,Age,13-15 Years,90.2,82.9 to 94.6,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2015,Age,13-15 Years,93.8,89.0 to 96.6,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2015,Age,13-17 Years,93.2,89.4 to 95.7,321
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2016,Age,13-17 Years,96.0,92.8 to 97.8,241
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2014,Age,13-17 Years,90.5,85.1 to 94.1,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2017,Age,13-17 Years,97.8,94.6 to 99.1,285
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2011,Age,13-17 Years,55.6,45.6 to 65.1,185
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2010,Age,13-17 Years,49.4,39.6 to 59.3,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2017,Age,13-17 Years,95.8,92.0 to 97.9,285
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2009,Age,13-15 Years,49.8,40.7 to 58.8,170
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2015,Age,13-17 Years,67.6,58.9 to 75.3,168
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2014,Age,13-17 Years,58.0,48.7 to 66.7,172
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2013,Age,13-17 Years,66.0,56.4 to 74.4,131
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2012,Age,13-17 Years,48.1,38.6 to 57.7,171
≥3 Doses HepB,,States/Local Areas,Michigan,2015,Age,13-17 Years,94.8,91.2 to 97.0,373
≥3 Doses HepB,,States/Local Areas,Michigan,2016,Age,13-17 Years,96.9,94.3 to 98.3,283
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2015,Age,13-17 Years,74.0,68.1 to 79.2,373
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2022,Age,13-17 Years,62.2,54.3 to 69.6,257
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2021,Age,13-17 Years,64.7,57.6 to 71.2,358
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2020,Age,13-17 Years,61.3,55.1 to 67.2,398
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2019,Age,13-17 Years,59.4,52.3 to 66.2,297
≥2 Doses MMR,,States/Local Areas,Michigan,2010,Age,13-17 Years,93.6,88.7 to 96.5,304
≥2 Doses MMR,,States/Local Areas,Michigan,2011,Age,13-17 Years,94.3,91.1 to 96.4,398
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2011,Age,13-17 Years,71.0,64.1 to 77.0,398
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2010,Age,13-17 Years,66.2,59.7 to 72.3,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2009,Age,13-17 Years,46.2,40.8 to 51.8,446
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2008,Age,13-17 Years,33.6,27.9 to 39.8,320
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2022,Age,13-15 Years,91.4,84.4 to 95.4,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2016,Age,13-17 Years,44.8,37.9 to 51.9,283
≥2 Doses MMR,,States/Local Areas,Michigan,2008,Age,13-17 Years,94.6,91.4 to 96.7,320
≥2 Doses MMR,,States/Local Areas,Michigan,2009,Age,13-17 Years,93.0,89.0 to 95.6,446
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2019,Age,13-17 Years,63.7,53.9 to 72.4,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2013,Age,13-17 Years,81.0,75.3 to 85.7,307
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2014,Age,13-17 Years,79.3,73.3 to 84.2,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2012,Age,13-17 Years,84.2,78.8 to 88.4,368
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2017,Age,13-17 Years,54.3,47.9 to 60.6,328
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2018,Age,13-17 Years,55.0,48.3 to 61.6,313
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2019,Age,13-15 Years,88.6,80.9 to 93.5,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2020,Age,13-15 Years,93.2,87.3 to 96.4,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2021,Age,13-15 Years,84.7,76.2 to 90.6,225
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2018,Age,13-15 Years,95.8,90.2 to 98.3,192
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2016,Age,13-17 Years,40.5,31.5 to 50.2,139
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2017,Age,13-17 Years,52.8,43.7 to 61.8,161
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2018,Age,13-17 Years,58.2,49.0 to 66.8,176
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2013,Age,13-17 Years,16.8,11.1 to 24.6,176
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2014,Age,13-17 Years,31.9,23.5 to 41.5,158
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2013,Age,13-15 Years,86.4,79.8 to 91.1,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2014,Age,13-15 Years,74.8,66.5 to 81.7,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2015,Age,13-15 Years,69.7,61.9 to 76.6,245
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2016,Age,13-15 Years,93.7,87.2 to 97.0,162
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2017,Age,13-15 Years,90.7,83.6 to 94.9,183
HPV,"≥2 Doses, Males",States/Local Areas,Michigan,2015,Age,13-17 Years,40.2,32.4 to 48.6,205
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2019,Age,13-17 Years,57.8,47.5 to 67.5,151
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2009,Age,13-15 Years,52.8,45.9 to 59.7,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2010,Age,13-15 Years,70.0,61.4 to 77.4,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2008,Age,13-15 Years,36.7,28.9 to 45.3,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2011,Age,13-15 Years,76.5,68.6 to 82.9,248
Tetanus,≥1 Dose Tdap,States/Local Areas,Michigan,2012,Age,13-15 Years,85.0,77.4 to 90.3,222
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2018,Age,13-17 Years,62.5,52.5 to 71.6,137
≥1 Dose MenACWY,,States/Local Areas,Michigan,2021,Age,13-15 Years,89.0,80.6 to 94.0,225
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2014,Age,13-17 Years,50.9,41.7 to 60.0,172
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2015,Age,13-17 Years,56.9,47.8 to 65.5,168
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2016,Age,13-17 Years,59.7,49.7 to 68.9,144
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2017,Age,13-17 Years,63.5,54.6 to 71.6,167
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2019,Age,13-17 Years,94.0,90.4 to 96.3,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2020,Age,13-17 Years,94.9,91.3 to 97.0,398
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2018,Age,13-17 Years,94.7,90.8 to 97.0,313
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2019,Age,13-15 Years,95.4,89.3 to 98.1,165
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2019,Age,13-17 Years,97.3,93.6 to 98.9,269
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2018,Age,13-17 Years,93.5,88.8 to 96.4,286
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2020,Age,13-17 Years,96.2,92.6 to 98.0,374
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2019,Age,13-17 Years,95.5,91.3 to 97.7,269
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2021,Age,13-17 Years,89.4,83.6 to 93.3,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2020,Age,13-17 Years,95.2,91.6 to 97.3,374
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2013,Age,13-17 Years,97.6,94.3 to 99.0,231
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2014,Age,13-17 Years,96.8,93.4 to 98.5,270
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2015,Age,13-17 Years,95.7,92.2 to 97.7,321
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2016,Age,13-17 Years,98.3,96.1 to 99.3,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2018,Age,13-17 Years,94.9,90.2 to 97.4,286
≥3 Doses HepB,,States/Local Areas,Michigan,2017,Age,13-17 Years,96.2,92.6 to 98.1,328
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2013,Age,13-17 Years,92.2,87.5 to 95.2,231
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2012,Age,13-17 Years,87.4,81.5 to 91.7,260
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2009,Age,13-17 Years,39.0,31.5 to 47.1,220
≥3 Doses HepB,,States/Local Areas,Michigan,2018,Age,13-17 Years,91.6,86.4 to 94.9,313
≥3 Doses HepB,,States/Local Areas,Michigan,2019,Age,13-17 Years,92.9,87.7 to 96.0,297
≥3 Doses HepB,,States/Local Areas,Michigan,2013,Age,13-17 Years,94.5,90.7 to 96.8,307
≥3 Doses HepB,,States/Local Areas,Michigan,2014,Age,13-17 Years,93.2,88.1 to 96.2,330
≥3 Doses HepB,,States/Local Areas,Michigan,2011,Age,13-17 Years,95.9,93.1 to 97.6,398
≥3 Doses HepB,,States/Local Areas,Michigan,2012,Age,13-17 Years,93.3,88.6 to 96.2,368
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2008,Age,13-17 Years,32.3,23.8 to 42.1,143
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2008,Age,13-17 Years,86.8,77.6 to 92.5,112
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2010,Age,13-17 Years,97.4,93.4 to 99.0,172
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2009,Age,13-17 Years,93.5,88.2 to 96.5,217
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2009,Age,13-17 Years,47.7,39.9 to 55.7,217
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2008,Age,13-17 Years,38.8,28.8 to 49.9,112
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2011,Age,13-17 Years,95.3,88.7 to 98.1,275
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2012,Age,13-17 Years,97.2,92.9 to 98.9,260
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2010,Age,13-17 Years,64.3,55.5 to 72.2,172
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2011,Age,13-17 Years,80.3,72.9 to 86.1,275
≥3 Doses HepB,,States/Local Areas,Michigan,2010,Age,13-17 Years,94.6,90.1 to 97.1,304
≥3 Doses HepB,,States/Local Areas,Michigan,2009,Age,13-17 Years,91.4,86.9 to 94.5,446
≥3 Doses HepB,,States/Local Areas,Michigan,2008,Age,13-17 Years,92.8,89.3 to 95.2,320
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2022,Age,13-15 Years,92.7,83.3 to 97.0,154
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2021,Age,13-17 Years,77.2,67.6 to 84.6,179
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2020,Age,13-17 Years,75.9,68.1 to 82.2,219
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2017,Age,13-17 Years,63.8,54.6 to 72.2,161
HPV,"≥2 Doses, Males and Females",States/Local Areas,Michigan,2019,Age,13-17 Years,60.8,53.7 to 67.5,297
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2013,Age,13-17 Years,30.0,22.6 to 38.6,176
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2014,Age,13-17 Years,39.8,30.8 to 49.6,158
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2015,Age,13-17 Years,52.3,43.9 to 60.4,205
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2016,Age,13-17 Years,52.5,42.6 to 62.2,139
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2009,Age,13-17 Years,29.2,22.4 to 37.1,220
≥1 Dose MenACWY,,States/Local Areas,Michigan,2020,Age,13-15 Years,96.8,93.3 to 98.5,230
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2010,Age,13-17 Years,39.1,30.1 to 48.9,145
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2011,Age,13-17 Years,48.2,38.6 to 57.9,185
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2013,Age,13-17 Years,49.4,39.7 to 59.3,131
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2012,Age,13-17 Years,39.2,30.1 to 49.1,171
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2008,Age,13-17 Years,69.9,63.9 to 75.3,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2009,Age,13-17 Years,69.3,64.0 to 74.2,446
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2019,Age,13-17 Years,73.7,67.3 to 79.2,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2022,Age,13-17 Years,94.4,89.9 to 97.0,257
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2021,Age,13-17 Years,91.5,86.2 to 94.9,358
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2022,Age,13-17 Years,76.3,69.1 to 82.3,257
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2021,Age,13-17 Years,79.0,72.6 to 84.2,358
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2020,Age,13-17 Years,76.9,71.4 to 81.7,398
≥1 Dose MenACWY,,States/Local Areas,Michigan,2017,Age,13-15 Years,91.1,84.4 to 95.1,183
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2010,Age,13-17 Years,81.6,76.1 to 86.2,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2011,Age,13-17 Years,81.7,75.3 to 86.7,398
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2013,Age,13-17 Years,88.7,83.8 to 92.2,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2012,Age,13-17 Years,87.9,82.7 to 91.6,368
≥1 Dose MenACWY,,States/Local Areas,Michigan,2011,Age,13-15 Years,81.2,73.8 to 86.8,248
≥1 Dose MenACWY,,States/Local Areas,Michigan,2010,Age,13-15 Years,73.8,65.8 to 80.5,193
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2019,Age,13-17 Years,75.2,66.5 to 82.2,146
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2022,Age,13-17 Years,70.5,59.5 to 79.6,130
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2022,Age,13-17 Years,82.5,72.8 to 89.2,127
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2021,Age,13-17 Years,80.8,71.7 to 87.5,179
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2020,Age,13-17 Years,78.1,69.6 to 84.7,179
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2019,Age,13-17 Years,72.2,62.4 to 80.2,151
HPV,"≥2 Doses, Males and Females",States/Local Areas,Michigan,2018,Age,13-17 Years,60.3,53.5 to 66.7,313
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2018,Age,13-17 Years,68.6,59.5 to 76.6,176
HPV,"≥2 Doses, Males and Females",States/Local Areas,Michigan,2016,Age,13-17 Years,49.9,42.9 to 56.9,283
HPV,"≥2 Doses, Males and Females",States/Local Areas,Michigan,2017,Age,13-17 Years,58.1,51.6 to 64.2,328
HPV,"≥1 Dose, Males",States/Local Areas,Michigan,2012,Age,13-17 Years,13.1,7.6 to 21.6,197
≥3 Doses HepB,,States/Local Areas,Michigan,2022,Age,13-17 Years,93.5,87.9 to 96.6,257
≥3 Doses HepB,,States/Local Areas,Michigan,2021,Age,13-17 Years,90.6,85.3 to 94.1,358
≥3 Doses HepB,,States/Local Areas,Michigan,2020,Age,13-17 Years,96.0,92.9 to 97.8,398
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2022,Age,13-17 Years,95.6,89.7 to 98.2,239
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2016,Age,13-17 Years,70.5,60.9 to 78.7,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Michigan,2022,Age,13-17 Years,92.0,85.5 to 95.8,239
Varicella,≥1 Dose with no disease history,States/Local Areas,Michigan,2021,Age,13-17 Years,93.1,88.1 to 96.0,338
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2017,Age,13-17 Years,71.0,62.5 to 78.2,167
HPV,"≥1 Dose, Females",States/Local Areas,Michigan,2018,Age,13-17 Years,76.4,67.1 to 83.8,137
HPV,"≥2 Doses, Females",States/Local Areas,Michigan,2008,Age,13-17 Years,22.1,15.5 to 30.5,143
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2015,Age,13-17 Years,76.1,70.3 to 81.1,373
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2014,Age,13-17 Years,82.1,76.5 to 86.6,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2016,Age,13-17 Years,95.5,92.4 to 97.3,283
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Michigan,2017,Age,13-17 Years,94.6,90.6 to 97.0,328
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2018,Age,13-17 Years,72.5,66.0 to 78.1,313
≥1 Dose MenACWY,,States/Local Areas,Michigan,2009,Age,13-15 Years,55.6,48.6 to 62.3,292
≥1 Dose MenACWY,,States/Local Areas,Michigan,2008,Age,13-15 Years,39.1,31.1 to 47.8,169
≥1 Dose MenACWY,,States/Local Areas,Michigan,2018,Age,13-15 Years,95.9,90.4 to 98.3,192
≥1 Dose MenACWY,,States/Local Areas,Michigan,2019,Age,13-15 Years,95.7,90.0 to 98.2,178
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2016,Age,13-17 Years,61.3,54.2 to 67.9,283
HPV,"≥1 Dose, Males and Females",States/Local Areas,Michigan,2017,Age,13-17 Years,67.3,61.1 to 73.0,328
≥1 Dose MenACWY,,States/Local Areas,Michigan,2013,Age,13-15 Years,94.6,90.2 to 97.1,175
≥1 Dose MenACWY,,States/Local Areas,Michigan,2012,Age,13-15 Years,89.4,83.3 to 93.4,222
≥1 Dose MenACWY,,States/Local Areas,Michigan,2016,Age,13-15 Years,94.2,89.3 to 96.9,162
≥1 Dose MenACWY,,States/Local Areas,Michigan,2014,Age,13-15 Years,88.6,80.9 to 93.4,195
≥1 Dose MenACWY,,States/Local Areas,Michigan,2015,Age,13-15 Years,94.3,89.3 to 97.0,245
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2023,Age,13-15 Years,97.2,91.5 to 99.1,135
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2023,Age,13-15 Years,58.9,44.9 to 71.7,79
HPV,"Up-to-Date, Females",States/Local Areas,Iowa,2023,Age,13-17 Years,69.8,59.1 to 78.6,136
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2023,Age,13-15 Years,67.6,53.3 to 79.2,70
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2023,Age,13-15 Years,63.2,53.2 to 72.2,149
≥1 Dose MenACWY,,States/Local Areas,Iowa,2023,Age,13-15 Years,92.7,86.2 to 96.3,149
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2023,Age,13-15 Years,94.2,88.7 to 97.1,149
≥2 Doses Hep A,,States/Local Areas,Iowa,2023,Age,13-17 Years,85.9,79.7 to 90.5,248
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2023,Age,13-17 Years,96.0,92.0 to 98.1,248
≥3 Doses HepB,,States/Local Areas,Iowa,2023,Age,13-17 Years,94.3,89.8 to 96.9,248
Varicella,History of disease,States/Local Areas,Iowa,2023,Age,13-17 Years,6.1,3.4 to 10.7,248
Varicella,≥1 Dose with no disease history,States/Local Areas,Iowa,2023,Age,13-17 Years,96.1,91.8 to 98.2,232
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2023,Age,13-17 Years,95.8,91.5 to 98.0,232
HPV,"Up-to-Date, Males",States/Local Areas,Iowa,2023,Age,13-17 Years,66.6,54.9 to 76.6,112
≥2 Doses MMR,,States/Local Areas,Iowa,2023,Age,13-17 Years,94.8,90.6 to 97.2,248
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2023,Age,13-17 Years,68.2,60.3 to 75.1,248
HPV,"≥1 Dose, Females",States/Local Areas,Iowa,2023,Age,13-17 Years,86.1,77.3 to 91.8,136
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2023,Age,13-17 Years,84.4,78.2 to 89.2,248
≥1 Dose MenACWY,,States/Local Areas,Iowa,2023,Age,13-17 Years,92.2,86.5 to 95.6,248
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2023,Age,13-17 Years,92.7,87.4 to 95.9,248
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Iowa,2023,Age,13-17 Years,93.5,88.1 to 96.6,248
HPV,"≥1 Dose, Males",States/Local Areas,Iowa,2023,Age,13-17 Years,82.9,73.1 to 89.6,112
HPV,"≥2 Doses, Males and Females",States/Local Areas,Iowa,2022,Age,13-17 Years,75.9,68.1 to 82.3,207
HPV,"≥2 Doses, Males",States/Local Areas,Iowa,2022,Age,13-17 Years,75.4,65.3 to 83.4,119
≥2 Doses MMR,,States/Local Areas,Iowa,2021,Age,13-17 Years,97.7,95.2 to 98.9,199
≥2 Doses MMR,,States/Local Areas,Iowa,2022,Age,13-17 Years,95.0,90.3 to 97.5,207
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018,Age,13-17 Years,89.2,83.9 to 92.9,280
≥1 Dose MenACWY,,States/Local Areas,Iowa,2019,Age,13-17 Years,93.6,89.8 to 96.1,302
≥1 Dose MenACWY,,States/Local Areas,Iowa,2020,Age,13-17 Years,90.7,86.1 to 93.9,280
≥1 Dose MenACWY,,States/Local Areas,Iowa,2021,Age,13-17 Years,95.0,88.7 to 97.9,199
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2012,Age,13-15 Years,22.4,13.9 to 34.0,88
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2011,Age,13-15 Years,30.1,19.5 to 43.4,100
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2010,Age,13-15 Years,33.0,23.2 to 44.6,83
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2009,Age,13-15 Years,32.7,23.2 to 43.8,105
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2008,Age,13-15 Years,27.0,15.8 to 42.2,63
≥1 Dose MenACWY,,States/Local Areas,Iowa,2022,Age,13-17 Years,97.9,94.0 to 99.3,207
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Overall,Overall,63.6,60.3 to 66.8,1268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Overall,Overall,78.1,75.2 to 80.7,1268
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a Non-MSA,93.2,90.3 to 95.2,444
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Principal City,80.8,75.8 to 84.9,393
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Non-Principal City,78.8,73.5 to 83.3,431
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a Non-MSA,74.0,69.0 to 78.4,444
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Principal City,64.9,58.9 to 70.5,393
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Non-Principal City,66.8,61.2 to 72.0,431
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a Non-MSA,58.0,52.5 to 63.4,444
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Principal City,94.2,90.7 to 96.4,393
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.4,91.0 to 96.6,431
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a Non-MSA,91.0,87.6 to 93.6,444
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"White, Non-Hispanic",62.7,58.9 to 66.2,1024
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Principal City,94.0,90.2 to 96.4,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.2,91.0 to 96.3,431
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",97.8,93.4 to 99.3,88
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",83.8,72.5 to 91.0,88
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,Hispanic,66.6,55.9 to 75.9,119
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",57.5,39.4 to 73.8,37
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",73.5,61.7 to 82.7,88
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.2,91.1 to 94.8,1024
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.4,91.3 to 95.0,1024
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.5,69.5 to 94.7,37
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,Hispanic,94.5,86.7 to 97.8,119
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,Hispanic,96.4,91.4 to 98.5,119
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",94.1,81.7 to 98.3,37
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",95.4,89.4 to 98.1,88
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"White, Non-Hispanic",77.1,73.8 to 80.1,1024
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",75.5,58.0 to 87.3,37
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Race and Ethnicity,Hispanic,83.3,73.6 to 89.9,119
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Poverty,Below Poverty Level,81.6,73.0 to 88.0,147
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Poverty,Living At or Above Poverty Level,77.5,74.4 to 80.4,1087
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Poverty,Living At or Above Poverty Level,93.7,91.8 to 95.2,1087
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Poverty,Below Poverty Level,92.5,85.7 to 96.2,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Poverty,Living At or Above Poverty Level,64.1,60.6 to 67.5,1087
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Poverty,Below Poverty Level,59.3,49.3 to 68.6,147
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Poverty,Living At or Above Poverty Level,94.1,92.2 to 95.6,1087
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Poverty,Below Poverty Level,92.5,85.9 to 96.2,147
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Insurance Coverage,Any Medicaid,91.0,86.8 to 94.0,373
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Insurance Coverage,Private Insurance Only,94.7,92.6 to 96.3,769
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Insurance Coverage,Other,95.2,90.1 to 97.8,103
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Insurance Coverage,Any Medicaid,76.5,71.0 to 81.2,373
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Insurance Coverage,Private Insurance Only,79.1,75.3 to 82.4,769
HPV,"≥1 Dose, Males and Females",States/Local Areas,Iowa,2018-2022,Insurance Coverage,Other,79.9,70.5 to 86.8,103
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Insurance Coverage,Private Insurance Only,65.5,61.2 to 69.5,769
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Insurance Coverage,Any Medicaid,60.1,53.9 to 65.9,373
HPV,"Up-to-Date, Males and Females",States/Local Areas,Iowa,2018-2022,Insurance Coverage,Other,68.9,58.2 to 77.9,103
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Insurance Coverage,Private Insurance Only,96.0,94.2 to 97.3,769
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Insurance Coverage,Any Medicaid,91.3,86.9 to 94.3,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Insurance Coverage,Other,91.2,84.2 to 95.3,103
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2013,Age,13-15 Years,33.3,24.2 to 43.8,122
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2014,Age,13-15 Years,28.5,18.5 to 41.3,82
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2015,Age,13-15 Years,39.9,30.0 to 50.6,121
HPV,"≥2 Doses, Females",States/Local Areas,Iowa,2022,Age,13-17 Years,76.3,63.7 to 85.6,88
≥2 Doses MMR,,States/Local Areas,Iowa,2012,Age,13-17 Years,91.5,86.7 to 94.7,325
≥2 Doses MMR,,States/Local Areas,Iowa,2013,Age,13-17 Years,90.2,85.5 to 93.5,383
HPV,"≥3 Doses, Males and Females",States/Local Areas,Iowa,2012,Age,13-17 Years,21.8,16.7 to 27.9,325
HPV,"≥3 Doses, Males and Females",States/Local Areas,Iowa,2011,Age,13-17 Years,20.4,15.1 to 26.9,359
≥1 Dose MenACWY,,States/Local Areas,Iowa,2016,Age,13-17 Years,74.9,69.4 to 79.7,382
≥1 Dose MenACWY,,States/Local Areas,Iowa,2015,Age,13-17 Years,75.0,69.3 to 79.9,383
≥1 Dose MenACWY,,States/Local Areas,Iowa,2013,Age,13-17 Years,63.6,57.6 to 69.3,383
≥1 Dose MenACWY,,States/Local Areas,Iowa,2014,Age,13-17 Years,64.4,57.3 to 71.0,328
HPV,"≥3 Doses, Males and Females",States/Local Areas,Iowa,2013,Age,13-17 Years,27.4,22.3 to 33.2,383
≥2 Doses MMR,,States/Local Areas,Iowa,2020,Age,13-17 Years,95.2,92.2 to 97.1,280
HPV,"≥3 Doses, Males and Females",States/Local Areas,Iowa,2015,Age,13-17 Years,36.6,30.9 to 42.7,383
HPV,"≥3 Doses, Males and Females",States/Local Areas,Iowa,2014,Age,13-17 Years,27.9,22.4 to 34.2,328
≥2 Doses MMR,,States/Local Areas,Iowa,2018,Age,13-17 Years,96.0,92.9 to 97.8,280
≥2 Doses MMR,,States/Local Areas,Iowa,2019,Age,13-17 Years,96.4,92.2 to 98.4,302
≥2 Doses MMR,,States/Local Areas,Iowa,2017,Age,13-17 Years,96.0,93.4 to 97.6,343
≥2 Doses MMR,,States/Local Areas,Iowa,2016,Age,13-17 Years,94.0,90.9 to 96.0,382
≥2 Doses MMR,,States/Local Areas,Iowa,2015,Age,13-17 Years,94.4,91.3 to 96.5,383
≥2 Doses MMR,,States/Local Areas,Iowa,2014,Age,13-17 Years,94.2,90.5 to 96.5,328
≥1 Dose MenACWY,,States/Local Areas,Iowa,2017,Age,13-17 Years,83.6,78.4 to 87.7,343
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2020,Age,13-17 Years,91.4,87.3 to 94.3,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2021,Age,13-17 Years,92.3,86.1 to 95.9,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2022,Age,13-17 Years,97.3,91.0 to 99.2,207
≥1 Dose MenACWY,,States/Local Areas,Iowa,2018-2022,Overall,Overall,93.3,91.5 to 94.8,1268
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018-2022,Overall,Overall,93.9,92.1 to 95.2,1268
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2018,Age,13-17 Years,94.0,90.3 to 96.3,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2017,Age,13-17 Years,93.4,89.8 to 95.8,343
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2019,Age,13-17 Years,94.1,90.6 to 96.3,302
≥2 Doses Hep A,,States/Local Areas,Iowa,2020,Age,13-17 Years,68.7,62.2 to 74.5,280
≥1 Dose MenACWY,,States/Local Areas,Iowa,2010,Age,13-17 Years,53.7,47.1 to 60.3,264
≥1 Dose MenACWY,,States/Local Areas,Iowa,2011,Age,13-17 Years,60.5,53.6 to 67.0,359
≥1 Dose MenACWY,,States/Local Areas,Iowa,2008,Age,13-17 Years,31.9,26.4 to 38.0,308
≥1 Dose MenACWY,,States/Local Areas,Iowa,2009,Age,13-17 Years,46.4,40.4 to 52.6,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Iowa,2016,Age,13-17 Years,89.2,85.0 to 92.2,382
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2010,Age,13-17 Years,36.2,27.8 to 45.5,128
≥1 Dose MenACWY,,States/Local Areas,Iowa,2012,Age,13-17 Years,64.4,57.4 to 70.8,325
≥1 Dose MenACWY,,States/Local Areas,Iowa,2022,Age,13-15 Years,96.7,90.4 to 98.9,131
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2011,Age,13-17 Years,40.7,31.0 to 51.1,169
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2015,Age,13-17 Years,49.8,41.3 to 58.3,190
≥2 Doses Hep A,,States/Local Areas,Iowa,2021,Age,13-17 Years,86.5,79.9 to 91.2,199
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2008,Age,13-17 Years,26.8,18.7 to 36.7,127
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2009,Age,13-17 Years,32.7,25.2 to 41.1,174
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2012,Age,13-17 Years,35.6,26.9 to 45.3,151
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2013,Age,13-17 Years,41.9,33.4 to 50.9,183
HPV,"≥3 Doses, Females",States/Local Areas,Iowa,2014,Age,13-17 Years,37.6,28.8 to 47.2,157
≥2 Doses Hep A,,States/Local Areas,Iowa,2022,Age,13-17 Years,86.6,80.2 to 91.1,207
HPV,"≥3 Doses, Males",States/Local Areas,Iowa,2013,Age,13-15 Years,14.4,8.8 to 22.6,135
HPV,"≥3 Doses, Males",States/Local Areas,Iowa,2015,Age,13-15 Years,20.8,13.6 to 30.3,131
HPV,"≥3 Doses, Males",States/Local Areas,Iowa,2014,Age,13-15 Years,20.0,12.1 to 31.2,96
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2020,Age,13-15 Years,96.6,93.1 to 98.4,151
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2021,Age,13-15 Years,96.4,91.7 to 98.5,120
HPV,"≥3 Doses, Males",States/Local Areas,Iowa,2013,Age,13-17 Years,13.7,9.1 to 20.1,200
HPV,"≥3 Doses, Males",States/Local Areas,Iowa,2015,Age,13-17 Years,23.9,17.5 to 31.9,193
HPV,"≥3 Doses, Males",States/Local Areas,Iowa,2014,Age,13-17 Years,18.7,12.5 to 27.2,171
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2010,Age,13-17 Years,76.7,70.5 to 81.9,264
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2009,Age,13-17 Years,76.1,70.1 to 81.2,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2014,Age,13-15 Years,79.2,70.2 to 86.1,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2015,Age,13-15 Years,81.8,74.8 to 87.2,219
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2019,Age,13-15 Years,97.0,93.6 to 98.6,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2017,Age,13-15 Years,94.3,88.5 to 97.3,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2016,Age,13-15 Years,85.6,79.0 to 90.4,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2018,Age,13-15 Years,96.9,91.7 to 98.9,152
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2017,Age,13-17 Years,90.5,86.2 to 93.5,343
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2016,Age,13-17 Years,85.6,81.1 to 89.1,382
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2018,Age,13-17 Years,94.9,90.9 to 97.1,280
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2015,Age,13-17 Years,83.5,78.4 to 87.5,383
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2020,Age,13-17 Years,96.6,93.8 to 98.1,280
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2021,Age,13-17 Years,97.3,94.5 to 98.7,199
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2022,Age,13-17 Years,96.1,91.6 to 98.2,207
Varicella,≥2 Doses with no disease history,States/Local Areas,Iowa,2008,Age,13-15 Years,30.7,18.9 to 45.7,58
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2019,Age,13-17 Years,97.1,94.7 to 98.4,302
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2012,Age,13-17 Years,78.8,72.9 to 83.7,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2011,Age,13-17 Years,77.0,70.8 to 82.2,359
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2013,Age,13-17 Years,74.8,69.0 to 79.8,383
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2014,Age,13-17 Years,79.1,73.0 to 84.2,328
Varicella,≥2 Doses or history of disease,States/Local Areas,Iowa,2008,Age,13-17 Years,76.9,71.0 to 81.9,308
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2023,Age,13-17 Years,75.6,65.7 to 83.3,161
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Uninsured,95.9,88.0 to 98.7,38
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Other,91.7,82.3 to 96.3,67
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Any Medicaid,92.6,89.8 to 94.7,748
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Private Insurance Only,93.2,90.6 to 95.2,756
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Other,44.0,29.7 to 59.3,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Uninsured,38.5,22.4 to 57.7,38
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Any Medicaid,69.0,64.6 to 73.0,748
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Private Insurance Only,48.5,43.9 to 53.2,756
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Uninsured,93.8,83.4 to 97.9,38
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Uninsured,57.4,37.1 to 75.5,38
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Other,73.1,58.3 to 84.1,67
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Private Insurance Only,66.3,61.9 to 70.5,756
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Any Medicaid,82.5,78.7 to 85.6,748
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Other,91.6,81.8 to 96.4,67
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Any Medicaid,89.8,86.6 to 92.2,748
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Insurance Coverage,Private Insurance Only,90.6,87.5 to 93.0,756
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Poverty,Below Poverty Level,90.0,84.8 to 93.5,315
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Poverty,Living At or Above Poverty Level,94.1,92.2 to 95.5,1221
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Poverty,Living At or Above Poverty Level,55.7,52.0 to 59.4,1221
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Poverty,Below Poverty Level,71.3,64.8 to 77.1,315
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Poverty,Below Poverty Level,89.1,83.7 to 92.9,315
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Poverty,Living At or Above Poverty Level,91.4,89.2 to 93.2,1221
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Poverty,Living At or Above Poverty Level,72.5,69.2 to 75.6,1221
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Poverty,Below Poverty Level,84.9,79.3 to 89.2,315
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,Hispanic,74.0,63.9 to 82.1,133
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.3,79.4 to 88.2,318
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.0,64.1 to 71.7,1006
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",93.5,87.8 to 96.6,152
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.7,87.8 to 94.5,318
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,Hispanic,89.9,78.7 to 95.6,133
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,Hispanic,87.4,78.6 to 92.9,133
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.0,84.5 to 92.3,318
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.3,88.8 to 93.3,1006
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.0,91.9 to 95.6,1006
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",71.8,62.2 to 79.7,152
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",70.6,64.7 to 75.8,318
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,Hispanic,64.8,54.2 to 74.1,133
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",84.2,75.7 to 90.1,152
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.3,84.0 to 95.4,152
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.1,90.3 to 95.1,737
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Principal City,93.0,90.0 to 95.1,646
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",49.2,45.3 to 53.2,1006
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a Non-MSA,91.8,86.0 to 95.3,226
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,88.4,84.9 to 91.3,737
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Principal City,91.6,88.6 to 93.9,646
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a Non-MSA,59.2,50.6 to 67.2,226
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,59.5,54.8 to 64.1,737
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Principal City,59.9,55.0 to 64.7,646
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a Non-MSA,77.0,69.7 to 83.0,226
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.4,70.1 to 78.4,737
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a MSA Principal City,76.2,71.9 to 80.0,646
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Urbanicity,Living In a Non-MSA,91.7,85.4 to 95.4,226
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018-2022,Overall,Overall,59.7,56.5 to 62.7,1609
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018-2022,Overall,Overall,75.5,72.8 to 78.1,1609
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018-2022,Overall,Overall,92.9,91.1 to 94.3,1609
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018-2022,Overall,Overall,90.2,88.2 to 92.0,1609
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2023,Age,13-17 Years,91.5,85.7 to 95.1,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2023,Age,13-17 Years,91.3,85.6 to 95.0,329
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2023,Age,13-17 Years,89.5,83.7 to 93.4,329
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2023,Age,13-17 Years,78.1,71.7 to 83.3,329
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2023,Age,13-17 Years,80.7,72.0 to 87.1,168
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2023,Age,13-17 Years,66.2,59.3 to 72.5,329
≥2 Doses MMR,,States/Local Areas,Louisiana,2023,Age,13-17 Years,93.5,89.1 to 96.3,329
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2023,Age,13-17 Years,65.6,55.5 to 74.4,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2023,Age,13-17 Years,95.1,91.1 to 97.4,313
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2023,Age,13-17 Years,96.4,92.3 to 98.3,313
≥3 Doses HepB,,States/Local Areas,Louisiana,2023,Age,13-17 Years,91.6,86.3 to 95.0,329
Varicella,History of disease,States/Local Areas,Louisiana,2023,Age,13-17 Years,6.9,3.9 to 12.0,329
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2023,Age,13-17 Years,95.4,91.7 to 97.5,329
≥2 Doses Hep A,,States/Local Areas,Louisiana,2023,Age,13-17 Years,91.7,86.6 to 95.0,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2023,Age,13-15 Years,87.9,78.9 to 93.4,190
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2023,Age,13-15 Years,86.6,77.9 to 92.2,190
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2023,Age,13-15 Years,58.1,48.5 to 67.1,190
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2023,Age,13-15 Years,94.1,87.1 to 97.4,180
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2023,Age,13-15 Years,61.9,48.9 to 73.4,98
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2023,Age,13-17 Years,66.8,57.1 to 75.3,168
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2023,Age,13-15 Years,53.0,39.3 to 66.3,92
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2022,Age,13-17 Years,66.2,56.8 to 74.5,161
HPV,"≥2 Doses, Males and Females",States/Local Areas,Louisiana,2022,Age,13-17 Years,69.5,62.8 to 75.4,330
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2022,Age,13-17 Years,72.9,63.3 to 80.8,169
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2020,Age,13-17 Years,90.1,84.9 to 93.7,356
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2021,Age,13-17 Years,82.6,74.7 to 88.4,174
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2020,Age,13-17 Years,73.5,64.7 to 80.8,185
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2018,Age,13-17 Years,64.0,54.4 to 72.7,160
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2012,Age,13-17 Years,20.6,13.6 to 29.9,184
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2019,Age,13-17 Years,71.4,61.3 to 79.8,174
HPV,"≥2 Doses, Males and Females",States/Local Areas,Louisiana,2018,Age,13-17 Years,52.0,44.8 to 59.2,284
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2022,Age,13-17 Years,81.6,72.5 to 88.2,169
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2011,Age,13-17 Years,15.8,10.4 to 23.3,259
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2021,Age,13-17 Years,79.6,69.9 to 86.8,129
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2020,Age,13-17 Years,77.1,68.1 to 84.2,171
HPV,"≥2 Doses, Males and Females",States/Local Areas,Louisiana,2016,Age,13-17 Years,49.7,43.5 to 55.9,336
HPV,"≥2 Doses, Males and Females",States/Local Areas,Louisiana,2017,Age,13-17 Years,55.8,49.5 to 61.9,341
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2017,Age,13-17 Years,64.6,56.4 to 72.0,185
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2016,Age,13-17 Years,51.5,43.1 to 59.9,182
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2015,Age,13-17 Years,49.5,41.7 to 57.4,219
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2014,Age,13-17 Years,44.7,35.8 to 54.0,167
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2013,Age,13-17 Years,27.0,19.7 to 35.8,160
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2009,Age,13-17 Years,48.6,37.6 to 59.7,127
HPV,"≥2 Doses, Males and Females",States/Local Areas,Louisiana,2019,Age,13-17 Years,62.7,55.0 to 69.8,336
≥3 Doses HepB,,States/Local Areas,Louisiana,2012,Age,13-17 Years,95.6,92.1 to 97.6,370
≥3 Doses HepB,,States/Local Areas,Louisiana,2011,Age,13-17 Years,97.1,94.9 to 98.3,473
≥3 Doses HepB,,States/Local Areas,Louisiana,2014,Age,13-17 Years,92.9,88.7 to 95.7,335
≥3 Doses HepB,,States/Local Areas,Louisiana,2013,Age,13-17 Years,98.5,96.2 to 99.4,298
≥3 Doses HepB,,States/Local Areas,Louisiana,2009,Age,13-17 Years,90.2,84.7 to 93.8,281
≥3 Doses HepB,,States/Local Areas,Louisiana,2010,Age,13-17 Years,94.1,90.3 to 96.4,347
≥3 Doses HepB,,States/Local Areas,Louisiana,2008,Age,13-17 Years,85.1,80.3 to 88.9,379
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2022,Age,13-15 Years,97.0,92.5 to 98.9,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2011,Age,13-17 Years,84.2,77.3 to 89.2,284
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2010,Age,13-17 Years,63.9,55.1 to 71.8,184
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2008,Age,13-17 Years,68.9,57.3 to 78.6,127
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2012,Age,13-17 Years,84.8,78.8 to 89.3,242
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2013,Age,13-17 Years,89.1,83.9 to 92.8,230
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2008,Age,13-17 Years,36.6,28.3 to 45.6,179
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2012,Age,13-17 Years,97.1,92.4 to 98.9,242
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2011,Age,13-17 Years,98.8,96.7 to 99.5,284
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2008,Age,13-17 Years,33.1,23.1 to 44.9,127
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2009,Age,13-17 Years,42.2,32.1 to 53.0,124
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2009,Age,13-17 Years,80.9,69.8 to 88.6,124
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2010,Age,13-17 Years,84.4,76.4 to 90.1,184
≥3 Doses HepB,,States/Local Areas,Louisiana,2017,Age,13-17 Years,95.0,91.6 to 97.1,341
≥3 Doses HepB,,States/Local Areas,Louisiana,2019,Age,13-17 Years,94.5,91.0 to 96.7,336
≥3 Doses HepB,,States/Local Areas,Louisiana,2018,Age,13-17 Years,93.4,88.2 to 96.4,284
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2019,Age,13-17 Years,95.5,92.1 to 97.4,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2021,Age,13-17 Years,94.3,89.6 to 96.9,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2020,Age,13-17 Years,95.7,92.5 to 97.6,329
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2018,Age,13-17 Years,93.2,87.4 to 96.5,245
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2020,Age,13-17 Years,96.7,93.4 to 98.3,329
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2019,Age,13-17 Years,96.0,92.6 to 97.9,308
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2018,Age,13-17 Years,96.0,90.9 to 98.3,245
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2017,Age,13-17 Years,95.2,91.1 to 97.4,305
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2010,Age,13-17 Years,54.2,44.9 to 63.2,142
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2011,Age,13-17 Years,63.0,53.9 to 71.4,214
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2016,Age,13-17 Years,95.2,91.4 to 97.4,279
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2015,Age,13-17 Years,93.2,89.6 to 95.5,326
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2017,Age,13-17 Years,97.7,94.0 to 99.1,305
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2014,Age,13-17 Years,90.3,84.7 to 94.0,262
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2012,Age,13-17 Years,62.1,53.2 to 70.3,186
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2013,Age,13-17 Years,59.8,50.4 to 68.6,138
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2014,Age,13-17 Years,53.2,43.7 to 62.4,168
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2015,Age,13-17 Years,60.3,51.4 to 68.5,163
≥3 Doses HepB,,States/Local Areas,Louisiana,2016,Age,13-17 Years,95.9,92.7 to 97.7,336
≥3 Doses HepB,,States/Local Areas,Louisiana,2015,Age,13-17 Years,95.5,92.5 to 97.3,382
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2009,Age,13-15 Years,50.9,38.7 to 63.0,95
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2015,Age,13-17 Years,94.1,91.1 to 96.2,382
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2016,Age,13-17 Years,95.4,92.3 to 97.3,336
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2017,Age,13-17 Years,93.2,89.4 to 95.7,341
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2014,Age,13-17 Years,94.7,91.6 to 96.7,335
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2015,Age,13-17 Years,93.5,89.8 to 95.9,382
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2012,Age,13-15 Years,93.3,88.2 to 96.3,230
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2013,Age,13-15 Years,87.2,80.0 to 92.0,175
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2015,Age,13-15 Years,88.7,82.1 to 93.0,237
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2014,Age,13-15 Years,91.8,86.4 to 95.2,196
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2016,Age,13-17 Years,69.9,61.1 to 77.4,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2022,Age,13-17 Years,95.8,92.4 to 97.7,302
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2021,Age,13-17 Years,95.5,91.3 to 97.7,287
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2017,Age,13-17 Years,73.8,65.3 to 80.9,156
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2016,Age,13-15 Years,92.4,87.3 to 95.5,212
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2018,Age,13-17 Years,70.4,60.4 to 78.8,124
HPV,"≥1 Dose, Females",States/Local Areas,Louisiana,2019,Age,13-17 Years,76.6,66.0 to 84.6,162
≥3 Doses HepB,,States/Local Areas,Louisiana,2022,Age,13-17 Years,95.6,92.5 to 97.4,330
≥3 Doses HepB,,States/Local Areas,Louisiana,2021,Age,13-17 Years,91.8,86.4 to 95.2,303
≥3 Doses HepB,,States/Local Areas,Louisiana,2020,Age,13-17 Years,94.7,90.8 to 97.0,356
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2022,Age,13-17 Years,97.3,94.4 to 98.7,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2009,Age,13-17 Years,70.1,63.0 to 76.4,281
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2008,Age,13-17 Years,74.9,69.3 to 79.8,379
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2011,Age,13-17 Years,52.1,42.9 to 61.1,214
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2010,Age,13-17 Years,46.9,37.8 to 56.1,142
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2009,Age,13-17 Years,36.2,25.9 to 47.9,127
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2020,Age,13-15 Years,90.2,83.2 to 94.5,223
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2012,Age,13-17 Years,93.5,89.6 to 96.0,370
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2013,Age,13-17 Years,88.2,82.9 to 92.0,298
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2011,Age,13-17 Years,92.1,88.2 to 94.8,473
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2010,Age,13-17 Years,84.9,80.2 to 88.7,347
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2018,Age,13-17 Years,67.2,60.3 to 73.4,284
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2008,Age,13-17 Years,27.5,19.9 to 36.6,179
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018,Age,13-15 Years,81.7,72.8 to 88.1,153
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2017,Age,13-15 Years,88.1,82.0 to 92.4,218
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2019,Age,13-15 Years,90.4,84.0 to 94.5,220
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2016,Age,13-17 Years,60.5,54.4 to 66.3,336
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2017,Age,13-17 Years,69.1,63.3 to 74.4,341
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2019,Age,13-17 Years,94.6,90.3 to 97.0,336
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2020,Age,13-17 Years,93.7,89.7 to 96.2,356
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2010,Age,13-15 Years,80.2,73.3 to 85.6,206
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2011,Age,13-15 Years,92.3,86.9 to 95.6,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2019,Age,13-17 Years,73.9,66.9 to 80.0,336
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2022,Age,13-17 Years,94.3,90.0 to 96.8,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2021,Age,13-17 Years,96.3,92.7 to 98.2,303
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Louisiana,2018,Age,13-17 Years,91.1,85.6 to 94.6,284
HPV,"≥1 Dose, Males",States/Local Areas,Louisiana,2022,Age,13-17 Years,78.2,69.4 to 84.9,161
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2012,Age,13-17 Years,52.6,43.5 to 61.5,186
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2013,Age,13-17 Years,54.1,44.5 to 63.4,138
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2008,Age,13-15 Years,52.7,44.6 to 60.7,221
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2009,Age,13-15 Years,69.1,60.0 to 76.9,190
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2021,Age,13-15 Years,92.2,86.0 to 95.8,193
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2022,Age,13-17 Years,79.8,73.8 to 84.8,330
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2021,Age,13-17 Years,81.1,75.1 to 86.0,303
HPV,"≥1 Dose, Males and Females",States/Local Areas,Louisiana,2020,Age,13-17 Years,75.3,69.1 to 80.5,356
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2016,Age,13-17 Years,58.8,49.8 to 67.3,154
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2017,Age,13-17 Years,66.6,57.7 to 74.4,156
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2015,Age,13-17 Years,53.3,44.3 to 62.0,163
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2014,Age,13-17 Years,43.8,34.8 to 53.1,168
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2018,Age,13-17 Years,59.1,48.4 to 68.9,124
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2012,Age,13-15 Years,90.5,84.2 to 94.4,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2011,Age,13-15 Years,89.8,83.7 to 93.9,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2008,Age,13-15 Years,41.4,33.7 to 49.5,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2010,Age,13-15 Years,70.6,63.1 to 77.1,206
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2009,Age,13-15 Years,54.0,44.9 to 62.8,190
HPV,"≥2 Doses, Females",States/Local Areas,Louisiana,2019,Age,13-17 Years,61.7,50.4 to 71.9,162
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2022,Age,13-17 Years,94.1,89.8 to 96.7,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2016,Age,13-17 Years,93.7,89.8 to 96.2,336
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2009,Age,13-17 Years,65.8,58.5 to 72.4,281
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2008,Age,13-17 Years,53.6,47.5 to 59.6,379
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2011,Age,13-17 Years,90.0,85.8 to 93.0,473
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2010,Age,13-17 Years,78.6,73.2 to 83.1,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2019,Age,13-17 Years,94.1,89.9 to 96.7,336
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2017,Age,13-17 Years,90.1,85.5 to 93.4,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018,Age,13-17 Years,90.8,85.3 to 94.4,284
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2012,Age,13-17 Years,90.8,86.5 to 93.8,370
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2022,Age,13-15 Years,88.5,81.4 to 93.2,210
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2017,Age,13-17 Years,89.0,84.3 to 92.5,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2021,Age,13-17 Years,93.1,88.4 to 96.0,303
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2020,Age,13-17 Years,92.1,87.9 to 94.9,356
≥2 Doses MMR,,States/Local Areas,Louisiana,2019,Age,13-17 Years,94.0,88.8 to 96.9,336
≥2 Doses MMR,,States/Local Areas,Louisiana,2018,Age,13-17 Years,94.8,90.4 to 97.3,284
≥2 Doses MMR,,States/Local Areas,Louisiana,2017,Age,13-17 Years,96.6,93.3 to 98.3,341
HPV,"≥3 Doses, Males and Females",States/Local Areas,Louisiana,2014,Age,13-17 Years,29.8,24.2 to 36.1,335
HPV,"≥3 Doses, Males and Females",States/Local Areas,Louisiana,2015,Age,13-17 Years,34.8,29.3 to 40.8,382
≥2 Doses MMR,,States/Local Areas,Louisiana,2020,Age,13-17 Years,95.7,92.2 to 97.7,356
HPV,"≥3 Doses, Males and Females",States/Local Areas,Louisiana,2013,Age,13-17 Years,27.5,21.6 to 34.2,298
≥2 Doses MMR,,States/Local Areas,Louisiana,2016,Age,13-17 Years,96.5,93.2 to 98.3,336
≥2 Doses MMR,,States/Local Areas,Louisiana,2014,Age,13-17 Years,91.8,87.2 to 94.9,335
≥2 Doses MMR,,States/Local Areas,Louisiana,2015,Age,13-17 Years,94.7,91.6 to 96.7,382
≥2 Doses MMR,,States/Local Areas,Louisiana,2012,Age,13-17 Years,93.6,90.0 to 96.0,370
≥2 Doses MMR,,States/Local Areas,Louisiana,2013,Age,13-17 Years,97.4,93.6 to 99.0,298
HPV,"≥3 Doses, Males and Females",States/Local Areas,Louisiana,2011,Age,13-17 Years,18.8,14.7 to 23.9,473
HPV,"≥3 Doses, Males and Females",States/Local Areas,Louisiana,2012,Age,13-17 Years,23.7,18.5 to 29.8,370
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2016,Age,13-17 Years,90.9,86.9 to 93.8,336
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2015,Age,13-17 Years,90.9,86.6 to 93.9,382
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2014,Age,13-17 Years,91.8,87.7 to 94.6,335
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2013,Age,13-17 Years,87.7,82.6 to 91.5,298
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2015,Age,13-15 Years,37.0,26.8 to 48.7,103
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2014,Age,13-15 Years,33.6,23.3 to 45.8,97
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2013,Age,13-15 Years,35.3,23.9 to 48.7,84
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2008,Age,13-15 Years,16.1,9.3 to 26.6,101
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2009,Age,13-15 Years,35.4,22.9 to 50.3,85
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2010,Age,13-15 Years,33.1,23.5 to 44.3,89
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2019,Age,13-17 Years,92.0,87.4 to 95.0,336
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2018,Age,13-17 Years,84.9,78.8 to 89.5,284
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2021,Age,13-17 Years,93.7,89.6 to 96.3,303
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2012,Age,13-15 Years,38.3,28.3 to 49.5,122
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2011,Age,13-15 Years,32.5,23.0 to 43.7,144
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2016,Age,13-15 Years,97.2,94.3 to 98.6,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2017,Age,13-15 Years,91.5,86.4 to 94.7,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2015,Age,13-15 Years,91.0,85.1 to 94.7,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2014,Age,13-15 Years,95.3,91.5 to 97.5,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2013,Age,13-15 Years,87.2,79.6 to 92.2,175
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2012,Age,13-17 Years,12.6,7.1 to 21.3,184
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2011,Age,13-17 Years,7.4,4.2 to 12.5,259
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2014,Age,13-17 Years,32.2,24.3 to 41.4,167
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2013,Age,13-17 Years,20.5,13.9 to 29.2,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2019,Age,13-15 Years,93.9,88.0 to 97.0,220
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2020,Age,13-15 Years,92.5,86.8 to 95.8,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2021,Age,13-15 Years,94.2,88.8 to 97.1,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2018,Age,13-15 Years,87.5,78.8 to 92.9,153
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2018,Age,13-17 Years,45.2,35.7 to 55.0,160
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2016,Age,13-17 Years,40.9,32.8 to 49.5,182
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2017,Age,13-17 Years,45.4,36.8 to 54.2,185
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2015,Age,13-17 Years,39.1,31.6 to 47.1,219
≥1 Dose MenACWY,,States/Local Areas,Louisiana,2022,Age,13-17 Years,90.4,85.2 to 93.9,330
≥2 Doses MMR,,States/Local Areas,Louisiana,2022,Age,13-17 Years,96.3,93.5 to 97.9,330
≥2 Doses MMR,,States/Local Areas,Louisiana,2021,Age,13-17 Years,94.1,89.5 to 96.7,303
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2016,Age,13-17 Years,41.8,35.8 to 48.1,336
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2012,Age,13-17 Years,89.8,85.5 to 92.9,370
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2018,Age,13-17 Years,46.7,39.5 to 54.1,284
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2017,Age,13-17 Years,52.9,46.5 to 59.1,341
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2019,Age,13-17 Years,59.5,51.7 to 66.8,336
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2014,Age,13-17 Years,93.8,90.3 to 96.0,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2013,Age,13-17 Years,87.9,82.6 to 91.8,298
HPV,"≥2 Doses, Males",States/Local Areas,Louisiana,2019,Age,13-17 Years,63.6,53.0 to 73.0,174
≥2 Doses MMR,,States/Local Areas,Louisiana,2011,Age,13-17 Years,95.8,92.2 to 97.8,473
≥2 Doses MMR,,States/Local Areas,Louisiana,2010,Age,13-17 Years,92.6,88.3 to 95.5,347
≥2 Doses MMR,,States/Local Areas,Louisiana,2009,Age,13-17 Years,91.6,86.4 to 94.9,281
≥2 Doses MMR,,States/Local Areas,Louisiana,2008,Age,13-17 Years,89.0,84.8 to 92.2,379
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2009,Age,13-17 Years,47.3,40.2 to 54.6,281
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2010,Age,13-17 Years,69.3,63.4 to 74.6,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2011,Age,13-17 Years,85.9,81.1 to 89.6,473
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2008,Age,13-17 Years,35.3,29.8 to 41.3,379
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2022,Age,13-15 Years,92.0,85.3 to 95.8,210
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2020,Age,13-17 Years,60.4,53.6 to 66.8,356
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2022,Age,13-17 Years,67.3,60.6 to 73.5,330
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2021,Age,13-17 Years,63.9,56.9 to 70.4,303
Tetanus,≥1 Dose Tdap,States/Local Areas,Louisiana,2015,Age,13-17 Years,91.0,86.9 to 93.9,382
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2009,Age,13-17 Years,29.8,20.4 to 41.2,127
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2008,Age,13-17 Years,16.5,11.0 to 24.1,179
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2010,Age,13-17 Years,39.3,30.6 to 48.6,142
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2015,Age,13-17 Years,39.3,30.9 to 48.4,163
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2016,Age,13-17 Years,97.3,93.9 to 98.8,279
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2015,Age,13-17 Years,96.6,93.6 to 98.3,326
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2014,Age,13-17 Years,96.4,92.2 to 98.4,262
Varicella,≥1 Dose with no disease history,States/Local Areas,Louisiana,2013,Age,13-17 Years,96.0,92.1 to 98.0,230
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2012,Age,13-15 Years,86.1,79.2 to 91.0,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2013,Age,13-15 Years,91.5,85.5 to 95.2,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2010,Age,13-15 Years,67.4,56.9 to 76.4,131
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2011,Age,13-15 Years,87.7,79.6 to 92.9,214
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2021,Age,13-15 Years,92.2,85.1 to 96.1,184
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2020,Age,13-15 Years,94.6,89.6 to 97.3,207
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2019,Age,13-15 Years,94.2,89.2 to 97.0,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2016,Age,13-15 Years,96.0,91.4 to 98.2,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2018,Age,13-15 Years,91.9,82.9 to 96.4,135
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2017,Age,13-15 Years,96.4,92.4 to 98.4,199
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2015,Age,13-15 Years,92.6,87.6 to 95.8,210
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2014,Age,13-15 Years,92.6,85.7 to 96.3,162
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2012,Age,13-17 Years,89.7,85.6 to 92.8,370
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2011,Age,13-17 Years,90.6,86.3 to 93.7,473
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2014,Age,13-17 Years,92.4,87.9 to 95.3,335
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2013,Age,13-17 Years,91.6,87.5 to 94.4,298
Varicella,≥2 Doses with no disease history,States/Local Areas,Louisiana,2008,Age,13-15 Years,36.6,24.5 to 50.7,89
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2022,Age,13-17 Years,96.1,92.9 to 97.9,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2021,Age,13-17 Years,94.5,90.0 to 97.0,303
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2020,Age,13-17 Years,96.1,93.1 to 97.8,356
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2009,Age,13-17 Years,77.2,70.3 to 82.9,281
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2010,Age,13-17 Years,80.7,75.0 to 85.4,347
HPV,"≥3 Doses, Males",States/Local Areas,Louisiana,2014,Age,13-15 Years,20.0,12.3 to 30.9,99
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2014,Age,13-17 Years,38.4,29.9 to 47.8,168
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2013,Age,13-17 Years,42.1,32.7 to 52.1,138
≥2 Doses Hep A,,States/Local Areas,Louisiana,2020,Age,13-17 Years,73.2,66.9 to 78.7,356
HPV,"≥3 Doses, Males",States/Local Areas,Louisiana,2013,Age,13-17 Years,13.5,8.1 to 21.5,160
HPV,"≥3 Doses, Males",States/Local Areas,Louisiana,2014,Age,13-17 Years,21.5,14.9 to 30.1,167
HPV,"≥3 Doses, Males",States/Local Areas,Louisiana,2015,Age,13-17 Years,30.5,23.6 to 38.4,219
HPV,"≥3 Doses, Males",States/Local Areas,Louisiana,2015,Age,13-15 Years,34.9,25.9 to 45.2,134
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2011,Age,13-17 Years,36.3,28.3 to 45.2,214
HPV,"≥3 Doses, Females",States/Local Areas,Louisiana,2012,Age,13-17 Years,40.5,31.9 to 49.7,186
≥2 Doses Hep A,,States/Local Areas,Louisiana,2021,Age,13-17 Years,79.7,73.6 to 84.7,303
≥2 Doses Hep A,,States/Local Areas,Louisiana,2022,Age,13-17 Years,88.9,84.1 to 92.4,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2008,Age,13-17 Years,75.8,70.0 to 80.8,379
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2019,Age,13-17 Years,95.9,92.9 to 97.7,336
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2016,Age,13-17 Years,96.0,92.8 to 97.8,336
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2018,Age,13-17 Years,94.1,89.0 to 96.9,284
Varicella,≥2 Doses or history of disease,States/Local Areas,Louisiana,2017,Age,13-17 Years,95.7,92.1 to 97.7,341
HPV,"Up-to-Date, Males",States/Local Areas,New York,2021,Age,13-17 Years,61.5,53.9 to 68.5,303
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2020,Age,13-15 Years,65.1,59.0 to 70.7,444
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2022,Age,13-15 Years,66.5,60.1 to 72.4,320
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2021,Age,13-15 Years,61.1,54.3 to 67.5,344
HPV,"Up-to-Date, Males",States/Local Areas,New York,2022,Age,13-17 Years,72.3,65.5 to 78.2,273
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2019,Age,13-15 Years,53.8,46.5 to 60.8,317
HPV,"Up-to-Date, Females",States/Local Areas,New York,2022,Age,13-15 Years,68.4,59.5 to 76.1,161
HPV,"Up-to-Date, Females",States/Local Areas,New York,2021,Age,13-15 Years,62.5,52.9 to 71.3,171
HPV,"Up-to-Date, Males",States/Local Areas,New York,2018,Age,13-17 Years,58.1,50.9 to 65.0,299
HPV,"Up-to-Date, Males",States/Local Areas,New York,2017,Age,13-17 Years,49.1,42.7 to 55.5,359
HPV,"Up-to-Date, Males",States/Local Areas,New York,2020,Age,13-17 Years,66.8,60.5 to 72.6,387
HPV,"Up-to-Date, Males",States/Local Areas,New York,2019,Age,13-17 Years,54.5,46.5 to 62.3,259
HPV,"Up-to-Date, Males",States/Local Areas,New York,2016,Age,13-17 Years,50.3,43.9 to 56.7,356
HPV,"Up-to-Date, Males",States/Local Areas,New York,2019,Age,13-15 Years,47.9,38.3 to 57.7,162
HPV,"Up-to-Date, Males",States/Local Areas,New York,2020,Age,13-15 Years,65.6,57.5 to 72.9,237
HPV,"Up-to-Date, Females",States/Local Areas,New York,2018,Age,13-17 Years,56.4,48.2 to 64.3,236
HPV,"Up-to-Date, Females",States/Local Areas,New York,2019,Age,13-17 Years,59.7,51.0 to 67.8,239
HPV,"Up-to-Date, Females",States/Local Areas,New York,2020,Age,13-17 Years,69.4,62.6 to 75.5,342
HPV,"Up-to-Date, Females",States/Local Areas,New York,2022,Age,13-17 Years,69.0,62.0 to 75.3,263
HPV,"Up-to-Date, Females",States/Local Areas,New York,2021,Age,13-17 Years,67.5,59.9 to 74.3,278
HPV,"Up-to-Date, Males",States/Local Areas,New York,2018,Age,13-15 Years,50.3,40.9 to 59.7,173
HPV,"Up-to-Date, Females",States/Local Areas,New York,2017,Age,13-17 Years,58.2,51.3 to 64.8,292
HPV,"Up-to-Date, Males",States/Local Areas,New York,2022,Age,13-15 Years,64.9,55.5 to 73.3,159
HPV,"Up-to-Date, Males",States/Local Areas,New York,2021,Age,13-15 Years,59.6,49.8 to 68.7,173
HPV,"Up-to-Date, Females",States/Local Areas,New York,2016,Age,13-17 Years,61.3,54.6 to 67.6,299
Varicella,History of disease,States/Local Areas,New York,2022,Age,13-17 Years,6.2,4.1 to 9.4,536
Varicella,History of disease,States/Local Areas,New York,2021,Age,13-17 Years,8.5,6.0 to 11.9,581
Varicella,History of disease,States/Local Areas,New York,2020,Age,13-17 Years,7.4,5.3 to 10.4,729
Varicella,History of disease,States/Local Areas,New York,2019,Age,13-17 Years,12.8,9.5 to 17.2,498
HPV,"Up-to-Date, Females",States/Local Areas,New York,2020,Age,13-15 Years,64.6,55.4 to 72.8,207
HPV,"Up-to-Date, Females",States/Local Areas,New York,2019,Age,13-15 Years,60.0,49.7 to 69.5,155
HPV,"Up-to-Date, Females",States/Local Areas,New York,2018,Age,13-15 Years,51.3,40.9 to 61.7,141
Varicella,History of disease,States/Local Areas,New York,2014,Age,13-17 Years,18.9,15.2 to 23.1,594
Varicella,History of disease,States/Local Areas,New York,2015,Age,13-17 Years,16.0,12.9 to 19.7,665
Varicella,History of disease,States/Local Areas,New York,2016,Age,13-17 Years,12.0,9.3 to 15.3,655
Varicella,History of disease,States/Local Areas,New York,2010,Age,13-17 Years,35.6,31.1 to 40.4,701
Varicella,History of disease,States/Local Areas,New York,2011,Age,13-17 Years,31.5,27.8 to 35.5,840
Varicella,History of disease,States/Local Areas,New York,2013,Age,13-17 Years,21.1,17.7 to 24.8,710
Varicella,History of disease,States/Local Areas,New York,2012,Age,13-17 Years,24.9,21.1 to 29.2,627
Varicella,History of disease,States/Local Areas,New York,2018,Age,13-17 Years,11.8,8.6 to 15.8,535
Varicella,History of disease,States/Local Areas,New York,2017,Age,13-17 Years,14.4,11.4 to 18.2,651
Varicella,History of disease,States/Local Areas,New York,2009,Age,13-17 Years,54.4,49.3 to 59.4,539
HPV,"≥2 Doses, Males",States/Local Areas,New York,2015,Age,13-17 Years,49.4,43.3 to 55.6,367
Varicella,History of disease,States/Local Areas,New York,2008,Age,13-17 Years,53.3,48.4 to 58.2,600
HPV,"≥2 Doses, Males",States/Local Areas,New York,2014,Age,13-17 Years,38.2,31.8 to 45.1,311
HPV,"≥2 Doses, Males",States/Local Areas,New York,2013,Age,13-17 Years,29.3,23.9 to 35.5,366
HPV,"≥2 Doses, Males",States/Local Areas,New York,2012,Age,13-17 Years,12.3,8.4 to 17.7,324
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2018,Age,13-15 Years,89.2,84.7 to 92.6,314
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2021,Age,13-15 Years,85.0,79.7 to 89.1,344
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2020,Age,13-15 Years,92.3,88.4 to 95.0,444
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2019,Age,13-15 Years,93.2,89.6 to 95.7,317
HPV,"≥2 Doses, Males",States/Local Areas,New York,2016,Age,13-17 Years,55.6,49.2 to 61.8,356
HPV,"≥2 Doses, Males",States/Local Areas,New York,2017,Age,13-17 Years,52.7,46.3 to 59.0,359
HPV,"≥2 Doses, Males",States/Local Areas,New York,2018,Age,13-17 Years,59.4,52.1 to 66.2,299
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2013,Age,13-15 Years,89.2,84.5 to 92.6,399
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2014,Age,13-15 Years,91.7,86.8 to 94.8,340
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2015,Age,13-15 Years,89.7,85.2 to 93.0,390
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2016,Age,13-15 Years,91.9,88.0 to 94.6,399
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2017,Age,13-15 Years,93.1,89.7 to 95.4,414
HPV,"≥2 Doses, Females",States/Local Areas,New York,2019,Age,13-17 Years,64.0,55.4 to 71.8,239
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2009,Age,13-15 Years,73.9,67.6 to 79.3,335
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2010,Age,13-15 Years,89.6,85.2 to 92.9,424
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2008,Age,13-15 Years,61.3,55.1 to 67.1,367
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2011,Age,13-15 Years,90.8,87.5 to 93.3,515
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2012,Age,13-15 Years,89.0,84.2 to 92.5,387
≥1 Dose MenACWY,,States/Local Areas,New York,2011,Age,13-15 Years,77.0,72.2 to 81.1,515
≥1 Dose MenACWY,,States/Local Areas,New York,2010,Age,13-15 Years,69.4,63.1 to 75.0,424
HPV,"≥2 Doses, Females",States/Local Areas,New York,2014,Age,13-17 Years,47.2,39.8 to 54.7,283
HPV,"≥2 Doses, Females",States/Local Areas,New York,2015,Age,13-17 Years,56.4,49.8 to 62.8,298
HPV,"≥2 Doses, Females",States/Local Areas,New York,2016,Age,13-17 Years,67.2,60.7 to 73.1,299
HPV,"≥2 Doses, Females",States/Local Areas,New York,2017,Age,13-17 Years,61.8,54.9 to 68.3,292
HPV,"≥2 Doses, Females",States/Local Areas,New York,2018,Age,13-17 Years,59.4,51.2 to 67.2,236
≥1 Dose MenACWY,,States/Local Areas,New York,2021,Age,13-15 Years,93.2,89.4 to 95.7,344
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2022,Age,13-17 Years,81.8,77.5 to 85.4,536
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2021,Age,13-17 Years,75.9,70.8 to 80.4,581
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2020,Age,13-17 Years,79.1,74.9 to 82.8,729
HPV,"≥2 Doses, Females",States/Local Areas,New York,2009,Age,13-17 Years,43.8,36.5 to 51.3,262
≥1 Dose MenACWY,,States/Local Areas,New York,2020,Age,13-15 Years,92.3,88.1 to 95.1,444
HPV,"≥2 Doses, Females",States/Local Areas,New York,2010,Age,13-17 Years,48.1,41.4 to 54.9,329
HPV,"≥2 Doses, Females",States/Local Areas,New York,2011,Age,13-17 Years,41.5,35.9 to 47.3,399
≥1 Dose MenACWY,,States/Local Areas,New York,2009,Age,13-15 Years,63.4,56.7 to 69.7,335
≥1 Dose MenACWY,,States/Local Areas,New York,2008,Age,13-15 Years,55.3,49.1 to 61.4,367
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2010,Age,13-17 Years,90.9,87.7 to 93.3,701
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2011,Age,13-17 Years,93.4,91.1 to 95.2,840
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2013,Age,13-17 Years,93.2,90.5 to 95.2,710
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2012,Age,13-17 Years,93.3,90.2 to 95.4,627
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2008,Age,13-17 Years,85.5,81.9 to 88.5,600
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2009,Age,13-17 Years,87.7,84.0 to 90.6,539
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2018,Age,13-17 Years,93.1,90.3 to 95.1,535
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2018,Age,13-17 Years,67.3,61.8 to 72.3,535
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2022,Age,13-17 Years,92.0,88.8 to 94.4,536
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2021,Age,13-17 Years,89.5,85.8 to 92.4,581
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2019,Age,13-17 Years,70.8,65.1 to 76.0,498
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2020,Age,13-17 Years,94.6,92.0 to 96.4,729
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2019,Age,13-17 Years,94.9,92.2 to 96.7,498
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2013,Age,13-17 Years,83.5,79.6 to 86.7,710
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2014,Age,13-17 Years,83.5,79.5 to 86.8,594
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2011,Age,13-17 Years,78.7,75.1 to 81.9,840
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2012,Age,13-17 Years,80.8,76.5 to 84.5,627
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2019,Age,13-15 Years,93.7,89.7 to 96.2,278
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2018,Age,13-15 Years,93.5,89.3 to 96.1,273
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2014,Age,13-15 Years,78.8,72.4 to 84.0,295
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2015,Age,13-15 Years,88.2,83.3 to 91.8,339
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2011,Age,13-15 Years,72.2,66.5 to 77.3,380
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2010,Age,13-15 Years,62.5,55.2 to 69.3,321
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2013,Age,13-15 Years,80.0,74.0 to 84.9,339
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2012,Age,13-15 Years,73.5,66.3 to 79.7,301
HPV,"≥1 Dose, Females",States/Local Areas,New York,2015,Age,13-17 Years,62.3,55.7 to 68.4,298
HPV,"≥1 Dose, Females",States/Local Areas,New York,2014,Age,13-17 Years,58.8,51.3 to 65.9,283
HPV,"≥1 Dose, Females",States/Local Areas,New York,2013,Age,13-17 Years,61.7,55.3 to 67.7,344
HPV,"≥1 Dose, Females",States/Local Areas,New York,2012,Age,13-17 Years,56.0,48.8 to 62.9,303
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2015,Age,13-17 Years,84.2,80.2 to 87.6,565
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2016,Age,13-17 Years,88.8,85.2 to 91.6,573
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2014,Age,13-17 Years,79.6,74.9 to 83.7,489
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2017,Age,13-17 Years,97.8,96.0 to 98.8,563
HPV,"≥1 Dose, Females",States/Local Areas,New York,2011,Age,13-17 Years,46.6,40.8 to 52.5,399
HPV,"≥1 Dose, Females",States/Local Areas,New York,2010,Age,13-17 Years,56.2,49.5 to 62.7,329
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2017,Age,13-17 Years,93.6,90.6 to 95.7,563
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2021,Age,13-15 Years,95.9,92.2 to 97.9,319
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2020,Age,13-15 Years,92.7,88.4 to 95.5,415
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2008,Age,13-15 Years,44.7,36.7 to 52.9,214
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2009,Age,13-15 Years,48.9,40.0 to 57.8,187
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2013,Age,13-17 Years,96.6,93.8 to 98.1,553
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2014,Age,13-17 Years,96.6,93.8 to 98.2,489
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2015,Age,13-17 Years,97.4,95.7 to 98.4,565
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2016,Age,13-17 Years,97.2,95.5 to 98.3,573
≥3 Doses HepB,,States/Local Areas,New York,2015,Age,13-17 Years,95.8,93.9 to 97.1,665
≥3 Doses HepB,,States/Local Areas,New York,2016,Age,13-17 Years,92.8,90.0 to 94.8,655
≥3 Doses HepB,,States/Local Areas,New York,2018,Age,13-17 Years,95.9,93.4 to 97.5,535
≥3 Doses HepB,,States/Local Areas,New York,2019,Age,13-17 Years,93.3,89.4 to 95.8,498
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2018,Age,13-17 Years,97.3,94.2 to 98.7,465
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2019,Age,13-17 Years,97.3,94.6 to 98.6,439
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2020,Age,13-17 Years,97.9,96.5 to 98.8,673
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2018,Age,13-17 Years,92.5,88.9 to 95.0,465
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2021,Age,13-17 Years,94.2,90.4 to 96.6,535
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2020,Age,13-17 Years,93.6,90.6 to 95.7,673
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2019,Age,13-17 Years,93.5,90.3 to 95.7,439
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2012,Age,13-17 Years,97.5,95.3 to 98.7,465
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2010,Age,13-17 Years,94.8,90.9 to 97.1,457
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2009,Age,13-17 Years,89.1,82.9 to 93.3,253
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2008,Age,13-17 Years,41.2,34.3 to 48.4,279
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2009,Age,13-17 Years,48.8,41.4 to 56.2,253
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2011,Age,13-17 Years,95.4,92.1 to 97.3,566
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2013,Age,13-17 Years,79.1,74.4 to 83.1,553
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2012,Age,13-17 Years,74.4,68.9 to 79.2,465
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2008,Age,13-17 Years,88.7,83.0 to 92.6,279
HPV,"≥1 Dose, Females",States/Local Areas,New York,2008,Age,13-17 Years,50.2,43.1 to 57.3,270
HPV,"≥1 Dose, Females",States/Local Areas,New York,2009,Age,13-17 Years,48.8,41.4 to 56.3,262
≥3 Doses HepB,,States/Local Areas,New York,2010,Age,13-17 Years,94.9,92.2 to 96.7,701
≥3 Doses HepB,,States/Local Areas,New York,2009,Age,13-17 Years,92.3,88.5 to 94.9,539
≥3 Doses HepB,,States/Local Areas,New York,2013,Age,13-17 Years,94.4,91.4 to 96.3,710
≥3 Doses HepB,,States/Local Areas,New York,2014,Age,13-17 Years,90.2,86.3 to 93.0,594
≥3 Doses HepB,,States/Local Areas,New York,2011,Age,13-17 Years,94.6,92.4 to 96.2,840
≥3 Doses HepB,,States/Local Areas,New York,2012,Age,13-17 Years,94.6,92.0 to 96.4,627
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2010,Age,13-17 Years,61.6,55.7 to 67.3,457
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2011,Age,13-17 Years,68.9,64.0 to 73.4,566
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2022,Age,13-15 Years,95.6,91.5 to 97.7,308
≥3 Doses HepB,,States/Local Areas,New York,2008,Age,13-17 Years,93.0,89.7 to 95.3,600
HPV,"≥2 Doses, Males and Females",States/Local Areas,New York,2019,Age,13-17 Years,60.5,54.6 to 66.1,498
HPV,"≥1 Dose, Males",States/Local Areas,New York,2019,Age,13-17 Years,68.2,60.1 to 75.4,259
HPV,"≥1 Dose, Males",States/Local Areas,New York,2017,Age,13-17 Years,66.0,59.8 to 71.7,359
HPV,"≥1 Dose, Males",States/Local Areas,New York,2013,Age,13-17 Years,38.6,32.7 to 44.9,366
HPV,"≥1 Dose, Males",States/Local Areas,New York,2014,Age,13-17 Years,49.8,43.0 to 56.6,311
HPV,"≥1 Dose, Males",States/Local Areas,New York,2015,Age,13-17 Years,60.3,54.1 to 66.2,367
HPV,"≥1 Dose, Males",States/Local Areas,New York,2016,Age,13-17 Years,68.2,62.1 to 73.8,356
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2021,Age,13-17 Years,96.9,94.0 to 98.4,535
Varicella,≥1 Dose with no disease history,States/Local Areas,New York,2022,Age,13-17 Years,98.0,96.4 to 98.9,507
HPV,"≥2 Doses, Males and Females",States/Local Areas,New York,2016,Age,13-17 Years,61.3,56.7 to 65.7,655
HPV,"≥2 Doses, Males and Females",States/Local Areas,New York,2017,Age,13-17 Years,57.1,52.5 to 61.7,651
HPV,"≥1 Dose, Males",States/Local Areas,New York,2011,Age,13-17 Years,6.4,4.1 to 9.7,441
HPV,"≥1 Dose, Females",States/Local Areas,New York,2022,Age,13-17 Years,81.6,75.4 to 86.5,263
HPV,"≥1 Dose, Females",States/Local Areas,New York,2021,Age,13-17 Years,79.9,72.5 to 85.6,278
HPV,"≥1 Dose, Females",States/Local Areas,New York,2020,Age,13-17 Years,81.1,74.8 to 86.1,342
HPV,"≥1 Dose, Females",States/Local Areas,New York,2019,Age,13-17 Years,73.5,65.3 to 80.4,239
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2022,Age,13-17 Years,95.8,93.1 to 97.4,507
HPV,"≥2 Doses, Males and Females",States/Local Areas,New York,2018,Age,13-17 Years,59.4,54.0 to 64.7,535
HPV,"≥1 Dose, Males",States/Local Areas,New York,2018,Age,13-17 Years,67.2,59.9 to 73.7,299
HPV,"≥1 Dose, Males",States/Local Areas,New York,2021,Age,13-17 Years,72.2,64.8 to 78.6,303
HPV,"≥1 Dose, Males",States/Local Areas,New York,2020,Age,13-17 Years,77.2,71.2 to 82.2,387
HPV,"≥1 Dose, Males",States/Local Areas,New York,2012,Age,13-17 Years,17.9,13.4 to 23.6,324
HPV,"≥1 Dose, Females",States/Local Areas,New York,2018,Age,13-17 Years,67.3,58.8 to 74.8,236
≥3 Doses HepB,,States/Local Areas,New York,2022,Age,13-17 Years,96.0,93.9 to 97.5,536
≥3 Doses HepB,,States/Local Areas,New York,2021,Age,13-17 Years,96.2,93.7 to 97.7,581
≥3 Doses HepB,,States/Local Areas,New York,2020,Age,13-17 Years,95.0,92.4 to 96.7,729
HPV,"≥1 Dose, Females",States/Local Areas,New York,2016,Age,13-17 Years,75.0,69.0 to 80.1,299
HPV,"≥1 Dose, Females",States/Local Areas,New York,2017,Age,13-17 Years,71.2,64.4 to 77.2,292
≥1 Dose MenACWY,,States/Local Areas,New York,2016,Age,13-15 Years,88.3,83.8 to 91.7,399
HPV,"≥1 Dose, Males",States/Local Areas,New York,2022,Age,13-17 Years,82.0,75.7 to 86.9,273
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2015,Age,13-17 Years,91.7,88.6 to 93.9,665
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2014,Age,13-17 Years,92.9,89.8 to 95.2,594
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2016,Age,13-17 Years,94.1,91.6 to 95.9,655
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New York,2017,Age,13-17 Years,94.9,92.7 to 96.5,651
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2016,Age,13-17 Years,71.5,67.3 to 75.4,655
HPV,"≥1 Dose, Males and Females",States/Local Areas,New York,2017,Age,13-17 Years,68.5,64.0 to 72.7,651
≥1 Dose MenACWY,,States/Local Areas,New York,2017,Age,13-15 Years,87.6,82.9 to 91.1,414
≥1 Dose MenACWY,,States/Local Areas,New York,2018,Age,13-15 Years,95.7,92.8 to 97.5,314
≥1 Dose MenACWY,,States/Local Areas,New York,2019,Age,13-15 Years,95.9,92.8 to 97.7,317
HPV,"≥2 Doses, Females",States/Local Areas,New York,2013,Age,13-17 Years,55.6,49.1 to 61.9,344
HPV,"≥2 Doses, Females",States/Local Areas,New York,2012,Age,13-17 Years,50.5,43.3 to 57.6,303
HPV,"≥2 Doses, Females",States/Local Areas,New York,2008,Age,13-17 Years,42.0,35.0 to 49.3,270
≥1 Dose MenACWY,,States/Local Areas,New York,2013,Age,13-15 Years,81.9,76.6 to 86.2,399
≥1 Dose MenACWY,,States/Local Areas,New York,2012,Age,13-15 Years,77.3,71.3 to 82.4,387
≥1 Dose MenACWY,,States/Local Areas,New York,2014,Age,13-15 Years,78.9,72.8 to 84.0,340
≥1 Dose MenACWY,,States/Local Areas,New York,2015,Age,13-15 Years,85.4,80.8 to 89.0,390
≥2 Doses Hep A,,States/Local Areas,New York,2021,Age,13-17 Years,82.2,77.7 to 85.9,581
≥2 Doses Hep A,,States/Local Areas,New York,2022,Age,13-17 Years,86.7,82.8 to 89.8,536
≥3 Doses HepB,,States/Local Areas,New York,2017,Age,13-17 Years,94.2,91.7 to 95.9,651
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2017,Age,13-17 Years,94.5,91.9 to 96.3,651
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2016,Age,13-17 Years,90.2,86.9 to 92.7,655
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2018,Age,13-17 Years,93.4,90.2 to 95.6,535
HPV,"≥3 Doses, Males",States/Local Areas,New York,2014,Age,13-15 Years,24.0,17.1 to 32.5,169
HPV,"≥3 Doses, Males",States/Local Areas,New York,2015,Age,13-15 Years,40.9,33.6 to 48.7,221
HPV,"≥3 Doses, Males",States/Local Areas,New York,2014,Age,13-17 Years,28.5,22.7 to 35.2,311
HPV,"≥3 Doses, Males",States/Local Areas,New York,2015,Age,13-17 Years,38.1,32.5 to 44.0,367
HPV,"≥3 Doses, Males",States/Local Areas,New York,2013,Age,13-17 Years,19.1,14.5 to 24.7,366
HPV,"≥3 Doses, Males",States/Local Areas,New York,2013,Age,13-15 Years,17.5,11.7 to 25.2,194
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2008,Age,13-17 Years,72.6,67.9 to 76.7,600
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2015,Age,13-17 Years,86.7,83.2 to 89.6,665
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2019,Age,13-17 Years,94.3,91.5 to 96.2,498
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2022,Age,13-17 Years,96.0,93.6 to 97.6,536
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2021,Age,13-17 Years,94.7,91.2 to 96.9,581
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2020,Age,13-17 Years,94.1,91.3 to 96.0,729
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2016,Age,13-15 Years,90.0,85.2 to 93.3,357
Varicella,≥2 Doses with no disease history,States/Local Areas,New York,2017,Age,13-15 Years,95.4,92.3 to 97.3,357
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2010,Age,13-17 Years,75.3,70.9 to 79.3,701
Varicella,≥2 Doses or history of disease,States/Local Areas,New York,2009,Age,13-17 Years,76.6,72.0 to 80.7,539
HPV,"≥3 Doses, Females",States/Local Areas,New York,2008,Age,13-17 Years,29.2,22.9 to 36.4,270
HPV,"≥3 Doses, Females",States/Local Areas,New York,2009,Age,13-17 Years,33.8,27.2 to 41.1,262
HPV,"≥3 Doses, Females",States/Local Areas,New York,2015,Age,13-17 Years,47.3,40.7 to 53.9,298
HPV,"≥3 Doses, Females",States/Local Areas,New York,2010,Age,13-17 Years,39.7,33.3 to 46.5,329
≥2 Doses Hep A,,States/Local Areas,New York,2020,Age,13-17 Years,76.8,72.4 to 80.7,729
HPV,"≥3 Doses, Females",States/Local Areas,New York,2013,Age,13-17 Years,45.4,38.9 to 52.1,344
HPV,"≥3 Doses, Females",States/Local Areas,New York,2014,Age,13-17 Years,40.1,33.0 to 47.6,283
HPV,"≥3 Doses, Females",States/Local Areas,New York,2011,Age,13-17 Years,34.2,29.0 to 39.9,399
HPV,"≥3 Doses, Females",States/Local Areas,New York,2012,Age,13-17 Years,39.7,32.8 to 47.1,303
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2015,Age,13-17 Years,89.0,85.7 to 91.6,665
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2022,Age,13-17 Years,70.7,65.9 to 75.1,536
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2021,Age,13-17 Years,64.4,59.1 to 69.4,581
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2020,Age,13-17 Years,68.1,63.5 to 72.4,729
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2019,Age,13-17 Years,57.0,51.1 to 62.7,498
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2008,Age,13-17 Years,53.8,48.9 to 58.6,600
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2022,Age,13-15 Years,86.7,81.3 to 90.7,320
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2011,Age,13-17 Years,88.5,85.7 to 90.8,840
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2010,Age,13-17 Years,82.9,79.2 to 86.1,701
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2009,Age,13-17 Years,69.2,64.3 to 73.7,539
≥2 Doses MMR,,States/Local Areas,New York,2010,Age,13-17 Years,94.4,91.2 to 96.5,701
≥2 Doses MMR,,States/Local Areas,New York,2011,Age,13-17 Years,93.4,91.0 to 95.2,840
≥2 Doses MMR,,States/Local Areas,New York,2008,Age,13-17 Years,92.6,89.7 to 94.8,600
≥2 Doses MMR,,States/Local Areas,New York,2009,Age,13-17 Years,92.1,89.1 to 94.4,539
HPV,"≥2 Doses, Males",States/Local Areas,New York,2019,Age,13-17 Years,57.1,49.0 to 64.9,259
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2016,Age,13-17 Years,55.7,51.0 to 60.2,655
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2013,Age,13-17 Years,89.5,86.2 to 92.0,710
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2014,Age,13-17 Years,91.5,88.1 to 93.9,594
HPV,"≥2 Doses, Males and Females",States/Local Areas,New York,2022,Age,13-17 Years,71.5,66.7 to 75.9,536
HPV,"≥2 Doses, Males",States/Local Areas,New York,2022,Age,13-17 Years,73.9,67.2 to 79.7,273
Tetanus,≥1 Dose Tdap,States/Local Areas,New York,2012,Age,13-17 Years,90.3,87.0 to 92.8,627
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2017,Age,13-17 Years,53.6,48.9 to 58.2,651
HPV,"Up-to-Date, Males and Females",States/Local Areas,New York,2018,Age,13-17 Years,57.3,51.8 to 62.6,535
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Overall,Overall,89.8,87.7 to 91.6,1584
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Overall,Overall,88.2,86.0 to 90.2,1584
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2023,Age,13-17 Years,57.9,46.8 to 68.3,131
HPV,"≥1 Dose, Males",States/Local Areas,Idaho,2023,Age,13-17 Years,72.9,62.7 to 81.2,144
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Idaho,2023,Age,13-17 Years,86.6,80.4 to 91.1,275
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2023,Age,13-17 Years,86.6,80.4 to 91.1,275
≥1 Dose MenACWY,,States/Local Areas,Idaho,2023,Age,13-17 Years,86.1,79.6 to 90.7,275
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2023,Age,13-17 Years,53.4,46.0 to 60.8,275
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2023,Age,13-17 Years,71.5,64.1 to 77.9,275
≥2 Doses MMR,,States/Local Areas,Idaho,2023,Age,13-17 Years,86.6,80.2 to 91.2,275
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2023,Age,13-17 Years,49.2,39.2 to 59.3,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2023,Age,13-17 Years,85.7,78.8 to 90.6,251
Varicella,≥1 Dose with no disease history,States/Local Areas,Idaho,2023,Age,13-17 Years,90.1,83.6 to 94.2,251
Varicella,History of disease,States/Local Areas,Idaho,2023,Age,13-17 Years,8.3,5.1 to 13.3,275
≥3 Doses HepB,,States/Local Areas,Idaho,2023,Age,13-17 Years,89.4,83.5 to 93.3,275
≥2 Doses Hep A,,States/Local Areas,Idaho,2023,Age,13-17 Years,88.0,81.8 to 92.2,275
Varicella,≥2 Doses or history of disease,States/Local Areas,Idaho,2023,Age,13-17 Years,86.9,80.5 to 91.4,275
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2023,Age,13-15 Years,86.1,77.3 to 91.8,173
≥1 Dose MenACWY,,States/Local Areas,Idaho,2023,Age,13-15 Years,84.0,74.8 to 90.3,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2023,Age,13-15 Years,50.0,40.6 to 59.4,173
HPV,"Up-to-Date, Males",States/Local Areas,Idaho,2023,Age,13-15 Years,47.5,35.2 to 60.1,96
HPV,"≥1 Dose, Females",States/Local Areas,Idaho,2023,Age,13-17 Years,70.1,58.9 to 79.2,131
HPV,"Up-to-Date, Females",States/Local Areas,Idaho,2023,Age,13-15 Years,52.9,38.8 to 66.6,77
Varicella,≥2 Doses with no disease history,States/Local Areas,Idaho,2023,Age,13-15 Years,84.5,75.1 to 90.8,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Uninsured,85.7,71.3 to 93.5,58
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Other,79.4,65.2 to 88.9,94
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Private Insurance Only,87.1,84.0 to 89.7,911
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Any Medicaid,91.6,88.1 to 94.1,521
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Other,37.9,26.1 to 51.2,94
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Uninsured,43.4,29.4 to 58.6,58
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Any Medicaid,61.3,56.0 to 66.4,521
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Private Insurance Only,52.3,48.2 to 56.5,911
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Uninsured,63.3,47.6 to 76.7,58
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Uninsured,76.9,61.5 to 87.4,58
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Other,57.0,43.7 to 69.4,94
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Any Medicaid,79.2,74.7 to 83.1,521
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Insurance Coverage,Private Insurance Only,69.7,65.7 to 73.3,911
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Other,82.5,68.7 to 91.1,94
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Private Insurance Only,89.8,86.9 to 92.1,911
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Insurance Coverage,Any Medicaid,92.2,88.9 to 94.6,521
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Poverty,Living At or Above Poverty Level,88.5,86.1 to 90.5,1378
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Poverty,Below Poverty Level,84.8,76.3 to 90.6,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Poverty,Below Poverty Level,56.9,47.6 to 65.9,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Poverty,Living At or Above Poverty Level,53.7,50.4 to 57.1,1378
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Poverty,Below Poverty Level,85.8,77.7 to 91.4,173
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Poverty,Living At or Above Poverty Level,90.4,88.2 to 92.2,1378
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Poverty,Living At or Above Poverty Level,71.1,68.0 to 74.0,1378
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Race and Ethnicity,Hispanic,81.9,74.6 to 87.5,207
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Poverty,Below Poverty Level,76.7,67.7 to 83.8,173
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.8,65.4 to 71.9,1245
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.2,75.1 to 91.6,113
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Race and Ethnicity,Hispanic,93.8,88.5 to 96.8,207
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Race and Ethnicity,Hispanic,91.7,86.2 to 95.2,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"White, Non-Hispanic",87.1,84.4 to 89.4,1245
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.3,86.8 to 91.4,1245
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",57.1,45.3 to 68.1,113
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Race and Ethnicity,Hispanic,59.8,51.4 to 67.6,207
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",77.4,65.9 to 85.9,113
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.4,80.1 to 94.7,113
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Principal City,89.1,85.3 to 92.0,581
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Non-Principal City,88.2,84.3 to 91.3,548
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Race and Ethnicity,"White, Non-Hispanic",52.6,49.1 to 56.1,1245
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a Non-MSA,87.3,82.6 to 90.8,455
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Principal City,90.4,86.6 to 93.1,581
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Non-Principal City,91.2,87.8 to 93.8,548
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a Non-MSA,49.9,43.9 to 55.9,455
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Non-Principal City,55.9,50.6 to 61.1,548
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Principal City,56.6,51.5 to 61.7,581
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a Non-MSA,68.0,62.3 to 73.2,455
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Non-Principal City,73.9,69.1 to 78.2,548
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a MSA Principal City,73.9,69.1 to 78.2,581
HPV,"≥1 Dose, Males and Females",States/Local Areas,Idaho,2018-2022,Overall,Overall,72.2,69.4 to 74.9,1584
HPV,"Up-to-Date, Males and Females",States/Local Areas,Idaho,2018-2022,Overall,Overall,54.5,51.4 to 57.6,1584
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018-2022,Urbanicity,Living In a Non-MSA,87.1,82.5 to 90.6,455
HPV,"≥2 Doses, Males",States/Local Areas,Idaho,2022,Age,13-17 Years,59.7,48.7 to 69.7,130
HPV,"≥2 Doses, Females",States/Local Areas,Idaho,2022,Age,13-17 Years,75.9,65.8 to 83.7,121
HPV,"≥2 Doses, Males and Females",States/Local Areas,Idaho,2022,Age,13-17 Years,67.5,60.1 to 74.2,251
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2016,Age,13-17 Years,87.5,83.0 to 90.9,358
≥1 Dose MenACWY,,States/Local Areas,Idaho,2009,Age,13-17 Years,34.2,27.3 to 41.8,227
≥1 Dose MenACWY,,States/Local Areas,Idaho,2008,Age,13-17 Years,29.9,24.1 to 36.5,268
≥1 Dose MenACWY,,States/Local Areas,Idaho,2011,Age,13-17 Years,50.5,43.3 to 57.6,385
≥1 Dose MenACWY,,States/Local Areas,Idaho,2010,Age,13-17 Years,40.8,35.0 to 47.0,318
≥1 Dose MenACWY,,States/Local Areas,Idaho,2012,Age,13-17 Years,63.2,56.8 to 69.3,357
≥1 Dose MenACWY,,States/Local Areas,Idaho,2022,Age,13-15 Years,88.0,79.0 to 93.5,158
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2019,Age,13-17 Years,88.0,82.5 to 91.9,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2017,Age,13-17 Years,87.3,82.1 to 91.1,353
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2018,Age,13-17 Years,86.7,81.2 to 90.8,291
≥2 Doses MMR,,States/Local Areas,Idaho,2012,Age,13-17 Years,84.5,79.1 to 88.7,357
≥2 Doses MMR,,States/Local Areas,Idaho,2013,Age,13-17 Years,85.2,78.9 to 89.9,272
HPV,"≥3 Doses, Males and Females",States/Local Areas,Idaho,2011,Age,13-17 Years,15.3,10.6 to 21.5,385
HPV,"≥3 Doses, Males and Females",States/Local Areas,Idaho,2012,Age,13-17 Years,15.9,11.6 to 21.5,357
≥1 Dose MenACWY,,States/Local Areas,Idaho,2014,Age,13-17 Years,78.1,71.7 to 83.4,341
≥1 Dose MenACWY,,States/Local Areas,Idaho,2013,Age,13-17 Years,71.6,64.0 to 78.0,272
≥1 Dose MenACWY,,States/Local Areas,Idaho,2015,Age,13-17 Years,81.4,75.6 to 86.0,356
≥1 Dose MenACWY,,States/Local Areas,Idaho,2016,Age,13-17 Years,86.5,81.4 to 90.4,358
≥2 Doses MMR,,States/Local Areas,Idaho,2014,Age,13-17 Years,84.5,79.0 to 88.8,341
≥2 Doses MMR,,States/Local Areas,Idaho,2015,Age,13-17 Years,80.4,74.7 to 85.0,356
≥2 Doses MMR,,States/Local Areas,Idaho,2017,Age,13-17 Years,87.8,82.2 to 91.8,353
≥2 Doses MMR,,States/Local Areas,Idaho,2016,Age,13-17 Years,85.7,81.0 to 89.4,358
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2022,Age,13-17 Years,89.9,84.1 to 93.8,251
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2021,Age,13-17 Years,89.4,84.1 to 93.1,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Idaho,2020,Age,13-17 Years,87.0,81.7 to 90.9,376
≥1 Dose MenACWY,,States/Local Areas,Idaho,2017,Age,13-17 Years,90.5,85.6 to 93.9,353
≥2 Doses MMR,,States/Local Areas,Idaho,2019,Age,13-17 Years,86.9,81.1 to 91.2,332
≥2 Doses MMR,,States/Local Areas,Idaho,2018,Age,13-17 Years,88.5,83.6 to 92.1,291
HPV,"≥3 Doses, Males and Females",States/Local Areas,Idaho,2014,Age,13-17 Years,27.4,21.8 to 34.0,341
HPV,"≥3 Doses, Males and Females",States/Local Areas,Idaho,2015,Age,13-17 Years,28.3,23.0 to 34.3,356
HPV,"≥3 Doses, Males and Females",States/Local Areas,Idaho,2013,Age,13-17 Years,19.7,14.6 to 26.0,272
≥2 Doses MMR,,States/Local Areas,Idaho,2020,Age,13-17 Years,89.7,85.1 to 93.0,376
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2015,Age,13-15 Years,27.9,18.6 to 39.6,104
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2014,Age,13-15 Years,39.4,28.4 to 51.5,112
HPV,"≥3 Doses, Females",States/Local Areas,Idaho,2013,Age,13-15 Years,28.3,18.6 to 40.6,87
≥1 Dose MenACWY,,States/Local Areas,Idaho,2021,Age,13-17 Years,89.1,83.7 to 92.9,334
≥1 Dose MenACWY,,States/Local Areas,Idaho,2020,Age,13-17 Years,88.7,83.8 to 92.2,376
≥1 Dose MenACWY,,States/Local Areas,Idaho,2019,Age,13-17 Years,91.3,86.9 to 94.3,332
≥1 Dose MenACWY,,States/Local Areas,Idaho,2018,Age,13-17 Years,89.4,84.3 to 93.0,291
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2023,Age,13-17 Years,78.4,72.4 to 83.3,506
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2023,Age,13-15 Years,88.6,84.4 to 91.7,605
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2023,Age,13-15 Years,59.3,50.5 to 67.6,298
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2023,Age,13-15 Years,58.5,52.4 to 64.2,651
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2023,Age,13-15 Years,57.7,49.4 to 65.6,353
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2023,Age,13-15 Years,81.6,76.5 to 85.7,651
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2023,Age,13-15 Years,86.6,82.5 to 89.9,651
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2023,Age,13-17 Years,89.4,86.3 to 91.9,1060
≥2 Doses Hep A,,HHS Regions/National,Region 10,2023,Age,13-17 Years,89.3,86.0 to 91.9,1060
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2023,Age,13-17 Years,88.5,85.1 to 91.2,977
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2023,Age,13-17 Years,92.0,89.0 to 94.3,977
≥3 Doses HepB,,HHS Regions/National,Region 10,2023,Age,13-17 Years,91.3,88.4 to 93.6,1060
Varicella,History of disease,HHS Regions/National,Region 10,2023,Age,13-17 Years,8.3,5.9 to 11.6,1060
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2023,Age,13-17 Years,63.8,57.3 to 69.8,554
≥2 Doses MMR,,HHS Regions/National,Region 10,2023,Age,13-17 Years,91.7,88.9 to 93.9,1060
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2023,Age,13-17 Years,79.7,75.9 to 83.1,1060
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2023,Age,13-17 Years,63.4,58.8 to 67.8,1060
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2023,Age,13-17 Years,88.1,84.9 to 90.6,1060
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2023,Age,13-17 Years,84.8,81.3 to 87.9,1060
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2023,Age,13-17 Years,88.4,85.3 to 90.9,1060
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2023,Age,13-17 Years,63.0,56.4 to 69.2,506
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2023,Age,13-17 Years,81.1,75.8 to 85.4,554
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2015,Age,13-17 Years,85.3,82.3 to 87.8,1455
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2017,Age,13-17 Years,87.2,84.5 to 89.5,1400
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2018,Age,13-17 Years,83.7,79.9 to 86.9,1266
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2010,Age,13-17 Years,58.0,54.5 to 61.5,1275
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2011,Age,13-17 Years,61.6,57.6 to 65.4,1423
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2009,Age,13-17 Years,47.9,44.1 to 51.7,1208
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2008,Age,13-17 Years,35.1,31.2 to 39.2,1082
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2022,Age,13-15 Years,84.2,80.0 to 87.6,658
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2016,Age,13-17 Years,85.5,82.3 to 88.1,1429
≥2 Doses MMR,,HHS Regions/National,Region 10,2015,Age,13-17 Years,87.9,85.3 to 90.2,1455
≥2 Doses MMR,,HHS Regions/National,Region 10,2014,Age,13-17 Years,87.1,84.4 to 89.5,1491
≥2 Doses MMR,,HHS Regions/National,Region 10,2012,Age,13-17 Years,88.3,85.0 to 90.9,1431
≥2 Doses MMR,,HHS Regions/National,Region 10,2013,Age,13-17 Years,90.0,87.4 to 92.2,1316
≥2 Doses MMR,,HHS Regions/National,Region 10,2016,Age,13-17 Years,88.5,85.6 to 90.8,1429
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 10,2011,Age,13-17 Years,19.3,16.3 to 22.7,1423
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2012,Age,13-17 Years,65.3,61.3 to 69.2,1431
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2013,Age,13-17 Years,72.7,69.0 to 76.1,1316
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2014,Age,13-17 Years,76.2,72.9 to 79.3,1491
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2015,Age,13-17 Years,75.1,71.8 to 78.1,1455
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2016,Age,13-17 Years,75.0,71.3 to 78.4,1429
≥2 Doses MMR,,HHS Regions/National,Region 10,2019,Age,13-17 Years,93.3,90.9 to 95.1,1332
≥2 Doses MMR,,HHS Regions/National,Region 10,2017,Age,13-17 Years,90.5,88.1 to 92.5,1400
≥2 Doses MMR,,HHS Regions/National,Region 10,2018,Age,13-17 Years,89.8,86.7 to 92.3,1266
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2020,Age,13-17 Years,89.2,86.3 to 91.5,1403
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2021,Age,13-17 Years,86.9,83.6 to 89.6,1245
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2007,Age,13-17 Years,19.0,12.3 to 28.2,118
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2019,Age,13-17 Years,89.2,86.4 to 91.4,1332
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2022,Age,13-17 Years,92.4,90.1 to 94.1,1034
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 10,2012,Age,13-17 Years,21.6,18.4 to 25.2,1431
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 10,2013,Age,13-17 Years,25.8,22.4 to 29.5,1316
≥2 Doses MMR,,HHS Regions/National,Region 10,2020,Age,13-17 Years,93.0,90.3 to 95.0,1403
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 10,2014,Age,13-17 Years,30.6,27.0 to 34.5,1491
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 10,2015,Age,13-17 Years,36.4,32.9 to 40.0,1455
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2022,Age,13-17 Years,67.7,62.0 to 73.0,567
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2022,Age,13-17 Years,70.5,63.9 to 76.3,467
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 10,2022,Age,13-17 Years,69.1,64.8 to 73.0,1034
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2023,Age,13-17 Years,84.9,80.8 to 88.2,2086
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2023,Age,13-17 Years,87.4,83.8 to 90.3,2086
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2023,Age,13-17 Years,85.8,82.0 to 88.9,2086
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2023,Age,13-17 Years,75.4,71.0 to 79.3,2086
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2023,Age,13-17 Years,78.1,72.0 to 83.1,1029
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2023,Age,13-17 Years,57.0,52.1 to 61.8,2086
≥2 Doses MMR,,HHS Regions/National,Region 6,2023,Age,13-17 Years,86.8,83.0 to 89.8,2086
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2023,Age,13-17 Years,54.1,47.1 to 61.0,1057
Varicella,History of disease,HHS Regions/National,Region 6,2023,Age,13-17 Years,9.5,6.7 to 13.3,2086
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2023,Age,13-17 Years,90.3,86.5 to 93.1,1922
≥3 Doses HepB,,HHS Regions/National,Region 6,2023,Age,13-17 Years,85.5,81.5 to 88.8,2086
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2023,Age,13-17 Years,86.5,82.4 to 89.7,1922
≥2 Doses Hep A,,HHS Regions/National,Region 6,2023,Age,13-17 Years,87.3,83.8 to 90.2,2086
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2023,Age,13-17 Years,87.7,84.0 to 90.7,2086
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2023,Age,13-15 Years,84.6,79.3 to 88.7,1280
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2023,Age,13-15 Years,85.2,80.1 to 89.1,1280
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2023,Age,13-15 Years,48.5,39.8 to 57.3,663
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2023,Age,13-15 Years,53.3,47.0 to 59.6,1280
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2023,Age,13-15 Years,86.9,81.3 to 91.0,1187
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2023,Age,13-17 Years,60.1,53.2 to 66.6,1029
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2023,Age,13-15 Years,58.7,49.6 to 67.2,617
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2023,Age,13-17 Years,72.9,66.3 to 78.6,1057
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2022,Age,13-17 Years,63.9,57.0 to 70.2,952
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2020,Age,13-17 Years,90.0,87.9 to 91.7,2509
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2017,Age,13-17 Years,84.4,82.4 to 86.2,3654
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2008,Age,13-15 Years,9.8,6.8 to 13.9,636
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2009,Age,13-15 Years,23.1,18.3 to 28.7,859
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2010,Age,13-15 Years,28.3,23.0 to 34.3,898
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2011,Age,13-15 Years,29.2,23.3 to 35.8,1134
≥2 Doses MMR,,HHS Regions/National,Region 6,2022,Age,13-17 Years,84.4,80.3 to 87.8,1981
≥2 Doses MMR,,HHS Regions/National,Region 6,2021,Age,13-17 Years,86.6,83.4 to 89.3,2184
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2014,Age,13-15 Years,34.0,28.0 to 40.4,917
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2015,Age,13-15 Years,38.8,34.2 to 43.7,1224
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2013,Age,13-15 Years,35.1,29.0 to 41.8,722
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2012,Age,13-15 Years,28.2,24.0 to 33.0,943
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 6,2012,Age,13-17 Years,19.0,16.8 to 21.3,2939
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2021,Age,13-17 Years,88.1,85.3 to 90.4,2184
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2020,Age,13-17 Years,85.7,82.8 to 88.3,2509
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2019,Age,13-17 Years,86.7,84.7 to 88.5,3289
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 6,2014,Age,13-17 Years,26.0,23.1 to 29.1,3089
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 6,2015,Age,13-17 Years,32.6,30.2 to 35.1,4048
≥2 Doses MMR,,HHS Regions/National,Region 6,2020,Age,13-17 Years,88.3,85.7 to 90.5,2509
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 6,2013,Age,13-17 Years,26.1,23.0 to 29.4,2505
≥2 Doses MMR,,HHS Regions/National,Region 6,2019,Age,13-17 Years,86.6,84.4 to 88.6,3289
≥2 Doses MMR,,HHS Regions/National,Region 6,2017,Age,13-17 Years,87.0,85.1 to 88.7,3654
≥2 Doses MMR,,HHS Regions/National,Region 6,2018,Age,13-17 Years,85.6,83.5 to 87.5,3326
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2006,Age,13-17 Years,8.7,5.5 to 13.6,268
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2022,Age,13-17 Years,86.9,83.3 to 89.8,1981
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2007,Age,13-17 Years,27.9,22.1 to 34.7,322
≥2 Doses MMR,,HHS Regions/National,Region 6,2013,Age,13-17 Years,89.0,86.3 to 91.2,2505
≥2 Doses MMR,,HHS Regions/National,Region 6,2012,Age,13-17 Years,88.4,86.3 to 90.2,2939
≥2 Doses MMR,,HHS Regions/National,Region 6,2015,Age,13-17 Years,87.1,85.2 to 88.8,4048
≥2 Doses MMR,,HHS Regions/National,Region 6,2014,Age,13-17 Years,86.1,83.3 to 88.6,3089
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 6,2011,Age,13-17 Years,16.0,13.6 to 18.7,3838
≥2 Doses MMR,,HHS Regions/National,Region 6,2016,Age,13-17 Years,86.2,84.1 to 88.1,3270
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2017,Age,13-17 Years,85.0,83.0 to 86.8,3654
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2018,Age,13-17 Years,85.2,83.1 to 87.0,3326
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2016,Age,13-17 Years,84.9,82.8 to 86.8,3270
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2015,Age,13-17 Years,86.4,84.6 to 88.0,4048
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2014,Age,13-17 Years,85.0,82.7 to 87.1,3089
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2013,Age,13-17 Years,81.5,78.8 to 83.9,2505
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2009,Age,13-17 Years,48.6,45.0 to 52.3,2856
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2008,Age,13-17 Years,36.6,32.2 to 41.3,2203
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2011,Age,13-17 Years,73.5,70.7 to 76.2,3838
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2010,Age,13-17 Years,61.6,58.3 to 64.9,3001
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2016,Age,13-17 Years,86.7,84.6 to 88.5,3270
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2022,Age,13-15 Years,85.2,80.2 to 89.0,1229
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2021,Age,13-17 Years,89.9,87.3 to 92.0,2184
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2022,Age,13-17 Years,87.0,83.6 to 89.8,1981
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2019,Age,13-17 Years,86.3,84.3 to 88.1,3289
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2018,Age,13-17 Years,85.3,83.3 to 87.0,3326
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2012,Age,13-17 Years,78.4,75.9 to 80.7,2939
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2023,Age,13-17 Years,63.2,51.9 to 73.2,116
HPV,"≥1 Dose, Females",States/Local Areas,Washington,2023,Age,13-17 Years,79.5,68.9 to 87.1,116
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2023,Age,13-15 Years,92.8,86.2 to 96.4,136
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2023,Age,13-15 Years,58.3,43.6 to 71.6,70
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2023,Age,13-15 Years,58.6,48.4 to 68.1,149
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2023,Age,13-15 Years,58.9,44.7 to 71.7,79
≥1 Dose MenACWY,,States/Local Areas,Washington,2023,Age,13-15 Years,83.2,74.6 to 89.3,149
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2023,Age,13-15 Years,89.3,82.7 to 93.6,149
≥2 Doses Hep A,,States/Local Areas,Washington,2023,Age,13-17 Years,87.9,82.0 to 92.0,236
Varicella,≥2 Doses or history of disease,States/Local Areas,Washington,2023,Age,13-17 Years,90.6,85.2 to 94.2,236
Varicella,≥2 Doses with no disease history,States/Local Areas,Washington,2023,Age,13-17 Years,89.7,83.7 to 93.6,216
Varicella,≥1 Dose with no disease history,States/Local Areas,Washington,2023,Age,13-17 Years,93.0,87.4 to 96.2,216
≥3 Doses HepB,,States/Local Areas,Washington,2023,Age,13-17 Years,90.8,85.3 to 94.4,236
Varicella,History of disease,States/Local Areas,Washington,2023,Age,13-17 Years,9.4,5.5 to 15.5,236
HPV,"Up-to-Date, Males",States/Local Areas,Washington,2023,Age,13-17 Years,67.0,55.7 to 76.7,120
≥2 Doses MMR,,States/Local Areas,Washington,2023,Age,13-17 Years,92.9,87.8 to 96.0,236
HPV,"≥1 Dose, Males and Females",States/Local Areas,Washington,2023,Age,13-17 Years,81.8,75.1 to 87.0,236
HPV,"Up-to-Date, Males and Females",States/Local Areas,Washington,2023,Age,13-17 Years,65.2,57.3 to 72.3,236
HPV,"≥1 Dose, Males",States/Local Areas,Washington,2023,Age,13-17 Years,84.0,74.8 to 90.3,120
≥1 Dose MenACWY,,States/Local Areas,Washington,2023,Age,13-17 Years,86.3,80.0 to 90.9,236
Tetanus,≥1 Dose Tdap,States/Local Areas,Washington,2023,Age,13-17 Years,90.4,85.1 to 94.0,236
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Washington,2023,Age,13-17 Years,90.4,85.1 to 94.0,236
≥3 Doses HepB,,States/Local Areas,West Virginia,2016,Age,13-17 Years,87.4,82.5 to 91.0,313
≥3 Doses HepB,,States/Local Areas,West Virginia,2019,Age,13-17 Years,92.3,87.2 to 95.5,309
≥3 Doses HepB,,States/Local Areas,West Virginia,2017,Age,13-17 Years,85.1,79.9 to 89.1,343
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2014,Age,13-17 Years,88.7,83.2 to 92.6,256
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2013,Age,13-17 Years,88.8,83.0 to 92.9,213
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2015,Age,13-17 Years,90.4,85.3 to 93.8,263
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2016,Age,13-17 Years,92.6,88.4 to 95.3,253
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2019,Age,13-17 Years,86.8,81.3 to 90.8,282
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2020,Age,13-17 Years,88.8,84.0 to 92.3,276
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2021,Age,13-17 Years,83.6,76.6 to 88.9,242
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2018,Age,13-17 Years,80.7,74.8 to 85.5,290
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2020,Age,13-17 Years,95.2,91.5 to 97.3,276
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2017,Age,13-17 Years,89.9,84.6 to 93.5,296
≥3 Doses HepB,,States/Local Areas,West Virginia,2015,Age,13-17 Years,86.5,81.7 to 90.2,344
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2014,Age,13-17 Years,58.0,48.5 to 67.0,162
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2013,Age,13-17 Years,49.7,40.5 to 59.0,152
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2012,Age,13-17 Years,45.2,35.0 to 55.9,134
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2020,Age,13-15 Years,92.7,87.4 to 95.9,161
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2018,Age,13-15 Years,80.6,72.5 to 86.8,188
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2016,Age,13-15 Years,81.3,73.3 to 87.3,160
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2008,Age,13-15 Years,20.2,12.2 to 31.6,84
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2009,Age,13-15 Years,40.0,28.9 to 52.3,74
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2010,Age,13-15 Years,45.5,35.2 to 56.3,98
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2011,Age,13-15 Years,54.9,45.1 to 64.3,160
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2013,Age,13-15 Years,64.0,54.1 to 72.9,146
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2012,Age,13-15 Years,65.6,53.7 to 75.8,112
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2017,Age,13-17 Years,75.8,69.4 to 81.2,296
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2010,Age,13-17 Years,42.4,34.3 to 51.0,164
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2011,Age,13-17 Years,50.6,41.4 to 59.6,179
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2014,Age,13-17 Years,60.8,53.1 to 68.0,256
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2013,Age,13-17 Years,59.4,51.1 to 67.2,213
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2015,Age,13-17 Years,69.8,62.8 to 76.0,263
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2016,Age,13-17 Years,77.2,70.7 to 82.6,253
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2014,Age,13-15 Years,60.4,51.0 to 69.2,171
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2015,Age,13-15 Years,72.6,63.8 to 79.9,163
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2021,Age,13-17 Years,85.3,78.9 to 90.0,267
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2013,Age,13-17 Years,73.5,67.2 to 79.0,328
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2011,Age,13-17 Years,67.5,61.7 to 72.9,403
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2012,Age,13-17 Years,76.7,70.0 to 82.3,282
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2017,Age,13-15 Years,79.6,72.2 to 85.5,196
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2022,Age,13-17 Years,92.8,87.7 to 95.9,244
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2020,Age,13-17 Years,90.1,85.8 to 93.2,310
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2014,Age,13-17 Years,71.1,64.7 to 76.7,350
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2015,Age,13-17 Years,76.8,71.0 to 81.7,344
HPV,"≥3 Doses, Males",States/Local Areas,West Virginia,2014,Age,13-17 Years,23.5,16.7 to 32.0,188
HPV,"≥3 Doses, Males",States/Local Areas,West Virginia,2015,Age,13-17 Years,27.1,20.2 to 35.3,180
HPV,"≥3 Doses, Males",States/Local Areas,West Virginia,2014,Age,13-15 Years,21.9,14.3 to 32.0,125
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2009,Age,13-17 Years,73.5,67.0 to 79.2,249
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2010,Age,13-17 Years,73.9,68.3 to 78.8,321
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2019,Age,13-17 Years,87.9,82.8 to 91.6,309
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2018,Age,13-17 Years,83.2,78.0 to 87.4,337
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2017,Age,13-17 Years,79.6,73.9 to 84.2,343
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2015,Age,13-17 Years,76.6,73.8 to 79.2,2120
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2016,Age,13-17 Years,81.3,75.8 to 85.8,313
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2008,Age,13-17 Years,66.9,60.2 to 72.9,295
≥2 Doses Hep A,,States/Local Areas,West Virginia,2021,Age,13-17 Years,81.3,74.8 to 86.5,267
HPV,"≥3 Doses, Males",States/Local Areas,West Virginia,2013,Age,13-17 Years,15.1,9.7 to 22.9,176
HPV,"≥3 Doses, Males",States/Local Areas,West Virginia,2013,Age,13-15 Years,18.8,10.8 to 30.6,100
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2011,Age,13-17 Years,28.6,21.2 to 37.3,179
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2012,Age,13-17 Years,36.1,26.6 to 46.7,134
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2014,Age,13-17 Years,40.0,31.4 to 49.3,162
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2013,Age,13-17 Years,38.4,29.9 to 47.6,152
HPV,"≥3 Doses, Males",States/Local Areas,West Virginia,2015,Age,13-15 Years,23.7,15.3 to 34.7,113
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2008,Age,13-17 Years,24.1,19.1 to 29.9,295
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2022,Age,13-15 Years,89.5,83.2 to 93.6,148
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2011,Age,13-17 Years,60.1,54.0 to 65.9,403
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2009,Age,13-17 Years,40.5,33.8 to 47.5,249
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2010,Age,13-17 Years,49.9,43.8 to 55.9,321
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2017,Age,13-17 Years,43.9,37.7 to 50.2,343
≥2 Doses MMR,,States/Local Areas,West Virginia,2011,Age,13-17 Years,79.8,74.4 to 84.3,403
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018,Age,13-17 Years,42.9,37.0 to 49.1,337
≥2 Doses MMR,,States/Local Areas,West Virginia,2010,Age,13-17 Years,79.7,74.3 to 84.3,321
≥2 Doses MMR,,States/Local Areas,West Virginia,2008,Age,13-17 Years,80.8,75.1 to 85.5,295
≥2 Doses MMR,,States/Local Areas,West Virginia,2009,Age,13-17 Years,79.9,73.2 to 85.3,249
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2021,Age,13-17 Years,56.4,49.2 to 63.3,267
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2019,Age,13-17 Years,46.0,37.8 to 54.4,186
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2014,Age,13-17 Years,77.9,71.5 to 83.2,350
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2013,Age,13-17 Years,76.7,70.7 to 81.8,328
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2012,Age,13-17 Years,68.2,60.7 to 74.8,282
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2021,Age,13-15 Years,86.2,79.0 to 91.2,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2016,Age,13-17 Years,41.2,34.7 to 47.9,313
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2010,Age,13-17 Years,25.3,18.9 to 32.9,164
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2008,Age,13-17 Years,17.1,11.3 to 25.1,156
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2009,Age,13-17 Years,27.0,19.2 to 36.4,118
≥2 Doses Hep A,,States/Local Areas,West Virginia,2020,Age,13-17 Years,77.7,72.1 to 82.4,310
≥2 Doses Hep A,,States/Local Areas,West Virginia,2022,Age,13-17 Years,91.6,86.9 to 94.7,244
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2015,Age,13-17 Years,39.2,31.0 to 48.0,164
HPV,"≥2 Doses, Males and Females",States/Local Areas,West Virginia,2016,Age,13-17 Years,45.5,38.9 to 52.2,313
HPV,"≥2 Doses, Males and Females",States/Local Areas,West Virginia,2017,Age,13-17 Years,48.2,41.9 to 54.5,343
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2021,Age,13-17 Years,90.8,84.7 to 94.6,242
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2011,Age,13-17 Years,6.9,4.2 to 11.2,224
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2022,Age,13-17 Years,71.9,61.5 to 80.4,110
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2020,Age,13-17 Years,63.6,54.1 to 72.1,148
HPV,"≥2 Doses, Males and Females",States/Local Areas,West Virginia,2018,Age,13-17 Years,49.5,43.4 to 55.6,337
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2022,Age,13-17 Years,92.2,86.8 to 95.5,226
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2014,Age,13-17 Years,42.7,34.1 to 51.7,188
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2013,Age,13-17 Years,29.4,21.7 to 38.5,176
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2015,Age,13-17 Years,45.3,37.1 to 53.8,180
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2016,Age,13-17 Years,50.0,40.9 to 59.2,166
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2021,Age,13-17 Years,81.8,73.1 to 88.2,123
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2019,Age,13-17 Years,67.5,57.3 to 76.3,123
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2012,Age,13-17 Years,61.5,51.8 to 70.3,166
HPV,"≥2 Doses, Males and Females",States/Local Areas,West Virginia,2019,Age,13-17 Years,49.4,42.9 to 56.0,309
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2009,Age,13-17 Years,78.7,68.3 to 86.4,104
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2010,Age,13-17 Years,74.2,65.3 to 81.4,141
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2011,Age,13-17 Years,46.8,38.9 to 54.9,237
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2010,Age,13-17 Years,40.2,31.8 to 49.2,141
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2008,Age,13-17 Years,33.6,25.7 to 42.6,156
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2009,Age,13-17 Years,38.5,29.5 to 48.4,118
≥3 Doses HepB,,States/Local Areas,West Virginia,2009,Age,13-17 Years,79.4,72.7 to 84.8,249
≥3 Doses HepB,,States/Local Areas,West Virginia,2010,Age,13-17 Years,77.4,71.8 to 82.2,321
≥3 Doses HepB,,States/Local Areas,West Virginia,2014,Age,13-17 Years,84.4,78.9 to 88.8,350
≥3 Doses HepB,,States/Local Areas,West Virginia,2013,Age,13-17 Years,84.5,79.5 to 88.4,328
≥3 Doses HepB,,States/Local Areas,West Virginia,2011,Age,13-17 Years,82.0,76.9 to 86.2,403
≥3 Doses HepB,,States/Local Areas,West Virginia,2012,Age,13-17 Years,84.4,77.6 to 89.4,282
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2008,Age,13-17 Years,16.6,10.6 to 25.2,119
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2009,Age,13-17 Years,33.9,24.8 to 44.4,104
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2022,Age,13-15 Years,97.3,94.1 to 98.8,139
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2011,Age,13-17 Years,77.3,69.9 to 83.4,237
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2008,Age,13-17 Years,66.5,55.0 to 76.3,119
≥3 Doses HepB,,States/Local Areas,West Virginia,2008,Age,13-17 Years,72.4,66.2 to 77.8,295
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2012,Age,13-17 Years,88.4,81.0 to 93.1,166
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2019,Age,13-15 Years,87.1,79.5 to 92.1,187
≥3 Doses HepB,,States/Local Areas,West Virginia,2018,Age,13-17 Years,88.2,83.8 to 91.6,337
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2018,Age,13-17 Years,91.6,87.4 to 94.5,290
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2021,Age,13-15 Years,86.1,78.0 to 91.6,146
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2019,Age,13-15 Years,89.8,82.7 to 94.2,206
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2017,Age,13-17 Years,60.9,54.6 to 66.9,343
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018,Age,13-15 Years,88.2,81.4 to 92.7,209
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2017,Age,13-15 Years,87.0,80.4 to 91.7,209
≥3 Doses HepB,,States/Local Areas,West Virginia,2020,Age,13-17 Years,93.3,89.6 to 95.7,310
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2022,Age,13-17 Years,96.1,92.7 to 98.0,226
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2020,Age,13-17 Years,56.1,47.1 to 64.8,162
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2017,Age,13-17 Years,54.7,46.0 to 63.0,190
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2012,Age,13-17 Years,18.3,11.2 to 28.3,148
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2018,Age,13-17 Years,53.7,45.2 to 61.9,181
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2013,Age,13-17 Years,79.3,73.4 to 84.2,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2014,Age,13-17 Years,79.6,73.3 to 84.7,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2015,Age,13-17 Years,87.8,83.4 to 91.2,344
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2016,Age,13-17 Years,92.4,88.4 to 95.1,313
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2019,Age,13-17 Years,62.0,53.5 to 69.9,186
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2016,Age,13-15 Years,88.4,82.1 to 92.7,197
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2014,Age,13-15 Years,79.6,71.8 to 85.6,224
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2015,Age,13-15 Years,85.8,79.5 to 90.5,210
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2013,Age,13-17 Years,43.6,34.8 to 52.9,152
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2012,Age,13-17 Years,41.2,31.1 to 52.0,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2016,Age,13-17 Years,54.2,47.5 to 60.8,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2017,Age,13-17 Years,89.4,84.9 to 92.6,343
≥3 Doses HepB,,States/Local Areas,West Virginia,2022,Age,13-17 Years,93.9,90.0 to 96.3,244
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2019,Age,13-17 Years,95.6,92.0 to 97.6,282
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2015,Age,13-17 Years,62.0,53.1 to 70.2,164
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2016,Age,13-17 Years,58.5,48.8 to 67.6,147
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2017,Age,13-17 Years,67.5,58.3 to 75.6,153
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2018,Age,13-17 Years,69.3,60.8 to 76.7,156
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2009,Age,13-17 Years,31.6,23.4 to 41.2,118
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2020,Age,13-15 Years,91.0,84.7 to 94.8,181
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2011,Age,13-17 Years,45.0,36.0 to 54.3,179
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2010,Age,13-17 Years,35.2,27.6 to 43.7,164
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2008,Age,13-17 Years,24.3,17.4 to 32.7,156
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2008,Age,13-17 Years,44.7,38.3 to 51.2,295
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2009,Age,13-17 Years,52.2,45.1 to 59.2,249
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2010,Age,13-15 Years,46.5,39.0 to 54.2,198
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2011,Age,13-15 Years,55.0,47.2 to 62.5,246
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2008,Age,13-15 Years,30.1,23.0 to 38.4,182
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2009,Age,13-15 Years,36.3,28.5 to 45.0,154
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2013,Age,13-15 Years,79.5,72.0 to 85.4,201
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2012,Age,13-15 Years,62.9,52.7 to 72.0,166
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2022,Age,13-17 Years,68.0,57.9 to 76.7,134
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2011,Age,13-17 Years,68.6,62.8 to 73.9,403
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2010,Age,13-17 Years,56.3,50.2 to 62.2,321
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2021,Age,13-17 Years,59.8,50.0 to 68.9,144
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018,Age,13-17 Years,61.3,55.2 to 67.0,337
≥3 Doses HepB,,States/Local Areas,West Virginia,2021,Age,13-17 Years,86.1,79.8 to 90.6,267
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2012,Age,13-17 Years,73.6,66.3 to 79.8,282
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2019,Age,13-17 Years,92.4,87.7 to 95.4,309
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2019,Age,13-17 Years,64.7,58.2 to 70.7,309
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2021,Age,13-17 Years,92.4,88.3 to 95.1,267
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2018,Age,13-17 Years,90.8,86.1 to 94.0,337
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2020,Age,13-17 Years,92.2,87.7 to 95.2,310
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2022,Age,13-17 Years,69.9,62.8 to 76.2,244
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2020,Age,13-17 Years,59.7,53.2 to 65.9,310
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2014,Age,13-17 Years,48.3,39.1 to 57.5,162
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2015,Age,13-17 Years,49.7,41.0 to 58.5,164
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2016,Age,13-17 Years,52.9,43.3 to 62.3,147
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2017,Age,13-17 Years,53.7,44.3 to 62.9,153
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2021,Age,13-17 Years,70.5,63.7 to 76.5,267
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2021,Age,13-15 Years,87.9,81.0 to 92.5,162
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2011,Age,13-15 Years,62.8,55.2 to 69.9,246
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2018,Age,13-17 Years,58.5,49.5 to 66.9,156
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2008,Age,13-15 Years,26.6,19.9 to 34.6,182
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2022,Age,13-17 Years,93.1,89.0 to 95.7,244
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2010,Age,13-15 Years,55.3,47.6 to 62.8,198
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2009,Age,13-15 Years,43.5,34.8 to 52.6,154
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2019,Age,13-15 Years,87.6,80.6 to 92.3,206
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2016,Age,13-17 Years,38.4,29.9 to 47.7,166
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2017,Age,13-17 Years,42.9,34.7 to 51.5,190
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2017,Age,13-15 Years,85.4,78.8 to 90.2,209
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018,Age,13-15 Years,86.2,78.8 to 91.3,209
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2020,Age,13-15 Years,91.5,85.2 to 95.3,181
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2018,Age,13-17 Years,41.0,33.1 to 49.5,181
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2012,Age,13-15 Years,65.3,55.3 to 74.2,166
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2013,Age,13-15 Years,79.2,71.5 to 85.3,201
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2019,Age,13-17 Years,53.0,42.9 to 63.0,123
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2015,Age,13-17 Years,36.6,28.8 to 45.2,180
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2013,Age,13-17 Years,19.2,12.9 to 27.5,176
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2014,Age,13-17 Years,28.8,21.5 to 37.3,188
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2014,Age,13-15 Years,79.9,72.1 to 85.9,224
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2015,Age,13-15 Years,85.9,80.1 to 90.2,210
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2016,Age,13-15 Years,89.2,83.2 to 93.2,197
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2019,Age,13-17 Years,91.0,86.0 to 94.4,309
HPV,"≥3 Doses, Males and Females",States/Local Areas,West Virginia,2012,Age,13-17 Years,19.4,14.3 to 25.8,282
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2022,Age,13-15 Years,91.3,85.0 to 95.2,148
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2008,Age,13-17 Years,30.2,24.6 to 36.4,295
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2009,Age,13-17 Years,39.0,32.5 to 45.9,249
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2011,Age,13-17 Years,54.9,48.8 to 60.8,403
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2010,Age,13-17 Years,45.7,39.7 to 51.8,321
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2016,Age,13-17 Years,89.7,85.3 to 92.9,313
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2015,Age,13-17 Years,85.8,81.2 to 89.5,344
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018,Age,13-17 Years,87.9,83.0 to 91.6,337
≥2 Doses MMR,,States/Local Areas,West Virginia,2013,Age,13-17 Years,83.2,77.9 to 87.5,328
≥2 Doses MMR,,States/Local Areas,West Virginia,2012,Age,13-17 Years,85.0,79.1 to 89.5,282
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2017,Age,13-17 Years,87.5,82.8 to 91.0,343
≥2 Doses MMR,,States/Local Areas,West Virginia,2016,Age,13-17 Years,86.8,81.7 to 90.6,313
≥2 Doses MMR,,States/Local Areas,West Virginia,2014,Age,13-17 Years,81.2,75.4 to 85.8,350
≥2 Doses MMR,,States/Local Areas,West Virginia,2015,Age,13-17 Years,82.1,76.9 to 86.4,344
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2012,Age,13-17 Years,64.1,56.4 to 71.1,282
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2014,Age,13-17 Years,78.9,72.7 to 84.0,350
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2013,Age,13-17 Years,77.3,71.3 to 82.3,328
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2015,Age,13-17 Years,86.0,81.1 to 89.7,344
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2016,Age,13-17 Years,89.0,84.5 to 92.3,313
HPV,"≥3 Doses, Males and Females",States/Local Areas,West Virginia,2011,Age,13-17 Years,14.8,11.0 to 19.7,403
HPV,"≥3 Doses, Males and Females",States/Local Areas,West Virginia,2015,Age,13-17 Years,33.0,27.5 to 38.9,344
HPV,"≥3 Doses, Males and Females",States/Local Areas,West Virginia,2014,Age,13-17 Years,31.6,25.9 to 37.8,350
HPV,"≥3 Doses, Males and Females",States/Local Areas,West Virginia,2013,Age,13-17 Years,26.5,21.3 to 32.5,328
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2020,Age,13-17 Years,92.2,87.7 to 95.2,310
≥2 Doses MMR,,States/Local Areas,West Virginia,2019,Age,13-17 Years,91.3,86.2 to 94.7,309
≥2 Doses MMR,,States/Local Areas,West Virginia,2017,Age,13-17 Years,85.0,80.0 to 89.0,343
≥2 Doses MMR,,States/Local Areas,West Virginia,2018,Age,13-17 Years,86.5,81.7 to 90.2,337
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2012,Age,13-15 Years,30.5,19.4 to 44.5,76
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2019,Age,13-17 Years,89.4,84.4 to 92.9,309
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2021,Age,13-17 Years,88.4,83.6 to 92.0,267
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2022,Age,13-17 Years,92.7,88.5 to 95.4,244
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2010,Age,13-15 Years,22.3,14.9 to 31.8,95
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2009,Age,13-15 Years,24.8,15.5 to 37.3,66
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2011,Age,13-15 Years,26.4,17.5 to 37.8,110
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2014,Age,13-15 Years,35.7,25.7 to 47.2,99
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2015,Age,13-15 Years,33.9,24.1 to 45.3,97
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2013,Age,13-15 Years,32.0,22.4 to 43.2,101
HPV,"≥3 Doses, Females",States/Local Areas,West Virginia,2008,Age,13-15 Years,15.6,8.5 to 27.0,92
≥2 Doses MMR,,States/Local Areas,West Virginia,2021,Age,13-17 Years,87.6,81.6 to 91.8,267
≥2 Doses MMR,,States/Local Areas,West Virginia,2020,Age,13-17 Years,92.8,89.3 to 95.2,310
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2021,Age,13-17 Years,90.7,85.6 to 94.1,267
≥2 Doses MMR,,States/Local Areas,West Virginia,2022,Age,13-17 Years,92.0,87.1 to 95.2,244
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018,Age,13-17 Years,88.7,84.0 to 92.2,337
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2020,Age,13-17 Years,91.4,86.9 to 94.4,310
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2017,Age,13-17 Years,87.9,83.1 to 91.5,343
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2022,Age,13-17 Years,94.2,90.0 to 96.7,244
Varicella,History of disease,States/Local Areas,West Virginia,2017,Age,13-17 Years,15.6,11.4 to 20.9,343
Varicella,History of disease,States/Local Areas,West Virginia,2018,Age,13-17 Years,13.1,9.6 to 17.6,337
Varicella,History of disease,States/Local Areas,West Virginia,2015,Age,13-17 Years,23.2,18.5 to 28.7,344
Varicella,History of disease,States/Local Areas,West Virginia,2016,Age,13-17 Years,18.0,13.5 to 23.6,313
Varicella,History of disease,States/Local Areas,West Virginia,2011,Age,13-17 Years,39.0,33.4 to 44.9,403
Varicella,History of disease,States/Local Areas,West Virginia,2010,Age,13-17 Years,56.4,50.3 to 62.2,321
Varicella,History of disease,States/Local Areas,West Virginia,2013,Age,13-17 Years,34.7,28.8 to 41.1,328
Varicella,History of disease,States/Local Areas,West Virginia,2012,Age,13-17 Years,39.5,32.5 to 46.9,282
Varicella,History of disease,States/Local Areas,West Virginia,2014,Age,13-17 Years,26.3,21.0 to 32.4,350
Varicella,History of disease,States/Local Areas,West Virginia,2009,Age,13-17 Years,60.0,53.0 to 66.6,249
Varicella,History of disease,States/Local Areas,West Virginia,2008,Age,13-17 Years,60.3,53.6 to 66.5,295
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2018,Age,13-15 Years,45.9,35.3 to 56.9,104
Varicella,History of disease,States/Local Areas,West Virginia,2019,Age,13-17 Years,8.2,5.2 to 12.7,309
Varicella,History of disease,States/Local Areas,West Virginia,2020,Age,13-17 Years,11.2,7.6 to 16.2,310
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2020,Age,13-15 Years,41.0,29.5 to 53.6,79
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2021,Age,13-15 Years,51.8,42.7 to 60.8,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2022,Age,13-15 Years,43.6,34.6 to 52.9,148
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2017,Age,13-17 Years,39.3,31.4 to 47.9,190
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2020,Age,13-17 Years,38.9,30.5 to 47.9,162
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2018,Age,13-17 Years,33.5,26.2 to 41.7,181
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2019,Age,13-15 Years,44.8,36.8 to 53.1,206
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2022,Age,13-17 Years,41.2,32.1 to 51.0,134
Varicella,History of disease,States/Local Areas,West Virginia,2022,Age,13-17 Years,7.1,4.2 to 11.9,244
Varicella,History of disease,States/Local Areas,West Virginia,2021,Age,13-17 Years,10.0,6.3 to 15.6,267
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2020,Age,13-17 Years,43.4,37.1 to 49.8,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2022,Age,13-17 Years,51.5,44.2 to 58.7,244
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2019,Age,13-17 Years,47.4,40.9 to 54.0,309
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2020,Age,13-15 Years,36.7,29.1 to 44.9,181
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2019,Age,13-17 Years,43.8,35.7 to 52.3,186
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2020,Age,13-17 Years,48.2,39.1 to 57.4,148
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2019,Age,13-15 Years,43.8,33.8 to 54.3,126
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2021,Age,13-17 Years,67.3,57.2 to 76.0,123
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2018,Age,13-15 Years,28.8,19.8 to 39.7,105
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2022,Age,13-17 Years,62.4,51.7 to 72.0,110
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2022,Age,13-15 Years,37.6,27.0 to 49.6,87
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2021,Age,13-15 Years,38.3,27.1 to 50.9,87
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2016,Age,13-17 Years,49.7,40.2 to 59.3,147
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2019,Age,13-17 Years,51.3,41.1 to 61.3,123
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2018,Age,13-17 Years,52.9,44.0 to 61.6,156
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2017,Age,13-17 Years,48.6,39.4 to 57.9,153
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2020,Age,13-15 Years,33.3,23.9 to 44.2,102
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2021,Age,13-17 Years,46.1,36.6 to 55.9,144
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2022,Age,13-15 Years,50.4,36.3 to 64.5,61
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2021,Age,13-15 Years,66.6,53.6 to 77.5,75
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2016,Age,13-17 Years,33.0,24.9 to 42.2,166
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2019,Age,13-15 Years,46.1,33.6 to 59.1,80
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2008,Age,13-17 Years,95.3,91.7 to 97.4,737
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2010,Age,13-17 Years,97.8,96.6 to 98.6,1192
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2009,Age,13-17 Years,95.9,93.6 to 97.4,1067
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2008,Age,13-17 Years,43.7,38.3 to 49.3,737
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2009,Age,13-17 Years,58.9,54.2 to 63.5,1067
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2006,Age,13-17 Years,84.4,70.7 to 92.4,46
≥3 Doses HepB,,HHS Regions/National,Region 1,2007,Age,13-17 Years,95.3,90.6 to 97.8,190
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2011,Age,13-17 Years,98.0,96.6 to 98.8,1653
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2010,Age,13-17 Years,76.1,71.8 to 79.9,1192
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2011,Age,13-17 Years,83.2,79.8 to 86.1,1653
≥3 Doses HepB,,HHS Regions/National,Region 1,2006,Age,13-17 Years,92.9,87.1 to 96.2,170
≥3 Doses HepB,,HHS Regions/National,Region 1,2010,Age,13-17 Years,95.5,93.8 to 96.7,2026
≥3 Doses HepB,,HHS Regions/National,Region 1,2009,Age,13-17 Years,95.4,94.0 to 96.4,2189
≥3 Doses HepB,,HHS Regions/National,Region 1,2017,Age,13-17 Years,95.0,93.3 to 96.3,2107
≥3 Doses HepB,,HHS Regions/National,Region 1,2018,Age,13-17 Years,96.9,95.2 to 98.0,1902
≥3 Doses HepB,,HHS Regions/National,Region 1,2019,Age,13-17 Years,95.5,93.6 to 96.9,2034
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2018,Age,13-17 Years,98.4,97.2 to 99.0,1708
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2019,Age,13-17 Years,95.2,93.1 to 96.6,1862
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2020,Age,13-17 Years,96.4,94.9 to 97.5,1984
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2021,Age,13-17 Years,96.0,93.6 to 97.5,1785
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2018,Age,13-17 Years,96.9,95.6 to 97.8,1708
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2020,Age,13-17 Years,98.0,96.8 to 98.8,1984
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2017,Age,13-17 Years,97.2,95.2 to 98.4,1816
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2019,Age,13-17 Years,97.2,95.2 to 98.3,1862
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2012,Age,13-17 Years,99.2,98.7 to 99.5,1366
≥3 Doses HepB,,HHS Regions/National,Region 1,2015,Age,13-17 Years,96.0,94.2 to 97.3,2188
≥3 Doses HepB,,HHS Regions/National,Region 1,2016,Age,13-17 Years,96.2,94.7 to 97.3,2097
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2013,Age,13-17 Years,97.9,96.5 to 98.8,1536
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2014,Age,13-17 Years,97.2,95.4 to 98.3,1862
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2015,Age,13-17 Years,98.7,97.7 to 99.2,1827
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2016,Age,13-17 Years,98.4,97.4 to 99.0,1815
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2012,Age,13-17 Years,64.2,59.3 to 68.8,900
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2013,Age,13-17 Years,61.9,57.2 to 66.4,978
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2014,Age,13-17 Years,67.8,63.1 to 72.2,1070
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2015,Age,13-17 Years,73.0,68.1 to 77.4,1026
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2011,Age,13-17 Years,62.1,57.3 to 66.7,1211
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2010,Age,13-17 Years,61.1,56.2 to 65.7,953
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2017,Age,13-17 Years,94.7,92.6 to 96.2,1816
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2013,Age,13-17 Years,90.9,88.4 to 93.0,1536
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2014,Age,13-17 Years,92.9,90.6 to 94.7,1862
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2015,Age,13-17 Years,94.3,92.4 to 95.7,1827
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2016,Age,13-17 Years,95.9,94.6 to 96.9,1815
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2007,Age,13-15 Years,23.5,13.1 to 38.5,52
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2020,Age,13-15 Years,96.8,94.8 to 98.1,1213
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2021,Age,13-15 Years,96.0,93.1 to 97.8,1109
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2015,Age,13-17 Years,95.1,93.5 to 96.4,2188
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2015,Age,13-15 Years,95.5,93.3 to 96.9,1137
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2014,Age,13-15 Years,94.3,91.3 to 96.3,1160
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2018,Age,13-15 Years,97.1,95.6 to 98.1,1043
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2019,Age,13-15 Years,95.3,92.3 to 97.1,1118
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2012,Age,13-15 Years,90.9,87.1 to 93.6,884
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2013,Age,13-15 Years,91.4,87.9 to 93.9,967
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2011,Age,13-15 Years,86.3,82.5 to 89.3,1111
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2010,Age,13-15 Years,77.5,72.2 to 82.0,833
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2008,Age,13-15 Years,46.2,39.8 to 52.7,552
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2009,Age,13-15 Years,60.9,55.3 to 66.2,778
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2017,Age,13-15 Years,95.6,93.0 to 97.3,1138
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2016,Age,13-15 Years,96.0,94.2 to 97.3,1083
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2010,Age,13-17 Years,85.2,82.3 to 87.6,2026
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2009,Age,13-17 Years,79.6,76.7 to 82.2,2189
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2007,Age,13-17 Years,70.5,62.1 to 77.7,190
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2020,Age,13-17 Years,96.6,95.3 to 97.6,2147
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2021,Age,13-17 Years,96.2,94.0 to 97.7,1923
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2022,Age,13-17 Years,96.6,95.2 to 97.6,1595
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2012,Age,13-17 Years,25.7,21.8 to 30.1,1016
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 1,2018,Age,13-17 Years,66.7,62.9 to 70.2,1902
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2019,Age,13-17 Years,81.6,77.1 to 85.3,950
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 1,2017,Age,13-17 Years,66.9,63.7 to 69.9,2107
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2022,Age,13-17 Years,96.3,94.9 to 97.4,1490
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2020,Age,13-17 Years,83.9,80.0 to 87.1,1015
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2021,Age,13-17 Years,85.4,80.4 to 89.3,898
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2011,Age,13-17 Years,9.2,7.0 to 12.1,1256
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2022,Age,13-17 Years,85.9,81.0 to 89.6,778
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 1,2016,Age,13-17 Years,61.5,58.2 to 64.7,2097
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2013,Age,13-17 Years,51.4,46.8 to 55.9,1072
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2014,Age,13-17 Years,54.1,49.4 to 58.8,1198
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2015,Age,13-17 Years,65.8,61.0 to 70.2,1162
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2016,Age,13-17 Years,65.1,60.5 to 69.5,1080
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2018,Age,13-17 Years,79.6,75.2 to 83.4,1007
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2019,Age,13-17 Years,79.3,74.6 to 83.2,1084
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2020,Age,13-17 Years,85.8,82.6 to 88.5,1132
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2021,Age,13-17 Years,84.1,80.0 to 87.5,1025
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2017,Age,13-17 Years,75.1,70.9 to 78.8,1118
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 1,2019,Age,13-17 Years,68.2,64.4 to 71.8,2034
≥3 Doses HepB,,HHS Regions/National,Region 1,2012,Age,13-17 Years,95.6,93.7 to 96.9,1916
≥3 Doses HepB,,HHS Regions/National,Region 1,2011,Age,13-17 Years,96.9,95.9 to 97.7,2467
≥3 Doses HepB,,HHS Regions/National,Region 1,2013,Age,13-17 Years,95.2,93.6 to 96.5,2050
≥3 Doses HepB,,HHS Regions/National,Region 1,2014,Age,13-17 Years,94.5,92.6 to 96.0,2268
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2009,Age,13-17 Years,63.6,59.0 to 67.8,1022
≥2 Doses Hep A,,HHS Regions/National,Region 1,2021,Age,13-17 Years,86.6,83.8 to 89.0,1923
≥3 Doses HepB,,HHS Regions/National,Region 1,2008,Age,13-17 Years,95.7,94.5 to 96.7,1838
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2007,Age,13-17 Years,37.6,25.7 to 51.2,90
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2007,Age,13-17 Years,92.0,81.4 to 96.8,72
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2007,Age,13-17 Years,19.3,11.2 to 31.1,72
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2012,Age,13-17 Years,89.9,87.0 to 92.2,1366
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2008,Age,13-17 Years,50.1,45.0 to 55.2,911
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2022,Age,13-15 Years,95.9,93.6 to 97.4,899
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2007,Age,13-15 Years,35.8,25.9 to 47.0,113
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2010,Age,13-17 Years,54.0,48.9 to 59.0,953
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2011,Age,13-17 Years,55.0,50.1 to 59.8,1211
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2009,Age,13-17 Years,54.7,50.0 to 59.3,1022
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2020,Age,13-15 Years,95.3,93.4 to 96.6,1297
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2012,Age,13-17 Years,56.3,51.2 to 61.2,900
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2013,Age,13-17 Years,51.8,47.0 to 56.5,978
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2008,Age,13-17 Years,41.8,36.8 to 46.9,911
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2016,Age,13-15 Years,90.1,87.4 to 92.3,1227
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2007,Age,13-17 Years,83.7,75.8 to 89.4,190
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2006,Age,13-17 Years,76.3,67.9 to 83.0,170
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2016,Age,13-17 Years,96.4,95.2 to 97.3,2097
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2014,Age,13-17 Years,95.0,93.3 to 96.3,2268
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2015,Age,13-17 Years,94.3,92.3 to 95.7,2188
≥3 Doses HepB,,HHS Regions/National,Region 1,2022,Age,13-17 Years,94.3,91.7 to 96.1,1595
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2018,Age,13-17 Years,78.3,73.3 to 82.6,895
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2022,Age,13-17 Years,97.9,96.7 to 98.7,1490
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2021,Age,13-17 Years,97.9,96.1 to 98.8,1785
≥3 Doses HepB,,HHS Regions/National,Region 1,2020,Age,13-17 Years,96.0,94.3 to 97.1,2147
≥3 Doses HepB,,HHS Regions/National,Region 1,2021,Age,13-17 Years,95.8,93.7 to 97.2,1923
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2015,Age,13-15 Years,90.8,87.8 to 93.1,1303
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2014,Age,13-15 Years,91.8,89.7 to 93.5,1357
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2012,Age,13-15 Years,85.8,82.7 to 88.4,1126
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2013,Age,13-15 Years,86.6,83.4 to 89.3,1201
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2017,Age,13-17 Years,81.6,77.7 to 84.9,989
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2016,Age,13-17 Years,74.9,70.7 to 78.7,1017
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2017,Age,13-15 Years,92.7,90.5 to 94.5,1302
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2018,Age,13-15 Years,90.7,87.3 to 93.3,1140
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2019,Age,13-15 Years,93.6,90.8 to 95.6,1209
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2017,Age,13-17 Years,95.8,94.7 to 96.7,2107
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2017,Age,13-17 Years,78.2,75.4 to 80.8,2107
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2016,Age,13-17 Years,69.9,66.7 to 72.9,2097
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2013,Age,13-17 Years,87.7,85.4 to 89.6,2050
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2014,Age,13-17 Years,90.8,88.8 to 92.5,2268
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2015,Age,13-17 Years,89.7,87.2 to 91.7,2188
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2016,Age,13-17 Years,90.8,88.7 to 92.6,2097
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2018,Age,13-17 Years,92.9,90.5 to 94.7,1902
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2017,Age,13-17 Years,94.6,93.1 to 95.7,2107
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2012,Age,13-17 Years,86.8,84.6 to 88.8,1916
≥2 Doses MMR,,HHS Regions/National,Region 1,2016,Age,13-17 Years,97.4,96.2 to 98.3,2097
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 1,2011,Age,13-17 Years,23.5,20.7 to 26.5,2467
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 1,2012,Age,13-17 Years,25.4,22.4 to 28.6,1916
≥2 Doses MMR,,HHS Regions/National,Region 1,2014,Age,13-17 Years,96.2,94.7 to 97.4,2268
≥2 Doses MMR,,HHS Regions/National,Region 1,2015,Age,13-17 Years,96.8,95.4 to 97.8,2188
≥2 Doses MMR,,HHS Regions/National,Region 1,2012,Age,13-17 Years,95.9,93.9 to 97.2,1916
≥2 Doses MMR,,HHS Regions/National,Region 1,2013,Age,13-17 Years,95.7,94.0 to 96.9,2050
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2007,Age,13-17 Years,33.7,26.1 to 42.2,190
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2022,Age,13-17 Years,93.7,91.4 to 95.4,1595
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2006,Age,13-17 Years,15.2,9.2 to 23.9,170
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2019,Age,13-17 Years,95.4,93.5 to 96.8,2034
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2020,Age,13-17 Years,93.6,91.6 to 95.1,2147
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2021,Age,13-17 Years,93.8,91.2 to 95.7,1923
≥2 Doses MMR,,HHS Regions/National,Region 1,2018,Age,13-17 Years,97.1,95.5 to 98.1,1902
≥2 Doses MMR,,HHS Regions/National,Region 1,2017,Age,13-17 Years,96.9,95.5 to 97.9,2107
≥2 Doses MMR,,HHS Regions/National,Region 1,2019,Age,13-17 Years,96.1,94.3 to 97.4,2034
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 1,2013,Age,13-17 Years,32.1,29.1 to 35.3,2050
≥2 Doses MMR,,HHS Regions/National,Region 1,2020,Age,13-17 Years,97.4,96.1 to 98.3,2147
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 1,2015,Age,13-17 Years,47.1,43.6 to 50.6,2188
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 1,2014,Age,13-17 Years,38.8,35.5 to 42.1,2268
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2017,Age,13-17 Years,92.5,90.8 to 93.9,2107
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2012,Age,13-15 Years,35.4,29.1 to 42.2,525
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2013,Age,13-15 Years,32.2,27.0 to 38.0,592
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2015,Age,13-15 Years,45.0,38.4 to 51.8,603
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2014,Age,13-15 Years,38.7,32.9 to 44.9,627
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2019,Age,13-17 Years,80.4,77.3 to 83.2,2034
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2018,Age,13-17 Years,79.0,75.8 to 81.9,1902
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2021,Age,13-17 Years,95.7,93.6 to 97.2,1923
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2010,Age,13-17 Years,92.8,91.0 to 94.3,2026
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2011,Age,13-17 Years,93.4,91.6 to 94.8,2467
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2008,Age,13-17 Years,87.1,84.7 to 89.2,1838
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2009,Age,13-17 Years,89.9,87.9 to 91.6,2189
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2022,Age,13-17 Years,82.7,77.9 to 86.6,817
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2012,Age,13-17 Years,95.3,93.8 to 96.5,1916
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2013,Age,13-17 Years,95.0,93.4 to 96.3,2050
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2009,Age,13-15 Years,67.2,63.2 to 71.0,1314
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2008,Age,13-15 Years,52.6,48.0 to 57.1,1094
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2011,Age,13-15 Years,80.7,76.7 to 84.1,1461
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2010,Age,13-15 Years,75.4,71.5 to 79.0,1213
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2020,Age,13-17 Years,84.9,82.4 to 87.0,2147
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2021,Age,13-17 Years,84.7,81.7 to 87.4,1923
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2018,Age,13-17 Years,94.6,92.5 to 96.1,1902
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2019,Age,13-17 Years,96.5,94.9 to 97.6,2034
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2020,Age,13-17 Years,94.8,92.9 to 96.3,2147
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2007,Age,13-17 Years,23.0,14.6 to 34.2,90
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2022,Age,13-17 Years,84.2,81.0 to 87.1,1595
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2017,Age,13-17 Years,70.8,66.2 to 75.0,989
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2016,Age,13-17 Years,66.6,62.0 to 70.9,1017
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2015,Age,13-17 Years,63.1,57.9 to 68.0,1026
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2014,Age,13-17 Years,61.0,56.1 to 65.7,1070
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2021,Age,13-15 Years,92.5,89.4 to 94.7,1186
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2018,Age,13-17 Years,65.7,60.2 to 70.8,895
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2019,Age,13-17 Years,69.3,63.7 to 74.4,950
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2007,Age,13-15 Years,38.3,27.6 to 50.2,113
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2012,Age,13-15 Years,93.1,90.8 to 94.9,1126
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2011,Age,13-15 Years,89.2,86.1 to 91.6,1461
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2009,Age,13-15 Years,73.7,70.0 to 77.1,1314
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2010,Age,13-15 Years,83.4,79.8 to 86.4,1213
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2008,Age,13-15 Years,51.2,46.6 to 55.8,1094
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2022,Age,13-17 Years,94.5,92.3 to 96.1,1595
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2017,Age,13-15 Years,94.3,92.4 to 95.8,1302
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2016,Age,13-15 Years,94.7,92.9 to 96.1,1227
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2015,Age,13-15 Years,94.3,92.2 to 95.9,1303
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2014,Age,13-15 Years,93.8,91.1 to 95.6,1357
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2013,Age,13-15 Years,93.2,90.8 to 95.0,1201
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2018,Age,13-17 Years,67.6,62.4 to 72.4,1007
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2017,Age,13-17 Years,63.1,58.7 to 67.3,1118
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2016,Age,13-17 Years,56.6,51.9 to 61.1,1080
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2022,Age,13-17 Years,93.5,90.9 to 95.3,1595
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2021,Age,13-17 Years,91.9,89.2 to 94.0,1923
≥2 Doses MMR,,HHS Regions/National,Region 1,2021,Age,13-17 Years,96.5,94.6 to 97.7,1923
≥2 Doses MMR,,HHS Regions/National,Region 1,2022,Age,13-17 Years,94.7,92.1 to 96.4,1595
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2011,Age,13-15 Years,34.2,28.3 to 40.7,697
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2010,Age,13-15 Years,36.5,30.2 to 43.3,566
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2009,Age,13-15 Years,37.2,31.5 to 43.2,614
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2008,Age,13-15 Years,24.1,19.3 to 29.6,543
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2018,Age,13-17 Years,92.4,90.1 to 94.2,1902
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2019,Age,13-17 Years,94.1,92.2 to 95.5,2034
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2020,Age,13-17 Years,95.1,93.6 to 96.2,2147
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2011,Age,13-17 Years,4.9,3.5 to 7.0,1256
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2012,Age,13-17 Years,14.4,11.6 to 17.6,1016
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2013,Age,13-17 Years,36.9,32.6 to 41.5,1072
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2014,Age,13-17 Years,44.4,39.8 to 49.1,1198
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2015,Age,13-17 Years,55.2,50.3 to 59.9,1162
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2019,Age,13-15 Years,94.3,91.0 to 96.4,1209
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2020,Age,13-15 Years,93.4,90.5 to 95.5,1297
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2021,Age,13-15 Years,93.1,89.2 to 95.7,1186
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2018,Age,13-15 Years,92.6,89.5 to 94.9,1140
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2012,Age,13-17 Years,92.4,90.2 to 94.2,1916
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2011,Age,13-17 Years,88.5,86.1 to 90.5,2467
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2013,Age,13-17 Years,93.1,91.1 to 94.7,2050
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2014,Age,13-17 Years,94.3,92.4 to 95.8,2268
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2019,Age,13-17 Years,95.6,93.7 to 96.9,2034
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2017,Age,13-17 Years,95.5,93.7 to 96.8,2107
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2018,Age,13-17 Years,97.2,96.1 to 98.0,1902
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2016,Age,13-17 Years,96.4,95.2 to 97.3,2097
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2008,Age,13-17 Years,76.8,73.5 to 79.7,1838
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2006,Age,13-17 Years,80.6,73.2 to 86.2,170
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2015,Age,13-17 Years,40.8,36.3 to 45.5,1162
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2014,Age,13-17 Years,29.0,25.0 to 33.3,1198
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2012,Age,13-15 Years,7.8,5.4 to 11.0,601
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2014,Age,13-15 Years,23.8,19.1 to 29.4,730
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2013,Age,13-17 Years,23.0,19.3 to 27.1,1072
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2012,Age,13-17 Years,8.2,6.2 to 11.0,1016
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2013,Age,13-15 Years,21.6,16.9 to 27.2,609
HPV,"≥3 Doses, Males",HHS Regions/National,Region 1,2015,Age,13-15 Years,36.3,30.9 to 42.0,700
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2012,Age,13-17 Years,43.4,38.4 to 48.6,900
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2011,Age,13-17 Years,47.2,42.3 to 52.0,1211
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2013,Age,13-17 Years,41.8,37.2 to 46.5,978
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2014,Age,13-17 Years,49.0,44.1 to 54.0,1070
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2008,Age,13-17 Years,26.4,22.3 to 30.9,911
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2009,Age,13-17 Years,45.1,40.5 to 49.8,1022
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2015,Age,13-17 Years,92.3,89.9 to 94.1,2188
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2010,Age,13-17 Years,45.0,40.0 to 50.2,953
≥2 Doses Hep A,,HHS Regions/National,Region 1,2020,Age,13-17 Years,78.8,75.9 to 81.5,2147
≥2 Doses Hep A,,HHS Regions/National,Region 1,2022,Age,13-17 Years,88.5,85.4 to 91.0,1595
HPV,"≥3 Doses, Females",HHS Regions/National,Region 1,2015,Age,13-17 Years,53.7,48.4 to 58.8,1026
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2007,Age,13-17 Years,31.8,24.1 to 40.6,190
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2018,Age,13-17 Years,63.4,59.6 to 67.0,1902
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2017,Age,13-17 Years,63.3,60.1 to 66.4,2107
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2012,Age,13-17 Years,92.5,90.5 to 94.1,1916
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2013,Age,13-17 Years,92.7,90.8 to 94.2,2050
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2014,Age,13-17 Years,93.0,90.9 to 94.6,2268
Varicella,History of disease,HHS Regions/National,Region 1,2008,Age,13-17 Years,58.7,55.2 to 62.2,1838
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2006,Age,13-17 Years,6.6,3.7 to 11.4,170
≥2 Doses MMR,,HHS Regions/National,Region 1,2007,Age,13-17 Years,95.1,89.7 to 97.8,190
≥2 Doses MMR,,HHS Regions/National,Region 1,2006,Age,13-17 Years,99.4,97.6 to 99.9,170
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2010,Age,13-17 Years,79.4,76.4 to 82.0,2026
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2009,Age,13-17 Years,64.4,61.3 to 67.4,2189
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2011,Age,13-17 Years,87.4,85.1 to 89.4,2467
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2016,Age,13-17 Years,55.0,51.7 to 58.3,2097
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2008,Age,13-17 Years,44.9,41.4 to 48.4,1838
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2022,Age,13-15 Years,93.5,90.6 to 95.5,947
≥2 Doses MMR,,HHS Regions/National,Region 1,2008,Age,13-17 Years,97.0,95.9 to 97.9,1838
≥2 Doses MMR,,HHS Regions/National,Region 1,2009,Age,13-17 Years,95.6,94.0 to 96.8,2189
≥2 Doses MMR,,HHS Regions/National,Region 1,2010,Age,13-17 Years,95.4,92.8 to 97.1,2026
≥2 Doses MMR,,HHS Regions/National,Region 1,2011,Age,13-17 Years,95.7,93.8 to 97.0,2467
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2021,Age,13-17 Years,71.6,67.7 to 75.2,1923
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2022,Age,13-17 Years,75.1,71.4 to 78.4,1595
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2019,Age,13-17 Years,66.1,62.2 to 69.8,2034
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2020,Age,13-17 Years,71.0,67.8 to 74.0,2147
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2019,Age,13-17 Years,67.2,61.9 to 72.2,1084
Varicella,History of disease,HHS Regions/National,Region 1,2012,Age,13-17 Years,25.2,22.3 to 28.2,1916
Varicella,History of disease,HHS Regions/National,Region 1,2013,Age,13-17 Years,24.0,21.3 to 27.0,2050
Varicella,History of disease,HHS Regions/National,Region 1,2010,Age,13-17 Years,38.0,34.7 to 41.3,2026
Varicella,History of disease,HHS Regions/National,Region 1,2011,Age,13-17 Years,31.8,28.7 to 34.9,2467
Varicella,History of disease,HHS Regions/National,Region 1,2014,Age,13-17 Years,19.5,16.7 to 22.6,2268
Varicella,History of disease,HHS Regions/National,Region 1,2006,Age,13-17 Years,76.7,68.5 to 83.3,170
Varicella,History of disease,HHS Regions/National,Region 1,2009,Age,13-17 Years,50.3,47.1 to 53.5,2189
Varicella,History of disease,HHS Regions/National,Region 1,2017,Age,13-17 Years,14.7,12.4 to 17.4,2107
Varicella,History of disease,HHS Regions/National,Region 1,2015,Age,13-17 Years,14.6,12.2 to 17.3,2188
Varicella,History of disease,HHS Regions/National,Region 1,2016,Age,13-17 Years,12.2,10.2 to 14.4,2097
Varicella,History of disease,HHS Regions/National,Region 1,2007,Age,13-17 Years,63.4,54.9 to 71.2,190
Varicella,History of disease,HHS Regions/National,Region 1,2018,Age,13-17 Years,11.4,8.9 to 14.4,1902
Varicella,History of disease,HHS Regions/National,Region 1,2022,Age,13-17 Years,7.0,5.1 to 9.5,1595
Varicella,History of disease,HHS Regions/National,Region 1,2020,Age,13-17 Years,6.9,5.4 to 8.7,2147
Varicella,History of disease,HHS Regions/National,Region 1,2019,Age,13-17 Years,8.4,6.4 to 11.0,2034
Varicella,History of disease,HHS Regions/National,Region 1,2021,Age,13-17 Years,6.5,4.6 to 9.1,1923
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2022,Age,13-15 Years,92.1,88.6 to 94.6,947
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2016,Age,13-17 Years,94.8,93.4 to 96.0,2097
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2010,Age,13-17 Years,75.6,72.7 to 78.4,2026
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2011,Age,13-17 Years,81.0,78.1 to 83.7,2467
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2008,Age,13-17 Years,50.1,46.6 to 53.7,1838
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2009,Age,13-17 Years,68.3,65.3 to 71.2,2189
HPV,"≥2 Doses, Females",HHS Regions/National,Region 1,2022,Age,13-17 Years,78.1,72.9 to 82.5,778
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 1,2022,Age,13-17 Years,76.8,73.3 to 80.0,1595
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 1,2023,Age,13-17 Years,93.2,90.5 to 95.1,1504
HPV,"≥1 Dose, Males",HHS Regions/National,Region 1,2023,Age,13-17 Years,84.2,79.7 to 87.9,798
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2023,Age,13-17 Years,78.6,73.3 to 83.0,706
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2023,Age,13-15 Years,70.4,63.3 to 76.6,467
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2023,Age,13-15 Years,94.9,91.8 to 96.9,816
HPV,"Up-to-Date, Females",HHS Regions/National,Region 1,2023,Age,13-15 Years,73.1,66.0 to 79.2,405
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2023,Age,13-15 Years,71.7,66.8 to 76.2,872
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2023,Age,13-15 Years,93.7,90.8 to 95.7,872
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2023,Age,13-15 Years,91.4,87.6 to 94.1,872
≥2 Doses Hep A,,HHS Regions/National,Region 1,2023,Age,13-17 Years,90.8,88.2 to 92.8,1504
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 1,2023,Age,13-17 Years,95.9,94.0 to 97.2,1504
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 1,2023,Age,13-17 Years,95.5,93.5 to 96.9,1409
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 1,2023,Age,13-17 Years,97.6,96.3 to 98.5,1409
Varicella,History of disease,HHS Regions/National,Region 1,2023,Age,13-17 Years,7.1,5.1 to 9.9,1504
≥2 Doses MMR,,HHS Regions/National,Region 1,2023,Age,13-17 Years,95.2,93.0 to 96.7,1504
≥3 Doses HepB,,HHS Regions/National,Region 1,2023,Age,13-17 Years,92.9,90.1 to 94.9,1504
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 1,2023,Age,13-17 Years,76.1,72.5 to 79.4,1504
HPV,"Up-to-Date, Males",HHS Regions/National,Region 1,2023,Age,13-17 Years,73.8,68.6 to 78.5,798
HPV,"≥1 Dose, Females",HHS Regions/National,Region 1,2023,Age,13-17 Years,87.2,82.7 to 90.7,706
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 1,2023,Age,13-17 Years,85.7,82.6 to 88.3,1504
≥1 Dose MenACWY,,HHS Regions/National,Region 1,2023,Age,13-17 Years,94.6,92.4 to 96.2,1504
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 1,2023,Age,13-17 Years,92.1,89.2 to 94.2,1504
HPV,"≥2 Doses, Males",HHS Regions/National,Region 1,2022,Age,13-17 Years,75.6,70.6 to 80.0,817
≥1 Dose MenACWY,,HHS Regions/National,United States,2021,Age,13-17 Years,89.0,87.9 to 90.0,18002
≥1 Dose MenACWY,,HHS Regions/National,United States,2022,Age,13-17 Years,88.6,87.6 to 89.6,16043
≥1 Dose MenACWY,,HHS Regions/National,United States,2020,Age,13-17 Years,89.3,88.4 to 90.2,20163
≥1 Dose MenACWY,,HHS Regions/National,United States,2019,Age,13-17 Years,88.9,88.0 to 89.8,18788
≥1 Dose MenACWY,,HHS Regions/National,United States,2018,Age,13-17 Years,86.6,85.6 to 87.5,18700
≥1 Dose MenACWY,,HHS Regions/National,United States,2017,Age,13-17 Years,85.1,84.2 to 86.1,20949
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2008,Age,13-15 Years,16.6,14.9 to 18.4,5231
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2009,Age,13-15 Years,22.9,21.2 to 24.7,5871
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2010,Age,13-15 Years,28.6,26.6 to 30.7,5636
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2011,Age,13-15 Years,30.0,28.0 to 32.1,6850
≥2 Doses MMR,,HHS Regions/National,United States,2022,Age,13-17 Years,91.2,90.2 to 92.1,16043
≥2 Doses MMR,,HHS Regions/National,United States,2021,Age,13-17 Years,92.2,91.2 to 93.2,18002
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2007,Age,13-15 Years,5.9,4.1 to 8.3,872
≥1 Dose MenACWY,,HHS Regions/National,United States,2012,Age,13-17 Years,74.0,72.9 to 75.1,19199
≥2 Doses MMR,,HHS Regions/National,United States,2019,Age,13-17 Years,91.9,90.8 to 92.8,18788
≥2 Doses MMR,,HHS Regions/National,United States,2017,Age,13-17 Years,92.1,91.3 to 92.8,20949
≥2 Doses MMR,,HHS Regions/National,United States,2018,Age,13-17 Years,91.9,91.2 to 92.6,18700
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2014,Age,13-15 Years,34.4,32.1 to 36.7,6181
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2015,Age,13-15 Years,37.1,34.8 to 39.5,6395
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2013,Age,13-15 Years,32.7,30.3 to 35.2,5402
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2012,Age,13-15 Years,28.1,26.1 to 30.2,5573
HPV,"≥3 Doses, Males and Females",HHS Regions/National,United States,2014,Age,13-17 Years,30.4,29.2 to 31.7,20827
HPV,"≥3 Doses, Males and Females",HHS Regions/National,United States,2015,Age,13-17 Years,34.9,33.7 to 36.1,21875
≥2 Doses MMR,,HHS Regions/National,United States,2020,Age,13-17 Years,92.4,91.6 to 93.2,20163
HPV,"≥3 Doses, Males and Females",HHS Regions/National,United States,2013,Age,13-17 Years,25.5,24.2 to 26.7,18264
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2021,Age,13-17 Years,89.6,88.6 to 90.5,18002
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2020,Age,13-17 Years,90.1,89.2 to 90.9,20163
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2019,Age,13-17 Years,90.2,89.2 to 91.1,18788
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2022,Age,13-17 Years,89.9,88.9 to 90.9,16043
≥1 Dose MenACWY,,HHS Regions/National,United States,2007,Age,13-17 Years,32.4,30.2 to 34.7,2947
≥1 Dose MenACWY,,HHS Regions/National,United States,2006,Age,13-17 Years,11.7,10.3 to 13.2,2882
≥2 Doses MMR,,HHS Regions/National,United States,2013,Age,13-17 Years,91.8,91.0 to 92.6,18264
≥2 Doses MMR,,HHS Regions/National,United States,2012,Age,13-17 Years,91.4,90.6 to 92.1,19199
≥2 Doses MMR,,HHS Regions/National,United States,2015,Age,13-17 Years,90.7,89.9 to 91.4,21875
≥2 Doses MMR,,HHS Regions/National,United States,2014,Age,13-17 Years,90.7,89.9 to 91.4,20827
HPV,"≥3 Doses, Males and Females",HHS Regions/National,United States,2012,Age,13-17 Years,19.8,18.8 to 20.9,19199
HPV,"≥3 Doses, Males and Females",HHS Regions/National,United States,2011,Age,13-17 Years,17.6,16.8 to 18.6,23564
≥2 Doses MMR,,HHS Regions/National,United States,2016,Age,13-17 Years,90.9,90.1 to 91.6,20475
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2017,Age,13-17 Years,88.7,87.8 to 89.6,20949
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018,Age,13-17 Years,88.9,88.0 to 89.7,18700
≥1 Dose MenACWY,,HHS Regions/National,United States,2016,Age,13-17 Years,82.2,81.2 to 83.2,20475
≥1 Dose MenACWY,,HHS Regions/National,United States,2015,Age,13-17 Years,81.3,80.2 to 82.3,21875
≥1 Dose MenACWY,,HHS Regions/National,United States,2014,Age,13-17 Years,79.3,78.2 to 80.3,20827
≥1 Dose MenACWY,,HHS Regions/National,United States,2013,Age,13-17 Years,77.8,76.7 to 78.9,18264
≥1 Dose MenACWY,,HHS Regions/National,United States,2009,Age,13-17 Years,53.6,52.4 to 54.9,20066
≥1 Dose MenACWY,,HHS Regions/National,United States,2008,Age,13-17 Years,41.8,40.3 to 43.2,17835
≥1 Dose MenACWY,,HHS Regions/National,United States,2011,Age,13-17 Years,70.5,69.4 to 71.5,23564
≥1 Dose MenACWY,,HHS Regions/National,United States,2010,Age,13-17 Years,62.7,61.5 to 63.9,19257
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2016,Age,13-17 Years,88.0,87.1 to 88.9,20475
≥1 Dose MenACWY,,HHS Regions/National,United States,2022,Age,13-15 Years,87.5,86.1 to 88.9,9816
HPV,"≥2 Doses, Males and Females",HHS Regions/National,United States,2022,Age,13-17 Years,64.0,62.6 to 65.4,16043
Varicella,History of disease,HHS Regions/National,Region 5,2017,Age,13-17 Years,14.2,12.6 to 16.1,2433
Varicella,History of disease,HHS Regions/National,Region 5,2020,Age,13-17 Years,7.7,6.3 to 9.3,2344
Varicella,History of disease,HHS Regions/National,Region 5,2019,Age,13-17 Years,9.2,7.8 to 10.8,2097
Varicella,History of disease,HHS Regions/National,Region 5,2021,Age,13-17 Years,7.4,5.8 to 9.3,2060
Varicella,History of disease,HHS Regions/National,Region 5,2022,Age,13-17 Years,6.8,5.3 to 8.5,2019
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2018,Age,13-15 Years,54.3,49.5 to 59.0,688
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2019,Age,13-15 Years,52.3,47.2 to 57.4,594
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2020,Age,13-15 Years,52.4,47.3 to 57.5,651
Varicella,History of disease,HHS Regions/National,Region 5,2015,Age,13-17 Years,17.8,16.0 to 19.8,2543
Varicella,History of disease,HHS Regions/National,Region 5,2016,Age,13-17 Years,18.2,16.2 to 20.3,2284
Varicella,History of disease,HHS Regions/National,Region 5,2007,Age,13-17 Years,69.0,64.2 to 73.5,584
Varicella,History of disease,HHS Regions/National,Region 5,2018,Age,13-17 Years,12.9,11.2 to 14.9,2276
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2016,Age,13-17 Years,38.0,34.4 to 41.7,1188
Varicella,History of disease,HHS Regions/National,Region 5,2012,Age,13-17 Years,36.1,33.3 to 39.0,2297
Varicella,History of disease,HHS Regions/National,Region 5,2013,Age,13-17 Years,30.1,27.7 to 32.6,2264
Varicella,History of disease,HHS Regions/National,Region 5,2010,Age,13-17 Years,49.0,46.3 to 51.6,2248
Varicella,History of disease,HHS Regions/National,Region 5,2011,Age,13-17 Years,39.0,36.5 to 41.6,2800
Varicella,History of disease,HHS Regions/National,Region 5,2014,Age,13-17 Years,22.5,20.4 to 24.8,2465
Varicella,History of disease,HHS Regions/National,Region 5,2006,Age,13-17 Years,74.5,69.1 to 79.3,458
Varicella,History of disease,HHS Regions/National,Region 5,2008,Age,13-17 Years,64.7,62.1 to 67.2,2361
Varicella,History of disease,HHS Regions/National,Region 5,2009,Age,13-17 Years,57.0,54.6 to 59.4,3105
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2007,Age,13-17 Years,27.1,22.9 to 31.7,584
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2018,Age,13-17 Years,55.0,52.4 to 57.6,2276
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2012,Age,13-17 Years,82.3,79.7 to 84.5,2297
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2013,Age,13-17 Years,86.3,84.2 to 88.1,2264
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2014,Age,13-17 Years,86.7,84.8 to 88.4,2465
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2017,Age,13-17 Years,49.0,46.5 to 51.4,2433
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2006,Age,13-17 Years,12.0,8.9 to 16.0,458
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2016,Age,13-17 Years,43.4,40.8 to 46.1,2284
≥2 Doses MMR,,HHS Regions/National,Region 5,2006,Age,13-17 Years,86.1,81.1 to 89.9,458
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2010,Age,13-17 Years,67.7,65.2 to 70.1,2248
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2009,Age,13-17 Years,53.5,51.1 to 55.9,3105
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2011,Age,13-17 Years,77.5,75.2 to 79.7,2800
≥2 Doses MMR,,HHS Regions/National,Region 5,2007,Age,13-17 Years,90.2,86.5 to 92.9,584
≥2 Doses MMR,,HHS Regions/National,Region 5,2008,Age,13-17 Years,90.2,88.5 to 91.7,2361
≥2 Doses MMR,,HHS Regions/National,Region 5,2009,Age,13-17 Years,92.0,90.6 to 93.2,3105
≥2 Doses MMR,,HHS Regions/National,Region 5,2010,Age,13-17 Years,92.5,91.0 to 93.8,2248
≥2 Doses MMR,,HHS Regions/National,Region 5,2011,Age,13-17 Years,91.8,90.1 to 93.2,2800
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2008,Age,13-17 Years,38.4,36.0 to 41.0,2361
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2022,Age,13-15 Years,91.9,89.4 to 93.8,1226
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2020,Age,13-17 Years,59.8,57.1 to 62.4,2344
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2019,Age,13-17 Years,54.8,51.0 to 58.5,1125
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2019,Age,13-17 Years,53.6,50.8 to 56.3,2097
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2021,Age,13-17 Years,62.2,59.3 to 65.1,2060
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2022,Age,13-17 Years,64.3,61.3 to 67.1,2019
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2015,Age,13-17 Years,85.8,83.8 to 87.6,2543
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2021,Age,13-17 Years,57.8,53.5 to 61.9,1069
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2019,Age,13-15 Years,51.7,48.2 to 55.3,1271
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2022,Age,13-17 Years,61.6,57.4 to 65.6,1070
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2021,Age,13-15 Years,57.4,53.6 to 61.2,1256
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2020,Age,13-15 Years,53.8,50.3 to 57.2,1415
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2019,Age,13-15 Years,51.2,46.2 to 56.1,677
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2020,Age,13-15 Years,55.1,50.4 to 59.7,764
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2020,Age,13-17 Years,60.9,57.0 to 64.7,1076
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2016,Age,13-17 Years,49.2,45.4 to 53.0,1096
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2017,Age,13-17 Years,53.1,49.5 to 56.6,1159
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2018,Age,13-15 Years,53.5,48.9 to 58.1,729
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2021,Age,13-17 Years,66.9,62.7 to 70.7,991
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2022,Age,13-17 Years,67.1,62.9 to 71.0,949
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2022,Age,13-15 Years,62.6,58.8 to 66.3,1226
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2018,Age,13-17 Years,52.2,48.6 to 55.7,1188
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2017,Age,13-17 Years,45.0,41.6 to 48.5,1274
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2019,Age,13-17 Years,51.7,48.0 to 55.5,1125
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2020,Age,13-17 Years,58.7,55.1 to 62.3,1268
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2021,Age,13-15 Years,61.7,56.3 to 66.9,603
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2022,Age,13-15 Years,64.1,58.6 to 69.2,592
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2021,Age,13-15 Years,53.3,47.8 to 58.7,653
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2022,Age,13-15 Years,61.1,55.6 to 66.2,634
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2018,Age,13-17 Years,58.0,54.2 to 61.7,1088
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2019,Age,13-17 Years,55.5,51.5 to 59.5,972
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2021,Age,13-15 Years,77.2,60.8 to 88.0,67
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2022,Age,13-15 Years,69.3,54.0 to 81.2,77
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2021,Age,13-15 Years,70.2,55.8 to 81.4,96
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2022,Age,13-15 Years,74.8,61.8 to 84.4,74
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2016,Age,13-17 Years,51.4,43.1 to 59.6,199
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2020,Age,13-15 Years,65.2,54.0 to 74.9,125
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2018,Age,13-17 Years,66.6,56.1 to 75.7,143
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2019,Age,13-17 Years,74.0,63.4 to 82.3,146
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2020,Age,13-17 Years,74.7,66.3 to 81.6,201
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2017,Age,13-17 Years,67.4,58.7 to 75.1,191
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2016,Age,13-17 Years,62.0,53.3 to 70.1,175
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2019,Age,13-15 Years,67.5,53.1 to 79.3,90
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2021,Age,13-17 Years,72.0,61.0 to 80.9,151
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2022,Age,13-15 Years,72.1,62.3 to 80.2,151
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2018,Age,13-17 Years,70.6,60.9 to 78.8,185
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2017,Age,13-17 Years,63.7,55.9 to 70.8,221
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2020,Age,13-17 Years,72.1,63.7 to 79.2,193
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2019,Age,13-17 Years,74.6,64.1 to 82.9,154
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2020,Age,13-15 Years,65.7,57.8 to 72.8,246
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2021,Age,13-15 Years,73.5,63.0 to 81.8,163
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2022,Age,13-17 Years,77.8,68.4 to 85.1,132
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2019,Age,13-15 Years,66.6,56.4 to 75.4,177
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2021,Age,13-17 Years,78.1,66.8 to 86.4,115
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2022,Age,13-17 Years,76.3,65.4 to 84.6,136
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2018,Age,13-15 Years,69.3,56.6 to 79.6,103
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2013,Age,13-17 Years,92.9,88.6 to 95.7,393
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2014,Age,13-17 Years,94.1,89.9 to 96.6,358
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2011,Age,13-17 Years,87.6,82.5 to 91.3,365
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2012,Age,13-17 Years,91.2,86.6 to 94.3,347
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2010,Age,13-17 Years,83.7,77.9 to 88.2,306
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2009,Age,13-17 Years,76.8,71.4 to 81.4,397
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2019,Age,13-15 Years,96.1,89.3 to 98.6,164
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2008,Age,13-17 Years,53.3,43.8 to 62.6,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2013,Age,13-17 Years,91.1,85.9 to 94.5,316
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2012,Age,13-17 Years,88.8,83.2 to 92.8,272
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2011,Age,13-15 Years,87.4,79.8 to 92.4,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2010,Age,13-15 Years,75.2,65.3 to 83.1,138
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2013,Age,13-15 Years,91.0,83.4 to 95.3,202
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2012,Age,13-15 Years,89.7,82.1 to 94.3,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2017,Age,13-15 Years,94.9,89.5 to 97.6,230
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2016,Age,13-15 Years,96.2,92.6 to 98.1,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2018,Age,13-15 Years,98.9,95.0 to 99.8,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2020,Age,13-15 Years,96.7,92.3 to 98.6,234
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2021,Age,13-15 Years,96.5,88.2 to 99.0,153
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2009,Age,13-15 Years,56.0,46.1 to 65.4,145
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2015,Age,13-17 Years,73.5,64.0 to 81.2,158
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2014,Age,13-17 Years,69.0,60.0 to 76.8,163
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2013,Age,13-17 Years,62.3,53.7 to 70.2,183
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2012,Age,13-17 Years,69.3,60.9 to 76.7,165
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2015,Age,13-17 Years,95.7,91.9 to 97.8,295
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2016,Age,13-17 Years,97.2,94.9 to 98.5,334
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2014,Age,13-17 Years,92.4,87.2 to 95.6,295
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2017,Age,13-17 Years,96.6,92.2 to 98.6,365
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2011,Age,13-17 Years,61.1,52.0 to 69.6,178
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2010,Age,13-17 Years,65.9,56.5 to 74.1,140
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2017,Age,13-17 Years,93.2,88.8 to 95.9,365
≥3 Doses HepB,,States/Local Areas,Massachusetts,2015,Age,13-17 Years,95.4,91.1 to 97.7,338
≥3 Doses HepB,,States/Local Areas,Massachusetts,2016,Age,13-17 Years,96.2,93.0 to 97.9,374
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2013,Age,13-17 Years,98.1,94.6 to 99.4,316
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2014,Age,13-17 Years,96.2,92.2 to 98.2,295
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2015,Age,13-17 Years,99.2,97.5 to 99.8,295
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2016,Age,13-17 Years,98.6,96.8 to 99.4,334
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2018,Age,13-17 Years,99.1,96.9 to 99.8,293
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2019,Age,13-17 Years,97.0,92.1 to 98.9,275
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2020,Age,13-17 Years,97.7,95.1 to 99.0,372
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2018,Age,13-17 Years,98.6,96.4 to 99.4,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2020,Age,13-17 Years,96.0,93.0 to 97.7,372
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2021,Age,13-17 Years,96.0,90.1 to 98.5,248
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2019,Age,13-17 Years,96.6,91.9 to 98.6,275
≥3 Doses HepB,,States/Local Areas,Massachusetts,2018,Age,13-17 Years,97.9,93.9 to 99.3,328
≥3 Doses HepB,,States/Local Areas,Massachusetts,2019,Age,13-17 Years,95.6,91.1 to 97.9,300
≥3 Doses HepB,,States/Local Areas,Massachusetts,2017,Age,13-17 Years,95.3,91.8 to 97.3,412
≥3 Doses HepB,,States/Local Areas,Massachusetts,2013,Age,13-17 Years,95.8,92.6 to 97.6,393
≥3 Doses HepB,,States/Local Areas,Massachusetts,2014,Age,13-17 Years,93.3,89.1 to 95.9,358
≥3 Doses HepB,,States/Local Areas,Massachusetts,2011,Age,13-17 Years,97.8,95.5 to 98.9,365
≥3 Doses HepB,,States/Local Areas,Massachusetts,2012,Age,13-17 Years,95.9,91.7 to 98.0,347
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2009,Age,13-17 Years,69.0,60.4 to 76.5,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2010,Age,13-17 Years,74.7,66.6 to 81.4,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2011,Age,13-17 Years,82.3,75.5 to 87.5,260
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2008,Age,13-17 Years,95.0,85.1 to 98.4,132
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2010,Age,13-17 Years,98.6,96.2 to 99.5,192
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2009,Age,13-17 Years,97.9,94.1 to 99.3,196
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2009,Age,13-17 Years,53.7,45.3 to 61.8,196
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2008,Age,13-17 Years,31.6,22.7 to 42.2,132
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2011,Age,13-17 Years,98.2,94.6 to 99.4,260
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2012,Age,13-17 Years,100.0,,272
≥3 Doses HepB,,States/Local Areas,Massachusetts,2008,Age,13-17 Years,97.4,95.0 to 98.6,333
≥3 Doses HepB,,States/Local Areas,Massachusetts,2010,Age,13-17 Years,95.7,91.9 to 97.8,306
≥3 Doses HepB,,States/Local Areas,Massachusetts,2009,Age,13-17 Years,97.5,95.4 to 98.7,397
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2022,Age,13-15 Years,96.0,91.1 to 98.3,135
HPV,"≥2 Doses, Males and Females",States/Local Areas,Massachusetts,2019,Age,13-17 Years,76.7,69.7 to 82.5,300
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2017,Age,13-17 Years,78.5,71.0 to 84.4,221
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2013,Age,13-17 Years,52.8,44.6 to 60.9,210
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2014,Age,13-17 Years,54.3,45.7 to 62.6,195
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2015,Age,13-17 Years,63.0,53.8 to 71.3,180
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2016,Age,13-17 Years,65.5,57.1 to 72.9,199
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2019,Age,13-17 Years,86.0,77.0 to 91.9,154
HPV,"≥2 Doses, Males and Females",States/Local Areas,Massachusetts,2016,Age,13-17 Years,63.4,57.5 to 69.0,374
HPV,"≥2 Doses, Males and Females",States/Local Areas,Massachusetts,2017,Age,13-17 Years,69.0,63.4 to 74.1,412
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2020,Age,13-17 Years,85.1,77.9 to 90.3,201
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2021,Age,13-17 Years,90.4,79.1 to 95.9,115
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2022,Age,13-17 Years,86.7,76.7 to 92.9,136
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2019,Age,13-17 Years,89.8,82.5 to 94.2,146
HPV,"≥2 Doses, Males and Females",States/Local Areas,Massachusetts,2018,Age,13-17 Years,71.8,64.7 to 77.9,328
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2018,Age,13-17 Years,87.6,79.3 to 92.9,185
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2020,Age,13-17 Years,89.7,84.0 to 93.5,193
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2021,Age,13-17 Years,88.2,80.0 to 93.4,151
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2012,Age,13-17 Years,25.5,18.4 to 34.1,182
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2022,Age,13-17 Years,98.0,95.3 to 99.2,244
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2018,Age,13-17 Years,82.8,72.9 to 89.5,143
≥3 Doses HepB,,States/Local Areas,Massachusetts,2020,Age,13-17 Years,95.5,91.9 to 97.5,394
≥3 Doses HepB,,States/Local Areas,Massachusetts,2021,Age,13-17 Years,95.9,91.0 to 98.2,266
≥3 Doses HepB,,States/Local Areas,Massachusetts,2022,Age,13-17 Years,92.7,87.0 to 96.0,268
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2015,Age,13-17 Years,93.5,89.3 to 96.1,338
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2014,Age,13-17 Years,96.0,92.4 to 98.0,358
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2016,Age,13-17 Years,98.2,96.6 to 99.0,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2017,Age,13-17 Years,98.3,96.3 to 99.2,412
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2021,Age,13-17 Years,97.8,93.1 to 99.3,248
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2022,Age,13-17 Years,97.4,94.7 to 98.7,244
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2016,Age,13-17 Years,77.6,69.7 to 83.9,175
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2017,Age,13-17 Years,85.4,78.5 to 90.4,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2015,Age,13-17 Years,91.2,86.1 to 94.5,338
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2021,Age,13-17 Years,75.0,67.3 to 81.4,266
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2022,Age,13-17 Years,77.1,70.1 to 82.9,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2020,Age,13-17 Years,73.4,67.6 to 78.5,394
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2022,Age,13-15 Years,93.4,87.1 to 96.7,151
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2008,Age,13-17 Years,43.3,37.1 to 49.8,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2011,Age,13-17 Years,91.6,87.4 to 94.5,365
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2010,Age,13-17 Years,82.4,76.5 to 87.0,306
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2009,Age,13-17 Years,62.7,56.8 to 68.2,397
≥2 Doses MMR,,States/Local Areas,Massachusetts,2010,Age,13-17 Years,93.7,87.5 to 96.9,306
≥2 Doses MMR,,States/Local Areas,Massachusetts,2011,Age,13-17 Years,95.4,91.4 to 97.6,365
≥2 Doses MMR,,States/Local Areas,Massachusetts,2008,Age,13-17 Years,99.5,98.2 to 99.8,333
≥2 Doses MMR,,States/Local Areas,Massachusetts,2009,Age,13-17 Years,97.3,94.4 to 98.7,397
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2019,Age,13-17 Years,77.1,67.1 to 84.7,154
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2013,Age,13-17 Years,94.9,91.6 to 96.9,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2014,Age,13-17 Years,93.2,88.9 to 95.9,358
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2016,Age,13-17 Years,56.6,50.6 to 62.5,374
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2017,Age,13-17 Years,65.5,59.7 to 70.8,412
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018,Age,13-17 Years,68.7,61.6 to 75.0,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2012,Age,13-17 Years,95.7,92.6 to 97.6,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018,Age,13-15 Years,91.1,84.3 to 95.1,186
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2021,Age,13-15 Years,93.9,83.4 to 98.0,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2020,Age,13-15 Years,93.1,87.0 to 96.4,246
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2019,Age,13-15 Years,93.7,86.3 to 97.2,177
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2019,Age,13-17 Years,74.3,67.0 to 80.4,300
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2013,Age,13-17 Years,37.8,30.1 to 46.1,210
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2014,Age,13-17 Years,46.2,37.8 to 54.8,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2013,Age,13-15 Years,97.2,93.6 to 98.8,242
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2012,Age,13-17 Years,10.4,6.3 to 16.6,182
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2015,Age,13-17 Years,50.9,41.9 to 59.9,180
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2016,Age,13-17 Years,58.6,50.2 to 66.5,199
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2017,Age,13-17 Years,65.4,57.7 to 72.4,221
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2018,Age,13-17 Years,72.4,62.6 to 80.5,185
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2011,Age,13-15 Years,84.6,76.4 to 90.4,214
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2010,Age,13-15 Years,83.8,75.8 to 89.5,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2014,Age,13-15 Years,93.7,87.8 to 96.8,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2015,Age,13-15 Years,95.9,91.4 to 98.1,203
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2016,Age,13-15 Years,96.5,93.6 to 98.1,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2017,Age,13-15 Years,96.4,92.3 to 98.4,262
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2018,Age,13-17 Years,71.1,60.5 to 79.7,143
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2019,Age,13-17 Years,76.4,65.8 to 84.4,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2009,Age,13-15 Years,75.2,68.3 to 81.1,241
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2010,Age,13-15 Years,85.3,78.0 to 90.4,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2008,Age,13-15 Years,49.8,41.7 to 57.9,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2011,Age,13-15 Years,94.6,88.8 to 97.5,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2012,Age,13-15 Years,95.6,90.7 to 98.0,210
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2014,Age,13-17 Years,62.5,53.2 to 71.0,163
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2015,Age,13-17 Years,63.0,53.0 to 71.9,158
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2016,Age,13-17 Years,68.4,59.9 to 75.9,175
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2017,Age,13-17 Years,72.7,64.3 to 79.7,191
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2021,Age,13-15 Years,93.6,86.3 to 97.2,163
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2020,Age,13-17 Years,87.4,83.1 to 90.8,394
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2021,Age,13-17 Years,89.3,83.0 to 93.4,266
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2022,Age,13-17 Years,85.6,79.3 to 90.3,268
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2010,Age,13-17 Years,95.8,92.0 to 97.9,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2011,Age,13-17 Years,96.7,93.0 to 98.5,365
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2013,Age,13-17 Years,97.3,94.2 to 98.8,393
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2008,Age,13-17 Years,94.4,90.5 to 96.8,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2009,Age,13-17 Years,93.7,89.9 to 96.2,397
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2018,Age,13-17 Years,93.7,89.3 to 96.4,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2021,Age,13-17 Years,96.4,91.5 to 98.5,266
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2022,Age,13-17 Years,94.5,89.8 to 97.1,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2019,Age,13-17 Years,87.9,82.3 to 91.8,300
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2022,Age,13-17 Years,84.5,75.4 to 90.7,132
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2020,Age,13-17 Years,94.3,90.3 to 96.7,394
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2019,Age,13-17 Years,97.4,93.6 to 99.0,300
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2016,Age,13-17 Years,71.4,65.7 to 76.5,374
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2017,Age,13-17 Years,81.9,76.9 to 85.9,412
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2017,Age,13-15 Years,94.9,90.4 to 97.4,262
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018,Age,13-15 Years,92.0,84.4 to 96.1,186
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2019,Age,13-15 Years,94.9,89.0 to 97.7,177
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2013,Age,13-17 Years,48.9,40.4 to 57.5,183
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2012,Age,13-17 Years,58.9,49.8 to 67.4,165
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2009,Age,13-15 Years,72.0,64.6 to 78.4,241
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2008,Age,13-15 Years,61.2,53.1 to 68.6,209
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2020,Age,13-15 Years,96.8,93.1 to 98.5,246
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2009,Age,13-17 Years,59.9,51.0 to 68.1,181
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2010,Age,13-17 Years,57.7,47.7 to 67.2,140
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2011,Age,13-17 Years,55.7,46.5 to 64.4,178
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2008,Age,13-17 Years,44.5,35.4 to 54.0,152
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2013,Age,13-15 Years,87.7,81.4 to 92.0,242
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2012,Age,13-15 Years,86.9,80.8 to 91.2,210
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2016,Age,13-15 Years,90.3,85.1 to 93.9,222
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2014,Age,13-15 Years,93.8,89.6 to 96.4,222
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2015,Age,13-15 Years,92.1,85.3 to 95.9,203
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2012,Age,13-17 Years,98.5,96.7 to 99.3,347
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018,Age,13-17 Years,85.2,79.1 to 89.8,328
Varicella,History of disease,States/Local Areas,Massachusetts,2009,Age,13-17 Years,49.9,44.1 to 55.8,397
Varicella,History of disease,States/Local Areas,Massachusetts,2008,Age,13-17 Years,59.7,53.2 to 65.9,333
Varicella,History of disease,States/Local Areas,Massachusetts,2018,Age,13-17 Years,13.9,9.3 to 20.3,328
Varicella,History of disease,States/Local Areas,Massachusetts,2015,Age,13-17 Years,13.8,9.6 to 19.4,338
Varicella,History of disease,States/Local Areas,Massachusetts,2010,Age,13-17 Years,35.6,29.4 to 42.2,306
Varicella,History of disease,States/Local Areas,Massachusetts,2011,Age,13-17 Years,29.9,24.5 to 35.8,365
Varicella,History of disease,States/Local Areas,Massachusetts,2013,Age,13-17 Years,20.1,15.8 to 25.4,393
Varicella,History of disease,States/Local Areas,Massachusetts,2012,Age,13-17 Years,21.4,16.6 to 27.1,347
Varicella,History of disease,States/Local Areas,Massachusetts,2016,Age,13-17 Years,11.4,8.2 to 15.6,374
Varicella,History of disease,States/Local Areas,Massachusetts,2017,Age,13-17 Years,13.1,9.3 to 18.0,412
Varicella,History of disease,States/Local Areas,Massachusetts,2014,Age,13-17 Years,21.4,16.3 to 27.5,358
Varicella,History of disease,States/Local Areas,Massachusetts,2020,Age,13-17 Years,6.2,3.8 to 10.0,394
Varicella,History of disease,States/Local Areas,Massachusetts,2022,Age,13-17 Years,8.6,5.1 to 14.0,268
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2020,Age,13-15 Years,66.3,54.8 to 76.2,121
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2019,Age,13-15 Years,65.4,50.7 to 77.7,87
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2018,Age,13-15 Years,61.3,47.7 to 73.4,83
Varicella,History of disease,States/Local Areas,Massachusetts,2019,Age,13-17 Years,8.6,5.2 to 14.0,300
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2019,Age,13-17 Years,96.9,92.6 to 98.7,300
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2014,Age,13-15 Years,93.3,85.9 to 96.9,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2015,Age,13-15 Years,97.1,92.2 to 98.9,183
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2020,Age,13-17 Years,96.2,93.4 to 97.9,394
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2021,Age,13-17 Years,96.3,90.8 to 98.6,266
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2022,Age,13-17 Years,97.6,95.1 to 98.8,268
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2008,Age,13-15 Years,34.8,24.2 to 47.0,104
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2020,Age,13-17 Years,91.8,86.8 to 95.0,404
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2021,Age,13-17 Years,90.2,85.5 to 93.6,409
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018,Age,13-17 Years,93.8,88.8 to 96.7,283
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2019,Age,13-17 Years,88.7,81.4 to 93.4,282
≥2 Doses MMR,,States/Local Areas,District of Columbia,2021,Age,13-17 Years,87.8,82.6 to 91.6,409
≥2 Doses MMR,,States/Local Areas,District of Columbia,2022,Age,13-17 Years,74.0,65.2 to 81.3,237
≥2 Doses MMR,,States/Local Areas,District of Columbia,2020,Age,13-17 Years,88.7,83.7 to 92.3,404
HPV,"≥3 Doses, Males and Females",States/Local Areas,District of Columbia,2013,Age,13-17 Years,27.4,19.4 to 37.0,192
HPV,"≥3 Doses, Males and Females",States/Local Areas,District of Columbia,2014,Age,13-17 Years,45.6,38.0 to 53.5,285
HPV,"≥3 Doses, Males and Females",States/Local Areas,District of Columbia,2015,Age,13-17 Years,49.8,43.4 to 56.2,418
≥2 Doses MMR,,States/Local Areas,District of Columbia,2018,Age,13-17 Years,75.5,67.5 to 82.0,283
≥2 Doses MMR,,States/Local Areas,District of Columbia,2019,Age,13-17 Years,89.1,82.1 to 93.6,282
≥2 Doses MMR,,States/Local Areas,District of Columbia,2013,Age,13-17 Years,85.9,75.0 to 92.5,192
≥2 Doses MMR,,States/Local Areas,District of Columbia,2012,Age,13-17 Years,93.6,88.6 to 96.4,342
HPV,"≥3 Doses, Males and Females",States/Local Areas,District of Columbia,2011,Age,13-17 Years,18.2,14.1 to 23.3,415
HPV,"≥3 Doses, Males and Females",States/Local Areas,District of Columbia,2012,Age,13-17 Years,21.6,16.6 to 27.6,342
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2014,Age,13-17 Years,93.5,90.1 to 95.9,285
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2013,Age,13-17 Years,91.3,81.2 to 96.3,192
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2015,Age,13-17 Years,90.9,86.9 to 93.8,418
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2016,Age,13-17 Years,86.9,81.3 to 91.0,377
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2022,Age,13-17 Years,89.7,84.1 to 93.5,237
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2015,Age,13-15 Years,58.9,46.9 to 69.9,120
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2014,Age,13-15 Years,55.9,42.0 to 68.9,93
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2009,Age,13-15 Years,22.4,15.3 to 31.4,136
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2010,Age,13-15 Years,31.4,22.5 to 41.8,113
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2022,Age,13-17 Years,92.9,88.4 to 95.7,237
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2013,Age,13-15 Years,25.7,14.7 to 41.2,59
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2020,Age,13-17 Years,85.8,79.9 to 90.2,404
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2021,Age,13-17 Years,87.3,82.2 to 91.1,409
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2017,Age,13-17 Years,91.3,85.7 to 94.9,318
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2008,Age,13-15 Years,13.8,7.8 to 23.4,92
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2011,Age,13-15 Years,32.5,22.8 to 44.0,123
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2012,Age,13-15 Years,35.5,24.5 to 48.1,103
≥2 Doses MMR,,States/Local Areas,District of Columbia,2016,Age,13-17 Years,94.8,91.3 to 96.9,377
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,48.6,36.8 to 60.5,131
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,72.5,61.5 to 81.3,111
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2020,Age,13-15 Years,50.6,36.4 to 64.6,75
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2019,Age,13-15 Years,61.0,44.6 to 75.2,64
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,44.2,31.8 to 57.3,94
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,50.6,37.0 to 64.1,82
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,57.8,43.2 to 71.2,90
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,55.7,41.7 to 68.9,73
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2018,Age,13-15 Years,46.8,32.7 to 61.5,61
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,68.7,54.2 to 80.3,94
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,54.2,41.7 to 66.1,85
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,61.6,47.5 to 74.1,87
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2022,Age,13-15 Years,53.3,36.0 to 69.9,60
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2021,Age,13-15 Years,52.2,34.5 to 69.4,40
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2022,Age,13-15 Years,58.4,44.9 to 70.7,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2021,Age,13-15 Years,60.5,46.8 to 72.7,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2020,Age,13-15 Years,58.3,47.5 to 68.3,143
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,68.9,53.5 to 81.0,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2019,Age,13-15 Years,60.1,47.9 to 71.2,120
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,47.8,36.5 to 59.4,101
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,59.7,47.2 to 71.0,105
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,49.8,38.5 to 61.2,110
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,54.2,40.6 to 67.3,87
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2020,Age,13-15 Years,67.6,52.1 to 80.0,68
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2019,Age,13-15 Years,59.0,40.6 to 75.2,56
Varicella,History of disease,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,55.8,46.7 to 64.6,233
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2018,Age,13-15 Years,57.5,41.3 to 72.3,53
Varicella,History of disease,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,18.9,13.9 to 25.1,379
Varicella,History of disease,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,10.3,5.8 to 17.5,174
Varicella,History of disease,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,32.7,26.8 to 39.1,490
Varicella,History of disease,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,42.2,36.1 to 48.6,413
Varicella,History of disease,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,23.6,17.9 to 30.5,278
Varicella,History of disease,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,27.4,21.8 to 33.8,393
Varicella,History of disease,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,14.5,9.7 to 21.1,259
Varicella,History of disease,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,11.9,7.3 to 18.8,225
Varicella,History of disease,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,7.9,4.4 to 13.7,186
Varicella,History of disease,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,12.1,7.3 to 19.6,187
Varicella,History of disease,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,42.1,34.0 to 50.7,239
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,85.3,79.5 to 89.6,379
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,82.5,76.1 to 87.5,259
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,27.1,19.1 to 36.9,182
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,22.7,15.7 to 31.7,143
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,17.5,11.6 to 25.6,159
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,15.1,8.8 to 24.8,204
≥2 Doses Hep A,,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,85.2,78.5 to 90.1,221
≥2 Doses Hep A,,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,86.6,77.6 to 92.3,157
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,86.3,79.6 to 91.1,278
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,85.0,79.6 to 89.1,490
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,83.7,77.5 to 88.5,393
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,69.5,60.4 to 77.3,239
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,81.7,76.4 to 86.1,413
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2014,Age,13-15 Years,27.7,17.8 to 40.5,115
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2015,Age,13-15 Years,16.3,9.8 to 26.0,88
HPV,"≥3 Doses, Males",States/Local Areas,TX-City of Houston,2013,Age,13-15 Years,18.9,11.4 to 29.8,90
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,76.1,69.5 to 81.6,490
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,52.6,44.0 to 61.0,239
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,71.3,65.2 to 76.7,413
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,87.8,82.4 to 91.7,379
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,86.5,79.8 to 91.2,278
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,82.5,76.1 to 87.4,393
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,50.9,42.4 to 59.3,186
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,55.2,45.9 to 64.2,187
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2022,Age,13-15 Years,87.2,75.9 to 93.7,98
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,42.6,34.0 to 51.8,233
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,46.4,37.6 to 55.3,225
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,87.7,83.1 to 91.2,490
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,82.3,76.7 to 86.8,413
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,78.6,70.8 to 84.8,239
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,87.0,80.2 to 91.7,233
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,61.9,48.0 to 74.0,87
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,83.3,77.4 to 88.0,259
≥2 Doses Hep A,,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,79.8,69.3 to 87.3,167
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,17.6,11.3 to 26.2,112
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,13.8,7.9 to 22.9,102
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,42.8,32.5 to 53.8,116
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,63.2,52.6 to 72.8,157
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,62.2,52.0 to 71.4,167
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,43.8,34.4 to 53.6,197
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,33.9,24.2 to 45.2,119
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,26.9,19.9 to 35.3,250
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,36.8,27.9 to 46.7,189
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,31.9,24.2 to 40.8,197
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,61.0,52.7 to 68.6,221
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,57.8,47.9 to 67.1,174
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,93.6,84.9 to 97.4,145
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,79.9,71.0 to 86.6,174
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,90.4,82.9 to 94.8,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,70.1,61.6 to 77.4,186
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2021,Age,13-15 Years,85.7,70.7 to 93.7,93
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2020,Age,13-15 Years,88.9,80.8 to 93.9,143
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2019,Age,13-15 Years,93.4,85.8 to 97.1,120
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2014,Age,13-17 Years,70.9,67.8 to 73.7,2290
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2013,Age,13-17 Years,67.0,63.6 to 70.2,1913
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2009,Age,13-17 Years,46.2,42.8 to 49.7,1974
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2008,Age,13-17 Years,30.3,26.9 to 33.9,1854
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2011,Age,13-17 Years,59.6,55.6 to 63.4,2242
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2010,Age,13-17 Years,53.2,49.7 to 56.7,1890
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2016,Age,13-17 Years,85.9,83.1 to 88.3,2022
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2022,Age,13-15 Years,87.8,84.5 to 90.5,1085
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2023,Age,13-17 Years,93.3,91.4 to 94.7,1742
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2023,Age,13-17 Years,89.3,86.8 to 91.5,1742
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2023,Age,13-17 Years,92.3,90.3 to 93.9,1742
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2023,Age,13-17 Years,79.6,76.3 to 82.6,1742
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2023,Age,13-17 Years,65.6,61.7 to 69.3,1742
≥2 Doses MMR,,HHS Regions/National,Region 8,2023,Age,13-17 Years,92.5,90.1 to 94.4,1742
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2023,Age,13-17 Years,66.2,60.9 to 71.1,956
Varicella,History of disease,HHS Regions/National,Region 8,2023,Age,13-17 Years,6.8,5.0 to 9.1,1742
≥3 Doses HepB,,HHS Regions/National,Region 8,2023,Age,13-17 Years,93.3,91.2 to 95.0,1742
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2023,Age,13-17 Years,96.3,94.6 to 97.5,1618
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2023,Age,13-17 Years,93.5,91.2 to 95.3,1618
≥2 Doses Hep A,,HHS Regions/National,Region 8,2023,Age,13-17 Years,89.0,86.4 to 91.2,1742
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2023,Age,13-17 Years,94.0,91.8 to 95.6,1742
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2023,Age,13-15 Years,91.7,89.0 to 93.8,1035
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2023,Age,13-15 Years,87.3,83.4 to 90.5,1035
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,46.4,36.7 to 56.5,143
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,49.2,37.7 to 60.7,101
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,53.2,41.3 to 64.7,131
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,62.0,49.5 to 73.1,105
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2017,Age,13-15 Years,92.9,85.1 to 96.8,104
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2014,Age,13-15 Years,87.3,79.9 to 92.2,233
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2015,Age,13-15 Years,82.9,74.8 to 88.7,168
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2016,Age,13-15 Years,89.9,80.1 to 95.2,136
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,85.8,78.4 to 90.9,186
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,89.3,82.8 to 93.5,221
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,93.5,87.4 to 96.8,174
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2021,Age,13-15 Years,92.4,80.7 to 97.3,93
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2013,Age,13-15 Years,85.3,75.5 to 91.6,161
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,60.7,48.0 to 72.2,85
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,69.3,55.3 to 80.4,87
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,38.6,29.6 to 48.5,182
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,27.8,20.2 to 37.0,159
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,23.8,16.0 to 34.0,204
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,89.1,81.1 to 94.0,157
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2008,Age,13-15 Years,43.7,32.3 to 55.7,136
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2010,Age,13-15 Years,73.4,65.5 to 80.0,256
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2009,Age,13-15 Years,53.6,43.2 to 63.8,141
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2011,Age,13-15 Years,72.2,63.6 to 79.5,299
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2012,Age,13-15 Years,82.9,75.2 to 88.5,239
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,55.2,45.5 to 64.5,197
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,58.1,47.1 to 68.3,116
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,47.7,34.9 to 60.7,94
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,57.9,44.0 to 70.6,82
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2017,Age,13-15 Years,92.4,85.3 to 96.2,104
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018,Age,13-15 Years,85.3,75.6 to 91.6,114
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2019,Age,13-15 Years,93.5,83.3 to 97.6,120
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,81.0,72.1 to 87.6,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,79.9,70.8 to 86.7,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,77.1,69.2 to 83.5,221
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,89.9,82.5 to 94.4,187
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,62.6,53.6 to 70.9,225
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,73.0,63.9 to 80.4,187
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,51.9,40.8 to 62.9,119
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,46.0,36.7 to 55.6,189
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2020,Age,13-15 Years,88.4,79.9 to 93.6,143
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,33.8,22.5 to 47.3,112
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,39.8,31.4 to 48.8,250
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,40.8,32.4 to 49.8,197
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,23.1,14.8 to 34.3,102
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2016,Age,13-15 Years,86.7,75.8 to 93.1,136
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,86.4,80.6 to 90.6,259
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,89.8,84.4 to 93.4,379
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,87.0,78.7 to 92.4,225
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2013,Age,13-15 Years,90.7,82.0 to 95.4,161
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2012,Age,13-15 Years,88.6,81.6 to 93.1,239
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2014,Age,13-15 Years,87.3,79.8 to 92.3,233
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2015,Age,13-15 Years,85.4,77.8 to 90.8,168
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,91.0,84.5 to 94.9,278
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,86.2,80.5 to 90.4,490
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,82.1,76.7 to 86.5,413
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,89.9,85.0 to 93.3,393
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,76.0,67.8 to 82.7,239
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,73.0,63.8 to 80.6,233
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,85.5,74.3 to 92.3,94
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2010,Age,13-15 Years,78.9,71.8 to 84.6,256
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2011,Age,13-15 Years,81.8,74.2 to 87.6,299
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,84.6,74.6 to 91.2,157
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,82.7,73.1 to 89.3,167
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,83.1,75.8 to 88.5,221
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,77.1,64.9 to 85.9,85
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,66.9,56.1 to 76.1,116
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,59.4,45.7 to 71.8,94
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,73.6,59.8 to 83.9,82
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,79.8,66.0 to 88.9,67
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2008,Age,13-15 Years,50.5,38.8 to 62.2,136
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2009,Age,13-15 Years,71.0,60.6 to 79.6,141
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,87.2,78.4 to 92.8,157
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,50.4,41.6 to 59.3,225
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,72.4,59.9 to 82.1,105
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,75.8,62.5 to 85.5,87
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,82.2,69.5 to 90.4,90
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,14.5,9.4 to 21.6,240
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,74.4,59.8 to 85.1,73
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,87.6,77.0 to 93.8,111
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,54.7,46.1 to 63.1,186
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,84.2,71.2 to 92.0,87
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,89.1,80.0 to 94.4,145
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,60.0,50.6 to 68.6,187
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,65.5,55.7 to 74.1,174
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,77.6,69.5 to 84.0,297
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,80.7,72.4 to 86.9,225
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,97.4,94.1 to 98.9,297
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,63.6,51.5 to 74.3,101
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,67.0,55.0 to 77.1,110
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,38.0,28.5 to 48.5,204
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,53.7,43.8 to 63.4,182
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,40.3,31.0 to 50.4,159
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,58.6,48.8 to 67.8,143
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,65.9,54.2 to 75.9,131
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,81.0,72.9 to 87.0,187
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,78.5,70.6 to 84.7,186
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,82.5,73.7 to 88.8,174
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,89.6,82.3 to 94.1,162
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,88.9,79.9 to 94.2,155
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,66.8,57.3 to 75.1,197
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,41.7,29.8 to 54.7,112
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,88.9,81.9 to 93.4,171
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,80.6,70.1 to 88.0,157
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,84.1,77.0 to 89.4,207
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,85.5,76.3 to 91.5,155
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,91.7,86.2 to 95.2,207
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,80.9,72.8 to 87.0,171
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,62.0,50.9 to 72.1,119
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,55.8,46.4 to 64.9,189
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,81.8,75.0 to 87.1,318
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,82.1,73.8 to 88.2,213
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,79.5,72.3 to 85.3,226
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,77.2,67.4 to 84.7,197
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,55.1,46.2 to 63.8,197
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,49.7,40.7 to 58.6,250
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,83.0,74.9 to 88.8,162
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,91.6,86.0 to 95.1,318
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,97.7,93.4 to 99.2,213
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,96.4,92.8 to 98.2,226
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,92.4,84.1 to 96.6,197
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,80.6,74.2 to 85.7,379
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,86.4,79.9 to 91.1,278
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,87.7,82.8 to 91.3,490
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,84.9,78.9 to 89.5,393
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,86.3,80.8 to 90.5,259
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,30.2,20.3 to 42.4,102
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,86.4,79.3 to 91.3,233
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2009,Age,13-15 Years,53.8,40.6 to 66.5,90
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,77.7,70.4 to 83.5,354
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,68.4,60.3 to 75.5,254
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,48.8,34.8 to 63.1,98
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,47.4,36.1 to 58.9,133
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,93.8,88.5 to 96.7,354
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,89.3,81.3 to 94.1,133
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,91.2,84.7 to 95.1,254
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,86.0,75.6 to 92.5,98
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2022,Age,13-15 Years,82.7,68.8 to 91.2,92
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,82.1,75.2 to 87.3,239
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,83.4,77.7 to 87.8,413
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2018,Age,13-15 Years,82.1,71.4 to 89.3,108
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2019,Age,13-15 Years,90.5,79.6 to 95.9,105
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2010,Age,13-15 Years,72.8,63.7 to 80.3,185
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2011,Age,13-15 Years,78.6,69.5 to 85.6,238
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2013,Age,13-15 Years,83.6,72.7 to 90.6,134
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2012,Age,13-15 Years,76.4,65.5 to 84.6,194
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2014,Age,13-15 Years,80.6,71.7 to 87.3,194
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2015,Age,13-15 Years,79.2,69.9 to 86.1,155
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2021,Age,13-15 Years,91.4,79.7 to 96.6,85
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2020,Age,13-15 Years,86.0,77.4 to 91.7,139
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2016,Age,13-15 Years,79.2,66.5 to 88.0,120
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2017,Age,13-15 Years,88.5,80.1 to 93.6,91
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2008,Age,13-15 Years,50.8,33.9 to 67.5,73
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,81.6,71.5 to 88.7,167
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,85.0,78.2 to 90.0,221
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,90.5,82.3 to 95.1,157
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,82.4,74.8 to 88.1,186
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,79.9,71.0 to 86.6,225
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,85.0,77.8 to 90.2,187
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,77.4,69.1 to 84.0,233
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,87.0,78.6 to 92.4,174
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2022,Age,13-15 Years,63.9,44.1 to 79.9,38
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2021,Age,13-15 Years,70.1,49.1 to 85.0,53
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,64.0,55.7 to 71.5,253
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,56.0,44.5 to 67.0,132
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,76.8,66.9 to 84.5,141
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2023,Age,13-15 Years,55.8,42.3 to 68.4,80
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2023,Age,13-15 Years,80.0,70.5 to 87.0,158
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,62.7,52.4 to 72.0,137
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2023,Age,13-15 Years,50.0,37.7 to 62.2,92
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2023,Age,13-15 Years,52.6,43.5 to 61.5,172
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2023,Age,13-15 Years,85.6,77.8 to 91.0,172
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2023,Age,13-15 Years,80.6,71.9 to 87.1,172
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,86.4,80.2 to 90.8,278
≥2 Doses Hep A,,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,83.8,77.1 to 88.8,278
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,84.6,77.8 to 89.6,249
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,87.5,80.8 to 92.1,249
Varicella,History of disease,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,11.7,7.7 to 17.3,278
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,86.9,81.1 to 91.1,278
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,52.6,42.2 to 62.6,141
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,85.1,78.8 to 89.7,278
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,57.6,50.3 to 64.6,278
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,78.3,68.3 to 85.9,137
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,87.4,81.7 to 91.5,278
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,77.6,70.7 to 83.2,278
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,86.0,79.9 to 90.5,278
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2023,Age,13-17 Years,84.7,78.4 to 89.4,278
Varicella,History of disease,States/Local Areas,California,2020,Age,13-17 Years,9.2,5.8 to 14.3,403
Varicella,History of disease,States/Local Areas,California,2022,Age,13-17 Years,4.3,2.5 to 7.4,321
HPV,"Up-to-Date, Females",States/Local Areas,California,2018,Age,13-15 Years,43.4,31.8 to 55.6,119
Varicella,History of disease,States/Local Areas,California,2017,Age,13-17 Years,13.4,9.0 to 19.6,306
HPV,"Up-to-Date, Females",States/Local Areas,California,2019,Age,13-15 Years,65.6,49.3 to 78.9,80
HPV,"Up-to-Date, Females",States/Local Areas,California,2020,Age,13-15 Years,64.2,51.2 to 75.4,126
Varicella,History of disease,States/Local Areas,California,2012,Age,13-17 Years,24.1,19.4 to 29.5,430
Varicella,History of disease,States/Local Areas,California,2013,Age,13-17 Years,23.1,17.8 to 29.6,309
Varicella,History of disease,States/Local Areas,California,2010,Age,13-17 Years,40.1,33.9 to 46.6,330
Varicella,History of disease,States/Local Areas,California,2011,Age,13-17 Years,32.5,27.8 to 37.5,583
Varicella,History of disease,States/Local Areas,California,2015,Age,13-17 Years,15.3,10.5 to 21.8,350
Varicella,History of disease,States/Local Areas,California,2014,Age,13-17 Years,17.5,12.8 to 23.5,356
Varicella,History of disease,States/Local Areas,California,2018,Age,13-17 Years,10.2,6.6 to 15.5,356
Varicella,History of disease,States/Local Areas,California,2019,Age,13-17 Years,6.0,3.4 to 10.4,274
Varicella,History of disease,States/Local Areas,California,2016,Age,13-17 Years,12.6,8.7 to 17.8,327
Varicella,History of disease,States/Local Areas,California,2008,Age,13-17 Years,51.6,44.1 to 59.1,316
HPV,"Up-to-Date, Males",States/Local Areas,California,2021,Age,13-17 Years,70.9,58.7 to 80.7,140
HPV,"Up-to-Date, Females",States/Local Areas,California,2017,Age,13-17 Years,60.9,49.9 to 70.8,135
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2019,Age,13-15 Years,60.8,49.0 to 71.5,170
HPV,"Up-to-Date, Males",States/Local Areas,California,2022,Age,13-17 Years,60.4,50.6 to 69.4,181
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2021,Age,13-15 Years,68.6,57.4 to 78.0,182
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2020,Age,13-15 Years,58.1,49.3 to 66.4,272
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2022,Age,13-15 Years,55.3,45.6 to 64.7,188
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2018,Age,13-17 Years,94.2,90.4 to 96.6,318
≥3 Doses HepB,,States/Local Areas,California,2018,Age,13-17 Years,88.8,83.6 to 92.5,356
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2018,Age,13-17 Years,86.7,80.8 to 91.0,318
≥3 Doses HepB,,States/Local Areas,California,2019,Age,13-17 Years,86.0,77.9 to 91.5,274
≥3 Doses HepB,,States/Local Areas,California,2017,Age,13-17 Years,89.8,84.2 to 93.6,306
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2016,Age,13-17 Years,92.1,86.5 to 95.6,284
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2015,Age,13-17 Years,90.2,84.0 to 94.2,304
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2013,Age,13-17 Years,93.0,86.5 to 96.5,242
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2014,Age,13-17 Years,96.7,94.0 to 98.2,302
≥3 Doses HepB,,States/Local Areas,California,2016,Age,13-17 Years,88.9,84.0 to 92.4,327
≥3 Doses HepB,,States/Local Areas,California,2015,Age,13-17 Years,84.9,78.9 to 89.5,350
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2014,Age,13-15 Years,82.1,74.1 to 88.0,196
Varicella,≥1 Dose with no disease history,States/Local Areas,California,2017,Age,13-17 Years,92.1,86.2 to 95.6,269
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2014,Age,13-17 Years,81.7,75.3 to 86.7,302
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2016,Age,13-17 Years,81.0,74.5 to 86.2,284
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2015,Age,13-17 Years,78.3,71.5 to 83.9,304
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2017,Age,13-17 Years,83.4,76.8 to 88.5,269
HPV,"≥1 Dose, Females",States/Local Areas,California,2011,Age,13-17 Years,65.0,57.9 to 71.5,270
HPV,"≥1 Dose, Females",States/Local Areas,California,2012,Age,13-17 Years,65.0,56.4 to 72.8,202
HPV,"≥1 Dose, Females",States/Local Areas,California,2013,Age,13-17 Years,67.6,57.5 to 76.2,148
HPV,"≥1 Dose, Females",States/Local Areas,California,2014,Age,13-17 Years,69.2,59.1 to 77.8,166
HPV,"≥1 Dose, Females",States/Local Areas,California,2015,Age,13-17 Years,66.7,56.5 to 75.5,174
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2009,Age,13-15 Years,62.6,52.6 to 71.6,153
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2020,Age,13-15 Years,90.0,82.8 to 94.3,250
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2021,Age,13-15 Years,86.3,74.7 to 93.1,172
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2020,Age,13-17 Years,87.1,81.3 to 91.2,403
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2021,Age,13-17 Years,89.2,82.0 to 93.7,286
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2022,Age,13-17 Years,85.5,79.4 to 90.1,321
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2008,Age,13-15 Years,46.7,34.7 to 59.1,108
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2012,Age,13-15 Years,72.1,63.7 to 79.2,220
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2013,Age,13-15 Years,84.8,77.0 to 90.3,163
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2010,Age,13-15 Years,68.1,58.9 to 76.0,140
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2011,Age,13-15 Years,69.4,61.9 to 76.0,276
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2015,Age,13-15 Years,80.5,71.7 to 87.0,190
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2019,Age,13-15 Years,88.6,77.5 to 94.6,158
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2012,Age,13-17 Years,81.3,75.9 to 85.7,430
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2011,Age,13-17 Years,77.4,72.7 to 81.5,583
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2013,Age,13-17 Years,83.9,78.1 to 88.3,309
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2014,Age,13-17 Years,84.9,79.5 to 89.1,356
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2009,Age,13-17 Years,74.1,68.1 to 79.3,379
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2010,Age,13-17 Years,74.4,68.3 to 79.6,330
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2017,Age,13-15 Years,84.9,76.5 to 90.7,172
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2018,Age,13-15 Years,88.4,81.0 to 93.2,200
Varicella,≥2 Doses with no disease history,States/Local Areas,California,2016,Age,13-15 Years,79.1,70.4 to 85.8,183
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2019,Age,13-17 Years,86.6,78.6 to 92.0,274
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2015,Age,13-17 Years,81.7,75.6 to 86.5,350
HPV,"≥3 Doses, Males",States/Local Areas,California,2013,Age,13-15 Years,19.7,11.4 to 32.0,110
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2017,Age,13-17 Years,85.7,79.7 to 90.1,306
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2018,Age,13-17 Years,88.0,82.7 to 91.9,356
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2016,Age,13-17 Years,83.4,77.6 to 87.9,327
Varicella,≥2 Doses or history of disease,States/Local Areas,California,2008,Age,13-17 Years,73.9,66.5 to 80.1,316
HPV,"≥3 Doses, Males",States/Local Areas,California,2014,Age,13-15 Years,29.5,19.7 to 41.7,122
HPV,"≥3 Doses, Males",States/Local Areas,California,2015,Age,13-15 Years,29.1,19.3 to 41.2,122
HPV,"≥3 Doses, Males",States/Local Areas,California,2013,Age,13-17 Years,16.6,10.1 to 26.2,161
HPV,"≥3 Doses, Males",States/Local Areas,California,2012,Age,13-17 Years,11.7,7.4 to 17.9,228
HPV,"≥3 Doses, Males",States/Local Areas,California,2014,Age,13-17 Years,31.1,22.9 to 40.6,190
HPV,"≥3 Doses, Males",States/Local Areas,California,2015,Age,13-17 Years,29.5,21.3 to 39.2,176
HPV,"≥3 Doses, Females",States/Local Areas,California,2015,Age,13-17 Years,48.4,38.6 to 58.3,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2017,Age,13-17 Years,53.4,46.3 to 60.4,306
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2018,Age,13-17 Years,52.6,45.4 to 59.8,356
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2019,Age,13-17 Years,56.4,47.3 to 65.0,274
≥2 Doses MMR,,States/Local Areas,California,2012,Age,13-17 Years,90.7,86.4 to 93.8,430
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2013,Age,13-17 Years,91.1,85.5 to 94.6,309
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2014,Age,13-17 Years,87.7,82.3 to 91.7,356
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2016,Age,13-17 Years,49.1,42.2 to 56.0,327
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2022,Age,13-15 Years,80.7,71.1 to 87.6,188
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2008,Age,13-17 Years,43.7,36.4 to 51.3,316
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2009,Age,13-17 Years,53.1,46.7 to 59.5,379
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2010,Age,13-17 Years,71.2,65.1 to 76.5,330
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2011,Age,13-17 Years,82.5,78.3 to 86.0,583
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2015,Age,13-17 Years,82.5,76.2 to 87.4,350
HPV,"≥2 Doses, Males",States/Local Areas,California,2019,Age,13-17 Years,54.5,42.2 to 66.4,148
≥2 Doses MMR,,States/Local Areas,California,2008,Age,13-17 Years,91.9,87.0 to 95.1,316
≥2 Doses MMR,,States/Local Areas,California,2009,Age,13-17 Years,87.2,82.6 to 90.8,379
≥2 Doses MMR,,States/Local Areas,California,2010,Age,13-17 Years,87.9,82.2 to 92.0,330
≥2 Doses MMR,,States/Local Areas,California,2011,Age,13-17 Years,90.3,86.7 to 93.0,583
Tetanus,≥1 Dose Tdap,States/Local Areas,California,2012,Age,13-17 Years,89.4,85.0 to 92.7,430
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2020,Age,13-17 Years,62.3,55.4 to 68.8,403
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2021,Age,13-17 Years,69.0,60.5 to 76.4,286
HPV,"Up-to-Date, Males and Females",States/Local Areas,California,2022,Age,13-17 Years,60.6,53.4 to 67.4,321
HPV,"≥3 Doses, Females",States/Local Areas,California,2010,Age,13-17 Years,32.0,24.5 to 40.6,163
HPV,"≥3 Doses, Females",States/Local Areas,California,2009,Age,13-17 Years,21.8,15.8 to 29.4,190
HPV,"≥3 Doses, Females",States/Local Areas,California,2008,Age,13-17 Years,22.1,14.2 to 32.8,150
HPV,"≥3 Doses, Males",States/Local Areas,California,2012,Age,13-15 Years,11.3,6.5 to 18.8,146
≥2 Doses Hep A,,States/Local Areas,California,2021,Age,13-17 Years,88.9,81.1 to 93.7,286
≥2 Doses Hep A,,States/Local Areas,California,2022,Age,13-17 Years,81.2,74.5 to 86.5,321
≥2 Doses Hep A,,States/Local Areas,California,2020,Age,13-17 Years,84.2,78.4 to 88.7,403
HPV,"≥3 Doses, Females",States/Local Areas,California,2012,Age,13-17 Years,35.8,28.0 to 44.5,202
HPV,"≥3 Doses, Females",States/Local Areas,California,2013,Age,13-17 Years,45.8,35.9 to 56.0,148
HPV,"≥3 Doses, Females",States/Local Areas,California,2014,Age,13-17 Years,47.7,38.1 to 57.5,166
HPV,"≥3 Doses, Females",States/Local Areas,California,2011,Age,13-17 Years,42.9,35.8 to 50.3,270
Varicella,History of disease,States/Local Areas,California,2009,Age,13-17 Years,40.0,34.1 to 46.2,379
HPV,"Up-to-Date, Females",States/Local Areas,California,2018,Age,13-17 Years,50.1,40.1 to 60.0,179
HPV,"Up-to-Date, Females",States/Local Areas,California,2019,Age,13-17 Years,61.5,48.2 to 73.3,126
HPV,"Up-to-Date, Females",States/Local Areas,California,2016,Age,13-17 Years,58.3,47.6 to 68.2,143
HPV,"Up-to-Date, Males",States/Local Areas,California,2018,Age,13-15 Years,58.8,45.7 to 70.8,107
HPV,"Up-to-Date, Females",States/Local Areas,California,2021,Age,13-17 Years,67.0,54.8 to 77.3,146
HPV,"Up-to-Date, Females",States/Local Areas,California,2022,Age,13-17 Years,60.8,50.1 to 70.6,140
HPV,"Up-to-Date, Males",States/Local Areas,California,2019,Age,13-15 Years,55.6,38.8 to 71.1,90
HPV,"Up-to-Date, Females",States/Local Areas,California,2020,Age,13-17 Years,68.7,58.5 to 77.5,184
HPV,"Up-to-Date, Females",States/Local Areas,California,2021,Age,13-15 Years,64.5,48.4 to 77.9,87
HPV,"Up-to-Date, Females",States/Local Areas,California,2022,Age,13-15 Years,54.8,40.7 to 68.2,81
HPV,"Up-to-Date, Males",States/Local Areas,California,2018,Age,13-17 Years,55.1,44.7 to 65.0,177
HPV,"Up-to-Date, Males",States/Local Areas,California,2019,Age,13-17 Years,51.4,39.2 to 63.4,148
HPV,"Up-to-Date, Males",States/Local Areas,California,2020,Age,13-17 Years,56.2,46.6 to 65.4,219
HPV,"Up-to-Date, Males",States/Local Areas,California,2017,Age,13-17 Years,46.3,37.1 to 55.7,171
HPV,"Up-to-Date, Males",States/Local Areas,California,2016,Age,13-17 Years,40.3,31.8 to 49.4,184
HPV,"Up-to-Date, Males",States/Local Areas,California,2021,Age,13-15 Years,72.1,55.9 to 84.0,95
HPV,"Up-to-Date, Males",States/Local Areas,California,2022,Age,13-15 Years,55.8,42.5 to 68.3,107
HPV,"Up-to-Date, Males",States/Local Areas,California,2020,Age,13-15 Years,51.6,39.7 to 63.3,146
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2023,Age,13-17 Years,77.7,68.3 to 84.9,410
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Other,86.1,76.9 to 92.0,305
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Uninsured,89.8,72.4 to 96.8,93
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Any Medicaid,92.2,89.4 to 94.2,1213
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Private Insurance Only,94.3,92.6 to 95.6,2218
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Uninsured,34.4,20.1 to 52.2,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Other,57.3,47.8 to 66.3,305
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Any Medicaid,66.3,61.9 to 70.4,1213
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Private Insurance Only,63.7,60.5 to 66.8,2218
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Uninsured,88.8,71.9 to 96.1,93
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Other,69.7,60.2 to 77.8,305
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Uninsured,66.3,46.5 to 81.7,93
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Other,90.4,83.3 to 94.6,305
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Any Medicaid,79.7,75.8 to 83.1,1213
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Private Insurance Only,75.6,72.7 to 78.4,2218
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Private Insurance Only,95.1,93.6 to 96.3,2218
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Poverty,Living At or Above Poverty Level,93.8,92.3 to 95.0,3096
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Insurance Coverage,Any Medicaid,94.0,91.7 to 95.7,1213
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Poverty,Below Poverty Level,88.9,83.9 to 92.4,580
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Poverty,Living At or Above Poverty Level,61.7,58.9 to 64.4,3096
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Poverty,Below Poverty Level,69.8,63.1 to 75.8,580
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Poverty,Living At or Above Poverty Level,94.2,92.8 to 95.4,3096
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Poverty,Below Poverty Level,92.7,88.7 to 95.4,580
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Poverty,Below Poverty Level,86.5,81.4 to 90.3,580
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Poverty,Living At or Above Poverty Level,74.0,71.4 to 76.4,3096
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",81.5,75.5 to 86.3,667
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"White, Non-Hispanic",74.1,71.2 to 76.9,2208
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,Hispanic,92.8,88.5 to 95.6,534
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.4,82.6 to 93.8,420
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,Hispanic,94.1,89.4 to 96.8,534
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.5,82.0 to 91.5,667
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.3,92.7 to 95.6,2208
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.5,94.1 to 96.6,2208
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",92.1,88.8 to 94.5,667
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,Hispanic,67.2,60.2 to 73.5,534
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.5,53.3 to 69.1,420
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",69.9,63.5 to 75.5,667
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",76.2,68.4 to 82.5,420
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,Hispanic,82.8,77.2 to 87.2,534
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.1,81.3 to 92.7,420
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Race and Ethnicity,"White, Non-Hispanic",61.7,58.5 to 64.8,2208
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Principal City,93.0,90.3 to 95.0,1606
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.3,91.5 to 94.7,2130
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,89.7,84.3 to 93.4,786
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,90.0,84.6 to 93.6,786
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,92.1,87.2 to 95.3,786
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2023,Age,13-17 Years,77.6,71.4 to 82.9,786
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2023,Age,13-17 Years,77.6,68.7 to 84.5,376
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2023,Age,13-17 Years,65.6,58.7 to 71.9,786
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,90.1,84.7 to 93.7,786
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,93.3,88.5 to 96.1,786
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2023,Age,13-17 Years,64.3,54.3 to 73.2,410
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,91.8,87.0 to 94.9,786
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,91.5,86.5 to 94.7,756
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,94.4,89.5 to 97.0,756
Varicella,History of disease,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,3.7,2.1 to 6.4,786
≥2 Doses Hep A,,States/Local Areas,Pennsylvania,2023,Age,13-17 Years,84.6,78.7 to 89.2,786
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2023,Age,13-15 Years,92.4,85.8 to 96.0,465
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2023,Age,13-15 Years,89.8,82.3 to 94.4,465
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2023,Age,13-15 Years,64.1,55.0 to 72.4,465
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2023,Age,13-15 Years,64.2,51.4 to 75.2,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2023,Age,13-15 Years,92.4,86.1 to 96.0,446
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2023,Age,13-15 Years,64.1,50.7 to 75.6,242
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2023,Age,13-17 Years,66.9,57.2 to 75.4,376
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Principal City,95.6,93.7 to 96.9,1606
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.9,92.3 to 95.2,2130
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a Non-MSA,91.5,81.5 to 96.3,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Principal City,71.4,67.1 to 75.3,1606
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a Non-MSA,51.3,39.3 to 63.2,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Non-Principal City,61.3,58.2 to 64.3,2130
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Principal City,84.5,80.9 to 87.5,1606
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.4,71.5 to 77.0,2130
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a Non-MSA,61.4,49.0 to 72.4,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Overall,Overall,63.4,60.9 to 65.8,3829
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Urbanicity,Living In a Non-MSA,85.5,74.1 to 92.4,93
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018-2022,Overall,Overall,76.3,74.0 to 78.4,3829
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018-2022,Overall,Overall,92.8,91.4 to 94.0,3829
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018-2022,Overall,Overall,94.2,93.0 to 95.2,3829
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2018,Age,13-15 Years,73.0,60.2 to 82.8,75
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,74.0,64.2 to 81.8,157
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,77.2,65.5 to 85.8,116
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,76.1,66.1 to 83.8,125
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2019,Age,13-15 Years,76.2,64.1 to 85.2,81
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2020,Age,13-15 Years,73.5,60.1 to 83.7,84
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2021,Age,13-15 Years,68.7,56.1 to 79.0,103
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2022,Age,13-15 Years,66.3,53.0 to 77.3,95
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2019,Age,13-15 Years,76.7,67.8 to 83.8,143
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,72.9,62.9 to 81.1,151
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2021,Age,13-15 Years,70.3,61.5 to 77.8,198
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2020,Age,13-15 Years,74.4,65.5 to 81.7,164
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2021,Age,13-15 Years,71.8,59.0 to 81.8,95
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2022,Age,13-15 Years,72.2,56.3 to 84.0,74
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,76.2,67.8 to 83.0,150
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,76.2,65.5 to 84.4,134
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,74.5,64.0 to 82.7,138
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,69.8,61.3 to 77.2,188
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,75.7,66.3 to 83.2,122
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,12.0,8.4 to 16.7,362
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,5.3,3.0 to 9.2,237
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,21.7,16.8 to 27.5,387
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,31.7,26.3 to 37.7,371
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,17.1,12.5 to 23.0,307
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,17.3,12.4 to 23.4,348
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,18.9,14.1 to 25.0,343
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2022,Age,13-15 Years,69.1,59.1 to 77.6,169
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,74.5,65.4 to 81.9,173
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,69.2,60.3 to 76.9,174
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,78.8,67.7 to 86.9,108
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,67.1,55.6 to 76.9,115
HPV,"Up-to-Date, Males",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,61.1,52.8 to 68.9,199
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,12.7,9.0 to 17.5,340
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,11.5,7.9 to 16.4,349
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,45.1,39.0 to 51.4,345
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,34.7,29.0 to 40.8,324
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2018,Age,13-15 Years,69.1,55.1 to 80.2,77
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,10.9,6.6 to 17.6,242
Varicella,History of disease,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,6.2,3.5 to 10.8,263
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,65.2,59.2 to 70.8,324
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,70.4,64.7 to 75.6,371
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,81.0,75.1 to 85.8,387
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,90.3,85.1 to 93.8,343
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,89.6,84.7 to 93.1,307
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,87.2,81.6 to 91.2,348
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,71.5,64.1 to 77.9,237
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,69.5,63.5 to 75.0,362
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2009,Age,13-15 Years,65.3,56.8 to 73.0,166
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2008,Age,13-15 Years,49.4,39.7 to 59.2,133
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2010,Age,13-15 Years,79.6,71.8 to 85.7,185
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2011,Age,13-15 Years,81.7,73.3 to 87.9,199
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2013,Age,13-15 Years,95.2,89.2 to 97.9,152
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2012,Age,13-15 Years,89.3,81.7 to 93.9,199
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,95.0,91.5 to 97.2,321
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,60.2,51.8 to 68.0,185
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,75.9,67.1 to 83.0,188
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,91.0,84.5 to 94.9,281
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,91.8,86.1 to 95.3,259
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,90.0,85.7 to 93.2,298
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,91.4,87.1 to 94.4,313
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2020,Age,13-15 Years,97.0,93.2 to 98.7,150
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2021,Age,13-15 Years,94.4,86.4 to 97.8,189
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,91.3,87.5 to 94.0,340
HPV,"≥3 Doses, Males",States/Local Areas,PA-Philadelphia,2015,Age,13-15 Years,36.2,25.3 to 48.8,96
HPV,"≥3 Doses, Males",States/Local Areas,PA-Philadelphia,2014,Age,13-15 Years,28.9,18.9 to 41.6,101
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,94.4,89.7 to 97.0,263
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,94.3,89.9 to 96.9,330
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,96.5,93.3 to 98.2,267
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2015,Age,13-15 Years,90.0,84.3 to 93.8,179
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2014,Age,13-15 Years,89.6,80.1 to 94.8,160
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2018,Age,13-15 Years,96.8,90.3 to 99.0,140
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2019,Age,13-15 Years,93.6,87.4 to 96.8,126
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,92.7,87.3 to 95.9,343
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,93.2,88.4 to 96.1,307
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,84.6,79.1 to 88.9,387
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,91.7,86.8 to 94.9,348
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2017,Age,13-15 Years,94.5,89.9 to 97.0,198
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2016,Age,13-15 Years,91.3,85.1 to 95.1,186
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,78.1,72.5 to 82.7,324
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,84.5,79.5 to 88.5,371
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,96.1,92.7 to 97.9,242
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,93.5,87.9 to 96.7,237
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,92.4,88.6 to 95.0,349
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,95.6,92.5 to 97.5,362
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,74.2,67.8 to 79.8,330
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,75.0,67.6 to 81.2,267
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2022,Age,13-15 Years,92.1,84.9 to 96.1,169
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,48.6,42.4 to 54.8,345
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,77.5,70.0 to 83.5,242
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,75.3,68.2 to 81.2,263
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,91.4,86.8 to 94.5,387
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,90.9,86.8 to 93.8,371
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,68.4,62.5 to 73.8,349
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,76.4,65.7 to 84.6,134
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,88.4,83.5 to 91.9,324
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,89.3,84.7 to 92.6,345
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,86.1,80.7 to 90.1,340
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2019,Age,13-15 Years,77.3,63.0 to 87.2,62
HPV,"Up-to-Date, Females",States/Local Areas,PA-Philadelphia,2020,Age,13-15 Years,75.3,62.6 to 84.8,80
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,38.5,30.6 to 47.0,185
Varicella,≥2 Doses or history of disease,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,72.6,66.7 to 77.8,345
HPV,"≥3 Doses, Males",States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,15.8,10.6 to 23.0,148
HPV,"≥3 Doses, Males",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,43.4,34.6 to 52.6,165
HPV,"≥3 Doses, Males",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,34.8,26.5 to 44.1,186
≥2 Doses Hep A,,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,95.8,91.0 to 98.1,267
≥2 Doses Hep A,,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,91.0,86.0 to 94.3,330
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,59.3,49.0 to 68.9,157
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,54.5,45.4 to 63.3,159
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,48.8,39.7 to 58.0,188
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,51.9,41.6 to 62.0,166
≥2 Doses Hep A,,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,90.8,85.5 to 94.4,263
HPV,"≥3 Doses, Males",States/Local Areas,PA-Philadelphia,2013,Age,13-15 Years,14.4,8.2 to 24.2,87
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,58.6,49.9 to 66.8,175
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,27.5,20.1 to 36.4,148
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,20.7,14.1 to 29.3,178
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2015,Age,13-15 Years,53.4,42.0 to 64.4,104
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2014,Age,13-15 Years,50.9,37.6 to 64.1,89
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2013,Age,13-15 Years,47.2,35.8 to 58.8,96
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2012,Age,13-15 Years,47.5,35.6 to 59.7,106
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2011,Age,13-15 Years,46.0,34.2 to 58.3,105
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2008,Age,13-15 Years,17.8,10.8 to 28.1,110
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,93.9,89.3 to 96.6,330
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,97.0,93.8 to 98.6,267
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,93.4,88.7 to 96.3,242
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,93.0,87.4 to 96.3,237
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,91.1,86.8 to 94.1,362
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,93.5,88.4 to 96.4,263
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,93.1,87.6 to 96.3,267
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,92.6,88.0 to 95.6,330
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2019,Age,13-15 Years,94.6,89.9 to 97.1,143
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2020,Age,13-15 Years,87.8,79.9 to 92.9,164
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2021,Age,13-15 Years,87.2,79.3 to 92.4,198
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018,Age,13-15 Years,89.7,82.0 to 94.3,152
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,35.7,27.3 to 45.0,148
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,49.9,40.6 to 59.3,186
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,6.2,3.5 to 10.9,199
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,27.5,19.5 to 37.4,182
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,77.1,67.7 to 84.4,122
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,75.2,66.9 to 81.9,188
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,65.5,57.2 to 73.0,199
HPV,"≥2 Doses, Males",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,61.2,52.3 to 69.4,165
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2013,Age,13-15 Years,88.7,82.0 to 93.2,183
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,95.2,90.5 to 97.6,242
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,91.7,86.5 to 95.0,263
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2008,Age,13-15 Years,53.1,45.0 to 60.9,205
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,94.3,89.4 to 97.0,267
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2010,Age,13-15 Years,74.2,67.2 to 80.2,231
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2009,Age,13-15 Years,66.0,58.5 to 72.7,216
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2011,Age,13-15 Years,81.7,74.2 to 87.4,232
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2012,Age,13-15 Years,87.8,79.8 to 92.9,219
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2017,Age,13-15 Years,90.5,84.9 to 94.2,223
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2016,Age,13-15 Years,87.7,81.2 to 92.2,203
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2015,Age,13-15 Years,86.4,79.2 to 91.3,200
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2014,Age,13-15 Years,87.9,79.4 to 93.1,190
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2021,Age,13-15 Years,91.9,84.6 to 95.9,198
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,84.3,75.0 to 90.6,108
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,71.7,60.2 to 81.0,115
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,84.8,78.3 to 89.5,263
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,87.1,81.8 to 91.1,330
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,91.1,85.0 to 94.8,267
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,70.3,61.5 to 77.9,174
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,80.9,72.7 to 87.1,150
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,68.1,59.6 to 75.6,175
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,74.1,64.4 to 82.0,157
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,89.7,85.4 to 92.8,387
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,86.1,81.4 to 89.7,371
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,91.5,87.0 to 94.6,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,92.0,87.1 to 95.1,348
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,90.0,84.2 to 93.8,242
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,89.8,84.3 to 93.5,237
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,90.6,85.6 to 93.9,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,94.2,89.3 to 96.9,237
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,82.0,77.0 to 86.0,324
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,79.7,73.9 to 84.5,345
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2010,Age,13-15 Years,83.9,77.6 to 88.7,231
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2011,Age,13-15 Years,89.6,83.9 to 93.5,232
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2008,Age,13-15 Years,67.3,59.2 to 74.6,205
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2009,Age,13-15 Years,76.1,69.2 to 81.8,216
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,98.5,95.6 to 99.5,257
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,96.1,92.4 to 98.0,315
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,71.2,62.6 to 78.5,159
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,68.5,58.6 to 77.0,166
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,63.5,54.0 to 72.1,188
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,54.8,46.4 to 63.0,185
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2020,Age,13-15 Years,92.6,85.2 to 96.4,164
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,41.6,33.0 to 50.8,148
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,91.8,83.7 to 96.0,151
HPV,"≥2 Doses, Females",States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,36.1,28.0 to 45.0,178
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2019,Age,13-15 Years,91.1,83.8 to 95.3,143
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018,Age,13-15 Years,94.1,88.0 to 97.2,152
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2017,Age,13-15 Years,91.2,85.6 to 94.7,223
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2016,Age,13-15 Years,88.3,82.0 to 92.6,203
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2013,Age,13-15 Years,90.9,84.2 to 95.0,183
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2012,Age,13-15 Years,92.7,85.5 to 96.5,219
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,84.9,80.0 to 88.7,362
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,80.7,75.4 to 85.0,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,93.9,90.3 to 96.2,362
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,92.5,88.6 to 95.1,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,93.0,87.9 to 96.0,343
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,90.9,86.8 to 93.9,340
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2015,Age,13-15 Years,89.3,82.9 to 93.5,200
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2014,Age,13-15 Years,91.6,84.2 to 95.7,190
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,84.6,77.2 to 89.9,174
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,88.2,81.2 to 92.8,150
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,86.3,76.7 to 92.4,115
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,94.3,89.7 to 96.9,263
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,95.2,92.0 to 97.2,330
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,94.7,89.9 to 97.3,267
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,46.7,37.1 to 56.6,182
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,82.9,72.6 to 89.9,138
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,83.6,74.6 to 89.8,173
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,93.1,86.8 to 96.5,122
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,85.2,78.2 to 90.2,188
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,74.4,67.2 to 80.6,237
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,91.2,84.3 to 95.3,108
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,96.4,93.0 to 98.1,257
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,86.8,78.5 to 92.2,125
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,90.9,84.9 to 94.7,157
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,19.0,13.2 to 26.6,199
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,90.3,79.6 to 95.7,116
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,72.8,66.9 to 78.0,362
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,72.9,67.1 to 78.0,349
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,62.8,53.3 to 71.4,186
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,55.8,46.0 to 65.2,148
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,79.5,71.5 to 85.7,165
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,73.7,65.7 to 80.3,199
HPV,"≥1 Dose, Males",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,88.7,78.6 to 94.4,134
HPV,"≥2 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,80.3,73.3 to 85.8,242
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,51.8,43.3 to 60.3,178
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,90.0,84.2 to 93.8,296
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,80.4,73.6 to 85.7,307
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,77.3,70.6 to 82.9,270
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,93.2,88.0 to 96.3,343
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,91.8,86.8 to 95.0,307
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,90.2,84.9 to 93.7,387
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,91.0,86.0 to 94.3,348
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,58.2,49.1 to 66.8,148
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,91.8,85.8 to 95.4,191
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2022,Age,13-15 Years,97.8,94.9 to 99.1,165
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,93.3,89.4 to 95.8,345
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,96.5,92.9 to 98.2,307
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,66.4,58.9 to 73.2,217
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,50.0,41.6 to 58.4,191
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,93.0,87.4 to 96.2,217
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,96.4,93.3 to 98.1,270
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,96.7,91.8 to 98.7,296
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,89.1,84.5 to 92.4,324
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,93.2,89.5 to 95.6,371
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,94.3,90.5 to 96.6,362
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,93.2,87.5 to 96.4,242
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,91.3,85.2 to 95.0,237
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,88.9,84.5 to 92.1,340
≥3 Doses HepB,,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,89.7,85.4 to 92.8,349
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,95.6,91.8 to 97.7,218
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,94.0,89.0 to 96.8,243
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,94.0,89.5 to 96.7,315
Varicella,≥2 Doses with no disease history,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,93.2,87.2 to 96.5,222
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,96.9,93.6 to 98.5,243
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,98.9,96.8 to 99.6,321
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,97.4,94.2 to 98.9,218
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,94.4,88.3 to 97.4,222
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,97.6,92.0 to 99.3,281
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,97.9,93.7 to 99.4,259
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,95.5,92.2 to 97.5,298
Varicella,≥1 Dose with no disease history,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,96.3,92.9 to 98.1,313
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,80.3,71.0 to 87.2,157
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,79.3,71.7 to 85.3,175
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,78.4,70.3 to 84.8,159
HPV,"≥1 Dose, Females",States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,76.2,67.0 to 83.5,166
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Overall,Overall,88.6,86.2 to 90.6,1339
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Overall,Overall,74.7,71.6 to 77.6,1339
HPV,"≥1 Dose, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Urbanicity,Living In a MSA Principal City,88.6,86.2 to 90.6,1339
HPV,"Up-to-Date, Males and Females",States/Local Areas,PA-Philadelphia,2018-2022,Urbanicity,Living In a MSA Principal City,74.7,71.6 to 77.6,1339
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Urbanicity,Living In a MSA Principal City,93.1,91.2 to 94.7,1339
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,93.0,89.5 to 95.4,349
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2022,Age,13-15 Years,91.9,83.6 to 96.2,169
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,89.8,85.4 to 93.0,349
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2009,Age,13-17 Years,75.3,69.7 to 80.2,324
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2008,Age,13-17 Years,66.3,60.1 to 72.1,345
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,88.7,84.2 to 92.0,387
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2010,Age,13-17 Years,84.5,79.6 to 88.4,371
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,30.7,24.4 to 37.8,348
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2011,Age,13-17 Years,25.0,20.1 to 30.7,387
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,92.9,88.2 to 95.8,348
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,92.6,87.9 to 95.5,343
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,92.1,87.4 to 95.1,307
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,91.2,87.0 to 94.1,340
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2016,Age,13-17 Years,91.2,87.1 to 94.1,349
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,91.6,87.4 to 94.5,362
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,90.1,84.3 to 93.9,237
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2013,Age,13-17 Years,90.2,84.6 to 93.9,307
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2012,Age,13-17 Years,90.9,85.2 to 94.6,348
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,95.8,91.7 to 97.9,263
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,50.7,44.4 to 57.0,340
HPV,"≥3 Doses, Males and Females",States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,46.9,40.1 to 53.8,343
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2014,Age,13-17 Years,96.6,92.9 to 98.4,343
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2015,Age,13-17 Years,91.5,87.5 to 94.3,340
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,92.9,87.1 to 96.2,242
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2020,Age,13-17 Years,90.1,84.7 to 93.8,263
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2021,Age,13-17 Years,88.9,83.8 to 92.6,330
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2022,Age,13-17 Years,93.2,88.1 to 96.2,267
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2019,Age,13-17 Years,96.6,93.3 to 98.4,242
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2018,Age,13-17 Years,94.7,89.7 to 97.4,237
≥2 Doses MMR,,States/Local Areas,PA-Philadelphia,2017,Age,13-17 Years,94.5,90.5 to 96.9,362
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2009,Age,13-15 Years,31.7,22.1 to 43.1,99
HPV,"≥3 Doses, Females",States/Local Areas,PA-Philadelphia,2010,Age,13-15 Years,36.1,26.1 to 47.5,112
≥1 Dose MenACWY,,States/Local Areas,PA-Philadelphia,2018-2022,Overall,Overall,93.1,91.2 to 94.7,1339
Tetanus,≥1 Dose Tdap,States/Local Areas,PA-Philadelphia,2018-2022,Overall,Overall,91.1,88.9 to 92.8,1339
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2017,Age,13-17 Years,48.8,39.5 to 58.2,156
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2016,Age,13-17 Years,47.3,37.8 to 57.1,158
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2022,Age,13-15 Years,57.8,44.0 to 70.5,83
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2021,Age,13-15 Years,80.3,70.0 to 87.7,122
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2020,Age,13-17 Years,74.7,65.9 to 81.8,146
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2016,Age,13-17 Years,30.5,23.0 to 39.2,184
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2022,Age,13-17 Years,64.3,52.8 to 74.2,129
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2021,Age,13-17 Years,78.3,70.7 to 84.4,202
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2018,Age,13-15 Years,52.9,41.7 to 63.7,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2022,Age,13-15 Years,65.5,55.9 to 74.1,158
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2019,Age,13-17 Years,59.2,48.9 to 68.8,124
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2018,Age,13-17 Years,46.3,37.8 to 55.0,169
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2018,Age,13-15 Years,41.1,30.5 to 52.5,98
Varicella,History of disease,States/Local Areas,South Dakota,2022,Age,13-17 Years,9.1,5.2 to 15.5,252
Varicella,History of disease,States/Local Areas,South Dakota,2021,Age,13-17 Years,7.8,5.0 to 11.8,445
Varicella,History of disease,States/Local Areas,South Dakota,2019,Age,13-17 Years,11.4,7.8 to 16.4,313
Varicella,History of disease,States/Local Areas,South Dakota,2020,Age,13-17 Years,9.9,6.3 to 15.2,317
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2020,Age,13-15 Years,74.7,63.4 to 83.5,95
HPV,"Up-to-Date, Females",States/Local Areas,South Dakota,2019,Age,13-15 Years,55.3,42.6 to 67.4,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2020,Age,13-15 Years,70.5,62.4 to 77.4,192
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2021,Age,13-15 Years,73.8,66.5 to 80.0,276
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2022,Age,13-17 Years,72.1,62.3 to 80.2,123
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2019,Age,13-15 Years,58.8,50.4 to 66.7,200
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2021,Age,13-17 Years,71.3,63.1 to 78.4,243
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2022,Age,13-15 Years,73.4,60.8 to 83.1,75
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2021,Age,13-15 Years,68.1,57.5 to 77.0,154
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2020,Age,13-15 Years,66.1,54.2 to 76.3,97
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2019,Age,13-15 Years,62.0,51.2 to 71.7,122
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2020,Age,13-17 Years,68.5,59.7 to 76.2,171
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2019,Age,13-17 Years,63.0,54.5 to 70.8,189
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2017,Age,13-17 Years,40.9,32.7 to 49.7,177
HPV,"Up-to-Date, Males",States/Local Areas,South Dakota,2018,Age,13-17 Years,52.5,43.8 to 61.0,171
Varicella,History of disease,States/Local Areas,South Dakota,2009,Age,13-17 Years,67.3,60.6 to 73.4,271
Varicella,History of disease,States/Local Areas,South Dakota,2011,Age,13-17 Years,55.5,45.4 to 65.1,355
Varicella,History of disease,States/Local Areas,South Dakota,2010,Age,13-17 Years,62.7,56.4 to 68.6,321
Varicella,History of disease,States/Local Areas,South Dakota,2013,Age,13-17 Years,33.0,27.1 to 39.5,292
Varicella,History of disease,States/Local Areas,South Dakota,2012,Age,13-17 Years,50.2,43.3 to 57.1,298
Varicella,History of disease,States/Local Areas,South Dakota,2018,Age,13-17 Years,13.1,9.4 to 18.1,340
Varicella,History of disease,States/Local Areas,South Dakota,2016,Age,13-17 Years,26.0,20.5 to 32.3,342
Varicella,History of disease,States/Local Areas,South Dakota,2015,Age,13-17 Years,27.3,22.0 to 33.3,349
Varicella,History of disease,States/Local Areas,South Dakota,2014,Age,13-17 Years,29.9,24.2 to 36.3,358
Varicella,History of disease,States/Local Areas,South Dakota,2008,Age,13-17 Years,70.9,65.0 to 76.3,344
Varicella,History of disease,States/Local Areas,South Dakota,2017,Age,13-17 Years,13.2,9.4 to 18.2,333
HPV,"≥3 Doses, Males",States/Local Areas,South Dakota,2015,Age,13-15 Years,22.5,14.7 to 32.9,120
HPV,"≥3 Doses, Males",States/Local Areas,South Dakota,2014,Age,13-15 Years,26.8,16.9 to 39.7,114
HPV,"≥3 Doses, Males",States/Local Areas,South Dakota,2014,Age,13-17 Years,23.5,16.1 to 32.9,181
HPV,"≥3 Doses, Males",States/Local Areas,South Dakota,2015,Age,13-17 Years,22.0,15.7 to 30.0,187
HPV,"≥3 Doses, Males",States/Local Areas,South Dakota,2013,Age,13-17 Years,8.4,5.0 to 13.6,151
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2016,Age,13-17 Years,83.4,77.8 to 87.8,342
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2017,Age,13-17 Years,86.0,81.0 to 89.9,333
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2019,Age,13-17 Years,91.9,87.3 to 94.9,313
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2008,Age,13-17 Years,72.6,66.8 to 77.7,344
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2014,Age,13-17 Years,74.1,67.9 to 79.4,358
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2015,Age,13-17 Years,75.1,69.3 to 80.2,349
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2022,Age,13-17 Years,95.0,91.2 to 97.2,252
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2018,Age,13-17 Years,92.6,88.5 to 95.3,340
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2021,Age,13-17 Years,98.1,96.3 to 99.1,445
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2020,Age,13-17 Years,95.8,92.2 to 97.8,317
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2013,Age,13-17 Years,66.9,60.2 to 73.0,292
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2011,Age,13-17 Years,72.0,62.8 to 79.6,355
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2012,Age,13-17 Years,72.0,65.9 to 77.3,298
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2016,Age,13-15 Years,85.0,76.0 to 91.0,155
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2017,Age,13-15 Years,90.1,83.2 to 94.3,173
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2009,Age,13-17 Years,71.5,64.9 to 77.3,271
Varicella,≥2 Doses or history of disease,States/Local Areas,South Dakota,2010,Age,13-17 Years,70.1,64.0 to 75.5,321
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2014,Age,13-15 Years,63.6,53.9 to 72.4,173
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2015,Age,13-15 Years,72.5,64.5 to 79.3,183
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2019,Age,13-15 Years,91.1,84.8 to 94.9,180
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2018,Age,13-15 Years,94.3,88.3 to 97.3,187
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2014,Age,13-17 Years,61.0,51.3 to 69.9,177
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2013,Age,13-17 Years,56.0,46.3 to 65.4,141
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2012,Age,13-17 Years,51.0,41.0 to 60.9,135
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2010,Age,13-15 Years,20.4,11.8 to 32.8,86
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2011,Age,13-15 Years,42.0,25.0 to 61.1,114
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2013,Age,13-15 Years,54.1,43.6 to 64.2,121
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2012,Age,13-15 Years,41.3,31.5 to 51.9,115
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2016,Age,13-17 Years,77.6,70.5 to 83.4,258
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2015,Age,13-17 Years,65.8,58.5 to 72.4,255
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2014,Age,13-17 Years,63.0,55.1 to 70.3,253
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2013,Age,13-17 Years,50.6,42.3 to 58.9,189
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2017,Age,13-17 Years,83.9,78.2 to 88.3,284
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2010,Age,13-17 Years,68.8,60.5 to 76.1,162
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2011,Age,13-17 Years,58.1,44.1 to 70.9,179
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2016,Age,13-17 Years,95.4,90.6 to 97.8,258
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2015,Age,13-17 Years,92.3,86.7 to 95.7,255
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2014,Age,13-17 Years,94.4,88.7 to 97.3,253
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2013,Age,13-17 Years,91.2,84.8 to 95.1,189
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2021,Age,13-15 Years,97.8,94.7 to 99.1,259
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2020,Age,13-15 Years,94.6,88.5 to 97.5,175
≥3 Doses HepB,,States/Local Areas,South Dakota,2015,Age,13-17 Years,90.1,85.4 to 93.5,349
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2017,Age,13-17 Years,95.3,91.8 to 97.4,284
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2020,Age,13-17 Years,97.8,95.3 to 98.9,290
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2018,Age,13-17 Years,91.5,86.9 to 94.6,298
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2021,Age,13-17 Years,98.0,95.9 to 99.0,413
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2020,Age,13-17 Years,95.4,91.4 to 97.6,290
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2019,Age,13-17 Years,90.9,85.8 to 94.3,280
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2018,Age,13-17 Years,96.7,93.2 to 98.5,298
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2012,Age,13-17 Years,88.4,81.4 to 93.0,161
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2019,Age,13-17 Years,94.5,90.1 to 97.0,280
≥3 Doses HepB,,States/Local Areas,South Dakota,2016,Age,13-17 Years,95.1,90.8 to 97.5,342
≥3 Doses HepB,,States/Local Areas,South Dakota,2019,Age,13-17 Years,93.9,89.7 to 96.5,313
≥3 Doses HepB,,States/Local Areas,South Dakota,2018,Age,13-17 Years,95.0,91.8 to 97.0,340
≥3 Doses HepB,,States/Local Areas,South Dakota,2017,Age,13-17 Years,93.0,89.3 to 95.5,333
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2022,Age,13-15 Years,95.8,90.5 to 98.2,153
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2014,Age,13-17 Years,28.4,20.5 to 37.9,181
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2013,Age,13-17 Years,17.0,11.6 to 24.4,151
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2012,Age,13-17 Years,10.7,5.9 to 18.4,163
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2018,Age,13-15 Years,87.5,81.0 to 92.1,205
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2021,Age,13-15 Years,96.1,91.5 to 98.3,276
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2020,Age,13-15 Years,92.5,86.8 to 95.9,192
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2019,Age,13-15 Years,88.9,82.1 to 93.3,200
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2015,Age,13-17 Years,28.6,21.4 to 37.0,187
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2013,Age,13-15 Years,69.4,60.6 to 77.0,171
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2016,Age,13-17 Years,34.9,26.9 to 43.8,184
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2017,Age,13-17 Years,44.8,36.3 to 53.6,177
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2018,Age,13-17 Years,54.9,46.1 to 63.3,171
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2014,Age,13-15 Years,73.7,65.2 to 80.7,223
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2015,Age,13-15 Years,73.1,65.4 to 79.7,221
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2016,Age,13-15 Years,77.4,69.0 to 84.1,198
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2017,Age,13-15 Years,80.1,72.3 to 86.1,190
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2022,Age,13-17 Years,93.5,88.6 to 96.4,252
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2008,Age,13-15 Years,23.4,17.4 to 30.8,199
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2010,Age,13-15 Years,53.7,45.4 to 61.9,198
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2009,Age,13-15 Years,49.4,40.6 to 58.1,159
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2011,Age,13-15 Years,61.2,48.0 to 72.9,209
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2012,Age,13-15 Years,60.0,51.5 to 67.9,195
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2019,Age,13-17 Years,59.2,48.9 to 68.8,124
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2018,Age,13-17 Years,50.0,41.3 to 58.7,169
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2014,Age,13-17 Years,44.0,34.9 to 53.6,177
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2015,Age,13-17 Years,42.3,33.7 to 51.4,162
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2016,Age,13-17 Years,55.2,45.3 to 64.6,158
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2017,Age,13-17 Years,54.0,44.5 to 63.3,156
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2020,Age,13-15 Years,93.7,88.0 to 96.8,192
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2009,Age,13-17 Years,55.8,46.3 to 64.9,142
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2011,Age,13-17 Years,54.7,40.9 to 67.7,179
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2010,Age,13-17 Years,61.5,52.6 to 69.6,162
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2010,Age,13-15 Years,32.8,25.5 to 41.0,198
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2011,Age,13-15 Years,39.6,27.3 to 53.3,209
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2008,Age,13-15 Years,9.6,6.0 to 15.0,199
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2009,Age,13-15 Years,24.2,17.6 to 32.3,159
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2022,Age,13-17 Years,82.8,74.3 to 89.0,123
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2011,Age,13-17 Years,57.8,47.3 to 67.7,355
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2010,Age,13-17 Years,60.8,54.4 to 66.8,321
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2012,Age,13-17 Years,68.3,61.7 to 74.3,298
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2009,Age,13-17 Years,58.0,51.2 to 64.4,271
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2008,Age,13-17 Years,45.3,39.3 to 51.4,344
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2021,Age,13-17 Years,97.0,94.4 to 98.4,445
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2018,Age,13-17 Years,68.7,62.7 to 74.2,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2019,Age,13-17 Years,73.6,67.3 to 79.0,313
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2022,Age,13-17 Years,79.0,72.1 to 84.6,252
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2021,Age,13-15 Years,97.1,94.4 to 98.6,276
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2021,Age,13-17 Years,87.4,82.8 to 90.9,445
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2020,Age,13-17 Years,84.5,79.7 to 88.4,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2020,Age,13-17 Years,92.2,87.6 to 95.2,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2019,Age,13-17 Years,91.4,86.8 to 94.5,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2018,Age,13-17 Years,88.4,83.8 to 91.8,340
≥3 Doses HepB,,States/Local Areas,South Dakota,2009,Age,13-17 Years,73.6,67.1 to 79.3,271
≥3 Doses HepB,,States/Local Areas,South Dakota,2010,Age,13-17 Years,78.3,71.9 to 83.5,321
≥3 Doses HepB,,States/Local Areas,South Dakota,2008,Age,13-17 Years,65.2,59.2 to 70.7,344
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2008,Age,13-17 Years,45.9,37.9 to 54.1,178
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2012,Age,13-17 Years,43.7,35.0 to 52.8,161
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2011,Age,13-17 Years,37.1,24.6 to 51.6,168
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2010,Age,13-17 Years,19.7,12.4 to 29.8,116
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2011,Age,13-17 Years,82.6,63.8 to 92.8,168
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2009,Age,13-17 Years,69.1,56.6 to 79.4,88
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2010,Age,13-17 Years,74.0,63.7 to 82.2,116
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2008,Age,13-17 Years,52.7,41.0 to 64.1,96
≥3 Doses HepB,,States/Local Areas,South Dakota,2014,Age,13-17 Years,93.4,88.8 to 96.1,358
≥3 Doses HepB,,States/Local Areas,South Dakota,2013,Age,13-17 Years,95.7,91.9 to 97.8,292
≥3 Doses HepB,,States/Local Areas,South Dakota,2011,Age,13-17 Years,87.3,78.0 to 93.1,355
≥3 Doses HepB,,States/Local Areas,South Dakota,2012,Age,13-17 Years,90.3,85.4 to 93.6,298
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2009,Age,13-17 Years,62.4,53.2 to 70.8,142
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Dakota,2019,Age,13-17 Years,61.7,55.0 to 67.9,313
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2017,Age,13-17 Years,58.8,49.8 to 67.2,177
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2018,Age,13-17 Years,70.8,62.4 to 78.0,171
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Dakota,2016,Age,13-17 Years,44.7,38.2 to 51.3,342
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2022,Age,13-17 Years,95.2,91.1 to 97.5,235
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2012,Age,13-17 Years,19.8,12.8 to 29.3,163
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2016,Age,13-17 Years,50.4,41.5 to 59.3,184
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2015,Age,13-17 Years,39.2,31.1 to 47.9,187
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2014,Age,13-17 Years,34.4,25.9 to 44.0,181
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2013,Age,13-17 Years,22.1,15.8 to 30.0,151
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2022,Age,13-17 Years,74.9,63.6 to 83.6,129
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2021,Age,13-17 Years,92.0,86.4 to 95.4,202
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2020,Age,13-17 Years,81.9,73.8 to 87.9,146
Varicella,≥2 Doses with no disease history,States/Local Areas,South Dakota,2022,Age,13-17 Years,94.5,90.4 to 96.9,235
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Dakota,2017,Age,13-17 Years,49.3,42.9 to 55.7,333
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2019,Age,13-17 Years,71.8,61.9 to 79.9,124
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Dakota,2018,Age,13-17 Years,52.5,46.3 to 58.6,340
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2021,Age,13-17 Years,83.0,75.4 to 88.6,243
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2020,Age,13-17 Years,87.0,81.1 to 91.3,171
HPV,"≥1 Dose, Males",States/Local Areas,South Dakota,2019,Age,13-17 Years,75.3,67.0 to 82.1,189
Varicella,≥1 Dose with no disease history,States/Local Areas,South Dakota,2021,Age,13-17 Years,98.9,97.5 to 99.5,413
≥3 Doses HepB,,States/Local Areas,South Dakota,2021,Age,13-17 Years,97.2,94.8 to 98.5,445
≥3 Doses HepB,,States/Local Areas,South Dakota,2020,Age,13-17 Years,96.5,93.9 to 98.0,317
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2018,Age,13-17 Years,66.5,57.7 to 74.3,169
≥3 Doses HepB,,States/Local Areas,South Dakota,2022,Age,13-17 Years,93.0,88.2 to 96.0,252
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2015,Age,13-17 Years,53.2,44.1 to 62.1,162
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2016,Age,13-17 Years,61.7,51.8 to 70.8,158
HPV,"≥1 Dose, Females",States/Local Areas,South Dakota,2017,Age,13-17 Years,67.9,58.4 to 76.1,156
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2013,Age,13-17 Years,72.7,66.0 to 78.5,292
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2014,Age,13-15 Years,58.3,49.6 to 66.4,223
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2015,Age,13-15 Years,54.7,46.8 to 62.3,221
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2013,Age,13-15 Years,49.6,40.9 to 58.2,171
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2012,Age,13-15 Years,37.3,29.7 to 45.5,195
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2015,Age,13-17 Years,75.6,69.7 to 80.7,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2014,Age,13-17 Years,76.1,69.8 to 81.4,358
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2016,Age,13-17 Years,80.3,74.1 to 85.3,342
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2019,Age,13-15 Years,89.7,83.3 to 93.8,200
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2018,Age,13-15 Years,87.6,81.8 to 91.8,205
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2017,Age,13-15 Years,76.9,68.6 to 83.5,190
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2013,Age,13-17 Years,52.0,42.3 to 61.5,141
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2012,Age,13-17 Years,46.5,36.7 to 56.6,135
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2008,Age,13-17 Years,41.6,33.8 to 49.8,178
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2016,Age,13-17 Years,55.9,49.2 to 62.3,342
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Dakota,2017,Age,13-17 Years,63.2,56.7 to 69.2,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Dakota,2017,Age,13-17 Years,80.3,74.4 to 85.1,333
≥1 Dose MenACWY,,States/Local Areas,South Dakota,2016,Age,13-15 Years,63.0,54.2 to 71.0,198
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2010,Age,13-17 Years,54.5,45.6 to 63.1,162
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2014,Age,13-17 Years,33.1,25.0 to 42.4,177
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2013,Age,13-17 Years,42.3,33.2 to 52.1,141
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2011,Age,13-17 Years,50.1,36.7 to 63.4,179
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2012,Age,13-17 Years,31.8,23.3 to 41.6,135
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2009,Age,13-17 Years,45.0,36.0 to 54.4,142
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2008,Age,13-17 Years,34.2,26.9 to 42.4,178
HPV,"≥3 Doses, Females",States/Local Areas,South Dakota,2015,Age,13-17 Years,32.4,24.4 to 41.6,162
≥2 Doses Hep A,,States/Local Areas,South Dakota,2022,Age,13-17 Years,87.3,81.9 to 91.2,252
≥2 Doses Hep A,,States/Local Areas,South Dakota,2020,Age,13-17 Years,84.1,79.3 to 88.0,317
≥2 Doses Hep A,,States/Local Areas,South Dakota,2021,Age,13-17 Years,87.2,82.7 to 90.7,445
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2015,Age,13-17 Years,72.4,66.2 to 77.7,349
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2022,Age,13-17 Years,68.3,60.8 to 74.9,252
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2021,Age,13-17 Years,74.7,69.2 to 79.6,445
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2020,Age,13-17 Years,71.5,65.4 to 76.9,317
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2019,Age,13-17 Years,64.0,55.5 to 71.7,189
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2022,Age,13-15 Years,95.7,90.4 to 98.1,158
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2008,Age,13-17 Years,19.3,15.1 to 24.4,344
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2011,Age,13-17 Years,54.4,44.1 to 64.3,355
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2009,Age,13-17 Years,39.6,33.2 to 46.4,271
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2010,Age,13-17 Years,52.5,46.1 to 58.7,321
≥2 Doses MMR,,States/Local Areas,South Dakota,2009,Age,13-17 Years,88.5,83.1 to 92.4,271
≥2 Doses MMR,,States/Local Areas,South Dakota,2008,Age,13-17 Years,86.7,82.1 to 90.2,344
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2016,Age,13-17 Years,38.6,32.4 to 45.2,342
≥2 Doses MMR,,States/Local Areas,South Dakota,2011,Age,13-17 Years,90.6,80.3 to 95.8,355
≥2 Doses MMR,,States/Local Areas,South Dakota,2010,Age,13-17 Years,84.6,78.5 to 89.2,321
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2014,Age,13-17 Years,75.0,68.7 to 80.4,358
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2013,Age,13-17 Years,70.0,63.3 to 76.0,292
Tetanus,≥1 Dose Tdap,States/Local Areas,South Dakota,2012,Age,13-17 Years,65.9,59.2 to 72.1,298
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2017,Age,13-17 Years,44.8,38.5 to 51.2,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2018,Age,13-17 Years,49.5,43.3 to 55.6,340
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Dakota,2022,Age,13-17 Years,69.0,61.5 to 75.6,252
HPV,"≥2 Doses, Males",States/Local Areas,South Dakota,2022,Age,13-17 Years,73.4,63.8 to 81.2,123
HPV,"≥2 Doses, Females",States/Local Areas,South Dakota,2022,Age,13-17 Years,64.3,52.8 to 74.2,129
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Dakota,2019,Age,13-17 Years,61.2,54.5 to 67.4,313
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2010,Age,13-17 Years,28.5,24.3 to 33.1,1438
≥2 Doses Hep A,,HHS Regions/National,Region 6,2021,Age,13-17 Years,84.6,81.4 to 87.4,2184
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2011,Age,13-15 Years,2.4,1.4 to 4.3,1265
≥2 Doses Hep A,,HHS Regions/National,Region 6,2022,Age,13-17 Years,82.9,78.8 to 86.4,1981
≥2 Doses Hep A,,HHS Regions/National,Region 6,2020,Age,13-17 Years,85.7,83.0 to 88.0,2509
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2015,Age,13-15 Years,26.5,22.8 to 30.4,1306
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2013,Age,13-15 Years,16.3,12.5 to 21.0,832
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2016,Age,13-17 Years,85.5,83.3 to 87.4,3270
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2018,Age,13-17 Years,85.9,83.8 to 87.7,3326
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2017,Age,13-17 Years,86.7,84.8 to 88.3,3654
≥3 Doses HepB,,HHS Regions/National,Region 6,2008,Age,13-17 Years,86.7,83.3 to 89.5,2203
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2007,Age,13-17 Years,22.9,15.5 to 32.7,156
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2014,Age,13-15 Years,18.1,13.9 to 23.3,945
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2012,Age,13-15 Years,6.7,4.9 to 9.1,906
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2014,Age,13-17 Years,18.2,14.7 to 22.2,1573
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2015,Age,13-17 Years,26.0,23.2 to 29.1,2086
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2012,Age,13-17 Years,7.1,5.5 to 9.3,1473
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2011,Age,13-17 Years,2.2,1.4 to 3.4,2031
HPV,"≥3 Doses, Males",HHS Regions/National,Region 6,2013,Age,13-17 Years,14.5,11.5 to 18.1,1346
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2006,Age,13-17 Years,72.3,65.4 to 78.3,268
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2008,Age,13-17 Years,75.5,71.3 to 79.3,2203
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2014,Age,13-17 Years,85.0,82.3 to 87.4,3089
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2015,Age,13-17 Years,86.0,84.0 to 87.7,4048
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2019,Age,13-17 Years,86.4,84.2 to 88.4,3289
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2019,Age,13-15 Years,87.7,84.8 to 90.0,1867
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2018,Age,13-15 Years,84.8,81.8 to 87.3,1805
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2014,Age,13-15 Years,81.9,77.4 to 85.7,1514
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2015,Age,13-15 Years,84.5,81.7 to 86.9,2129
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2007,Age,13-17 Years,75.6,69.2 to 81.0,322
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2022,Age,13-17 Years,85.2,81.3 to 88.4,1981
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2021,Age,13-17 Years,87.8,84.7 to 90.4,2184
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2020,Age,13-17 Years,90.0,87.6 to 92.0,2509
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2009,Age,13-17 Years,74.1,70.9 to 77.1,2856
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2010,Age,13-17 Years,77.2,74.4 to 79.9,3001
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2013,Age,13-17 Years,83.3,80.4 to 85.8,2505
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2011,Age,13-17 Years,81.2,78.5 to 83.7,3838
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 6,2012,Age,13-17 Years,83.2,81.0 to 85.1,2939
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2016,Age,13-15 Years,86.5,84.0 to 88.7,1757
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2017,Age,13-15 Years,85.7,82.9 to 88.1,1994
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2009,Age,13-15 Years,44.5,38.3 to 50.9,1030
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2008,Age,13-15 Years,31.4,23.5 to 40.6,618
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2010,Age,13-15 Years,59.4,54.2 to 64.3,1230
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2011,Age,13-15 Years,73.6,68.7 to 78.0,1734
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2013,Age,13-15 Years,81.5,77.4 to 85.0,1229
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2012,Age,13-15 Years,79.0,75.4 to 82.1,1434
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2016,Age,13-17 Years,82.6,80.1 to 84.8,2765
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2015,Age,13-17 Years,82.6,80.3 to 84.7,3296
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2014,Age,13-17 Years,80.4,76.9 to 83.4,2416
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2013,Age,13-17 Years,77.8,74.1 to 81.1,1878
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2017,Age,13-17 Years,84.5,82.4 to 86.4,3164
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2010,Age,13-17 Years,47.6,42.7 to 52.6,1438
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2011,Age,13-17 Years,50.1,45.4 to 54.8,1807
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2021,Age,13-15 Years,88.7,84.5 to 91.8,1252
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2020,Age,13-15 Years,88.8,85.1 to 91.6,1424
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2015,Age,13-17 Years,60.5,56.6 to 64.2,1962
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2014,Age,13-17 Years,53.0,48.0 to 57.9,1516
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2013,Age,13-17 Years,56.2,50.9 to 61.4,1159
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2012,Age,13-17 Years,52.1,47.8 to 56.3,1466
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2016,Age,13-17 Years,93.8,92.1 to 95.2,2765
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2015,Age,13-17 Years,94.7,93.3 to 95.9,3296
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2014,Age,13-17 Years,93.7,91.2 to 95.5,2416
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2013,Age,13-17 Years,94.1,91.2 to 96.1,1878
≥3 Doses HepB,,HHS Regions/National,Region 6,2015,Age,13-17 Years,87.9,86.0 to 89.5,4048
≥3 Doses HepB,,HHS Regions/National,Region 6,2009,Age,13-17 Years,87.0,84.4 to 89.1,2856
≥3 Doses HepB,,HHS Regions/National,Region 6,2010,Age,13-17 Years,88.6,86.1 to 90.7,3001
≥3 Doses HepB,,HHS Regions/National,Region 6,2006,Age,13-17 Years,80.9,74.4 to 86.1,268
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2012,Age,13-17 Years,94.4,92.3 to 96.0,2075
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2019,Age,13-17 Years,91.7,89.8 to 93.2,2948
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2017,Age,13-17 Years,92.7,91.1 to 94.1,3164
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2020,Age,13-17 Years,93.7,91.5 to 95.3,2291
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2018,Age,13-17 Years,83.8,81.5 to 85.9,2896
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2021,Age,13-17 Years,86.9,83.6 to 89.6,2039
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2020,Age,13-17 Years,88.9,86.2 to 91.1,2291
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2019,Age,13-17 Years,84.8,82.3 to 86.9,2948
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2018,Age,13-17 Years,90.9,89.0 to 92.4,2896
≥3 Doses HepB,,HHS Regions/National,Region 6,2019,Age,13-17 Years,86.3,84.1 to 88.2,3289
≥3 Doses HepB,,HHS Regions/National,Region 6,2018,Age,13-17 Years,85.8,83.7 to 87.6,3326
≥3 Doses HepB,,HHS Regions/National,Region 6,2017,Age,13-17 Years,86.9,85.1 to 88.6,3654
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2022,Age,13-15 Years,82.8,77.4 to 87.2,1153
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2011,Age,13-17 Years,70.2,66.2 to 73.9,2476
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2010,Age,13-17 Years,56.2,51.7 to 60.6,1674
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2011,Age,13-17 Years,93.4,89.4 to 95.9,2476
≥3 Doses HepB,,HHS Regions/National,Region 6,2007,Age,13-17 Years,85.7,80.2 to 89.9,322
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2006,Age,13-17 Years,73.1,61.8 to 82.0,83
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2009,Age,13-17 Years,42.3,37.0 to 47.8,1395
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2008,Age,13-17 Years,28.7,22.3 to 36.2,830
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2009,Age,13-17 Years,87.1,83.3 to 90.1,1395
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2010,Age,13-17 Years,90.9,88.1 to 93.1,1674
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2008,Age,13-17 Years,78.2,70.4 to 84.4,830
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2008,Age,13-17 Years,32.8,26.8 to 39.4,1018
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2012,Age,13-17 Years,75.5,72.5 to 78.3,2075
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2007,Age,13-17 Years,77.7,66.7 to 85.9,102
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2012,Age,13-17 Years,22.6,19.2 to 26.5,1473
≥3 Doses HepB,,HHS Regions/National,Region 6,2014,Age,13-17 Years,87.3,84.7 to 89.6,3089
≥3 Doses HepB,,HHS Regions/National,Region 6,2013,Age,13-17 Years,91.3,88.9 to 93.2,2505
≥3 Doses HepB,,HHS Regions/National,Region 6,2011,Age,13-17 Years,90.7,88.8 to 92.3,3838
≥3 Doses HepB,,HHS Regions/National,Region 6,2012,Age,13-17 Years,89.7,87.6 to 91.5,2939
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2009,Age,13-17 Years,39.7,35.1 to 44.6,1352
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 6,2019,Age,13-17 Years,53.0,50.2 to 55.7,3289
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2010,Age,13-17 Years,3.4,1.9 to 6.0,1563
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2017,Age,13-17 Years,57.0,53.4 to 60.5,1968
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2021,Age,13-17 Years,90.1,87.0 to 92.6,2039
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 6,2022,Age,13-17 Years,88.0,84.0 to 91.1,1834
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2016,Age,13-17 Years,47.0,43.3 to 50.8,1778
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2015,Age,13-17 Years,44.1,40.6 to 47.7,2086
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2014,Age,13-17 Years,38.2,33.7 to 43.0,1573
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2013,Age,13-17 Years,33.1,28.7 to 37.8,1346
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 6,2016,Age,13-17 Years,39.7,37.1 to 42.5,3270
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2022,Age,13-17 Years,77.9,71.4 to 83.2,952
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2011,Age,13-17 Years,10.4,8.2 to 13.1,2031
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2021,Age,13-17 Years,74.8,69.0 to 79.9,1022
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2020,Age,13-17 Years,75.0,70.6 to 79.0,1227
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 6,2022,Age,13-17 Years,83.7,79.4 to 87.2,1834
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 6,2017,Age,13-17 Years,45.4,42.9 to 48.0,3654
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2019,Age,13-17 Years,66.5,62.6 to 70.2,1577
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 6,2018,Age,13-17 Years,47.2,44.5 to 49.8,3326
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2021,Age,13-17 Years,71.1,66.0 to 75.8,1162
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2020,Age,13-17 Years,70.0,65.1 to 74.5,1282
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2019,Age,13-17 Years,66.6,63.0 to 70.1,1712
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2018,Age,13-17 Years,56.9,53.1 to 60.6,1782
≥3 Doses HepB,,HHS Regions/National,Region 6,2021,Age,13-17 Years,86.5,83.3 to 89.2,2184
≥3 Doses HepB,,HHS Regions/National,Region 6,2020,Age,13-17 Years,88.2,85.6 to 90.4,2509
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2018,Age,13-17 Years,65.7,61.9 to 69.3,1544
≥3 Doses HepB,,HHS Regions/National,Region 6,2022,Age,13-17 Years,84.5,80.5 to 87.9,1981
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2015,Age,13-17 Years,89.7,88.0 to 91.2,4048
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2014,Age,13-17 Years,89.3,87.0 to 91.3,3089
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2016,Age,13-17 Years,89.2,87.3 to 90.9,3270
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2007,Age,13-17 Years,13.7,8.5 to 21.3,156
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2016,Age,13-17 Years,57.3,53.2 to 61.2,1492
HPV,"≥1 Dose, Females",HHS Regions/National,Region 6,2017,Age,13-17 Years,62.5,58.7 to 66.1,1686
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2014,Age,13-17 Years,27.1,23.1 to 31.5,1573
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2013,Age,13-17 Years,24.2,20.3 to 28.6,1346
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2012,Age,13-17 Years,13.4,10.8 to 16.7,1473
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2011,Age,13-17 Years,4.8,3.6 to 6.4,2031
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2013,Age,13-15 Years,88.0,84.8 to 90.6,1554
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2014,Age,13-15 Years,89.4,86.4 to 91.7,1862
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2015,Age,13-15 Years,86.9,84.5 to 89.1,2530
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2016,Age,13-15 Years,87.1,84.4 to 89.3,2031
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2017,Age,13-15 Years,83.9,81.1 to 86.3,2247
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2022,Age,13-17 Years,88.2,84.7 to 90.9,1981
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2008,Age,13-15 Years,45.4,39.0 to 52.0,1345
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2010,Age,13-15 Years,71.9,68.1 to 75.5,1869
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2009,Age,13-15 Years,58.2,53.6 to 62.6,1794
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2011,Age,13-15 Years,79.7,76.4 to 82.7,2399
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2012,Age,13-15 Years,84.2,81.1 to 86.9,1849
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2007,Age,13-15 Years,39.8,30.9 to 49.5,191
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2006,Age,13-15 Years,13.0,7.5 to 21.6,166
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2019,Age,13-17 Years,54.7,50.8 to 58.6,1577
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2018,Age,13-17 Years,51.9,48.0 to 55.8,1544
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2014,Age,13-17 Years,44.6,39.7 to 49.6,1516
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2015,Age,13-17 Years,50.2,46.4 to 54.1,1962
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2016,Age,13-17 Years,46.3,42.3 to 50.3,1492
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2017,Age,13-17 Years,50.1,46.4 to 53.9,1686
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2021,Age,13-15 Years,89.0,85.6 to 91.7,1333
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2022,Age,13-17 Years,71.8,67.4 to 75.9,1981
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2021,Age,13-17 Years,72.9,69.1 to 76.4,2184
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2020,Age,13-17 Years,72.5,69.2 to 75.6,2509
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2020,Age,13-15 Years,89.0,86.1 to 91.3,1541
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2009,Age,13-17 Years,31.8,27.4 to 36.5,1352
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2011,Age,13-17 Years,40.1,35.5 to 45.0,1807
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2010,Age,13-17 Years,36.6,32.1 to 41.5,1438
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2010,Age,13-15 Years,67.3,63.2 to 71.1,1869
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2011,Age,13-15 Years,75.6,71.7 to 79.1,2399
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2008,Age,13-15 Years,38.7,32.7 to 45.0,1345
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2009,Age,13-15 Years,50.6,45.9 to 55.2,1794
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2011,Age,13-17 Years,84.6,82.5 to 86.5,3838
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2010,Age,13-17 Years,80.0,77.4 to 82.5,3001
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2013,Age,13-17 Years,88.4,85.9 to 90.4,2505
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2012,Age,13-17 Years,86.7,84.5 to 88.7,2939
HPV,"≥1 Dose, Males",HHS Regions/National,Region 6,2022,Age,13-17 Years,66.1,59.8 to 71.8,1029
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2009,Age,13-17 Years,72.0,68.7 to 75.1,2856
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2008,Age,13-17 Years,74.3,70.3 to 77.9,2203
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2021,Age,13-17 Years,90.7,88.2 to 92.7,2184
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2018,Age,13-17 Years,61.2,58.5 to 63.8,3326
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2019,Age,13-17 Years,66.6,63.9 to 69.1,3289
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2020,Age,13-17 Years,89.1,86.6 to 91.2,2509
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2019,Age,13-17 Years,88.4,86.4 to 90.1,3289
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2018,Age,13-17 Years,87.6,85.6 to 89.3,3326
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2019,Age,13-15 Years,85.5,82.8 to 87.9,2058
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2018,Age,13-15 Years,84.0,81.4 to 86.3,2025
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2017,Age,13-15 Years,82.5,79.7 to 85.0,2247
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2008,Age,13-17 Years,22.1,17.1 to 28.0,1018
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2006,Age,13-17 Years,59.0,51.9 to 65.8,268
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2007,Age,13-17 Years,74.8,68.7 to 80.1,322
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2007,Age,13-15 Years,27.5,20.3 to 36.0,191
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2006,Age,13-15 Years,10.5,5.9 to 18.0,166
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2013,Age,13-17 Years,46.9,41.7 to 52.2,1159
HPV,"≥2 Doses, Females",HHS Regions/National,Region 6,2012,Age,13-17 Years,42.5,38.4 to 46.7,1466
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2016,Age,13-17 Years,52.0,49.3 to 54.8,3270
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 6,2017,Age,13-17 Years,59.7,57.1 to 62.2,3654
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 6,2017,Age,13-17 Years,87.6,85.7 to 89.3,3654
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2013,Age,13-15 Years,84.1,81.1 to 86.7,1554
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2012,Age,13-15 Years,80.5,77.3 to 83.3,1849
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2014,Age,13-15 Years,86.4,83.5 to 88.8,1862
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2015,Age,13-15 Years,86.5,84.2 to 88.4,2530
≥1 Dose MenACWY,,HHS Regions/National,Region 6,2016,Age,13-15 Years,85.3,82.8 to 87.6,2031
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2022,Age,13-17 Years,55.7,49.5 to 61.7,1029
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 6,2022,Age,13-17 Years,59.7,55.1 to 64.1,1981
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2009,Age,13-17 Years,23.4,19.5 to 27.9,1352
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2008,Age,13-17 Years,11.6,8.6 to 15.5,1018
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2014,Age,13-17 Years,34.2,29.6 to 39.0,1516
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2013,Age,13-17 Years,38.1,33.1 to 43.5,1159
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2011,Age,13-17 Years,30.4,26.0 to 35.2,1807
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2012,Age,13-17 Years,31.3,27.6 to 35.3,1466
HPV,"≥3 Doses, Females",HHS Regions/National,Region 6,2015,Age,13-17 Years,39.5,35.8 to 43.3,1962
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2015,Age,13-17 Years,86.1,84.1 to 87.9,4048
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2022,Age,13-17 Years,58.2,53.6 to 62.7,1981
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2021,Age,13-17 Years,53.8,49.8 to 57.8,2184
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2019,Age,13-17 Years,51.3,47.5 to 55.1,1712
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2011,Age,13-17 Years,77.6,75.0 to 80.0,3838
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2009,Age,13-17 Years,52.7,49.0 to 56.3,2856
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2010,Age,13-17 Years,67.9,64.7 to 70.9,3001
≥2 Doses MMR,,HHS Regions/National,Region 6,2006,Age,13-17 Years,88.6,83.5 to 92.3,268
≥2 Doses MMR,,HHS Regions/National,Region 6,2007,Age,13-17 Years,87.8,83.0 to 91.4,322
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2020,Age,13-17 Years,54.5,50.8 to 58.1,2509
≥3 Doses HepB,,HHS Regions/National,Region 6,2016,Age,13-17 Years,86.9,84.8 to 88.7,3270
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2019,Age,13-17 Years,49.6,46.9 to 52.4,3289
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2016,Age,13-17 Years,35.0,32.5 to 37.7,3270
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2006,Age,13-17 Years,9.0,5.4 to 14.6,268
≥2 Doses MMR,,HHS Regions/National,Region 6,2011,Age,13-17 Years,89.4,87.3 to 91.1,3838
≥2 Doses MMR,,HHS Regions/National,Region 6,2010,Age,13-17 Years,86.0,83.4 to 88.3,3001
≥2 Doses MMR,,HHS Regions/National,Region 6,2009,Age,13-17 Years,83.8,80.8 to 86.4,2856
≥2 Doses MMR,,HHS Regions/National,Region 6,2008,Age,13-17 Years,84.1,80.1 to 87.4,2203
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2022,Age,13-15 Years,86.1,81.3 to 89.9,1229
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2008,Age,13-17 Years,38.3,33.6 to 43.2,2203
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2017,Age,13-17 Years,41.3,38.9 to 43.8,3654
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2014,Age,13-17 Years,87.8,85.5 to 89.9,3089
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2013,Age,13-17 Years,84.9,82.2 to 87.3,2505
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2012,Age,13-17 Years,81.5,79.1 to 83.8,2939
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2018,Age,13-17 Years,43.9,41.3 to 46.5,3326
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2007,Age,13-17 Years,29.5,23.2 to 36.7,322
Varicella,History of disease,HHS Regions/National,Region 6,2006,Age,13-17 Years,70.4,63.5 to 76.5,268
Varicella,History of disease,HHS Regions/National,Region 6,2008,Age,13-17 Years,65.6,61.0 to 70.0,2203
Varicella,History of disease,HHS Regions/National,Region 6,2014,Age,13-17 Years,23.8,20.8 to 27.0,3089
Varicella,History of disease,HHS Regions/National,Region 6,2009,Age,13-17 Years,55.2,51.5 to 58.8,2856
Varicella,History of disease,HHS Regions/National,Region 6,2011,Age,13-17 Years,37.0,34.1 to 40.1,3838
Varicella,History of disease,HHS Regions/National,Region 6,2010,Age,13-17 Years,48.0,44.6 to 51.5,3001
Varicella,History of disease,HHS Regions/National,Region 6,2013,Age,13-17 Years,24.9,21.9 to 28.1,2505
Varicella,History of disease,HHS Regions/National,Region 6,2012,Age,13-17 Years,31.2,28.5 to 34.0,2939
Varicella,History of disease,HHS Regions/National,Region 6,2018,Age,13-17 Years,12.5,10.9 to 14.4,3326
Varicella,History of disease,HHS Regions/National,Region 6,2007,Age,13-17 Years,71.7,65.2 to 77.5,322
Varicella,History of disease,HHS Regions/National,Region 6,2016,Age,13-17 Years,16.6,14.5 to 18.9,3270
Varicella,History of disease,HHS Regions/National,Region 6,2015,Age,13-17 Years,19.1,17.1 to 21.4,4048
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2020,Age,13-15 Years,53.2,46.7 to 59.7,750
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2019,Age,13-15 Years,50.7,45.7 to 55.7,998
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2018,Age,13-15 Years,44.0,39.3 to 48.9,939
Varicella,History of disease,HHS Regions/National,Region 6,2017,Age,13-17 Years,13.8,12.1 to 15.7,3654
Varicella,History of disease,HHS Regions/National,Region 6,2022,Age,13-17 Years,9.4,6.7 to 13.1,1981
Varicella,History of disease,HHS Regions/National,Region 6,2021,Age,13-17 Years,6.8,5.0 to 9.2,2184
Varicella,History of disease,HHS Regions/National,Region 6,2019,Age,13-17 Years,11.0,9.4 to 13.0,3289
Varicella,History of disease,HHS Regions/National,Region 6,2020,Age,13-17 Years,10.1,8.0 to 12.7,2509
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2021,Age,13-17 Years,51.7,46.3 to 57.0,1162
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2020,Age,13-17 Years,52.2,47.1 to 57.3,1282
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2019,Age,13-17 Years,48.2,44.4 to 52.0,1712
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2017,Age,13-17 Years,36.2,33.0 to 39.6,1968
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2018,Age,13-17 Years,39.6,36.1 to 43.2,1782
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2018,Age,13-15 Years,83.3,80.4 to 85.8,2025
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2021,Age,13-15 Years,88.2,84.4 to 91.1,1333
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2020,Age,13-15 Years,86.3,82.6 to 89.3,1541
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 6,2019,Age,13-15 Years,87.0,84.4 to 89.2,2058
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2015,Age,13-17 Years,34.7,31.5 to 38.1,2086
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2016,Age,13-17 Years,33.5,30.1 to 37.0,1778
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2017,Age,13-17 Years,40.9,37.5 to 44.3,1968
HPV,"≥2 Doses, Males",HHS Regions/National,Region 6,2018,Age,13-17 Years,42.6,39.1 to 46.2,1782
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2019,Age,13-17 Years,51.1,47.2 to 55.0,1577
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2018,Age,13-17 Years,48.4,44.5 to 52.2,1544
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2020,Age,13-15 Years,51.3,46.7 to 55.9,1541
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2021,Age,13-15 Years,48.6,43.5 to 53.7,1333
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2022,Age,13-17 Years,54.4,48.2 to 60.5,1029
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2019,Age,13-15 Years,48.7,45.2 to 52.1,2058
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2020,Age,13-17 Years,56.9,51.7 to 61.9,1227
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2020,Age,13-15 Years,49.5,43.1 to 55.9,791
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2019,Age,13-15 Years,46.7,41.9 to 51.5,1060
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 6,2022,Age,13-15 Years,53.8,47.9 to 59.6,1229
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2022,Age,13-15 Years,50.2,42.2 to 58.2,633
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2021,Age,13-15 Years,48.1,41.2 to 55.1,701
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2016,Age,13-17 Years,28.9,25.8 to 32.3,1778
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2016,Age,13-17 Years,41.3,37.4 to 45.4,1492
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2022,Age,13-17 Years,62.1,55.3 to 68.5,952
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2021,Age,13-17 Years,56.0,50.1 to 61.8,1022
HPV,"Up-to-Date, Males",HHS Regions/National,Region 6,2018,Age,13-15 Years,36.8,32.6 to 41.3,1086
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2022,Age,13-15 Years,57.3,48.7 to 65.5,596
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2021,Age,13-15 Years,49.1,41.7 to 56.5,632
HPV,"Up-to-Date, Females",HHS Regions/National,Region 6,2017,Age,13-17 Years,46.6,42.9 to 50.3,1686
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Insurance Coverage,Uninsured,83.6,71.1 to 91.4,98
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Overall,Overall,80.7,77.8 to 83.2,1640
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Overall,Overall,91.5,89.5 to 93.2,1640
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Overall,Overall,52.5,49.0 to 55.9,1640
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Overall,Overall,68.8,65.5 to 71.9,1640
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Principal City,68.1,63.6 to 72.3,914
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Non-Principal City,69.0,64.1 to 73.6,694
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Principal City,81.7,77.8 to 85.1,914
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Urbanicity,Living In a Non-MSA,83.2,61.9 to 93.8,32
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Principal City,51.6,46.9 to 56.2,914
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Non-Principal City,52.9,47.6 to 58.2,694
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Principal City,90.8,87.6 to 93.2,914
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Urbanicity,Living In a Non-MSA,67.8,45.0 to 84.4,32
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Non-Principal City,79.5,75.0 to 83.3,694
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Urbanicity,Living In a Non-MSA,75.0,53.1 to 88.8,32
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,"White, Non-Hispanic",49.0,44.2 to 53.9,848
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Urbanicity,Living In a Non-MSA,89.6,69.3 to 97.0,32
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.6,89.8 to 94.7,694
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",80.4,70.0 to 87.7,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",71.6,61.3 to 80.0,149
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",54.6,45.3 to 63.5,178
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,Hispanic,55.7,49.3 to 61.9,465
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",52.2,41.2 to 63.0,149
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",82.3,73.9 to 88.4,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.1,87.9 to 93.4,848
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Race and Ethnicity,"White, Non-Hispanic",77.0,72.6 to 80.8,848
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Race and Ethnicity,Hispanic,84.5,79.5 to 88.5,465
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",93.3,87.1 to 96.7,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Race and Ethnicity,Hispanic,90.8,86.5 to 93.8,465
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.4,84.4 to 96.5,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.9,64.9 to 81.2,178
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,"White, Non-Hispanic",64.8,60.1 to 69.3,848
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Race and Ethnicity,Hispanic,70.1,63.9 to 75.6,465
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Poverty,Below Poverty Level,72.2,64.1 to 79.0,237
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Poverty,Living At or Above Poverty Level,69.6,65.9 to 73.0,1339
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Poverty,Living At or Above Poverty Level,81.9,78.8 to 84.7,1339
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Poverty,Below Poverty Level,79.8,72.4 to 85.5,237
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Poverty,Below Poverty Level,56.7,48.2 to 64.8,237
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Poverty,Living At or Above Poverty Level,52.9,49.0 to 56.8,1339
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Poverty,Below Poverty Level,92.2,86.0 to 95.7,237
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Poverty,Living At or Above Poverty Level,91.4,89.1 to 93.3,1339
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Insurance Coverage,Private Insurance Only,82.4,78.5 to 85.7,892
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Insurance Coverage,Any Medicaid,81.2,76.4 to 85.2,503
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Insurance Coverage,Other,74.7,62.2 to 84.1,147
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Private Insurance Only,69.3,64.7 to 73.5,892
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Any Medicaid,73.7,68.4 to 78.4,503
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Other,61.3,48.5 to 72.7,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Private Insurance Only,52.4,47.7 to 57.2,892
≥1 Dose MenACWY,,States/Local Areas,Florida,2018-2022,Insurance Coverage,Uninsured,72.9,58.9 to 83.4,98
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Uninsured,49.5,36.3 to 62.8,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Any Medicaid,58.4,52.6 to 64.0,503
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Other,44.2,31.6 to 57.6,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2018-2022,Insurance Coverage,Uninsured,31.7,20.7 to 45.2,98
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Insurance Coverage,Private Insurance Only,93.0,90.3 to 95.0,892
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Insurance Coverage,Any Medicaid,91.3,87.5 to 94.0,503
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018-2022,Insurance Coverage,Other,92.3,85.8 to 96.0,147
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2023,Age,13-17 Years,89.5,83.8 to 93.4,283
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2023,Age,13-17 Years,90.6,84.9 to 94.2,283
≥1 Dose MenACWY,,States/Local Areas,Florida,2023,Age,13-17 Years,80.8,73.4 to 86.5,283
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2023,Age,13-17 Years,74.5,66.7 to 81.0,283
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2023,Age,13-17 Years,83.2,74.4 to 89.4,129
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2023,Age,13-17 Years,64.4,56.4 to 71.6,283
≥2 Doses MMR,,States/Local Areas,Florida,2023,Age,13-17 Years,91.3,85.3 to 95.0,283
≥3 Doses HepB,,States/Local Areas,Florida,2023,Age,13-17 Years,92.1,86.1 to 95.7,283
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2023,Age,13-17 Years,52.7,41.5 to 63.7,154
Varicella,History of disease,States/Local Areas,Florida,2023,Age,13-17 Years,9.6,5.4 to 16.5,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2023,Age,13-17 Years,91.6,85.1 to 95.5,263
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2023,Age,13-17 Years,95.1,89.3 to 97.9,263
≥2 Doses Hep A,,States/Local Areas,Florida,2023,Age,13-17 Years,83.3,76.0 to 88.7,283
Varicella,≥2 Doses or history of disease,States/Local Areas,Florida,2023,Age,13-17 Years,92.4,86.5 to 95.9,283
HPV,"Up-to-Date, Males",States/Local Areas,Florida,2023,Age,13-15 Years,44.6,31.6 to 58.2,95
≥1 Dose MenACWY,,States/Local Areas,Florida,2023,Age,13-15 Years,74.5,64.0 to 82.8,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2023,Age,13-15 Years,87.0,78.5 to 92.4,169
HPV,"Up-to-Date, Males and Females",States/Local Areas,Florida,2023,Age,13-15 Years,58.4,48.1 to 68.1,169
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2023,Age,13-15 Years,73.9,60.4 to 84.0,74
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2023,Age,13-15 Years,92.8,84.2 to 96.9,156
HPV,"Up-to-Date, Females",States/Local Areas,Florida,2023,Age,13-17 Years,76.6,67.1 to 84.0,129
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2023,Age,13-17 Years,66.3,54.3 to 76.5,154
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2022,Age,13-17 Years,54.1,43.1 to 64.6,158
HPV,"≥2 Doses, Males and Females",States/Local Areas,Florida,2022,Age,13-17 Years,60.6,53.0 to 67.8,307
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2022,Age,13-17 Years,67.5,56.9 to 76.6,149
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2014,Age,13-15 Years,21.4,12.6 to 33.9,111
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2015,Age,13-15 Years,30.5,20.9 to 42.1,102
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2013,Age,13-15 Years,27.2,17.1 to 40.3,98
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2017,Age,13-17 Years,92.2,88.2 to 94.9,415
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2016,Age,13-17 Years,93.7,89.4 to 96.4,376
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2014,Age,13-17 Years,93.3,88.9 to 96.0,363
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2015,Age,13-17 Years,90.1,84.6 to 93.7,321
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2019,Age,13-17 Years,64.4,52.3 to 74.9,171
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2017,Age,13-17 Years,57.2,47.8 to 66.1,222
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2018,Age,13-17 Years,62.3,52.8 to 71.0,177
≥1 Dose MenACWY,,States/Local Areas,Florida,2017,Age,13-15 Years,78.6,70.7 to 84.8,248
≥1 Dose MenACWY,,States/Local Areas,Florida,2016,Age,13-15 Years,72.4,63.7 to 79.8,224
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2016,Age,13-17 Years,53.5,44.4 to 62.5,195
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2015,Age,13-17 Years,45.3,35.7 to 55.2,160
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2013,Age,13-17 Years,27.8,20.0 to 37.2,166
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2014,Age,13-17 Years,41.0,31.4 to 51.3,190
HPV,"≥2 Doses, Males and Females",States/Local Areas,Florida,2019,Age,13-17 Years,58.3,49.8 to 66.4,329
HPV,"≥2 Doses, Males and Females",States/Local Areas,Florida,2018,Age,13-17 Years,51.3,44.4 to 58.2,337
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2022,Age,13-17 Years,77.3,67.4 to 85.0,149
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2021,Age,13-17 Years,65.3,52.4 to 76.3,127
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2020,Age,13-17 Years,68.6,58.0 to 77.5,162
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2012,Age,13-17 Years,21.4,13.5 to 32.1,175
HPV,"≥2 Doses, Males and Females",States/Local Areas,Florida,2017,Age,13-17 Years,46.2,39.6 to 52.8,415
HPV,"≥2 Doses, Males and Females",States/Local Areas,Florida,2016,Age,13-17 Years,46.1,39.5 to 52.8,376
≥3 Doses HepB,,States/Local Areas,Florida,2022,Age,13-17 Years,97.7,94.8 to 99.0,307
≥3 Doses HepB,,States/Local Areas,Florida,2021,Age,13-17 Years,95.7,90.9 to 98.1,312
≥3 Doses HepB,,States/Local Areas,Florida,2020,Age,13-17 Years,95.1,91.6 to 97.1,355
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2019,Age,13-17 Years,71.5,59.7 to 81.0,158
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2022,Age,13-17 Years,99.3,97.8 to 99.8,292
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2017,Age,13-17 Years,62.4,52.9 to 71.1,193
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2016,Age,13-17 Years,58.4,48.6 to 67.6,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2022,Age,13-17 Years,97.8,95.8 to 98.9,292
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2021,Age,13-17 Years,97.1,92.2 to 99.0,296
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2018,Age,13-17 Years,66.0,56.1 to 74.7,160
≥3 Doses HepB,,States/Local Areas,Florida,2010,Age,13-17 Years,96.8,93.6 to 98.5,344
≥3 Doses HepB,,States/Local Areas,Florida,2009,Age,13-17 Years,95.9,92.6 to 97.7,412
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2009,Age,13-17 Years,39.3,31.3 to 48.0,216
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2022,Age,13-15 Years,98.0,95.4 to 99.2,177
≥3 Doses HepB,,States/Local Areas,Florida,2008,Age,13-17 Years,92.8,87.6 to 96.0,284
≥3 Doses HepB,,States/Local Areas,Florida,2011,Age,13-17 Years,95.7,92.6 to 97.5,483
≥3 Doses HepB,,States/Local Areas,Florida,2013,Age,13-17 Years,94.3,90.2 to 96.7,323
≥3 Doses HepB,,States/Local Areas,Florida,2014,Age,13-17 Years,95.4,91.3 to 97.6,363
≥3 Doses HepB,,States/Local Areas,Florida,2012,Age,13-17 Years,98.7,96.5 to 99.5,325
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2010,Age,13-17 Years,44.5,36.1 to 53.2,194
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2011,Age,13-17 Years,66.1,58.4 to 73.0,313
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2011,Age,13-17 Years,95.5,90.7 to 97.9,313
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2008,Age,13-17 Years,20.3,13.4 to 29.4,117
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2009,Age,13-17 Years,38.7,31.3 to 46.8,209
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2008,Age,13-17 Years,80.0,66.1 to 89.1,117
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2010,Age,13-17 Years,89.4,80.2 to 94.6,194
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2009,Age,13-17 Years,88.2,81.5 to 92.7,209
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2012,Age,13-17 Years,73.3,63.9 to 80.9,242
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2013,Age,13-17 Years,76.0,68.3 to 82.2,257
HPV,"≥1 Dose, Females",States/Local Areas,Florida,2008,Age,13-17 Years,36.7,26.8 to 48.0,149
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2020,Age,13-17 Years,95.9,92.1 to 97.9,335
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2018,Age,13-17 Years,94.2,89.7 to 96.8,303
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2019,Age,13-17 Years,93.5,87.5 to 96.7,304
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2021,Age,13-17 Years,95.4,90.6 to 97.8,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Florida,2020,Age,13-17 Years,94.8,90.9 to 97.1,335
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2012,Age,13-17 Years,98.6,96.1 to 99.5,242
Varicella,≥1 Dose with no disease history,States/Local Areas,Florida,2019,Age,13-17 Years,95.7,90.8 to 98.0,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2019,Age,13-17 Years,97.2,94.8 to 98.6,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2020,Age,13-17 Years,91.2,85.5 to 94.7,355
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2019,Age,13-17 Years,67.9,59.6 to 75.2,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2022,Age,13-17 Years,97.2,94.7 to 98.5,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2021,Age,13-17 Years,93.0,87.4 to 96.2,312
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2018,Age,13-17 Years,92.7,88.5 to 95.4,337
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2008,Age,13-17 Years,26.8,18.8 to 36.7,149
≥1 Dose MenACWY,,States/Local Areas,Florida,2014,Age,13-15 Years,72.9,64.1 to 80.3,222
≥1 Dose MenACWY,,States/Local Areas,Florida,2015,Age,13-15 Years,64.9,55.9 to 72.9,201
≥1 Dose MenACWY,,States/Local Areas,Florida,2013,Age,13-15 Years,69.4,60.3 to 77.3,195
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2021,Age,13-17 Years,70.0,59.5 to 78.7,185
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2020,Age,13-17 Years,68.1,58.4 to 76.4,193
≥1 Dose MenACWY,,States/Local Areas,Florida,2012,Age,13-15 Years,67.1,58.1 to 75.0,205
≥1 Dose MenACWY,,States/Local Areas,Florida,2010,Age,13-15 Years,60.0,51.4 to 67.9,199
≥1 Dose MenACWY,,States/Local Areas,Florida,2011,Age,13-15 Years,64.3,56.4 to 71.5,287
≥1 Dose MenACWY,,States/Local Areas,Florida,2008,Age,13-15 Years,37.9,29.0 to 47.7,177
≥1 Dose MenACWY,,States/Local Areas,Florida,2009,Age,13-15 Years,54.2,46.6 to 61.6,267
HPV,"≥1 Dose, Males",States/Local Areas,Florida,2022,Age,13-17 Years,73.9,63.4 to 82.2,158
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2012,Age,13-17 Years,33.4,24.6 to 43.5,150
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2013,Age,13-17 Years,40.7,31.1 to 50.9,157
≥1 Dose MenACWY,,States/Local Areas,Florida,2018,Age,13-15 Years,77.9,70.1 to 84.1,208
≥1 Dose MenACWY,,States/Local Areas,Florida,2019,Age,13-15 Years,84.4,75.7 to 90.5,215
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2008,Age,13-17 Years,79.4,70.3 to 86.2,284
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2009,Age,13-17 Years,86.8,80.9 to 91.1,412
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2010,Age,13-17 Years,37.0,27.6 to 47.4,147
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2011,Age,13-17 Years,42.5,34.1 to 51.3,240
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2009,Age,13-17 Years,33.2,25.8 to 41.5,216
≥1 Dose MenACWY,,States/Local Areas,Florida,2020,Age,13-15 Years,76.4,67.1 to 83.7,225
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2014,Age,13-17 Years,39.6,30.1 to 49.9,173
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2012,Age,13-17 Years,93.4,88.5 to 96.3,325
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2013,Age,13-17 Years,88.0,81.9 to 92.2,323
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2010,Age,13-17 Years,89.8,84.8 to 93.3,344
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Florida,2011,Age,13-17 Years,91.7,87.0 to 94.8,483
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2017,Age,13-17 Years,59.8,53.1 to 66.1,415
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2016,Age,13-17 Years,55.9,49.2 to 62.5,376
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2018,Age,13-17 Years,64.1,57.3 to 70.4,337
≥1 Dose MenACWY,,States/Local Areas,Florida,2021,Age,13-15 Years,73.8,63.1 to 82.3,201
≥1 Dose MenACWY,,States/Local Areas,Florida,2022,Age,13-15 Years,82.5,73.3 to 89.1,183
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2022,Age,13-17 Years,75.6,68.5 to 81.5,307
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2021,Age,13-17 Years,67.7,59.5 to 74.9,312
HPV,"≥1 Dose, Males and Females",States/Local Areas,Florida,2020,Age,13-17 Years,68.3,61.3 to 74.6,355
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2017,Age,13-17 Years,51.0,41.7 to 60.3,193
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2016,Age,13-17 Years,50.1,40.4 to 59.8,181
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2015,Age,13-17 Years,44.6,35.2 to 54.4,161
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2018,Age,13-17 Years,55.6,45.4 to 65.2,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2010,Age,13-15 Years,77.4,69.4 to 83.7,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2009,Age,13-15 Years,62.8,55.0 to 70.0,267
HPV,"≥2 Doses, Females",States/Local Areas,Florida,2019,Age,13-17 Years,58.7,46.6 to 69.8,158
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2012,Age,13-15 Years,88.4,81.0 to 93.1,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2011,Age,13-15 Years,86.2,79.4 to 91.0,287
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2008,Age,13-15 Years,37.6,28.9 to 47.1,177
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2017,Age,13-15 Years,90.4,84.8 to 94.0,248
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2016,Age,13-15 Years,87.7,79.0 to 93.1,224
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2014,Age,13-15 Years,89.4,81.7 to 94.1,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2015,Age,13-15 Years,87.8,80.2 to 92.8,201
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2010,Age,13-15 Years,21.9,13.0 to 34.4,79
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2009,Age,13-15 Years,22.1,14.6 to 32.0,143
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2012,Age,13-15 Years,26.7,16.6 to 39.9,95
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2011,Age,13-15 Years,30.5,21.3 to 41.6,142
HPV,"≥3 Doses, Females",States/Local Areas,Florida,2008,Age,13-15 Years,22.0,13.3 to 34.2,95
≥1 Dose MenACWY,,States/Local Areas,Florida,2022,Age,13-17 Years,86.9,80.8 to 91.3,307
≥2 Doses MMR,,States/Local Areas,Florida,2022,Age,13-17 Years,96.3,92.6 to 98.2,307
≥2 Doses MMR,,States/Local Areas,Florida,2021,Age,13-17 Years,95.2,90.0 to 97.8,312
≥1 Dose MenACWY,,States/Local Areas,Florida,2018,Age,13-17 Years,76.3,70.0 to 81.5,337
≥1 Dose MenACWY,,States/Local Areas,Florida,2019,Age,13-17 Years,82.9,75.7 to 88.3,329
≥1 Dose MenACWY,,States/Local Areas,Florida,2021,Age,13-17 Years,76.9,69.3 to 83.1,312
≥1 Dose MenACWY,,States/Local Areas,Florida,2020,Age,13-17 Years,80.0,73.3 to 85.4,355
HPV,"≥3 Doses, Males and Females",States/Local Areas,Florida,2015,Age,13-17 Years,28.1,22.6 to 34.3,321
HPV,"≥3 Doses, Males and Females",States/Local Areas,Florida,2014,Age,13-17 Years,22.9,17.4 to 29.5,363
HPV,"≥3 Doses, Males and Females",States/Local Areas,Florida,2013,Age,13-17 Years,23.5,18.0 to 30.0,323
≥2 Doses MMR,,States/Local Areas,Florida,2020,Age,13-17 Years,95.4,92.0 to 97.3,355
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2022,Age,13-17 Years,96.0,93.2 to 97.6,307
≥2 Doses MMR,,States/Local Areas,Florida,2018,Age,13-17 Years,96.1,91.7 to 98.2,337
≥2 Doses MMR,,States/Local Areas,Florida,2019,Age,13-17 Years,94.5,88.6 to 97.4,329
HPV,"≥3 Doses, Males and Females",States/Local Areas,Florida,2012,Age,13-17 Years,16.3,11.8 to 22.2,325
HPV,"≥3 Doses, Males and Females",States/Local Areas,Florida,2011,Age,13-17 Years,17.4,13.2 to 22.6,483
≥1 Dose MenACWY,,States/Local Areas,Florida,2017,Age,13-17 Years,80.2,74.3 to 85.0,415
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2021,Age,13-17 Years,89.7,83.1 to 93.9,312
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2020,Age,13-17 Years,86.1,79.6 to 90.8,355
≥1 Dose MenACWY,,States/Local Areas,Florida,2016,Age,13-17 Years,76.3,70.2 to 81.5,376
≥1 Dose MenACWY,,States/Local Areas,Florida,2015,Age,13-17 Years,70.4,63.6 to 76.4,321
≥1 Dose MenACWY,,States/Local Areas,Florida,2013,Age,13-17 Years,72.3,65.5 to 78.2,323
≥1 Dose MenACWY,,States/Local Areas,Florida,2014,Age,13-17 Years,72.2,65.0 to 78.3,363
≥2 Doses MMR,,States/Local Areas,Florida,2017,Age,13-17 Years,93.6,89.1 to 96.3,415
≥2 Doses MMR,,States/Local Areas,Florida,2016,Age,13-17 Years,95.6,92.9 to 97.3,376
≥2 Doses MMR,,States/Local Areas,Florida,2014,Age,13-17 Years,94.1,90.0 to 96.6,363
≥2 Doses MMR,,States/Local Areas,Florida,2015,Age,13-17 Years,93.4,88.5 to 96.3,321
≥2 Doses MMR,,States/Local Areas,Florida,2012,Age,13-17 Years,96.7,93.2 to 98.4,325
≥2 Doses MMR,,States/Local Areas,Florida,2013,Age,13-17 Years,93.5,88.5 to 96.5,323
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2017,Age,13-17 Years,41.5,32.7 to 50.9,222
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2016,Age,13-17 Years,42.3,33.5 to 51.5,195
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2018,Age,13-17 Years,47.2,38.0 to 56.6,177
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2014,Age,13-17 Years,30.0,21.5 to 40.3,190
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2013,Age,13-17 Years,16.0,10.4 to 23.7,166
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2015,Age,13-17 Years,33.2,24.8 to 42.9,160
HPV,"≥2 Doses, Males",States/Local Areas,Florida,2012,Age,13-17 Years,15.4,8.9 to 25.5,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018,Age,13-15 Years,89.2,83.0 to 93.3,208
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2019,Age,13-15 Years,96.5,92.7 to 98.3,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2020,Age,13-15 Years,85.7,77.0 to 91.6,225
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2021,Age,13-15 Years,91.5,84.0 to 95.6,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2013,Age,13-15 Years,87.3,78.2 to 92.9,195
≥1 Dose MenACWY,,States/Local Areas,Florida,2012,Age,13-17 Years,68.6,61.5 to 75.0,325
≥1 Dose MenACWY,,States/Local Areas,Florida,2010,Age,13-17 Years,55.1,48.5 to 61.6,344
≥1 Dose MenACWY,,States/Local Areas,Florida,2011,Age,13-17 Years,61.2,55.0 to 67.1,483
≥1 Dose MenACWY,,States/Local Areas,Florida,2008,Age,13-17 Years,33.6,26.7 to 41.2,284
≥1 Dose MenACWY,,States/Local Areas,Florida,2009,Age,13-17 Years,52.7,46.6 to 58.7,412
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2018,Age,13-17 Years,90.1,85.5 to 93.3,337
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2017,Age,13-17 Years,91.1,87.1 to 94.0,415
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2019,Age,13-17 Years,95.6,91.4 to 97.8,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Florida,2016,Age,13-17 Years,89.7,84.5 to 93.3,376
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2009,Age,13-17 Years,82.8,77.9 to 86.9,323
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2010,Age,13-17 Years,75.6,70.3 to 80.3,366
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2017,Age,13-15 Years,94.0,89.6 to 96.7,204
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2016,Age,13-15 Years,78.5,69.7 to 85.2,191
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2012,Age,13-17 Years,79.1,73.1 to 84.0,347
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2011,Age,13-17 Years,76.7,70.4 to 82.0,347
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2014,Age,13-17 Years,77.8,72.3 to 82.5,372
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2013,Age,13-17 Years,79.4,73.4 to 84.2,306
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2020,Age,13-17 Years,96.6,92.4 to 98.5,327
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2021,Age,13-17 Years,93.3,86.9 to 96.7,266
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2022,Age,13-17 Years,95.7,92.0 to 97.8,361
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2019,Age,13-17 Years,92.1,87.5 to 95.1,305
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2018,Age,13-17 Years,91.2,86.8 to 94.3,341
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2016,Age,13-17 Years,81.4,75.5 to 86.1,366
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2017,Age,13-17 Years,92.0,88.1 to 94.7,336
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2008,Age,13-17 Years,66.7,60.0 to 72.7,326
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2015,Age,13-15 Years,29.8,20.8 to 40.6,124
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2014,Age,13-15 Years,20.0,12.2 to 30.9,131
≥2 Doses Hep A,,States/Local Areas,North Carolina,2022,Age,13-17 Years,89.2,83.8 to 92.9,361
≥2 Doses Hep A,,States/Local Areas,North Carolina,2021,Age,13-17 Years,90.8,83.6 to 95.0,266
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2010,Age,13-17 Years,39.3,30.6 to 48.6,156
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2015,Age,13-17 Years,37.8,29.6 to 46.7,172
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2009,Age,13-17 Years,30.5,22.7 to 39.6,157
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2008,Age,13-17 Years,17.8,12.2 to 25.3,157
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2013,Age,13-15 Years,15.0,8.2 to 25.7,105
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2013,Age,13-17 Years,12.4,7.4 to 20.2,157
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2012,Age,13-17 Years,8.6,4.7 to 15.1,184
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2015,Age,13-17 Years,29.8,22.5 to 38.3,186
HPV,"≥3 Doses, Males",States/Local Areas,North Carolina,2014,Age,13-17 Years,20.9,14.5 to 29.1,199
≥2 Doses Hep A,,States/Local Areas,North Carolina,2020,Age,13-17 Years,88.1,82.3 to 92.1,327
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2012,Age,13-17 Years,35.5,26.7 to 45.6,163
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2011,Age,13-17 Years,32.3,23.6 to 42.5,161
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2014,Age,13-17 Years,54.0,44.8 to 63.0,173
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2013,Age,13-17 Years,32.8,24.3 to 42.5,149
≥3 Doses HepB,,States/Local Areas,North Carolina,2009,Age,13-17 Years,86.9,81.7 to 90.8,323
≥3 Doses HepB,,States/Local Areas,North Carolina,2010,Age,13-17 Years,89.2,85.1 to 92.3,366
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2008,Age,13-17 Years,57.7,47.1 to 67.7,135
≥3 Doses HepB,,States/Local Areas,North Carolina,2012,Age,13-17 Years,95.6,92.0 to 97.6,347
≥3 Doses HepB,,States/Local Areas,North Carolina,2011,Age,13-17 Years,89.3,84.5 to 92.8,347
≥3 Doses HepB,,States/Local Areas,North Carolina,2014,Age,13-17 Years,93.3,89.2 to 95.9,372
≥3 Doses HepB,,States/Local Areas,North Carolina,2013,Age,13-17 Years,93.6,89.3 to 96.2,306
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2011,Age,13-17 Years,62.7,53.7 to 70.8,212
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2010,Age,13-17 Years,52.1,44.1 to 59.9,201
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2011,Age,13-17 Years,86.5,79.4 to 91.5,212
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2008,Age,13-17 Years,34.4,26.3 to 43.6,157
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2012,Age,13-17 Years,66.7,58.4 to 74.1,229
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2013,Age,13-17 Years,74.0,66.9 to 80.1,241
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2012,Age,13-17 Years,92.7,86.1 to 96.3,229
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2009,Age,13-15 Years,57.6,45.2 to 69.1,92
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2008,Age,13-15 Years,25.3,17.2 to 35.6,95
≥3 Doses HepB,,States/Local Areas,North Carolina,2017,Age,13-17 Years,90.8,86.3 to 93.9,336
≥3 Doses HepB,,States/Local Areas,North Carolina,2019,Age,13-17 Years,94.1,89.6 to 96.8,305
≥3 Doses HepB,,States/Local Areas,North Carolina,2018,Age,13-17 Years,93.2,88.7 to 96.0,341
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2019,Age,13-17 Years,91.3,86.3 to 94.6,282
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2020,Age,13-17 Years,96.4,91.9 to 98.4,303
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2021,Age,13-17 Years,92.5,85.5 to 96.3,247
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2018,Age,13-17 Years,89.7,84.6 to 93.3,291
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2020,Age,13-17 Years,98.2,93.5 to 99.5,303
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2017,Age,13-17 Years,95.3,91.7 to 97.4,303
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2019,Age,13-17 Years,96.0,91.7 to 98.1,282
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2018,Age,13-17 Years,93.6,88.7 to 96.4,291
≥3 Doses HepB,,States/Local Areas,North Carolina,2016,Age,13-17 Years,92.5,88.2 to 95.3,366
≥3 Doses HepB,,States/Local Areas,North Carolina,2015,Age,13-17 Years,93.3,88.9 to 96.0,358
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2016,Age,13-17 Years,93.1,87.8 to 96.2,305
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2015,Age,13-17 Years,95.4,91.4 to 97.6,297
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2014,Age,13-17 Years,94.7,90.6 to 97.1,306
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2013,Age,13-17 Years,93.0,87.8 to 96.1,241
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2020,Age,13-15 Years,97.5,93.5 to 99.0,194
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2021,Age,13-15 Years,93.5,84.8 to 97.4,158
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2015,Age,13-17 Years,85.9,81.1 to 89.6,358
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2017,Age,13-17 Years,91.3,87.0 to 94.2,303
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2010,Age,13-17 Years,51.9,42.8 to 60.9,156
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2011,Age,13-17 Years,54.4,44.6 to 63.9,161
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2016,Age,13-17 Years,77.4,70.6 to 83.0,305
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2015,Age,13-17 Years,83.0,77.4 to 87.5,297
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2014,Age,13-17 Years,72.4,65.9 to 78.1,306
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2012,Age,13-17 Years,53.3,43.6 to 62.8,163
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2013,Age,13-17 Years,59.3,49.6 to 68.3,149
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2014,Age,13-17 Years,71.1,62.4 to 78.4,173
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2015,Age,13-17 Years,65.7,56.8 to 73.6,172
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2012,Age,13-15 Years,72.9,62.9 to 81.0,157
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2013,Age,13-15 Years,78.5,70.1 to 85.0,166
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2010,Age,13-15 Years,55.5,46.2 to 64.3,151
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2011,Age,13-15 Years,66.1,55.2 to 75.5,149
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2015,Age,13-15 Years,84.2,77.0 to 89.4,202
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2014,Age,13-15 Years,73.6,65.4 to 80.4,205
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2018,Age,13-15 Years,89.3,81.7 to 94.0,195
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2019,Age,13-15 Years,91.5,84.0 to 95.7,171
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2020,Age,13-17 Years,82.3,74.3 to 88.2,158
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2021,Age,13-17 Years,87.5,76.4 to 93.8,122
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2022,Age,13-17 Years,70.9,60.9 to 79.3,175
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Carolina,2017,Age,13-17 Years,56.1,49.5 to 62.5,336
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Carolina,2016,Age,13-17 Years,47.4,41.0 to 53.9,366
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2020,Age,13-17 Years,78.4,68.6 to 85.8,169
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2021,Age,13-17 Years,82.6,73.1 to 89.3,144
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2018,Age,13-17 Years,65.2,55.7 to 73.7,180
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2019,Age,13-17 Years,68.9,59.0 to 77.4,162
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Carolina,2018,Age,13-17 Years,56.4,49.7 to 62.8,341
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2019,Age,13-17 Years,73.7,63.8 to 81.7,143
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2022,Age,13-17 Years,95.4,91.3 to 97.6,335
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2016,Age,13-17 Years,57.1,47.8 to 66.0,174
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2015,Age,13-17 Years,48.0,39.5 to 56.7,186
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2014,Age,13-17 Years,45.2,36.6 to 54.1,199
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2013,Age,13-17 Years,33.2,25.1 to 42.5,157
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2017,Age,13-17 Years,66.8,58.2 to 74.4,185
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Carolina,2019,Age,13-17 Years,54.3,47.2 to 61.2,305
≥3 Doses HepB,,States/Local Areas,North Carolina,2008,Age,13-17 Years,81.4,75.2 to 86.4,326
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2022,Age,13-15 Years,94.4,88.3 to 97.4,215
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2009,Age,13-17 Years,54.0,43.7 to 64.0,128
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2008,Age,13-17 Years,20.8,14.6 to 28.7,135
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2009,Age,13-17 Years,81.3,72.6 to 87.8,128
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2010,Age,13-17 Years,80.0,73.2 to 85.5,201
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2009,Age,13-17 Years,50.3,40.9 to 59.6,157
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2016,Age,13-15 Years,74.2,66.3 to 80.9,218
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2017,Age,13-17 Years,93.7,90.1 to 96.0,336
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2016,Age,13-17 Years,90.0,85.4 to 93.3,366
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2014,Age,13-17 Years,92.6,87.9 to 95.5,372
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2015,Age,13-17 Years,94.3,90.9 to 96.5,358
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2017,Age,13-17 Years,66.8,57.1 to 75.3,151
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2016,Age,13-17 Years,57.9,48.8 to 66.5,192
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2018,Age,13-17 Years,72.2,63.2 to 79.7,161
≥3 Doses HepB,,States/Local Areas,North Carolina,2020,Age,13-17 Years,97.7,93.7 to 99.2,327
≥3 Doses HepB,,States/Local Areas,North Carolina,2021,Age,13-17 Years,95.5,88.9 to 98.2,266
≥3 Doses HepB,,States/Local Areas,North Carolina,2022,Age,13-17 Years,95.9,93.2 to 97.6,361
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2022,Age,13-17 Years,97.1,94.0 to 98.7,335
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2021,Age,13-17 Years,97.3,90.9 to 99.2,247
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2012,Age,13-17 Years,18.8,12.7 to 26.8,184
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2009,Age,13-17 Years,73.8,67.7 to 79.1,323
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2008,Age,13-17 Years,63.6,56.9 to 69.8,326
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2008,Age,13-17 Years,28.1,20.8 to 36.7,157
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2011,Age,13-17 Years,40.2,30.8 to 50.3,161
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2010,Age,13-17 Years,45.0,36.2 to 54.2,156
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2020,Age,13-15 Years,96.3,92.8 to 98.2,206
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2009,Age,13-17 Years,39.1,30.5 to 48.4,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2017,Age,13-17 Years,66.8,60.4 to 72.6,336
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2016,Age,13-17 Years,57.5,51.0 to 63.8,366
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2015,Age,13-15 Years,76.8,69.5 to 82.9,231
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2014,Age,13-15 Years,74.3,66.6 to 80.8,241
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2012,Age,13-15 Years,62.9,54.2 to 70.9,226
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2013,Age,13-15 Years,73.8,66.4 to 80.1,202
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2012,Age,13-17 Years,46.5,37.0 to 56.3,163
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2013,Age,13-17 Years,47.4,37.8 to 57.1,149
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2019,Age,13-15 Years,93.9,87.2 to 97.2,185
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018,Age,13-15 Years,87.4,80.2 to 92.3,224
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2017,Age,13-15 Years,84.5,77.3 to 89.7,222
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Carolina,2012,Age,13-17 Years,21.7,16.6 to 27.9,347
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Carolina,2011,Age,13-17 Years,16.2,11.6 to 22.2,347
≥2 Doses MMR,,States/Local Areas,North Carolina,2014,Age,13-17 Years,88.3,83.3 to 92.0,372
≥2 Doses MMR,,States/Local Areas,North Carolina,2015,Age,13-17 Years,91.5,87.0 to 94.5,358
≥2 Doses MMR,,States/Local Areas,North Carolina,2012,Age,13-17 Years,93.2,89.2 to 95.8,347
≥2 Doses MMR,,States/Local Areas,North Carolina,2013,Age,13-17 Years,87.1,81.6 to 91.1,306
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2016,Age,13-17 Years,75.7,69.7 to 80.9,366
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2015,Age,13-17 Years,78.5,72.9 to 83.2,358
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2014,Age,13-17 Years,74.1,68.2 to 79.3,372
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2013,Age,13-17 Years,72.4,66.4 to 77.7,306
≥2 Doses MMR,,States/Local Areas,North Carolina,2016,Age,13-17 Years,87.5,82.2 to 91.4,366
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2019,Age,13-17 Years,92.0,86.7 to 95.3,305
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2017,Age,13-17 Years,84.8,79.4 to 89.0,336
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2020,Age,13-17 Years,92.5,87.3 to 95.7,327
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2021,Age,13-17 Years,94.5,88.9 to 97.4,266
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2022,Age,13-17 Years,91.2,86.3 to 94.5,361
≥2 Doses MMR,,States/Local Areas,North Carolina,2019,Age,13-17 Years,94.3,90.6 to 96.6,305
≥2 Doses MMR,,States/Local Areas,North Carolina,2018,Age,13-17 Years,92.5,88.2 to 95.3,341
≥2 Doses MMR,,States/Local Areas,North Carolina,2017,Age,13-17 Years,93.0,89.2 to 95.5,336
≥2 Doses MMR,,States/Local Areas,North Carolina,2020,Age,13-17 Years,95.5,90.6 to 97.9,327
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Carolina,2013,Age,13-17 Years,22.4,17.2 to 28.6,306
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Carolina,2015,Age,13-17 Years,33.7,28.1 to 39.8,358
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Carolina,2014,Age,13-17 Years,37.1,31.0 to 43.6,372
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2012,Age,13-15 Years,25.1,16.2 to 36.8,102
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2013,Age,13-15 Years,31.9,22.0 to 43.8,97
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2015,Age,13-15 Years,37.1,26.9 to 48.8,107
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2014,Age,13-15 Years,49.8,38.1 to 61.6,110
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2008,Age,13-15 Years,19.8,12.4 to 30.0,102
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2010,Age,13-15 Years,30.8,21.2 to 42.4,101
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2009,Age,13-15 Years,26.9,17.4 to 39.1,91
HPV,"≥3 Doses, Females",States/Local Areas,North Carolina,2011,Age,13-15 Years,34.0,24.0 to 45.7,107
≥2 Doses MMR,,States/Local Areas,North Carolina,2021,Age,13-17 Years,95.3,88.8 to 98.1,266
≥2 Doses MMR,,States/Local Areas,North Carolina,2022,Age,13-17 Years,96.1,92.6 to 98.0,361
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2019,Age,13-17 Years,71.3,64.4 to 77.3,305
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018,Age,13-17 Years,68.6,62.2 to 74.5,341
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2022,Age,13-17 Years,93.8,89.5 to 96.4,361
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2021,Age,13-17 Years,95.5,89.9 to 98.1,266
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2018,Age,13-17 Years,90.4,85.6 to 93.7,341
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2010,Age,13-15 Years,57.0,49.5 to 64.1,235
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2011,Age,13-15 Years,69.4,61.4 to 76.4,215
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2008,Age,13-15 Years,36.0,28.7 to 44.0,204
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2009,Age,13-15 Years,42.9,34.9 to 51.3,200
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2012,Age,13-17 Years,91.4,86.4 to 94.7,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2013,Age,13-17 Years,91.7,87.3 to 94.6,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2011,Age,13-17 Years,83.6,77.9 to 88.0,347
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2010,Age,13-17 Years,77.8,72.3 to 82.4,366
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2022,Age,13-17 Years,75.3,65.9 to 82.7,186
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2019,Age,13-17 Years,92.0,86.8 to 95.3,305
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2020,Age,13-17 Years,93.4,88.1 to 96.4,327
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2017,Age,13-17 Years,54.8,44.9 to 64.4,151
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2016,Age,13-17 Years,51.3,42.3 to 60.2,192
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2015,Age,13-17 Years,53.5,44.5 to 62.2,172
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2014,Age,13-17 Years,60.0,50.7 to 68.6,173
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2020,Age,13-17 Years,80.3,74.1 to 85.3,327
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2021,Age,13-17 Years,85.0,78.2 to 90.0,266
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2022,Age,13-17 Years,73.1,66.4 to 78.9,361
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2021,Age,13-15 Years,95.6,91.7 to 97.7,167
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2019,Age,13-17 Years,56.8,46.6 to 66.5,143
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2018,Age,13-17 Years,56.3,46.8 to 65.4,161
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2012,Age,13-15 Years,93.9,88.8 to 96.8,226
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2011,Age,13-15 Years,87.1,80.9 to 91.5,215
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2008,Age,13-15 Years,34.0,27.0 to 41.7,204
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2010,Age,13-15 Years,78.5,71.6 to 84.0,235
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2009,Age,13-15 Years,58.6,50.3 to 66.5,200
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2017,Age,13-15 Years,93.9,89.4 to 96.5,222
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2016,Age,13-15 Years,87.0,80.2 to 91.7,218
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2015,Age,13-15 Years,94.1,89.3 to 96.8,231
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2014,Age,13-15 Years,90.7,83.4 to 95.0,241
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2012,Age,13-17 Years,11.8,7.2 to 18.7,184
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2013,Age,13-15 Years,93.2,88.0 to 96.2,202
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2018,Age,13-17 Years,56.4,47.0 to 65.4,180
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2017,Age,13-17 Years,57.3,48.5 to 65.6,185
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2016,Age,13-17 Years,43.7,34.8 to 53.1,174
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2015,Age,13-17 Years,40.3,32.2 to 49.0,186
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2019,Age,13-15 Years,92.2,84.6 to 96.2,185
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2020,Age,13-15 Years,95.4,90.6 to 97.8,206
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2021,Age,13-15 Years,96.2,92.2 to 98.1,167
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018,Age,13-15 Years,88.9,82.3 to 93.3,224
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2022,Age,13-17 Years,92.8,87.9 to 95.8,361
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2013,Age,13-17 Years,24.4,17.3 to 33.3,157
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2014,Age,13-17 Years,31.9,24.2 to 40.8,199
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2019,Age,13-17 Years,93.2,88.3 to 96.1,305
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018,Age,13-17 Years,86.1,80.8 to 90.1,341
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2020,Age,13-17 Years,94.4,90.1 to 96.8,327
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2021,Age,13-17 Years,93.3,87.6 to 96.5,266
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Overall,Overall,75.7,72.9 to 78.3,1600
HPV,"≥2 Doses, Females",States/Local Areas,North Carolina,2022,Age,13-17 Years,56.3,46.2 to 65.8,175
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2012,Age,13-17 Years,68.2,61.6 to 74.2,347
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2022,Age,13-15 Years,90.9,83.6 to 95.2,229
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2009,Age,13-17 Years,46.8,40.4 to 53.3,323
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2008,Age,13-17 Years,30.7,25.2 to 36.9,326
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2011,Age,13-17 Years,65.9,59.4 to 71.9,347
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2010,Age,13-17 Years,52.4,46.3 to 58.3,366
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018,Age,13-17 Years,89.1,84.3 to 92.6,341
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2016,Age,13-17 Years,89.1,84.5 to 92.5,366
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2017,Age,13-17 Years,91.9,87.8 to 94.7,336
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Overall,Overall,92.0,90.0 to 93.6,1600
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Overall,Overall,91.9,89.9 to 93.5,1600
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2019,Age,13-15 Years,43.4,31.8 to 55.7,99
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2020,Age,13-15 Years,52.2,39.2 to 64.9,99
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2016,Age,13-17 Years,35.7,27.3 to 45.1,174
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2017,Age,13-17 Years,50.0,40.2 to 59.7,151
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2019,Age,13-17 Years,53.4,43.2 to 63.4,143
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2018,Age,13-17 Years,53.7,44.2 to 62.9,161
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2018,Age,13-15 Years,47.0,35.2 to 59.2,110
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2021,Age,13-17 Years,72.8,60.0 to 82.7,122
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2022,Age,13-17 Years,53.5,43.6 to 63.2,175
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2020,Age,13-17 Years,65.8,55.3 to 74.9,158
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2021,Age,13-15 Years,60.4,47.5 to 72.0,99
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2022,Age,13-15 Years,50.2,38.4 to 61.9,118
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2016,Age,13-17 Years,46.9,38.1 to 56.0,192
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2019,Age,13-15 Years,43.0,34.4 to 52.0,185
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2022,Age,13-17 Years,56.0,46.4 to 65.2,186
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2021,Age,13-15 Years,65.6,55.2 to 74.7,167
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2020,Age,13-15 Years,60.2,51.0 to 68.8,206
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2022,Age,13-15 Years,52.3,43.7 to 60.8,229
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2021,Age,13-15 Years,72.3,54.3 to 85.2,68
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2022,Age,13-15 Years,54.5,42.1 to 66.4,111
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2021,Age,13-17 Years,62.9,52.2 to 72.5,144
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2019,Age,13-17 Years,45.8,36.5 to 55.3,162
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2020,Age,13-17 Years,55.8,45.7 to 65.4,169
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2017,Age,13-17 Years,53.7,44.9 to 62.3,185
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2018,Age,13-17 Years,50.5,41.1 to 59.9,180
Varicella,History of disease,States/Local Areas,North Carolina,2016,Age,13-17 Years,17.4,12.9 to 22.9,366
Varicella,History of disease,States/Local Areas,North Carolina,2015,Age,13-17 Years,16.7,12.8 to 21.7,358
Varicella,History of disease,States/Local Areas,North Carolina,2009,Age,13-17 Years,62.7,56.3 to 68.7,323
Varicella,History of disease,States/Local Areas,North Carolina,2017,Age,13-17 Years,8.7,5.7 to 13.0,336
Varicella,History of disease,States/Local Areas,North Carolina,2008,Age,13-17 Years,57.9,51.3 to 64.2,326
Varicella,History of disease,States/Local Areas,North Carolina,2012,Age,13-17 Years,37.1,30.8 to 43.8,347
Varicella,History of disease,States/Local Areas,North Carolina,2013,Age,13-17 Years,20.5,15.7 to 26.3,306
Varicella,History of disease,States/Local Areas,North Carolina,2011,Age,13-17 Years,37.5,31.2 to 44.3,347
Varicella,History of disease,States/Local Areas,North Carolina,2010,Age,13-17 Years,49.2,43.2 to 55.2,366
Varicella,History of disease,States/Local Areas,North Carolina,2014,Age,13-17 Years,19.7,14.9 to 25.6,372
Varicella,History of disease,States/Local Areas,North Carolina,2018,Age,13-17 Years,14.7,10.5 to 20.1,341
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2019,Age,13-15 Years,42.6,30.5 to 55.6,86
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2020,Age,13-15 Years,68.3,55.5 to 78.8,107
Varicella,History of disease,States/Local Areas,North Carolina,2019,Age,13-17 Years,9.0,5.3 to 14.8,305
Varicella,History of disease,States/Local Areas,North Carolina,2020,Age,13-17 Years,5.7,3.3 to 9.8,327
Varicella,History of disease,States/Local Areas,North Carolina,2022,Age,13-17 Years,7.7,4.6 to 12.7,361
Varicella,History of disease,States/Local Areas,North Carolina,2021,Age,13-17 Years,10.2,5.8 to 17.2,266
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2018,Age,13-15 Years,45.9,35.0 to 57.3,114
≥2 Doses MMR,,States/Local Areas,North Carolina,2011,Age,13-17 Years,89.4,84.6 to 92.8,347
≥2 Doses MMR,,States/Local Areas,North Carolina,2010,Age,13-17 Years,85.7,80.8 to 89.5,366
≥2 Doses MMR,,States/Local Areas,North Carolina,2009,Age,13-17 Years,84.1,77.7 to 88.9,323
≥2 Doses MMR,,States/Local Areas,North Carolina,2008,Age,13-17 Years,82.2,76.4 to 86.8,326
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2022,Age,13-15 Years,93.2,87.6 to 96.4,229
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2008,Age,13-17 Years,28.0,22.8 to 33.8,326
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2019,Age,13-17 Years,49.5,42.6 to 56.5,305
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2020,Age,13-17 Years,60.7,53.4 to 67.5,327
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2021,Age,13-17 Years,67.8,59.6 to 75.0,266
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2022,Age,13-17 Years,54.8,47.9 to 61.5,361
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2015,Age,13-17 Years,93.4,89.7 to 95.8,358
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2019,Age,13-17 Years,51.8,42.1 to 61.3,162
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2009,Age,13-17 Years,54.7,48.3 to 61.1,323
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2010,Age,13-17 Years,67.7,61.7 to 73.1,366
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2011,Age,13-17 Years,77.8,71.7 to 82.8,347
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2016,Age,13-17 Years,41.2,35.0 to 47.7,366
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2012,Age,13-17 Years,87.9,82.6 to 91.8,347
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2014,Age,13-17 Years,92.3,87.6 to 95.3,372
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2013,Age,13-17 Years,89.4,84.7 to 92.8,306
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018,Age,13-17 Years,52.1,45.4 to 58.7,341
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2017,Age,13-17 Years,51.9,45.3 to 58.4,336
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2015,Age,13-15 Years,27.1,25.1 to 29.2,7093
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2012,Age,13-15 Years,6.9,5.8 to 8.3,6217
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2014,Age,13-15 Years,20.6,18.6 to 22.8,6583
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2013,Age,13-15 Years,13.5,11.8 to 15.5,5819
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2011,Age,13-17 Years,1.3,1.0 to 1.7,12328
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2012,Age,13-17 Years,6.8,5.9 to 7.8,10141
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2013,Age,13-17 Years,13.9,12.5 to 15.3,9554
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2014,Age,13-17 Years,21.6,20.0 to 23.3,10743
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2015,Age,13-17 Years,28.1,26.6 to 29.7,11367
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2010,Age,13-17 Years,32.0,30.3 to 33.6,9220
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2014,Age,13-17 Years,39.7,37.8 to 41.6,10084
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2013,Age,13-17 Years,37.6,35.7 to 39.6,8710
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2011,Age,13-17 Years,35.4,33.8 to 37.1,11236
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2012,Age,13-17 Years,33.4,31.7 to 35.2,9058
HPV,"≥3 Doses, Males",HHS Regions/National,United States,2011,Age,13-15 Years,1.4,1.0 to 2.0,7505
≥2 Doses Hep A,,HHS Regions/National,United States,2022,Age,13-17 Years,85.0,83.8 to 86.1,16043
≥2 Doses Hep A,,HHS Regions/National,United States,2020,Age,13-17 Years,82.1,81.1 to 83.1,20163
≥2 Doses Hep A,,HHS Regions/National,United States,2021,Age,13-17 Years,85.0,83.8 to 86.1,18002
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2009,Age,13-17 Years,26.7,25.2 to 28.2,9621
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2008,Age,13-17 Years,17.9,16.3 to 19.6,8607
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2007,Age,13-17 Years,5.9,4.4 to 7.8,1441
HPV,"≥3 Doses, Females",HHS Regions/National,United States,2015,Age,13-17 Years,41.9,40.1 to 43.7,10508
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2015,Age,13-17 Years,86.4,85.4 to 87.3,21875
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2022,Age,13-17 Years,62.6,61.1 to 64.0,16043
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2021,Age,13-17 Years,61.7,60.2 to 63.2,18002
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2020,Age,13-17 Years,58.6,57.3 to 60.0,20163
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2019,Age,13-17 Years,54.2,52.7 to 55.8,18788
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2011,Age,13-17 Years,78.2,77.2 to 79.1,23564
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2009,Age,13-17 Years,55.6,54.3 to 56.8,20066
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2010,Age,13-17 Years,68.7,67.5 to 69.8,19257
≥2 Doses MMR,,HHS Regions/National,United States,2006,Age,13-17 Years,86.9,85.2 to 88.5,2882
≥2 Doses MMR,,HHS Regions/National,United States,2007,Age,13-17 Years,88.9,87.3 to 90.4,2947
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2022,Age,13-15 Years,89.1,87.6 to 90.4,9816
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2008,Age,13-17 Years,40.8,39.3 to 42.2,17835
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2019,Age,13-17 Years,54.8,52.7 to 56.9,9872
≥2 Doses MMR,,HHS Regions/National,United States,2011,Age,13-17 Years,91.1,90.4 to 91.8,23564
≥2 Doses MMR,,HHS Regions/National,United States,2010,Age,13-17 Years,90.5,89.6 to 91.3,19257
≥2 Doses MMR,,HHS Regions/National,United States,2009,Age,13-17 Years,89.1,88.3 to 89.9,20066
≥2 Doses MMR,,HHS Regions/National,United States,2008,Age,13-17 Years,89.3,88.4 to 90.2,17835
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2016,Age,13-17 Years,43.4,42.1 to 44.7,20475
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2006,Age,13-17 Years,10.8,9.4 to 12.3,2882
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2014,Age,13-17 Years,87.6,86.7 to 88.5,20827
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2013,Age,13-17 Years,86.0,85.1 to 87.0,18264
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2012,Age,13-17 Years,84.6,83.7 to 85.5,19199
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018,Age,13-17 Years,51.1,49.8 to 52.5,18700
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2007,Age,13-17 Years,30.4,28.2 to 32.7,2947
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2017,Age,13-17 Years,48.6,47.3 to 49.9,20949
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2006,Age,13-17 Years,71.1,68.9 to 73.2,2882
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2008,Age,13-17 Years,73.5,72.2 to 74.8,17835
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2016,Age,13-17 Years,87.8,86.9 to 88.6,20475
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2018,Age,13-17 Years,90.8,90.0 to 91.6,18700
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2017,Age,13-17 Years,90.1,89.3 to 90.9,20949
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2019,Age,13-15 Years,91.7,90.3 to 92.9,10708
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2018,Age,13-15 Years,91.1,90.0 to 92.0,10318
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2014,Age,13-15 Years,82.1,80.6 to 83.4,10555
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2015,Age,13-15 Years,84.6,83.2 to 85.9,11494
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2019,Age,13-17 Years,91.5,90.4 to 92.4,18788
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2015,Age,13-17 Years,86.1,85.2 to 87.0,21875
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2022,Age,13-17 Years,91.5,90.5 to 92.4,16043
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2021,Age,13-17 Years,92.2,91.2 to 93.1,18002
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2020,Age,13-17 Years,92.6,91.7 to 93.3,20163
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2007,Age,13-17 Years,72.3,70.1 to 74.4,2947
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2009,Age,13-17 Years,75.7,74.6 to 76.8,20066
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2010,Age,13-17 Years,76.8,75.7 to 77.9,19257
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2014,Age,13-17 Years,85.0,84.0 to 85.9,20827
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2013,Age,13-17 Years,84.0,82.9 to 85.0,18264
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2011,Age,13-17 Years,79.9,78.9 to 80.8,23564
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2012,Age,13-17 Years,82.6,81.6 to 83.6,19199
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2016,Age,13-15 Years,87.0,85.6 to 88.3,10938
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2017,Age,13-15 Years,90.3,89.2 to 91.4,11464
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2009,Age,13-15 Years,51.5,49.3 to 53.8,6835
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2008,Age,13-15 Years,36.7,34.1 to 39.5,5093
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2010,Age,13-15 Years,62.4,60.5 to 64.3,7507
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2011,Age,13-15 Years,71.8,70.1 to 73.4,10201
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2013,Age,13-15 Years,80.7,79.2 to 82.1,8843
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2012,Age,13-15 Years,76.8,75.1 to 78.4,8868
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2007,Age,13-15 Years,20.6,17.1 to 24.6,761
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2006,Age,13-15 Years,4.6,3.0 to 6.9,648
≥3 Doses HepB,,HHS Regions/National,United States,2008,Age,13-17 Years,87.9,86.9 to 88.8,17835
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2008,Age,13-17 Years,81.9,80.2 to 83.6,6982
≥3 Doses HepB,,HHS Regions/National,United States,2016,Age,13-17 Years,91.4,90.7 to 92.1,20475
≥3 Doses HepB,,HHS Regions/National,United States,2015,Age,13-17 Years,91.1,90.2 to 91.9,21875
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2021,Age,13-15 Years,91.7,90.2 to 93.0,10456
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2020,Age,13-15 Years,92.7,91.6 to 93.6,11544
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2016,Age,13-17 Years,85.6,84.5 to 86.6,17328
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2015,Age,13-17 Years,83.1,82.0 to 84.2,17892
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2014,Age,13-17 Years,81.0,79.8 to 82.1,16461
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2013,Age,13-17 Years,78.5,77.2 to 79.8,13428
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2017,Age,13-17 Years,88.6,87.6 to 89.5,18152
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2010,Age,13-17 Years,48.7,46.9 to 50.5,9220
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2011,Age,13-17 Years,53.0,51.4 to 54.7,11236
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2015,Age,13-17 Years,62.8,61.0 to 64.5,10508
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2014,Age,13-17 Years,60.0,58.1 to 61.8,10084
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2013,Age,13-17 Years,57.3,55.4 to 59.2,8710
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2012,Age,13-17 Years,53.8,52.0 to 55.7,9058
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2016,Age,13-17 Years,95.0,94.2 to 95.6,17328
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2015,Age,13-17 Years,94.9,94.1 to 95.6,17892
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2014,Age,13-17 Years,95.2,94.6 to 95.7,16461
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2013,Age,13-17 Years,94.9,94.0 to 95.7,13428
≥3 Doses HepB,,HHS Regions/National,United States,2019,Age,13-17 Years,91.6,90.6 to 92.6,18788
≥3 Doses HepB,,HHS Regions/National,United States,2018,Age,13-17 Years,92.1,91.3 to 92.8,18700
≥3 Doses HepB,,HHS Regions/National,United States,2017,Age,13-17 Years,91.9,91.1 to 92.6,20949
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2012,Age,13-17 Years,94.7,93.9 to 95.4,13197
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2019,Age,13-17 Years,95.2,94.3 to 95.9,17010
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2017,Age,13-17 Years,95.5,94.8 to 96.1,18152
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2020,Age,13-17 Years,95.6,94.9 to 96.2,18513
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2018,Age,13-17 Years,89.6,88.7 to 90.4,16483
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2021,Age,13-17 Years,91.5,90.5 to 92.5,16725
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2020,Age,13-17 Years,91.9,91.0 to 92.7,18513
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2019,Age,13-17 Years,90.6,89.5 to 91.7,17010
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2018,Age,13-17 Years,94.9,94.3 to 95.4,16483
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2022,Age,13-15 Years,90.8,89.4 to 92.1,9232
≥3 Doses HepB,,HHS Regions/National,United States,2006,Age,13-17 Years,81.3,79.4 to 83.1,2882
≥3 Doses HepB,,HHS Regions/National,United States,2009,Age,13-17 Years,89.9,89.2 to 90.6,20066
≥3 Doses HepB,,HHS Regions/National,United States,2010,Age,13-17 Years,91.6,90.8 to 92.4,19257
≥3 Doses HepB,,HHS Regions/National,United States,2007,Age,13-17 Years,87.6,86.0 to 89.0,2947
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2006,Age,13-17 Years,65.5,61.4 to 69.4,901
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2009,Age,13-17 Years,48.6,46.6 to 50.6,9391
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2008,Age,13-17 Years,34.1,31.8 to 36.5,6982
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2009,Age,13-17 Years,87.0,85.7 to 88.2,9391
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2010,Age,13-17 Years,90.5,89.4 to 91.5,10542
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2011,Age,13-17 Years,68.3,66.9 to 69.6,14882
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2010,Age,13-17 Years,58.1,56.4 to 59.8,10542
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2011,Age,13-17 Years,92.3,91.3 to 93.2,14882
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2006,Age,13-17 Years,1.0,0.6 to 1.8,1335
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2007,Age,13-17 Years,25.1,22.3 to 28.1,1441
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2008,Age,13-17 Years,37.2,35.1 to 39.3,8607
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2012,Age,13-17 Years,74.9,73.5 to 76.3,13197
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2006,Age,13-17 Years,4.1,2.8 to 5.9,901
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2007,Age,13-17 Years,19.0,16.1 to 22.2,1047
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2007,Age,13-17 Years,75.7,72.2 to 79.0,1047
≥3 Doses HepB,,HHS Regions/National,United States,2014,Age,13-17 Years,91.4,90.6 to 92.1,20827
≥3 Doses HepB,,HHS Regions/National,United States,2013,Age,13-17 Years,93.2,92.4 to 93.9,18264
≥3 Doses HepB,,HHS Regions/National,United States,2011,Age,13-17 Years,92.3,91.6 to 92.9,23564
≥3 Doses HepB,,HHS Regions/National,United States,2012,Age,13-17 Years,92.8,92.1 to 93.5,19199
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2009,Age,13-17 Years,44.3,42.4 to 46.1,9621
HPV,"≥2 Doses, Males and Females",HHS Regions/National,United States,2019,Age,13-17 Years,57.7,56.2 to 59.2,18788
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2009,Age,13-17 Years,NA,,
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2010,Age,13-17 Years,1.4,1.1 to 1.8,10037
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2017,Age,13-17 Years,62.6,60.9 to 64.2,11104
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2018,Age,13-17 Years,66.3,64.6 to 68.0,9772
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2022,Age,13-17 Years,94.1,93.2 to 94.8,14960
HPV,"≥2 Doses, Males and Females",HHS Regions/National,United States,2017,Age,13-17 Years,53.2,51.9 to 54.5,20949
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2019,Age,13-17 Years,73.2,71.3 to 75.0,8916
HPV,"≥2 Doses, Males and Females",HHS Regions/National,United States,2018,Age,13-17 Years,55.0,53.7 to 56.4,18700
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2021,Age,13-17 Years,75.4,73.5 to 77.2,9579
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2020,Age,13-17 Years,73.1,71.5 to 74.8,10587
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2019,Age,13-17 Years,69.8,67.9 to 71.7,9872
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2016,Age,13-17 Years,56.0,54.3 to 57.7,10814
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2015,Age,13-17 Years,49.8,48.0 to 51.6,11367
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2014,Age,13-17 Years,41.7,39.9 to 43.6,10743
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2013,Age,13-17 Years,34.6,32.7 to 36.5,9554
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2022,Age,13-17 Years,77.8,75.8 to 79.6,7623
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2011,Age,13-17 Years,8.3,7.4 to 9.3,12328
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2021,Age,13-17 Years,78.5,76.6 to 80.4,8423
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2020,Age,13-17 Years,77.1,75.4 to 78.7,9576
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2022,Age,13-17 Years,90.8,89.8 to 91.8,14960
HPV,"≥2 Doses, Males and Females",HHS Regions/National,United States,2016,Age,13-17 Years,49.2,47.9 to 50.4,20475
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2012,Age,13-17 Years,20.8,19.4 to 22.4,10141
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2021,Age,13-17 Years,94.9,94.0 to 95.7,16725
≥3 Doses HepB,,HHS Regions/National,United States,2021,Age,13-17 Years,92.3,91.3 to 93.1,18002
≥3 Doses HepB,,HHS Regions/National,United States,2020,Age,13-17 Years,92.6,91.8 to 93.3,20163
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2018,Age,13-17 Years,69.9,68.1 to 71.6,8928
≥3 Doses HepB,,HHS Regions/National,United States,2022,Age,13-17 Years,91.2,90.2 to 92.1,16043
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2015,Age,13-17 Years,89.6,88.7 to 90.4,21875
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2014,Age,13-17 Years,89.8,89.0 to 90.6,20827
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2016,Age,13-17 Years,90.6,89.7 to 91.4,20475
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2007,Age,13-17 Years,16.9,14.6 to 19.6,1441
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2013,Age,13-17 Years,47.7,45.7 to 49.6,8710
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2012,Age,13-17 Years,43.4,41.5 to 45.2,9058
≥1 Dose MenACWY,,HHS Regions/National,United States,2010,Age,13-15 Years,64.8,63.2 to 66.2,11774
≥1 Dose MenACWY,,HHS Regions/National,United States,2011,Age,13-15 Years,71.5,70.1 to 72.8,14355
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2006,Age,13-17 Years,60.1,57.8 to 62.4,2882
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2007,Age,13-17 Years,72.3,70.3 to 74.3,2947
≥1 Dose MenACWY,,HHS Regions/National,United States,2007,Age,13-15 Years,32.7,29.9 to 35.7,1787
≥1 Dose MenACWY,,HHS Regions/National,United States,2006,Age,13-15 Years,12.6,10.8 to 14.7,1768
≥1 Dose MenACWY,,HHS Regions/National,United States,2020,Age,13-15 Years,88.5,87.3 to 89.7,12447
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2009,Age,13-17 Years,35.8,34.1 to 37.6,9621
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2011,Age,13-17 Years,43.9,42.3 to 45.6,11236
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2010,Age,13-17 Years,40.7,38.9 to 42.5,9220
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2017,Age,13-17 Years,90.7,89.8 to 91.5,20949
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2016,Age,13-17 Years,60.4,59.2 to 61.6,20475
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2017,Age,13-17 Years,65.5,64.3 to 66.7,20949
≥1 Dose MenACWY,,HHS Regions/National,United States,2019,Age,13-15 Years,89.1,88.1 to 90.1,11687
≥1 Dose MenACWY,,HHS Regions/National,United States,2018,Age,13-15 Years,86.2,84.9 to 87.4,11468
≥1 Dose MenACWY,,HHS Regions/National,United States,2017,Age,13-15 Years,84.9,83.6 to 86.0,12924
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2008,Age,13-17 Years,28.3,26.4 to 30.3,8607
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2016,Age,13-17 Years,65.1,63.3 to 66.8,9661
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2017,Age,13-17 Years,68.6,66.9 to 70.2,9845
≥1 Dose MenACWY,,HHS Regions/National,United States,2013,Age,13-15 Years,78.1,76.7 to 79.4,11221
≥1 Dose MenACWY,,HHS Regions/National,United States,2012,Age,13-15 Years,73.8,72.3 to 75.2,11790
≥1 Dose MenACWY,,HHS Regions/National,United States,2014,Age,13-15 Years,79.4,78.0 to 80.7,12764
≥1 Dose MenACWY,,HHS Regions/National,United States,2015,Age,13-15 Years,80.8,79.4 to 82.1,13488
≥1 Dose MenACWY,,HHS Regions/National,United States,2016,Age,13-15 Years,81.8,80.4 to 83.1,12578
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2014,Age,13-17 Years,50.3,48.4 to 52.2,10084
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2015,Age,13-17 Years,52.2,50.3 to 54.0,10508
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2016,Age,13-17 Years,55.0,53.1 to 56.8,9661
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2017,Age,13-17 Years,57.7,55.9 to 59.6,9845
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2022,Age,13-17 Years,76.0,74.7 to 77.3,16043
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2020,Age,13-17 Years,92.0,91.2 to 92.8,20163
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2019,Age,13-17 Years,91.9,90.9 to 92.7,18788
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2018,Age,13-17 Years,91.2,90.4 to 91.9,18700
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2011,Age,13-17 Years,85.3,84.5 to 86.1,23564
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2010,Age,13-17 Years,81.2,80.2 to 82.2,19257
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2013,Age,13-17 Years,89.1,88.1 to 89.9,18264
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2012,Age,13-17 Years,88.5,87.6 to 89.3,19199
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2022,Age,13-17 Years,74.4,72.5 to 76.1,8420
≥1 Dose MenACWY,,HHS Regions/National,United States,2008,Age,13-15 Years,43.9,42.0 to 45.7,10762
≥1 Dose MenACWY,,HHS Regions/National,United States,2009,Age,13-15 Years,54.8,53.2 to 56.4,12280
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2009,Age,13-17 Years,76.2,75.1 to 77.2,20066
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2008,Age,13-17 Years,72.2,70.8 to 73.4,17835
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2021,Age,13-17 Years,92.2,91.2 to 93.0,18002
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018,Age,13-17 Years,68.1,66.8 to 69.3,18700
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2019,Age,13-17 Years,71.5,70.1 to 72.8,18788
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2021,Age,13-17 Years,76.9,75.6 to 78.2,18002
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2020,Age,13-17 Years,75.1,73.9 to 76.2,20163
≥1 Dose MenACWY,,HHS Regions/National,United States,2021,Age,13-15 Years,88.5,87.0 to 89.8,11161
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2019,Age,13-17 Years,60.7,58.6 to 62.8,8916
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2018,Age,13-17 Years,57.4,55.5 to 59.3,8928
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2014,Age,13-15 Years,88.3,87.2 to 89.3,12764
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2015,Age,13-15 Years,87.1,85.9 to 88.2,13488
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2016,Age,13-15 Years,88.0,86.7 to 89.2,12578
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2017,Age,13-15 Years,88.6,87.4 to 89.6,12924
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2022,Age,13-17 Years,91.7,90.8 to 92.5,16043
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2008,Age,13-15 Years,46.7,44.8 to 48.6,10762
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2010,Age,13-15 Years,74.2,72.8 to 75.6,11774
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2009,Age,13-15 Years,62.2,60.6 to 63.7,12280
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2011,Age,13-15 Years,80.5,79.2 to 81.6,14355
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2012,Age,13-15 Years,85.3,84.1 to 86.5,11790
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2007,Age,13-15 Years,35.9,33.0 to 39.0,1787
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2006,Age,13-15 Years,13.4,11.5 to 15.5,1768
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018,Age,13-15 Years,88.2,87.0 to 89.3,11468
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2021,Age,13-15 Years,89.8,88.6 to 90.8,11161
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2020,Age,13-15 Years,89.7,88.5 to 90.7,12447
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2019,Age,13-15 Years,90.8,89.7 to 91.8,11687
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2015,Age,13-17 Years,39.0,37.3 to 40.8,11367
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2016,Age,13-17 Years,43.6,41.9 to 45.3,10814
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2017,Age,13-17 Years,48.8,47.1 to 50.6,11104
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2018,Age,13-17 Years,52.8,50.9 to 54.6,9772
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2014,Age,13-17 Years,31.4,29.7 to 33.2,10743
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2013,Age,13-17 Years,23.5,21.8 to 25.3,9554
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2012,Age,13-17 Years,12.7,11.5 to 14.0,10141
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2011,Age,13-17 Years,3.8,3.2 to 4.5,12328
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2013,Age,13-15 Years,87.5,86.4 to 88.6,11221
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2009,Age,13-17 Years,NA,,
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2010,Age,13-17 Years,0.4,0.3 to 0.7,10037
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2017,Age,13-17 Years,50.4,39.5 to 61.3,232
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2020,Age,13-17 Years,48.2,39.4 to 57.1,324
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2022,Age,13-17 Years,61.0,53.6 to 68.0,314
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2019,Age,13-17 Years,57.8,46.3 to 68.6,188
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2018,Age,13-17 Years,50.8,37.7 to 63.8,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2022,Age,13-15 Years,58.2,51.3 to 64.8,365
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2019,Age,13-15 Years,47.6,37.7 to 57.8,247
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2021,Age,13-15 Years,63.1,53.8 to 71.5,345
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2019,Age,13-15 Years,40.5,28.2 to 54.2,129
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2022,Age,13-15 Years,56.6,46.3 to 66.3,163
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2021,Age,13-15 Years,73.5,60.6 to 83.3,150
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2017,Age,13-17 Years,68.0,56.5 to 77.6,181
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2018,Age,13-17 Years,59.1,45.6 to 71.4,167
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2019,Age,13-17 Years,52.5,40.7 to 64.0,175
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2020,Age,13-15 Years,37.2,27.2 to 48.6,202
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2021,Age,13-17 Years,73.5,63.4 to 81.6,259
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2022,Age,13-15 Years,59.6,50.2 to 68.3,202
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2021,Age,13-15 Years,52.5,39.5 to 65.1,195
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2020,Age,13-17 Years,64.8,56.0 to 72.8,353
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2022,Age,13-17 Years,64.4,56.7 to 71.4,281
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2018,Age,13-15 Years,37.6,22.3 to 55.8,100
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2016,Age,13-17 Years,41.1,30.8 to 52.3,209
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2019,Age,13-15 Years,55.4,40.7 to 69.3,118
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2016,Age,13-17 Years,37.4,28.0 to 47.9,242
HPV,"Up-to-Date, Males",States/Local Areas,Virginia,2021,Age,13-17 Years,56.7,46.4 to 66.4,307
HPV,"Up-to-Date, Males and Females",States/Local Areas,Virginia,2020,Age,13-15 Years,48.5,40.3 to 56.7,418
Varicella,History of disease,States/Local Areas,Virginia,2018,Age,13-17 Years,11.2,6.4 to 19.0,327
Varicella,History of disease,States/Local Areas,Virginia,2017,Age,13-17 Years,10.9,6.7 to 17.4,413
Varicella,History of disease,States/Local Areas,Virginia,2016,Age,13-17 Years,13.2,8.8 to 19.3,451
Varicella,History of disease,States/Local Areas,Virginia,2015,Age,13-17 Years,19.6,14.0 to 26.8,385
Varicella,History of disease,States/Local Areas,Virginia,2013,Age,13-17 Years,18.2,12.3 to 26.1,302
Varicella,History of disease,States/Local Areas,Virginia,2012,Age,13-17 Years,28.5,22.2 to 35.9,334
Varicella,History of disease,States/Local Areas,Virginia,2011,Age,13-17 Years,35.6,29.7 to 42.1,417
Varicella,History of disease,States/Local Areas,Virginia,2010,Age,13-17 Years,36.0,29.7 to 42.8,332
Varicella,History of disease,States/Local Areas,Virginia,2009,Age,13-17 Years,54.1,47.8 to 60.3,358
Varicella,History of disease,States/Local Areas,Virginia,2014,Age,13-17 Years,13.3,9.4 to 18.5,350
Varicella,History of disease,States/Local Areas,Virginia,2008,Age,13-17 Years,53.3,46.2 to 60.2,272
Varicella,History of disease,States/Local Areas,Virginia,2022,Age,13-17 Years,7.0,4.7 to 10.2,595
Varicella,History of disease,States/Local Areas,Virginia,2019,Age,13-17 Years,12.6,7.9 to 19.6,363
Varicella,History of disease,States/Local Areas,Virginia,2020,Age,13-17 Years,8.6,5.6 to 13.1,677
≥1 Dose MenACWY,,States/Local Areas,Virginia,2013,Age,13-15 Years,58.0,46.6 to 68.7,190
≥1 Dose MenACWY,,States/Local Areas,Virginia,2012,Age,13-15 Years,66.5,56.8 to 75.1,212
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2008,Age,13-17 Years,70.3,63.6 to 76.3,272
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2009,Age,13-17 Years,79.9,74.3 to 84.6,358
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2016,Age,13-17 Years,88.8,82.6 to 92.9,451
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2014,Age,13-17 Years,94.4,90.0 to 96.9,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2015,Age,13-17 Years,85.7,78.5 to 90.8,385
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2012,Age,13-17 Years,91.1,86.0 to 94.4,334
≥1 Dose MenACWY,,States/Local Areas,Virginia,2010,Age,13-15 Years,51.3,42.7 to 59.8,195
≥1 Dose MenACWY,,States/Local Areas,Virginia,2011,Age,13-15 Years,61.5,53.4 to 69.0,265
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2021,Age,13-17 Years,70.1,60.0 to 78.6,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2011,Age,13-17 Years,83.4,77.2 to 88.2,417
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2010,Age,13-17 Years,82.9,76.9 to 87.6,332
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2019,Age,13-17 Years,78.9,68.4 to 86.6,188
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2016,Age,13-17 Years,41.8,31.4 to 53.0,209
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2014,Age,13-17 Years,51.1,40.7 to 61.4,166
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2015,Age,13-17 Years,43.9,33.0 to 55.4,171
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2020,Age,13-17 Years,92.8,88.6 to 95.6,677
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2018,Age,13-17 Years,91.5,85.0 to 95.3,327
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2020,Age,13-17 Years,73.7,67.7 to 79.0,677
≥1 Dose MenACWY,,States/Local Areas,Virginia,2008,Age,13-15 Years,52.0,43.1 to 60.7,175
≥1 Dose MenACWY,,States/Local Areas,Virginia,2009,Age,13-15 Years,49.8,42.4 to 57.3,235
HPV,"≥1 Dose, Males",States/Local Areas,Virginia,2022,Age,13-17 Years,74.7,67.4 to 80.8,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2021,Age,13-17 Years,91.7,86.5 to 95.1,566
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2019,Age,13-17 Years,75.2,67.4 to 81.6,363
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2022,Age,13-17 Years,77.5,72.6 to 81.7,595
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2018,Age,13-17 Years,67.2,58.0 to 75.3,327
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2019,Age,13-17 Years,91.4,85.1 to 95.2,363
≥3 Doses HepB,,States/Local Areas,Virginia,2021,Age,13-17 Years,92.2,87.2 to 95.3,566
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2022,Age,13-17 Years,91.8,88.4 to 94.3,557
≥3 Doses HepB,,States/Local Areas,Virginia,2022,Age,13-17 Years,89.8,86.1 to 92.5,595
≥3 Doses HepB,,States/Local Areas,Virginia,2020,Age,13-17 Years,94.6,91.2 to 96.7,677
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2013,Age,13-17 Years,41.4,29.8 to 54.0,155
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2012,Age,13-17 Years,38.0,28.4 to 48.7,155
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2009,Age,13-17 Years,30.4,22.9 to 39.1,175
≥1 Dose MenACWY,,States/Local Areas,Virginia,2020,Age,13-15 Years,80.0,72.1 to 86.0,418
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2011,Age,13-17 Years,36.5,27.9 to 46.0,176
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2010,Age,13-17 Years,51.1,41.4 to 60.7,162
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2008,Age,13-17 Years,27.4,20.0 to 36.2,151
≥1 Dose MenACWY,,States/Local Areas,Virginia,2014,Age,13-15 Years,66.7,57.1 to 75.0,218
≥1 Dose MenACWY,,States/Local Areas,Virginia,2015,Age,13-15 Years,65.2,54.7 to 74.3,241
≥1 Dose MenACWY,,States/Local Areas,Virginia,2016,Age,13-15 Years,70.0,60.2 to 78.3,289
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2013,Age,13-17 Years,85.7,78.5 to 90.8,302
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2018,Age,13-17 Years,70.6,57.4 to 81.1,167
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2017,Age,13-17 Years,82.5,72.7 to 89.3,181
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2016,Age,13-17 Years,50.7,39.6 to 61.6,209
Varicella,≥1 Dose with no disease history,States/Local Areas,Virginia,2019,Age,13-17 Years,96.4,91.6 to 98.5,330
HPV,"≥1 Dose, Females",States/Local Areas,Virginia,2015,Age,13-17 Years,61.2,49.7 to 71.6,171
≥1 Dose MenACWY,,States/Local Areas,Virginia,2018,Age,13-15 Years,79.7,68.9 to 87.4,210
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2017,Age,13-17 Years,75.6,68.4 to 81.6,413
≥1 Dose MenACWY,,States/Local Areas,Virginia,2019,Age,13-15 Years,85.0,75.8 to 91.1,247
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2016,Age,13-17 Years,53.6,46.0 to 61.0,451
≥1 Dose MenACWY,,States/Local Areas,Virginia,2017,Age,13-15 Years,79.8,69.9 to 87.0,259
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2017,Age,13-17 Years,93.3,88.2 to 96.3,413
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2018,Age,13-15 Years,51.5,35.4 to 67.3,110
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2017,Age,13-17 Years,52.7,41.7 to 63.4,232
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2016,Age,13-17 Years,44.7,34.8 to 55.0,242
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2016,Age,13-15 Years,86.7,78.5 to 92.1,289
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2014,Age,13-15 Years,93.3,87.6 to 96.4,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2015,Age,13-15 Years,83.2,73.2 to 89.9,241
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2015,Age,13-17 Years,32.0,23.0 to 42.5,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2020,Age,13-15 Years,89.1,82.3 to 93.5,418
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2018,Age,13-15 Years,91.1,81.6 to 95.9,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2017,Age,13-15 Years,90.1,81.2 to 95.1,259
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2018,Age,13-17 Years,55.6,42.3 to 68.1,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2019,Age,13-15 Years,92.2,84.7 to 96.2,247
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2018,Age,13-17 Years,60.1,46.6 to 72.3,167
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2017,Age,13-17 Years,73.1,62.0 to 81.9,181
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2012,Age,13-15 Years,90.3,84.1 to 94.3,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2011,Age,13-15 Years,78.1,69.3 to 85.0,265
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2008,Age,13-15 Years,62.5,53.9 to 70.3,175
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Virginia,2022,Age,13-17 Years,91.9,88.4 to 94.5,595
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2010,Age,13-15 Years,83.5,76.4 to 88.8,195
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2009,Age,13-15 Years,69.9,62.5 to 76.4,235
HPV,"≥1 Dose, Males and Females",States/Local Areas,Virginia,2021,Age,13-17 Years,77.3,70.6 to 82.9,566
≥1 Dose MenACWY,,States/Local Areas,Virginia,2021,Age,13-15 Years,85.7,77.6 to 91.2,345
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2013,Age,13-17 Years,22.4,13.7 to 34.4,147
HPV,"≥2 Doses, Males",States/Local Areas,Virginia,2014,Age,13-17 Years,29.7,20.8 to 40.4,184
Tetanus,≥1 Dose Tdap,States/Local Areas,Virginia,2013,Age,13-15 Years,85.4,75.5 to 91.8,190
HPV,"≥2 Doses, Females",States/Local Areas,Virginia,2019,Age,13-17 Years,56.6,44.6 to 67.9,175
HPV,"Up-to-Date, Females",States/Local Areas,Virginia,2020,Age,13-15 Years,59.9,48.1 to 70.7,216
HPV,"≥2 Doses, Males and Females",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,72.8,68.2 to 77.0,671
HPV,"≥2 Doses, Females",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,72.4,65.5 to 78.4,323
HPV,"≥2 Doses, Males",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,73.2,66.7 to 78.8,348
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,83.5,75.6 to 89.2,230
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,87.9,82.9 to 91.6,339
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,89.2,85.0 to 92.3,405
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,91.2,87.5 to 93.9,405
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2022,Age,13-15 Years,87.9,83.1 to 91.5,393
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,91.2,84.6 to 95.1,230
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,94.5,90.4 to 96.9,339
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,92.7,88.7 to 95.3,405
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,96.0,87.5 to 98.8,216
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,86.9,76.5 to 93.1,216
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,70.0,58.5 to 79.4,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,85.4,80.5 to 89.3,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,85.5,81.6 to 88.6,671
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2023,Age,13-17 Years,75.1,66.5 to 82.0,211
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2023,Age,13-17 Years,89.4,82.9 to 93.6,211
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2023,Age,13-15 Years,85.7,78.6 to 90.7,257
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2023,Age,13-15 Years,70.4,58.2 to 80.3,117
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2023,Age,13-15 Years,69.3,57.7 to 78.8,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2023,Age,13-15 Years,69.8,61.6 to 76.9,263
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2023,Age,13-15 Years,87.9,81.2 to 92.4,263
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2023,Age,13-15 Years,86.8,79.7 to 91.6,263
≥2 Doses Hep A,,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,81.3,75.9 to 85.7,453
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,87.7,82.8 to 91.3,453
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,87.4,82.4 to 91.1,444
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,89.7,85.0 to 93.1,444
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,87.7,82.9 to 91.3,453
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2023,Age,13-17 Years,77.0,68.6 to 83.7,242
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,87.7,82.8 to 91.3,453
HPV,"≥1 Dose, Males and Females",States/Local Areas,Puerto Rico,2023,Age,13-17 Years,88.6,84.1 to 92.0,453
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2023,Age,13-17 Years,87.9,80.8 to 92.7,242
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2023,Age,13-17 Years,76.0,70.2 to 81.1,453
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,91.0,86.6 to 94.0,453
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,88.2,83.3 to 91.9,453
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2023,Age,13-17 Years,90.5,85.9 to 93.7,453
HPV,"≥3 Doses, Females",States/Local Areas,Puerto Rico,2015,Age,13-15 Years,34.7,23.8 to 47.4,88
HPV,"≥3 Doses, Females",States/Local Areas,Puerto Rico,2014,Age,13-15 Years,34.3,21.7 to 49.5,64
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,67.5,55.7 to 77.4,169
HPV,"≥3 Doses, Males and Females",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,36.2,30.1 to 42.8,339
HPV,"≥3 Doses, Males and Females",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,36.4,28.3 to 45.4,230
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,80.9,74.9 to 85.8,350
≥2 Doses MMR,,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,88.4,85.0 to 91.1,671
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,89.8,86.5 to 92.4,671
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,88.0,83.2 to 91.5,350
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,93.5,83.7 to 97.6,216
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,77.2,66.5 to 85.2,169
HPV,"≥2 Doses, Males",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,41.6,29.9 to 54.4,123
HPV,"≥2 Doses, Males",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,53.2,44.4 to 61.7,208
HPV,"≥2 Doses, Males",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,44.3,35.5 to 53.5,181
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2019,Age,13-15 Years,87.3,72.3 to 94.8,124
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2020,Age,13-15 Years,73.5,58.7 to 84.4,94
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2021,Age,13-15 Years,83.5,76.2 to 88.9,205
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,89.9,86.7 to 92.5,671
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2016,Age,13-15 Years,92.3,87.2 to 95.5,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2015,Age,13-15 Years,83.4,75.8 to 89.0,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2014,Age,13-15 Years,86.0,75.4 to 92.4,132
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2021,Age,13-15 Years,86.0,79.0 to 91.0,205
HPV,"≥2 Doses, Females",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,61.1,45.6 to 74.7,107
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2015,Age,13-15 Years,88.6,81.8 to 93.0,207
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2014,Age,13-15 Years,84.1,73.5 to 91.0,132
HPV,"≥1 Dose, Males and Females",States/Local Areas,Puerto Rico,2020,Age,13-17 Years,69.9,58.5 to 79.4,169
HPV,"≥1 Dose, Males and Females",States/Local Areas,Puerto Rico,2021,Age,13-17 Years,86.1,81.4 to 89.8,350
HPV,"≥1 Dose, Males and Females",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,88.4,84.9 to 91.1,671
HPV,"≥2 Doses, Females",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,67.3,58.3 to 75.2,197
HPV,"≥2 Doses, Females",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,52.7,43.1 to 62.2,158
HPV,"≥2 Doses, Females",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,60.7,47.5 to 72.6,107
HPV,"≥1 Dose, Males and Females",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,75.7,64.9 to 84.0,216
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,89.6,85.5 to 92.7,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,90.5,80.5 to 95.6,216
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,74.5,63.2 to 83.3,169
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,90.2,85.9 to 93.3,348
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2016,Age,13-15 Years,90.6,84.9 to 94.3,230
HPV,"≥1 Dose, Males and Females",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,75.8,70.2 to 80.6,405
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2019,Age,13-15 Years,90.4,75.9 to 96.6,124
≥1 Dose MenACWY,,States/Local Areas,Puerto Rico,2020,Age,13-15 Years,79.1,65.2 to 88.4,94
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,92.8,89.3 to 95.2,405
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,85.5,77.9 to 90.8,230
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,87.2,82.0 to 91.0,339
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,80.8,72.7 to 86.9,197
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,70.8,59.0 to 80.4,169
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,84.0,78.3 to 88.5,350
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,89.5,86.1 to 92.1,671
HPV,"≥2 Doses, Males and Females",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,61.6,51.0 to 71.2,216
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,86.2,80.9 to 90.2,339
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,88.9,85.4 to 91.6,661
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,86.0,80.3 to 90.2,339
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,54.3,41.8 to 66.3,123
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,68.1,59.0 to 76.0,181
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,71.1,62.9 to 78.1,208
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,79.8,65.1 to 89.3,109
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2020,Age,13-17 Years,76.0,61.6 to 86.2,102
HPV,"≥1 Dose, Males",States/Local Areas,Puerto Rico,2021,Age,13-17 Years,82.9,75.3 to 88.5,175
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,71.4,54.8 to 83.8,107
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,86.6,82.9 to 89.6,661
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2020,Age,13-17 Years,63.6,46.4 to 78.0,67
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2021,Age,13-17 Years,89.4,83.4 to 93.5,175
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,86.4,80.7 to 90.7,323
HPV,"≥2 Doses, Males and Females",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,60.0,53.7 to 66.0,405
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,92.8,85.7 to 96.5,230
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,96.7,92.9 to 98.5,339
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,93.0,89.0 to 95.6,405
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,91.8,82.7 to 96.3,206
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,67.0,54.8 to 77.2,162
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,82.0,76.1 to 86.7,339
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,70.7,58.3 to 80.7,162
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,94.6,85.7 to 98.1,206
≥3 Doses HepB,,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,93.2,84.1 to 97.3,216
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2022,Age,13-15 Years,85.6,80.3 to 89.6,386
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,77.3,67.9 to 84.6,205
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,85.0,79.3 to 89.4,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,89.1,84.6 to 92.4,374
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,76.1,64.3 to 84.9,107
HPV,"≥1 Dose, Females",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,77.4,68.7 to 84.2,158
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,95.1,87.9 to 98.1,205
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,97.2,93.9 to 98.8,308
Varicella,≥1 Dose with no disease history,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,95.9,92.4 to 97.8,374
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2015,Age,13-15 Years,86.0,78.4 to 91.2,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2014,Age,13-15 Years,80.6,68.5 to 88.8,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2019,Age,13-15 Years,92.7,80.4 to 97.5,119
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2020,Age,13-15 Years,70.8,54.7 to 83.0,91
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2021,Age,13-15 Years,82.8,75.3 to 88.4,201
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,67.8,55.8 to 77.8,169
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,82.5,76.7 to 87.1,350
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,86.8,83.2 to 89.8,671
HPV,"≥3 Doses, Females",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,49.9,37.2 to 62.7,107
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,79.5,70.8 to 86.1,230
Varicella,≥2 Doses with no disease history,States/Local Areas,Puerto Rico,2016,Age,13-15 Years,91.4,85.2 to 95.2,217
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2021,Age,13-15 Years,65.4,53.1 to 75.9,105
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2022,Age,13-15 Years,69.5,60.7 to 77.1,198
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,61.9,52.8 to 70.3,197
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,81.7,73.4 to 87.8,230
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,59.7,44.3 to 73.4,107
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,44.1,35.7 to 53.0,208
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2018,Age,13-15 Years,NA,,
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2021,Age,13-17 Years,68.6,59.3 to 76.6,175
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,68.9,61.8 to 75.2,323
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2020,Age,13-17 Years,47.5,32.1 to 63.3,67
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2021,Age,13-15 Years,62.7,49.9 to 73.9,100
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2022,Age,13-15 Years,70.3,61.1 to 78.1,195
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2019,Age,13-17 Years,92.1,83.4 to 96.4,216
HPV,"≥3 Doses, Males",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,30.8,22.9 to 40.1,181
HPV,"≥3 Doses, Males",States/Local Areas,Puerto Rico,2014,Age,13-17 Years,23.7,14.5 to 36.1,123
Varicella,≥2 Doses or history of disease,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,90.0,85.8 to 93.0,405
≥2 Doses Hep A,,States/Local Areas,Puerto Rico,2020,Age,13-17 Years,44.9,34.0 to 56.4,169
≥2 Doses Hep A,,States/Local Areas,Puerto Rico,2022,Age,13-17 Years,74.3,69.6 to 78.5,671
≥2 Doses Hep A,,States/Local Areas,Puerto Rico,2021,Age,13-17 Years,62.6,55.8 to 68.9,350
HPV,"≥3 Doses, Males",States/Local Areas,Puerto Rico,2015,Age,13-15 Years,30.3,20.8 to 41.8,119
HPV,"≥3 Doses, Males",States/Local Areas,Puerto Rico,2014,Age,13-15 Years,28.6,15.9 to 45.9,68
HPV,"≥3 Doses, Females",States/Local Areas,Puerto Rico,2015,Age,13-17 Years,42.0,32.9 to 51.6,158
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2022,Age,13-15 Years,84.6,79.4 to 88.7,393
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,58.4,47.9 to 68.2,216
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2020,Age,13-17 Years,49.8,38.6 to 61.1,169
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2021,Age,13-17 Years,67.2,60.7 to 73.1,350
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,70.3,65.5 to 74.7,671
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2016,Age,13-17 Years,52.8,46.4 to 59.0,405
HPV,"≥2 Doses, Males",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,62.1,47.4 to 74.8,109
Tetanus,≥1 Dose Tdap,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,82.5,76.7 to 87.1,339
Varicella,History of disease,States/Local Areas,Puerto Rico,2015,Age,13-17 Years,7.8,5.2 to 11.5,339
Varicella,History of disease,States/Local Areas,Puerto Rico,2016,Age,13-17 Years,8.2,5.3 to 12.5,405
Varicella,History of disease,States/Local Areas,Puerto Rico,2014,Age,13-17 Years,9.7,5.5 to 16.3,230
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2019,Age,13-15 Years,61.7,41.8 to 78.3,64
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2020,Age,13-15 Years,51.7,31.5 to 71.3,38
HPV,"Up-to-Date, Females",States/Local Areas,Puerto Rico,2018,Age,13-15 Years,NA,,
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2019,Age,13-17 Years,57.1,42.7 to 70.4,109
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2020,Age,13-17 Years,52.1,36.2 to 67.6,102
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2019,Age,13-15 Years,56.1,42.3 to 68.9,124
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2022,Age,13-17 Years,71.6,65.0 to 77.4,348
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2021,Age,13-15 Years,64.1,55.3 to 72.0,205
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2020,Age,13-15 Years,54.6,39.5 to 68.8,94
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2019,Age,13-15 Years,50.4,32.0 to 68.7,60
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2020,Age,13-15 Years,57.3,35.9 to 76.3,56
HPV,"Up-to-Date, Males and Females",States/Local Areas,Puerto Rico,2022,Age,13-15 Years,69.9,63.6 to 75.5,393
HPV,"Up-to-Date, Males",States/Local Areas,Puerto Rico,2021,Age,13-17 Years,65.9,56.5 to 74.1,175
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Overall,Overall,89.7,87.8 to 91.4,2935
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Overall,Overall,93.3,91.7 to 94.7,2935
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2023,Age,13-17 Years,78.8,69.7 to 85.8,256
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2023,Age,13-17 Years,88.6,83.0 to 92.6,476
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2023,Age,13-17 Years,89.7,84.1 to 93.4,476
≥1 Dose MenACWY,,States/Local Areas,Maryland,2023,Age,13-17 Years,92.6,88.4 to 95.4,476
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2023,Age,13-17 Years,81.2,75.1 to 86.1,476
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2023,Age,13-17 Years,83.7,74.9 to 89.9,220
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2023,Age,13-17 Years,67.2,60.5 to 73.2,476
≥3 Doses HepB,,States/Local Areas,Maryland,2023,Age,13-17 Years,89.6,84.1 to 93.4,476
≥2 Doses MMR,,States/Local Areas,Maryland,2023,Age,13-17 Years,89.1,83.6 to 92.9,476
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2023,Age,13-17 Years,64.3,54.8 to 72.8,256
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2023,Age,13-17 Years,88.7,83.0 to 92.6,476
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2023,Age,13-17 Years,88.4,82.5 to 92.4,449
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2023,Age,13-17 Years,92.1,86.3 to 95.5,449
≥2 Doses Hep A,,States/Local Areas,Maryland,2023,Age,13-17 Years,84.0,78.0 to 88.6,476
≥1 Dose MenACWY,,States/Local Areas,Maryland,2023,Age,13-15 Years,92.4,86.7 to 95.8,287
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2023,Age,13-15 Years,92.8,87.1 to 96.1,287
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2023,Age,13-15 Years,63.6,55.0 to 71.4,287
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2023,Age,13-15 Years,65.6,52.9 to 76.4,124
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2023,Age,13-15 Years,88.7,80.7 to 93.6,268
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2023,Age,13-15 Years,62.1,50.3 to 72.6,163
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2023,Age,13-17 Years,70.2,60.4 to 78.3,220
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2022,Age,13-17 Years,69.6,58.3 to 78.9,185
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2022,Age,13-17 Years,80.2,69.4 to 87.8,161
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maryland,2022,Age,13-17 Years,74.8,67.1 to 81.1,346
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Uninsured,86.4,69.1 to 94.7,47
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Other,95.9,92.3 to 97.8,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Any Medicaid,87.8,83.4 to 91.2,569
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Private Insurance Only,90.0,87.7 to 92.0,2139
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Other,58.7,47.4 to 69.1,180
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Uninsured,51.9,31.5 to 71.7,47
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Any Medicaid,67.9,62.3 to 73.0,569
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Private Insurance Only,68.9,65.6 to 72.1,2139
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Uninsured,89.4,66.6 to 97.3,47
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Uninsured,88.4,73.1 to 95.5,47
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Other,69.8,58.5 to 79.0,180
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Private Insurance Only,81.8,78.8 to 84.4,2139
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Insurance Coverage,Any Medicaid,82.3,77.4 to 86.3,569
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Other,94.1,86.6 to 97.5,180
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Any Medicaid,92.2,88.5 to 94.8,569
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Insurance Coverage,Private Insurance Only,93.9,92.0 to 95.4,2139
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Poverty,Below Poverty Level,90.4,84.4 to 94.2,243
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Poverty,Living At or Above Poverty Level,90.2,88.2 to 91.9,2603
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Poverty,Living At or Above Poverty Level,67.8,64.8 to 70.6,2603
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Poverty,Below Poverty Level,63.5,54.9 to 71.3,243
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Poverty,Below Poverty Level,96.2,93.1 to 97.9,243
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Poverty,Living At or Above Poverty Level,93.2,91.4 to 94.6,2603
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Poverty,Living At or Above Poverty Level,81.0,78.4 to 83.3,2603
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,Hispanic,84.8,77.9 to 89.8,440
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Poverty,Below Poverty Level,84.0,76.7 to 89.3,243
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"White, Non-Hispanic",82.0,78.6 to 85.0,1481
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",79.9,75.0 to 84.1,638
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.2,90.8 to 96.4,376
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,Hispanic,84.2,76.8 to 89.5,440
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.2,85.3 to 92.1,638
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,Hispanic,89.5,83.0 to 93.7,440
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.4,92.1 to 96.1,1481
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.7,87.9 to 92.9,1481
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",93.3,89.9 to 95.6,638
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",65.9,57.9 to 73.2,376
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,Hispanic,69.5,61.8 to 76.3,440
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",66.1,60.6 to 71.1,638
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",78.0,70.6 to 83.9,376
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.2,90.4 to 96.6,376
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Principal City,89.4,85.5 to 92.4,884
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.6,64.7 to 72.2,1481
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.9,87.6 to 91.8,2006
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a Non-MSA,100.0,,45
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.7,90.6 to 94.4,2006
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Principal City,94.3,91.5 to 96.2,884
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a Non-MSA,86.0,72.4 to 93.5,45
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Non-Principal City,66.1,62.7 to 69.2,2006
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Principal City,69.8,64.7 to 74.5,884
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a Non-MSA,92.7,83.5 to 97.0,45
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Non-Principal City,80.3,77.4 to 83.0,2006
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a MSA Principal City,82.6,78.1 to 86.3,884
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018-2022,Urbanicity,Living In a Non-MSA,89.0,65.3 to 97.2,45
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018-2022,Overall,Overall,67.6,64.9 to 70.2,2935
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018-2022,Overall,Overall,81.3,78.9 to 83.4,2935
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Overall,Overall,92.3,90.5 to 93.8,1642
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Overall,Overall,89.3,87.1 to 91.2,1642
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2010,Age,13-17 Years,81.7,75.9 to 86.4,399
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2011,Age,13-17 Years,85.9,81.2 to 89.6,432
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2008,Age,13-17 Years,60.6,54.2 to 66.6,390
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2009,Age,13-17 Years,71.4,65.7 to 76.5,427
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2021,Age,13-17 Years,91.8,86.4 to 95.2,292
≥2 Doses MMR,,States/Local Areas,New Jersey,2022,Age,13-17 Years,93.5,89.5 to 96.1,289
≥2 Doses MMR,,States/Local Areas,New Jersey,2021,Age,13-17 Years,90.0,84.1 to 93.9,292
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2011,Age,13-15 Years,28.5,20.3 to 38.3,128
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2012,Age,13-15 Years,27.1,18.0 to 38.6,90
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2009,Age,13-15 Years,22.1,14.8 to 31.6,107
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2010,Age,13-15 Years,20.2,12.9 to 30.3,114
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2008,Age,13-15 Years,24.5,15.9 to 35.8,107
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2013,Age,13-15 Years,30.9,20.4 to 43.9,97
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2014,Age,13-15 Years,24.2,15.7 to 35.4,95
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2015,Age,13-15 Years,36.4,26.4 to 47.7,109
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2016,Age,13-17 Years,89.9,85.5 to 93.1,422
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018,Age,13-17 Years,88.4,83.5 to 92.0,351
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2017,Age,13-17 Years,90.0,85.3 to 93.3,366
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Jersey,2014,Age,13-17 Years,27.7,21.9 to 34.4,328
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Jersey,2015,Age,13-17 Years,37.8,31.9 to 44.1,364
≥2 Doses MMR,,States/Local Areas,New Jersey,2020,Age,13-17 Years,92.9,88.4 to 95.8,379
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Jersey,2013,Age,13-17 Years,22.6,17.2 to 29.0,322
≥2 Doses MMR,,States/Local Areas,New Jersey,2017,Age,13-17 Years,88.5,83.4 to 92.1,366
≥2 Doses MMR,,States/Local Areas,New Jersey,2018,Age,13-17 Years,90.5,85.2 to 94.1,351
≥2 Doses MMR,,States/Local Areas,New Jersey,2019,Age,13-17 Years,92.1,87.3 to 95.2,331
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2022,Age,13-17 Years,86.0,80.0 to 90.4,289
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2021,Age,13-17 Years,88.9,82.7 to 93.1,292
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2020,Age,13-17 Years,94.5,90.2 to 97.0,379
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2017,Age,13-17 Years,93.3,89.4 to 95.9,366
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2019,Age,13-17 Years,89.0,83.6 to 92.8,331
≥2 Doses MMR,,States/Local Areas,New Jersey,2013,Age,13-17 Years,94.9,90.5 to 97.3,322
≥2 Doses MMR,,States/Local Areas,New Jersey,2012,Age,13-17 Years,93.7,89.2 to 96.3,330
≥2 Doses MMR,,States/Local Areas,New Jersey,2015,Age,13-17 Years,90.2,85.6 to 93.4,364
≥2 Doses MMR,,States/Local Areas,New Jersey,2014,Age,13-17 Years,94.8,90.3 to 97.3,328
≥2 Doses MMR,,States/Local Areas,New Jersey,2016,Age,13-17 Years,94.1,90.7 to 96.2,422
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2013,Age,13-17 Years,91.8,86.7 to 95.1,322
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2014,Age,13-17 Years,94.9,90.5 to 97.3,328
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2015,Age,13-17 Years,95.7,92.6 to 97.5,364
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2016,Age,13-17 Years,91.7,87.9 to 94.4,422
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Jersey,2011,Age,13-17 Years,19.4,15.1 to 24.7,432
HPV,"≥3 Doses, Males and Females",States/Local Areas,New Jersey,2012,Age,13-17 Years,19.0,14.5 to 24.4,330
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2022,Age,13-15 Years,90.4,83.3 to 94.7,158
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2012,Age,13-17 Years,91.6,86.8 to 94.7,330
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2022,Age,13-17 Years,91.0,86.1 to 94.4,289
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2020,Age,13-17 Years,96.2,93.5 to 97.8,379
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018,Age,13-17 Years,91.9,87.6 to 94.9,351
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2019,Age,13-17 Years,90.6,85.4 to 94.1,331
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2023,Age,13-17 Years,69.5,61.0 to 76.9,193
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2023,Age,13-17 Years,90.3,85.7 to 93.5,334
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2023,Age,13-17 Years,91.6,87.2 to 94.6,334
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2023,Age,13-17 Years,93.8,89.8 to 96.3,334
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2023,Age,13-17 Years,65.8,59.3 to 71.8,334
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2023,Age,13-17 Years,61.9,52.0 to 71.0,141
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2023,Age,13-17 Years,53.3,44.7 to 61.7,193
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2023,Age,13-17 Years,50.2,43.8 to 56.7,334
≥3 Doses HepB,,States/Local Areas,New Jersey,2023,Age,13-17 Years,91.3,86.3 to 94.6,334
≥2 Doses MMR,,States/Local Areas,New Jersey,2023,Age,13-17 Years,90.4,86.1 to 93.5,334
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2023,Age,13-17 Years,88.4,83.5 to 91.9,334
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2023,Age,13-17 Years,87.5,82.4 to 91.3,318
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2023,Age,13-17 Years,92.9,88.6 to 95.7,318
Varicella,History of disease,States/Local Areas,New Jersey,2023,Age,13-17 Years,6.6,3.8 to 11.2,334
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2023,Age,13-15 Years,92.0,86.4 to 95.5,209
≥2 Doses Hep A,,States/Local Areas,New Jersey,2023,Age,13-17 Years,79.3,73.1 to 84.4,334
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2023,Age,13-15 Years,93.5,88.3 to 96.5,209
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2023,Age,13-15 Years,42.7,34.9 to 50.9,209
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2023,Age,13-15 Years,37.4,26.9 to 49.3,91
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2023,Age,13-15 Years,90.0,84.0 to 93.9,197
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2023,Age,13-17 Years,47.0,37.4 to 56.8,141
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2023,Age,13-15 Years,49.3,38.3 to 60.3,118
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Uninsured,91.8,80.2 to 96.8,41
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Other,82.5,59.4 to 93.8,47
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Any Medicaid,84.0,78.6 to 88.3,362
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Private Insurance Only,91.9,89.6 to 93.8,1192
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Uninsured,50.9,31.8 to 69.8,41
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Other,57.4,36.7 to 75.8,47
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Any Medicaid,57.6,51.0 to 63.9,362
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Uninsured,60.2,40.4 to 77.1,41
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Uninsured,92.7,82.8 to 97.1,41
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Private Insurance Only,55.0,51.3 to 58.7,1192
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Other,73.3,51.1 to 87.9,47
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Other,91.3,78.3 to 96.8,47
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Any Medicaid,72.7,66.6 to 78.1,362
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Private Insurance Only,68.1,64.6 to 71.5,1192
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Any Medicaid,90.8,86.2 to 94.0,362
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Insurance Coverage,Private Insurance Only,93.0,90.9 to 94.7,1192
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Poverty,Below Poverty Level,84.3,76.2 to 90.0,167
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Poverty,Living At or Above Poverty Level,90.8,88.6 to 92.6,1395
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Poverty,Living At or Above Poverty Level,54.6,51.1 to 58.0,1395
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Poverty,Below Poverty Level,65.6,56.2 to 74.0,167
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Poverty,Living At or Above Poverty Level,92.9,90.9 to 94.4,1395
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Poverty,Below Poverty Level,90.3,82.8 to 94.7,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Poverty,Living At or Above Poverty Level,68.5,65.2 to 71.6,1395
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Poverty,Below Poverty Level,77.7,68.8 to 84.7,167
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",69.8,59.6 to 78.4,122
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"White, Non-Hispanic",65.2,61.0 to 69.3,900
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.4,86.5 to 95.9,284
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,Hispanic,89.7,84.8 to 93.2,336
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.6,70.8 to 87.7,122
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,Hispanic,92.2,87.6 to 95.2,336
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.4,87.6 to 92.6,900
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.9,89.3 to 94.0,900
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.3,84.1 to 95.4,122
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,Hispanic,63.3,56.6 to 69.5,336
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",54.1,46.5 to 61.6,284
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",66.5,58.8 to 73.3,284
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"White, Non-Hispanic",52.2,47.9 to 56.5,900
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",55.1,44.4 to 65.3,122
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.4,89.4 to 97.1,284
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Principal City,86.3,79.1 to 91.3,176
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.8,87.5 to 91.8,1466
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Race and Ethnicity,Hispanic,78.3,72.4 to 83.3,336
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Principal City,92.3,86.0 to 95.9,176
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.3,90.3 to 93.9,1466
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Principal City,63.5,54.1 to 71.9,176
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Non-Principal City,54.4,51.0 to 57.8,1466
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Principal City,74.2,65.2 to 81.5,176
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Urbanicity,Living In a MSA Non-Principal City,68.6,65.4 to 71.6,1466
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018-2022,Overall,Overall,55.7,52.5 to 58.9,1642
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018-2022,Overall,Overall,69.4,66.4 to 72.2,1642
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2022,Age,13-17 Years,63.4,52.6 to 72.9,133
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2022,Age,13-17 Years,67.6,57.5 to 76.3,156
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Jersey,2022,Age,13-17 Years,65.5,58.2 to 72.2,289
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2015,Age,13-17 Years,45.0,36.4 to 53.9,178
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2010,Age,13-17 Years,25.4,18.6 to 33.7,180
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2008,Age,13-17 Years,20.4,14.2 to 28.3,187
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2009,Age,13-17 Years,28.0,21.6 to 35.5,197
≥2 Doses Hep A,,States/Local Areas,New Jersey,2021,Age,13-17 Years,80.0,72.7 to 85.8,292
≥2 Doses Hep A,,States/Local Areas,New Jersey,2022,Age,13-17 Years,86.4,80.4 to 90.8,289
HPV,"≥3 Doses, Males",States/Local Areas,New Jersey,2014,Age,13-15 Years,22.6,13.5 to 35.4,116
HPV,"≥3 Doses, Males",States/Local Areas,New Jersey,2015,Age,13-15 Years,22.9,14.5 to 34.1,102
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2013,Age,13-17 Years,79.2,71.8 to 85.0,264
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2012,Age,13-17 Years,73.8,66.0 to 80.4,252
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2008,Age,13-17 Years,86.2,78.9 to 91.2,182
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2013,Age,13-17 Years,31.4,23.0 to 41.2,157
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2014,Age,13-17 Years,34.5,25.8 to 44.3,145
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2011,Age,13-17 Years,38.7,30.9 to 47.3,219
HPV,"≥3 Doses, Females",States/Local Areas,New Jersey,2012,Age,13-17 Years,31.6,23.7 to 40.6,145
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2017,Age,13-17 Years,87.8,83.1 to 91.3,366
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2016,Age,13-17 Years,89.0,84.7 to 92.2,422
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2018,Age,13-17 Years,87.1,81.4 to 91.2,351
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2019,Age,13-15 Years,87.2,79.0 to 92.5,207
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2018,Age,13-15 Years,86.3,77.6 to 91.9,178
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2014,Age,13-15 Years,84.2,77.1 to 89.3,182
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2015,Age,13-15 Years,85.6,78.2 to 90.8,186
≥2 Doses Hep A,,States/Local Areas,New Jersey,2020,Age,13-17 Years,81.9,76.3 to 86.5,379
HPV,"≥3 Doses, Males",States/Local Areas,New Jersey,2014,Age,13-17 Years,21.2,14.0 to 30.8,183
HPV,"≥3 Doses, Males",States/Local Areas,New Jersey,2015,Age,13-17 Years,30.9,23.3 to 39.7,186
HPV,"≥3 Doses, Males",States/Local Areas,New Jersey,2013,Age,13-17 Years,14.2,8.5 to 22.7,165
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2008,Age,13-17 Years,70.6,64.8 to 75.7,390
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2015,Age,13-17 Years,87.4,82.5 to 91.1,364
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2019,Age,13-17 Years,90.1,84.8 to 93.7,331
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2022,Age,13-17 Years,91.5,86.8 to 94.6,289
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2021,Age,13-17 Years,86.8,80.4 to 91.3,292
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2020,Age,13-17 Years,90.9,86.0 to 94.2,379
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2016,Age,13-15 Years,88.0,81.7 to 92.4,232
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2017,Age,13-15 Years,85.7,78.2 to 91.0,193
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2010,Age,13-17 Years,79.1,73.5 to 83.8,399
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2009,Age,13-17 Years,73.8,68.4 to 78.5,427
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2013,Age,13-17 Years,83.4,77.3 to 88.2,322
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2014,Age,13-17 Years,86.1,81.0 to 89.9,328
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2011,Age,13-17 Years,80.9,76.0 to 84.9,432
Varicella,≥2 Doses or history of disease,States/Local Areas,New Jersey,2012,Age,13-17 Years,80.4,74.0 to 85.5,330
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2021,Age,13-15 Years,87.8,78.6 to 93.4,173
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2020,Age,13-15 Years,92.6,87.5 to 95.7,239
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2011,Age,13-15 Years,76.7,68.9 to 83.0,183
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2010,Age,13-15 Years,62.9,52.5 to 72.2,158
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2013,Age,13-15 Years,77.6,68.1 to 85.0,173
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2012,Age,13-15 Years,74.4,64.4 to 82.3,171
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2013,Age,13-17 Years,95.8,90.5 to 98.2,264
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2014,Age,13-17 Years,98.7,96.9 to 99.5,276
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2015,Age,13-17 Years,97.3,94.7 to 98.7,309
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2016,Age,13-17 Years,97.1,94.6 to 98.4,377
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2015,Age,13-17 Years,69.0,60.6 to 76.2,178
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2014,Age,13-17 Years,48.0,38.3 to 57.8,145
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2013,Age,13-17 Years,45.8,36.4 to 55.5,157
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2012,Age,13-17 Years,54.6,44.9 to 64.0,145
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2015,Age,13-17 Years,85.1,79.4 to 89.4,309
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2016,Age,13-17 Years,87.7,83.0 to 91.3,377
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2014,Age,13-17 Years,83.2,77.3 to 87.8,276
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2017,Age,13-17 Years,94.4,89.9 to 97.0,324
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2011,Age,13-17 Years,55.5,47.3 to 63.4,219
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2010,Age,13-17 Years,35.4,27.0 to 44.9,180
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2017,Age,13-17 Years,86.2,81.0 to 90.1,324
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2008,Age,13-15 Years,33.9,24.2 to 45.1,134
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2009,Age,13-15 Years,50.7,41.4 to 60.0,153
≥3 Doses HepB,,States/Local Areas,New Jersey,2015,Age,13-17 Years,96.0,93.0 to 97.7,364
≥3 Doses HepB,,States/Local Areas,New Jersey,2016,Age,13-17 Years,93.7,90.2 to 96.0,422
≥3 Doses HepB,,States/Local Areas,New Jersey,2018,Age,13-17 Years,93.4,88.4 to 96.3,351
≥3 Doses HepB,,States/Local Areas,New Jersey,2019,Age,13-17 Years,94.3,89.5 to 97.0,331
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2018,Age,13-17 Years,93.9,88.5 to 96.9,306
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2019,Age,13-17 Years,95.1,90.5 to 97.5,309
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2020,Age,13-17 Years,95.7,91.6 to 97.9,361
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2018,Age,13-17 Years,85.0,78.6 to 89.8,306
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2021,Age,13-17 Years,86.1,79.4 to 90.8,276
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2020,Age,13-17 Years,90.4,85.3 to 93.9,361
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2019,Age,13-17 Years,89.4,83.7 to 93.3,309
≥3 Doses HepB,,States/Local Areas,New Jersey,2017,Age,13-17 Years,90.5,85.9 to 93.8,366
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2010,Age,13-17 Years,91.0,83.9 to 95.1,238
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2009,Age,13-17 Years,88.2,81.8 to 92.6,232
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2008,Age,13-17 Years,37.3,28.6 to 46.8,182
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2009,Age,13-17 Years,51.1,43.5 to 58.8,232
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2011,Age,13-17 Years,96.6,92.9 to 98.4,285
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2012,Age,13-17 Years,92.6,86.9 to 96.0,252
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2008,Age,13-17 Years,43.0,34.3 to 52.1,187
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2009,Age,13-17 Years,42.2,34.4 to 50.4,197
≥3 Doses HepB,,States/Local Areas,New Jersey,2010,Age,13-17 Years,95.4,91.0 to 97.7,399
≥3 Doses HepB,,States/Local Areas,New Jersey,2009,Age,13-17 Years,92.8,88.6 to 95.6,427
≥3 Doses HepB,,States/Local Areas,New Jersey,2008,Age,13-17 Years,94.5,91.0 to 96.7,390
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2012,Age,13-17 Years,90.9,86.0 to 94.2,330
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2013,Age,13-17 Years,85.5,79.5 to 90.0,322
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2014,Age,13-17 Years,90.1,84.7 to 93.7,328
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2017,Age,13-17 Years,49.6,43.4 to 55.8,366
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2018,Age,13-17 Years,48.5,41.9 to 55.2,351
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2015,Age,13-17 Years,41.4,33.1 to 50.2,186
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2018,Age,13-15 Years,87.8,81.2 to 92.4,203
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2021,Age,13-15 Years,89.2,81.3 to 94.0,183
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2020,Age,13-15 Years,92.3,85.4 to 96.1,248
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2019,Age,13-15 Years,87.7,80.1 to 92.7,219
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2016,Age,13-17 Years,43.3,35.2 to 51.8,201
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2017,Age,13-17 Years,49.7,41.2 to 58.2,197
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2018,Age,13-17 Years,48.2,39.0 to 57.6,174
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2013,Age,13-15 Years,87.8,79.9 to 92.9,201
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2014,Age,13-17 Years,26.7,18.9 to 36.3,183
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2013,Age,13-17 Years,25.7,18.2 to 35.0,165
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2012,Age,13-17 Years,10.7,6.3 to 17.8,185
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2014,Age,13-15 Years,89.7,82.3 to 94.3,211
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2015,Age,13-15 Years,84.6,77.4 to 89.8,211
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2016,Age,13-15 Years,89.1,82.6 to 93.4,254
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2017,Age,13-15 Years,87.0,79.5 to 92.0,217
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2010,Age,13-17 Years,85.3,80.1 to 89.4,399
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2011,Age,13-17 Years,91.9,88.2 to 94.6,432
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2013,Age,13-17 Years,90.5,85.1 to 94.1,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2012,Age,13-17 Years,94.3,90.2 to 96.8,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2008,Age,13-17 Years,78.1,72.4 to 83.0,390
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2009,Age,13-17 Years,81.2,76.2 to 85.4,427
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2011,Age,13-15 Years,87.1,81.0 to 91.4,252
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2010,Age,13-15 Years,84.0,76.5 to 89.5,244
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2014,Age,13-17 Years,39.9,30.8 to 49.8,145
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2015,Age,13-17 Years,56.3,47.6 to 64.6,178
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2016,Age,13-17 Years,58.8,50.4 to 66.7,221
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2017,Age,13-17 Years,59.1,50.1 to 67.6,169
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2019,Age,13-17 Years,55.1,45.3 to 64.5,166
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2009,Age,13-15 Years,68.5,61.0 to 75.1,238
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2010,Age,13-15 Years,75.2,67.3 to 81.8,244
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2008,Age,13-15 Years,47.7,39.8 to 55.7,229
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2011,Age,13-15 Years,84.3,77.9 to 89.1,252
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2012,Age,13-15 Years,92.2,85.3 to 96.0,215
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2018,Age,13-17 Years,51.7,42.3 to 61.1,177
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2021,Age,13-15 Years,93.3,86.0 to 97.0,183
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2022,Age,13-17 Years,75.5,68.6 to 81.2,289
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2021,Age,13-17 Years,65.4,57.7 to 72.4,292
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2020,Age,13-17 Years,73.1,67.1 to 78.4,379
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2018,Age,13-17 Years,93.1,88.7 to 95.9,351
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2018,Age,13-17 Years,65.4,58.6 to 71.6,351
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2022,Age,13-17 Years,89.6,84.3 to 93.3,289
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2021,Age,13-17 Years,93.1,87.7 to 96.2,292
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2019,Age,13-17 Years,67.1,60.3 to 73.3,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2020,Age,13-17 Years,97.1,94.5 to 98.5,379
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2019,Age,13-17 Years,92.1,87.3 to 95.2,331
≥3 Doses HepB,,States/Local Areas,New Jersey,2013,Age,13-17 Years,97.5,93.7 to 99.1,322
≥3 Doses HepB,,States/Local Areas,New Jersey,2014,Age,13-17 Years,95.3,91.7 to 97.4,328
≥3 Doses HepB,,States/Local Areas,New Jersey,2011,Age,13-17 Years,95.5,92.1 to 97.5,432
≥3 Doses HepB,,States/Local Areas,New Jersey,2012,Age,13-17 Years,96.9,93.4 to 98.6,330
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2010,Age,13-17 Years,62.2,53.8 to 69.9,238
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2011,Age,13-17 Years,71.5,64.9 to 77.3,285
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Jersey,2019,Age,13-17 Years,53.4,46.5 to 60.3,331
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2019,Age,13-17 Years,62.8,52.7 to 71.8,165
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2022,Age,13-15 Years,89.9,82.4 to 94.4,153
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2017,Age,13-17 Years,60.3,51.8 to 68.1,197
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2013,Age,13-17 Years,32.4,24.2 to 41.9,165
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2014,Age,13-17 Years,35.5,26.7 to 45.3,183
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2015,Age,13-17 Years,50.9,42.1 to 59.6,186
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2016,Age,13-17 Years,51.2,42.7 to 59.7,201
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Jersey,2016,Age,13-17 Years,50.9,44.9 to 56.8,422
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Jersey,2017,Age,13-17 Years,54.3,48.1 to 60.4,366
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2022,Age,13-17 Years,73.4,62.9 to 81.7,133
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2021,Age,13-17 Years,66.3,54.5 to 76.4,122
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2020,Age,13-17 Years,75.2,66.6 to 82.1,171
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2019,Age,13-17 Years,71.6,62.3 to 79.3,166
Varicella,≥2 Doses with no disease history,States/Local Areas,New Jersey,2022,Age,13-17 Years,90.9,85.9 to 94.2,272
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Jersey,2018,Age,13-17 Years,49.9,43.3 to 56.6,351
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2018,Age,13-17 Years,61.3,51.6 to 70.2,174
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2021,Age,13-17 Years,64.5,54.3 to 73.6,170
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2020,Age,13-17 Years,71.2,62.4 to 78.6,208
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2012,Age,13-17 Years,19.8,13.1 to 28.9,185
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2021,Age,13-17 Years,94.7,89.1 to 97.4,276
Varicella,≥1 Dose with no disease history,States/Local Areas,New Jersey,2022,Age,13-17 Years,95.8,92.1 to 97.8,272
≥3 Doses HepB,,States/Local Areas,New Jersey,2022,Age,13-17 Years,93.6,89.0 to 96.4,289
≥3 Doses HepB,,States/Local Areas,New Jersey,2021,Age,13-17 Years,91.5,85.4 to 95.2,292
≥3 Doses HepB,,States/Local Areas,New Jersey,2020,Age,13-17 Years,94.6,90.5 to 97.0,379
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2018,Age,13-17 Years,69.7,60.1 to 77.8,177
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2008,Age,13-17 Years,31.6,23.9 to 40.6,187
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2016,Age,13-17 Years,66.0,57.8 to 73.4,221
HPV,"≥1 Dose, Females",States/Local Areas,New Jersey,2017,Age,13-17 Years,71.6,62.9 to 78.9,169
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2016,Age,13-15 Years,91.6,86.1 to 95.1,254
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2016,Age,13-17 Years,58.5,52.4 to 64.3,422
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Jersey,2017,Age,13-17 Years,65.8,59.8 to 71.3,366
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2017,Age,13-15 Years,94.3,88.4 to 97.3,217
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2018,Age,13-15 Years,90.4,83.7 to 94.5,203
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2019,Age,13-15 Years,91.7,85.1 to 95.6,219
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2013,Age,13-17 Years,39.1,30.1 to 49.0,157
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2012,Age,13-17 Years,44.9,35.5 to 54.6,145
HPV,"≥1 Dose, Males",States/Local Areas,New Jersey,2022,Age,13-17 Years,77.5,68.0 to 84.8,156
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2009,Age,13-15 Years,75.2,67.7 to 81.5,238
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2008,Age,13-15 Years,64.3,56.4 to 71.6,229
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2009,Age,13-17 Years,35.2,28.0 to 43.1,197
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2020,Age,13-15 Years,94.6,90.5 to 97.1,248
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2010,Age,13-17 Years,29.8,22.3 to 38.5,180
HPV,"≥2 Doses, Females",States/Local Areas,New Jersey,2011,Age,13-17 Years,49.5,41.3 to 57.7,219
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2015,Age,13-17 Years,95.1,91.9 to 97.1,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2014,Age,13-17 Years,95.3,91.5 to 97.5,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2016,Age,13-17 Years,94.0,90.4 to 96.4,422
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Jersey,2017,Age,13-17 Years,93.1,88.8 to 95.8,366
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2013,Age,13-15 Years,91.3,84.1 to 95.4,201
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2012,Age,13-15 Years,93.1,86.6 to 96.6,215
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2014,Age,13-15 Years,95.4,90.1 to 97.9,211
≥1 Dose MenACWY,,States/Local Areas,New Jersey,2015,Age,13-15 Years,96.2,92.7 to 98.1,211
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2015,Age,13-17 Years,87.2,82.2 to 90.9,364
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2022,Age,13-17 Years,63.7,56.3 to 70.4,289
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2021,Age,13-17 Years,54.8,47.1 to 62.4,292
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2020,Age,13-17 Years,59.7,53.1 to 66.0,379
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2019,Age,13-17 Years,51.4,44.5 to 58.3,331
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2008,Age,13-17 Years,43.0,37.0 to 49.3,390
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2022,Age,13-15 Years,85.3,76.7 to 91.1,158
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2011,Age,13-17 Years,78.9,73.5 to 83.5,432
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2010,Age,13-17 Years,68.9,62.6 to 74.6,399
Tetanus,≥1 Dose Tdap,States/Local Areas,New Jersey,2009,Age,13-17 Years,61.1,55.4 to 66.5,427
≥2 Doses MMR,,States/Local Areas,New Jersey,2010,Age,13-17 Years,92.6,88.2 to 95.4,399
≥2 Doses MMR,,States/Local Areas,New Jersey,2011,Age,13-17 Years,93.4,89.4 to 96.0,432
≥2 Doses MMR,,States/Local Areas,New Jersey,2008,Age,13-17 Years,91.8,87.6 to 94.6,390
≥2 Doses MMR,,States/Local Areas,New Jersey,2009,Age,13-17 Years,90.8,86.7 to 93.7,427
HPV,"≥2 Doses, Males",States/Local Areas,New Jersey,2019,Age,13-17 Years,51.8,42.0 to 61.5,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2016,Age,13-17 Years,42.8,37.0 to 48.8,422
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2017,Age,13-17 Years,53.8,44.8 to 62.5,169
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2020,Age,13-15 Years,58.0,46.1 to 69.0,139
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2022,Age,13-15 Years,58.2,43.1 to 72.0,70
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2021,Age,13-15 Years,64.9,51.0 to 76.7,85
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2022,Age,13-15 Years,64.5,50.8 to 76.1,88
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2021,Age,13-15 Years,39.9,28.0 to 53.2,98
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2019,Age,13-15 Years,46.9,35.6 to 58.5,120
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2020,Age,13-17 Years,60.3,50.7 to 69.2,171
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2016,Age,13-17 Years,50.1,41.8 to 58.5,221
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2016,Age,13-17 Years,35.8,28.2 to 44.1,201
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2022,Age,13-17 Years,61.3,50.5 to 71.1,133
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2021,Age,13-17 Years,63.0,51.3 to 73.4,122
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2018,Age,13-15 Years,44.6,33.0 to 56.9,98
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2018,Age,13-17 Years,51.5,42.0 to 60.8,177
HPV,"Up-to-Date, Females",States/Local Areas,New Jersey,2019,Age,13-17 Years,52.5,42.8 to 62.1,166
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2021,Age,13-17 Years,47.0,37.2 to 57.0,170
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2018,Age,13-17 Years,45.7,36.6 to 55.1,174
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2017,Age,13-17 Years,45.5,37.2 to 54.2,197
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2020,Age,13-17 Years,59.2,50.0 to 67.8,208
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2019,Age,13-17 Years,50.3,40.5 to 60.1,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2020,Age,13-15 Years,52.9,44.2 to 61.4,248
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2022,Age,13-15 Years,61.5,51.3 to 70.7,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2021,Age,13-15 Years,53.4,43.6 to 62.9,183
HPV,"Up-to-Date, Males",States/Local Areas,New Jersey,2022,Age,13-17 Years,66.0,55.8 to 74.8,156
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Jersey,2019,Age,13-15 Years,44.9,36.5 to 53.6,219
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2023,Age,13-15 Years,69.1,54.5 to 80.7,78
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2023,Age,13-17 Years,73.5,61.3 to 82.9,108
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2023,Age,13-15 Years,91.4,82.4 to 96.0,141
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2023,Age,13-15 Years,74.9,60.6 to 85.3,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2023,Age,13-15 Years,72.0,62.0 to 80.2,151
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2023,Age,13-15 Years,96.3,91.7 to 98.4,151
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2023,Age,13-15 Years,91.7,83.9 to 95.9,151
≥2 Doses Hep A,,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,88.9,82.8 to 93.0,228
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,95.9,90.2 to 98.4,211
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,92.4,86.0 to 96.0,211
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,92.9,87.0 to 96.3,228
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,92.7,87.1 to 96.0,228
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,91.1,84.4 to 95.1,228
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2023,Age,13-17 Years,74.7,66.6 to 81.4,228
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2023,Age,13-17 Years,77.9,65.5 to 86.7,108
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2023,Age,13-17 Years,75.9,64.4 to 84.5,120
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2023,Age,13-17 Years,82.2,74.7 to 87.9,228
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,95.7,91.4 to 97.9,228
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,94.6,90.5 to 97.0,228
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2023,Age,13-17 Years,91.4,85.6 to 95.0,228
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2023,Age,13-17 Years,86.3,76.6 to 92.4,120
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,74.6,67.1 to 80.8,222
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,81.4,71.7 to 88.3,110
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,67.3,55.9 to 76.9,112
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Overall,Overall,93.9,92.2 to 95.2,1418
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Overall,Overall,78.2,75.2 to 80.9,1418
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Overall,Overall,66.6,63.4 to 69.7,1418
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Urbanicity,Living In a MSA Principal City,78.2,75.2 to 80.9,1418
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Urbanicity,Living In a MSA Principal City,66.6,63.4 to 69.7,1418
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Urbanicity,Living In a MSA Principal City,93.9,92.2 to 95.2,1418
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",54.0,47.5 to 60.3,378
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,Hispanic,85.1,81.0 to 88.4,552
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Urbanicity,Living In a MSA Principal City,88.7,86.5 to 90.6,1418
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.2,86.9 to 97.5,256
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.9,78.8 to 90.9,256
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",64.3,56.7 to 71.3,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,Hispanic,74.5,69.7 to 78.8,552
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",71.5,63.6 to 78.3,256
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",93.2,88.8 to 96.0,232
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.7,91.3 to 96.9,378
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.0,82.8 to 91.8,378
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,Hispanic,93.6,91.0 to 95.5,552
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",88.7,83.5 to 92.5,232
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,Hispanic,88.3,84.6 to 91.2,552
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.6,85.3 to 94.2,256
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.7,66.3 to 80.0,232
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Race and Ethnicity,"White, Non-Hispanic",67.3,60.8 to 73.2,378
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Poverty,Below Poverty Level,81.3,75.4 to 86.1,377
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Poverty,Living At or Above Poverty Level,77.6,73.9 to 80.8,939
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Poverty,Below Poverty Level,92.9,89.5 to 95.2,377
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Poverty,Living At or Above Poverty Level,94.8,92.7 to 96.3,939
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Poverty,Below Poverty Level,68.3,61.9 to 74.0,377
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Poverty,Living At or Above Poverty Level,66.8,62.9 to 70.5,939
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Poverty,Living At or Above Poverty Level,89.7,86.9 to 92.0,939
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Poverty,Below Poverty Level,86.5,82.0 to 90.0,377
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Private Insurance Only,95.8,93.6 to 97.2,640
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Any Medicaid,92.3,89.0 to 94.7,580
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Private Insurance Only,76.9,72.3 to 80.9,640
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Any Medicaid,81.8,77.4 to 85.6,580
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Other,69.5,59.9 to 77.7,176
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Other,92.9,87.2 to 96.2,176
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Private Insurance Only,62.6,57.6 to 67.3,640
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Any Medicaid,72.4,67.6 to 76.8,580
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Other,59.2,49.7 to 68.2,176
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Private Insurance Only,90.3,86.9 to 92.9,640
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Any Medicaid,88.4,85.1 to 91.1,580
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Insurance Coverage,Other,85.4,77.4 to 90.9,176
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,92.1,87.5 to 95.2,247
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2010,Age,13-17 Years,62.7,54.3 to 70.4,182
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2011,Age,13-17 Years,56.8,48.8 to 64.4,209
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,96.0,92.2 to 98.0,247
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,83.7,76.8 to 88.8,232
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,85.8,79.5 to 90.4,246
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,81.9,75.6 to 86.8,269
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2012,Age,13-17 Years,53.6,44.7 to 62.2,158
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2013,Age,13-17 Years,64.2,54.8 to 72.7,154
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,58.0,47.6 to 67.8,144
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,65.3,56.2 to 73.4,142
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2020,Age,13-15 Years,89.6,83.0 to 93.8,218
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2021,Age,13-15 Years,92.6,85.0 to 96.5,168
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,84.4,78.9 to 88.6,313
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,77.2,70.6 to 82.7,312
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,78.7,73.6 to 83.0,435
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,87.4,81.8 to 91.4,288
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,84.5,78.7 to 89.0,300
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2015,Age,13-15 Years,86.3,78.3 to 91.7,158
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2014,Age,13-15 Years,84.4,75.7 to 90.4,139
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2018,Age,13-15 Years,95.0,90.0 to 97.6,140
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2019,Age,13-15 Years,91.7,84.6 to 95.7,142
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,70.2,62.3 to 77.1,269
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,77.3,71.5 to 82.2,388
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2017,Age,13-15 Years,91.6,85.1 to 95.5,165
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2016,Age,13-15 Years,86.6,77.4 to 92.4,152
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,90.3,85.3 to 93.7,381
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,92.1,86.1 to 95.6,297
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,94.0,88.4 to 97.0,222
HPV,"≥3 Doses, Males",States/Local Areas,NY-City of New York,2015,Age,13-15 Years,54.9,43.6 to 65.7,101
HPV,"≥3 Doses, Males",States/Local Areas,NY-City of New York,2014,Age,13-15 Years,31.3,19.0 to 46.8,73
≥2 Doses Hep A,,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,85.8,78.7 to 90.9,222
≥2 Doses Hep A,,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,90.1,85.0 to 93.6,297
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,90.1,83.9 to 94.1,257
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,93.8,89.4 to 96.4,261
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,87.7,82.2 to 91.7,291
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,92.9,88.7 to 95.7,281
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,75.1,68.3 to 80.8,293
HPV,"≥3 Doses, Males",States/Local Areas,NY-City of New York,2013,Age,13-15 Years,26.8,16.8 to 39.8,83
HPV,"≥3 Doses, Males",States/Local Areas,NY-City of New York,2013,Age,13-17 Years,29.6,21.4 to 39.3,146
HPV,"≥3 Doses, Males",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,47.9,39.4 to 56.5,171
HPV,"≥3 Doses, Males",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,35.0,25.8 to 45.5,144
≥2 Doses Hep A,,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,86.1,81.0 to 90.1,381
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2012,Age,13-17 Years,37.3,28.8 to 46.5,158
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2011,Age,13-17 Years,38.6,31.4 to 46.4,209
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,38.3,28.9 to 48.6,144
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2013,Age,13-17 Years,45.2,35.9 to 54.8,154
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2009,Age,13-17 Years,27.3,19.1 to 37.4,137
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2008,Age,13-17 Years,24.3,16.2 to 34.9,135
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2010,Age,13-17 Years,42.4,34.0 to 51.3,182
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,46.1,37.0 to 55.4,142
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,60.6,49.8 to 70.5,123
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,54.9,43.5 to 65.7,122
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2020,Age,13-15 Years,58.5,46.3 to 69.7,125
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2019,Age,13-15 Years,57.9,43.3 to 71.2,79
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,53.9,44.2 to 63.2,155
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,69.9,60.0 to 78.3,133
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,69.9,60.5 to 77.8,136
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2021,Age,13-15 Years,66.9,54.2 to 77.5,93
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2022,Age,13-15 Years,68.9,55.8 to 79.5,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2022,Age,13-15 Years,72.2,63.1 to 79.9,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2020,Age,13-15 Years,65.2,56.5 to 73.0,233
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2021,Age,13-15 Years,70.1,57.4 to 80.3,86
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2022,Age,13-15 Years,75.4,62.1 to 85.2,68
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,65.4,54.5 to 75.0,134
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2020,Age,13-17 Years,63.7,54.1 to 72.4,201
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,52.4,42.8 to 61.9,148
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,61.6,51.5 to 70.8,139
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2019,Age,13-15 Years,59.5,49.6 to 68.6,163
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,79.0,69.2 to 86.4,110
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2021,Age,13-15 Years,68.4,59.6 to 76.1,179
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2018,Age,13-15 Years,59.0,46.5 to 70.4,91
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2021,Age,13-17 Years,72.8,63.1 to 80.7,150
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,67.3,55.9 to 76.9,112
HPV,"Up-to-Date, Females",States/Local Areas,NY-City of New York,2020,Age,13-17 Years,72.5,63.2 to 80.2,180
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,72.2,65.1 to 78.4,269
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,82.0,76.9 to 86.2,388
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,87.0,82.8 to 90.2,435
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,66.4,55.4 to 75.9,134
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,88.9,83.3 to 92.8,269
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,89.7,84.0 to 93.5,293
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,86.4,81.2 to 90.3,312
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,88.7,82.9 to 92.7,288
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,88.9,83.6 to 92.7,300
HPV,"Up-to-Date, Males",States/Local Areas,NY-City of New York,2021,Age,13-17 Years,68.0,57.6 to 76.9,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,58.3,50.6 to 65.6,261
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,61.0,54.1 to 67.5,281
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2021,Age,13-17 Years,70.3,63.3 to 76.5,297
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,73.3,65.9 to 79.7,222
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2022,Age,13-15 Years,90.2,82.2 to 94.8,146
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,49.4,42.3 to 56.5,293
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,63.0,55.4 to 70.1,257
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2020,Age,13-17 Years,68.1,61.4 to 74.1,381
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,90.8,87.0 to 93.6,435
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,94.5,90.6 to 96.8,388
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,61.7,54.9 to 68.1,291
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,90.6,86.4 to 93.6,313
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2012,Age,13-17 Years,19.2,11.9 to 29.5,154
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2013,Age,13-17 Years,36.0,27.4 to 45.7,146
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,46.3,36.4 to 56.5,144
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2017,Age,13-15 Years,91.9,87.0 to 95.1,190
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2016,Age,13-15 Years,93.2,88.8 to 95.9,173
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2015,Age,13-15 Years,90.9,85.0 to 94.6,181
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2014,Age,13-15 Years,88.6,80.1 to 93.7,164
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2012,Age,13-15 Years,83.6,76.4 to 88.9,200
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2011,Age,13-15 Years,89.1,84.5 to 92.4,267
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2008,Age,13-15 Years,56.1,46.7 to 65.1,180
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2010,Age,13-15 Years,88.9,83.0 to 92.9,233
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2009,Age,13-15 Years,75.7,67.3 to 82.5,188
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,62.7,51.9 to 72.4,123
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,57.4,45.9 to 68.1,122
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2021,Age,13-15 Years,90.2,84.0 to 94.1,179
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2020,Age,13-17 Years,81.0,74.9 to 86.0,381
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2021,Age,13-17 Years,80.0,73.3 to 85.3,297
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,84.3,77.8 to 89.2,222
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,74.5,64.9 to 82.1,133
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,76.8,68.2 to 83.7,136
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,60.0,50.7 to 68.6,142
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,46.2,36.3 to 56.5,144
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,73.3,65.7 to 79.6,257
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,86.2,80.1 to 90.6,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,93.1,87.8 to 96.2,222
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,72.1,64.5 to 78.5,261
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,89.6,84.9 to 93.0,261
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2010,Age,13-15 Years,73.6,65.9 to 80.1,233
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2011,Age,13-15 Years,79.4,72.9 to 84.7,267
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2008,Age,13-15 Years,54.3,45.0 to 63.4,180
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2009,Age,13-15 Years,61.0,51.4 to 69.7,188
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,91.7,87.3 to 94.7,312
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,92.0,87.2 to 95.1,300
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,93.1,89.6 to 95.4,435
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,92.9,89.6 to 95.1,388
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,85.9,76.5 to 92.0,110
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,89.1,84.2 to 92.6,269
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,85.4,80.0 to 89.5,293
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2008,Age,13-17 Years,38.7,28.9 to 49.6,135
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2011,Age,13-17 Years,51.4,43.6 to 59.2,209
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2010,Age,13-17 Years,54.8,46.2 to 63.1,182
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2020,Age,13-15 Years,91.5,85.2 to 95.3,233
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2009,Age,13-17 Years,37.1,27.3 to 48.1,137
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2012,Age,13-17 Years,49.0,40.2 to 57.9,158
HPV,"≥2 Doses, Females",States/Local Areas,NY-City of New York,2013,Age,13-17 Years,56.1,46.6 to 65.2,154
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2019,Age,13-15 Years,96.4,92.8 to 98.2,163
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018,Age,13-15 Years,93.6,88.6 to 96.5,162
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2017,Age,13-15 Years,84.7,77.0 to 90.2,190
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,82.4,73.8 to 88.6,133
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,81.9,73.8 to 87.9,136
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,73.3,66.9 to 78.9,281
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,76.8,70.8 to 81.9,291
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2015,Age,13-15 Years,83.0,75.5 to 88.6,181
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2014,Age,13-15 Years,86.1,78.2 to 91.4,164
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2012,Age,13-15 Years,76.3,68.2 to 82.8,200
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2013,Age,13-15 Years,79.7,71.2 to 86.1,173
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2016,Age,13-15 Years,91.4,84.3 to 95.5,173
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,95.9,93.1 to 97.6,281
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,92.5,88.4 to 95.2,291
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,91.5,86.1 to 94.9,288
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,92.0,87.9 to 94.8,313
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,70.0,58.0 to 79.8,122
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,93.3,89.7 to 95.7,381
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,93.2,88.3 to 96.2,297
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,93.2,88.4 to 96.1,222
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,97.8,94.8 to 99.1,216
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,94.5,89.3 to 97.2,277
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2020,Age,13-17 Years,79.8,70.4 to 86.7,201
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2021,Age,13-17 Years,74.4,63.7 to 82.7,147
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,74.1,64.5 to 81.8,139
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2012,Age,13-17 Years,27.3,18.9 to 37.7,154
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,74.2,63.0 to 82.9,134
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,64.6,57.0 to 71.5,257
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,90.9,86.0 to 94.1,293
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2022,Age,13-15 Years,92.1,83.4 to 96.5,144
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,60.8,53.1 to 68.0,261
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,93.8,88.0 to 96.9,216
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2019,Age,13-17 Years,72.3,61.7 to 80.9,123
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2020,Age,13-17 Years,82.3,73.7 to 88.6,180
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2021,Age,13-17 Years,85.9,78.1 to 91.3,150
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2022,Age,13-17 Years,82.7,72.7 to 89.5,112
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2011,Age,13-17 Years,10.1,6.6 to 15.1,226
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,64.4,57.6 to 70.7,281
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,68.9,62.5 to 74.7,291
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,71.9,62.9 to 79.5,155
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,72.3,64.3 to 79.1,171
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,56.6,46.6 to 66.0,144
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2013,Age,13-17 Years,46.2,36.9 to 55.9,146
HPV,"≥1 Dose, Males",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,64.5,55.0 to 73.0,148
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,87.3,79.0 to 92.7,269
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,93.8,89.9 to 96.3,388
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2009,Age,13-17 Years,43.2,32.4 to 54.7,137
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,70.7,64.2 to 76.5,302
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,66.7,59.1 to 73.5,262
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,92.9,88.1 to 95.9,312
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,92.1,88.5 to 94.6,435
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,90.8,85.7 to 94.2,288
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,92.7,87.3 to 95.9,300
HPV,"≥1 Dose, Females",States/Local Areas,NY-City of New York,2008,Age,13-17 Years,48.3,38.0 to 58.7,135
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,85.7,75.1 to 92.3,144
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,70.2,62.2 to 77.1,235
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,80.6,73.5 to 86.1,238
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,97.1,93.9 to 98.7,302
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,39.1,29.5 to 49.7,131
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,50.1,39.7 to 60.4,144
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,87.4,76.3 to 93.7,131
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,95.0,90.7 to 97.4,262
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,94.8,89.6 to 97.4,235
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2009,Age,13-15 Years,42.7,31.0 to 55.2,101
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2008,Age,13-15 Years,56.7,45.2 to 67.6,114
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,92.5,88.1 to 95.4,281
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,91.4,85.6 to 95.0,257
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,94.5,91.1 to 96.6,261
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,89.0,82.2 to 93.4,228
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,89.6,84.3 to 93.2,350
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,91.4,85.0 to 95.2,277
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,92.9,88.0 to 95.9,222
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,95.7,92.4 to 97.6,350
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,94.5,88.1 to 97.6,228
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,98.5,96.3 to 99.4,222
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,86.7,80.7 to 91.0,291
≥3 Doses HepB,,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,91.8,87.5 to 94.7,313
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,96.8,94.0 to 98.3,246
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,94.9,90.9 to 97.2,269
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,96.2,92.7 to 98.1,232
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,98.0,95.0 to 99.2,238
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2012,Age,13-15 Years,71.5,61.3 to 79.9,159
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2013,Age,13-15 Years,80.5,71.2 to 87.3,144
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2010,Age,13-15 Years,67.8,58.4 to 76.0,182
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-City of New York,2011,Age,13-15 Years,74.9,67.4 to 81.2,204
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,88.8,82.9 to 92.8,257
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,94.9,91.4 to 97.1,261
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,92.7,88.8 to 95.3,281
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2015,Age,13-15 Years,39.4,28.0 to 52.2,80
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2014,Age,13-15 Years,29.4,19.7 to 41.4,91
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2012,Age,13-15 Years,29.8,20.5 to 41.3,98
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2013,Age,13-15 Years,37.5,26.1 to 50.6,90
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2008,Age,13-15 Years,25.8,15.7 to 39.5,93
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2010,Age,13-15 Years,34.1,23.6 to 46.4,106
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2009,Age,13-15 Years,19.3,11.7 to 30.1,98
HPV,"≥3 Doses, Females",States/Local Areas,NY-City of New York,2011,Age,13-15 Years,36.2,27.4 to 46.0,133
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,91.5,86.0 to 95.0,297
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,94.0,88.4 to 97.0,222
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,91.2,86.2 to 94.5,297
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,92.3,87.4 to 95.4,257
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,93.0,88.8 to 95.7,381
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,95.3,92.2 to 97.1,257
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,93.9,89.4 to 96.6,261
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,93.2,88.6 to 96.1,381
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,95.7,90.6 to 98.1,222
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2019,Age,13-15 Years,90.3,83.2 to 94.6,163
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2020,Age,13-15 Years,90.6,85.0 to 94.3,233
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2021,Age,13-15 Years,81.6,73.6 to 87.6,179
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018,Age,13-15 Years,86.7,79.8 to 91.5,162
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2013,Age,13-15 Years,87.2,79.6 to 92.3,173
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2018,Age,13-17 Years,64.1,54.0 to 73.1,139
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2017,Age,13-17 Years,54.6,45.0 to 63.9,148
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2016,Age,13-17 Years,61.3,51.8 to 70.1,155
HPV,"≥2 Doses, Males",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,60.1,51.4 to 68.3,171
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,75.3,69.0 to 80.6,312
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2022,Age,13-15 Years,95.3,89.9 to 97.8,146
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2009,Age,13-17 Years,61.0,53.0 to 68.4,269
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2008,Age,13-17 Years,53.5,46.4 to 60.5,293
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2011,Age,13-17 Years,79.1,74.0 to 83.3,435
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2010,Age,13-17 Years,75.5,69.7 to 80.5,388
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,92.9,89.0 to 95.5,281
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018,Age,13-17 Years,88.5,83.6 to 92.1,261
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,88.9,84.1 to 92.3,291
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-City of New York,2012,Age,13-17 Years,23.2,17.8 to 29.8,312
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-City of New York,2011,Age,13-17 Years,19.9,16.0 to 24.6,435
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,91.0,85.8 to 94.4,288
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,90.5,86.2 to 93.6,313
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2012,Age,13-17 Years,89.4,84.1 to 93.0,312
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,90.9,85.8 to 94.3,300
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,89.6,84.4 to 93.2,291
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2015,Age,13-17 Years,84.8,79.6 to 88.9,313
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2014,Age,13-17 Years,86.8,81.1 to 91.0,288
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2013,Age,13-17 Years,83.0,77.2 to 87.6,300
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2016,Age,13-17 Years,88.0,82.3 to 92.0,291
≥2 Doses MMR,,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,92.1,88.2 to 94.7,381
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-City of New York,2015,Age,13-17 Years,47.0,40.8 to 53.4,313
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-City of New York,2014,Age,13-17 Years,36.6,30.0 to 43.8,288
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2019,Age,13-17 Years,88.9,83.4 to 92.8,257
≥1 Dose MenACWY,,States/Local Areas,NY-City of New York,2017,Age,13-17 Years,88.8,83.6 to 92.6,281
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2020,Age,13-17 Years,91.6,87.2 to 94.6,381
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2021,Age,13-17 Years,82.6,76.3 to 87.4,297
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2022,Age,13-17 Years,91.7,86.1 to 95.2,222
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-City of New York,2018-2022,Overall,Overall,88.7,86.5 to 90.6,1418
≥3 Doses HepB,,States/Local Areas,Arkansas,2022,Age,13-17 Years,94.0,90.0 to 96.4,332
≥3 Doses HepB,,States/Local Areas,Arkansas,2021,Age,13-17 Years,94.1,90.0 to 96.6,314
≥3 Doses HepB,,States/Local Areas,Arkansas,2020,Age,13-17 Years,95.8,92.0 to 97.8,322
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2012,Age,13-17 Years,12.7,7.5 to 20.9,166
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arkansas,2019,Age,13-17 Years,52.4,45.8 to 59.0,329
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arkansas,2018,Age,13-17 Years,45.6,38.9 to 52.5,308
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arkansas,2017,Age,13-17 Years,38.3,32.3 to 44.5,357
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arkansas,2016,Age,13-17 Years,39.6,33.6 to 45.8,352
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2022,Age,13-17 Years,78.8,70.3 to 85.3,159
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2021,Age,13-17 Years,76.2,67.7 to 83.0,149
HPV,"≥1 Dose, Females",States/Local Areas,Arkansas,2020,Age,13-17 Years,72.8,62.8 to 81.0,162
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2018,Age,13-17 Years,56.0,46.4 to 65.1,153
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2014,Age,13-17 Years,35.1,26.8 to 44.4,185
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2013,Age,13-17 Years,17.7,11.4 to 26.4,155
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2015,Age,13-17 Years,44.2,36.3 to 52.4,200
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2016,Age,13-17 Years,55.4,47.3 to 63.3,203
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2017,Age,13-17 Years,55.7,47.2 to 64.0,206
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2019,Age,13-17 Years,64.9,56.0 to 72.9,179
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2017,Age,13-15 Years,91.0,84.8 to 94.8,191
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2016,Age,13-15 Years,89.0,83.5 to 92.8,210
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2011,Age,13-17 Years,54.9,46.9 to 62.7,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2010,Age,13-17 Years,55.0,48.5 to 61.4,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2013,Age,13-17 Years,78.9,73.1 to 83.7,312
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2012,Age,13-17 Years,69.8,63.1 to 75.8,322
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2021,Age,13-17 Years,70.4,61.6 to 78.0,165
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2020,Age,13-17 Years,69.1,59.8 to 77.1,160
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2011,Age,13-15 Years,30.0,21.8 to 39.6,214
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2010,Age,13-15 Years,32.0,24.7 to 40.3,196
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2012,Age,13-15 Years,37.9,29.9 to 46.6,205
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2008,Age,13-17 Years,46.1,40.4 to 52.0,382
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2009,Age,13-17 Years,52.7,46.7 to 58.6,363
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2015,Age,13-15 Years,83.0,76.6 to 88.0,217
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2014,Age,13-15 Years,65.4,57.2 to 72.8,215
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2015,Age,13-17 Years,91.9,87.9 to 94.6,362
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2014,Age,13-17 Years,85.4,80.1 to 89.5,368
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2017,Age,13-17 Years,93.0,89.3 to 95.5,357
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2016,Age,13-17 Years,91.6,87.8 to 94.3,352
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2013,Age,13-15 Years,40.2,31.9 to 49.0,185
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2008,Age,13-17 Years,11.5,7.2 to 17.9,185
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2013,Age,13-17 Years,35.4,27.1 to 44.7,157
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2012,Age,13-17 Years,32.4,23.2 to 43.1,156
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2018,Age,13-17 Years,92.0,87.6 to 95.0,308
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2011,Age,13-17 Years,29.7,19.0 to 43.1,152
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2010,Age,13-17 Years,24.1,17.0 to 33.0,135
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2009,Age,13-17 Years,25.6,18.5 to 34.2,176
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2020,Age,13-15 Years,94.0,87.5 to 97.2,191
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2014,Age,13-17 Years,37.8,29.6 to 46.8,183
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2009,Age,13-15 Years,21.2,15.6 to 28.2,228
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2008,Age,13-15 Years,20.3,14.9 to 27.1,240
HPV,"≥1 Dose, Males",States/Local Areas,Arkansas,2022,Age,13-17 Years,70.8,62.2 to 78.2,173
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2015,Age,13-15 Years,91.0,85.2 to 94.6,217
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2014,Age,13-15 Years,87.9,80.7 to 92.6,215
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2017,Age,13-15 Years,93.5,88.9 to 96.3,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2016,Age,13-15 Years,91.1,86.3 to 94.4,210
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2019,Age,13-17 Years,58.2,48.5 to 67.4,150
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2011,Age,13-15 Years,56.4,46.1 to 66.1,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2012,Age,13-15 Years,73.9,65.4 to 81.0,205
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2018,Age,13-17 Years,48.3,38.8 to 57.9,155
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2010,Age,13-15 Years,47.0,38.8 to 55.4,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2009,Age,13-15 Years,38.4,31.0 to 46.4,228
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2008,Age,13-15 Years,31.3,24.7 to 38.9,240
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2015,Age,13-17 Years,49.4,40.7 to 58.2,162
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2021,Age,13-15 Years,93.8,88.6 to 96.7,196
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2022,Age,13-15 Years,94.8,90.3 to 97.3,193
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2019,Age,13-15 Years,94.5,90.0 to 97.0,210
≥1 Dose MenACWY,,States/Local Areas,Arkansas,2018,Age,13-15 Years,91.5,84.9 to 95.4,181
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2018,Age,13-17 Years,60.8,54.1 to 67.1,308
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2017,Age,13-17 Years,61.1,54.7 to 67.0,357
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2016,Age,13-17 Years,54.4,48.1 to 60.5,352
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2017,Age,13-17 Years,47.0,37.7 to 56.5,151
HPV,"≥2 Doses, Females",States/Local Areas,Arkansas,2016,Age,13-17 Years,41.3,32.4 to 50.9,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2022,Age,13-17 Years,74.7,68.8 to 79.8,332
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2021,Age,13-17 Years,73.2,67.2 to 78.5,314
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2020,Age,13-17 Years,70.9,64.3 to 76.8,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2022,Age,13-17 Years,94.4,91.0 to 96.5,332
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2021,Age,13-17 Years,95.2,91.2 to 97.5,314
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arkansas,2019,Age,13-17 Years,67.9,61.5 to 73.6,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2020,Age,13-17 Years,95.3,91.6 to 97.4,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arkansas,2019,Age,13-17 Years,96.0,93.2 to 97.6,329
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2022,Age,13-15 Years,51.4,39.3 to 63.2,99
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2021,Age,13-15 Years,54.5,42.5 to 66.0,96
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2016,Age,13-17 Years,34.5,28.9 to 40.7,352
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2018,Age,13-17 Years,46.4,37.0 to 56.1,155
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2019,Age,13-17 Years,55.2,45.5 to 64.5,150
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2017,Age,13-17 Years,46.6,37.4 to 56.2,151
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2018,Age,13-15 Years,88.1,81.0 to 92.8,181
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2019,Age,13-17 Years,46.9,38.0 to 56.0,179
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2016,Age,13-17 Years,35.5,27.1 to 45.0,149
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2021,Age,13-17 Years,54.7,45.5 to 63.7,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2021,Age,13-15 Years,92.9,86.6 to 96.4,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2020,Age,13-15 Years,94.8,88.9 to 97.6,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2019,Age,13-15 Years,90.8,84.4 to 94.7,210
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2015,Age,13-17 Years,28.9,22.2 to 36.6,200
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2014,Age,13-17 Years,21.8,15.0 to 30.6,185
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2018,Age,13-17 Years,43.0,33.8 to 52.7,153
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2017,Age,13-17 Years,29.9,23.2 to 37.7,206
HPV,"≥2 Doses, Males",States/Local Areas,Arkansas,2016,Age,13-17 Years,37.9,30.3 to 46.1,203
Tetanus,≥1 Dose Tdap,States/Local Areas,Arkansas,2013,Age,13-15 Years,84.7,78.0 to 89.6,185
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2022,Age,13-17 Years,56.9,47.2 to 66.2,159
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2021,Age,13-17 Years,58.9,49.4 to 67.7,149
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2018,Age,13-15 Years,36.5,25.2 to 49.4,89
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2020,Age,13-15 Years,45.8,37.3 to 54.5,191
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2021,Age,13-15 Years,52.0,43.4 to 60.4,196
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2022,Age,13-17 Years,54.5,45.4 to 63.3,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2019,Age,13-15 Years,42.1,34.1 to 50.5,210
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arkansas,2022,Age,13-15 Years,51.4,42.8 to 60.0,193
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2020,Age,13-17 Years,45.9,36.5 to 55.6,160
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2019,Age,13-17 Years,46.1,37.2 to 55.2,179
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2018,Age,13-17 Years,39.0,30.0 to 48.8,153
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2017,Age,13-17 Years,24.3,18.3 to 31.6,206
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2020,Age,13-15 Years,45.3,33.7 to 57.6,95
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2020,Age,13-15 Years,46.2,34.3 to 58.7,96
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2020,Age,13-17 Years,53.5,43.5 to 63.2,162
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2019,Age,13-15 Years,37.0,26.7 to 48.6,114
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2022,Age,13-15 Years,51.6,39.4 to 63.5,94
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2021,Age,13-15 Years,49.0,37.0 to 61.1,100
HPV,"Up-to-Date, Males",States/Local Areas,Arkansas,2016,Age,13-17 Years,33.6,26.3 to 41.7,203
Varicella,History of disease,States/Local Areas,Arkansas,2016,Age,13-17 Years,12.9,9.4 to 17.4,352
Varicella,History of disease,States/Local Areas,Arkansas,2014,Age,13-17 Years,18.1,13.9 to 23.2,368
Varicella,History of disease,States/Local Areas,Arkansas,2015,Age,13-17 Years,19.2,14.7 to 24.6,362
Varicella,History of disease,States/Local Areas,Arkansas,2011,Age,13-17 Years,44.7,37.0 to 52.7,350
Varicella,History of disease,States/Local Areas,Arkansas,2010,Age,13-17 Years,45.1,38.7 to 51.7,313
Varicella,History of disease,States/Local Areas,Arkansas,2013,Age,13-17 Years,31.4,25.5 to 38.1,312
Varicella,History of disease,States/Local Areas,Arkansas,2012,Age,13-17 Years,31.0,24.6 to 38.1,322
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2018,Age,13-15 Years,36.4,25.5 to 48.8,92
HPV,"Up-to-Date, Females",States/Local Areas,Arkansas,2019,Age,13-15 Years,47.9,36.0 to 60.0,96
Varicella,History of disease,States/Local Areas,Arkansas,2022,Age,13-17 Years,5.4,3.1 to 9.3,332
Varicella,History of disease,States/Local Areas,Arkansas,2021,Age,13-17 Years,6.6,4.1 to 10.4,314
Varicella,History of disease,States/Local Areas,Arkansas,2020,Age,13-17 Years,6.4,3.9 to 10.2,322
Varicella,History of disease,States/Local Areas,Arkansas,2017,Age,13-17 Years,13.6,10.2 to 18.0,357
Varicella,History of disease,States/Local Areas,Arkansas,2008,Age,13-17 Years,64.6,58.9 to 69.9,382
Varicella,History of disease,States/Local Areas,Arkansas,2009,Age,13-17 Years,55.6,49.6 to 61.5,363
Varicella,History of disease,States/Local Areas,Arkansas,2019,Age,13-17 Years,11.4,7.9 to 16.2,329
Varicella,History of disease,States/Local Areas,Arkansas,2018,Age,13-17 Years,13.1,8.9 to 18.7,308
Varicella,History of disease,States/Local Areas,Texas,2008,Age,13-17 Years,67.2,60.3 to 73.4,840
Varicella,History of disease,States/Local Areas,Texas,2018,Age,13-17 Years,13.1,11.0 to 15.6,2079
Varicella,History of disease,States/Local Areas,Texas,2016,Age,13-17 Years,17.9,15.0 to 21.1,1927
Varicella,History of disease,States/Local Areas,Texas,2015,Age,13-17 Years,20.7,17.9 to 23.8,2617
Varicella,History of disease,States/Local Areas,Texas,2017,Age,13-17 Years,14.0,11.8 to 16.5,2256
Varicella,History of disease,States/Local Areas,Texas,2014,Age,13-17 Years,24.7,20.6 to 29.3,1652
Varicella,History of disease,States/Local Areas,Texas,2011,Age,13-17 Years,35.4,31.3 to 39.7,2224
Varicella,History of disease,States/Local Areas,Texas,2010,Age,13-17 Years,48.5,43.6 to 53.5,1709
Varicella,History of disease,States/Local Areas,Texas,2013,Age,13-17 Years,24.5,20.4 to 29.1,1112
Varicella,History of disease,States/Local Areas,Texas,2012,Age,13-17 Years,31.4,27.7 to 35.3,1594
Varicella,History of disease,States/Local Areas,Texas,2009,Age,13-17 Years,54.4,49.1 to 59.5,1470
Varicella,History of disease,States/Local Areas,Texas,2022,Age,13-17 Years,10.1,6.5 to 15.4,794
Varicella,History of disease,States/Local Areas,Texas,2021,Age,13-17 Years,7.0,4.6 to 10.5,990
Varicella,History of disease,States/Local Areas,Texas,2019,Age,13-17 Years,11.0,8.8 to 13.6,1850
Varicella,History of disease,States/Local Areas,Texas,2020,Age,13-17 Years,10.9,8.0 to 14.6,1141
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 9,2022,Age,13-17 Years,62.2,56.5 to 67.5,1090
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2022,Age,13-17 Years,61.4,53.0 to 69.2,495
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2022,Age,13-17 Years,62.9,55.2 to 69.9,595
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2023,Age,13-17 Years,63.8,55.4 to 71.4,574
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2023,Age,13-17 Years,71.3,62.2 to 79.0,598
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2023,Age,13-15 Years,90.0,83.7 to 94.0,672
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2023,Age,13-15 Years,63.6,52.6 to 73.4,347
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2023,Age,13-17 Years,79.1,71.9 to 84.8,574
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2023,Age,13-15 Years,55.9,47.6 to 63.8,714
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2023,Age,13-15 Years,48.6,37.3 to 60.1,367
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2023,Age,13-15 Years,83.1,76.3 to 88.2,714
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2023,Age,13-15 Years,87.6,81.7 to 91.8,714
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2023,Age,13-17 Years,88.7,84.1 to 92.1,1172
≥2 Doses Hep A,,HHS Regions/National,Region 9,2023,Age,13-17 Years,83.5,77.7 to 88.1,1172
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2023,Age,13-17 Years,87.9,83.0 to 91.5,1093
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2023,Age,13-17 Years,93.6,89.7 to 96.1,1093
≥3 Doses HepB,,HHS Regions/National,Region 9,2023,Age,13-17 Years,87.1,81.6 to 91.1,1172
Varicella,History of disease,HHS Regions/National,Region 9,2023,Age,13-17 Years,7.0,4.1 to 11.6,1172
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2023,Age,13-17 Years,52.8,43.6 to 61.7,598
≥2 Doses MMR,,HHS Regions/National,Region 9,2023,Age,13-17 Years,86.5,80.9 to 90.7,1172
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2023,Age,13-17 Years,58.1,51.7 to 64.2,1172
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2023,Age,13-17 Years,75.1,69.3 to 80.1,1172
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2023,Age,13-17 Years,85.6,80.9 to 89.3,1172
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2023,Age,13-17 Years,88.4,84.0 to 91.7,1172
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2023,Age,13-17 Years,86.7,82.2 to 90.3,1172
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2021,Age,13-17 Years,91.0,88.8 to 92.8,2263
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2020,Age,13-17 Years,89.8,87.6 to 91.6,2466
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2019,Age,13-17 Years,92.5,90.9 to 93.9,2387
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2014,Age,13-15 Years,32.6,28.0 to 37.5,887
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2015,Age,13-15 Years,32.6,28.3 to 37.3,844
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2013,Age,13-15 Years,28.7,24.2 to 33.7,723
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2012,Age,13-15 Years,26.2,21.8 to 31.2,750
≥2 Doses MMR,,HHS Regions/National,Region 4,2019,Age,13-17 Years,94.6,92.9 to 95.9,2387
≥2 Doses MMR,,HHS Regions/National,Region 4,2017,Age,13-17 Years,93.7,92.2 to 94.9,2846
≥2 Doses MMR,,HHS Regions/National,Region 4,2018,Age,13-17 Years,94.5,93.1 to 95.6,2507
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 4,2014,Age,13-17 Years,26.4,24.0 to 28.9,2896
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 4,2015,Age,13-17 Years,29.1,26.7 to 31.5,2793
≥2 Doses MMR,,HHS Regions/National,Region 4,2020,Age,13-17 Years,95.4,94.1 to 96.4,2466
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 4,2013,Age,13-17 Years,22.3,19.9 to 24.8,2374
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2006,Age,13-17 Years,6.2,4.4 to 8.6,608
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2022,Age,13-17 Years,92.3,90.8 to 93.6,2291
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2007,Age,13-17 Years,27.0,22.2 to 32.4,501
≥2 Doses MMR,,HHS Regions/National,Region 4,2013,Age,13-17 Years,92.2,90.4 to 93.6,2374
≥2 Doses MMR,,HHS Regions/National,Region 4,2012,Age,13-17 Years,94.4,93.1 to 95.5,2612
≥2 Doses MMR,,HHS Regions/National,Region 4,2015,Age,13-17 Years,92.9,91.3 to 94.2,2793
≥2 Doses MMR,,HHS Regions/National,Region 4,2014,Age,13-17 Years,92.9,91.5 to 94.2,2896
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 4,2011,Age,13-17 Years,15.4,13.5 to 17.4,3171
≥2 Doses MMR,,HHS Regions/National,Region 4,2016,Age,13-17 Years,93.3,91.9 to 94.4,2757
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2012,Age,13-17 Years,66.2,63.3 to 68.9,2612
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2017,Age,13-17 Years,90.9,89.3 to 92.2,2846
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2018,Age,13-17 Years,90.2,88.5 to 91.7,2507
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2016,Age,13-17 Years,77.7,75.4 to 79.9,2757
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2015,Age,13-17 Years,75.1,72.6 to 77.4,2793
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2014,Age,13-17 Years,71.8,69.2 to 74.3,2896
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2013,Age,13-17 Years,70.9,68.2 to 73.5,2374
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2009,Age,13-17 Years,46.7,44.2 to 49.2,2984
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2008,Age,13-17 Years,32.7,30.0 to 35.5,2788
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2011,Age,13-17 Years,61.2,58.7 to 63.7,3171
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2010,Age,13-17 Years,51.9,49.4 to 54.5,2679
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2016,Age,13-17 Years,88.9,87.1 to 90.5,2757
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2022,Age,13-15 Years,85.4,82.1 to 88.1,1406
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2022,Age,13-17 Years,62.8,58.5 to 66.8,1118
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2023,Age,13-17 Years,89.6,87.4 to 91.5,2257
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2023,Age,13-17 Years,90.9,88.7 to 92.6,2257
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2023,Age,13-17 Years,85.2,82.6 to 87.4,2257
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2023,Age,13-17 Years,72.3,69.1 to 75.3,2257
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2023,Age,13-17 Years,75.1,70.8 to 78.9,1035
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2023,Age,13-17 Years,56.2,52.8 to 59.5,2257
≥3 Doses HepB,,HHS Regions/National,Region 4,2023,Age,13-17 Years,93.6,91.7 to 95.1,2257
≥2 Doses MMR,,HHS Regions/National,Region 4,2023,Age,13-17 Years,93.8,91.9 to 95.2,2257
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2023,Age,13-17 Years,53.0,48.2 to 57.7,1222
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2023,Age,13-17 Years,96.3,94.8 to 97.4,2126
Varicella,History of disease,HHS Regions/National,Region 4,2023,Age,13-17 Years,7.0,5.3 to 9.2,2257
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2023,Age,13-17 Years,93.0,90.9 to 94.7,2126
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2023,Age,13-17 Years,93.5,91.6 to 95.0,2257
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2023,Age,13-15 Years,89.2,86.0 to 91.6,1392
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2023,Age,13-15 Years,51.4,45.4 to 57.5,736
≥2 Doses Hep A,,HHS Regions/National,Region 4,2023,Age,13-17 Years,87.5,85.1 to 89.6,2257
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2023,Age,13-15 Years,82.7,78.9 to 85.9,1392
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2023,Age,13-15 Years,53.2,48.8 to 57.5,1392
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2023,Age,13-15 Years,54.9,48.6 to 61.0,656
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2023,Age,13-15 Years,94.5,92.0 to 96.3,1314
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2023,Age,13-17 Years,59.5,54.7 to 64.1,1035
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2023,Age,13-17 Years,69.6,64.8 to 74.0,1222
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2021,Age,13-17 Years,84.9,82.3 to 87.2,2263
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2022,Age,13-17 Years,86.9,84.7 to 88.8,2291
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2020,Age,13-17 Years,85.7,83.5 to 87.7,2466
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2019,Age,13-17 Years,86.4,84.0 to 88.4,2387
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2018,Age,13-17 Years,82.5,80.3 to 84.5,2507
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2017,Age,13-17 Years,82.2,80.0 to 84.1,2846
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2008,Age,13-15 Years,15.6,12.2 to 19.8,821
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2009,Age,13-15 Years,20.9,17.5 to 24.7,872
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2010,Age,13-15 Years,24.7,21.0 to 28.9,808
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2011,Age,13-15 Years,28.4,24.3 to 32.9,903
≥2 Doses MMR,,HHS Regions/National,Region 4,2022,Age,13-17 Years,95.0,93.7 to 96.1,2291
≥2 Doses MMR,,HHS Regions/National,Region 4,2021,Age,13-17 Years,95.1,93.4 to 96.4,2263
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 4,2012,Age,13-17 Years,17.0,15.0 to 19.3,2612
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,United States,2023,Age,13-17 Years,90.5,89.5 to 91.4,16568
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2023,Age,13-17 Years,89.0,87.9 to 90.0,16568
≥1 Dose MenACWY,,HHS Regions/National,United States,2023,Age,13-17 Years,88.4,87.3 to 89.4,16568
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2023,Age,13-17 Years,76.8,75.4 to 78.1,16568
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2023,Age,13-17 Years,59.0,56.7 to 61.2,8711
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2023,Age,13-17 Years,61.4,59.9 to 63.0,16568
HPV,"≥1 Dose, Females",HHS Regions/National,United States,2023,Age,13-17 Years,78.5,76.7 to 80.2,7857
≥3 Doses HepB,,HHS Regions/National,United States,2023,Age,13-17 Years,90.9,89.8 to 91.9,16568
≥2 Doses MMR,,HHS Regions/National,United States,2023,Age,13-17 Years,91.3,90.2 to 92.3,16568
Varicella,History of disease,HHS Regions/National,United States,2023,Age,13-17 Years,7.3,6.4 to 8.2,16568
Varicella,≥1 Dose with no disease history,HHS Regions/National,United States,2023,Age,13-17 Years,94.6,93.8 to 95.4,15501
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2023,Age,13-17 Years,90.8,89.8 to 91.8,15501
Varicella,≥2 Doses or history of disease,HHS Regions/National,United States,2023,Age,13-17 Years,91.5,90.5 to 92.4,16568
≥2 Doses Hep A,,HHS Regions/National,United States,2023,Age,13-17 Years,86.9,85.7 to 88.0,16568
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2023,Age,13-15 Years,88.8,87.4 to 90.1,10014
≥1 Dose MenACWY,,HHS Regions/National,United States,2023,Age,13-15 Years,86.9,85.3 to 88.3,10014
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2023,Age,13-15 Years,57.3,55.3 to 59.4,10014
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2023,Age,13-15 Years,59.9,57.0 to 62.7,4742
Varicella,≥2 Doses with no disease history,HHS Regions/National,United States,2023,Age,13-15 Years,91.5,90.2 to 92.7,9394
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2023,Age,13-15 Years,54.9,51.9 to 57.8,5272
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2023,Age,13-17 Years,64.0,61.9 to 66.1,7857
HPV,"≥1 Dose, Males",HHS Regions/National,United States,2023,Age,13-17 Years,75.1,73.0 to 77.1,8711
HPV,"≥2 Doses, Females",HHS Regions/National,United States,2022,Age,13-17 Years,65.8,63.7 to 67.8,7623
HPV,"≥2 Doses, Males",HHS Regions/National,United States,2022,Age,13-17 Years,62.3,60.3 to 64.2,8420
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Overall,Overall,88.5,88.1 to 88.9,91696
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Overall,Overall,57.7,57.1 to 58.4,91696
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Overall,Overall,73.5,73.0 to 74.1,91696
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Non-Principal City,72.5,71.7 to 73.3,38031
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Principal City,76.5,75.5 to 77.4,36713
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Overall,Overall,89.7,89.3 to 90.1,91696
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Urbanicity,Living In a Non-MSA,66.9,65.6 to 68.2,16952
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Principal City,88.7,88.0 to 89.4,36713
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Principal City,89.6,88.9 to 90.2,36713
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Urbanicity,Living In a Non-MSA,49.9,48.5 to 51.3,16952
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Non-Principal City,56.9,56.0 to 57.8,38031
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Urbanicity,Living In a Non-MSA,84.5,83.5 to 85.4,16952
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Principal City,60.7,59.6 to 61.7,36713
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.2,88.5 to 89.8,38031
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Urbanicity,Living In a Non-MSA,89.0,88.1 to 89.8,16952
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.1,89.4 to 90.7,38031
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",59.8,57.9 to 61.6,7808
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",75.5,73.8 to 77.2,10891
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,Hispanic,60.9,59.3 to 62.6,16518
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.3,87.8 to 88.8,56479
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",60.9,59.0 to 62.8,10891
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.1,87.9 to 90.1,7808
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.8,90.3 to 91.2,56479
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Race and Ethnicity,Hispanic,88.0,86.8 to 89.1,16518
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.5,88.3 to 90.6,7808
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.0,87.8 to 90.2,10891
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Race and Ethnicity,Hispanic,88.2,87.0 to 89.4,16518
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.3,88.1 to 90.5,10891
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",76.6,75.0 to 78.1,7808
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.1,69.4 to 70.8,56479
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,Hispanic,77.9,76.5 to 79.2,16518
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Race and Ethnicity,"White, Non-Hispanic",54.8,54.1 to 55.6,56479
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Poverty,Below Poverty Level,88.2,87.1 to 89.3,12976
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Poverty,Living At or Above Poverty Level,72.3,71.7 to 73.0,75678
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Poverty,Living At or Above Poverty Level,88.6,88.1 to 89.0,75678
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Poverty,Below Poverty Level,61.6,59.9 to 63.2,12976
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Poverty,Below Poverty Level,88.8,87.7 to 89.9,12976
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Poverty,Living At or Above Poverty Level,56.9,56.2 to 57.6,75678
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Poverty,Living At or Above Poverty Level,90.0,89.5 to 90.4,75678
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Any Medicaid,77.3,76.3 to 78.3,27403
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Insurance Coverage,Other,86.6,84.9 to 88.2,7253
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Poverty,Below Poverty Level,79.2,77.9 to 80.6,12976
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Insurance Coverage,Any Medicaid,88.3,87.5 to 89.0,27403
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Other,69.5,67.4 to 71.5,7253
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Insurance Coverage,Uninsured,79.9,76.7 to 82.8,2929
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Uninsured,60.8,57.3 to 64.2,2929
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Private Insurance Only,57.7,56.9 to 58.6,54111
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Insurance Coverage,Private Insurance Only,90.8,90.3 to 91.3,54111
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Other,52.4,50.2 to 54.7,7253
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Any Medicaid,60.8,59.6 to 61.9,27403
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Uninsured,38.4,35.1 to 41.8,2929
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Insurance Coverage,Any Medicaid,89.0,88.1 to 89.7,27403
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Insurance Coverage,Other,89.0,87.4 to 90.4,7253
≥1 Dose MenACWY,,HHS Regions/National,United States,2018-2022,Insurance Coverage,Private Insurance Only,89.5,88.9 to 90.0,54111
Tetanus,≥1 Dose Tdap,HHS Regions/National,United States,2018-2022,Insurance Coverage,Uninsured,83.9,81.0 to 86.4,2929
HPV,"≥1 Dose, Males and Females",HHS Regions/National,United States,2018-2022,Insurance Coverage,Private Insurance Only,72.5,71.7 to 73.2,54111
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2023,Age,13-17 Years,88.2,79.8 to 93.4,161
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2023,Age,13-17 Years,72.9,60.9 to 82.3,140
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2023,Age,13-15 Years,69.8,54.4 to 81.8,97
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2023,Age,13-15 Years,90.3,82.9 to 94.7,178
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2023,Age,13-15 Years,69.1,53.2 to 81.4,91
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2023,Age,13-15 Years,69.4,58.5 to 78.5,188
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2023,Age,13-15 Years,88.6,81.1 to 93.4,188
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2023,Age,13-15 Years,84.9,75.6 to 91.1,188
≥2 Doses Hep A,,States/Local Areas,District of Columbia,2023,Age,13-17 Years,85.4,78.7 to 90.3,301
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2023,Age,13-17 Years,87.4,81.1 to 91.9,290
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2023,Age,13-17 Years,87.9,81.8 to 92.2,301
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2023,Age,13-17 Years,90.2,84.5 to 94.0,290
≥3 Doses HepB,,States/Local Areas,District of Columbia,2023,Age,13-17 Years,82.8,75.9 to 88.1,301
≥2 Doses MMR,,States/Local Areas,District of Columbia,2023,Age,13-17 Years,87.6,81.5 to 91.9,301
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2023,Age,13-17 Years,72.4,64.4 to 79.2,301
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2023,Age,13-17 Years,84.1,74.0 to 90.7,140
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2023,Age,13-17 Years,71.9,60.6 to 80.9,161
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2023,Age,13-17 Years,86.1,79.9 to 90.6,301
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2023,Age,13-17 Years,88.1,81.9 to 92.4,301
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2023,Age,13-17 Years,88.4,82.5 to 92.4,301
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2023,Age,13-17 Years,88.0,82.2 to 92.2,301
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2022,Age,13-17 Years,75.1,62.7 to 84.3,113
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Overall,Overall,87.1,84.6 to 89.2,1615
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2012,Age,13-17 Years,92.1,88.0 to 94.8,342
≥2 Doses MMR,,States/Local Areas,District of Columbia,2015,Age,13-17 Years,90.0,85.3 to 93.3,418
≥2 Doses MMR,,States/Local Areas,District of Columbia,2014,Age,13-17 Years,92.7,87.5 to 95.9,285
≥2 Doses MMR,,States/Local Areas,District of Columbia,2017,Age,13-17 Years,92.9,87.8 to 95.9,318
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2016,Age,13-17 Years,86.5,81.5 to 90.3,377
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2009,Age,13-17 Years,78.3,72.6 to 83.1,412
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2008,Age,13-17 Years,58.1,51.7 to 64.2,329
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2011,Age,13-17 Years,90.3,86.0 to 93.4,415
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2010,Age,13-17 Years,89.5,85.1 to 92.8,355
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018,Age,13-17 Years,86.1,79.5 to 90.8,283
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2017,Age,13-17 Years,86.1,80.2 to 90.4,318
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2019,Age,13-17 Years,86.0,78.9 to 90.9,282
HPV,"≥2 Doses, Males and Females",States/Local Areas,District of Columbia,2022,Age,13-17 Years,77.8,69.8 to 84.2,237
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2022,Age,13-17 Years,80.6,69.3 to 88.4,124
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2018,Age,13-17 Years,88.9,79.5 to 94.3,149
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2020,Age,13-17 Years,89.4,81.0 to 94.4,215
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2021,Age,13-17 Years,90.9,84.3 to 94.9,212
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2014,Age,13-17 Years,68.1,58.0 to 76.8,143
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2013,Age,13-17 Years,67.7,52.6 to 79.8,108
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2015,Age,13-17 Years,73.0,64.5 to 80.0,219
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2016,Age,13-17 Years,77.7,69.5 to 84.3,196
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2017,Age,13-17 Years,92.1,86.4 to 95.5,153
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2012,Age,13-17 Years,33.8,24.9 to 44.1,184
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2022,Age,13-17 Years,84.5,76.1 to 90.3,222
≥3 Doses HepB,,States/Local Areas,District of Columbia,2020,Age,13-17 Years,86.1,80.5 to 90.3,404
≥3 Doses HepB,,States/Local Areas,District of Columbia,2021,Age,13-17 Years,85.6,80.2 to 89.7,409
≥3 Doses HepB,,States/Local Areas,District of Columbia,2022,Age,13-17 Years,73.0,64.3 to 80.3,237
HPV,"≥2 Doses, Males and Females",States/Local Areas,District of Columbia,2017,Age,13-17 Years,80.6,74.0 to 85.9,318
HPV,"≥2 Doses, Males and Females",States/Local Areas,District of Columbia,2016,Age,13-17 Years,68.8,62.3 to 74.6,377
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2020,Age,13-17 Years,85.4,76.6 to 91.3,189
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2021,Age,13-17 Years,88.4,81.5 to 93.0,197
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2022,Age,13-17 Years,88.0,79.3 to 93.3,113
HPV,"≥2 Doses, Males and Females",States/Local Areas,District of Columbia,2018,Age,13-17 Years,73.9,66.4 to 80.2,283
HPV,"≥2 Doses, Males and Females",States/Local Areas,District of Columbia,2019,Age,13-17 Years,79.6,71.9 to 85.6,282
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2019,Age,13-17 Years,84.0,72.0 to 91.4,121
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2018,Age,13-17 Years,83.1,73.1 to 89.9,134
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2011,Age,13-17 Years,92.2,87.2 to 95.3,321
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2010,Age,13-17 Years,84.9,78.8 to 89.5,257
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2008,Age,13-17 Years,96.4,92.1 to 98.4,177
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2009,Age,13-17 Years,72.0,64.2 to 78.7,270
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2008,Age,13-17 Years,43.5,35.2 to 52.2,177
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2011,Age,13-17 Years,96.2,91.2 to 98.4,321
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2012,Age,13-17 Years,97.6,92.2 to 99.3,282
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2017,Age,13-17 Years,91.8,84.3 to 95.9,165
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2021,Age,13-17 Years,93.4,89.3 to 96.0,387
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2022,Age,13-17 Years,75.0,65.9 to 82.3,222
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2016,Age,13-17 Years,80.7,72.2 to 87.0,181
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2008,Age,13-17 Years,38.7,30.0 to 48.3,161
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2013,Age,13-17 Years,82.1,69.6 to 90.1,157
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2012,Age,13-17 Years,92.3,85.7 to 96.0,282
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2009,Age,13-17 Years,96.6,91.6 to 98.7,270
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2010,Age,13-17 Years,97.5,94.8 to 98.8,257
≥3 Doses HepB,,States/Local Areas,District of Columbia,2012,Age,13-17 Years,92.7,86.8 to 96.1,342
≥3 Doses HepB,,States/Local Areas,District of Columbia,2014,Age,13-17 Years,90.6,85.1 to 94.2,285
≥3 Doses HepB,,States/Local Areas,District of Columbia,2013,Age,13-17 Years,83.9,73.2 to 90.9,192
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2009,Age,13-17 Years,60.0,51.4 to 68.0,198
≥3 Doses HepB,,States/Local Areas,District of Columbia,2011,Age,13-17 Years,97.1,93.4 to 98.8,415
≥3 Doses HepB,,States/Local Areas,District of Columbia,2008,Age,13-17 Years,94.8,90.7 to 97.2,329
≥3 Doses HepB,,States/Local Areas,District of Columbia,2009,Age,13-17 Years,97.9,94.1 to 99.3,412
≥3 Doses HepB,,States/Local Areas,District of Columbia,2010,Age,13-17 Years,98.5,96.6 to 99.3,355
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2022,Age,13-15 Years,78.3,67.0 to 86.5,143
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2019,Age,13-17 Years,90.9,83.9 to 95.0,265
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2020,Age,13-17 Years,86.4,80.8 to 90.6,372
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2021,Age,13-17 Years,85.8,80.0 to 90.1,387
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2019,Age,13-17 Years,86.7,79.0 to 91.8,265
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2018,Age,13-17 Years,78.8,70.6 to 85.3,259
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2020,Age,13-17 Years,93.5,89.3 to 96.1,372
≥3 Doses HepB,,States/Local Areas,District of Columbia,2018,Age,13-17 Years,74.7,66.8 to 81.2,283
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2018,Age,13-17 Years,76.0,67.8 to 82.7,259
≥3 Doses HepB,,States/Local Areas,District of Columbia,2019,Age,13-17 Years,87.0,79.7 to 92.0,282
≥3 Doses HepB,,States/Local Areas,District of Columbia,2017,Age,13-17 Years,87.4,81.2 to 91.7,318
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2014,Age,13-17 Years,92.2,86.5 to 95.6,260
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2013,Age,13-17 Years,88.6,76.3 to 94.9,157
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2015,Age,13-17 Years,93.4,89.0 to 96.2,388
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2016,Age,13-17 Years,98.7,97.2 to 99.4,339
≥3 Doses HepB,,States/Local Areas,District of Columbia,2015,Age,13-17 Years,89.3,84.5 to 92.8,418
≥3 Doses HepB,,States/Local Areas,District of Columbia,2016,Age,13-17 Years,94.3,90.5 to 96.6,377
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2015,Age,13-17 Years,76.5,67.9 to 83.3,199
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2014,Age,13-17 Years,75.2,64.7 to 83.4,142
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2013,Age,13-17 Years,55.6,41.0 to 69.3,84
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2012,Age,13-17 Years,57.8,47.5 to 67.5,158
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2019,Age,13-15 Years,88.9,80.5 to 94.0,163
HPV,"≥3 Doses, Males",States/Local Areas,District of Columbia,2015,Age,13-15 Years,32.6,22.9 to 44.2,135
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2022,Age,13-17 Years,85.1,74.4 to 91.8,124
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2009,Age,13-15 Years,80.8,74.1 to 86.1,260
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2008,Age,13-15 Years,59.5,51.0 to 67.4,191
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2011,Age,13-15 Years,90.3,84.6 to 94.0,239
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2010,Age,13-15 Years,90.8,84.8 to 94.6,231
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2012,Age,13-15 Years,92.2,87.3 to 95.3,216
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2020,Age,13-17 Years,87.4,81.7 to 91.6,404
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2021,Age,13-17 Years,89.6,85.1 to 92.9,409
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2022,Age,13-17 Years,86.5,80.0 to 91.2,237
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2009,Age,13-17 Years,89.3,85.4 to 92.2,412
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2008,Age,13-17 Years,84.7,79.9 to 88.6,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2015,Age,13-17 Years,87.4,82.7 to 91.0,418
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2014,Age,13-17 Years,86.4,80.2 to 90.9,285
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2017,Age,13-17 Years,90.2,84.8 to 93.8,318
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2016,Age,13-17 Years,90.2,85.8 to 93.3,377
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2008,Age,13-17 Years,21.0,14.4 to 29.6,161
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2013,Age,13-15 Years,92.0,79.1 to 97.2,129
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2015,Age,13-15 Years,91.0,85.7 to 94.4,255
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2014,Age,13-15 Years,92.3,86.9 to 95.6,179
HPV,"≥1 Dose, Males",States/Local Areas,District of Columbia,2019,Age,13-17 Years,89.6,81.1 to 94.6,161
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2014,Age,13-17 Years,67.8,56.8 to 77.1,142
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2020,Age,13-15 Years,92.2,86.1 to 95.8,245
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2009,Age,13-17 Years,37.8,30.1 to 46.1,198
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2011,Age,13-17 Years,45.2,36.4 to 54.3,210
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2010,Age,13-17 Years,44.4,35.9 to 53.2,176
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2018,Age,13-17 Years,89.1,83.0 to 93.2,283
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2017,Age,13-17 Years,91.9,87.6 to 94.8,318
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2016,Age,13-17 Years,79.2,73.5 to 84.0,377
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2017,Age,13-15 Years,88.9,80.9 to 93.8,215
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2016,Age,13-15 Years,85.1,77.4 to 90.5,242
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018,Age,13-15 Years,92.1,84.2 to 96.3,181
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018,Age,13-17 Years,86.0,79.5 to 90.6,283
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2011,Age,13-17 Years,92.5,88.1 to 95.3,415
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2010,Age,13-17 Years,89.7,85.5 to 92.8,355
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2013,Age,13-17 Years,87.2,77.9 to 93.0,192
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2012,Age,13-17 Years,90.4,85.0 to 94.0,342
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2013,Age,13-17 Years,43.0,29.5 to 57.6,84
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2012,Age,13-17 Years,52.8,42.7 to 62.7,158
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2019,Age,13-15 Years,84.1,73.9 to 90.9,171
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2020,Age,13-17 Years,87.3,81.5 to 91.4,404
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2019,Age,13-17 Years,88.1,81.0 to 92.7,282
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2021,Age,13-17 Years,90.0,85.4 to 93.3,409
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,District of Columbia,2022,Age,13-17 Years,91.3,85.9 to 94.8,237
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2019,Age,13-17 Years,86.8,79.8 to 91.6,282
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2022,Age,13-15 Years,92.1,85.5 to 95.9,152
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2021,Age,13-15 Years,91.1,85.0 to 94.9,261
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2018,Age,13-17 Years,75.7,65.3 to 83.8,134
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2009,Age,13-15 Years,50.9,43.3 to 58.3,260
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2010,Age,13-15 Years,73.0,65.7 to 79.2,231
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2008,Age,13-15 Years,34.6,27.2 to 42.9,191
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2011,Age,13-15 Years,84.1,77.2 to 89.2,239
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2012,Age,13-15 Years,86.0,77.8 to 91.6,216
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2013,Age,13-15 Years,84.3,72.4 to 91.7,129
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2019,Age,13-17 Years,75.4,62.8 to 84.8,121
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2015,Age,13-17 Years,57.6,48.5 to 66.1,219
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2013,Age,13-17 Years,40.2,26.9 to 55.1,108
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2014,Age,13-17 Years,54.3,43.3 to 64.8,143
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2012,Age,13-17 Years,12.3,7.4 to 19.8,184
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2015,Age,13-17 Years,67.5,58.2 to 75.5,199
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2017,Age,13-17 Years,79.6,69.6 to 86.9,165
HPV,"≥2 Doses, Females",States/Local Areas,District of Columbia,2016,Age,13-17 Years,74.8,65.6 to 82.1,181
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Other,95.6,84.5 to 98.9,44
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Any Medicaid,86.5,82.4 to 89.7,549
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Private Insurance Only,87.7,84.6 to 90.3,1006
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Other,78.1,59.2 to 89.7,44
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Any Medicaid,75.7,70.7 to 80.1,549
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Private Insurance Only,75.8,71.6 to 79.6,1006
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Other,90.2,76.3 to 96.4,44
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Any Medicaid,90.1,86.5 to 92.8,549
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Private Insurance Only,84.6,80.9 to 87.8,1006
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Other,95.5,80.1 to 99.1,44
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Any Medicaid,92.4,89.2 to 94.7,549
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Insurance Coverage,Private Insurance Only,91.0,87.9 to 93.3,1006
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Poverty,Living At or Above Poverty Level,86.4,83.5 to 88.8,1290
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Poverty,Below Poverty Level,89.4,83.4 to 93.4,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Poverty,Living At or Above Poverty Level,75.5,71.8 to 78.8,1290
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Poverty,Below Poverty Level,74.1,66.2 to 80.7,268
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Poverty,Below Poverty Level,95.9,91.5 to 98.0,268
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Poverty,Living At or Above Poverty Level,90.8,88.3 to 92.8,1290
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Poverty,Living At or Above Poverty Level,86.1,83.2 to 88.6,1290
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Poverty,Below Poverty Level,90.3,83.9 to 94.3,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,Hispanic,93.6,89.1 to 96.3,325
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.8,81.9 to 89.0,623
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.3,82.5 to 89.4,534
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.7,70.7 to 89.2,133
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,Hispanic,88.2,82.4 to 92.3,325
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.4,83.6 to 90.3,534
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,Hispanic,95.5,91.2 to 97.8,325
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.3,85.6 to 92.1,623
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",86.4,82.7 to 89.4,623
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.5,88.3 to 94.0,534
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",72.8,61.3 to 82.0,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,Hispanic,80.2,73.2 to 85.7,325
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.0,68.3 to 77.3,534
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",84.7,74.4 to 91.3,133
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",86.4,76.2 to 92.7,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",79.5,75.1 to 83.4,623
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018-2022,Urbanicity,Living In a MSA Principal City,87.1,84.6 to 89.2,1615
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Urbanicity,Living In a MSA Principal City,75.4,72.2 to 78.3,1615
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Urbanicity,Living In a MSA Principal City,91.5,89.4 to 93.3,1615
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Urbanicity,Living In a MSA Principal City,87.3,84.8 to 89.4,1615
HPV,"≥1 Dose, Males and Females",States/Local Areas,District of Columbia,2018-2022,Overall,Overall,87.3,84.8 to 89.4,1615
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018-2022,Overall,Overall,75.4,72.2 to 78.3,1615
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2015,Age,13-15 Years,84.9,78.6 to 89.6,255
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2014,Age,13-15 Years,80.9,72.0 to 87.4,179
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2017,Age,13-15 Years,83.1,74.8 to 89.1,215
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2016,Age,13-15 Years,83.9,77.2 to 89.0,242
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2017,Age,13-17 Years,81.6,72.1 to 88.4,153
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2016,Age,13-17 Years,62.8,53.4 to 71.3,196
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2018,Age,13-17 Years,72.1,60.9 to 81.1,149
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2018,Age,13-15 Years,89.1,80.3 to 94.2,181
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2021,Age,13-15 Years,88.6,82.3 to 92.8,261
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2020,Age,13-15 Years,87.6,80.4 to 92.5,245
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2019,Age,13-15 Years,83.2,73.3 to 90.0,171
≥1 Dose MenACWY,,States/Local Areas,District of Columbia,2018-2022,Overall,Overall,91.5,89.4 to 93.3,1615
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2021,Age,13-17 Years,77.7,68.3 to 84.9,212
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2022,Age,13-15 Years,77.2,67.0 to 85.0,152
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2018,Age,13-17 Years,69.2,57.7 to 78.6,149
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2020,Age,13-17 Years,71.2,60.4 to 79.9,215
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2019,Age,13-17 Years,78.0,67.1 to 86.1,161
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2021,Age,13-15 Years,79.3,71.7 to 85.3,261
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2022,Age,13-17 Years,80.6,69.3 to 88.4,124
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2019,Age,13-15 Years,74.2,63.8 to 82.5,171
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2020,Age,13-15 Years,69.3,60.1 to 77.2,245
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2020,Age,13-15 Years,74.1,61.8 to 83.5,116
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2019,Age,13-15 Years,70.5,54.0 to 83.0,73
Varicella,History of disease,States/Local Areas,District of Columbia,2020,Age,13-17 Years,4.7,2.6 to 8.2,404
Varicella,History of disease,States/Local Areas,District of Columbia,2021,Age,13-17 Years,7.7,4.6 to 12.7,409
Varicella,History of disease,States/Local Areas,District of Columbia,2016,Age,13-17 Years,10.2,6.9 to 14.9,377
Varicella,History of disease,States/Local Areas,District of Columbia,2017,Age,13-17 Years,10.3,6.5 to 16.0,318
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2018,Age,13-15 Years,75.2,61.3 to 85.4,83
Varicella,History of disease,States/Local Areas,District of Columbia,2008,Age,13-17 Years,45.4,39.1 to 51.8,329
Varicella,History of disease,States/Local Areas,District of Columbia,2009,Age,13-17 Years,37.2,31.4 to 43.3,412
Varicella,History of disease,States/Local Areas,District of Columbia,2018,Age,13-17 Years,6.9,4.2 to 11.2,283
Varicella,History of disease,States/Local Areas,District of Columbia,2014,Age,13-17 Years,9.1,5.3 to 15.0,285
Varicella,History of disease,States/Local Areas,District of Columbia,2015,Age,13-17 Years,9.8,6.4 to 14.8,418
Varicella,History of disease,States/Local Areas,District of Columbia,2011,Age,13-17 Years,23.8,18.6 to 29.9,415
Varicella,History of disease,States/Local Areas,District of Columbia,2010,Age,13-17 Years,30.5,25.0 to 36.5,355
Varicella,History of disease,States/Local Areas,District of Columbia,2013,Age,13-17 Years,23.1,15.2 to 33.6,192
Varicella,History of disease,States/Local Areas,District of Columbia,2012,Age,13-17 Years,16.4,11.8 to 22.2,342
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2009,Age,13-15 Years,76.1,67.3 to 83.2,196
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2011,Age,13-15 Years,95.0,90.1 to 97.6,203
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2010,Age,13-15 Years,86.5,78.6 to 91.8,180
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2013,Age,13-15 Years,83.5,67.4 to 92.6,110
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2012,Age,13-15 Years,94.0,85.9 to 97.6,183
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2014,Age,13-17 Years,91.1,85.5 to 94.7,260
Varicella,≥1 Dose with no disease history,States/Local Areas,District of Columbia,2017,Age,13-17 Years,94.8,89.8 to 97.5,288
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2015,Age,13-17 Years,88.2,83.0 to 91.9,388
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2016,Age,13-17 Years,95.4,92.6 to 97.2,339
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2010,Age,13-17 Years,57.5,48.6 to 66.0,176
HPV,"≥1 Dose, Females",States/Local Areas,District of Columbia,2011,Age,13-17 Years,55.0,45.5 to 64.1,210
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2017,Age,13-17 Years,91.4,85.3 to 95.1,288
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2020,Age,13-15 Years,88.6,82.1 to 93.0,226
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2021,Age,13-15 Years,86.5,79.0 to 91.6,248
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2017,Age,13-15 Years,87.2,77.9 to 92.9,195
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2018,Age,13-15 Years,79.4,69.1 to 86.9,165
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2016,Age,13-15 Years,94.4,90.5 to 96.7,220
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2015,Age,13-15 Years,89.1,83.1 to 93.2,240
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2014,Age,13-15 Years,92.1,85.2 to 96.0,166
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2014,Age,13-17 Years,91.9,86.7 to 95.2,285
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2013,Age,13-17 Years,86.2,75.9 to 92.5,192
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2011,Age,13-17 Years,94.0,90.2 to 96.4,415
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2012,Age,13-17 Years,93.6,87.9 to 96.7,342
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2009,Age,13-17 Years,82.4,76.8 to 86.9,412
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2010,Age,13-17 Years,89.5,85.0 to 92.8,355
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2019,Age,13-17 Years,87.3,80.0 to 92.2,282
HPV,"≥3 Doses, Males",States/Local Areas,District of Columbia,2014,Age,13-15 Years,37.6,23.9 to 53.6,86
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2015,Age,13-17 Years,58.8,49.4 to 67.6,199
HPV,"≥3 Doses, Males",States/Local Areas,District of Columbia,2015,Age,13-17 Years,40.9,32.6 to 49.8,219
HPV,"≥3 Doses, Males",States/Local Areas,District of Columbia,2014,Age,13-17 Years,34.5,24.4 to 46.1,143
HPV,"≥3 Doses, Males",States/Local Areas,District of Columbia,2013,Age,13-17 Years,24.5,13.8 to 39.6,108
HPV,"≥3 Doses, Males",States/Local Areas,District of Columbia,2012,Age,13-17 Years,4.8,2.8 to 8.1,184
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2020,Age,13-17 Years,87.0,81.7 to 91.0,404
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2021,Age,13-17 Years,86.9,81.5 to 90.8,409
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2022,Age,13-17 Years,76.8,68.1 to 83.6,237
Varicella,≥2 Doses with no disease history,States/Local Areas,District of Columbia,2008,Age,13-15 Years,48.6,38.4 to 58.9,124
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2015,Age,13-17 Years,89.3,84.6 to 92.7,418
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2017,Age,13-17 Years,92.3,86.8 to 95.6,318
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2018,Age,13-17 Years,77.7,69.9 to 83.9,283
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2016,Age,13-17 Years,95.9,93.4 to 97.5,377
Varicella,≥2 Doses or history of disease,States/Local Areas,District of Columbia,2008,Age,13-17 Years,69.2,63.0 to 74.7,329
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2010,Age,13-17 Years,33.8,26.2 to 42.5,176
≥2 Doses Hep A,,States/Local Areas,District of Columbia,2021,Age,13-17 Years,84.2,78.5 to 88.6,409
≥2 Doses Hep A,,States/Local Areas,District of Columbia,2022,Age,13-17 Years,75.3,66.6 to 82.3,237
≥2 Doses Hep A,,States/Local Areas,District of Columbia,2020,Age,13-17 Years,84.6,78.6 to 89.1,404
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2014,Age,13-17 Years,81.4,74.8 to 86.6,285
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2013,Age,13-17 Years,83.1,73.2 to 89.8,192
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2017,Age,13-17 Years,78.0,71.1 to 83.6,318
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2018,Age,13-17 Years,71.3,63.6 to 78.0,283
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2019,Age,13-17 Years,75.5,67.4 to 82.2,282
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2015,Age,13-17 Years,81.3,75.8 to 85.8,418
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2016,Age,13-17 Years,62.0,55.3 to 68.2,377
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2009,Age,13-17 Years,46.2,40.2 to 52.2,412
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2010,Age,13-17 Years,71.6,65.7 to 76.8,355
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2011,Age,13-17 Years,82.0,76.5 to 86.5,415
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2022,Age,13-15 Years,89.9,82.8 to 94.3,152
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2008,Age,13-17 Years,32.7,27.1 to 38.9,329
Tetanus,≥1 Dose Tdap,States/Local Areas,District of Columbia,2012,Age,13-17 Years,84.5,78.6 to 89.0,342
≥2 Doses MMR,,States/Local Areas,District of Columbia,2011,Age,13-17 Years,96.9,93.0 to 98.7,415
≥2 Doses MMR,,States/Local Areas,District of Columbia,2010,Age,13-17 Years,98.4,96.6 to 99.3,355
≥2 Doses MMR,,States/Local Areas,District of Columbia,2009,Age,13-17 Years,99.4,98.2 to 99.8,412
≥2 Doses MMR,,States/Local Areas,District of Columbia,2008,Age,13-17 Years,94.6,89.9 to 97.2,329
HPV,"≥2 Doses, Males",States/Local Areas,District of Columbia,2019,Age,13-17 Years,83.8,74.2 to 90.3,161
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2014,Age,13-17 Years,56.9,45.9 to 67.3,142
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2013,Age,13-17 Years,30.2,19.5 to 43.7,84
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2012,Age,13-17 Years,38.5,29.4 to 48.5,158
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2009,Age,13-17 Years,22.8,16.9 to 30.2,198
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2008,Age,13-17 Years,12.4,7.7 to 19.3,161
HPV,"≥3 Doses, Females",States/Local Areas,District of Columbia,2011,Age,13-17 Years,36.0,28.0 to 44.9,210
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2020,Age,13-17 Years,72.3,65.1 to 78.5,404
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2021,Age,13-17 Years,79.4,73.5 to 84.4,409
HPV,"Up-to-Date, Males and Females",States/Local Areas,District of Columbia,2022,Age,13-17 Years,77.8,69.8 to 84.2,237
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2019,Age,13-15 Years,50.0,36.0 to 63.9,94
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2020,Age,13-17 Years,73.2,63.0 to 81.4,146
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2018,Age,13-15 Years,54.3,40.8 to 67.3,94
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2021,Age,13-17 Years,69.5,58.0 to 78.9,135
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2022,Age,13-17 Years,65.6,55.8 to 74.1,152
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2017,Age,13-17 Years,48.6,39.7 to 57.5,174
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2021,Age,13-15 Years,55.1,42.7 to 66.8,99
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2022,Age,13-15 Years,63.6,51.1 to 74.5,95
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2016,Age,13-17 Years,46.4,37.7 to 55.3,174
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2018,Age,13-17 Years,62.2,51.0 to 72.2,131
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2019,Age,13-17 Years,64.0,52.4 to 74.1,129
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2016,Age,13-17 Years,42.0,33.9 to 50.6,201
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2020,Age,13-15 Years,63.0,51.3 to 73.4,116
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2021,Age,13-15 Years,68.9,54.1 to 80.7,83
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2022,Age,13-15 Years,56.7,44.5 to 68.2,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2022,Age,13-15 Years,59.9,51.1 to 68.1,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2020,Age,13-15 Years,67.9,59.5 to 75.2,213
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2018,Age,13-17 Years,55.6,45.2 to 65.5,154
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2017,Age,13-17 Years,45.4,36.7 to 54.4,182
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2019,Age,13-17 Years,50.0,39.1 to 60.9,147
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2020,Age,13-17 Years,65.3,56.3 to 73.4,184
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2021,Age,13-17 Years,62.0,52.4 to 70.8,161
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2019,Age,13-15 Years,59.6,48.8 to 69.5,165
HPV,"Up-to-Date, Males",States/Local Areas,Minnesota,2022,Age,13-17 Years,71.5,62.7 to 79.0,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,Minnesota,2021,Age,13-15 Years,61.9,52.4 to 70.5,182
Varicella,History of disease,States/Local Areas,Minnesota,2017,Age,13-17 Years,15.5,11.3 to 20.9,356
Varicella,History of disease,States/Local Areas,Minnesota,2009,Age,13-17 Years,56.8,50.8 to 62.7,336
Varicella,History of disease,States/Local Areas,Minnesota,2018,Age,13-17 Years,13.7,9.0 to 20.4,285
Varicella,History of disease,States/Local Areas,Minnesota,2012,Age,13-17 Years,40.2,33.2 to 47.6,322
Varicella,History of disease,States/Local Areas,Minnesota,2013,Age,13-17 Years,29.4,24.0 to 35.4,369
Varicella,History of disease,States/Local Areas,Minnesota,2011,Age,13-17 Years,39.0,32.2 to 46.1,327
Varicella,History of disease,States/Local Areas,Minnesota,2010,Age,13-17 Years,46.0,39.8 to 52.3,310
Varicella,History of disease,States/Local Areas,Minnesota,2015,Age,13-17 Years,18.2,13.8 to 23.6,366
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2019,Age,13-15 Years,71.3,55.8 to 83.1,71
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2020,Age,13-15 Years,73.1,60.8 to 82.6,97
Varicella,History of disease,States/Local Areas,Minnesota,2020,Age,13-17 Years,8.1,5.2 to 12.5,330
Varicella,History of disease,States/Local Areas,Minnesota,2022,Age,13-17 Years,5.3,3.0 to 9.2,331
Varicella,History of disease,States/Local Areas,Minnesota,2021,Age,13-17 Years,5.9,3.4 to 10.2,296
Varicella,History of disease,States/Local Areas,Minnesota,2016,Age,13-17 Years,20.6,16.1 to 26.0,375
HPV,"Up-to-Date, Females",States/Local Areas,Minnesota,2018,Age,13-15 Years,54.6,39.8 to 68.7,74
Varicella,History of disease,States/Local Areas,Minnesota,2008,Age,13-17 Years,59.4,53.2 to 65.3,338
Varicella,History of disease,States/Local Areas,Minnesota,2014,Age,13-17 Years,21.4,16.1 to 27.9,286
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2018,Age,13-17 Years,53.7,44.4 to 62.7,167
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2019,Age,13-17 Years,56.1,46.2 to 65.6,161
Varicella,History of disease,States/Local Areas,Georgia,2012,Age,13-17 Years,30.6,24.1 to 38.1,328
Varicella,History of disease,States/Local Areas,Georgia,2013,Age,13-17 Years,21.5,16.0 to 28.2,253
Varicella,History of disease,States/Local Areas,Georgia,2011,Age,13-17 Years,40.2,34.2 to 46.6,425
Varicella,History of disease,States/Local Areas,Georgia,2010,Age,13-17 Years,46.0,40.1 to 52.0,373
Varicella,History of disease,States/Local Areas,Georgia,2015,Age,13-17 Years,13.3,9.6 to 18.2,374
Varicella,History of disease,States/Local Areas,Georgia,2016,Age,13-17 Years,11.5,8.0 to 16.2,367
Varicella,History of disease,States/Local Areas,Georgia,2014,Age,13-17 Years,18.9,14.2 to 24.9,373
Varicella,History of disease,States/Local Areas,Georgia,2018,Age,13-17 Years,8.3,5.3 to 12.6,345
Varicella,History of disease,States/Local Areas,Georgia,2017,Age,13-17 Years,10.9,7.1 to 16.4,343
Varicella,History of disease,States/Local Areas,Georgia,2009,Age,13-17 Years,54.0,47.9 to 60.0,383
Varicella,History of disease,States/Local Areas,Georgia,2019,Age,13-17 Years,8.6,5.6 to 13.0,315
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2019,Age,13-15 Years,51.5,39.5 to 63.4,105
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2020,Age,13-15 Years,53.6,40.2 to 66.5,87
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2018,Age,13-15 Years,47.9,36.6 to 59.4,113
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2021,Age,13-15 Years,63.9,48.7 to 76.7,66
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2022,Age,13-15 Years,64.2,50.7 to 75.8,91
Varicella,History of disease,States/Local Areas,Georgia,2008,Age,13-17 Years,63.4,57.0 to 69.4,345
HPV,"Up-to-Date, Females",States/Local Areas,Georgia,2016,Age,13-17 Years,55.4,46.2 to 64.2,193
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,96.0,93.1 to 97.7,364
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,95.6,91.0 to 97.9,284
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,94.0,89.8 to 96.5,348
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,95.5,91.2 to 97.8,274
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,94.8,90.4 to 97.2,241
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,96.1,92.6 to 98.0,314
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,95.9,91.0 to 98.2,284
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2009,Age,13-15 Years,35.7,23.9 to 49.6,69
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2010,Age,13-15 Years,27.4,18.7 to 38.3,94
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2008,Age,13-15 Years,31.0,20.3 to 44.1,81
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2013,Age,13-15 Years,38.3,27.7 to 50.0,115
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2012,Age,13-15 Years,38.5,26.6 to 51.9,93
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2014,Age,13-15 Years,29.9,19.2 to 43.4,80
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2015,Age,13-15 Years,42.8,31.5 to 54.9,89
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,32.6,26.5 to 39.5,306
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,39.7,33.8 to 45.9,352
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,95.8,91.8 to 97.9,348
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,95.1,91.5 to 97.2,370
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,95.4,90.9 to 97.7,274
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,94.8,88.6 to 97.7,241
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,89.5,84.6 to 93.0,314
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,90.5,85.1 to 94.0,284
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,93.9,89.7 to 96.5,348
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,89.5,84.9 to 92.9,370
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,96.2,92.5 to 98.1,241
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,94.8,90.6 to 97.1,410
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,96.6,91.2 to 98.7,315
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,97.2,95.3 to 98.3,352
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,92.0,87.1 to 95.1,306
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,83.6,78.7 to 87.5,410
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,75.1,68.6 to 80.6,306
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,87.1,82.5 to 90.6,352
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,89.0,84.5 to 92.3,364
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,97.1,94.4 to 98.5,314
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2011,Age,13-15 Years,23.8,16.3 to 33.4,115
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,15.8,12.2 to 20.2,405
HPV,"≥3 Doses, Males and Females",States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,21.5,16.1 to 28.2,315
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,92.6,88.6 to 95.3,364
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,93.8,89.6 to 96.4,274
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,92.8,89.1 to 95.4,370
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2022,Age,13-15 Years,96.5,93.0 to 98.3,174
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,80.5,74.3 to 85.4,315
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,68.4,61.5 to 74.5,313
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,72.3,66.6 to 77.4,405
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,57.7,51.1 to 64.0,307
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,64.2,57.4 to 70.4,270
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Overall,Overall,95.4,93.9 to 96.6,1461
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Overall,Overall,92.8,91.0 to 94.2,1461
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,32.5,23.9 to 42.5,135
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,38.2,29.1 to 48.2,125
≥2 Doses Hep A,,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,76.9,70.2 to 82.6,284
≥2 Doses Hep A,,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,87.3,82.4 to 91.0,314
≥2 Doses Hep A,,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,70.8,64.3 to 76.5,348
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,48.0,39.1 to 57.0,156
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,37.9,29.1 to 47.6,147
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,88.0,83.1 to 91.7,352
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,68.1,61.8 to 73.8,348
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,53.2,44.9 to 61.2,241
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,56.8,50.1 to 63.2,307
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2022,Age,13-15 Years,84.2,76.2 to 89.8,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,69.0,62.5 to 74.8,314
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,60.5,53.0 to 67.5,284
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,51.8,45.6 to 58.0,364
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,94.6,91.2 to 96.8,307
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,94.3,90.5 to 96.7,270
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,51.3,40.4 to 62.0,125
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,89.5,85.6 to 92.5,405
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,83.6,78.1 to 87.8,313
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,67.2,60.4 to 73.2,270
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,94.4,89.1 to 97.2,313
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,95.0,91.6 to 97.1,405
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,48.8,42.6 to 55.0,370
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,56.7,49.2 to 63.9,274
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,89.8,85.4 to 93.0,410
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,93.2,88.8 to 96.0,306
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,92.7,87.9 to 95.7,315
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,69.5,63.1 to 75.3,314
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,68.9,59.6 to 76.9,163
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,70.2,60.9 to 78.1,151
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,89.4,84.9 to 92.6,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,92.9,88.9 to 95.5,331
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,95.0,91.4 to 97.2,331
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,77.5,71.4 to 82.6,331
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,62.4,53.2 to 70.7,169
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,76.7,67.7 to 83.8,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,64.4,57.9 to 70.4,331
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,96.3,93.2 to 98.0,331
≥2 Doses MMR,,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,95.9,92.4 to 97.8,331
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,97.2,94.9 to 98.5,331
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,96.8,94.2 to 98.3,301
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,98.9,97.5 to 99.5,301
Varicella,History of disease,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,11.4,7.7 to 16.7,331
≥2 Doses Hep A,,States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,89.1,84.4 to 92.5,331
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2023,Age,13-15 Years,89.1,83.4 to 93.0,199
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2023,Age,13-15 Years,96.8,93.3 to 98.5,199
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2023,Age,13-15 Years,54.4,46.0 to 62.6,199
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2023,Age,13-15 Years,54.0,41.9 to 65.7,95
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2023,Age,13-15 Years,95.7,91.5 to 97.9,179
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,66.5,57.0 to 74.8,162
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2023,Age,13-15 Years,54.8,43.2 to 65.8,104
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2023,Age,13-17 Years,78.2,69.5 to 84.9,169
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Other,94.4,89.8 to 97.0,189
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,90.0,85.2 to 93.4,317
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,93.6,91.5 to 95.2,941
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,67.2,60.5 to 73.3,317
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Other,58.6,49.5 to 67.2,189
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,60.4,56.3 to 64.4,941
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Other,97.5,94.2 to 98.9,189
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Other,73.6,64.6 to 81.0,189
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,77.3,71.1 to 82.5,317
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,71.7,67.7 to 75.4,941
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,95.6,92.0 to 97.7,317
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Poverty,Below Poverty Level,91.9,85.4 to 95.7,156
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,95.3,93.3 to 96.7,941
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,93.1,91.2 to 94.6,1241
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,61.0,57.4 to 64.4,1241
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,95.7,94.1 to 96.9,1241
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Poverty,Below Poverty Level,67.1,57.7 to 75.3,156
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Poverty,Below Poverty Level,96.2,92.6 to 98.1,156
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,71.7,68.3 to 74.9,1241
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Poverty,Below Poverty Level,81.2,72.9 to 87.4,156
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",71.5,67.7 to 75.1,955
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",65.2,52.2 to 76.3,90
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.7,80.9 to 93.6,179
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.1,82.4 to 95.7,90
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,Hispanic,91.9,86.5 to 95.3,237
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,Hispanic,97.7,95.5 to 98.9,237
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.0,92.0 to 95.6,955
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",96.1,88.3 to 98.8,90
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",66.4,57.1 to 74.6,179
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.9,92.7 to 96.4,955
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,Hispanic,63.3,55.1 to 70.9,237
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",79.9,71.3 to 86.4,179
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,Hispanic,78.0,70.5 to 84.0,237
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.6,88.7 to 97.5,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",57.9,45.2 to 69.6,90
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,93.3,89.0 to 96.0,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",60.7,56.7 to 64.5,955
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.7,90.4 to 94.4,1005
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,96.9,93.7 to 98.5,310
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,96.0,94.2 to 97.2,1005
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,87.1,77.7 to 92.9,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,74.9,68.1 to 80.6,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,51.8,41.2 to 62.3,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,58.3,54.4 to 62.1,1005
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,80.3,73.8 to 85.5,310
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,71.7,68.0 to 75.2,1005
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,63.0,51.5 to 73.2,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Overall,Overall,61.5,58.2 to 64.6,1461
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,92.4,85.9 to 96.1,146
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018-2022,Overall,Overall,72.9,69.8 to 75.8,1461
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,45.6,36.9 to 54.5,190
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,41.2,31.6 to 51.6,139
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,31.5,24.5 to 39.3,190
HPV,"≥3 Doses, Females",States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,41.3,31.5 to 51.8,145
HPV,"≥3 Doses, Males",States/Local Areas,NY-Rest of state,2014,Age,13-15 Years,20.2,12.7 to 30.5,96
HPV,"≥3 Doses, Males",States/Local Areas,NY-Rest of state,2015,Age,13-15 Years,32.5,23.7 to 42.8,120
HPV,"≥3 Doses, Males",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,24.4,17.3 to 33.4,167
HPV,"≥3 Doses, Males",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,31.7,24.7 to 39.7,196
HPV,"≥3 Doses, Males",States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,12.5,7.7 to 19.7,220
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,95.2,91.8 to 97.2,370
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,95.5,91.8 to 97.6,370
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,91.7,87.4 to 94.6,364
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,93.1,88.3 to 96.0,274
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2019,Age,13-15 Years,95.1,89.9 to 97.7,136
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2018,Age,13-15 Years,92.4,85.6 to 96.1,133
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2014,Age,13-15 Years,75.7,66.8 to 82.9,156
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2015,Age,13-15 Years,89.4,82.7 to 93.7,181
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,70.9,64.5 to 76.5,307
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,88.3,83.5 to 91.8,352
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,97.0,94.4 to 98.5,241
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,97.4,95.0 to 98.6,314
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,96.5,91.0 to 98.7,284
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,96.5,92.5 to 98.4,348
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,82.8,77.5 to 87.0,410
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,81.0,75.4 to 85.6,306
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,78.7,73.6 to 83.0,405
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,83.0,77.1 to 87.7,315
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2016,Age,13-15 Years,91.9,85.9 to 95.4,205
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2017,Age,13-15 Years,98.0,94.4 to 99.3,192
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,74.0,67.6 to 79.6,313
Varicella,≥2 Doses or history of disease,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,81.0,75.3 to 85.6,270
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2021,Age,13-15 Years,98.2,92.8 to 99.6,151
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2020,Age,13-15 Years,94.8,87.7 to 97.9,197
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2011,Age,13-15 Years,70.2,61.7 to 77.5,176
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2010,Age,13-15 Years,58.8,48.3 to 68.5,139
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2013,Age,13-15 Years,79.7,71.5 to 86.0,195
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2012,Age,13-15 Years,75.0,64.5 to 83.2,142
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,98.3,96.8 to 99.2,352
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,96.7,93.9 to 98.2,364
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,60.3,51.3 to 68.7,156
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,59.3,48.9 to 69.0,139
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,60.1,51.4 to 68.2,190
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,57.5,47.2 to 67.2,145
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,85.8,80.1 to 90.0,296
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,90.7,85.9 to 94.0,327
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,77.3,70.7 to 82.7,257
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,99.0,96.8 to 99.7,316
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,40.3,32.6 to 48.6,190
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,52.0,42.4 to 61.4,147
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,94.6,90.1 to 97.1,316
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,95.7,91.2 to 97.9,315
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,96.8,92.2 to 98.7,257
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,99.1,97.8 to 99.6,296
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,97.5,94.8 to 98.9,327
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,96.5,91.3 to 98.6,243
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,99.1,97.5 to 99.7,211
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,99.3,98.0 to 99.8,323
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,92.2,86.9 to 95.5,243
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,96.2,90.2 to 98.5,258
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,96.2,91.9 to 98.3,323
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,96.5,93.4 to 98.2,211
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2008,Age,13-15 Years,34.0,24.3 to 45.3,100
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2009,Age,13-15 Years,54.0,41.6 to 65.9,86
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,96.9,92.4 to 98.8,274
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,94.4,88.3 to 97.4,241
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,99.2,96.9 to 99.8,230
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,94.6,87.9 to 97.7,195
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,90.5,82.1 to 95.2,122
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,34.4,25.8 to 44.3,135
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,56.2,46.0 to 65.8,122
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,94.2,88.8 to 97.1,264
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,78.1,71.7 to 83.4,315
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,77.1,69.5 to 83.3,230
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,90.9,84.1 to 95.0,135
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,51.5,41.9 to 61.0,135
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,95.4,91.5 to 97.6,410
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,89.8,84.0 to 93.6,306
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,96.2,92.8 to 98.0,405
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,95.7,92.2 to 97.7,315
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,58.0,49.4 to 66.2,195
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,67.6,60.6 to 74.0,264
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,52.6,42.8 to 62.2,125
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,95.6,91.5 to 97.8,313
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,95.7,92.4 to 97.6,270
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,94.5,89.3 to 97.3,307
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2022,Age,13-15 Years,98.2,94.5 to 99.4,164
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,57.9,49.5 to 65.8,241
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,64.5,53.1 to 74.5,125
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,66.9,58.6 to 74.2,211
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,33.8,26.4 to 42.0,220
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,45.5,36.6 to 54.7,167
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,52.6,44.1 to 60.9,196
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,65.9,57.6 to 73.3,201
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,62.8,52.7 to 71.9,160
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,70.7,60.3 to 79.4,156
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,75.5,67.5 to 82.1,186
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,56.4,50.2 to 62.4,364
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,52.5,46.3 to 58.7,370
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,80.9,72.4 to 87.2,151
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,75.8,64.8 to 84.3,128
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,80.4,71.2 to 87.1,162
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,74.3,62.1 to 83.6,116
Varicella,≥2 Doses with no disease history,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,97.1,94.6 to 98.5,291
HPV,"≥2 Doses, Males and Females",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,58.5,51.0 to 65.7,274
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,12.1,7.6 to 18.7,170
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,94.2,89.4 to 96.9,315
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,98.6,92.4 to 99.7,258
Varicella,≥1 Dose with no disease history,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,98.1,95.9 to 99.1,291
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,97.9,95.8 to 99.0,314
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,98.1,94.9 to 99.3,284
≥3 Doses HepB,,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,96.1,92.0 to 98.1,348
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,65.6,53.7 to 75.7,114
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2016,Age,13-15 Years,86.6,80.3 to 91.1,226
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,70.5,62.0 to 77.8,163
HPV,"≥1 Dose, Females",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,64.0,54.6 to 72.5,159
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,68.1,62.3 to 73.5,364
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,65.5,59.3 to 71.2,370
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,55.3,46.6 to 63.7,190
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,51.4,41.2 to 61.5,145
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,91.5,87.0 to 94.5,352
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,93.8,89.5 to 96.5,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,95.2,91.6 to 97.3,364
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,94.3,90.9 to 96.5,370
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2013,Age,13-15 Years,83.2,76.1 to 88.6,226
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2012,Age,13-15 Years,78.0,69.1 to 84.8,187
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2014,Age,13-15 Years,75.0,66.4 to 82.0,176
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2015,Age,13-15 Years,86.8,80.7 to 91.2,209
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2017,Age,13-15 Years,89.4,83.1 to 93.6,224
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2018,Age,13-15 Years,97.1,92.5 to 98.9,152
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2019,Age,13-15 Years,95.6,90.2 to 98.1,154
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,48.3,38.6 to 58.1,125
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2020,Age,13-15 Years,92.8,86.6 to 96.3,211
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,43.7,34.4 to 53.5,147
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,35.3,28.0 to 43.4,190
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,44.2,34.8 to 54.0,135
HPV,"≥1 Dose, Males",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,79.3,70.6 to 86.0,163
Varicella,History of disease,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,11.3,7.2 to 17.2,274
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2009,Age,13-15 Years,65.5,56.0 to 74.0,147
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2008,Age,13-15 Years,56.1,47.7 to 64.1,187
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,95.6,91.9 to 97.7,348
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,96.5,92.9 to 98.4,241
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,89.6,84.6 to 93.1,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,93.7,90.4 to 95.9,405
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,94.0,90.4 to 96.3,410
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,85.6,80.6 to 89.5,307
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,86.7,81.3 to 90.8,270
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,95.3,91.3 to 97.5,274
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,64.1,56.5 to 71.1,274
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,91.3,86.8 to 94.4,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,91.8,86.6 to 95.1,284
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,69.3,61.0 to 76.4,241
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2021,Age,13-15 Years,95.2,89.4 to 97.9,165
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2011,Age,13-15 Years,75.4,68.6 to 81.1,248
≥1 Dose MenACWY,,States/Local Areas,NY-Rest of state,2010,Age,13-15 Years,66.7,57.6 to 74.6,191
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,47.8,37.7 to 58.0,139
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,54.1,45.1 to 62.8,156
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,61.0,52.0 to 69.3,163
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,53.6,44.4 to 62.5,159
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,80.1,74.2 to 84.9,314
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,73.2,65.8 to 79.5,284
HPV,"≥1 Dose, Males and Females",States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,77.9,72.0 to 82.8,348
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,60.8,49.2 to 71.3,114
HPV,"≥2 Doses, Females",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,64.8,52.3 to 75.6,116
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2009,Age,13-15 Years,72.4,63.0 to 80.2,147
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2010,Age,13-15 Years,90.1,83.3 to 94.4,191
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2008,Age,13-15 Years,65.0,56.7 to 72.5,187
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2011,Age,13-15 Years,91.9,86.9 to 95.1,248
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2012,Age,13-15 Years,92.7,85.0 to 96.6,187
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2014,Age,13-15 Years,93.4,86.6 to 96.9,176
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2015,Age,13-15 Years,89.0,82.2 to 93.4,209
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2016,Age,13-15 Years,91.2,85.3 to 94.9,226
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2017,Age,13-15 Years,93.8,88.6 to 96.7,224
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,33.1,25.1 to 42.3,167
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,25.1,18.4 to 33.3,220
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2018,Age,13-15 Years,90.9,84.1 to 95.0,152
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2021,Age,13-15 Years,87.2,79.6 to 92.3,165
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2020,Age,13-15 Years,93.4,87.4 to 96.7,211
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2019,Age,13-15 Years,95.4,91.1 to 97.7,154
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,67.4,57.7 to 75.8,162
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,70.2,60.9 to 78.1,151
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,64.0,53.1 to 73.7,128
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2018,Age,13-15 Years,44.4,31.7 to 57.8,82
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,48.0,39.7 to 56.4,201
Varicella,History of disease,States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,9.0,5.7 to 13.8,284
Varicella,History of disease,States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,8.1,5.0 to 12.8,314
Varicella,History of disease,States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,7.9,5.0 to 12.4,348
Varicella,History of disease,States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,14.5,9.7 to 21.1,241
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2020,Age,13-15 Years,59.9,47.0 to 71.5,99
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2019,Age,13-15 Years,59.3,43.9 to 73.1,71
Varicella,History of disease,States/Local Areas,NY-Rest of state,2014,Age,13-17 Years,16.6,12.1 to 22.3,306
Varicella,History of disease,States/Local Areas,NY-Rest of state,2010,Age,13-17 Years,38.1,31.7 to 45.0,313
Varicella,History of disease,States/Local Areas,NY-Rest of state,2011,Age,13-17 Years,34.2,28.9 to 39.9,405
Varicella,History of disease,States/Local Areas,NY-Rest of state,2013,Age,13-17 Years,21.4,17.1 to 26.5,410
Varicella,History of disease,States/Local Areas,NY-Rest of state,2012,Age,13-17 Years,25.8,20.6 to 31.9,315
Varicella,History of disease,States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,17.5,13.1 to 22.8,352
Varicella,History of disease,States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,11.1,7.6 to 15.8,364
Varicella,History of disease,States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,17.3,12.9 to 22.8,370
Varicella,History of disease,States/Local Areas,NY-Rest of state,2009,Age,13-17 Years,56.6,49.8 to 63.2,270
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2018,Age,13-15 Years,53.0,38.6 to 66.9,70
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2015,Age,13-17 Years,42.6,34.6 to 51.0,196
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,52.0,43.6 to 60.3,201
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,51.5,43.0 to 59.8,211
HPV,"≥2 Doses, Males",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,56.4,46.5 to 65.8,160
Tetanus,≥1 Dose Tdap,States/Local Areas,NY-Rest of state,2013,Age,13-15 Years,90.5,83.9 to 94.6,226
Varicella,History of disease,States/Local Areas,NY-Rest of state,2008,Age,13-17 Years,55.6,48.9 to 62.0,307
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2022,Age,13-15 Years,62.4,53.5 to 70.5,174
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,55.9,46.0 to 65.4,160
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,47.0,38.7 to 55.4,211
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2020,Age,13-17 Years,68.8,60.4 to 76.2,186
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,47.6,37.0 to 58.3,125
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2021,Age,13-17 Years,57.0,46.7 to 66.8,156
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2017,Age,13-17 Years,50.7,41.6 to 59.7,159
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2022,Age,13-15 Years,68.0,55.5 to 78.3,83
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2021,Age,13-15 Years,59.5,45.7 to 71.9,78
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2016,Age,13-17 Years,55.8,46.7 to 64.5,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2020,Age,13-15 Years,65.0,56.5 to 72.6,211
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2021,Age,13-15 Years,56.2,46.6 to 65.3,165
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2022,Age,13-17 Years,67.8,58.5 to 75.9,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,NY-Rest of state,2019,Age,13-15 Years,49.6,39.5 to 59.7,154
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2018,Age,13-17 Years,57.5,46.1 to 68.1,114
HPV,"Up-to-Date, Females",States/Local Areas,NY-Rest of state,2019,Age,13-17 Years,59.1,46.6 to 70.5,116
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2019,Age,13-15 Years,41.5,29.5 to 54.6,83
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2020,Age,13-15 Years,70.7,60.0 to 79.5,112
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2022,Age,13-15 Years,57.6,45.0 to 69.3,91
HPV,"Up-to-Date, Males",States/Local Areas,NY-Rest of state,2021,Age,13-15 Years,52.9,39.7 to 65.7,87
Varicella,History of disease,States/Local Areas,Washington,2014,Age,13-17 Years,24.8,19.5 to 30.9,374
Varicella,History of disease,States/Local Areas,Washington,2012,Age,13-17 Years,38.7,32.2 to 45.6,353
Varicella,History of disease,States/Local Areas,Washington,2013,Age,13-17 Years,36.9,30.6 to 43.6,360
Varicella,History of disease,States/Local Areas,Washington,2010,Age,13-17 Years,57.2,51.4 to 62.8,361
Varicella,History of disease,States/Local Areas,Washington,2011,Age,13-17 Years,43.2,36.9 to 49.8,346
Varicella,History of disease,States/Local Areas,Washington,2009,Age,13-17 Years,61.5,55.3 to 67.3,321
Varicella,History of disease,States/Local Areas,Washington,2017,Age,13-17 Years,14.2,10.4 to 19.0,339
Varicella,History of disease,States/Local Areas,Washington,2018,Age,13-17 Years,10.4,6.7 to 15.7,286
Varicella,History of disease,States/Local Areas,Washington,2016,Age,13-17 Years,21.4,16.3 to 27.5,361
Varicella,History of disease,States/Local Areas,Washington,2015,Age,13-17 Years,26.6,21.7 to 32.1,396
Varicella,History of disease,States/Local Areas,Washington,2008,Age,13-17 Years,67.7,61.0 to 73.7,275
Varicella,History of disease,States/Local Areas,Washington,2019,Age,13-17 Years,11.4,7.3 to 17.3,304
Varicella,History of disease,States/Local Areas,Washington,2020,Age,13-17 Years,11.2,7.2 to 17.0,417
Varicella,History of disease,States/Local Areas,Washington,2022,Age,13-17 Years,10.2,6.3 to 16.1,280
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2020,Age,13-15 Years,59.8,48.2 to 70.4,142
HPV,"Up-to-Date, Females",States/Local Areas,Washington,2018,Age,13-15 Years,52.9,40.9 to 64.6,108
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2021,Age,13-17 Years,95.5,90.9 to 97.8,191
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2020,Age,13-17 Years,93.8,89.7 to 96.3,401
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018,Age,13-17 Years,92.5,87.5 to 95.7,287
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2019,Age,13-17 Years,95.8,93.1 to 97.5,319
≥2 Doses MMR,,States/Local Areas,North Dakota,2022,Age,13-17 Years,97.6,93.8 to 99.1,280
≥2 Doses MMR,,States/Local Areas,North Dakota,2021,Age,13-17 Years,98.3,95.7 to 99.3,191
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2009,Age,13-15 Years,31.5,21.2 to 44.0,77
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2008,Age,13-15 Years,13.1,7.7 to 21.5,108
≥2 Doses MMR,,States/Local Areas,North Dakota,2017,Age,13-17 Years,93.0,89.5 to 95.3,379
≥2 Doses MMR,,States/Local Areas,North Dakota,2018,Age,13-17 Years,96.4,92.4 to 98.4,287
≥2 Doses MMR,,States/Local Areas,North Dakota,2019,Age,13-17 Years,97.4,94.2 to 98.9,319
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2014,Age,13-15 Years,41.4,29.7 to 54.1,100
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2015,Age,13-15 Years,43.7,32.4 to 55.8,90
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2013,Age,13-15 Years,38.5,28.0 to 50.3,107
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2012,Age,13-15 Years,40.1,29.0 to 52.3,95
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Dakota,2014,Age,13-17 Years,33.3,27.4 to 39.8,327
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Dakota,2015,Age,13-17 Years,42.7,36.5 to 49.1,323
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Dakota,2013,Age,13-17 Years,29.5,23.9 to 35.8,344
≥2 Doses MMR,,States/Local Areas,North Dakota,2020,Age,13-17 Years,97.0,94.0 to 98.5,401
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2022,Age,13-17 Years,93.8,89.1 to 96.6,280
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2021,Age,13-17 Years,94.9,90.0 to 97.5,191
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2020,Age,13-17 Years,91.0,85.9 to 94.4,401
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2017,Age,13-17 Years,91.9,88.3 to 94.4,379
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2019,Age,13-17 Years,96.7,94.5 to 98.1,319
≥2 Doses MMR,,States/Local Areas,North Dakota,2016,Age,13-17 Years,92.7,87.7 to 95.7,293
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2016,Age,13-17 Years,92.0,87.5 to 94.9,293
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018,Age,13-17 Years,90.2,85.0 to 93.8,287
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2017,Age,13-17 Years,90.6,86.8 to 93.5,379
≥2 Doses MMR,,States/Local Areas,North Dakota,2013,Age,13-17 Years,96.1,93.7 to 97.7,344
≥2 Doses MMR,,States/Local Areas,North Dakota,2012,Age,13-17 Years,89.8,83.7 to 93.8,324
≥2 Doses MMR,,States/Local Areas,North Dakota,2015,Age,13-17 Years,89.1,83.8 to 92.8,323
≥2 Doses MMR,,States/Local Areas,North Dakota,2014,Age,13-17 Years,91.3,86.2 to 94.7,327
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2011,Age,13-15 Years,31.5,19.0 to 47.4,78
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2022,Age,13-17 Years,96.0,91.9 to 98.0,280
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Overall,Overall,93.4,91.6 to 94.8,1478
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Overall,Overall,94.8,93.2 to 96.0,1478
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2013,Age,13-17 Years,93.7,89.6 to 96.3,344
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2014,Age,13-17 Years,91.8,87.8 to 94.6,327
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2015,Age,13-17 Years,91.6,86.7 to 94.8,323
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2016,Age,13-17 Years,92.0,87.5 to 94.9,293
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Dakota,2011,Age,13-17 Years,14.5,9.9 to 20.8,314
HPV,"≥3 Doses, Males and Females",States/Local Areas,North Dakota,2012,Age,13-17 Years,22.6,17.5 to 28.6,324
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2022,Age,13-15 Years,95.3,88.9 to 98.1,177
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2012,Age,13-17 Years,88.1,82.3 to 92.2,324
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2010,Age,13-17 Years,76.8,71.2 to 81.5,299
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2011,Age,13-17 Years,84.2,76.0 to 90.0,314
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2008,Age,13-17 Years,47.4,41.7 to 53.1,362
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2009,Age,13-17 Years,66.0,59.5 to 72.0,272
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2023,Age,13-17 Years,79.7,69.8 to 87.0,121
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2023,Age,13-17 Years,81.2,71.8 to 88.0,141
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2023,Age,13-17 Years,90.1,84.4 to 93.9,262
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2023,Age,13-17 Years,90.7,84.9 to 94.4,262
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2023,Age,13-17 Years,93.1,88.0 to 96.1,262
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2023,Age,13-17 Years,83.7,77.4 to 88.5,262
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2023,Age,13-17 Years,78.3,71.7 to 83.8,262
≥2 Doses MMR,,States/Local Areas,North Dakota,2023,Age,13-17 Years,94.4,89.5 to 97.1,262
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2023,Age,13-17 Years,77.0,67.5 to 84.4,141
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2023,Age,13-17 Years,93.7,88.9 to 96.5,245
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2023,Age,13-17 Years,96.6,92.2 to 98.6,245
Varicella,History of disease,States/Local Areas,North Dakota,2023,Age,13-17 Years,9.5,5.3 to 16.3,262
≥3 Doses HepB,,States/Local Areas,North Dakota,2023,Age,13-17 Years,92.4,86.4 to 95.9,262
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2023,Age,13-17 Years,94.3,89.9 to 96.8,262
≥2 Doses Hep A,,States/Local Areas,North Dakota,2023,Age,13-17 Years,94.0,89.0 to 96.8,262
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2023,Age,13-15 Years,91.2,83.6 to 95.5,155
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2023,Age,13-15 Years,93.7,86.6 to 97.2,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2023,Age,13-15 Years,78.5,69.3 to 85.6,155
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2023,Age,13-15 Years,77.7,64.0 to 87.2,74
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2023,Age,13-17 Years,86.4,77.0 to 92.3,121
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2023,Age,13-15 Years,79.3,65.7 to 88.5,81
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2023,Age,13-15 Years,96.2,90.6 to 98.5,145
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Uninsured,82.9,64.7 to 92.8,48
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Other,94.6,88.7 to 97.5,148
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Any Medicaid,90.5,85.2 to 94.1,267
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Private Insurance Only,94.6,92.5 to 96.1,1015
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Uninsured,62.8,44.8 to 77.7,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Other,67.2,57.1 to 76.0,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Any Medicaid,72.4,65.3 to 78.6,267
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Uninsured,73.1,55.4 to 85.6,48
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Uninsured,82.4,64.1 to 92.4,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Private Insurance Only,72.5,68.7 to 76.0,1015
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Other,76.8,67.2 to 84.3,148
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Other,95.9,91.8 to 98.0,148
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Any Medicaid,82.8,76.5 to 87.7,267
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Private Insurance Only,83.8,80.6 to 86.5,1015
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Private Insurance Only,95.6,93.7 to 97.0,1015
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Insurance Coverage,Any Medicaid,93.4,88.9 to 96.1,267
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Poverty,Below Poverty Level,92.3,82.5 to 96.8,109
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Poverty,Living At or Above Poverty Level,93.4,91.6 to 94.9,1322
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Poverty,Living At or Above Poverty Level,71.7,68.5 to 74.8,1322
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Poverty,Below Poverty Level,67.6,55.5 to 77.8,109
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Poverty,Living At or Above Poverty Level,94.6,92.9 to 95.9,1322
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Poverty,Below Poverty Level,94.4,85.8 to 97.9,109
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Poverty,Living At or Above Poverty Level,82.4,79.6 to 84.9,1322
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",93.9,84.7 to 97.7,40
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Poverty,Below Poverty Level,81.1,70.0 to 88.8,109
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",81.3,78.2 to 84.1,1184
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,Hispanic,89.8,77.9 to 95.7,67
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.4,86.1 to 96.0,187
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.3,67.6 to 95.0,40
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,Hispanic,91.7,80.1 to 96.8,67
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.2,92.4 to 95.7,1184
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.8,92.9 to 96.1,1184
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",98.1,87.6 to 99.7,40
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,Hispanic,70.0,56.1 to 81.0,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",73.6,64.7 to 80.8,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",71.7,53.3 to 84.9,40
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",84.6,76.8 to 90.1,187
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,Hispanic,82.7,70.6 to 90.5,67
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",94.9,89.7 to 97.5,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Race and Ethnicity,"White, Non-Hispanic",71.3,67.8 to 74.6,1184
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,94.0,90.7 to 96.2,468
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,91.6,85.3 to 95.3,215
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,96.4,94.1 to 97.9,468
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.4,86.2 to 95.9,215
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a Non-MSA,94.4,92.0 to 96.1,795
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,73.8,68.3 to 78.6,468
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a Non-MSA,70.0,65.7 to 74.0,795
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,72.1,63.5 to 79.4,215
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Principal City,87.3,83.0 to 90.6,468
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a MSA Non-Principal City,81.7,73.9 to 87.6,215
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a Non-MSA,79.5,75.6 to 82.9,795
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018-2022,Overall,Overall,71.6,68.5 to 74.5,1478
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018-2022,Urbanicity,Living In a Non-MSA,93.5,91.0 to 95.4,795
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018-2022,Overall,Overall,82.5,79.8 to 84.8,1478
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2009,Age,13-17 Years,21.1,16.2 to 26.9,333
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2011,Age,13-17 Years,31.5,26.9 to 36.6,485
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2010,Age,13-17 Years,31.9,25.1 to 39.7,231
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,78.9,73.7 to 83.2,428
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,92.0,88.4 to 94.6,332
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,91.7,88.8 to 93.9,547
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,88.6,85.0 to 91.5,458
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,84.8,80.1 to 88.5,428
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2016,Age,13-17 Years,61.3,55.5 to 66.7,428
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2015,Age,13-17 Years,56.0,50.6 to 61.3,458
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,38.4,32.6 to 44.5,332
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2012,Age,13-17 Years,38.1,33.4 to 43.0,547
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,81.3,73.5 to 87.2,218
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,79.2,71.2 to 85.4,218
Tetanus,≥1 Dose Tdap,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,81.5,73.7 to 87.4,245
HPV,"≥3 Doses, Males and Females",States/Local Areas,U.S. Virgin Islands,2013,Age,13-17 Years,7.0,4.5 to 10.7,332
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,82.9,75.4 to 88.5,245
≥2 Doses MMR,,States/Local Areas,U.S. Virgin Islands,2021,Age,13-17 Years,85.2,77.0 to 90.8,245
≥1 Dose MenACWY,,States/Local Areas,U.S. Virgin Islands,2019,Age,13-17 Years,75.0,67.1 to 81.5,218
HPV,"≥3 Doses, Females",States/Local Areas,U.S. Virgin Islands,2011,Age,13-15 Years,9.4,5.2 to 16.4,142
HPV,"≥3 Doses, Females",States/Local Areas,U.S. Virgin Islands,2015,Age,13-15 Years,10.3,6.1 to 16.9,151
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Other,90.8,77.1 to 96.6,72
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Uninsured,82.4,71.6 to 89.8,93
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Any Medicaid,86.5,81.4 to 90.4,343
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Private Insurance Only,89.2,84.2 to 92.8,397
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Uninsured,45.2,33.3 to 57.8,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Other,48.4,34.8 to 62.2,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Private Insurance Only,64.8,58.3 to 70.7,397
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Any Medicaid,59.9,53.0 to 66.4,343
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Uninsured,85.4,76.4 to 91.4,93
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Other,85.6,69.5 to 94.0,72
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Uninsured,71.4,59.6 to 80.9,93
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Other,73.4,58.4 to 84.5,72
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Private Insurance Only,78.8,73.3 to 83.5,397
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Any Medicaid,79.2,73.0 to 84.2,343
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Private Insurance Only,91.5,87.4 to 94.4,397
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Poverty,Living At or Above Poverty Level,90.2,86.4 to 93.0,562
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Insurance Coverage,Any Medicaid,89.9,85.2 to 93.3,343
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Poverty,Below Poverty Level,83.6,77.7 to 88.2,285
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Poverty,Below Poverty Level,55.2,47.9 to 62.3,285
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Poverty,Living At or Above Poverty Level,63.5,58.1 to 68.6,562
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Poverty,Below Poverty Level,87.3,81.9 to 91.3,285
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Poverty,Living At or Above Poverty Level,91.5,88.0 to 94.1,562
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",79.1,69.9 to 86.1,131
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Poverty,Living At or Above Poverty Level,77.2,72.3 to 81.4,562
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Poverty,Below Poverty Level,76.2,69.4 to 81.8,285
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"White, Non-Hispanic",80.3,72.9 to 86.0,213
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.9,78.9 to 95.5,82
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,Hispanic,84.9,80.3 to 88.6,479
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.5,82.5 to 93.9,131
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,Hispanic,87.9,83.9 to 91.1,479
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.4,88.9 to 96.2,213
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.9,82.0 to 94.5,131
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"White, Non-Hispanic",95.6,91.9 to 97.6,213
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",58.8,48.5 to 68.3,131
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,Hispanic,57.0,51.3 to 62.5,479
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",59.0,43.1 to 73.2,82
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,Hispanic,76.3,71.2 to 80.8,479
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",79.2,63.8 to 89.2,82
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.7,80.3 to 95.9,82
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Race and Ethnicity,"White, Non-Hispanic",67.7,58.6 to 75.6,213
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Urbanicity,Living In a MSA Principal City,87.5,84.4 to 90.0,905
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Urbanicity,Living In a MSA Principal City,89.7,86.9 to 91.9,905
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Urbanicity,Living In a MSA Principal City,59.1,54.9 to 63.2,905
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Urbanicity,Living In a MSA Principal City,77.7,74.0 to 81.0,905
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Overall,Overall,77.7,74.0 to 81.0,905
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2018-2022,Overall,Overall,59.1,54.9 to 63.2,905
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018-2022,Overall,Overall,89.7,86.9 to 91.9,905
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018-2022,Overall,Overall,87.5,84.4 to 90.0,905
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,90.1,83.3 to 94.3,214
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,90.6,83.7 to 94.8,214
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,84.9,77.6 to 90.1,214
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,91.2,84.6 to 95.2,214
HPV,"≥1 Dose, Females",States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,90.1,80.5 to 95.2,109
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,70.5,62.4 to 77.4,214
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,82.8,75.1 to 88.5,214
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,68.3,56.3 to 78.3,105
≥3 Doses HepB,,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,84.0,76.6 to 89.4,214
Varicella,History of disease,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,8.5,4.7 to 14.9,214
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,90.0,82.6 to 94.4,201
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,85.5,78.0 to 90.7,201
≥2 Doses Hep A,,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,82.8,75.2 to 88.4,214
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,86.7,79.8 to 91.5,214
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2023,Age,13-15 Years,93.6,86.7 to 97.0,137
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2023,Age,13-15 Years,90.6,81.1 to 95.6,137
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-City of Houston,2023,Age,13-15 Years,68.1,57.8 to 76.8,137
HPV,"Up-to-Date, Males",States/Local Areas,TX-City of Houston,2023,Age,13-15 Years,65.4,50.2 to 78.1,63
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,72.5,61.3 to 81.5,109
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-City of Houston,2023,Age,13-15 Years,84.7,74.5 to 91.3,129
HPV,"Up-to-Date, Females",States/Local Areas,TX-City of Houston,2023,Age,13-15 Years,70.2,55.8 to 81.5,74
HPV,"≥1 Dose, Males",States/Local Areas,TX-City of Houston,2023,Age,13-17 Years,79.6,67.6 to 87.9,105
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,68.8,58.4 to 77.6,157
HPV,"≥2 Doses, Males",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,69.6,54.1 to 81.6,67
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018,Age,13-15 Years,83.0,72.1 to 90.3,114
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,12.5,8.7 to 17.5,441
HPV,"≥3 Doses, Females",States/Local Areas,TX-Dallas County,2011,Age,13-15 Years,26.1,16.2 to 39.2,115
HPV,"≥3 Doses, Females",States/Local Areas,TX-Dallas County,2009,Age,13-15 Years,20.3,12.6 to 31.0,80
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,86.6,80.6 to 91.0,271
≥2 Doses MMR,,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,81.0,74.1 to 86.3,294
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,87.7,82.0 to 91.8,294
≥2 Doses MMR,,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,80.2,73.3 to 85.6,271
≥2 Doses MMR,,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,77.8,70.4 to 83.8,263
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,85.1,78.8 to 89.7,263
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,84.6,78.8 to 89.1,271
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,77.0,69.8 to 83.0,263
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,83.0,76.7 to 87.9,294
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,72.9,65.5 to 79.3,304
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,75.7,68.9 to 81.4,441
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,52.5,45.2 to 59.6,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,23.9,18.8 to 30.0,294
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,72.5,65.2 to 78.7,304
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,54.4,47.1 to 61.5,296
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,76.9,70.2 to 82.5,441
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,35.7,28.8 to 43.1,263
HPV,"≥2 Doses, Males",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,49.2,39.1 to 59.3,143
≥2 Doses MMR,,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,77.4,70.5 to 83.1,296
≥2 Doses MMR,,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,81.4,73.9 to 87.0,304
≥2 Doses MMR,,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,84.8,78.8 to 89.4,441
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,50.5,43.1 to 57.8,271
HPV,"≥3 Doses, Females",States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,18.6,12.0 to 27.7,135
HPV,"≥3 Doses, Females",States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,23.4,16.2 to 32.5,196
HPV,"≥3 Doses, Females",States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,21.0,13.9 to 30.4,131
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2019,Age,13-15 Years,80.2,70.7 to 87.1,160
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,58.8,49.9 to 67.2,192
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,70.6,62.5 to 77.6,296
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,81.3,75.4 to 86.0,441
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,75.9,69.7 to 81.2,304
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,72.6,65.7 to 78.6,296
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,73.8,66.1 to 80.2,263
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,82.3,76.0 to 87.3,294
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,93.7,88.9 to 96.5,192
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,88.7,81.3 to 93.4,154
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,94.0,86.8 to 97.4,296
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,46.1,36.4 to 56.0,154
HPV,"≥1 Dose, Females",States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,47.0,36.7 to 57.7,131
HPV,"≥1 Dose, Males",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,42.7,33.4 to 52.5,153
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,80.5,73.7 to 85.8,271
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2011,Age,13-15 Years,77.4,67.9 to 84.7,204
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2010,Age,13-15 Years,60.1,49.5 to 69.8,139
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2009,Age,13-15 Years,47.7,36.1 to 59.6,103
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2017,Age,13-15 Years,71.6,61.3 to 80.1,152
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2016,Age,13-15 Years,79.0,69.7 to 86.0,162
≥3 Doses HepB,,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,83.2,75.9 to 88.6,304
≥3 Doses HepB,,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,82.3,75.4 to 87.6,296
≥3 Doses HepB,,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,87.8,82.0 to 91.9,441
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,91.1,85.3 to 94.8,260
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,70.3,62.0 to 77.5,235
HPV,"≥1 Dose, Females",States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,41.2,32.2 to 50.8,196
HPV,"≥1 Dose, Females",States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,34.4,24.6 to 45.7,135
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,79.9,72.9 to 85.5,260
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,85.6,79.0 to 90.4,240
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,89.2,83.0 to 93.4,235
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,77.8,70.4 to 83.8,240
≥3 Doses HepB,,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,80.8,74.1 to 86.1,271
≥3 Doses HepB,,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,76.6,69.3 to 82.6,263
≥3 Doses HepB,,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,81.1,74.1 to 86.5,294
HPV,"≥1 Dose, Males",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,67.6,57.9 to 76.1,143
HPV,"≥1 Dose, Males",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,45.2,35.1 to 55.7,140
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2009,Age,13-15 Years,49.3,40.2 to 58.4,176
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,52.2,44.9 to 59.5,271
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,43.6,36.3 to 51.3,263
HPV,"≥1 Dose, Females",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,68.5,57.7 to 77.6,128
HPV,"≥1 Dose, Males",States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,12.9,8.1 to 20.0,245
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2011,Age,13-15 Years,87.6,81.9 to 91.7,276
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2010,Age,13-15 Years,76.1,67.1 to 83.3,206
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,28.9,23.1 to 35.4,294
HPV,"≥1 Dose, Females",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,64.3,53.5 to 73.9,123
HPV,"≥1 Dose, Females",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,48.8,37.9 to 59.8,141
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,76.2,68.9 to 82.2,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,80.6,73.5 to 86.2,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,86.0,79.8 to 90.6,441
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,84.8,78.6 to 89.4,294
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2016,Age,13-15 Years,87.6,80.5 to 92.4,176
HPV,"≥2 Doses, Females",States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,22.5,15.2 to 32.0,135
HPV,"≥2 Doses, Females",States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,29.7,21.8 to 38.9,196
HPV,"≥2 Doses, Females",States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,39.9,30.1 to 50.5,131
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,54.5,46.9 to 62.0,263
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,45.7,38.5 to 53.1,294
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,83.3,76.9 to 88.3,263
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2019,Age,13-15 Years,88.7,81.9 to 93.2,178
≥1 Dose MenACWY,,States/Local Areas,TX-Dallas County,2017,Age,13-15 Years,83.5,75.0 to 89.5,169
HPV,"≥2 Doses, Females",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,49.7,38.9 to 60.4,123
HPV,"≥2 Doses, Females",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,29.4,21.0 to 39.5,141
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,86.6,80.8 to 90.8,271
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,68.1,60.9 to 74.4,271
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2011,Age,13-15 Years,82.6,75.6 to 88.0,276
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2009,Age,13-15 Years,55.4,46.0 to 64.5,176
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2010,Age,13-15 Years,75.5,66.8 to 82.5,206
HPV,"≥2 Doses, Males",States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,5.4,3.0 to 9.4,245
HPV,"≥2 Doses, Females",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,55.4,44.7 to 65.6,128
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2016,Age,13-15 Years,85.0,77.4 to 90.4,176
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2019,Age,13-15 Years,87.0,80.2 to 91.7,178
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Dallas County,2017,Age,13-15 Years,82.8,74.4 to 88.8,169
HPV,"≥2 Doses, Males",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,37.9,28.3 to 48.5,140
HPV,"≥2 Doses, Males",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,28.3,20.8 to 37.2,153
HPV,"Up-to-Date, Males",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,23.6,16.9 to 32.0,153
HPV,"Up-to-Date, Males",States/Local Areas,TX-Dallas County,2019,Age,13-15 Years,51.9,39.1 to 64.4,93
HPV,"Up-to-Date, Males",States/Local Areas,TX-Dallas County,2018,Age,13-15 Years,NA,,
HPV,"Up-to-Date, Females",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,52.7,42.1 to 63.1,128
Varicella,History of disease,States/Local Areas,TX-Dallas County,2010,Age,13-17 Years,41.4,34.1 to 49.1,304
Varicella,History of disease,States/Local Areas,TX-Dallas County,2011,Age,13-17 Years,36.3,29.8 to 43.3,441
Varicella,History of disease,States/Local Areas,TX-Dallas County,2009,Age,13-17 Years,49.2,42.0 to 56.4,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Dallas County,2019,Age,13-15 Years,51.9,42.8 to 60.9,178
HPV,"Up-to-Date, Males",States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,48.3,38.3 to 58.5,143
HPV,"Up-to-Date, Males",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,29.9,21.5 to 40.0,140
HPV,"Up-to-Date, Females",States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,41.7,31.5 to 52.6,123
HPV,"Up-to-Date, Females",States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,24.3,16.8 to 33.6,141
HPV,"Up-to-Date, Females",States/Local Areas,TX-Dallas County,2019,Age,13-15 Years,51.9,39.2 to 64.4,85
HPV,"Up-to-Date, Females",States/Local Areas,TX-Dallas County,2018,Age,13-15 Years,NA,,
Varicella,History of disease,States/Local Areas,TX-Dallas County,2019,Age,13-17 Years,11.9,7.8 to 17.8,271
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,86.2,77.9 to 91.7,225
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,82.8,75.1 to 88.5,186
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,87.9,80.2 to 92.9,187
Varicella,History of disease,States/Local Areas,TX-Dallas County,2017,Age,13-17 Years,11.5,7.5 to 17.3,263
Varicella,History of disease,States/Local Areas,TX-Dallas County,2016,Age,13-17 Years,11.9,7.8 to 17.9,294
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2009,Age,13-17 Years,64.8,56.0 to 72.8,239
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2008,Age,13-17 Years,51.9,42.9 to 60.7,233
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,83.3,77.6 to 87.8,490
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2010,Age,13-17 Years,75.9,69.9 to 81.0,413
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,91.8,85.7 to 95.4,174
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2022,Age,13-15 Years,85.5,74.2 to 92.4,98
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,86.0,76.9 to 91.9,167
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,87.6,80.9 to 92.1,221
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,25.8,20.0 to 32.6,393
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,82.2,74.7 to 87.9,186
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,83.8,76.3 to 89.3,187
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,85.6,77.1 to 91.3,174
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,89.1,81.1 to 94.0,157
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,35.2,28.8 to 42.2,379
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,32.7,26.2 to 40.0,259
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,85.6,79.0 to 90.4,221
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,87.6,82.3 to 91.5,393
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,87.4,81.6 to 91.6,379
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,91.4,85.5 to 95.0,278
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,87.2,81.6 to 91.2,259
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,82.9,73.8 to 89.3,225
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-City of Houston,2011,Age,13-17 Years,14.8,11.1 to 19.6,490
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2016,Age,13-17 Years,77.5,68.8 to 84.4,225
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2013,Age,13-17 Years,86.8,80.6 to 91.3,278
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2012,Age,13-17 Years,84.0,77.7 to 88.7,393
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2015,Age,13-17 Years,83.2,76.8 to 88.0,259
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2014,Age,13-17 Years,81.1,74.5 to 86.2,379
HPV,"≥2 Doses, Females",States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,68.0,53.4 to 79.8,90
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,93.1,86.4 to 96.6,167
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,87.4,79.3 to 92.6,157
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2017,Age,13-17 Years,91.4,85.1 to 95.2,187
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2020,Age,13-17 Years,89.2,82.6 to 93.5,221
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2018,Age,13-17 Years,86.7,80.1 to 91.4,186
≥1 Dose MenACWY,,States/Local Areas,TX-City of Houston,2019,Age,13-17 Years,92.0,84.7 to 96.0,174
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2022,Age,13-17 Years,86.7,77.7 to 92.4,157
≥2 Doses MMR,,States/Local Areas,TX-City of Houston,2021,Age,13-17 Years,77.5,66.8 to 85.5,167
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2014,Age,13-15 Years,41.2,29.5 to 53.9,118
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2015,Age,13-15 Years,36.8,25.0 to 50.4,80
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2013,Age,13-15 Years,30.5,19.2 to 44.6,71
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2012,Age,13-15 Years,33.9,22.6 to 47.3,116
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2009,Age,13-15 Years,23.1,13.8 to 36.2,64
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2010,Age,13-15 Years,31.3,21.8 to 42.7,126
HPV,"≥3 Doses, Females",States/Local Areas,TX-City of Houston,2011,Age,13-15 Years,17.5,11.4 to 26.0,145
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,84.6,78.8 to 89.0,320
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,91.3,86.3 to 94.6,280
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,43.0,38.0 to 48.1,558
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,38.3,31.3 to 45.9,397
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,91.6,86.5 to 94.8,345
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,85.5,81.2 to 88.9,558
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,91.7,86.5 to 95.0,397
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,25.4,20.1 to 31.6,355
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,85.7,80.2 to 89.9,345
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,78.9,72.1 to 84.4,397
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,77.9,73.0 to 82.1,558
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,89.5,84.4 to 93.0,320
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,93.5,89.5 to 96.1,280
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2015,Age,13-15 Years,48.3,38.7 to 58.0,162
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2014,Age,13-15 Years,49.7,35.7 to 63.7,120
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2009,Age,13-15 Years,32.6,22.9 to 44.0,85
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2010,Age,13-15 Years,36.8,27.0 to 47.7,93
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2011,Age,13-15 Years,45.3,33.5 to 57.6,109
HPV,"≥2 Doses, Males",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,70.3,61.0 to 78.2,173
HPV,"≥2 Doses, Males",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,63.1,53.3 to 72.0,165
HPV,"≥2 Doses, Males",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,47.8,40.7 to 55.0,282
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2017,Age,13-15 Years,90.0,83.5 to 94.2,195
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2019,Age,13-15 Years,87.6,80.3 to 92.4,178
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2016,Age,13-15 Years,81.9,72.8 to 88.5,216
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2015,Age,13-15 Years,86.7,81.4 to 90.7,330
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2014,Age,13-15 Years,92.5,87.1 to 95.8,240
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,77.0,68.2 to 84.0,142
HPV,"≥2 Doses, Males",States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,15.3,9.8 to 23.2,186
HPV,"≥2 Doses, Males",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,42.9,33.1 to 53.2,208
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2010,Age,13-15 Years,83.7,77.1 to 88.7,194
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2009,Age,13-15 Years,75.2,68.1 to 81.2,190
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2011,Age,13-15 Years,85.7,78.7 to 90.7,222
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,71.8,61.8 to 80.0,172
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,69.7,59.7 to 78.1,155
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,64.6,57.1 to 71.4,276
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,61.7,50.6 to 71.7,189
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,83.9,78.4 to 88.1,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,93.0,88.8 to 95.8,280
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2010,Age,13-15 Years,87.0,81.2 to 91.2,194
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2011,Age,13-15 Years,85.6,77.8 to 91.0,222
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2017,Age,13-15 Years,90.5,84.3 to 94.4,195
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2019,Age,13-15 Years,93.3,87.6 to 96.5,178
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,91.5,86.8 to 94.6,320
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,79.8,73.6 to 84.9,345
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,82.8,77.2 to 87.2,320
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,46.3,37.9 to 54.9,153
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,59.0,49.3 to 68.1,169
HPV,"≥2 Doses, Females",States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,55.4,46.4 to 64.0,148
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2015,Age,13-15 Years,89.1,83.7 to 92.8,330
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2014,Age,13-15 Years,95.5,92.1 to 97.5,240
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2016,Age,13-15 Years,89.5,82.1 to 94.1,216
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,71.0,64.4 to 76.9,345
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,88.1,81.7 to 92.4,345
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,90.4,85.0 to 94.0,397
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,86.7,82.7 to 89.9,558
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,87.5,82.2 to 91.5,355
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,87.9,83.4 to 91.3,313
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,84.9,80.2 to 88.6,325
HPV,"≥1 Dose, Males",States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,27.6,20.2 to 36.5,186
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,85.4,78.0 to 90.7,142
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,66.4,59.4 to 72.7,320
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2009,Age,13-15 Years,73.9,66.3 to 80.3,190
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,78.4,68.4 to 85.9,172
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,75.4,68.3 to 81.4,276
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,84.8,76.4 to 90.6,155
HPV,"≥1 Dose, Males",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,80.9,72.8 to 87.0,165
HPV,"≥1 Dose, Males",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,82.3,73.9 to 88.5,138
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,68.2,61.4 to 74.3,280
HPV,"≥1 Dose, Males",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,81.1,73.0 to 87.2,173
HPV,"≥1 Dose, Males",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,60.7,53.3 to 67.7,282
HPV,"≥1 Dose, Males",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,54.2,43.9 to 64.2,208
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,86.8,81.1 to 91.0,320
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,90.9,85.9 to 94.2,280
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,85.0,79.5 to 89.2,345
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,82.5,77.9 to 86.3,558
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,90.3,84.5 to 94.0,247
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2023,Age,13-15 Years,62.1,57.1 to 66.9,1035
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,92.9,88.4 to 95.8,278
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,93.7,88.6 to 96.6,247
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,90.5,86.0 to 93.7,355
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,81.1,74.4 to 86.4,397
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,71.9,61.1 to 80.7,189
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,82.6,75.6 to 88.0,287
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,77.2,71.7 to 82.0,442
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,76.9,68.7 to 83.5,303
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,67.4,58.8 to 74.9,148
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,75.0,66.2 to 82.1,169
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,84.4,78.0 to 89.2,278
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,92.1,86.1 to 95.6,287
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,88.8,84.3 to 92.1,442
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,93.5,87.6 to 96.7,303
HPV,"≥1 Dose, Females",States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,57.8,49.0 to 66.1,153
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,75.1,67.0 to 81.7,223
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,65.2,57.0 to 72.5,168
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,87.0,82.0 to 90.8,325
≥3 Doses HepB,,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,91.1,87.1 to 93.9,313
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2015,Age,13-15 Years,80.8,73.9 to 86.2,280
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2014,Age,13-15 Years,80.8,70.6 to 88.1,192
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,51.8,43.3 to 60.3,159
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,93.7,88.5 to 96.6,223
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,86.8,79.5 to 91.7,159
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,94.4,89.4 to 97.1,168
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2019,Age,13-15 Years,90.7,84.0 to 94.8,158
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2016,Age,13-15 Years,81.5,72.0 to 88.3,181
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2017,Age,13-15 Years,83.8,75.6 to 89.6,172
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2009,Age,13-15 Years,56.6,46.1 to 66.5,109
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2010,Age,13-15 Years,69.3,59.7 to 77.5,116
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-El Paso County,2011,Age,13-15 Years,79.2,69.3 to 86.5,152
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,91.2,86.0 to 94.6,280
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,85.6,79.6 to 90.1,345
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,86.5,80.9 to 90.7,320
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,81.9,77.3 to 85.8,558
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,82.5,75.8 to 87.6,397
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,84.4,78.8 to 88.7,355
HPV,"≥3 Doses, Males",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,34.4,28.1 to 41.3,282
HPV,"≥3 Doses, Males",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,31.8,23.0 to 42.1,208
HPV,"Up-to-Date, Males",States/Local Areas,TX-El Paso County,2018,Age,13-15 Years,NA,,
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,76.5,71.0 to 81.3,325
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,82.0,77.0 to 86.1,313
HPV,"≥3 Doses, Males",States/Local Areas,TX-El Paso County,2014,Age,13-15 Years,32.9,21.0 to 47.4,120
HPV,"≥3 Doses, Males",States/Local Areas,TX-El Paso County,2015,Age,13-15 Years,32.4,24.3 to 41.7,168
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,28.4,21.4 to 36.6,153
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,45.6,35.0 to 56.6,189
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,39.4,31.1 to 48.3,148
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,45.1,35.8 to 54.7,169
HPV,"≥3 Doses, Females",States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,52.2,44.8 to 59.5,276
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,63.7,56.8 to 70.1,280
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,83.4,79.1 to 87.0,558
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,88.4,83.8 to 91.9,355
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,87.5,82.7 to 91.1,313
≥2 Doses MMR,,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,85.6,80.5 to 89.5,325
HPV,"≥2 Doses, Males",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,59.7,49.6 to 69.1,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,60.0,52.9 to 66.6,320
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,86.3,80.4 to 90.6,397
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,83.6,78.1 to 87.9,355
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,64.5,58.7 to 70.0,325
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,79.5,74.2 to 83.9,313
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,66.0,59.0 to 72.4,345
Varicella,History of disease,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,17.3,12.5 to 23.6,345
Varicella,History of disease,States/Local Areas,TX-El Paso County,2015,Age,13-17 Years,20.6,16.8 to 25.0,558
Varicella,History of disease,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,13.8,9.7 to 19.2,320
HPV,"Up-to-Date, Females",States/Local Areas,TX-El Paso County,2018,Age,13-15 Years,NA,,
Varicella,History of disease,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,10.0,6.7 to 14.5,280
Varicella,History of disease,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,51.2,45.3 to 57.1,325
Varicella,History of disease,States/Local Areas,TX-El Paso County,2014,Age,13-17 Years,24.2,18.3 to 31.2,397
Varicella,History of disease,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,37.4,31.2 to 44.1,355
Varicella,History of disease,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,48.3,42.2 to 54.4,313
HPV,"Up-to-Date, Females",States/Local Areas,TX-El Paso County,2019,Age,13-15 Years,71.6,59.8 to 81.1,88
HPV,"Up-to-Date, Females",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,69.0,58.9 to 77.6,172
HPV,"Up-to-Date, Females",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,65.4,55.4 to 74.2,155
HPV,"Up-to-Date, Males",States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,54.6,44.8 to 64.2,165
HPV,"Up-to-Date, Males",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,56.3,46.2 to 65.8,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-El Paso County,2019,Age,13-15 Years,61.6,52.8 to 69.7,178
HPV,"Up-to-Date, Females",States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,71.4,62.0 to 79.3,142
HPV,"Up-to-Date, Males",States/Local Areas,TX-El Paso County,2019,Age,13-15 Years,51.6,39.1 to 63.9,90
HPV,"Up-to-Date, Males",States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,63.2,53.2 to 72.1,173
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,84.7,79.2 to 88.9,364
≥2 Doses MMR,,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,85.1,80.0 to 89.1,364
≥1 Dose MenACWY,,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,87.6,82.6 to 91.3,364
HPV,"≥2 Doses, Males",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,49.5,40.7 to 58.3,194
≥3 Doses HepB,,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,83.6,78.1 to 88.0,364
HPV,"≥2 Doses, Females",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,47.3,38.1 to 56.7,170
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Tarrant County,2018,Age,13-15 Years,86.7,80.2 to 91.3,223
HPV,"≥1 Dose, Females",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,63.8,54.6 to 72.2,170
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,48.4,42.0 to 54.9,364
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,84.7,79.3 to 88.9,321
HPV,"Up-to-Date, Males",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,46.4,37.7 to 55.2,194
≥1 Dose MenACWY,,States/Local Areas,TX-Tarrant County,2018,Age,13-15 Years,89.0,82.9 to 93.1,223
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,87.6,82.5 to 91.3,364
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,62.8,56.4 to 68.7,364
HPV,"≥1 Dose, Males",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,61.7,52.8 to 69.9,194
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,91.8,87.4 to 94.8,321
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Tarrant County,2018,Age,13-15 Years,85.4,78.6 to 90.4,202
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,86.6,81.9 to 90.3,364
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,45.9,39.6 to 52.4,364
HPV,"Up-to-Date, Females",States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,45.5,36.4 to 54.9,170
Varicella,History of disease,States/Local Areas,TX-Tarrant County,2018,Age,13-17 Years,12.6,8.9 to 17.4,364
HPV,"Up-to-Date, Females",States/Local Areas,TX-Tarrant County,2018,Age,13-15 Years,50.7,38.9 to 62.4,103
HPV,"Up-to-Date, Males",States/Local Areas,TX-Tarrant County,2018,Age,13-15 Years,48.0,37.3 to 59.0,120
≥1 Dose MenACWY,,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,88.2,81.6 to 92.6,314
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,37.3,32.6 to 42.3,486
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,83.8,76.9 to 89.0,314
≥2 Doses MMR,,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,78.3,71.2 to 83.9,314
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,49.4,41.8 to 57.1,314
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,82.9,76.4 to 87.9,314
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Hidalgo County,2018,Age,13-15 Years,75.9,65.8 to 83.8,165
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,87.1,79.9 to 92.0,265
HPV,"Up-to-Date, Males",States/Local Areas,TX-Hidalgo County,2018,Age,13-15 Years,46.3,33.9 to 59.2,98
HPV,"≥1 Dose, Males",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,63.5,53.1 to 72.7,170
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,53.3,45.6 to 60.9,314
≥3 Doses HepB,,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,77.4,70.3 to 83.3,314
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,78.7,71.0 to 84.8,265
HPV,"≥1 Dose, Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,69.4,57.4 to 79.2,144
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,66.3,58.6 to 73.3,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,88.8,82.2 to 93.2,314
≥1 Dose MenACWY,,States/Local Areas,TX-Hidalgo County,2018,Age,13-15 Years,83.3,73.4 to 89.9,190
HPV,"≥2 Doses, Males",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,54.3,44.0 to 64.1,170
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Hidalgo County,2018,Age,13-15 Years,80.4,70.3 to 87.7,190
HPV,"≥2 Doses, Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,52.3,40.7 to 63.7,144
HPV,"Up-to-Date, Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,49.7,38.3 to 61.1,144
Varicella,History of disease,States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,19.9,14.1 to 27.3,314
HPV,"Up-to-Date, Males",States/Local Areas,TX-Hidalgo County,2018,Age,13-17 Years,49.2,39.1 to 59.4,170
HPV,"Up-to-Date, Females",States/Local Areas,TX-Hidalgo County,2018,Age,13-15 Years,44.3,30.7 to 58.7,92
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2019,Age,13-17 Years,89.1,84.0 to 92.7,280
Varicella,History of disease,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,21.9,18.0 to 26.5,486
HPV,"≥3 Doses, Males",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,34.1,27.6 to 41.2,235
≥2 Doses MMR,,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,81.8,77.6 to 85.3,486
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,90.2,86.0 to 93.2,381
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,76.1,70.8 to 80.6,381
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,81.3,77.0 to 85.0,486
≥3 Doses HepB,,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,82.5,78.2 to 86.1,486
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Hidalgo County,2015,Age,13-15 Years,84.1,78.8 to 88.2,310
≥1 Dose MenACWY,,States/Local Areas,TX-Hidalgo County,2015,Age,13-15 Years,89.5,84.7 to 93.0,310
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Hidalgo County,2015,Age,13-15 Years,79.8,73.4 to 85.0,244
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,85.5,81.4 to 88.8,486
HPV,"≥3 Doses, Females",States/Local Areas,TX-Hidalgo County,2015,Age,13-15 Years,37.0,28.9 to 45.8,159
HPV,"≥3 Doses, Males",States/Local Areas,TX-Hidalgo County,2015,Age,13-15 Years,36.4,28.1 to 45.7,151
HPV,"≥3 Doses, Females",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,40.7,34.0 to 47.8,251
HPV,"≥1 Dose, Males",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,52.3,45.0 to 59.5,235
HPV,"≥2 Doses, Males",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,43.7,36.7 to 51.0,235
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,81.3,76.9 to 85.0,486
≥1 Dose MenACWY,,States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,88.8,85.1 to 91.7,486
HPV,"≥1 Dose, Females",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,66.9,59.9 to 73.2,251
HPV,"≥2 Doses, Females",States/Local Areas,TX-Hidalgo County,2015,Age,13-17 Years,56.7,49.5 to 63.6,251
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2009,Age,13-17 Years,67.4,61.5 to 72.9,325
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2011,Age,13-17 Years,84.2,78.4 to 88.6,355
≥1 Dose MenACWY,,States/Local Areas,TX-El Paso County,2010,Age,13-17 Years,80.8,75.8 to 85.0,313
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2016,Age,13-17 Years,83.4,76.6 to 88.6,345
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-El Paso County,2017,Age,13-17 Years,89.6,84.8 to 93.0,320
HPV,"≥1 Dose, Males",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,62.6,53.5 to 70.9,155
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,56.7,50.1 to 63.1,304
≥3 Doses HepB,,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,88.7,84.2 to 92.0,304
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,94.1,90.1 to 96.5,256
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,84.2,78.1 to 88.8,256
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Travis County,2017,Age,13-15 Years,84.1,76.6 to 89.5,179
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,86.8,81.6 to 90.7,304
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,52.0,45.4 to 58.5,304
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,85.9,80.9 to 89.8,304
≥2 Doses MMR,,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,86.5,81.5 to 90.3,304
≥1 Dose MenACWY,,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,89.1,84.4 to 92.4,304
Varicella,History of disease,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,16.4,11.9 to 22.1,304
HPV,"Up-to-Date, Females",States/Local Areas,TX-Travis County,2018,Age,13-15 Years,NA,,
HPV,"Up-to-Date, Males",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,46.9,38.1 to 55.9,155
HPV,"Up-to-Date, Females",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,57.0,47.3 to 66.2,149
HPV,"Up-to-Date, Males",States/Local Areas,TX-Travis County,2018,Age,13-15 Years,NA,,
HPV,"≥2 Doses, Males",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,52.8,43.8 to 61.7,155
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Travis County,2017,Age,13-15 Years,86.8,80.2 to 91.4,200
HPV,"≥2 Doses, Females",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,60.6,50.8 to 69.5,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,69.7,63.3 to 75.4,304
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Travis County,2017,Age,13-17 Years,88.7,84.0 to 92.1,304
≥1 Dose MenACWY,,States/Local Areas,TX-Travis County,2017,Age,13-15 Years,87.7,81.4 to 92.0,200
HPV,"≥1 Dose, Females",States/Local Areas,TX-Travis County,2017,Age,13-17 Years,76.8,67.6 to 84.0,149
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2016,Age,13-17 Years,50.8,41.7 to 59.8,154
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2022,Age,13-15 Years,63.0,49.6 to 74.7,101
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2021,Age,13-15 Years,57.4,44.7 to 69.3,88
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2019,Age,13-17 Years,58.2,46.9 to 68.7,162
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2018,Age,13-17 Years,52.9,42.2 to 63.3,124
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2017,Age,13-17 Years,64.3,55.3 to 72.3,156
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2019,Age,13-15 Years,63.3,49.8 to 75.1,109
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2018,Age,13-15 Years,39.7,27.5 to 53.4,85
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2022,Age,13-17 Years,69.3,59.3 to 77.8,169
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2021,Age,13-17 Years,60.7,50.0 to 70.4,129
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2020,Age,13-15 Years,57.3,45.3 to 68.4,116
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2019,Age,13-17 Years,60.7,50.0 to 70.4,174
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2020,Age,13-17 Years,58.0,48.6 to 66.7,185
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2017,Age,13-17 Years,41.9,33.5 to 50.8,185
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2018,Age,13-17 Years,40.8,31.5 to 50.8,160
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2021,Age,13-17 Years,67.1,57.9 to 75.1,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2019,Age,13-15 Years,63.8,54.4 to 72.2,220
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2022,Age,13-17 Years,65.5,56.0 to 73.8,161
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2021,Age,13-15 Years,58.1,49.2 to 66.6,193
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2020,Age,13-15 Years,59.4,50.7 to 67.5,223
HPV,"Up-to-Date, Males and Females",States/Local Areas,Louisiana,2022,Age,13-15 Years,64.1,55.4 to 72.0,210
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2016,Age,13-17 Years,33.2,25.7 to 41.7,182
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2022,Age,13-15 Years,65.0,53.4 to 75.1,109
HPV,"Up-to-Date, Males",States/Local Areas,Louisiana,2021,Age,13-15 Years,58.9,46.4 to 70.3,105
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2019,Age,13-15 Years,64.2,51.0 to 75.5,111
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2020,Age,13-15 Years,61.9,49.3 to 73.1,107
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2018,Age,13-15 Years,41.4,28.0 to 56.1,68
Varicella,History of disease,States/Local Areas,Louisiana,2018,Age,13-17 Years,13.2,9.2 to 18.6,284
Varicella,History of disease,States/Local Areas,Louisiana,2016,Age,13-17 Years,17.2,13.0 to 22.6,336
Varicella,History of disease,States/Local Areas,Louisiana,2017,Age,13-17 Years,11.2,7.8 to 15.9,341
Varicella,History of disease,States/Local Areas,Louisiana,2014,Age,13-17 Years,21.9,16.9 to 27.9,335
Varicella,History of disease,States/Local Areas,Louisiana,2012,Age,13-17 Years,32.5,26.8 to 38.8,370
Varicella,History of disease,States/Local Areas,Louisiana,2013,Age,13-17 Years,22.8,17.6 to 29.0,298
Varicella,History of disease,States/Local Areas,Louisiana,2011,Age,13-17 Years,40.7,34.7 to 47.0,473
Varicella,History of disease,States/Local Areas,Louisiana,2010,Age,13-17 Years,46.6,40.5 to 52.7,347
Varicella,History of disease,States/Local Areas,Louisiana,2015,Age,13-17 Years,14.5,10.7 to 19.3,382
Varicella,History of disease,States/Local Areas,Louisiana,2022,Age,13-17 Years,7.7,4.7 to 12.2,330
Varicella,History of disease,States/Local Areas,Louisiana,2021,Age,13-17 Years,3.9,2.3 to 6.7,303
Varicella,History of disease,States/Local Areas,Louisiana,2020,Age,13-17 Years,8.4,5.3 to 13.2,356
Varicella,History of disease,States/Local Areas,Louisiana,2019,Age,13-17 Years,9.4,5.7 to 15.1,336
HPV,"Up-to-Date, Females",States/Local Areas,Louisiana,2020,Age,13-17 Years,62.9,52.9 to 71.9,171
Varicella,History of disease,States/Local Areas,Louisiana,2009,Age,13-17 Years,60.5,53.3 to 67.3,281
Varicella,History of disease,States/Local Areas,Louisiana,2008,Age,13-17 Years,63.8,57.4 to 69.7,379
≥3 Doses HepB,,HHS Regions/National,Region 3,2017,Age,13-17 Years,93.4,91.4 to 94.9,2745
≥3 Doses HepB,,HHS Regions/National,Region 3,2018,Age,13-17 Years,93.9,92.1 to 95.4,2295
≥3 Doses HepB,,HHS Regions/National,Region 3,2019,Age,13-17 Years,92.9,90.8 to 94.6,2520
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2018,Age,13-17 Years,95.7,94.1 to 96.9,2080
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2019,Age,13-17 Years,93.7,91.8 to 95.1,2323
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2020,Age,13-17 Years,93.3,91.5 to 94.7,3077
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2021,Age,13-17 Years,92.1,90.2 to 93.7,3141
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2018,Age,13-17 Years,91.1,88.6 to 93.2,2080
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2020,Age,13-17 Years,96.0,94.6 to 97.1,3077
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2017,Age,13-17 Years,96.8,95.3 to 97.9,2437
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2019,Age,13-17 Years,96.7,95.2 to 97.7,2323
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2012,Age,13-17 Years,95.7,94.1 to 97.0,1804
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2013,Age,13-17 Years,96.6,94.4 to 98.0,1764
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2014,Age,13-17 Years,95.7,93.8 to 97.0,2147
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2015,Age,13-17 Years,95.4,93.2 to 96.9,2339
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2016,Age,13-17 Years,94.4,92.4 to 95.9,2518
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2012,Age,13-17 Years,52.2,47.1 to 57.4,1089
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2013,Age,13-17 Years,55.1,49.6 to 60.5,1101
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2014,Age,13-17 Years,62.5,57.7 to 67.2,1222
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2015,Age,13-17 Years,63.0,58.1 to 67.7,1295
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2007,Age,13-15 Years,28.2,18.5 to 40.6,101
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2011,Age,13-17 Years,49.5,44.9 to 54.1,1458
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2010,Age,13-17 Years,50.4,45.8 to 55.1,1161
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2017,Age,13-17 Years,89.5,87.0 to 91.6,2437
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2013,Age,13-17 Years,80.4,76.7 to 83.6,1764
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2014,Age,13-17 Years,84.9,81.9 to 87.4,2147
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2015,Age,13-17 Years,81.9,78.6 to 84.8,2339
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2016,Age,13-17 Years,85.0,82.2 to 87.5,2518
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2012,Age,13-15 Years,82.7,78.8 to 86.1,1201
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2013,Age,13-15 Years,81.4,76.7 to 85.3,1145
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2011,Age,13-15 Years,73.3,68.9 to 77.3,1428
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2010,Age,13-15 Years,68.1,63.6 to 72.3,1054
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2008,Age,13-15 Years,43.0,37.5 to 48.7,808
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2009,Age,13-15 Years,55.7,49.8 to 61.3,890
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2015,Age,13-15 Years,83.8,79.7 to 87.3,1477
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2014,Age,13-15 Years,84.6,80.8 to 87.8,1341
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2018,Age,13-15 Years,92.3,89.3 to 94.5,1319
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2019,Age,13-15 Years,94.1,91.7 to 95.8,1467
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2017,Age,13-15 Years,92.2,89.5 to 94.2,1577
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2016,Age,13-15 Years,87.3,83.8 to 90.1,1591
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2010,Age,13-17 Years,77.3,74.6 to 79.8,2436
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2009,Age,13-17 Years,76.1,72.9 to 79.1,2214
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2007,Age,13-17 Years,73.1,67.2 to 78.4,370
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2012,Age,13-17 Years,86.0,83.4 to 88.3,2365
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2011,Age,13-17 Years,80.8,78.2 to 83.1,3073
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2013,Age,13-17 Years,84.4,81.4 to 87.0,2241
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2020,Age,13-17 Years,93.9,92.3 to 95.2,3331
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2021,Age,13-17 Years,92.6,90.7 to 94.0,3338
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2022,Age,13-17 Years,92.0,90.1 to 93.5,2424
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2015,Age,13-17 Years,84.8,81.9 to 87.3,2742
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2014,Age,13-17 Years,87.0,84.5 to 89.2,2553
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2012,Age,13-15 Years,3.3,2.0 to 5.3,799
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2014,Age,13-15 Years,20.9,16.2 to 26.5,817
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2013,Age,13-17 Years,14.6,11.2 to 18.7,1140
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2012,Age,13-17 Years,4.6,3.2 to 6.4,1276
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2015,Age,13-17 Years,32.9,28.7 to 37.4,1447
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2014,Age,13-17 Years,24.8,20.8 to 29.3,1331
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2019,Age,13-17 Years,94.2,92.5 to 95.6,2520
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2017,Age,13-17 Years,90.7,88.4 to 92.6,2745
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2018,Age,13-17 Years,92.0,89.7 to 93.8,2295
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2016,Age,13-17 Years,87.0,84.5 to 89.1,2842
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2008,Age,13-17 Years,70.3,67.1 to 73.2,2306
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2006,Age,13-17 Years,66.9,60.6 to 72.6,347
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2013,Age,13-15 Years,13.9,10.0 to 19.1,711
HPV,"≥3 Doses, Males",HHS Regions/National,Region 3,2015,Age,13-15 Years,29.8,24.5 to 35.7,910
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2011,Age,13-17 Years,35.1,30.9 to 39.5,1458
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2013,Age,13-17 Years,37.8,32.9 to 43.1,1101
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2014,Age,13-17 Years,42.5,37.7 to 47.4,1222
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2012,Age,13-17 Years,36.8,32.1 to 41.8,1089
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2010,Age,13-17 Years,38.3,33.9 to 43.0,1161
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2015,Age,13-17 Years,44.2,39.3 to 49.1,1295
≥2 Doses Hep A,,HHS Regions/National,Region 3,2020,Age,13-17 Years,82.8,80.2 to 85.1,3331
≥2 Doses Hep A,,HHS Regions/National,Region 3,2022,Age,13-17 Years,86.6,84.3 to 88.7,2424
≥2 Doses Hep A,,HHS Regions/National,Region 3,2021,Age,13-17 Years,85.8,83.5 to 87.9,3338
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2018,Age,13-17 Years,67.6,61.9 to 72.8,1182
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2019,Age,13-17 Years,76.6,72.2 to 80.4,1344
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2020,Age,13-17 Years,76.0,71.8 to 79.7,1699
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2021,Age,13-17 Years,76.2,72.3 to 79.7,1792
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 3,2018,Age,13-17 Years,58.8,54.7 to 62.8,2295
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2019,Age,13-17 Years,76.0,71.2 to 80.2,1176
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 3,2017,Age,13-17 Years,58.9,55.5 to 62.3,2745
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2022,Age,13-17 Years,91.4,89.4 to 93.0,2266
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2020,Age,13-17 Years,78.3,74.3 to 81.9,1632
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2021,Age,13-17 Years,82.2,78.6 to 85.4,1546
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2011,Age,13-17 Years,9.2,7.1 to 11.8,1615
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2022,Age,13-17 Years,79.4,75.4 to 82.9,1131
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 3,2016,Age,13-17 Years,52.4,49.1 to 55.7,2842
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2017,Age,13-17 Years,66.5,61.9 to 70.8,1471
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2007,Age,13-17 Years,27.1,19.5 to 36.3,183
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2007,Age,13-17 Years,83.5,75.9 to 89.0,145
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2007,Age,13-17 Years,30.1,21.1 to 41.1,145
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2012,Age,13-17 Years,81.2,77.8 to 84.2,1804
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2008,Age,13-17 Years,42.8,38.4 to 47.4,1176
≥3 Doses HepB,,HHS Regions/National,Region 3,2008,Age,13-17 Years,90.1,87.8 to 92.0,2306
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2020,Age,13-15 Years,93.3,90.8 to 95.2,1919
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2021,Age,13-15 Years,92.2,89.7 to 94.1,1977
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2008,Age,13-17 Years,85.1,81.0 to 88.4,1124
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2010,Age,13-17 Years,93.0,90.7 to 94.8,1538
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2009,Age,13-17 Years,92.6,90.0 to 94.6,1213
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2008,Age,13-17 Years,39.5,35.0 to 44.2,1124
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2009,Age,13-17 Years,55.0,50.0 to 59.9,1213
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2006,Age,13-17 Years,73.3,63.8 to 81.0,135
≥3 Doses HepB,,HHS Regions/National,Region 3,2007,Age,13-17 Years,88.9,84.8 to 92.0,370
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2011,Age,13-17 Years,94.0,92.0 to 95.4,2161
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2010,Age,13-17 Years,64.2,60.4 to 67.9,1538
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2011,Age,13-17 Years,72.3,68.8 to 75.5,2161
≥3 Doses HepB,,HHS Regions/National,Region 3,2006,Age,13-17 Years,85.2,79.9 to 89.3,347
≥3 Doses HepB,,HHS Regions/National,Region 3,2010,Age,13-17 Years,92.4,90.2 to 94.0,2436
≥3 Doses HepB,,HHS Regions/National,Region 3,2009,Age,13-17 Years,91.3,89.1 to 93.2,2214
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2022,Age,13-15 Years,92.6,90.2 to 94.5,1410
≥3 Doses HepB,,HHS Regions/National,Region 3,2015,Age,13-17 Years,91.2,89.0 to 93.0,2742
≥3 Doses HepB,,HHS Regions/National,Region 3,2016,Age,13-17 Years,90.8,88.6 to 92.6,2842
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2016,Age,13-17 Years,91.3,89.1 to 93.0,2842
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2014,Age,13-17 Years,92.4,90.5 to 93.9,2553
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2015,Age,13-17 Years,90.1,87.7 to 92.0,2742
≥3 Doses HepB,,HHS Regions/National,Region 3,2022,Age,13-17 Years,91.8,90.0 to 93.2,2424
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2018,Age,13-17 Years,74.3,69.0 to 78.9,1113
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2022,Age,13-17 Years,95.2,93.7 to 96.3,2266
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2021,Age,13-17 Years,95.1,93.5 to 96.3,3141
≥3 Doses HepB,,HHS Regions/National,Region 3,2020,Age,13-17 Years,94.2,92.5 to 95.5,3331
≥3 Doses HepB,,HHS Regions/National,Region 3,2021,Age,13-17 Years,92.1,90.2 to 93.6,3338
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2012,Age,13-17 Years,18.9,15.8 to 22.6,1276
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2013,Age,13-17 Years,36.5,31.7 to 41.6,1140
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2014,Age,13-17 Years,44.4,39.6 to 49.4,1331
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2015,Age,13-17 Years,51.1,46.4 to 55.8,1447
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2016,Age,13-17 Years,57.6,53.0 to 62.0,1522
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 3,2019,Age,13-17 Years,63.6,60.1 to 67.0,2520
≥3 Doses HepB,,HHS Regions/National,Region 3,2012,Age,13-17 Years,93.5,91.7 to 95.0,2365
≥3 Doses HepB,,HHS Regions/National,Region 3,2011,Age,13-17 Years,93.1,91.3 to 94.5,3073
≥3 Doses HepB,,HHS Regions/National,Region 3,2013,Age,13-17 Years,93.0,90.8 to 94.6,2241
≥3 Doses HepB,,HHS Regions/National,Region 3,2014,Age,13-17 Years,91.4,89.2 to 93.2,2553
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2007,Age,13-17 Years,75.2,69.8 to 79.9,370
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2006,Age,13-17 Years,65.0,58.3 to 71.2,347
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2015,Age,13-15 Years,84.2,80.5 to 87.3,1683
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2014,Age,13-15 Years,84.7,81.1 to 87.6,1552
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2007,Age,13-17 Years,17.6,12.3 to 24.5,183
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2009,Age,13-17 Years,45.3,40.1 to 50.6,1049
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2017,Age,13-17 Years,74.2,69.5 to 78.3,1274
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2016,Age,13-17 Years,65.0,60.2 to 69.5,1320
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2016,Age,13-15 Years,85.3,81.7 to 88.3,1768
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2012,Age,13-15 Years,77.6,73.5 to 81.2,1473
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2013,Age,13-15 Years,77.4,72.8 to 81.4,1381
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2017,Age,13-17 Years,91.2,88.9 to 93.1,2745
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2017,Age,13-17 Years,70.3,67.0 to 73.3,2745
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2016,Age,13-17 Years,61.2,57.9 to 64.4,2842
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2008,Age,13-17 Years,76.1,73.2 to 78.8,2306
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2009,Age,13-17 Years,80.4,77.5 to 83.1,2214
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2022,Age,13-17 Years,77.2,73.3 to 80.7,1293
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2012,Age,13-17 Years,88.2,85.8 to 90.2,2365
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2013,Age,13-17 Years,88.9,86.2 to 91.1,2241
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2010,Age,13-17 Years,81.4,78.7 to 83.9,2436
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2011,Age,13-17 Years,85.8,83.3 to 87.9,3073
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2009,Age,13-15 Years,59.9,55.4 to 64.2,1381
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2008,Age,13-15 Years,55.0,50.8 to 59.1,1401
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2008,Age,13-17 Years,32.3,28.2 to 36.7,1176
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2011,Age,13-15 Years,73.4,69.6 to 76.9,1850
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2010,Age,13-15 Years,69.9,66.3 to 73.3,1486
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2006,Age,13-15 Years,15.8,11.3 to 21.7,209
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2007,Age,13-15 Years,42.5,33.8 to 51.7,221
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2010,Age,13-17 Years,46.4,41.8 to 51.1,1161
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2011,Age,13-17 Years,41.6,37.3 to 46.2,1458
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2009,Age,13-17 Years,36.8,31.9 to 42.0,1049
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2020,Age,13-15 Years,89.4,86.5 to 91.8,2067
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2012,Age,13-17 Years,45.4,40.4 to 50.5,1089
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2013,Age,13-17 Years,48.0,42.6 to 53.4,1101
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2017,Age,13-15 Years,89.3,86.0 to 91.9,1721
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2018,Age,13-15 Years,89.2,85.7 to 91.9,1439
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2019,Age,13-15 Years,90.5,87.4 to 93.0,1589
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2018,Age,13-17 Years,91.8,89.2 to 93.7,2295
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2019,Age,13-17 Years,93.3,91.2 to 94.9,2520
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2020,Age,13-17 Years,93.9,92.4 to 95.1,3331
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2019,Age,13-17 Years,76.3,73.1 to 79.2,2520
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2018,Age,13-17 Years,70.9,67.0 to 74.4,2295
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2021,Age,13-17 Years,92.0,90.2 to 93.5,3338
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2020,Age,13-17 Years,77.1,74.3 to 79.8,3331
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2021,Age,13-17 Years,79.1,76.5 to 81.5,3338
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2017,Age,13-17 Years,65.2,60.3 to 69.9,1274
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2016,Age,13-17 Years,56.1,51.2 to 60.8,1320
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2015,Age,13-17 Years,53.9,48.9 to 58.8,1295
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2014,Age,13-17 Years,54.3,49.4 to 59.2,1222
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2022,Age,13-17 Years,78.3,75.5 to 80.8,2424
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2018,Age,13-17 Years,64.3,58.7 to 69.6,1113
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2019,Age,13-17 Years,64.0,58.8 to 68.8,1176
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2021,Age,13-15 Years,90.3,87.6 to 92.5,2095
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2018,Age,13-17 Years,53.6,47.7 to 59.3,1182
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2017,Age,13-17 Years,52.9,48.1 to 57.6,1471
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2016,Age,13-17 Years,48.9,44.4 to 53.5,1522
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2006,Age,13-15 Years,12.3,8.2 to 18.1,209
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2007,Age,13-15 Years,42.9,34.0 to 52.4,221
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2012,Age,13-15 Years,85.5,82.4 to 88.2,1473
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2011,Age,13-15 Years,77.9,74.1 to 81.2,1850
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2009,Age,13-15 Years,66.1,61.6 to 70.3,1381
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2010,Age,13-15 Years,76.5,72.9 to 79.7,1486
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2008,Age,13-15 Years,53.2,49.1 to 57.3,1401
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2022,Age,13-17 Years,92.2,90.2 to 93.8,2424
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2017,Age,13-15 Years,90.3,87.1 to 92.7,1721
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2016,Age,13-15 Years,88.7,85.7 to 91.1,1768
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2015,Age,13-15 Years,88.4,85.1 to 91.0,1683
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2014,Age,13-15 Years,91.0,88.4 to 93.0,1552
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2013,Age,13-15 Years,85.1,81.3 to 88.3,1381
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2011,Age,13-17 Years,3.9,2.6 to 5.9,1615
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2012,Age,13-17 Years,11.5,9.1 to 14.6,1276
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2013,Age,13-17 Years,24.5,20.3 to 29.3,1140
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2014,Age,13-17 Years,34.5,30.0 to 39.3,1331
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2015,Age,13-17 Years,43.0,38.4 to 47.6,1447
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2019,Age,13-15 Years,91.6,88.8 to 93.7,1589
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2020,Age,13-15 Years,90.9,88.3 to 92.9,2067
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2021,Age,13-15 Years,89.8,87.2 to 92.0,2095
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2018,Age,13-15 Years,89.5,85.7 to 92.4,1439
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2022,Age,13-17 Years,91.2,89.3 to 92.8,2424
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2021,Age,13-17 Years,91.4,89.4 to 93.0,3338
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2022,Age,13-15 Years,90.0,87.4 to 92.2,1494
≥2 Doses MMR,,HHS Regions/National,Region 3,2016,Age,13-17 Years,90.2,88.0 to 92.0,2842
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 3,2011,Age,13-17 Years,18.1,15.9 to 20.6,3073
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2016,Age,13-17 Years,88.9,86.6 to 90.8,2842
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2010,Age,13-17 Years,68.8,65.8 to 71.7,2436
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2011,Age,13-17 Years,75.0,72.2 to 77.6,3073
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2008,Age,13-17 Years,52.7,49.4 to 56.0,2306
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2009,Age,13-17 Years,60.9,57.4 to 64.3,2214
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2013,Age,13-17 Years,79.7,76.3 to 82.7,2241
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2014,Age,13-17 Years,85.9,83.4 to 88.1,2553
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2015,Age,13-17 Years,84.6,81.8 to 87.1,2742
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2016,Age,13-17 Years,84.7,81.9 to 87.1,2842
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2018,Age,13-17 Years,89.6,86.9 to 91.8,2295
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2017,Age,13-17 Years,89.5,87.0 to 91.6,2745
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2012,Age,13-17 Years,77.2,74.0 to 80.1,2365
≥2 Doses MMR,,HHS Regions/National,Region 3,2014,Age,13-17 Years,90.8,88.4 to 92.7,2553
≥2 Doses MMR,,HHS Regions/National,Region 3,2015,Age,13-17 Years,90.6,88.2 to 92.5,2742
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2007,Age,13-17 Years,40.6,34.2 to 47.4,370
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2022,Age,13-17 Years,91.4,89.4 to 93.1,2424
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2006,Age,13-17 Years,15.4,11.7 to 20.0,347
≥2 Doses MMR,,HHS Regions/National,Region 3,2012,Age,13-17 Years,91.5,89.2 to 93.4,2365
≥2 Doses MMR,,HHS Regions/National,Region 3,2013,Age,13-17 Years,92.6,90.4 to 94.4,2241
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2019,Age,13-17 Years,91.5,89.2 to 93.4,2520
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2020,Age,13-17 Years,92.3,90.7 to 93.7,3331
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2021,Age,13-17 Years,89.7,87.7 to 91.4,3338
≥2 Doses MMR,,HHS Regions/National,Region 3,2018,Age,13-17 Years,93.8,92.0 to 95.2,2295
≥2 Doses MMR,,HHS Regions/National,Region 3,2017,Age,13-17 Years,94.5,92.8 to 95.8,2745
≥2 Doses MMR,,HHS Regions/National,Region 3,2019,Age,13-17 Years,93.4,91.3 to 95.0,2520
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 3,2012,Age,13-17 Years,20.3,17.7 to 23.2,2365
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 3,2013,Age,13-17 Years,25.9,22.9 to 29.3,2241
≥2 Doses MMR,,HHS Regions/National,Region 3,2020,Age,13-17 Years,94.2,92.5 to 95.5,3331
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 3,2015,Age,13-17 Years,38.4,35.2 to 41.7,2742
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 3,2014,Age,13-17 Years,33.4,30.3 to 36.8,2553
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2012,Age,13-15 Years,26.7,21.8 to 32.2,674
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2013,Age,13-15 Years,30.2,24.5 to 36.5,670
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2015,Age,13-15 Years,38.4,32.3 to 44.9,773
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2014,Age,13-15 Years,34.2,28.4 to 40.4,735
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2017,Age,13-17 Years,88.8,86.3 to 91.0,2745
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2018,Age,13-17 Years,89.1,86.3 to 91.3,2295
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2019,Age,13-17 Years,91.7,89.4 to 93.6,2520
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2020,Age,13-17 Years,91.4,89.5 to 93.0,3331
≥2 Doses MMR,,HHS Regions/National,Region 3,2021,Age,13-17 Years,93.4,91.7 to 94.8,3338
≥2 Doses MMR,,HHS Regions/National,Region 3,2022,Age,13-17 Years,92.3,90.5 to 93.8,2424
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2011,Age,13-15 Years,27.8,23.0 to 33.2,895
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2010,Age,13-15 Years,35.1,29.4 to 41.2,690
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2009,Age,13-15 Years,25.9,20.8 to 31.6,647
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2008,Age,13-15 Years,22.6,18.0 to 28.0,725
HPV,"≥1 Dose, Males",HHS Regions/National,Region 3,2023,Age,13-17 Years,80.8,76.1 to 84.7,1288
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2023,Age,13-17 Years,65.1,59.4 to 70.4,1185
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2023,Age,13-15 Years,60.8,53.6 to 67.6,790
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2023,Age,13-15 Years,91.7,88.2 to 94.2,1416
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2023,Age,13-15 Years,61.3,53.6 to 68.5,708
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2023,Age,13-15 Years,61.1,55.8 to 66.1,1498
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2023,Age,13-15 Years,90.3,86.7 to 92.9,1498
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2023,Age,13-15 Years,91.5,88.2 to 93.9,1498
≥2 Doses Hep A,,HHS Regions/National,Region 3,2023,Age,13-17 Years,85.2,82.0 to 87.9,2473
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 3,2023,Age,13-17 Years,91.3,88.8 to 93.3,2473
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 3,2023,Age,13-17 Years,90.9,88.3 to 93.0,2349
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 3,2023,Age,13-17 Years,94.3,91.9 to 96.1,2349
Varicella,History of disease,HHS Regions/National,Region 3,2023,Age,13-17 Years,4.4,3.1 to 6.3,2473
≥2 Doses MMR,,HHS Regions/National,Region 3,2023,Age,13-17 Years,92.2,89.8 to 94.1,2473
≥3 Doses HepB,,HHS Regions/National,Region 3,2023,Age,13-17 Years,90.6,87.9 to 92.7,2473
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2023,Age,13-17 Years,64.6,60.7 to 68.4,2473
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2023,Age,13-17 Years,64.2,58.6 to 69.4,1288
HPV,"≥1 Dose, Females",HHS Regions/National,Region 3,2023,Age,13-17 Years,79.9,75.1 to 84.0,1185
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 3,2023,Age,13-17 Years,80.3,77.1 to 83.2,2473
≥1 Dose MenACWY,,HHS Regions/National,Region 3,2023,Age,13-17 Years,90.7,88.1 to 92.8,2473
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 3,2023,Age,13-17 Years,91.2,88.6 to 93.2,2473
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2023,Age,13-17 Years,90.7,88.1 to 92.7,2473
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 3,2022,Age,13-17 Years,67.9,64.9 to 70.7,2424
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2022,Age,13-17 Years,66.3,62.1 to 70.2,1293
HPV,"≥2 Doses, Females",HHS Regions/National,Region 3,2022,Age,13-17 Years,69.6,65.3 to 73.6,1131
HPV,"≥2 Doses, Males and Females",States/Local Areas,New Mexico,2022,Age,13-17 Years,62.6,55.2 to 69.5,276
HPV,"≥2 Doses, Males",States/Local Areas,New Mexico,2022,Age,13-17 Years,60.1,49.6 to 69.9,128
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2023,Age,13-15 Years,69.2,56.4 to 79.6,90
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2023,Age,13-15 Years,93.0,86.9 to 96.4,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2023,Age,13-15 Years,64.3,55.0 to 72.6,173
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2023,Age,13-15 Years,92.6,86.1 to 96.1,173
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2023,Age,13-15 Years,90.1,82.4 to 94.7,173
≥2 Doses Hep A,,States/Local Areas,New Mexico,2023,Age,13-17 Years,90.1,84.7 to 93.8,271
Varicella,≥2 Doses or history of disease,States/Local Areas,New Mexico,2023,Age,13-17 Years,93.5,89.6 to 96.0,271
≥3 Doses HepB,,States/Local Areas,New Mexico,2023,Age,13-17 Years,91.7,86.8 to 94.8,271
Varicella,History of disease,States/Local Areas,New Mexico,2023,Age,13-17 Years,10.4,6.5 to 16.5,271
Varicella,≥1 Dose with no disease history,States/Local Areas,New Mexico,2023,Age,13-17 Years,95.4,91.6 to 97.5,247
Varicella,≥2 Doses with no disease history,States/Local Areas,New Mexico,2023,Age,13-17 Years,92.8,88.4 to 95.6,247
HPV,"Up-to-Date, Males",States/Local Areas,New Mexico,2023,Age,13-17 Years,64.7,54.3 to 73.9,141
≥2 Doses MMR,,States/Local Areas,New Mexico,2023,Age,13-17 Years,92.0,87.3 to 95.0,271
HPV,"Up-to-Date, Males and Females",States/Local Areas,New Mexico,2023,Age,13-17 Years,60.9,53.4 to 67.9,271
HPV,"≥1 Dose, Females",States/Local Areas,New Mexico,2023,Age,13-17 Years,83.2,73.7 to 89.8,130
HPV,"≥1 Dose, Males and Females",States/Local Areas,New Mexico,2023,Age,13-17 Years,84.5,78.5 to 89.1,271
≥1 Dose MenACWY,,States/Local Areas,New Mexico,2023,Age,13-17 Years,92.8,88.2 to 95.8,271
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,New Mexico,2023,Age,13-17 Years,91.9,86.7 to 95.2,271
Tetanus,≥1 Dose Tdap,States/Local Areas,New Mexico,2023,Age,13-17 Years,91.1,85.7 to 94.6,271
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2009,Age,13-17 Years,53.2,43.8 to 62.4,262
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,94.8,91.6 to 96.8,741
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,93.5,89.8 to 95.9,880
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,92.9,88.9 to 95.6,751
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,94.6,91.4 to 96.6,785
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,97.7,94.8 to 99.0,599
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,95.4,92.6 to 97.1,851
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,94.5,91.1 to 96.7,734
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,97.2,95.1 to 98.4,649
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,93.0,90.1 to 95.2,875
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,93.3,90.2 to 95.4,832
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,96.6,94.3 to 97.9,684
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,92.3,88.9 to 94.7,886
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,94.5,90.9 to 96.7,709
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,95.7,92.8 to 97.4,604
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,97.0,94.1 to 98.5,709
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,98.6,96.8 to 99.4,760
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,97.6,95.4 to 98.8,684
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,97.7,95.5 to 98.8,604
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,96.8,94.5 to 98.1,782
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,97.5,94.2 to 98.9,729
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,97.2,92.8 to 98.9,613
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,99.3,98.4 to 99.7,652
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2021,Age,13-15 Years,92.0,87.4 to 95.0,535
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2020,Age,13-15 Years,93.3,87.5 to 96.5,430
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2012,Age,13-15 Years,92.7,88.2 to 95.6,392
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2013,Age,13-15 Years,92.8,87.0 to 96.1,385
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2011,Age,13-15 Years,86.3,79.0 to 91.3,431
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2010,Age,13-15 Years,83.2,77.1 to 87.9,360
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2008,Age,13-15 Years,50.9,42.1 to 59.6,261
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2009,Age,13-15 Years,65.3,54.9 to 74.4,268
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,94.5,91.5 to 96.5,760
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2011,Age,13-17 Years,51.9,44.0 to 59.8,435
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2010,Age,13-17 Years,52.3,44.7 to 59.7,360
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,91.8,88.4 to 94.3,782
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,91.2,86.8 to 94.3,729
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,92.1,88.0 to 95.0,613
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,94.4,90.7 to 96.6,652
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,57.4,49.3 to 65.2,337
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,59.5,51.3 to 67.3,379
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,62.2,54.3 to 69.5,397
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,66.8,59.1 to 73.8,380
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2018,Age,13-15 Years,96.3,92.8 to 98.1,368
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2019,Age,13-15 Years,96.3,93.0 to 98.1,406
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2014,Age,13-15 Years,93.5,87.5 to 96.7,392
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2015,Age,13-15 Years,92.8,87.7 to 95.9,442
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2017,Age,13-15 Years,95.9,92.4 to 97.8,471
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2016,Age,13-15 Years,93.7,89.9 to 96.1,474
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,96.0,93.4 to 97.6,649
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,92.9,89.9 to 95.1,875
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,95.1,92.3 to 96.9,851
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,92.2,88.3 to 94.9,832
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,72.4,67.3 to 77.0,682
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,15.4,10.6 to 21.8,372
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,5.3,3.1 to 9.0,404
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,26.0,19.9 to 33.2,405
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,38.3,31.7 to 45.5,435
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,87.4,83.6 to 90.4,742
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,80.9,75.1 to 85.5,579
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,92.6,88.5 to 95.3,741
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,89.0,85.0 to 92.1,880
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,93.9,90.6 to 96.1,751
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,95.3,92.2 to 97.2,785
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,96.8,94.7 to 98.1,734
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,92.7,89.3 to 95.1,752
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,92.7,89.5 to 95.0,929
Varicella,≥2 Doses or history of disease,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,95.0,91.7 to 97.0,765
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2014,Age,13-15 Years,20.1,13.2 to 29.4,234
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2008,Age,13-17 Years,25.7,19.5 to 33.0,346
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2009,Age,13-17 Years,37.5,28.9 to 46.9,262
HPV,"≥2 Doses, Males and Females",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,58.6,51.9 to 65.1,649
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,78.9,71.7 to 84.7,351
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,92.2,88.5 to 94.7,709
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,57.2,49.9 to 64.1,485
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,55.9,48.7 to 62.9,435
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,44.1,36.5 to 52.0,372
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,47.4,39.6 to 55.3,405
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,65.6,58.5 to 72.0,458
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,95.3,91.8 to 97.4,682
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,93.7,89.9 to 96.2,742
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,95.2,92.0 to 97.1,579
HPV,"≥2 Doses, Males and Females",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,63.9,58.3 to 69.1,734
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2022,Age,13-15 Years,94.6,90.5 to 97.0,449
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,96.0,92.0 to 98.0,508
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,97.2,94.5 to 98.6,358
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,48.4,41.1 to 55.7,370
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,67.5,58.9 to 75.0,358
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,97.9,96.0 to 98.9,664
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,94.2,89.7 to 96.8,370
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,80.5,75.0 to 85.0,508
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,85.0,79.7 to 89.1,664
Varicella,≥2 Doses with no disease history,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,90.4,85.1 to 93.9,599
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2008,Age,13-17 Years,46.1,38.7 to 53.7,346
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,95.0,92.6 to 96.6,752
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,92.6,89.4 to 94.9,929
≥3 Doses HepB,,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,95.0,91.2 to 97.2,765
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,75.9,67.5 to 82.7,314
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,94.2,91.1 to 96.3,886
Varicella,≥1 Dose with no disease history,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,97.3,95.3 to 98.4,709
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,21.9,16.5 to 28.4,404
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,76.1,68.8 to 82.1,339
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2011,Age,13-17 Years,8.5,5.5 to 12.9,445
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2021,Age,13-17 Years,77.4,70.8 to 82.8,434
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2020,Age,13-17 Years,77.0,69.0 to 83.4,394
HPV,"≥2 Doses, Males and Females",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,57.5,52.3 to 62.6,851
HPV,"≥2 Doses, Males and Females",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,57.4,52.3 to 62.4,875
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2021,Age,13-17 Years,78.0,72.0 to 83.0,495
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2020,Age,13-17 Years,79.8,71.9 to 85.9,371
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,68.3,58.7 to 76.6,335
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,75.2,68.0 to 81.3,383
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2012,Age,13-15 Years,88.9,83.2 to 92.8,461
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2013,Age,13-15 Years,88.9,82.9 to 93.0,459
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,91.1,87.1 to 93.9,851
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,95.0,92.4 to 96.7,875
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,94.0,91.3 to 95.9,832
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,94.4,91.4 to 96.4,785
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2014,Age,13-15 Years,96.6,93.8 to 98.2,455
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2015,Age,13-15 Years,94.5,91.5 to 96.4,492
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,69.2,61.3 to 76.1,393
HPV,"≥1 Dose, Females",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,72.0,65.1 to 78.1,390
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2016,Age,13-15 Years,93.0,89.0 to 95.6,515
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,52.1,44.0 to 60.1,337
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,53.5,45.3 to 61.5,379
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2019,Age,13-15 Years,94.0,89.9 to 96.5,436
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018,Age,13-15 Years,94.6,90.6 to 96.9,392
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2017,Age,13-15 Years,93.8,90.0 to 96.3,520
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,77.0,72.0 to 81.4,734
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,72.0,65.7 to 77.6,649
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,94.1,90.9 to 96.2,752
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,92.4,89.5 to 94.5,929
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,92.5,87.7 to 95.5,649
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,82.0,77.1 to 86.0,682
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,84.7,79.6 to 88.7,579
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,91.4,87.8 to 94.1,741
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,93.5,90.0 to 95.8,751
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,84.7,79.9 to 88.5,742
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,89.3,85.2 to 92.3,880
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2008,Age,13-17 Years,37.0,30.0 to 44.5,346
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,67.3,62.2 to 72.1,851
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,64.4,59.3 to 69.2,875
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2009,Age,13-17 Years,43.3,34.3 to 52.6,262
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2020,Age,13-15 Years,93.5,88.5 to 96.4,468
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2010,Age,13-17 Years,48.8,41.3 to 56.3,360
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2011,Age,13-17 Years,46.2,38.5 to 54.0,435
HPV,"≥1 Dose, Males",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,76.7,69.9 to 82.3,413
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2009,Age,13-15 Years,68.2,60.0 to 75.3,373
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2008,Age,13-15 Years,59.1,52.0 to 65.8,406
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2011,Age,13-15 Years,83.9,77.3 to 88.9,526
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2010,Age,13-15 Years,82.5,77.5 to 86.6,471
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,62.5,54.6 to 69.7,393
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,64.7,57.3 to 71.4,390
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,57.9,49.7 to 65.6,380
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,56.4,48.6 to 64.0,397
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,94.9,91.8 to 96.9,734
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,96.5,94.4 to 97.9,765
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,76.4,71.5 to 80.6,752
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2021,Age,13-17 Years,77.7,73.4 to 81.5,929
HPV,"≥1 Dose, Males and Females",States/Local Areas,Pennsylvania,2020,Age,13-17 Years,78.4,73.0 to 83.0,765
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2021,Age,13-15 Years,92.7,88.9 to 95.3,561
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,66.7,58.8 to 73.8,351
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,67.8,58.9 to 75.5,314
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2012,Age,13-15 Years,88.8,83.3 to 92.6,461
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2011,Age,13-15 Years,82.7,76.4 to 87.5,526
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2009,Age,13-15 Years,69.2,61.1 to 76.3,373
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2010,Age,13-15 Years,79.2,73.4 to 84.0,471
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2008,Age,13-15 Years,55.2,48.3 to 62.0,406
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2017,Age,13-15 Years,90.9,85.7 to 94.3,520
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2016,Age,13-15 Years,90.7,86.2 to 93.8,515
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2014,Age,13-15 Years,94.8,91.3 to 96.9,455
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2015,Age,13-15 Years,92.3,88.6 to 94.9,492
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2019,Age,13-15 Years,92.8,88.3 to 95.7,436
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2020,Age,13-15 Years,93.5,89.1 to 96.2,468
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2021,Age,13-15 Years,90.8,87.0 to 93.6,561
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018,Age,13-15 Years,87.0,79.6 to 92.0,392
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,49.9,40.4 to 59.5,335
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,52.8,45.8 to 59.6,458
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,50.5,43.4 to 57.6,485
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2013,Age,13-15 Years,87.1,81.1 to 91.4,459
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,13.2,9.1 to 18.8,404
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,79.8,75.0 to 83.9,742
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,83.8,79.2 to 87.6,880
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,59.7,54.2 to 65.1,682
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,71.9,65.8 to 77.3,579
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2022,Age,13-15 Years,94.6,91.0 to 96.8,471
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,92.5,88.9 to 94.9,832
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,92.8,88.9 to 95.4,785
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,93.4,90.7 to 95.3,875
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,93.1,89.2 to 95.7,741
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,93.8,90.4 to 96.1,751
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,90.6,86.7 to 93.5,851
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,90.0,84.9 to 93.5,649
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,92.0,88.9 to 94.2,875
HPV,"≥3 Doses, Males and Females",States/Local Areas,Pennsylvania,2011,Age,13-17 Years,21.1,17.1 to 25.8,880
HPV,"≥3 Doses, Males and Females",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,24.4,19.8 to 29.7,741
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,93.9,90.7 to 96.1,752
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,92.7,89.6 to 94.9,875
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,94.7,92.3 to 96.5,832
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,90.4,86.1 to 93.5,751
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,95.2,92.9 to 96.8,785
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,89.4,85.3 to 92.5,741
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,93.8,90.3 to 96.0,734
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,91.1,88.2 to 93.4,929
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,95.2,92.5 to 96.9,765
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,95.8,93.0 to 97.5,734
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,96.2,93.6 to 97.8,649
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,95.7,93.3 to 97.2,851
HPV,"≥3 Doses, Males and Females",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,36.8,31.6 to 42.4,785
HPV,"≥3 Doses, Males and Females",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,42.9,37.8 to 48.2,832
HPV,"≥3 Doses, Males and Females",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,30.2,25.4 to 35.6,751
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,95.4,91.9 to 97.4,765
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2008,Age,13-15 Years,28.8,20.4 to 39.0,211
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2011,Age,13-15 Years,31.0,22.7 to 40.7,261
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2012,Age,13-15 Years,29.4,21.3 to 38.9,212
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2013,Age,13-15 Years,36.3,27.2 to 46.6,223
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2014,Age,13-15 Years,43.9,33.4 to 55.0,221
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2015,Age,13-15 Years,43.6,33.7 to 53.9,232
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2010,Age,13-15 Years,39.1,30.2 to 48.9,227
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2009,Age,13-15 Years,27.5,19.0 to 38.1,167
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,92.8,90.0 to 94.9,929
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,94.5,91.7 to 96.4,752
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,94.0,90.5 to 96.2,734
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,94.3,91.0 to 96.4,649
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,93.4,90.3 to 95.6,851
≥1 Dose MenACWY,,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,95.5,92.4 to 97.3,765
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,35.9,28.8 to 43.6,405
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,26.8,20.4 to 34.3,372
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,48.2,41.2 to 55.3,435
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,94.9,92.1 to 96.7,752
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,92.7,89.6 to 95.0,929
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,68.6,61.8 to 74.8,413
HPV,"≥2 Doses, Males and Females",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,68.5,63.5 to 73.0,752
HPV,"≥2 Doses, Females",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,68.2,60.8 to 74.8,339
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2020,Age,13-17 Years,66.8,58.5 to 74.1,394
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2022,Age,13-15 Years,66.9,58.0 to 74.7,251
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2021,Age,13-15 Years,62.9,54.6 to 70.5,300
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2019,Age,13-15 Years,56.9,46.5 to 66.7,224
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2020,Age,13-15 Years,59.3,48.0 to 69.6,232
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,61.2,53.2 to 68.7,351
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,62.3,53.2 to 70.6,314
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,44.4,37.5 to 51.5,485
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,56.1,48.2 to 63.7,393
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,59.1,51.2 to 66.6,383
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2020,Age,13-17 Years,67.3,58.7 to 74.9,371
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,49.1,42.3 to 56.0,458
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,46.3,37.0 to 55.9,335
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,58.0,50.6 to 65.1,390
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2020,Age,13-15 Years,57.4,49.6 to 64.9,468
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2022,Age,13-15 Years,67.3,58.2 to 75.3,220
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2021,Age,13-15 Years,68.6,59.9 to 76.2,261
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2021,Age,13-17 Years,69.2,62.9 to 74.9,495
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2019,Age,13-15 Years,56.5,49.2 to 63.5,436
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,66.3,59.3 to 72.6,413
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2021,Age,13-15 Years,65.8,59.9 to 71.3,561
HPV,"Up-to-Date, Males",States/Local Areas,Pennsylvania,2018,Age,13-15 Years,40.6,29.5 to 52.8,196
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,67.2,59.8 to 73.9,339
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2021,Age,13-17 Years,68.2,61.4 to 74.3,434
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2022,Age,13-15 Years,67.1,60.8 to 72.8,471
Varicella,History of disease,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,41.2,35.2 to 47.4,579
Varicella,History of disease,States/Local Areas,Pennsylvania,2017,Age,13-17 Years,9.9,7.2 to 13.6,851
Varicella,History of disease,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,23.0,18.6 to 28.2,741
Varicella,History of disease,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,22.2,17.7 to 27.5,751
Varicella,History of disease,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,35.1,30.3 to 40.3,742
Varicella,History of disease,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,26.6,22.2 to 31.6,880
Varicella,History of disease,States/Local Areas,Pennsylvania,2018,Age,13-17 Years,8.1,4.9 to 13.0,649
Varicella,History of disease,States/Local Areas,Pennsylvania,2016,Age,13-17 Years,13.0,9.6 to 17.2,875
Varicella,History of disease,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,11.2,8.5 to 14.6,832
Varicella,History of disease,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,46.6,41.1 to 52.1,682
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2019,Age,13-15 Years,56.1,45.8 to 65.9,212
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2020,Age,13-15 Years,55.6,44.8 to 66.0,236
Varicella,History of disease,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,16.4,12.8 to 20.8,785
HPV,"Up-to-Date, Females",States/Local Areas,Pennsylvania,2018,Age,13-15 Years,65.1,54.0 to 74.8,196
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2018,Age,13-17 Years,54.1,47.4 to 60.7,649
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2017,Age,13-17 Years,52.5,47.3 to 57.7,851
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2012,Age,13-17 Years,88.4,84.5 to 91.5,741
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2016,Age,13-17 Years,51.0,45.9 to 56.1,875
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2013,Age,13-17 Years,89.9,85.8 to 92.9,751
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2014,Age,13-17 Years,93.0,89.8 to 95.2,785
HPV,"≥2 Doses, Males",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,61.2,53.3 to 68.6,383
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,51.2,45.8 to 56.7,682
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2022,Age,13-15 Years,93.1,88.4 to 95.9,471
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,81.0,76.3 to 85.0,880
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,74.0,68.8 to 78.6,742
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,67.9,61.7 to 73.5,579
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2008,Age,13-17 Years,94.6,91.5 to 96.6,682
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2009,Age,13-17 Years,93.5,89.6 to 96.1,579
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2010,Age,13-17 Years,96.2,94.2 to 97.6,742
≥2 Doses MMR,,States/Local Areas,Pennsylvania,2011,Age,13-17 Years,93.3,89.3 to 95.9,880
Tetanus,≥1 Dose Tdap,States/Local Areas,Pennsylvania,2015,Age,13-17 Years,91.7,88.6 to 94.0,832
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2022,Age,13-17 Years,66.7,61.7 to 71.4,752
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2021,Age,13-17 Years,68.7,64.2 to 73.0,929
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2019,Age,13-17 Years,60.1,54.5 to 65.5,734
HPV,"Up-to-Date, Males and Females",States/Local Areas,Pennsylvania,2020,Age,13-17 Years,67.1,61.2 to 72.5,765
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2010,Age,13-17 Years,41.7,34.4 to 49.3,360
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2013,Age,13-15 Years,15.4,9.5 to 24.1,236
HPV,"≥3 Doses, Males",States/Local Areas,Pennsylvania,2015,Age,13-15 Years,35.9,27.4 to 45.5,260
≥2 Doses Hep A,,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,86.7,82.9 to 89.8,929
≥2 Doses Hep A,,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,87.8,83.8 to 90.9,752
≥2 Doses Hep A,,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,85.9,81.0 to 89.8,765
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2012,Age,13-17 Years,44.6,36.5 to 52.9,337
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2011,Age,13-17 Years,41.0,33.6 to 48.8,435
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2013,Age,13-17 Years,45.9,37.9 to 54.0,379
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2014,Age,13-17 Years,48.2,40.2 to 56.2,380
HPV,"≥3 Doses, Females",States/Local Areas,Pennsylvania,2015,Age,13-17 Years,47.8,40.2 to 55.5,397
Varicella,History of disease,States/Local Areas,Pennsylvania,2022,Age,13-17 Years,7.1,4.7 to 10.5,752
Varicella,History of disease,States/Local Areas,Pennsylvania,2021,Age,13-17 Years,5.4,3.5 to 8.2,929
Varicella,History of disease,States/Local Areas,Pennsylvania,2019,Age,13-17 Years,7.5,4.8 to 11.5,734
Varicella,History of disease,States/Local Areas,Pennsylvania,2020,Age,13-17 Years,8.8,5.9 to 13.0,765
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2016,Age,13-17 Years,24.5,17.8 to 32.7,209
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2018,Age,13-15 Years,28.9,18.8 to 41.7,88
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2022,Age,13-17 Years,37.0,26.6 to 48.9,116
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2021,Age,13-17 Years,32.6,23.9 to 42.6,146
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2020,Age,13-17 Years,32.6,24.3 to 42.2,140
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2019,Age,13-15 Years,27.7,17.4 to 41.1,89
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2020,Age,13-15 Years,32.9,22.3 to 45.6,88
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2017,Age,13-17 Years,34.4,26.4 to 43.5,159
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2022,Age,13-15 Years,32.3,20.2 to 47.4,75
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2021,Age,13-15 Years,33.4,22.9 to 45.7,103
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2019,Age,13-15 Years,24.5,16.7 to 34.3,160
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2022,Age,13-17 Years,39.8,28.8 to 52.0,116
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2021,Age,13-15 Years,35.9,27.7 to 45.0,189
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2020,Age,13-15 Years,31.7,24.2 to 40.2,177
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2018,Age,13-17 Years,38.1,28.9 to 48.3,136
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2019,Age,13-17 Years,32.1,22.1 to 44.0,126
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2016,Age,13-17 Years,33.9,25.6 to 43.3,168
HPV,"Up-to-Date, Males and Females",States/Local Areas,Mississippi,2022,Age,13-15 Years,33.1,24.0 to 43.6,147
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2022,Age,13-15 Years,34.0,21.6 to 49.0,72
HPV,"Up-to-Date, Females",States/Local Areas,Mississippi,2021,Age,13-15 Years,38.8,26.7 to 52.6,86
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2018,Age,13-17 Years,27.3,19.6 to 36.7,149
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2017,Age,13-17 Years,23.4,16.9 to 31.6,188
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2019,Age,13-17 Years,29.0,20.4 to 39.4,144
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2020,Age,13-17 Years,31.2,23.1 to 40.7,142
HPV,"Up-to-Date, Males",States/Local Areas,Mississippi,2021,Age,13-17 Years,32.8,24.3 to 42.6,157
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2012,Age,13-15 Years,78.8,74.7 to 82.3,1040
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2013,Age,13-15 Years,83.4,80.2 to 86.1,1060
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2011,Age,13-15 Years,76.1,72.3 to 79.4,1193
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2010,Age,13-15 Years,62.1,57.8 to 66.2,829
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2008,Age,13-15 Years,36.8,31.9 to 42.0,614
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2009,Age,13-15 Years,50.4,46.0 to 54.8,971
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2012,Age,13-17 Years,84.2,81.9 to 86.3,2297
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2011,Age,13-17 Years,83.7,81.6 to 85.6,2800
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2013,Age,13-17 Years,88.1,86.2 to 89.7,2264
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2007,Age,13-17 Years,77.4,73.2 to 81.1,584
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2015,Age,13-17 Years,89.2,87.3 to 90.8,2543
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2014,Age,13-17 Years,87.8,85.9 to 89.5,2465
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2012,Age,13-15 Years,6.8,4.2 to 10.8,735
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2014,Age,13-15 Years,19.9,16.4 to 23.9,788
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2013,Age,13-17 Years,12.2,9.9 to 15.0,1188
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2012,Age,13-17 Years,5.5,3.7 to 8.0,1208
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2015,Age,13-17 Years,26.2,23.4 to 29.2,1311
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2014,Age,13-17 Years,20.6,17.8 to 23.7,1259
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2019,Age,13-17 Years,94.4,93.0 to 95.5,2097
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2017,Age,13-17 Years,94.2,93.0 to 95.2,2433
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2018,Age,13-17 Years,94.2,92.8 to 95.3,2276
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2016,Age,13-17 Years,91.8,90.2 to 93.1,2284
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2008,Age,13-17 Years,76.6,74.4 to 78.8,2361
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2006,Age,13-17 Years,75.1,69.7 to 79.9,458
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2013,Age,13-15 Years,10.8,8.2 to 14.2,732
HPV,"≥3 Doses, Males",HHS Regions/National,Region 5,2015,Age,13-15 Years,23.6,20.3 to 27.1,838
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2012,Age,13-17 Years,30.4,26.7 to 34.4,1089
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2011,Age,13-17 Years,33.9,30.4 to 37.6,1338
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2013,Age,13-17 Years,35.0,31.5 to 38.7,1076
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2014,Age,13-17 Years,41.9,38.4 to 45.6,1206
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2008,Age,13-17 Years,14.6,12.2 to 17.5,1123
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2009,Age,13-17 Years,24.5,21.6 to 27.6,1507
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2015,Age,13-17 Years,41.0,37.5 to 44.6,1232
≥2 Doses Hep A,,HHS Regions/National,Region 5,2020,Age,13-17 Years,79.7,77.5 to 81.7,2344
≥2 Doses Hep A,,HHS Regions/National,Region 5,2022,Age,13-17 Years,85.3,82.8 to 87.5,2019
≥2 Doses Hep A,,HHS Regions/National,Region 5,2021,Age,13-17 Years,84.9,82.6 to 87.0,2060
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2010,Age,13-17 Years,30.0,26.8 to 33.3,1099
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2018,Age,13-17 Years,66.7,63.3 to 70.0,1188
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2019,Age,13-17 Years,69.6,66.1 to 72.9,1125
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2020,Age,13-17 Years,75.1,71.9 to 78.1,1268
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2021,Age,13-17 Years,73.0,68.9 to 76.8,1069
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 5,2018,Age,13-17 Years,58.2,55.6 to 60.7,2276
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2019,Age,13-17 Years,72.9,69.2 to 76.3,972
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 5,2017,Age,13-17 Years,53.4,50.9 to 55.8,2433
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2022,Age,13-17 Years,92.9,90.9 to 94.5,1894
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2020,Age,13-17 Years,77.9,74.5 to 81.0,1076
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2021,Age,13-17 Years,80.1,76.4 to 83.4,991
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2011,Age,13-17 Years,5.8,4.2 to 8.0,1462
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2022,Age,13-17 Years,81.3,77.6 to 84.5,949
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 5,2016,Age,13-17 Years,48.7,46.1 to 51.4,2284
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2013,Age,13-17 Years,28.3,25.0 to 31.7,1188
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2014,Age,13-17 Years,39.6,36.2 to 43.2,1259
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2015,Age,13-17 Years,47.1,43.7 to 50.6,1311
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2016,Age,13-17 Years,53.7,49.9 to 57.4,1188
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2017,Age,13-17 Years,63.3,59.9 to 66.5,1274
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2010,Age,13-17 Years,1.1,0.6 to 1.9,1149
≥3 Doses HepB,,HHS Regions/National,Region 5,2012,Age,13-17 Years,92.0,89.9 to 93.6,2297
≥3 Doses HepB,,HHS Regions/National,Region 5,2011,Age,13-17 Years,93.4,91.9 to 94.6,2800
≥3 Doses HepB,,HHS Regions/National,Region 5,2013,Age,13-17 Years,94.8,93.4 to 95.8,2264
≥3 Doses HepB,,HHS Regions/National,Region 5,2014,Age,13-17 Years,92.4,90.7 to 93.8,2465
≥3 Doses HepB,,HHS Regions/National,Region 5,2008,Age,13-17 Years,87.7,85.9 to 89.4,2361
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2007,Age,13-17 Years,20.3,15.2 to 26.6,281
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2007,Age,13-17 Years,77.2,69.4 to 83.5,194
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2007,Age,13-17 Years,27.1,19.2 to 36.9,194
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2012,Age,13-17 Years,75.3,72.0 to 78.4,1527
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2008,Age,13-17 Years,31.2,27.8 to 34.8,1123
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2022,Age,13-15 Years,93.8,91.3 to 95.6,1160
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2008,Age,13-17 Years,79.3,75.3 to 82.8,867
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2010,Age,13-17 Years,91.7,89.6 to 93.4,1167
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2009,Age,13-17 Years,86.7,83.7 to 89.2,1368
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2008,Age,13-17 Years,33.8,29.7 to 38.1,867
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2009,Age,13-17 Years,47.6,43.9 to 51.3,1368
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2006,Age,13-17 Years,65.6,52.5 to 76.6,118
≥3 Doses HepB,,HHS Regions/National,Region 5,2007,Age,13-17 Years,89.7,86.5 to 92.2,584
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2011,Age,13-17 Years,92.9,90.7 to 94.7,1731
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2010,Age,13-17 Years,58.9,55.3 to 62.4,1167
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2011,Age,13-17 Years,73.3,70.2 to 76.2,1731
≥3 Doses HepB,,HHS Regions/National,Region 5,2006,Age,13-17 Years,78.1,72.3 to 82.9,458
≥3 Doses HepB,,HHS Regions/National,Region 5,2010,Age,13-17 Years,93.0,91.6 to 94.3,2248
≥3 Doses HepB,,HHS Regions/National,Region 5,2009,Age,13-17 Years,91.8,90.4 to 93.0,3105
≥3 Doses HepB,,HHS Regions/National,Region 5,2017,Age,13-17 Years,95.0,93.9 to 96.0,2433
≥3 Doses HepB,,HHS Regions/National,Region 5,2018,Age,13-17 Years,94.1,92.7 to 95.2,2276
≥3 Doses HepB,,HHS Regions/National,Region 5,2019,Age,13-17 Years,94.3,92.8 to 95.5,2097
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2020,Age,13-15 Years,95.0,93.3 to 96.4,1319
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2021,Age,13-15 Years,93.7,91.4 to 95.5,1188
≥3 Doses HepB,,HHS Regions/National,Region 5,2016,Age,13-17 Years,94.2,92.9 to 95.3,2284
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2018,Age,13-17 Years,95.7,94.4 to 96.7,2001
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2019,Age,13-17 Years,93.9,92.3 to 95.1,1900
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2020,Age,13-17 Years,94.4,93.0 to 95.6,2164
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2021,Age,13-17 Years,93.4,91.6 to 94.8,1930
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2018,Age,13-17 Years,93.3,91.8 to 94.6,2001
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2020,Age,13-17 Years,96.5,95.3 to 97.4,2164
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2017,Age,13-17 Years,97.2,96.3 to 97.9,2117
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2019,Age,13-17 Years,97.0,95.8 to 97.8,1900
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2012,Age,13-17 Years,93.5,91.1 to 95.3,1527
≥3 Doses HepB,,HHS Regions/National,Region 5,2015,Age,13-17 Years,93.0,91.6 to 94.1,2543
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2013,Age,13-17 Years,95.5,94.0 to 96.7,1604
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2014,Age,13-17 Years,94.8,93.3 to 96.1,1936
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2015,Age,13-17 Years,95.5,94.2 to 96.6,2096
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2016,Age,13-17 Years,96.1,94.8 to 97.2,1887
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2012,Age,13-17 Years,49.7,45.4 to 53.9,1089
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2013,Age,13-17 Years,57.4,53.6 to 61.1,1076
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2014,Age,13-17 Years,61.9,58.3 to 65.4,1206
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2015,Age,13-17 Years,62.0,58.3 to 65.4,1232
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2020,Age,13-17 Years,94.9,93.6 to 95.9,2344
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2021,Age,13-17 Years,93.9,92.2 to 95.2,2060
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2022,Age,13-17 Years,93.4,91.5 to 94.9,2019
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2007,Age,13-15 Years,32.0,22.0 to 43.9,145
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2011,Age,13-17 Years,51.5,47.8 to 55.3,1338
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2010,Age,13-17 Years,45.0,41.3 to 48.7,1099
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2017,Age,13-17 Years,93.2,91.9 to 94.3,2117
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2013,Age,13-17 Years,83.0,80.4 to 85.2,1604
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2014,Age,13-17 Years,84.3,81.9 to 86.4,1936
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2015,Age,13-17 Years,86.8,84.6 to 88.7,2096
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2016,Age,13-17 Years,89.9,88.0 to 91.5,1887
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2015,Age,13-15 Years,87.8,85.1 to 90.1,1384
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2014,Age,13-15 Years,84.8,81.8 to 87.3,1276
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2018,Age,13-15 Years,95.0,93.4 to 96.2,1278
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2019,Age,13-15 Years,94.0,92.1 to 95.5,1176
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2017,Age,13-15 Years,94.2,92.6 to 95.5,1289
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2016,Age,13-15 Years,90.5,88.1 to 92.5,1192
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2010,Age,13-17 Years,79.0,76.8 to 81.1,2248
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2009,Age,13-17 Years,77.5,75.3 to 79.5,3105
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2012,Age,13-15 Years,73.8,70.4 to 77.0,1419
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2013,Age,13-15 Years,80.0,77.2 to 82.5,1382
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2007,Age,13-17 Years,12.2,8.5 to 17.2,281
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2009,Age,13-17 Years,39.6,36.2 to 43.1,1507
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2017,Age,13-17 Years,67.9,64.5 to 71.1,1159
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2016,Age,13-17 Years,63.4,59.7 to 67.0,1096
≥3 Doses HepB,,HHS Regions/National,Region 5,2022,Age,13-17 Years,93.9,92.1 to 95.3,2019
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2018,Age,13-17 Years,73.4,70.0 to 76.5,1088
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2016,Age,13-17 Years,93.8,92.4 to 95.0,2284
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2014,Age,13-17 Years,88.9,87.1 to 90.5,2465
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2015,Age,13-17 Years,88.4,86.5 to 90.0,2543
≥3 Doses HepB,,HHS Regions/National,Region 5,2020,Age,13-17 Years,94.6,93.3 to 95.7,2344
≥3 Doses HepB,,HHS Regions/National,Region 5,2021,Age,13-17 Years,94.1,92.5 to 95.4,2060
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2022,Age,13-17 Years,95.8,94.2 to 97.0,1894
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2021,Age,13-17 Years,96.4,94.9 to 97.4,1930
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 5,2019,Age,13-17 Years,56.7,54.0 to 59.4,2097
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2012,Age,13-17 Years,17.7,14.8 to 21.1,1208
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2007,Age,13-17 Years,68.5,63.5 to 73.0,584
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2006,Age,13-17 Years,59.4,53.5 to 65.0,458
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2008,Age,13-17 Years,22.9,20.0 to 26.2,1123
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2016,Age,13-15 Years,84.9,82.2 to 87.3,1374
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2017,Age,13-15 Years,88.5,86.3 to 90.4,1462
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2018,Age,13-15 Years,90.1,88.1 to 91.8,1417
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2019,Age,13-15 Years,91.8,89.7 to 93.5,1271
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2015,Age,13-15 Years,82.7,80.0 to 85.1,1605
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2014,Age,13-15 Years,79.3,76.4 to 81.9,1542
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2017,Age,13-17 Years,93.8,92.5 to 94.9,2433
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2017,Age,13-17 Years,65.5,63.2 to 67.8,2433
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2016,Age,13-17 Years,58.4,55.8 to 61.0,2284
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2011,Age,13-15 Years,72.8,69.7 to 75.7,1703
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2010,Age,13-15 Years,62.5,59.2 to 65.7,1361
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2006,Age,13-15 Years,13.3,9.2 to 18.9,272
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2007,Age,13-15 Years,32.6,26.9 to 38.9,377
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2010,Age,13-17 Years,38.0,34.5 to 41.7,1099
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2011,Age,13-17 Years,43.4,39.7 to 47.2,1338
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2009,Age,13-17 Years,32.2,29.0 to 35.6,1507
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2020,Age,13-15 Years,93.6,91.8 to 95.0,1415
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2012,Age,13-17 Years,38.4,34.3 to 42.5,1089
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2013,Age,13-17 Years,46.1,42.4 to 50.0,1076
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2008,Age,13-17 Years,68.4,65.9 to 70.9,2361
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2009,Age,13-17 Years,72.0,69.8 to 74.2,3105
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2022,Age,13-17 Years,76.6,72.7 to 80.1,1070
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2012,Age,13-17 Years,85.9,83.5 to 88.0,2297
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2013,Age,13-17 Years,90.5,88.7 to 92.1,2264
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2009,Age,13-15 Years,52.8,49.7 to 55.9,1863
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2008,Age,13-15 Years,41.7,38.4 to 45.1,1396
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2019,Age,13-17 Years,71.2,68.7 to 73.6,2097
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2018,Age,13-17 Years,70.0,67.6 to 72.3,2276
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2021,Age,13-17 Years,93.3,91.5 to 94.7,2060
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2010,Age,13-17 Years,80.1,78.0 to 82.1,2248
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2011,Age,13-17 Years,84.5,82.4 to 86.4,2800
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2020,Age,13-17 Years,76.5,74.2 to 78.6,2344
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2021,Age,13-17 Years,76.5,73.7 to 79.1,2060
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2018,Age,13-17 Years,93.1,91.7 to 94.3,2276
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2019,Age,13-17 Years,93.2,91.7 to 94.4,2097
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2020,Age,13-17 Years,94.2,92.9 to 95.2,2344
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2017,Age,13-17 Years,57.6,54.1 to 61.1,1159
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2016,Age,13-17 Years,54.7,50.9 to 58.4,1096
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2015,Age,13-17 Years,50.9,47.3 to 54.6,1232
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2014,Age,13-17 Years,52.7,49.1 to 56.4,1206
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2021,Age,13-15 Years,90.3,87.5 to 92.5,1256
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2018,Age,13-17 Years,60.9,57.2 to 64.5,1088
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2019,Age,13-17 Years,58.7,54.6 to 62.6,972
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2006,Age,13-15 Years,16.4,11.9 to 22.3,272
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2007,Age,13-15 Years,29.0,23.9 to 34.8,377
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2012,Age,13-15 Years,83.0,79.8 to 85.8,1419
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2011,Age,13-15 Years,79.4,76.5 to 82.0,1703
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2009,Age,13-15 Years,57.3,54.2 to 60.4,1863
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2010,Age,13-15 Years,70.7,67.5 to 73.7,1361
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2008,Age,13-15 Years,43.9,40.5 to 47.3,1396
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2022,Age,13-17 Years,93.8,92.2 to 95.2,2019
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2017,Age,13-15 Years,90.7,88.6 to 92.4,1462
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2016,Age,13-15 Years,90.3,88.0 to 92.3,1374
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2015,Age,13-15 Years,84.9,82.2 to 87.2,1605
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2014,Age,13-15 Years,86.9,84.5 to 89.1,1542
≥2 Doses MMR,,HHS Regions/National,Region 5,2021,Age,13-17 Years,94.2,92.5 to 95.5,2060
≥2 Doses MMR,,HHS Regions/National,Region 5,2022,Age,13-17 Years,93.1,91.2 to 94.6,2019
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2011,Age,13-15 Years,27.7,23.8 to 32.1,825
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2010,Age,13-15 Years,25.9,22.2 to 30.0,682
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2009,Age,13-15 Years,21.3,17.8 to 25.2,882
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2008,Age,13-15 Years,12.9,10.0 to 16.5,661
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2018,Age,13-17 Years,55.5,52.0 to 59.1,1188
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2017,Age,13-17 Years,49.3,45.9 to 52.7,1274
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2016,Age,13-17 Years,43.0,39.4 to 46.7,1188
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2015,Age,13-17 Years,36.0,32.8 to 39.3,1311
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2019,Age,13-15 Years,91.5,89.2 to 93.3,1271
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2020,Age,13-15 Years,92.5,90.6 to 94.1,1415
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2021,Age,13-15 Years,87.9,85.0 to 90.4,1256
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2018,Age,13-15 Years,91.3,89.3 to 92.9,1417
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2022,Age,13-17 Years,92.5,90.7 to 94.0,2019
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2021,Age,13-17 Years,91.6,89.7 to 93.3,2060
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2017,Age,13-17 Years,89.4,87.8 to 90.7,2433
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2018,Age,13-17 Years,89.8,88.2 to 91.1,2276
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2019,Age,13-17 Years,91.8,90.2 to 93.1,2097
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2020,Age,13-17 Years,93.6,92.2 to 94.7,2344
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2013,Age,13-15 Years,87.8,85.3 to 89.9,1382
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2022,Age,13-17 Years,78.9,76.3 to 81.3,2019
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2011,Age,13-17 Years,3.0,2.0 to 4.6,1462
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2012,Age,13-17 Years,10.5,8.2 to 13.4,1208
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2013,Age,13-17 Years,18.2,15.4 to 21.2,1188
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2014,Age,13-17 Years,31.2,28.0 to 34.7,1259
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2016,Age,13-17 Years,91.2,89.5 to 92.6,2284
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2010,Age,13-17 Years,63.7,61.2 to 66.1,2248
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2011,Age,13-17 Years,72.4,69.9 to 74.8,2800
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2008,Age,13-17 Years,40.1,37.6 to 42.8,2361
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2009,Age,13-17 Years,51.2,48.8 to 53.6,3105
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2013,Age,13-17 Years,79.9,77.7 to 82.0,2264
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2014,Age,13-17 Years,80.1,78.0 to 82.1,2465
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2015,Age,13-17 Years,83.9,81.9 to 85.7,2543
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2016,Age,13-17 Years,85.9,84.0 to 87.7,2284
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2018,Age,13-17 Years,90.5,88.9 to 91.9,2276
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2017,Age,13-17 Years,91.8,90.4 to 93.0,2433
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2012,Age,13-17 Years,75.0,72.3 to 77.4,2297
≥2 Doses MMR,,HHS Regions/National,Region 5,2016,Age,13-17 Years,94.0,92.7 to 95.1,2284
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 5,2011,Age,13-17 Years,17.1,15.2 to 19.2,2800
≥2 Doses MMR,,HHS Regions/National,Region 5,2014,Age,13-17 Years,92.1,90.5 to 93.5,2465
≥2 Doses MMR,,HHS Regions/National,Region 5,2015,Age,13-17 Years,92.6,91.2 to 93.8,2543
≥2 Doses MMR,,HHS Regions/National,Region 5,2012,Age,13-17 Years,90.8,88.6 to 92.5,2297
≥2 Doses MMR,,HHS Regions/National,Region 5,2013,Age,13-17 Years,93.6,92.1 to 94.8,2264
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2007,Age,13-17 Years,32.0,27.4 to 36.8,584
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2022,Age,13-17 Years,92.8,91.0 to 94.2,2019
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2006,Age,13-17 Years,13.7,10.4 to 18.0,458
≥2 Doses MMR,,HHS Regions/National,Region 5,2018,Age,13-17 Years,93.2,91.6 to 94.5,2276
≥2 Doses MMR,,HHS Regions/National,Region 5,2017,Age,13-17 Years,95.0,94.0 to 95.9,2433
≥2 Doses MMR,,HHS Regions/National,Region 5,2019,Age,13-17 Years,95.1,93.8 to 96.1,2097
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2019,Age,13-17 Years,91.4,89.7 to 92.8,2097
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2020,Age,13-17 Years,92.5,91.1 to 93.7,2344
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2021,Age,13-17 Years,89.4,87.3 to 91.1,2060
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 5,2012,Age,13-17 Years,17.7,15.5 to 20.1,2297
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2012,Age,13-15 Years,27.3,22.9 to 32.2,684
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2013,Age,13-15 Years,27.8,23.7 to 32.2,650
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2015,Age,13-15 Years,36.3,32.0 to 40.8,767
HPV,"≥3 Doses, Females",HHS Regions/National,Region 5,2014,Age,13-15 Years,36.1,31.8 to 40.7,754
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 5,2013,Age,13-17 Years,23.4,21.2 to 25.7,2264
≥2 Doses MMR,,HHS Regions/National,Region 5,2020,Age,13-17 Years,94.9,93.6 to 95.9,2344
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 5,2015,Age,13-17 Years,33.5,31.2 to 35.8,2543
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 5,2014,Age,13-17 Years,31.0,28.7 to 33.5,2465
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 5,2022,Age,13-17 Years,66.2,63.2 to 69.0,2019
HPV,"≥2 Doses, Males",HHS Regions/National,Region 5,2022,Age,13-17 Years,64.2,60.0 to 68.1,1070
HPV,"≥1 Dose, Males",HHS Regions/National,Region 5,2023,Age,13-17 Years,77.9,74.5 to 81.0,1179
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2023,Age,13-17 Years,70.7,66.7 to 74.4,1063
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2023,Age,13-15 Years,93.1,90.9 to 94.8,1274
HPV,"Up-to-Date, Females",HHS Regions/National,Region 5,2023,Age,13-15 Years,64.1,58.7 to 69.2,651
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2023,Age,13-15 Years,62.3,58.6 to 65.8,1339
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2023,Age,13-15 Years,90.2,87.5 to 92.4,1339
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2023,Age,13-15 Years,90.3,87.7 to 92.4,1339
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2023,Age,13-15 Years,60.4,55.3 to 65.3,688
≥2 Doses Hep A,,HHS Regions/National,Region 5,2023,Age,13-17 Years,88.2,86.3 to 89.9,2242
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 5,2023,Age,13-17 Years,93.3,91.7 to 94.5,2242
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 5,2023,Age,13-17 Years,92.7,91.1 to 94.1,2106
≥3 Doses HepB,,HHS Regions/National,Region 5,2023,Age,13-17 Years,93.5,92.0 to 94.7,2242
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 5,2023,Age,13-17 Years,96.6,95.5 to 97.4,2106
Varicella,History of disease,HHS Regions/National,Region 5,2023,Age,13-17 Years,7.1,5.7 to 8.9,2242
HPV,"Up-to-Date, Males",HHS Regions/National,Region 5,2023,Age,13-17 Years,64.8,61.0 to 68.5,1179
≥2 Doses MMR,,HHS Regions/National,Region 5,2023,Age,13-17 Years,94.2,92.8 to 95.4,2242
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 5,2023,Age,13-17 Years,67.7,65.0 to 70.4,2242
HPV,"≥1 Dose, Females",HHS Regions/National,Region 5,2023,Age,13-17 Years,82.5,79.0 to 85.5,1063
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 5,2023,Age,13-17 Years,80.1,77.7 to 82.3,2242
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2023,Age,13-17 Years,91.9,90.2 to 93.4,2242
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 5,2023,Age,13-17 Years,92.5,90.8 to 93.9,2242
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 5,2023,Age,13-17 Years,91.2,89.3 to 92.7,2242
HPV,"≥2 Doses, Females",HHS Regions/National,Region 5,2022,Age,13-17 Years,68.3,64.1 to 72.2,949
≥1 Dose MenACWY,,HHS Regions/National,Region 5,2022,Age,13-15 Years,92.2,89.6 to 94.1,1226
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2016,Age,13-17 Years,35.4,29.5 to 41.7,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alabama,2022,Age,13-15 Years,61.8,52.5 to 70.4,157
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2018,Age,13-17 Years,48.4,39.1 to 57.8,172
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2019,Age,13-17 Years,42.5,33.2 to 52.5,153
HPV,"Up-to-Date, Males",States/Local Areas,Alabama,2020,Age,13-17 Years,49.1,40.3 to 57.9,163
Varicella,History of disease,States/Local Areas,Wisconsin,2012,Age,13-17 Years,35.3,28.5 to 42.9,307
Varicella,History of disease,States/Local Areas,Wisconsin,2013,Age,13-17 Years,27.1,21.7 to 33.3,330
Varicella,History of disease,States/Local Areas,Wisconsin,2010,Age,13-17 Years,47.0,40.3 to 53.9,277
Varicella,History of disease,States/Local Areas,Wisconsin,2011,Age,13-17 Years,37.3,31.1 to 43.8,416
Varicella,History of disease,States/Local Areas,Wisconsin,2009,Age,13-17 Years,49.5,43.4 to 55.7,345
Varicella,History of disease,States/Local Areas,Wisconsin,2014,Age,13-17 Years,24.2,18.7 to 30.6,340
Varicella,History of disease,States/Local Areas,Wisconsin,2018,Age,13-17 Years,10.6,7.4 to 14.9,332
Varicella,History of disease,States/Local Areas,Wisconsin,2017,Age,13-17 Years,14.6,10.6 to 19.9,324
Varicella,History of disease,States/Local Areas,Wisconsin,2016,Age,13-17 Years,14.4,10.3 to 19.7,333
Varicella,History of disease,States/Local Areas,Wisconsin,2015,Age,13-17 Years,17.4,13.1 to 22.7,365
Varicella,History of disease,States/Local Areas,Wisconsin,2008,Age,13-17 Years,64.9,58.2 to 71.1,264
Varicella,History of disease,States/Local Areas,Wisconsin,2019,Age,13-17 Years,11.1,7.8 to 15.7,331
Varicella,History of disease,States/Local Areas,Wisconsin,2020,Age,13-17 Years,8.7,5.4 to 13.7,277
Varicella,History of disease,States/Local Areas,Wisconsin,2022,Age,13-17 Years,6.5,3.7 to 11.2,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2017,Age,13-15 Years,94.5,89.8 to 97.1,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2020,Age,13-15 Years,95.1,88.2 to 98.0,156
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2017,Age,13-17 Years,97.2,94.2 to 98.7,279
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2010,Age,13-17 Years,88.4,83.5 to 91.9,277
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2009,Age,13-17 Years,85.8,81.1 to 89.5,345
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2012,Age,13-17 Years,92.2,87.8 to 95.1,307
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2011,Age,13-17 Years,91.6,86.1 to 95.1,416
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2013,Age,13-17 Years,95.2,91.5 to 97.3,330
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2015,Age,13-15 Years,94.1,89.2 to 96.9,198
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2014,Age,13-15 Years,86.1,77.3 to 91.8,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2016,Age,13-15 Years,92.7,87.0 to 96.0,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2018,Age,13-15 Years,90.2,84.3 to 94.0,196
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2021,Age,13-17 Years,94.9,90.8 to 97.2,306
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2016,Age,13-17 Years,93.7,89.7 to 96.2,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2015,Age,13-17 Years,92.5,88.1 to 95.3,305
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2013,Age,13-17 Years,93.4,88.5 to 96.3,246
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2014,Age,13-17 Years,90.7,84.7 to 94.5,269
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2017,Age,13-17 Years,95.4,92.2 to 97.3,279
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2011,Age,13-17 Years,65.7,56.8 to 73.6,210
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2010,Age,13-17 Years,54.4,44.5 to 63.9,135
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2012,Age,13-15 Years,88.2,79.2 to 93.6,135
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2013,Age,13-15 Years,94.8,89.1 to 97.6,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2011,Age,13-15 Years,86.8,73.9 to 93.8,169
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2010,Age,13-15 Years,83.8,74.9 to 89.9,103
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2009,Age,13-15 Years,74.8,65.2 to 82.5,109
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2008,Age,13-15 Years,41.2,28.5 to 55.1,60
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2012,Age,13-17 Years,50.5,39.8 to 61.1,133
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2013,Age,13-17 Years,59.4,50.1 to 68.0,160
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2014,Age,13-17 Years,61.0,50.8 to 70.2,165
≥3 Doses HepB,,States/Local Areas,Wisconsin,2015,Age,13-17 Years,93.2,89.4 to 95.7,365
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2018,Age,13-17 Years,91.4,86.8 to 94.5,297
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2020,Age,13-17 Years,95.6,91.0 to 97.9,256
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2019,Age,13-17 Years,95.8,92.6 to 97.7,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2021,Age,13-17 Years,94.4,90.0 to 96.9,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2020,Age,13-17 Years,93.5,88.6 to 96.4,256
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2016,Age,13-17 Years,97.4,94.5 to 98.8,287
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2015,Age,13-17 Years,97.6,95.1 to 98.9,305
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2013,Age,13-17 Years,96.9,92.9 to 98.7,246
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2014,Age,13-17 Years,95.4,90.0 to 97.9,269
≥3 Doses HepB,,States/Local Areas,Wisconsin,2019,Age,13-17 Years,94.7,91.3 to 96.8,331
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2018,Age,13-17 Years,93.2,88.7 to 95.9,297
≥3 Doses HepB,,States/Local Areas,Wisconsin,2018,Age,13-17 Years,94.3,90.6 to 96.6,332
≥3 Doses HepB,,States/Local Areas,Wisconsin,2017,Age,13-17 Years,94.7,90.9 to 97.0,324
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2012,Age,13-17 Years,98.4,95.8 to 99.4,211
≥3 Doses HepB,,States/Local Areas,Wisconsin,2008,Age,13-17 Years,87.8,82.4 to 91.7,264
≥3 Doses HepB,,States/Local Areas,Wisconsin,2016,Age,13-17 Years,95.1,91.4 to 97.3,333
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2021,Age,13-15 Years,93.3,86.1 to 96.9,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2009,Age,13-17 Years,71.8,63.4 to 78.9,158
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2008,Age,13-17 Years,37.9,27.6 to 49.4,88
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2019,Age,13-15 Years,95.2,90.8 to 97.6,176
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2008,Age,13-17 Years,84.4,73.1 to 91.5,88
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2011,Age,13-17 Years,94.0,84.2 to 97.9,261
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2022,Age,13-15 Years,94.8,90.0 to 97.3,152
≥3 Doses HepB,,States/Local Areas,Wisconsin,2010,Age,13-17 Years,89.9,84.9 to 93.4,277
≥3 Doses HepB,,States/Local Areas,Wisconsin,2009,Age,13-17 Years,93.4,89.5 to 95.9,345
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2008,Age,13-17 Years,47.0,37.0 to 57.1,113
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2010,Age,13-17 Years,78.1,69.7 to 84.6,150
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2011,Age,13-17 Years,86.6,78.4 to 92.0,261
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2010,Age,13-17 Years,93.8,86.6 to 97.2,150
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2009,Age,13-17 Years,95.7,91.2 to 98.0,158
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2012,Age,13-17 Years,87.9,81.4 to 92.4,211
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wisconsin,2019,Age,13-17 Years,62.3,56.0 to 68.3,331
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2009,Age,13-17 Years,49.2,40.7 to 57.6,178
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2021,Age,13-17 Years,83.9,75.5 to 89.8,144
≥3 Doses HepB,,States/Local Areas,Wisconsin,2012,Age,13-17 Years,94.1,91.0 to 96.2,307
≥3 Doses HepB,,States/Local Areas,Wisconsin,2011,Age,13-17 Years,90.7,84.9 to 94.4,416
≥3 Doses HepB,,States/Local Areas,Wisconsin,2013,Age,13-17 Years,92.8,88.5 to 95.5,330
≥3 Doses HepB,,States/Local Areas,Wisconsin,2014,Age,13-17 Years,92.6,87.6 to 95.7,340
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2018,Age,13-17 Years,67.1,58.8 to 74.4,176
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2020,Age,13-17 Years,74.3,65.3 to 81.7,155
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2017,Age,13-17 Years,65.1,56.4 to 73.0,177
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2019,Age,13-17 Years,78.2,69.2 to 85.1,155
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2016,Age,13-17 Years,56.0,47.3 to 64.4,183
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2015,Age,13-17 Years,46.4,38.4 to 54.5,194
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2013,Age,13-17 Years,31.7,23.8 to 40.8,170
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2014,Age,13-17 Years,49.3,40.0 to 58.6,175
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2012,Age,13-17 Years,19.3,12.5 to 28.5,174
≥3 Doses HepB,,States/Local Areas,Wisconsin,2022,Age,13-17 Years,93.0,88.1 to 96.0,274
≥3 Doses HepB,,States/Local Areas,Wisconsin,2020,Age,13-17 Years,93.0,88.1 to 95.9,277
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wisconsin,2017,Age,13-17 Years,57.4,50.9 to 63.7,324
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2021,Age,13-17 Years,98.1,94.9 to 99.3,282
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2022,Age,13-17 Years,77.9,67.6 to 85.6,137
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2020,Age,13-17 Years,81.5,72.4 to 88.1,122
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wisconsin,2016,Age,13-17 Years,50.7,44.3 to 57.1,333
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wisconsin,2018,Age,13-17 Years,57.7,51.5 to 63.6,332
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2022,Age,13-17 Years,93.3,88.0 to 96.4,257
≥3 Doses HepB,,States/Local Areas,Wisconsin,2021,Age,13-17 Years,95.2,90.7 to 97.5,306
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2022,Age,13-17 Years,96.3,91.9 to 98.4,257
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2017,Age,13-17 Years,62.4,52.9 to 71.1,147
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2018,Age,13-17 Years,62.1,53.2 to 70.4,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2011,Age,13-15 Years,93.0,86.8 to 96.4,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2009,Age,13-15 Years,75.3,67.0 to 82.0,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2010,Age,13-15 Years,85.4,78.6 to 90.3,166
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2022,Age,13-17 Years,92.8,87.7 to 95.9,274
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2008,Age,13-15 Years,61.8,52.7 to 70.2,147
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2016,Age,13-17 Years,56.7,47.0 to 65.8,150
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2015,Age,13-17 Years,53.2,44.3 to 61.9,171
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2014,Age,13-17 Years,52.1,42.1 to 61.9,165
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2021,Age,13-15 Years,90.1,83.5 to 94.3,175
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2021,Age,13-17 Years,82.4,76.8 to 86.8,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2020,Age,13-17 Years,92.6,88.0 to 95.6,277
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2019,Age,13-17 Years,72.2,66.0 to 77.6,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2021,Age,13-17 Years,95.9,92.8 to 97.8,306
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018,Age,13-17 Years,69.8,64.0 to 75.1,332
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2019,Age,13-17 Years,92.1,87.6 to 95.1,331
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2022,Age,13-17 Years,80.5,73.8 to 85.8,274
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2018,Age,13-17 Years,91.7,87.3 to 94.6,332
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2021,Age,13-17 Years,80.9,73.0 to 87.0,162
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2010,Age,13-17 Years,91.6,87.4 to 94.5,277
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2011,Age,13-17 Years,95.0,91.0 to 97.3,416
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2012,Age,13-17 Years,92.6,87.8 to 95.5,307
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2012,Age,13-15 Years,74.0,64.6 to 81.6,178
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2013,Age,13-15 Years,81.2,74.4 to 86.6,212
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2015,Age,13-15 Years,80.0,73.2 to 85.3,232
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2014,Age,13-15 Years,74.6,65.9 to 81.6,216
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2022,Age,13-17 Years,82.9,73.6 to 89.4,137
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2019,Age,13-17 Years,66.4,57.7 to 74.2,176
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2009,Age,13-15 Years,54.1,46.0 to 62.0,194
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2008,Age,13-15 Years,52.9,44.0 to 61.7,147
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2011,Age,13-15 Years,72.4,63.9 to 79.5,229
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2010,Age,13-15 Years,66.5,57.7 to 74.4,166
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2009,Age,13-17 Years,85.3,80.1 to 89.3,345
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2008,Age,13-17 Years,75.4,69.1 to 80.8,264
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2016,Age,13-15 Years,87.3,81.7 to 91.3,199
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2010,Age,13-17 Years,49.1,39.4 to 58.9,135
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2011,Age,13-17 Years,59.3,49.9 to 68.0,210
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2020,Age,13-15 Years,88.9,81.6 to 93.5,168
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2009,Age,13-17 Years,38.6,30.6 to 47.2,178
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2016,Age,13-17 Years,96.5,94.1 to 98.0,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2015,Age,13-17 Years,91.5,87.2 to 94.4,365
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2014,Age,13-17 Years,94.1,89.4 to 96.8,340
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2013,Age,13-17 Years,96.1,92.8 to 97.9,330
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2012,Age,13-17 Years,45.0,34.6 to 55.8,133
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2013,Age,13-17 Years,47.8,38.6 to 57.2,160
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018,Age,13-15 Years,88.6,82.9 to 92.6,214
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2017,Age,13-17 Years,69.2,63.0 to 74.8,324
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2019,Age,13-15 Years,90.3,83.8 to 94.3,192
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2018,Age,13-17 Years,72.8,64.1 to 80.0,156
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2017,Age,13-17 Years,73.5,64.3 to 81.0,147
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2016,Age,13-17 Years,68.1,58.6 to 76.2,150
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2019,Age,13-17 Years,98.2,95.3 to 99.3,293
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2015,Age,13-17 Years,60.5,51.5 to 68.8,171
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2016,Age,13-17 Years,61.9,55.5 to 67.9,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2017,Age,13-17 Years,92.0,87.9 to 94.9,324
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2008,Age,13-17 Years,34.9,25.7 to 45.4,113
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2017,Age,13-15 Years,80.7,73.2 to 86.5,196
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2020,Age,13-17 Years,77.8,71.6 to 83.0,277
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2018,Age,13-15 Years,56.6,45.4 to 67.2,100
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2020,Age,13-15 Years,56.4,41.6 to 70.2,66
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2019,Age,13-17 Years,54.1,45.4 to 62.6,176
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2017,Age,13-17 Years,48.8,40.1 to 57.6,177
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2020,Age,13-17 Years,59.6,50.2 to 68.3,155
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2018,Age,13-17 Years,50.7,42.2 to 59.1,176
Varicella,History of disease,States/Local Areas,Wisconsin,2021,Age,13-17 Years,9.1,5.9 to 13.9,306
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2021,Age,13-15 Years,57.0,48.1 to 65.4,175
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2022,Age,13-17 Years,70.4,60.2 to 78.8,137
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2020,Age,13-15 Years,56.0,46.9 to 64.7,168
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2016,Age,13-17 Years,53.6,44.1 to 63.0,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2022,Age,13-15 Years,64.3,54.9 to 72.8,160
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2019,Age,13-15 Years,63.4,51.4 to 73.9,92
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2017,Age,13-17 Years,56.0,46.3 to 65.1,147
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2018,Age,13-17 Years,61.0,52.0 to 69.3,156
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2019,Age,13-17 Years,67.2,58.0 to 75.2,155
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2021,Age,13-17 Years,59.9,50.7 to 68.4,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2019,Age,13-15 Years,56.2,47.8 to 64.2,192
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2019,Age,13-15 Years,48.9,37.5 to 60.4,100
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2016,Age,13-17 Years,37.8,29.7 to 46.5,183
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2013,Age,13-15 Years,87.4,80.1 to 92.3,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2012,Age,13-15 Years,88.2,80.1 to 93.3,178
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2012,Age,13-17 Years,10.3,5.8 to 17.7,174
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2019,Age,13-17 Years,68.3,59.1 to 76.3,155
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2016,Age,13-17 Years,45.0,36.6 to 53.8,183
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2017,Age,13-17 Years,52.7,43.9 to 61.3,177
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2014,Age,13-17 Years,39.3,30.3 to 49.0,175
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2013,Age,13-17 Years,20.9,14.3 to 29.6,170
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2018,Age,13-17 Years,53.5,45.0 to 61.8,176
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018,Age,13-15 Years,85.5,78.6 to 90.4,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2017,Age,13-15 Years,87.4,80.8 to 92.0,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2020,Age,13-15 Years,90.9,83.9 to 95.0,168
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2019,Age,13-15 Years,90.4,83.8 to 94.5,192
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2015,Age,13-17 Years,42.1,34.3 to 50.4,194
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2016,Age,13-15 Years,89.9,83.4 to 94.1,199
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2015,Age,13-15 Years,88.5,82.6 to 92.7,232
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2014,Age,13-15 Years,93.7,87.2 to 97.0,216
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2021,Age,13-17 Years,66.9,57.3 to 75.3,144
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2020,Age,13-15 Years,55.7,44.3 to 66.5,102
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2021,Age,13-15 Years,54.3,42.4 to 65.7,98
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2022,Age,13-15 Years,66.6,52.6 to 78.1,77
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2021,Age,13-15 Years,59.8,46.6 to 71.8,77
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2022,Age,13-15 Years,62.4,49.3 to 73.8,83
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2018,Age,13-15 Years,49.7,39.1 to 60.3,114
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2022,Age,13-17 Years,67.6,57.2 to 76.6,137
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2020,Age,13-17 Years,63.4,52.8 to 72.9,122
HPV,"≥1 Dose, Males",States/Local Areas,Wisconsin,2023,Age,13-17 Years,78.2,70.6 to 84.3,230
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2023,Age,13-17 Years,74.4,66.4 to 81.0,196
HPV,"Up-to-Date, Females",States/Local Areas,Wisconsin,2023,Age,13-15 Years,69.6,57.9 to 79.2,111
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2023,Age,13-15 Years,63.6,55.6 to 70.9,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2023,Age,13-15 Years,92.5,86.5 to 96.0,239
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2023,Age,13-15 Years,58.3,47.4 to 68.4,138
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2023,Age,13-15 Years,88.9,82.9 to 93.0,249
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2023,Age,13-15 Years,91.2,86.1 to 94.5,249
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2023,Age,13-17 Years,93.9,90.2 to 96.3,426
≥2 Doses Hep A,,States/Local Areas,Wisconsin,2023,Age,13-17 Years,90.8,86.6 to 93.8,426
Varicella,≥2 Doses with no disease history,States/Local Areas,Wisconsin,2023,Age,13-17 Years,93.7,89.8 to 96.1,406
Varicella,≥1 Dose with no disease history,States/Local Areas,Wisconsin,2023,Age,13-17 Years,96.8,93.8 to 98.4,406
≥3 Doses HepB,,States/Local Areas,Wisconsin,2023,Age,13-17 Years,94.9,91.8 to 96.8,426
Varicella,History of disease,States/Local Areas,Wisconsin,2023,Age,13-17 Years,3.9,2.4 to 6.4,426
HPV,"Up-to-Date, Males",States/Local Areas,Wisconsin,2023,Age,13-17 Years,65.7,57.4 to 73.2,230
≥2 Doses MMR,,States/Local Areas,Wisconsin,2023,Age,13-17 Years,96.2,93.3 to 97.9,426
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2023,Age,13-17 Years,69.9,64.2 to 75.1,426
HPV,"≥1 Dose, Females",States/Local Areas,Wisconsin,2023,Age,13-17 Years,86.2,79.9 to 90.8,196
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2023,Age,13-17 Years,82.1,77.2 to 86.1,426
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2023,Age,13-17 Years,89.8,85.6 to 92.8,426
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Wisconsin,2023,Age,13-17 Years,92.6,89.2 to 95.1,426
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2023,Age,13-17 Years,91.5,87.9 to 94.1,426
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2022,Age,13-17 Years,74.0,64.2 to 81.8,137
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2015,Age,13-17 Years,47.3,38.5 to 56.2,171
HPV,"≥3 Doses, Males",States/Local Areas,Wisconsin,2015,Age,13-15 Years,33.3,24.3 to 43.7,127
HPV,"≥3 Doses, Males",States/Local Areas,Wisconsin,2014,Age,13-15 Years,24.9,15.9 to 36.8,114
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2013,Age,13-17 Years,36.8,28.3 to 46.2,160
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2014,Age,13-17 Years,40.9,31.5 to 51.0,165
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2012,Age,13-17 Years,37.5,27.7 to 48.4,133
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2011,Age,13-17 Years,46.2,36.7 to 56.0,210
≥2 Doses Hep A,,States/Local Areas,Wisconsin,2022,Age,13-17 Years,85.0,78.4 to 89.9,274
≥2 Doses Hep A,,States/Local Areas,Wisconsin,2020,Age,13-17 Years,77.1,70.9 to 82.3,277
≥2 Doses Hep A,,States/Local Areas,Wisconsin,2021,Age,13-17 Years,82.2,76.3 to 86.9,306
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2018,Age,13-17 Years,92.3,88.1 to 95.1,332
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2019,Age,13-17 Years,96.3,93.4 to 97.9,331
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2022,Age,13-17 Years,93.8,88.7 to 96.6,274
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2020,Age,13-17 Years,94.1,89.6 to 96.7,277
HPV,"≥3 Doses, Males",States/Local Areas,Wisconsin,2013,Age,13-17 Years,13.7,8.2 to 21.8,170
HPV,"≥3 Doses, Males",States/Local Areas,Wisconsin,2015,Age,13-17 Years,33.5,26.2 to 41.7,194
HPV,"≥3 Doses, Males",States/Local Areas,Wisconsin,2014,Age,13-17 Years,23.6,16.4 to 32.7,175
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2016,Age,13-17 Years,94.6,91.2 to 96.8,333
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2017,Age,13-17 Years,96.0,93.3 to 97.7,324
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2015,Age,13-17 Years,93.8,90.1 to 96.2,365
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2014,Age,13-17 Years,93.0,88.3 to 95.9,340
Varicella,≥2 Doses or history of disease,States/Local Areas,Wisconsin,2008,Age,13-17 Years,78.2,71.9 to 83.4,264
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2009,Age,13-17 Years,28.9,21.9 to 37.2,178
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2008,Age,13-17 Years,22.6,14.9 to 32.7,113
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2016,Age,13-17 Years,45.5,39.2 to 52.0,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2021,Age,13-15 Years,92.3,86.1 to 95.9,175
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2010,Age,13-17 Years,44.1,34.7 to 54.0,135
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2013,Age,13-17 Years,89.6,84.6 to 93.1,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2014,Age,13-17 Years,93.3,88.5 to 96.1,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2012,Age,13-17 Years,89.8,84.5 to 93.4,307
HPV,"≥2 Doses, Males",States/Local Areas,Wisconsin,2019,Age,13-17 Years,56.6,47.8 to 65.0,176
≥2 Doses MMR,,States/Local Areas,Wisconsin,2009,Age,13-17 Years,91.8,87.9 to 94.5,345
≥2 Doses MMR,,States/Local Areas,Wisconsin,2008,Age,13-17 Years,93.0,89.0 to 95.7,264
≥2 Doses MMR,,States/Local Areas,Wisconsin,2010,Age,13-17 Years,90.3,85.5 to 93.6,277
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018,Age,13-17 Years,55.7,49.6 to 61.7,332
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2017,Age,13-17 Years,52.3,45.8 to 58.7,324
≥2 Doses MMR,,States/Local Areas,Wisconsin,2011,Age,13-17 Years,90.9,84.8 to 94.7,416
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2019,Age,13-17 Years,60.5,54.1 to 66.5,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2010,Age,13-17 Years,81.3,75.2 to 86.1,277
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2009,Age,13-17 Years,72.3,66.3 to 77.5,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2011,Age,13-17 Years,89.7,84.8 to 93.1,416
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2022,Age,13-15 Years,91.9,85.9 to 95.5,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2008,Age,13-17 Years,53.8,47.1 to 60.4,264
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2020,Age,13-17 Years,61.5,54.4 to 68.0,277
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2022,Age,13-17 Years,69.0,61.9 to 75.4,274
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2021,Age,13-17 Years,63.3,56.7 to 69.4,306
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2013,Age,13-15 Years,24.8,16.2 to 36.0,97
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2015,Age,13-15 Years,41.8,30.9 to 53.6,105
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2014,Age,13-15 Years,29.4,19.5 to 41.8,102
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2012,Age,13-15 Years,37.2,23.9 to 52.7,72
HPV,"≥2 Doses, Females",States/Local Areas,Wisconsin,2022,Age,13-17 Years,69.1,58.7 to 77.9,137
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2020,Age,13-17 Years,91.6,86.8 to 94.7,277
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2019,Age,13-17 Years,90.7,86.1 to 93.9,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2021,Age,13-17 Years,93.5,89.5 to 96.1,306
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2022,Age,13-17 Years,90.2,85.0 to 93.7,274
≥2 Doses MMR,,States/Local Areas,Wisconsin,2018,Age,13-17 Years,93.9,89.8 to 96.4,332
≥2 Doses MMR,,States/Local Areas,Wisconsin,2017,Age,13-17 Years,96.2,93.2 to 97.9,324
≥2 Doses MMR,,States/Local Areas,Wisconsin,2019,Age,13-17 Years,96.9,94.1 to 98.4,331
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wisconsin,2011,Age,13-17 Years,24.2,18.9 to 30.4,416
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wisconsin,2012,Age,13-17 Years,21.7,16.2 to 28.5,307
≥2 Doses MMR,,States/Local Areas,Wisconsin,2015,Age,13-17 Years,94.9,91.3 to 97.1,365
≥2 Doses MMR,,States/Local Areas,Wisconsin,2014,Age,13-17 Years,94.3,90.0 to 96.8,340
≥2 Doses MMR,,States/Local Areas,Wisconsin,2012,Age,13-17 Years,94.0,90.3 to 96.3,307
≥2 Doses MMR,,States/Local Areas,Wisconsin,2013,Age,13-17 Years,93.9,89.8 to 96.4,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wisconsin,2013,Age,13-17 Years,25.0,19.7 to 31.1,330
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wisconsin,2014,Age,13-17 Years,32.0,25.9 to 38.8,340
HPV,"≥3 Doses, Males and Females",States/Local Areas,Wisconsin,2015,Age,13-17 Years,40.2,34.5 to 46.3,365
≥2 Doses MMR,,States/Local Areas,Wisconsin,2016,Age,13-17 Years,96.4,93.2 to 98.1,333
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2016,Age,13-17 Years,85.6,80.7 to 89.4,333
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2015,Age,13-17 Years,81.6,76.5 to 85.8,365
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2013,Age,13-17 Years,81.4,76.0 to 85.8,330
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2014,Age,13-17 Years,73.8,67.2 to 79.5,340
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2012,Age,13-17 Years,74.4,67.7 to 80.1,307
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2010,Age,13-17 Years,69.4,62.7 to 75.3,277
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2011,Age,13-17 Years,74.5,68.4 to 79.8,416
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2009,Age,13-17 Years,55.7,49.5 to 61.8,345
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2008,Age,13-17 Years,52.2,45.5 to 58.9,264
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2022,Age,13-15 Years,90.7,84.7 to 94.5,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018,Age,13-17 Years,87.2,82.1 to 91.0,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2017,Age,13-17 Years,90.3,85.8 to 93.5,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2015,Age,13-17 Years,88.0,83.2 to 91.5,365
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2016,Age,13-17 Years,91.6,87.2 to 94.5,333
HPV,"≥2 Doses, Males and Females",States/Local Areas,Wisconsin,2022,Age,13-17 Years,71.6,64.6 to 77.7,274
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Overall,Overall,76.6,74.0 to 79.0,1520
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Overall,Overall,89.7,87.8 to 91.4,1520
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Overall,Overall,62.1,59.1 to 64.9,1520
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a Non-MSA,91.0,86.2 to 94.3,331
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Principal City,82.2,78.2 to 85.6,581
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.5,70.1 to 78.4,608
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a Non-MSA,84.6,79.5 to 88.7,331
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Principal City,67.2,62.5 to 71.6,581
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Non-Principal City,59.8,55.2 to 64.3,608
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Principal City,92.5,89.6 to 94.7,581
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a Non-MSA,69.7,63.6 to 75.2,331
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.4,86.1 to 92.0,608
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Principal City,91.9,89.0 to 94.1,581
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a Non-MSA,56.4,49.8 to 62.7,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.2,85.8 to 91.8,608
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",93.7,87.2 to 97.0,139
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.6,78.3 to 90.7,139
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,Hispanic,85.5,77.8 to 90.8,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",63.0,50.9 to 73.7,87
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"White, Non-Hispanic",60.9,57.5 to 64.2,1129
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,Hispanic,62.2,52.9 to 70.6,165
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.7,86.3 to 90.7,1129
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",69.6,60.1 to 77.7,139
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.9,80.6 to 96.0,87
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.5,88.2 to 92.4,1129
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,Hispanic,91.5,85.3 to 95.3,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.1,77.0 to 93.2,87
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,Hispanic,91.6,85.5 to 95.2,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",93.0,86.5 to 96.5,139
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"White, Non-Hispanic",73.0,69.8 to 76.0,1129
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.2,74.0 to 90.9,87
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Poverty,Below Poverty Level,84.8,78.2 to 89.7,168
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Poverty,Living At or Above Poverty Level,89.3,87.2 to 91.2,1306
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Poverty,Below Poverty Level,91.3,85.3 to 95.0,168
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Poverty,Living At or Above Poverty Level,75.0,72.1 to 77.7,1306
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Other,77.8,60.4 to 88.9,55
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Any Medicaid,64.4,59.1 to 69.4,454
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Private Insurance Only,63.1,59.5 to 66.6,986
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Other,37.5,24.0 to 53.3,55
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Private Insurance Only,92.7,90.6 to 94.4,986
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Any Medicaid,88.3,84.2 to 91.4,454
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Poverty,Below Poverty Level,64.2,55.5 to 72.0,168
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wisconsin,2018-2022,Poverty,Living At or Above Poverty Level,63.1,57.9 to 64.2,1306
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Poverty,Below Poverty Level,92.0,85.3 to 95.8,168
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Any Medicaid,90.5,87.0 to 93.2,454
HPV,"Up-to-Date, Males",HHS Regions/National,Region 8,2023,Age,13-15 Years,63.3,56.4 to 69.7,562
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Poverty,Living At or Above Poverty Level,90.2,88.1 to 92.0,1306
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Private Insurance Only,91.2,88.9 to 93.0,986
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Any Medicaid,79.7,75.1 to 83.7,454
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Private Insurance Only,76.9,73.7 to 79.9,986
HPV,"≥1 Dose, Males and Females",States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Other,51.3,35.8 to 66.5,55
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018-2022,Insurance Coverage,Other,68.6,51.8 to 81.7,55
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2017,Age,13-17 Years,83.8,78.4 to 88.2,324
≥2 Doses MMR,,States/Local Areas,Wisconsin,2021,Age,13-17 Years,98.6,96.3 to 99.5,306
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2021,Age,13-17 Years,91.7,87.3 to 94.6,306
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2022,Age,13-17 Years,90.3,85.0 to 93.8,274
Tetanus,≥1 Dose Tdap,States/Local Areas,Wisconsin,2018-2022,Overall,Overall,90.6,88.7 to 92.2,1520
≥2 Doses MMR,,States/Local Areas,Wisconsin,2020,Age,13-17 Years,94.9,91.1 to 97.1,277
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2018,Age,13-17 Years,85.8,80.9 to 89.5,332
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2020,Age,13-17 Years,90.2,85.4 to 93.6,277
≥1 Dose MenACWY,,States/Local Areas,Wisconsin,2019,Age,13-17 Years,90.6,86.2 to 93.8,331
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2011,Age,13-15 Years,38.4,26.0 to 52.5,119
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2009,Age,13-15 Years,23.2,14.8 to 34.4,102
HPV,"≥3 Doses, Females",States/Local Areas,Wisconsin,2010,Age,13-15 Years,39.0,27.4 to 52.0,76
≥2 Doses MMR,,States/Local Areas,Wisconsin,2022,Age,13-17 Years,93.3,88.1 to 96.4,274
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2020,Age,13-15 Years,56.4,46.2 to 66.1,200
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2019,Age,13-15 Years,52.7,43.4 to 61.9,173
Varicella,History of disease,States/Local Areas,Illinois,2009,Age,13-17 Years,60.4,55.6 to 65.0,754
Varicella,History of disease,States/Local Areas,Illinois,2022,Age,13-17 Years,6.9,4.4 to 10.7,630
Varicella,History of disease,States/Local Areas,Illinois,2021,Age,13-17 Years,5.9,3.8 to 9.2,578
Varicella,History of disease,States/Local Areas,Illinois,2020,Age,13-17 Years,6.0,4.2 to 8.6,699
Varicella,History of disease,States/Local Areas,Illinois,2019,Age,13-17 Years,11.0,8.1 to 14.8,602
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2018,Age,13-15 Years,54.3,46.2 to 62.2,226
≥2 Doses MMR,,States/Local Areas,Illinois,2010,Age,13-17 Years,93.7,91.1 to 95.6,739
≥2 Doses MMR,,States/Local Areas,Illinois,2011,Age,13-17 Years,93.7,91.4 to 95.5,848
≥2 Doses MMR,,States/Local Areas,Illinois,2008,Age,13-17 Years,89.5,85.1 to 92.7,783
≥2 Doses MMR,,States/Local Areas,Illinois,2009,Age,13-17 Years,90.9,87.7 to 93.4,754
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2019,Age,13-17 Years,57.7,50.7 to 64.3,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2013,Age,13-17 Years,86.2,81.5 to 89.9,558
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2014,Age,13-17 Years,91.9,89.1 to 94.0,709
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2017,Age,13-17 Years,50.4,45.8 to 55.0,683
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018,Age,13-17 Years,53.4,48.9 to 57.9,721
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2019,Age,13-17 Years,54.9,49.8 to 59.8,602
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2012,Age,13-17 Years,77.3,71.5 to 82.2,632
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2021,Age,13-15 Years,90.1,85.4 to 93.4,355
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2020,Age,13-15 Years,90.8,86.2 to 94.0,420
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2019,Age,13-15 Years,91.9,87.3 to 95.0,382
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2016,Age,13-17 Years,47.8,42.9 to 52.7,605
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018,Age,13-15 Years,92.7,89.1 to 95.1,452
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2016,Age,13-17 Years,47.8,41.0 to 54.6,312
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2017,Age,13-17 Years,56.0,49.7 to 62.1,373
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2018,Age,13-17 Years,55.4,49.1 to 61.6,362
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2015,Age,13-17 Years,34.3,28.6 to 40.4,378
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2014,Age,13-15 Years,92.7,89.7 to 94.9,464
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2015,Age,13-15 Years,88.5,84.0 to 91.8,501
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2017,Age,13-15 Years,91.1,86.6 to 94.3,403
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2016,Age,13-15 Years,90.8,86.4 to 93.8,362
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2013,Age,13-17 Years,21.2,15.4 to 28.6,290
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2014,Age,13-17 Years,34.2,28.2 to 40.8,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2013,Age,13-15 Years,87.0,80.9 to 91.4,335
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2019,Age,13-17 Years,59.1,51.7 to 66.2,274
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2018,Age,13-17 Years,59.6,53.1 to 65.7,359
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2009,Age,13-15 Years,57.4,51.1 to 63.4,462
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2010,Age,13-15 Years,64.9,58.6 to 70.8,454
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2011,Age,13-17 Years,3.9,2.2 to 6.8,444
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2012,Age,13-17 Years,15.0,9.4 to 23.0,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2012,Age,13-15 Years,76.8,69.1 to 83.0,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2011,Age,13-15 Years,69.1,62.9 to 74.8,524
≥1 Dose MenACWY,,States/Local Areas,Illinois,2021,Age,13-15 Years,95.7,92.5 to 97.6,355
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2008,Age,13-15 Years,48.1,40.9 to 55.4,474
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2016,Age,13-17 Years,58.2,51.2 to 64.9,293
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2017,Age,13-17 Years,54.0,47.1 to 60.7,310
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2015,Age,13-17 Years,52.0,45.9 to 58.1,401
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2019,Age,13-17 Years,91.9,88.4 to 94.4,602
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2020,Age,13-17 Years,93.2,90.2 to 95.4,699
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2019,Age,13-17 Years,71.7,66.8 to 76.1,602
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2021,Age,13-17 Years,94.5,91.7 to 96.4,578
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2022,Age,13-17 Years,94.6,91.3 to 96.6,630
≥1 Dose MenACWY,,States/Local Areas,Illinois,2020,Age,13-15 Years,92.0,87.8 to 94.8,420
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2009,Age,13-17 Years,31.2,25.0 to 38.0,365
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2010,Age,13-17 Years,31.7,25.9 to 38.1,362
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2011,Age,13-17 Years,42.7,35.2 to 50.6,404
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2020,Age,13-17 Years,75.9,71.0 to 80.2,699
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2021,Age,13-17 Years,76.6,71.8 to 80.7,578
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2022,Age,13-17 Years,80.3,75.4 to 84.4,630
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2014,Age,13-17 Years,58.0,51.2 to 64.5,349
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018,Age,13-15 Years,90.3,86.4 to 93.2,452
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2013,Age,13-17 Years,42.6,35.3 to 50.3,268
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2012,Age,13-17 Years,28.5,21.4 to 36.7,308
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2017,Age,13-17 Years,69.6,63.6 to 75.0,373
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2020,Age,13-17 Years,75.0,68.4 to 80.5,367
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2021,Age,13-17 Years,76.6,70.0 to 82.2,296
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2019,Age,13-17 Years,71.3,64.7 to 77.1,328
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2018,Age,13-17 Years,65.8,59.6 to 71.5,362
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2020,Age,13-17 Years,76.9,69.3 to 83.1,332
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2021,Age,13-17 Years,76.5,69.4 to 82.4,282
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2022,Age,13-17 Years,81.5,74.4 to 87.0,294
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2011,Age,13-17 Years,6.2,3.8 to 9.9,444
HPV,"≥2 Doses, Males and Females",States/Local Areas,Illinois,2018,Age,13-17 Years,57.4,52.9 to 61.8,721
HPV,"≥2 Doses, Males and Females",States/Local Areas,Illinois,2016,Age,13-17 Years,52.9,48.0 to 57.7,605
HPV,"≥2 Doses, Males and Females",States/Local Areas,Illinois,2017,Age,13-17 Years,55.0,50.3 to 59.5,683
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2012,Age,13-17 Years,24.3,17.3 to 32.8,324
≥3 Doses HepB,,States/Local Areas,Illinois,2020,Age,13-17 Years,94.2,91.3 to 96.1,699
≥3 Doses HepB,,States/Local Areas,Illinois,2021,Age,13-17 Years,96.1,93.9 to 97.6,578
≥3 Doses HepB,,States/Local Areas,Illinois,2022,Age,13-17 Years,94.2,91.0 to 96.3,630
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2022,Age,13-17 Years,96.5,93.7 to 98.1,591
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2019,Age,13-17 Years,72.1,64.7 to 78.4,274
≥1 Dose MenACWY,,States/Local Areas,Illinois,2017,Age,13-15 Years,88.9,84.3 to 92.3,403
≥1 Dose MenACWY,,States/Local Areas,Illinois,2016,Age,13-15 Years,81.3,75.7 to 85.8,362
≥1 Dose MenACWY,,States/Local Areas,Illinois,2009,Age,13-15 Years,55.8,49.6 to 61.8,462
≥1 Dose MenACWY,,States/Local Areas,Illinois,2008,Age,13-15 Years,41.6,34.7 to 48.9,474
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2016,Age,13-17 Years,68.5,61.7 to 74.5,293
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2021,Age,13-17 Years,97.0,95.0 to 98.3,548
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2022,Age,13-17 Years,93.4,90.2 to 95.6,591
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2017,Age,13-17 Years,62.3,55.4 to 68.8,310
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2018,Age,13-17 Years,73.2,67.2 to 78.5,359
≥1 Dose MenACWY,,States/Local Areas,Illinois,2014,Age,13-15 Years,76.9,71.1 to 81.8,464
≥1 Dose MenACWY,,States/Local Areas,Illinois,2015,Age,13-15 Years,77.3,72.1 to 81.8,501
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018,Age,13-17 Years,69.4,65.2 to 73.4,721
≥1 Dose MenACWY,,States/Local Areas,Illinois,2012,Age,13-15 Years,67.2,59.2 to 74.3,393
≥1 Dose MenACWY,,States/Local Areas,Illinois,2011,Age,13-15 Years,65.2,58.7 to 71.1,524
≥1 Dose MenACWY,,States/Local Areas,Illinois,2010,Age,13-15 Years,52.6,46.2 to 58.8,454
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2022,Age,13-17 Years,79.1,72.0 to 84.8,336
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2008,Age,13-17 Years,72.9,67.7 to 77.6,783
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2009,Age,13-17 Years,72.1,67.3 to 76.4,754
≥1 Dose MenACWY,,States/Local Areas,Illinois,2013,Age,13-15 Years,80.3,74.3 to 85.1,335
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2013,Age,13-17 Years,90.2,85.9 to 93.3,558
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2012,Age,13-17 Years,80.2,74.3 to 85.0,632
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2010,Age,13-17 Years,78.4,74.0 to 82.3,739
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2011,Age,13-17 Years,79.9,75.5 to 83.7,848
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2008,Age,13-17 Years,19.6,14.4 to 26.1,373
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2016,Age,13-17 Years,63.5,58.6 to 68.1,605
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2017,Age,13-17 Years,66.1,61.5 to 70.4,683
≥1 Dose MenACWY,,States/Local Areas,Illinois,2019,Age,13-15 Years,93.0,89.2 to 95.5,382
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2018,Age,13-17 Years,93.8,91.3 to 95.6,721
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2016,Age,13-17 Years,94.7,92.2 to 96.5,605
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2017,Age,13-17 Years,94.6,92.0 to 96.4,683
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2015,Age,13-17 Years,91.4,88.3 to 93.7,779
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2014,Age,13-17 Years,94.4,92.0 to 96.1,709
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2015,Age,13-17 Years,89.1,85.8 to 91.7,779
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2021,Age,13-17 Years,62.2,56.9 to 67.1,578
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2022,Age,13-17 Years,65.7,60.3 to 70.7,630
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2020,Age,13-17 Years,63.1,57.9 to 68.1,699
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2022,Age,13-15 Years,91.6,86.3 to 95.0,383
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2008,Age,13-17 Years,45.4,39.9 to 51.0,783
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2011,Age,13-17 Years,71.8,66.9 to 76.2,848
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2010,Age,13-17 Years,66.2,61.4 to 70.8,739
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2009,Age,13-17 Years,59.5,54.5 to 64.3,754
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2016,Age,13-17 Years,43.2,36.6 to 50.1,312
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2021,Age,13-15 Years,56.5,47.0 to 65.6,179
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2022,Age,13-15 Years,65.4,55.4 to 74.3,203
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2021,Age,13-15 Years,58.9,52.3 to 65.3,355
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2022,Age,13-17 Years,64.3,56.6 to 71.4,336
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2019,Age,13-15 Years,50.1,43.7 to 56.5,382
Varicella,History of disease,States/Local Areas,Illinois,2008,Age,13-17 Years,65.2,59.9 to 70.1,783
Varicella,History of disease,States/Local Areas,Illinois,2013,Age,13-17 Years,31.0,26.1 to 36.5,558
Varicella,History of disease,States/Local Areas,Illinois,2012,Age,13-17 Years,36.2,30.4 to 42.3,632
Varicella,History of disease,States/Local Areas,Illinois,2010,Age,13-17 Years,49.0,44.1 to 53.9,739
Varicella,History of disease,States/Local Areas,Illinois,2011,Age,13-17 Years,36.9,32.0 to 42.2,848
Varicella,History of disease,States/Local Areas,Illinois,2015,Age,13-17 Years,17.4,14.3 to 20.9,779
Varicella,History of disease,States/Local Areas,Illinois,2014,Age,13-17 Years,21.8,17.9 to 26.2,709
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2018,Age,13-17 Years,55.9,49.5 to 62.2,359
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2019,Age,13-17 Years,55.2,47.8 to 62.4,274
Varicella,History of disease,States/Local Areas,Illinois,2016,Age,13-17 Years,18.5,14.9 to 22.9,605
Varicella,History of disease,States/Local Areas,Illinois,2017,Age,13-17 Years,11.8,9.1 to 15.2,683
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2017,Age,13-17 Years,48.9,42.2 to 55.6,310
Varicella,History of disease,States/Local Areas,Illinois,2018,Age,13-17 Years,12.5,9.8 to 15.9,721
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2017,Age,13-17 Years,51.8,45.6 to 58.1,373
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2020,Age,13-15 Years,59.4,49.8 to 68.3,220
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2021,Age,13-15 Years,61.3,52.0 to 69.9,176
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2022,Age,13-15 Years,67.2,57.3 to 75.8,180
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2016,Age,13-17 Years,52.6,45.6 to 59.5,293
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2022,Age,13-15 Years,66.3,59.3 to 72.6,383
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2019,Age,13-15 Years,47.6,38.9 to 56.4,209
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2018,Age,13-15 Years,53.9,45.9 to 61.7,226
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2021,Age,13-17 Years,64.8,57.3 to 71.7,282
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2022,Age,13-17 Years,67.1,59.4 to 74.1,294
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2020,Age,13-17 Years,64.3,56.5 to 71.4,332
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2021,Age,13-17 Years,59.6,52.3 to 66.6,296
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2018,Age,13-17 Years,51.0,44.7 to 57.3,362
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2019,Age,13-17 Years,54.5,47.6 to 61.3,328
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2020,Age,13-17 Years,62.0,54.8 to 68.7,367
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2020,Age,13-15 Years,58.0,51.0 to 64.7,420
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2018,Age,13-17 Years,60.8,55.1 to 66.2,1113
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2019,Age,13-17 Years,59.8,54.6 to 64.8,1176
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2019,Age,13-15 Years,52.3,45.8 to 58.7,745
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2020,Age,13-15 Years,59.2,53.3 to 65.0,1002
Varicella,History of disease,HHS Regions/National,Region 3,2020,Age,13-17 Years,8.6,6.9 to 10.7,3331
Varicella,History of disease,HHS Regions/National,Region 3,2019,Age,13-17 Years,8.9,6.9 to 11.4,2520
Varicella,History of disease,HHS Regions/National,Region 3,2021,Age,13-17 Years,5.7,4.5 to 7.3,3338
Varicella,History of disease,HHS Regions/National,Region 3,2022,Age,13-17 Years,7.0,5.6 to 8.8,2424
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2018,Age,13-15 Years,57.0,49.8 to 63.9,717
Varicella,History of disease,HHS Regions/National,Region 3,2017,Age,13-17 Years,11.2,9.1 to 13.6,2745
Varicella,History of disease,HHS Regions/National,Region 3,2015,Age,13-17 Years,15.9,13.6 to 18.6,2742
Varicella,History of disease,HHS Regions/National,Region 3,2016,Age,13-17 Years,12.9,10.8 to 15.4,2842
Varicella,History of disease,HHS Regions/National,Region 3,2007,Age,13-17 Years,61.6,54.8 to 67.9,370
Varicella,History of disease,HHS Regions/National,Region 3,2018,Age,13-17 Years,9.7,7.4 to 12.5,2295
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2016,Age,13-17 Years,42.1,37.7 to 46.6,1522
Varicella,History of disease,HHS Regions/National,Region 3,2012,Age,13-17 Years,25.6,22.6 to 28.8,2365
Varicella,History of disease,HHS Regions/National,Region 3,2013,Age,13-17 Years,20.5,17.6 to 23.8,2241
Varicella,History of disease,HHS Regions/National,Region 3,2010,Age,13-17 Years,36.6,33.6 to 39.7,2436
Varicella,History of disease,HHS Regions/National,Region 3,2011,Age,13-17 Years,30.7,27.9 to 33.6,3073
Varicella,History of disease,HHS Regions/National,Region 3,2014,Age,13-17 Years,14.3,12.3 to 16.7,2553
Varicella,History of disease,HHS Regions/National,Region 3,2006,Age,13-17 Years,64.5,58.2 to 70.4,347
Varicella,History of disease,HHS Regions/National,Region 3,2008,Age,13-17 Years,50.8,47.5 to 54.1,2306
Varicella,History of disease,HHS Regions/National,Region 3,2009,Age,13-17 Years,47.0,43.4 to 50.5,2214
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2007,Age,13-17 Years,36.3,29.7 to 43.4,370
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2018,Age,13-17 Years,54.9,50.8 to 58.9,2295
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2012,Age,13-17 Years,84.9,82.3 to 87.1,2365
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2013,Age,13-17 Years,85.8,82.9 to 88.2,2241
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2014,Age,13-17 Years,89.8,87.7 to 91.6,2553
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2017,Age,13-17 Years,54.5,51.0 to 57.9,2745
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2006,Age,13-17 Years,11.7,8.5 to 16.0,347
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2016,Age,13-17 Years,46.9,43.6 to 50.2,2842
≥2 Doses MMR,,HHS Regions/National,Region 3,2010,Age,13-17 Years,92.3,90.5 to 93.8,2436
≥2 Doses MMR,,HHS Regions/National,Region 3,2011,Age,13-17 Years,91.9,89.9 to 93.5,3073
≥2 Doses MMR,,HHS Regions/National,Region 3,2007,Age,13-17 Years,87.5,82.9 to 91.0,370
≥2 Doses MMR,,HHS Regions/National,Region 3,2006,Age,13-17 Years,86.7,82.0 to 90.3,347
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2010,Age,13-17 Years,69.2,66.1 to 72.1,2436
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2009,Age,13-17 Years,59.2,55.6 to 62.6,2214
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2011,Age,13-17 Years,77.3,74.5 to 79.9,3073
≥2 Doses MMR,,HHS Regions/National,Region 3,2008,Age,13-17 Years,90.3,88.1 to 92.1,2306
≥2 Doses MMR,,HHS Regions/National,Region 3,2009,Age,13-17 Years,91.8,89.5 to 93.6,2214
HPV,"≥2 Doses, Males",HHS Regions/National,Region 3,2019,Age,13-17 Years,63.2,58.3 to 67.9,1344
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2008,Age,13-17 Years,45.9,42.6 to 49.2,2306
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2022,Age,13-15 Years,90.2,87.3 to 92.5,1494
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2007,Age,13-17 Years,7.0,4.1 to 11.6,183
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2021,Age,13-17 Years,67.8,64.8 to 70.6,3338
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2022,Age,13-17 Years,66.0,63.0 to 68.9,2424
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2020,Age,13-17 Years,62.6,59.4 to 65.7,3331
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2019,Age,13-17 Years,60.0,56.4 to 63.4,2520
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 3,2015,Age,13-17 Years,87.4,84.9 to 89.6,2742
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2008,Age,13-17 Years,21.5,18.0 to 25.5,1176
HPV,"≥3 Doses, Females",HHS Regions/National,Region 3,2009,Age,13-17 Years,31.5,26.7 to 36.7,1049
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2020,Age,13-17 Years,66.1,61.7 to 70.2,1632
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2016,Age,13-17 Years,51.9,47.1 to 56.6,1320
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2017,Age,13-17 Years,59.8,54.6 to 64.7,1274
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2021,Age,13-17 Years,64.6,60.5 to 68.6,1792
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2019,Age,13-15 Years,55.0,50.4 to 59.5,1589
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2022,Age,13-17 Years,63.5,59.3 to 67.6,1293
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2021,Age,13-15 Years,64.8,61.0 to 68.5,2095
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2020,Age,13-15 Years,55.6,51.4 to 59.7,2067
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2019,Age,13-15 Years,57.8,51.3 to 63.9,844
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2020,Age,13-15 Years,52.1,46.2 to 57.9,1065
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2018,Age,13-15 Years,41.9,34.8 to 49.4,722
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2021,Age,13-17 Years,71.0,66.9 to 74.9,1546
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2022,Age,13-17 Years,68.6,64.3 to 72.6,1131
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 3,2022,Age,13-15 Years,63.8,60.0 to 67.5,1494
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2018,Age,13-17 Years,49.2,43.4 to 55.0,1182
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2017,Age,13-17 Years,49.4,44.6 to 54.1,1471
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2019,Age,13-17 Years,60.1,55.1 to 64.9,1344
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2020,Age,13-17 Years,59.2,54.6 to 63.7,1699
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2021,Age,13-15 Years,70.3,65.0 to 75.1,966
HPV,"Up-to-Date, Females",HHS Regions/National,Region 3,2022,Age,13-15 Years,65.0,59.3 to 70.3,696
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2021,Age,13-15 Years,59.2,53.7 to 64.4,1129
HPV,"Up-to-Date, Males",HHS Regions/National,Region 3,2022,Age,13-15 Years,62.7,57.3 to 67.7,798
HPV,"≥1 Dose, Males",States/Local Areas,West Virginia,2023,Age,13-17 Years,64.5,55.6 to 72.5,154
HPV,"≥2 Doses, Females",States/Local Areas,West Virginia,2022,Age,13-17 Years,62.7,52.0 to 72.4,110
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2023,Age,13-17 Years,90.7,86.3 to 93.8,298
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,West Virginia,2023,Age,13-17 Years,91.6,87.3 to 94.5,298
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2023,Age,13-17 Years,91.8,87.7 to 94.7,298
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2023,Age,13-17 Years,67.1,60.8 to 72.8,298
HPV,"≥1 Dose, Females",States/Local Areas,West Virginia,2023,Age,13-17 Years,69.9,60.8 to 77.6,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2023,Age,13-17 Years,49.8,43.4 to 56.1,298
≥2 Doses MMR,,States/Local Areas,West Virginia,2023,Age,13-17 Years,88.2,83.3 to 91.8,298
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2023,Age,13-17 Years,45.0,36.4 to 53.9,154
Varicella,History of disease,States/Local Areas,West Virginia,2023,Age,13-17 Years,8.2,5.3 to 12.4,298
≥3 Doses HepB,,States/Local Areas,West Virginia,2023,Age,13-17 Years,89.6,85.1 to 92.9,298
Varicella,≥1 Dose with no disease history,States/Local Areas,West Virginia,2023,Age,13-17 Years,95.2,91.4 to 97.4,274
Varicella,≥2 Doses or history of disease,States/Local Areas,West Virginia,2023,Age,13-17 Years,87.6,82.7 to 91.3,298
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2023,Age,13-17 Years,86.5,81.3 to 90.5,274
HPV,"Up-to-Date, Males",States/Local Areas,West Virginia,2023,Age,13-15 Years,42.7,31.9 to 54.2,96
≥2 Doses Hep A,,States/Local Areas,West Virginia,2023,Age,13-17 Years,86.2,81.0 to 90.2,298
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2023,Age,13-15 Years,91.0,85.4 to 94.6,188
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2023,Age,13-15 Years,89.8,83.6 to 93.8,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2023,Age,13-15 Years,48.2,40.2 to 56.3,188
Varicella,≥2 Doses with no disease history,States/Local Areas,West Virginia,2023,Age,13-15 Years,86.5,79.7 to 91.3,173
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2023,Age,13-15 Years,53.9,42.4 to 65.1,92
HPV,"Up-to-Date, Females",States/Local Areas,West Virginia,2023,Age,13-17 Years,54.8,45.5 to 63.7,144
HPV,"≥2 Doses, Males and Females",States/Local Areas,West Virginia,2022,Age,13-17 Years,52.3,45.0 to 59.5,244
HPV,"≥2 Doses, Males",States/Local Areas,West Virginia,2022,Age,13-17 Years,42.5,33.3 to 52.3,134
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Other,96.1,89.3 to 98.6,99
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Uninsured,56.2,34.6 to 75.6,30
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Other,72.6,61.8 to 81.3,99
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Uninsured,85.7,67.9 to 94.5,30
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Private Insurance Only,58.8,54.6 to 62.8,735
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Any Medicaid,70.7,66.2 to 74.8,603
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Private Insurance Only,91.1,88.4 to 93.2,735
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Poverty,Living At or Above Poverty Level,90.3,88.2 to 92.1,1129
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Any Medicaid,90.9,87.7 to 93.4,603
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Poverty,Below Poverty Level,89.7,84.9 to 93.1,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Poverty,Living At or Above Poverty Level,44.6,41.2 to 48.0,1129
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Poverty,Below Poverty Level,57.2,50.5 to 63.6,296
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Any Medicaid,89.0,85.7 to 91.7,603
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Private Insurance Only,90.7,88.2 to 92.8,735
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Uninsured,34.2,18.1 to 54.9,30
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Other,50.0,38.8 to 61.2,99
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Private Insurance Only,45.6,41.4 to 49.8,735
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Any Medicaid,51.3,46.6 to 55.9,603
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Other,94.9,87.6 to 98.0,99
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Insurance Coverage,Uninsured,88.6,74.0 to 95.5,30
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Poverty,Below Poverty Level,91.9,87.6 to 94.8,296
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Poverty,Living At or Above Poverty Level,91.4,89.2 to 93.1,1129
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Poverty,Living At or Above Poverty Level,61.4,58.0 to 64.7,1129
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Poverty,Below Poverty Level,75.0,69.1 to 80.2,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",65.8,46.5 to 80.9,35
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",64.3,61.2 to 67.3,1270
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.6,80.7 to 94.7,102
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,Hispanic,86.4,70.8 to 94.4,60
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.4,72.9 to 97.0,35
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,Hispanic,91.6,76.5 to 97.4,60
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.3,88.3 to 92.0,1270
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",95.7,86.3 to 98.7,35
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",52.0,41.0 to 62.7,102
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",91.0,88.9 to 92.7,1270
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,Hispanic,42.1,28.3 to 57.3,60
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.2,45.0 to 51.5,1270
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",48.8,30.7 to 67.1,35
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,Hispanic,67.8,50.8 to 81.1,60
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",75.5,65.4 to 83.4,102
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.4,84.1 to 96.5,102
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.7,86.2 to 92.4,489
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a Non-MSA,45.5,40.6 to 50.6,528
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,91.2,87.8 to 93.7,450
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,91.9,88.7 to 94.2,489
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a Non-MSA,63.0,58.1 to 67.6,528
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,90.7,86.9 to 93.5,450
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,47.9,42.7 to 53.1,489
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,52.0,46.5 to 57.4,450
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a Non-MSA,91.0,87.5 to 93.6,528
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Non-Principal City,63.4,58.4 to 68.3,489
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a MSA Principal City,69.8,64.6 to 74.6,450
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Urbanicity,Living In a Non-MSA,89.6,86.1 to 92.4,528
HPV,"Up-to-Date, Males and Females",States/Local Areas,West Virginia,2018-2022,Overall,Overall,48.3,45.3 to 51.3,1467
HPV,"≥1 Dose, Males and Females",States/Local Areas,West Virginia,2018-2022,Overall,Overall,65.2,62.3 to 68.0,1467
≥1 Dose MenACWY,,States/Local Areas,West Virginia,2018-2022,Overall,Overall,91.2,89.3 to 92.8,1467
Tetanus,≥1 Dose Tdap,States/Local Areas,West Virginia,2018-2022,Overall,Overall,90.1,88.2 to 91.8,1467
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2016,Age,13-17 Years,41.1,31.9 to 51.0,160
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2021,Age,13-15 Years,46.3,31.5 to 61.9,73
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2022,Age,13-15 Years,59.7,45.9 to 72.1,86
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2018,Age,13-15 Years,64.1,51.8 to 74.8,90
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2021,Age,13-17 Years,69.0,57.2 to 78.8,129
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2022,Age,13-17 Years,65.1,53.2 to 75.4,123
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2020,Age,13-17 Years,49.7,40.0 to 59.5,156
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2019,Age,13-15 Years,49.6,37.0 to 62.2,92
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2020,Age,13-15 Years,51.7,39.6 to 63.6,108
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2019,Age,13-17 Years,52.4,42.4 to 62.2,137
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2018,Age,13-17 Years,59.1,49.9 to 67.7,168
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2017,Age,13-17 Years,54.9,46.7 to 62.9,206
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2019,Age,13-17 Years,46.8,37.7 to 56.2,165
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2020,Age,13-17 Years,56.5,47.2 to 65.3,182
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2017,Age,13-17 Years,39.3,31.6 to 47.6,202
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2018,Age,13-17 Years,57.3,48.0 to 66.1,161
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2016,Age,13-17 Years,42.5,33.7 to 51.9,178
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2022,Age,13-15 Years,61.5,51.1 to 70.9,163
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2021,Age,13-15 Years,63.7,48.5 to 76.6,83
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2022,Age,13-15 Years,63.2,47.6 to 76.4,77
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2021,Age,13-17 Years,55.6,43.4 to 67.2,125
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2019,Age,13-15 Years,47.4,38.3 to 56.7,166
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2022,Age,13-17 Years,60.5,49.5 to 70.5,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2021,Age,13-15 Years,55.2,44.2 to 65.7,156
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2020,Age,13-15 Years,45.3,36.8 to 54.2,205
Varicella,History of disease,States/Local Areas,Ohio,2008,Age,13-17 Years,66.7,60.4 to 72.6,311
Varicella,History of disease,States/Local Areas,Ohio,2009,Age,13-17 Years,57.3,50.9 to 63.4,351
Varicella,History of disease,States/Local Areas,Ohio,2017,Age,13-17 Years,19.3,15.0 to 24.3,408
Varicella,History of disease,States/Local Areas,Ohio,2018,Age,13-17 Years,16.6,11.9 to 22.6,329
Varicella,History of disease,States/Local Areas,Ohio,2016,Age,13-17 Years,20.2,15.3 to 26.4,338
Varicella,History of disease,States/Local Areas,Ohio,2015,Age,13-17 Years,19.3,14.6 to 25.2,332
Varicella,History of disease,States/Local Areas,Ohio,2014,Age,13-17 Years,22.8,18.1 to 28.3,430
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2018,Age,13-15 Years,54.3,43.0 to 65.3,110
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2019,Age,13-15 Years,45.4,32.5 to 58.8,74
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2020,Age,13-15 Years,40.2,28.7 to 52.9,97
Varicella,History of disease,States/Local Areas,Ohio,2012,Age,13-17 Years,38.1,31.3 to 45.5,327
Varicella,History of disease,States/Local Areas,Ohio,2013,Age,13-17 Years,30.6,24.9 to 37.0,319
Varicella,History of disease,States/Local Areas,Ohio,2011,Age,13-17 Years,41.7,35.7 to 47.9,381
Varicella,History of disease,States/Local Areas,Ohio,2010,Age,13-17 Years,46.4,40.2 to 52.8,302
≥3 Doses HepB,,States/Local Areas,Ohio,2020,Age,13-17 Years,93.3,89.3 to 95.8,338
≥3 Doses HepB,,States/Local Areas,Ohio,2021,Age,13-17 Years,94.1,88.3 to 97.1,254
≥3 Doses HepB,,States/Local Areas,Ohio,2022,Age,13-17 Years,91.9,85.8 to 95.5,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2022,Age,13-17 Years,93.7,87.8 to 96.8,254
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2021,Age,13-17 Years,96.7,90.4 to 98.9,237
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2008,Age,13-17 Years,77.4,65.9 to 85.9,106
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2012,Age,13-17 Years,15.2,9.7 to 23.2,168
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2020,Age,13-17 Years,77.7,69.1 to 84.4,182
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2021,Age,13-17 Years,63.0,50.2 to 74.3,125
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2018,Age,13-17 Years,66.9,57.9 to 74.9,161
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2019,Age,13-17 Years,66.0,56.7 to 74.1,165
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2016,Age,13-17 Years,55.0,45.2 to 64.3,160
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2015,Age,13-17 Years,43.7,35.0 to 52.8,186
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2014,Age,13-17 Years,36.8,29.1 to 45.2,228
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2013,Age,13-17 Years,26.5,19.1 to 35.5,163
HPV,"≥2 Doses, Males and Females",States/Local Areas,Ohio,2018,Age,13-17 Years,59.0,52.5 to 65.3,329
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2019,Age,13-17 Years,73.7,64.4 to 81.3,137
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2022,Age,13-17 Years,90.0,82.9 to 94.3,254
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2020,Age,13-17 Years,73.2,64.3 to 80.6,156
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2021,Age,13-17 Years,82.2,70.8 to 89.8,129
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2022,Age,13-17 Years,81.9,70.6 to 89.5,123
HPV,"≥2 Doses, Males and Females",States/Local Areas,Ohio,2017,Age,13-17 Years,51.1,45.4 to 56.9,408
HPV,"≥2 Doses, Males and Females",States/Local Areas,Ohio,2016,Age,13-17 Years,48.1,41.4 to 54.9,338
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2017,Age,13-17 Years,58.8,50.8 to 66.5,202
HPV,"≥2 Doses, Males and Females",States/Local Areas,Ohio,2019,Age,13-17 Years,51.9,45.1 to 58.7,302
≥3 Doses HepB,,States/Local Areas,Ohio,2008,Age,13-17 Years,76.9,71.0 to 82.0,311
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2022,Age,13-15 Years,92.8,84.8 to 96.8,159
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2008,Age,13-17 Years,29.1,21.6 to 37.9,154
≥3 Doses HepB,,States/Local Areas,Ohio,2009,Age,13-17 Years,91.1,87.4 to 93.8,351
≥3 Doses HepB,,States/Local Areas,Ohio,2010,Age,13-17 Years,90.3,85.8 to 93.4,302
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2011,Age,13-17 Years,59.9,51.9 to 67.4,231
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2010,Age,13-17 Years,48.0,39.5 to 56.6,163
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2011,Age,13-17 Years,89.9,83.1 to 94.2,231
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2009,Age,13-17 Years,40.3,31.1 to 50.2,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2008,Age,13-17 Years,38.4,28.1 to 49.8,106
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2009,Age,13-17 Years,82.9,73.0 to 89.6,145
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2010,Age,13-17 Years,92.4,86.8 to 95.7,163
≥3 Doses HepB,,States/Local Areas,Ohio,2012,Age,13-17 Years,88.4,81.9 to 92.8,327
≥3 Doses HepB,,States/Local Areas,Ohio,2011,Age,13-17 Years,90.6,85.7 to 93.9,381
≥3 Doses HepB,,States/Local Areas,Ohio,2014,Age,13-17 Years,87.7,82.7 to 91.4,430
≥3 Doses HepB,,States/Local Areas,Ohio,2013,Age,13-17 Years,93.9,89.8 to 96.4,319
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2009,Age,13-17 Years,40.6,31.8 to 49.9,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2012,Age,13-17 Years,62.0,52.8 to 70.3,206
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2012,Age,13-17 Years,90.3,81.9 to 95.0,206
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2009,Age,13-15 Years,45.0,33.8 to 56.7,106
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2008,Age,13-15 Years,38.2,26.4 to 51.5,83
≥3 Doses HepB,,States/Local Areas,Ohio,2017,Age,13-17 Years,94.6,91.7 to 96.5,408
≥3 Doses HepB,,States/Local Areas,Ohio,2019,Age,13-17 Years,91.8,87.5 to 94.8,302
≥3 Doses HepB,,States/Local Areas,Ohio,2018,Age,13-17 Years,94.7,91.3 to 96.8,329
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2016,Age,13-17 Years,91.9,86.1 to 95.4,281
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2015,Age,13-17 Years,94.2,89.4 to 96.9,266
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2014,Age,13-17 Years,91.2,85.7 to 94.7,329
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2013,Age,13-17 Years,92.4,86.8 to 95.7,227
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2019,Age,13-17 Years,92.3,88.0 to 95.2,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2020,Age,13-17 Years,91.8,87.3 to 94.8,317
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2021,Age,13-17 Years,94.6,88.2 to 97.6,237
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2018,Age,13-17 Years,91.3,86.5 to 94.5,282
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2020,Age,13-17 Years,95.8,91.8 to 97.9,317
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2017,Age,13-17 Years,95.5,92.6 to 97.3,339
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2019,Age,13-17 Years,95.6,91.6 to 97.7,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2018,Age,13-17 Years,95.1,91.1 to 97.4,282
≥3 Doses HepB,,States/Local Areas,Ohio,2016,Age,13-17 Years,92.8,88.6 to 95.6,338
≥3 Doses HepB,,States/Local Areas,Ohio,2015,Age,13-17 Years,92.0,87.9 to 94.8,332
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2020,Age,13-15 Years,91.4,84.9 to 95.3,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2021,Age,13-15 Years,95.0,87.1 to 98.2,146
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2012,Age,13-15 Years,62.8,51.9 to 72.5,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2013,Age,13-15 Years,63.6,54.2 to 72.1,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2010,Age,13-15 Years,50.8,40.8 to 60.8,114
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2011,Age,13-15 Years,59.9,50.6 to 68.6,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2017,Age,13-17 Years,88.8,84.7 to 91.9,339
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2010,Age,13-17 Years,44.0,35.3 to 53.0,150
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2011,Age,13-17 Years,45.5,37.2 to 54.1,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2016,Age,13-17 Years,80.6,73.9 to 85.9,281
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2015,Age,13-17 Years,75.7,68.2 to 81.9,266
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2014,Age,13-17 Years,74.2,67.2 to 80.1,329
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2013,Age,13-17 Years,66.2,58.5 to 73.1,227
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2012,Age,13-17 Years,56.4,45.8 to 66.4,159
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2013,Age,13-17 Years,54.8,45.5 to 63.9,156
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2014,Age,13-17 Years,61.0,52.3 to 69.1,202
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2015,Age,13-17 Years,61.0,50.7 to 70.4,146
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2015,Age,13-15 Years,79.4,69.8 to 86.5,170
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2014,Age,13-15 Years,77.1,68.2 to 84.1,214
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2018,Age,13-15 Years,93.8,88.5 to 96.8,177
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2019,Age,13-15 Years,93.7,88.4 to 96.7,152
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2012,Age,13-17 Years,76.5,69.6 to 82.2,327
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2011,Age,13-17 Years,76.6,70.7 to 81.6,381
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2014,Age,13-17 Years,80.1,74.3 to 84.8,430
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2013,Age,13-17 Years,76.6,70.6 to 81.6,319
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2020,Age,13-17 Years,92.4,88.1 to 95.2,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2021,Age,13-17 Years,95.0,89.2 to 97.8,254
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2022,Age,13-17 Years,90.6,83.9 to 94.7,269
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2009,Age,13-17 Years,74.5,68.4 to 79.8,351
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2010,Age,13-17 Years,72.2,66.0 to 77.6,302
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2017,Age,13-15 Years,92.4,87.8 to 95.4,209
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2016,Age,13-15 Years,84.4,76.1 to 90.2,176
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2019,Age,13-17 Years,92.9,88.9 to 95.6,302
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2015,Age,13-17 Years,80.4,74.0 to 85.5,332
HPV,"≥3 Doses, Males",States/Local Areas,Ohio,2015,Age,13-15 Years,16.1,10.1 to 24.8,112
HPV,"≥3 Doses, Males",States/Local Areas,Ohio,2014,Age,13-15 Years,21.1,13.3 to 31.9,142
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2015,Age,13-17 Years,37.8,28.9 to 47.6,146
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2014,Age,13-17 Years,35.2,27.4 to 43.9,202
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2013,Age,13-17 Years,35.0,26.7 to 44.2,156
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2018,Age,13-17 Years,92.7,88.7 to 95.4,329
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2016,Age,13-17 Years,84.5,79.0 to 88.8,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2017,Age,13-17 Years,91.0,87.6 to 93.5,408
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2008,Age,13-17 Years,79.5,73.9 to 84.2,311
HPV,"≥3 Doses, Males",States/Local Areas,Ohio,2013,Age,13-17 Years,14.7,9.4 to 22.4,163
HPV,"≥3 Doses, Males",States/Local Areas,Ohio,2015,Age,13-17 Years,21.0,15.1 to 28.4,186
HPV,"≥3 Doses, Males",States/Local Areas,Ohio,2014,Age,13-17 Years,23.3,16.8 to 31.4,228
≥2 Doses Hep A,,States/Local Areas,Ohio,2022,Age,13-17 Years,75.7,67.6 to 82.3,269
≥2 Doses Hep A,,States/Local Areas,Ohio,2021,Age,13-17 Years,83.8,76.5 to 89.2,254
≥2 Doses Hep A,,States/Local Areas,Ohio,2020,Age,13-17 Years,75.5,69.5 to 80.5,338
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2010,Age,13-17 Years,31.1,23.6 to 39.8,150
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2012,Age,13-17 Years,31.9,22.4 to 43.2,159
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2011,Age,13-17 Years,32.6,25.0 to 41.3,181
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2009,Age,13-17 Years,25.0,17.9 to 33.9,176
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2008,Age,13-17 Years,15.6,10.0 to 23.5,154
Varicella,History of disease,States/Local Areas,Ohio,2019,Age,13-17 Years,7.6,5.0 to 11.4,302
Varicella,History of disease,States/Local Areas,Ohio,2020,Age,13-17 Years,6.7,3.7 to 11.6,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2015,Age,13-17 Years,86.7,80.8 to 91.0,332
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2019,Age,13-17 Years,48.7,39.4 to 58.0,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2009,Age,13-17 Years,50.2,44.0 to 56.4,351
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2010,Age,13-17 Years,60.3,54.0 to 66.2,302
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2011,Age,13-17 Years,72.7,66.9 to 77.8,381
≥2 Doses MMR,,States/Local Areas,Ohio,2011,Age,13-17 Years,86.5,81.1 to 90.6,381
≥2 Doses MMR,,States/Local Areas,Ohio,2010,Age,13-17 Years,90.7,86.5 to 93.7,302
≥2 Doses MMR,,States/Local Areas,Ohio,2009,Age,13-17 Years,94.4,91.3 to 96.5,351
≥2 Doses MMR,,States/Local Areas,Ohio,2008,Age,13-17 Years,84.8,79.7 to 88.8,311
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2022,Age,13-15 Years,91.5,83.3 to 95.9,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2008,Age,13-17 Years,30.6,25.2 to 36.7,311
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2019,Age,13-17 Years,49.6,42.7 to 56.4,302
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2020,Age,13-17 Years,53.2,46.4 to 59.8,338
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2021,Age,13-17 Years,62.2,53.5 to 70.1,254
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2022,Age,13-17 Years,62.7,54.7 to 70.1,269
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2016,Age,13-17 Years,41.8,35.3 to 48.6,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2012,Age,13-17 Years,73.8,66.5 to 80.0,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2014,Age,13-17 Years,83.0,77.7 to 87.3,430
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2013,Age,13-17 Years,84.4,78.9 to 88.7,319
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018,Age,13-17 Years,58.2,51.6 to 64.4,329
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2017,Age,13-17 Years,47.0,41.2 to 52.8,408
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2007,Age,13-17 Years,35.4,28.6 to 42.8,366
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2018,Age,13-17 Years,52.5,46.7 to 58.1,1305
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2017,Age,13-17 Years,53.1,47.5 to 58.7,1299
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2012,Age,13-17 Years,88.6,85.2 to 91.4,1461
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2013,Age,13-17 Years,89.7,85.6 to 92.8,1318
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2014,Age,13-17 Years,87.1,83.0 to 90.3,1491
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2006,Age,13-17 Years,11.5,8.1 to 16.1,362
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2016,Age,13-17 Years,48.0,42.5 to 53.5,1303
≥2 Doses MMR,,HHS Regions/National,Region 9,2007,Age,13-17 Years,88.0,81.7 to 92.3,366
≥2 Doses MMR,,HHS Regions/National,Region 9,2006,Age,13-17 Years,83.2,77.1 to 88.0,362
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2010,Age,13-17 Years,71.4,66.6 to 75.8,1311
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2009,Age,13-17 Years,55.3,50.1 to 60.4,1320
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2011,Age,13-17 Years,82.4,79.0 to 85.3,1750
≥2 Doses MMR,,HHS Regions/National,Region 9,2008,Age,13-17 Years,90.5,86.7 to 93.2,1118
≥2 Doses MMR,,HHS Regions/National,Region 9,2009,Age,13-17 Years,86.7,83.0 to 89.6,1320
≥2 Doses MMR,,HHS Regions/National,Region 9,2010,Age,13-17 Years,87.7,83.3 to 91.0,1311
≥2 Doses MMR,,HHS Regions/National,Region 9,2011,Age,13-17 Years,89.9,87.0 to 92.2,1750
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2008,Age,13-17 Years,44.9,38.9 to 51.0,1118
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2022,Age,13-15 Years,81.9,74.6 to 87.4,639
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2019,Age,13-17 Years,56.5,49.4 to 63.3,1199
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2021,Age,13-17 Years,67.2,60.6 to 73.1,1173
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2022,Age,13-17 Years,61.1,55.5 to 66.4,1090
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2015,Age,13-17 Years,83.3,78.4 to 87.2,1506
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2020,Age,13-17 Years,60.3,54.9 to 65.5,1402
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2019,Age,13-17 Years,55.7,45.9 to 65.0,607
≥2 Doses Hep A,,HHS Regions/National,Region 9,2020,Age,13-17 Years,85.1,80.6 to 88.7,1402
≥2 Doses Hep A,,HHS Regions/National,Region 9,2022,Age,13-17 Years,83.1,78.0 to 87.3,1090
≥2 Doses Hep A,,HHS Regions/National,Region 9,2021,Age,13-17 Years,88.5,82.8 to 92.5,1173
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2010,Age,13-17 Years,32.0,25.9 to 38.9,612
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2009,Age,13-17 Years,49.5,42.0 to 57.1,648
≥3 Doses HepB,,HHS Regions/National,Region 9,2008,Age,13-17 Years,88.8,84.2 to 92.2,1118
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2007,Age,13-17 Years,72.3,61.3 to 81.1,160
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2007,Age,13-17 Years,19.5,12.9 to 28.2,160
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2012,Age,13-17 Years,74.9,69.5 to 79.6,1048
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2008,Age,13-17 Years,46.1,37.6 to 54.9,549
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2008,Age,13-17 Years,90.6,86.2 to 93.7,505
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2010,Age,13-17 Years,90.7,85.5 to 94.2,772
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2009,Age,13-17 Years,86.9,81.7 to 90.8,687
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2008,Age,13-17 Years,43.5,34.4 to 53.0,505
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2009,Age,13-17 Years,56.2,48.9 to 63.1,687
≥3 Doses HepB,,HHS Regions/National,Region 9,2007,Age,13-17 Years,86.9,80.7 to 91.3,366
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2006,Age,13-17 Years,65.0,54.8 to 74.1,135
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2011,Age,13-17 Years,87.5,82.9 to 91.0,1197
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2010,Age,13-17 Years,58.2,51.3 to 64.9,772
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2011,Age,13-17 Years,65.2,60.2 to 69.9,1197
≥3 Doses HepB,,HHS Regions/National,Region 9,2006,Age,13-17 Years,87.4,83.0 to 90.9,362
≥3 Doses HepB,,HHS Regions/National,Region 9,2010,Age,13-17 Years,88.8,84.6 to 92.0,1311
≥3 Doses HepB,,HHS Regions/National,Region 9,2009,Age,13-17 Years,88.9,85.6 to 91.4,1320
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2022,Age,13-15 Years,85.6,78.2 to 90.8,591
≥3 Doses HepB,,HHS Regions/National,Region 9,2017,Age,13-17 Years,89.8,85.5 to 92.8,1299
≥3 Doses HepB,,HHS Regions/National,Region 9,2018,Age,13-17 Years,88.9,84.9 to 92.0,1305
≥3 Doses HepB,,HHS Regions/National,Region 9,2019,Age,13-17 Years,86.7,80.6 to 91.1,1199
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2019,Age,13-17 Years,93.5,88.3 to 96.5,1095
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2012,Age,13-17 Years,94.5,90.7 to 96.8,1048
≥3 Doses HepB,,HHS Regions/National,Region 9,2016,Age,13-17 Years,88.3,84.5 to 91.2,1303
≥3 Doses HepB,,HHS Regions/National,Region 9,2015,Age,13-17 Years,85.3,80.7 to 89.0,1506
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2018,Age,13-17 Years,93.4,90.4 to 95.4,1154
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2019,Age,13-17 Years,85.9,79.4 to 90.5,1095
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2020,Age,13-17 Years,85.6,80.9 to 89.3,1289
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2021,Age,13-17 Years,88.4,82.7 to 92.4,1083
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2018,Age,13-17 Years,86.1,81.5 to 89.6,1154
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2020,Age,13-17 Years,92.4,88.7 to 94.9,1289
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2017,Age,13-17 Years,92.7,88.3 to 95.6,1142
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2013,Age,13-17 Years,93.0,88.1 to 96.0,1017
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2014,Age,13-17 Years,95.8,93.8 to 97.2,1210
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2015,Age,13-17 Years,90.8,86.0 to 94.1,1265
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2016,Age,13-17 Years,92.2,87.9 to 95.1,1111
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2020,Age,13-15 Years,89.6,84.3 to 93.3,797
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2021,Age,13-15 Years,86.9,78.3 to 92.4,675
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2012,Age,13-17 Years,63.4,56.5 to 69.8,691
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2013,Age,13-17 Years,66.0,58.1 to 73.0,610
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2014,Age,13-17 Years,66.7,58.8 to 73.7,730
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2015,Age,13-17 Years,67.3,59.4 to 74.4,727
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2007,Age,13-15 Years,18.2,11.1 to 28.3,124
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2011,Age,13-17 Years,63.4,57.6 to 68.8,804
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2010,Age,13-17 Years,55.4,48.0 to 62.5,612
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2017,Age,13-17 Years,83.7,78.6 to 87.8,1142
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2013,Age,13-17 Years,77.4,71.8 to 82.2,1017
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2014,Age,13-17 Years,79.7,74.7 to 83.9,1210
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2015,Age,13-17 Years,78.6,73.3 to 83.1,1265
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2016,Age,13-17 Years,80.6,75.5 to 84.8,1111
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2012,Age,13-15 Years,72.4,65.6 to 78.3,717
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2013,Age,13-15 Years,82.7,76.7 to 87.4,699
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2011,Age,13-15 Years,69.5,63.4 to 75.0,824
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2010,Age,13-15 Years,67.0,59.7 to 73.6,558
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2008,Age,13-15 Years,45.0,35.1 to 55.2,368
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2009,Age,13-15 Years,61.0,52.8 to 68.6,505
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2015,Age,13-15 Years,81.0,74.0 to 86.4,809
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2014,Age,13-15 Years,80.4,74.2 to 85.3,816
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2018,Age,13-15 Years,87.9,82.3 to 91.9,711
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2019,Age,13-15 Years,87.7,79.6 to 92.8,688
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2017,Age,13-15 Years,85.1,78.6 to 89.9,726
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2016,Age,13-15 Years,79.5,72.6 to 85.0,722
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2010,Age,13-17 Years,75.3,70.5 to 79.5,1311
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2009,Age,13-17 Years,74.8,70.1 to 79.1,1320
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2007,Age,13-17 Years,66.2,58.8 to 72.8,366
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2012,Age,13-17 Years,81.4,77.2 to 85.0,1461
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2011,Age,13-17 Years,77.0,73.2 to 80.3,1750
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2013,Age,13-17 Years,82.8,78.3 to 86.5,1318
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2020,Age,13-17 Years,86.9,82.5 to 90.2,1402
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2021,Age,13-17 Years,89.3,84.0 to 93.0,1173
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2022,Age,13-17 Years,87.0,82.3 to 90.6,1090
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2015,Age,13-17 Years,82.0,77.4 to 85.9,1506
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2014,Age,13-17 Years,83.5,79.3 to 86.9,1491
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2014,Age,13-15 Years,27.3,19.3 to 37.0,494
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2012,Age,13-15 Years,10.3,6.4 to 16.2,483
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2013,Age,13-17 Years,16.4,11.0 to 23.8,708
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2012,Age,13-17 Years,10.6,7.2 to 15.5,770
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2015,Age,13-17 Years,29.0,22.4 to 36.5,779
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2014,Age,13-17 Years,28.2,21.7 to 35.8,761
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2015,Age,13-15 Years,28.8,20.7 to 38.5,497
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2019,Age,13-17 Years,86.9,80.8 to 91.2,1199
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2017,Age,13-17 Years,85.9,81.3 to 89.4,1299
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2018,Age,13-17 Years,87.6,83.5 to 90.8,1305
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2016,Age,13-17 Years,83.2,78.8 to 86.9,1303
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2008,Age,13-17 Years,73.6,67.7 to 78.7,1118
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 9,2006,Age,13-17 Years,65.6,59.2 to 71.4,362
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2012,Age,13-17 Years,36.2,29.8 to 43.2,691
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2011,Age,13-17 Years,41.6,35.8 to 47.7,804
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2008,Age,13-17 Years,21.3,14.7 to 29.7,549
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2009,Age,13-17 Years,23.2,18.1 to 29.3,648
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2015,Age,13-17 Years,47.6,39.8 to 55.4,727
HPV,"≥3 Doses, Males",HHS Regions/National,Region 9,2013,Age,13-15 Years,18.2,11.2 to 28.1,445
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2013,Age,13-17 Years,43.3,35.5 to 51.6,610
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2014,Age,13-17 Years,45.0,37.4 to 52.8,730
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2013,Age,13-17 Years,90.7,86.6 to 93.6,1318
≥3 Doses HepB,,HHS Regions/National,Region 9,2022,Age,13-17 Years,86.8,82.1 to 90.4,1090
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2018,Age,13-17 Years,68.0,60.0 to 75.1,644
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2022,Age,13-17 Years,90.6,86.6 to 93.5,1022
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 9,2021,Age,13-17 Years,93.4,88.2 to 96.4,1083
≥3 Doses HepB,,HHS Regions/National,Region 9,2020,Age,13-17 Years,88.5,84.6 to 91.5,1402
≥3 Doses HepB,,HHS Regions/National,Region 9,2021,Age,13-17 Years,89.9,84.9 to 93.4,1173
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2012,Age,13-17 Years,27.4,21.9 to 33.8,770
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2013,Age,13-17 Years,48.7,41.0 to 56.4,708
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2014,Age,13-17 Years,50.2,42.8 to 57.5,761
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2015,Age,13-17 Years,56.8,49.0 to 64.3,779
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2016,Age,13-17 Years,66.1,59.1 to 72.5,688
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 9,2019,Age,13-17 Years,61.9,55.0 to 68.5,1199
≥3 Doses HepB,,HHS Regions/National,Region 9,2012,Age,13-17 Years,91.2,87.9 to 93.7,1461
≥3 Doses HepB,,HHS Regions/National,Region 9,2011,Age,13-17 Years,89.5,86.4 to 92.0,1750
≥3 Doses HepB,,HHS Regions/National,Region 9,2013,Age,13-17 Years,91.7,87.8 to 94.4,1318
≥3 Doses HepB,,HHS Regions/National,Region 9,2014,Age,13-17 Years,91.1,87.8 to 93.5,1491
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2018,Age,13-17 Years,76.3,69.2 to 82.2,661
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2019,Age,13-17 Years,76.7,67.5 to 83.9,607
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2020,Age,13-17 Years,72.9,65.9 to 79.0,741
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2021,Age,13-17 Years,81.9,73.0 to 88.4,599
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 9,2018,Age,13-17 Years,58.9,53.3 to 64.4,1305
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2019,Age,13-17 Years,77.7,68.8 to 84.5,592
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 9,2017,Age,13-17 Years,58.9,53.4 to 64.3,1299
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 9,2022,Age,13-17 Years,86.3,81.4 to 90.1,1022
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2020,Age,13-17 Years,80.8,73.7 to 86.3,661
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2021,Age,13-17 Years,80.7,71.9 to 87.2,574
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2011,Age,13-17 Years,12.0,8.5 to 16.8,946
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2022,Age,13-17 Years,71.6,63.3 to 78.8,495
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 9,2016,Age,13-17 Years,55.8,50.4 to 61.2,1303
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2017,Age,13-17 Years,66.6,59.6 to 72.9,684
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2007,Age,13-17 Years,29.0,20.5 to 39.2,170
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2008,Age,13-17 Years,71.5,65.8 to 76.6,1118
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2009,Age,13-17 Years,77.6,73.1 to 81.5,1320
HPV,"≥1 Dose, Males",HHS Regions/National,Region 9,2022,Age,13-17 Years,74.9,67.7 to 80.9,595
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2012,Age,13-17 Years,92.0,88.8 to 94.3,1461
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2010,Age,13-17 Years,82.0,77.7 to 85.6,1311
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2011,Age,13-17 Years,87.1,84.0 to 89.7,1750
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2009,Age,13-15 Years,61.6,55.3 to 67.6,822
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2008,Age,13-15 Years,49.4,41.9 to 57.0,692
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2011,Age,13-15 Years,76.0,71.1 to 80.3,1103
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2010,Age,13-15 Years,70.9,64.8 to 76.4,821
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2007,Age,13-15 Years,31.3,23.5 to 40.2,216
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2006,Age,13-15 Years,14.2,9.4 to 20.8,212
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2007,Age,13-17 Years,71.8,65.1 to 77.7,366
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2006,Age,13-17 Years,59.0,52.4 to 65.4,362
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2010,Age,13-17 Years,43.0,36.0 to 50.2,612
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2011,Age,13-17 Years,52.4,46.4 to 58.3,804
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2009,Age,13-17 Years,37.3,30.6 to 44.6,648
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2020,Age,13-15 Years,85.2,79.1 to 89.7,862
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2012,Age,13-17 Years,47.7,40.8 to 54.8,691
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2013,Age,13-17 Years,54.8,46.7 to 62.5,610
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2008,Age,13-17 Years,34.9,26.8 to 43.9,549
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2007,Age,13-17 Years,23.9,15.9 to 34.3,170
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2016,Age,13-15 Years,79.4,72.7 to 84.7,816
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2017,Age,13-15 Years,83.5,77.7 to 88.0,811
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2018,Age,13-15 Years,84.5,78.2 to 89.2,809
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2019,Age,13-15 Years,91.3,87.5 to 94.1,741
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2012,Age,13-15 Years,75.8,70.1 to 80.8,910
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2013,Age,13-15 Years,82.8,77.2 to 87.3,845
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2017,Age,13-17 Years,74.5,66.9 to 80.8,615
HPV,"≥1 Dose, Females",HHS Regions/National,Region 9,2016,Age,13-17 Years,75.3,68.0 to 81.4,615
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2016,Age,13-17 Years,85.7,81.2 to 89.3,1303
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2014,Age,13-17 Years,89.4,85.6 to 92.3,1491
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2015,Age,13-17 Years,88.3,84.1 to 91.4,1506
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2015,Age,13-15 Years,79.3,72.7 to 84.7,937
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2014,Age,13-15 Years,78.4,72.0 to 83.7,949
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2017,Age,13-17 Years,85.3,80.6 to 89.0,1299
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2017,Age,13-17 Years,70.4,65.4 to 75.0,1299
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2016,Age,13-17 Years,70.6,65.6 to 75.2,1303
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2018,Age,13-17 Years,91.2,87.3 to 93.9,1305
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2019,Age,13-17 Years,88.5,82.9 to 92.5,1199
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2020,Age,13-17 Years,89.7,85.6 to 92.7,1402
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2019,Age,13-17 Years,77.2,71.0 to 82.4,1199
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2018,Age,13-17 Years,72.2,66.9 to 77.0,1305
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2021,Age,13-17 Years,91.0,86.4 to 94.1,1173
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2020,Age,13-17 Years,76.8,71.9 to 81.0,1402
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2021,Age,13-17 Years,81.3,75.3 to 86.2,1173
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2017,Age,13-17 Years,65.1,56.9 to 72.6,615
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2016,Age,13-17 Years,63.9,55.6 to 71.3,615
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2015,Age,13-17 Years,59.2,51.2 to 66.7,727
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2014,Age,13-17 Years,58.0,50.2 to 65.5,730
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2021,Age,13-15 Years,88.3,80.6 to 93.1,727
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2018,Age,13-17 Years,56.3,48.3 to 64.0,644
HPV,"≥2 Doses, Females",HHS Regions/National,Region 9,2019,Age,13-17 Years,68.5,58.9 to 76.7,592
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2018,Age,13-17 Years,61.5,53.5 to 68.9,661
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2017,Age,13-17 Years,53.0,45.6 to 60.3,684
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2016,Age,13-17 Years,48.1,41.0 to 55.4,688
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2007,Age,13-15 Years,41.2,32.1 to 50.8,216
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2006,Age,13-15 Years,12.8,8.3 to 19.4,212
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2012,Age,13-15 Years,87.1,82.0 to 90.8,910
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2011,Age,13-15 Years,81.3,76.6 to 85.2,1103
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2009,Age,13-15 Years,66.2,60.0 to 71.9,822
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2010,Age,13-15 Years,77.2,71.4 to 82.2,821
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2008,Age,13-15 Years,49.6,42.1 to 57.2,692
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 9,2022,Age,13-17 Years,88.1,83.9 to 91.4,1090
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2017,Age,13-15 Years,85.2,79.5 to 89.5,811
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2016,Age,13-15 Years,83.3,76.9 to 88.2,816
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2015,Age,13-15 Years,86.4,80.8 to 90.6,937
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2014,Age,13-15 Years,87.3,82.1 to 91.1,949
≥2 Doses MMR,,HHS Regions/National,Region 9,2021,Age,13-17 Years,89.0,83.6 to 92.7,1173
≥2 Doses MMR,,HHS Regions/National,Region 9,2022,Age,13-17 Years,86.4,81.7 to 90.0,1090
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2011,Age,13-15 Years,37.0,29.7 to 44.9,504
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2010,Age,13-15 Years,29.5,22.0 to 38.2,375
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2009,Age,13-15 Years,17.3,12.4 to 23.6,409
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2008,Age,13-15 Years,16.9,11.1 to 25.0,341
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2013,Age,13-15 Years,92.1,87.8 to 95.0,845
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2012,Age,13-17 Years,18.0,13.4 to 23.6,770
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2013,Age,13-17 Years,32.5,25.3 to 40.6,708
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2014,Age,13-17 Years,38.8,31.8 to 46.3,761
HPV,"≥2 Doses, Males",HHS Regions/National,Region 9,2015,Age,13-17 Years,41.3,33.9 to 49.1,779
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2019,Age,13-15 Years,90.6,84.9 to 94.3,741
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2020,Age,13-15 Years,88.3,83.1 to 92.1,862
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2021,Age,13-15 Years,91.6,86.5 to 94.9,727
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2018,Age,13-15 Years,87.4,81.4 to 91.6,809
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2022,Age,13-17 Years,82.7,77.7 to 86.8,1090
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2021,Age,13-17 Years,87.5,81.8 to 91.5,1173
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2022,Age,13-15 Years,81.7,74.8 to 87.1,639
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2010,Age,13-17 Years,67.5,62.6 to 72.1,1311
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2011,Age,13-17 Years,75.4,71.7 to 78.8,1750
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2008,Age,13-17 Years,47.4,41.5 to 53.4,1118
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2009,Age,13-17 Years,58.8,53.6 to 63.7,1320
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2016,Age,13-17 Years,82.7,77.9 to 86.6,1303
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2013,Age,13-17 Years,80.6,75.7 to 84.7,1318
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2014,Age,13-17 Years,79.5,74.5 to 83.6,1491
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2015,Age,13-17 Years,78.7,73.8 to 83.0,1506
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2016,Age,13-17 Years,80.3,75.5 to 84.4,1303
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2018,Age,13-17 Years,88.4,84.2 to 91.5,1305
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2017,Age,13-17 Years,83.3,78.5 to 87.2,1299
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2012,Age,13-17 Years,76.6,71.9 to 80.7,1461
≥2 Doses MMR,,HHS Regions/National,Region 9,2016,Age,13-17 Years,87.9,84.0 to 90.9,1303
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 9,2011,Age,13-17 Years,21.1,17.8 to 24.8,1750
≥2 Doses MMR,,HHS Regions/National,Region 9,2014,Age,13-17 Years,90.0,86.9 to 92.5,1491
≥2 Doses MMR,,HHS Regions/National,Region 9,2015,Age,13-17 Years,87.6,83.4 to 90.8,1506
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2006,Age,13-17 Years,14.3,10.4 to 19.3,362
≥2 Doses MMR,,HHS Regions/National,Region 9,2012,Age,13-17 Years,90.2,86.8 to 92.8,1461
≥2 Doses MMR,,HHS Regions/National,Region 9,2013,Age,13-17 Years,90.7,86.8 to 93.6,1318
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2007,Age,13-17 Years,35.3,28.6 to 42.8,366
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2022,Age,13-17 Years,83.7,78.5 to 87.8,1090
≥2 Doses MMR,,HHS Regions/National,Region 9,2018,Age,13-17 Years,90.7,87.3 to 93.2,1305
≥2 Doses MMR,,HHS Regions/National,Region 9,2017,Age,13-17 Years,89.9,85.6 to 93.0,1299
≥2 Doses MMR,,HHS Regions/National,Region 9,2019,Age,13-17 Years,87.6,81.6 to 91.8,1199
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2019,Age,13-17 Years,86.9,81.3 to 91.1,1199
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2020,Age,13-17 Years,88.9,84.8 to 92.0,1402
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 9,2021,Age,13-17 Years,89.2,84.4 to 92.7,1173
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2017,Age,13-17 Years,82.2,77.4 to 86.2,1299
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2018,Age,13-17 Years,85.8,81.3 to 89.3,1305
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2019,Age,13-17 Years,88.8,84.0 to 92.3,1199
≥1 Dose MenACWY,,HHS Regions/National,Region 9,2020,Age,13-17 Years,85.5,80.8 to 89.2,1402
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 9,2012,Age,13-17 Years,23.1,19.3 to 27.4,1461
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 9,2013,Age,13-17 Years,29.6,24.5 to 35.2,1318
≥2 Doses MMR,,HHS Regions/National,Region 9,2020,Age,13-17 Years,86.4,82.1 to 89.8,1402
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 9,2015,Age,13-17 Years,38.1,32.9 to 43.6,1506
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 9,2014,Age,13-17 Years,36.4,31.3 to 41.8,1491
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2012,Age,13-15 Years,28.6,21.7 to 36.6,427
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2013,Age,13-15 Years,44.5,34.4 to 55.0,400
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2015,Age,13-15 Years,41.3,31.3 to 52.0,440
HPV,"≥3 Doses, Females",HHS Regions/National,Region 9,2014,Age,13-15 Years,39.2,29.8 to 49.6,455
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 9,2022,Age,13-17 Years,73.3,67.9 to 78.1,1090
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2019,Age,13-15 Years,63.3,50.6 to 74.4,355
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2020,Age,13-15 Years,60.8,50.8 to 70.0,409
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2018,Age,13-15 Years,45.5,36.2 to 55.2,412
Varicella,History of disease,HHS Regions/National,Region 9,2020,Age,13-17 Years,9.0,6.2 to 12.8,1402
Varicella,History of disease,HHS Regions/National,Region 9,2019,Age,13-17 Years,7.1,4.8 to 10.4,1199
Varicella,History of disease,HHS Regions/National,Region 9,2021,Age,13-17 Years,7.8,4.6 to 13.0,1173
Varicella,History of disease,HHS Regions/National,Region 9,2022,Age,13-17 Years,4.8,3.2 to 7.1,1090
Varicella,History of disease,HHS Regions/National,Region 9,2017,Age,13-17 Years,13.1,9.5 to 17.8,1299
HPV,"Series Completion (3 Dose) Among HPV Vaccination Initiators, Females",HHS Regions/National,Region 9,2007,Age,13-17 Years,54.5,32.3 to 75.0,37
Varicella,History of disease,HHS Regions/National,Region 9,2015,Age,13-17 Years,15.9,12.0 to 20.9,1506
Varicella,History of disease,HHS Regions/National,Region 9,2016,Age,13-17 Years,13.6,10.4 to 17.6,1303
Varicella,History of disease,HHS Regions/National,Region 9,2007,Age,13-17 Years,58.0,50.6 to 65.1,366
Varicella,History of disease,HHS Regions/National,Region 9,2018,Age,13-17 Years,10.7,7.7 to 14.7,1305
Varicella,History of disease,HHS Regions/National,Region 9,2012,Age,13-17 Years,26.1,22.2 to 30.4,1461
Varicella,History of disease,HHS Regions/National,Region 9,2013,Age,13-17 Years,23.8,19.4 to 28.9,1318
Varicella,History of disease,HHS Regions/National,Region 9,2010,Age,13-17 Years,40.8,35.8 to 46.0,1311
Varicella,History of disease,HHS Regions/National,Region 9,2011,Age,13-17 Years,33.8,29.9 to 37.9,1750
Varicella,History of disease,HHS Regions/National,Region 9,2009,Age,13-17 Years,42.6,37.7 to 47.6,1320
Varicella,History of disease,HHS Regions/National,Region 9,2006,Age,13-17 Years,64.9,58.5 to 70.8,362
Varicella,History of disease,HHS Regions/National,Region 9,2008,Age,13-17 Years,53.2,47.1 to 59.3,1118
Varicella,History of disease,HHS Regions/National,Region 9,2014,Age,13-17 Years,18.6,14.8 to 23.3,1491
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2019,Age,13-15 Years,54.0,41.3 to 66.2,386
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2020,Age,13-15 Years,51.6,42.2 to 60.9,453
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2021,Age,13-17 Years,68.5,59.2 to 76.6,599
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2019,Age,13-15 Years,58.7,49.7 to 67.3,741
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2022,Age,13-17 Years,60.9,53.3 to 68.1,595
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2021,Age,13-15 Years,65.3,56.8 to 72.9,727
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2020,Age,13-15 Years,56.3,49.4 to 63.0,862
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2018,Age,13-17 Years,54.4,46.2 to 62.3,661
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2017,Age,13-17 Years,46.5,39.2 to 54.0,684
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2019,Age,13-17 Years,52.4,42.8 to 61.8,607
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2020,Age,13-17 Years,55.6,48.0 to 62.9,741
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2021,Age,13-15 Years,61.6,49.5 to 72.5,349
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2022,Age,13-15 Years,55.4,44.2 to 66.0,279
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2021,Age,13-15 Years,68.4,56.3 to 78.5,378
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2022,Age,13-15 Years,56.3,45.9 to 66.1,360
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2016,Age,13-17 Years,55.8,47.5 to 63.8,615
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2017,Age,13-17 Years,60.0,51.4 to 68.0,615
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2016,Age,13-17 Years,40.5,33.6 to 47.7,688
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2020,Age,13-17 Years,65.2,57.3 to 72.3,661
HPV,"Up-to-Date, Males",HHS Regions/National,Region 9,2018,Age,13-15 Years,56.2,45.9 to 66.0,397
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2021,Age,13-17 Years,65.7,56.3 to 74.1,574
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2022,Age,13-17 Years,61.2,52.9 to 69.0,495
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 9,2022,Age,13-15 Years,55.8,48.2 to 63.2,639
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2018,Age,13-17 Years,50.5,42.6 to 58.3,644
HPV,"Up-to-Date, Females",HHS Regions/National,Region 9,2019,Age,13-17 Years,60.7,50.4 to 70.1,592
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Overall,Overall,86.0,83.7 to 88.0,1534
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Colorado,2023,Age,13-17 Years,93.5,90.1 to 95.8,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2023,Age,13-17 Years,92.2,88.5 to 94.7,332
≥1 Dose MenACWY,,States/Local Areas,Colorado,2023,Age,13-17 Years,89.9,85.6 to 93.0,332
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2023,Age,13-17 Years,80.5,74.9 to 85.1,332
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2023,Age,13-17 Years,68.5,62.2 to 74.2,332
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2023,Age,13-17 Years,68.3,59.4 to 76.0,180
≥2 Doses MMR,,States/Local Areas,Colorado,2023,Age,13-17 Years,91.3,86.8 to 94.3,332
≥3 Doses HepB,,States/Local Areas,Colorado,2023,Age,13-17 Years,93.7,89.9 to 96.1,332
Varicella,History of disease,States/Local Areas,Colorado,2023,Age,13-17 Years,7.4,4.6 to 11.7,332
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2023,Age,13-17 Years,92.5,88.0 to 95.4,309
Varicella,≥1 Dose with no disease history,States/Local Areas,Colorado,2023,Age,13-17 Years,96.3,93.1 to 98.1,309
Varicella,≥2 Doses or history of disease,States/Local Areas,Colorado,2023,Age,13-17 Years,93.1,88.8 to 95.8,332
≥2 Doses Hep A,,States/Local Areas,Colorado,2023,Age,13-17 Years,87.2,82.1 to 91.0,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2023,Age,13-15 Years,92.2,87.3 to 95.4,195
≥1 Dose MenACWY,,States/Local Areas,Colorado,2023,Age,13-15 Years,88.6,82.2 to 92.9,195
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2023,Age,13-15 Years,65.2,57.0 to 72.6,195
HPV,"Up-to-Date, Males",States/Local Areas,Colorado,2023,Age,13-15 Years,67.2,55.8 to 76.8,105
HPV,"≥1 Dose, Females",States/Local Areas,Colorado,2023,Age,13-17 Years,81.4,73.1 to 87.6,152
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2023,Age,13-15 Years,63.3,51.2 to 73.9,90
Varicella,≥2 Doses with no disease history,States/Local Areas,Colorado,2023,Age,13-15 Years,92.4,86.8 to 95.8,179
HPV,"Up-to-Date, Females",States/Local Areas,Colorado,2023,Age,13-17 Years,68.8,59.4 to 76.8,152
HPV,"≥1 Dose, Males",States/Local Areas,Colorado,2023,Age,13-17 Years,79.7,71.5 to 86.0,180
HPV,"≥2 Doses, Females",States/Local Areas,Colorado,2022,Age,13-17 Years,69.4,60.4 to 77.1,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Uninsured,75.0,55.9 to 87.6,37
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Overall,Overall,90.8,88.8 to 92.5,1534
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Overall,Overall,65.5,62.4 to 68.5,1534
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Overall,Overall,79.7,77.1 to 82.2,1534
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Principal City,82.9,79.4 to 85.8,778
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Non-Principal City,76.5,71.7 to 80.7,592
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a Non-MSA,74.6,65.6 to 81.9,164
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Principal City,87.4,84.2 to 90.0,778
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Non-Principal City,84.8,80.7 to 88.2,592
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a Non-MSA,82.3,74.1 to 88.4,164
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Principal City,68.1,63.9 to 72.1,778
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Non-Principal City,64.0,58.8 to 68.8,592
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a Non-MSA,55.5,45.3 to 65.3,164
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Principal City,91.7,88.9 to 93.8,778
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.3,86.7 to 93.0,592
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Urbanicity,Living In a Non-MSA,88.0,80.5 to 92.8,164
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"White, Non-Hispanic",62.9,58.9 to 66.7,999
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",83.1,74.0 to 89.4,145
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",78.6,69.7 to 85.5,145
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Race and Ethnicity,Hispanic,70.2,64.3 to 75.5,365
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",65.6,56.0 to 74.1,145
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.8,88.1 to 92.9,999
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.5,82.5 to 88.0,999
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Race and Ethnicity,Hispanic,88.8,84.4 to 92.0,365
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Race and Ethnicity,Hispanic,93.1,89.7 to 95.5,365
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.5,76.4 to 91.5,145
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Race and Ethnicity,"White, Non-Hispanic",77.8,74.3 to 80.9,999
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Race and Ethnicity,Hispanic,84.0,79.1 to 87.9,365
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Poverty,Below Poverty Level,83.8,75.7 to 89.5,157
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Poverty,Living At or Above Poverty Level,79.1,76.2 to 81.7,1331
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Poverty,Living At or Above Poverty Level,85.7,83.2 to 87.9,1331
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Poverty,Below Poverty Level,85.5,77.6 to 90.9,157
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Poverty,Below Poverty Level,64.2,54.6 to 72.7,157
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Poverty,Living At or Above Poverty Level,65.7,62.4 to 68.9,1331
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2023,Age,13-17 Years,80.3,75.4 to 84.4,786
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Poverty,Below Poverty Level,90.0,83.6 to 94.1,157
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Poverty,Living At or Above Poverty Level,91.1,88.8 to 92.9,1331
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Private Insurance Only,86.8,83.9 to 89.3,950
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Any Medicaid,84.8,80.0 to 88.6,414
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Other,88.4,81.7 to 92.8,133
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Private Insurance Only,81.1,77.8 to 84.0,950
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Any Medicaid,79.3,74.2 to 83.7,414
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Other,75.7,64.1 to 84.4,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Private Insurance Only,67.9,64.0 to 71.5,950
≥1 Dose MenACWY,,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Uninsured,74.5,55.9 to 87.0,37
HPV,"≥1 Dose, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Uninsured,66.3,46.9 to 81.5,37
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Any Medicaid,64.2,58.3 to 69.7,414
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Other,56.8,44.8 to 68.1,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,Colorado,2018-2022,Insurance Coverage,Uninsured,56.3,37.9 to 73.1,37
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Private Insurance Only,92.1,89.8 to 94.0,950
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Any Medicaid,89.1,84.7 to 92.3,414
Tetanus,≥1 Dose Tdap,States/Local Areas,Colorado,2018-2022,Insurance Coverage,Other,93.7,87.8 to 96.9,133
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arizona,2022,Age,13-17 Years,63.8,56.6 to 70.4,273
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2022,Age,13-17 Years,60.2,49.4 to 70.1,129
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2022,Age,13-17 Years,67.2,57.7 to 75.5,144
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2023,Age,13-17 Years,75.6,66.3 to 83.0,158
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2023,Age,13-17 Years,63.6,53.2 to 72.8,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2023,Age,13-15 Years,89.4,82.4 to 93.8,172
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2023,Age,13-15 Years,58.2,44.3 to 71.0,85
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2023,Age,13-17 Years,76.3,66.9 to 83.6,145
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2023,Age,13-15 Years,56.9,44.5 to 68.6,95
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2023,Age,13-15 Years,57.6,48.2 to 66.5,180
≥1 Dose MenACWY,,States/Local Areas,Arizona,2023,Age,13-15 Years,88.2,80.1 to 93.2,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2023,Age,13-15 Years,86.7,78.6 to 92.1,180
≥2 Doses Hep A,,States/Local Areas,Arizona,2023,Age,13-17 Years,90.5,85.8 to 93.8,303
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2023,Age,13-17 Years,91.0,86.4 to 94.1,303
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2023,Age,13-17 Years,94.2,89.9 to 96.7,287
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2023,Age,13-17 Years,90.6,85.8 to 93.9,287
≥3 Doses HepB,,States/Local Areas,Arizona,2023,Age,13-17 Years,89.2,84.2 to 92.8,303
Varicella,History of disease,States/Local Areas,Arizona,2023,Age,13-17 Years,3.9,2.3 to 6.8,303
≥2 Doses MMR,,States/Local Areas,Arizona,2023,Age,13-17 Years,91.3,86.9 to 94.3,303
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2023,Age,13-17 Years,62.6,52.8 to 71.4,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2023,Age,13-17 Years,63.1,56.0 to 69.6,303
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2023,Age,13-17 Years,75.9,69.5 to 81.3,303
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2023,Age,13-17 Years,87.3,81.5 to 91.4,303
≥1 Dose MenACWY,,States/Local Areas,Arizona,2023,Age,13-17 Years,89.4,84.2 to 93.1,303
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2023,Age,13-17 Years,87.8,82.1 to 91.9,303
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Private Insurance Only,67.8,63.8 to 71.6,826
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Uninsured,76.0,63.7 to 85.1,84
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Other,82.1,72.0 to 89.1,119
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Any Medicaid,88.7,85.3 to 91.5,476
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Private Insurance Only,87.4,84.2 to 90.1,826
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Uninsured,48.6,36.1 to 61.4,84
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Other,51.9,40.2 to 63.4,119
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Any Medicaid,64.4,59.1 to 69.4,476
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Uninsured,65.3,52.5 to 76.2,84
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Uninsured,83.3,71.6 to 90.8,84
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Private Insurance Only,52.3,48.1 to 56.5,826
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Other,68.9,57.1 to 78.7,119
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Insurance Coverage,Any Medicaid,83.4,79.2 to 86.8,476
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Other,83.5,73.3 to 90.3,119
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Any Medicaid,90.0,86.5 to 92.7,476
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Insurance Coverage,Private Insurance Only,87.4,84.1 to 90.1,826
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Poverty,Below Poverty Level,87.5,82.0 to 91.5,230
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Poverty,Living At or Above Poverty Level,84.8,82.1 to 87.2,1217
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Poverty,Below Poverty Level,92.1,87.8 to 95.0,230
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Poverty,Living At or Above Poverty Level,53.7,50.2 to 57.1,1217
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Poverty,Below Poverty Level,70.1,62.9 to 76.5,230
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Poverty,Living At or Above Poverty Level,86.2,83.5 to 88.5,1217
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Poverty,Below Poverty Level,93.5,89.1 to 96.2,230
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Poverty,Living At or Above Poverty Level,70.0,66.7 to 73.0,1217
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.7,44.3 to 53.0,759
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,Hispanic,80.0,75.6 to 83.7,511
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",80.3,66.9 to 89.1,48
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"White, Non-Hispanic",65.6,61.3 to 69.6,759
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.9,78.5 to 91.0,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,Hispanic,88.1,84.4 to 91.0,511
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.0,84.1 to 93.8,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",84.9,72.5 to 92.3,48
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,Hispanic,89.3,85.5 to 92.2,511
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.1,73.8 to 93.1,48
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.9,82.4 to 88.7,759
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.9,82.5 to 88.6,759
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.0,52.0 to 69.3,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",43.6,28.2 to 60.4,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,Hispanic,64.1,59.1 to 68.9,511
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",75.5,66.9 to 82.4,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a Non-MSA,89.2,80.4 to 94.3,88
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Non-Principal City,88.1,84.6 to 90.8,582
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Principal City,85.8,82.7 to 88.4,835
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a Non-MSA,62.5,49.6 to 73.8,88
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Non-Principal City,54.2,49.3 to 59.0,582
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Principal City,57.8,53.6 to 61.8,835
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a Non-MSA,88.4,77.9 to 94.3,88
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.8,84.0 to 90.8,582
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Principal City,87.8,84.8 to 90.3,835
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a Non-MSA,75.0,63.1 to 84.0,88
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Non-Principal City,70.9,66.4 to 75.0,582
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Urbanicity,Living In a MSA Principal City,75.3,71.5 to 78.7,835
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018-2022,Overall,Overall,86.8,84.6 to 88.7,1505
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018-2022,Overall,Overall,56.6,53.5 to 59.7,1505
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2013,Age,13-15 Years,34.5,24.2 to 46.4,120
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2014,Age,13-15 Years,24.3,16.0 to 35.1,119
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2015,Age,13-15 Years,41.2,31.1 to 52.2,128
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018-2022,Overall,Overall,73.6,70.8 to 76.2,1505
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018-2022,Overall,Overall,87.8,85.6 to 89.8,1505
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2012,Age,13-17 Years,91.2,86.9 to 94.2,360
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2013,Age,13-17 Years,88.5,83.1 to 92.4,359
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2010,Age,13-17 Years,88.1,83.4 to 91.6,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2011,Age,13-17 Years,89.9,83.9 to 93.8,416
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2017,Age,13-17 Years,61.4,52.1 to 69.9,173
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2016,Age,13-17 Years,60.9,51.6 to 69.5,175
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2015,Age,13-17 Years,51.3,43.1 to 59.4,229
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2013,Age,13-17 Years,44.4,35.9 to 53.3,188
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2014,Age,13-17 Years,40.6,32.7 to 49.1,227
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2020,Age,13-17 Years,69.9,60.2 to 78.1,160
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2021,Age,13-17 Years,83.2,74.7 to 89.2,127
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2022,Age,13-17 Years,74.0,63.6 to 82.3,129
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2011,Age,13-17 Years,8.4,5.0 to 14.0,225
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arizona,2018,Age,13-17 Years,56.2,49.3 to 62.9,288
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arizona,2019,Age,13-17 Years,60.5,53.5 to 67.1,308
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arizona,2016,Age,13-17 Years,50.1,43.4 to 56.8,329
HPV,"≥2 Doses, Males and Females",States/Local Areas,Arizona,2017,Age,13-17 Years,55.5,48.7 to 62.0,335
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2012,Age,13-17 Years,19.7,13.6 to 27.7,182
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2019,Age,13-17 Years,70.6,61.6 to 78.3,162
≥3 Doses HepB,,States/Local Areas,Arizona,2020,Age,13-17 Years,84.7,79.1 to 89.0,340
≥3 Doses HepB,,States/Local Areas,Arizona,2021,Age,13-17 Years,86.2,80.4 to 90.6,296
≥3 Doses HepB,,States/Local Areas,Arizona,2022,Age,13-17 Years,91.1,86.6 to 94.2,273
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2022,Age,13-17 Years,94.0,90.1 to 96.4,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2020,Age,13-17 Years,91.2,86.2 to 94.6,312
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2019,Age,13-17 Years,85.1,79.4 to 89.4,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2020,Age,13-17 Years,84.2,78.6 to 88.6,312
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2021,Age,13-17 Years,88.1,82.7 to 92.0,276
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2016,Age,13-17 Years,65.4,56.1 to 73.6,154
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2021,Age,13-17 Years,94.5,90.8 to 96.8,276
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2022,Age,13-17 Years,92.2,87.7 to 95.2,257
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2017,Age,13-17 Years,68.9,59.1 to 77.2,162
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2018,Age,13-17 Years,65.3,54.9 to 74.5,135
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2019,Age,13-17 Years,91.4,86.4 to 94.7,282
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2018,Age,13-17 Years,88.8,82.8 to 92.9,254
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2012,Age,13-17 Years,54.3,44.7 to 63.5,178
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2013,Age,13-17 Years,64.1,55.0 to 72.3,171
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2014,Age,13-17 Years,58.2,48.7 to 67.2,194
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2015,Age,13-17 Years,68.3,60.6 to 75.2,215
≥3 Doses HepB,,States/Local Areas,Arizona,2018,Age,13-17 Years,89.1,83.8 to 92.8,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2018,Age,13-17 Years,81.5,74.8 to 86.7,254
≥3 Doses HepB,,States/Local Areas,Arizona,2019,Age,13-17 Years,89.4,84.3 to 93.0,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2016,Age,13-17 Years,75.4,68.4 to 81.2,277
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2015,Age,13-17 Years,78.0,72.2 to 82.9,357
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2017,Age,13-17 Years,95.3,91.7 to 97.3,288
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2014,Age,13-17 Years,71.9,64.7 to 78.1,329
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2017,Age,13-17 Years,83.1,77.2 to 87.7,288
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2011,Age,13-17 Years,55.3,44.9 to 65.2,191
≥3 Doses HepB,,States/Local Areas,Arizona,2017,Age,13-17 Years,88.6,84.0 to 92.0,335
≥3 Doses HepB,,States/Local Areas,Arizona,2016,Age,13-17 Years,83.7,78.0 to 88.2,329
≥3 Doses HepB,,States/Local Areas,Arizona,2015,Age,13-17 Years,83.5,78.3 to 87.7,444
≥3 Doses HepB,,States/Local Areas,Arizona,2011,Age,13-17 Years,86.4,79.8 to 91.1,416
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2022,Age,13-15 Years,92.4,85.9 to 96.1,149
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2016,Age,13-17 Years,91.1,85.5 to 94.7,277
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2015,Age,13-17 Years,91.9,87.6 to 94.8,357
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2013,Age,13-17 Years,90.1,84.4 to 93.9,254
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2014,Age,13-17 Years,92.3,87.1 to 95.5,329
≥3 Doses HepB,,States/Local Areas,Arizona,2008,Age,13-17 Years,83.9,77.9 to 88.5,250
≥3 Doses HepB,,States/Local Areas,Arizona,2009,Age,13-17 Years,84.3,79.0 to 88.4,349
≥3 Doses HepB,,States/Local Areas,Arizona,2010,Age,13-17 Years,85.4,79.8 to 89.7,331
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2008,Age,13-17 Years,85.4,74.1 to 92.3,95
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2009,Age,13-17 Years,78.0,68.8 to 85.0,166
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2010,Age,13-17 Years,91.0,84.1 to 95.1,183
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2011,Age,13-17 Years,93.3,86.4 to 96.9,262
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2008,Age,13-17 Years,35.6,25.6 to 47.0,95
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2009,Age,13-17 Years,57.8,48.5 to 66.6,166
Varicella,≥1 Dose with no disease history,States/Local Areas,Arizona,2012,Age,13-17 Years,92.4,87.3 to 95.6,239
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2008,Age,13-17 Years,50.5,40.3 to 60.7,120
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2010,Age,13-17 Years,64.5,55.8 to 72.3,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2011,Age,13-17 Years,60.5,51.6 to 68.7,262
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2008,Age,13-17 Years,29.8,21.6 to 39.5,120
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2022,Age,13-17 Years,78.8,70.3 to 85.3,144
≥1 Dose MenACWY,,States/Local Areas,Arizona,2008,Age,13-15 Years,54.2,45.0 to 63.1,159
≥1 Dose MenACWY,,States/Local Areas,Arizona,2009,Age,13-15 Years,70.7,62.2 to 77.9,210
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2020,Age,13-17 Years,71.4,63.1 to 78.6,180
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2021,Age,13-17 Years,79.5,71.3 to 85.8,169
≥1 Dose MenACWY,,States/Local Areas,Arizona,2013,Age,13-15 Years,90.9,84.8 to 94.7,224
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2016,Age,13-17 Years,88.5,83.6 to 92.1,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2017,Age,13-17 Years,84.1,78.6 to 88.5,335
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2014,Age,13-17 Years,85.2,79.8 to 89.4,421
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2015,Age,13-17 Years,88.4,84.3 to 91.6,444
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2009,Age,13-17 Years,83.6,78.3 to 87.8,349
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2008,Age,13-17 Years,74.0,66.4 to 80.4,250
≥1 Dose MenACWY,,States/Local Areas,Arizona,2012,Age,13-15 Years,86.3,78.9 to 91.4,231
≥1 Dose MenACWY,,States/Local Areas,Arizona,2010,Age,13-15 Years,87.3,81.1 to 91.6,209
≥1 Dose MenACWY,,States/Local Areas,Arizona,2011,Age,13-15 Years,83.6,74.7 to 89.8,269
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2019,Age,13-17 Years,73.0,63.2 to 81.0,146
HPV,"≥1 Dose, Males",States/Local Areas,Arizona,2018,Age,13-17 Years,69.1,60.1 to 76.8,153
≥1 Dose MenACWY,,States/Local Areas,Arizona,2016,Age,13-15 Years,86.5,79.1 to 91.6,206
≥1 Dose MenACWY,,States/Local Areas,Arizona,2017,Age,13-15 Years,82.2,74.2 to 88.2,193
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2014,Age,13-17 Years,46.2,37.1 to 55.6,194
≥1 Dose MenACWY,,States/Local Areas,Arizona,2014,Age,13-15 Years,86.3,79.2 to 91.2,267
≥1 Dose MenACWY,,States/Local Areas,Arizona,2015,Age,13-15 Years,87.7,82.4 to 91.6,272
≥1 Dose MenACWY,,States/Local Areas,Arizona,2020,Age,13-15 Years,87.2,80.9 to 91.7,203
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2009,Age,13-17 Years,40.8,32.1 to 50.1,184
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2010,Age,13-17 Years,40.7,31.7 to 50.3,151
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2011,Age,13-17 Years,45.2,35.3 to 55.5,191
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2012,Age,13-17 Years,43.4,34.3 to 53.0,178
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2013,Age,13-17 Years,47.9,38.6 to 57.4,171
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2019,Age,13-17 Years,92.7,89.1 to 95.1,308
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2020,Age,13-17 Years,88.6,83.8 to 92.2,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2019,Age,13-17 Years,71.8,65.3 to 77.6,308
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2021,Age,13-17 Years,91.5,87.4 to 94.3,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2022,Age,13-17 Years,86.6,80.3 to 91.1,273
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2020,Age,13-17 Years,70.7,64.4 to 76.3,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2021,Age,13-17 Years,81.3,75.6 to 85.9,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2022,Age,13-17 Years,76.5,69.9 to 81.9,273
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Arizona,2018,Age,13-17 Years,89.8,85.1 to 93.1,288
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018,Age,13-15 Years,88.8,82.5 to 93.1,187
≥1 Dose MenACWY,,States/Local Areas,Arizona,2019,Age,13-15 Years,82.0,73.5 to 88.3,191
≥1 Dose MenACWY,,States/Local Areas,Arizona,2022,Age,13-15 Years,86.8,79.2 to 91.9,159
≥1 Dose MenACWY,,States/Local Areas,Arizona,2021,Age,13-15 Years,88.7,82.0 to 93.1,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2012,Age,13-15 Years,89.0,82.6 to 93.3,231
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2011,Age,13-15 Years,83.4,74.6 to 89.6,269
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2016,Age,13-17 Years,53.9,44.4 to 63.2,154
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2017,Age,13-17 Years,59.7,49.8 to 68.9,162
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2016,Age,13-17 Years,63.1,56.6 to 69.2,329
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2017,Age,13-17 Years,65.0,58.4 to 71.2,335
HPV,"≥1 Dose, Males and Females",States/Local Areas,Arizona,2018,Age,13-17 Years,67.2,60.4 to 73.4,288
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2008,Age,13-15 Years,58.9,49.6 to 67.6,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2009,Age,13-15 Years,73.7,65.7 to 80.4,210
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2010,Age,13-15 Years,81.8,73.9 to 87.7,209
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2018,Age,13-17 Years,56.4,46.2 to 66.0,135
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2019,Age,13-17 Years,59.8,50.2 to 68.7,162
≥1 Dose MenACWY,,States/Local Areas,Arizona,2022,Age,13-17 Years,86.7,80.8 to 91.0,273
≥1 Dose MenACWY,,States/Local Areas,Arizona,2018,Age,13-17 Years,89.1,84.1 to 92.7,288
≥1 Dose MenACWY,,States/Local Areas,Arizona,2019,Age,13-17 Years,87.2,81.5 to 91.4,308
≥1 Dose MenACWY,,States/Local Areas,Arizona,2020,Age,13-17 Years,87.3,82.2 to 91.1,340
≥1 Dose MenACWY,,States/Local Areas,Arizona,2021,Age,13-17 Years,88.8,83.6 to 92.5,296
≥2 Doses MMR,,States/Local Areas,Arizona,2021,Age,13-17 Years,86.4,80.9 to 90.5,296
≥2 Doses MMR,,States/Local Areas,Arizona,2022,Age,13-17 Years,91.0,86.3 to 94.2,273
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2008,Age,13-15 Years,22.3,13.2 to 35.1,75
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2009,Age,13-15 Years,28.5,18.1 to 41.7,101
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2010,Age,13-15 Years,35.4,23.9 to 48.8,88
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2012,Age,13-15 Years,33.1,22.7 to 45.5,116
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2011,Age,13-15 Years,31.8,21.7 to 44.0,128
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2016,Age,13-15 Years,84.8,77.5 to 90.0,206
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2017,Age,13-15 Years,81.3,72.7 to 87.7,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2014,Age,13-15 Years,84.1,77.1 to 89.3,267
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2015,Age,13-15 Years,86.3,80.4 to 90.6,272
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2012,Age,13-17 Years,12.8,8.1 to 19.8,182
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2013,Age,13-17 Years,33.5,25.7 to 42.4,188
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2014,Age,13-17 Years,28.2,21.3 to 36.3,227
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2015,Age,13-17 Years,40.6,32.7 to 49.1,229
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2013,Age,13-15 Years,86.7,79.9 to 91.4,224
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2016,Age,13-17 Years,46.4,37.2 to 56.0,175
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2017,Age,13-17 Years,51.3,42.2 to 60.4,173
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2018,Age,13-17 Years,56.0,46.6 to 65.1,153
HPV,"≥2 Doses, Males",States/Local Areas,Arizona,2019,Age,13-17 Years,61.2,51.0 to 70.5,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018,Age,13-15 Years,82.6,75.1 to 88.2,187
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2018,Age,13-17 Years,82.9,77.0 to 87.6,288
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2017,Age,13-17 Years,82.4,76.7 to 87.0,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2019,Age,13-17 Years,89.9,85.7 to 93.0,308
≥1 Dose MenACWY,,States/Local Areas,Arizona,2008,Age,13-17 Years,51.5,44.2 to 58.7,250
≥1 Dose MenACWY,,States/Local Areas,Arizona,2009,Age,13-17 Years,69.7,63.4 to 75.3,349
≥1 Dose MenACWY,,States/Local Areas,Arizona,2010,Age,13-17 Years,78.9,73.1 to 83.7,331
≥1 Dose MenACWY,,States/Local Areas,Arizona,2011,Age,13-17 Years,82.9,76.6 to 87.8,416
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2016,Age,13-17 Years,84.3,78.7 to 88.6,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2019,Age,13-15 Years,88.6,82.9 to 92.6,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2020,Age,13-15 Years,87.7,81.9 to 91.9,203
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2021,Age,13-15 Years,88.8,82.7 to 92.9,179
≥1 Dose MenACWY,,States/Local Areas,Arizona,2012,Age,13-17 Years,85.5,79.7 to 89.8,360
≥2 Doses MMR,,States/Local Areas,Arizona,2020,Age,13-17 Years,85.3,80.0 to 89.3,340
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arizona,2013,Age,13-17 Years,28.3,22.8 to 34.4,359
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arizona,2014,Age,13-17 Years,26.1,21.1 to 31.7,421
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arizona,2015,Age,13-17 Years,35.4,30.0 to 41.3,444
≥2 Doses MMR,,States/Local Areas,Arizona,2016,Age,13-17 Years,81.7,75.6 to 86.6,329
≥2 Doses MMR,,States/Local Areas,Arizona,2017,Age,13-17 Years,89.2,84.7 to 92.5,335
≥2 Doses MMR,,States/Local Areas,Arizona,2014,Age,13-17 Years,83.5,77.5 to 88.1,421
≥2 Doses MMR,,States/Local Areas,Arizona,2015,Age,13-17 Years,85.4,80.5 to 89.3,444
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arizona,2011,Age,13-17 Years,19.5,14.5 to 25.8,416
HPV,"≥3 Doses, Males and Females",States/Local Areas,Arizona,2012,Age,13-17 Years,21.2,16.2 to 27.2,360
≥1 Dose MenACWY,,States/Local Areas,Arizona,2016,Age,13-17 Years,85.2,79.7 to 89.3,329
≥1 Dose MenACWY,,States/Local Areas,Arizona,2015,Age,13-17 Years,87.6,83.3 to 90.9,444
≥1 Dose MenACWY,,States/Local Areas,Arizona,2013,Age,13-17 Years,86.7,81.4 to 90.7,359
≥1 Dose MenACWY,,States/Local Areas,Arizona,2014,Age,13-17 Years,85.9,80.6 to 90.0,421
≥1 Dose MenACWY,,States/Local Areas,Arizona,2017,Age,13-17 Years,83.8,78.3 to 88.1,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2020,Age,13-17 Years,86.6,81.5 to 90.4,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2021,Age,13-17 Years,89.4,84.9 to 92.7,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2022,Age,13-17 Years,85.2,78.9 to 89.8,273
≥2 Doses MMR,,States/Local Areas,Arizona,2018,Age,13-17 Years,88.3,82.9 to 92.2,288
≥2 Doses MMR,,States/Local Areas,Arizona,2019,Age,13-17 Years,87.6,82.3 to 91.5,308
≥2 Doses MMR,,States/Local Areas,Arizona,2013,Age,13-17 Years,85.4,80.2 to 89.4,359
HPV,"≥2 Doses, Females",States/Local Areas,Arizona,2015,Age,13-17 Years,56.1,47.9 to 63.9,215
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Overall,Overall,75.7,73.0 to 78.2,1628
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Overall,Overall,70.6,67.8 to 73.3,1628
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Alaska,2023,Age,13-17 Years,82.4,75.2 to 87.9,249
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2023,Age,13-17 Years,81.0,73.7 to 86.6,249
≥1 Dose MenACWY,,States/Local Areas,Alaska,2023,Age,13-17 Years,74.9,67.4 to 81.1,249
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2023,Age,13-17 Years,71.8,64.3 to 78.2,249
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2023,Age,13-17 Years,54.4,46.8 to 61.9,249
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2023,Age,13-17 Years,52.0,41.7 to 62.1,136
≥2 Doses MMR,,States/Local Areas,Alaska,2023,Age,13-17 Years,91.3,85.5 to 95.0,249
Varicella,History of disease,States/Local Areas,Alaska,2023,Age,13-17 Years,7.2,4.4 to 11.6,249
≥3 Doses HepB,,States/Local Areas,Alaska,2023,Age,13-17 Years,90.4,84.4 to 94.2,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2023,Age,13-17 Years,89.5,83.2 to 93.6,230
Varicella,≥1 Dose with no disease history,States/Local Areas,Alaska,2023,Age,13-17 Years,92.1,85.8 to 95.8,230
Varicella,≥2 Doses or history of disease,States/Local Areas,Alaska,2023,Age,13-17 Years,90.2,84.3 to 94.1,249
≥2 Doses Hep A,,States/Local Areas,Alaska,2023,Age,13-17 Years,91.6,85.7 to 95.2,249
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2023,Age,13-15 Years,76.1,66.1 to 83.9,150
≥1 Dose MenACWY,,States/Local Areas,Alaska,2023,Age,13-15 Years,69.4,59.2 to 78.0,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2023,Age,13-15 Years,47.5,37.7 to 57.6,150
HPV,"Up-to-Date, Males",States/Local Areas,Alaska,2023,Age,13-15 Years,45.1,32.2 to 58.8,86
HPV,"≥1 Dose, Females",States/Local Areas,Alaska,2023,Age,13-17 Years,71.9,60.4 to 81.1,113
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2023,Age,13-15 Years,50.4,35.8 to 64.9,64
Varicella,≥2 Doses with no disease history,States/Local Areas,Alaska,2023,Age,13-15 Years,89.3,80.8 to 94.4,143
HPV,"Up-to-Date, Females",States/Local Areas,Alaska,2023,Age,13-17 Years,57.1,45.8 to 67.8,113
HPV,"≥1 Dose, Males",States/Local Areas,Alaska,2023,Age,13-17 Years,71.6,61.5 to 79.9,136
HPV,"≥2 Doses, Males",States/Local Areas,Alaska,2022,Age,13-17 Years,55.1,44.7 to 65.1,141
HPV,"≥2 Doses, Females",States/Local Areas,Alaska,2022,Age,13-17 Years,63.2,50.9 to 74.1,99
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alaska,2022,Age,13-17 Years,59.0,51.1 to 66.6,240
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Poverty,Living At or Above Poverty Level,53.2,50.0 to 56.4,1449
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Poverty,Below Poverty Level,75.3,65.7 to 82.9,139
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Poverty,Living At or Above Poverty Level,83.1,80.5 to 85.4,1449
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Poverty,Below Poverty Level,72.1,62.4 to 80.1,139
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Private Insurance Only,73.5,69.5 to 77.1,794
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Any Medicaid,76.1,71.2 to 80.3,474
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Other,80.8,74.6 to 85.9,316
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Any Medicaid,72.3,67.3 to 76.8,474
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Other,73.2,66.6 to 78.9,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Private Insurance Only,51.8,47.4 to 56.1,794
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Any Medicaid,54.1,48.6 to 59.5,474
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Uninsured,67.4,48.2 to 82.1,44
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Uninsured,60.3,41.5 to 76.4,44
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Other,55.8,48.8 to 62.6,316
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Uninsured,42.9,25.2 to 62.6,44
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Private Insurance Only,83.6,79.9 to 86.8,794
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Any Medicaid,81.6,77.1 to 85.3,474
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Other,82.0,75.8 to 86.9,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Insurance Coverage,Uninsured,75.9,58.3 to 87.6,44
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Insurance Coverage,Private Insurance Only,68.8,64.5 to 72.7,794
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Overall,Overall,53.1,50.1 to 56.1,1628
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Overall,Overall,82.4,79.9 to 84.6,1628
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Principal City,73.4,69.5 to 76.9,896
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,58.2,50.8 to 65.3,272
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a Non-MSA,72.5,67.3 to 77.2,460
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Principal City,77.2,73.6 to 80.4,896
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,65.0,57.6 to 71.7,272
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a Non-MSA,79.0,74.1 to 83.1,460
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Principal City,56.8,52.7 to 60.9,896
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,40.4,33.6 to 47.7,272
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a Non-MSA,53.0,47.3 to 58.6,460
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Principal City,83.8,80.5 to 86.6,896
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a MSA Non-Principal City,75.0,67.6 to 81.1,272
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Urbanicity,Living In a Non-MSA,83.9,79.2 to 87.6,460
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",78.6,73.8 to 82.8,477
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,Hispanic,56.8,46.4 to 66.8,134
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",75.8,55.4 to 88.8,37
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",58.9,53.3 to 64.3,477
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",73.0,69.4 to 76.3,980
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",81.5,78.2 to 84.4,980
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",74.4,53.0 to 88.2,37
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,Hispanic,75.2,65.5 to 82.9,134
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",80.6,75.8 to 84.7,477
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.1,70.5 to 97.2,37
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,Hispanic,82.9,74.2 to 89.2,134
Tetanus,≥1 Dose Tdap,States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",82.9,78.1 to 86.9,477
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",65.5,61.6 to 69.1,980
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",81.1,59.5 to 92.6,37
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,Hispanic,71.0,60.9 to 79.4,134
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.0,44.1 to 52.0,980
HPV,"≥1 Dose, Males and Females",States/Local Areas,Alaska,2018-2022,Poverty,Living At or Above Poverty Level,70.3,67.3 to 73.2,1449
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Poverty,Living At or Above Poverty Level,75.6,72.7 to 78.2,1449
≥1 Dose MenACWY,,States/Local Areas,Alaska,2018-2022,Poverty,Below Poverty Level,76.1,66.7 to 83.6,139
HPV,"Up-to-Date, Males and Females",States/Local Areas,Alaska,2018-2022,Poverty,Below Poverty Level,53.3,43.4 to 62.9,139
Varicella,History of disease,States/Local Areas,Delaware,2017,Age,13-17 Years,12.6,8.8 to 17.8,350
Varicella,History of disease,States/Local Areas,Delaware,2016,Age,13-17 Years,11.7,8.2 to 16.6,375
Varicella,History of disease,States/Local Areas,Delaware,2019,Age,13-17 Years,6.4,3.9 to 10.3,308
Varicella,History of disease,States/Local Areas,Delaware,2018,Age,13-17 Years,6.0,3.6 to 9.7,306
Varicella,History of disease,States/Local Areas,Delaware,2008,Age,13-17 Years,56.0,49.5 to 62.2,334
Varicella,History of disease,States/Local Areas,Delaware,2009,Age,13-17 Years,52.5,46.2 to 58.8,371
Varicella,History of disease,States/Local Areas,Delaware,2012,Age,13-17 Years,32.0,26.0 to 38.7,341
Varicella,History of disease,States/Local Areas,Delaware,2013,Age,13-17 Years,25.0,19.8 to 30.9,348
Varicella,History of disease,States/Local Areas,Delaware,2010,Age,13-17 Years,43.6,37.3 to 50.0,348
Varicella,History of disease,States/Local Areas,Delaware,2011,Age,13-17 Years,31.5,26.3 to 37.2,442
Varicella,History of disease,States/Local Areas,Delaware,2015,Age,13-17 Years,18.6,14.2 to 24.0,360
Varicella,History of disease,States/Local Areas,Delaware,2014,Age,13-17 Years,16.0,11.5 to 21.9,374
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2018,Age,13-15 Years,61.3,48.6 to 72.7,102
Varicella,History of disease,States/Local Areas,Delaware,2021,Age,13-17 Years,8.1,5.0 to 12.9,310
Varicella,History of disease,States/Local Areas,Delaware,2020,Age,13-17 Years,10.3,6.6 to 15.6,360
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2019,Age,13-15 Years,58.3,44.9 to 70.5,82
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2020,Age,13-15 Years,55.1,43.1 to 66.6,103
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2017,Age,13-17 Years,59.6,50.1 to 68.4,161
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2016,Age,13-17 Years,66.8,58.4 to 74.3,180
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2022,Age,13-15 Years,71.9,57.7 to 82.7,78
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2021,Age,13-15 Years,66.3,53.9 to 76.8,94
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2019,Age,13-17 Years,60.7,50.9 to 69.7,145
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2018,Age,13-17 Years,63.9,53.7 to 73.0,157
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2016,Age,13-17 Years,47.3,38.8 to 55.9,195
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2022,Age,13-15 Years,66.0,51.4 to 78.1,67
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2021,Age,13-15 Years,60.7,48.8 to 71.4,100
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2019,Age,13-15 Years,54.9,43.7 to 65.6,112
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2017,Age,13-17 Years,56.7,47.6 to 65.4,189
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2020,Age,13-15 Years,60.1,47.3 to 71.7,119
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2018,Age,13-15 Years,50.6,38.8 to 62.4,93
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2022,Age,13-17 Years,67.5,56.5 to 77.0,127
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2021,Age,13-17 Years,68.8,59.0 to 77.1,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2019,Age,13-15 Years,56.3,47.7 to 64.5,194
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2022,Age,13-17 Years,68.8,57.9 to 78.0,123
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2021,Age,13-15 Years,63.6,55.1 to 71.3,194
HPV,"Up-to-Date, Females",States/Local Areas,Delaware,2020,Age,13-17 Years,62.2,52.8 to 70.7,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2020,Age,13-15 Years,57.5,48.7 to 65.8,222
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2021,Age,13-17 Years,68.9,59.7 to 76.9,166
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2019,Age,13-17 Years,57.7,48.3 to 66.6,163
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2020,Age,13-17 Years,64.1,54.9 to 72.4,198
HPV,"Up-to-Date, Males",States/Local Areas,Delaware,2018,Age,13-17 Years,53.1,43.3 to 62.7,149
HPV,"Up-to-Date, Males and Females",States/Local Areas,Delaware,2022,Age,13-15 Years,69.2,59.2 to 77.7,145
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2021,Age,13-15 Years,44.0,34.9 to 53.5,169
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2020,Age,13-17 Years,52.7,42.7 to 62.5,143
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2022,Age,13-17 Years,52.4,41.5 to 63.1,134
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2018,Age,13-15 Years,35.3,24.2 to 48.2,80
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2020,Age,13-15 Years,40.0,29.7 to 51.3,106
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2019,Age,13-15 Years,39.3,31.2 to 47.9,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2020,Age,13-15 Years,46.5,37.9 to 55.4,184
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2021,Age,13-17 Years,48.7,38.2 to 59.3,137
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2022,Age,13-17 Years,46.2,36.7 to 56.0,160
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2021,Age,13-17 Years,47.4,36.8 to 58.4,124
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2022,Age,13-15 Years,48.9,37.2 to 60.7,109
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2021,Age,13-15 Years,37.6,25.6 to 51.3,77
HPV,"Up-to-Date, Males and Females",States/Local Areas,Wyoming,2022,Age,13-15 Years,43.1,34.2 to 52.5,188
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2018,Age,13-17 Years,30.3,21.6 to 40.7,124
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2020,Age,13-17 Years,37.3,29.4 to 46.0,181
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2017,Age,13-17 Years,28.4,21.2 to 36.8,191
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2019,Age,13-17 Years,40.4,32.0 to 49.5,178
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2022,Age,13-15 Years,35.9,23.2 to 50.9,79
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2021,Age,13-15 Years,49.8,37.0 to 62.7,92
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2019,Age,13-17 Years,42.6,33.7 to 52.1,151
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2018,Age,13-17 Years,54.4,43.6 to 64.9,117
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2017,Age,13-17 Years,33.6,25.9 to 42.3,169
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2019,Age,13-15 Years,42.3,31.3 to 54.0,100
HPV,"Up-to-Date, Males",States/Local Areas,Wyoming,2016,Age,13-17 Years,19.9,14.1 to 27.3,205
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2016,Age,13-17 Years,33.9,26.1 to 42.7,168
Varicella,History of disease,States/Local Areas,Wyoming,2017,Age,13-17 Years,16.5,12.2 to 22.0,360
Varicella,History of disease,States/Local Areas,Wyoming,2018,Age,13-17 Years,15.1,10.3 to 21.5,241
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2019,Age,13-15 Years,35.5,24.4 to 48.3,79
Varicella,History of disease,States/Local Areas,Wyoming,2015,Age,13-17 Years,21.8,16.9 to 27.7,331
Varicella,History of disease,States/Local Areas,Wyoming,2016,Age,13-17 Years,21.6,17.1 to 26.9,373
Varicella,History of disease,States/Local Areas,Wyoming,2011,Age,13-17 Years,44.8,36.8 to 53.0,364
Varicella,History of disease,States/Local Areas,Wyoming,2010,Age,13-17 Years,59.1,52.7 to 65.2,295
Varicella,History of disease,States/Local Areas,Wyoming,2013,Age,13-17 Years,31.4,25.8 to 37.6,325
Varicella,History of disease,States/Local Areas,Wyoming,2012,Age,13-17 Years,43.1,36.7 to 49.8,333
Varicella,History of disease,States/Local Areas,Wyoming,2009,Age,13-17 Years,61.2,55.5 to 66.6,375
Varicella,History of disease,States/Local Areas,Wyoming,2014,Age,13-17 Years,28.4,23.5 to 33.9,446
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2018,Age,13-15 Years,54.4,40.0 to 68.1,63
Varicella,History of disease,States/Local Areas,Wyoming,2022,Age,13-17 Years,14.1,9.5 to 20.4,294
Varicella,History of disease,States/Local Areas,Wyoming,2020,Age,13-17 Years,10.1,6.6 to 15.1,324
Varicella,History of disease,States/Local Areas,Wyoming,2019,Age,13-17 Years,14.1,10.1 to 19.2,329
Varicella,History of disease,States/Local Areas,Wyoming,2008,Age,13-17 Years,64.3,57.9 to 70.2,280
HPV,"Up-to-Date, Females",States/Local Areas,Wyoming,2020,Age,13-15 Years,53.9,40.3 to 67.0,78
Varicella,History of disease,States/Local Areas,Wyoming,2021,Age,13-17 Years,9.8,6.4 to 14.9,261
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Carolina,2022,Age,13-17 Years,55.9,48.4 to 63.2,269
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2022,Age,13-17 Years,46.2,36.4 to 56.2,134
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Overall,Overall,83.3,80.9 to 85.5,1480
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Overall,Overall,91.0,89.0 to 92.6,1480
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2023,Age,13-17 Years,79.8,71.5 to 86.2,162
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2023,Age,13-17 Years,63.3,53.5 to 72.1,144
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2023,Age,13-15 Years,95.6,91.5 to 97.8,176
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2023,Age,13-15 Years,57.1,44.1 to 69.2,81
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2023,Age,13-15 Years,56.3,47.4 to 64.9,182
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2023,Age,13-15 Years,87.4,80.4 to 92.2,182
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2023,Age,13-15 Years,96.2,90.9 to 98.5,182
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2023,Age,13-15 Years,55.7,43.5 to 67.2,101
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2023,Age,13-17 Years,92.0,87.2 to 95.1,306
≥2 Doses Hep A,,States/Local Areas,South Carolina,2023,Age,13-17 Years,83.6,77.9 to 88.0,306
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2023,Age,13-17 Years,91.5,86.4 to 94.8,289
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2023,Age,13-17 Years,95.3,90.8 to 97.7,289
Varicella,History of disease,States/Local Areas,South Carolina,2023,Age,13-17 Years,5.9,3.3 to 10.5,306
≥3 Doses HepB,,States/Local Areas,South Carolina,2023,Age,13-17 Years,93.5,89.3 to 96.2,306
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2023,Age,13-17 Years,58.9,49.2 to 67.9,162
≥2 Doses MMR,,States/Local Areas,South Carolina,2023,Age,13-17 Years,92.2,87.4 to 95.2,306
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2023,Age,13-17 Years,77.5,68.5 to 84.5,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2023,Age,13-17 Years,61.0,54.2 to 67.5,306
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2023,Age,13-17 Years,86.2,80.9 to 90.2,306
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2023,Age,13-17 Years,78.7,72.7 to 83.6,306
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2023,Age,13-17 Years,92.1,86.9 to 95.3,306
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2023,Age,13-17 Years,92.1,86.9 to 95.3,306
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2016,Age,13-17 Years,65.1,55.4 to 73.7,181
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2021,Age,13-15 Years,76.1,64.9 to 84.6,125
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2022,Age,13-15 Years,72.5,56.5 to 84.2,72
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2021,Age,13-17 Years,81.2,73.3 to 87.2,197
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2022,Age,13-17 Years,75.1,62.7 to 84.3,113
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2018,Age,13-15 Years,67.2,52.8 to 79.0,98
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2018,Age,13-17 Years,73.5,62.8 to 82.0,134
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2019,Age,13-17 Years,73.0,60.3 to 82.8,121
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2019,Age,13-15 Years,78.2,65.1 to 87.3,98
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2020,Age,13-17 Years,73.4,63.3 to 81.6,189
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2020,Age,13-15 Years,65.5,52.1 to 76.8,129
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2017,Age,13-17 Years,76.6,66.4 to 84.4,153
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2021,Age,13-15 Years,82.8,71.6 to 90.2,136
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2022,Age,13-15 Years,81.4,67.6 to 90.2,80
HPV,"Up-to-Date, Males",States/Local Areas,District of Columbia,2016,Age,13-17 Years,58.8,49.4 to 67.6,196
HPV,"Up-to-Date, Females",States/Local Areas,District of Columbia,2017,Age,13-17 Years,79.4,69.4 to 86.7,165
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2021,Age,13-17 Years,59.8,57.6 to 61.8,9579
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2020,Age,13-15 Years,56.4,53.9 to 58.8,5937
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2019,Age,13-15 Years,54.6,51.8 to 57.4,5500
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2018,Age,13-15 Years,48.9,46.5 to 51.3,5582
Varicella,History of disease,HHS Regions/National,United States,2022,Age,13-17 Years,7.0,6.3 to 7.8,16043
Varicella,History of disease,HHS Regions/National,United States,2021,Age,13-17 Years,7.3,6.5 to 8.2,18002
Varicella,History of disease,HHS Regions/National,United States,2019,Age,13-17 Years,9.1,8.4 to 9.9,18788
Varicella,History of disease,HHS Regions/National,United States,2020,Age,13-17 Years,8.4,7.6 to 9.2,20163
Varicella,History of disease,HHS Regions/National,United States,2017,Age,13-17 Years,13.2,12.3 to 14.2,20949
Varicella,History of disease,HHS Regions/National,United States,2006,Age,13-17 Years,69.9,67.7 to 72.0,2882
Varicella,History of disease,HHS Regions/National,United States,2011,Age,13-17 Years,36.6,35.5 to 37.7,23564
Varicella,History of disease,HHS Regions/National,United States,2010,Age,13-17 Years,44.7,43.5 to 46.0,19257
Varicella,History of disease,HHS Regions/National,United States,2013,Age,13-17 Years,25.4,24.2 to 26.6,18264
Varicella,History of disease,HHS Regions/National,United States,2012,Age,13-17 Years,30.6,29.4 to 31.8,19199
Varicella,History of disease,HHS Regions/National,United States,2008,Age,13-17 Years,59.8,58.4 to 61.3,17835
Varicella,History of disease,HHS Regions/National,United States,2009,Age,13-17 Years,52.7,51.4 to 54.0,20066
Varicella,History of disease,HHS Regions/National,United States,2014,Age,13-17 Years,21.0,19.9 to 22.1,20827
HPV,"Series Completion (3 Dose) Among HPV Vaccination Initiators, Females",HHS Regions/National,United States,2007,Age,13-17 Years,45.2,35.9 to 54.9,188
Varicella,History of disease,HHS Regions/National,United States,2018,Age,13-17 Years,11.9,11.0 to 12.7,18700
Varicella,History of disease,HHS Regions/National,United States,2007,Age,13-17 Years,65.8,63.5 to 68.0,2947
Varicella,History of disease,HHS Regions/National,United States,2016,Age,13-17 Years,15.2,14.3 to 16.1,20475
Varicella,History of disease,HHS Regions/National,United States,2015,Age,13-17 Years,17.8,16.8 to 18.9,21875
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2016,Age,13-17 Years,37.5,35.8 to 39.2,10814
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2020,Age,13-15 Years,54.5,52.8 to 56.2,12447
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2021,Age,13-15 Years,58.5,56.5 to 60.5,11161
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2022,Age,13-17 Years,60.6,58.6 to 62.6,8420
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2019,Age,13-15 Years,52.3,50.3 to 54.2,11687
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2020,Age,13-15 Years,52.6,50.2 to 54.9,6510
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2019,Age,13-15 Years,50.0,47.3 to 52.6,6187
HPV,"Up-to-Date, Males and Females",HHS Regions/National,United States,2022,Age,13-15 Years,58.6,56.7 to 60.5,9816
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2020,Age,13-17 Years,56.0,54.1 to 57.8,10587
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2019,Age,13-17 Years,51.8,49.7 to 53.9,9872
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2017,Age,13-17 Years,44.3,42.6 to 46.0,11104
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2018,Age,13-17 Years,48.7,46.8 to 50.6,9772
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2020,Age,13-17 Years,61.4,59.5 to 63.3,9576
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2017,Age,13-17 Years,53.1,51.2 to 55.0,9845
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2016,Age,13-17 Years,49.5,47.6 to 51.4,9661
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2022,Age,13-17 Years,64.6,62.5 to 66.6,7623
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2021,Age,13-17 Years,63.8,61.5 to 65.9,8423
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2018,Age,13-15 Years,47.1,44.7 to 49.6,5886
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2022,Age,13-15 Years,60.7,57.9 to 63.4,4644
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2021,Age,13-15 Years,60.0,57.1 to 62.7,5217
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2022,Age,13-15 Years,56.6,53.9 to 59.2,5172
HPV,"Up-to-Date, Males",HHS Regions/National,United States,2021,Age,13-15 Years,57.1,54.3 to 59.9,5944
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2019,Age,13-17 Years,56.8,54.6 to 59.0,8916
HPV,"Up-to-Date, Females",HHS Regions/National,United States,2018,Age,13-17 Years,53.7,51.8 to 55.6,8928
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2014,Age,13-15 Years,16.3,12.5 to 20.8,920
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2012,Age,13-15 Years,6.0,3.8 to 9.4,843
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2016,Age,13-17 Years,89.1,87.5 to 90.6,2757
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2018,Age,13-17 Years,93.2,91.7 to 94.4,2507
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2017,Age,13-17 Years,91.2,89.6 to 92.5,2846
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2008,Age,13-17 Years,28.9,25.3 to 32.8,1333
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2012,Age,13-17 Years,71.0,67.6 to 74.3,1779
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2007,Age,13-17 Years,15.2,9.7 to 22.9,188
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2007,Age,13-17 Years,72.8,64.9 to 79.5,188
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2019,Age,13-17 Years,93.6,91.9 to 95.0,2387
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2006,Age,13-17 Years,70.3,65.4 to 74.7,608
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2008,Age,13-17 Years,69.4,66.5 to 72.1,2788
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2014,Age,13-17 Years,16.7,13.9 to 20.0,1510
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2015,Age,13-17 Years,22.5,19.7 to 25.7,1418
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2012,Age,13-17 Years,6.1,4.4 to 8.4,1382
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2011,Age,13-17 Years,0.8,0.5 to 1.4,1666
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2013,Age,13-17 Years,11.1,8.8 to 14.1,1209
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2014,Age,13-17 Years,83.8,81.8 to 85.6,2896
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2015,Age,13-17 Years,86.9,84.9 to 88.6,2793
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2022,Age,13-17 Years,95.1,93.8 to 96.1,2291
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2021,Age,13-17 Years,94.8,93.0 to 96.1,2263
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2020,Age,13-17 Years,95.3,94.0 to 96.3,2466
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2007,Age,13-17 Years,68.7,63.4 to 73.5,501
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2013,Age,13-17 Years,82.0,79.7 to 84.1,2374
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2011,Age,13-17 Years,77.2,74.9 to 79.2,3171
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2012,Age,13-17 Years,80.3,77.7 to 82.6,2612
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2016,Age,13-15 Years,89.9,87.4 to 91.9,1449
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2017,Age,13-15 Years,93.1,91.4 to 94.5,1605
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2019,Age,13-15 Years,94.0,91.9 to 95.5,1385
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2018,Age,13-15 Years,93.3,91.4 to 94.9,1405
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2014,Age,13-15 Years,80.5,77.4 to 83.3,1503
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2015,Age,13-15 Years,85.2,82.4 to 87.7,1481
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2015,Age,13-17 Years,59.4,55.5 to 63.2,1375
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2014,Age,13-17 Years,58.4,54.3 to 62.3,1386
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2013,Age,13-17 Years,53.0,48.9 to 57.2,1165
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2012,Age,13-17 Years,47.0,42.7 to 51.3,1230
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2009,Age,13-17 Years,73.4,71.1 to 75.5,2984
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 4,2010,Age,13-17 Years,73.1,70.7 to 75.4,2679
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2021,Age,13-15 Years,94.1,91.3 to 96.1,1327
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2020,Age,13-15 Years,95.1,93.2 to 96.4,1473
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2009,Age,13-15 Years,46.4,42.3 to 50.7,1002
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2008,Age,13-15 Years,25.5,21.4 to 30.1,787
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2010,Age,13-15 Years,54.8,50.8 to 58.7,1075
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2011,Age,13-15 Years,67.5,63.8 to 71.0,1356
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2013,Age,13-15 Years,78.8,75.2 to 82.0,1175
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2012,Age,13-15 Years,75.5,71.5 to 79.1,1193
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2016,Age,13-17 Years,87.3,85.3 to 89.0,2341
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2015,Age,13-17 Years,83.9,81.6 to 86.0,2287
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2014,Age,13-17 Years,79.4,76.9 to 81.6,2312
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2013,Age,13-17 Years,76.5,73.6 to 79.2,1790
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2017,Age,13-17 Years,90.0,88.2 to 91.5,2496
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2010,Age,13-17 Years,42.3,38.5 to 46.1,1272
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2011,Age,13-17 Years,47.9,44.1 to 51.7,1505
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2007,Age,13-15 Years,17.3,10.4 to 27.5,126
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2016,Age,13-17 Years,96.8,95.7 to 97.6,2341
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2015,Age,13-17 Years,96.4,94.8 to 97.5,2287
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2014,Age,13-17 Years,96.4,95.1 to 97.4,2312
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2013,Age,13-17 Years,95.2,93.4 to 96.6,1790
≥3 Doses HepB,,HHS Regions/National,Region 4,2016,Age,13-17 Years,94.5,93.2 to 95.5,2757
≥3 Doses HepB,,HHS Regions/National,Region 4,2015,Age,13-17 Years,94.5,93.1 to 95.7,2793
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2012,Age,13-17 Years,95.4,93.9 to 96.5,1779
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2019,Age,13-17 Years,96.2,94.7 to 97.2,2186
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2017,Age,13-17 Years,96.7,95.7 to 97.5,2496
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2020,Age,13-17 Years,97.5,96.3 to 98.3,2285
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2018,Age,13-17 Years,92.2,90.6 to 93.6,2209
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2021,Age,13-17 Years,94.4,92.5 to 95.8,2088
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2020,Age,13-17 Years,94.9,93.5 to 96.0,2285
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2019,Age,13-17 Years,93.1,91.2 to 94.6,2186
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2018,Age,13-17 Years,96.4,95.2 to 97.3,2209
≥3 Doses HepB,,HHS Regions/National,Region 4,2019,Age,13-17 Years,94.9,93.4 to 96.1,2387
≥3 Doses HepB,,HHS Regions/National,Region 4,2018,Age,13-17 Years,95.0,93.7 to 96.0,2507
≥3 Doses HepB,,HHS Regions/National,Region 4,2017,Age,13-17 Years,93.7,92.4 to 94.8,2846
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2022,Age,13-15 Years,94.3,92.4 to 95.8,1335
≥3 Doses HepB,,HHS Regions/National,Region 4,2009,Age,13-17 Years,91.1,89.7 to 92.3,2984
≥3 Doses HepB,,HHS Regions/National,Region 4,2010,Age,13-17 Years,93.5,92.3 to 94.5,2679
≥3 Doses HepB,,HHS Regions/National,Region 4,2006,Age,13-17 Years,76.5,72.0 to 80.4,608
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2007,Age,13-17 Years,21.0,15.5 to 27.8,262
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2012,Age,13-17 Years,19.2,15.9 to 23.1,1382
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2011,Age,13-17 Years,63.2,60.0 to 66.3,1961
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2010,Age,13-17 Years,49.8,46.3 to 53.3,1447
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2011,Age,13-17 Years,93.2,91.3 to 94.6,1961
≥3 Doses HepB,,HHS Regions/National,Region 4,2007,Age,13-17 Years,86.5,82.7 to 89.6,501
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2006,Age,13-17 Years,59.1,49.9 to 67.7,192
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2009,Age,13-17 Years,41.0,37.5 to 44.6,1367
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2008,Age,13-17 Years,22.4,19.1 to 26.1,1078
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2009,Age,13-17 Years,83.8,81.0 to 86.3,1367
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2010,Age,13-17 Years,86.7,83.9 to 89.1,1447
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2008,Age,13-17 Years,73.0,68.3 to 77.2,1078
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2009,Age,13-17 Years,23.4,20.6 to 26.5,1416
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2008,Age,13-17 Years,14.5,12.0 to 17.5,1333
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2010,Age,13-17 Years,26.8,23.5 to 30.4,1272
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2014,Age,13-17 Years,36.5,32.7 to 40.4,1386
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2013,Age,13-17 Years,33.9,30.1 to 38.0,1165
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2011,Age,13-17 Years,30.7,27.2 to 34.3,1505
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2012,Age,13-17 Years,28.5,24.9 to 32.4,1230
≥2 Doses Hep A,,HHS Regions/National,Region 4,2021,Age,13-17 Years,81.9,78.9 to 84.5,2263
≥2 Doses Hep A,,HHS Regions/National,Region 4,2022,Age,13-17 Years,84.9,82.4 to 87.1,2291
≥2 Doses Hep A,,HHS Regions/National,Region 4,2020,Age,13-17 Years,79.9,77.5 to 82.0,2466
HPV,"≥3 Doses, Females",HHS Regions/National,Region 4,2015,Age,13-17 Years,35.9,32.3 to 39.6,1375
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2015,Age,13-15 Years,23.4,19.8 to 27.5,902
HPV,"≥3 Doses, Males",HHS Regions/National,Region 4,2013,Age,13-15 Years,10.0,7.3 to 13.5,739
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2015,Age,13-17 Years,86.9,84.9 to 88.6,2793
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2022,Age,13-17 Years,57.7,54.6 to 60.7,2291
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2021,Age,13-17 Years,56.6,53.3 to 59.9,2263
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2020,Age,13-17 Years,52.8,49.9 to 55.8,2466
≥3 Doses HepB,,HHS Regions/National,Region 4,2008,Age,13-17 Years,86.0,84.1 to 87.8,2788
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2019,Age,13-17 Years,50.3,47.1 to 53.5,2387
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2011,Age,13-17 Years,70.6,68.2 to 72.9,3171
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2009,Age,13-17 Years,47.1,44.6 to 49.6,2984
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2010,Age,13-17 Years,59.6,57.1 to 62.1,2679
≥2 Doses MMR,,HHS Regions/National,Region 4,2006,Age,13-17 Years,88.0,84.4 to 90.9,608
≥2 Doses MMR,,HHS Regions/National,Region 4,2007,Age,13-17 Years,91.4,87.8 to 94.0,501
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2019,Age,13-17 Years,50.1,45.5 to 54.7,1235
≥2 Doses MMR,,HHS Regions/National,Region 4,2009,Age,13-17 Years,89.7,87.8 to 91.4,2984
≥2 Doses MMR,,HHS Regions/National,Region 4,2008,Age,13-17 Years,90.3,88.2 to 92.0,2788
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2022,Age,13-15 Years,92.7,90.7 to 94.3,1406
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2008,Age,13-17 Years,31.4,28.8 to 34.1,2788
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2016,Age,13-17 Years,38.7,36.1 to 41.4,2757
≥2 Doses MMR,,HHS Regions/National,Region 4,2011,Age,13-17 Years,92.7,91.2 to 93.9,3171
≥2 Doses MMR,,HHS Regions/National,Region 4,2010,Age,13-17 Years,91.8,90.3 to 93.2,2679
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2006,Age,13-17 Years,7.9,5.6 to 11.0,608
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2014,Age,13-17 Years,86.8,84.9 to 88.5,2896
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2013,Age,13-17 Years,82.5,80.1 to 84.6,2374
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2012,Age,13-17 Years,80.7,78.3 to 82.8,2612
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2017,Age,13-17 Years,43.0,40.3 to 45.7,2846
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2018,Age,13-17 Years,46.7,43.9 to 49.5,2507
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2007,Age,13-17 Years,21.2,16.9 to 26.2,501
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2022,Age,13-17 Years,55.7,51.3 to 59.9,1173
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 4,2022,Age,13-17 Years,59.1,56.1 to 62.1,2291
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2009,Age,13-17 Years,39.8,36.4 to 43.4,1416
≥3 Doses HepB,,HHS Regions/National,Region 4,2014,Age,13-17 Years,94.4,93.0 to 95.5,2896
≥3 Doses HepB,,HHS Regions/National,Region 4,2013,Age,13-17 Years,94.6,93.1 to 95.7,2374
≥3 Doses HepB,,HHS Regions/National,Region 4,2011,Age,13-17 Years,94.2,92.9 to 95.2,3171
≥3 Doses HepB,,HHS Regions/National,Region 4,2012,Age,13-17 Years,96.5,95.5 to 97.3,2612
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2017,Age,13-17 Years,57.6,53.8 to 61.3,1489
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 4,2019,Age,13-17 Years,53.4,50.2 to 56.6,2387
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2021,Age,13-17 Years,97.0,95.4 to 98.0,2088
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 4,2022,Age,13-17 Years,96.8,95.7 to 97.6,2156
≥3 Doses HepB,,HHS Regions/National,Region 4,2021,Age,13-17 Years,95.1,93.4 to 96.3,2263
≥3 Doses HepB,,HHS Regions/National,Region 4,2020,Age,13-17 Years,95.6,94.3 to 96.5,2466
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2018,Age,13-17 Years,66.8,62.9 to 70.4,1205
≥3 Doses HepB,,HHS Regions/National,Region 4,2022,Age,13-17 Years,94.9,93.6 to 95.9,2291
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2016,Age,13-17 Years,52.3,48.5 to 56.0,1438
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2015,Age,13-17 Years,43.7,39.9 to 47.5,1418
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2014,Age,13-17 Years,36.7,32.9 to 40.7,1510
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2013,Age,13-17 Years,28.4,24.8 to 32.4,1209
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 4,2016,Age,13-17 Years,44.6,41.9 to 47.3,2757
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2022,Age,13-17 Years,74.5,70.6 to 78.1,1118
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2011,Age,13-17 Years,6.7,5.1 to 8.7,1666
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2021,Age,13-17 Years,75.1,70.4 to 79.3,1023
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2020,Age,13-17 Years,72.9,68.9 to 76.5,1171
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 4,2022,Age,13-17 Years,94.7,93.4 to 95.8,2156
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 4,2017,Age,13-17 Years,47.6,44.9 to 50.3,2846
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2019,Age,13-17 Years,71.2,66.9 to 75.1,1152
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 4,2018,Age,13-17 Years,50.8,48.0 to 53.6,2507
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2021,Age,13-17 Years,74.3,70.2 to 77.9,1240
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2020,Age,13-17 Years,69.9,66.0 to 73.5,1295
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2019,Age,13-17 Years,63.3,58.8 to 67.5,1235
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2018,Age,13-17 Years,61.9,58.1 to 65.6,1302
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2013,Age,13-17 Years,42.9,38.9 to 47.0,1165
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2012,Age,13-17 Years,37.1,33.1 to 41.3,1230
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2010,Age,13-15 Years,55.9,52.7 to 59.1,1680
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2011,Age,13-15 Years,62.8,59.5 to 65.9,1934
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2006,Age,13-17 Years,58.2,53.3 to 63.0,608
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2007,Age,13-17 Years,70.2,65.4 to 74.6,501
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2007,Age,13-15 Years,29.2,22.8 to 36.5,291
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2006,Age,13-15 Years,7.4,5.0 to 10.9,400
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2008,Age,13-15 Years,36.8,33.3 to 40.5,1695
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2009,Age,13-15 Years,47.1,44.0 to 50.2,1846
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2009,Age,13-17 Years,72.6,70.4 to 74.7,2984
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2008,Age,13-17 Years,67.2,64.3 to 69.9,2788
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2020,Age,13-15 Years,84.9,81.7 to 87.6,1570
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2009,Age,13-17 Years,32.3,29.1 to 35.7,1416
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2011,Age,13-17 Years,38.5,34.8 to 42.3,1505
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2010,Age,13-17 Years,35.5,31.8 to 39.3,1272
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2016,Age,13-17 Years,59.6,55.7 to 63.3,1319
HPV,"≥1 Dose, Females",HHS Regions/National,Region 4,2017,Age,13-17 Years,62.4,58.5 to 66.1,1357
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2015,Age,13-17 Years,89.4,87.6 to 91.0,2793
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2014,Age,13-17 Years,88.7,86.9 to 90.2,2896
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2016,Age,13-17 Years,91.5,90.0 to 92.8,2757
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2007,Age,13-17 Years,14.8,10.1 to 21.2,262
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2013,Age,13-15 Years,70.9,67.4 to 74.2,1462
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2012,Age,13-15 Years,65.4,61.8 to 68.9,1593
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2019,Age,13-15 Years,86.9,84.1 to 89.3,1501
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2018,Age,13-15 Years,82.6,79.8 to 85.0,1562
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2017,Age,13-15 Years,81.6,78.8 to 84.1,1787
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2008,Age,13-17 Years,22.2,19.1 to 25.6,1333
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2016,Age,13-17 Years,55.8,53.1 to 58.5,2757
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2017,Age,13-17 Years,60.0,57.3 to 62.6,2846
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2017,Age,13-17 Years,92.5,91.1 to 93.8,2846
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2014,Age,13-15 Years,73.5,70.3 to 76.5,1807
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2015,Age,13-15 Years,74.3,71.1 to 77.3,1746
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2016,Age,13-15 Years,78.1,75.0 to 80.8,1670
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2014,Age,13-15 Years,87.8,85.2 to 90.0,1807
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2015,Age,13-15 Years,87.7,85.2 to 89.9,1746
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2016,Age,13-15 Years,89.3,86.6 to 91.5,1670
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2017,Age,13-15 Years,91.2,89.2 to 92.8,1787
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2022,Age,13-17 Years,93.7,92.3 to 94.9,2291
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2008,Age,13-15 Years,37.9,34.3 to 41.5,1695
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2010,Age,13-15 Years,68.7,65.7 to 71.5,1680
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2009,Age,13-15 Years,55.0,51.8 to 58.1,1846
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2011,Age,13-15 Years,76.5,73.7 to 79.1,1934
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2012,Age,13-15 Years,83.4,80.5 to 85.9,1593
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2007,Age,13-15 Years,26.5,20.4 to 33.7,291
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2006,Age,13-15 Years,9.5,6.4 to 13.8,400
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2019,Age,13-17 Years,56.9,52.3 to 61.3,1152
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2018,Age,13-17 Years,54.2,50.2 to 58.2,1205
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2014,Age,13-17 Years,46.3,42.2 to 50.3,1386
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2015,Age,13-17 Years,45.0,41.2 to 48.9,1375
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2016,Age,13-17 Years,49.0,45.1 to 53.0,1319
HPV,"≥2 Doses, Females",HHS Regions/National,Region 4,2017,Age,13-17 Years,51.2,47.3 to 55.1,1357
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2022,Age,13-17 Years,72.5,69.8 to 75.1,2291
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2011,Age,13-17 Years,80.8,78.8 to 82.7,3171
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2010,Age,13-17 Years,77.3,75.3 to 79.2,2679
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2013,Age,13-17 Years,85.6,83.4 to 87.6,2374
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2012,Age,13-17 Years,85.9,83.9 to 87.6,2612
HPV,"≥1 Dose, Males",HHS Regions/National,Region 4,2022,Age,13-17 Years,70.6,66.6 to 74.4,1173
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2021,Age,13-17 Years,93.5,91.6 to 95.0,2263
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2018,Age,13-17 Years,64.3,61.6 to 66.9,2507
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2019,Age,13-17 Years,67.1,64.1 to 70.1,2387
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2020,Age,13-17 Years,92.4,90.6 to 94.0,2466
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2019,Age,13-17 Years,94.3,93.0 to 95.4,2387
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 4,2018,Age,13-17 Years,91.9,90.4 to 93.3,2507
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2021,Age,13-17 Years,74.7,71.7 to 77.5,2263
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 4,2020,Age,13-17 Years,71.3,68.6 to 73.9,2466
≥1 Dose MenACWY,,HHS Regions/National,Region 4,2021,Age,13-15 Years,84.0,80.4 to 87.0,1412
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2014,Age,13-17 Years,25.6,22.2 to 29.4,1510
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2013,Age,13-17 Years,18.6,15.7 to 22.0,1209
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2012,Age,13-17 Years,11.5,8.9 to 14.7,1382
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2011,Age,13-17 Years,2.6,1.8 to 3.8,1666
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2013,Age,13-15 Years,85.0,81.9 to 87.6,1462
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2018,Age,13-15 Years,89.4,87.1 to 91.3,1562
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2021,Age,13-15 Years,91.8,89.3 to 93.7,1412
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2020,Age,13-15 Years,89.8,86.9 to 92.1,1570
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 4,2019,Age,13-15 Years,93.0,91.0 to 94.5,1501
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2015,Age,13-17 Years,33.7,30.2 to 37.4,1418
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2016,Age,13-17 Years,40.2,36.5 to 44.1,1438
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2017,Age,13-17 Years,44.1,40.3 to 47.9,1489
HPV,"≥2 Doses, Males",HHS Regions/National,Region 4,2018,Age,13-17 Years,47.6,43.7 to 51.5,1302
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2020,Age,13-17 Years,50.5,46.4 to 54.5,1295
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2019,Age,13-17 Years,46.7,42.1 to 51.3,1235
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2017,Age,13-17 Years,40.2,36.5 to 44.0,1489
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2018,Age,13-17 Years,42.8,39.0 to 46.7,1302
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2020,Age,13-15 Years,50.8,47.0 to 54.6,1570
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2021,Age,13-15 Years,55.4,51.0 to 59.6,1412
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2022,Age,13-17 Years,54.5,50.2 to 58.8,1173
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2019,Age,13-15 Years,47.3,43.2 to 51.4,1501
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2021,Age,13-17 Years,55.0,50.5 to 59.4,1240
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2020,Age,13-17 Years,55.3,51.0 to 59.5,1171
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2016,Age,13-17 Years,32.9,29.3 to 36.6,1438
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2016,Age,13-17 Years,44.8,40.9 to 48.7,1319
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2022,Age,13-17 Years,61.0,56.7 to 65.2,1118
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2021,Age,13-17 Years,58.3,53.3 to 63.3,1023
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2018,Age,13-15 Years,40.7,36.0 to 45.6,799
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2020,Age,13-15 Years,48.2,42.9 to 53.5,812
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2019,Age,13-15 Years,44.1,38.5 to 49.8,782
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 4,2022,Age,13-15 Years,52.5,48.4 to 56.5,1406
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2022,Age,13-15 Years,57.2,51.4 to 62.8,672
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2021,Age,13-15 Years,55.4,48.7 to 61.9,618
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2022,Age,13-15 Years,48.0,42.6 to 53.5,734
HPV,"Up-to-Date, Males",HHS Regions/National,Region 4,2021,Age,13-15 Years,55.3,49.8 to 60.8,794
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2017,Age,13-17 Years,46.0,42.1 to 49.9,1357
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2019,Age,13-17 Years,54.1,49.5 to 58.6,1152
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2018,Age,13-17 Years,50.7,46.6 to 54.7,1205
Varicella,History of disease,HHS Regions/National,Region 4,2011,Age,13-17 Years,38.0,35.4 to 40.5,3171
Varicella,History of disease,HHS Regions/National,Region 4,2010,Age,13-17 Years,46.5,43.9 to 49.1,2679
Varicella,History of disease,HHS Regions/National,Region 4,2013,Age,13-17 Years,23.5,21.1 to 26.0,2374
Varicella,History of disease,HHS Regions/National,Region 4,2012,Age,13-17 Years,31.9,29.1 to 34.8,2612
Varicella,History of disease,HHS Regions/National,Region 4,2018,Age,13-17 Years,11.9,10.3 to 13.8,2507
Varicella,History of disease,HHS Regions/National,Region 4,2007,Age,13-17 Years,63.1,57.6 to 68.2,501
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2018,Age,13-15 Years,44.1,39.0 to 49.4,763
Varicella,History of disease,HHS Regions/National,Region 4,2016,Age,13-17 Years,14.6,12.8 to 16.6,2757
Varicella,History of disease,HHS Regions/National,Region 4,2015,Age,13-17 Years,18.4,16.3 to 20.7,2793
Varicella,History of disease,HHS Regions/National,Region 4,2014,Age,13-17 Years,21.4,19.0 to 24.0,2896
Varicella,History of disease,HHS Regions/National,Region 4,2022,Age,13-17 Years,6.7,5.3 to 8.4,2291
Varicella,History of disease,HHS Regions/National,Region 4,2021,Age,13-17 Years,7.7,6.1 to 9.6,2263
Varicella,History of disease,HHS Regions/National,Region 4,2019,Age,13-17 Years,7.9,6.4 to 9.7,2387
Varicella,History of disease,HHS Regions/National,Region 4,2020,Age,13-17 Years,6.8,5.5 to 8.4,2466
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2020,Age,13-15 Years,53.4,47.9 to 58.8,758
HPV,"Up-to-Date, Females",HHS Regions/National,Region 4,2019,Age,13-15 Years,50.4,44.6 to 56.3,719
Varicella,History of disease,HHS Regions/National,Region 4,2017,Age,13-17 Years,11.7,10.1 to 13.5,2846
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2016,Age,13-17 Years,43.5,34.3 to 53.0,157
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2022,Age,13-15 Years,53.1,39.2 to 66.5,74
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2021,Age,13-15 Years,55.3,42.0 to 67.8,76
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2018,Age,13-17 Years,55.7,45.7 to 65.2,137
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2019,Age,13-17 Years,41.5,31.6 to 52.1,126
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2020,Age,13-15 Years,39.8,28.2 to 52.5,89
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2017,Age,13-17 Years,33.5,25.5 to 42.5,179
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2022,Age,13-15 Years,55.8,43.6 to 67.4,93
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2021,Age,13-15 Years,48.0,35.7 to 60.6,87
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2016,Age,13-17 Years,24.7,18.1 to 32.8,193
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2021,Age,13-17 Years,48.7,39.1 to 58.5,146
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2020,Age,13-15 Years,50.3,38.3 to 62.3,90
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2019,Age,13-15 Years,33.2,23.0 to 45.1,89
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2017,Age,13-17 Years,48.4,38.6 to 58.3,155
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2020,Age,13-17 Years,60.0,49.9 to 69.4,141
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2019,Age,13-15 Years,41.6,31.0 to 53.2,99
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2020,Age,13-15 Years,45.8,37.1 to 54.8,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2022,Age,13-15 Years,54.4,45.1 to 63.5,167
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2021,Age,13-15 Years,51.5,42.4 to 60.6,163
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2022,Age,13-17 Years,55.8,45.9 to 65.3,142
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2019,Age,13-15 Years,37.2,29.6 to 45.5,188
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2022,Age,13-17 Years,63.5,52.5 to 73.3,116
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2021,Age,13-17 Years,62.0,51.4 to 71.6,122
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2018,Age,13-15 Years,39.3,28.9 to 50.8,100
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2018,Age,13-17 Years,42.5,34.0 to 51.6,159
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2020,Age,13-17 Years,47.1,37.7 to 56.7,161
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2019,Age,13-17 Years,40.9,32.5 to 49.8,163
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2018,Age,13-15 Years,47.7,35.6 to 60.0,91
Varicella,History of disease,States/Local Areas,Indiana,2019,Age,13-17 Years,10.3,6.5 to 15.9,289
Varicella,History of disease,States/Local Areas,Indiana,2022,Age,13-17 Years,8.5,5.0 to 14.0,258
Varicella,History of disease,States/Local Areas,Indiana,2021,Age,13-17 Years,8.1,4.8 to 13.4,268
Varicella,History of disease,States/Local Areas,Indiana,2020,Age,13-17 Years,10.6,6.9 to 16.1,302
Varicella,History of disease,States/Local Areas,Indiana,2014,Age,13-17 Years,30.3,24.6 to 36.6,370
Varicella,History of disease,States/Local Areas,Indiana,2008,Age,13-17 Years,66.8,60.9 to 72.2,345
Varicella,History of disease,States/Local Areas,Indiana,2009,Age,13-17 Years,64.7,59.3 to 69.8,873
Varicella,History of disease,States/Local Areas,Indiana,2015,Age,13-17 Years,21.6,16.8 to 27.4,328
Varicella,History of disease,States/Local Areas,Indiana,2011,Age,13-17 Years,46.8,40.7 to 53.0,430
Varicella,History of disease,States/Local Areas,Indiana,2010,Age,13-17 Years,60.1,53.7 to 66.3,316
Varicella,History of disease,States/Local Areas,Indiana,2012,Age,13-17 Years,38.5,32.1 to 45.3,341
Varicella,History of disease,States/Local Areas,Indiana,2013,Age,13-17 Years,37.9,32.4 to 43.8,381
Varicella,History of disease,States/Local Areas,Indiana,2018,Age,13-17 Years,15.8,11.4 to 21.5,296
Varicella,History of disease,States/Local Areas,Indiana,2016,Age,13-17 Years,20.0,15.3 to 25.7,350
≥2 Doses Hep A,,States/Local Areas,Indiana,2021,Age,13-17 Years,90.6,85.2 to 94.2,268
≥2 Doses Hep A,,States/Local Areas,Indiana,2022,Age,13-17 Years,94.4,90.2 to 96.9,258
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2009,Age,13-15 Years,36.3,26.9 to 46.9,234
HPV,"≥3 Doses, Males",States/Local Areas,Indiana,2014,Age,13-15 Years,13.7,8.5 to 21.2,115
HPV,"≥3 Doses, Males",States/Local Areas,Indiana,2015,Age,13-15 Years,24.5,16.0 to 35.6,95
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2019,Age,13-17 Years,94.8,90.6 to 97.2,289
HPV,"≥3 Doses, Males",States/Local Areas,Indiana,2014,Age,13-17 Years,12.8,8.5 to 18.8,186
HPV,"≥3 Doses, Males",States/Local Areas,Indiana,2015,Age,13-17 Years,27.5,20.1 to 36.3,161
HPV,"≥3 Doses, Males",States/Local Areas,Indiana,2013,Age,13-17 Years,8.1,4.8 to 13.5,187
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2008,Age,13-17 Years,74.8,69.1 to 79.7,345
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2015,Age,13-17 Years,94.0,90.3 to 96.3,328
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2017,Age,13-17 Years,96.7,93.2 to 98.5,334
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2016,Age,13-17 Years,93.0,89.0 to 95.7,350
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2018,Age,13-17 Years,97.8,95.0 to 99.0,296
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2008,Age,13-15 Years,27.8,19.0 to 38.6,92
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2022,Age,13-17 Years,95.4,91.5 to 97.6,258
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2021,Age,13-17 Years,92.7,87.4 to 95.9,268
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2020,Age,13-17 Years,97.4,95.0 to 98.7,302
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2009,Age,13-17 Years,77.1,71.9 to 81.5,873
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2010,Age,13-17 Years,83.3,78.2 to 87.4,316
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2015,Age,13-15 Years,92.8,86.6 to 96.2,156
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2014,Age,13-15 Years,93.1,86.7 to 96.5,181
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2019,Age,13-15 Years,93.4,87.0 to 96.8,176
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2012,Age,13-17 Years,90.7,85.4 to 94.2,341
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2011,Age,13-17 Years,92.7,88.3 to 95.5,430
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2014,Age,13-17 Years,92.5,88.8 to 95.0,370
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2013,Age,13-17 Years,94.9,91.6 to 97.0,381
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2017,Age,13-15 Years,97.6,94.2 to 99.0,185
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2016,Age,13-15 Years,89.2,82.8 to 93.5,193
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2018,Age,13-15 Years,97.0,92.4 to 98.9,170
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2014,Age,13-17 Years,61.4,52.6 to 69.5,184
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2015,Age,13-17 Years,53.7,44.7 to 62.5,167
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2012,Age,13-17 Years,48.4,38.7 to 58.2,154
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2013,Age,13-17 Years,54.1,45.8 to 62.3,194
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2015,Age,13-17 Years,92.3,87.7 to 95.3,254
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2016,Age,13-17 Years,91.3,86.3 to 94.6,282
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2014,Age,13-17 Years,89.2,84.1 to 92.8,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2017,Age,13-17 Years,99.3,98.0 to 99.7,302
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2010,Age,13-17 Years,37.0,29.2 to 45.6,168
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2011,Age,13-17 Years,40.8,32.0 to 50.2,199
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2017,Age,13-17 Years,96.3,92.3 to 98.3,302
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2013,Age,13-15 Years,92.8,85.6 to 96.5,161
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2012,Age,13-15 Years,88.7,79.1 to 94.2,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2010,Age,13-15 Years,57.4,45.5 to 68.5,95
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2011,Age,13-15 Years,92.5,86.4 to 96.0,148
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2014,Age,13-17 Years,97.9,94.4 to 99.2,269
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2013,Age,13-17 Years,98.3,95.3 to 99.4,237
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2015,Age,13-17 Years,96.6,93.2 to 98.4,254
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2016,Age,13-17 Years,97.1,94.0 to 98.6,282
≥3 Doses HepB,,States/Local Areas,Indiana,2015,Age,13-17 Years,91.4,86.8 to 94.4,328
≥3 Doses HepB,,States/Local Areas,Indiana,2016,Age,13-17 Years,91.3,86.7 to 94.4,350
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2009,Age,13-17 Years,37.1,30.2 to 44.6,404
≥3 Doses HepB,,States/Local Areas,Indiana,2018,Age,13-17 Years,95.9,92.8 to 97.7,296
≥3 Doses HepB,,States/Local Areas,Indiana,2019,Age,13-17 Years,96.3,93.3 to 98.0,289
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2018,Age,13-17 Years,98.1,95.1 to 99.3,251
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2019,Age,13-17 Years,96.3,92.9 to 98.2,264
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2020,Age,13-17 Years,98.7,96.8 to 99.5,275
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2018,Age,13-17 Years,97.3,94.1 to 98.8,251
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2021,Age,13-17 Years,92.1,86.3 to 95.5,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2020,Age,13-17 Years,97.1,94.5 to 98.5,275
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2019,Age,13-17 Years,94.2,89.5 to 96.8,264
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2021,Age,13-15 Years,91.0,83.0 to 95.4,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2020,Age,13-15 Years,97.4,93.8 to 98.9,169
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2013,Age,13-15 Years,90.6,85.1 to 94.2,221
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2015,Age,13-15 Years,89.1,82.5 to 93.4,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2014,Age,13-15 Years,90.1,83.6 to 94.2,233
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2016,Age,13-15 Years,89.3,83.0 to 93.5,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2017,Age,13-15 Years,94.0,89.9 to 96.6,208
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2014,Age,13-17 Years,17.0,11.8 to 23.8,186
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2013,Age,13-17 Years,13.5,8.8 to 20.0,187
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2012,Age,13-17 Years,10.8,6.1 to 18.3,187
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2019,Age,13-17 Years,48.5,38.2 to 58.9,126
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2008,Age,13-15 Years,33.1,26.6 to 40.3,213
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2010,Age,13-15 Years,74.6,66.2 to 81.5,188
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2009,Age,13-15 Years,44.1,37.1 to 51.3,504
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2011,Age,13-15 Years,93.8,88.7 to 96.7,254
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2012,Age,13-15 Years,96.9,93.2 to 98.6,218
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2018,Age,13-17 Years,57.6,47.6 to 67.0,137
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2015,Age,13-17 Years,43.1,34.6 to 52.1,167
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2014,Age,13-17 Years,54.3,45.4 to 63.0,184
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2016,Age,13-17 Years,49.5,40.1 to 58.9,157
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2017,Age,13-17 Years,53.3,43.3 to 63.1,155
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2022,Age,13-17 Years,75.5,68.4 to 81.4,258
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2009,Age,13-17 Years,57.9,52.3 to 63.3,873
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2008,Age,13-17 Years,53.6,47.4 to 59.7,345
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2020,Age,13-17 Years,96.4,93.9 to 97.9,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2019,Age,13-17 Years,94.0,89.2 to 96.8,289
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2022,Age,13-17 Years,95.3,91.5 to 97.4,258
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2021,Age,13-17 Years,92.2,86.9 to 95.5,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2019,Age,13-17 Years,66.3,59.4 to 72.5,289
≥1 Dose MenACWY,,States/Local Areas,Indiana,2008,Age,13-15 Years,34.7,28.2 to 42.0,213
≥1 Dose MenACWY,,States/Local Areas,Indiana,2009,Age,13-15 Years,39.0,32.5 to 46.1,504
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2011,Age,13-17 Years,33.8,25.7 to 42.9,199
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2010,Age,13-17 Years,31.2,23.9 to 39.6,168
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2009,Age,13-17 Years,28.5,22.3 to 35.5,404
≥1 Dose MenACWY,,States/Local Areas,Indiana,2020,Age,13-15 Years,93.5,87.8 to 96.7,179
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2014,Age,13-17 Years,90.1,85.4 to 93.4,370
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2015,Age,13-17 Years,91.8,87.4 to 94.7,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2016,Age,13-17 Years,90.6,85.8 to 93.9,350
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2017,Age,13-17 Years,95.7,92.9 to 97.4,334
≥1 Dose MenACWY,,States/Local Areas,Indiana,2013,Age,13-15 Years,93.1,88.0 to 96.1,221
≥1 Dose MenACWY,,States/Local Areas,Indiana,2012,Age,13-15 Years,93.2,87.2 to 96.4,218
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018,Age,13-17 Years,65.0,58.6 to 70.9,296
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2018,Age,13-17 Years,92.3,87.9 to 95.2,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2016,Age,13-17 Years,45.2,38.9 to 51.7,350
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2017,Age,13-17 Years,59.3,52.8 to 65.5,334
≥1 Dose MenACWY,,States/Local Areas,Indiana,2019,Age,13-15 Years,90.5,83.5 to 94.8,188
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018,Age,13-15 Years,87.4,81.3 to 91.7,191
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2011,Age,13-17 Years,94.0,90.6 to 96.2,430
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2010,Age,13-17 Years,79.8,74.3 to 84.4,316
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2012,Age,13-17 Years,96.9,93.6 to 98.6,341
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2013,Age,13-17 Years,92.8,89.1 to 95.3,381
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2012,Age,13-17 Years,42.7,33.4 to 52.5,154
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2013,Age,13-17 Years,44.2,36.2 to 52.5,194
≥1 Dose MenACWY,,States/Local Areas,Indiana,2010,Age,13-15 Years,72.7,64.3 to 79.8,188
≥1 Dose MenACWY,,States/Local Areas,Indiana,2011,Age,13-15 Years,94.5,89.3 to 97.2,254
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2022,Age,13-17 Years,73.6,63.5 to 81.7,142
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2021,Age,13-17 Years,72.1,65.2 to 78.1,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2020,Age,13-17 Years,73.6,67.3 to 79.0,302
≥3 Doses HepB,,States/Local Areas,Indiana,2017,Age,13-17 Years,95.7,91.1 to 98.0,334
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2012,Age,13-17 Years,84.8,76.8 to 90.4,206
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2013,Age,13-17 Years,91.8,86.6 to 95.2,237
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2008,Age,13-17 Years,26.1,19.8 to 33.6,173
≥3 Doses HepB,,States/Local Areas,Indiana,2012,Age,13-17 Years,94.9,90.5 to 97.3,341
≥3 Doses HepB,,States/Local Areas,Indiana,2011,Age,13-17 Years,94.4,90.2 to 96.8,430
≥3 Doses HepB,,States/Local Areas,Indiana,2014,Age,13-17 Years,94.7,90.4 to 97.1,370
≥3 Doses HepB,,States/Local Areas,Indiana,2013,Age,13-17 Years,95.6,92.3 to 97.5,381
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2008,Age,13-17 Years,70.4,59.8 to 79.1,115
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2011,Age,13-17 Years,86.2,78.6 to 91.5,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2010,Age,13-17 Years,58.1,48.0 to 67.6,129
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2012,Age,13-17 Years,95.1,88.7 to 98.0,206
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2011,Age,13-17 Years,94.8,86.1 to 98.2,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2008,Age,13-17 Years,24.0,16.7 to 33.3,115
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2009,Age,13-17 Years,35.0,27.1 to 43.7,352
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2009,Age,13-17 Years,75.0,64.7 to 83.1,352
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2010,Age,13-17 Years,85.8,77.8 to 91.3,129
≥3 Doses HepB,,States/Local Areas,Indiana,2009,Age,13-17 Years,89.0,85.5 to 91.7,873
≥3 Doses HepB,,States/Local Areas,Indiana,2010,Age,13-17 Years,93.9,90.1 to 96.3,316
≥3 Doses HepB,,States/Local Areas,Indiana,2008,Age,13-17 Years,86.2,81.4 to 90.0,345
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2019,Age,13-17 Years,65.2,56.1 to 73.3,163
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2022,Age,13-15 Years,95.7,89.7 to 98.3,155
HPV,"≥2 Doses, Males and Females",States/Local Areas,Indiana,2019,Age,13-17 Years,47.1,40.4 to 54.0,289
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2017,Age,13-17 Years,51.0,42.3 to 59.6,179
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2012,Age,13-17 Years,17.2,10.9 to 25.9,187
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2014,Age,13-17 Years,23.2,17.0 to 30.8,186
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2013,Age,13-17 Years,18.2,12.8 to 25.3,187
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2015,Age,13-17 Years,43.2,34.6 to 52.4,161
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2016,Age,13-17 Years,36.9,29.0 to 45.5,193
HPV,"≥2 Doses, Males and Females",States/Local Areas,Indiana,2016,Age,13-17 Years,38.7,32.6 to 45.2,350
HPV,"≥2 Doses, Males and Females",States/Local Areas,Indiana,2017,Age,13-17 Years,46.3,39.7 to 52.9,334
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2022,Age,13-17 Years,77.5,66.9 to 85.4,116
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2021,Age,13-17 Years,75.3,64.9 to 83.4,122
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2020,Age,13-17 Years,80.8,71.7 to 87.4,141
HPV,"≥2 Doses, Males and Females",States/Local Areas,Indiana,2018,Age,13-17 Years,51.3,44.7 to 58.0,296
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2018,Age,13-17 Years,63.3,54.7 to 71.1,159
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2021,Age,13-17 Years,69.0,59.4 to 77.2,146
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2020,Age,13-17 Years,66.7,57.5 to 74.8,161
≥1 Dose MenACWY,,States/Local Areas,Indiana,2021,Age,13-15 Years,88.5,80.6 to 93.4,163
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2022,Age,13-17 Years,96.1,92.3 to 98.1,239
≥3 Doses HepB,,States/Local Areas,Indiana,2022,Age,13-17 Years,96.5,92.7 to 98.3,258
≥3 Doses HepB,,States/Local Areas,Indiana,2021,Age,13-17 Years,92.9,87.4 to 96.1,268
≥3 Doses HepB,,States/Local Areas,Indiana,2020,Age,13-17 Years,95.6,91.8 to 97.6,302
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2018,Age,13-17 Years,66.9,57.1 to 75.4,137
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2019,Age,13-17 Years,67.4,56.9 to 76.4,126
≥1 Dose MenACWY,,States/Local Areas,Indiana,2016,Age,13-15 Years,87.2,80.4 to 91.8,223
≥1 Dose MenACWY,,States/Local Areas,Indiana,2017,Age,13-15 Years,92.6,87.2 to 95.8,208
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2022,Age,13-17 Years,95.0,90.7 to 97.4,239
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2021,Age,13-17 Years,96.0,90.8 to 98.3,249
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2016,Age,13-17 Years,53.9,44.5 to 63.1,157
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2017,Age,13-17 Years,68.0,58.4 to 76.3,155
≥1 Dose MenACWY,,States/Local Areas,Indiana,2015,Age,13-15 Years,89.5,83.2 to 93.7,191
≥1 Dose MenACWY,,States/Local Areas,Indiana,2014,Age,13-15 Years,90.5,84.2 to 94.4,233
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2008,Age,13-17 Years,18.5,13.1 to 25.4,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2020,Age,13-17 Years,53.4,46.4 to 60.2,302
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2009,Age,13-17 Years,44.4,39.0 to 49.9,873
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2010,Age,13-17 Years,72.3,66.2 to 77.7,316
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2011,Age,13-17 Years,92.7,89.1 to 95.1,430
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2008,Age,13-17 Years,31.2,26.1 to 36.7,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2022,Age,13-15 Years,92.6,86.0 to 96.2,167
≥2 Doses MMR,,States/Local Areas,Indiana,2011,Age,13-17 Years,95.2,91.1 to 97.4,430
≥2 Doses MMR,,States/Local Areas,Indiana,2010,Age,13-17 Years,92.6,88.6 to 95.2,316
≥2 Doses MMR,,States/Local Areas,Indiana,2009,Age,13-17 Years,89.5,85.7 to 92.3,873
≥2 Doses MMR,,States/Local Areas,Indiana,2008,Age,13-17 Years,91.7,88.2 to 94.1,345
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2019,Age,13-17 Years,45.8,37.2 to 54.7,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2015,Age,13-17 Years,89.7,85.0 to 93.1,328
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2016,Age,13-17 Years,33.9,28.0 to 40.2,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2012,Age,13-17 Years,94.4,90.6 to 96.8,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2014,Age,13-17 Years,88.6,83.8 to 92.1,370
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2013,Age,13-17 Years,90.6,86.8 to 93.4,381
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2017,Age,13-17 Years,40.8,34.4 to 47.5,334
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018,Age,13-17 Years,48.9,42.3 to 55.7,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2019,Age,13-17 Years,41.2,34.6 to 48.1,289
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018,Age,13-15 Years,89.1,83.1 to 93.1,191
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2021,Age,13-15 Years,85.8,77.9 to 91.3,163
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2020,Age,13-15 Years,93.0,87.4 to 96.2,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2019,Age,13-15 Years,90.9,83.9 to 95.1,188
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2015,Age,13-17 Years,34.3,26.3 to 43.3,161
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2016,Age,13-17 Years,28.4,21.4 to 36.7,193
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2017,Age,13-17 Years,39.5,31.2 to 48.5,179
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2018,Age,13-17 Years,45.4,36.7 to 54.4,159
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2022,Age,13-17 Years,59.6,52.2 to 66.6,258
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2021,Age,13-17 Years,55.2,48.0 to 62.2,268
Varicella,History of disease,States/Local Areas,Indiana,2017,Age,13-17 Years,11.0,7.2 to 16.4,334
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alabama,2011,Age,13-17 Years,15.4,11.4 to 20.6,403
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alabama,2012,Age,13-17 Years,18.6,13.3 to 25.3,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2016,Age,13-17 Years,91.7,87.8 to 94.4,333
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2018,Age,13-17 Years,89.4,84.0 to 93.2,327
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2017,Age,13-17 Years,88.7,84.3 to 92.0,367
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2019,Age,13-17 Years,91.8,87.1 to 94.9,296
≥1 Dose MenACWY,,States/Local Areas,Alabama,2008,Age,13-17 Years,29.9,24.8 to 35.5,406
≥1 Dose MenACWY,,States/Local Areas,Alabama,2009,Age,13-17 Years,43.5,37.5 to 49.8,339
≥1 Dose MenACWY,,States/Local Areas,Alabama,2010,Age,13-17 Years,47.7,41.3 to 54.2,296
≥1 Dose MenACWY,,States/Local Areas,Alabama,2011,Age,13-17 Years,64.3,58.3 to 69.9,403
≥1 Dose MenACWY,,States/Local Areas,Alabama,2012,Age,13-17 Years,60.5,53.1 to 67.3,317
HPV,"≥2 Doses, Females",States/Local Areas,Alabama,2022,Age,13-17 Years,60.2,50.4 to 69.2,139
HPV,"≥2 Doses, Males and Females",States/Local Areas,Alabama,2022,Age,13-17 Years,60.2,53.1 to 66.8,269
HPV,"≥2 Doses, Males",States/Local Areas,Alabama,2022,Age,13-17 Years,60.2,49.9 to 69.6,130
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2013,Age,13-15 Years,36.7,26.1 to 48.7,92
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2014,Age,13-15 Years,36.8,25.7 to 49.4,93
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2015,Age,13-15 Years,39.0,27.5 to 51.9,95
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2008,Age,13-15 Years,15.7,9.7 to 24.2,119
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2009,Age,13-15 Years,24.0,16.0 to 34.3,95
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2010,Age,13-15 Years,24.2,16.0 to 34.9,91
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2011,Age,13-15 Years,27.1,17.5 to 39.4,93
HPV,"≥3 Doses, Females",States/Local Areas,Alabama,2012,Age,13-15 Years,18.2,10.6 to 29.6,84
≥2 Doses MMR,,States/Local Areas,Alabama,2021,Age,13-17 Years,95.8,91.9 to 97.9,304
≥2 Doses MMR,,States/Local Areas,Alabama,2022,Age,13-17 Years,95.7,91.5 to 97.8,269
≥2 Doses MMR,,States/Local Areas,Alabama,2013,Age,13-17 Years,93.4,89.4 to 96.0,317
≥2 Doses MMR,,States/Local Areas,Alabama,2014,Age,13-17 Years,95.0,91.4 to 97.2,378
≥2 Doses MMR,,States/Local Areas,Alabama,2015,Age,13-17 Years,93.7,89.3 to 96.4,361
≥2 Doses MMR,,States/Local Areas,Alabama,2016,Age,13-17 Years,93.7,89.7 to 96.2,333
≥2 Doses MMR,,States/Local Areas,Alabama,2017,Age,13-17 Years,93.4,90.0 to 95.8,367
≥1 Dose MenACWY,,States/Local Areas,Alabama,2022,Age,13-17 Years,84.4,78.9 to 88.6,269
≥1 Dose MenACWY,,States/Local Areas,Alabama,2018,Age,13-17 Years,80.0,74.2 to 84.8,327
≥1 Dose MenACWY,,States/Local Areas,Alabama,2019,Age,13-17 Years,86.8,81.5 to 90.8,296
≥1 Dose MenACWY,,States/Local Areas,Alabama,2020,Age,13-17 Years,82.7,76.8 to 87.2,298
≥1 Dose MenACWY,,States/Local Areas,Alabama,2021,Age,13-17 Years,88.3,82.9 to 92.1,304
≥2 Doses MMR,,States/Local Areas,Alabama,2018,Age,13-17 Years,92.8,87.6 to 95.9,327
≥2 Doses MMR,,States/Local Areas,Alabama,2019,Age,13-17 Years,95.3,91.4 to 97.4,296
≥2 Doses MMR,,States/Local Areas,Alabama,2020,Age,13-17 Years,95.7,92.1 to 97.7,298
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alabama,2013,Age,13-17 Years,22.7,17.8 to 28.5,317
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alabama,2014,Age,13-17 Years,21.9,17.2 to 27.4,378
HPV,"≥3 Doses, Males and Females",States/Local Areas,Alabama,2015,Age,13-17 Years,31.6,25.8 to 38.0,361
≥1 Dose MenACWY,,States/Local Areas,Alabama,2013,Age,13-17 Years,69.5,63.2 to 75.2,317
≥1 Dose MenACWY,,States/Local Areas,Alabama,2014,Age,13-17 Years,71.6,65.6 to 76.9,378
≥1 Dose MenACWY,,States/Local Areas,Alabama,2015,Age,13-17 Years,72.1,66.0 to 77.4,361
≥1 Dose MenACWY,,States/Local Areas,Alabama,2016,Age,13-17 Years,72.4,66.4 to 77.7,333
≥1 Dose MenACWY,,States/Local Areas,Alabama,2017,Age,13-17 Years,78.3,73.0 to 82.9,367
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2020,Age,13-17 Years,92.1,87.5 to 95.1,298
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2021,Age,13-17 Years,91.2,85.8 to 94.6,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Alabama,2022,Age,13-17 Years,93.4,89.0 to 96.1,269
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2020,Age,13-15 Years,80.2,69.5 to 87.9,91
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2019,Age,13-15 Years,83.2,72.7 to 90.2,109
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2020,Age,13-17 Years,79.9,69.9 to 87.2,112
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2022,Age,13-15 Years,81.9,67.4 to 90.8,80
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2021,Age,13-15 Years,81.8,67.4 to 90.7,87
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2022,Age,13-15 Years,80.8,66.7 to 89.8,88
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2021,Age,13-15 Years,88.8,78.9 to 94.4,80
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2016,Age,13-17 Years,73.0,63.5 to 80.8,149
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2022,Age,13-17 Years,85.2,75.5 to 91.5,139
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2021,Age,13-17 Years,80.1,68.4 to 88.2,138
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2018,Age,13-15 Years,81.1,70.4 to 88.5,112
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2016,Age,13-17 Years,68.7,59.8 to 76.4,177
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2020,Age,13-15 Years,77.0,68.5 to 83.8,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2021,Age,13-15 Years,85.4,77.0 to 91.1,167
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2022,Age,13-17 Years,85.2,75.7 to 91.4,146
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2019,Age,13-15 Years,80.8,72.3 to 87.2,186
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2021,Age,13-17 Years,86.3,77.1 to 92.2,116
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2019,Age,13-17 Years,77.8,67.1 to 85.7,140
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2018,Age,13-17 Years,76.1,67.6 to 83.0,156
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2017,Age,13-17 Years,76.8,67.5 to 84.1,145
HPV,"Up-to-Date, Males and Females",States/Local Areas,Rhode Island,2022,Age,13-15 Years,81.3,71.8 to 88.2,168
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2020,Age,13-17 Years,86.0,78.0 to 91.4,159
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2019,Age,13-17 Years,80.0,71.9 to 86.3,179
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2017,Age,13-17 Years,78.4,70.0 to 85.0,174
HPV,"Up-to-Date, Males",States/Local Areas,Rhode Island,2018,Age,13-17 Years,80.0,71.7 to 86.3,181
Varicella,History of disease,States/Local Areas,Rhode Island,2008,Age,13-17 Years,51.3,44.2 to 58.5,297
Varicella,History of disease,States/Local Areas,Rhode Island,2014,Age,13-17 Years,15.4,11.5 to 20.4,414
Varicella,History of disease,States/Local Areas,Rhode Island,2018,Age,13-17 Years,9.2,6.0 to 13.7,337
Varicella,History of disease,States/Local Areas,Rhode Island,2016,Age,13-17 Years,13.0,9.0 to 18.4,326
Varicella,History of disease,States/Local Areas,Rhode Island,2015,Age,13-17 Years,15.4,11.6 to 20.1,419
Varicella,History of disease,States/Local Areas,Rhode Island,2009,Age,13-17 Years,43.8,37.7 to 50.1,409
Varicella,History of disease,States/Local Areas,Rhode Island,2011,Age,13-17 Years,26.1,21.1 to 31.7,449
Varicella,History of disease,States/Local Areas,Rhode Island,2010,Age,13-17 Years,31.8,26.3 to 37.9,330
Varicella,History of disease,States/Local Areas,Rhode Island,2013,Age,13-17 Years,18.4,13.7 to 24.2,315
Varicella,History of disease,States/Local Areas,Rhode Island,2012,Age,13-17 Years,22.3,17.1 to 28.4,327
Varicella,History of disease,States/Local Areas,Rhode Island,2017,Age,13-17 Years,10.7,7.1 to 15.9,319
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2010,Age,13-17 Years,55.1,46.0 to 63.9,159
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2014,Age,13-17 Years,53.7,45.2 to 62.0,194
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2013,Age,13-17 Years,56.5,47.1 to 65.5,147
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2011,Age,13-17 Years,56.8,47.5 to 65.7,203
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2012,Age,13-17 Years,57.7,47.6 to 67.3,153
≥2 Doses Hep A,,States/Local Areas,Rhode Island,2021,Age,13-17 Years,85.9,79.4 to 90.6,254
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2015,Age,13-15 Years,50.7,41.2 to 60.2,131
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2013,Age,13-15 Years,39.5,28.1 to 52.1,88
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2012,Age,13-15 Years,15.8,9.6 to 24.8,105
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2014,Age,13-15 Years,38.0,28.5 to 48.6,128
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2014,Age,13-17 Years,42.9,35.2 to 51.0,220
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2015,Age,13-17 Years,58.1,50.6 to 65.3,218
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2012,Age,13-17 Years,17.7,12.3 to 25.0,174
HPV,"≥3 Doses, Males",States/Local Areas,Rhode Island,2013,Age,13-17 Years,43.2,34.5 to 52.3,168
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2016,Age,13-17 Years,94.6,90.5 to 97.0,326
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2018,Age,13-17 Years,96.4,93.2 to 98.2,337
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2017,Age,13-17 Years,96.6,92.9 to 98.4,319
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2019,Age,13-17 Years,95.9,92.6 to 97.8,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2014,Age,13-15 Years,97.0,91.6 to 99.0,211
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2015,Age,13-15 Years,95.0,90.6 to 97.3,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2019,Age,13-15 Years,97.7,94.3 to 99.1,167
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2018,Age,13-15 Years,95.1,89.7 to 97.7,194
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2008,Age,13-17 Years,80.7,74.0 to 85.9,297
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2014,Age,13-17 Years,96.9,94.0 to 98.4,414
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2015,Age,13-17 Years,96.6,94.0 to 98.1,419
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2022,Age,13-17 Years,95.7,91.5 to 97.8,285
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2021,Age,13-17 Years,94.8,89.1 to 97.6,254
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2020,Age,13-17 Years,96.4,92.7 to 98.3,271
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2009,Age,13-17 Years,83.4,78.7 to 87.2,409
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2010,Age,13-17 Years,90.0,85.6 to 93.2,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2013,Age,13-17 Years,94.5,90.7 to 96.8,315
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2011,Age,13-17 Years,87.5,82.0 to 91.5,449
Varicella,≥2 Doses or history of disease,States/Local Areas,Rhode Island,2012,Age,13-17 Years,94.8,90.9 to 97.1,327
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2016,Age,13-15 Years,94.4,89.4 to 97.1,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2017,Age,13-15 Years,97.7,93.7 to 99.2,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2021,Age,13-15 Years,94.8,88.6 to 97.8,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2020,Age,13-15 Years,96.7,90.2 to 98.9,146
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2009,Age,13-17 Years,51.7,42.5 to 60.8,176
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2008,Age,13-17 Years,31.4,23.2 to 40.9,152
HPV,"≥3 Doses, Females",States/Local Areas,Rhode Island,2015,Age,13-17 Years,68.0,60.2 to 75.0,201
≥2 Doses Hep A,,States/Local Areas,Rhode Island,2022,Age,13-17 Years,93.5,89.0 to 96.3,285
≥2 Doses Hep A,,States/Local Areas,Rhode Island,2020,Age,13-17 Years,88.0,82.7 to 91.8,271
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2009,Age,13-15 Years,73.0,64.1 to 80.3,174
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2023,Age,13-15 Years,60.8,53.4 to 67.9,473
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2008,Age,13-15 Years,63.6,51.1 to 74.5,113
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2010,Age,13-15 Years,89.0,81.7 to 93.6,153
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2011,Age,13-15 Years,83.9,74.7 to 90.2,229
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2013,Age,13-15 Years,95.1,88.7 to 97.9,148
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2012,Age,13-15 Years,94.8,88.9 to 97.6,153
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2016,Age,13-17 Years,93.8,89.2 to 96.6,289
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2015,Age,13-17 Years,96.0,92.9 to 97.8,361
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2014,Age,13-17 Years,96.3,92.9 to 98.1,358
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2013,Age,13-17 Years,93.2,88.7 to 96.0,264
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2017,Age,13-17 Years,96.1,92.1 to 98.2,289
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2010,Age,13-17 Years,73.0,64.6 to 80.0,159
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2011,Age,13-17 Years,76.1,68.1 to 82.5,203
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2015,Age,13-17 Years,87.9,82.1 to 92.1,201
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2014,Age,13-17 Years,76.0,67.5 to 82.8,194
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2013,Age,13-17 Years,76.6,67.6 to 83.7,147
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2012,Age,13-17 Years,73.7,63.3 to 82.0,153
≥3 Doses HepB,,States/Local Areas,Rhode Island,2015,Age,13-17 Years,95.1,92.1 to 96.9,419
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2016,Age,13-17 Years,97.8,94.0 to 99.2,289
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2015,Age,13-17 Years,99.6,98.5 to 99.9,361
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2014,Age,13-17 Years,99.3,97.1 to 99.8,358
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2013,Age,13-17 Years,98.5,95.1 to 99.6,264
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2017,Age,13-17 Years,98.3,95.4 to 99.4,289
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2020,Age,13-17 Years,97.3,94.1 to 98.8,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2018,Age,13-17 Years,96.1,92.6 to 98.0,307
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2021,Age,13-17 Years,94.5,88.5 to 97.4,240
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2020,Age,13-17 Years,96.1,92.1 to 98.1,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2019,Age,13-17 Years,95.4,91.8 to 97.5,284
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2018,Age,13-17 Years,98.5,95.6 to 99.5,307
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2012,Age,13-17 Years,98.7,94.3 to 99.7,257
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2019,Age,13-17 Years,97.6,94.2 to 99.0,284
≥3 Doses HepB,,States/Local Areas,Rhode Island,2016,Age,13-17 Years,95.1,91.2 to 97.4,326
≥3 Doses HepB,,States/Local Areas,Rhode Island,2009,Age,13-17 Years,93.8,89.3 to 96.5,409
≥3 Doses HepB,,States/Local Areas,Rhode Island,2010,Age,13-17 Years,93.6,89.3 to 96.3,330
≥3 Doses HepB,,States/Local Areas,Rhode Island,2019,Age,13-17 Years,97.0,94.4 to 98.4,319
≥3 Doses HepB,,States/Local Areas,Rhode Island,2018,Age,13-17 Years,96.9,94.4 to 98.3,337
≥3 Doses HepB,,States/Local Areas,Rhode Island,2017,Age,13-17 Years,96.2,92.7 to 98.1,319
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2022,Age,13-15 Years,95.2,89.1 to 98.0,167
≥3 Doses HepB,,States/Local Areas,Rhode Island,2008,Age,13-17 Years,98.4,96.7 to 99.3,297
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2008,Age,13-17 Years,54.7,44.2 to 64.8,152
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2012,Age,13-17 Years,93.3,88.4 to 96.3,257
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2011,Age,13-17 Years,83.1,76.1 to 88.4,333
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2010,Age,13-17 Years,85.3,79.2 to 89.9,226
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2011,Age,13-17 Years,96.1,87.5 to 98.8,333
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2009,Age,13-17 Years,70.5,63.2 to 76.8,249
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2008,Age,13-17 Years,60.3,50.0 to 69.8,149
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2009,Age,13-17 Years,96.5,92.4 to 98.4,249
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2010,Age,13-17 Years,99.7,98.1 to 100.0,226
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2008,Age,13-17 Years,97.8,89.1 to 99.6,149
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2009,Age,13-17 Years,68.3,58.9 to 76.4,176
≥3 Doses HepB,,States/Local Areas,Rhode Island,2014,Age,13-17 Years,95.2,91.4 to 97.3,414
≥3 Doses HepB,,States/Local Areas,Rhode Island,2013,Age,13-17 Years,96.2,93.1 to 98.0,315
≥3 Doses HepB,,States/Local Areas,Rhode Island,2011,Age,13-17 Years,95.6,92.7 to 97.4,449
≥3 Doses HepB,,States/Local Areas,Rhode Island,2012,Age,13-17 Years,94.3,89.5 to 97.0,327
HPV,"≥2 Doses, Males and Females",States/Local Areas,Rhode Island,2019,Age,13-17 Years,82.9,76.7 to 87.7,319
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2018,Age,13-17 Years,91.5,84.1 to 95.6,181
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2020,Age,13-17 Years,91.2,84.0 to 95.3,159
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2019,Age,13-17 Years,90.5,84.5 to 94.4,179
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2017,Age,13-17 Years,88.7,80.5 to 93.7,174
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2022,Age,13-17 Years,93.3,87.7 to 96.5,139
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2011,Age,13-17 Years,24.6,18.5 to 31.9,246
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2021,Age,13-17 Years,90.9,78.2 to 96.5,138
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2020,Age,13-17 Years,94.9,87.8 to 98.0,112
Varicella,≥2 Doses with no disease history,States/Local Areas,Rhode Island,2022,Age,13-17 Years,95.4,91.0 to 97.7,273
HPV,"≥2 Doses, Males and Females",States/Local Areas,Rhode Island,2017,Age,13-17 Years,80.7,74.8 to 85.5,319
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2019,Age,13-17 Years,93.4,84.9 to 97.3,140
HPV,"≥2 Doses, Males and Females",States/Local Areas,Rhode Island,2018,Age,13-17 Years,80.5,74.8 to 85.1,337
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2021,Age,13-17 Years,89.2,80.4 to 94.4,116
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2016,Age,13-17 Years,87.8,81.7 to 92.1,177
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2015,Age,13-17 Years,80.6,74.1 to 85.8,218
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2014,Age,13-17 Years,69.0,61.1 to 75.9,220
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2013,Age,13-17 Years,69.3,60.2 to 77.1,168
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2020,Age,13-15 Years,96.0,91.3 to 98.2,160
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2009,Age,13-17 Years,64.7,55.4 to 73.0,176
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2011,Age,13-17 Years,71.1,62.7 to 78.2,203
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2010,Age,13-17 Years,65.8,57.0 to 73.6,159
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2014,Age,13-17 Years,67.8,59.2 to 75.4,194
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2015,Age,13-17 Years,77.9,70.4 to 83.8,201
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2016,Age,13-17 Years,81.4,72.6 to 87.9,149
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2017,Age,13-17 Years,81.5,72.7 to 88.0,145
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2022,Age,13-17 Years,94.6,90.7 to 96.9,285
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2020,Age,13-17 Years,96.4,92.4 to 98.3,271
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2019,Age,13-17 Years,96.7,94.1 to 98.2,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2018,Age,13-17 Years,98.5,96.7 to 99.3,337
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2008,Age,13-15 Years,62.0,52.6 to 70.7,172
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2009,Age,13-15 Years,73.5,65.9 to 79.8,244
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2009,Age,13-17 Years,91.4,87.9 to 94.0,409
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2008,Age,13-17 Years,91.5,86.5 to 94.8,297
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2022,Age,13-17 Years,95.8,88.8 to 98.5,146
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2011,Age,13-17 Years,95.7,93.2 to 97.3,449
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2010,Age,13-17 Years,96.6,93.9 to 98.2,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2012,Age,13-17 Years,96.9,93.9 to 98.4,327
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2021,Age,13-17 Years,96.6,90.8 to 98.8,254
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2018,Age,13-17 Years,89.3,84.5 to 92.7,337
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2019,Age,13-17 Years,91.9,87.4 to 95.0,319
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2021,Age,13-17 Years,90.1,83.2 to 94.3,254
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2020,Age,13-17 Years,93.0,88.4 to 95.9,271
HPV,"≥2 Doses, Males and Females",States/Local Areas,Rhode Island,2016,Age,13-17 Years,79.0,73.2 to 83.8,326
HPV,"≥1 Dose, Males",States/Local Areas,Rhode Island,2012,Age,13-17 Years,55.2,45.9 to 64.1,174
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2022,Age,13-17 Years,98.5,95.8 to 99.5,273
Varicella,≥1 Dose with no disease history,States/Local Areas,Rhode Island,2021,Age,13-17 Years,95.3,89.1 to 98.0,240
≥3 Doses HepB,,States/Local Areas,Rhode Island,2021,Age,13-17 Years,96.3,90.8 to 98.5,254
≥3 Doses HepB,,States/Local Areas,Rhode Island,2020,Age,13-17 Years,94.3,89.7 to 97.0,271
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2018,Age,13-17 Years,87.0,79.8 to 91.9,156
≥3 Doses HepB,,States/Local Areas,Rhode Island,2022,Age,13-17 Years,96.5,93.3 to 98.2,285
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2013,Age,13-17 Years,95.9,92.0 to 97.9,315
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2016,Age,13-17 Years,90.1,83.4 to 94.2,149
HPV,"≥1 Dose, Females",States/Local Areas,Rhode Island,2017,Age,13-17 Years,88.5,80.5 to 93.5,145
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2019,Age,13-15 Years,98.0,95.4 to 99.2,186
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2018,Age,13-15 Years,98.0,95.1 to 99.2,209
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2017,Age,13-15 Years,94.5,89.4 to 97.2,196
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2016,Age,13-17 Years,88.9,84.7 to 92.1,326
HPV,"≥1 Dose, Males and Females",States/Local Areas,Rhode Island,2017,Age,13-17 Years,88.6,83.3 to 92.4,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2017,Age,13-17 Years,95.0,91.3 to 97.1,319
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2008,Age,13-17 Years,50.7,40.5 to 60.8,152
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2013,Age,13-17 Years,68.5,59.2 to 76.5,147
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2012,Age,13-17 Years,67.8,57.3 to 76.7,153
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2010,Age,13-15 Years,82.5,75.3 to 87.9,198
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2011,Age,13-15 Years,90.9,83.2 to 95.3,279
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2015,Age,13-17 Years,98.0,96.1 to 98.9,419
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2014,Age,13-17 Years,94.7,90.9 to 97.0,414
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2016,Age,13-17 Years,97.3,95.0 to 98.5,326
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2013,Age,13-15 Years,92.2,86.0 to 95.8,176
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2012,Age,13-15 Years,98.0,94.3 to 99.3,190
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2014,Age,13-15 Years,94.5,88.0 to 97.6,235
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2015,Age,13-15 Years,97.6,94.9 to 98.9,254
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2016,Age,13-15 Years,95.1,89.9 to 97.7,200
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2018,Age,13-15 Years,71.8,60.3 to 81.1,97
Varicella,History of disease,States/Local Areas,Rhode Island,2019,Age,13-17 Years,10.3,6.8 to 15.4,319
Varicella,History of disease,States/Local Areas,Rhode Island,2020,Age,13-17 Years,7.8,4.7 to 12.6,271
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2020,Age,13-15 Years,73.6,59.7 to 84.0,69
HPV,"Up-to-Date, Females",States/Local Areas,Rhode Island,2019,Age,13-15 Years,77.8,62.9 to 87.8,77
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2014,Age,13-17 Years,56.8,48.6 to 64.7,220
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2013,Age,13-17 Years,58.0,48.8 to 66.6,168
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2012,Age,13-17 Years,34.8,26.6 to 43.9,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2018,Age,13-15 Years,95.5,90.5 to 98.0,209
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2021,Age,13-15 Years,91.9,82.3 to 96.5,167
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2020,Age,13-15 Years,94.1,87.9 to 97.2,160
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2019,Age,13-15 Years,96.9,93.4 to 98.6,186
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2015,Age,13-17 Years,66.6,59.2 to 73.3,218
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2016,Age,13-17 Years,76.7,68.6 to 83.3,177
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2017,Age,13-17 Years,79.9,71.4 to 86.3,174
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2018,Age,13-17 Years,82.4,74.2 to 88.4,181
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2013,Age,13-15 Years,95.2,90.0 to 97.8,176
HPV,"≥2 Doses, Males",States/Local Areas,Rhode Island,2011,Age,13-17 Years,10.3,6.8 to 15.4,246
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2014,Age,13-15 Years,94.9,89.2 to 97.7,235
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2015,Age,13-15 Years,96.4,93.2 to 98.1,254
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2016,Age,13-15 Years,95.3,91.4 to 97.5,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2017,Age,13-15 Years,94.8,90.2 to 97.3,196
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Rhode Island,2022,Age,13-17 Years,96.4,92.7 to 98.2,285
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2008,Age,13-15 Years,45.4,36.2 to 54.8,172
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2010,Age,13-15 Years,92.5,88.0 to 95.4,198
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2009,Age,13-15 Years,62.8,54.7 to 70.3,244
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2011,Age,13-15 Years,91.7,87.4 to 94.6,279
Tetanus,≥1 Dose Tdap,States/Local Areas,Rhode Island,2012,Age,13-15 Years,94.5,89.3 to 97.3,190
≥1 Dose MenACWY,,States/Local Areas,Rhode Island,2021,Age,13-15 Years,92.8,84.8 to 96.8,167
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2019,Age,13-17 Years,82.2,71.9 to 89.3,140
HPV,"≥2 Doses, Females",States/Local Areas,Rhode Island,2018,Age,13-17 Years,78.5,70.1 to 85.0,156
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maryland,2019,Age,13-17 Years,71.4,65.1 to 77.0,524
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2022,Age,13-15 Years,94.7,87.7 to 97.8,202
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2008,Age,13-17 Years,86.7,78.4 to 92.1,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2011,Age,13-17 Years,69.7,62.9 to 75.8,343
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2010,Age,13-17 Years,59.4,51.5 to 66.9,226
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2012,Age,13-17 Years,94.4,89.5 to 97.1,259
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2011,Age,13-17 Years,97.8,95.3 to 99.0,343
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2008,Age,13-17 Years,34.6,26.5 to 43.7,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2009,Age,13-17 Years,49.8,39.6 to 60.1,136
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2009,Age,13-17 Years,96.5,90.2 to 98.8,136
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2010,Age,13-17 Years,97.6,94.9 to 98.9,226
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2012,Age,13-17 Years,80.4,72.6 to 86.4,259
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2013,Age,13-17 Years,78.9,71.0 to 85.1,265
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2008,Age,13-17 Years,41.1,32.4 to 50.5,198
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2009,Age,13-17 Years,39.6,28.7 to 51.6,110
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2009,Age,13-15 Years,53.1,40.8 to 65.1,97
≥3 Doses HepB,,States/Local Areas,Maryland,2017,Age,13-17 Years,90.6,85.0 to 94.2,470
≥3 Doses HepB,,States/Local Areas,Maryland,2012,Age,13-17 Years,94.5,89.9 to 97.1,325
≥3 Doses HepB,,States/Local Areas,Maryland,2011,Age,13-17 Years,94.8,91.9 to 96.7,516
≥3 Doses HepB,,States/Local Areas,Maryland,2014,Age,13-17 Years,91.2,86.0 to 94.6,409
≥3 Doses HepB,,States/Local Areas,Maryland,2013,Age,13-17 Years,93.8,88.7 to 96.7,320
≥3 Doses HepB,,States/Local Areas,Maryland,2019,Age,13-17 Years,90.4,85.0 to 93.9,524
≥3 Doses HepB,,States/Local Areas,Maryland,2018,Age,13-17 Years,93.4,88.7 to 96.2,393
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2016,Age,13-17 Years,95.0,91.0 to 97.3,407
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2015,Age,13-17 Years,96.9,92.0 to 98.8,337
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2014,Age,13-17 Years,93.9,88.8 to 96.7,361
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2013,Age,13-17 Years,98.3,95.6 to 99.4,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2019,Age,13-17 Years,92.7,88.5 to 95.4,479
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2021,Age,13-17 Years,92.5,89.5 to 94.6,804
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2020,Age,13-17 Years,93.7,91.0 to 95.6,754
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2018,Age,13-17 Years,92.6,88.1 to 95.5,356
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2020,Age,13-17 Years,95.8,93.2 to 97.5,754
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2019,Age,13-17 Years,95.8,91.9 to 97.9,479
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2018,Age,13-17 Years,97.1,94.0 to 98.6,356
≥3 Doses HepB,,States/Local Areas,Maryland,2016,Age,13-17 Years,91.5,86.9 to 94.6,451
≥3 Doses HepB,,States/Local Areas,Maryland,2015,Age,13-17 Years,90.6,85.4 to 94.1,403
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2021,Age,13-15 Years,92.9,89.3 to 95.4,539
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2020,Age,13-15 Years,93.9,90.4 to 96.2,499
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2015,Age,13-17 Years,85.6,80.1 to 89.7,403
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2019,Age,13-15 Years,93.4,88.0 to 96.5,311
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2012,Age,13-15 Years,82.2,73.3 to 88.7,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2013,Age,13-15 Years,82.1,72.8 to 88.8,173
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2010,Age,13-15 Years,60.7,50.7 to 69.9,147
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2011,Age,13-15 Years,67.5,58.9 to 75.1,234
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2017,Age,13-17 Years,87.2,80.3 to 92.0,415
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2010,Age,13-17 Years,41.6,32.6 to 51.3,140
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2011,Age,13-17 Years,45.7,37.6 to 54.0,255
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2017,Age,13-17 Years,94.5,88.5 to 97.5,415
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2014,Age,13-17 Years,82.3,75.9 to 87.3,361
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2016,Age,13-17 Years,80.8,74.4 to 86.0,407
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2015,Age,13-17 Years,82.3,75.9 to 87.3,337
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2012,Age,13-17 Years,42.7,32.4 to 53.8,148
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2013,Age,13-17 Years,50.0,38.7 to 61.2,148
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2014,Age,13-17 Years,57.9,47.8 to 67.4,192
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2015,Age,13-17 Years,66.0,56.5 to 74.3,203
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2015,Age,13-15 Years,83.2,74.6 to 89.3,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2014,Age,13-15 Years,79.6,70.8 to 86.2,218
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2018,Age,13-15 Years,91.8,84.9 to 95.8,228
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2016,Age,13-15 Years,84.1,76.0 to 89.9,275
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2017,Age,13-15 Years,86.4,77.0 to 92.3,287
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2012,Age,13-17 Years,84.8,78.5 to 89.5,325
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2011,Age,13-17 Years,78.9,74.0 to 83.1,516
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2014,Age,13-17 Years,83.7,77.8 to 88.3,409
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2013,Age,13-17 Years,82.1,75.2 to 87.4,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2009,Age,13-17 Years,73.0,65.7 to 79.3,245
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2010,Age,13-17 Years,73.3,67.1 to 78.8,338
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2008,Age,13-15 Years,37.1,27.5 to 47.7,147
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2022,Age,13-17 Years,94.2,89.0 to 97.0,346
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2021,Age,13-17 Years,92.9,90.0 to 94.9,857
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2020,Age,13-17 Years,94.2,91.7 to 95.9,815
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2019,Age,13-17 Years,93.2,89.3 to 95.8,524
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2018,Age,13-17 Years,93.4,89.3 to 95.9,393
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2016,Age,13-17 Years,83.0,77.1 to 87.6,451
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2017,Age,13-17 Years,88.9,82.7 to 93.0,470
≥2 Doses MMR,,States/Local Areas,Maryland,2011,Age,13-17 Years,93.4,89.3 to 96.0,516
≥2 Doses MMR,,States/Local Areas,Maryland,2010,Age,13-17 Years,95.1,91.9 to 97.0,338
≥2 Doses MMR,,States/Local Areas,Maryland,2009,Age,13-17 Years,92.5,86.5 to 95.9,245
≥2 Doses MMR,,States/Local Areas,Maryland,2008,Age,13-17 Years,92.3,88.2 to 95.1,394
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2009,Age,13-17 Years,51.8,43.9 to 59.7,245
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2010,Age,13-17 Years,61.2,54.7 to 67.3,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2011,Age,13-17 Years,72.9,67.3 to 77.9,516
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2008,Age,13-17 Years,37.9,32.2 to 44.0,394
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2022,Age,13-15 Years,87.4,77.3 to 93.3,213
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2020,Age,13-17 Years,66.8,61.9 to 71.3,815
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2022,Age,13-17 Years,72.0,64.2 to 78.7,346
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2021,Age,13-17 Years,71.9,67.5 to 76.0,857
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2015,Age,13-17 Years,86.5,81.3 to 90.4,403
≥2 Doses Hep A,,States/Local Areas,Maryland,2021,Age,13-17 Years,85.6,82.0 to 88.5,857
≥2 Doses Hep A,,States/Local Areas,Maryland,2022,Age,13-17 Years,87.4,80.6 to 92.0,346
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2010,Age,13-17 Years,30.8,22.9 to 40.0,140
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2011,Age,13-17 Years,29.9,23.3 to 37.4,255
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2009,Age,13-17 Years,29.5,19.8 to 41.7,110
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2008,Age,13-17 Years,14.2,9.7 to 20.5,198
Varicella,≥2 Doses or history of disease,States/Local Areas,Maryland,2008,Age,13-17 Years,69.7,63.4 to 75.4,394
HPV,"≥3 Doses, Males",States/Local Areas,Maryland,2014,Age,13-17 Years,24.5,16.9 to 34.0,217
HPV,"≥3 Doses, Males",States/Local Areas,Maryland,2015,Age,13-17 Years,31.3,23.1 to 40.8,200
HPV,"≥3 Doses, Males",States/Local Areas,Maryland,2014,Age,13-15 Years,20.8,12.5 to 32.6,135
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2015,Age,13-17 Years,43.7,34.7 to 53.2,203
≥2 Doses Hep A,,States/Local Areas,Maryland,2020,Age,13-17 Years,80.8,76.6 to 84.4,815
HPV,"≥3 Doses, Males",States/Local Areas,Maryland,2015,Age,13-15 Years,24.0,15.5 to 35.2,134
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2012,Age,13-17 Years,30.9,22.4 to 41.0,148
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2014,Age,13-17 Years,39.4,30.2 to 49.5,192
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2013,Age,13-17 Years,33.4,23.7 to 44.8,148
≥1 Dose MenACWY,,States/Local Areas,Maryland,2009,Age,13-17 Years,59.3,51.1 to 67.0,245
≥1 Dose MenACWY,,States/Local Areas,Maryland,2008,Age,13-17 Years,54.6,48.2 to 60.7,394
≥1 Dose MenACWY,,States/Local Areas,Maryland,2011,Age,13-17 Years,78.5,73.4 to 82.9,516
≥1 Dose MenACWY,,States/Local Areas,Maryland,2010,Age,13-17 Years,68.9,62.5 to 74.7,338
≥1 Dose MenACWY,,States/Local Areas,Maryland,2012,Age,13-17 Years,74.9,67.5 to 81.2,325
≥1 Dose MenACWY,,States/Local Areas,Maryland,2022,Age,13-15 Years,90.9,82.5 to 95.5,213
≥2 Doses MMR,,States/Local Areas,Maryland,2016,Age,13-17 Years,89.2,84.4 to 92.7,451
≥2 Doses MMR,,States/Local Areas,Maryland,2014,Age,13-17 Years,91.6,86.5 to 94.9,409
≥2 Doses MMR,,States/Local Areas,Maryland,2015,Age,13-17 Years,93.6,88.7 to 96.5,403
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2019,Age,13-17 Years,91.6,87.1 to 94.6,524
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2017,Age,13-17 Years,88.3,82.2 to 92.5,470
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018,Age,13-17 Years,88.4,83.6 to 92.0,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2016,Age,13-17 Years,85.0,79.7 to 89.2,451
≥2 Doses MMR,,States/Local Areas,Maryland,2012,Age,13-17 Years,92.6,87.2 to 95.8,325
≥2 Doses MMR,,States/Local Areas,Maryland,2013,Age,13-17 Years,93.8,88.6 to 96.7,320
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2008,Age,13-15 Years,13.5,8.4 to 21.0,131
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2009,Age,13-15 Years,19.5,10.8 to 32.7,62
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2010,Age,13-15 Years,26.6,16.5 to 40.1,72
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2022,Age,13-17 Years,89.0,81.9 to 93.5,346
≥1 Dose MenACWY,,States/Local Areas,Maryland,2016,Age,13-17 Years,84.8,79.0 to 89.3,451
≥1 Dose MenACWY,,States/Local Areas,Maryland,2015,Age,13-17 Years,87.3,82.1 to 91.1,403
≥1 Dose MenACWY,,States/Local Areas,Maryland,2014,Age,13-17 Years,86.5,80.7 to 90.7,409
≥1 Dose MenACWY,,States/Local Areas,Maryland,2013,Age,13-17 Years,78.0,70.6 to 83.9,320
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maryland,2011,Age,13-17 Years,15.3,11.9 to 19.5,516
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maryland,2012,Age,13-17 Years,18.4,13.8 to 24.0,325
≥1 Dose MenACWY,,States/Local Areas,Maryland,2017,Age,13-17 Years,91.8,86.5 to 95.1,470
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2021,Age,13-17 Years,89.5,86.4 to 91.9,857
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2020,Age,13-17 Years,90.2,86.9 to 92.7,815
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maryland,2014,Age,13-17 Years,31.8,25.7 to 38.6,409
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maryland,2015,Age,13-17 Years,37.4,31.1 to 44.0,403
≥2 Doses MMR,,States/Local Areas,Maryland,2020,Age,13-17 Years,93.8,90.8 to 95.8,815
HPV,"≥3 Doses, Males and Females",States/Local Areas,Maryland,2013,Age,13-17 Years,21.6,16.0 to 28.6,320
≥2 Doses MMR,,States/Local Areas,Maryland,2019,Age,13-17 Years,93.8,89.6 to 96.3,524
≥2 Doses MMR,,States/Local Areas,Maryland,2018,Age,13-17 Years,94.1,89.9 to 96.6,393
≥2 Doses MMR,,States/Local Areas,Maryland,2017,Age,13-17 Years,92.4,86.8 to 95.7,470
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2015,Age,13-15 Years,34.4,23.7 to 46.9,123
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2014,Age,13-15 Years,30.3,19.7 to 43.4,110
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2013,Age,13-15 Years,22.8,13.4 to 36.1,91
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2017,Age,13-17 Years,73.2,62.9 to 81.5,221
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2016,Age,13-17 Years,69.0,59.9 to 76.8,213
Varicella,≥2 Doses with no disease history,States/Local Areas,Maryland,2022,Age,13-17 Years,93.8,88.2 to 96.8,318
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2021,Age,13-17 Years,95.6,93.6 to 97.0,804
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2017,Age,13-17 Years,89.2,83.4 to 93.2,470
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2016,Age,13-17 Years,87.2,81.9 to 91.2,451
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2014,Age,13-17 Years,89.5,84.0 to 93.2,409
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2015,Age,13-17 Years,88.8,83.8 to 92.4,403
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2018,Age,13-17 Years,76.4,67.1 to 83.7,185
≥3 Doses HepB,,States/Local Areas,Maryland,2022,Age,13-17 Years,89.6,83.2 to 93.7,346
≥3 Doses HepB,,States/Local Areas,Maryland,2021,Age,13-17 Years,93.2,90.4 to 95.2,857
≥3 Doses HepB,,States/Local Areas,Maryland,2020,Age,13-17 Years,93.2,90.2 to 95.3,815
Varicella,≥1 Dose with no disease history,States/Local Areas,Maryland,2022,Age,13-17 Years,96.4,90.4 to 98.7,318
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2012,Age,13-17 Years,20.2,13.7 to 28.7,177
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2021,Age,13-17 Years,83.1,77.9 to 87.4,468
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2020,Age,13-17 Years,78.8,72.3 to 84.0,429
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2018,Age,13-17 Years,73.1,63.7 to 80.8,208
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2017,Age,13-17 Years,65.4,55.1 to 74.5,249
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maryland,2018,Age,13-17 Years,61.7,54.8 to 68.2,393
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2019,Age,13-17 Years,78.3,69.3 to 85.2,261
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2022,Age,13-17 Years,85.5,74.8 to 92.2,161
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2011,Age,13-17 Years,14.0,8.8 to 21.4,261
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2021,Age,13-17 Years,87.9,83.3 to 91.4,389
HPV,"≥1 Dose, Females",States/Local Areas,Maryland,2020,Age,13-17 Years,87.7,83.1 to 91.2,386
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maryland,2017,Age,13-17 Years,57.7,50.3 to 64.9,470
HPV,"≥2 Doses, Males and Females",States/Local Areas,Maryland,2016,Age,13-17 Years,54.4,47.9 to 60.8,451
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2019,Age,13-17 Years,79.4,70.9 to 86.0,263
≥3 Doses HepB,,States/Local Areas,Maryland,2009,Age,13-17 Years,92.2,85.8 to 95.8,245
≥3 Doses HepB,,States/Local Areas,Maryland,2010,Age,13-17 Years,96.9,94.4 to 98.4,338
≥3 Doses HepB,,States/Local Areas,Maryland,2008,Age,13-17 Years,91.2,87.1 to 94.1,394
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2016,Age,13-17 Years,60.2,51.0 to 68.7,238
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2015,Age,13-17 Years,55.0,45.5 to 64.1,200
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2014,Age,13-17 Years,46.9,37.4 to 56.5,217
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2013,Age,13-17 Years,34.2,24.9 to 45.0,172
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2019,Age,13-17 Years,78.9,72.9 to 83.8,524
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2022,Age,13-17 Years,89.0,82.0 to 93.5,346
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2021,Age,13-17 Years,91.9,89.2 to 94.0,857
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2018,Age,13-17 Years,91.3,87.2 to 94.2,393
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2018,Age,13-17 Years,74.7,68.3 to 80.2,393
≥1 Dose MenACWY,,States/Local Areas,Maryland,2015,Age,13-15 Years,88.7,82.3 to 93.0,257
≥1 Dose MenACWY,,States/Local Areas,Maryland,2014,Age,13-15 Years,87.6,80.4 to 92.4,245
≥1 Dose MenACWY,,States/Local Areas,Maryland,2016,Age,13-15 Years,89.9,83.5 to 94.0,305
≥1 Dose MenACWY,,States/Local Areas,Maryland,2012,Age,13-15 Years,72.5,62.9 to 80.3,196
≥1 Dose MenACWY,,States/Local Areas,Maryland,2013,Age,13-15 Years,76.8,67.2 to 84.2,196
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2008,Age,13-17 Years,31.8,23.7 to 41.2,198
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2012,Age,13-17 Years,82.2,75.2 to 87.5,325
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2013,Age,13-17 Years,86.7,79.7 to 91.6,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2011,Age,13-17 Years,85.8,81.3 to 89.4,516
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2010,Age,13-17 Years,79.0,73.0 to 84.0,338
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2012,Age,13-17 Years,39.3,29.4 to 50.1,148
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2013,Age,13-17 Years,45.5,34.5 to 56.9,148
≥1 Dose MenACWY,,States/Local Areas,Maryland,2019,Age,13-15 Years,93.7,88.6 to 96.6,335
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018,Age,13-15 Years,91.6,84.6 to 95.5,252
≥1 Dose MenACWY,,States/Local Areas,Maryland,2017,Age,13-15 Years,93.6,86.9 to 97.0,311
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2017,Age,13-17 Years,69.2,62.1 to 75.6,470
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2016,Age,13-17 Years,64.5,58.1 to 70.5,451
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2019,Age,13-17 Years,93.6,89.9 to 96.0,524
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2020,Age,13-17 Years,92.0,89.1 to 94.2,815
≥1 Dose MenACWY,,States/Local Areas,Maryland,2010,Age,13-15 Years,70.9,62.1 to 78.4,192
≥1 Dose MenACWY,,States/Local Areas,Maryland,2011,Age,13-15 Years,73.1,65.5 to 79.5,307
≥1 Dose MenACWY,,States/Local Areas,Maryland,2008,Age,13-15 Years,56.1,48.1 to 63.8,253
≥1 Dose MenACWY,,States/Local Areas,Maryland,2009,Age,13-15 Years,61.0,50.0 to 71.0,144
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2009,Age,13-17 Years,80.2,72.5 to 86.2,245
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Maryland,2008,Age,13-17 Years,79.0,73.0 to 83.9,394
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2011,Age,13-17 Years,36.3,29.1 to 44.2,255
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2010,Age,13-17 Years,37.5,28.8 to 47.0,140
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2009,Age,13-17 Years,31.8,21.8 to 43.8,110
≥1 Dose MenACWY,,States/Local Areas,Maryland,2020,Age,13-15 Years,93.7,90.5 to 95.9,533
HPV,"≥1 Dose, Males",States/Local Areas,Maryland,2022,Age,13-17 Years,82.5,72.2 to 89.5,185
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2022,Age,13-17 Years,84.0,77.0 to 89.2,346
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2021,Age,13-17 Years,85.5,82.1 to 88.4,857
HPV,"≥1 Dose, Males and Females",States/Local Areas,Maryland,2020,Age,13-17 Years,83.1,79.2 to 86.5,815
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2017,Age,13-17 Years,62.8,52.1 to 72.3,221
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2016,Age,13-17 Years,55.6,46.4 to 64.5,213
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2015,Age,13-17 Years,61.7,52.3 to 70.3,203
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2014,Age,13-17 Years,52.6,42.7 to 62.4,192
≥1 Dose MenACWY,,States/Local Areas,Maryland,2021,Age,13-15 Years,93.0,89.7 to 95.3,572
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2018,Age,13-17 Years,63.5,53.7 to 72.3,185
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2012,Age,13-15 Years,78.5,70.1 to 85.0,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2011,Age,13-15 Years,71.1,63.5 to 77.6,307
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2008,Age,13-15 Years,45.8,38.0 to 53.7,253
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2010,Age,13-15 Years,67.1,58.2 to 75.0,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2009,Age,13-15 Years,61.9,50.9 to 71.8,144
HPV,"≥2 Doses, Females",States/Local Areas,Maryland,2019,Age,13-17 Years,70.7,61.3 to 78.6,261
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2017,Age,13-15 Years,91.1,83.8 to 95.3,311
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2016,Age,13-15 Years,87.7,81.4 to 92.1,305
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2015,Age,13-15 Years,88.5,81.7 to 93.0,257
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2014,Age,13-15 Years,84.6,76.3 to 90.4,245
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2012,Age,13-17 Years,13.8,8.6 to 21.4,177
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2014,Age,13-17 Years,37.3,28.4 to 47.1,217
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2013,Age,13-17 Years,23.1,15.4 to 33.2,172
≥1 Dose MenACWY,,States/Local Areas,Maryland,2022,Age,13-17 Years,92.4,86.4 to 95.9,346
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2018,Age,13-17 Years,60.0,50.2 to 69.0,208
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2017,Age,13-17 Years,52.9,42.5 to 63.1,249
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2016,Age,13-17 Years,53.2,44.0 to 62.1,238
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2015,Age,13-17 Years,46.6,37.3 to 56.1,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2013,Age,13-15 Years,82.8,73.7 to 89.3,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2019,Age,13-15 Years,90.4,84.2 to 94.3,335
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2020,Age,13-15 Years,89.4,85.1 to 92.6,533
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2021,Age,13-15 Years,89.7,85.9 to 92.6,572
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2018,Age,13-15 Years,93.2,88.2 to 96.2,252
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2012,Age,13-15 Years,24.5,15.4 to 36.7,85
HPV,"≥3 Doses, Females",States/Local Areas,Maryland,2011,Age,13-15 Years,24.6,17.2 to 33.8,155
≥2 Doses MMR,,States/Local Areas,Maryland,2022,Age,13-17 Years,92.0,85.9 to 95.5,346
≥2 Doses MMR,,States/Local Areas,Maryland,2021,Age,13-17 Years,94.8,92.4 to 96.4,857
≥1 Dose MenACWY,,States/Local Areas,Maryland,2019,Age,13-17 Years,94.9,91.4 to 97.0,524
≥1 Dose MenACWY,,States/Local Areas,Maryland,2018,Age,13-17 Years,91.8,87.0 to 94.9,393
≥1 Dose MenACWY,,States/Local Areas,Maryland,2021,Age,13-17 Years,93.7,91.1 to 95.5,857
≥1 Dose MenACWY,,States/Local Areas,Maryland,2020,Age,13-17 Years,94.0,91.4 to 95.8,815
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2017,Age,13-17 Years,57.5,46.8 to 67.6,221
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2019,Age,13-17 Years,68.6,59.1 to 76.8,261
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2018,Age,13-17 Years,60.9,51.0 to 70.0,185
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2018,Age,13-15 Years,50.5,38.4 to 62.6,130
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2022,Age,13-17 Years,78.6,67.9 to 86.5,161
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2021,Age,13-17 Years,73.8,67.4 to 79.4,389
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2019,Age,13-15 Years,66.4,54.7 to 76.4,166
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2022,Age,13-15 Years,73.0,57.8 to 84.3,102
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2021,Age,13-15 Years,70.1,61.9 to 77.2,261
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2016,Age,13-17 Years,51.8,42.6 to 60.9,213
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2020,Age,13-15 Years,61.1,52.4 to 69.2,281
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2019,Age,13-17 Years,69.1,60.2 to 76.8,263
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2020,Age,13-17 Years,62.5,55.5 to 69.0,429
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2017,Age,13-17 Years,48.4,38.2 to 58.8,249
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2018,Age,13-17 Years,55.4,45.8 to 64.7,208
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2022,Age,13-15 Years,68.8,58.3 to 77.7,213
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2019,Age,13-15 Years,64.5,56.3 to 72.0,335
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2022,Age,13-17 Years,65.7,54.2 to 75.6,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2021,Age,13-15 Years,67.9,62.2 to 73.1,572
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2020,Age,13-15 Years,65.3,59.2 to 70.9,533
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2016,Age,13-17 Years,44.5,35.6 to 53.7,238
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2022,Age,13-15 Years,64.6,49.8 to 77.0,111
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2021,Age,13-15 Years,65.6,57.4 to 72.9,311
HPV,"Up-to-Date, Males",States/Local Areas,Maryland,2021,Age,13-17 Years,70.2,63.9 to 75.8,468
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2019,Age,13-15 Years,62.7,50.9 to 73.2,169
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2020,Age,13-15 Years,69.6,61.2 to 76.9,252
Varicella,History of disease,States/Local Areas,Maryland,2014,Age,13-17 Years,8.2,5.3 to 12.4,409
Varicella,History of disease,States/Local Areas,Maryland,2012,Age,13-17 Years,22.6,16.8 to 29.7,325
Varicella,History of disease,States/Local Areas,Maryland,2013,Age,13-17 Years,15.3,10.6 to 21.7,320
Varicella,History of disease,States/Local Areas,Maryland,2011,Age,13-17 Years,30.3,25.5 to 35.6,516
Varicella,History of disease,States/Local Areas,Maryland,2010,Age,13-17 Years,34.3,28.3 to 40.8,338
Varicella,History of disease,States/Local Areas,Maryland,2015,Age,13-17 Years,18.5,13.6 to 24.5,403
Varicella,History of disease,States/Local Areas,Maryland,2018,Age,13-17 Years,10.4,6.8 to 15.7,393
Varicella,History of disease,States/Local Areas,Maryland,2016,Age,13-17 Years,11.3,7.7 to 16.3,451
Varicella,History of disease,States/Local Areas,Maryland,2017,Age,13-17 Years,12.7,8.5 to 18.7,470
Varicella,History of disease,States/Local Areas,Maryland,2021,Age,13-17 Years,5.0,3.4 to 7.2,857
Varicella,History of disease,States/Local Areas,Maryland,2020,Age,13-17 Years,7.5,5.2 to 10.8,815
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2020,Age,13-17 Years,71.3,64.5 to 77.2,386
HPV,"Up-to-Date, Females",States/Local Areas,Maryland,2018,Age,13-15 Years,50.0,38.0 to 62.1,122
Varicella,History of disease,States/Local Areas,Maryland,2019,Age,13-17 Years,7.5,4.8 to 11.6,524
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2018,Age,13-17 Years,58.1,51.2 to 64.7,393
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2017,Age,13-17 Years,52.9,45.4 to 60.2,470
Varicella,History of disease,States/Local Areas,Maryland,2009,Age,13-17 Years,46.2,38.4 to 54.2,245
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2019,Age,13-17 Years,68.9,62.5 to 74.6,524
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2012,Age,13-17 Years,78.1,70.8 to 84.0,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2014,Age,13-17 Years,85.0,78.9 to 89.6,409
Tetanus,≥1 Dose Tdap,States/Local Areas,Maryland,2013,Age,13-17 Years,83.2,76.0 to 88.6,320
HPV,"≥2 Doses, Males",States/Local Areas,Maryland,2019,Age,13-17 Years,72.1,63.2 to 79.5,263
HPV,"Up-to-Date, Males and Females",States/Local Areas,Maryland,2016,Age,13-17 Years,48.1,41.6 to 54.6,451
Varicella,History of disease,States/Local Areas,Maryland,2008,Age,13-17 Years,53.7,47.3 to 59.9,394
Varicella,History of disease,States/Local Areas,New Mexico,2012,Age,13-17 Years,30.6,24.4 to 37.7,331
Varicella,History of disease,States/Local Areas,New Mexico,2013,Age,13-17 Years,24.1,19.1 to 29.8,357
Varicella,History of disease,States/Local Areas,New Mexico,2011,Age,13-17 Years,39.5,33.4 to 46.0,431
Varicella,History of disease,States/Local Areas,New Mexico,2010,Age,13-17 Years,51.2,45.0 to 57.4,332
Varicella,History of disease,States/Local Areas,New Mexico,2009,Age,13-17 Years,50.5,44.9 to 56.1,406
Varicella,History of disease,States/Local Areas,New Mexico,2017,Age,13-17 Years,13.4,9.4 to 18.8,362
Varicella,History of disease,States/Local Areas,New Mexico,2016,Age,13-17 Years,16.3,12.3 to 21.2,374
Varicella,History of disease,States/Local Areas,New Mexico,2015,Age,13-17 Years,16.2,12.5 to 20.7,396
Varicella,History of disease,States/Local Areas,New Mexico,2008,Age,13-17 Years,58.5,51.8 to 64.9,310
Varicella,History of disease,States/Local Areas,New Mexico,2014,Age,13-17 Years,24.7,19.5 to 30.8,378
Varicella,History of disease,States/Local Areas,New Mexico,2018,Age,13-17 Years,11.8,8.0 to 17.0,295
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2019,Age,13-15 Years,49.4,38.8 to 60.1,136
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2020,Age,13-15 Years,58.5,46.8 to 69.3,91
HPV,"Up-to-Date, Females",States/Local Areas,New Mexico,2018,Age,13-15 Years,49.7,37.2 to 62.2,87
Varicella,History of disease,States/Local Areas,New Mexico,2019,Age,13-17 Years,10.8,7.3 to 15.8,405
Varicella,History of disease,States/Local Areas,New Mexico,2020,Age,13-17 Years,7.9,5.2 to 11.8,352
Varicella,History of disease,States/Local Areas,New Mexico,2021,Age,13-17 Years,8.2,5.0 to 13.1,337
Varicella,History of disease,States/Local Areas,New Mexico,2022,Age,13-17 Years,6.3,3.5 to 11.2,276
HPV,"≥1 Dose, Males",States/Local Areas,North Carolina,2023,Age,13-17 Years,77.6,67.8 to 85.0,193
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Carolina,2022,Age,13-17 Years,57.3,50.3 to 64.0,361
HPV,"≥2 Doses, Males",States/Local Areas,North Carolina,2022,Age,13-17 Years,58.3,48.6 to 67.4,186
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2023,Age,13-17 Years,64.4,52.7 to 74.6,140
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2023,Age,13-15 Years,95.7,88.5 to 98.4,193
HPV,"Up-to-Date, Females",States/Local Areas,North Carolina,2023,Age,13-15 Years,64.3,49.9 to 76.5,97
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2023,Age,13-15 Years,61.2,51.3 to 70.2,215
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2023,Age,13-15 Years,91.9,84.6 to 95.9,215
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2023,Age,13-15 Years,92.6,85.6 to 96.4,215
≥2 Doses Hep A,,States/Local Areas,North Carolina,2023,Age,13-17 Years,89.9,84.4 to 93.6,333
Varicella,≥2 Doses or history of disease,States/Local Areas,North Carolina,2023,Age,13-17 Years,93.8,88.5 to 96.7,333
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2023,Age,13-15 Years,58.0,44.4 to 70.5,118
≥3 Doses HepB,,States/Local Areas,North Carolina,2023,Age,13-17 Years,92.8,87.3 to 96.1,333
Varicella,History of disease,States/Local Areas,North Carolina,2023,Age,13-17 Years,9.0,5.3 to 15.0,333
Varicella,≥1 Dose with no disease history,States/Local Areas,North Carolina,2023,Age,13-17 Years,97.9,95.6 to 99.0,306
Varicella,≥2 Doses with no disease history,States/Local Areas,North Carolina,2023,Age,13-17 Years,93.2,87.5 to 96.4,306
HPV,"Up-to-Date, Males",States/Local Areas,North Carolina,2023,Age,13-17 Years,62.7,52.3 to 72.0,193
≥2 Doses MMR,,States/Local Areas,North Carolina,2023,Age,13-17 Years,96.1,92.1 to 98.1,333
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2023,Age,13-17 Years,63.5,55.8 to 70.6,333
HPV,"≥1 Dose, Females",States/Local Areas,North Carolina,2023,Age,13-17 Years,70.7,58.9 to 80.3,140
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2023,Age,13-17 Years,74.2,66.7 to 80.5,333
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2023,Age,13-17 Years,91.7,86.3 to 95.1,333
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Carolina,2023,Age,13-17 Years,90.3,84.1 to 94.2,333
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2023,Age,13-17 Years,89.7,83.6 to 93.7,333
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a Non-MSA,92.0,86.2 to 95.5,238
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Overall,Overall,57.0,53.8 to 60.2,1600
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a Non-MSA,75.6,68.0 to 81.8,238
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.5,70.0 to 78.5,672
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,76.7,72.3 to 80.7,690
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,55.7,50.7 to 60.5,672
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a Non-MSA,61.8,53.5 to 69.5,238
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,56.7,51.7 to 61.5,690
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a Non-MSA,91.2,85.7 to 94.7,238
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.9,90.0 to 95.0,672
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,91.4,88.1 to 93.9,690
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,92.2,89.0 to 94.5,672
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,91.6,88.3 to 94.0,690
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",57.5,53.5 to 61.4,994
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.7,86.6 to 96.1,187
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,Hispanic,81.3,73.7 to 87.1,223
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",82.0,74.3 to 87.7,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",52.4,44.1 to 60.6,196
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",64.4,55.1 to 72.6,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,Hispanic,56.9,48.6 to 64.9,223
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",92.6,87.5 to 95.8,196
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.7,90.2 to 94.6,994
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.5,91.2 to 95.2,994
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,Hispanic,88.3,80.9 to 93.0,223
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.1,85.3 to 94.7,196
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.5,82.8 to 94.9,187
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,Hispanic,88.9,82.1 to 93.4,223
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",73.1,69.4 to 76.5,994
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Poverty,Below Poverty Level,80.9,73.7 to 86.5,223
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",74.6,66.7 to 81.1,196
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Poverty,Living At or Above Poverty Level,74.2,71.0 to 77.2,1329
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Poverty,Below Poverty Level,91.7,85.9 to 95.3,223
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Poverty,Living At or Above Poverty Level,91.9,89.7 to 93.7,1329
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Poverty,Below Poverty Level,55.5,47.2 to 63.6,223
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Poverty,Living At or Above Poverty Level,57.3,53.7 to 60.8,1329
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Poverty,Living At or Above Poverty Level,92.6,90.4 to 94.3,1329
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Poverty,Below Poverty Level,88.5,81.9 to 92.9,223
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Any Medicaid,92.2,88.7 to 94.7,471
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Private Insurance Only,92.3,89.4 to 94.5,906
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Private Insurance Only,75.5,71.5 to 79.1,906
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Any Medicaid,77.6,72.6 to 81.8,471
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Other,89.5,81.8 to 94.2,153
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Other,68.6,57.8 to 77.7,153
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Private Insurance Only,57.5,53.2 to 61.7,906
≥1 Dose MenACWY,,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Uninsured,90.5,77.7 to 96.4,70
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Uninsured,76.4,62.7 to 86.2,70
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Any Medicaid,59.9,54.2 to 65.3,471
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Other,53.8,42.8 to 64.5,153
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Uninsured,35.5,21.4 to 52.6,70
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Private Insurance Only,92.3,89.4 to 94.4,906
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Any Medicaid,91.3,87.5 to 94.1,471
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Other,93.2,87.6 to 96.4,153
Tetanus,≥1 Dose Tdap,States/Local Areas,North Carolina,2018-2022,Insurance Coverage,Uninsured,89.6,77.0 to 95.7,70
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2012,Age,13-15 Years,59.8,48.9 to 69.8,152
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2013,Age,13-15 Years,62.5,52.2 to 71.8,152
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2011,Age,13-15 Years,53.8,43.1 to 64.2,164
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2010,Age,13-15 Years,37.9,28.8 to 48.0,129
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2009,Age,13-15 Years,26.4,17.9 to 37.0,106
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2015,Age,13-15 Years,70.9,62.8 to 77.8,193
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2014,Age,13-15 Years,61.9,52.7 to 70.3,201
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2017,Age,13-15 Years,79.7,71.5 to 86.1,196
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2016,Age,13-15 Years,78.8,69.6 to 85.9,149
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2010,Age,13-17 Years,63.6,56.9 to 69.8,317
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2009,Age,13-17 Years,60.2,53.2 to 66.9,299
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2012,Age,13-17 Years,71.6,64.5 to 77.7,310
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2011,Age,13-17 Years,68.1,60.9 to 74.6,362
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2013,Age,13-17 Years,68.5,61.4 to 74.8,296
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2020,Age,13-17 Years,90.8,85.4 to 94.3,311
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2021,Age,13-17 Years,95.4,92.0 to 97.4,263
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2022,Age,13-17 Years,93.3,88.0 to 96.3,269
HPV,"≥3 Doses, Males",States/Local Areas,South Carolina,2015,Age,13-15 Years,25.4,16.8 to 36.4,122
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2019,Age,13-17 Years,92.3,88.1 to 95.0,319
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2017,Age,13-17 Years,81.2,75.3 to 86.0,328
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2018,Age,13-17 Years,87.0,82.3 to 90.6,318
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2016,Age,13-17 Years,77.0,70.6 to 82.3,314
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2008,Age,13-17 Years,63.4,57.5 to 68.9,367
HPV,"≥3 Doses, Males",States/Local Areas,South Carolina,2015,Age,13-17 Years,21.0,14.5 to 29.5,188
HPV,"≥3 Doses, Males",States/Local Areas,South Carolina,2014,Age,13-17 Years,16.1,10.4 to 24.1,187
≥2 Doses Hep A,,States/Local Areas,South Carolina,2021,Age,13-17 Years,68.4,60.9 to 75.2,263
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2015,Age,13-17 Years,34.3,26.4 to 43.3,172
≥2 Doses Hep A,,States/Local Areas,South Carolina,2020,Age,13-17 Years,52.4,45.5 to 59.2,311
≥2 Doses Hep A,,States/Local Areas,South Carolina,2022,Age,13-17 Years,80.9,74.1 to 86.3,269
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2012,Age,13-17 Years,26.6,18.2 to 37.0,153
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2011,Age,13-17 Years,23.3,15.8 to 32.9,161
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2013,Age,13-17 Years,40.7,30.9 to 51.4,145
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2014,Age,13-17 Years,35.9,27.4 to 45.5,193
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2008,Age,13-17 Years,13.8,9.0 to 20.7,183
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2009,Age,13-17 Years,16.6,11.1 to 24.1,148
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2010,Age,13-17 Years,29.5,21.5 to 39.0,164
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Carolina,2016,Age,13-17 Years,33.6,27.5 to 40.3,314
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2022,Age,13-17 Years,92.9,87.3 to 96.1,257
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2020,Age,13-17 Years,69.3,59.8 to 77.4,144
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2021,Age,13-17 Years,77.8,68.2 to 85.2,123
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2022,Age,13-17 Years,75.5,64.3 to 84.0,135
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2019,Age,13-17 Years,68.0,58.7 to 76.0,168
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2020,Age,13-17 Years,70.9,61.8 to 78.6,167
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2021,Age,13-17 Years,85.6,78.4 to 90.7,140
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Carolina,2018,Age,13-17 Years,45.1,38.5 to 51.9,318
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2019,Age,13-17 Years,75.7,66.6 to 82.9,151
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Carolina,2017,Age,13-17 Years,47.3,40.5 to 54.1,328
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2013,Age,13-17 Years,22.2,14.5 to 32.5,151
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2014,Age,13-17 Years,29.4,21.6 to 38.5,187
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2015,Age,13-17 Years,35.1,27.4 to 43.8,188
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2016,Age,13-17 Years,38.2,29.7 to 47.5,169
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2018,Age,13-17 Years,60.7,51.3 to 69.4,159
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2017,Age,13-17 Years,59.3,49.9 to 68.1,174
HPV,"≥2 Doses, Males and Females",States/Local Areas,South Carolina,2019,Age,13-17 Years,55.6,48.6 to 62.3,319
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2009,Age,13-17 Years,28.5,21.0 to 37.4,148
≥3 Doses HepB,,States/Local Areas,South Carolina,2012,Age,13-17 Years,92.9,88.1 to 95.9,310
≥3 Doses HepB,,States/Local Areas,South Carolina,2011,Age,13-17 Years,95.2,91.2 to 97.5,362
≥3 Doses HepB,,States/Local Areas,South Carolina,2013,Age,13-17 Years,94.2,90.0 to 96.7,296
≥3 Doses HepB,,States/Local Areas,South Carolina,2014,Age,13-17 Years,93.3,89.6 to 95.8,380
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2012,Age,13-17 Years,58.3,49.5 to 66.5,218
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2008,Age,13-17 Years,18.7,13.2 to 25.9,183
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2010,Age,13-17 Years,32.3,25.0 to 40.7,172
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2011,Age,13-17 Years,49.7,40.9 to 58.5,230
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2008,Age,13-17 Years,61.0,51.3 to 69.9,146
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2010,Age,13-17 Years,81.9,73.2 to 88.3,172
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2009,Age,13-17 Years,76.4,64.6 to 85.1,142
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2009,Age,13-17 Years,19.9,13.6 to 28.1,142
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2011,Age,13-17 Years,93.8,87.0 to 97.2,230
≥3 Doses HepB,,States/Local Areas,South Carolina,2008,Age,13-17 Years,92.0,88.4 to 94.5,367
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2019,Age,13-17 Years,97.5,95.1 to 98.7,300
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2012,Age,13-17 Years,92.8,87.0 to 96.1,218
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2022,Age,13-15 Years,91.6,82.5 to 96.1,149
≥3 Doses HepB,,States/Local Areas,South Carolina,2010,Age,13-17 Years,95.3,92.3 to 97.2,317
≥3 Doses HepB,,States/Local Areas,South Carolina,2009,Age,13-17 Years,91.5,87.0 to 94.5,299
≥3 Doses HepB,,States/Local Areas,South Carolina,2017,Age,13-17 Years,92.3,88.1 to 95.1,328
≥3 Doses HepB,,States/Local Areas,South Carolina,2018,Age,13-17 Years,93.0,88.6 to 95.8,318
≥3 Doses HepB,,States/Local Areas,South Carolina,2019,Age,13-17 Years,96.3,93.1 to 98.0,319
≥3 Doses HepB,,States/Local Areas,South Carolina,2016,Age,13-17 Years,90.8,86.0 to 94.1,314
≥3 Doses HepB,,States/Local Areas,South Carolina,2015,Age,13-17 Years,91.8,87.8 to 94.6,360
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2018,Age,13-17 Years,94.8,90.7 to 97.2,289
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2019,Age,13-17 Years,91.8,87.3 to 94.7,300
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2020,Age,13-17 Years,90.1,84.4 to 93.9,289
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2021,Age,13-17 Years,95.2,91.6 to 97.3,249
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2018,Age,13-17 Years,85.4,80.2 to 89.4,289
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2020,Age,13-17 Years,95.9,91.6 to 98.0,289
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2017,Age,13-17 Years,93.7,89.4 to 96.4,296
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2013,Age,13-17 Years,95.8,92.1 to 97.8,226
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2014,Age,13-17 Years,94.5,90.4 to 96.9,309
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2015,Age,13-17 Years,95.1,91.1 to 97.3,289
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2016,Age,13-17 Years,92.1,87.1 to 95.3,259
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2012,Age,13-17 Years,41.9,31.8 to 52.7,153
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2013,Age,13-17 Years,60.4,50.4 to 69.6,145
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2014,Age,13-17 Years,52.1,42.6 to 61.5,193
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2011,Age,13-17 Years,38.7,28.7 to 49.7,161
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2010,Age,13-17 Years,41.5,32.6 to 51.0,164
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2017,Age,13-17 Years,79.0,72.5 to 84.2,296
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2013,Age,13-17 Years,58.6,50.3 to 66.5,226
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2014,Age,13-17 Years,60.0,52.6 to 66.9,309
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2015,Age,13-17 Years,68.6,61.9 to 74.6,289
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2016,Age,13-17 Years,72.9,65.6 to 79.1,259
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2020,Age,13-15 Years,93.6,86.6 to 97.1,196
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2021,Age,13-15 Years,94.9,90.0 to 97.4,166
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2015,Age,13-17 Years,74.5,68.7 to 79.5,360
Varicella,≥2 Doses or history of disease,States/Local Areas,South Carolina,2014,Age,13-17 Years,66.8,60.2 to 72.7,380
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2018,Age,13-15 Years,88.2,81.9 to 92.5,187
Varicella,≥2 Doses with no disease history,States/Local Areas,South Carolina,2019,Age,13-15 Years,92.5,87.0 to 95.8,186
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2013,Age,13-17 Years,74.6,67.6 to 80.5,296
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2017,Age,13-17 Years,59.8,50.0 to 68.9,154
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2016,Age,13-17 Years,50.5,40.2 to 60.7,145
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2015,Age,13-17 Years,53.7,44.7 to 62.4,172
≥3 Doses HepB,,States/Local Areas,South Carolina,2022,Age,13-17 Years,95.2,90.3 to 97.7,269
HPV,"≥1 Dose, Females",States/Local Areas,South Carolina,2018,Age,13-17 Years,66.7,57.1 to 75.0,159
≥3 Doses HepB,,States/Local Areas,South Carolina,2020,Age,13-17 Years,95.4,91.3 to 97.6,311
≥3 Doses HepB,,States/Local Areas,South Carolina,2021,Age,13-17 Years,95.0,90.6 to 97.3,263
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2022,Age,13-17 Years,97.2,93.9 to 98.8,257
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2012,Age,13-17 Years,18.1,10.9 to 28.7,157
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2015,Age,13-15 Years,72.8,65.4 to 79.2,223
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2014,Age,13-15 Years,67.3,58.9 to 74.6,236
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2016,Age,13-17 Years,81.8,75.6 to 86.7,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2014,Age,13-17 Years,74.8,68.3 to 80.4,380
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2015,Age,13-17 Years,82.4,76.6 to 86.9,360
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2012,Age,13-15 Years,54.6,45.2 to 63.6,197
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2013,Age,13-15 Years,71.9,63.2 to 79.2,187
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2012,Age,13-17 Years,31.6,22.7 to 42.1,153
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2013,Age,13-17 Years,53.0,42.9 to 62.9,145
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2008,Age,13-17 Years,17.3,11.9 to 24.3,183
Varicella,≥1 Dose with no disease history,States/Local Areas,South Carolina,2021,Age,13-17 Years,98.2,95.5 to 99.3,249
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2016,Age,13-15 Years,68.2,58.8 to 76.3,175
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2017,Age,13-15 Years,78.2,70.0 to 84.7,209
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018,Age,13-15 Years,74.6,66.5 to 81.3,204
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2019,Age,13-15 Years,82.0,74.2 to 87.9,195
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2017,Age,13-17 Years,90.3,85.5 to 93.6,328
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2017,Age,13-17 Years,59.6,52.7 to 66.0,328
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2016,Age,13-17 Years,44.2,37.4 to 51.3,314
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2011,Age,13-15 Years,60.8,52.2 to 68.7,229
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2010,Age,13-15 Years,50.4,42.1 to 58.6,197
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2008,Age,13-17 Years,53.7,47.8 to 59.5,367
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2009,Age,13-17 Years,52.7,45.8 to 59.5,299
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2010,Age,13-17 Years,34.9,26.4 to 44.5,164
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2011,Age,13-17 Years,30.7,21.9 to 41.1,161
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2009,Age,13-17 Years,21.8,15.3 to 30.0,148
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2020,Age,13-15 Years,80.5,72.7 to 86.5,211
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2012,Age,13-17 Years,67.9,60.5 to 74.5,310
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2010,Age,13-17 Years,60.1,53.5 to 66.4,317
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2011,Age,13-17 Years,67.0,60.0 to 73.4,362
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2018,Age,13-17 Years,90.9,86.4 to 94.0,318
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2019,Age,13-17 Years,93.2,89.3 to 95.8,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2020,Age,13-17 Years,90.9,85.3 to 94.4,311
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2009,Age,13-15 Years,36.1,28.6 to 44.4,180
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2008,Age,13-15 Years,27.0,20.7 to 34.5,237
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2019,Age,13-17 Years,71.8,65.4 to 77.4,319
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018,Age,13-17 Years,63.7,57.0 to 69.8,318
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2021,Age,13-17 Years,94.1,89.8 to 96.6,263
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2017,Age,13-17 Years,54.3,44.7 to 63.6,154
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2016,Age,13-17 Years,37.0,27.9 to 47.1,145
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2015,Age,13-17 Years,43.3,34.6 to 52.3,172
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2014,Age,13-17 Years,46.5,37.2 to 56.0,193
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2020,Age,13-17 Years,70.1,63.7 to 75.9,311
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2021,Age,13-17 Years,81.8,75.9 to 86.5,263
HPV,"≥1 Dose, Males",States/Local Areas,South Carolina,2022,Age,13-17 Years,64.5,53.9 to 73.9,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2022,Age,13-17 Years,69.9,62.3 to 76.6,269
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2021,Age,13-15 Years,85.4,77.5 to 90.8,174
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2018,Age,13-17 Years,48.6,39.3 to 58.1,159
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2019,Age,13-17 Years,60.7,50.6 to 70.0,151
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2012,Age,13-15 Years,65.2,55.7 to 73.7,197
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2011,Age,13-15 Years,64.5,55.9 to 72.3,229
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2009,Age,13-15 Years,41.7,33.6 to 50.2,180
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2010,Age,13-15 Years,56.3,48.0 to 64.4,197
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2008,Age,13-15 Years,33.0,26.4 to 40.3,237
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,South Carolina,2022,Age,13-17 Years,93.8,88.6 to 96.7,269
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2017,Age,13-15 Years,90.5,84.3 to 94.4,209
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2016,Age,13-15 Years,81.3,72.4 to 87.8,175
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2015,Age,13-15 Years,84.3,77.7 to 89.2,223
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2014,Age,13-15 Years,77.5,69.4 to 83.9,236
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2018,Age,13-17 Years,41.7,32.6 to 51.3,159
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2017,Age,13-17 Years,40.4,31.4 to 50.2,174
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2016,Age,13-17 Years,30.3,22.6 to 39.4,169
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2013,Age,13-15 Years,74.2,65.0 to 81.6,187
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2012,Age,13-17 Years,15.9,9.1 to 26.3,157
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2013,Age,13-17 Years,13.1,7.7 to 21.4,151
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2014,Age,13-17 Years,22.5,15.7 to 31.3,187
≥2 Doses MMR,,States/Local Areas,South Carolina,2021,Age,13-17 Years,95.3,91.9 to 97.3,263
≥2 Doses MMR,,States/Local Areas,South Carolina,2022,Age,13-17 Years,94.9,90.0 to 97.5,269
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2011,Age,13-15 Years,24.2,15.3 to 36.1,108
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2010,Age,13-15 Years,30.4,20.6 to 42.4,104
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2009,Age,13-15 Years,10.9,6.2 to 18.4,91
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2008,Age,13-15 Years,13.2,7.3 to 22.5,114
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018,Age,13-17 Years,79.7,74.0 to 84.4,318
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2019,Age,13-17 Years,86.4,81.2 to 90.4,319
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2020,Age,13-17 Years,78.7,72.5 to 83.8,311
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2022,Age,13-17 Years,85.3,79.0 to 89.9,269
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2021,Age,13-17 Years,86.3,80.6 to 90.5,263
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2015,Age,13-17 Years,26.4,19.4 to 34.8,188
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2019,Age,13-15 Years,91.9,86.4 to 95.3,195
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2020,Age,13-15 Years,90.6,83.0 to 95.0,211
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2021,Age,13-15 Years,91.2,84.4 to 95.2,174
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018,Age,13-15 Years,86.6,79.7 to 91.4,204
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2010,Age,13-17 Years,44.7,38.3 to 51.2,317
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2011,Age,13-17 Years,55.4,48.4 to 62.2,362
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2008,Age,13-17 Years,25.1,20.1 to 30.8,367
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2009,Age,13-17 Years,34.5,28.6 to 40.9,299
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2016,Age,13-17 Years,77.5,70.7 to 83.1,314
≥2 Doses MMR,,States/Local Areas,South Carolina,2016,Age,13-17 Years,89.9,85.3 to 93.2,314
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Carolina,2011,Age,13-17 Years,11.8,8.1 to 17.1,362
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2013,Age,13-17 Years,68.7,61.7 to 74.9,296
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2014,Age,13-17 Years,67.3,60.7 to 73.3,380
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2015,Age,13-17 Years,69.0,62.8 to 74.6,360
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2016,Age,13-17 Years,68.9,61.9 to 75.2,314
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018,Age,13-17 Years,88.9,84.1 to 92.3,318
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2017,Age,13-17 Years,89.4,84.5 to 92.8,328
≥2 Doses MMR,,States/Local Areas,South Carolina,2014,Age,13-17 Years,85.8,80.4 to 90.0,380
≥2 Doses MMR,,States/Local Areas,South Carolina,2015,Age,13-17 Years,89.5,84.8 to 92.8,360
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2022,Age,13-17 Years,93.6,88.4 to 96.5,269
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2012,Age,13-17 Years,58.5,51.0 to 65.6,310
≥2 Doses MMR,,States/Local Areas,South Carolina,2012,Age,13-17 Years,90.1,85.0 to 93.6,310
≥2 Doses MMR,,States/Local Areas,South Carolina,2013,Age,13-17 Years,91.0,86.5 to 94.2,296
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2019,Age,13-17 Years,91.9,87.9 to 94.7,319
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2020,Age,13-17 Years,89.2,83.6 to 93.0,311
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2021,Age,13-17 Years,91.1,86.1 to 94.4,263
≥2 Doses MMR,,States/Local Areas,South Carolina,2018,Age,13-17 Years,92.5,88.1 to 95.4,318
≥2 Doses MMR,,States/Local Areas,South Carolina,2017,Age,13-17 Years,89.9,84.9 to 93.4,328
≥2 Doses MMR,,States/Local Areas,South Carolina,2019,Age,13-17 Years,94.7,91.2 to 96.8,319
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2013,Age,13-15 Years,36.2,24.3 to 50.1,91
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2015,Age,13-15 Years,34.2,24.1 to 46.0,101
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2014,Age,13-15 Years,33.4,23.4 to 45.3,122
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Carolina,2012,Age,13-17 Years,16.1,11.5 to 22.2,310
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Carolina,2013,Age,13-17 Years,23.3,17.4 to 30.4,296
≥2 Doses MMR,,States/Local Areas,South Carolina,2020,Age,13-17 Years,92.3,87.4 to 95.4,311
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Carolina,2015,Age,13-17 Years,27.6,22.3 to 33.6,360
HPV,"≥3 Doses, Males and Females",States/Local Areas,South Carolina,2014,Age,13-17 Years,25.8,20.4 to 32.0,380
HPV,"≥3 Doses, Females",States/Local Areas,South Carolina,2012,Age,13-15 Years,28.3,17.9 to 41.7,102
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2017,Age,13-17 Years,78.6,72.4 to 83.7,328
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Overall,Overall,71.5,68.6 to 74.3,1480
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Overall,Overall,51.7,48.5 to 54.8,1480
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a Non-MSA,94.4,88.4 to 97.4,163
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,75.6,70.8 to 79.9,512
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,69.3,65.2 to 73.0,805
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a Non-MSA,67.7,58.1 to 76.0,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,50.2,45.9 to 54.5,805
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a Non-MSA,44.8,35.2 to 54.8,163
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,55.5,50.0 to 60.8,512
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,82.6,79.2 to 85.5,805
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a Non-MSA,76.9,68.1 to 83.9,163
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,85.9,81.7 to 89.3,512
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.6,86.7 to 91.9,805
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Urbanicity,Living In a MSA Principal City,91.9,88.5 to 94.4,512
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.1,44.3 to 52.0,987
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",85.1,75.4 to 91.4,94
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",74.9,62.9 to 84.0,94
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,Hispanic,82.0,74.4 to 87.7,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",55.3,48.4 to 62.1,249
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",55.1,43.0 to 66.6,94
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,Hispanic,58.1,48.0 to 67.6,150
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",83.8,78.0 to 88.2,249
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",82.0,78.9 to 84.7,987
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.5,88.1 to 92.5,987
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.6,85.6 to 94.0,249
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,Hispanic,88.4,81.2 to 93.1,150
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",90.6,82.8 to 95.1,94
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,Hispanic,95.0,88.2 to 97.9,150
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.2,64.6 to 71.6,987
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",73.5,66.9 to 79.2,249
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Poverty,Living At or Above Poverty Level,70.0,66.7 to 73.1,1214
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Poverty,Below Poverty Level,76.7,69.5 to 82.6,221
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Poverty,Below Poverty Level,81.8,74.5 to 87.3,221
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Poverty,Below Poverty Level,57.1,49.2 to 64.6,221
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Poverty,Living At or Above Poverty Level,83.6,81.0 to 85.9,1214
≥3 Doses HepB,,HHS Regions/National,Region 8,2016,Age,13-17 Years,89.1,86.4 to 91.3,2022
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Poverty,Living At or Above Poverty Level,49.8,46.3 to 53.3,1214
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Poverty,Below Poverty Level,92.0,85.7 to 95.6,221
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Any Medicaid,84.2,80.1 to 87.7,523
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Poverty,Living At or Above Poverty Level,90.3,88.1 to 92.1,1214
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Private Insurance Only,83.5,80.2 to 86.4,805
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Other,83.5,73.1 to 90.4,98
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Any Medicaid,75.8,71.1 to 80.0,523
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Private Insurance Only,69.0,64.9 to 72.7,805
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Uninsured,64.2,49.4 to 76.8,54
HPV,"≥1 Dose, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Other,63.5,50.5 to 74.7,98
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Uninsured,68.6,53.8 to 80.4,54
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Any Medicaid,54.8,49.6 to 59.9,523
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Private Insurance Only,51.3,47.0 to 55.5,805
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Other,41.2,29.5 to 53.9,98
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Uninsured,33.6,20.9 to 49.3,54
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Private Insurance Only,91.9,89.3 to 93.8,805
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Any Medicaid,90.9,87.4 to 93.5,523
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Uninsured,88.3,75.1 to 94.9,54
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2018-2022,Insurance Coverage,Other,86.0,75.3 to 92.6,98
HPV,"≥2 Doses, Females",States/Local Areas,South Carolina,2022,Age,13-17 Years,66.0,55.0 to 75.6,135
≥1 Dose MenACWY,,States/Local Areas,South Carolina,2022,Age,13-15 Years,84.5,75.4 to 90.6,155
Varicella,History of disease,States/Local Areas,South Carolina,2008,Age,13-17 Years,59.7,53.8 to 65.4,367
Varicella,History of disease,States/Local Areas,South Carolina,2015,Age,13-17 Years,18.9,14.4 to 24.4,360
Varicella,History of disease,States/Local Areas,South Carolina,2016,Age,13-17 Years,15.2,10.9 to 20.6,314
Varicella,History of disease,States/Local Areas,South Carolina,2018,Age,13-17 Years,10.9,7.1 to 16.4,318
Varicella,History of disease,States/Local Areas,South Carolina,2012,Age,13-17 Years,31.9,25.3 to 39.2,310
Varicella,History of disease,States/Local Areas,South Carolina,2013,Age,13-17 Years,23.9,18.0 to 30.9,296
Varicella,History of disease,States/Local Areas,South Carolina,2010,Age,13-17 Years,46.2,39.8 to 52.8,317
Varicella,History of disease,States/Local Areas,South Carolina,2011,Age,13-17 Years,36.6,30.2 to 43.5,362
Varicella,History of disease,States/Local Areas,South Carolina,2009,Age,13-17 Years,50.4,43.6 to 57.2,299
Varicella,History of disease,States/Local Areas,South Carolina,2014,Age,13-17 Years,16.9,12.7 to 22.3,380
Varicella,History of disease,States/Local Areas,South Carolina,2017,Age,13-17 Years,10.6,7.0 to 15.9,328
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2019,Age,13-15 Years,57.9,45.3 to 69.6,96
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2020,Age,13-15 Years,50.0,38.0 to 62.0,99
Varicella,History of disease,States/Local Areas,South Carolina,2020,Age,13-17 Years,6.6,4.0 to 10.6,311
Varicella,History of disease,States/Local Areas,South Carolina,2019,Age,13-17 Years,6.0,3.5 to 10.3,319
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2021,Age,13-17 Years,63.2,52.9 to 72.3,140
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2021,Age,13-17 Years,62.1,54.7 to 69.0,263
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2022,Age,13-17 Years,54.4,46.8 to 61.7,269
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2015,Age,13-17 Years,77.8,71.8 to 82.8,360
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2020,Age,13-17 Years,47.0,40.2 to 53.8,311
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2018,Age,13-17 Years,41.2,34.7 to 47.9,318
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2017,Age,13-17 Years,42.7,36.1 to 49.5,328
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2012,Age,13-17 Years,64.9,57.4 to 71.7,310
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2013,Age,13-17 Years,71.9,64.8 to 78.0,296
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2014,Age,13-17 Years,72.6,66.0 to 78.3,380
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2016,Age,13-17 Years,29.1,23.3 to 35.6,314
≥2 Doses MMR,,States/Local Areas,South Carolina,2010,Age,13-17 Years,89.4,84.9 to 92.7,317
≥2 Doses MMR,,States/Local Areas,South Carolina,2011,Age,13-17 Years,91.7,87.0 to 94.8,362
≥2 Doses MMR,,States/Local Areas,South Carolina,2008,Age,13-17 Years,90.9,87.0 to 93.7,367
≥2 Doses MMR,,States/Local Areas,South Carolina,2009,Age,13-17 Years,89.7,85.3 to 92.9,299
HPV,"≥2 Doses, Males",States/Local Areas,South Carolina,2019,Age,13-17 Years,50.6,40.9 to 60.2,168
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2010,Age,13-17 Years,48.1,41.6 to 54.6,317
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2009,Age,13-17 Years,37.5,31.4 to 44.0,299
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2011,Age,13-17 Years,59.4,52.3 to 66.2,362
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2008,Age,13-17 Years,27.3,22.4 to 32.9,367
Tetanus,≥1 Dose Tdap,States/Local Areas,South Carolina,2022,Age,13-15 Years,93.4,85.0 to 97.2,155
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2019,Age,13-17 Years,53.0,46.0 to 59.9,319
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2019,Age,13-15 Years,39.4,27.9 to 52.3,99
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2020,Age,13-15 Years,37.3,27.3 to 48.6,112
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2022,Age,13-15 Years,45.1,35.8 to 54.6,155
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2018,Age,13-17 Years,37.7,28.9 to 47.3,159
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2017,Age,13-17 Years,38.0,29.2 to 47.8,174
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2019,Age,13-17 Years,47.0,37.4 to 56.7,168
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2020,Age,13-17 Years,46.9,37.7 to 56.3,167
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2021,Age,13-15 Years,62.7,49.8 to 74.0,88
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2022,Age,13-15 Years,34.5,23.4 to 47.6,75
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2016,Age,13-17 Years,27.4,20.0 to 36.4,169
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2019,Age,13-15 Years,49.1,40.3 to 58.0,195
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2022,Age,13-17 Years,44.3,34.7 to 54.4,134
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2021,Age,13-15 Years,61.2,51.9 to 69.8,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,South Carolina,2020,Age,13-15 Years,44.0,35.9 to 52.5,211
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2018,Age,13-15 Years,33.0,22.3 to 45.8,97
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2020,Age,13-17 Years,47.1,37.4 to 57.0,144
HPV,"Up-to-Date, Males",States/Local Areas,South Carolina,2018,Age,13-15 Years,32.8,23.3 to 43.8,107
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2021,Age,13-17 Years,61.0,50.1 to 71.0,123
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2022,Age,13-17 Years,64.7,53.7 to 74.4,135
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2018,Age,13-17 Years,44.8,35.6 to 54.3,159
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2019,Age,13-17 Years,59.2,49.1 to 68.5,151
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2016,Age,13-17 Years,30.8,22.5 to 40.6,145
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2017,Age,13-17 Years,47.4,38.0 to 57.0,154
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2021,Age,13-15 Years,59.9,46.5 to 72.0,86
HPV,"Up-to-Date, Females",States/Local Areas,South Carolina,2022,Age,13-15 Years,57.1,43.5 to 69.7,80
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2021,Age,13-17 Years,93.2,90.6 to 95.1,873
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2022,Age,13-17 Years,94.7,92.5 to 96.2,825
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2019,Age,13-17 Years,93.5,91.1 to 95.3,829
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2018,Age,13-17 Years,93.9,91.7 to 95.6,886
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2020,Age,13-17 Years,94.5,92.5 to 96.1,1108
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2017,Age,13-17 Years,90.6,88.1 to 92.6,1017
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2021,Age,13-17 Years,87.9,84.7 to 90.5,873
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2020,Age,13-17 Years,93.5,91.3 to 95.2,1108
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2019,Age,13-17 Years,91.9,89.4 to 93.9,829
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2014,Age,13-15 Years,28.0,21.7 to 35.2,266
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2015,Age,13-15 Years,39.8,33.2 to 46.8,278
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2013,Age,13-15 Years,35.8,29.2 to 43.0,302
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2012,Age,13-15 Years,32.6,25.9 to 40.1,281
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2008,Age,13-15 Years,27.4,21.2 to 34.7,281
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2009,Age,13-15 Years,26.5,20.4 to 33.5,274
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2010,Age,13-15 Years,26.7,21.2 to 33.0,314
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2011,Age,13-15 Years,28.7,23.7 to 34.3,376
≥2 Doses MMR,,HHS Regions/National,Region 2,2022,Age,13-17 Years,94.7,92.5 to 96.2,825
≥2 Doses MMR,,HHS Regions/National,Region 2,2021,Age,13-17 Years,92.8,90.0 to 94.8,873
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 2,2014,Age,13-17 Years,32.1,28.4 to 36.0,922
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 2,2015,Age,13-17 Years,41.0,37.5 to 44.6,1029
≥2 Doses MMR,,HHS Regions/National,Region 2,2020,Age,13-17 Years,93.9,91.7 to 95.5,1108
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 2,2013,Age,13-17 Years,28.9,25.5 to 32.5,1032
≥2 Doses MMR,,HHS Regions/National,Region 2,2019,Age,13-17 Years,92.3,89.5 to 94.5,829
≥2 Doses MMR,,HHS Regions/National,Region 2,2017,Age,13-17 Years,92.3,90.0 to 94.1,1017
≥2 Doses MMR,,HHS Regions/National,Region 2,2018,Age,13-17 Years,93.7,91.2 to 95.4,886
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2006,Age,13-17 Years,14.2,9.7 to 20.4,227
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2022,Age,13-17 Years,88.9,85.9 to 91.3,825
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2007,Age,13-17 Years,47.8,39.9 to 55.8,219
≥2 Doses MMR,,HHS Regions/National,Region 2,2013,Age,13-17 Years,93.8,91.5 to 95.5,1032
≥2 Doses MMR,,HHS Regions/National,Region 2,2012,Age,13-17 Years,93.8,91.3 to 95.6,957
≥2 Doses MMR,,HHS Regions/National,Region 2,2015,Age,13-17 Years,93.1,91.2 to 94.7,1029
≥2 Doses MMR,,HHS Regions/National,Region 2,2014,Age,13-17 Years,92.6,90.1 to 94.6,922
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 2,2011,Age,13-17 Years,18.0,15.6 to 20.7,1272
≥2 Doses MMR,,HHS Regions/National,Region 2,2016,Age,13-17 Years,93.3,91.2 to 94.9,1077
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2012,Age,13-17 Years,82.8,79.5 to 85.6,957
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2017,Age,13-17 Years,91.9,89.7 to 93.7,1017
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2018,Age,13-17 Years,90.6,88.2 to 92.6,886
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2016,Age,13-17 Years,90.0,87.6 to 92.0,1077
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2015,Age,13-17 Years,89.3,86.9 to 91.3,1029
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2014,Age,13-17 Years,84.6,81.3 to 87.4,922
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2013,Age,13-17 Years,86.1,83.3 to 88.5,1032
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2009,Age,13-17 Years,65.5,61.6 to 69.3,966
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2008,Age,13-17 Years,57.4,53.6 to 61.2,990
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2011,Age,13-17 Years,78.5,75.4 to 81.3,1272
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2010,Age,13-17 Years,74.5,70.9 to 77.9,1100
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2016,Age,13-17 Years,90.8,88.4 to 92.7,1077
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2022,Age,13-15 Years,94.2,91.4 to 96.1,478
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2023,Age,13-17 Years,90.2,87.6 to 92.3,893
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2023,Age,13-17 Years,92.9,90.7 to 94.6,893
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2023,Age,13-17 Years,94.8,92.7 to 96.3,893
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2023,Age,13-17 Years,74.7,71.0 to 78.1,893
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2023,Age,13-17 Years,71.9,66.2 to 77.0,411
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2023,Age,13-17 Years,62.9,57.3 to 68.1,482
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2023,Age,13-17 Years,62.3,58.3 to 66.1,893
≥3 Doses HepB,,HHS Regions/National,Region 2,2023,Age,13-17 Years,93.2,90.7 to 95.1,893
≥2 Doses MMR,,HHS Regions/National,Region 2,2023,Age,13-17 Years,93.2,90.9 to 94.9,893
Varicella,History of disease,HHS Regions/National,Region 2,2023,Age,13-17 Years,8.7,6.5 to 11.5,893
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2023,Age,13-17 Years,96.0,94.1 to 97.3,830
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2023,Age,13-17 Years,92.4,89.9 to 94.3,830
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2023,Age,13-17 Years,93.0,90.8 to 94.8,893
≥2 Doses Hep A,,HHS Regions/National,Region 2,2023,Age,13-17 Years,85.7,82.6 to 88.3,893
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2023,Age,13-15 Years,95.5,93.3 to 97.0,559
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2023,Age,13-15 Years,90.8,87.6 to 93.3,559
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2023,Age,13-15 Years,55.2,50.1 to 60.2,559
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2023,Age,13-15 Years,53.3,46.0 to 60.6,259
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2023,Age,13-15 Years,92.5,89.3 to 94.8,517
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2023,Age,13-15 Years,57.1,49.9 to 63.9,300
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2023,Age,13-17 Years,61.6,55.7 to 67.2,411
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2023,Age,13-17 Years,77.4,72.4 to 81.7,482
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 2,2012,Age,13-17 Years,21.1,18.0 to 24.7,957
HPV,"≥1 Dose, Males",States/Local Areas,Massachusetts,2023,Age,13-17 Years,85.5,77.6 to 90.9,184
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Overall,Overall,87.1,84.7 to 89.1,1556
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Overall,Overall,73.7,70.7 to 76.5,1556
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Principal City,92.0,87.7 to 94.9,268
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Non-Principal City,86.1,83.4 to 88.5,1275
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Principal City,79.1,72.3 to 84.5,268
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Non-Principal City,72.7,69.3 to 75.9,1275
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Principal City,94.5,90.5 to 96.9,268
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.7,92.6 to 96.2,1275
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.5,91.4 to 95.2,1275
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"White, Non-Hispanic",72.2,68.5 to 75.7,1063
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Urbanicity,Living In a MSA Principal City,94.0,88.8 to 96.8,268
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",96.6,91.2 to 98.7,183
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.1,83.3 to 93.1,183
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",83.5,72.0 to 90.9,96
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,Hispanic,73.8,65.4 to 80.8,214
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",74.2,65.7 to 81.3,183
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",96.2,88.1 to 98.8,96
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.7,91.3 to 95.4,1063
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.5,90.9 to 95.4,1063
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,Hispanic,96.6,93.0 to 98.3,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",94.3,86.4 to 97.8,96
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,Hispanic,91.8,85.2 to 95.7,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",95.9,90.3 to 98.3,183
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.3,81.5 to 96.2,96
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,"White, Non-Hispanic",85.2,82.0 to 87.9,1063
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Poverty,Below Poverty Level,89.8,82.4 to 94.3,158
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Race and Ethnicity,Hispanic,90.3,83.6 to 94.5,214
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Poverty,Living At or Above Poverty Level,86.1,83.4 to 88.5,1335
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Poverty,Living At or Above Poverty Level,94.6,92.7 to 96.1,1335
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Poverty,Below Poverty Level,96.7,91.6 to 98.7,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Poverty,Below Poverty Level,72.4,62.7 to 80.4,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Poverty,Living At or Above Poverty Level,74.1,70.8 to 77.1,1335
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Poverty,Living At or Above Poverty Level,94.1,92.0 to 95.6,1335
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Poverty,Below Poverty Level,90.8,83.6 to 95.0,158
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Private Insurance Only,94.2,91.9 to 95.9,1143
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Any Medicaid,96.1,92.5 to 98.0,332
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Any Medicaid,87.7,82.6 to 91.5,332
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Private Insurance Only,86.4,83.5 to 88.9,1143
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Other,92.1,80.6 to 97.0,67
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Other,96.0,82.6 to 99.2,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Private Insurance Only,73.8,70.3 to 77.1,1143
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Any Medicaid,72.8,66.3 to 78.4,332
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Other,75.1,59.2 to 86.3,67
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Private Insurance Only,93.8,91.6 to 95.5,1143
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Any Medicaid,92.8,88.1 to 95.8,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Insurance Coverage,Other,95.9,88.0 to 98.7,67
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2010,Age,13-17 Years,46.8,37.1 to 56.9,140
≥2 Doses Hep A,,States/Local Areas,Massachusetts,2020,Age,13-17 Years,77.4,71.9 to 82.1,394
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2017,Age,13-17 Years,94.1,90.2 to 96.5,412
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2016,Age,13-17 Years,97.5,95.4 to 98.6,374
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2018,Age,13-17 Years,98.8,96.9 to 99.5,328
HPV,"≥3 Doses, Males",States/Local Areas,Massachusetts,2013,Age,13-15 Years,22.2,14.3 to 32.7,131
HPV,"≥3 Doses, Males",States/Local Areas,Massachusetts,2015,Age,13-17 Years,35.2,27.2 to 44.1,180
HPV,"≥3 Doses, Males",States/Local Areas,Massachusetts,2014,Age,13-17 Years,27.3,20.3 to 35.6,195
HPV,"≥3 Doses, Males",States/Local Areas,Massachusetts,2013,Age,13-17 Years,21.8,15.6 to 29.6,210
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2015,Age,13-17 Years,96.3,93.0 to 98.1,338
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2008,Age,13-17 Years,72.5,66.2 to 77.9,333
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2008,Age,13-17 Years,29.1,21.7 to 37.8,152
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2009,Age,13-17 Years,49.4,40.8 to 58.1,181
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2011,Age,13-17 Years,48.5,39.5 to 57.6,178
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2013,Age,13-17 Years,39.3,31.3 to 48.0,183
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2014,Age,13-17 Years,49.5,40.4 to 58.6,163
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2012,Age,13-17 Years,43.0,34.2 to 52.3,165
≥2 Doses Hep A,,States/Local Areas,Massachusetts,2022,Age,13-17 Years,86.5,80.3 to 91.0,268
≥2 Doses Hep A,,States/Local Areas,Massachusetts,2021,Age,13-17 Years,87.6,81.8 to 91.7,266
HPV,"≥3 Doses, Males",States/Local Areas,Massachusetts,2015,Age,13-15 Years,30.8,22.2 to 41.0,117
HPV,"≥3 Doses, Males",States/Local Areas,Massachusetts,2014,Age,13-15 Years,23.2,15.0 to 34.2,125
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2015,Age,13-17 Years,52.8,43.1 to 62.3,158
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018-2022,Overall,Overall,94.6,92.8 to 96.0,1556
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018-2022,Overall,Overall,93.7,91.8 to 95.1,1556
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2023,Age,13-17 Years,86.2,78.4 to 91.4,146
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2023,Age,13-15 Years,78.5,67.3 to 86.6,109
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2023,Age,13-15 Years,94.6,88.9 to 97.4,185
HPV,"Up-to-Date, Females",States/Local Areas,Massachusetts,2023,Age,13-15 Years,82.1,71.6 to 89.3,87
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2023,Age,13-15 Years,80.2,72.8 to 86.0,196
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2023,Age,13-15 Years,94.4,88.8 to 97.2,196
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2023,Age,13-15 Years,91.3,83.7 to 95.6,196
≥2 Doses Hep A,,States/Local Areas,Massachusetts,2023,Age,13-17 Years,89.6,84.7 to 93.1,330
Varicella,≥1 Dose with no disease history,States/Local Areas,Massachusetts,2023,Age,13-17 Years,97.3,94.2 to 98.7,309
Varicella,History of disease,States/Local Areas,Massachusetts,2023,Age,13-17 Years,8.0,4.8 to 13.0,330
Varicella,≥2 Doses with no disease history,States/Local Areas,Massachusetts,2023,Age,13-17 Years,95.0,91.1 to 97.2,309
Varicella,≥2 Doses or history of disease,States/Local Areas,Massachusetts,2023,Age,13-17 Years,95.4,91.8 to 97.4,330
≥2 Doses MMR,,States/Local Areas,Massachusetts,2023,Age,13-17 Years,92.6,87.8 to 95.6,330
≥3 Doses HepB,,States/Local Areas,Massachusetts,2023,Age,13-17 Years,93.7,89.0 to 96.5,330
HPV,"Up-to-Date, Males and Females",States/Local Areas,Massachusetts,2023,Age,13-17 Years,82.3,76.7 to 86.8,330
HPV,"≥1 Dose, Females",States/Local Areas,Massachusetts,2023,Age,13-17 Years,93.8,86.6 to 97.3,146
HPV,"Up-to-Date, Males",States/Local Areas,Massachusetts,2023,Age,13-17 Years,78.7,70.1 to 85.3,184
HPV,"≥1 Dose, Males and Females",States/Local Areas,Massachusetts,2023,Age,13-17 Years,89.6,84.5 to 93.1,330
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2023,Age,13-17 Years,94.0,89.3 to 96.7,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2023,Age,13-17 Years,91.3,86.0 to 94.7,330
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Massachusetts,2023,Age,13-17 Years,93.1,88.2 to 96.1,330
HPV,"≥2 Doses, Females",States/Local Areas,Massachusetts,2022,Age,13-17 Years,80.9,70.6 to 88.2,136
HPV,"≥2 Doses, Males and Females",States/Local Areas,Massachusetts,2022,Age,13-17 Years,80.1,73.5 to 85.4,268
HPV,"≥2 Doses, Males",States/Local Areas,Massachusetts,2022,Age,13-17 Years,79.4,70.1 to 86.3,132
≥2 Doses MMR,,States/Local Areas,Massachusetts,2017,Age,13-17 Years,97.5,94.5 to 98.8,412
≥2 Doses MMR,,States/Local Areas,Massachusetts,2018,Age,13-17 Years,97.9,93.9 to 99.3,328
≥2 Doses MMR,,States/Local Areas,Massachusetts,2019,Age,13-17 Years,96.0,91.8 to 98.1,300
HPV,"≥3 Doses, Males and Females",States/Local Areas,Massachusetts,2013,Age,13-17 Years,30.3,25.1 to 36.1,393
≥2 Doses MMR,,States/Local Areas,Massachusetts,2020,Age,13-17 Years,97.6,94.9 to 98.8,394
HPV,"≥3 Doses, Males and Females",States/Local Areas,Massachusetts,2015,Age,13-17 Years,43.8,37.3 to 50.5,338
HPV,"≥3 Doses, Males and Females",States/Local Areas,Massachusetts,2014,Age,13-17 Years,38.2,32.3 to 44.4,358
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2013,Age,13-17 Years,89.6,85.4 to 92.8,393
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2014,Age,13-17 Years,92.1,88.1 to 94.9,358
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2015,Age,13-17 Years,89.5,84.1 to 93.1,338
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2016,Age,13-17 Years,90.4,86.2 to 93.5,374
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2022,Age,13-17 Years,94.1,89.5 to 96.8,268
HPV,"≥3 Doses, Males and Females",States/Local Areas,Massachusetts,2012,Age,13-17 Years,24.4,19.3 to 30.3,347
HPV,"≥3 Doses, Males and Females",States/Local Areas,Massachusetts,2011,Age,13-17 Years,23.7,18.6 to 29.6,365
≥2 Doses MMR,,States/Local Areas,Massachusetts,2013,Age,13-17 Years,95.8,92.3 to 97.7,393
≥2 Doses MMR,,States/Local Areas,Massachusetts,2012,Age,13-17 Years,95.2,90.7 to 97.6,347
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2016,Age,13-17 Years,96.7,94.4 to 98.0,374
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2018,Age,13-17 Years,91.2,86.1 to 94.6,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2017,Age,13-17 Years,96.2,93.4 to 97.8,412
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2019,Age,13-17 Years,95.7,91.1 to 98.0,300
≥2 Doses MMR,,States/Local Areas,Massachusetts,2015,Age,13-17 Years,97.1,94.2 to 98.6,338
≥2 Doses MMR,,States/Local Areas,Massachusetts,2014,Age,13-17 Years,95.3,91.9 to 97.3,358
≥2 Doses MMR,,States/Local Areas,Massachusetts,2016,Age,13-17 Years,97.2,94.3 to 98.7,374
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2022,Age,13-15 Years,91.5,83.9 to 95.7,151
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2012,Age,13-17 Years,89.2,84.8 to 92.4,347
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2010,Age,13-17 Years,82.9,77.0 to 87.5,306
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2011,Age,13-17 Years,84.4,78.3 to 89.0,365
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2008,Age,13-17 Years,55.9,49.4 to 62.2,333
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2009,Age,13-17 Years,74.0,68.6 to 78.8,397
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2022,Age,13-17 Years,93.9,88.7 to 96.8,268
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2020,Age,13-17 Years,96.4,93.3 to 98.1,394
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2021,Age,13-17 Years,91.8,85.7 to 95.5,266
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2018,Age,13-17 Years,94.7,90.2 to 97.2,328
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2019,Age,13-17 Years,96.2,92.7 to 98.1,300
≥2 Doses MMR,,States/Local Areas,Massachusetts,2021,Age,13-17 Years,97.0,92.5 to 98.8,266
≥2 Doses MMR,,States/Local Areas,Massachusetts,2022,Age,13-17 Years,93.4,87.8 to 96.5,268
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2011,Age,13-15 Years,35.4,24.7 to 47.8,100
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2012,Age,13-15 Years,35.1,24.4 to 47.5,92
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2010,Age,13-15 Years,35.8,24.2 to 49.3,83
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2009,Age,13-15 Years,40.7,30.0 to 52.3,106
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2008,Age,13-15 Years,22.5,14.9 to 32.6,92
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2020,Age,13-17 Years,93.0,88.9 to 95.6,394
Tetanus,≥1 Dose Tdap,States/Local Areas,Massachusetts,2021,Age,13-17 Years,94.3,88.2 to 97.4,266
≥1 Dose MenACWY,,States/Local Areas,Massachusetts,2017,Age,13-17 Years,94.0,90.7 to 96.2,412
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2013,Age,13-15 Years,28.6,20.0 to 39.1,111
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2014,Age,13-15 Years,38.3,27.7 to 50.0,97
HPV,"≥3 Doses, Females",States/Local Areas,Massachusetts,2015,Age,13-15 Years,44.3,32.1 to 57.2,86
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2021,Age,13-17 Years,88.2,85.2 to 90.6,1789
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2022,Age,13-17 Years,86.9,84.3 to 89.2,1736
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2020,Age,13-17 Years,87.6,85.0 to 89.8,2007
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2019,Age,13-17 Years,86.7,83.9 to 89.1,1845
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2018,Age,13-17 Years,83.8,80.7 to 86.6,1746
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2017,Age,13-17 Years,81.4,78.7 to 83.8,2108
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2008,Age,13-15 Years,14.8,10.6 to 20.3,540
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2009,Age,13-15 Years,28.0,22.6 to 34.2,560
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2010,Age,13-15 Years,33.7,28.1 to 39.7,563
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2011,Age,13-15 Years,21.8,16.9 to 27.5,642
≥2 Doses MMR,,HHS Regions/National,Region 8,2022,Age,13-17 Years,91.4,88.8 to 93.4,1736
≥2 Doses MMR,,HHS Regions/National,Region 8,2021,Age,13-17 Years,94.8,93.1 to 96.1,1789
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2018,Age,13-17 Years,50.4,40.9 to 59.8,153
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2019,Age,13-17 Years,56.3,46.0 to 66.1,146
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2020,Age,13-17 Years,51.2,42.4 to 59.9,180
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2022,Age,13-15 Years,57.7,48.1 to 66.8,159
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2020,Age,13-17 Years,51.6,42.3 to 60.8,160
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2021,Age,13-15 Years,53.9,40.5 to 66.8,72
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2022,Age,13-15 Years,54.5,40.3 to 68.0,76
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2019,Age,13-17 Years,57.4,47.7 to 66.6,162
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2018,Age,13-17 Years,51.0,41.0 to 60.9,135
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2017,Age,13-17 Years,57.9,48.0 to 67.1,162
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2016,Age,13-17 Years,44.1,37.5 to 51.0,329
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2021,Age,13-17 Years,60.3,50.6 to 69.2,169
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2016,Age,13-17 Years,46.6,37.2 to 56.2,154
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2019,Age,13-15 Years,50.2,41.2 to 59.1,191
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2022,Age,13-17 Years,64.8,54.8 to 73.5,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2021,Age,13-15 Years,53.8,44.8 to 62.5,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2020,Age,13-15 Years,49.4,41.3 to 57.6,203
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2020,Age,13-15 Years,49.0,37.3 to 60.7,99
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2012,Age,13-17 Years,87.5,82.3 to 91.4,360
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2013,Age,13-17 Years,84.4,78.8 to 88.8,359
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2014,Age,13-17 Years,84.2,78.8 to 88.4,421
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2017,Age,13-17 Years,53.0,46.3 to 59.6,335
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2018,Age,13-17 Years,50.7,43.8 to 57.6,288
≥2 Doses MMR,,States/Local Areas,Arizona,2012,Age,13-17 Years,85.4,79.1 to 90.1,360
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2019,Age,13-17 Years,56.9,49.8 to 63.7,308
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2022,Age,13-15 Years,83.9,75.2 to 90.0,159
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2008,Age,13-17 Years,53.8,46.4 to 60.9,250
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2009,Age,13-17 Years,66.6,60.0 to 72.7,349
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2010,Age,13-17 Years,76.5,70.3 to 81.7,331
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2011,Age,13-17 Years,85.3,79.2 to 89.9,416
Tetanus,≥1 Dose Tdap,States/Local Areas,Arizona,2015,Age,13-17 Years,86.6,82.3 to 90.0,444
≥2 Doses MMR,,States/Local Areas,Arizona,2008,Age,13-17 Years,82.4,75.7 to 87.6,250
≥2 Doses MMR,,States/Local Areas,Arizona,2009,Age,13-17 Years,81.4,75.8 to 85.9,349
≥2 Doses MMR,,States/Local Areas,Arizona,2010,Age,13-17 Years,84.5,79.2 to 88.6,331
≥2 Doses MMR,,States/Local Areas,Arizona,2011,Age,13-17 Years,88.2,82.5 to 92.2,416
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2020,Age,13-17 Years,51.4,45.0 to 57.7,340
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2021,Age,13-17 Years,61.7,54.6 to 68.3,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,Arizona,2022,Age,13-17 Years,62.1,54.8 to 68.8,273
≥2 Doses Hep A,,States/Local Areas,Arizona,2021,Age,13-17 Years,85.9,80.1 to 90.2,296
≥2 Doses Hep A,,States/Local Areas,Arizona,2022,Age,13-17 Years,90.8,86.2 to 94.0,273
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2010,Age,13-17 Years,33.1,24.7 to 42.8,151
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2008,Age,13-17 Years,20.8,13.8 to 30.1,120
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2009,Age,13-17 Years,31.2,23.0 to 40.7,184
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2015,Age,13-17 Years,44.2,36.1 to 52.6,215
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2012,Age,13-17 Years,73.8,66.5 to 80.0,239
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2013,Age,13-17 Years,67.8,60.3 to 74.5,254
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2009,Age,13-17 Years,52.8,43.6 to 61.7,184
≥3 Doses HepB,,States/Local Areas,Arizona,2013,Age,13-17 Years,85.3,79.9 to 89.5,359
≥3 Doses HepB,,States/Local Areas,Arizona,2014,Age,13-17 Years,82.8,76.7 to 87.5,421
HPV,"≥1 Dose, Females",States/Local Areas,Arizona,2010,Age,13-17 Years,52.8,43.4 to 62.0,151
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2020,Age,13-15 Years,89.0,83.0 to 93.1,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2021,Age,13-15 Years,88.5,81.5 to 93.1,168
≥3 Doses HepB,,States/Local Areas,Arizona,2012,Age,13-17 Years,84.5,78.2 to 89.2,360
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2015,Age,13-15 Years,81.5,74.9 to 86.7,230
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2019,Age,13-15 Years,82.1,74.0 to 88.0,175
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2014,Age,13-15 Years,73.9,65.3 to 81.0,221
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2009,Age,13-15 Years,60.4,49.2 to 70.6,119
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2020,Age,13-17 Years,85.6,80.4 to 89.6,340
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2021,Age,13-17 Years,89.1,84.1 to 92.7,296
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2022,Age,13-17 Years,92.7,88.4 to 95.4,273
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2008,Age,13-15 Years,41.1,28.5 to 55.0,68
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2017,Age,13-15 Years,84.3,76.3 to 89.9,171
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2016,Age,13-15 Years,77.3,68.1 to 84.4,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2018,Age,13-15 Years,84.2,76.3 to 89.9,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2012,Age,13-15 Years,73.6,64.8 to 80.9,172
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2013,Age,13-15 Years,70.7,61.6 to 78.4,176
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2010,Age,13-15 Years,63.9,53.5 to 73.1,135
Varicella,≥2 Doses with no disease history,States/Local Areas,Arizona,2011,Age,13-15 Years,75.3,65.6 to 83.0,178
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2019,Age,13-17 Years,86.6,81.4 to 90.6,308
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2008,Age,13-17 Years,75.8,68.6 to 81.8,250
HPV,"≥3 Doses, Males",States/Local Areas,Arizona,2013,Age,13-17 Years,19.5,13.5 to 27.4,188
HPV,"≥3 Doses, Males",States/Local Areas,Arizona,2014,Age,13-17 Years,16.7,11.7 to 23.3,227
HPV,"≥3 Doses, Males",States/Local Areas,Arizona,2015,Age,13-17 Years,27.0,20.3 to 34.9,229
≥2 Doses Hep A,,States/Local Areas,Arizona,2020,Age,13-17 Years,88.1,83.5 to 91.6,340
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2011,Age,13-17 Years,36.7,27.4 to 47.1,191
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2012,Age,13-17 Years,36.9,28.2 to 46.6,178
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2013,Age,13-17 Years,37.4,28.7 to 47.0,171
HPV,"≥3 Doses, Females",States/Local Areas,Arizona,2014,Age,13-17 Years,35.8,27.6 to 45.0,194
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2009,Age,13-17 Years,81.0,75.7 to 85.5,349
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2010,Age,13-17 Years,80.0,74.4 to 84.6,331
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2017,Age,13-17 Years,85.1,79.9 to 89.2,335
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2016,Age,13-17 Years,79.5,73.4 to 84.4,329
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2018,Age,13-17 Years,83.8,77.8 to 88.4,288
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2015,Age,13-17 Years,82.1,77.2 to 86.1,444
HPV,"≥3 Doses, Males",States/Local Areas,Arizona,2013,Age,13-15 Years,12.7,7.1 to 21.8,104
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2012,Age,13-17 Years,83.1,78.0 to 87.2,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2011,Age,13-17 Years,76.2,69.6 to 81.7,416
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2013,Age,13-17 Years,76.7,70.7 to 81.7,359
Varicella,≥2 Doses or history of disease,States/Local Areas,Arizona,2014,Age,13-17 Years,78.2,72.3 to 83.2,421
HPV,"≥3 Doses, Males",States/Local Areas,Arizona,2014,Age,13-15 Years,16.8,10.7 to 25.4,148
HPV,"≥3 Doses, Males",States/Local Areas,Arizona,2015,Age,13-15 Years,29.3,20.6 to 39.7,144
Varicella,History of disease,States/Local Areas,Arizona,2018,Age,13-17 Years,12.5,8.5 to 17.9,288
Varicella,History of disease,States/Local Areas,Arizona,2019,Age,13-17 Years,10.4,6.4 to 16.5,308
Varicella,History of disease,States/Local Areas,Arizona,2017,Age,13-17 Years,11.9,8.3 to 16.9,335
Varicella,History of disease,States/Local Areas,Arizona,2016,Age,13-17 Years,16.6,12.2 to 22.2,329
Varicella,History of disease,States/Local Areas,Arizona,2008,Age,13-17 Years,62.4,55.1 to 69.2,250
Varicella,History of disease,States/Local Areas,Arizona,2009,Age,13-17 Years,55.1,48.5 to 61.5,349
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2020,Age,13-15 Years,49.9,38.6 to 61.1,104
Varicella,History of disease,States/Local Areas,Arizona,2022,Age,13-17 Years,5.4,3.0 to 9.3,273
Varicella,History of disease,States/Local Areas,Arizona,2020,Age,13-17 Years,8.4,5.5 to 12.8,340
Varicella,History of disease,States/Local Areas,Arizona,2021,Age,13-17 Years,8.5,5.1 to 14.0,296
Varicella,History of disease,States/Local Areas,Arizona,2012,Age,13-17 Years,35.6,29.4 to 42.2,360
Varicella,History of disease,States/Local Areas,Arizona,2013,Age,13-17 Years,27.6,22.3 to 33.6,359
Varicella,History of disease,States/Local Areas,Arizona,2010,Age,13-17 Years,43.6,37.3 to 50.0,331
Varicella,History of disease,States/Local Areas,Arizona,2011,Age,13-17 Years,39.7,32.9 to 47.0,416
Varicella,History of disease,States/Local Areas,Arizona,2015,Age,13-17 Years,18.4,14.4 to 23.2,444
Varicella,History of disease,States/Local Areas,Arizona,2014,Age,13-17 Years,22.4,17.6 to 28.2,421
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2018,Age,13-15 Years,43.1,31.6 to 55.4,93
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2021,Age,13-17 Years,63.1,52.7 to 72.4,127
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2022,Age,13-17 Years,59.2,48.5 to 69.2,129
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2017,Age,13-17 Years,48.4,39.3 to 57.5,173
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2016,Age,13-17 Years,41.7,32.7 to 51.3,175
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2021,Age,13-15 Years,53.6,41.8 to 65.1,107
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2022,Age,13-15 Years,60.9,48.0 to 72.4,83
HPV,"Up-to-Date, Males",States/Local Areas,Arizona,2019,Age,13-15 Years,48.8,36.7 to 61.0,101
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2019,Age,13-15 Years,51.9,38.8 to 64.7,90
HPV,"Up-to-Date, Females",States/Local Areas,Arizona,2018,Age,13-15 Years,54.0,41.8 to 65.6,94
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 8,2022,Age,13-17 Years,62.8,59.1 to 66.2,1736
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2015,Age,13-17 Years,87.5,85.2 to 89.5,2120
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2022,Age,13-17 Years,61.8,58.2 to 65.3,1736
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2021,Age,13-17 Years,65.0,61.1 to 68.7,1789
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2020,Age,13-17 Years,58.3,54.6 to 61.9,2007
≥3 Doses HepB,,HHS Regions/National,Region 8,2008,Age,13-17 Years,82.6,80.0 to 84.9,1854
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2019,Age,13-17 Years,55.8,51.5 to 60.0,1845
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2011,Age,13-17 Years,81.8,78.3 to 84.8,2242
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2009,Age,13-17 Years,67.4,64.3 to 70.4,1974
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2010,Age,13-17 Years,76.3,73.4 to 78.9,1890
≥2 Doses MMR,,HHS Regions/National,Region 8,2006,Age,13-17 Years,88.5,79.4 to 93.9,118
≥2 Doses MMR,,HHS Regions/National,Region 8,2007,Age,13-17 Years,86.2,72.5 to 93.7,112
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2022,Age,13-15 Years,92.9,90.1 to 94.9,1085
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2008,Age,13-17 Years,50.7,46.9 to 54.6,1854
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2019,Age,13-17 Years,55.7,49.8 to 61.4,1005
≥2 Doses MMR,,HHS Regions/National,Region 8,2011,Age,13-17 Years,88.3,85.1 to 91.0,2242
≥2 Doses MMR,,HHS Regions/National,Region 8,2010,Age,13-17 Years,89.9,87.8 to 91.7,1890
≥2 Doses MMR,,HHS Regions/National,Region 8,2009,Age,13-17 Years,87.9,85.6 to 89.9,1974
≥2 Doses MMR,,HHS Regions/National,Region 8,2008,Age,13-17 Years,87.7,85.2 to 89.8,1854
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2016,Age,13-17 Years,40.6,36.9 to 44.4,2022
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2014,Age,13-17 Years,87.1,84.7 to 89.1,2290
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2013,Age,13-17 Years,86.1,83.3 to 88.4,1913
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2012,Age,13-17 Years,86.9,84.0 to 89.3,1936
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2017,Age,13-17 Years,46.8,43.4 to 50.3,2108
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 8,2018,Age,13-17 Years,53.6,49.6 to 57.5,1746
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2007,Age,13-17 Years,45.8,33.9 to 58.1,112
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2022,Age,13-17 Years,60.0,54.9 to 64.8,902
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2022,Age,13-17 Years,65.7,60.5 to 70.6,834
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2014,Age,13-15 Years,34.7,28.9 to 40.9,695
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2015,Age,13-15 Years,28.6,23.3 to 34.7,604
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2013,Age,13-15 Years,27.3,22.1 to 33.3,579
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2012,Age,13-15 Years,25.3,19.4 to 32.3,554
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 8,2012,Age,13-17 Years,20.7,17.1 to 25.0,1936
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2021,Age,13-17 Years,91.6,89.0 to 93.6,1789
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2020,Age,13-17 Years,90.2,87.8 to 92.3,2007
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2019,Age,13-17 Years,90.0,87.1 to 92.3,1845
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 8,2014,Age,13-17 Years,26.9,24.0 to 30.0,2290
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 8,2015,Age,13-17 Years,32.7,29.4 to 36.0,2120
≥2 Doses MMR,,HHS Regions/National,Region 8,2020,Age,13-17 Years,92.5,90.4 to 94.1,2007
HPV,"≥3 Doses, Males and Females",HHS Regions/National,Region 8,2013,Age,13-17 Years,20.5,17.9 to 23.4,1913
≥2 Doses MMR,,HHS Regions/National,Region 8,2019,Age,13-17 Years,91.0,87.9 to 93.4,1845
≥2 Doses MMR,,HHS Regions/National,Region 8,2017,Age,13-17 Years,90.4,87.9 to 92.4,2108
≥2 Doses MMR,,HHS Regions/National,Region 8,2018,Age,13-17 Years,92.1,89.5 to 94.1,1746
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2022,Age,13-17 Years,92.6,90.3 to 94.3,1736
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2007,Age,13-17 Years,24.8,16.3 to 35.8,112
≥2 Doses MMR,,HHS Regions/National,Region 8,2013,Age,13-17 Years,91.0,88.7 to 92.9,1913
≥2 Doses MMR,,HHS Regions/National,Region 8,2012,Age,13-17 Years,89.7,87.2 to 91.8,1936
≥2 Doses MMR,,HHS Regions/National,Region 8,2015,Age,13-17 Years,89.6,87.4 to 91.4,2120
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2023,Age,13-15 Years,93.3,90.1 to 95.6,962
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2023,Age,13-17 Years,79.0,74.3 to 83.1,956
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2023,Age,13-17 Years,64.9,59.0 to 70.4,786
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2009,Age,13-17 Years,77.4,74.5 to 80.0,1974
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2010,Age,13-17 Years,77.5,74.6 to 80.3,1890
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2021,Age,13-15 Years,93.9,91.2 to 95.8,1025
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2020,Age,13-15 Years,91.4,88.1 to 93.8,1120
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2009,Age,13-15 Years,45.4,39.6 to 51.3,581
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2008,Age,13-15 Years,38.7,31.1 to 46.9,427
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2010,Age,13-15 Years,61.6,55.5 to 67.3,595
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2011,Age,13-15 Years,70.3,64.2 to 75.7,846
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2013,Age,13-15 Years,74.2,69.4 to 78.4,857
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2012,Age,13-15 Years,73.0,67.1 to 78.2,796
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2016,Age,13-17 Years,82.4,79.0 to 85.2,1620
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2015,Age,13-17 Years,80.7,77.7 to 83.3,1619
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2014,Age,13-17 Years,76.3,72.9 to 79.4,1667
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2013,Age,13-17 Years,71.8,67.8 to 75.4,1284
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2017,Age,13-17 Years,87.4,84.8 to 89.6,1784
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2010,Age,13-17 Years,48.7,43.9 to 53.6,970
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2011,Age,13-17 Years,50.6,44.7 to 56.4,1090
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2016,Age,13-17 Years,92.1,89.6 to 94.0,1620
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2015,Age,13-17 Years,93.7,91.8 to 95.2,1619
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2014,Age,13-17 Years,92.7,90.3 to 94.5,1667
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2013,Age,13-17 Years,93.0,90.5 to 94.9,1284
≥3 Doses HepB,,HHS Regions/National,Region 8,2015,Age,13-17 Years,90.3,88.2 to 92.1,2120
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2017,Age,13-17 Years,95.3,93.5 to 96.6,1784
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2020,Age,13-17 Years,95.0,93.0 to 96.5,1834
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2018,Age,13-17 Years,89.6,86.6 to 92.0,1536
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2021,Age,13-17 Years,93.9,91.9 to 95.5,1632
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2020,Age,13-17 Years,92.0,89.6 to 93.8,1834
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2019,Age,13-17 Years,90.5,87.6 to 92.8,1642
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2018,Age,13-17 Years,96.5,94.9 to 97.6,1536
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2012,Age,13-17 Years,93.7,90.3 to 95.9,1189
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2019,Age,13-17 Years,95.0,92.6 to 96.7,1642
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2008,Age,13-17 Years,28.3,23.9 to 33.1,911
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2012,Age,13-17 Years,71.2,66.6 to 75.4,1189
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2007,Age,13-17 Years,54.5,33.1 to 74.3,36
≥3 Doses HepB,,HHS Regions/National,Region 8,2009,Age,13-17 Years,84.9,82.5 to 87.0,1974
≥3 Doses HepB,,HHS Regions/National,Region 8,2010,Age,13-17 Years,89.8,87.8 to 91.5,1890
≥3 Doses HepB,,HHS Regions/National,Region 8,2006,Age,13-17 Years,65.7,51.9 to 77.4,118
≥3 Doses HepB,,HHS Regions/National,Region 8,2019,Age,13-17 Years,91.1,88.2 to 93.3,1845
≥3 Doses HepB,,HHS Regions/National,Region 8,2018,Age,13-17 Years,92.5,90.0 to 94.4,1746
≥3 Doses HepB,,HHS Regions/National,Region 8,2017,Age,13-17 Years,89.7,87.2 to 91.8,2108
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2022,Age,13-15 Years,95.1,92.8 to 96.7,1008
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2011,Age,13-17 Years,64.2,59.2 to 68.9,1234
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2010,Age,13-17 Years,56.3,51.2 to 61.3,851
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2011,Age,13-17 Years,89.6,86.1 to 92.3,1234
≥3 Doses HepB,,HHS Regions/National,Region 8,2007,Age,13-17 Years,77.5,68.2 to 84.7,112
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2009,Age,13-17 Years,43.8,38.6 to 49.1,797
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2008,Age,13-17 Years,30.6,24.6 to 37.4,621
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2009,Age,13-17 Years,81.5,77.2 to 85.2,797
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2010,Age,13-17 Years,90.2,87.2 to 92.6,851
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2008,Age,13-17 Years,76.3,70.9 to 81.0,621
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2009,Age,13-17 Years,45.2,40.3 to 50.2,962
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2007,Age,13-17 Years,20.3,11.6 to 33.1,54
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2012,Age,13-17 Years,21.3,15.6 to 28.3,1028
≥3 Doses HepB,,HHS Regions/National,Region 8,2014,Age,13-17 Years,90.8,88.8 to 92.5,2290
≥3 Doses HepB,,HHS Regions/National,Region 8,2013,Age,13-17 Years,91.4,89.2 to 93.2,1913
≥3 Doses HepB,,HHS Regions/National,Region 8,2011,Age,13-17 Years,88.5,85.2 to 91.1,2242
≥3 Doses HepB,,HHS Regions/National,Region 8,2012,Age,13-17 Years,91.8,89.6 to 93.5,1936
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 8,2019,Age,13-17 Years,59.9,55.7 to 64.0,1845
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2017,Age,13-17 Years,62.9,58.3 to 67.3,1126
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2021,Age,13-17 Years,96.5,94.9 to 97.6,1632
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 8,2022,Age,13-17 Years,94.2,91.8 to 95.9,1600
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2016,Age,13-17 Years,50.9,45.7 to 56.1,1069
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2015,Age,13-17 Years,52.0,47.2 to 56.8,1094
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2014,Age,13-17 Years,35.2,30.9 to 39.9,1137
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2013,Age,13-17 Years,24.3,20.2 to 29.0,994
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 8,2016,Age,13-17 Years,44.9,41.2 to 48.7,2022
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2022,Age,13-17 Years,78.0,73.2 to 82.2,834
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2011,Age,13-17 Years,8.9,5.9 to 13.2,1152
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2021,Age,13-17 Years,81.4,76.6 to 85.4,840
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2020,Age,13-17 Years,77.5,72.9 to 81.5,957
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2022,Age,13-17 Years,92.1,89.5 to 94.0,1600
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 8,2017,Age,13-17 Years,50.6,47.2 to 54.1,2108
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2019,Age,13-17 Years,79.0,73.9 to 83.3,840
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 8,2018,Age,13-17 Years,56.5,52.5 to 60.3,1746
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2021,Age,13-17 Years,78.6,74.0 to 82.6,949
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2020,Age,13-17 Years,74.9,70.2 to 79.1,1050
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2019,Age,13-17 Years,70.0,64.4 to 75.1,1005
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2018,Age,13-17 Years,69.7,64.8 to 74.2,901
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2008,Age,13-17 Years,20.4,16.7 to 24.7,911
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2006,Age,13-17 Years,53.0,40.0 to 65.6,118
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2007,Age,13-17 Years,62.6,49.6 to 74.1,112
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2007,Age,13-15 Years,26.2,16.2 to 39.4,72
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2010,Age,13-15 Years,55.1,50.6 to 59.5,1126
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2011,Age,13-15 Years,62.0,56.7 to 67.0,1332
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2008,Age,13-15 Years,33.2,28.7 to 38.1,1098
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2009,Age,13-15 Years,46.1,41.8 to 50.5,1184
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2009,Age,13-17 Years,78.6,75.8 to 81.1,1974
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2008,Age,13-17 Years,70.0,66.3 to 73.4,1854
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2020,Age,13-15 Years,87.6,84.1 to 90.4,1211
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2009,Age,13-17 Years,37.2,32.5 to 42.2,962
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2011,Age,13-17 Years,39.5,34.1 to 45.1,1090
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2010,Age,13-17 Years,42.3,37.6 to 47.2,970
≥3 Doses HepB,,HHS Regions/National,Region 8,2021,Age,13-17 Years,93.7,91.6 to 95.3,1789
≥3 Doses HepB,,HHS Regions/National,Region 8,2020,Age,13-17 Years,91.3,88.9 to 93.2,2007
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2018,Age,13-17 Years,73.2,67.8 to 78.0,845
≥3 Doses HepB,,HHS Regions/National,Region 8,2022,Age,13-17 Years,90.5,87.9 to 92.5,1736
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2016,Age,13-17 Years,64.1,58.6 to 69.3,953
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2017,Age,13-17 Years,68.6,63.8 to 73.0,982
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2013,Age,13-17 Years,88.7,86.2 to 90.8,1913
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2014,Age,13-15 Years,69.7,65.7 to 73.5,1399
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2015,Age,13-15 Years,73.2,69.2 to 76.8,1273
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2015,Age,13-17 Years,89.5,87.4 to 91.3,2120
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2014,Age,13-17 Years,89.5,87.4 to 91.3,2290
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2016,Age,13-17 Years,86.8,84.0 to 89.1,2022
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2016,Age,13-17 Years,57.4,53.6 to 61.0,2022
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2017,Age,13-17 Years,65.7,62.4 to 68.8,2108
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2017,Age,13-17 Years,90.0,87.8 to 91.9,2108
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2019,Age,13-15 Years,86.3,82.5 to 89.4,1129
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2018,Age,13-15 Years,85.4,81.3 to 88.7,1058
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2017,Age,13-15 Years,81.9,78.4 to 84.8,1310
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2013,Age,13-17 Years,43.4,38.5 to 48.4,919
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2012,Age,13-17 Years,43.5,37.6 to 49.5,908
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2013,Age,13-15 Years,67.2,62.8 to 71.3,1166
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2012,Age,13-15 Years,65.7,60.7 to 70.4,1200
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2016,Age,13-15 Years,74.0,69.6 to 77.9,1263
≥2 Doses Hep A,,HHS Regions/National,Region 8,2021,Age,13-17 Years,89.3,87.0 to 91.3,1789
≥2 Doses Hep A,,HHS Regions/National,Region 8,2022,Age,13-17 Years,86.1,83.3 to 88.4,1736
≥2 Doses Hep A,,HHS Regions/National,Region 8,2020,Age,13-17 Years,85.0,82.2 to 87.4,2007
HPV,"≥3 Doses, Males",HHS Regions/National,Region 8,2015,Age,13-15 Years,25.9,20.7 to 32.0,669
HPV,"≥3 Doses, Males",HHS Regions/National,Region 8,2013,Age,13-15 Years,8.3,5.7 to 11.8,587
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2016,Age,13-17 Years,85.1,82.3 to 87.6,2022
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2018,Age,13-17 Years,90.8,88.1 to 93.0,1746
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2017,Age,13-17 Years,89.2,86.9 to 91.1,2108
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2015,Age,13-17 Years,57.8,52.8 to 62.5,1026
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2014,Age,13-17 Years,60.3,55.6 to 64.8,1153
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2013,Age,13-17 Years,52.6,47.6 to 57.6,919
HPV,"≥1 Dose, Females",HHS Regions/National,Region 8,2012,Age,13-17 Years,54.6,48.5 to 60.5,908
HPV,"≥3 Doses, Males",HHS Regions/National,Region 8,2014,Age,13-15 Years,19.4,14.9 to 24.9,704
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2019,Age,13-17 Years,91.5,88.9 to 93.6,1845
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2019,Age,13-15 Years,91.7,87.8 to 94.3,1022
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2018,Age,13-15 Years,90.8,86.6 to 93.9,959
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2014,Age,13-15 Years,79.6,75.4 to 83.2,1087
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2015,Age,13-15 Years,80.5,76.7 to 83.8,1041
HPV,"≥3 Doses, Males",HHS Regions/National,Region 8,2014,Age,13-17 Years,18.1,14.7 to 22.1,1137
HPV,"≥3 Doses, Males",HHS Regions/National,Region 8,2015,Age,13-17 Years,28.7,24.3 to 33.6,1094
HPV,"≥3 Doses, Males",HHS Regions/National,Region 8,2013,Age,13-17 Years,8.6,6.4 to 11.4,994
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2006,Age,13-17 Years,75.3,63.3 to 84.4,118
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2008,Age,13-17 Years,76.2,72.8 to 79.3,1854
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2014,Age,13-17 Years,82.3,79.7 to 84.7,2290
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2015,Age,13-17 Years,84.6,82.2 to 86.7,2120
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2022,Age,13-17 Years,92.6,90.3 to 94.5,1736
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2021,Age,13-17 Years,94.5,92.6 to 95.9,1789
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2020,Age,13-17 Years,92.7,90.6 to 94.4,2007
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2007,Age,13-17 Years,71.4,58.3 to 81.7,112
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2013,Age,13-17 Years,79.8,76.8 to 82.5,1913
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2011,Age,13-17 Years,79.8,76.5 to 82.7,2242
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 8,2012,Age,13-17 Years,81.0,77.7 to 83.9,1936
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2016,Age,13-15 Years,84.1,79.8 to 87.6,1041
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 8,2017,Age,13-15 Years,88.6,85.2 to 91.3,1151
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2009,Age,13-17 Years,28.7,24.2 to 33.5,962
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2008,Age,13-17 Years,15.3,12.0 to 19.3,911
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2010,Age,13-17 Years,35.0,30.5 to 39.8,970
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2014,Age,13-17 Years,36.2,31.7 to 40.9,1153
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2013,Age,13-17 Years,33.1,28.6 to 38.0,919
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2011,Age,13-17 Years,27.8,23.5 to 32.5,1090
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2012,Age,13-17 Years,33.5,27.9 to 39.5,908
HPV,"≥3 Doses, Females",HHS Regions/National,Region 8,2015,Age,13-17 Years,36.8,32.2 to 41.6,1026
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2013,Age,13-15 Years,86.3,82.7 to 89.3,1166
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2014,Age,13-15 Years,87.6,84.7 to 90.1,1399
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2015,Age,13-15 Years,86.8,83.6 to 89.4,1273
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2016,Age,13-15 Years,86.4,82.6 to 89.4,1263
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2017,Age,13-15 Years,87.5,84.1 to 90.3,1310
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2022,Age,13-17 Years,93.0,90.8 to 94.8,1736
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2008,Age,13-15 Years,59.4,54.6 to 64.0,1098
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2010,Age,13-15 Years,79.9,76.3 to 83.1,1126
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2009,Age,13-15 Years,72.3,68.3 to 76.0,1184
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2011,Age,13-15 Years,85.1,80.3 to 88.9,1332
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2012,Age,13-15 Years,84.5,80.2 to 88.0,1200
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2007,Age,13-15 Years,47.9,33.9 to 62.2,72
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2019,Age,13-17 Years,64.4,58.4 to 69.9,840
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2018,Age,13-17 Years,58.0,52.2 to 63.7,845
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2014,Age,13-17 Years,48.5,43.7 to 53.3,1153
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2015,Age,13-17 Years,47.9,43.1 to 52.9,1026
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2016,Age,13-17 Years,51.6,46.0 to 57.1,953
HPV,"≥2 Doses, Females",HHS Regions/National,Region 8,2017,Age,13-17 Years,51.6,46.6 to 56.6,982
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2022,Age,13-17 Years,77.2,73.9 to 80.2,1736
≥1 Dose MenACWY,,HHS Regions/National,Region 8,2021,Age,13-15 Years,86.3,82.2 to 89.6,1112
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2020,Age,13-17 Years,91.5,89.2 to 93.3,2007
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2019,Age,13-17 Years,91.2,88.4 to 93.4,1845
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2018,Age,13-17 Years,91.5,89.0 to 93.4,1746
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2011,Age,13-17 Years,85.1,81.6 to 88.0,2242
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2010,Age,13-17 Years,83.3,80.7 to 85.6,1890
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2012,Age,13-17 Years,88.6,85.9 to 90.8,1936
HPV,"≥1 Dose, Males",HHS Regions/National,Region 8,2022,Age,13-17 Years,76.4,71.7 to 80.5,902
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 8,2021,Age,13-17 Years,93.1,90.6 to 95.0,1789
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2018,Age,13-17 Years,71.4,67.8 to 74.7,1746
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2019,Age,13-17 Years,74.4,70.6 to 77.8,1845
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2021,Age,13-17 Years,80.0,76.7 to 82.9,1789
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 8,2020,Age,13-17 Years,76.2,72.9 to 79.1,2007
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2014,Age,13-17 Years,25.7,21.8 to 30.1,1137
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2013,Age,13-17 Years,16.6,13.1 to 20.7,994
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2012,Age,13-17 Years,13.0,8.1 to 20.4,1028
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2016,Age,13-17 Years,38.6,33.5 to 43.8,1069
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2017,Age,13-17 Years,49.7,44.9 to 54.4,1126
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2018,Age,13-17 Years,54.9,49.5 to 60.2,901
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2018,Age,13-15 Years,89.8,86.2 to 92.5,1058
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2021,Age,13-15 Years,90.1,86.3 to 93.0,1112
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2020,Age,13-15 Years,89.7,86.2 to 92.4,1211
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 8,2019,Age,13-15 Years,90.3,86.5 to 93.2,1129
HPV,"≥2 Doses, Males",HHS Regions/National,Region 8,2015,Age,13-17 Years,42.6,37.7 to 47.6,1094
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2022,Age,13-15 Years,65.9,59.3 to 72.0,501
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2021,Age,13-15 Years,62.1,54.6 to 69.0,527
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2017,Age,13-17 Years,48.8,43.8 to 53.8,982
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2019,Age,13-17 Years,60.2,54.0 to 66.1,840
HPV,"Up-to-Date, Females",HHS Regions/National,Region 8,2018,Age,13-17 Years,54.9,49.0 to 60.6,845
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2021,Age,13-17 Years,63.3,52.6 to 72.8,129
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2022,Age,13-17 Years,67.0,56.3 to 76.2,116
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2018,Age,13-15 Years,57.9,45.1 to 69.7,91
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2020,Age,13-17 Years,64.5,54.3 to 73.5,129
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2021,Age,13-15 Years,65.5,53.0 to 76.1,103
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2022,Age,13-15 Years,59.0,46.8 to 70.2,98
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2020,Age,13-15 Years,54.2,42.9 to 65.1,103
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2019,Age,13-15 Years,56.2,43.2 to 68.4,89
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2021,Age,13-15 Years,54.5,41.6 to 66.7,89
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2022,Age,13-15 Years,61.1,47.2 to 73.4,72
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2016,Age,13-17 Years,44.7,36.1 to 53.7,170
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2017,Age,13-17 Years,55.1,46.6 to 63.4,183
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2020,Age,13-15 Years,53.8,45.2 to 62.2,188
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2016,Age,13-17 Years,50.3,40.7 to 59.9,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2021,Age,13-15 Years,59.6,50.5 to 68.0,192
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2022,Age,13-17 Years,64.2,54.5 to 72.8,147
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2019,Age,13-15 Years,59.7,50.2 to 68.6,177
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2018,Age,13-17 Years,57.5,47.5 to 67.0,146
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2017,Age,13-17 Years,54.4,45.6 to 63.0,176
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2020,Age,13-17 Years,58.9,50.3 to 67.0,179
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2019,Age,13-17 Years,58.0,47.7 to 67.7,136
HPV,"Up-to-Date, Males",States/Local Areas,Oregon,2021,Age,13-17 Years,70.6,61.2 to 78.5,165
HPV,"Up-to-Date, Males and Females",States/Local Areas,Oregon,2022,Age,13-15 Years,60.0,50.8 to 68.5,170
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2018,Age,13-17 Years,59.0,49.3 to 68.0,151
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2019,Age,13-17 Years,63.7,52.7 to 73.3,134
Varicella,History of disease,States/Local Areas,Oregon,2008,Age,13-17 Years,61.3,54.0 to 68.1,235
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2020,Age,13-15 Years,53.4,40.7 to 65.7,85
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2019,Age,13-15 Years,63.3,49.2 to 75.4,88
Varicella,History of disease,States/Local Areas,Oregon,2020,Age,13-17 Years,10.2,6.7 to 15.2,308
Varicella,History of disease,States/Local Areas,Oregon,2019,Age,13-17 Years,10.5,6.6 to 16.2,270
Varicella,History of disease,States/Local Areas,Oregon,2021,Age,13-17 Years,6.5,4.0 to 10.5,294
Varicella,History of disease,States/Local Areas,Oregon,2022,Age,13-17 Years,9.7,6.1 to 15.1,263
Varicella,History of disease,States/Local Areas,Oregon,2009,Age,13-17 Years,46.9,41.3 to 52.5,386
Varicella,History of disease,States/Local Areas,Oregon,2011,Age,13-17 Years,35.2,28.8 to 42.2,362
Varicella,History of disease,States/Local Areas,Oregon,2010,Age,13-17 Years,44.4,38.0 to 50.9,302
Varicella,History of disease,States/Local Areas,Oregon,2013,Age,13-17 Years,27.0,21.9 to 32.8,364
Varicella,History of disease,States/Local Areas,Oregon,2012,Age,13-17 Years,24.9,20.0 to 30.5,381
Varicella,History of disease,States/Local Areas,Oregon,2015,Age,13-17 Years,21.1,16.3 to 26.8,353
Varicella,History of disease,States/Local Areas,Oregon,2016,Age,13-17 Years,12.9,9.2 to 17.7,318
Varicella,History of disease,States/Local Areas,Oregon,2017,Age,13-17 Years,15.5,11.6 to 20.2,359
Varicella,History of disease,States/Local Areas,Oregon,2018,Age,13-17 Years,11.5,7.7 to 16.8,297
Varicella,History of disease,States/Local Areas,Oregon,2014,Age,13-17 Years,18.8,14.3 to 24.4,399
HPV,"Up-to-Date, Females",States/Local Areas,Oregon,2018,Age,13-15 Years,59.4,46.2 to 71.4,80
HPV,"≥2 Doses, Males and Females",States/Local Areas,Montana,2022,Age,13-17 Years,61.9,55.0 to 68.3,297
HPV,"≥2 Doses, Males",States/Local Areas,Montana,2022,Age,13-17 Years,63.5,54.3 to 71.9,155
HPV,"≥2 Doses, Females",States/Local Areas,Montana,2022,Age,13-17 Years,60.1,49.7 to 69.6,142
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2012,Age,13-15 Years,31.9,20.9 to 45.4,89
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2011,Age,13-15 Years,35.6,22.2 to 51.8,113
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2009,Age,13-15 Years,18.9,11.3 to 29.9,75
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2010,Age,13-15 Years,26.0,17.0 to 37.7,94
≥1 Dose MenACWY,,States/Local Areas,Montana,2022,Age,13-17 Years,81.6,75.6 to 86.4,297
≥2 Doses MMR,,States/Local Areas,Montana,2022,Age,13-17 Years,93.4,89.9 to 95.8,297
≥2 Doses MMR,,States/Local Areas,Montana,2021,Age,13-17 Years,94.2,90.5 to 96.5,290
≥1 Dose MenACWY,,States/Local Areas,Montana,2018,Age,13-17 Years,75.6,69.2 to 81.0,290
≥1 Dose MenACWY,,States/Local Areas,Montana,2019,Age,13-17 Years,73.1,66.6 to 78.8,297
≥1 Dose MenACWY,,States/Local Areas,Montana,2021,Age,13-17 Years,77.1,70.7 to 82.5,290
≥1 Dose MenACWY,,States/Local Areas,Montana,2020,Age,13-17 Years,75.8,69.3 to 81.4,307
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2013,Age,13-15 Years,23.6,15.7 to 33.9,95
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2014,Age,13-15 Years,39.1,28.3 to 51.1,116
HPV,"≥3 Doses, Females",States/Local Areas,Montana,2015,Age,13-15 Years,24.4,16.5 to 34.5,113
≥1 Dose MenACWY,,States/Local Areas,Montana,2016,Age,13-17 Years,67.6,61.3 to 73.3,375
≥1 Dose MenACWY,,States/Local Areas,Montana,2015,Age,13-17 Years,65.8,60.2 to 71.0,406
≥1 Dose MenACWY,,States/Local Areas,Montana,2013,Age,13-17 Years,51.6,45.0 to 58.2,320
≥1 Dose MenACWY,,States/Local Areas,Montana,2014,Age,13-17 Years,60.2,53.6 to 66.5,367
HPV,"≥3 Doses, Males and Females",States/Local Areas,Montana,2011,Age,13-17 Years,19.7,13.5 to 27.7,385
HPV,"≥3 Doses, Males and Females",States/Local Areas,Montana,2012,Age,13-17 Years,22.3,16.9 to 28.9,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Overall,Overall,88.5,86.2 to 90.3,1481
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Overall,Overall,76.7,74.0 to 79.3,1481
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Insurance Coverage,Other,88.7,80.4 to 93.7,150
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Insurance Coverage,Any Medicaid,85.4,81.1 to 88.9,481
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Insurance Coverage,Private Insurance Only,91.0,88.3 to 93.1,823
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Insurance Coverage,Other,45.7,36.6 to 55.2,150
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Insurance Coverage,Any Medicaid,51.6,46.3 to 56.8,481
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Insurance Coverage,Private Insurance Only,55.6,51.5 to 59.6,823
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Insurance Coverage,Other,64.6,55.0 to 73.1,150
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Insurance Coverage,Other,80.6,72.0 to 87.0,150
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Insurance Coverage,Private Insurance Only,72.9,69.1 to 76.4,823
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Insurance Coverage,Any Medicaid,74.6,69.7 to 78.8,481
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Insurance Coverage,Any Medicaid,73.8,68.8 to 78.2,481
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Insurance Coverage,Private Insurance Only,79.7,76.2 to 82.8,823
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Poverty,Below Poverty Level,85.2,77.3 to 90.7,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Poverty,Living At or Above Poverty Level,89.5,87.2 to 91.4,1284
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Poverty,Living At or Above Poverty Level,53.3,50.0 to 56.5,1284
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Poverty,Below Poverty Level,52.4,43.5 to 61.2,165
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Poverty,Living At or Above Poverty Level,77.8,74.9 to 80.4,1284
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Poverty,Below Poverty Level,72.2,63.3 to 79.6,165
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Poverty,Living At or Above Poverty Level,72.8,69.8 to 75.6,1284
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Poverty,Below Poverty Level,73.4,64.5 to 80.7,165
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.5,67.2 to 73.5,1181
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.2,82.9 to 93.4,185
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Race and Ethnicity,Hispanic,86.8,74.0 to 93.9,100
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Race and Ethnicity,Hispanic,80.7,69.3 to 88.5,100
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.7,86.2 to 90.8,1181
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",75.3,72.1 to 78.2,1181
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",53.9,45.3 to 62.2,185
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Race and Ethnicity,Hispanic,60.9,48.9 to 71.7,100
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.2,73.7 to 87.0,185
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",82.1,74.8 to 87.7,185
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Principal City,91.3,88.0 to 93.8,511
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Race and Ethnicity,Hispanic,71.8,59.5 to 81.5,100
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",52.0,48.5 to 55.3,1181
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,87.7,77.0 to 93.8,75
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Principal City,84.1,80.1 to 87.4,511
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Urbanicity,Living In a Non-MSA,71.5,67.7 to 75.1,895
≥1 Dose MenACWY,,States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,76.5,63.0 to 86.1,75
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Principal City,60.2,55.1 to 65.1,511
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,52.8,39.8 to 65.5,75
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Urbanicity,Living In a Non-MSA,47.2,43.3 to 51.2,895
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Principal City,81.1,77.0 to 84.7,511
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,71.3,57.9 to 81.8,75
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Urbanicity,Living In a Non-MSA,66.2,62.3 to 69.9,895
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2018-2022,Overall,Overall,52.6,49.6 to 55.6,1481
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2018-2022,Urbanicity,Living In a Non-MSA,86.5,83.2 to 89.2,895
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2018-2022,Overall,Overall,72.3,69.5 to 75.0,1481
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2023,Age,13-17 Years,88.7,83.9 to 92.1,345
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Montana,2023,Age,13-17 Years,89.1,84.4 to 92.5,345
≥1 Dose MenACWY,,States/Local Areas,Montana,2023,Age,13-17 Years,80.0,74.4 to 84.7,345
HPV,"≥1 Dose, Males and Females",States/Local Areas,Montana,2023,Age,13-17 Years,75.7,69.9 to 80.8,345
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2023,Age,13-17 Years,59.0,52.5 to 65.2,345
≥2 Doses MMR,,States/Local Areas,Montana,2023,Age,13-17 Years,92.9,88.4 to 95.8,345
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2023,Age,13-17 Years,58.6,49.7 to 67.0,189
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2023,Age,13-17 Years,92.2,87.5 to 95.3,316
Varicella,≥1 Dose with no disease history,States/Local Areas,Montana,2023,Age,13-17 Years,96.5,92.8 to 98.4,316
≥3 Doses HepB,,States/Local Areas,Montana,2023,Age,13-17 Years,91.6,87.3 to 94.6,345
Varicella,History of disease,States/Local Areas,Montana,2023,Age,13-17 Years,8.1,5.3 to 12.4,345
Varicella,≥2 Doses or history of disease,States/Local Areas,Montana,2023,Age,13-17 Years,92.9,88.5 to 95.7,345
≥2 Doses Hep A,,States/Local Areas,Montana,2023,Age,13-17 Years,82.9,77.6 to 87.1,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Montana,2023,Age,13-15 Years,86.5,80.2 to 91.0,212
≥1 Dose MenACWY,,States/Local Areas,Montana,2023,Age,13-15 Years,79.9,72.9 to 85.5,212
HPV,"Up-to-Date, Males and Females",States/Local Areas,Montana,2023,Age,13-15 Years,54.5,46.3 to 62.6,212
HPV,"Up-to-Date, Males",States/Local Areas,Montana,2023,Age,13-15 Years,56.1,44.9 to 66.7,119
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2023,Age,13-15 Years,52.6,40.5 to 64.4,93
Varicella,≥2 Doses with no disease history,States/Local Areas,Montana,2023,Age,13-15 Years,92.9,86.8 to 96.3,195
HPV,"≥1 Dose, Females",States/Local Areas,Montana,2023,Age,13-17 Years,74.0,65.1 to 81.3,156
HPV,"≥1 Dose, Males",States/Local Areas,Montana,2023,Age,13-17 Years,77.4,69.2 to 83.9,189
HPV,"Up-to-Date, Females",States/Local Areas,Montana,2023,Age,13-17 Years,59.4,49.8 to 68.3,156
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2023,Age,13-17 Years,76.9,70.6 to 82.2,348
HPV,"≥2 Doses, Males and Females",States/Local Areas,Illinois,2022,Age,13-17 Years,67.1,61.7 to 72.1,630
HPV,"≥2 Doses, Males",States/Local Areas,Illinois,2022,Age,13-17 Years,66.0,58.3 to 73.0,336
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2015,Age,13-17 Years,40.2,34.4 to 46.4,401
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2008,Age,13-17 Years,12.8,8.5 to 18.9,373
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2009,Age,13-17 Years,23.4,17.9 to 29.9,365
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2010,Age,13-17 Years,26.0,20.6 to 32.2,362
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2011,Age,13-17 Years,34.0,26.5 to 42.3,404
HPV,"≥3 Doses, Males",States/Local Areas,Illinois,2014,Age,13-15 Years,21.6,15.4 to 29.5,239
HPV,"≥3 Doses, Males",States/Local Areas,Illinois,2015,Age,13-15 Years,23.3,17.6 to 30.1,240
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Overall,Overall,59.9,57.6 to 62.1,3230
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Overall,Overall,74.8,72.7 to 76.7,3230
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Principal City,79.1,75.8 to 82.1,1398
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.6,71.9 to 77.2,1608
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a Non-MSA,60.0,52.1 to 67.5,224
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Principal City,65.5,61.9 to 68.9,1398
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Non-Principal City,59.4,56.3 to 62.4,1608
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a Non-MSA,42.7,34.8 to 51.0,224
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Principal City,92.2,90.0 to 93.9,1398
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.5,91.9 to 94.8,1608
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a Non-MSA,89.0,83.1 to 93.0,224
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"White, Non-Hispanic",57.0,53.8 to 60.1,1636
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a Non-MSA,95.1,90.9 to 97.4,224
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.9,88.9 to 92.5,1608
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Urbanicity,Living In a MSA Principal City,91.3,89.1 to 93.2,1398
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",79.1,72.5 to 84.5,340
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",97.1,94.9 to 98.4,340
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,Hispanic,64.1,59.5 to 68.4,865
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",59.7,53.4 to 65.7,389
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",63.7,56.4 to 70.4,340
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.7,90.9 to 94.2,1636
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"White, Non-Hispanic",93.0,91.1 to 94.5,1636
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",89.6,85.6 to 92.5,389
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,Hispanic,92.2,89.5 to 94.2,865
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,Hispanic,90.4,87.3 to 92.8,865
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.4,82.9 to 90.8,389
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.9,87.9 to 95.9,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.7,67.7 to 73.5,1636
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",76.8,71.1 to 81.6,389
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Race and Ethnicity,Hispanic,79.9,75.8 to 83.4,865
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Poverty,Below Poverty Level,76.3,71.3 to 80.6,607
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Poverty,Living At or Above Poverty Level,74.6,72.3 to 76.8,2501
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Poverty,Living At or Above Poverty Level,93.0,91.6 to 94.3,2501
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Poverty,Below Poverty Level,90.5,87.3 to 93.0,607
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Poverty,Below Poverty Level,60.9,55.3 to 66.2,607
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Poverty,Below Poverty Level,91.3,88.1 to 93.7,607
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Poverty,Living At or Above Poverty Level,59.8,57.3 to 62.3,2501
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Poverty,Living At or Above Poverty Level,91.3,89.6 to 92.7,2501
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Private Insurance Only,94.4,92.9 to 95.6,1944
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Any Medicaid,90.8,88.4 to 92.7,1112
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Other,88.1,78.5 to 93.7,101
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Private Insurance Only,74.5,71.8 to 77.0,1944
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Any Medicaid,77.0,73.6 to 80.1,1112
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Other,53.9,39.6 to 67.6,101
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Uninsured,67.7,52.1 to 80.2,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Private Insurance Only,61.3,58.4 to 64.1,1944
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Uninsured,85.5,73.8 to 92.5,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Any Medicaid,59.8,55.9 to 63.6,1112
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Other,41.2,28.7 to 54.9,101
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2018-2022,Insurance Coverage,Uninsured,43.1,29.7 to 57.6,73
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Private Insurance Only,92.5,90.8 to 94.0,1944
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Other,81.3,67.6 to 90.1,101
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Any Medicaid,90.3,87.8 to 92.3,1112
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Insurance Coverage,Uninsured,88.9,76.0 to 95.3,73
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2013,Age,13-17 Years,33.8,27.0 to 41.3,268
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2014,Age,13-17 Years,47.7,40.8 to 54.6,349
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2012,Age,13-17 Years,21.1,15.4 to 28.1,308
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2023,Age,13-17 Years,74.3,67.9 to 79.8,316
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2023,Age,13-15 Years,89.1,84.6 to 92.5,374
HPV,"Up-to-Date, Females",States/Local Areas,Illinois,2023,Age,13-15 Years,67.2,58.7 to 74.8,199
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2023,Age,13-15 Years,63.0,56.8 to 68.9,391
≥1 Dose MenACWY,,States/Local Areas,Illinois,2023,Age,13-15 Years,92.1,88.4 to 94.7,391
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2023,Age,13-15 Years,92.9,89.5 to 95.3,391
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2023,Age,13-15 Years,58.8,49.7 to 67.3,192
≥2 Doses Hep A,,States/Local Areas,Illinois,2023,Age,13-17 Years,80.2,76.0 to 83.8,664
≥3 Doses HepB,,States/Local Areas,Illinois,2023,Age,13-17 Years,92.2,89.6 to 94.2,664
Varicella,History of disease,States/Local Areas,Illinois,2023,Age,13-17 Years,6.2,4.2 to 9.1,664
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2023,Age,13-17 Years,89.7,86.6 to 92.2,627
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2023,Age,13-17 Years,95.2,93.0 to 96.7,627
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2023,Age,13-17 Years,90.4,87.4 to 92.7,664
≥2 Doses MMR,,States/Local Areas,Illinois,2023,Age,13-17 Years,92.4,89.8 to 94.3,664
HPV,"Up-to-Date, Males",States/Local Areas,Illinois,2023,Age,13-17 Years,64.2,57.5 to 70.3,348
HPV,"Up-to-Date, Males and Females",States/Local Areas,Illinois,2023,Age,13-17 Years,69.1,64.5 to 73.4,664
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2023,Age,13-17 Years,84.5,79.0 to 88.7,316
HPV,"≥1 Dose, Males and Females",States/Local Areas,Illinois,2023,Age,13-17 Years,80.6,76.5 to 84.2,664
≥1 Dose MenACWY,,States/Local Areas,Illinois,2023,Age,13-17 Years,92.8,90.3 to 94.7,664
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2023,Age,13-17 Years,92.5,89.8 to 94.5,664
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Illinois,2023,Age,13-17 Years,92.9,90.2 to 94.9,664
HPV,"≥3 Doses, Males",States/Local Areas,Illinois,2013,Age,13-17 Years,16.5,11.1 to 23.9,290
HPV,"≥3 Doses, Males",States/Local Areas,Illinois,2015,Age,13-17 Years,26.8,21.6 to 32.8,378
HPV,"≥3 Doses, Males",States/Local Areas,Illinois,2014,Age,13-17 Years,22.6,17.5 to 28.8,360
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2010,Age,13-17 Years,75.8,71.3 to 79.8,739
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2009,Age,13-17 Years,76.8,72.6 to 80.6,754
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2008,Age,13-17 Years,74.4,69.4 to 78.8,783
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2017,Age,13-17 Years,94.0,91.8 to 95.7,683
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2016,Age,13-17 Years,93.6,91.1 to 95.4,605
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2018,Age,13-17 Years,94.5,92.1 to 96.2,721
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2015,Age,13-17 Years,87.5,84.2 to 90.2,779
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2019,Age,13-17 Years,93.2,90.0 to 95.4,602
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2011,Age,13-15 Years,66.2,58.5 to 73.0,369
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2010,Age,13-15 Years,54.3,46.3 to 62.2,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2012,Age,13-15 Years,68.4,59.1 to 76.4,291
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2013,Age,13-15 Years,83.9,77.6 to 88.7,264
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2014,Age,13-15 Years,83.0,77.3 to 87.6,398
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2015,Age,13-15 Years,85.0,79.9 to 88.9,434
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2019,Age,13-15 Years,91.8,87.4 to 94.7,352
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2010,Age,13-17 Years,52.5,45.7 to 59.3,387
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2011,Age,13-17 Years,63.7,57.3 to 69.7,546
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2008,Age,13-17 Years,74.2,65.0 to 81.6,308
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2020,Age,13-17 Years,94.4,91.6 to 96.3,699
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2021,Age,13-17 Years,94.4,91.5 to 96.4,578
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2022,Age,13-17 Years,93.8,90.9 to 95.9,630
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2008,Age,13-15 Years,32.3,23.5 to 42.7,210
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2017,Age,13-15 Years,92.9,89.3 to 95.3,361
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2018,Age,13-15 Years,95.1,91.6 to 97.1,408
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2016,Age,13-15 Years,93.2,89.4 to 95.6,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2009,Age,13-15 Years,42.7,34.4 to 51.4,246
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2020,Age,13-15 Years,94.5,91.2 to 96.7,391
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2021,Age,13-15 Years,95.9,92.3 to 97.9,339
≥3 Doses HepB,,States/Local Areas,Illinois,2008,Age,13-17 Years,93.2,89.5 to 95.7,783
≥3 Doses HepB,,States/Local Areas,Illinois,2010,Age,13-17 Years,95.3,93.2 to 96.8,739
≥3 Doses HepB,,States/Local Areas,Illinois,2009,Age,13-17 Years,93.7,91.0 to 95.5,754
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2022,Age,13-15 Years,92.1,87.3 to 95.2,360
≥3 Doses HepB,,States/Local Areas,Illinois,2011,Age,13-17 Years,94.7,92.4 to 96.3,848
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2010,Age,13-17 Years,87.2,81.7 to 91.1,387
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2009,Age,13-17 Years,82.1,75.6 to 87.1,351
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2009,Age,13-17 Years,41.6,34.6 to 48.9,351
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2008,Age,13-17 Years,26.5,19.7 to 34.5,308
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2011,Age,13-17 Years,91.7,88.2 to 94.3,546
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2012,Age,13-17 Years,88.4,82.1 to 92.7,439
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2008,Age,13-17 Years,27.0,20.8 to 34.2,373
≥3 Doses HepB,,States/Local Areas,Illinois,2012,Age,13-17 Years,90.7,85.6 to 94.0,632
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2013,Age,13-17 Years,79.9,74.3 to 84.6,407
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2012,Age,13-17 Years,63.4,55.9 to 70.3,439
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2009,Age,13-17 Years,34.3,28.0 to 41.3,365
≥3 Doses HepB,,States/Local Areas,Illinois,2013,Age,13-17 Years,95.7,93.2 to 97.3,558
≥3 Doses HepB,,States/Local Areas,Illinois,2014,Age,13-17 Years,94.1,91.4 to 96.0,709
≥3 Doses HepB,,States/Local Areas,Illinois,2017,Age,13-17 Years,94.1,91.8 to 95.8,683
≥3 Doses HepB,,States/Local Areas,Illinois,2016,Age,13-17 Years,95.3,93.3 to 96.8,605
≥3 Doses HepB,,States/Local Areas,Illinois,2015,Age,13-17 Years,93.1,90.7 to 95.0,779
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2016,Age,13-17 Years,92.1,89.1 to 94.3,497
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2015,Age,13-17 Years,84.9,80.9 to 88.1,645
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2017,Age,13-17 Years,97.1,95.4 to 98.2,605
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2014,Age,13-17 Years,82.4,77.8 to 86.3,576
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2017,Age,13-17 Years,93.2,90.7 to 95.1,605
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2011,Age,13-17 Years,51.6,44.1 to 59.0,404
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2010,Age,13-17 Years,39.7,33.3 to 46.4,362
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2016,Age,13-17 Years,96.6,94.2 to 98.0,497
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2015,Age,13-17 Years,95.3,92.7 to 96.9,645
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2013,Age,13-17 Years,95.0,91.8 to 97.0,407
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2014,Age,13-17 Years,94.8,91.7 to 96.7,576
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2019,Age,13-17 Years,96.9,94.1 to 98.4,544
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2018,Age,13-17 Years,93.7,91.0 to 95.6,636
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2020,Age,13-17 Years,95.8,93.1 to 97.5,642
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2019,Age,13-17 Years,92.3,88.7 to 94.8,544
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2020,Age,13-17 Years,94.0,91.0 to 96.1,642
Varicella,≥2 Doses with no disease history,States/Local Areas,Illinois,2021,Age,13-17 Years,94.0,91.0 to 96.1,548
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2013,Age,13-17 Years,53.2,45.6 to 60.7,268
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2012,Age,13-17 Years,41.2,33.1 to 49.8,308
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2015,Age,13-17 Years,62.0,55.9 to 67.7,401
HPV,"≥1 Dose, Females",States/Local Areas,Illinois,2014,Age,13-17 Years,64.4,57.7 to 70.6,349
Varicella,≥1 Dose with no disease history,States/Local Areas,Illinois,2018,Age,13-17 Years,96.7,94.6 to 98.0,636
≥3 Doses HepB,,States/Local Areas,Illinois,2018,Age,13-17 Years,94.5,92.2 to 96.1,721
≥3 Doses HepB,,States/Local Areas,Illinois,2019,Age,13-17 Years,95.7,93.2 to 97.3,602
HPV,"≥2 Doses, Males and Females",States/Local Areas,Illinois,2019,Age,13-17 Years,58.4,53.3 to 63.3,602
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2016,Age,13-17 Years,58.7,51.8 to 65.3,312
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2015,Age,13-17 Years,44.3,38.1 to 50.7,378
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2013,Age,13-17 Years,34.8,27.7 to 42.7,290
HPV,"≥1 Dose, Males",States/Local Areas,Illinois,2014,Age,13-17 Years,44.7,38.2 to 51.3,360
≥2 Doses Hep A,,States/Local Areas,Illinois,2020,Age,13-17 Years,77.2,72.7 to 81.1,699
≥2 Doses Hep A,,States/Local Areas,Illinois,2022,Age,13-17 Years,83.5,78.9 to 87.2,630
≥2 Doses Hep A,,States/Local Areas,Illinois,2021,Age,13-17 Years,81.2,76.6 to 85.1,578
HPV,"≥3 Doses, Males",States/Local Areas,Illinois,2013,Age,13-15 Years,15.3,9.2 to 24.4,177
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2013,Age,13-17 Years,86.2,82.0 to 89.5,558
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2014,Age,13-17 Years,86.3,82.5 to 89.3,709
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2011,Age,13-17 Years,77.1,72.6 to 81.1,848
Varicella,≥2 Doses or history of disease,States/Local Areas,Illinois,2012,Age,13-17 Years,76.7,71.0 to 81.5,632
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018-2022,Overall,Overall,92.7,91.5 to 93.8,3230
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018-2022,Overall,Overall,91.3,90.0 to 92.6,3230
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2019,Age,13-15 Years,62.2,48.4 to 74.2,100
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,68.9,57.3 to 78.4,137
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2021,Age,13-15 Years,64.9,50.2 to 77.2,94
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,64.4,48.2 to 77.9,72
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2022,Age,13-15 Years,63.3,52.7 to 72.7,161
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,74.6,63.5 to 83.3,142
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2022,Age,13-17 Years,69.6,57.1 to 79.7,119
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2021,Age,13-17 Years,76.5,60.2 to 87.5,72
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2018,Age,13-15 Years,69.8,52.8 to 82.7,63
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2019,Age,13-15 Years,56.0,37.0 to 73.5,53
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2020,Age,13-17 Years,70.0,57.8 to 79.9,129
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,64.3,49.5 to 76.8,86
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,66.3,52.2 to 78.1,94
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2020,Age,13-15 Years,66.6,50.6 to 79.5,78
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,60.2,47.2 to 72.0,109
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,65.3,51.5 to 76.9,76
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2022,Age,13-15 Years,65.8,50.4 to 78.5,80
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2021,Age,13-15 Years,72.5,51.4 to 86.8,47
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2022,Age,13-15 Years,60.8,45.9 to 73.8,81
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2021,Age,13-15 Years,56.7,36.7 to 74.7,47
HPV,"Up-to-Date, Males",States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,46.4,32.8 to 60.6,81
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,73.0,61.3 to 82.2,95
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2019,Age,13-17 Years,64.1,48.5 to 77.2,74
HPV,"Up-to-Date, Females",States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,63.6,48.8 to 76.2,98
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2014,Age,13-17 Years,16.4,11.3 to 23.2,274
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2015,Age,13-17 Years,14.5,10.4 to 19.9,283
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2011,Age,13-17 Years,36.5,30.5 to 42.9,407
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2010,Age,13-17 Years,46.6,40.2 to 53.1,366
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2012,Age,13-17 Years,26.6,20.6 to 33.6,287
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2013,Age,13-17 Years,21.8,15.3 to 30.2,209
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2017,Age,13-17 Years,14.8,9.4 to 22.7,204
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2016,Age,13-17 Years,17.5,11.0 to 26.5,157
Varicella,History of disease,States/Local Areas,IL-City of Chicago,2018,Age,13-17 Years,12.1,6.9 to 20.4,192
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-City of Chicago,2020,Age,13-15 Years,68.8,58.1 to 77.7,171
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2012,Age,13-15 Years,22.2,14.7 to 32.0,203
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2011,Age,13-15 Years,23.2,16.7 to 31.2,253
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2010,Age,13-15 Years,22.0,15.9 to 29.6,236
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2009,Age,13-15 Years,19.5,13.4 to 27.6,210
≥1 Dose MenACWY,,States/Local Areas,Illinois,2022,Age,13-17 Years,93.9,90.7 to 96.0,630
≥2 Doses MMR,,States/Local Areas,Illinois,2021,Age,13-17 Years,96.0,93.6 to 97.5,578
≥2 Doses MMR,,States/Local Areas,Illinois,2022,Age,13-17 Years,93.0,89.4 to 95.4,630
≥1 Dose MenACWY,,States/Local Areas,Illinois,2018,Age,13-17 Years,91.5,88.8 to 93.6,721
≥1 Dose MenACWY,,States/Local Areas,Illinois,2019,Age,13-17 Years,91.0,87.7 to 93.5,602
≥1 Dose MenACWY,,States/Local Areas,Illinois,2020,Age,13-17 Years,92.5,89.5 to 94.6,699
≥1 Dose MenACWY,,States/Local Areas,Illinois,2021,Age,13-17 Years,94.7,92.0 to 96.5,578
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2013,Age,13-15 Years,30.4,21.8 to 40.7,158
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2014,Age,13-15 Years,44.0,35.6 to 52.8,225
HPV,"≥3 Doses, Females",States/Local Areas,Illinois,2015,Age,13-15 Years,37.8,30.8 to 45.3,261
HPV,"≥2 Doses, Females",States/Local Areas,Illinois,2022,Age,13-17 Years,68.3,60.6 to 75.1,294
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2018,Age,13-17 Years,91.7,88.9 to 93.9,721
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2017,Age,13-17 Years,92.4,89.4 to 94.6,683
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2019,Age,13-17 Years,90.4,86.8 to 93.2,602
≥1 Dose MenACWY,,States/Local Areas,Illinois,2010,Age,13-17 Years,56.6,51.6 to 61.4,739
≥1 Dose MenACWY,,States/Local Areas,Illinois,2011,Age,13-17 Years,66.5,61.3 to 71.4,848
≥1 Dose MenACWY,,States/Local Areas,Illinois,2008,Age,13-17 Years,41.9,36.5 to 47.6,783
≥1 Dose MenACWY,,States/Local Areas,Illinois,2009,Age,13-17 Years,53.5,48.5 to 58.4,754
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2016,Age,13-17 Years,91.0,87.9 to 93.3,605
≥1 Dose MenACWY,,States/Local Areas,Illinois,2022,Age,13-15 Years,93.6,88.5 to 96.5,383
≥1 Dose MenACWY,,States/Local Areas,Illinois,2012,Age,13-17 Years,67.7,61.5 to 73.4,632
≥2 Doses MMR,,States/Local Areas,Illinois,2013,Age,13-17 Years,93.5,90.5 to 95.6,558
≥2 Doses MMR,,States/Local Areas,Illinois,2012,Age,13-17 Years,87.8,82.4 to 91.7,632
HPV,"≥3 Doses, Males and Females",States/Local Areas,Illinois,2012,Age,13-17 Years,15.5,11.5 to 20.5,632
HPV,"≥3 Doses, Males and Females",States/Local Areas,Illinois,2011,Age,13-17 Years,17.3,13.2 to 22.4,848
≥1 Dose MenACWY,,States/Local Areas,Illinois,2016,Age,13-17 Years,83.9,79.9 to 87.3,605
≥1 Dose MenACWY,,States/Local Areas,Illinois,2015,Age,13-17 Years,79.0,75.0 to 82.5,779
≥1 Dose MenACWY,,States/Local Areas,Illinois,2013,Age,13-17 Years,79.0,74.2 to 83.2,558
≥1 Dose MenACWY,,States/Local Areas,Illinois,2014,Age,13-17 Years,77.1,72.6 to 81.0,709
≥2 Doses MMR,,States/Local Areas,Illinois,2020,Age,13-17 Years,93.3,90.5 to 95.3,699
HPV,"≥3 Doses, Males and Females",States/Local Areas,Illinois,2013,Age,13-17 Years,25.0,20.4 to 30.1,558
HPV,"≥3 Doses, Males and Females",States/Local Areas,Illinois,2015,Age,13-17 Years,33.4,29.4 to 37.7,779
HPV,"≥3 Doses, Males and Females",States/Local Areas,Illinois,2014,Age,13-17 Years,34.9,30.4 to 39.7,709
≥2 Doses MMR,,States/Local Areas,Illinois,2018,Age,13-17 Years,94.6,92.4 to 96.3,721
≥2 Doses MMR,,States/Local Areas,Illinois,2019,Age,13-17 Years,95.3,92.6 to 97.0,602
≥2 Doses MMR,,States/Local Areas,Illinois,2016,Age,13-17 Years,93.5,90.8 to 95.4,605
≥2 Doses MMR,,States/Local Areas,Illinois,2017,Age,13-17 Years,93.1,90.6 to 95.0,683
≥2 Doses MMR,,States/Local Areas,Illinois,2015,Age,13-17 Years,89.9,86.8 to 92.3,779
≥2 Doses MMR,,States/Local Areas,Illinois,2014,Age,13-17 Years,93.1,90.2 to 95.1,709
≥1 Dose MenACWY,,States/Local Areas,Illinois,2017,Age,13-17 Years,89.2,85.9 to 91.8,683
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2020,Age,13-17 Years,91.4,88.2 to 93.8,699
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2021,Age,13-17 Years,89.5,85.7 to 92.4,578
Tetanus,≥1 Dose Tdap,States/Local Areas,Illinois,2022,Age,13-17 Years,93.6,90.3 to 95.9,630
≥3 Doses HepB,,HHS Regions/National,Region 10,2017,Age,13-17 Years,90.1,87.7 to 92.2,1400
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2017,Age,13-17 Years,95.9,94.1 to 97.1,1169
≥3 Doses HepB,,HHS Regions/National,Region 10,2019,Age,13-17 Years,91.7,88.9 to 93.8,1332
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2018,Age,13-17 Years,94.7,92.4 to 96.4,1102
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2022,Age,13-17 Years,91.3,88.0 to 93.7,1034
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2020,Age,13-17 Years,93.1,90.7 to 94.9,1403
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2019,Age,13-17 Years,91.2,88.2 to 93.4,1190
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2021,Age,13-17 Years,90.4,87.2 to 92.9,1143
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2020,Age,13-17 Years,92.2,89.6 to 94.2,1264
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2020,Age,13-17 Years,95.9,94.0 to 97.2,1264
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2018,Age,13-17 Years,86.2,82.5 to 89.2,1102
≥3 Doses HepB,,HHS Regions/National,Region 10,2015,Age,13-17 Years,86.9,84.0 to 89.3,1455
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2013,Age,13-17 Years,93.6,90.6 to 95.7,880
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2014,Age,13-17 Years,92.1,89.4 to 94.2,1131
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2015,Age,13-17 Years,93.0,90.5 to 94.9,1119
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2016,Age,13-17 Years,92.1,88.9 to 94.5,1184
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2018,Age,13-15 Years,90.0,85.6 to 93.1,691
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2011,Age,13-15 Years,67.6,61.4 to 73.2,547
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2010,Age,13-15 Years,64.4,58.1 to 70.2,416
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2012,Age,13-15 Years,75.1,69.0 to 80.4,592
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2013,Age,13-15 Years,79.1,73.3 to 83.9,609
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2009,Age,13-15 Years,49.8,43.4 to 56.2,397
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2008,Age,13-15 Years,26.7,19.6 to 35.1,260
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2016,Age,13-15 Years,85.2,80.6 to 88.9,771
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2017,Age,13-15 Years,89.1,85.5 to 91.9,708
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2011,Age,13-17 Years,63.8,58.2 to 69.1,673
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2010,Age,13-17 Years,57.8,52.7 to 62.8,590
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2017,Age,13-17 Years,88.8,86.2 to 90.9,1169
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2013,Age,13-17 Years,75.3,70.5 to 79.6,880
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2014,Age,13-17 Years,75.3,71.2 to 79.0,1131
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2015,Age,13-17 Years,79.9,76.2 to 83.1,1119
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2016,Age,13-17 Years,82.6,78.8 to 85.7,1184
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2012,Age,13-17 Years,60.5,54.4 to 66.3,633
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2013,Age,13-17 Years,61.0,55.1 to 66.7,609
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2014,Age,13-17 Years,63.6,58.1 to 68.9,728
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2021,Age,13-17 Years,91.1,88.1 to 93.5,1245
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2020,Age,13-15 Years,91.8,88.1 to 94.4,818
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2015,Age,13-15 Years,80.4,75.7 to 84.4,727
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2014,Age,13-15 Years,77.9,72.8 to 82.3,747
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2008,Age,13-17 Years,74.9,71.1 to 78.4,1082
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2010,Age,13-17 Years,38.4,33.3 to 43.8,590
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2015,Age,13-17 Years,29.5,25.1 to 34.2,757
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2014,Age,13-17 Years,19.5,15.3 to 24.3,763
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2013,Age,13-17 Years,11.6,8.8 to 15.2,707
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2012,Age,13-17 Years,4.9,2.8 to 8.5,798
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2007,Age,13-17 Years,76.7,66.5 to 84.5,118
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2018,Age,13-17 Years,67.6,61.3 to 73.3,633
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2013,Age,13-17 Years,32.0,27.2 to 37.2,707
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2014,Age,13-17 Years,45.0,39.7 to 50.5,763
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2015,Age,13-17 Years,49.5,44.5 to 54.5,757
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2016,Age,13-17 Years,58.9,53.5 to 64.1,764
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2012,Age,13-17 Years,14.9,11.5 to 19.1,798
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2019,Age,13-17 Years,73.3,67.4 to 78.5,644
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2021,Age,13-17 Years,79.5,74.4 to 83.8,594
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2021,Age,13-15 Years,92.6,89.5 to 94.9,740
≥3 Doses HepB,,HHS Regions/National,Region 10,2006,Age,13-17 Years,77.4,68.5 to 84.3,159
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 10,2019,Age,13-17 Years,56.5,51.8 to 61.1,1332
≥3 Doses HepB,,HHS Regions/National,Region 10,2008,Age,13-17 Years,82.5,79.1 to 85.5,1082
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2012,Age,13-17 Years,72.4,67.4 to 76.9,882
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2009,Age,13-17 Years,52.9,47.6 to 58.2,599
≥3 Doses HepB,,HHS Regions/National,Region 10,2010,Age,13-17 Years,87.3,84.6 to 89.7,1275
≥3 Doses HepB,,HHS Regions/National,Region 10,2009,Age,13-17 Years,85.6,82.6 to 88.2,1208
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2007,Age,13-17 Years,78.8,60.4 to 90.1,37
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2008,Age,13-17 Years,40.3,34.4 to 46.5,521
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2010,Age,13-17 Years,59.3,54.0 to 64.3,589
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2011,Age,13-17 Years,62.2,56.7 to 67.3,787
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2010,Age,13-17 Years,84.4,79.9 to 88.1,589
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2009,Age,13-17 Years,82.9,77.8 to 86.9,535
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2008,Age,13-17 Years,79.9,73.5 to 85.0,345
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2011,Age,13-17 Years,91.0,87.1 to 93.8,787
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2022,Age,13-15 Years,90.8,86.3 to 93.9,606
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2006,Age,13-17 Years,54.3,37.9 to 69.9,40
≥3 Doses HepB,,HHS Regions/National,Region 10,2007,Age,13-17 Years,82.9,73.7 to 89.3,118
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2009,Age,13-17 Years,47.0,41.5 to 52.5,535
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2008,Age,13-17 Years,24.4,18.4 to 31.5,345
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2019,Age,13-15 Years,92.5,88.9 to 95.0,769
≥3 Doses HepB,,HHS Regions/National,Region 10,2013,Age,13-17 Years,90.3,87.6 to 92.5,1316
≥3 Doses HepB,,HHS Regions/National,Region 10,2014,Age,13-17 Years,87.1,84.3 to 89.5,1491
≥3 Doses HepB,,HHS Regions/National,Region 10,2011,Age,13-17 Years,88.7,85.6 to 91.1,1423
≥3 Doses HepB,,HHS Regions/National,Region 10,2012,Age,13-17 Years,89.1,85.8 to 91.8,1431
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2012,Age,13-17 Years,91.9,87.5 to 94.9,882
≥3 Doses HepB,,HHS Regions/National,Region 10,2018,Age,13-17 Years,90.8,87.9 to 93.0,1266
≥3 Doses HepB,,HHS Regions/National,Region 10,2016,Age,13-17 Years,88.5,85.5 to 90.9,1429
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2019,Age,13-15 Years,83.5,78.9 to 87.3,854
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2017,Age,13-17 Years,69.9,66.3 to 73.3,1400
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2018,Age,13-15 Years,81.3,76.2 to 85.5,775
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2015,Age,13-17 Years,65.3,60.2 to 70.1,698
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2019,Age,13-17 Years,95.0,92.4 to 96.7,1190
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2016,Age,13-17 Years,66.5,61.1 to 71.5,665
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2017,Age,13-17 Years,70.7,65.5 to 75.4,698
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2018,Age,13-17 Years,74.7,69.2 to 79.5,633
≥3 Doses HepB,,HHS Regions/National,Region 10,2020,Age,13-17 Years,91.5,88.6 to 93.7,1403
≥3 Doses HepB,,HHS Regions/National,Region 10,2022,Age,13-17 Years,91.7,88.6 to 94.0,1034
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2017,Age,13-17 Years,69.2,64.0 to 73.9,702
≥3 Doses HepB,,HHS Regions/National,Region 10,2021,Age,13-17 Years,91.2,88.4 to 93.4,1245
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2020,Age,13-17 Years,73.2,67.8 to 78.0,730
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 10,2016,Age,13-17 Years,51.3,47.4 to 55.3,1429
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2021,Age,13-17 Years,94.5,91.9 to 96.3,1143
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 10,2017,Age,13-17 Years,57.7,53.9 to 61.5,1400
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2011,Age,13-17 Years,8.0,5.4 to 11.5,750
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2022,Age,13-17 Years,85.6,80.8 to 89.3,467
HPV,"≥1 Dose, Females",HHS Regions/National,Region 10,2020,Age,13-17 Years,77.3,71.9 to 82.0,673
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 10,2022,Age,13-17 Years,90.3,86.7 to 93.0,940
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 10,2018,Age,13-17 Years,55.4,51.0 to 59.8,1266
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 10,2022,Age,13-17 Years,94.5,91.5 to 96.4,940
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2012,Age,13-17 Years,86.1,83.0 to 88.7,1431
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2012,Age,13-15 Years,65.8,60.3 to 70.8,863
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2013,Age,13-15 Years,74.4,69.8 to 78.5,840
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2009,Age,13-17 Years,71.8,68.1 to 75.1,1208
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2008,Age,13-17 Years,62.7,58.5 to 66.8,1082
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2015,Age,13-17 Years,88.4,85.8 to 90.6,1455
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2014,Age,13-17 Years,87.6,84.9 to 89.9,1491
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2016,Age,13-17 Years,88.1,85.1 to 90.6,1429
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2013,Age,13-17 Years,88.2,85.3 to 90.5,1316
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2016,Age,13-15 Years,73.5,68.6 to 77.9,900
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2015,Age,13-15 Years,75.4,71.1 to 79.3,885
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2014,Age,13-15 Years,76.8,72.4 to 80.6,930
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2008,Age,13-17 Years,34.6,28.8 to 40.8,521
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2017,Age,13-15 Years,83.8,79.8 to 87.1,820
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2016,Age,13-17 Years,62.6,58.8 to 66.3,1429
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2017,Age,13-17 Years,89.8,87.4 to 91.8,1400
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2010,Age,13-17 Years,49.3,44.0 to 54.5,590
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2011,Age,13-17 Years,51.7,45.8 to 57.5,673
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2020,Age,13-15 Years,86.5,82.5 to 89.6,898
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2009,Age,13-17 Years,42.7,37.5 to 48.2,599
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2012,Age,13-17 Years,50.1,44.1 to 56.1,633
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2013,Age,13-17 Years,51.2,45.3 to 57.1,609
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2017,Age,13-17 Years,81.4,78.2 to 84.2,1400
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2021,Age,13-17 Years,84.6,81.3 to 87.3,1245
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2022,Age,13-17 Years,87.0,83.9 to 89.6,1034
≥2 Doses MMR,,HHS Regions/National,Region 10,2021,Age,13-17 Years,92.3,89.8 to 94.2,1245
≥2 Doses MMR,,HHS Regions/National,Region 10,2022,Age,13-17 Years,93.8,91.0 to 95.7,1034
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2020,Age,13-17 Years,87.4,84.4 to 89.9,1403
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2018,Age,13-17 Years,83.6,80.0 to 86.6,1266
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2008,Age,13-15 Years,13.3,9.1 to 19.0,323
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2019,Age,13-17 Years,84.5,81.0 to 87.5,1332
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2011,Age,13-15 Years,37.2,30.5 to 44.4,431
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2009,Age,13-15 Years,28.4,22.7 to 34.9,392
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2010,Age,13-15 Years,33.4,27.2 to 40.2,361
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2019,Age,13-17 Years,90.2,87.5 to 92.4,1332
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2018,Age,13-17 Years,71.1,66.9 to 74.9,1266
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2022,Age,13-17 Years,83.0,79.6 to 85.9,1034
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2022,Age,13-17 Years,80.5,75.4 to 84.7,567
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2019,Age,13-17 Years,69.5,63.3 to 75.1,688
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2009,Age,13-15 Years,50.9,46.1 to 55.6,776
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2008,Age,13-15 Years,35.1,30.2 to 40.2,662
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2007,Age,13-15 Years,27.0,17.0 to 40.0,76
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2011,Age,13-15 Years,62.5,57.4 to 67.4,873
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2010,Age,13-15 Years,57.8,53.2 to 62.3,775
HPV,"≥1 Dose, Males",HHS Regions/National,Region 10,2021,Age,13-17 Years,79.4,74.0 to 83.9,651
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2010,Age,13-17 Years,77.1,74.0 to 79.9,1275
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2011,Age,13-17 Years,81.2,77.8 to 84.2,1423
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2006,Age,13-17 Years,52.9,43.4 to 62.1,159
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2007,Age,13-17 Years,63.1,53.3 to 71.9,118
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2018,Age,13-17 Years,87.4,83.9 to 90.3,1266
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2020,Age,13-17 Years,90.6,87.9 to 92.7,1403
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2015,Age,13-17 Years,53.4,48.2 to 58.6,698
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2014,Age,13-17 Years,52.9,47.2 to 58.6,728
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2016,Age,13-17 Years,55.6,49.9 to 61.2,665
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2019,Age,13-17 Years,71.4,67.1 to 75.3,1332
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2021,Age,13-17 Years,89.4,86.2 to 91.9,1245
≥1 Dose MenACWY,,HHS Regions/National,Region 10,2021,Age,13-15 Years,85.7,82.0 to 88.7,798
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2020,Age,13-17 Years,75.2,71.4 to 78.6,1403
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2011,Age,13-15 Years,76.7,71.7 to 81.0,873
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2012,Age,13-15 Years,82.2,77.5 to 86.1,863
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2007,Age,13-15 Years,26.5,17.1 to 38.6,76
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2009,Age,13-15 Years,61.7,57.1 to 66.1,776
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2010,Age,13-15 Years,73.6,69.2 to 77.5,775
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 10,2022,Age,13-17 Years,93.6,91.6 to 95.2,1034
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2008,Age,13-15 Years,39.4,34.5 to 44.5,662
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2017,Age,13-17 Years,59.4,54.0 to 64.7,698
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 10,2021,Age,13-17 Years,79.4,75.8 to 82.6,1245
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2018,Age,13-17 Years,60.1,54.1 to 65.8,633
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2019,Age,13-15 Years,89.2,85.8 to 92.0,854
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2018,Age,13-17 Years,51.0,44.6 to 57.4,633
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2017,Age,13-15 Years,86.9,83.2 to 89.9,820
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2018,Age,13-15 Years,82.2,76.9 to 86.5,775
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2020,Age,13-15 Years,88.1,84.2 to 91.1,898
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2015,Age,13-15 Years,87.2,83.8 to 90.0,885
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2014,Age,13-15 Years,84.5,80.9 to 87.5,930
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2016,Age,13-15 Years,85.6,81.5 to 88.9,900
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2015,Age,13-17 Years,41.9,37.1 to 47.0,757
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2016,Age,13-17 Years,47.3,41.9 to 52.7,764
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2017,Age,13-17 Years,56.1,50.5 to 61.4,702
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2015,Age,13-15 Years,40.0,33.7 to 46.7,439
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2014,Age,13-15 Years,41.2,34.3 to 48.5,466
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2013,Age,13-15 Years,36.1,29.0 to 43.9,390
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2012,Age,13-15 Years,29.3,23.1 to 36.5,374
HPV,"≥2 Doses, Females",HHS Regions/National,Region 10,2019,Age,13-17 Years,62.2,55.7 to 68.3,644
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2011,Age,13-17 Years,3.9,2.2 to 7.0,750
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2013,Age,13-15 Years,85.9,81.9 to 89.2,840
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2012,Age,13-17 Years,8.9,6.1 to 12.7,798
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2013,Age,13-17 Years,19.3,15.6 to 23.6,707
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2014,Age,13-17 Years,32.9,27.9 to 38.3,763
≥2 Doses Hep A,,HHS Regions/National,Region 10,2022,Age,13-17 Years,88.8,85.2 to 91.6,1034
≥2 Doses Hep A,,HHS Regions/National,Region 10,2020,Age,13-17 Years,89.8,86.7 to 92.2,1403
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2009,Age,13-17 Years,31.1,26.4 to 36.3,599
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2008,Age,13-17 Years,18.8,14.2 to 24.5,521
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2015,Age,13-17 Years,43.6,38.5 to 48.9,698
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2010,Age,13-17 Years,81.2,78.3 to 83.8,1275
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2009,Age,13-17 Years,77.3,73.9 to 80.3,1208
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2011,Age,13-17 Years,78.2,74.6 to 81.4,1423
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2012,Age,13-17 Years,82.2,78.7 to 85.2,1431
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2013,Age,13-17 Years,84.0,80.6 to 86.9,1316
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2019,Age,13-17 Years,92.1,89.5 to 94.1,1332
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2018,Age,13-17 Years,87.8,84.6 to 90.5,1266
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2006,Age,13-17 Years,74.5,66.0 to 81.4,159
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2016,Age,13-17 Years,85.8,82.7 to 88.5,1429
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2017,Age,13-17 Years,90.5,88.3 to 92.3,1400
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2015,Age,13-17 Years,85.0,82.1 to 87.5,1455
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 10,2014,Age,13-17 Years,81.3,78.0 to 84.1,1491
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2013,Age,13-15 Years,11.0,7.5 to 16.0,450
≥2 Doses Hep A,,HHS Regions/National,Region 10,2021,Age,13-17 Years,89.4,86.3 to 91.8,1245
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2015,Age,13-15 Years,31.1,25.3 to 37.5,446
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2012,Age,13-15 Years,4.1,2.3 to 7.0,489
HPV,"≥3 Doses, Males",HHS Regions/National,Region 10,2014,Age,13-15 Years,21.4,16.0 to 28.2,464
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2013,Age,13-17 Years,40.7,35.0 to 46.7,609
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2014,Age,13-17 Years,42.3,36.8 to 48.1,728
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2011,Age,13-17 Years,38.3,32.8 to 44.1,673
HPV,"≥3 Doses, Females",HHS Regions/National,Region 10,2012,Age,13-17 Years,39.2,33.6 to 45.2,633
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2021,Age,13-17 Years,66.0,61.9 to 69.9,1245
≥2 Doses MMR,,HHS Regions/National,Region 10,2010,Age,13-17 Years,86.2,83.4 to 88.6,1275
HPV,"≥2 Doses, Males",HHS Regions/National,Region 10,2019,Age,13-17 Years,51.0,44.4 to 57.6,688
≥2 Doses MMR,,HHS Regions/National,Region 10,2009,Age,13-17 Years,85.9,83.0 to 88.4,1208
≥2 Doses MMR,,HHS Regions/National,Region 10,2008,Age,13-17 Years,80.6,76.9 to 83.8,1082
≥2 Doses MMR,,HHS Regions/National,Region 10,2011,Age,13-17 Years,86.3,82.9 to 89.0,1423
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2017,Age,13-17 Years,52.8,48.9 to 56.6,1400
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2007,Age,13-17 Years,26.7,17.7 to 38.0,118
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2018,Age,13-17 Years,51.8,47.4 to 56.2,1266
≥2 Doses MMR,,HHS Regions/National,Region 10,2007,Age,13-17 Years,79.0,69.5 to 86.1,118
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2010,Age,13-17 Years,66.2,62.7 to 69.5,1275
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2009,Age,13-17 Years,55.7,51.9 to 59.5,1208
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2011,Age,13-17 Years,74.4,70.6 to 78.0,1423
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2022,Age,13-15 Years,91.0,88.0 to 93.3,658
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2008,Age,13-17 Years,36.0,32.1 to 40.0,1082
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2013,Age,13-17 Years,84.1,80.9 to 86.9,1316
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2014,Age,13-17 Years,85.1,82.3 to 87.5,1491
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2012,Age,13-17 Years,82.5,79.3 to 85.4,1431
≥2 Doses MMR,,HHS Regions/National,Region 10,2006,Age,13-17 Years,79.3,70.3 to 86.1,159
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2021,Age,13-15 Years,89.2,85.8 to 91.8,798
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 10,2006,Age,13-17 Years,6.6,3.7 to 11.5,159
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2016,Age,13-17 Years,46.7,42.8 to 50.7,1429
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2022,Age,13-17 Years,68.2,63.9 to 72.2,1034
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2020,Age,13-17 Years,58.9,54.8 to 62.8,1403
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2019,Age,13-17 Years,54.0,49.3 to 58.6,1332
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2019,Age,13-17 Years,59.3,52.7 to 65.6,644
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2018,Age,13-17 Years,55.2,49.1 to 61.1,633
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2017,Age,13-17 Years,55.0,49.6 to 60.3,698
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2021,Age,13-15 Years,57.0,49.5 to 64.2,383
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2022,Age,13-15 Years,65.6,56.9 to 73.4,295
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2019,Age,13-15 Years,58.5,49.9 to 66.7,402
Varicella,History of disease,HHS Regions/National,Region 10,2010,Age,13-17 Years,53.9,50.3 to 57.5,1275
Varicella,History of disease,HHS Regions/National,Region 10,2011,Age,13-17 Years,42.4,38.4 to 46.4,1423
Varicella,History of disease,HHS Regions/National,Region 10,2012,Age,13-17 Years,35.4,31.6 to 39.5,1431
Varicella,History of disease,HHS Regions/National,Region 10,2013,Age,13-17 Years,35.1,31.4 to 39.1,1316
Varicella,History of disease,HHS Regions/National,Region 10,2009,Age,13-17 Years,57.1,53.3 to 60.8,1208
Varicella,History of disease,HHS Regions/National,Region 10,2014,Age,13-17 Years,24.2,20.9 to 27.8,1491
Varicella,History of disease,HHS Regions/National,Region 10,2007,Age,13-17 Years,68.9,58.2 to 77.9,118
Varicella,History of disease,HHS Regions/National,Region 10,2017,Age,13-17 Years,15.4,13.0 to 18.3,1400
Varicella,History of disease,HHS Regions/National,Region 10,2018,Age,13-17 Years,11.8,9.3 to 14.8,1266
Varicella,History of disease,HHS Regions/National,Region 10,2015,Age,13-17 Years,25.4,22.3 to 28.8,1455
Varicella,History of disease,HHS Regions/National,Region 10,2016,Age,13-17 Years,18.7,15.7 to 22.2,1429
Varicella,History of disease,HHS Regions/National,Region 10,2006,Age,13-17 Years,73.4,64.9 to 80.4,159
Varicella,History of disease,HHS Regions/National,Region 10,2008,Age,13-17 Years,66.8,62.7 to 70.7,1082
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2020,Age,13-15 Years,57.9,50.4 to 65.1,432
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2018,Age,13-15 Years,52.6,44.9 to 60.3,388
Varicella,History of disease,HHS Regions/National,Region 10,2021,Age,13-17 Years,7.5,5.5 to 10.0,1245
Varicella,History of disease,HHS Regions/National,Region 10,2022,Age,13-17 Years,10.3,7.8 to 13.6,1034
Varicella,History of disease,HHS Regions/National,Region 10,2020,Age,13-17 Years,11.4,8.8 to 14.6,1403
Varicella,History of disease,HHS Regions/National,Region 10,2019,Age,13-17 Years,10.8,8.2 to 14.2,1332
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2020,Age,13-17 Years,54.5,48.8 to 60.0,730
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2017,Age,13-17 Years,50.6,45.1 to 56.1,702
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2020,Age,13-15 Years,54.8,49.6 to 59.9,898
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2021,Age,13-17 Years,67.7,61.9 to 73.0,651
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2021,Age,13-15 Years,60.2,54.8 to 65.3,798
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2022,Age,13-17 Years,66.5,60.7 to 71.8,567
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2019,Age,13-15 Years,52.5,46.6 to 58.5,854
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2019,Age,13-15 Years,46.9,38.8 to 55.1,452
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2021,Age,13-17 Years,64.3,58.4 to 69.9,594
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2020,Age,13-15 Years,51.5,44.5 to 58.5,466
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2016,Age,13-17 Years,41.9,36.6 to 47.4,764
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2018,Age,13-15 Years,49.1,41.0 to 57.3,387
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2022,Age,13-17 Years,70.1,63.5 to 75.9,467
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2020,Age,13-17 Years,63.5,57.6 to 68.9,673
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2018,Age,13-17 Years,48.6,42.2 to 55.0,633
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2019,Age,13-17 Years,48.9,42.4 to 55.5,688
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2022,Age,13-15 Years,59.9,52.6 to 66.8,363
HPV,"Up-to-Date, Males",HHS Regions/National,Region 10,2021,Age,13-15 Years,63.6,55.8 to 70.6,415
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 10,2022,Age,13-15 Years,62.8,57.2 to 68.1,658
HPV,"Up-to-Date, Females",HHS Regions/National,Region 10,2016,Age,13-17 Years,51.7,46.0 to 57.4,665
HPV,"≥1 Dose, Males",States/Local Areas,Indiana,2023,Age,13-17 Years,79.3,70.1 to 86.3,154
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Indiana,2023,Age,13-17 Years,97.4,94.8 to 98.7,298
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2023,Age,13-17 Years,96.9,94.2 to 98.4,298
≥1 Dose MenACWY,,States/Local Areas,Indiana,2023,Age,13-17 Years,95.4,91.7 to 97.5,298
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2023,Age,13-17 Years,76.7,69.7 to 82.5,298
HPV,"≥1 Dose, Females",States/Local Areas,Indiana,2023,Age,13-17 Years,73.9,62.9 to 82.6,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2023,Age,13-17 Years,61.8,54.5 to 68.7,298
≥2 Doses MMR,,States/Local Areas,Indiana,2023,Age,13-17 Years,96.6,92.7 to 98.4,298
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2023,Age,13-17 Years,68.1,58.5 to 76.3,154
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2023,Age,13-17 Years,97.4,94.4 to 98.8,281
Varicella,≥1 Dose with no disease history,States/Local Areas,Indiana,2023,Age,13-17 Years,98.4,95.5 to 99.5,281
Varicella,History of disease,States/Local Areas,Indiana,2023,Age,13-17 Years,6.0,3.4 to 10.3,298
≥3 Doses HepB,,States/Local Areas,Indiana,2023,Age,13-17 Years,94.0,89.1 to 96.8,298
Varicella,≥2 Doses or history of disease,States/Local Areas,Indiana,2023,Age,13-17 Years,97.5,94.8 to 98.8,298
≥2 Doses Hep A,,States/Local Areas,Indiana,2023,Age,13-17 Years,93.2,87.7 to 96.3,298
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2023,Age,13-15 Years,97.0,92.6 to 98.8,179
≥1 Dose MenACWY,,States/Local Areas,Indiana,2023,Age,13-15 Years,94.2,87.9 to 97.3,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2023,Age,13-15 Years,57.1,47.5 to 66.3,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Indiana,2023,Age,13-15 Years,98.1,95.5 to 99.2,171
HPV,"Up-to-Date, Males",States/Local Areas,Indiana,2023,Age,13-15 Years,64.2,51.2 to 75.4,86
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2023,Age,13-17 Years,55.2,44.4 to 65.6,144
HPV,"Up-to-Date, Females",States/Local Areas,Indiana,2023,Age,13-15 Years,50.7,37.6 to 63.8,93
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Overall,Overall,91.6,89.7 to 93.2,1413
HPV,"≥2 Doses, Males",States/Local Areas,Indiana,2022,Age,13-17 Years,59.6,49.6 to 68.9,142
HPV,"≥2 Doses, Males and Females",States/Local Areas,Indiana,2022,Age,13-17 Years,62.9,55.6 to 69.7,258
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2015,Age,13-17 Years,30.9,23.5 to 39.5,167
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2011,Age,13-17 Years,28.4,21.0 to 37.1,199
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2010,Age,13-17 Years,24.8,18.4 to 32.7,168
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2009,Age,13-17 Years,22.3,16.8 to 28.9,404
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2008,Age,13-17 Years,11.6,7.4 to 17.6,173
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2012,Age,13-17 Years,35.2,26.7 to 44.8,154
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2014,Age,13-17 Years,44.4,35.6 to 53.5,184
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2013,Age,13-17 Years,34.6,27.3 to 42.7,194
≥2 Doses Hep A,,States/Local Areas,Indiana,2020,Age,13-17 Years,84.5,78.6 to 89.0,302
≥2 Doses MMR,,States/Local Areas,Indiana,2017,Age,13-17 Years,95.7,92.0 to 97.8,334
≥2 Doses MMR,,States/Local Areas,Indiana,2018,Age,13-17 Years,95.9,92.6 to 97.8,296
≥2 Doses MMR,,States/Local Areas,Indiana,2019,Age,13-17 Years,95.4,91.2 to 97.7,289
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2022,Age,13-17 Years,94.2,90.1 to 96.6,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2021,Age,13-17 Years,87.9,82.1 to 91.9,268
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2020,Age,13-17 Years,94.4,90.9 to 96.6,302
≥1 Dose MenACWY,,States/Local Areas,Indiana,2017,Age,13-17 Years,93.1,89.0 to 95.8,334
≥2 Doses MMR,,States/Local Areas,Indiana,2012,Age,13-17 Years,91.6,86.9 to 94.8,341
≥2 Doses MMR,,States/Local Areas,Indiana,2013,Age,13-17 Years,93.7,89.8 to 96.2,381
≥2 Doses MMR,,States/Local Areas,Indiana,2014,Age,13-17 Years,93.7,89.6 to 96.2,370
≥2 Doses MMR,,States/Local Areas,Indiana,2015,Age,13-17 Years,94.1,90.6 to 96.3,328
≥2 Doses MMR,,States/Local Areas,Indiana,2016,Age,13-17 Years,93.3,89.5 to 95.7,350
≥1 Dose MenACWY,,States/Local Areas,Indiana,2014,Age,13-17 Years,90.0,85.3 to 93.3,370
≥1 Dose MenACWY,,States/Local Areas,Indiana,2013,Age,13-17 Years,93.5,90.1 to 95.7,381
≥1 Dose MenACWY,,States/Local Areas,Indiana,2015,Age,13-17 Years,92.3,88.2 to 95.1,328
≥1 Dose MenACWY,,States/Local Areas,Indiana,2016,Age,13-17 Years,88.0,82.7 to 91.8,350
HPV,"≥3 Doses, Males and Females",States/Local Areas,Indiana,2011,Age,13-17 Years,14.1,10.4 to 18.9,430
HPV,"≥3 Doses, Males and Females",States/Local Areas,Indiana,2012,Age,13-17 Years,19.7,15.0 to 25.5,341
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2016,Age,13-17 Years,89.5,84.6 to 92.9,350
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018,Age,13-17 Years,88.5,83.4 to 92.3,296
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2017,Age,13-17 Years,95.1,92.3 to 96.9,334
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2019,Age,13-17 Years,93.1,88.2 to 96.0,289
≥1 Dose MenACWY,,States/Local Areas,Indiana,2009,Age,13-17 Years,41.7,36.5 to 47.2,873
≥1 Dose MenACWY,,States/Local Areas,Indiana,2008,Age,13-17 Years,31.8,26.5 to 37.8,345
≥1 Dose MenACWY,,States/Local Areas,Indiana,2011,Age,13-17 Years,92.1,87.6 to 95.0,430
≥1 Dose MenACWY,,States/Local Areas,Indiana,2010,Age,13-17 Years,70.6,64.4 to 76.1,316
HPV,"≥2 Doses, Females",States/Local Areas,Indiana,2022,Age,13-17 Years,66.4,55.5 to 75.8,116
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Uninsured,92.1,80.9 to 97.0,58
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Other,94.1,81.5 to 98.3,41
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Any Medicaid,90.4,86.8 to 93.1,467
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Private Insurance Only,92.3,89.8 to 94.3,847
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Other,49.9,31.3 to 68.5,41
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Uninsured,26.9,15.6 to 42.1,58
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Any Medicaid,53.4,48.1 to 58.7,467
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Uninsured,69.1,53.6 to 81.3,58
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Uninsured,95.6,86.9 to 98.6,58
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Private Insurance Only,53.0,49.0 to 57.0,847
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Other,64.1,45.0 to 79.6,41
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Private Insurance Only,70.0,66.3 to 73.5,847
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Insurance Coverage,Any Medicaid,72.0,66.9 to 76.6,467
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Other,85.9,69.1 to 94.4,41
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Private Insurance Only,93.0,90.6 to 94.8,847
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Insurance Coverage,Any Medicaid,91.1,87.5 to 93.7,467
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Poverty,Living At or Above Poverty Level,92.7,90.6 to 94.3,1138
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Poverty,Below Poverty Level,88.0,82.6 to 91.8,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Poverty,Below Poverty Level,51.3,43.9 to 58.7,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Poverty,Living At or Above Poverty Level,51.8,48.3 to 55.2,1138
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Poverty,Below Poverty Level,88.2,82.6 to 92.2,232
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Poverty,Living At or Above Poverty Level,93.3,91.3 to 94.8,1138
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Poverty,Living At or Above Poverty Level,70.3,67.1 to 73.4,1138
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,Hispanic,70.8,61.9 to 78.4,175
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Poverty,Below Poverty Level,72.5,65.4 to 78.6,232
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",72.2,61.3 to 81.0,107
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.0,66.6 to 73.3,1013
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.9,84.3 to 96.9,118
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",88.2,79.5 to 93.5,107
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,Hispanic,89.2,82.8 to 93.4,175
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,Hispanic,92.9,87.7 to 96.0,175
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",91.3,82.8 to 95.8,107
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.4,90.1 to 94.1,1013
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.3,90.0 to 94.1,1013
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",60.7,50.0 to 70.5,118
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",52.6,41.6 to 63.3,107
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,Hispanic,49.6,40.6 to 58.7,175
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",72.1,62.1 to 80.3,118
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.0,84.7 to 96.0,118
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.0,91.4 to 95.9,556
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Principal City,88.8,85.2 to 91.6,604
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Race and Ethnicity,"White, Non-Hispanic",50.9,47.2 to 54.5,1013
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a Non-MSA,91.6,87.3 to 94.6,253
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,94.0,91.3 to 95.9,556
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Principal City,90.9,87.6 to 93.4,604
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a Non-MSA,45.6,38.4 to 53.0,253
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,52.4,47.4 to 57.4,556
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Principal City,53.5,48.7 to 58.2,604
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a Non-MSA,63.8,56.4 to 70.6,253
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Non-Principal City,68.1,63.3 to 72.5,556
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a MSA Principal City,75.2,70.9 to 79.1,604
Tetanus,≥1 Dose Tdap,States/Local Areas,Indiana,2018-2022,Urbanicity,Living In a Non-MSA,93.7,90.0 to 96.1,253
HPV,"≥1 Dose, Males and Females",States/Local Areas,Indiana,2018-2022,Overall,Overall,70.5,67.6 to 73.3,1413
HPV,"Up-to-Date, Males and Females",States/Local Areas,Indiana,2018-2022,Overall,Overall,51.8,48.6 to 54.9,1413
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018-2022,Overall,Overall,92.2,90.4 to 93.7,1413
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2008,Age,13-15 Years,15.2,9.2 to 24.1,105
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2009,Age,13-15 Years,17.4,11.3 to 25.8,232
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2010,Age,13-15 Years,23.8,15.8 to 34.1,101
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2011,Age,13-15 Years,26.9,17.7 to 38.6,122
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2012,Age,13-15 Years,28.9,19.7 to 40.3,97
≥1 Dose MenACWY,,States/Local Areas,Indiana,2012,Age,13-17 Years,92.0,87.2 to 95.1,341
≥1 Dose MenACWY,,States/Local Areas,Indiana,2022,Age,13-15 Years,91.8,85.0 to 95.7,167
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2015,Age,13-15 Years,26.3,17.5 to 37.4,96
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2014,Age,13-15 Years,39.4,28.8 to 51.2,118
HPV,"≥3 Doses, Females",States/Local Areas,Indiana,2013,Age,13-15 Years,32.0,22.9 to 42.7,114
HPV,"≥3 Doses, Males and Females",States/Local Areas,Indiana,2014,Age,13-17 Years,28.2,22.9 to 34.3,370
HPV,"≥3 Doses, Males and Females",States/Local Areas,Indiana,2015,Age,13-17 Years,29.2,23.8 to 35.2,328
≥2 Doses MMR,,States/Local Areas,Indiana,2020,Age,13-17 Years,98.3,96.5 to 99.2,302
HPV,"≥3 Doses, Males and Females",States/Local Areas,Indiana,2013,Age,13-17 Years,21.1,16.9 to 26.1,381
≥1 Dose MenACWY,,States/Local Areas,Indiana,2021,Age,13-17 Years,91.3,85.9 to 94.8,268
≥1 Dose MenACWY,,States/Local Areas,Indiana,2020,Age,13-17 Years,94.9,91.4 to 97.0,302
≥1 Dose MenACWY,,States/Local Areas,Indiana,2018,Age,13-17 Years,89.3,84.8 to 92.6,296
≥1 Dose MenACWY,,States/Local Areas,Indiana,2019,Age,13-17 Years,92.8,87.9 to 95.8,289
≥2 Doses MMR,,States/Local Areas,Indiana,2022,Age,13-17 Years,95.7,91.3 to 97.9,258
≥2 Doses MMR,,States/Local Areas,Indiana,2021,Age,13-17 Years,92.5,86.9 to 95.8,268
≥1 Dose MenACWY,,States/Local Areas,Indiana,2022,Age,13-17 Years,92.8,88.1 to 95.7,258
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2006,Age,13-17 Years,65.6,57.5 to 73.0,227
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2008,Age,13-17 Years,71.9,68.3 to 75.3,990
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2015,Age,13-17 Years,87.0,84.2 to 89.3,1029
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2019,Age,13-17 Years,92.9,90.5 to 94.8,829
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2019,Age,13-15 Years,91.3,87.5 to 94.0,485
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2018,Age,13-15 Years,91.0,87.2 to 93.8,451
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2014,Age,13-15 Years,80.5,75.7 to 84.6,477
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2015,Age,13-15 Years,87.3,83.4 to 90.4,525
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2022,Age,13-17 Years,94.5,92.3 to 96.0,825
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2021,Age,13-17 Years,92.0,89.1 to 94.3,873
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2020,Age,13-17 Years,93.0,90.7 to 94.8,1108
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2007,Age,13-17 Years,72.7,65.1 to 79.2,219
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2014,Age,13-17 Years,84.3,81.3 to 86.9,922
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2013,Age,13-17 Years,83.5,80.3 to 86.2,1032
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2011,Age,13-17 Years,79.4,76.6 to 82.0,1272
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2012,Age,13-17 Years,80.7,77.2 to 83.7,957
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2009,Age,13-17 Years,75.7,72.2 to 78.9,966
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2010,Age,13-17 Years,76.5,73.1 to 79.7,1100
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2016,Age,13-15 Years,89.3,85.7 to 92.1,589
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2017,Age,13-15 Years,92.3,89.3 to 94.6,550
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2009,Age,13-15 Years,49.5,42.7 to 56.2,340
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2008,Age,13-15 Years,41.2,34.9 to 47.8,348
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2010,Age,13-15 Years,62.6,56.6 to 68.2,479
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2011,Age,13-15 Years,73.6,69.1 to 77.7,563
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2013,Age,13-15 Years,79.2,74.2 to 83.4,512
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2012,Age,13-15 Years,73.8,68.1 to 78.8,472
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2016,Age,13-17 Years,88.4,85.7 to 90.8,950
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2015,Age,13-17 Years,84.5,81.3 to 87.2,874
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2014,Age,13-17 Years,80.8,77.2 to 84.0,765
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2013,Age,13-17 Years,79.1,75.2 to 82.5,817
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2017,Age,13-17 Years,91.1,88.6 to 93.1,887
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2010,Age,13-17 Years,49.6,44.1 to 55.1,509
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2011,Age,13-17 Years,49.5,44.7 to 54.3,618
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2015,Age,13-17 Years,64.5,59.3 to 69.3,476
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2014,Age,13-17 Years,55.3,49.3 to 61.1,428
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2013,Age,13-17 Years,56.5,51.1 to 61.7,501
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2012,Age,13-17 Years,55.5,49.8 to 61.2,448
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2016,Age,13-17 Years,97.2,95.8 to 98.1,950
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2015,Age,13-17 Years,97.4,96.1 to 98.2,874
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2014,Age,13-17 Years,97.3,95.5 to 98.4,765
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2013,Age,13-17 Years,96.3,94.0 to 97.7,817
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2021,Age,13-15 Years,93.1,89.2 to 95.6,492
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2020,Age,13-15 Years,92.6,89.5 to 94.9,654
≥3 Doses HepB,,HHS Regions/National,Region 2,2016,Age,13-17 Years,93.1,91.0 to 94.7,1077
≥3 Doses HepB,,HHS Regions/National,Region 2,2015,Age,13-17 Years,95.8,94.4 to 96.9,1029
≥3 Doses HepB,,HHS Regions/National,Region 2,2009,Age,13-17 Years,92.5,89.6 to 94.6,966
≥3 Doses HepB,,HHS Regions/National,Region 2,2010,Age,13-17 Years,95.1,92.9 to 96.6,1100
≥3 Doses HepB,,HHS Regions/National,Region 2,2006,Age,13-17 Years,91.9,84.7 to 95.9,227
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2012,Age,13-17 Years,95.9,93.7 to 97.4,717
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2019,Age,13-17 Years,96.5,94.3 to 97.8,748
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2017,Age,13-17 Years,96.7,94.9 to 97.8,887
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2020,Age,13-17 Years,97.2,95.6 to 98.2,1034
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2018,Age,13-17 Years,90.1,87.0 to 92.5,771
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2021,Age,13-17 Years,91.4,88.2 to 93.8,811
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2020,Age,13-17 Years,92.5,90.0 to 94.4,1034
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2019,Age,13-17 Years,92.1,89.3 to 94.1,748
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2018,Age,13-17 Years,96.2,93.7 to 97.7,771
≥3 Doses HepB,,HHS Regions/National,Region 2,2019,Age,13-17 Years,93.6,90.7 to 95.6,829
≥3 Doses HepB,,HHS Regions/National,Region 2,2018,Age,13-17 Years,95.1,92.9 to 96.7,886
≥3 Doses HepB,,HHS Regions/National,Region 2,2017,Age,13-17 Years,93.0,90.8 to 94.6,1017
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2022,Age,13-15 Years,93.7,90.3 to 95.9,461
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2011,Age,13-17 Years,69.7,65.8 to 73.4,851
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2010,Age,13-17 Years,61.8,56.9 to 66.4,695
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2011,Age,13-17 Years,95.8,93.4 to 97.3,851
≥3 Doses HepB,,HHS Regions/National,Region 2,2007,Age,13-17 Years,92.1,85.4 to 95.9,219
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2006,Age,13-17 Years,66.6,51.3 to 79.1,85
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2009,Age,13-17 Years,49.6,44.0 to 55.2,485
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2008,Age,13-17 Years,40.0,34.5 to 45.7,461
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2009,Age,13-17 Years,88.8,84.4 to 92.1,485
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2010,Age,13-17 Years,93.7,90.5 to 95.9,695
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2008,Age,13-17 Years,87.9,83.6 to 91.2,461
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2008,Age,13-17 Years,48.0,42.3 to 53.7,457
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2012,Age,13-17 Years,74.2,69.8 to 78.2,717
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2007,Age,13-17 Years,81.3,66.2 to 90.6,77
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2007,Age,13-17 Years,38.2,28.1 to 49.5,105
≥3 Doses HepB,,HHS Regions/National,Region 2,2014,Age,13-17 Years,91.8,89.1 to 93.9,922
≥3 Doses HepB,,HHS Regions/National,Region 2,2013,Age,13-17 Years,95.4,93.2 to 96.9,1032
≥3 Doses HepB,,HHS Regions/National,Region 2,2011,Age,13-17 Years,94.9,93.1 to 96.2,1272
≥3 Doses HepB,,HHS Regions/National,Region 2,2012,Age,13-17 Years,95.4,93.4 to 96.8,957
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2009,Age,13-17 Years,46.8,41.1 to 52.5,459
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 2,2019,Age,13-17 Years,58.1,53.6 to 62.5,829
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2017,Age,13-17 Years,64.1,59.1 to 68.8,556
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2012,Age,13-17 Years,18.6,14.6 to 23.3,509
≥3 Doses HepB,,HHS Regions/National,Region 2,2021,Age,13-17 Years,94.6,92.1 to 96.3,873
≥3 Doses HepB,,HHS Regions/National,Region 2,2020,Age,13-17 Years,94.9,92.8 to 96.3,1108
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2021,Age,13-17 Years,96.1,93.7 to 97.7,811
Varicella,≥1 Dose with no disease history,HHS Regions/National,Region 2,2022,Age,13-17 Years,97.2,95.7 to 98.2,779
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2018,Age,13-17 Years,68.1,61.7 to 73.9,413
≥3 Doses HepB,,HHS Regions/National,Region 2,2022,Age,13-17 Years,95.2,93.2 to 96.6,825
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2015,Age,13-17 Years,92.8,90.6 to 94.5,1029
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2014,Age,13-17 Years,93.7,91.4 to 95.4,922
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2016,Age,13-17 Years,94.1,92.1 to 95.6,1077
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2016,Age,13-17 Years,62.7,57.6 to 67.4,557
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2015,Age,13-17 Years,57.2,52.1 to 62.2,553
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2014,Age,13-17 Years,45.1,39.6 to 50.7,494
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2013,Age,13-17 Years,36.6,31.7 to 41.8,531
≥2 Doses Hep A,,HHS Regions/National,Region 2,2021,Age,13-17 Years,81.5,77.7 to 84.7,873
≥2 Doses Hep A,,HHS Regions/National,Region 2,2022,Age,13-17 Years,86.6,83.4 to 89.3,825
≥2 Doses Hep A,,HHS Regions/National,Region 2,2020,Age,13-17 Years,78.5,75.1 to 81.6,1108
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2014,Age,13-15 Years,23.5,17.7 to 30.4,285
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2012,Age,13-15 Years,7.4,4.2 to 12.8,321
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2014,Age,13-17 Years,26.1,21.4 to 31.5,494
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2015,Age,13-17 Years,35.7,31.1 to 40.6,553
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2012,Age,13-17 Years,5.9,3.6 to 9.4,509
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2013,Age,13-17 Years,17.5,13.7 to 22.0,531
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2010,Age,13-17 Years,35.2,30.1 to 40.5,509
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2012,Age,13-17 Years,37.1,31.6 to 42.9,448
≥3 Doses HepB,,HHS Regions/National,Region 2,2008,Age,13-17 Years,93.5,91.1 to 95.3,990
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2015,Age,13-15 Years,35.1,29.3 to 41.4,323
HPV,"≥3 Doses, Males",HHS Regions/National,Region 2,2013,Age,13-15 Years,15.0,10.6 to 20.9,298
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2016,Age,13-17 Years,89.8,87.3 to 91.8,1077
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2018,Age,13-17 Years,91.3,88.6 to 93.4,886
Varicella,≥2 Doses or history of disease,HHS Regions/National,Region 2,2017,Age,13-17 Years,92.3,90.1 to 94.0,1017
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2014,Age,13-17 Years,38.3,32.7 to 44.2,428
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2013,Age,13-17 Years,40.8,35.5 to 46.3,501
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2011,Age,13-17 Years,35.7,31.2 to 40.4,618
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2009,Age,13-17 Years,32.0,27.0 to 37.5,459
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2008,Age,13-17 Years,26.4,21.6 to 32.0,457
HPV,"≥3 Doses, Females",HHS Regions/National,Region 2,2015,Age,13-17 Years,46.5,41.3 to 51.8,476
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2015,Age,13-17 Years,88.4,85.8 to 90.6,1029
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2020,Age,13-17 Years,65.3,61.5 to 68.9,1108
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2019,Age,13-17 Years,55.2,50.6 to 59.6,829
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2022,Age,13-17 Years,68.3,64.3 to 72.1,825
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2021,Age,13-17 Years,61.2,56.8 to 65.4,873
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2022,Age,13-15 Years,86.2,81.8 to 89.7,478
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2008,Age,13-17 Years,50.4,46.6 to 54.3,990
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2019,Age,13-17 Years,55.4,49.1 to 61.5,424
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2011,Age,13-17 Years,85.4,82.8 to 87.6,1272
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2009,Age,13-17 Years,66.7,62.9 to 70.2,966
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2010,Age,13-17 Years,78.5,75.2 to 81.3,1100
≥2 Doses MMR,,HHS Regions/National,Region 2,2006,Age,13-17 Years,86.3,78.9 to 91.4,227
≥2 Doses MMR,,HHS Regions/National,Region 2,2007,Age,13-17 Years,90.5,84.8 to 94.3,219
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2016,Age,13-17 Years,51.4,47.7 to 55.1,1077
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2022,Age,13-17 Years,67.1,61.2 to 72.5,396
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2022,Age,13-17 Years,71.8,66.3 to 76.7,429
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 2,2022,Age,13-17 Years,69.5,65.5 to 73.2,825
≥2 Doses MMR,,HHS Regions/National,Region 2,2011,Age,13-17 Years,93.4,91.4 to 95.0,1272
≥2 Doses MMR,,HHS Regions/National,Region 2,2010,Age,13-17 Years,93.8,91.4 to 95.6,1100
≥2 Doses MMR,,HHS Regions/National,Region 2,2009,Age,13-17 Years,91.7,89.4 to 93.6,966
≥2 Doses MMR,,HHS Regions/National,Region 2,2008,Age,13-17 Years,92.4,90.1 to 94.2,990
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2006,Age,13-17 Years,13.5,8.7 to 20.5,227
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2014,Age,13-17 Years,91.0,88.3 to 93.1,922
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2013,Age,13-17 Years,88.2,85.3 to 90.5,1032
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2012,Age,13-17 Years,90.5,87.9 to 92.6,957
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2018,Age,13-17 Years,54.4,50.1 to 58.6,886
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2007,Age,13-17 Years,35.4,28.3 to 43.3,219
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2017,Age,13-17 Years,52.3,48.5 to 56.0,1017
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2021,Age,13-15 Years,93.2,90.0 to 95.5,527
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2019,Age,13-17 Years,61.0,54.5 to 67.2,405
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2018,Age,13-17 Years,56.9,50.5 to 63.0,413
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2014,Age,13-17 Years,44.8,39.0 to 50.8,428
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2015,Age,13-17 Years,56.4,51.1 to 61.5,476
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2016,Age,13-17 Years,64.4,59.3 to 69.3,520
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2017,Age,13-17 Years,60.9,55.5 to 66.1,461
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2006,Age,13-17 Years,59.8,51.5 to 67.6,227
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2007,Age,13-17 Years,81.2,73.8 to 86.9,219
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2007,Age,13-15 Years,43.9,33.8 to 54.4,135
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2006,Age,13-15 Years,16.7,10.5 to 25.5,141
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2010,Age,13-15 Years,74.1,69.3 to 78.5,668
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2011,Age,13-15 Years,80.2,76.5 to 83.4,767
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2008,Age,13-15 Years,58.1,53.2 to 62.9,596
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2009,Age,13-15 Years,67.0,61.8 to 71.8,573
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2013,Age,13-17 Years,92.3,89.9 to 94.2,1032
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2012,Age,13-17 Years,93.6,91.3 to 95.4,957
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2022,Age,13-17 Years,80.4,75.4 to 84.7,429
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2009,Age,13-17 Years,85.7,82.8 to 88.1,966
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2008,Age,13-17 Years,83.2,80.2 to 85.8,990
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2011,Age,13-17 Years,92.9,91.1 to 94.5,1272
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2010,Age,13-17 Years,89.1,86.5 to 91.3,1100
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2021,Age,13-17 Years,90.7,87.8 to 93.0,873
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2018,Age,13-17 Years,66.6,62.4 to 70.6,886
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2019,Age,13-17 Years,69.6,65.2 to 73.6,829
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2022,Age,13-17 Years,79.6,76.0 to 82.8,825
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2021,Age,13-17 Years,72.4,68.2 to 76.2,873
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2020,Age,13-17 Years,77.1,73.7 to 80.2,1108
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2020,Age,13-17 Years,95.4,93.6 to 96.7,1108
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2019,Age,13-17 Years,94.0,91.7 to 95.6,829
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2018,Age,13-17 Years,93.1,90.8 to 94.8,886
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 2,2016,Age,13-17 Years,57.9,54.2 to 61.4,1077
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2022,Age,13-17 Years,78.8,73.5 to 83.3,396
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2011,Age,13-17 Years,6.0,4.2 to 8.5,654
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2021,Age,13-17 Years,75.3,69.1 to 80.6,400
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2020,Age,13-17 Years,79.1,74.2 to 83.3,513
Varicella,≥2 Doses with no disease history,HHS Regions/National,Region 2,2022,Age,13-17 Years,94.1,91.8 to 95.8,779
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 2,2017,Age,13-17 Years,56.2,52.5 to 59.9,1017
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2019,Age,13-17 Years,72.9,66.7 to 78.3,405
HPV,"≥2 Doses, Males and Females",HHS Regions/National,Region 2,2018,Age,13-17 Years,56.3,52.0 to 60.5,886
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2021,Age,13-17 Years,69.6,63.7 to 74.9,473
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2020,Age,13-17 Years,75.2,70.3 to 79.5,595
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2019,Age,13-17 Years,66.4,60.1 to 72.2,424
HPV,"≥1 Dose, Males",HHS Regions/National,Region 2,2018,Age,13-17 Years,65.2,59.5 to 70.6,473
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2016,Age,13-17 Years,72.0,67.2 to 76.4,520
HPV,"≥1 Dose, Females",HHS Regions/National,Region 2,2017,Age,13-17 Years,71.4,66.1 to 76.1,461
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2007,Age,13-17 Years,26.2,17.8 to 36.7,105
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2014,Age,13-15 Years,84.5,80.1 to 88.0,551
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2015,Age,13-15 Years,89.0,85.8 to 91.6,601
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2013,Age,13-15 Years,85.0,81.0 to 88.3,600
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2012,Age,13-15 Years,82.6,78.2 to 86.3,602
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2020,Age,13-15 Years,93.1,90.1 to 95.2,692
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2009,Age,13-17 Years,41.1,35.6 to 46.8,459
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2011,Age,13-17 Years,44.1,39.4 to 48.9,618
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2010,Age,13-17 Years,42.3,36.9 to 47.8,509
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2019,Age,13-15 Years,94.5,91.6 to 96.4,536
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2018,Age,13-15 Years,93.9,91.1 to 95.9,517
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2017,Age,13-15 Years,89.7,86.1 to 92.4,631
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2008,Age,13-17 Years,38.8,33.3 to 44.5,457
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2016,Age,13-17 Years,67.2,63.8 to 70.5,1077
HPV,"≥1 Dose, Males and Females",HHS Regions/National,Region 2,2017,Age,13-17 Years,67.6,64.1 to 71.0,1017
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2017,Age,13-17 Years,94.3,92.4 to 95.8,1017
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2013,Age,13-17 Years,50.2,44.8 to 55.6,501
HPV,"≥2 Doses, Females",HHS Regions/National,Region 2,2012,Age,13-17 Years,48.6,42.9 to 54.4,448
≥1 Dose MenACWY,,HHS Regions/National,Region 2,2016,Age,13-15 Years,89.4,85.9 to 92.1,653
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2014,Age,13-17 Years,34.5,29.3 to 40.0,494
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2013,Age,13-17 Years,28.1,23.6 to 33.2,531
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2012,Age,13-17 Years,11.8,8.6 to 15.9,509
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2011,Age,13-17 Years,3.3,1.9 to 5.6,654
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2013,Age,13-15 Years,88.8,84.9 to 91.7,600
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2016,Age,13-17 Years,51.6,46.4 to 56.7,557
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2017,Age,13-17 Years,51.7,46.6 to 56.8,556
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2018,Age,13-17 Years,55.7,49.9 to 61.3,473
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2014,Age,13-15 Years,91.0,87.2 to 93.8,551
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2015,Age,13-15 Years,88.0,84.3 to 90.9,601
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2016,Age,13-15 Years,91.0,87.8 to 93.4,653
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2017,Age,13-15 Years,91.2,88.0 to 93.6,631
Tetanus,≥1 Dose Td or Tdap,HHS Regions/National,Region 2,2022,Age,13-17 Years,91.2,88.5 to 93.3,825
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2008,Age,13-15 Years,57.0,52.1 to 61.9,596
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2010,Age,13-15 Years,84.9,81.1 to 88.1,668
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2009,Age,13-15 Years,72.3,67.4 to 76.7,573
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2011,Age,13-15 Years,88.7,85.8 to 91.1,767
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2012,Age,13-15 Years,90.1,86.4 to 92.9,602
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2007,Age,13-15 Years,40.8,31.2 to 51.2,135
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2006,Age,13-15 Years,16.9,10.4 to 26.2,141
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2018,Age,13-15 Years,88.8,85.2 to 91.6,517
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2021,Age,13-15 Years,86.4,82.2 to 89.7,527
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2020,Age,13-15 Years,92.3,89.1 to 94.6,692
Tetanus,≥1 Dose Tdap,HHS Regions/National,Region 2,2019,Age,13-15 Years,91.3,87.9 to 93.8,536
HPV,"≥2 Doses, Males",HHS Regions/National,Region 2,2015,Age,13-17 Years,46.8,41.8 to 51.8,553
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2020,Age,13-15 Years,61.0,56.1 to 65.8,692
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2021,Age,13-15 Years,58.4,52.8 to 63.8,527
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2022,Age,13-17 Years,70.2,64.6 to 75.2,429
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2019,Age,13-15 Years,50.6,45.1 to 56.2,536
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2021,Age,13-17 Years,56.6,50.6 to 62.4,473
HPV,"Up-to-Date, Males and Females",HHS Regions/National,Region 2,2022,Age,13-15 Years,64.9,59.4 to 69.9,478
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2020,Age,13-17 Years,64.3,59.1 to 69.2,595
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2019,Age,13-17 Years,53.1,46.9 to 59.2,424
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2017,Age,13-17 Years,47.9,42.8 to 53.1,556
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2018,Age,13-17 Years,54.0,48.3 to 59.7,473
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2020,Age,13-17 Years,66.3,60.8 to 71.4,513
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2020,Age,13-15 Years,63.0,56.3 to 69.2,376
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2019,Age,13-15 Years,47.5,40.1 to 55.1,282
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2022,Age,13-17 Years,66.4,60.5 to 71.8,396
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2021,Age,13-17 Years,66.0,59.6 to 71.8,400
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2018,Age,13-15 Years,48.5,41.0 to 56.1,271
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2016,Age,13-17 Years,45.5,40.5 to 50.7,557
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2017,Age,13-17 Years,56.8,51.3 to 62.1,461
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2022,Age,13-15 Years,65.0,57.2 to 72.1,231
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2021,Age,13-15 Years,63.4,55.5 to 70.6,256
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2022,Age,13-15 Years,64.7,57.1 to 71.7,247
HPV,"Up-to-Date, Males",HHS Regions/National,Region 2,2021,Age,13-15 Years,53.1,45.3 to 60.8,271
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2016,Age,13-17 Years,57.6,52.3 to 62.8,520
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2019,Age,13-17 Years,57.3,50.7 to 63.6,405
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2018,Age,13-17 Years,54.8,48.5 to 61.0,413
Varicella,History of disease,HHS Regions/National,Region 2,2008,Age,13-17 Years,53.3,49.4 to 57.1,990
Varicella,History of disease,HHS Regions/National,Region 2,2009,Age,13-17 Years,51.9,47.9 to 55.8,966
Varicella,History of disease,HHS Regions/National,Region 2,2014,Age,13-17 Years,18.2,15.2 to 21.6,922
Varicella,History of disease,HHS Regions/National,Region 2,2018,Age,13-17 Years,12.4,9.9 to 15.6,886
Varicella,History of disease,HHS Regions/National,Region 2,2007,Age,13-17 Years,69.6,61.9 to 76.3,219
Varicella,History of disease,HHS Regions/National,Region 2,2016,Age,13-17 Years,11.4,9.3 to 13.9,1077
Varicella,History of disease,HHS Regions/National,Region 2,2015,Age,13-17 Years,15.9,13.3 to 18.8,1029
Varicella,History of disease,HHS Regions/National,Region 2,2017,Age,13-17 Years,13.6,11.1 to 16.4,1017
Varicella,History of disease,HHS Regions/National,Region 2,2006,Age,13-17 Years,64.3,56.1 to 71.6,227
Varicella,History of disease,HHS Regions/National,Region 2,2022,Age,13-17 Years,6.3,4.4 to 8.9,825
Varicella,History of disease,HHS Regions/National,Region 2,2021,Age,13-17 Years,7.4,5.5 to 9.9,873
Varicella,History of disease,HHS Regions/National,Region 2,2019,Age,13-17 Years,10.8,8.3 to 14.0,829
Varicella,History of disease,HHS Regions/National,Region 2,2020,Age,13-17 Years,6.6,4.9 to 8.9,1108
Varicella,History of disease,HHS Regions/National,Region 2,2011,Age,13-17 Years,31.9,28.9 to 35.1,1272
Varicella,History of disease,HHS Regions/National,Region 2,2010,Age,13-17 Years,38.5,34.8 to 42.4,1100
Varicella,History of disease,HHS Regions/National,Region 2,2013,Age,13-17 Years,20.9,18.0 to 24.0,1032
Varicella,History of disease,HHS Regions/National,Region 2,2012,Age,13-17 Years,25.0,21.8 to 28.5,957
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2018,Age,13-15 Years,48.4,40.5 to 56.4,246
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2020,Age,13-15 Years,59.1,51.7 to 66.2,316
HPV,"Up-to-Date, Females",HHS Regions/National,Region 2,2019,Age,13-15 Years,54.2,46.1 to 62.0,254
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2016,Age,13-17 Years,34.6,26.1 to 44.3,139
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2020,Age,13-17 Years,61.6,52.4 to 70.1,179
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2019,Age,13-15 Years,67.8,54.8 to 78.5,83
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2022,Age,13-15 Years,56.6,42.1 to 70.0,80
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2021,Age,13-15 Years,59.0,46.1 to 70.7,117
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2018,Age,13-15 Years,53.5,42.0 to 64.6,105
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2022,Age,13-17 Years,72.6,62.3 to 80.9,127
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2021,Age,13-17 Years,68.9,58.9 to 77.4,179
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2020,Age,13-15 Years,56.7,45.5 to 67.2,129
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2016,Age,13-17 Years,55.4,45.5 to 65.0,144
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2017,Age,13-17 Years,60.4,51.4 to 68.7,167
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2022,Age,13-15 Years,74.2,62.5 to 83.2,85
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2021,Age,13-15 Years,61.4,48.5 to 72.9,108
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2018,Age,13-17 Years,56.9,46.8 to 66.4,137
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2019,Age,13-17 Years,57.7,47.3 to 67.4,151
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2019,Age,13-15 Years,63.6,54.3 to 71.9,178
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2022,Age,13-17 Years,52.4,41.3 to 63.3,130
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2021,Age,13-15 Years,60.1,51.0 to 68.5,225
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2020,Age,13-15 Years,53.7,45.4 to 61.8,230
HPV,"Up-to-Date, Males and Females",States/Local Areas,Michigan,2022,Age,13-15 Years,65.4,55.6 to 74.1,165
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2018,Age,13-17 Years,53.3,44.3 to 62.1,176
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2017,Age,13-17 Years,48.5,39.5 to 57.7,161
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2019,Age,13-17 Years,61.1,51.3 to 70.1,146
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2020,Age,13-17 Years,61.1,52.7 to 68.8,219
HPV,"Up-to-Date, Males",States/Local Areas,Michigan,2021,Age,13-17 Years,60.7,50.4 to 70.2,179
Varicella,History of disease,States/Local Areas,Michigan,2009,Age,13-17 Years,51.9,46.3 to 57.4,446
Varicella,History of disease,States/Local Areas,Michigan,2014,Age,13-17 Years,17.6,13.1 to 23.4,330
Varicella,History of disease,States/Local Areas,Michigan,2019,Age,13-17 Years,7.8,5.1 to 11.7,297
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2018,Age,13-15 Years,57.6,44.9 to 69.4,87
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2019,Age,13-15 Years,59.5,46.4 to 71.4,95
HPV,"Up-to-Date, Females",States/Local Areas,Michigan,2020,Age,13-15 Years,50.2,38.2 to 62.1,101
Varicella,History of disease,States/Local Areas,Michigan,2008,Age,13-17 Years,63.0,56.7 to 69.0,320
Varicella,History of disease,States/Local Areas,Michigan,2016,Age,13-17 Years,14.8,10.5 to 20.3,283
Varicella,History of disease,States/Local Areas,Michigan,2017,Age,13-17 Years,12.9,9.2 to 17.8,328
Varicella,History of disease,States/Local Areas,Michigan,2022,Age,13-17 Years,7.1,4.2 to 11.7,257
Varicella,History of disease,States/Local Areas,Michigan,2020,Age,13-17 Years,7.9,5.0 to 12.3,398
Varicella,History of disease,States/Local Areas,Michigan,2018,Age,13-17 Years,8.2,5.1 to 12.9,313
Varicella,History of disease,States/Local Areas,Michigan,2015,Age,13-17 Years,14.0,10.2 to 18.9,373
Varicella,History of disease,States/Local Areas,Michigan,2010,Age,13-17 Years,47.2,40.3 to 54.2,304
Varicella,History of disease,States/Local Areas,Michigan,2011,Age,13-17 Years,34.5,28.3 to 41.1,398
Varicella,History of disease,States/Local Areas,Michigan,2013,Age,13-17 Years,25.3,19.9 to 31.4,307
Varicella,History of disease,States/Local Areas,Michigan,2012,Age,13-17 Years,30.2,24.3 to 36.9,368
Varicella,History of disease,States/Local Areas,Nebraska,2008,Age,13-17 Years,65.7,59.9 to 71.0,365
Varicella,History of disease,States/Local Areas,Nebraska,2009,Age,13-17 Years,57.8,51.3 to 63.9,286
Varicella,History of disease,States/Local Areas,Nebraska,2017,Age,13-17 Years,15.8,11.7 to 21.0,324
Varicella,History of disease,States/Local Areas,Nebraska,2012,Age,13-17 Years,33.7,27.1 to 40.9,328
Varicella,History of disease,States/Local Areas,Nebraska,2013,Age,13-17 Years,28.2,22.7 to 34.5,301
Varicella,History of disease,States/Local Areas,Nebraska,2011,Age,13-17 Years,40.3,34.0 to 47.0,368
Varicella,History of disease,States/Local Areas,Nebraska,2010,Age,13-17 Years,53.2,46.7 to 59.6,307
Varicella,History of disease,States/Local Areas,Nebraska,2018,Age,13-17 Years,13.7,9.5 to 19.2,295
Varicella,History of disease,States/Local Areas,Nebraska,2016,Age,13-17 Years,17.6,13.1 to 23.2,330
Varicella,History of disease,States/Local Areas,Nebraska,2015,Age,13-17 Years,18.3,14.3 to 23.1,393
Varicella,History of disease,States/Local Areas,Nebraska,2014,Age,13-17 Years,24.5,19.1 to 30.8,321
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2018,Age,13-15 Years,65.5,52.5 to 76.5,88
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2019,Age,13-15 Years,63.1,49.6 to 74.9,81
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2020,Age,13-15 Years,59.9,48.7 to 70.2,113
Varicella,History of disease,States/Local Areas,Nebraska,2019,Age,13-17 Years,7.7,5.0 to 11.9,285
Varicella,History of disease,States/Local Areas,Nebraska,2020,Age,13-17 Years,8.6,5.8 to 12.5,405
Varicella,History of disease,States/Local Areas,Nebraska,2021,Age,13-17 Years,7.3,4.4 to 11.9,315
Varicella,History of disease,States/Local Areas,Nebraska,2022,Age,13-17 Years,4.2,2.4 to 7.3,247
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2019,Age,13-15 Years,60.0,47.0 to 71.7,100
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2020,Age,13-17 Years,62.2,53.4 to 70.3,184
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2018,Age,13-15 Years,55.1,42.2 to 67.4,93
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2021,Age,13-17 Years,63.2,52.5 to 72.7,147
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2022,Age,13-17 Years,56.5,46.1 to 66.2,134
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2020,Age,13-15 Years,65.8,54.7 to 75.4,125
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2021,Age,13-15 Years,57.8,45.8 to 68.9,111
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2022,Age,13-15 Years,70.5,56.7 to 81.4,65
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2016,Age,13-17 Years,41.3,32.6 to 50.6,179
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2017,Age,13-17 Years,61.4,51.8 to 70.3,145
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2019,Age,13-17 Years,62.1,51.4 to 71.7,132
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2018,Age,13-17 Years,66.6,56.3 to 75.5,134
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2016,Age,13-17 Years,50.6,41.1 to 60.0,151
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2021,Age,13-17 Years,60.7,50.9 to 69.7,168
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2019,Age,13-17 Years,59.0,48.7 to 68.5,153
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2020,Age,13-17 Years,67.3,59.2 to 74.4,221
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2017,Age,13-17 Years,55.3,46.7 to 63.6,179
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2018,Age,13-17 Years,59.0,49.1 to 68.2,161
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2019,Age,13-15 Years,61.5,52.2 to 70.1,181
HPV,"Up-to-Date, Males",States/Local Areas,Nebraska,2022,Age,13-17 Years,73.9,63.9 to 82.0,113
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2021,Age,13-15 Years,55.6,46.4 to 64.4,196
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2022,Age,13-15 Years,59.2,49.8 to 68.0,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2015,Age,13-17 Years,87.7,82.9 to 91.2,393
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2009,Age,13-17 Years,33.9,25.5 to 43.3,143
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2008,Age,13-17 Years,17.5,12.4 to 24.3,186
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2015,Age,13-15 Years,33.3,24.7 to 43.1,134
HPV,"≥3 Doses, Males",States/Local Areas,Nebraska,2014,Age,13-15 Years,23.0,14.5 to 34.4,101
≥2 Doses Hep A,,States/Local Areas,Nebraska,2022,Age,13-17 Years,86.6,80.9 to 90.9,247
≥2 Doses Hep A,,States/Local Areas,Nebraska,2021,Age,13-17 Years,83.8,78.4 to 88.1,315
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2012,Age,13-17 Years,37.3,27.9 to 47.7,146
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2011,Age,13-17 Years,32.6,24.7 to 41.7,174
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2014,Age,13-17 Years,43.3,34.1 to 52.8,154
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2013,Age,13-17 Years,41.5,32.7 to 50.8,141
≥2 Doses Hep A,,States/Local Areas,Nebraska,2020,Age,13-17 Years,76.9,71.5 to 81.5,405
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2010,Age,13-17 Years,42.5,33.3 to 52.2,148
HPV,"≥3 Doses, Females",States/Local Areas,Nebraska,2015,Age,13-17 Years,48.2,39.8 to 56.8,184
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2016,Age,13-17 Years,45.9,39.4 to 52.5,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2009,Age,13-17 Years,51.6,45.1 to 57.9,286
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2010,Age,13-17 Years,70.3,64.1 to 75.8,307
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2011,Age,13-17 Years,81.8,76.0 to 86.4,368
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2021,Age,13-17 Years,61.9,54.8 to 68.6,315
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2022,Age,13-17 Years,65.4,58.1 to 72.1,247
≥2 Doses MMR,,States/Local Areas,Nebraska,2009,Age,13-17 Years,89.4,84.7 to 92.7,286
≥2 Doses MMR,,States/Local Areas,Nebraska,2008,Age,13-17 Years,88.5,83.7 to 92.0,365
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2014,Age,13-17 Years,82.2,76.2 to 87.0,321
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2013,Age,13-17 Years,86.1,80.7 to 90.2,301
HPV,"≥2 Doses, Males",States/Local Areas,Nebraska,2019,Age,13-17 Years,62.0,51.6 to 71.3,153
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2022,Age,13-15 Years,88.1,80.3 to 93.0,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2008,Age,13-17 Years,42.2,36.5 to 48.0,365
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2019,Age,13-17 Years,60.5,53.1 to 67.4,285
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2020,Age,13-17 Years,64.8,58.9 to 70.3,405
≥2 Doses MMR,,States/Local Areas,Nebraska,2011,Age,13-17 Years,94.0,89.6 to 96.6,368
≥2 Doses MMR,,States/Local Areas,Nebraska,2010,Age,13-17 Years,92.8,88.9 to 95.5,307
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2018,Age,13-17 Years,62.7,55.6 to 69.3,295
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2017,Age,13-17 Years,58.3,51.9 to 64.5,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Nebraska,2012,Age,13-17 Years,81.4,74.9 to 86.5,328
HPV,"Up-to-Date, Males and Females",States/Local Areas,Nebraska,2020,Age,13-15 Years,62.9,55.1 to 70.1,238
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2021,Age,13-15 Years,52.9,39.0 to 66.3,85
HPV,"Up-to-Date, Females",States/Local Areas,Nebraska,2022,Age,13-15 Years,49.7,37.6 to 61.9,91
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2023,Age,13-15 Years,57.3,43.0 to 70.4,82
HPV,"Up-to-Date, Females",States/Local Areas,Ohio,2023,Age,13-17 Years,65.1,53.9 to 74.9,128
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2023,Age,13-15 Years,64.2,50.8 to 75.7,97
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2023,Age,13-15 Years,91.1,82.8 to 95.6,164
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2023,Age,13-15 Years,60.6,50.7 to 69.7,179
≥1 Dose MenACWY,,States/Local Areas,Ohio,2023,Age,13-15 Years,86.5,77.7 to 92.1,179
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2023,Age,13-15 Years,84.0,75.6 to 89.9,179
≥2 Doses Hep A,,States/Local Areas,Ohio,2023,Age,13-17 Years,86.7,80.5 to 91.1,280
Varicella,≥2 Doses or history of disease,States/Local Areas,Ohio,2023,Age,13-17 Years,92.0,86.7 to 95.3,280
≥3 Doses HepB,,States/Local Areas,Ohio,2023,Age,13-17 Years,92.4,87.5 to 95.4,280
Varicella,History of disease,States/Local Areas,Ohio,2023,Age,13-17 Years,12.0,7.9 to 18.0,280
Varicella,≥1 Dose with no disease history,States/Local Areas,Ohio,2023,Age,13-17 Years,96.2,92.1 to 98.3,252
Varicella,≥2 Doses with no disease history,States/Local Areas,Ohio,2023,Age,13-17 Years,90.9,84.9 to 94.7,252
HPV,"Up-to-Date, Males",States/Local Areas,Ohio,2023,Age,13-17 Years,61.8,51.4 to 71.3,152
≥2 Doses MMR,,States/Local Areas,Ohio,2023,Age,13-17 Years,93.4,88.2 to 96.4,280
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2023,Age,13-17 Years,63.4,55.9 to 70.4,280
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2023,Age,13-17 Years,79.8,69.5 to 87.2,128
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2023,Age,13-17 Years,79.2,72.6 to 84.6,280
≥1 Dose MenACWY,,States/Local Areas,Ohio,2023,Age,13-17 Years,88.9,83.0 to 92.9,280
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2023,Age,13-17 Years,89.2,83.6 to 93.0,280
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2023,Age,13-17 Years,88.0,82.4 to 92.1,280
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Overall,Overall,90.6,88.5 to 92.3,1492
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Overall,Overall,91.8,89.9 to 93.4,1492
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Overall,Overall,72.6,69.5 to 75.4,1492
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a Non-MSA,88.5,81.7 to 93.0,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Overall,Overall,57.2,53.9 to 60.4,1492
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a Non-MSA,60.8,52.1 to 68.9,232
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Non-Principal City,71.8,67.4 to 75.9,747
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Principal City,78.7,74.1 to 82.7,513
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Non-Principal City,56.9,52.2 to 61.5,747
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a Non-MSA,43.9,35.9 to 52.3,232
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Principal City,63.5,58.1 to 68.5,513
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a Non-MSA,85.7,78.6 to 90.7,232
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.0,90.4 to 95.0,747
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Principal City,89.6,85.9 to 92.4,513
HPV,"≥2 Doses, Males and Females",States/Local Areas,Ohio,2022,Age,13-17 Years,64.7,56.7 to 72.0,269
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2023,Age,13-17 Years,78.7,69.4 to 85.7,152
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2022,Age,13-17 Years,62.9,51.8 to 72.7,146
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2012,Age,13-17 Years,39.5,29.5 to 50.5,159
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2013,Age,13-17 Years,47.6,38.4 to 57.0,156
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2017,Age,13-17 Years,69.5,61.7 to 76.4,206
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2016,Age,13-17 Years,57.6,48.1 to 66.5,178
≥1 Dose MenACWY,,States/Local Areas,Ohio,2015,Age,13-15 Years,75.3,66.4 to 82.5,200
≥1 Dose MenACWY,,States/Local Areas,Ohio,2014,Age,13-15 Years,72.4,64.6 to 79.0,265
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2017,Age,13-17 Years,64.1,58.4 to 69.3,408
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2016,Age,13-17 Years,56.2,49.5 to 62.8,338
≥1 Dose MenACWY,,States/Local Areas,Ohio,2016,Age,13-15 Years,76.8,68.1 to 83.7,201
≥1 Dose MenACWY,,States/Local Areas,Ohio,2012,Age,13-15 Years,61.9,53.0 to 70.0,202
≥1 Dose MenACWY,,States/Local Areas,Ohio,2013,Age,13-15 Years,67.0,59.0 to 74.1,209
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2017,Age,13-17 Years,93.1,89.9 to 95.4,408
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2016,Age,13-17 Years,92.8,87.9 to 95.8,338
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2014,Age,13-17 Years,85.0,79.8 to 89.0,430
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2015,Age,13-17 Years,90.0,84.4 to 93.8,332
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2009,Age,13-17 Years,67.7,61.6 to 73.2,351
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2008,Age,13-17 Years,57.8,51.2 to 64.1,311
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2008,Age,13-17 Years,21.8,15.2 to 30.3,154
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2011,Age,13-17 Years,36.7,28.9 to 45.4,181
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2010,Age,13-17 Years,40.1,31.5 to 49.3,150
≥1 Dose MenACWY,,States/Local Areas,Ohio,2020,Age,13-15 Years,94.1,89.0 to 96.9,205
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2009,Age,13-17 Years,33.9,25.6 to 43.4,176
HPV,"≥1 Dose, Males",States/Local Areas,Ohio,2022,Age,13-17 Years,71.9,60.7 to 80.9,146
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2012,Age,13-17 Years,78.9,71.8 to 84.5,327
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2013,Age,13-17 Years,86.9,81.6 to 90.9,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2011,Age,13-17 Years,79.0,73.4 to 83.6,381
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2010,Age,13-17 Years,69.3,63.2 to 74.8,302
≥1 Dose MenACWY,,States/Local Areas,Ohio,2008,Age,13-15 Years,42.7,34.8 to 51.1,190
≥1 Dose MenACWY,,States/Local Areas,Ohio,2009,Age,13-15 Years,55.9,47.7 to 63.7,207
≥1 Dose MenACWY,,States/Local Areas,Ohio,2019,Age,13-15 Years,91.7,85.9 to 95.2,166
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018,Age,13-15 Years,86.4,80.5 to 90.7,200
≥1 Dose MenACWY,,States/Local Areas,Ohio,2017,Age,13-15 Years,86.7,81.2 to 90.8,247
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2019,Age,13-17 Years,69.7,63.3 to 75.5,302
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018,Age,13-17 Years,68.3,62.0 to 73.9,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2022,Age,13-17 Years,92.1,86.3 to 95.5,269
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2021,Age,13-17 Years,92.8,86.3 to 96.4,254
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2018,Age,13-17 Years,91.5,87.6 to 94.3,329
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2019,Age,13-17 Years,94.7,91.4 to 96.8,302
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Ohio,2020,Age,13-17 Years,93.9,90.6 to 96.1,338
≥1 Dose MenACWY,,States/Local Areas,Ohio,2010,Age,13-15 Years,59.9,51.8 to 67.5,180
≥1 Dose MenACWY,,States/Local Areas,Ohio,2011,Age,13-15 Years,65.0,56.9 to 72.3,244
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2020,Age,13-17 Years,75.5,69.5 to 80.7,338
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2021,Age,13-17 Years,72.4,63.6 to 79.8,254
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2022,Age,13-17 Years,76.8,69.1 to 83.1,269
≥1 Dose MenACWY,,States/Local Areas,Ohio,2021,Age,13-15 Years,87.9,78.5 to 93.6,156
HPV,"≥1 Dose, Females",States/Local Areas,Ohio,2018,Age,13-17 Years,69.7,60.9 to 77.2,168
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2017,Age,13-17 Years,60.1,52.0 to 67.7,206
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2016,Age,13-17 Years,49.8,40.5 to 59.1,178
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2015,Age,13-17 Years,47.8,38.1 to 57.6,146
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2014,Age,13-17 Years,47.3,38.7 to 56.1,202
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2019,Age,13-17 Years,55.3,45.2 to 64.9,137
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2018,Age,13-17 Years,60.0,50.8 to 68.6,168
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2012,Age,13-15 Years,76.8,68.2 to 83.6,202
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2011,Age,13-15 Years,73.9,66.6 to 80.1,244
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2008,Age,13-15 Years,38.3,30.7 to 46.5,190
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2010,Age,13-15 Years,63.0,54.9 to 70.4,180
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2009,Age,13-15 Years,55.7,47.6 to 63.4,207
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2017,Age,13-15 Years,90.8,85.6 to 94.2,247
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2016,Age,13-15 Years,87.8,80.2 to 92.7,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2015,Age,13-15 Years,87.2,78.9 to 92.6,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2014,Age,13-15 Years,84.7,77.6 to 89.9,265
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2011,Age,13-15 Years,25.5,16.9 to 36.5,109
≥2 Doses MMR,,States/Local Areas,Ohio,2021,Age,13-17 Years,95.0,89.8 to 97.6,254
≥2 Doses MMR,,States/Local Areas,Ohio,2022,Age,13-17 Years,89.6,83.0 to 93.9,269
≥1 Dose MenACWY,,States/Local Areas,Ohio,2019,Age,13-17 Years,91.9,87.8 to 94.7,302
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018,Age,13-17 Years,85.2,80.4 to 89.0,329
≥1 Dose MenACWY,,States/Local Areas,Ohio,2020,Age,13-17 Years,93.4,89.7 to 95.9,338
≥1 Dose MenACWY,,States/Local Areas,Ohio,2021,Age,13-17 Years,90.3,83.5 to 94.5,254
≥1 Dose MenACWY,,States/Local Areas,Ohio,2022,Age,13-17 Years,92.1,86.1 to 95.6,269
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2013,Age,13-15 Years,87.5,80.9 to 92.0,209
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2012,Age,13-17 Years,6.9,3.9 to 11.9,168
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2018,Age,13-17 Years,58.1,48.8 to 66.9,161
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2017,Age,13-17 Years,42.6,34.8 to 50.8,202
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2016,Age,13-17 Years,46.5,37.1 to 56.2,160
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2015,Age,13-17 Years,32.0,24.5 to 40.6,186
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2013,Age,13-17 Years,19.7,13.5 to 27.8,163
HPV,"≥2 Doses, Males",States/Local Areas,Ohio,2014,Age,13-17 Years,29.3,22.2 to 37.5,228
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2019,Age,13-15 Years,94.8,89.7 to 97.5,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2020,Age,13-15 Years,93.8,88.9 to 96.6,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2021,Age,13-15 Years,86.9,77.0 to 93.0,156
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018,Age,13-15 Years,90.8,85.1 to 94.4,200
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2012,Age,13-15 Years,25.3,16.2 to 37.3,103
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2013,Age,13-15 Years,25.8,17.6 to 36.3,100
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2015,Age,13-15 Years,28.0,18.6 to 39.9,88
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2014,Age,13-15 Years,29.0,20.0 to 40.0,123
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2009,Age,13-15 Years,18.0,10.7 to 28.7,100
HPV,"≥3 Doses, Females",States/Local Areas,Ohio,2010,Age,13-15 Years,24.3,16.0 to 35.3,86
HPV,"≥2 Doses, Females",States/Local Areas,Ohio,2022,Age,13-17 Years,66.6,54.7 to 76.8,123
≥1 Dose MenACWY,,States/Local Areas,Ohio,2009,Age,13-17 Years,53.7,47.5 to 59.9,351
≥1 Dose MenACWY,,States/Local Areas,Ohio,2008,Age,13-17 Years,37.7,31.7 to 44.1,311
≥1 Dose MenACWY,,States/Local Areas,Ohio,2011,Age,13-17 Years,66.0,59.7 to 71.8,381
≥1 Dose MenACWY,,States/Local Areas,Ohio,2010,Age,13-17 Years,61.6,55.3 to 67.4,302
≥1 Dose MenACWY,,States/Local Areas,Ohio,2012,Age,13-17 Years,66.4,59.2 to 72.8,327
≥1 Dose MenACWY,,States/Local Areas,Ohio,2022,Age,13-15 Years,90.8,81.9 to 95.5,163
≥2 Doses MMR,,States/Local Areas,Ohio,2014,Age,13-17 Years,88.2,83.3 to 91.7,430
≥2 Doses MMR,,States/Local Areas,Ohio,2015,Age,13-17 Years,90.0,85.4 to 93.2,332
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2017,Age,13-17 Years,90.6,86.9 to 93.3,408
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018,Age,13-17 Years,89.1,84.6 to 92.4,329
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2016,Age,13-17 Years,90.8,85.6 to 94.3,338
≥2 Doses MMR,,States/Local Areas,Ohio,2016,Age,13-17 Years,93.3,89.0 to 96.0,338
≥2 Doses MMR,,States/Local Areas,Ohio,2012,Age,13-17 Years,86.6,79.9 to 91.4,327
≥2 Doses MMR,,States/Local Areas,Ohio,2013,Age,13-17 Years,92.9,88.7 to 95.6,319
HPV,"≥3 Doses, Males and Females",States/Local Areas,Ohio,2012,Age,13-17 Years,16.7,11.6 to 23.5,327
HPV,"≥3 Doses, Males and Females",States/Local Areas,Ohio,2011,Age,13-17 Years,16.2,12.1 to 21.3,381
≥1 Dose MenACWY,,States/Local Areas,Ohio,2016,Age,13-17 Years,79.6,73.4 to 84.7,338
≥1 Dose MenACWY,,States/Local Areas,Ohio,2015,Age,13-17 Years,76.1,69.6 to 81.6,332
≥1 Dose MenACWY,,States/Local Areas,Ohio,2014,Age,13-17 Years,73.7,67.9 to 78.7,430
≥1 Dose MenACWY,,States/Local Areas,Ohio,2013,Age,13-17 Years,69.2,62.8 to 74.9,319
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2019,Age,13-17 Years,94.2,90.7 to 96.4,302
≥1 Dose MenACWY,,States/Local Areas,Ohio,2017,Age,13-17 Years,87.3,83.4 to 90.4,408
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2020,Age,13-17 Years,93.4,90.0 to 95.7,338
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2021,Age,13-17 Years,90.8,84.4 to 94.8,254
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2022,Age,13-17 Years,91.7,86.0 to 95.2,269
≥2 Doses MMR,,States/Local Areas,Ohio,2019,Age,13-17 Years,92.7,88.7 to 95.3,302
≥2 Doses MMR,,States/Local Areas,Ohio,2018,Age,13-17 Years,89.5,84.7 to 93.0,329
≥2 Doses MMR,,States/Local Areas,Ohio,2017,Age,13-17 Years,94.2,91.4 to 96.1,408
≥2 Doses MMR,,States/Local Areas,Ohio,2020,Age,13-17 Years,93.3,89.2 to 95.9,338
HPV,"≥3 Doses, Males and Females",States/Local Areas,Ohio,2013,Age,13-17 Years,24.6,19.5 to 30.6,319
HPV,"≥3 Doses, Males and Females",States/Local Areas,Ohio,2015,Age,13-17 Years,29.2,23.7 to 35.4,332
HPV,"≥3 Doses, Males and Females",States/Local Areas,Ohio,2014,Age,13-17 Years,29.1,23.9 to 35.0,430
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.5,90.9 to 95.3,747
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Urbanicity,Living In a MSA Principal City,91.2,87.8 to 93.7,513
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"White, Non-Hispanic",53.5,49.6 to 57.3,1110
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.5,86.0 to 94.9,138
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,Hispanic,72.6,59.8 to 82.5,117
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",79.2,70.3 to 86.0,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",71.2,61.4 to 79.4,127
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.2,50.9 to 70.6,138
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,Hispanic,60.6,47.9 to 72.0,117
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",94.5,88.7 to 97.4,127
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.7,87.0 to 91.9,1110
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.9,88.3 to 92.9,1110
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,Hispanic,90.2,80.8 to 95.3,117
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",96.9,92.9 to 98.7,127
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",91.2,85.3 to 94.9,138
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Race and Ethnicity,Hispanic,92.1,84.2 to 96.2,117
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.6,64.9 to 72.1,1110
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Poverty,Below Poverty Level,80.6,73.0 to 86.5,209
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",87.5,78.9 to 92.9,127
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Poverty,Living At or Above Poverty Level,70.2,66.7 to 73.4,1244
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Poverty,Below Poverty Level,87.9,81.3 to 92.4,209
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Poverty,Living At or Above Poverty Level,90.9,88.6 to 92.7,1244
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Poverty,Below Poverty Level,60.4,51.9 to 68.3,209
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Poverty,Living At or Above Poverty Level,55.9,52.2 to 59.4,1244
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Poverty,Living At or Above Poverty Level,92.0,89.9 to 93.7,1244
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Poverty,Below Poverty Level,88.9,82.3 to 93.3,209
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Insurance Coverage,Any Medicaid,89.3,85.5 to 92.2,451
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Insurance Coverage,Private Insurance Only,92.5,90.0 to 94.4,951
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Insurance Coverage,Private Insurance Only,72.0,68.1 to 75.5,951
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Insurance Coverage,Any Medicaid,75.6,70.3 to 80.2,451
≥1 Dose MenACWY,,States/Local Areas,Ohio,2018-2022,Insurance Coverage,Other,78.6,59.6 to 90.1,65
HPV,"≥1 Dose, Males and Females",States/Local Areas,Ohio,2018-2022,Insurance Coverage,Other,67.0,50.3 to 80.2,65
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Insurance Coverage,Private Insurance Only,57.3,53.2 to 61.3,951
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Insurance Coverage,Any Medicaid,58.5,52.8 to 64.1,451
HPV,"Up-to-Date, Males and Females",States/Local Areas,Ohio,2018-2022,Insurance Coverage,Other,52.8,36.5 to 68.6,65
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Insurance Coverage,Private Insurance Only,92.2,89.6 to 94.2,951
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Insurance Coverage,Any Medicaid,92.9,89.7 to 95.2,451
Tetanus,≥1 Dose Tdap,States/Local Areas,Ohio,2018-2022,Insurance Coverage,Other,81.3,66.5 to 90.5,65
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2018,Age,13-17 Years,64.3,55.8 to 71.9,178
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2022,Age,13-17 Years,70.3,60.6 to 78.5,148
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2019,Age,13-15 Years,57.3,49.9 to 64.4,291
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2021,Age,13-17 Years,69.5,62.6 to 75.6,272
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2021,Age,13-15 Years,62.4,55.3 to 69.0,283
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2020,Age,13-15 Years,68.5,61.0 to 75.2,247
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2016,Age,13-17 Years,53.1,45.2 to 60.7,209
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2018,Age,13-15 Years,57.3,46.1 to 67.8,102
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2022,Age,13-17 Years,73.7,63.7 to 81.7,143
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2020,Age,13-17 Years,75.3,66.8 to 82.3,195
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2022,Age,13-15 Years,61.9,52.4 to 70.7,164
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2019,Age,13-17 Years,60.3,52.3 to 67.7,244
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2019,Age,13-15 Years,56.8,47.1 to 66.1,165
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2021,Age,13-17 Years,63.8,55.8 to 71.1,216
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2020,Age,13-15 Years,62.4,51.3 to 72.4,121
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2021,Age,13-15 Years,56.5,45.8 to 66.7,123
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2022,Age,13-15 Years,66.4,52.6 to 77.9,83
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2019,Age,13-15 Years,58.0,46.6 to 68.6,126
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2016,Age,13-17 Years,58.4,49.7 to 66.7,171
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2020,Age,13-17 Years,65.9,57.4 to 73.4,203
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2017,Age,13-17 Years,60.8,52.3 to 68.7,192
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2017,Age,13-15 Years,94.6,89.3 to 97.4,191
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2015,Age,13-15 Years,96.8,93.0 to 98.6,211
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2022,Age,13-17 Years,92.7,87.5 to 95.8,291
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2020,Age,13-17 Years,95.8,92.6 to 97.6,398
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2016,Age,13-15 Years,95.4,89.4 to 98.1,175
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2010,Age,13-17 Years,91.9,87.6 to 94.8,320
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2009,Age,13-17 Years,86.2,82.0 to 89.6,426
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2011,Age,13-17 Years,89.9,85.1 to 93.2,404
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2012,Age,13-17 Years,95.3,92.3 to 97.2,322
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2013,Age,13-17 Years,94.2,90.4 to 96.5,326
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2019,Age,13-17 Years,95.9,92.5 to 97.8,472
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2018,Age,13-17 Years,94.9,91.8 to 96.9,324
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2008,Age,13-17 Years,78.5,72.2 to 83.7,283
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2016,Age,13-17 Years,96.0,93.0 to 97.8,380
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2017,Age,13-17 Years,94.6,90.9 to 96.8,366
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2015,Age,13-17 Years,97.1,94.8 to 98.4,404
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2014,Age,13-17 Years,94.8,90.6 to 97.1,367
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2012,Age,13-17 Years,10.6,6.1 to 17.6,164
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2013,Age,13-17 Years,21.7,15.0 to 30.4,165
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2015,Age,13-17 Years,41.1,33.6 to 49.0,215
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2014,Age,13-17 Years,30.5,22.7 to 39.5,185
≥2 Doses Hep A,,States/Local Areas,Vermont,2022,Age,13-17 Years,85.0,79.5 to 89.2,291
≥2 Doses Hep A,,States/Local Areas,Vermont,2020,Age,13-17 Years,72.5,66.8 to 77.6,398
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2013,Age,13-15 Years,23.4,14.3 to 36.0,88
≥2 Doses Hep A,,States/Local Areas,Vermont,2021,Age,13-17 Years,79.7,75.3 to 83.5,488
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2010,Age,13-17 Years,38.6,30.2 to 47.7,155
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2012,Age,13-17 Years,46.2,36.9 to 55.8,158
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2019,Age,13-17 Years,63.6,57.9 to 68.9,472
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2022,Age,13-17 Years,71.9,65.1 to 77.9,291
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2021,Age,13-17 Years,66.7,61.5 to 71.6,488
≥2 Doses MMR,,States/Local Areas,Vermont,2010,Age,13-17 Years,96.8,94.1 to 98.3,320
≥2 Doses MMR,,States/Local Areas,Vermont,2011,Age,13-17 Years,92.5,87.5 to 95.6,404
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2017,Age,13-17 Years,64.5,58.4 to 70.2,366
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018,Age,13-17 Years,62.0,55.8 to 67.9,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2010,Age,13-17 Years,82.7,76.9 to 87.2,320
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2009,Age,13-17 Years,70.7,65.4 to 75.6,426
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2011,Age,13-17 Years,90.1,86.3 to 92.9,404
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2022,Age,13-15 Years,93.0,86.0 to 96.7,164
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2008,Age,13-17 Years,49.2,42.5 to 55.9,283
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2013,Age,13-17 Years,91.8,87.4 to 94.8,326
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2014,Age,13-17 Years,93.4,89.1 to 96.0,367
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2012,Age,13-17 Years,93.1,88.5 to 96.0,322
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2019,Age,13-17 Years,61.7,53.7 to 69.0,244
≥2 Doses MMR,,States/Local Areas,Vermont,2009,Age,13-17 Years,96.5,94.2 to 97.9,426
≥2 Doses MMR,,States/Local Areas,Vermont,2008,Age,13-17 Years,95.2,91.5 to 97.4,283
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2016,Age,13-17 Years,55.7,49.9 to 61.3,380
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2021,Age,13-15 Years,94.7,90.6 to 97.1,283
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2015,Age,13-15 Years,37.9,29.0 to 47.8,136
HPV,"≥3 Doses, Males",States/Local Areas,Vermont,2014,Age,13-15 Years,30.9,21.4 to 42.2,113
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2009,Age,13-17 Years,39.1,31.4 to 47.3,184
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2008,Age,13-17 Years,25.8,18.2 to 35.2,144
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2020,Age,13-17 Years,70.5,64.5 to 75.8,398
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2015,Age,13-17 Years,54.4,46.0 to 62.6,189
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2013,Age,13-17 Years,42.7,33.9 to 52.0,161
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2014,Age,13-17 Years,49.8,40.7 to 58.9,182
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2011,Age,13-17 Years,50.1,41.4 to 58.9,205
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2019,Age,13-17 Years,67.0,58.9 to 74.3,228
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2018,Age,13-17 Years,59.6,50.3 to 68.2,146
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2017,Age,13-17 Years,68.5,59.5 to 76.3,174
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2022,Age,13-15 Years,57.6,44.2 to 69.9,81
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2021,Age,13-15 Years,67.8,58.7 to 75.7,160
Varicella,History of disease,States/Local Areas,Vermont,2015,Age,13-17 Years,22.5,18.1 to 27.7,404
Varicella,History of disease,States/Local Areas,Vermont,2016,Age,13-17 Years,18.3,14.4 to 22.9,380
Varicella,History of disease,States/Local Areas,Vermont,2017,Age,13-17 Years,18.0,13.5 to 23.6,366
Varicella,History of disease,States/Local Areas,Vermont,2018,Age,13-17 Years,17.0,12.6 to 22.4,324
Varicella,History of disease,States/Local Areas,Vermont,2010,Age,13-17 Years,56.9,50.5 to 63.0,320
Varicella,History of disease,States/Local Areas,Vermont,2011,Age,13-17 Years,44.5,38.6 to 50.7,404
Varicella,History of disease,States/Local Areas,Vermont,2012,Age,13-17 Years,38.3,32.1 to 44.9,322
Varicella,History of disease,States/Local Areas,Vermont,2013,Age,13-17 Years,36.1,30.0 to 42.6,326
Varicella,History of disease,States/Local Areas,Vermont,2009,Age,13-17 Years,57.3,51.7 to 62.7,426
Varicella,History of disease,States/Local Areas,Vermont,2014,Age,13-17 Years,27.7,22.1 to 34.2,367
Varicella,History of disease,States/Local Areas,Vermont,2008,Age,13-17 Years,65.1,58.2 to 71.4,283
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2018,Age,13-15 Years,53.5,42.2 to 64.5,98
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2020,Age,13-15 Years,74.6,64.4 to 82.7,126
Varicella,History of disease,States/Local Areas,Vermont,2021,Age,13-17 Years,8.5,6.2 to 11.6,488
Varicella,History of disease,States/Local Areas,Vermont,2022,Age,13-17 Years,7.8,4.7 to 12.7,291
Varicella,History of disease,States/Local Areas,Vermont,2020,Age,13-17 Years,9.0,6.0 to 13.1,398
Varicella,History of disease,States/Local Areas,Vermont,2019,Age,13-17 Years,13.9,10.1 to 18.8,472
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2023,Age,13-17 Years,86.2,75.4 to 92.7,119
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2023,Age,13-15 Years,57.4,41.6 to 71.8,73
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2023,Age,13-17 Years,70.8,59.2 to 80.3,104
HPV,"Up-to-Date, Females",States/Local Areas,Vermont,2023,Age,13-15 Years,66.3,50.6 to 79.2,59
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2023,Age,13-15 Years,95.0,86.0 to 98.3,123
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2023,Age,13-15 Years,61.5,50.3 to 71.7,132
≥1 Dose MenACWY,,States/Local Areas,Vermont,2023,Age,13-15 Years,86.0,75.5 to 92.4,132
≥2 Doses Hep A,,States/Local Areas,Vermont,2023,Age,13-17 Years,90.3,83.8 to 94.3,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2023,Age,13-15 Years,94.0,85.7 to 97.6,132
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2023,Age,13-17 Years,96.4,91.6 to 98.5,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2023,Age,13-17 Years,96.2,91.2 to 98.4,212
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2023,Age,13-17 Years,96.7,91.4 to 98.7,212
≥2 Doses MMR,,States/Local Areas,Vermont,2023,Age,13-17 Years,93.9,88.6 to 96.8,223
≥3 Doses HepB,,States/Local Areas,Vermont,2023,Age,13-17 Years,93.5,88.3 to 96.5,223
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2023,Age,13-17 Years,68.3,60.1 to 75.5,223
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2023,Age,13-17 Years,80.8,69.2 to 88.7,104
HPV,"Up-to-Date, Males",States/Local Areas,Vermont,2023,Age,13-17 Years,66.0,54.1 to 76.2,119
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2023,Age,13-17 Years,83.6,76.1 to 89.1,223
≥1 Dose MenACWY,,States/Local Areas,Vermont,2023,Age,13-17 Years,88.0,81.1 to 92.6,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2023,Age,13-17 Years,93.4,88.1 to 96.4,223
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2023,Age,13-17 Years,95.1,90.0 to 97.6,223
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2022,Age,13-17 Years,74.2,64.2 to 82.1,143
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2022,Age,13-17 Years,71.3,61.6 to 79.4,148
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2012,Age,13-17 Years,92.4,87.6 to 95.4,189
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2012,Age,13-17 Years,95.8,91.8 to 97.9,189
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2009,Age,13-17 Years,60.7,52.5 to 68.4,184
≥3 Doses HepB,,States/Local Areas,Vermont,2013,Age,13-17 Years,93.1,89.1 to 95.7,326
≥3 Doses HepB,,States/Local Areas,Vermont,2014,Age,13-17 Years,93.1,88.6 to 95.9,367
≥3 Doses HepB,,States/Local Areas,Vermont,2011,Age,13-17 Years,94.0,89.9 to 96.5,404
≥3 Doses HepB,,States/Local Areas,Vermont,2012,Age,13-17 Years,93.4,88.7 to 96.3,322
≥3 Doses HepB,,States/Local Areas,Vermont,2018,Age,13-17 Years,96.6,94.1 to 98.1,324
≥3 Doses HepB,,States/Local Areas,Vermont,2016,Age,13-17 Years,94.0,90.1 to 96.4,380
≥3 Doses HepB,,States/Local Areas,Vermont,2019,Age,13-17 Years,92.2,88.3 to 94.8,472
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2017,Age,13-17 Years,96.5,92.7 to 98.3,308
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2018,Age,13-17 Years,98.2,96.3 to 99.1,276
≥3 Doses HepB,,States/Local Areas,Vermont,2015,Age,13-17 Years,96.1,93.7 to 97.6,404
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2019,Age,13-17 Years,95.2,91.4 to 97.4,418
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2021,Age,13-17 Years,95.0,92.2 to 96.8,442
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2020,Age,13-17 Years,95.3,91.9 to 97.4,364
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2020,Age,13-17 Years,97.9,95.8 to 99.0,364
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2018,Age,13-17 Years,93.9,90.2 to 96.3,276
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2013,Age,13-17 Years,96.7,93.1 to 98.4,217
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2014,Age,13-17 Years,96.8,92.8 to 98.7,274
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2015,Age,13-17 Years,99.0,97.5 to 99.6,312
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2016,Age,13-17 Years,97.8,95.5 to 99.0,305
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2018,Age,13-15 Years,94.0,89.1 to 96.8,180
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2011,Age,13-15 Years,89.9,82.4 to 94.4,145
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2010,Age,13-15 Years,86.8,76.7 to 93.0,107
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2012,Age,13-15 Years,94.2,88.6 to 97.1,116
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2013,Age,13-15 Years,89.6,81.0 to 94.6,136
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2009,Age,13-15 Years,75.0,66.3 to 82.1,137
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2008,Age,13-15 Years,36.2,24.7 to 49.4,73
Varicella,≥2 Doses or history of disease,States/Local Areas,Vermont,2021,Age,13-17 Years,95.4,92.9 to 97.1,488
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2011,Age,13-17 Years,63.0,54.6 to 70.6,205
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2010,Age,13-17 Years,49.6,40.4 to 58.8,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2017,Age,13-17 Years,93.4,89.0 to 96.1,308
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2013,Age,13-17 Years,90.9,85.3 to 94.5,217
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2014,Age,13-17 Years,92.8,87.2 to 96.0,274
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2015,Age,13-17 Years,96.2,93.3 to 97.9,312
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2016,Age,13-17 Years,95.2,91.4 to 97.3,305
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2012,Age,13-17 Years,66.4,56.9 to 74.8,158
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2013,Age,13-17 Years,60.2,51.0 to 68.8,161
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2014,Age,13-17 Years,63.4,54.2 to 71.7,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2020,Age,13-15 Years,94.2,88.9 to 97.0,234
HPV,"≥2 Doses, Males and Females",States/Local Areas,Vermont,2016,Age,13-17 Years,62.4,56.6 to 67.8,380
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2021,Age,13-17 Years,97.4,95.4 to 98.6,442
HPV,"≥2 Doses, Males and Females",States/Local Areas,Vermont,2017,Age,13-17 Years,68.5,62.5 to 73.9,366
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2022,Age,13-17 Years,89.4,80.9 to 94.4,143
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2020,Age,13-17 Years,86.8,79.5 to 91.7,195
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2022,Age,13-17 Years,92.1,86.4 to 95.5,268
HPV,"≥2 Doses, Males and Females",States/Local Areas,Vermont,2018,Age,13-17 Years,64.2,58.0 to 69.9,324
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2013,Age,13-17 Years,41.3,32.8 to 50.3,165
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2014,Age,13-17 Years,50.5,41.3 to 59.7,185
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2015,Age,13-17 Years,66.1,58.1 to 73.3,215
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2016,Age,13-17 Years,69.5,61.8 to 76.3,209
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2019,Age,13-17 Years,85.9,79.7 to 90.4,228
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2021,Age,13-17 Years,84.8,77.9 to 89.8,216
≥3 Doses HepB,,States/Local Areas,Vermont,2017,Age,13-17 Years,91.8,87.7 to 94.6,366
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2018,Age,13-17 Years,73.9,66.0 to 80.5,178
≥3 Doses HepB,,States/Local Areas,Vermont,2008,Age,13-17 Years,94.8,91.4 to 96.9,283
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2021,Age,13-15 Years,95.6,91.9 to 97.7,260
HPV,"≥2 Doses, Males and Females",States/Local Areas,Vermont,2019,Age,13-17 Years,65.1,59.4 to 70.3,472
≥3 Doses HepB,,States/Local Areas,Vermont,2010,Age,13-17 Years,95.8,92.5 to 97.7,320
≥3 Doses HepB,,States/Local Areas,Vermont,2009,Age,13-17 Years,94.7,92.0 to 96.6,426
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2008,Age,13-17 Years,93.0,83.8 to 97.2,92
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2011,Age,13-17 Years,92.0,84.7 to 96.0,229
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2022,Age,13-15 Years,93.7,85.8 to 97.3,155
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2009,Age,13-17 Years,67.8,59.4 to 75.1,179
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2008,Age,13-17 Years,38.4,27.5 to 50.7,92
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2019,Age,13-15 Years,95.2,90.0 to 97.7,265
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2008,Age,13-17 Years,50.4,40.9 to 59.8,144
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2010,Age,13-17 Years,81.2,72.4 to 87.7,149
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2011,Age,13-17 Years,81.7,73.9 to 87.6,229
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2010,Age,13-17 Years,93.8,88.4 to 96.8,149
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2009,Age,13-17 Years,90.0,83.3 to 94.3,179
≥1 Dose MenACWY,,States/Local Areas,Vermont,2019,Age,13-15 Years,92.5,87.9 to 95.4,291
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2017,Age,13-17 Years,78.7,73.2 to 83.3,366
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018,Age,13-15 Years,88.5,82.8 to 92.4,200
≥3 Doses HepB,,States/Local Areas,Vermont,2022,Age,13-17 Years,92.4,87.4 to 95.5,291
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2017,Age,13-17 Years,73.9,65.6 to 80.7,192
≥3 Doses HepB,,States/Local Areas,Vermont,2021,Age,13-17 Years,94.1,91.1 to 96.1,488
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2022,Age,13-17 Years,96.5,92.5 to 98.4,268
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2020,Age,13-17 Years,87.2,80.6 to 91.8,203
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2012,Age,13-17 Years,25.7,18.3 to 34.7,164
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2015,Age,13-17 Years,97.1,94.4 to 98.5,404
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2014,Age,13-17 Years,94.9,90.6 to 97.2,367
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2016,Age,13-17 Years,95.9,93.0 to 97.6,380
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2013,Age,13-17 Years,93.8,89.8 to 96.3,326
≥1 Dose MenACWY,,States/Local Areas,Vermont,2016,Age,13-15 Years,84.7,78.1 to 89.5,212
≥1 Dose MenACWY,,States/Local Areas,Vermont,2015,Age,13-15 Years,83.6,77.1 to 88.5,246
≥1 Dose MenACWY,,States/Local Areas,Vermont,2014,Age,13-15 Years,80.5,73.3 to 86.1,216
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2008,Age,13-17 Years,44.8,35.5 to 54.5,144
≥1 Dose MenACWY,,States/Local Areas,Vermont,2017,Age,13-15 Years,84.1,77.3 to 89.1,223
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2016,Age,13-17 Years,70.3,64.6 to 75.5,380
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2015,Age,13-17 Years,68.7,60.1 to 76.2,189
Varicella,≥1 Dose with no disease history,States/Local Areas,Vermont,2019,Age,13-17 Years,97.0,93.7 to 98.6,418
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2016,Age,13-17 Years,71.2,62.4 to 78.6,171
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2017,Age,13-17 Years,83.8,76.4 to 89.3,174
HPV,"≥1 Dose, Females",States/Local Areas,Vermont,2018,Age,13-17 Years,82.9,75.4 to 88.5,146
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2017,Age,13-17 Years,93.1,89.5 to 95.5,366
≥3 Doses HepB,,States/Local Areas,Vermont,2020,Age,13-17 Years,93.3,89.4 to 95.8,398
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2010,Age,13-17 Years,48.2,39.1 to 57.5,155
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2011,Age,13-17 Years,55.8,47.1 to 64.2,205
≥1 Dose MenACWY,,States/Local Areas,Vermont,2020,Age,13-15 Years,92.4,87.1 to 95.6,247
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2009,Age,13-17 Years,49.9,41.7 to 58.1,184
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2012,Age,13-17 Years,58.0,48.5 to 66.9,158
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2013,Age,13-17 Years,53.5,44.3 to 62.5,161
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2022,Age,13-17 Years,86.6,78.9 to 91.8,148
≥1 Dose MenACWY,,States/Local Areas,Vermont,2009,Age,13-15 Years,43.9,36.9 to 51.1,258
≥1 Dose MenACWY,,States/Local Areas,Vermont,2008,Age,13-15 Years,19.8,14.0 to 27.3,179
≥1 Dose MenACWY,,States/Local Areas,Vermont,2011,Age,13-15 Years,63.7,55.5 to 71.1,226
≥1 Dose MenACWY,,States/Local Areas,Vermont,2010,Age,13-15 Years,55.7,47.3 to 63.9,193
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2021,Age,13-17 Years,82.2,75.9 to 87.1,272
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2010,Age,13-17 Years,89.6,84.3 to 93.3,320
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2011,Age,13-17 Years,93.0,89.4 to 95.4,404
≥1 Dose MenACWY,,States/Local Areas,Vermont,2012,Age,13-15 Years,70.1,61.2 to 77.8,178
≥1 Dose MenACWY,,States/Local Areas,Vermont,2013,Age,13-15 Years,77.0,68.9 to 83.6,186
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2012,Age,13-17 Years,94.5,89.8 to 97.1,322
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2009,Age,13-17 Years,87.0,82.7 to 90.3,426
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2008,Age,13-17 Years,79.8,73.7 to 84.8,283
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2019,Age,13-17 Years,95.3,91.8 to 97.3,472
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018,Age,13-17 Years,78.3,73.0 to 82.8,324
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2022,Age,13-17 Years,88.0,82.6 to 91.8,291
HPV,"≥1 Dose, Males",States/Local Areas,Vermont,2019,Age,13-17 Years,78.3,71.1 to 84.1,244
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2019,Age,13-17 Years,82.0,77.3 to 85.8,472
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2021,Age,13-17 Years,95.5,92.8 to 97.2,488
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2018,Age,13-17 Years,96.0,93.2 to 97.7,324
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2020,Age,13-17 Years,96.9,94.7 to 98.2,398
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2015,Age,13-17 Years,59.1,50.6 to 67.1,189
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2014,Age,13-17 Years,55.8,46.6 to 64.7,182
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2016,Age,13-17 Years,63.4,54.7 to 71.4,171
≥1 Dose MenACWY,,States/Local Areas,Vermont,2021,Age,13-15 Years,87.0,81.6 to 91.0,283
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2021,Age,13-17 Years,83.4,79.0 to 87.1,488
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2020,Age,13-17 Years,87.0,82.3 to 90.6,398
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2011,Age,13-15 Years,91.6,86.5 to 94.9,226
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2012,Age,13-15 Years,94.4,86.4 to 97.8,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2009,Age,13-15 Years,78.5,72.5 to 83.6,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2010,Age,13-15 Years,85.2,77.6 to 90.6,193
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Vermont,2022,Age,13-17 Years,95.1,91.0 to 97.4,291
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2008,Age,13-15 Years,54.5,46.0 to 62.7,179
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2017,Age,13-17 Years,72.4,63.7 to 79.7,174
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2019,Age,13-15 Years,92.4,86.7 to 95.8,291
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2018,Age,13-17 Years,62.5,53.2 to 71.0,146
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2015,Age,13-15 Years,95.1,90.6 to 97.5,246
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2014,Age,13-15 Years,95.4,90.8 to 97.7,216
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2016,Age,13-15 Years,93.7,88.2 to 96.7,212
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2018,Age,13-17 Years,65.7,57.4 to 73.2,178
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2017,Age,13-15 Years,92.8,88.2 to 95.7,223
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018,Age,13-15 Years,93.7,88.7 to 96.6,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2020,Age,13-15 Years,96.0,92.4 to 97.9,247
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2015,Age,13-17 Years,56.9,48.9 to 64.5,215
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2016,Age,13-17 Years,61.4,53.5 to 68.6,209
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2017,Age,13-17 Years,64.8,56.3 to 72.4,192
HPV,"≥2 Doses, Females",States/Local Areas,Vermont,2019,Age,13-17 Years,68.7,60.6 to 75.8,228
≥2 Doses MMR,,States/Local Areas,Vermont,2019,Age,13-17 Years,98.1,96.3 to 99.0,472
≥2 Doses MMR,,States/Local Areas,Vermont,2017,Age,13-17 Years,93.9,89.6 to 96.5,366
≥2 Doses MMR,,States/Local Areas,Vermont,2018,Age,13-17 Years,96.0,93.3 to 97.6,324
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2020,Age,13-17 Years,95.1,92.4 to 96.9,398
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2021,Age,13-17 Years,94.2,91.4 to 96.2,488
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2019,Age,13-17 Years,94.3,90.8 to 96.6,472
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2022,Age,13-17 Years,92.1,87.0 to 95.3,291
HPV,"≥3 Doses, Males and Females",States/Local Areas,Vermont,2012,Age,13-17 Years,28.0,22.3 to 34.5,322
HPV,"≥3 Doses, Males and Females",States/Local Areas,Vermont,2013,Age,13-17 Years,31.9,26.2 to 38.3,326
HPV,"≥3 Doses, Males and Females",States/Local Areas,Vermont,2014,Age,13-17 Years,39.8,33.7 to 46.3,367
HPV,"≥3 Doses, Males and Females",States/Local Areas,Vermont,2015,Age,13-17 Years,47.6,41.9 to 53.3,404
≥1 Dose MenACWY,,States/Local Areas,Vermont,2021,Age,13-17 Years,88.8,85.1 to 91.6,488
≥1 Dose MenACWY,,States/Local Areas,Vermont,2022,Age,13-17 Years,91.2,86.4 to 94.5,291
≥2 Doses MMR,,States/Local Areas,Vermont,2021,Age,13-17 Years,97.1,94.5 to 98.4,488
≥2 Doses MMR,,States/Local Areas,Vermont,2020,Age,13-17 Years,97.2,93.8 to 98.7,398
≥2 Doses MMR,,States/Local Areas,Vermont,2022,Age,13-17 Years,95.3,91.9 to 97.3,291
≥1 Dose MenACWY,,States/Local Areas,Vermont,2020,Age,13-17 Years,91.0,86.8 to 94.0,398
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018,Age,13-17 Years,90.0,85.9 to 93.1,324
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2008,Age,13-15 Years,23.9,15.6 to 34.8,88
≥1 Dose MenACWY,,States/Local Areas,Vermont,2019,Age,13-17 Years,93.6,90.3 to 95.8,472
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2011,Age,13-15 Years,42.2,30.9 to 54.3,110
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2009,Age,13-15 Years,35.9,26.9 to 46.0,117
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2010,Age,13-15 Years,28.9,20.1 to 39.8,97
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2015,Age,13-15 Years,48.0,37.2 to 59.0,110
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2014,Age,13-15 Years,42.8,31.8 to 54.7,103
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2013,Age,13-15 Years,30.6,21.0 to 42.2,98
HPV,"≥3 Doses, Females",States/Local Areas,Vermont,2012,Age,13-15 Years,39.7,28.3 to 52.2,95
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2012,Age,13-17 Years,19.4,12.7 to 28.3,164
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2014,Age,13-17 Years,40.5,31.9 to 49.8,185
HPV,"≥2 Doses, Males",States/Local Areas,Vermont,2013,Age,13-17 Years,26.3,19.1 to 35.0,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2013,Age,13-15 Years,90.1,83.4 to 94.2,186
HPV,"≥2 Doses, Males and Females",States/Local Areas,Vermont,2022,Age,13-17 Years,72.7,65.9 to 78.6,291
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Overall,Overall,83.8,81.7 to 85.6,1973
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Overall,Overall,67.0,64.3 to 69.5,1973
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a Non-MSA,93.6,91.5 to 95.2,1184
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Principal City,83.4,76.8 to 88.4,222
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Non-Principal City,82.1,77.7 to 85.8,567
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Principal City,65.5,57.6 to 72.7,222
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Non-Principal City,65.8,60.6 to 70.6,567
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Principal City,93.5,89.1 to 96.2,222
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a Non-MSA,84.6,82.1 to 86.9,1184
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.6,86.8 to 93.4,567
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a Non-MSA,90.6,88.5 to 92.4,1184
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Principal City,93.0,87.6 to 96.1,222
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a Non-MSA,67.9,64.5 to 71.0,1184
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Urbanicity,Living In a MSA Non-Principal City,95.8,93.5 to 97.3,567
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"White, Non-Hispanic",66.7,63.9 to 69.4,1750
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.5,82.0 to 94.1,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",82.1,73.4 to 88.4,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Race and Ethnicity,Hispanic,94.8,86.9 to 98.1,63
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Race and Ethnicity,Hispanic,70.7,54.9 to 82.7,63
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.8,89.0 to 92.4,1750
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",69.9,60.2 to 78.2,134
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"White, Non-Hispanic",94.7,93.2 to 95.8,1750
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Race and Ethnicity,Hispanic,93.3,83.3 to 97.5,63
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Race and Ethnicity,Hispanic,98.3,88.8 to 99.8,63
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",89.0,81.0 to 93.9,134
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Race and Ethnicity,"White, Non-Hispanic",83.5,81.3 to 85.5,1750
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Poverty,Below Poverty Level,77.9,68.9 to 84.8,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Poverty,Living At or Above Poverty Level,84.9,82.8 to 86.7,1780
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Poverty,Below Poverty Level,58.8,49.1 to 67.9,149
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Poverty,Living At or Above Poverty Level,91.2,89.5 to 92.6,1780
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Poverty,Below Poverty Level,91.8,85.1 to 95.7,149
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Insurance Coverage,Other,93.6,80.5 to 98.1,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Insurance Coverage,Any Medicaid,62.6,58.0 to 66.9,690
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Insurance Coverage,Private Insurance Only,70.7,67.5 to 73.8,1194
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Insurance Coverage,Other,64.1,50.2 to 75.9,78
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Insurance Coverage,Private Insurance Only,95.0,93.2 to 96.3,1194
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Insurance Coverage,Any Medicaid,93.0,90.3 to 95.0,690
HPV,"Up-to-Date, Males and Females",States/Local Areas,Vermont,2018-2022,Poverty,Living At or Above Poverty Level,68.2,65.5 to 70.8,1780
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Poverty,Below Poverty Level,95.3,90.8 to 97.6,149
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Insurance Coverage,Any Medicaid,90.2,87.3 to 92.5,690
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Poverty,Living At or Above Poverty Level,94.4,92.8 to 95.6,1780
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Insurance Coverage,Private Insurance Only,91.2,89.0 to 93.1,1194
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Insurance Coverage,Any Medicaid,83.4,79.9 to 86.4,690
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Insurance Coverage,Private Insurance Only,84.2,81.5 to 86.6,1194
HPV,"≥1 Dose, Males and Females",States/Local Areas,Vermont,2018-2022,Insurance Coverage,Other,83.2,70.4 to 91.2,78
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Insurance Coverage,Other,95.2,87.9 to 98.2,78
≥1 Dose MenACWY,,States/Local Areas,Vermont,2017,Age,13-17 Years,84.2,78.9 to 88.3,366
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018-2022,Overall,Overall,94.2,92.7 to 95.3,1973
≥1 Dose MenACWY,,States/Local Areas,Vermont,2018-2022,Overall,Overall,90.9,89.3 to 92.4,1973
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2015,Age,13-17 Years,95.8,92.6 to 97.7,404
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2017,Age,13-17 Years,92.8,89.2 to 95.2,366
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2018,Age,13-17 Years,95.1,91.8 to 97.1,324
≥1 Dose MenACWY,,States/Local Areas,Vermont,2010,Age,13-17 Years,54.1,47.6 to 60.5,320
≥1 Dose MenACWY,,States/Local Areas,Vermont,2011,Age,13-17 Years,65.7,59.7 to 71.2,404
≥1 Dose MenACWY,,States/Local Areas,Vermont,2009,Age,13-17 Years,43.9,38.5 to 49.5,426
≥1 Dose MenACWY,,States/Local Areas,Vermont,2008,Age,13-17 Years,20.0,15.2 to 25.8,283
≥1 Dose MenACWY,,States/Local Areas,Vermont,2022,Age,13-15 Years,89.3,81.5 to 94.1,164
Tetanus,≥1 Dose Tdap,States/Local Areas,Vermont,2016,Age,13-17 Years,93.8,90.4 to 96.1,380
≥2 Doses MMR,,States/Local Areas,Vermont,2015,Age,13-17 Years,97.0,94.8 to 98.3,404
≥2 Doses MMR,,States/Local Areas,Vermont,2014,Age,13-17 Years,95.2,91.3 to 97.4,367
≥2 Doses MMR,,States/Local Areas,Vermont,2012,Age,13-17 Years,95.9,93.0 to 97.6,322
≥2 Doses MMR,,States/Local Areas,Vermont,2013,Age,13-17 Years,94.5,91.1 to 96.7,326
≥2 Doses MMR,,States/Local Areas,Vermont,2016,Age,13-17 Years,93.7,89.7 to 96.2,380
HPV,"≥3 Doses, Males and Females",States/Local Areas,Vermont,2011,Age,13-17 Years,24.6,19.5 to 30.6,404
≥1 Dose MenACWY,,States/Local Areas,Vermont,2012,Age,13-17 Years,72.6,66.2 to 78.3,322
≥1 Dose MenACWY,,States/Local Areas,Vermont,2013,Age,13-17 Years,79.2,73.4 to 84.0,326
≥1 Dose MenACWY,,States/Local Areas,Vermont,2014,Age,13-17 Years,81.3,75.7 to 85.9,367
≥1 Dose MenACWY,,States/Local Areas,Vermont,2015,Age,13-17 Years,84.4,79.6 to 88.2,404
≥1 Dose MenACWY,,States/Local Areas,Vermont,2016,Age,13-17 Years,86.4,82.0 to 89.9,380
Varicella,≥2 Doses with no disease history,States/Local Areas,Vermont,2014,Age,13-15 Years,95.0,89.9 to 97.6,169
HPV,"≥1 Dose, Males",States/Local Areas,Utah,2023,Age,13-17 Years,77.4,66.8 to 85.4,125
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2023,Age,13-17 Years,59.4,46.2 to 71.3,89
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Utah,2023,Age,13-17 Years,95.6,91.5 to 97.8,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2023,Age,13-17 Years,94.7,90.2 to 97.2,214
≥1 Dose MenACWY,,States/Local Areas,Utah,2023,Age,13-17 Years,91.5,84.9 to 95.3,214
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2023,Age,13-17 Years,61.2,52.6 to 69.2,214
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2023,Age,13-17 Years,78.7,71.3 to 84.7,214
≥2 Doses MMR,,States/Local Areas,Utah,2023,Age,13-17 Years,92.9,87.1 to 96.2,214
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2023,Age,13-17 Years,63.0,51.6 to 73.1,125
≥3 Doses HepB,,States/Local Areas,Utah,2023,Age,13-17 Years,93.1,87.8 to 96.2,214
Varicella,≥1 Dose with no disease history,States/Local Areas,Utah,2023,Age,13-17 Years,96.5,92.0 to 98.5,201
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2023,Age,13-17 Years,95.3,90.0 to 97.8,201
≥2 Doses Hep A,,States/Local Areas,Utah,2023,Age,13-17 Years,93.4,88.0 to 96.5,214
Varicella,≥2 Doses or history of disease,States/Local Areas,Utah,2023,Age,13-17 Years,95.5,90.5 to 98.0,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2023,Age,13-15 Years,93.6,86.8 to 97.0,128
≥1 Dose MenACWY,,States/Local Areas,Utah,2023,Age,13-15 Years,87.6,77.2 to 93.7,128
HPV,"Up-to-Date, Males",States/Local Areas,Utah,2023,Age,13-15 Years,59.1,44.5 to 72.3,77
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2023,Age,13-15 Years,58.4,47.4 to 68.6,128
HPV,"Up-to-Date, Females",States/Local Areas,Utah,2023,Age,13-15 Years,57.5,41.1 to 72.4,51
Varicella,≥2 Doses with no disease history,States/Local Areas,Utah,2023,Age,13-15 Years,93.7,84.9 to 97.5,121
HPV,"≥1 Dose, Females",States/Local Areas,Utah,2023,Age,13-17 Years,80.1,68.7 to 88.1,89
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2021,Age,13-15 Years,92.6,86.0 to 96.2,191
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2016,Age,13-17 Years,30.5,24.9 to 36.9,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2008,Age,13-17 Years,46.8,39.4 to 54.3,222
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2022,Age,13-15 Years,94.7,88.3 to 97.7,166
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2011,Age,13-17 Years,81.4,74.7 to 86.7,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2009,Age,13-17 Years,64.1,57.9 to 70.0,339
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2010,Age,13-17 Years,68.8,62.5 to 74.5,325
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018,Age,13-17 Years,43.2,36.4 to 50.2,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2017,Age,13-17 Years,37.4,31.5 to 43.7,356
≥2 Doses MMR,,States/Local Areas,Utah,2011,Age,13-17 Years,87.4,80.7 to 92.0,393
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2012,Age,13-17 Years,81.5,74.4 to 87.0,345
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2014,Age,13-17 Years,84.8,79.7 to 88.8,398
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2013,Age,13-17 Years,86.2,80.6 to 90.4,301
≥2 Doses MMR,,States/Local Areas,Utah,2010,Age,13-17 Years,86.7,81.9 to 90.3,325
≥2 Doses MMR,,States/Local Areas,Utah,2008,Age,13-17 Years,82.6,76.5 to 87.4,222
≥2 Doses MMR,,States/Local Areas,Utah,2009,Age,13-17 Years,87.3,82.1 to 91.2,339
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2021,Age,13-17 Years,61.4,54.1 to 68.2,304
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2022,Age,13-17 Years,55.2,47.7 to 62.5,271
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2020,Age,13-17 Years,45.0,38.1 to 52.1,304
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2019,Age,13-17 Years,44.6,37.6 to 51.9,325
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2019,Age,13-17 Years,44.9,35.0 to 55.2,159
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Insurance Coverage,Uninsured,90.5,77.2 to 96.4,63
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Uninsured,73.9,59.2 to 84.7,63
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Insurance Coverage,Other,91.4,80.9 to 96.4,103
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Other,71.0,58.2 to 81.2,103
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Private Insurance Only,69.8,66.2 to 73.1,1130
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Any Medicaid,79.1,72.2 to 84.6,218
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Insurance Coverage,Private Insurance Only,89.2,86.6 to 91.3,1130
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Poverty,Living At or Above Poverty Level,91.8,89.7 to 93.6,1362
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Insurance Coverage,Any Medicaid,90.4,84.7 to 94.1,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Poverty,Below Poverty Level,86.9,77.3 to 92.9,118
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Poverty,Living At or Above Poverty Level,50.7,47.3 to 54.1,1362
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Insurance Coverage,Any Medicaid,91.6,86.1 to 95.1,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Insurance Coverage,Private Insurance Only,90.4,87.9 to 92.5,1130
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Uninsured,34.7,22.0 to 50.0,63
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Other,54.5,41.9 to 66.5,103
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Private Insurance Only,49.4,45.6 to 53.1,1130
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Insurance Coverage,Any Medicaid,55.4,47.3 to 63.3,218
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Insurance Coverage,Uninsured,93.6,83.1 to 97.7,63
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Insurance Coverage,Other,92.7,82.0 to 97.3,103
HPV,"≥2 Doses, Males",States/Local Areas,Utah,2022,Age,13-17 Years,48.5,38.4 to 58.8,130
HPV,"≥2 Doses, Females",States/Local Areas,Utah,2022,Age,13-17 Years,62.5,51.8 to 72.2,141
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Poverty,Below Poverty Level,87.7,79.1 to 93.1,118
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Poverty,Living At or Above Poverty Level,90.0,87.8 to 91.9,1362
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Poverty,Below Poverty Level,53.6,42.6 to 64.2,118
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Poverty,Living At or Above Poverty Level,71.1,67.9 to 74.0,1362
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Poverty,Below Poverty Level,86.0,77.9 to 91.4,118
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Race and Ethnicity,"White, Non-Hispanic",68.2,64.7 to 71.5,1210
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.8,85.1 to 96.7,91
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Race and Ethnicity,Hispanic,92.7,86.7 to 96.2,193
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Race and Ethnicity,Hispanic,92.8,86.9 to 96.2,193
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Race and Ethnicity,"White, Non-Hispanic",90.6,88.2 to 92.6,1210
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",61.2,47.7 to 73.2,91
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Race and Ethnicity,"White, Non-Hispanic",88.6,86.1 to 90.8,1210
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Race and Ethnicity,Hispanic,53.1,44.5 to 61.5,193
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Race and Ethnicity,Hispanic,81.4,73.8 to 87.2,193
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",83.9,73.7 to 90.6,91
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.9,84.3 to 97.0,91
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Race and Ethnicity,"White, Non-Hispanic",48.0,44.5 to 51.7,1210
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.4,87.6 to 92.7,898
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Principal City,93.2,89.7 to 95.6,467
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Urbanicity,Living In a Non-MSA,80.6,70.4 to 87.9,149
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Non-Principal City,89.2,86.3 to 91.5,898
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Principal City,92.6,89.0 to 95.0,467
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Urbanicity,Living In a Non-MSA,32.8,23.1 to 44.3,149
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Non-Principal City,49.4,45.2 to 53.6,898
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018,Age,13-17 Years,89.9,85.0 to 93.4,310
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Principal City,55.3,49.6 to 61.0,467
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Urbanicity,Living In a Non-MSA,56.2,44.9 to 66.9,149
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Non-Principal City,71.9,68.1 to 75.5,898
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Urbanicity,Living In a MSA Principal City,75.0,69.7 to 79.6,467
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Urbanicity,Living In a Non-MSA,85.8,76.0 to 92.0,149
HPV,"Up-to-Date, Males and Females",States/Local Areas,Utah,2018-2022,Overall,Overall,50.0,46.8 to 53.3,1514
HPV,"≥1 Dose, Males and Females",States/Local Areas,Utah,2018-2022,Overall,Overall,71.7,68.7 to 74.5,1514
≥2 Doses MMR,,States/Local Areas,Utah,2022,Age,13-17 Years,88.2,81.7 to 92.6,271
≥2 Doses MMR,,States/Local Areas,Utah,2021,Age,13-17 Years,93.1,89.1 to 95.7,304
HPV,"≥3 Doses, Males and Females",States/Local Areas,Utah,2015,Age,13-17 Years,22.2,17.3 to 28.0,357
HPV,"≥3 Doses, Males and Females",States/Local Areas,Utah,2014,Age,13-17 Years,19.0,14.9 to 24.0,398
≥2 Doses MMR,,States/Local Areas,Utah,2020,Age,13-17 Years,87.9,82.9 to 91.6,304
HPV,"≥3 Doses, Males and Females",States/Local Areas,Utah,2013,Age,13-17 Years,12.4,8.7 to 17.5,301
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2022,Age,13-17 Years,93.5,87.9 to 96.6,271
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2019,Age,13-17 Years,86.8,80.7 to 91.3,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2021,Age,13-17 Years,92.9,88.3 to 95.8,304
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2020,Age,13-17 Years,91.3,86.7 to 94.4,304
≥1 Dose MenACWY,,States/Local Areas,Utah,2012,Age,13-17 Years,56.5,49.4 to 63.3,345
≥2 Doses MMR,,States/Local Areas,Utah,2018,Age,13-17 Years,89.5,84.7 to 93.0,310
≥2 Doses MMR,,States/Local Areas,Utah,2017,Age,13-17 Years,87.6,82.7 to 91.2,356
≥2 Doses MMR,,States/Local Areas,Utah,2019,Age,13-17 Years,89.7,84.2 to 93.4,325
≥1 Dose MenACWY,,States/Local Areas,Utah,2016,Age,13-17 Years,76.6,70.5 to 81.7,317
≥1 Dose MenACWY,,States/Local Areas,Utah,2015,Age,13-17 Years,71.5,65.4 to 76.9,357
≥1 Dose MenACWY,,States/Local Areas,Utah,2014,Age,13-17 Years,66.9,60.8 to 72.5,398
≥1 Dose MenACWY,,States/Local Areas,Utah,2013,Age,13-17 Years,61.0,54.1 to 67.4,301
HPV,"≥3 Doses, Males and Females",States/Local Areas,Utah,2011,Age,13-17 Years,10.0,7.0 to 14.0,393
≥2 Doses MMR,,States/Local Areas,Utah,2016,Age,13-17 Years,80.0,74.3 to 84.8,317
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2016,Age,13-17 Years,83.9,78.5 to 88.2,317
≥2 Doses MMR,,States/Local Areas,Utah,2013,Age,13-17 Years,87.5,82.1 to 91.4,301
≥2 Doses MMR,,States/Local Areas,Utah,2012,Age,13-17 Years,82.6,76.5 to 87.4,345
≥2 Doses MMR,,States/Local Areas,Utah,2014,Age,13-17 Years,82.0,76.6 to 86.3,398
≥2 Doses MMR,,States/Local Areas,Utah,2015,Age,13-17 Years,84.9,80.0 to 88.8,357
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2015,Age,13-17 Years,82.0,76.2 to 86.6,357
≥1 Dose MenACWY,,States/Local Areas,Utah,2022,Age,13-15 Years,94.2,87.4 to 97.4,166
≥1 Dose MenACWY,,States/Local Areas,Utah,2008,Age,13-17 Years,31.3,24.9 to 38.6,222
≥1 Dose MenACWY,,States/Local Areas,Utah,2009,Age,13-17 Years,42.1,36.0 to 48.3,339
≥1 Dose MenACWY,,States/Local Areas,Utah,2011,Age,13-17 Years,58.5,51.3 to 65.2,393
≥1 Dose MenACWY,,States/Local Areas,Utah,2010,Age,13-17 Years,48.8,42.6 to 55.1,325
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2017,Age,13-17 Years,91.6,87.7 to 94.3,356
≥1 Dose MenACWY,,States/Local Areas,Utah,2017,Age,13-17 Years,85.1,80.3 to 88.9,356
≥1 Dose MenACWY,,States/Local Areas,Utah,2022,Age,13-17 Years,91.5,85.8 to 95.0,271
≥1 Dose MenACWY,,States/Local Areas,Utah,2021,Age,13-17 Years,94.0,90.0 to 96.5,304
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2010,Age,13-15 Years,24.8,16.8 to 34.9,108
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2009,Age,13-15 Years,20.9,12.5 to 32.8,99
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2011,Age,13-15 Years,17.7,10.7 to 27.8,107
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2012,Age,13-15 Years,22.3,13.7 to 34.2,104
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2013,Age,13-15 Years,19.8,11.5 to 31.9,97
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2014,Age,13-15 Years,25.2,17.1 to 35.5,120
HPV,"≥3 Doses, Females",States/Local Areas,Utah,2015,Age,13-15 Years,18.6,11.2 to 29.2,99
≥1 Dose MenACWY,,States/Local Areas,Utah,2018,Age,13-17 Years,85.2,79.4 to 89.5,310
≥1 Dose MenACWY,,States/Local Areas,Utah,2020,Age,13-17 Years,90.3,85.5 to 93.6,304
HPV,"≥3 Doses, Males and Females",States/Local Areas,Utah,2012,Age,13-17 Years,14.0,9.8 to 19.5,345
≥1 Dose MenACWY,,States/Local Areas,Utah,2019,Age,13-17 Years,86.6,80.8 to 90.9,325
≥1 Dose MenACWY,,States/Local Areas,Utah,2018-2022,Overall,Overall,89.6,87.5 to 91.4,1514
Tetanus,≥1 Dose Tdap,States/Local Areas,Utah,2018-2022,Overall,Overall,91.0,88.9 to 92.7,1514
HPV,"≥2 Doses, Males and Females",States/Local Areas,Utah,2022,Age,13-17 Years,55.3,47.8 to 62.6,271
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2021,Age,13-15 Years,56.8,44.1 to 68.6,101
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2022,Age,13-15 Years,69.8,57.0 to 80.1,80
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2016,Age,13-17 Years,56.9,48.1 to 65.3,191
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2017,Age,13-17 Years,63.5,54.0 to 72.1,143
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2020,Age,13-17 Years,70.0,61.1 to 77.7,159
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2019,Age,13-17 Years,56.3,45.4 to 66.7,128
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2018,Age,13-17 Years,54.7,44.9 to 64.2,139
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2021,Age,13-15 Years,58.4,46.5 to 69.4,111
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2022,Age,13-15 Years,62.6,49.2 to 74.3,87
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2016,Age,13-17 Years,41.5,32.8 to 50.7,166
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2022,Age,13-15 Years,65.9,56.6 to 74.2,167
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2020,Age,13-17 Years,63.9,54.6 to 72.2,172
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2019,Age,13-17 Years,51.3,41.3 to 61.2,166
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2018,Age,13-17 Years,51.6,41.9 to 61.1,154
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2021,Age,13-17 Years,65.8,56.8 to 73.8,181
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2019,Age,13-15 Years,45.9,33.4 to 59.0,98
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2021,Age,13-17 Years,67.1,57.0 to 75.8,159
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2022,Age,13-17 Years,74.3,64.2 to 82.3,125
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2018,Age,13-15 Years,52.6,40.0 to 64.9,88
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2020,Age,13-15 Years,61.5,53.1 to 69.2,200
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2020,Age,13-15 Years,61.0,48.7 to 72.0,101
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2017,Age,13-17 Years,52.7,43.7 to 61.5,187
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2021,Age,13-15 Years,57.6,48.9 to 65.9,212
HPV,"Up-to-Date, Males",States/Local Areas,Connecticut,2022,Age,13-17 Years,69.5,58.9 to 78.4,133
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2019,Age,13-15 Years,45.8,36.1 to 55.7,165
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2015,Age,13-17 Years,42.0,34.0 to 50.4,203
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2014,Age,13-17 Years,27.0,19.9 to 35.5,201
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2015,Age,13-15 Years,38.9,28.8 to 50.0,112
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2014,Age,13-15 Years,19.9,12.7 to 29.7,127
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2008,Age,13-17 Years,81.4,75.3 to 86.2,292
HPV,"≥3 Doses, Males",States/Local Areas,Connecticut,2013,Age,13-15 Years,20.2,12.0 to 32.0,98
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2015,Age,13-17 Years,94.4,90.9 to 96.6,358
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2016,Age,13-17 Years,96.9,93.8 to 98.5,357
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2018,Age,13-17 Years,96.8,93.3 to 98.6,293
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2017,Age,13-17 Years,98.1,94.4 to 99.4,330
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2019,Age,13-17 Years,94.7,90.2 to 97.2,294
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2019,Age,13-15 Years,94.9,88.4 to 97.9,156
≥3 Doses HepB,,States/Local Areas,Connecticut,2008,Age,13-17 Years,98.4,94.8 to 99.5,292
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2016,Age,13-15 Years,98.4,94.4 to 99.6,178
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2018,Age,13-15 Years,96.9,92.8 to 98.7,166
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2017,Age,13-15 Years,97.4,89.4 to 99.4,170
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2020,Age,13-17 Years,96.9,93.8 to 98.5,331
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2021,Age,13-17 Years,96.4,92.6 to 98.2,340
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2022,Age,13-17 Years,95.8,91.9 to 97.9,258
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2008,Age,13-15 Years,62.3,50.0 to 73.1,95
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2014,Age,13-17 Years,95.8,92.5 to 97.7,386
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2013,Age,13-17 Years,97.0,93.5 to 98.6,328
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2011,Age,13-17 Years,91.4,87.5 to 94.2,453
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2012,Age,13-17 Years,95.1,90.7 to 97.5,323
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2009,Age,13-17 Years,79.8,73.7 to 84.8,351
Varicella,≥2 Doses or history of disease,States/Local Areas,Connecticut,2010,Age,13-17 Years,86.4,81.0 to 90.5,408
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2015,Age,13-15 Years,95.0,90.0 to 97.6,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2014,Age,13-15 Years,97.1,93.8 to 98.7,214
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2015,Age,13-17 Years,70.9,62.1 to 78.4,155
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2014,Age,13-17 Years,63.5,54.7 to 71.5,185
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2013,Age,13-17 Years,56.0,46.6 to 64.9,157
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2012,Age,13-17 Years,57.6,47.1 to 67.4,141
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2010,Age,13-17 Years,57.9,49.4 to 65.9,182
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2011,Age,13-17 Years,60.5,51.8 to 68.6,223
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2017,Age,13-17 Years,97.7,93.3 to 99.2,279
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2015,Age,13-17 Years,93.6,89.6 to 96.1,312
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2016,Age,13-17 Years,96.5,93.0 to 98.3,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2014,Age,13-17 Years,95.0,91.0 to 97.3,329
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2017,Age,13-17 Years,97.9,93.3 to 99.4,279
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2020,Age,13-15 Years,96.6,91.5 to 98.7,187
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2021,Age,13-15 Years,95.3,89.1 to 98.1,204
≥3 Doses HepB,,States/Local Areas,Connecticut,2015,Age,13-17 Years,97.3,94.4 to 98.7,358
≥3 Doses HepB,,States/Local Areas,Connecticut,2016,Age,13-17 Years,97.3,94.2 to 98.7,357
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2014,Age,13-17 Years,98.0,94.2 to 99.3,329
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2013,Age,13-17 Years,99.1,97.2 to 99.7,255
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2015,Age,13-17 Years,97.5,94.4 to 98.9,312
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2016,Age,13-17 Years,98.5,94.6 to 99.6,322
≥3 Doses HepB,,States/Local Areas,Connecticut,2017,Age,13-17 Years,95.0,91.0 to 97.3,330
≥3 Doses HepB,,States/Local Areas,Connecticut,2019,Age,13-17 Years,96.8,93.4 to 98.5,294
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2018,Age,13-17 Years,96.5,92.6 to 98.4,265
≥3 Doses HepB,,States/Local Areas,Connecticut,2018,Age,13-17 Years,95.9,91.4 to 98.0,293
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2009,Age,13-15 Years,64.3,53.1 to 74.1,130
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2011,Age,13-15 Years,87.2,79.9 to 92.1,217
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2010,Age,13-15 Years,80.0,70.9 to 86.8,182
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2013,Age,13-15 Years,97.1,90.3 to 99.2,168
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2012,Age,13-15 Years,94.1,86.3 to 97.6,164
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2018,Age,13-17 Years,97.5,93.6 to 99.0,265
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2022,Age,13-15 Years,95.7,90.1 to 98.2,161
≥3 Doses HepB,,States/Local Areas,Connecticut,2012,Age,13-17 Years,95.7,92.0 to 97.8,323
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2022,Age,13-17 Years,97.7,94.2 to 99.1,246
≥3 Doses HepB,,States/Local Areas,Connecticut,2011,Age,13-17 Years,98.5,95.8 to 99.5,453
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2020,Age,13-17 Years,96.7,93.5 to 98.4,309
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2021,Age,13-17 Years,96.2,92.3 to 98.2,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2019,Age,13-17 Years,94.3,89.5 to 96.9,278
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2020,Age,13-17 Years,98.5,95.2 to 99.5,309
≥3 Doses HepB,,States/Local Areas,Connecticut,2009,Age,13-17 Years,96.3,91.7 to 98.4,351
≥3 Doses HepB,,States/Local Areas,Connecticut,2010,Age,13-17 Years,97.1,93.5 to 98.8,408
≥3 Doses HepB,,States/Local Areas,Connecticut,2014,Age,13-17 Years,97.4,94.2 to 98.8,386
≥3 Doses HepB,,States/Local Areas,Connecticut,2013,Age,13-17 Years,96.4,91.8 to 98.4,328
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2008,Age,13-17 Years,45.0,35.6 to 54.8,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2013,Age,13-17 Years,95.8,91.2 to 98.1,255
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2012,Age,13-17 Years,93.5,87.7 to 96.6,241
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2009,Age,13-17 Years,61.2,52.7 to 69.2,191
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2019,Age,13-17 Years,53.8,46.4 to 61.0,294
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2018,Age,13-17 Years,53.1,46.2 to 59.9,293
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2017,Age,13-17 Years,58.0,51.4 to 64.3,330
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2014,Age,13-17 Years,94.8,90.5 to 97.2,386
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2013,Age,13-17 Years,90.8,85.5 to 94.2,328
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2021,Age,13-15 Years,92.6,85.8 to 96.3,212
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2020,Age,13-15 Years,93.2,86.6 to 96.7,200
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2019,Age,13-15 Years,96.6,91.5 to 98.7,165
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2018,Age,13-15 Years,94.8,89.2 to 97.6,184
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2015,Age,13-17 Years,58.2,50.0 to 66.1,203
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2013,Age,13-17 Years,36.4,28.1 to 45.7,171
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2014,Age,13-17 Years,38.4,30.1 to 47.4,201
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2013,Age,13-15 Years,89.6,82.1 to 94.2,196
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2018,Age,13-17 Years,59.2,49.4 to 68.4,154
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2016,Age,13-17 Years,48.4,39.3 to 57.5,166
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2017,Age,13-17 Years,56.8,47.8 to 65.4,187
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2011,Age,13-17 Years,10.0,6.0 to 16.2,230
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2012,Age,13-17 Years,14.6,9.6 to 21.7,182
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2022,Age,13-17 Years,76.8,66.2 to 84.9,133
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2009,Age,13-15 Years,67.6,59.2 to 75.0,214
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2008,Age,13-15 Years,46.4,37.7 to 55.4,173
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2011,Age,13-15 Years,79.3,71.8 to 85.2,277
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2010,Age,13-15 Years,68.9,61.2 to 75.7,242
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2012,Age,13-15 Years,88.5,82.7 to 92.6,198
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2008,Age,13-15 Years,51.0,42.1 to 59.8,173
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2011,Age,13-15 Years,82.4,74.5 to 88.2,277
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2012,Age,13-15 Years,91.8,86.2 to 95.3,198
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2018,Age,13-17 Years,55.4,45.5 to 64.8,139
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2019,Age,13-17 Years,57.9,46.9 to 68.2,128
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2009,Age,13-15 Years,77.2,69.9 to 83.2,214
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2010,Age,13-15 Years,80.7,73.8 to 86.1,242
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2015,Age,13-15 Years,94.6,89.8 to 97.2,205
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2014,Age,13-15 Years,96.2,91.5 to 98.4,238
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2016,Age,13-15 Years,94.9,88.6 to 97.8,192
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2017,Age,13-15 Years,94.0,89.5 to 96.6,193
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2022,Age,13-15 Years,92.5,85.2 to 96.3,167
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2021,Age,13-17 Years,95.5,91.0 to 97.8,340
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2022,Age,13-17 Years,93.5,88.4 to 96.4,258
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2019,Age,13-17 Years,70.6,63.5 to 76.8,294
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2020,Age,13-17 Years,95.0,90.6 to 97.3,331
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2019,Age,13-17 Years,96.5,93.1 to 98.3,294
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2011,Age,13-17 Years,87.2,81.7 to 91.3,318
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2010,Age,13-17 Years,79.5,72.0 to 85.5,268
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2008,Age,13-17 Years,97.6,91.6 to 99.4,129
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2019,Age,13-17 Years,69.1,58.1 to 78.2,128
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2018,Age,13-17 Years,70.1,60.3 to 78.4,139
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2021,Age,13-17 Years,98.8,96.2 to 99.6,322
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2022,Age,13-17 Years,95.6,91.5 to 97.8,246
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2016,Age,13-17 Years,68.9,60.3 to 76.4,191
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2017,Age,13-17 Years,75.4,66.2 to 82.8,143
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2009,Age,13-17 Years,62.6,53.4 to 71.0,183
Varicella,≥2 Doses with no disease history,States/Local Areas,Connecticut,2008,Age,13-17 Years,58.7,48.1 to 68.5,129
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2011,Age,13-17 Years,99.5,98.0 to 99.9,318
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2012,Age,13-17 Years,99.9,99.3 to 100.0,241
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2009,Age,13-17 Years,94.0,85.8 to 97.6,183
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2010,Age,13-17 Years,98.1,95.1 to 99.3,268
≥3 Doses HepB,,States/Local Areas,Connecticut,2020,Age,13-17 Years,97.9,94.8 to 99.2,331
≥3 Doses HepB,,States/Local Areas,Connecticut,2021,Age,13-17 Years,96.4,92.9 to 98.2,340
≥3 Doses HepB,,States/Local Areas,Connecticut,2022,Age,13-17 Years,96.7,93.4 to 98.4,258
HPV,"≥2 Doses, Males and Females",States/Local Areas,Connecticut,2016,Age,13-17 Years,54.5,48.1 to 60.7,357
HPV,"≥2 Doses, Males and Females",States/Local Areas,Connecticut,2017,Age,13-17 Years,61.8,55.3 to 68.0,330
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2012,Age,13-17 Years,20.3,14.4 to 27.8,182
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2020,Age,13-17 Years,82.3,73.8 to 88.5,159
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2021,Age,13-17 Years,76.3,66.3 to 84.1,159
HPV,"≥1 Dose, Females",States/Local Areas,Connecticut,2022,Age,13-17 Years,83.3,74.0 to 89.7,125
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2011,Age,13-17 Years,17.3,11.9 to 24.5,230
HPV,"≥2 Doses, Males and Females",States/Local Areas,Connecticut,2019,Age,13-17 Years,55.8,48.4 to 62.9,294
HPV,"≥2 Doses, Males and Females",States/Local Areas,Connecticut,2018,Age,13-17 Years,57.3,50.4 to 64.0,293
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2017,Age,13-17 Years,67.3,58.3 to 75.2,187
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2018,Age,13-17 Years,70.8,61.0 to 79.0,154
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2019,Age,13-17 Years,72.0,62.5 to 79.9,166
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2014,Age,13-17 Years,50.3,41.3 to 59.2,201
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2013,Age,13-17 Years,52.3,43.1 to 61.3,171
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2015,Age,13-17 Years,65.3,57.1 to 72.7,203
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2016,Age,13-17 Years,55.8,46.6 to 64.6,166
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2020,Age,13-17 Years,82.0,74.3 to 87.8,172
HPV,"≥1 Dose, Males",States/Local Areas,Connecticut,2021,Age,13-17 Years,79.3,71.6 to 85.4,181
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2017,Age,13-15 Years,94.8,89.6 to 97.5,193
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2016,Age,13-15 Years,94.0,88.0 to 97.1,192
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2013,Age,13-15 Years,91.9,85.5 to 95.6,196
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2015,Age,13-15 Years,94.5,89.5 to 97.2,205
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2014,Age,13-15 Years,97.3,94.2 to 98.8,238
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2015,Age,13-17 Years,95.3,91.9 to 97.3,358
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2014,Age,13-17 Years,96.2,92.3 to 98.1,386
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2016,Age,13-17 Years,95.3,91.3 to 97.5,357
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2017,Age,13-17 Years,95.2,92.3 to 97.1,330
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2008,Age,13-17 Years,37.2,28.4 to 46.8,143
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2012,Age,13-17 Years,92.5,87.5 to 95.6,323
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2020,Age,13-15 Years,94.7,90.0 to 97.3,200
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2009,Age,13-17 Years,50.3,41.7 to 58.9,191
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2011,Age,13-17 Years,51.7,42.8 to 60.5,223
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2010,Age,13-17 Years,52.0,43.6 to 60.4,182
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2011,Age,13-17 Years,90.6,85.9 to 93.8,453
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2010,Age,13-17 Years,91.1,86.7 to 94.2,408
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2013,Age,13-17 Years,93.2,88.4 to 96.1,328
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2009,Age,13-17 Years,88.9,84.2 to 92.4,351
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2008,Age,13-17 Years,79.8,73.2 to 85.0,292
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2015,Age,13-17 Years,64.3,55.3 to 72.4,155
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2016,Age,13-17 Years,60.9,52.0 to 69.1,191
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2017,Age,13-17 Years,67.1,57.7 to 75.3,143
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2020,Age,13-17 Years,82.2,76.6 to 86.6,331
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2021,Age,13-17 Years,77.9,71.7 to 83.0,340
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2022,Age,13-17 Years,80.0,73.1 to 85.4,258
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2014,Age,13-17 Years,59.9,51.0 to 68.2,185
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2013,Age,13-17 Years,49.0,39.8 to 58.2,157
HPV,"≥2 Doses, Females",States/Local Areas,Connecticut,2012,Age,13-17 Years,53.9,43.5 to 64.0,141
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2021,Age,13-15 Years,94.7,89.4 to 97.4,212
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2019,Age,13-15 Years,94.8,87.5 to 97.9,165
≥1 Dose MenACWY,,States/Local Areas,Connecticut,2018,Age,13-15 Years,92.3,85.3 to 96.1,184
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,Connecticut,2018,Age,13-17 Years,95.7,91.9 to 97.8,293
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2018,Age,13-17 Years,70.5,63.7 to 76.5,293
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2016,Age,13-17 Years,62.2,55.8 to 68.2,357
HPV,"≥1 Dose, Males and Females",States/Local Areas,Connecticut,2017,Age,13-17 Years,71.3,64.9 to 76.9,330
Varicella,History of disease,States/Local Areas,Connecticut,2014,Age,13-17 Years,16.6,12.2 to 22.3,386
Varicella,History of disease,States/Local Areas,Connecticut,2015,Age,13-17 Years,12.8,9.3 to 17.4,358
Varicella,History of disease,States/Local Areas,Connecticut,2011,Age,13-17 Years,32.8,27.1 to 39.1,453
Varicella,History of disease,States/Local Areas,Connecticut,2010,Age,13-17 Years,33.4,28.3 to 39.0,408
Varicella,History of disease,States/Local Areas,Connecticut,2013,Age,13-17 Years,27.1,21.3 to 33.8,328
Varicella,History of disease,States/Local Areas,Connecticut,2012,Age,13-17 Years,24.9,19.6 to 31.1,323
Varicella,History of disease,States/Local Areas,Connecticut,2008,Age,13-17 Years,54.9,47.7 to 61.9,292
Varicella,History of disease,States/Local Areas,Connecticut,2020,Age,13-17 Years,5.5,3.2 to 9.4,331
Varicella,History of disease,States/Local Areas,Connecticut,2009,Age,13-17 Years,46.1,39.9 to 52.5,351
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2020,Age,13-15 Years,61.9,50.3 to 72.3,99
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2019,Age,13-15 Years,45.6,31.2 to 60.7,67
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2020,Age,13-17 Years,66.9,60.5 to 72.7,331
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2021,Age,13-17 Years,66.4,59.8 to 72.5,340
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2022,Age,13-17 Years,71.9,64.6 to 78.1,258
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2009,Age,13-17 Years,68.3,62.2 to 73.8,351
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2010,Age,13-17 Years,76.2,70.8 to 80.8,408
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2011,Age,13-17 Years,83.0,77.6 to 87.3,453
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2022,Age,13-15 Years,93.1,87.5 to 96.3,167
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2008,Age,13-17 Years,45.4,38.5 to 52.5,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2015,Age,13-17 Years,93.7,90.0 to 96.1,358
≥2 Doses MMR,,States/Local Areas,Connecticut,2011,Age,13-17 Years,96.1,92.2 to 98.1,453
≥2 Doses MMR,,States/Local Areas,Connecticut,2010,Age,13-17 Years,97.6,94.5 to 99.0,408
≥2 Doses MMR,,States/Local Areas,Connecticut,2009,Age,13-17 Years,94.4,89.1 to 97.2,351
≥2 Doses MMR,,States/Local Areas,Connecticut,2008,Age,13-17 Years,95.7,91.5 to 97.9,292
Tetanus,≥1 Dose Tdap,States/Local Areas,Connecticut,2012,Age,13-17 Years,89.3,83.4 to 93.2,323
HPV,"≥2 Doses, Males",States/Local Areas,Connecticut,2019,Age,13-17 Years,53.7,43.7 to 63.4,166
HPV,"Up-to-Date, Males and Females",States/Local Areas,Connecticut,2016,Age,13-17 Years,49.0,42.7 to 55.3,357
Varicella,History of disease,States/Local Areas,Connecticut,2017,Age,13-17 Years,17.7,13.0 to 23.7,330
HPV,"Up-to-Date, Females",States/Local Areas,Connecticut,2018,Age,13-15 Years,48.8,37.2 to 60.5,96
Varicella,History of disease,States/Local Areas,Connecticut,2016,Age,13-17 Years,10.6,7.2 to 15.4,357
Varicella,History of disease,States/Local Areas,Connecticut,2019,Age,13-17 Years,7.2,4.1 to 12.3,294
Varicella,History of disease,States/Local Areas,Connecticut,2018,Age,13-17 Years,8.9,5.8 to 13.4,293
Varicella,≥1 Dose with no disease history,States/Local Areas,Connecticut,2019,Age,13-17 Years,98.2,94.9 to 99.4,278
Varicella,History of disease,States/Local Areas,North Dakota,2014,Age,13-17 Years,31.1,25.1 to 37.7,327
Varicella,History of disease,States/Local Areas,North Dakota,2017,Age,13-17 Years,14.7,11.1 to 19.2,379
Varicella,History of disease,States/Local Areas,North Dakota,2009,Age,13-17 Years,61.2,54.7 to 67.4,272
Varicella,History of disease,States/Local Areas,North Dakota,2015,Age,13-17 Years,27.2,21.7 to 33.4,323
Varicella,History of disease,States/Local Areas,North Dakota,2016,Age,13-17 Years,20.4,15.3 to 26.5,293
Varicella,History of disease,States/Local Areas,North Dakota,2018,Age,13-17 Years,11.9,7.9 to 17.5,287
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2018,Age,13-15 Years,71.4,58.3 to 81.7,83
Varicella,History of disease,States/Local Areas,North Dakota,2022,Age,13-17 Years,5.1,3.0 to 8.7,280
Varicella,History of disease,States/Local Areas,North Dakota,2020,Age,13-17 Years,8.0,5.2 to 12.3,401
Varicella,History of disease,States/Local Areas,North Dakota,2019,Age,13-17 Years,7.9,5.0 to 12.4,319
Varicella,History of disease,States/Local Areas,North Dakota,2010,Age,13-17 Years,56.1,49.8 to 62.2,299
Varicella,History of disease,States/Local Areas,North Dakota,2011,Age,13-17 Years,45.1,36.9 to 53.6,314
Varicella,History of disease,States/Local Areas,North Dakota,2013,Age,13-17 Years,37.4,31.2 to 44.1,344
Varicella,History of disease,States/Local Areas,North Dakota,2012,Age,13-17 Years,40.4,33.7 to 47.5,324
Varicella,History of disease,States/Local Areas,North Dakota,2008,Age,13-17 Years,66.3,60.7 to 71.5,362
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2018,Age,13-17 Years,55.5,45.7 to 64.8,155
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2017,Age,13-17 Years,53.2,45.0 to 61.2,204
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2020,Age,13-17 Years,63.2,53.8 to 71.6,203
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2019,Age,13-17 Years,77.2,68.3 to 84.2,167
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2021,Age,13-17 Years,75.6,63.8 to 84.4,104
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2020,Age,13-15 Years,69.9,58.5 to 79.3,126
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2019,Age,13-15 Years,70.4,58.7 to 79.9,93
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2022,Age,13-15 Years,75.4,66.4 to 82.6,177
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2017,Age,13-17 Years,93.5,90.2 to 95.8,379
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2016,Age,13-17 Years,93.4,88.7 to 96.2,293
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2018,Age,13-17 Years,96.7,93.6 to 98.3,287
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2019,Age,13-15 Years,96.7,91.2 to 98.8,181
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2018,Age,13-15 Years,96.0,91.0 to 98.2,157
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2014,Age,13-15 Years,86.3,77.4 to 92.1,154
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2015,Age,13-15 Years,92.7,84.3 to 96.8,151
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2019,Age,13-17 Years,95.9,91.8 to 98.0,319
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2015,Age,13-17 Years,92.6,88.0 to 95.5,323
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2022,Age,13-17 Years,97.1,93.3 to 98.7,280
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2021,Age,13-17 Years,95.2,90.4 to 97.7,191
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2020,Age,13-17 Years,97.2,94.3 to 98.7,401
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2011,Age,13-15 Years,62.5,47.8 to 75.2,107
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2010,Age,13-15 Years,69.9,58.0 to 79.5,83
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2013,Age,13-15 Years,87.6,80.8 to 92.2,154
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2012,Age,13-15 Years,70.2,59.2 to 79.3,137
≥3 Doses HepB,,States/Local Areas,North Dakota,2015,Age,13-17 Years,91.7,87.1 to 94.8,323
≥3 Doses HepB,,States/Local Areas,North Dakota,2016,Age,13-17 Years,93.0,88.7 to 95.7,293
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2016,Age,13-15 Years,92.7,85.5 to 96.5,152
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2017,Age,13-15 Years,93.8,88.7 to 96.7,203
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2010,Age,13-17 Years,84.0,78.8 to 88.1,299
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2009,Age,13-17 Years,82.3,76.8 to 86.7,272
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2013,Age,13-17 Years,91.2,87.2 to 94.1,344
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2014,Age,13-17 Years,89.5,84.1 to 93.2,327
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2011,Age,13-17 Years,78.8,70.8 to 85.1,314
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2012,Age,13-17 Years,81.3,74.6 to 86.6,324
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2021,Age,13-15 Years,94.8,88.7 to 97.7,95
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2020,Age,13-15 Years,96.5,91.5 to 98.6,233
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2015,Age,13-17 Years,70.5,61.8 to 78.0,159
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2014,Age,13-17 Years,60.9,51.2 to 69.8,168
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2013,Age,13-17 Years,57.5,48.0 to 66.6,168
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2012,Age,13-17 Years,60.3,50.2 to 69.5,151
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2014,Age,13-17 Years,84.7,77.4 to 90.0,228
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2015,Age,13-17 Years,89.8,83.7 to 93.7,240
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2016,Age,13-17 Years,91.7,85.9 to 95.2,237
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2011,Age,13-17 Years,51.2,38.8 to 63.5,142
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2010,Age,13-17 Years,41.7,33.7 to 50.2,159
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2017,Age,13-17 Years,92.4,88.5 to 95.1,321
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2013,Age,13-17 Years,96.3,91.6 to 98.4,224
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2014,Age,13-17 Years,95.8,90.5 to 98.2,228
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2015,Age,13-17 Years,96.8,92.8 to 98.6,240
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2016,Age,13-17 Years,94.9,90.6 to 97.3,237
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2008,Age,13-15 Years,36.8,26.1 to 48.9,80
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2009,Age,13-15 Years,60.2,47.8 to 71.4,73
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2018,Age,13-17 Years,98.1,95.4 to 99.2,256
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2019,Age,13-17 Years,96.1,91.6 to 98.2,292
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2017,Age,13-17 Years,96.0,92.5 to 97.9,321
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2020,Age,13-17 Years,98.8,96.6 to 99.6,368
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2018,Age,13-17 Years,96.2,92.8 to 98.1,256
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2021,Age,13-17 Years,94.9,89.7 to 97.5,174
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2020,Age,13-17 Years,97.0,93.8 to 98.6,368
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2019,Age,13-17 Years,95.5,91.1 to 97.8,292
≥3 Doses HepB,,States/Local Areas,North Dakota,2018,Age,13-17 Years,97.5,94.1 to 98.9,287
≥3 Doses HepB,,States/Local Areas,North Dakota,2019,Age,13-17 Years,94.3,89.8 to 96.9,319
≥3 Doses HepB,,States/Local Areas,North Dakota,2017,Age,13-17 Years,92.1,88.2 to 94.8,379
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2013,Age,13-17 Years,86.0,79.9 to 90.4,224
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2012,Age,13-17 Years,68.6,59.1 to 76.7,206
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2012,Age,13-17 Years,93.2,84.8 to 97.1,206
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2008,Age,13-17 Years,28.7,21.9 to 36.7,177
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2009,Age,13-17 Years,45.1,36.0 to 54.6,133
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2010,Age,13-17 Years,90.7,83.8 to 94.9,127
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2009,Age,13-17 Years,88.9,80.8 to 93.8,107
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2008,Age,13-17 Years,30.9,22.6 to 40.8,118
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2009,Age,13-17 Years,54.3,44.0 to 64.2,107
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2011,Age,13-17 Years,83.9,72.0 to 91.3,166
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2010,Age,13-17 Years,63.6,54.1 to 72.1,127
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2011,Age,13-17 Years,61.4,49.7 to 71.9,166
≥3 Doses HepB,,States/Local Areas,North Dakota,2010,Age,13-17 Years,96.6,94.2 to 98.0,299
≥3 Doses HepB,,States/Local Areas,North Dakota,2009,Age,13-17 Years,89.8,85.4 to 93.0,272
≥3 Doses HepB,,States/Local Areas,North Dakota,2008,Age,13-17 Years,87.9,83.4 to 91.3,362
≥3 Doses HepB,,States/Local Areas,North Dakota,2013,Age,13-17 Years,94.9,91.6 to 97.0,344
≥3 Doses HepB,,States/Local Areas,North Dakota,2014,Age,13-17 Years,92.6,87.8 to 95.6,327
≥3 Doses HepB,,States/Local Areas,North Dakota,2011,Age,13-17 Years,91.7,84.6 to 95.7,314
≥3 Doses HepB,,States/Local Areas,North Dakota,2012,Age,13-17 Years,91.2,85.1 to 95.0,324
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2008,Age,13-17 Years,76.1,66.1 to 83.8,118
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Dakota,2019,Age,13-17 Years,79.3,73.5 to 84.1,319
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2022,Age,13-15 Years,96.2,89.9 to 98.6,168
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2017,Age,13-17 Years,70.4,62.4 to 77.3,204
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2013,Age,13-17 Years,36.1,27.5 to 45.6,176
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2014,Age,13-17 Years,37.6,29.1 to 46.9,159
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2015,Age,13-17 Years,62.3,53.1 to 70.7,164
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2016,Age,13-17 Years,66.9,57.9 to 74.7,163
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2019,Age,13-17 Years,89.5,82.6 to 93.8,167
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2022,Age,13-17 Years,84.5,74.9 to 90.9,152
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2018,Age,13-17 Years,82.9,73.6 to 89.4,132
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2018,Age,13-17 Years,70.7,60.9 to 78.9,155
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2021,Age,13-17 Years,87.5,77.7 to 93.3,104
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2020,Age,13-17 Years,76.9,68.4 to 83.7,203
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2022,Age,13-15 Years,73.9,60.2 to 84.1,77
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2021,Age,13-15 Years,46.7,31.5 to 62.5,48
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2020,Age,13-15 Years,62.0,53.7 to 69.6,256
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2021,Age,13-15 Years,59.9,48.2 to 70.7,104
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2022,Age,13-17 Years,74.4,64.4 to 82.4,152
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2019,Age,13-15 Years,70.1,61.7 to 77.4,192
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2020,Age,13-17 Years,77.8,69.5 to 84.3,198
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2022,Age,13-17 Years,74.4,63.7 to 82.8,128
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2021,Age,13-17 Years,68.6,56.0 to 78.9,87
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2018,Age,13-15 Years,53.5,41.2 to 65.5,90
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2018,Age,13-17 Years,72.2,62.1 to 80.4,132
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2019,Age,13-17 Years,76.6,68.1 to 83.4,152
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2020,Age,13-15 Years,54.7,43.2 to 65.8,130
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2019,Age,13-15 Years,69.9,57.1 to 80.2,99
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2017,Age,13-17 Years,62.6,54.1 to 70.3,175
HPV,"Up-to-Date, Females",States/Local Areas,North Dakota,2016,Age,13-17 Years,60.2,50.1 to 69.5,130
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2022,Age,13-15 Years,76.8,64.3 to 85.9,100
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2021,Age,13-15 Years,72.5,55.7 to 84.6,56
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2018,Age,13-15 Years,89.6,82.7 to 93.9,173
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2021,Age,13-15 Years,92.4,84.1 to 96.6,104
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2020,Age,13-15 Years,87.5,80.0 to 92.5,256
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2019,Age,13-15 Years,96.7,93.3 to 98.4,192
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2015,Age,13-17 Years,53.1,44.0 to 61.9,164
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2016,Age,13-17 Years,50.0,41.0 to 59.0,163
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2017,Age,13-17 Years,60.4,52.3 to 68.1,204
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2018,Age,13-17 Years,55.5,45.7 to 64.8,155
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2013,Age,13-15 Years,94.4,89.6 to 97.0,213
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2014,Age,13-17 Years,32.1,24.4 to 41.0,159
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2013,Age,13-17 Years,26.6,19.0 to 35.8,176
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2014,Age,13-15 Years,91.2,84.7 to 95.1,195
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2015,Age,13-15 Years,88.0,79.7 to 93.2,186
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2016,Age,13-15 Years,91.5,85.9 to 95.1,180
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2017,Age,13-15 Years,89.3,83.6 to 93.2,232
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2012,Age,13-17 Years,13.1,7.6 to 21.5,173
HPV,"Up-to-Date, Males",States/Local Areas,North Dakota,2016,Age,13-17 Years,45.5,36.6 to 54.6,163
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2009,Age,13-15 Years,80.4,72.6 to 86.5,154
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2010,Age,13-15 Years,86.1,78.8 to 91.1,154
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2008,Age,13-15 Years,61.8,54.0 to 69.0,209
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2011,Age,13-15 Years,88.1,77.1 to 94.2,171
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2012,Age,13-15 Years,89.0,81.1 to 93.9,206
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2010,Age,13-17 Years,88.4,83.7 to 91.8,299
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2011,Age,13-17 Years,92.0,85.6 to 95.7,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2013,Age,13-17 Years,96.2,93.3 to 97.9,344
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2012,Age,13-17 Years,92.2,86.3 to 95.7,324
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2008,Age,13-17 Years,75.0,69.4 to 79.9,362
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2009,Age,13-17 Years,85.7,80.4 to 89.8,272
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2011,Age,13-15 Years,87.2,75.8 to 93.7,171
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2010,Age,13-15 Years,85.2,77.9 to 90.4,154
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2018,Age,13-17 Years,75.8,65.7 to 83.7,132
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2019,Age,13-17 Years,77.8,69.5 to 84.3,152
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2014,Age,13-17 Years,48.7,39.3 to 58.2,168
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2015,Age,13-17 Years,60.9,51.7 to 69.5,159
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2016,Age,13-17 Years,63.6,53.4 to 72.6,130
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2017,Age,13-17 Years,68.9,60.7 to 76.2,175
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2020,Age,13-17 Years,92.3,87.6 to 95.3,401
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2019,Age,13-17 Years,97.3,95.2 to 98.5,319
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2022,Age,13-17 Years,82.9,76.3 to 88.0,280
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2021,Age,13-17 Years,83.8,76.4 to 89.2,191
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2020,Age,13-17 Years,79.8,74.2 to 84.5,401
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2021,Age,13-15 Years,92.7,85.0 to 96.7,104
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Dakota,2016,Age,13-17 Years,56.6,49.9 to 63.1,293
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Dakota,2017,Age,13-17 Years,64.6,58.8 to 70.0,379
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2022,Age,13-17 Years,81.3,71.0 to 88.5,128
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2021,Age,13-17 Years,80.1,68.0 to 88.3,87
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2020,Age,13-17 Years,82.8,74.9 to 88.6,198
Varicella,≥2 Doses with no disease history,States/Local Areas,North Dakota,2022,Age,13-17 Years,96.9,93.0 to 98.7,264
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2019,Age,13-17 Years,88.1,82.1 to 92.3,152
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Dakota,2018,Age,13-17 Years,65.4,58.3 to 71.9,287
HPV,"≥1 Dose, Males",States/Local Areas,North Dakota,2012,Age,13-17 Years,18.6,12.3 to 27.2,173
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2021,Age,13-17 Years,97.9,94.7 to 99.1,174
Varicella,≥1 Dose with no disease history,States/Local Areas,North Dakota,2022,Age,13-17 Years,98.3,95.4 to 99.4,264
≥3 Doses HepB,,States/Local Areas,North Dakota,2022,Age,13-17 Years,95.8,91.7 to 97.9,280
≥3 Doses HepB,,States/Local Areas,North Dakota,2021,Age,13-17 Years,93.1,87.0 to 96.4,191
≥3 Doses HepB,,States/Local Areas,North Dakota,2020,Age,13-17 Years,94.6,91.6 to 96.6,401
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2016,Age,13-17 Years,68.3,58.2 to 76.9,130
HPV,"≥1 Dose, Females",States/Local Areas,North Dakota,2017,Age,13-17 Years,74.7,66.9 to 81.2,175
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2016,Age,13-15 Years,91.1,85.4 to 94.8,180
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2013,Age,13-17 Years,51.0,41.7 to 60.3,168
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2012,Age,13-17 Years,49.7,39.8 to 59.5,151
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2017,Age,13-15 Years,91.6,86.5 to 94.9,232
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2018,Age,13-15 Years,92.8,86.2 to 96.4,173
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2019,Age,13-15 Years,95.6,91.9 to 97.7,192
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2009,Age,13-17 Years,41.0,32.1 to 50.6,133
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2020,Age,13-15 Years,90.9,84.9 to 94.7,256
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2010,Age,13-17 Years,34.1,26.7 to 42.5,159
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2011,Age,13-17 Years,38.8,27.8 to 51.1,142
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2008,Age,13-17 Years,23.9,17.6 to 31.6,177
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2009,Age,13-15 Years,73.9,65.5 to 80.9,154
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2008,Age,13-15 Years,50.8,43.3 to 58.2,209
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2018,Age,13-17 Years,91.1,85.9 to 94.6,287
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2021,Age,13-17 Years,96.6,92.6 to 98.5,191
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2022,Age,13-17 Years,94.3,89.6 to 97.0,280
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2018,Age,13-17 Years,76.7,70.0 to 82.2,287
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2019,Age,13-17 Years,88.8,84.5 to 92.0,319
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2015,Age,13-17 Years,90.4,85.1 to 94.0,323
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2014,Age,13-17 Years,94.2,90.0 to 96.7,327
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2016,Age,13-17 Years,92.9,88.6 to 95.7,293
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,North Dakota,2017,Age,13-17 Years,92.4,89.0 to 94.8,379
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2013,Age,13-15 Years,94.7,91.2 to 96.9,213
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2012,Age,13-15 Years,87.9,80.7 to 92.6,206
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2014,Age,13-15 Years,88.8,82.6 to 93.1,195
≥1 Dose MenACWY,,States/Local Areas,North Dakota,2015,Age,13-15 Years,92.1,84.6 to 96.2,186
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2016,Age,13-17 Years,67.6,60.9 to 73.5,293
HPV,"≥1 Dose, Males and Females",States/Local Areas,North Dakota,2017,Age,13-17 Years,72.5,67.0 to 77.4,379
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2013,Age,13-17 Years,41.1,32.3 to 50.4,168
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2014,Age,13-17 Years,41.7,32.7 to 51.3,168
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2011,Age,13-17 Years,27.8,18.7 to 39.2,142
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2012,Age,13-17 Years,40.9,31.7 to 50.7,151
≥2 Doses Hep A,,States/Local Areas,North Dakota,2020,Age,13-17 Years,88.7,83.7 to 92.3,401
≥2 Doses Hep A,,States/Local Areas,North Dakota,2021,Age,13-17 Years,96.9,93.9 to 98.4,191
≥2 Doses Hep A,,States/Local Areas,North Dakota,2022,Age,13-17 Years,94.5,89.2 to 97.3,280
HPV,"≥3 Doses, Males",States/Local Areas,North Dakota,2014,Age,13-15 Years,18.1,11.1 to 28.0,95
HPV,"≥3 Doses, Males",States/Local Areas,North Dakota,2015,Age,13-15 Years,45.5,34.2 to 57.2,96
HPV,"≥3 Doses, Males",States/Local Areas,North Dakota,2014,Age,13-17 Years,25.3,18.3 to 33.9,159
HPV,"≥3 Doses, Males",States/Local Areas,North Dakota,2015,Age,13-17 Years,38.4,30.3 to 47.3,164
HPV,"≥3 Doses, Males",States/Local Areas,North Dakota,2013,Age,13-17 Years,18.4,12.1 to 27.1,176
HPV,"≥3 Doses, Males",States/Local Areas,North Dakota,2013,Age,13-15 Years,26.3,16.9 to 38.6,106
Varicella,≥2 Doses or history of disease,States/Local Areas,North Dakota,2008,Age,13-17 Years,76.8,71.5 to 81.3,362
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2008,Age,13-17 Years,15.9,10.8 to 22.8,177
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2009,Age,13-17 Years,31.7,23.6 to 41.1,133
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2015,Age,13-17 Years,47.1,38.1 to 56.2,159
HPV,"≥3 Doses, Females",States/Local Areas,North Dakota,2010,Age,13-17 Years,26.3,19.8 to 34.0,159
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2015,Age,13-17 Years,88.9,83.5 to 92.7,323
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2022,Age,13-17 Years,74.4,67.3 to 80.5,280
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2021,Age,13-17 Years,72.2,63.7 to 79.3,191
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2020,Age,13-17 Years,70.3,64.0 to 76.0,401
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2019,Age,13-17 Years,76.9,70.9 to 82.0,319
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2008,Age,13-17 Years,47.8,42.2 to 53.5,362
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2022,Age,13-15 Years,94.0,87.8 to 97.2,177
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2011,Age,13-17 Years,87.5,80.1 to 92.4,314
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2010,Age,13-17 Years,83.1,77.9 to 87.3,299
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2009,Age,13-17 Years,71.6,65.4 to 77.1,272
≥2 Doses MMR,,States/Local Areas,North Dakota,2010,Age,13-17 Years,94.2,90.6 to 96.5,299
≥2 Doses MMR,,States/Local Areas,North Dakota,2011,Age,13-17 Years,90.7,83.6 to 94.9,314
≥2 Doses MMR,,States/Local Areas,North Dakota,2008,Age,13-17 Years,93.7,90.4 to 96.0,362
≥2 Doses MMR,,States/Local Areas,North Dakota,2009,Age,13-17 Years,96.0,92.6 to 97.9,272
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2019,Age,13-17 Years,80.7,71.9 to 87.3,167
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2016,Age,13-17 Years,52.7,46.0 to 59.3,293
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2013,Age,13-17 Years,95.0,91.2 to 97.2,344
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2014,Age,13-17 Years,92.1,87.1 to 95.3,327
Tetanus,≥1 Dose Tdap,States/Local Areas,North Dakota,2012,Age,13-17 Years,89.5,83.3 to 93.6,324
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2017,Age,13-17 Years,57.8,51.9 to 63.5,379
HPV,"Up-to-Date, Males and Females",States/Local Areas,North Dakota,2018,Age,13-17 Years,63.6,56.5 to 70.2,287
HPV,"≥2 Doses, Males and Females",States/Local Areas,North Dakota,2022,Age,13-17 Years,76.0,69.0 to 81.8,280
HPV,"≥2 Doses, Males",States/Local Areas,North Dakota,2022,Age,13-17 Years,76.2,66.5 to 83.8,152
HPV,"≥2 Doses, Females",States/Local Areas,North Dakota,2022,Age,13-17 Years,75.8,65.0 to 84.0,128
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2020,Age,13-17 Years,57.6,48.0 to 66.7,163
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2020,Age,13-15 Years,49.8,39.4 to 60.3,130
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2017,Age,13-17 Years,30.4,23.2 to 38.8,188
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2019,Age,13-15 Years,50.3,39.2 to 61.4,131
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2022,Age,13-17 Years,61.9,51.6 to 71.3,137
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2021,Age,13-17 Years,70.6,60.0 to 79.4,140
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2018,Age,13-15 Years,48.7,36.8 to 60.7,93
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2022,Age,13-15 Years,58.3,46.6 to 69.2,105
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2021,Age,13-15 Years,52.2,39.2 to 64.9,95
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2016,Age,13-17 Years,26.0,18.7 to 35.0,166
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2019,Age,13-17 Years,46.6,37.2 to 56.2,182
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2018,Age,13-17 Years,38.1,29.2 to 48.0,138
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2016,Age,13-17 Years,45.6,36.6 to 54.9,156
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2017,Age,13-17 Years,38.5,29.7 to 48.2,150
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2022,Age,13-15 Years,59.5,46.7 to 71.2,83
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2021,Age,13-15 Years,72.6,60.0 to 82.5,85
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2020,Age,13-17 Years,49.2,40.7 to 57.6,201
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2019,Age,13-17 Years,52.3,43.3 to 61.1,199
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2018,Age,13-17 Years,43.2,34.3 to 52.6,159
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2020,Age,13-15 Years,52.3,44.3 to 60.2,232
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2021,Age,13-17 Years,58.3,47.9 to 67.9,160
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2022,Age,13-15 Years,58.9,50.3 to 67.0,188
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2021,Age,13-15 Years,62.2,52.7 to 70.8,180
HPV,"Up-to-Date, Males",States/Local Areas,Kansas,2022,Age,13-17 Years,59.5,50.2 to 68.1,173
HPV,"Up-to-Date, Males and Females",States/Local Areas,Kansas,2019,Age,13-15 Years,46.9,38.6 to 55.4,238
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2020,Age,13-15 Years,55.0,42.9 to 66.6,102
HPV,"Up-to-Date, Females",States/Local Areas,Kansas,2019,Age,13-15 Years,43.1,31.1 to 56.0,107
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,65.4,56.3 to 73.5,199
HPV,"≥2 Doses, Males and Females",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,66.6,60.3 to 72.4,374
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,67.9,58.8 to 75.8,175
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,54.7,48.8 to 60.5,373
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,65.2,58.8 to 71.0,441
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,42.1,35.5 to 49.1,440
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,52.2,46.2 to 58.2,365
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2022,Age,13-15 Years,94.1,87.4 to 97.4,222
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,65.4,57.9 to 72.3,345
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,90.4,86.2 to 93.5,442
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,92.8,89.2 to 95.3,479
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,91.5,88.3 to 93.8,529
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,92.5,89.2 to 94.8,448
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,12.6,8.2 to 18.9,345
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,18.1,13.2 to 24.3,441
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,94.6,91.9 to 96.5,479
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,93.7,90.5 to 95.8,448
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,89.5,85.8 to 92.4,496
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,93.7,90.3 to 96.0,435
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,94.6,90.9 to 96.8,349
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,87.6,80.9 to 92.2,345
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,82.3,77.6 to 86.3,448
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,78.1,73.4 to 82.2,496
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,78.0,72.2 to 82.9,349
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,75.6,70.3 to 80.3,435
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,88.9,85.0 to 91.8,479
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,92.1,88.3 to 94.7,428
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,89.6,85.3 to 92.8,434
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,94.3,90.1 to 96.8,374
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,96.0,92.8 to 97.8,442
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,94.6,92.0 to 96.4,529
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,93.7,90.3 to 95.9,428
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,30.9,26.3 to 36.0,496
HPV,"≥3 Doses, Males and Females",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,33.9,28.7 to 39.6,435
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2013,Age,13-15 Years,28.9,18.8 to 41.7,98
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2014,Age,13-15 Years,44.3,34.6 to 54.4,137
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2015,Age,13-15 Years,36.7,28.7 to 45.6,167
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,90.6,86.7 to 93.5,442
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,91.0,87.8 to 93.4,529
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,93.0,89.6 to 95.4,428
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,95.7,92.9 to 97.4,434
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2012,Age,13-15 Years,17.7,9.6 to 30.3,106
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2011,Age,13-15 Years,22.7,15.2 to 32.4,142
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2010,Age,13-15 Years,20.6,13.7 to 29.8,123
HPV,"≥3 Doses, Females",States/Local Areas,IL-Rest of state,2009,Age,13-15 Years,20.5,13.2 to 30.6,96
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,19.4,12.8 to 28.4,175
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,31.9,25.1 to 39.7,227
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,52.6,45.5 to 59.6,268
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,54.1,47.0 to 61.1,264
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,46.2,38.7 to 53.9,231
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,29.9,23.5 to 37.3,242
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2013,Age,13-15 Years,86.8,79.2 to 91.9,209
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2017,Age,13-15 Years,90.6,85.1 to 94.2,283
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2016,Age,13-15 Years,92.1,87.1 to 95.3,258
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2014,Age,13-15 Years,94.6,91.3 to 96.7,289
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2015,Age,13-15 Years,89.1,83.6 to 92.8,316
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2009,Age,13-15 Years,57.5,49.9 to 64.7,223
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2010,Age,13-15 Years,63.9,56.3 to 70.9,228
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,58.3,51.1 to 65.1,261
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,77.9,69.4 to 84.6,199
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2011,Age,13-15 Years,63.9,56.2 to 71.0,274
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2010,Age,13-15 Years,49.1,41.6 to 56.7,228
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2012,Age,13-15 Years,76.5,67.0 to 83.9,210
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2011,Age,13-15 Years,69.4,61.8 to 76.1,274
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2021,Age,13-15 Years,96.3,92.7 to 98.1,261
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,73.7,67.9 to 78.8,428
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,75.2,69.7 to 79.9,434
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,79.7,73.9 to 84.5,374
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,49.7,42.0 to 57.5,215
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,55.8,47.8 to 63.5,217
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,49.9,42.8 to 57.0,254
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2009,Age,13-15 Years,54.7,47.2 to 62.0,223
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2008,Age,13-15 Years,40.4,31.9 to 49.5,253
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,69.7,64.2 to 74.8,442
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,94.9,91.9 to 96.9,434
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,95.1,91.0 to 97.4,374
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,91.8,87.9 to 94.6,442
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,93.1,89.4 to 95.5,428
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2016,Age,13-17 Years,46.1,40.6 to 51.7,448
HPV,"≥2 Doses, Males",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,55.9,48.1 to 63.4,242
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,91.0,85.2 to 94.7,440
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,92.5,88.4 to 95.2,365
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,95.0,91.8 to 97.0,373
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,94.2,91.2 to 96.1,441
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2013,Age,13-17 Years,85.4,79.7 to 89.7,349
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2014,Age,13-17 Years,93.6,90.4 to 95.7,435
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2012,Age,13-17 Years,77.0,69.8 to 82.9,345
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,52.9,47.2 to 58.5,442
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018,Age,13-17 Years,51.0,45.9 to 56.0,529
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2017,Age,13-17 Years,46.9,41.7 to 52.2,479
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2008,Age,13-15 Years,47.9,39.0 to 57.0,253
HPV,"≥2 Doses, Females",States/Local Areas,IL-Rest of state,2019,Age,13-17 Years,57.8,49.4 to 65.8,200
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2019,Age,13-15 Years,91.4,85.9 to 94.8,282
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2020,Age,13-15 Years,91.4,85.9 to 94.9,249
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2021,Age,13-15 Years,90.5,85.2 to 94.0,261
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018,Age,13-15 Years,92.6,88.5 to 95.3,334
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2022,Age,13-15 Years,91.8,84.9 to 95.7,222
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2008,Age,13-17 Years,45.7,39.0 to 52.6,440
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2011,Age,13-17 Years,72.3,66.4 to 77.5,441
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2010,Age,13-17 Years,65.4,59.5 to 70.8,373
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2009,Age,13-17 Years,59.6,53.6 to 65.5,365
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2015,Age,13-17 Years,89.5,85.5 to 92.5,496
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,60.4,54.5 to 66.0,434
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,64.9,58.5 to 70.8,374
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2020,Age,13-17 Years,61.2,55.1 to 67.0,428
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2021,Age,13-17 Years,96.8,94.6 to 98.1,434
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,93.2,88.8 to 96.0,374
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2022,Age,13-17 Years,94.9,91.0 to 97.2,374
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Uninsured,90.3,72.6 to 97.0,44
HPV,"≥1 Dose, Males",States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,75.1,67.8 to 81.2,252
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2023,Age,13-15 Years,65.0,54.8 to 74.1,125
HPV,"Up-to-Date, Females",States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,73.4,65.8 to 79.8,208
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2023,Age,13-15 Years,90.2,85.0 to 93.8,246
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2023,Age,13-15 Years,54.6,44.2 to 64.6,132
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2023,Age,13-15 Years,59.7,52.3 to 66.6,257
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2023,Age,13-15 Years,92.4,88.0 to 95.2,257
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2023,Age,13-15 Years,94.2,90.2 to 96.6,257
≥2 Doses Hep A,,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,80.5,75.7 to 84.6,460
Varicella,≥2 Doses or history of disease,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,92.2,89.0 to 94.5,460
≥3 Doses HepB,,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,93.6,90.7 to 95.6,460
Varicella,History of disease,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,6.2,3.9 to 9.7,460
Varicella,≥2 Doses with no disease history,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,91.7,88.3 to 94.2,434
Varicella,≥1 Dose with no disease history,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,95.9,93.4 to 97.5,434
HPV,"Up-to-Date, Males",States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,62.7,55.1 to 69.7,252
≥2 Doses MMR,,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,93.7,90.8 to 95.7,460
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,67.9,62.5 to 72.8,460
HPV,"≥1 Dose, Females",States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,82.9,76.3 to 88.0,208
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,78.9,74.0 to 83.0,460
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,93.4,90.6 to 95.5,460
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,93.6,90.6 to 95.7,460
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,IL-Rest of state,2023,Age,13-17 Years,93.9,90.9 to 96.0,460
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Overall,Overall,58.1,55.5 to 60.6,2207
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Overall,Overall,72.9,70.5 to 75.2,2207
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,73.0,66.9 to 78.4,375
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,74.6,71.9 to 77.2,1608
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,60.0,52.1 to 67.5,224
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,59.4,56.3 to 62.4,1608
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,42.7,34.8 to 51.0,224
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,93.7,89.9 to 96.1,375
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,93.5,91.9 to 94.8,1608
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,89.0,83.1 to 93.0,224
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,61.7,55.3 to 67.7,375
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",56.2,52.9 to 59.4,1375
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a Non-MSA,95.1,90.9 to 97.4,224
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Principal City,92.8,88.8 to 95.5,375
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.9,88.9 to 92.5,1608
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",78.0,70.8 to 83.8,256
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",97.0,94.6 to 98.4,256
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,Hispanic,60.7,54.7 to 66.4,405
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",58.5,49.5 to 67.0,171
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",62.3,54.3 to 69.6,256
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.5,90.6 to 94.1,1375
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",92.7,90.8 to 94.3,1375
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",90.4,84.8 to 94.2,171
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,Hispanic,93.1,89.6 to 95.5,405
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,Hispanic,90.0,85.6 to 93.2,405
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",88.7,82.4 to 92.9,171
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.7,87.2 to 95.9,256
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"White, Non-Hispanic",70.0,66.9 to 73.0,1375
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",75.4,67.1 to 82.1,171
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Race and Ethnicity,Hispanic,76.6,71.1 to 81.3,405
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Poverty,Below Poverty Level,73.2,66.7 to 78.8,294
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,72.9,70.3 to 75.4,1834
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,92.8,91.2 to 94.1,1834
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Poverty,Below Poverty Level,93.1,89.2 to 95.7,294
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2012,Age,13-15 Years,26.2,20.5 to 32.8,512
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Poverty,Below Poverty Level,56.8,49.7 to 63.7,294
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Poverty,Below Poverty Level,92.5,88.3 to 95.3,294
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,58.0,55.2 to 60.8,1834
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,94.1,92.5 to 95.5,1474
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Poverty,Living At or Above Poverty Level,91.2,89.4 to 92.8,1834
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,91.8,88.9 to 94.0,616
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,73.3,70.4 to 76.1,1474
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Other,88.1,77.4 to 94.1,73
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,74.7,70.4 to 78.6,616
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Other,49.6,34.3 to 64.9,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,60.2,57.0 to 63.2,1474
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Uninsured,85.9,71.1 to 93.8,44
HPV,"≥1 Dose, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Uninsured,59.6,40.8 to 76.0,44
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,56.8,51.9 to 61.5,616
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Other,37.2,24.0 to 52.7,73
HPV,"Up-to-Date, Males and Females",States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Uninsured,40.6,24.8 to 58.7,44
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Private Insurance Only,92.4,90.4 to 94.0,1474
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Any Medicaid,91.0,87.9 to 93.3,616
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Insurance Coverage,Other,81.7,65.9 to 91.1,73
≥1 Dose MenACWY,,States/Local Areas,IL-Rest of state,2018-2022,Overall,Overall,93.1,91.7 to 94.2,2207
Tetanus,≥1 Dose Tdap,States/Local Areas,IL-Rest of state,2018-2022,Overall,Overall,91.6,90.0 to 92.9,2207
≥1 Dose MenACWY,,States/Local Areas,Texas,2021,Age,13-17 Years,90.0,86.3 to 92.7,990
≥1 Dose MenACWY,,States/Local Areas,Texas,2022,Age,13-17 Years,86.5,81.6 to 90.2,794
≥1 Dose MenACWY,,States/Local Areas,Texas,2020,Age,13-17 Years,91.2,88.3 to 93.4,1141
≥1 Dose MenACWY,,States/Local Areas,Texas,2019,Age,13-17 Years,85.9,83.2 to 88.3,1850
≥1 Dose MenACWY,,States/Local Areas,Texas,2018,Age,13-17 Years,86.7,84.1 to 88.9,2079
≥1 Dose MenACWY,,States/Local Areas,Texas,2017,Age,13-17 Years,85.1,82.4 to 87.5,2256
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2009,Age,13-15 Years,21.7,15.4 to 29.6,434
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2010,Age,13-15 Years,28.6,21.5 to 37.0,530
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2011,Age,13-15 Years,31.1,22.6 to 41.0,646
≥2 Doses MMR,,States/Local Areas,Texas,2022,Age,13-17 Years,80.9,75.1 to 85.6,794
≥2 Doses MMR,,States/Local Areas,Texas,2021,Age,13-17 Years,84.1,79.6 to 87.8,990
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2014,Age,13-15 Years,34.4,26.3 to 43.6,473
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2015,Age,13-15 Years,40.7,34.4 to 47.3,810
HPV,"≥3 Doses, Females",States/Local Areas,Texas,2013,Age,13-15 Years,36.8,28.4 to 46.1,325
HPV,"≥3 Doses, Males and Females",States/Local Areas,Texas,2014,Age,13-17 Years,25.6,21.6 to 30.1,1652
HPV,"≥3 Doses, Males and Females",States/Local Areas,Texas,2015,Age,13-17 Years,32.3,29.2 to 35.6,2617
≥2 Doses MMR,,States/Local Areas,Texas,2020,Age,13-17 Years,85.9,82.2 to 89.0,1141
HPV,"≥3 Doses, Males and Females",States/Local Areas,Texas,2013,Age,13-17 Years,26.7,22.4 to 31.4,1112
HPV,"≥3 Doses, Males and Females",States/Local Areas,Texas,2012,Age,13-17 Years,18.4,15.5 to 21.6,1594
≥1 Dose MenACWY,,States/Local Areas,Texas,2012,Age,13-17 Years,84.6,81.0 to 87.6,1594
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2021,Age,13-17 Years,87.1,83.1 to 90.3,990
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2020,Age,13-17 Years,84.0,79.9 to 87.5,1141
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2019,Age,13-17 Years,84.8,81.9 to 87.3,1850
≥2 Doses MMR,,States/Local Areas,Texas,2019,Age,13-17 Years,84.2,81.1 to 86.8,1850
≥2 Doses MMR,,States/Local Areas,Texas,2017,Age,13-17 Years,84.7,82.1 to 87.0,2256
≥2 Doses MMR,,States/Local Areas,Texas,2018,Age,13-17 Years,83.1,80.2 to 85.6,2079
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2022,Age,13-17 Years,85.0,79.9 to 89.0,794
≥2 Doses MMR,,States/Local Areas,Texas,2013,Age,13-17 Years,87.3,83.3 to 90.4,1112
≥2 Doses MMR,,States/Local Areas,Texas,2012,Age,13-17 Years,86.9,83.8 to 89.4,1594
≥2 Doses MMR,,States/Local Areas,Texas,2015,Age,13-17 Years,84.7,82.0 to 87.1,2617
≥2 Doses MMR,,States/Local Areas,Texas,2014,Age,13-17 Years,84.3,80.2 to 87.7,1652
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2017,Age,13-17 Years,83.2,80.4 to 85.7,2256
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2018,Age,13-17 Years,83.4,80.6 to 85.9,2079
≥1 Dose MenACWY,,States/Local Areas,Texas,2016,Age,13-17 Years,85.5,82.6 to 88.0,1927
≥1 Dose MenACWY,,States/Local Areas,Texas,2015,Age,13-17 Years,89.6,87.1 to 91.5,2617
≥1 Dose MenACWY,,States/Local Areas,Texas,2014,Age,13-17 Years,88.6,85.2 to 91.3,1652
≥1 Dose MenACWY,,States/Local Areas,Texas,2013,Age,13-17 Years,87.6,83.7 to 90.7,1112
HPV,"≥3 Doses, Males and Females",States/Local Areas,Texas,2011,Age,13-17 Years,16.6,13.3 to 20.6,2224
≥2 Doses MMR,,States/Local Areas,Texas,2016,Age,13-17 Years,83.5,80.5 to 86.1,1927
Tetanus,≥1 Dose Tdap,States/Local Areas,Texas,2016,Age,13-17 Years,85.0,82.1 to 87.5,1927
≥1 Dose MenACWY,,States/Local Areas,Texas,2009,Age,13-17 Years,51.0,45.7 to 56.2,1470
≥1 Dose MenACWY,,States/Local Areas,Texas,2008,Age,13-17 Years,37.4,30.9 to 44.3,840
≥1 Dose MenACWY,,States/Local Areas,Texas,2011,Age,13-17 Years,79.1,74.9 to 82.7,2224
≥1 Dose MenACWY,,States/Local Areas,Texas,2010,Age,13-17 Years,65.4,60.5 to 70.0,1709
≥1 Dose MenACWY,,States/Local Areas,Texas,2022,Age,13-15 Years,84.0,77.0 to 89.2,488
HPV,"≥2 Doses, Females",States/Local Areas,Texas,2022,Age,13-17 Years,65.0,55.4 to 73.6,367
Varicella,History of disease,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,23.1,17.7 to 29.7,334
Varicella,History of disease,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,17.5,13.2 to 22.9,368
Varicella,History of disease,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,16.1,11.5 to 22.1,298
Varicella,History of disease,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,13.3,9.7 to 18.0,336
Varicella,History of disease,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,66.1,58.7 to 72.8,269
Varicella,History of disease,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,53.1,45.9 to 60.2,305
Varicella,History of disease,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,27.3,20.9 to 34.7,346
Varicella,History of disease,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,30.4,24.7 to 36.9,317
Varicella,History of disease,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,44.2,38.3 to 50.3,382
Varicella,History of disease,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,35.2,29.6 to 41.2,448
Varicella,History of disease,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,11.7,7.6 to 17.4,293
Varicella,History of disease,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,8.1,5.0 to 12.9,314
Varicella,History of disease,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,9.8,5.8 to 16.1,253
Varicella,History of disease,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,27.2,21.5 to 33.7,385
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2018,Age,13-15 Years,49.8,38.6 to 61.0,104
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2019,Age,13-15 Years,47.4,34.8 to 60.3,83
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2020,Age,13-15 Years,61.3,49.1 to 72.2,90
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2019,Age,13-15 Years,45.2,36.6 to 54.1,181
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,55.6,44.1 to 66.6,132
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2020,Age,13-15 Years,60.3,51.8 to 68.2,186
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,58.4,48.0 to 68.1,146
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,47.3,38.1 to 56.7,155
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,59.4,50.1 to 68.0,161
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,37.2,29.3 to 45.9,176
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,43.6,34.2 to 53.5,147
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,55.6,46.7 to 64.3,160
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,45.2,35.8 to 55.0,156
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2021,Age,13-15 Years,62.0,52.5 to 70.7,174
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2022,Age,13-15 Years,59.5,48.5 to 69.7,151
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,83.2,77.9 to 87.5,368
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,91.8,86.9 to 95.0,346
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,93.6,89.9 to 96.0,448
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,86.6,81.5 to 90.5,317
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,89.4,85.4 to 92.4,385
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,96.6,93.3 to 98.3,271
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,92.5,87.8 to 95.5,309
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,95.8,91.3 to 98.1,230
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,95.8,92.1 to 97.8,303
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,81.9,75.3 to 87.0,253
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,89.0,84.3 to 92.5,288
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,85.5,79.2 to 90.1,263
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,84.5,79.0 to 88.8,288
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,84.7,78.2 to 89.6,276
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,90.5,85.0 to 94.2,253
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,90.0,84.2 to 93.8,263
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,93.1,88.2 to 96.0,288
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,85.8,80.0 to 90.1,288
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,51.5,42.7 to 60.2,213
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,44.2,36.4 to 52.2,203
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,82.8,76.5 to 87.7,271
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,79.8,73.5 to 85.0,309
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,78.9,72.0 to 84.4,230
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,82.2,76.0 to 87.0,303
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,43.0,33.0 to 53.5,176
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,54.8,45.6 to 63.6,155
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,47.7,38.6 to 57.1,179
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,85.7,80.5 to 89.7,334
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,87.6,82.1 to 91.6,293
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,83.0,76.8 to 87.8,298
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,83.8,78.1 to 88.3,336
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,48.5,39.7 to 57.4,178
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,40.3,31.7 to 49.5,170
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,32.4,24.4 to 41.7,162
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,35.6,27.4 to 44.9,206
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,74.2,65.1 to 81.6,161
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,59.7,49.7 to 69.0,147
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,68.8,59.4 to 76.9,155
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,57.1,48.2 to 65.5,176
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,88.9,82.9 to 93.0,276
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,42.9,36.5 to 49.6,334
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,49.3,42.4 to 56.3,293
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,49.0,42.8 to 55.2,336
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,90.2,84.8 to 93.8,232
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,65.7,55.4 to 74.6,138
HPV,"≥2 Doses, Males and Females",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,53.1,46.2 to 59.9,298
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,77.2,68.7 to 83.9,153
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,82.5,74.1 to 88.5,150
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,12.1,7.4 to 19.3,235
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,85.9,76.6 to 91.9,121
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,16.6,9.8 to 26.6,170
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,86.6,80.6 to 91.0,253
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,83.7,78.3 to 87.9,314
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,85.3,79.0 to 90.0,296
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,92.1,86.8 to 95.4,232
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,68.8,59.7 to 76.7,160
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,58.3,48.6 to 67.5,156
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,56.2,47.6 to 64.4,198
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,71.1,61.4 to 79.2,151
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,66.0,54.1 to 76.2,132
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,90.2,85.6 to 93.5,317
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2009,Age,13-15 Years,55.3,46.0 to 64.2,202
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2008,Age,13-15 Years,42.9,34.3 to 51.9,173
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2011,Age,13-15 Years,86.7,80.8 to 91.0,282
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2010,Age,13-15 Years,75.3,68.3 to 81.1,244
HPV,"≥1 Dose, Males",States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,72.1,62.0 to 80.3,146
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2016,Age,13-15 Years,86.9,80.2 to 91.6,205
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,77.7,71.0 to 83.2,269
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,79.3,72.7 to 84.7,305
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,87.7,80.9 to 92.3,346
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,86.1,81.4 to 89.8,382
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,93.1,90.0 to 95.3,448
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,90.9,86.1 to 94.2,334
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,89.3,85.1 to 92.4,385
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,87.5,82.4 to 91.3,368
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2015,Age,13-15 Years,88.0,82.1 to 92.2,245
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2014,Age,13-15 Years,84.6,76.8 to 90.1,225
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2012,Age,13-15 Years,84.4,74.4 to 91.0,221
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2013,Age,13-15 Years,92.5,86.8 to 95.9,194
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,26.5,18.0 to 37.1,114
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,36.0,28.8 to 43.9,203
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,46.1,37.4 to 55.0,213
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,29.1,21.1 to 38.7,145
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2020,Age,13-15 Years,89.6,83.3 to 93.7,186
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,33.4,24.5 to 43.8,176
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,45.7,36.8 to 54.9,155
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,62.9,56.6 to 68.8,336
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,53.4,46.7 to 59.9,334
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,86.9,81.2 to 91.0,336
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,75.7,69.6 to 80.9,314
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,77.3,70.9 to 82.7,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,75.9,68.1 to 82.3,253
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2019,Age,13-15 Years,86.8,79.4 to 91.8,181
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018,Age,13-15 Years,89.2,83.1 to 93.3,201
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2017,Age,13-15 Years,83.5,75.8 to 89.1,211
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,65.4,58.4 to 71.7,298
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,87.3,82.0 to 91.2,296
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,67.2,60.4 to 73.4,293
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2013,Age,13-15 Years,88.5,81.7 to 93.0,194
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2021,Age,13-15 Years,91.0,84.5 to 95.0,174
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,87.2,81.2 to 91.5,293
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,89.7,84.8 to 93.2,314
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,89.9,85.2 to 93.2,298
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,59.1,50.1 to 67.6,160
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,50.5,40.8 to 60.1,156
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,46.5,38.1 to 55.1,198
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,39.0,30.4 to 48.3,179
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2012,Age,13-15 Years,80.6,70.0 to 88.1,221
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2011,Age,13-15 Years,91.2,86.9 to 94.2,282
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2009,Age,13-15 Years,59.8,50.6 to 68.3,202
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2010,Age,13-15 Years,75.8,68.8 to 81.6,244
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2008,Age,13-15 Years,49.7,40.6 to 58.8,173
Tetanus,≥1 Dose Td or Tdap,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,88.2,81.7 to 92.6,253
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,19.1,13.2 to 26.9,162
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,26.2,18.7 to 35.6,206
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,49.5,39.4 to 59.6,138
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,57.0,47.2 to 66.3,151
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2018,Age,13-15 Years,38.4,27.8 to 50.3,97
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,60.9,50.6 to 70.4,150
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,71.6,59.9 to 80.9,121
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,62.1,52.8 to 70.5,153
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2021,Age,13-15 Years,65.6,52.0 to 77.0,89
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2022,Age,13-15 Years,69.1,53.5 to 81.3,71
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,47.7,37.7 to 57.9,138
HPV,"Up-to-Date, Females",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,52.5,42.9 to 62.0,151
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2016,Age,13-15 Years,84.9,78.1 to 89.8,205
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2015,Age,13-15 Years,85.6,79.3 to 90.2,245
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2014,Age,13-15 Years,86.1,79.2 to 90.9,225
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2017,Age,13-15 Years,82.5,74.7 to 88.3,211
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,39.0,31.0 to 47.6,176
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,35.4,27.6 to 44.2,178
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,49.3,39.5 to 59.1,147
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,28.9,21.3 to 37.8,170
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2019,Age,13-15 Years,84.9,76.7 to 90.5,181
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2020,Age,13-15 Years,85.3,77.8 to 90.5,186
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2021,Age,13-15 Years,84.1,76.5 to 89.5,174
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,33.3,25.6 to 42.1,178
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2021,Age,13-15 Years,58.3,44.7 to 70.7,85
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2022,Age,13-15 Years,50.3,35.5 to 65.2,80
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2019,Age,13-15 Years,43.2,31.9 to 55.2,98
HPV,"Up-to-Date, Males",States/Local Areas,TX-Bexar County,2020,Age,13-15 Years,59.3,47.4 to 70.2,96
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018,Age,13-15 Years,86.6,79.2 to 91.6,201
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,73.7,66.4 to 79.9,269
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,76.1,70.6 to 80.9,382
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,68.5,61.2 to 75.0,305
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,87.7,82.6 to 91.4,336
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,86.8,81.7 to 90.6,334
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,87.2,81.5 to 91.3,293
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2008,Age,13-15 Years,26.8,16.2 to 40.9,70
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2009,Age,13-15 Years,36.0,25.9 to 47.5,123
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2020,Age,13-15 Years,88.1,82.2 to 92.3,174
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2021,Age,13-15 Years,87.5,79.5 to 92.6,163
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2019,Age,13-15 Years,86.6,79.0 to 91.7,169
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2018,Age,13-15 Years,84.3,77.0 to 89.6,175
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,57.2,49.1 to 64.9,212
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,71.5,64.4 to 77.7,293
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,84.8,79.1 to 89.2,298
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,91.1,86.3 to 94.4,253
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,85.8,80.7 to 89.7,314
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,85.5,79.2 to 90.1,296
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2015,Age,13-15 Years,78.6,70.8 to 84.8,211
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2014,Age,13-15 Years,83.6,75.4 to 89.4,190
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2012,Age,13-15 Years,77.8,66.0 to 86.3,173
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2013,Age,13-15 Years,83.5,74.9 to 89.5,145
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2011,Age,13-15 Years,78.1,69.4 to 84.8,206
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2010,Age,13-15 Years,64.0,55.2 to 72.0,164
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2017,Age,13-15 Years,85.8,78.3 to 91.0,185
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2016,Age,13-15 Years,84.3,76.6 to 89.8,175
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,83.9,76.7 to 89.3,269
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,88.7,84.4 to 91.9,382
≥3 Doses HepB,,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,82.0,75.3 to 87.2,305
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2022,Age,13-15 Years,90.7,82.5 to 95.3,139
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,83.6,71.0 to 91.4,90
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,93.3,88.9 to 96.0,212
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,87.3,79.2 to 92.5,151
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,97.7,95.1 to 98.9,293
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,32.8,24.2 to 42.7,151
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,22.4,13.9 to 34.1,90
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,40.7,30.6 to 51.7,114
Varicella,≥1 Dose with no disease history,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,95.3,89.4 to 98.0,250
HPV,"≥1 Dose, Females",States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,47.7,37.7 to 57.9,145
Varicella,≥2 Doses with no disease history,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,72.5,63.2 to 80.1,250
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,20.2,12.9 to 30.2,114
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,20.6,13.7 to 29.7,145
HPV,"≥3 Doses, Males",States/Local Areas,TX-Bexar County,2013,Age,13-15 Years,12.2,6.6 to 21.2,95
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,83.4,77.9 to 87.7,368
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,87.0,82.4 to 90.6,385
HPV,"≥3 Doses, Males",States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,9.6,5.8 to 15.4,162
HPV,"≥3 Doses, Males",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,19.9,13.6 to 28.1,170
HPV,"≥3 Doses, Males",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,15.0,9.5 to 23.0,206
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,80.0,72.6 to 85.7,346
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,81.5,76.5 to 85.7,448
Varicella,≥2 Doses or history of disease,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,85.3,80.2 to 89.3,317
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,47.5,40.7 to 54.5,293
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,60.7,54.2 to 66.9,314
≥2 Doses Hep A,,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,87.3,82.4 to 90.9,314
HPV,"≥3 Doses, Males",States/Local Areas,TX-Bexar County,2015,Age,13-15 Years,23.1,14.5 to 34.6,111
HPV,"≥3 Doses, Males",States/Local Areas,TX-Bexar County,2014,Age,13-15 Years,16.5,9.5 to 27.3,130
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,26.7,20.5 to 34.0,203
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,26.3,18.1 to 36.6,176
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,31.9,24.2 to 40.8,213
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,32.5,24.4 to 41.8,155
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,30.8,23.0 to 39.9,179
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,59.7,52.4 to 66.6,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,63.6,55.3 to 71.1,253
≥2 Doses Hep A,,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,86.5,80.4 to 90.9,296
≥2 Doses Hep A,,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,87.5,81.1 to 92.0,253
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,32.8,25.1 to 41.5,198
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,85.7,80.6 to 89.7,368
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,72.1,66.5 to 77.0,382
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,56.4,49.1 to 63.4,305
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,85.2,80.8 to 88.8,448
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,78.6,70.6 to 84.9,346
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,86.6,81.4 to 90.5,317
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,85.7,80.8 to 89.5,385
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,42.0,35.0 to 49.3,269
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2022,Age,13-15 Years,85.2,75.6 to 91.4,151
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,46.4,40.2 to 52.7,336
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,48.0,41.2 to 54.9,298
HPV,"≥2 Doses, Males",States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,49.1,39.8 to 58.5,155
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,82.2,75.6 to 87.2,269
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,80.7,73.9 to 86.1,305
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,85.6,80.9 to 89.2,382
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,93.4,89.9 to 95.8,448
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Overall,Overall,72.4,69.4 to 75.2,1454
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Overall,Overall,56.0,52.8 to 59.2,1454
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Principal City,73.3,70.2 to 76.2,1302
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Non-Principal City,64.3,54.2 to 73.2,152
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Non-Principal City,46.4,36.9 to 56.3,152
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Principal City,57.1,53.7 to 60.4,1302
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Principal City,89.7,87.5 to 91.6,1302
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Non-Principal City,90.4,82.9 to 94.8,152
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Non-Principal City,82.5,72.9 to 89.1,152
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Urbanicity,Living In a MSA Principal City,86.3,83.8 to 88.5,1302
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",92.3,83.0 to 96.7,96
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"White, Non-Hispanic",50.2,43.5 to 56.8,384
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",81.6,71.5 to 88.6,96
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,Hispanic,74.6,71.0 to 77.8,907
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",55.3,42.7 to 67.3,96
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,Hispanic,58.9,55.0 to 62.8,907
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",42.8,30.2 to 56.5,67
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"White, Non-Hispanic",89.2,83.9 to 92.9,384
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",93.7,82.6 to 97.9,67
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"White, Non-Hispanic",87.4,81.9 to 91.3,384
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,Hispanic,89.4,86.8 to 91.5,907
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",86.1,72.9 to 93.4,67
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,Hispanic,85.4,82.3 to 88.0,907
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Other or Multiple Races, Non-Hispanic",88.2,79.5 to 93.5,96
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"White, Non-Hispanic",67.9,61.4 to 73.7,384
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Poverty,Below Poverty Level,80.3,74.6 to 85.0,322
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Poverty,Living At or Above Poverty Level,69.5,65.9 to 72.9,1090
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Race and Ethnicity,"Black, Non-Hispanic",55.7,41.8 to 68.7,67
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Poverty,Below Poverty Level,91.8,87.3 to 94.8,322
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Poverty,Living At or Above Poverty Level,89.3,86.8 to 91.4,1090
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Poverty,Living At or Above Poverty Level,52.8,49.0 to 56.5,1090
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Poverty,Below Poverty Level,64.3,57.8 to 70.4,322
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Poverty,Below Poverty Level,88.7,83.7 to 92.3,322
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Any Medicaid,90.9,87.3 to 93.5,487
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Poverty,Living At or Above Poverty Level,84.8,81.8 to 87.4,1090
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Private Insurance Only,89.1,86.0 to 91.6,678
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Any Medicaid,79.8,75.2 to 83.7,487
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Private Insurance Only,66.2,61.5 to 70.6,678
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Other,72.1,63.4 to 79.4,211
HPV,"≥1 Dose, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Uninsured,62.5,48.8 to 74.5,78
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Other,87.2,79.7 to 92.2,211
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Uninsured,92.5,84.5 to 96.6,78
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Any Medicaid,64.4,59.2 to 69.4,487
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Private Insurance Only,51.2,46.4 to 56.0,678
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Other,49.0,40.6 to 57.5,211
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Private Insurance Only,84.7,80.9 to 87.8,678
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Uninsured,45.7,32.4 to 59.7,78
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Any Medicaid,88.0,84.1 to 91.1,487
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Uninsured,83.7,71.4 to 91.3,78
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Insurance Coverage,Other,84.2,76.1 to 89.9,211
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2008,Age,13-15 Years,16.8,9.1 to 28.8,62
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,86.0,80.3 to 90.3,336
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2012,Age,13-15 Years,19.0,10.8 to 31.2,113
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2013,Age,13-15 Years,24.1,16.0 to 34.7,99
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2015,Age,13-15 Years,24.6,16.2 to 35.5,134
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2014,Age,13-15 Years,24.2,15.1 to 36.5,95
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2011,Age,13-15 Years,27.3,18.7 to 37.9,140
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2010,Age,13-15 Years,25.7,18.4 to 34.8,127
HPV,"≥3 Doses, Females",States/Local Areas,TX-Bexar County,2009,Age,13-15 Years,16.8,10.3 to 26.2,96
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,87.4,81.5 to 91.5,293
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,89.1,84.4 to 92.6,298
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,90.6,86.3 to 93.7,314
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,91.2,85.4 to 94.9,253
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,90.5,85.8 to 93.8,296
HPV,"Up-to-Date, Males and Females",States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,39.2,33.0 to 45.8,334
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2010,Age,13-17 Years,72.0,66.3 to 77.1,382
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,82.2,77.3 to 86.2,448
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2008,Age,13-17 Years,43.2,36.2 to 50.5,269
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2009,Age,13-17 Years,54.8,47.5 to 61.9,305
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,87.2,82.1 to 90.9,314
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,84.3,78.6 to 88.7,296
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,83.8,77.3 to 88.7,293
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2022,Age,13-15 Years,87.4,77.9 to 93.2,151
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,83.7,77.8 to 88.3,336
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,86.2,80.7 to 90.4,298
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,85.4,80.1 to 89.5,334
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,88.0,83.8 to 91.3,385
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,84.7,79.5 to 88.8,368
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,88.6,82.2 to 92.9,346
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,87.0,81.9 to 90.8,317
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Bexar County,2011,Age,13-17 Years,16.9,12.7 to 22.1,448
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,86.8,81.8 to 90.6,334
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2016,Age,13-17 Years,87.2,81.8 to 91.2,334
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,88.5,83.5 to 92.1,368
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2013,Age,13-17 Years,87.2,82.4 to 90.8,317
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,84.3,78.7 to 88.7,385
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,83.6,76.7 to 88.7,346
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,88.1,81.6 to 92.5,253
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2019,Age,13-17 Years,89.1,83.9 to 92.8,293
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2017,Age,13-17 Years,83.3,77.6 to 87.7,336
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2018,Age,13-17 Years,85.8,80.3 to 90.0,298
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Bexar County,2012,Age,13-17 Years,15.5,10.8 to 21.7,346
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2020,Age,13-17 Years,85.0,79.8 to 89.0,314
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Bexar County,2015,Age,13-17 Years,26.4,21.2 to 32.3,368
HPV,"≥3 Doses, Males and Females",States/Local Areas,TX-Bexar County,2014,Age,13-17 Years,23.0,18.0 to 28.9,385
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2021,Age,13-17 Years,85.5,79.3 to 90.1,296
≥2 Doses MMR,,States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,90.4,85.1 to 93.9,253
HPV,"≥2 Doses, Females",States/Local Areas,TX-Bexar County,2022,Age,13-17 Years,72.0,60.3 to 81.3,121
Tetanus,≥1 Dose Tdap,States/Local Areas,TX-Bexar County,2018-2022,Overall,Overall,85.9,83.5 to 88.1,1454
≥1 Dose MenACWY,,States/Local Areas,TX-Bexar County,2018-2022,Overall,Overall,89.8,87.7 to 91.6,1454
Varicella,History of disease,HHS Regions/National,Region 4,2008,Age,13-17 Years,60.6,57.6 to 63.4,2788
Varicella,History of disease,HHS Regions/National,Region 4,2006,Age,13-17 Years,69.9,65.0 to 74.4,608
Varicella,History of disease,HHS Regions/National,Region 4,2009,Age,13-17 Years,54.9,52.4 to 57.4,2984
